32911311/	CD	@card@
Critical	JJ	critical
illness-associated	JJ	illness-associated
cerebral	JJ	cerebral
microbleeds	NNS	<unknown>
in	IN	in
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
Neurologic	JJ	neurologic
complications	NNS	complication
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
have	VBP	have
been	VBN	be
recently	RB	recently
described	VBN	describe
and	CC	and
include	VBP	include
dizziness	NN	dizziness
,	,	,
headache	NN	headache
,	,	,
loss	NN	loss
of	IN	of
taste	NN	taste
and	CC	and
smell	NN	smell
,	,	,
stroke	NN	stroke
,	,	,
and	CC	and
encephalopathy	NN	<unknown>
.	SENT	.
Brain	NP	Brain
MRI	NP	MRI
in	IN	in
these	DT	these
patients	NNS	patient
have	VBP	have
revealed	VBN	reveal
various	JJ	various
findings	NNS	finding
including	VBG	include
ischemia	NN	ischemia
,	,	,
hemorrhage	NN	hemorrhage
,	,	,
inflammation	NN	inflammation
,	,	,
and	CC	and
demyelination	NN	demyelination
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
report	VBP	report
a	DT	a
case	NN	case
of	IN	of
critical	JJ	critical
illness-associated	JJ	illness-associated
cerebral	JJ	cerebral
microbleeds	NNS	<unknown>
identified	VBN	identify
on	IN	on
MRI	NP	MRI
in	IN	in
a	DT	a
patient	NN	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
and	CC	and
discuss	VB	discuss
the	DT	the
potential	JJ	potential
etiologies	NNS	etiology
of	IN	of
these	DT	these
neuroimaging	VBG	neuroimage
findings	NNS	finding
.	SENT	.
Neurological	JJ	neurological
symptoms	NNS	symptom
are	VBP	be
common	JJ	common
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Critical	JJ	critical
illness-associated	JJ	illness-associated
cerebral	JJ	cerebral
microbleeds	NNS	<unknown>
can	MD	can
be	VB	be
seen	VBN	see
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
severe	JJ	severe
COVID-19	NP	<unknown>
.	SENT	.
Critical	JJ	critical
illness-associated	JJ	illness-associated
cerebral	JJ	cerebral
microbleeds	NNS	<unknown>
are	VBP	be
a	DT	a
neuroimaging	NN	neuroimaging
finding	NN	finding
thought	VBD	think
to	TO	to
be	VB	be
related	VBN	relate
to	TO	to
hypoxemia	NN	<unknown>
,	,	,
ECMO-related	JJ	ECMO-related
complications	NNS	complication
and/or	CC	and/or
DIC	JJ	DIC
.	SENT	.
In	IN	in
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
,	,	,
other	JJ	other
potential	JJ	potential
etiologies	NNS	etiology
of	IN	of
cerebral	JJ	cerebral
microbleeds	NNS	<unknown>
are	VBP	be
endotheliopathy	NN	<unknown>
,	,	,
encephalitis	NN	encephalitis
and	CC	and
immune	JJ	immune
response	NN	response
.	SENT	.
34061905/	CD	@card@
Extensive	JJ	extensive
C-&gt	NP	<unknown>
;	:	;
U	NP	U
transition	NN	transition
biases	NNS	bias
in	IN	in
the	DT	the
genomes	NNS	genome
of	IN	of
a	DT	a
wide	JJ	wide
range	NN	range
of	IN	of
mammalian	JJ	mammalian
RNA	NP	RNA
viruses	NNS	virus
;	:	;
potential	JJ	potential
associations	NNS	association
with	IN	with
transcriptional	JJ	transcriptional
mutations	NNS	mutation
,	,	,
damage-	NN	<unknown>
or	CC	or
host-mediated	JJ	<unknown>
editing	VBG	edit
of	IN	of
viral	JJ	viral
RNA	NP	RNA
The	DT	the
rapid	JJ	rapid
evolution	NN	evolution
of	IN	of
RNA	NP	RNA
viruses	NNS	virus
has	VBZ	have
been	VBN	be
long	RB	long
considered	VBN	consider
to	TO	to
result	VB	result
from	IN	from
a	DT	a
combination	NN	combination
of	IN	of
high	JJ	high
copying	NN	copying
error	NN	error
frequencies	NNS	frequency
during	IN	during
RNA	NP	RNA
replication	NN	replication
,	,	,
short	JJ	short
generation	NN	generation
times	NNS	time
and	CC	and
the	DT	the
consequent	JJ	consequent
extensive	JJ	extensive
fixation	NN	fixation
of	IN	of
neutral	JJ	neutral
or	CC	or
adaptive	JJ	adaptive
changes	NNS	change
over	IN	over
short	JJ	short
periods	NNS	period
.	SENT	.
While	IN	while
both	CC	both
the	DT	the
identities	NNS	identity
and	CC	and
sites	NNS	site
of	IN	of
mutations	NNS	mutation
are	VBP	be
typically	RB	typically
modelled	VBN	model
as	IN	as
being	VBG	be
random	JJ	random
,	,	,
recent	JJ	recent
investigations	NNS	investigation
of	IN	of
sequence	NN	sequence
diversity	NN	diversity
of	IN	of
SARS	NP	<unknown>
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
have	VBP	have
identified	VBN	identify
a	DT	a
preponderance	NN	preponderance
of	IN	of
C-&gt	NP	<unknown>
;	:	;
U	NP	U
transitions	NNS	transition
,	,	,
proposed	VBN	propose
to	TO	to
be	VB	be
driven	VBN	drive
by	IN	by
an	DT	an
APOBEC-like	JJ	<unknown>
RNA	NP	RNA
editing	VBG	edit
process	NN	process
.	SENT	.
The	DT	the
current	JJ	current
study	NN	study
investigated	VBN	investigate
whether	IN	whether
this	DT	this
phenomenon	NN	phenomenon
could	MD	could
be	VB	be
observed	VBN	observe
in	IN	in
datasets	NNS	<unknown>
of	IN	of
other	JJ	other
RNA	NP	RNA
viruses	NNS	virus
.	SENT	.
Using	VBG	use
a	DT	a
5	CD	@card@
%	NN	%
divergence	NN	divergence
filter	NN	filter
to	TO	to
infer	VB	infer
directionality	NN	directionality
,	,	,
18	CD	@card@
from	IN	from
36	CD	@card@
datasets	NNS	<unknown>
of	IN	of
aligned	VBN	align
coding	VBG	code
region	NN	region
sequences	NNS	sequence
from	IN	from
a	DT	a
diverse	JJ	diverse
range	NN	range
of	IN	of
mammalian	JJ	mammalian
RNA	NP	RNA
viruses	NNS	virus
(	(	(
including	VBG	include
Picornaviridae	NP	<unknown>
,	,	,
Flaviviridae	NP	<unknown>
,	,	,
Matonaviridae	NP	<unknown>
,	,	,
Caliciviridae	NP	<unknown>
and	CC	and
Coronaviridae	NP	<unknown>
)	)	)
showed	VBD	show
a	DT	a
&gt	NN	&gt
;	:	;
2-fold	JJ	<unknown>
base	NN	base
composition	NN	composition
normalised	VBD	normalise
excess	JJ	excess
of	IN	of
C-&gt	NP	<unknown>
;	:	;
U	NP	U
transitions	NNS	transition
compared	VBN	compare
to	TO	to
U-&gt	NP	<unknown>
;	:	;
C	NP	C
(	(	(
range	NN	range
2.1x-7.5x	NN	<unknown>
)	)	)
,	,	,
with	IN	with
a	DT	a
consistently	RB	consistently
observed	VBN	observe
favoured	VBD	favour
5	CD	@card@
'	POS	'
U	NP	U
upstream	JJ	upstream
context	NN	context
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
genome	NN	genome
scale	NN	scale
RNA	NP	RNA
secondary	JJ	secondary
structure	NN	structure
(	(	(
GORS	NP	<unknown>
)	)	)
was	VBD	be
the	DT	the
only	RB	only
other	JJ	other
genomic	JJ	<unknown>
or	CC	or
structural	JJ	structural
parameter	NN	parameter
significantly	RB	significantly
associated	VBN	associate
with	IN	with
C-&gt	NP	<unknown>
;	:	;
U/U-&gt	NP	<unknown>
;	:	;
C	NP	C
transition	NN	transition
asymmetries	NNS	asymmetry
by	IN	by
multivariable	JJ	multivariable
analysis	NN	analysis
(	(	(
ANOVA	NP	<unknown>
)	)	)
,	,	,
potentially	RB	potentially
reflecting	VBG	reflect
RNA	NP	RNA
structure	NN	structure
dependence	NN	dependence
of	IN	of
sites	NNS	site
targeted	VBN	target
for	IN	for
C-&gt	NP	<unknown>
;	:	;
U	NP	U
mutations	NNS	mutation
.	SENT	.
Using	VBG	use
the	DT	the
association	NN	association
index	NN	index
metric	NN	metric
,	,	,
C-&gt	NP	<unknown>
;	:	;
U	NP	U
changes	NNS	change
were	VBD	be
specifically	RB	specifically
over-represented	VBN	over-represent
at	IN	at
phylogenetically	RB	phylogenetically
uninformative	JJ	uninformative
sites	NNS	site
,	,	,
potentially	RB	potentially
paralleling	VBG	parallel
extensive	JJ	extensive
homoplasy	NN	homoplasy
of	IN	of
this	DT	this
transition	NN	transition
reported	VBD	report
in	IN	in
SARS-CoV-2	NP	<unknown>
.	SENT	.
Although	IN	although
mechanisms	NNS	mechanism
remain	VBP	remain
to	TO	to
be	VB	be
functionally	RB	functionally
characterised	VBN	characterise
,	,	,
excess	JJ	excess
C-&gt	NP	<unknown>
;	:	;
U	NP	U
substitutions	NNS	substitution
accounted	VBD	account
for	IN	for
11-14	CD	@card@
%	NN	%
of	IN	of
standing	VBG	stand
sequence	NN	sequence
variability	NN	variability
of	IN	of
structured	JJ	structured
viruses	NNS	virus
and	CC	and
may	MD	may
therefore	RB	therefore
represent	VB	represent
a	DT	a
potent	JJ	potent
driver	NN	driver
of	IN	of
their	PP$	their
sequence	NN	sequence
diversification	NN	diversification
and	CC	and
longer-term	JJ	longer-term
evolution	NN	evolution
.	SENT	.
The	DT	the
rapid	JJ	rapid
evolution	NN	evolution
of	IN	of
RNA	NP	RNA
viruses	NNS	virus
is	VBZ	be
thought	VBN	think
to	TO	to
arise	VB	arise
from	IN	from
high	JJ	high
mutation	NN	mutation
frequencies	NNS	frequency
during	IN	during
replication	NN	replication
and	CC	and
the	DT	the
rapid	JJ	rapid
accumulation	NN	accumulation
of	IN	of
genetic	JJ	genetic
changes	NNS	change
over	IN	over
time	NN	time
in	IN	in
response	NN	response
to	TO	to
its	PP$	its
changing	VBG	change
environments	NNS	environment
.	SENT	.
This	DT	this
study	NN	study
describes	VBZ	describe
an	DT	an
additional	JJ	additional
potent	JJ	potent
factor	NN	factor
that	WDT	that
contributes	VBZ	contribute
to	TO	to
the	DT	the
evolution	NN	evolution
of	IN	of
RNA	NP	RNA
viruses	NNS	virus
infecting	VBG	infect
mammals	NNS	mammal
,	,	,
the	DT	the
occurrence	NN	occurrence
of	IN	of
specific	JJ	specific
C-&gt	NP	<unknown>
;	:	;
U	NP	U
mutations	NNS	mutation
in	IN	in
a	DT	a
subset	NN	subset
that	WDT	that
possess	VBP	possess
intensely	RB	intensely
structured	JJ	structured
genomes	NNS	genome
.	SENT	.
This	DT	this
mutational	JJ	mutational
process	NN	process
substantially	RB	substantially
damages	VBZ	damage
the	DT	the
virus	NN	virus
's	POS	's
ability	NN	ability
to	TO	to
replicate	VB	replicate
and	CC	and
is	VBZ	be
potentially	RB	potentially
akin	JJ	akin
to	TO	to
"	``	"
genome	NN	genome
editing	VBG	edit
"	``	"
of	IN	of
HIV-1	NP	<unknown>
and	CC	and
other	JJ	other
retrovirus	NN	retrovirus
genome	NN	genome
sequences	NNS	sequence
by	IN	by
APOBEC	NP	<unknown>
,	,	,
one	CD	one
of	IN	of
the	DT	the
principal	JJ	principal
components	NNS	component
of	IN	of
vertebrate	JJ	vertebrate
antiretroviral	JJ	antiretroviral
defence	NN	defence
mechanisms	NNS	mechanism
.	SENT	.
This	DT	this
study	NN	study
however	RB	however
provides	VBZ	provide
evidence	NN	evidence
for	IN	for
a	DT	a
wider	JJR	wide
mutational	JJ	mutational
activity	NN	activity
against	IN	against
several	JJ	several
human	JJ	human
and	CC	and
veterinary	JJ	veterinary
RNA	NP	RNA
viruses	NNS	virus
,	,	,
including	VBG	include
HCV	NP	HCV
and	CC	and
foot	NN	foot
and	CC	and
mouth	NN	mouth
disease	NN	disease
virus	NN	virus
.	SENT	.
The	DT	the
C-&gt	NP	<unknown>
;	:	;
U	NP	U
mutational	JJ	mutational
process	NN	process
accounted	VBD	account
for	IN	for
15-20	CD	@card@
%	NN	%
of	IN	of
standing	VBG	stand
sequence	NN	sequence
variability	NN	variability
of	IN	of
these	DT	these
RNA	NP	RNA
viruses	NNS	virus
,	,	,
representing	VBG	represent
a	DT	a
potent	JJ	potent
driver	NN	driver
of	IN	of
their	PP$	their
sequence	NN	sequence
diversification	NN	diversification
and	CC	and
longer-term	JJ	longer-term
evolution	NN	evolution
.	SENT	.
34898715/	CD	@card@
Effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
integration	NN	integration
of	IN	of
women	NNS	woman
refugees	NNS	refugee
into	IN	into
Turkish	JJ	Turkish
society	NN	society
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
research	NN	research
is	VBZ	be
to	TO	to
determine	VB	determine
how	WRB	how
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
influenced	VBD	influence
integration	NN	integration
of	IN	of
women	NNS	woman
refugees	NNS	refugee
into	IN	into
Turkish	JJ	Turkish
society	NN	society
.	SENT	.
The	DT	the
study	NN	study
was	VBD	be
designed	VBN	design
as	IN	as
a	DT	a
qualitative	JJ	qualitative
study	NN	study
between	IN	between
March	NP	March
2020	CD	@card@
and	CC	and
June	NP	June
2020	CD	@card@
.	SENT	.
The	DT	the
notion	NN	notion
of	IN	of
integration	NN	integration
is	VBZ	be
redefined	VBN	redefin
as	IN	as
an	DT	an
eight-dimensional	JJ	eight-dimensional
model	NN	model
composed	VBN	compose
of	IN	of
education	NN	education
,	,	,
sociocultural	JJ	sociocultural
,	,	,
health	NN	health
,	,	,
economy	NN	economy
,	,	,
legal	JJ	legal
,	,	,
shelter	NN	shelter
,	,	,
family	NN	family
and	CC	and
security	NN	security
.	SENT	.
Semi-structured	JJ	semi-structured
interviews	NNS	interview
were	VBD	be
conducted	VBN	conduct
by	IN	by
telephone	NN	telephone
,	,	,
with	IN	with
50	CD	@card@
women	NNS	woman
refugees	NNS	refugee
in	IN	in
Turkey	NP	Turkey
,	,	,
about	IN	about
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
integration	NN	integration
.	SENT	.
The	DT	the
results	NNS	result
of	IN	of
the	DT	the
research	NN	research
indicate	VBP	indicate
that	IN	that
most	JJS	most
women	NNS	woman
refugees	NNS	refugee
had	VBD	have
both	DT	both
positive	JJ	positive
and	CC	and
negative	JJ	negative
experiences	NNS	experience
in	IN	in
economic	JJ	economic
,	,	,
education	NN	education
and	CC	and
sociocultural	JJ	sociocultural
dimensions	NNS	dimension
of	IN	of
integration	NN	integration
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
affected	VBD	affect
their	PP$	their
integration	NN	integration
in	IN	in
an	DT	an
unprecedented	JJ	unprecedented
way	NN	way
,	,	,
especially	RB	especially
in	IN	in
daily	JJ	daily
and	CC	and
work	NN	work
life	NN	life
as	RB	as
well	RB	well
as	IN	as
access	NN	access
to	TO	to
health	NN	health
services	NNS	service
.	SENT	.
Similarly	RB	similarly
,	,	,
language	NN	language
barriers	NNS	barrier
faced	VBN	face
by	IN	by
refugee	NN	refugee
women	NNS	woman
create	VBP	create
significant	JJ	significant
challenges	NNS	challenge
and	CC	and
obstacles	NNS	obstacle
,	,	,
making	VBG	make
the	DT	the
integration	NN	integration
process	NN	process
more	RBR	more
complex	JJ	complex
.	SENT	.
Refugee	NN	refugee
women	NNS	woman
stated	VBD	state
that	IN	that
COVID-19	NP	<unknown>
positively	RB	positively
influenced	VBD	influence
the	DT	the
security	NN	security
dimension	NN	dimension
of	IN	of
integration	NN	integration
.	SENT	.
34910338/	CD	@card@
Time	NN	time
course	NN	course
of	IN	of
antibody	NN	antibody
concentrations	NNS	concentration
against	IN	against
the	DT	the
spike	NN	spike
protein	NN	protein
of	IN	of
SARS-CoV-2	NP	<unknown>
among	IN	among
healthy	JJ	healthy
hospital	NN	hospital
workers	NNS	worker
up	RB	up
to	TO	to
200	CD	@card@
days	NNS	day
after	IN	after
their	PP$	their
first	JJ	first
COVID-19	NP	<unknown>
vaccination	NN	vaccination
32292259/	CD	@card@
Understanding	NN	understanding
of	IN	of
guidance	NN	guidance
for	IN	for
acupuncture	NN	acupuncture
and	CC	and
moxibustion	NN	<unknown>
interventions	NNS	intervention
on	IN	on
COVID-19	NP	<unknown>
(	(	(
Second	NP	Second
edition	NN	edition
)	)	)
issued	VBN	issue
by	IN	by
CAAM	NP	<unknown>
At	IN	at
present	NN	present
,	,	,
the	DT	the
situation	NN	situation
of	IN	of
global	JJ	global
fight	NN	fight
against	IN	against
COVID-19	NP	<unknown>
is	VBZ	be
serious	JJ	serious
.	SENT	.
WHO	WP	who
(	(	(
World	NP	World
Health	NP	Health
Organization)-China	NP	Organization)-China
Joint	NP	Joint
Mission	NP	Mission
fully	RB	fully
confirms	VBZ	confirm
the	DT	the
success	NN	success
of	IN	of
"	``	"
China	NP	China
's	POS	's
model	NN	model
"	''	"
against	IN	against
COVID-19	NP	<unknown>
in	IN	in
the	DT	the
report	NN	report
.	SENT	.
In	IN	in
fact	NN	fact
,	,	,
one	CD	one
particular	JJ	particular
power	NN	power
in	IN	in
"	``	"
China	NP	China
's	POS	's
model	NN	model
"	``	"
is	VBZ	be
acupuncture	NN	acupuncture
and	CC	and
moxibustion	NN	<unknown>
of	IN	of
traditional	JJ	traditional
Chinese	JJ	Chinese
medicine	NN	medicine
.	SENT	.
To	TO	to
better	RBR	well
apply	VB	apply
"	``	"
non-pharmaceutic	JJ	non-pharmaceutic
measures":the	NN	<unknown>
external	JJ	external
technique	NN	technique
of	IN	of
traditional	JJ	traditional
Chinese	JJ	Chinese
medicine	NN	medicine
,	,	,
in	IN	in
the	DT	the
article	NN	article
,	,	,
the	DT	the
main	JJ	main
content	NN	content
of	IN	of
Guidance	NN	guidance
for	IN	for
acupuncture	NN	acupuncture
and	CC	and
moxibustion	NN	<unknown>
interventions	NNS	intervention
on	IN	on
COVID-19	NP	<unknown>
(	(	(
Second	NP	Second
edition	NN	edition
)	)	)
issued	VBN	issue
by	IN	by
China	NP	China
Association	NP	Association
of	IN	of
Acupuncture-Moxibution	NP	<unknown>
is	VBZ	be
introduced	VBN	introduce
and	CC	and
the	DT	the
discussion	NN	discussion
is	VBZ	be
stressed	VBN	stress
on	IN	on
the	DT	the
selection	NN	selection
of	IN	of
moxibustion	NN	<unknown>
device	NN	device
and	CC	and
the	DT	the
duration	NN	duration
of	IN	of
its	PP$	its
exertion	NN	exertion
.	SENT	.
35519622/	CD	@card@
The	DT	the
Potential	JJ	potential
of	IN	of
Eukaryotic	NP	<unknown>
Cell-Free	NP	<unknown>
Systems	NPS	Systems
as	IN	as
a	DT	a
Rapid	NP	Rapid
Response	NP	Response
to	TO	to
Novel	NP	Novel
Zoonotic	NP	<unknown>
Pathogens	NNS	pathogen
:	:	:
Analysis	NN	analysis
of	IN	of
SARS-CoV-2	NP	<unknown>
Viral	JJ	viral
Proteins	NPS	Proteins
The	DT	the
ongoing	JJ	ongoing
pandemic	NN	pandemic
caused	VBN	cause
by	IN	by
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
has	VBZ	have
led	VBN	lead
to	TO	to
more	JJR	more
than	IN	than
445	CD	@card@
million	CD	million
infections	NNS	infection
and	CC	and
the	DT	the
underlying	VBG	underlie
disease	NN	disease
,	,	,
COVID-19	NP	<unknown>
,	,	,
resulted	VBN	result
in	IN	in
more	JJR	more
than	IN	than
6	CD	@card@
million	CD	million
deaths	NNS	death
worldwide	RB	worldwide
.	SENT	.
The	DT	the
scientific	JJ	scientific
world	NN	world
is	VBZ	be
already	RB	already
predicting	VBG	predict
future	JJ	future
zoonotic	JJ	<unknown>
diseases	NNS	disease
.	SENT	.
Hence	RB	hence
,	,	,
rapid	JJ	rapid
response	NN	response
systems	NNS	system
are	VBP	be
needed	VBN	need
to	TO	to
tackle	VB	tackle
future	JJ	future
epidemics	NNS	epidemic
and	CC	and
pandemics	NNS	pandemic
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
present	VBP	present
the	DT	the
use	NN	use
of	IN	of
eukaryotic	JJ	<unknown>
cell-free	JJ	<unknown>
systems	NNS	system
for	IN	for
the	DT	the
rapid	JJ	rapid
response	NN	response
to	TO	to
novel	JJ	novel
zoonotic	JJ	<unknown>
diseases	NNS	disease
represented	VBN	represent
by	IN	by
SARS-CoV-2	NP	<unknown>
.	SENT	.
Non-structural	JJ	non-structural
,	,	,
structural	JJ	structural
and	CC	and
accessory	JJ	accessory
proteins	NNS	protein
encoded	VBN	encode
by	IN	by
SARS-CoV-2	NP	<unknown>
were	VBD	be
synthesized	VBN	synthesize
by	IN	by
cell-free	JJ	<unknown>
protein	NN	protein
synthesis	NN	synthesis
in	IN	in
a	DT	a
fast	JJ	fast
and	CC	and
efficient	JJ	efficient
manner	NN	manner
.	SENT	.
The	DT	the
inhibitory	JJ	inhibitory
effect	NN	effect
of	IN	of
the	DT	the
non-structural	JJ	non-structural
protein	NN	protein
1	CD	@card@
on	IN	on
protein	NN	protein
synthesis	NN	synthesis
could	MD	could
be	VB	be
shown	VBN	show
in	IN	in
vitro	NN	<unknown>
.	SENT	.
Structural	JJ	structural
proteins	NNS	protein
were	VBD	be
quantitatively	RB	quantitatively
detected	VBN	detect
by	IN	by
commercial	JJ	commercial
antibodies	NNS	antibody
,	,	,
therefore	RB	therefore
facilitating	VBG	facilitate
cell-free	JJ	<unknown>
systems	NNS	system
for	IN	for
the	DT	the
validation	NN	validation
of	IN	of
available	JJ	available
antibodies	NNS	antibody
.	SENT	.
The	DT	the
cytotoxic	JJ	cytotoxic
envelope	NN	envelope
protein	NN	protein
was	VBD	be
characterized	VBN	characterize
in	IN	in
electrophysiological	JJ	electrophysiological
planar	JJ	planar
lipid	NN	lipid
bilayer	NN	bilayer
measurements	NNS	measurement
.	SENT	.
Hence	RB	hence
,	,	,
our	PP$	our
study	NN	study
demonstrates	VBZ	demonstrate
the	DT	the
potential	NN	potential
of	IN	of
eukaryotic	JJ	<unknown>
cell-free	JJ	<unknown>
systems	NNS	system
as	IN	as
a	DT	a
rapid	JJ	rapid
response	NN	response
mechanism	NN	mechanism
for	IN	for
the	DT	the
synthesis	NN	synthesis
,	,	,
functional	JJ	functional
characterization	NN	characterization
and	CC	and
antibody	NN	antibody
validation	NN	validation
against	IN	against
a	DT	a
viral	JJ	viral
pathogen	NN	pathogen
.	SENT	.
35013628/	CD	@card@
Recognition	NP	Recognition
efficiency	NN	efficiency
of	IN	of
atypical	JJ	atypical
cardiovascular	JJ	cardiovascular
readings	NNS	reading
on	IN	on
ECG	NP	ECG
devices	NNS	device
through	IN	through
fogged	JJ	fogged
goggles	NNS	goggle
In	IN	in
their	PP$	their
continuing	JJ	continuing
battle	NN	battle
against	IN	against
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
medical	JJ	medical
workers	NNS	worker
in	IN	in
hospitals	NNS	hospital
worldwide	RB	worldwide
need	VBP	need
to	TO	to
wear	VB	wear
safety	NN	safety
glasses	NNS	glass
and	CC	and
goggles	NNS	goggle
to	TO	to
protect	VB	protect
their	PP$	their
eyes	NNS	eye
from	IN	from
the	DT	the
possible	JJ	possible
transmission	NN	transmission
of	IN	of
the	DT	the
virus	NN	virus
.	SENT	.
However	RB	however
,	,	,
they	PP	they
work	VBP	work
for	IN	for
long	JJ	long
hours	NNS	hour
and	CC	and
need	VBP	need
to	TO	to
wear	VB	wear
a	DT	a
mask	NN	mask
and	CC	and
other	JJ	other
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
,	,	,
which	WDT	which
causes	VBZ	cause
their	PP$	their
protective	JJ	protective
eye	NN	eye
wear	NN	wear
to	TO	to
fog	VB	fog
up	RP	up
.	SENT	.
This	DT	this
fogging	VBG	fog
up	RP	up
of	IN	of
eye	NN	eye
wear	NN	wear
,	,	,
in	IN	in
turn	NN	turn
,	,	,
has	VBZ	have
a	DT	a
substantial	JJ	substantial
impact	NN	impact
in	IN	in
the	DT	the
speed	NN	speed
and	CC	and
accuracy	NN	accuracy
of	IN	of
reading	VBG	read
information	NN	information
on	IN	on
the	DT	the
interface	NN	interface
of	IN	of
electrocardiogram	NN	electrocardiogram
(	(	(
ECG	NP	ECG
)	)	)
machines	NNS	machine
.	SENT	.
To	TO	to
gain	VB	gain
a	DT	a
better	JJR	good
understanding	NN	understanding
of	IN	of
the	DT	the
extent	NN	extent
of	IN	of
the	DT	the
impact	NN	impact
,	,	,
this	DT	this
study	NN	study
experimentally	RB	experimentally
simulates	VBZ	simulate
the	DT	the
fogging	VBG	fog
of	IN	of
protective	JJ	protective
goggles	NNS	goggle
when	WRB	when
viewing	VBG	view
the	DT	the
interface	NN	interface
with	IN	with
three	CD	three
variables	NNS	variable
:	:	:
the	DT	the
degree	NN	degree
of	IN	of
fogging	VBG	fog
of	IN	of
the	DT	the
goggles	NNS	goggle
,	,	,
brightness	NN	brightness
of	IN	of
the	DT	the
screen	NN	screen
,	,	,
and	CC	and
color	NN	color
of	IN	of
the	DT	the
font	NN	font
of	IN	of
the	DT	the
cardiovascular	JJ	cardiovascular
readings	NNS	reading
.	SENT	.
This	DT	this
experimental	JJ	experimental
study	NN	study
on	IN	on
the	DT	the
target	NN	target
recognition	NN	recognition
of	IN	of
digital	JJ	digital
font	NN	font
is	VBZ	be
carried	VBN	carry
out	RP	out
by	IN	by
simulating	VBG	simulate
the	DT	the
interface	NN	interface
of	IN	of
an	DT	an
ECG	NP	ECG
machine	NN	machine
and	CC	and
readability	NN	readability
of	IN	of
the	DT	the
ECG	NP	ECG
machine	NN	machine
with	IN	with
fogged	JJ	fogged
eye	NN	eye
wear	NN	wear
.	SENT	.
The	DT	the
experimental	JJ	experimental
results	NNS	result
indicate	VBP	indicate
that	IN	that
the	DT	the
fogging	VBG	fog
of	IN	of
the	DT	the
lenses	NNS	lens
has	VBZ	have
a	DT	a
significant	JJ	significant
impact	NN	impact
on	IN	on
the	DT	the
recognition	NN	recognition
speed	NN	speed
and	CC	and
the	DT	the
degree	NN	degree
of	IN	of
fogging	VBG	fog
has	VBZ	have
a	DT	a
significant	JJ	significant
correlation	NN	correlation
with	IN	with
the	DT	the
font	NN	font
color	NN	color
and	CC	and
brightness	NN	brightness
of	IN	of
the	DT	the
screen	NN	screen
.	SENT	.
With	IN	with
a	DT	a
reduction	NN	reduction
in	IN	in
screen	NN	screen
brightness	NN	brightness
,	,	,
its	PP$	its
influence	NN	influence
on	IN	on
recognition	NN	recognition
speed	NN	speed
shows	VBZ	show
a	DT	a
v-shaped	JJ	V-shaped
trend	NN	trend
,	,	,
and	CC	and
the	DT	the
response	NN	response
time	NN	time
is	VBZ	be
the	DT	the
shortest	JJS	short
when	WRB	when
the	DT	the
screen	NN	screen
brightness	NN	brightness
is	VBZ	be
150	CD	@card@
cd/m2	NN	<unknown>
.	SENT	.
When	WRB	when
eyewear	NP	eyewear
is	VBZ	be
fogged	JJ	fogged
,	,	,
yellow	JJ	yellow
and	CC	and
green	JJ	green
font	NN	font
colors	NNS	color
allow	VBP	allow
a	DT	a
quicker	JJR	quick
response	NN	response
with	IN	with
a	DT	a
higher	JJR	high
accuracy	NN	accuracy
.	SENT	.
On	IN	on
the	DT	the
whole	NN	whole
,	,	,
the	DT	the
subjects	NNS	subject
show	VBP	show
a	DT	a
better	JJR	good
performance	NN	performance
with	IN	with
the	DT	the
use	NN	use
of	IN	of
green	JJ	green
font	NN	font
,	,	,
but	CC	but
there	EX	there
are	VBP	be
inconsistencies	NNS	inconsistency
.	SENT	.
In	IN	in
terms	NNS	term
of	IN	of
the	DT	the
interaction	NN	interaction
among	IN	among
the	DT	the
three	CD	three
variables	NNS	variable
,	,	,
the	DT	the
same	JJ	same
results	NNS	result
are	VBP	be
also	RB	also
found	VBN	find
and	CC	and
the	DT	the
same	JJ	same
conclusion	NN	conclusion
can	MD	can
be	VB	be
made	VBN	make
accordingly	RB	accordingly
.	SENT	.
This	DT	this
research	NN	research
study	NN	study
can	MD	can
act	VB	act
as	IN	as
a	DT	a
reference	NN	reference
for	IN	for
the	DT	the
interface	NN	interface
design	NN	design
of	IN	of
medical	JJ	medical
equipment	NN	equipment
in	IN	in
events	NNS	event
where	WRB	where
medical	JJ	medical
staff	NN	staff
wear	VBP	wear
protective	JJ	protective
eyewear	NN	eyewear
for	IN	for
a	DT	a
long	JJ	long
period	NN	period
of	IN	of
time	NN	time
.	SENT	.
33073247/	CD	@card@
COVID-19	NP	<unknown>
Front	NP	Front
Line	NP	Line
-	NN	<unknown>
Why	WRB	why
Focused	VBN	focus
Lung	NP	Lung
and	CC	and
Cardiovascular	NP	Cardiovascular
Ultrasound	NN	ultrasound
?	SENT	?
33782759/	CD	@card@
Online	JJ	online
informational	JJ	informational
bariatric	JJ	bariatric
seminars	NNS	seminar
:	:	:
increasing	VBG	increase
access	NN	access
to	TO	to
bariatric	JJ	bariatric
surgery	NN	surgery
or	CC	or
widening	VBG	widen
a	DT	a
divide	NN	divide
?	SENT	?
Historically	RB	historically
our	PP$	our
institution	NN	institution
has	VBZ	have
required	VBN	require
prospective	JJ	prospective
bariatric	JJ	bariatric
patients	NNS	patient
attend	VBP	attend
an	DT	an
in-person	NN	in-person
introductory	JJ	introductory
seminar	NN	seminar
prior	RB	prior
to	TO	to
their	PP$	their
first	JJ	first
clinic	NN	clinic
visit	NN	visit
.	SENT	.
Utilization	NN	utilization
of	IN	of
the	DT	the
internet	NN	Internet
has	VBZ	have
increased	VBN	increase
dramatically	RB	dramatically
over	IN	over
the	DT	the
last	JJ	last
10	CD	@card@
years	NNS	year
and	CC	and
in	IN	in
2016	CD	@card@
,	,	,
we	PP	we
added	VBD	add
an	DT	an
online	JJ	online
seminar	NN	seminar
.	SENT	.
With	IN	with
the	DT	the
emergence	NN	emergence
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
new	JJ	new
rules	NNS	rule
regarding	VBG	regard
social	JJ	social
distancing	NN	distancing
,	,	,
we	PP	we
are	VBP	be
currently	RB	currently
relying	VBG	rely
exclusively	RB	exclusively
on	IN	on
web-based	JJ	<unknown>
orientation	NN	orientation
.	SENT	.
Research	NP	Research
suggests	VBZ	suggest
there	EX	there
are	VBP	be
racial	JJ	racial
and	CC	and
socioeconomic	JJ	socioeconomic
disparities	NNS	disparity
in	IN	in
the	DT	the
utilization	NN	utilization
of	IN	of
internet	NN	Internet
health	NN	health
resources	NNS	resource
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
To	TO	to
our	PP$	our
knowledge	NN	knowledge
this	DT	this
has	VBZ	have
not	RB	not
been	VBN	be
studied	VBN	study
in	IN	in
regard	NN	regard
to	TO	to
the	DT	the
bariatric	JJ	bariatric
population	NN	population
.	SENT	.
A	DT	a
retrospective	JJ	retrospective
chart	NN	chart
review	NN	review
was	VBD	be
performed	VBN	perform
on	IN	on
patients	NNS	patient
who	WP	who
attended	VBD	attend
online	JJ	online
(	(	(
OS	NN	os
)	)	)
and	CC	and
in-person	NN	in-person
seminars	NNS	seminar
(	(	(
IPS	NP	IPS
)	)	)
.	SENT	.
Our	PP$	our
primary	JJ	primary
endpoint	NN	endpoint
was	VBD	be
to	TO	to
compare	VB	compare
the	DT	the
percentage	NN	percentage
of	IN	of
patients	NNS	patient
who	WP	who
underwent	VBD	undergo
surgery	NN	surgery
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
included	VBD	include
differences	NNS	difference
in	IN	in
demographic	JJ	demographic
and	CC	and
clinical	JJ	clinical
characteristics	NNS	characteristic
between	IN	between
the	DT	the
patients	NNS	patient
who	WP	who
attended	VBD	attend
the	DT	the
OS	NN	os
versus	IN	versus
the	DT	the
IPS	NN	IPS
.	SENT	.
Of	IN	of
the	DT	the
1152	CD	@card@
patients	NNS	patient
who	WP	who
attended	VBD	attend
a	DT	a
bariatric	JJ	bariatric
orientation	NN	orientation
,	,	,
71.2	CD	@card@
%	NN	%
scheduled	VBN	schedule
an	DT	an
office	NN	office
visit	NN	visit
.	SENT	.
The	DT	the
IPS	JJ	IPS
patients	NNS	patient
had	VBD	have
a	DT	a
higher	JJR	high
rate	NN	rate
of	IN	of
office	NN	office
visits	NNS	visit
and	CC	and
shorter	JJR	short
time	NN	time
between	IN	between
orientation	NN	orientation
and	CC	and
first	JJ	first
visit	NN	visit
.	SENT	.
Of	IN	of
patients	NNS	patient
eligible	JJ	eligible
for	IN	for
surgery	NN	surgery
,	,	,
there	EX	there
was	VBD	be
a	DT	a
higher	JJR	high
percentage	NN	percentage
of	IN	of
Caucasians	NNS	Caucasians
in	IN	in
the	DT	the
OS	NN	os
group	NN	group
while	IN	while
the	DT	the
IPS	JJ	IPS
group	NN	group
had	VBD	have
higher	JJR	high
rates	NNS	rate
of	IN	of
Hispanic	JJ	Hispanic
and	CC	and
African	JJ	African
Americans	NPS	Americans
.	SENT	.
Patients	NNS	patient
from	IN	from
the	DT	the
OS	NN	os
group	NN	group
had	VBD	have
higher	JJR	high
rates	NNS	rate
of	IN	of
marriage	NN	marriage
and	CC	and
employment	NN	employment
,	,	,
and	CC	and
lower	JJR	low
rates	NNS	rate
of	IN	of
medical	JJ	medical
co-morbidities	NNS	co-morbidity
.	SENT	.
When	WRB	when
controlling	VBG	control
for	IN	for
age	NN	age
,	,	,
sex	NN	sex
,	,	,
race/ethnicity	NN	race/ethnicity
,	,	,
marital	JJ	marital
status	NN	status
,	,	,
employment	NN	employment
status	NN	status
and	CC	and
medical	JJ	medical
co-morbidities	NNS	co-morbidity
,	,	,
there	EX	there
was	VBD	be
no	DT	no
significant	JJ	significant
impact	NN	impact
of	IN	of
type	NN	type
of	IN	of
orientation	NN	orientation
on	IN	on
progression	NN	progression
to	TO	to
surgery	NN	surgery
.	SENT	.
We	PP	we
found	VBD	find
that	IN	that
there	EX	there
was	VBD	be
no	DT	no
difference	NN	difference
in	IN	in
progression	NN	progression
to	TO	to
surgery	NN	surgery
between	IN	between
the	DT	the
two	CD	two
orientation	NN	orientation
groups	NNS	group
.	SENT	.
Importantly	RB	importantly
,	,	,
however	RB	however
,	,	,
we	PP	we
detected	VBD	detect
marked	JJ	marked
demographic	JJ	demographic
and	CC	and
clinical	JJ	clinical
differences	NNS	difference
between	IN	between
the	DT	the
two	CD	two
patient	JJ	patient
populations	NNS	population
.	SENT	.
There	EX	there
is	VBZ	be
an	DT	an
urgent	JJ	urgent
need	NN	need
to	TO	to
address	VB	address
these	DT	these
disparities	NNS	disparity
as	IN	as
we	PP	we
are	VBP	be
now	RB	now
heavily	RB	heavily
relying	VBG	rely
on	IN	on
patient	JJ	patient
outreach	NN	outreach
and	CC	and
education	NN	education
via	IN	via
the	DT	the
internet	NN	Internet
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s00464-021-08453-7	JJ	10.1007/s@card@
.	SENT	.
32878481/	CD	@card@
SARS-CoV-2	NP	<unknown>
transmission	NN	transmission
,	,	,
the	DT	the
ambiguous	JJ	ambiguous
role	NN	role
of	IN	of
children	NNS	child
and	CC	and
considerations	NNS	consideration
for	IN	for
the	DT	the
reopening	VBG	reopen
of	IN	of
schools	NNS	school
in	IN	in
the	DT	the
fall	NN	fall
33439908/	CD	@card@
Sex	NN	sex
differences	NNS	difference
in	IN	in
susceptibility	NN	susceptibility
,	,	,
severity	NN	severity
,	,	,
and	CC	and
outcomes	NNS	outcome
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
:	:	:
Cross-sectional	JJ	cross-sectional
analysis	NN	analysis
from	IN	from
a	DT	a
diverse	JJ	diverse
US	NP	US
metropolitan	JJ	metropolitan
area	NN	area
Sex	NN	sex
is	VBZ	be
increasingly	RB	increasingly
recognized	VBN	recognize
as	IN	as
an	DT	an
important	JJ	important
factor	NN	factor
in	IN	in
the	DT	the
epidemiology	NN	epidemiology
and	CC	and
outcome	NN	outcome
of	IN	of
many	JJ	many
diseases	NNS	disease
.	SENT	.
This	DT	this
also	RB	also
appears	VBZ	appear
to	TO	to
hold	VB	hold
for	IN	for
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
Evidence	NN	evidence
from	IN	from
China	NP	China
and	CC	and
Europe	NP	Europe
has	VBZ	have
suggested	VBN	suggest
that	DT	that
mortality	NN	mortality
from	IN	from
COVID-19	NP	<unknown>
infection	NN	infection
is	VBZ	be
higher	JJR	high
in	IN	in
men	NNS	man
than	IN	than
women	NNS	woman
,	,	,
but	CC	but
evidence	NN	evidence
from	IN	from
US	NP	US
populations	NNS	population
is	VBZ	be
lacking	VBG	lack
.	SENT	.
Utilizing	VBG	utilize
data	NNS	datum
from	IN	from
a	DT	a
large	JJ	large
healthcare	NN	<unknown>
provider	NN	provider
,	,	,
we	PP	we
determined	VBD	determine
if	IN	if
males	NNS	male
,	,	,
as	RB	as
compared	VBN	compare
to	TO	to
females	NNS	female
have	VBP	have
a	DT	a
higher	JJR	high
likelihood	NN	likelihood
of	IN	of
SARS-CoV-2	NP	<unknown>
susceptibility	NN	susceptibility
,	,	,
and	CC	and
if	IN	if
among	IN	among
the	DT	the
hospitalized	VBN	hospitalize
COVID-19	NN	<unknown>
patients	NNS	patient
,	,	,
male	JJ	male
sex	NN	sex
is	VBZ	be
independently	RB	independently
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
severity	NN	severity
and	CC	and
poor	JJ	poor
in-hospital	JJ	in-hospital
outcomes	NNS	outcome
.	SENT	.
Using	VBG	use
the	DT	the
Strengthening	NN	strengthening
the	DT	the
Reporting	NP	Reporting
of	IN	of
Observational	JJ	observational
Studies	NNS	study
in	IN	in
Epidemiology	NN	epidemiology
(	(	(
STROBE	NN	strobe
)	)	)
guidelines	NNS	guideline
,	,	,
we	PP	we
conducted	VBD	conduct
a	DT	a
cross-sectional	JJ	cross-sectional
analysis	NN	analysis
of	IN	of
data	NNS	datum
from	IN	from
a	DT	a
COVID-19	NP	<unknown>
Surveillance	NN	surveillance
and	CC	and
Outcomes	NNS	outcome
Registry	NN	registry
(	(	(
CURATOR	NN	curator
)	)	)
.	SENT	.
Data	NNS	datum
were	VBD	be
extracted	VBN	extract
from	IN	from
Electronic	NP	Electronic
Medical	NP	Medical
Records	NPS	Records
(	(	(
EMR	NP	Emr
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
96,473	CD	@card@
individuals	NNS	individual
tested	VBN	test
for	IN	for
SARS-CoV-2	NP	<unknown>
RNA	NP	RNA
in	IN	in
nasopharyngeal	JJ	nasopharyngeal
swab	NN	swab
specimens	NNS	specimen
via	IN	via
Polymerized	VBN	polymerize
Chain	NP	Chain
Reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
tests	NNS	test
were	VBD	be
included	VBN	include
.	SENT	.
For	IN	for
hospital-based	JJ	hospital-based
analyses	NNS	analysis
,	,	,
all	DT	all
patients	NNS	patient
admitted	VBN	admit
during	IN	during
the	DT	the
same	JJ	same
time-period	NN	time-period
were	VBD	be
included	VBN	include
.	SENT	.
Of	IN	of
the	DT	the
96,473	CD	@card@
patients	NNS	patient
tested	VBN	test
,	,	,
14,992	CD	@card@
(	(	(
15.6	CD	@card@
%	NN	%
)	)	)
tested	VBD	test
positive	JJ	positive
,	,	,
of	IN	of
whom	WP	whom
4,785	CD	@card@
(	(	(
31.9	CD	@card@
%	NN	%
)	)	)
were	VBD	be
hospitalized	VBN	hospitalize
and	CC	and
452	CD	@card@
(	(	(
9.5	CD	@card@
%	NN	%
)	)	)
died	VBD	die
.	SENT	.
Among	IN	among
all	DT	all
patients	NNS	patient
tested	VBD	test
,	,	,
men	NNS	man
were	VBD	be
significantly	RB	significantly
older	JJR	old
.	SENT	.
The	DT	the
overall	JJ	overall
SARS-CoV-2	NP	<unknown>
positivity	NN	<unknown>
among	IN	among
all	DT	all
tested	VBN	test
individuals	NNS	individual
was	VBD	be
15.5	CD	@card@
%	NN	%
,	,	,
and	CC	and
was	VBD	be
higher	JJR	high
in	IN	in
males	NNS	male
as	IN	as
compared	VBN	compare
to	TO	to
females	NNS	female
17.0	CD	@card@
%	NN	%
vs.	IN	vs.
14.6	CD	@card@
%	NN	%
[	SYM	[
OR	CC	or
1.20	CD	@card@
]	SYM	]
.	SENT	.
This	DT	this
sex	NN	sex
difference	NN	difference
held	VBN	hold
after	IN	after
adjusting	VBG	adjust
for	IN	for
age	NN	age
,	,	,
race	NN	race
,	,	,
ethnicity	NN	ethnicity
,	,	,
marital	JJ	marital
status	NN	status
,	,	,
insurance	NN	insurance
type	NN	type
,	,	,
median	JJ	median
income	NN	income
,	,	,
BMI	NP	BMI
,	,	,
smoking	NN	smoking
and	CC	and
17	CD	@card@
comorbidities	NNS	comorbidity
included	VBN	include
in	IN	in
Charlson	NP	Charlson
Comorbidity	NP	<unknown>
Index	NP	Index
(	(	(
CCI	NP	CCI
)	)	)
[	SYM	[
aOR	NP	aOR
1.39	CD	@card@
]	SYM	]
.	SENT	.
A	DT	a
higher	JJR	high
proportion	NN	proportion
of	IN	of
males	NNS	male
(	(	(
vs.	CC	vs.
females	NNS	female
)	)	)
experienced	VBD	experience
pulmonary	JJ	pulmonary
(	(	(
ARDS	NP	<unknown>
,	,	,
hypoxic	JJ	hypoxic
respiratory	JJ	respiratory
failure	NN	failure
)	)	)
and	CC	and
extra-pulmonary	JJ	extra-pulmonary
(	(	(
acute	JJ	acute
renal	JJ	renal
injury	NN	injury
)	)	)
complications	NNS	complication
during	IN	during
their	PP$	their
hospital	NN	hospital
course	NN	course
.	SENT	.
After	IN	after
adjustment	NN	adjustment
,	,	,
length	NN	length
of	IN	of
stay	NN	stay
(	(	(
LOS	NP	los
)	)	)
,	,	,
need	NN	need
for	IN	for
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
and	CC	and
in-hospital	JJ	in-hospital
mortality	NN	mortality
were	VBD	be
significantly	RB	significantly
higher	JJR	high
in	IN	in
males	NNS	male
as	IN	as
compared	VBN	compare
to	TO	to
females	NNS	female
.	SENT	.
In	IN	in
this	DT	this
analysis	NN	analysis
of	IN	of
a	DT	a
large	JJ	large
US	NP	US
cohort	NN	cohort
,	,	,
males	NNS	male
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
test	VB	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
hospitalized	VBN	hospitalize
patients	NNS	patient
,	,	,
males	NNS	male
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
have	VB	have
complications	NNS	complication
,	,	,
require	VBP	require
ICU	NP	ICU
admission	NN	admission
and	CC	and
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
and	CC	and
had	VBD	have
higher	JJR	high
mortality	NN	mortality
than	IN	than
females	NNS	female
,	,	,
independent	JJ	independent
of	IN	of
age	NN	age
.	SENT	.
Sex	NN	sex
disparities	NNS	disparity
in	IN	in
COVID-19	NP	<unknown>
vulnerability	NN	vulnerability
are	VBP	be
present	JJ	present
,	,	,
and	CC	and
emphasize	VB	emphasize
the	DT	the
importance	NN	importance
of	IN	of
examining	VBG	examine
sex-disaggregated	JJ	<unknown>
data	NNS	datum
to	TO	to
improve	VB	improve
our	PP$	our
understanding	NN	understanding
of	IN	of
the	DT	the
biological	JJ	biological
processes	NNS	process
involved	VBN	involve
to	TO	to
potentially	RB	potentially
tailor	VB	tailor
treatment	NN	treatment
and	CC	and
risk	NN	risk
stratify	VBP	stratify
patients	NNS	patient
.	SENT	.
32996588/	CD	@card@
Blood	NP	Blood
supply	NN	supply
sufficiency	NN	sufficiency
and	CC	and
safety	NN	safety
management	NN	management
in	IN	in
Iran	NP	Iran
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
COVID-19	NP	<unknown>
first	RB	first
appeared	VBD	appear
in	IN	in
Iran	NP	Iran
on	IN	on
19	CD	@card@
February	NP	February
2020	CD	@card@
,	,	,
and	CC	and
then	RB	then
spread	VBN	spread
rapidly	RB	rapidly
over	IN	over
the	DT	the
country	NN	country
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
review	VBP	review
the	DT	the
action	NN	action
plan	NN	plan
of	IN	of
the	DT	the
Iranian	JJ	Iranian
Blood	NP	Blood
Transfusion	NN	transfusion
Organization	NP	Organization
with	IN	with
respect	NN	respect
to	TO	to
this	DT	this
disease	NN	disease
.	SENT	.
We	PP	we
collected	VBD	collect
data	NNS	datum
on	IN	on
blood	NN	blood
donations	NNS	donation
and	CC	and
RBC	NP	RBC
inventory	NN	inventory
for	IN	for
the	DT	the
first	JJ	first
8	CD	@card@
weeks	NNS	week
of	IN	of
the	DT	the
outbreak	NN	outbreak
.	SENT	.
We	PP	we
also	RB	also
evaluated	VBD	evaluate
the	DT	the
trend	NN	trend
of	IN	of
blood	NN	blood
donations	NNS	donation
and	CC	and
RBC	NP	RBC
inventory	NN	inventory
and	CC	and
compared	VBN	compare
them	PP	them
with	IN	with
the	DT	the
data	NNS	datum
of	IN	of
the	DT	the
past	JJ	past
year	NN	year
.	SENT	.
We	PP	we
include	VBP	include
a	DT	a
summary	NN	summary
of	IN	of
actions	NNS	action
taken	VBN	take
by	IN	by
the	DT	the
National	NP	National
Committee	NP	Committee
on	IN	on
Management	NP	Management
of	IN	of
COVID-19	NP	<unknown>
outbreak	NN	outbreak
.	SENT	.
Blood	NN	blood
donations	NNS	donation
decreased	VBD	decrease
from	IN	from
33	CD	@card@
275	CD	@card@
to	TO	to
23	CD	@card@
465	CD	@card@
units	NNS	unit
during	IN	during
the	DT	the
first	JJ	first
2	CD	@card@
weeks	NNS	week
of	IN	of
the	DT	the
outbreak	NN	outbreak
with	IN	with
a	DT	a
corresponding	JJ	corresponding
decrease	NN	decrease
in	IN	in
the	DT	the
RBC	NP	RBC
inventory	NN	inventory
.	SENT	.
But	CC	but
after	IN	after
that	DT	that
,	,	,
donations	NNS	donation
gradually	RB	gradually
increased	VBN	increase
from	IN	from
23	CD	@card@
465	CD	@card@
to	TO	to
29	CD	@card@
665	CD	@card@
units	NNS	unit
.	SENT	.
RBC	NP	RBC
inventory	NN	inventory
levels	NNS	level
improved	VBN	improve
at	IN	at
the	DT	the
same	JJ	same
time	NN	time
.	SENT	.
Then	RB	then
,	,	,
the	DT	the
Iranian	NP	Iranian
New	NP	New
Year	NP	Year
's	POS	's
holiday	NN	holiday
resulted	VBD	result
in	IN	in
another	DT	another
downward	JJ	downward
trend	NN	trend
.	SENT	.
After	IN	after
the	DT	the
holiday	NN	holiday
,	,	,
blood	NN	blood
donations	NNS	donation
revived	VBN	revive
,	,	,
along	RB	along
with	IN	with
the	DT	the
RBC	NP	RBC
inventory	NN	inventory
.	SENT	.
Although	IN	although
it	PP	it
appears	VBZ	appear
that	IN	that
this	DT	this
virus	NN	virus
cannot	MD	can
be	VB	be
transmitted	VBN	transmit
through	IN	through
transfusion	NN	transfusion
,	,	,
changes	NNS	change
in	IN	in
lifestyle	NN	lifestyle
had	VBD	have
a	DT	a
significant	JJ	significant
impact	NN	impact
on	IN	on
reducing	VBG	reduce
blood	NN	blood
supply	NN	supply
.	SENT	.
Following	VBG	follow
implemented	VBN	implement
measures	NNS	measure
,	,	,
we	PP	we
saw	VBD	see
an	DT	an
upward	JJ	upward
trend	NN	trend
in	IN	in
blood	NN	blood
donations	NNS	donation
and	CC	and
an	DT	an
adequate	JJ	adequate
supply	NN	supply
of	IN	of
RBC	NP	RBC
units	NNS	unit
in	IN	in
blood	NN	blood
centres	NNS	centre
,	,	,
helped	VBN	help
by	IN	by
a	DT	a
reduction	NN	reduction
in	IN	in
demand	NN	demand
by	IN	by
hospitals	NNS	hospital
.	SENT	.
Blood	NN	blood
centres	NNS	centre
need	VBP	need
to	TO	to
be	VB	be
more	RBR	more
prepared	JJ	prepared
to	TO	to
manage	VB	manage
future	JJ	future
viral	JJ	viral
disasters	NNS	disaster
,	,	,
especially	RB	especially
in	IN	in
case	NN	case
of	IN	of
transfusion-transmissible	JJ	transfusion-transmissible
infections	NNS	infection
.	SENT	.
33315061/	CD	@card@
Assessment	NP	Assessment
of	IN	of
the	DT	the
risk	NN	risk
of	IN	of
SARS-CoV-2	NP	<unknown>
reinfection	NN	reinfection
in	IN	in
an	DT	an
intense	JJ	intense
re-exposure	NN	re-exposure
setting	VBG	set
Risk	NN	risk
of	IN	of
reinfection	NN	reinfection
with	IN	with
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
unknown	JJ	unknown
.	SENT	.
We	PP	we
assessed	VBD	assess
risk	NN	risk
and	CC	and
incidence	NN	incidence
rate	NN	rate
of	IN	of
documented	VBN	document
SARS-CoV-2	JJ	<unknown>
reinfection	NN	reinfection
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
laboratory-confirmed	JJ	laboratory-confirmed
cases	NNS	case
in	IN	in
Qatar	NP	Qatar
.	SENT	.
All	DT	all
SARS-CoV-2	NP	<unknown>
laboratory-confirmed	JJ	laboratory-confirmed
cases	NNS	case
with	IN	with
at	IN	at
least	JJS	least
one	CD	one
PCR	NP	PCR
positive	JJ	positive
swab	NN	swab
that	WDT	that
is	VBZ	be
&gt	JJ	<unknown>
;	:	;
=45	JJ	=@card@
days	NNS	day
after	IN	after
a	DT	a
first-positive	JJ	first-positive
swab	NN	swab
were	VBD	be
individually	RB	individually
investigated	VBN	investigate
for	IN	for
evidence	NN	evidence
of	IN	of
reinfection	NN	reinfection
,	,	,
and	CC	and
classified	VBN	classify
as	IN	as
showing	VBG	show
strong	JJ	strong
,	,	,
good	JJ	good
,	,	,
some	RB	some
,	,	,
or	CC	or
weak/no	NN	<unknown>
evidence	NN	evidence
for	IN	for
reinfection	NN	reinfection
.	SENT	.
Viral	JJ	viral
genome	NN	genome
sequencing	VBG	sequence
of	IN	of
the	DT	the
paired	VBN	pair
first-positive	NN	first-positive
and	CC	and
reinfection	NN	reinfection
viral	JJ	viral
specimens	NNS	specimen
was	VBD	be
conducted	VBN	conduct
to	TO	to
confirm	VB	confirm
reinfection	NN	reinfection
.	SENT	.
Risk	NN	risk
and	CC	and
incidence	NN	incidence
rate	NN	rate
of	IN	of
reinfection	NN	reinfection
were	VBD	be
estimated	VBN	estimate
.	SENT	.
Out	RB	out
of	IN	of
133,266	CD	@card@
laboratory-confirmed	JJ	laboratory-confirmed
SARS-CoV-2	NP	<unknown>
cases	NNS	case
,	,	,
243	CD	@card@
persons	NNS	person
(	(	(
0.18	CD	@card@
%	NN	%
)	)	)
had	VBD	have
at	IN	at
least	JJS	least
one	CD	one
subsequent	JJ	subsequent
positive	JJ	positive
swab	NN	swab
&gt	NN	&gt
;	:	;
=45	JJ	=@card@
days	NNS	day
after	IN	after
the	DT	the
first-positive	JJ	first-positive
swab	NN	swab
.	SENT	.
Of	IN	of
these	DT	these
,	,	,
54	CD	@card@
cases	NNS	case
(	(	(
22.2	CD	@card@
%	NN	%
)	)	)
had	VBD	have
strong	JJ	strong
or	CC	or
good	JJ	good
evidence	NN	evidence
for	IN	for
reinfection	NN	reinfection
.	SENT	.
Median	JJ	Median
time	NN	time
between	IN	between
first	JJ	first
and	CC	and
reinfection	NN	reinfection
swab	NN	swab
was	VBD	be
64.5	CD	@card@
days	NNS	day
(	(	(
range	VB	range
:	:	:
45-129	LS	@card@
)	)	)
.	SENT	.
Twenty-three	NN	Twenty-three
of	IN	of
the	DT	the
54	CD	@card@
cases	NNS	case
(	(	(
42.6	CD	@card@
%	NN	%
)	)	)
were	VBD	be
diagnosed	VBN	diagnose
at	IN	at
a	DT	a
health	NN	health
facility	NN	facility
suggesting	VBG	suggest
presence	NN	presence
of	IN	of
symptoms	NNS	symptom
,	,	,
while	IN	while
31	CD	@card@
(	(	(
57.4	CD	@card@
%	NN	%
)	)	)
were	VBD	be
identified	VBN	identify
incidentally	RB	incidentally
through	IN	through
random	JJ	random
testing	NN	testing
campaigns/surveys	NNS	campaigns/survey
or	CC	or
contact	NN	contact
tracing	NN	tracing
.	SENT	.
Only	RB	only
one	CD	one
person	NN	person
was	VBD	be
hospitalized	VBN	hospitalize
at	IN	at
time	NN	time
of	IN	of
reinfection	NN	reinfection
,	,	,
but	CC	but
was	VBD	be
discharged	VBN	discharge
the	DT	the
next	JJ	next
day	NN	day
.	SENT	.
No	DT	no
deaths	NNS	death
were	VBD	be
recorded	VBN	record
.	SENT	.
Viral	JJ	viral
genome	NN	genome
sequencing	NP	sequencing
confirmed	VBD	confirm
four	CD	four
reinfections	NNS	reinfection
out	RB	out
of	IN	of
12	CD	@card@
cases	NNS	case
with	IN	with
available	JJ	available
genetic	JJ	genetic
evidence	NN	evidence
.	SENT	.
Reinfection	NN	Reinfection
risk	NN	risk
was	VBD	be
estimated	VBN	estimate
at	IN	at
0.02	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.01-0.02	CD	@card@
%	NN	%
)	)	)
and	CC	and
reinfection	NN	reinfection
incidence	NN	incidence
rate	NN	rate
at	IN	at
0.36	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.28-0.47	LS	@card@
)	)	)
per	IN	per
10,000	CD	@card@
person-weeks	NNS	person-week
.	SENT	.
SARS-CoV-2	JJ	<unknown>
reinfection	NN	reinfection
can	MD	can
occur	VB	occur
but	CC	but
is	VBZ	be
a	DT	a
rare	JJ	rare
phenomenon	NN	phenomenon
suggestive	JJ	suggestive
of	IN	of
protective	JJ	protective
immunity	NN	immunity
against	IN	against
reinfection	NN	reinfection
that	WDT	that
lasts	VBZ	last
for	IN	for
at	IN	at
least	JJS	least
a	DT	a
few	JJ	few
months	NNS	month
post	IN	post
primary	JJ	primary
infection	NN	infection
.	SENT	.
34145263/	CD	@card@
Immunological	JJ	immunological
imprinting	NN	imprinting
of	IN	of
the	DT	the
antibody	NN	antibody
response	NN	response
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
In	IN	in
addition	NN	addition
to	TO	to
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
humans	NNS	human
are	VBP	be
also	RB	also
susceptible	JJ	susceptible
to	TO	to
six	CD	six
other	JJ	other
coronaviruses	NNS	coronavirus
,	,	,
for	IN	for
which	WDT	which
consecutive	JJ	consecutive
exposures	NNS	exposure
to	TO	to
antigenically	RB	antigenically
related	JJ	related
and	CC	and
divergent	JJ	divergent
seasonal	JJ	seasonal
coronaviruses	NNS	coronavirus
are	VBP	be
frequent	JJ	frequent
.	SENT	.
Despite	IN	despite
the	DT	the
prevalence	NN	prevalence
of	IN	of
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
and	CC	and
ongoing	JJ	ongoing
research	NN	research
,	,	,
the	DT	the
nature	NN	nature
of	IN	of
the	DT	the
antibody	NN	antibody
response	NN	response
against	IN	against
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
unclear	JJ	unclear
.	SENT	.
Here	RB	here
we	PP	we
longitudinally	RB	longitudinally
profile	VB	profile
the	DT	the
early	JJ	early
humoral	JJ	humoral
immune	JJ	immune
response	NN	response
against	IN	against
SARS-CoV-2	NP	<unknown>
in	IN	in
hospitalized	VBN	hospitalize
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
patients	NNS	patient
and	CC	and
quantify	VB	quantify
levels	NNS	level
of	IN	of
pre-existing	VBG	pre-exist
immunity	NN	immunity
to	TO	to
OC43	NP	<unknown>
,	,	,
HKU1	NP	<unknown>
and	CC	and
229E	JJ	<unknown>
seasonal	JJ	seasonal
coronaviruses	NNS	coronavirus
,	,	,
and	CC	and
find	VB	find
a	DT	a
strong	JJ	strong
back-boosting	NN	back-boosting
effect	NN	effect
to	TO	to
conserved	VBN	conserve
but	CC	but
not	RB	not
variable	JJ	variable
regions	NNS	region
of	IN	of
OC43	NP	<unknown>
and	CC	and
HKU1	NP	<unknown>
betacoronaviruses	NNS	betacoronavirus
spike	NN	spike
protein	NN	protein
.	SENT	.
However	RB	however
,	,	,
such	JJ	such
antibody	NN	antibody
memory	NN	memory
boost	NN	boost
to	TO	to
human	JJ	human
coronaviruses	NNS	coronavirus
negatively	RB	negatively
correlates	VBZ	correlate
with	IN	with
the	DT	the
induction	NN	induction
of	IN	of
IgG	NP	IgG
and	CC	and
IgM	NP	Igm
against	IN	against
SARS-CoV-2	NP	<unknown>
spike	NN	spike
and	CC	and
nucleocapsid	NN	nucleocapsid
protein	NN	protein
.	SENT	.
Our	PP$	our
findings	NNS	finding
thus	RB	thus
provide	VBP	provide
evidence	NN	evidence
of	IN	of
immunological	JJ	immunological
imprinting	NN	imprinting
by	IN	by
previous	JJ	previous
seasonal	JJ	seasonal
coronavirus	NN	coronavirus
infections	NNS	infection
that	WDT	that
can	MD	can
potentially	RB	potentially
modulate	VB	modulate
the	DT	the
antibody	NN	antibody
profile	NN	profile
to	TO	to
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
In	IN	in
addition	NN	addition
to	TO	to
SARS-CoV-2	NP	<unknown>
,	,	,
other	JJ	other
coronaviruses	NNS	coronavirus
also	RB	also
infect	VBP	infect
human	JJ	human
,	,	,
but	CC	but
whether	IN	whether
consecutive	JJ	consecutive
infections	NNS	infection
cross-modulate	VBP	cross-modulate
the	DT	the
induced	VBN	induce
immune	JJ	immune
response	NN	response
is	VBZ	be
still	RB	still
unclear	JJ	unclear
.	SENT	.
Here	RB	here
the	DT	the
authors	NNS	author
show	VBP	show
that	IN	that
SARS-CoV-2	NP	<unknown>
infection	NN	infection
boosts	VBZ	boost
pre-existing	VBG	pre-exist
responses	NNS	response
to	TO	to
other	JJ	other
coronaviruses	NNS	coronavirus
,	,	,
yet	RB	yet
such	JJ	such
back-boosting	NN	back-boosting
hampers	VBZ	hamper
the	DT	the
induction	NN	induction
of	IN	of
specific	JJ	specific
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
.	SENT	.
34127735/	CD	@card@
Embedding	VBG	embed
supervised	JJ	supervised
exercise	NN	exercise
training	NN	training
for	IN	for
men	NNS	man
on	IN	on
androgen	NN	androgen
deprivation	NN	deprivation
therapy	NN	therapy
into	IN	into
standard	JJ	standard
prostate	NN	prostate
cancer	NN	cancer
care	NN	care
:	:	:
a	DT	a
feasibility	NN	feasibility
and	CC	and
acceptability	NN	acceptability
study	NN	study
(	(	(
the	DT	the
STAMINA	NN	stamina
trial	NN	trial
)	)	)
Lifestyle	NP	Lifestyle
interventions	NNS	intervention
involving	VBG	involve
exercise	NN	exercise
training	NN	training
offset	VBD	offset
the	DT	the
adverse	JJ	adverse
effects	NNS	effect
of	IN	of
androgen	NN	androgen
deprivation	NN	deprivation
therapy	NN	therapy
in	IN	in
men	NNS	man
with	IN	with
prostate	NN	prostate
cancer	NN	cancer
.	SENT	.
Yet	RB	yet
provision	NN	provision
of	IN	of
integrated	JJ	integrated
exercise	NN	exercise
pathways	NNS	pathway
in	IN	in
cancer	NN	cancer
care	NN	care
is	VBZ	be
sparse	JJ	sparse
.	SENT	.
This	DT	this
study	NN	study
assessed	VBD	assess
the	DT	the
feasibility	NN	feasibility
and	CC	and
acceptability	NN	acceptability
of	IN	of
an	DT	an
embedded	VBN	embed
supervised	JJ	supervised
exercise	NN	exercise
training	NN	training
intervention	NN	intervention
into	IN	into
standard	JJ	standard
prostate	NN	prostate
cancer	NN	cancer
care	NN	care
in	IN	in
a	DT	a
single-arm	NN	<unknown>
,	,	,
multicentre	JJ	<unknown>
prospective	JJ	prospective
cohort	NN	cohort
study	NN	study
.	SENT	.
Feasibility	NN	feasibility
included	VBD	include
recruitment	NN	recruitment
,	,	,
retention	NN	retention
,	,	,
adherence	NN	adherence
,	,	,
fidelity	NN	fidelity
and	CC	and
safety	NN	safety
.	SENT	.
Acceptability	NN	acceptability
of	IN	of
behaviourally	RB	<unknown>
informed	VBN	inform
healthcare	NN	<unknown>
and	CC	and
exercise	VB	exercise
professional	JJ	professional
training	NN	training
was	VBD	be
assessed	VBN	assess
qualitatively	RB	qualitatively
.	SENT	.
Despite	IN	despite
the	DT	the
imposition	NN	imposition
of	IN	of
lockdown	NN	<unknown>
for	IN	for
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
referral	NN	referral
rates	NNS	rate
into	IN	into
and	CC	and
adherence	NN	adherence
to	TO	to
,	,	,
the	DT	the
intervention	NN	intervention
was	VBD	be
high	JJ	high
.	SENT	.
Of	IN	of
the	DT	the
45	CD	@card@
men	NNS	man
eligible	JJ	eligible
for	IN	for
participation	NN	participation
,	,	,
79	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
36	CD	@card@
)	)	)
received	VBD	receive
the	DT	the
intervention	NN	intervention
and	CC	and
47	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
21	CD	@card@
)	)	)
completed	VBD	complete
the	DT	the
intervention	NN	intervention
before	IN	before
a	DT	a
government	NN	government
mandated	VBD	mandate
national	JJ	national
lockdown	NN	<unknown>
was	VBD	be
enforced	VBN	enforce
in	IN	in
the	DT	the
United	NP	United
Kingdom	NP	Kingdom
.	SENT	.
Patients	NNS	patient
completed	VBD	complete
a	DT	a
mean	NN	mean
of	IN	of
27	CD	@card@
min	NN	min
of	IN	of
aerobic	JJ	aerobic
exercise	NN	exercise
per	IN	per
session	NN	session
(	(	(
SD	NP	SD
=	SYM	=
3.48	CD	@card@
)	)	)
,	,	,
at	IN	at
77	CD	@card@
%	NN	%
heart	NN	heart
rate	NN	rate
maximum	NN	maximum
(	(	(
92	CD	@card@
%	NN	%
of	IN	of
target	NN	target
dose	NN	dose
)	)	)
,	,	,
and	CC	and
3	CD	@card@
sets	NNS	set
of	IN	of
10	CD	@card@
reps	NNS	rep
of	IN	of
3	CD	@card@
resistance	NN	resistance
exercises	VBZ	exercise
twice	RB	twice
weekly	JJ	weekly
for	IN	for
12	CD	@card@
weeks	NNS	week
,	,	,
without	IN	without
serious	JJ	serious
adverse	JJ	adverse
event	NN	event
.	SENT	.
The	DT	the
intervention	NN	intervention
was	VBD	be
delivered	VBN	deliver
by	IN	by
26	CD	@card@
healthcare	NN	<unknown>
professionals	NNS	professional
and	CC	and
16	CD	@card@
exercise	NN	exercise
trainers	NNS	trainer
with	IN	with
moderate	JJ	moderate
to	TO	to
high	JJ	high
fidelity	NN	fidelity
,	,	,
and	CC	and
the	DT	the
intervention	NN	intervention
was	VBD	be
deemed	VBN	deem
highly	RB	highly
acceptable	JJ	acceptable
to	TO	to
patients	NNS	patient
.	SENT	.
The	DT	the
impact	NN	impact
of	IN	of
societal	JJ	societal
changes	NNS	change
due	JJ	due
to	TO	to
the	DT	the
pandemic	NN	pandemic
on	IN	on
the	DT	the
delivery	NN	delivery
of	IN	of
this	DT	this
face-to-face	JJ	face-to-face
intervention	NN	intervention
remain	VBP	remain
uncertain	JJ	uncertain
but	CC	but
positive	JJ	positive
impacts	NNS	impact
of	IN	of
embedding	VBG	embed
exercise	NN	exercise
provision	NN	provision
into	IN	into
prostate	NN	prostate
cancer	NN	cancer
care	NN	care
warrant	NN	warrant
long-term	JJ	long-term
investigation	NN	investigation
.	SENT	.
34219197/	CD	@card@
Appendectomy	NN	appendectomy
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Italy	NP	Italy
:	:	:
a	DT	a
multicenter	NN	multicenter
ambispective	JJ	<unknown>
cohort	NN	cohort
study	NN	study
by	IN	by
the	DT	the
Italian	JJ	Italian
Society	NP	Society
of	IN	of
Endoscopic	JJ	endoscopic
Surgery	NN	surgery
and	CC	and
new	JJ	new
technologies	NNS	technology
(	(	(
the	DT	the
CRAC	NP	<unknown>
study	NN	study
)	)	)
Major	JJ	major
surgical	JJ	surgical
societies	NNS	society
advised	VBD	advise
using	VBG	use
non-operative	JJ	non-operative
management	NN	management
of	IN	of
appendicitis	NN	appendicitis
and	CC	and
suggested	VBD	suggest
against	IN	against
laparoscopy	NN	<unknown>
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
hypothesis	NN	hypothesis
is	VBZ	be
that	IN	that
a	DT	a
significant	JJ	significant
reduction	NN	reduction
in	IN	in
the	DT	the
number	NN	number
of	IN	of
emergent	JJ	emergent
appendectomies	NNS	appendectomy
was	VBD	be
observed	VBN	observe
during	IN	during
the	DT	the
pandemic	NN	pandemic
,	,	,
restricted	VBN	restrict
to	TO	to
complex	JJ	complex
cases	NNS	case
.	SENT	.
The	DT	the
study	NN	study
aimed	VBN	aim
to	TO	to
analyse	VB	analyse
emergent	JJ	emergent
surgical	JJ	surgical
appendectomies	NNS	appendectomy
during	IN	during
pandemic	NN	pandemic
on	IN	on
a	DT	a
national	JJ	national
basis	NN	basis
and	CC	and
compare	VB	compare
it	PP	it
to	TO	to
the	DT	the
same	JJ	same
period	NN	period
of	IN	of
the	DT	the
previous	JJ	previous
year	NN	year
.	SENT	.
This	DT	this
is	VBZ	be
a	DT	a
multicentre	NN	multicentre
,	,	,
retrospective	JJ	retrospective
,	,	,
observational	JJ	observational
study	NN	study
investigating	VBG	investigate
the	DT	the
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
undergoing	VBG	undergo
emergent	JJ	emergent
appendectomy	NN	appendectomy
in	IN	in
March-April	NP	March-April
2019	CD	@card@
vs	NP	vs
March-April	NP	March-April
2020	CD	@card@
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
was	VBD	be
the	DT	the
number	NN	number
of	IN	of
appendectomies	NNS	appendectomy
performed	VBN	perform
,	,	,
classified	VBN	classify
according	VBG	accord
to	TO	to
the	DT	the
American	NP	American
Association	NP	Association
for	IN	for
the	DT	the
Surgery	NN	surgery
of	IN	of
Trauma	NN	trauma
(	(	(
AAST	JJ	<unknown>
)	)	)
score	NN	score
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
were	VBD	be
the	DT	the
type	NN	type
of	IN	of
surgical	JJ	surgical
technique	NN	technique
employed	VBN	employ
(	(	(
laparoscopic	JJ	<unknown>
vs	NP	vs
open	NN	open
)	)	)
and	CC	and
the	DT	the
complication	NN	complication
rates	NNS	rate
.	SENT	.
One	CD	one
thousand	CD	thousand
five	CD	five
hundred	CD	hundred
forty	NN	forty
one	CD	one
patients	NNS	patient
with	IN	with
acute	JJ	acute
appendicitis	NN	appendicitis
underwent	VBD	undergo
surgery	NN	surgery
during	IN	during
the	DT	the
two	CD	two
study	NN	study
periods	NNS	period
.	SENT	.
1337	CD	@card@
(	(	(
86.8	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
met	VBD	meet
the	DT	the
inclusion	NN	inclusion
criteria	NNS	criterion
:	:	:
546	CD	@card@
(	(	(
40.8	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
underwent	VBD	undergo
surgery	NN	surgery
for	IN	for
acute	JJ	acute
appendicitis	NN	appendicitis
in	IN	in
2020	CD	@card@
and	CC	and
791	CD	@card@
(	(	(
59.2	CD	@card@
%	NN	%
)	)	)
in	IN	in
2019	CD	@card@
.	SENT	.
According	VBG	accord
to	TO	to
AAST	NNS	<unknown>
,	,	,
patients	NNS	patient
with	IN	with
complicated	JJ	complicated
appendicitis	NN	appendicitis
operated	VBN	operate
in	IN	in
2019	CD	@card@
were	VBD	be
30.3	CD	@card@
%	NN	%
vs	NP	vs
39.9	CD	@card@
%	NN	%
in	IN	in
2020	CD	@card@
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
.	SENT	.
We	PP	we
observed	VBD	observe
an	DT	an
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
post-operative	JJ	post-operative
complications	NNS	complication
in	IN	in
2020	CD	@card@
(	(	(
15.9	CD	@card@
%	NN	%
)	)	)
compared	VBN	compare
to	TO	to
2019	CD	@card@
(	(	(
9.6	CD	@card@
%	NN	%
)	)	)
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
following	VBG	follow
determinants	NNS	determinant
increased	VBD	increase
the	DT	the
likelihood	NN	likelihood
of	IN	of
complication	NN	complication
occurrence	NN	occurrence
:	:	:
undergoing	VBG	undergo
surgery	NN	surgery
during	IN	during
2020	CD	@card@
(	(	(
+	SYM	+
67	CD	@card@
%	NN	%
)	)	)
,	,	,
the	DT	the
increase	NN	increase
of	IN	of
a	DT	a
unit	NN	unit
in	IN	in
the	DT	the
AAST	JJ	<unknown>
score	NN	score
(	(	(
+	SYM	+
26	CD	@card@
%	NN	%
)	)	)
,	,	,
surgery	NN	surgery
performed	VBD	perform
&gt	NN	&gt
;	:	;
24	CD	@card@
h	NN	h
after	IN	after
admission	NN	admission
(	(	(
+	SYM	+
58	CD	@card@
%	NN	%
)	)	)
,	,	,
open	JJ	open
surgery	NN	surgery
(	(	(
+	SYM	+
112	CD	@card@
%	NN	%
)	)	)
and	CC	and
conversion	NN	conversion
to	TO	to
open	JJ	open
surgery	NN	surgery
(	(	(
+	SYM	+
166	CD	@card@
%	NN	%
)	)	)
.	SENT	.
In	IN	in
Italian	JJ	Italian
hospitals	NNS	hospital
,	,	,
in	IN	in
March	NP	March
and	CC	and
April	NP	April
2020	CD	@card@
,	,	,
the	DT	the
number	NN	number
of	IN	of
appendectomies	NNS	appendectomy
has	VBZ	have
drastically	RB	drastically
dropped	VBN	drop
.	SENT	.
During	IN	during
the	DT	the
first	JJ	first
pandemic	JJ	pandemic
wave	NN	wave
,	,	,
patients	NNS	patient
undergoing	VBG	undergo
surgery	NN	surgery
were	VBD	be
more	JJR	more
frequently	RB	frequently
affected	VBN	affect
by	IN	by
more	JJR	more
severe	JJ	severe
appendicitis	NN	appendicitis
than	IN	than
the	DT	the
previous	JJ	previous
year	NN	year
's	POS	's
timeframe	NN	timeframe
and	CC	and
experienced	VBD	experience
a	DT	a
higher	JJR	high
number	NN	number
of	IN	of
complications	NNS	complication
.	SENT	.
Trial	NN	trial
registration	NN	registration
number	NN	number
and	CC	and
date	NN	date
:	:	:
Research	NP	Research
Registry	NP	Registry
ID	NN	id
5789	CD	@card@
,	,	,
May	NP	May
7th	JJ	7th
,	,	,
2020	CD	@card@
32759252/	CD	@card@
Inferred	VBN	infer
duration	NN	duration
of	IN	of
infectious	JJ	infectious
period	NN	period
of	IN	of
SARS-CoV-2	NP	<unknown>
:	:	:
rapid	JJ	rapid
scoping	NN	scoping
review	NN	review
and	CC	and
analysis	NN	analysis
of	IN	of
available	JJ	available
evidence	NN	evidence
for	IN	for
asymptomatic	JJ	asymptomatic
and	CC	and
symptomatic	JJ	symptomatic
COVID-19	JJ	<unknown>
cases	NNS	case
Our	PP$	our
objective	NN	objective
was	VBD	be
to	TO	to
review	VB	review
the	DT	the
literature	NN	literature
on	IN	on
the	DT	the
inferred	VBN	infer
duration	NN	duration
of	IN	of
the	DT	the
infectious	JJ	infectious
period	NN	period
of	IN	of
COVID-19	NP	<unknown>
,	,	,
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
virus	NN	virus
,	,	,
and	CC	and
provide	VB	provide
an	DT	an
overview	NN	overview
of	IN	of
the	DT	the
variation	NN	variation
depending	VBG	depend
on	IN	on
the	DT	the
methodological	JJ	methodological
approach	NN	approach
.	SENT	.
Rapid	JJ	rapid
scoping	NN	scoping
review	NN	review
.	SENT	.
Literature	NN	literature
review	NN	review
with	IN	with
fixed	VBN	fix
search	NN	search
terms	NNS	term
,	,	,
up	RB	up
to	TO	to
1	CD	@card@
April	NP	April
2020	CD	@card@
.	SENT	.
Central	JJ	central
tendency	NN	tendency
and	CC	and
variation	NN	variation
of	IN	of
the	DT	the
parameter	NN	parameter
estimates	VBZ	estimate
for	IN	for
infectious	JJ	infectious
period	NN	period
in	IN	in
(	(	(
A	NP	A
)	)	)
asymptomatic	JJ	asymptomatic
and	CC	and
(	(	(
B	NP	B
)	)	)
symptomatic	JJ	symptomatic
cases	NNS	case
from	IN	from
(	(	(
1	LS	1
)	)	)
virological	JJ	virological
studies	NNS	study
(	(	(
repeated	VBN	repeat
testing	NN	testing
)	)	)
,	,	,
(	(	(
2	LS	2
)	)	)
tracing	VBG	trace
studies	NNS	study
and	CC	and
(	(	(
3	LS	3
)	)	)
modelling	VBG	model
studies	NNS	study
were	VBD	be
gathered	VBN	gather
.	SENT	.
Narrative	JJ	narrative
review	NN	review
of	IN	of
viral	JJ	viral
dynamics	NNS	dynamics
.	SENT	.
Search	NN	search
strategies	NNS	strategy
developed	VBD	develop
and	CC	and
the	DT	the
following	NN	following
searched	VBD	search
:	:	:
PubMed	NP	<unknown>
,	,	,
Google	NP	<unknown>
Scholar	NN	scholar
,	,	,
MedRxiv	NP	<unknown>
and	CC	and
BioRxiv	NP	<unknown>
.	SENT	.
Additionally	RB	additionally
,	,	,
the	DT	the
Health	NP	Health
Information	NP	Information
Quality	NP	Quality
Authority	NP	Authority
(	(	(
Ireland	NP	Ireland
)	)	)
viral	JJ	viral
load	NN	load
synthesis	NN	synthesis
was	VBD	be
used	VBN	use
,	,	,
which	WDT	which
screened	VBD	screen
literature	NN	literature
from	IN	from
PubMed	NP	<unknown>
,	,	,
Embase	NP	<unknown>
,	,	,
ScienceDirect	NP	ScienceDirect
,	,	,
NHS	NN	NHS
evidence	NN	evidence
,	,	,
Cochrane	NP	Cochrane
,	,	,
medRxiv	NP	<unknown>
and	CC	and
bioRxiv	NP	<unknown>
,	,	,
and	CC	and
HRB	NP	HRB
open	JJ	open
databases	NNS	database
.	SENT	.
There	EX	there
was	VBD	be
substantial	JJ	substantial
variation	NN	variation
in	IN	in
the	DT	the
estimates	NNS	estimate
,	,	,
and	CC	and
how	WRB	how
infectious	JJ	infectious
period	NN	period
was	VBD	be
inferred	VBN	infer
.	SENT	.
One	CD	one
study	NN	study
provided	VBD	provide
approximate	JJ	approximate
median	JJ	median
infectious	JJ	infectious
period	NN	period
for	IN	for
asymptomatic	JJ	asymptomatic
cases	NNS	case
of	IN	of
6.5-9.5	CD	@card@
days	NNS	day
.	SENT	.
Median	JJ	Median
presymptomatic	JJ	presymptomatic
infectious	JJ	infectious
period	NN	period
across	IN	across
studies	NNS	study
varied	VBN	vary
over	IN	over
&lt	NN	&lt
;	:	;
1-4	CD	@card@
days	NNS	day
.	SENT	.
Estimated	VBN	estimate
mean	JJ	mean
time	NN	time
from	IN	from
symptom	NN	symptom
onset	NN	onset
to	TO	to
two	CD	two
negative	JJ	negative
RT-PCR	NP	<unknown>
tests	NNS	test
was	VBD	be
13.4	CD	@card@
days	NNS	day
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
10.9	CD	@card@
to	TO	to
15.8	CD	@card@
)	)	)
but	CC	but
was	VBD	be
shorter	JJR	short
when	WRB	when
studies	NNS	study
included	VBD	include
children	NNS	child
or	CC	or
less	JJR	less
severe	JJ	severe
cases	NNS	case
.	SENT	.
Estimated	VBN	estimate
mean	JJ	mean
duration	NN	duration
from	IN	from
symptom	NN	symptom
onset	NN	onset
to	TO	to
hospital	NN	hospital
discharge	NN	discharge
or	CC	or
death	NN	death
(	(	(
potential	JJ	potential
maximal	JJ	maximal
infectious	JJ	infectious
period	NN	period
)	)	)
was	VBD	be
18.1	CD	@card@
days	NNS	day
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
15.1	CD	@card@
to	TO	to
21.0	CD	@card@
)	)	)
;	:	;
time	NN	time
to	TO	to
discharge	VB	discharge
was	VBD	be
on	IN	on
average	JJ	average
4	CD	@card@
days	NNS	day
shorter	JJR	short
than	IN	than
time	NN	time
to	TO	to
death	NN	death
.	SENT	.
Viral	JJ	viral
dynamic	JJ	dynamic
data	NNS	datum
and	CC	and
model	JJ	model
infectious	JJ	infectious
parameters	NNS	parameter
were	VBD	be
often	RB	often
shorter	JJR	short
than	IN	than
repeated	VBN	repeat
diagnostic	JJ	diagnostic
data	NNS	datum
.	SENT	.
There	EX	there
are	VBP	be
limitations	NNS	limitation
of	IN	of
inferring	VBG	infer
infectiousness	NN	infectiousness
from	IN	from
repeated	JJ	repeated
diagnosis	NN	diagnosis
,	,	,
viral	JJ	viral
loads	NNS	load
and	CC	and
viral	JJ	viral
replication	NN	replication
data	NNS	datum
alone	RB	alone
and	CC	and
also	RB	also
potential	JJ	potential
patient	JJ	patient
recall	NN	recall
bias	NN	bias
relevant	JJ	relevant
to	TO	to
estimating	VBG	estimate
exposure	NN	exposure
and	CC	and
symptom	NN	symptom
onset	NN	onset
times	NNS	time
.	SENT	.
Despite	IN	despite
this	DT	this
,	,	,
available	JJ	available
data	NNS	datum
provide	VBP	provide
a	DT	a
preliminary	JJ	preliminary
evidence	NN	evidence
base	NN	base
to	TO	to
inform	VB	inform
models	NNS	model
of	IN	of
central	JJ	central
tendency	NN	tendency
for	IN	for
key	JJ	key
parameters	NNS	parameter
and	CC	and
variation	NN	variation
for	IN	for
exploring	VBG	explore
parameter	NN	parameter
space	NN	space
and	CC	and
sensitivity	NN	sensitivity
analysis	NN	analysis
.	SENT	.
34988861/	CD	@card@
The	DT	the
symptomatic	JJ	symptomatic
breast	NN	breast
services	NNS	service
in	IN	in
a	DT	a
university	NN	university
hospital	NN	hospital
:	:	:
pandemic	JJ	pandemic
peak	NN	peak
compared	VBN	compare
to	TO	to
the	DT	the
pre-pandemic	JJ	pre-pandemic
year	NN	year
and	CC	and
future	JJ	future
implications	NNS	implication
COVID-19	NP	<unknown>
infection	NN	infection
led	VBD	lead
to	TO	to
a	DT	a
substantial	JJ	substantial
overhaul	NN	overhaul
of	IN	of
the	DT	the
symptomatic	JJ	symptomatic
breast	NN	breast
services	NNS	service
within	IN	within
the	DT	the
UK	NP	UK
.	SENT	.
The	DT	the
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
evaluate	VB	evaluate
the	DT	the
pattern	NN	pattern
of	IN	of
primary	JJ	primary
care	NN	care
referrals	NNS	referral
to	TO	to
the	DT	the
symptomatic	JJ	symptomatic
one-stop	JJ	one-stop
clinic	NN	clinic
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
This	DT	this
study	NN	study
also	RB	also
provides	VBZ	provide
a	DT	a
snapshot	NN	snapshot
of	IN	of
the	DT	the
workings	NNS	working
of	IN	of
symptomatic	JJ	symptomatic
breast	NN	breast
services	NNS	service
and	CC	and
the	DT	the
scope	NN	scope
for	IN	for
improvements	NNS	improvement
.	SENT	.
The	DT	the
data	NNS	datum
points	NNS	point
were	VBD	be
collected	VBN	collect
for	IN	for
1	CD	@card@
month	NN	month
during	IN	during
the	DT	the
peak	NN	peak
of	IN	of
the	DT	the
pandemic	JJ	pandemic
(	(	(
April	NP	April
2020	CD	@card@
)	)	)
and	CC	and
compared	VBN	compare
to	TO	to
corresponding	JJ	corresponding
data	NNS	datum
points	NNS	point
for	IN	for
the	DT	the
same	JJ	same
month	NN	month
in	IN	in
the	DT	the
previous	JJ	previous
year	NN	year
(	(	(
April	NP	April
2019	CD	@card@
)	)	)
.	SENT	.
This	DT	this
was	VBD	be
compared	VBN	compare
to	TO	to
the	DT	the
monthly	JJ	monthly
data	NNS	datum
from	IN	from
Wales	NP	Wales
Cancer	NP	Cancer
Network	NP	Network
(	(	(
WCN	NP	WCN
)	)	)
data	NN	data
source	NN	source
.	SENT	.
A	DT	a
hundred	CD	hundred
patients	NNS	patient
from	IN	from
each	DT	each
month	NN	month
over	IN	over
2	CD	@card@
years	NNS	year
were	VBD	be
evaluated	VBN	evaluate
to	TO	to
get	VB	get
a	DT	a
snapshot	NN	snapshot
into	IN	into
the	DT	the
working	NN	working
of	IN	of
the	DT	the
breast	NN	breast
clinic	NN	clinic
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
516	CD	@card@
patients	NNS	patient
were	VBD	be
referred	VBN	refer
from	IN	from
primary	JJ	primary
care	NN	care
or	CC	or
General	JJ	general
Practitioners	NNS	practitioner
(	(	(
GPs	NNS	GP
)	)	)
,	,	,
and	CC	and
were	VBD	be
seen	VBN	see
in	IN	in
the	DT	the
Hospital	NP	Hospital
'	POS	'
one-stop	JJ	one-stop
breast	NN	breast
clinic	NN	clinic
'	''	'
in	IN	in
April	NP	April
2019	CD	@card@
.	SENT	.
This	DT	this
number	NN	number
dropped	VBD	drop
to	TO	to
330	CD	@card@
patients	NNS	patient
during	IN	during
the	DT	the
peak	NN	peak
of	IN	of
the	DT	the
pandemic	NN	pandemic
in	IN	in
April	NP	April
2020	CD	@card@
.	SENT	.
Ninety	CD	ninety
percent	NN	percent
of	IN	of
referrals	NNS	referral
from	IN	from
the	DT	the
GP	NN	GP
were	VBD	be
urgent	JJ	urgent
suspected	JJ	suspected
cancers	NNS	cancer
or	CC	or
urgent	JJ	urgent
referrals	NNS	referral
.	SENT	.
This	DT	this
trend	NN	trend
of	IN	of
referrals	NNS	referral
did	VBD	do
not	RB	not
change	VB	change
over	IN	over
2	CD	@card@
years	NNS	year
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
5	CD	@card@
%	NN	%
and	CC	and
7	CD	@card@
%	NN	%
cancer	NN	cancer
diagnosis	NN	diagnosis
rate	NN	rate
in	IN	in
2020	CD	@card@
and	CC	and
2019	CD	@card@
,	,	,
respectively	RB	respectively
.	SENT	.
Most	JJS	most
patients	NNS	patient
were	VBD	be
referred	VBN	refer
from	IN	from
GP	NN	GP
as	RB	as
'	POS	'
urgent	JJ	urgent
'	''	'
or	CC	or
'	POS	'
urgent	JJ	urgent
suspected	JJ	suspected
cancer	NN	cancer
'	POS	'
.	SENT	.
The	DT	the
cancer	NN	cancer
diagnosis	NN	diagnosis
rate	NN	rate
reduced	VBN	reduce
from	IN	from
7	CD	@card@
to	TO	to
5	CD	@card@
%	NN	%
during	IN	during
the	DT	the
pandemic	JJ	pandemic
peak	NN	peak
but	CC	but
the	DT	the
number	NN	number
of	IN	of
'	''	'
worried	JJ	worried
well	NN	well
'	POS	'
patients	NNS	patient
did	VBD	do
not	RB	not
reduce	VB	reduce
.	SENT	.
The	DT	the
total	JJ	total
number	NN	number
of	IN	of
referrals	NNS	referral
reduced	VBN	reduce
,	,	,
which	WDT	which
is	VBZ	be
predictive	JJ	predictive
of	IN	of
increased	VBN	increase
demand	NN	demand
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
The	DT	the
authors	NNS	author
have	VBP	have
suggested	VBN	suggest
ways	NNS	way
to	TO	to
meet	VB	meet
this	DT	this
demand	NN	demand
.	SENT	.
35383994/	CD	@card@
Letter	NN	letter
to	TO	to
the	DT	the
editor	NN	editor
:	:	:
Clinical	JJ	clinical
Features	NNS	feature
of	IN	of
Patients	NNS	patient
Infected	VBN	infect
With	IN	with
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
With	IN	with
Elevated	JJ	elevated
Liver	NN	liver
Biochemistries	NNS	biochemistry
:	:	:
A	DT	a
Multicenter	NN	multicenter
,	,	,
Retrospective	JJ	retrospective
Study	NN	study
-	NN	<unknown>
33424954/	CD	@card@
Collection	NN	collection
of	IN	of
SARS-CoV-2	NP	<unknown>
Virus	NN	virus
from	IN	from
the	DT	the
Air	NP	Air
of	IN	of
a	DT	a
Clinic	NP	Clinic
Within	IN	within
a	DT	a
University	NP	University
Student	NP	Student
Health	NP	Health
Care	NP	Care
Center	NP	Center
and	CC	and
Analyses	NNS	analysis
of	IN	of
the	DT	the
Viral	JJ	viral
Genomic	JJ	<unknown>
Sequence	NN	sequence
The	DT	the
progression	NN	progression
of	IN	of
COVID-19	NP	<unknown>
worldwide	RB	worldwide
can	MD	can
be	VB	be
tracked	VBN	track
by	IN	by
identifying	VBG	identify
mutations	NNS	mutation
within	IN	within
the	DT	the
genomic	JJ	<unknown>
sequence	NN	sequence
of	IN	of
SARS-CoV-2	NP	<unknown>
that	WDT	that
occur	VBP	occur
as	IN	as
a	DT	a
function	NN	function
of	IN	of
time	NN	time
.	SENT	.
Such	JJ	such
efforts	NNS	effort
currently	RB	currently
rely	VBP	rely
on	IN	on
sequencing	VBG	sequence
the	DT	the
genome	NN	genome
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
patient	JJ	patient
specimens	NNS	specimen
(	(	(
direct	VB	direct
sequencing	VBG	sequence
)	)	)
or	CC	or
of	IN	of
virus	NN	virus
isolated	VBN	isolate
from	IN	from
patient	JJ	patient
specimens	NNS	specimen
in	IN	in
cell	NN	cell
cultures	NNS	culture
.	SENT	.
A	DT	a
pilot	JJ	pilot
SARS-CoV-2	NP	<unknown>
air	NN	air
sampling	NN	sampling
study	NN	study
conducted	VBN	conduct
at	IN	at
a	DT	a
clinic	NN	clinic
within	IN	within
a	DT	a
university	NN	university
student	NN	student
health	NN	health
care	NN	care
center	NN	center
detected	VBD	detect
the	DT	the
virus	NN	virus
vRNA	NN	<unknown>
,	,	,
with	IN	with
an	DT	an
estimated	JJ	estimated
concentration	NN	concentration
of	IN	of
0.87	CD	@card@
virus	NN	virus
genomes	NNS	genome
L-1	JJ	L@card@
air	NN	air
.	SENT	.
To	TO	to
determine	VB	determine
whether	IN	whether
the	DT	the
virus	NN	virus
detected	VBD	detect
was	VBD	be
viable	JJ	viable
(	(	(
'	''	'
live	VB	live
'	''	'
)	)	)
,	,	,
attempts	NNS	attempt
were	VBD	be
made	VBN	make
to	TO	to
isolate	VB	isolate
the	DT	the
virus	NN	virus
in	IN	in
cell	NN	cell
cultures	NNS	culture
.	SENT	.
Virus-induced	JJ	<unknown>
cytopathic	JJ	<unknown>
effects	NNS	effect
(	(	(
CPE	NP	CPE
)	)	)
were	VBD	be
observed	VBN	observe
within	IN	within
two	CD	two
days	NNS	day
post-inoculation	NN	post-inoculation
of	IN	of
Vero	NP	Vero
E6	NP	<unknown>
cells	NNS	cell
with	IN	with
collection	NN	collection
media	NNS	medium
from	IN	from
air	NN	air
samples	NNS	sample
;	:	;
however	RB	however
,	,	,
rtRT-PCR	NN	<unknown>
tests	NNS	test
for	IN	for
SARS-CoV-2	JJ	<unknown>
vRNA	NN	<unknown>
from	IN	from
cell	NN	cell
culture	NN	culture
were	VBD	be
negative	JJ	negative
.	SENT	.
Instead	RB	instead
,	,	,
three	CD	three
other	JJ	other
fast-growing	JJ	fast-growing
human	JJ	human
respiratory	JJ	respiratory
viruses	NNS	virus
were	VBD	be
isolated	VBN	isolate
and	CC	and
subsequently	RB	subsequently
identified	VBN	identify
,	,	,
illustrating	VBG	illustrate
the	DT	the
challenge	NN	challenge
in	IN	in
isolating	JJ	isolating
SARS-CoV-2	NP	<unknown>
when	WRB	when
multiple	JJ	multiple
viruses	NNS	virus
are	VBP	be
present	JJ	present
in	IN	in
a	DT	a
test	NN	test
sample	NN	sample
.	SENT	.
The	DT	the
complete	JJ	complete
SAR-CoV-2	NP	<unknown>
genomic	JJ	<unknown>
sequence	NN	sequence
was	VBD	be
nevertheless	RB	nevertheless
determined	VBN	determine
by	IN	by
Sanger	NP	Sanger
sequencing	NP	sequencing
and	CC	and
most	RBS	most
closely	RB	closely
resembles	VBZ	resemble
SARS-CoV-2	JJ	<unknown>
genomes	NNS	genome
previously	RB	previously
described	VBN	describe
in	IN	in
Georgia	NP	Georgia
,	,	,
USA	NP	USA
.	SENT	.
Results	NNS	result
of	IN	of
this	DT	this
study	NN	study
illustrate	VBP	illustrate
the	DT	the
feasibility	NN	feasibility
of	IN	of
tracking	VBG	track
progression	NN	progression
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
using	VBG	use
environmental	JJ	environmental
aerosol	NN	aerosol
samples	NNS	sample
instead	RB	instead
of	IN	of
human	JJ	human
specimens	NNS	specimen
.	SENT	.
Collection	NN	collection
of	IN	of
a	DT	a
positive	JJ	positive
sample	NN	sample
from	IN	from
a	DT	a
distance	NN	distance
more	JJR	more
than	IN	than
2	CD	@card@
m	NN	m
away	RB	away
from	IN	from
the	DT	the
nearest	JJS	near
patient	NN	patient
traffic	NN	traffic
implies	VBZ	imply
the	DT	the
virus	NN	virus
was	VBD	be
in	IN	in
an	DT	an
aerosol	NN	aerosol
.	SENT	.
33963250/	CD	@card@
A	DT	a
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
of	IN	of
regional	JJ	regional
risk	NN	risk
factors	NNS	factor
for	IN	for
critical	JJ	critical
outcomes	NNS	outcome
of	IN	of
COVID-19	NP	<unknown>
during	IN	during
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
pandemic	NN	pandemic
The	DT	the
mortality	NN	mortality
rates	NNS	rate
of	IN	of
COVID-19	NP	<unknown>
vary	VBP	vary
across	IN	across
the	DT	the
globe	NN	globe
.	SENT	.
While	IN	while
some	DT	some
risk	NN	risk
factors	NNS	factor
for	IN	for
poor	JJ	poor
prognosis	NN	prognosis
of	IN	of
the	DT	the
disease	NN	disease
are	VBP	be
known	VBN	know
,	,	,
regional	JJ	regional
differences	NNS	difference
are	VBP	be
suspected	VBN	suspect
.	SENT	.
We	PP	we
reviewed	VBD	review
the	DT	the
risk	NN	risk
factors	NNS	factor
for	IN	for
critical	JJ	critical
outcomes	NNS	outcome
of	IN	of
COVID-19	NP	<unknown>
according	VBG	accord
to	TO	to
the	DT	the
location	NN	location
of	IN	of
the	DT	the
infected	JJ	infected
patients	NNS	patient
,	,	,
from	IN	from
various	JJ	various
literature	NN	literature
databases	NNS	database
from	IN	from
January	NP	January
1	CD	@card@
through	IN	through
June	NP	June
8	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
Candidate	NN	candidate
variables	NNS	variable
to	TO	to
predict	VB	predict
the	DT	the
outcome	NN	outcome
included	VBD	include
patient	JJ	patient
demographics	NNS	demographic
,	,	,
underlying	VBG	underlie
medical	JJ	medical
conditions	NNS	condition
,	,	,
symptoms	NNS	symptom
,	,	,
and	CC	and
laboratory	NN	laboratory
findings	NNS	finding
.	SENT	.
The	DT	the
risk	NN	risk
factors	NNS	factor
in	IN	in
the	DT	the
overall	JJ	overall
population	NN	population
included	VBD	include
sex	NN	sex
,	,	,
age	NN	age
,	,	,
and	CC	and
all	RB	all
inspected	VBD	inspect
underlying	VBG	underlie
medical	JJ	medical
conditions	NNS	condition
.	SENT	.
Symptoms	NNS	symptom
of	IN	of
dyspnea	NN	dyspnea
,	,	,
anorexia	NN	anorexia
,	,	,
dizziness	NN	dizziness
,	,	,
fatigue	NN	fatigue
,	,	,
and	CC	and
certain	JJ	certain
laboratory	NN	laboratory
findings	NNS	finding
were	VBD	be
also	RB	also
indicators	NNS	indicator
of	IN	of
the	DT	the
critical	JJ	critical
outcome	NN	outcome
.	SENT	.
Underlying	VBG	underlie
respiratory	JJ	respiratory
disease	NN	disease
was	VBD	be
associated	VBN	associate
higher	JJR	high
risk	NN	risk
of	IN	of
the	DT	the
critical	JJ	critical
outcome	NN	outcome
in	IN	in
studies	NNS	study
from	IN	from
Asia	NP	Asia
and	CC	and
Europe	NP	Europe
,	,	,
but	CC	but
not	RB	not
North	NP	North
America	NP	America
.	SENT	.
Underlying	VBG	underlie
hepatic	JJ	hepatic
disease	NN	disease
was	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
higher	JJR	high
risk	NN	risk
of	IN	of
the	DT	the
critical	JJ	critical
outcome	NN	outcome
from	IN	from
Europe	NP	Europe
,	,	,
but	CC	but
not	RB	not
from	IN	from
Asia	NP	Asia
and	CC	and
North	NP	North
America	NP	America
.	SENT	.
Symptoms	NNS	symptom
of	IN	of
vomiting	NN	vomiting
,	,	,
anorexia	NN	anorexia
,	,	,
dizziness	NN	dizziness
,	,	,
and	CC	and
fatigue	NN	fatigue
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
the	DT	the
critical	JJ	critical
outcome	NN	outcome
in	IN	in
studies	NNS	study
from	IN	from
Asia	NP	Asia
,	,	,
but	CC	but
not	RB	not
from	IN	from
Europe	NP	Europe
and	CC	and
North	NP	North
America	NP	America
.	SENT	.
Hemoglobin	NN	hemoglobin
and	CC	and
platelet	NN	platelet
count	NN	count
affected	VBD	affect
patients	NNS	patient
differently	RB	differently
in	IN	in
Asia	NP	Asia
compared	VBN	compare
to	TO	to
those	DT	those
in	IN	in
Europe	NP	Europe
and	CC	and
North	NP	North
America	NP	America
.	SENT	.
Such	JJ	such
regional	JJ	regional
discrepancies	NNS	discrepancy
should	MD	should
be	VB	be
considered	VBN	consider
when	WRB	when
treating	VBG	treat
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
34881119/	CD	@card@
Pericarditis	NN	pericarditis
Following	VBG	follow
Recovery	NP	Recovery
From	IN	from
COVID-19	NP	<unknown>
Infection	NN	infection
in	IN	in
a	DT	a
15-Year-Old	JJ	<unknown>
Boy	NP	Boy
:	:	:
A	DT	a
Postinflammatory	NP	<unknown>
Immune-Mediated	NP	<unknown>
Presentation	NP	Presentation
or	CC	or
a	DT	a
New-Onset	NN	<unknown>
Autoimmune	JJ	autoimmune
Disease	NN	disease
As	IN	as
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
evolves	VBZ	evolve
,	,	,
the	DT	the
medical	JJ	medical
community	NN	community
continues	VBZ	continue
to	TO	to
report	VB	report
a	DT	a
variety	NN	variety
of	IN	of
clinical	JJ	clinical
manifestations	NNS	manifestation
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
the	DT	the
pediatric	JJ	pediatric
population	NN	population
.	SENT	.
Although	IN	although
younger	JJR	young
age	NN	age
groups	NNS	group
experience	VBP	experience
less	RBR	less
severe	JJ	severe
disease	NN	disease
,	,	,
attention	NN	attention
is	VBZ	be
given	VBN	give
to	TO	to
the	DT	the
immunologic	JJ	immunologic
manifestations	NNS	manifestation
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
Pericarditis	NN	pericarditis
is	VBZ	be
a	DT	a
rare	JJ	rare
cardiac	JJ	cardiac
complication	NN	complication
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
We	PP	we
discuss	VBP	discuss
the	DT	the
first	JJ	first
case	NN	case
of	IN	of
delayed	JJ	delayed
presentation	NN	presentation
of	IN	of
pericarditis	NN	pericarditis
following	VBG	follow
recovery	NN	recovery
from	IN	from
COVID-19	NP	<unknown>
infection	NN	infection
in	IN	in
the	DT	the
pediatric	JJ	pediatric
population	NN	population
.	SENT	.
A	DT	a
15-year-old	JJ	15-year-old
male	JJ	male
adolescent	NN	adolescent
presented	VBN	present
to	TO	to
the	DT	the
emergency	NN	emergency
department	NN	department
(	(	(
ED	NN	editor
)	)	)
with	IN	with
a	DT	a
two-day	JJ	two-day
history	NN	history
of	IN	of
left-sided	JJ	<unknown>
,	,	,
sub-sternal	JJ	sub-sternal
chest	NN	chest
pain	NN	pain
that	WDT	that
worsened	VBD	worsen
during	IN	during
inspiration	NN	inspiration
and	CC	and
a	DT	a
low-grade	NN	low-grade
fever	NN	fever
.	SENT	.
Twenty	CD	twenty
days	NNS	day
prior	RB	prior
to	TO	to
this	DT	this
presentation	NN	presentation
,	,	,
the	DT	the
patient	JJ	patient
experienced	JJ	experienced
fever	NN	fever
and	CC	and
was	VBD	be
tested	VBN	test
positive	JJ	positive
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
His	PP$	his
family	NN	family
history	NN	history
was	VBD	be
remarkable	JJ	remarkable
for	IN	for
Hashimoto	NP	Hashimoto
thyroiditis	NN	thyroiditis
and	CC	and
rheumatoid	JJ	rheumatoid
arthritis	NN	arthritis
,	,	,
with	IN	with
his	PP$	his
mother	NN	mother
having	VBG	have
experienced	VBN	experience
18	CD	@card@
episodes	NNS	episode
of	IN	of
pericarditis	NN	pericarditis
during	IN	during
the	DT	the
exacerbations	NNS	exacerbation
of	IN	of
her	PP$	her
disease	NN	disease
.	SENT	.
RT-PCR	NP	<unknown>
for	IN	for
SARS-CoV-2	NP	<unknown>
was	VBD	be
negative	JJ	negative
on	IN	on
this	DT	this
occasion	NN	occasion
and	CC	and
the	DT	the
serology	NN	serology
assay	NN	assay
identified	VBD	identify
positive	JJ	positive
IgG	NP	IgG
antibodies	NNS	antibody
against	IN	against
the	DT	the
virus	NN	virus
.	SENT	.
The	DT	the
ECG	NP	ECG
was	VBD	be
suggestive	JJ	suggestive
for	IN	for
pericarditis	NN	pericarditis
and	CC	and
the	DT	the
diagnosis	NN	diagnosis
was	VBD	be
confirmed	VBN	confirm
by	IN	by
the	DT	the
presence	NN	presence
of	IN	of
pericardial	JJ	pericardial
effusion	NN	effusion
on	IN	on
ECHO	NN	echo
.	SENT	.
The	DT	the
rest	NN	rest
of	IN	of
the	DT	the
aetiological	JJ	aetiological
investigations	NNS	investigation
for	IN	for
pericarditis	NN	pericarditis
were	VBD	be
negative	JJ	negative
.	SENT	.
In	IN	in
view	NN	view
of	IN	of
the	DT	the
strong	JJ	strong
family	NN	family
history	NN	history
of	IN	of
autoimmunity	NN	autoimmunity
,	,	,
questions	NNS	question
were	VBD	be
raised	VBN	raise
in	IN	in
the	DT	the
medical	JJ	medical
team	NN	team
of	IN	of
our	PP$	our
hospital	NN	hospital
regarding	VBG	regard
the	DT	the
etiology	NN	etiology
of	IN	of
his	PP$	his
pericarditis	NN	pericarditis
and	CC	and
on	IN	on
whether	IN	whether
it	PP	it
represented	VBD	represent
a	DT	a
postinflammatory	JJ	postinflammatory
immune-mediated	JJ	<unknown>
presentation	NN	presentation
of	IN	of
SARS-CoV-2	NP	<unknown>
or	CC	or
a	DT	a
new-onset	NN	new-onset
autoimmune	JJ	autoimmune
disease	NN	disease
.	SENT	.
34622966/	CD	@card@
Dysphagia	NN	dysphagia
,	,	,
Dysphonia	NN	dysphonia
,	,	,
and	CC	and
Dysarthria	NP	<unknown>
Outcomes	NNS	outcome
Among	IN	among
Adults	NNS	adult
Hospitalized	VBN	hospitalize
With	IN	with
COVID-19	NP	<unknown>
Across	IN	across
Ireland	NP	Ireland
To	TO	to
investigate	VB	investigate
the	DT	the
presence	NN	presence
,	,	,
degree	NN	degree
,	,	,
predictors	NNS	predictor
,	,	,
and	CC	and
trajectory	NN	trajectory
of	IN	of
dysphagia	NN	dysphagia
,	,	,
dysphonia	NN	dysphonia
,	,	,
and	CC	and
dysarthria	NNS	<unknown>
among	IN	among
adults	NNS	adult
hospitalized	VBN	hospitalize
with	IN	with
COVID-19	NP	<unknown>
across	IN	across
the	DT	the
Republic	NP	Republic
of	IN	of
Ireland	NP	Ireland
(	(	(
ROI	NP	Roi
)	)	)
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Prospective	JJ	prospective
observational	JJ	observational
cohort	NN	cohort
study	NN	study
.	SENT	.
Adults	NNS	adult
with	IN	with
confirmed	JJ	confirmed
COVID-19	NP	<unknown>
who	WP	who
were	VBD	be
admitted	VBN	admit
into	IN	into
14	CD	@card@
participating	VBG	participate
acute	JJ	acute
hospitals	NNS	hospital
across	IN	across
ROI	NP	Roi
and	CC	and
referred	VBD	refer
to	TO	to
speech	NN	speech
and	CC	and
language	NN	language
therapy	NN	therapy
between	IN	between
March	NP	March
1st	JJ	1st
and	CC	and
June	NP	June
30th	JJ	30th
,	,	,
2020	CD	@card@
were	VBD	be
recruited	VBN	recruit
.	SENT	.
Outcomes	NNS	outcome
obtained	VBN	obtain
at	IN	at
initial	JJ	initial
SLT	NP	<unknown>
evaluation	NN	evaluation
and	CC	and
at	IN	at
discharge	NN	discharge
were	VBD	be
oral	JJ	oral
intake	NN	intake
status	NN	status
(	(	(
Functional	JJ	functional
Oral	NP	Oral
Intake	NN	intake
Scale	NP	Scale
)	)	)
,	,	,
perceptual	JJ	perceptual
voice	NN	voice
quality	NN	quality
(	(	(
GRBAS	NP	<unknown>
)	)	)
,	,	,
and	CC	and
global	JJ	global
dysarthria	NN	<unknown>
rating	NN	rating
(	(	(
Dysarthria	NP	<unknown>
Severity	NN	severity
Scale	NP	Scale
)	)	)
.	SENT	.
Data	NNS	datum
from	IN	from
315	CD	@card@
adults	NNS	adult
were	VBD	be
analyzed	VBN	analyze
.	SENT	.
At	IN	at
initial	JJ	initial
SLT	NP	<unknown>
assessment	NN	assessment
,	,	,
84	CD	@card@
%	NN	%
required	VBN	require
modified	JJ	modified
oral	JJ	oral
diets	NNS	diet
,	,	,
and	CC	and
31	CD	@card@
%	NN	%
required	JJ	required
tube	NN	tube
feeding	NN	feeding
.	SENT	.
There	EX	there
were	VBD	be
high	JJ	high
rates	NNS	rate
of	IN	of
dysphonia	NN	dysphonia
(	(	(
42	CD	@card@
%	NN	%
)	)	)
and	CC	and
dysarthria	NNS	<unknown>
(	(	(
23	CD	@card@
%	NN	%
)	)	)
.	SENT	.
History	NN	history
of	IN	of
intubation	NN	intubation
(	(	(
OR	CC	or
19.959	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
6.272	CD	@card@
,	,	,
63.513	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.000	CD	@card@
)	)	)
,	,	,
COVID-19	NP	<unknown>
neurological	JJ	neurological
manifestations	NNS	manifestation
(	(	(
OR	CC	or
3.592	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.733	CD	@card@
,	,	,
7.445	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.001	CD	@card@
)	)	)
,	,	,
and	CC	and
age	NN	age
(	(	(
OR	CC	or
1.034	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
1.002	CD	@card@
,	,	,
1.066	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.036	CD	@card@
)	)	)
were	VBD	be
predictive	JJ	predictive
of	IN	of
oral	JJ	oral
intake	NN	intake
status	NN	status
.	SENT	.
History	NN	history
of	IN	of
intubation	NN	intubation
was	VBD	be
predictive	JJ	predictive
of	IN	of
voice	NN	voice
quality	NN	quality
(	(	(
OR	CC	or
4.250	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.838	CD	@card@
,	,	,
9.827	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.001	CD	@card@
)	)	)
and	CC	and
COVID-19	NP	<unknown>
neurological	JJ	neurological
manifestations	NNS	manifestation
were	VBD	be
predictive	JJ	predictive
of	IN	of
dysarthria	NN	<unknown>
(	(	(
OR	CC	or
2.275	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
1.162	CD	@card@
,	,	,
4.456	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.017	CD	@card@
)	)	)
.	SENT	.
At	IN	at
discharge	NN	discharge
,	,	,
there	EX	there
were	VBD	be
significant	JJ	significant
improvements	NNS	improvement
in	IN	in
oral	JJ	oral
intake	NN	intake
(	(	(
Z	NP	Z
=	SYM	=
-7.971	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.000	CD	@card@
)	)	)
,	,	,
voice	NN	voice
quality	NN	quality
(	(	(
Z	NP	Z
=	SYM	=
-5.971	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.000	CD	@card@
)	)	)
,	,	,
and	CC	and
dysarthria	NN	<unknown>
severity	NN	severity
(	(	(
Z	NP	Z
=	SYM	=
-2.619	CD	@card@
;	:	;
P	NN	P
=	SYM	=
.009	CD	@card@
)	)	)
,	,	,
although	IN	although
need	NN	need
for	IN	for
modified	JJ	modified
oral	JJ	oral
intake	NN	intake
(	(	(
59	CD	@card@
%	NN	%
)	)	)
,	,	,
dysphonia	NN	dysphonia
(	(	(
23	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
dysarthria	NNS	<unknown>
(	(	(
14	CD	@card@
%	NN	%
)	)	)
persisted	VBD	persist
.	SENT	.
Dysphagia	NN	dysphagia
,	,	,
dysphonia	NN	dysphonia
,	,	,
and	CC	and
dysarthria	NNS	<unknown>
were	VBD	be
widespread	JJ	widespread
among	IN	among
adults	NNS	adult
hospitalized	VBN	hospitalize
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
they	PP	they
persisted	VBD	persist
for	IN	for
many	JJ	many
at	IN	at
discharge	NN	discharge
.	SENT	.
Prompt	JJ	prompt
SLT	NP	<unknown>
evaluation	NN	evaluation
is	VBZ	be
required	VBN	require
to	TO	to
minimize	VB	minimize
complications	NNS	complication
.	SENT	.
3	CD	@card@
Laryngoscope	NN	laryngoscope
,	,	,
2021	CD	@card@
35132343/	CD	@card@
Mortalidad	NP	<unknown>
por	NP	por
COVID-19	NP	<unknown>
y	NP	y
su	NP	Su
relacion	NN	<unknown>
con	NN	con
las	NNS	la
busquedas	NNS	<unknown>
en	IN	en
internet	NN	Internet
sobre	NN	<unknown>
salud	NN	<unknown>
mental	JJ	mental
durante	NN	<unknown>
el	NN	el
primer	NN	primer
ano	NP	Ano
de	NP	de
pandemia	NN	<unknown>
32602111/	CD	@card@
The	DT	the
COVID-19	NP	<unknown>
Airway	NN	airway
Management	NP	Management
Isolation	NN	isolation
Chamber	NP	Chamber
(	(	(
CAMIC	NP	Camic
)	)	)
for	IN	for
Ears	NNS	ear
32897869/	CD	@card@
Cybersecurity	NN	Cybersecurity
Risks	NNS	risk
in	IN	in
a	DT	a
Pandemic	JJ	pandemic
Cybersecurity	NN	Cybersecurity
threats	NNS	threat
are	VBP	be
estimated	VBN	estimate
to	TO	to
cost	VB	cost
the	DT	the
world	NN	world
US	NP	US
$6	NN	<unknown>
trillion	CD	trillion
a	DT	a
year	NN	year
by	IN	by
2021	CD	@card@
,	,	,
and	CC	and
the	DT	the
number	NN	number
of	IN	of
attacks	NNS	attack
has	VBZ	have
increased	VBN	increase
five-fold	NN	five-fold
after	IN	after
COVID-19	NP	<unknown>
.	SENT	.
Although	IN	although
there	EX	there
is	VBZ	be
substantial	JJ	substantial
literature	NN	literature
on	IN	on
the	DT	the
threats	NNS	threat
technological	JJ	technological
vulnerabilities	NNS	vulnerability
have	VBP	have
on	IN	on
the	DT	the
health	NN	health
care	NN	care
industry	NN	industry
,	,	,
less	JJR	less
research	NN	research
exists	VBZ	exist
on	IN	on
how	WRB	how
pandemics	NNS	pandemic
like	IN	like
COVID-19	NP	<unknown>
are	VBP	be
opportunistic	JJ	opportunistic
for	IN	for
cybercriminals	NNS	cybercriminal
.	SENT	.
This	DT	this
paper	NN	paper
outlines	VBZ	outline
why	WRB	why
cyberattacks	NNS	cyberattack
have	VBP	have
been	VBN	be
particularly	RB	particularly
problematic	JJ	problematic
during	IN	during
COVID-19	NP	<unknown>
and	CC	and
ways	NNS	way
that	IN	that
health	NN	health
care	NN	care
industries	NNS	industry
can	MD	can
better	RBR	well
protect	VB	protect
patient	JJ	patient
data	NNS	datum
.	SENT	.
The	DT	the
Office	NP	Office
for	IN	for
Civil	NP	Civil
Rights	NPS	Rights
has	VBZ	have
loosened	VBN	loosen
enforcement	NN	enforcement
of	IN	of
the	DT	the
Health	NP	Health
Insurance	NP	Insurance
Portability	NN	portability
and	CC	and
Accountability	NN	accountability
Act	NN	act
,	,	,
which	WDT	which
,	,	,
although	IN	although
useful	JJ	useful
in	IN	in
using	VBG	use
new	JJ	new
platforms	NNS	platform
like	IN	like
Zoom	NN	zoom
,	,	,
has	VBZ	have
also	RB	also
loosened	VBN	loosen
physical	JJ	physical
and	CC	and
technical	JJ	technical
safeguards	NNS	safeguard
to	TO	to
cyberattacks	NNS	cyberattack
.	SENT	.
This	DT	this
is	VBZ	be
especially	RB	especially
problematic	JJ	problematic
given	VBN	give
that	IN	that
90	CD	@card@
%	NN	%
of	IN	of
health	NN	health
care	NN	care
providers	NNS	provider
had	VBD	have
already	RB	already
encountered	VBN	encounter
data	NN	data
breaches	NNS	breach
.	SENT	.
Companies	NNS	company
must	MD	must
implement	VB	implement
well-defined	JJ	well-defined
software	NN	software
upgrade	NN	upgrade
procedures	NNS	procedure
,	,	,
should	MD	should
use	VB	use
secure	JJ	secure
networks	NNS	network
like	IN	like
virtual	JJ	virtual
local	JJ	local
area	NN	area
networks	NNS	network
,	,	,
and	CC	and
conduct	VB	conduct
regular	JJ	regular
penetration	NN	penetration
tests	NNS	test
of	IN	of
their	PP$	their
systems	NNS	system
.	SENT	.
By	IN	by
understanding	VBG	understand
factors	NNS	factor
that	WDT	that
make	VBP	make
individuals	NNS	individual
,	,	,
health	NN	health
care	NN	care
organizations	NNS	organization
,	,	,
and	CC	and
employers	NNS	employer
more	RBR	more
susceptible	JJ	susceptible
to	TO	to
cyberattacks	NNS	cyberattack
,	,	,
we	PP	we
can	MD	can
better	RBR	well
prepare	VB	prepare
for	IN	for
the	DT	the
next	JJ	next
pandemic	NN	pandemic
.	SENT	.
33692744/	CD	@card@
Case	NP	Case
Report	NP	Report
:	:	:
Decompressive	JJ	Decompressive
Craniectomy	NN	<unknown>
for	IN	for
COVID-19	NP	<unknown>
Malignant	JJ	malignant
Cerebral	JJ	cerebral
Artery	NN	artery
Infarction	NN	infarction
.	SENT	.
Is	VBZ	be
Surgery	NN	surgery
a	DT	a
Good	JJ	good
Option	NN	option
?	SENT	?
SARS-CoV2	JJ	<unknown>
infection	NN	infection
can	MD	can
lead	VB	lead
to	TO	to
a	DT	a
prothrombotic	JJ	prothrombotic
state	NN	state
.	SENT	.
Large	JJ	large
vessel	NN	vessel
occlusion	NN	occlusion
,	,	,
as	RB	as
well	RB	well
as	IN	as
malignant	JJ	malignant
cerebral	JJ	cerebral
stroke	NN	stroke
have	VBP	have
been	VBN	be
described	VBN	describe
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
In	IN	in
the	DT	the
following	VBG	follow
months	NNS	month
,	,	,
given	VBN	give
the	DT	the
increase	NN	increase
in	IN	in
COVID-19	NP	<unknown>
cases	NNS	case
,	,	,
an	DT	an
increase	NN	increase
in	IN	in
malignant	JJ	malignant
cerebral	JJ	cerebral
SARS-CoV2	JJ	<unknown>
associated	JJ	associated
strokes	NNS	stroke
are	VBP	be
expected	VBN	expect
.	SENT	.
The	DT	the
baseline	JJ	baseline
situation	NN	situation
of	IN	of
the	DT	the
patients	NNS	patient
as	RB	as
well	RB	well
as	IN	as
the	DT	the
risk	NN	risk
of	IN	of
evolution	NN	evolution
to	TO	to
a	DT	a
serious	JJ	serious
disease	NN	disease
due	JJ	due
to	TO	to
the	DT	the
virus	NN	virus
,	,	,
depict	VBP	depict
a	DT	a
unique	JJ	unique
scenario	NN	scenario
.	SENT	.
Decompressive	JJ	Decompressive
craniectomy	NN	<unknown>
is	VBZ	be
a	DT	a
life-saving	JJ	life-saving
procedure	NN	procedure
indicated	VBN	indicate
in	IN	in
patients	NNS	patient
who	WP	who
suffer	VBP	suffer
a	DT	a
malignant	JJ	malignant
cerebral	JJ	cerebral
stroke	NN	stroke
;	:	;
however	RB	however
,	,	,
it	PP	it
is	VBZ	be
unclear	JJ	unclear
whether	IN	whether
the	DT	the
same	JJ	same
eligibility	NN	eligibility
criteria	NNS	criterion
should	MD	should
be	VB	be
used	VBN	use
for	IN	for
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
To	TO	to
our	PP$	our
knowledge	NN	knowledge
seven	CD	seven
cases	NNS	case
of	IN	of
decompressive	JJ	decompressive
craniectomy	NN	<unknown>
and	CC	and
malignant	JJ	malignant
cerebral	JJ	cerebral
stroke	NN	stroke
have	VBP	have
been	VBN	be
described	VBN	describe
to	TO	to
date	NN	date
.	SENT	.
We	PP	we
report	VBP	report
on	IN	on
a	DT	a
39-year-old	JJ	39-year-old
female	NN	female
with	IN	with
no	DT	no
major	JJ	major
risk	NN	risk
factors	NNS	factor
for	IN	for
cerebrovascular	JJ	cerebrovascular
disease	NN	disease
,	,	,
apart	RB	apart
from	IN	from
oral	JJ	oral
contraception	NN	contraception
,	,	,
and	CC	and
mild	JJ	mild
COVID-19	NP	<unknown>
symptoms	NNS	symptom
who	WP	who
suffered	VBD	suffer
from	IN	from
left	JJ	left
hemispheric	JJ	hemispheric
syndrome	NN	syndrome
.	SENT	.
The	DT	the
patient	NN	patient
underwent	VBD	undergo
endovascular	JJ	endovascular
treatment	NN	treatment
with	IN	with
stenting	NN	<unknown>
and	CC	and
afterward	RB	afterward
decompressive	JJ	decompressive
craniectomy	NN	<unknown>
due	JJ	due
to	TO	to
a	DT	a
worsening	VBG	worsen
neurological	JJ	neurological
status	NN	status
with	IN	with
unilateral	JJ	unilateral
unreactive	JJ	unreactive
mydriasis	NN	mydriasis
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
case	NN	case
and	CC	and
provide	VB	provide
a	DT	a
comprehensive	JJ	comprehensive
review	NN	review
of	IN	of
the	DT	the
available	JJ	available
literature	NN	literature
related	VBN	relate
to	TO	to
the	DT	the
surgical	JJ	surgical
treatment	NN	treatment
for	IN	for
COVID-19	NP	<unknown>
associated	VBN	associate
malignant	JJ	malignant
strokes	NNS	stroke
,	,	,
to	TO	to
establish	VB	establish
whether	IN	whether
the	DT	the
same	JJ	same
eligibility	NN	eligibility
criteria	NNS	criterion
for	IN	for
non-COVID-19	JJ	<unknown>
associated	VBN	associate
strokes	NNS	stroke
should	MD	should
be	VB	be
used	VBN	use
.	SENT	.
Eight	CD	eight
patients	NNS	patient
,	,	,
including	VBG	include
our	PP$	our
case	NN	case
,	,	,
were	VBD	be
surgically	RB	surgically
managed	VBN	manage
due	JJ	due
to	TO	to
malignant	JJ	malignant
cerebral	JJ	cerebral
stroke	NN	stroke
.	SENT	.
Seven	CD	seven
of	IN	of
these	DT	these
patients	NNS	patient
received	VBD	receive
decompressive	JJ	decompressive
craniectomy	NN	<unknown>
,	,	,
and	CC	and
six	CD	six
of	IN	of
them	PP	them
met	VBD	meet
the	DT	the
eligibility	NN	eligibility
criteria	NNS	criterion
of	IN	of
the	DT	the
current	JJ	current
stroke	NN	stroke
guidelines	NNS	guideline
.	SENT	.
The	DT	the
mortality	NN	mortality
rate	NN	rate
was	VBD	be
33	CD	@card@
%	NN	%
,	,	,
similar	JJ	similar
to	TO	to
that	DT	that
described	VBN	describe
in	IN	in
non-COVID-19	JJ	<unknown>
cases	NNS	case
.	SENT	.
Two	CD	two
patients	NNS	patient
had	VBD	have
a	DT	a
left	VBN	leave
middle	JJ	middle
cerebral	JJ	cerebral
artery	NN	artery
(	(	(
MCA	NP	MCA
)	)	)
and	CC	and
both	DT	both
survived	VBN	survive
after	IN	after
decompressive	JJ	decompressive
craniectomy	NN	<unknown>
.	SENT	.
Our	PP$	our
results	NNS	result
support	VBP	support
that	IN	that
decompressive	JJ	decompressive
craniectomy	NN	<unknown>
,	,	,
using	VBG	use
the	DT	the
current	JJ	current
stroke	NN	stroke
guidelines	NNS	guideline
,	,	,
should	MD	should
be	VB	be
considered	VBN	consider
an	DT	an
effective	JJ	effective
life-saving	JJ	life-saving
treatment	NN	treatment
for	IN	for
COVID-19-related	JJ	COVID-19-related
malignant	JJ	malignant
cerebral	JJ	cerebral
strokes	NNS	stroke
.	SENT	.
32659213/	CD	@card@
Coagulation	NN	coagulation
disorder	NN	disorder
in	IN	in
COVID-19	NP	<unknown>
32621859/	CD	@card@
Protection	NP	Protection
challenges	NNS	challenge
of	IN	of
pregnant	JJ	pregnant
women	NNS	woman
against	IN	against
vertical	JJ	vertical
transmission	NN	transmission
during	IN	during
COVID-19	NP	<unknown>
epidemic	NN	epidemic
:	:	:
A	DT	a
narrative	JJ	narrative
review	NN	review
A	DT	a
narrative	JJ	narrative
review	NN	review
of	IN	of
the	DT	the
emerging	VBG	emerge
literature	NN	literature
on	IN	on
the	DT	the
challenges	NNS	challenge
of	IN	of
pregnant	JJ	pregnant
women	NNS	woman
protection	NN	protection
during	IN	during
COVID-19	NP	<unknown>
infection	NN	infection
was	VBD	be
conducted	VBN	conduct
.	SENT	.
Most	JJS	most
review	NN	review
studies	NNS	study
presented	VBD	present
that	IN	that
no	DT	no
vertical	JJ	vertical
transmission	NN	transmission
of	IN	of
COVID-19	NP	<unknown>
from	IN	from
pregnant	JJ	pregnant
women	NNS	woman
to	TO	to
neonates	NNS	neonate
was	VBD	be
found	VBN	find
.	SENT	.
Potential	JJ	potential
risks	NNS	risk
of	IN	of
vertical	JJ	vertical
transmission	NN	transmission
of	IN	of
COVID-19	NP	<unknown>
remain	VBP	remain
with	IN	with
pregnant	JJ	pregnant
women	NNS	woman
and	CC	and
neonates	NNS	neonate
.	SENT	.
Special	JJ	special
care	NN	care
has	VBZ	have
been	VBN	be
suggested	VBN	suggest
for	IN	for
pregnant	JJ	pregnant
women	NNS	woman
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
paper	NN	paper
presents	VBZ	present
a	DT	a
narrative	JJ	narrative
review	NN	review
study	NN	study
of	IN	of
5	CD	@card@
popular	JJ	popular
data	NNS	datum
repositories	NNS	repository
focusing	VBG	focus
on	IN	on
challenges	NNS	challenge
of	IN	of
pregnant	JJ	pregnant
women	NNS	woman
protection	NN	protection
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
study	NN	study
concludes	VBZ	conclude
that	IN	that
the	DT	the
likelihood	NN	likelihood
of	IN	of
a	DT	a
vertical	JJ	vertical
transmission	NN	transmission
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
from	IN	from
pregnant	JJ	pregnant
women	NNS	woman
to	TO	to
neonates	NNS	neonate
was	VBD	be
not	RB	not
observed	VBN	observe
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
it	PP	it
remains	VBZ	remain
a	DT	a
serious	JJ	serious
risk	NN	risk
for	IN	for
them	PP	them
during	IN	during
their	PP$	their
earlier	JJR	early
stage	NN	stage
of	IN	of
pregnancy	NN	pregnancy
,	,	,
thus	RB	thus
,	,	,
special	JJ	special
attention	NN	attention
from	IN	from
health	NN	health
professionals	NNS	professional
has	VBZ	have
been	VBN	be
recommended	VBN	recommend
.	SENT	.
35378801/	CD	@card@
Training	NP	Training
in	IN	in
the	DT	the
Era	NN	era
of	IN	of
COVID-19	NP	<unknown>
34493506/	CD	@card@
Investigating	VBG	investigate
and	CC	and
addressing	VBG	address
the	DT	the
immediate	JJ	immediate
and	CC	and
long-term	JJ	long-term
consequences	NNS	consequence
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
patients	NNS	patient
with	IN	with
substance	NN	substance
use	NN	use
disorders	NNS	disorder
:	:	:
a	DT	a
scoping	JJ	<unknown>
review	NN	review
and	CC	and
evidence	NN	evidence
map	NN	map
protocol	NN	protocol
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
driven	VBN	drive
unprecedented	JJ	unprecedented
social	JJ	social
and	CC	and
economic	JJ	economic
reform	NN	reform
in	IN	in
efforts	NNS	effort
to	TO	to
curb	VB	curb
the	DT	the
impact	NN	impact
of	IN	of
disease	NN	disease
.	SENT	.
Governments	NNS	government
worldwide	RB	worldwide
have	VBP	have
legislated	VBN	legislate
non-essential	JJ	non-essential
service	NN	service
shutdowns	NNS	shutdown
and	CC	and
adapted	VBN	adapt
essential	JJ	essential
service	NN	service
provision	NN	provision
in	IN	in
order	NN	order
to	TO	to
minimise	VB	minimise
face-to-face	JJ	face-to-face
contact	NN	contact
.	SENT	.
We	PP	we
anticipate	VBP	anticipate
major	JJ	major
consequences	NNS	consequence
resulting	VBG	result
from	IN	from
such	JJ	such
policies	NNS	policy
,	,	,
with	IN	with
marginalised	JJ	<unknown>
populations	NNS	population
expected	VBN	expect
to	TO	to
bear	VB	bear
the	DT	the
greatest	JJS	great
burden	NN	burden
of	IN	of
such	JJ	such
measures	NNS	measure
,	,	,
especially	RB	especially
those	DT	those
with	IN	with
substance	NN	substance
use	NN	use
disorders	NNS	disorder
(	(	(
SUDs	NN	suds
)	)	)
.	SENT	.
We	PP	we
aim	VBP	aim
to	TO	to
conduct	VB	conduct
(	(	(
1	LS	1
)	)	)
a	DT	a
scoping	JJ	<unknown>
review	NN	review
to	TO	to
summarise	VB	summarise
the	DT	the
available	JJ	available
evidence	NN	evidence
evaluating	VBG	evaluate
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
patients	NNS	patient
with	IN	with
SUDs	NN	suds
,	,	,
and	CC	and
(	(	(
2	LS	2
)	)	)
an	DT	an
evidence	NN	evidence
map	NN	map
to	TO	to
visually	RB	visually
plot	VB	plot
and	CC	and
categorise	VB	categorise
the	DT	the
current	JJ	current
available	JJ	available
evidence	NN	evidence
evaluating	VBG	evaluate
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
patients	NNS	patient
with	IN	with
SUDs	NN	suds
to	TO	to
identify	VB	identify
gaps	NNS	gap
in	IN	in
addressing	VBG	address
high-risk	JJ	high-risk
populations	NNS	population
.	SENT	.
Ethics	NP	Ethics
approval	NN	approval
is	VBZ	be
not	RB	not
required	VBN	require
for	IN	for
this	DT	this
scoping	JJ	<unknown>
review	NN	review
as	IN	as
we	PP	we
plan	VBP	plan
to	TO	to
review	VB	review
publicly	RB	publicly
available	JJ	available
data	NNS	datum
.	SENT	.
This	DT	this
is	VBZ	be
part	NN	part
of	IN	of
a	DT	a
multistep	NN	multistep
project	NN	project
,	,	,
whereby	WRB	whereby
we	PP	we
intend	VBP	intend
to	TO	to
use	VB	use
the	DT	the
findings	NNS	finding
generated	VBN	generate
from	IN	from
this	DT	this
review	NN	review
in	IN	in
combination	NN	combination
with	IN	with
data	NNS	datum
from	IN	from
an	DT	an
ongoing	JJ	ongoing
prospective	JJ	prospective
cohort	NN	cohort
study	VB	study
our	PP$	our
team	NN	team
is	VBZ	be
leading	VBG	lead
,	,	,
encompassing	VBG	encompass
over	IN	over
2000	CD	@card@
patients	NNS	patient
with	IN	with
SUDs	NN	suds
receiving	VBG	receive
medication-assisted	JJ	<unknown>
therapy	NN	therapy
in	IN	in
Ontario	NP	Ontario
prior	RB	prior
to	TO	to
and	CC	and
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
33651340/	CD	@card@
Impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
the	DT	the
pain	NN	pain
and	CC	and
disability	NN	disability
of	IN	of
patients	NNS	patient
with	IN	with
adult	JJ	adult
spinal	JJ	spinal
deformity	NN	deformity
To	TO	to
evaluate	VB	evaluate
the	DT	the
pain	NN	pain
and	CC	and
functional	JJ	functional
effect	NN	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
patients	NNS	patient
with	IN	with
ASD	NNS	<unknown>
reflected	VBN	reflect
by	IN	by
their	PP$	their
response	NN	response
to	TO	to
SRS-22	NP	<unknown>
,	,	,
ODI	NP	ODI
,	,	,
and	CC	and
SF-36	NP	<unknown>
questionnaires	NNS	questionnaire
.	SENT	.
Patients	NNS	patient
who	WP	who
had	VBD	have
stable	JJ	stable
pain	NN	pain
and	CC	and
functional	JJ	functional
outcome	NN	outcome
scores	NNS	score
over	IN	over
the	DT	the
preceding	JJ	preceding
2	CD	@card@
years	NNS	year
were	VBD	be
enrolled	VBN	enroll
in	IN	in
a	DT	a
local	JJ	local
prospectively	RB	prospectively
collected	VBN	collect
adult	JJ	adult
spinal	JJ	spinal
deformity	NN	deformity
(	(	(
ASD	JJ	<unknown>
)	)	)
database	NN	database
.	SENT	.
A	DT	a
reanalysis	NN	reanalysis
of	IN	of
their	PP$	their
SRS22	NP	<unknown>
,	,	,
ODI	NP	ODI
and	CC	and
SF-36	NP	<unknown>
data	NNS	datum
14	CD	@card@
days	NNS	day
into	IN	into
confinement	NN	confinement
were	VBD	be
compared	VBN	compare
to	TO	to
their	PP$	their
last	JJ	last
pre-confinement	NN	pre-confinement
scores	NNS	score
.	SENT	.
89	CD	@card@
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
study	NN	study
(	(	(
average	JJ	average
age	NN	age
60.7	CD	@card@
years	NNS	year
,	,	,
91	CD	@card@
%	NN	%
female	NN	female
)	)	)
with	IN	with
an	DT	an
average	JJ	average
time	NN	time
from	IN	from
last	JJ	last
FU	NP	fu
until	IN	until
confinement	NN	confinement
of	IN	of
9.6	CD	@card@
months	NNS	month
.	SENT	.
The	DT	the
ODI	NP	ODI
total	JJ	total
score	NN	score
worsened	VBN	worsen
by	IN	by
5	CD	@card@
points	NNS	point
post-confinement	NN	post-confinement
with	IN	with
no	DT	no
difference	NN	difference
seen	VBN	see
in	IN	in
personal	JJ	personal
care	NN	care
,	,	,
walking	NN	walking
and	CC	and
social	JJ	social
life	NN	life
.	SENT	.
In	IN	in
contrast	NN	contrast
,	,	,
the	DT	the
SRS-22	NP	<unknown>
score	NN	score
showed	VBD	show
small	JJ	small
improvements	NNS	improvement
in	IN	in
function/activity	NN	function/activity
and	CC	and
satisfaction	NN	satisfaction
,	,	,
but	CC	but
no	DT	no
significant	JJ	significant
differences	NNS	difference
for	IN	for
the	DT	the
other	JJ	other
domains	NNS	domain
.	SENT	.
Similarly	RB	similarly
,	,	,
the	DT	the
SF-36	NP	<unknown>
showed	VBD	show
small	JJ	small
improvements	NNS	improvement
in	IN	in
physical	JJ	physical
function	NN	function
,	,	,
physical	JJ	physical
and	CC	and
emotional	JJ	emotional
role	NN	role
,	,	,
vitality	NN	vitality
and	CC	and
PCS	NP	PCS
.	SENT	.
The	DT	the
global	JJ	global
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
ensuing	VBG	ensue
confinement	NN	confinement
had	VBD	have
variable	JJ	variable
overall	JJ	overall
effects	NNS	effect
on	IN	on
ASD	JJ	<unknown>
patients	NNS	patient
,	,	,
without	IN	without
the	DT	the
expected	VBN	expect
marked	JJ	marked
worsening	NN	worsening
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
this	DT	this
study	NN	study
illustrates	VBZ	illustrate
that	IN	that
the	DT	the
SRS-22	NP	<unknown>
questionnaire	NN	questionnaire
is	VBZ	be
less	RBR	less
influenced	VBN	influence
by	IN	by
environmental	JJ	environmental
and	CC	and
psychological	JJ	psychological
factors	NNS	factor
than	IN	than
the	DT	the
ODI	NP	ODI
supporting	VBG	support
its	PP$	its
objectivity	NN	objectivity
and	CC	and
accuracy	NN	accuracy
in	IN	in
the	DT	the
evaluation	NN	evaluation
of	IN	of
the	DT	the
QoL	NN	QoL
of	IN	of
ASD	JJ	<unknown>
patients	NNS	patient
.	SENT	.
32610808/	CD	@card@
Coronavirus	NP	<unknown>
:	:	:
Where	WRB	where
Has	VBZ	have
All	PDT	all
the	DT	the
Health	NP	Health
Economics	NP	Economics
Gone	VBN	go
?	SENT	?
As	IN	as
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
continues	VBZ	continue
to	TO	to
unfold	VB	unfold
there	EX	there
is	VBZ	be
an	DT	an
untold	JJ	untold
number	NN	number
of	IN	of
trade-offs	NNS	trade-off
being	VBG	be
made	VBN	make
in	IN	in
every	DT	every
country	NN	country
around	IN	around
the	DT	the
globe	NN	globe
.	SENT	.
The	DT	the
experience	NN	experience
in	IN	in
the	DT	the
United	NP	United
Kingdom	NP	Kingdom
and	CC	and
Canada	NP	Canada
to	TO	to
date	VB	date
has	VBZ	have
not	RB	not
seen	VBN	see
much	JJ	much
uptake	NN	uptake
of	IN	of
health	NN	health
economics	NNS	economics
methods	NNS	method
.	SENT	.
We	PP	we
provide	VBP	provide
some	DT	some
thoughts	NNS	thought
on	IN	on
how	WRB	how
this	DT	this
could	MD	could
take	VB	take
place	NN	place
,	,	,
specifically	RB	specifically
in	IN	in
three	CD	three
areas	NNS	area
.	SENT	.
Firstly	RB	firstly
,	,	,
this	DT	this
can	MD	can
involve	VB	involve
understanding	VBG	understand
the	DT	the
impact	NN	impact
of	IN	of
lockdown	JJ	<unknown>
policies	NNS	policy
on	IN	on
national	JJ	national
productivity	NN	productivity
.	SENT	.
Secondly	RB	secondly
,	,	,
there	EX	there
is	VBZ	be
great	JJ	great
importance	NN	importance
in	IN	in
studying	VBG	study
trade-offs	NNS	trade-off
with	IN	with
respect	NN	respect
to	TO	to
enhancing	VBG	enhance
health	NN	health
system	NN	system
capacity	NN	capacity
and	CC	and
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
mix	NN	mix
of	IN	of
private-public	JJ	private-public
financing	NN	financing
.	SENT	.
Finally	RB	finally
,	,	,
there	EX	there
are	VBP	be
key	JJ	key
trade-offs	NNS	trade-off
that	WDT	that
will	MD	will
continue	VB	continue
to	TO	to
be	VB	be
made	VBN	make
both	CC	both
in	IN	in
terms	NNS	term
of	IN	of
access	NN	access
to	TO	to
testing	NN	testing
and	CC	and
ventilators	NNS	ventilator
which	WDT	which
would	MD	would
benefit	VB	benefit
greatly	RB	greatly
from	IN	from
economic	JJ	economic
appraisal	NN	appraisal
.	SENT	.
In	IN	in
short	JJ	short
,	,	,
health	NN	health
economics	NNS	economics
could	MD	could
-	NN	<unknown>
and	CC	and
we	PP	we
would	MD	would
argue	VB	argue
most	RBS	most
certainly	RB	certainly
should	MD	should
-	NNS	<unknown>
play	VB	play
a	DT	a
much	RB	much
more	RBR	more
prominent	JJ	prominent
role	NN	role
in	IN	in
policy-making	NN	policy-making
as	IN	as
it	PP	it
relates	VBZ	relate
to	TO	to
the	DT	the
current	JJ	current
as	RB	as
well	RB	well
as	IN	as
future	JJ	future
pandemics	NNS	pandemic
.	SENT	.
33542501/	CD	@card@
SARS-CoV-2	NP	<unknown>
variant	NN	variant
evades	VBZ	evade
antibodies	NNS	antibody
whilst	IN	whilst
maintaining	VBG	maintain
fitness	NN	fitness
34107113/	CD	@card@
Changes	NP	Changes
of	IN	of
serum	NN	serum
IL-10	NP	<unknown>
,	,	,
IL-1beta	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
MCP-1	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
,	,	,
IP-10	NP	<unknown>
and	CC	and
IL-4	NN	IL-4
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
Studies	NNS	study
have	VBP	have
shown	VBN	show
that	IN	that
some	DT	some
cytokines	NNS	cytokine
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
elevated	VBN	elevate
.	SENT	.
This	DT	this
study	NN	study
aims	VBZ	aim
to	TO	to
assess	VB	assess
whether	IN	whether
IL-10	NP	<unknown>
,	,	,
IL-1beta	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
MCP-1	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
,	,	,
IP-10	NP	<unknown>
and	CC	and
IL-4	NN	IL-4
serve	VBP	serve
as	IN	as
potential	JJ	potential
diagnostic	JJ	diagnostic
biomarkers	NNS	biomarker
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
above	JJ	above
serum	NN	serum
cytokines	NNS	cytokine
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
and	CC	and
non	JJ	non
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
detected	VBN	detect
by	IN	by
ELISA	NP	Elisa
,	,	,
SARS-CoV-2	NP	<unknown>
IgM	NP	Igm
and	CC	and
IgG	NP	IgG
were	VBD	be
detected	VBN	detect
by	IN	by
chemiluminescence	NN	chemiluminescence
method	NN	method
.	SENT	.
Independent-samples	NP	Independent-samples
Mann-Whitney	NP	Mann-Whitney
U-test	NN	<unknown>
was	VBD	be
utilized	VBN	utilize
to	TO	to
compare	VB	compare
cytokines	NNS	cytokine
levels	NNS	level
in	IN	in
different	JJ	different
groups	NNS	group
and	CC	and
course	NN	course
,	,	,
Levene	NP	Levene
T-test	NP	<unknown>
,	,	,
T'-test	NN	<unknown>
were	VBD	be
utilized	VBN	utilize
to	TO	to
compare	VB	compare
they	PP	they
in	IN	in
different	JJ	different
genders	NNS	gender
,	,	,
and	CC	and
Spearman	NP	Spearman
Correlation	NN	correlation
test	NN	test
was	VBD	be
utilized	VBN	utilize
to	TO	to
analyze	VB	analyze
the	DT	the
correlation	NN	correlation
between	IN	between
the	DT	the
cytokines	NNS	cytokine
levels	NNS	level
with	IN	with
ages	NNS	age
,	,	,
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
and	CC	and
IgM	NP	Igm
.	SENT	.
Serum	NN	serum
levels	NNS	level
of	IN	of
IL-10	NP	<unknown>
,	,	,
IL-1beta	NP	<unknown>
,	,	,
MCP-1	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
and	CC	and
IL-4	NN	IL-4
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
those	DT	those
in	IN	in
non-COVID-19	JJ	<unknown>
patients	NNS	patient
,	,	,
while	IN	while
IL-6	NP	<unknown>
were	VBD	be
only	RB	only
significantly	RB	significantly
higher	JJR	high
than	IN	than
in	IN	in
healthy	JJ	healthy
people	NNS	people
,	,	,
IP-10	NP	<unknown>
were	VBD	be
significantly	RB	significantly
lower	JJR	low
than	IN	than
in	IN	in
other	JJ	other
diseases	NNS	disease
patients	NNS	patient
.	SENT	.
AUCs	NNS	<unknown>
of	IN	of
COVID-19	NP	<unknown>
diagnosed	VBD	diagnose
by	IN	by
IL-10	NP	<unknown>
,	,	,
IL-1beta	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
MCP-1	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
,	,	,
IP-10	NP	<unknown>
and	CC	and
IL-4	NN	IL-4
were	VBD	be
0.735	CD	@card@
,	,	,
0.775	CD	@card@
,	,	,
0.595	CD	@card@
,	,	,
0.821	CD	@card@
,	,	,
0.848	CD	@card@
,	,	,
0.387	CD	@card@
and	CC	and
0.682	CD	@card@
,	,	,
respectively	RB	respectively
.	SENT	.
In	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
'	POS	'
serum	NN	serum
,	,	,
the	DT	the
levels	NNS	level
of	IN	of
IL-10	NP	<unknown>
and	CC	and
MCP-1	NP	<unknown>
of	IN	of
male	JJ	male
had	VBD	have
noticeably	RB	noticeably
higher	JJR	high
than	IN	than
those	DT	those
of	IN	of
female	JJ	female
,	,	,
and	CC	and
all	DT	all
cytokines	NNS	cytokine
were	VBD	be
significantly	RB	significantly
positively	RB	positively
correlated	VBN	correlate
with	IN	with
age	NN	age
,	,	,
IL-1beta	NP	<unknown>
and	CC	and
IL-4	NN	IL-4
were	VBD	be
significantly	RB	significantly
negatively	RB	negatively
correlated	VBN	correlate
with	IN	with
SARS-CoV-2	NP	<unknown>
IgM	NP	Igm
,	,	,
while	IN	while
IL-10	NP	<unknown>
,	,	,
IL-1beta	NP	<unknown>
,	,	,
IL-6	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
and	CC	and
IP-10	NP	<unknown>
were	VBD	be
significantly	RB	significantly
negatively	RB	negatively
correlated	VBN	correlate
with	IN	with
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
.	SENT	.
IL-10	NP	<unknown>
on	IN	on
43-56	CD	@card@
days	NNS	day
were	VBD	be
significantly	RB	significantly
lower	JJR	low
than	IN	than
at	IN	at
29-42	CD	@card@
days	NNS	day
,	,	,
TNF-alpha	NP	TNF-alpha
at	IN	at
15-42	CD	@card@
days	NNS	day
were	VBD	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
at	IN	at
0-14	CD	@card@
days	NNS	day
,	,	,
IP-10	JJ	<unknown>
at	IN	at
0-14	CD	@card@
days	NNS	day
were	VBD	be
the	DT	the
highest	JJS	high
,	,	,
IL-4	NN	IL-4
at	IN	at
29-42	CD	@card@
days	NNS	day
were	VBD	be
significant	JJ	significant
higher	JJR	high
than	IN	than
on	IN	on
0-14	CD	@card@
days	NNS	day
.	SENT	.
The	DT	the
detection	NN	detection
of	IN	of
IL-10	NP	<unknown>
,	,	,
IL-1	JJ	<unknown>
beta	NN	beta
,	,	,
IL-6	NP	<unknown>
,	,	,
MCP-1	NP	<unknown>
,	,	,
TNF-alpha	NP	TNF-alpha
and	CC	and
IL-4	NN	IL-4
would	MD	would
assist	VB	assist
the	DT	the
clinical	JJ	clinical
study	NN	study
of	IN	of
COVID-19	NP	<unknown>
,	,	,
and	CC	and
IP-10	NP	<unknown>
may	MD	may
be	VB	be
the	DT	the
cytokine	NN	<unknown>
`	``	'
of	IN	of
early	JJ	early
elevation	NN	elevation
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
35308830/	CD	@card@
Alloreactivity	NN	Alloreactivity
of	IN	of
Allogeneic	JJ	<unknown>
Mesenchymal	JJ	mesenchymal
Stem/Stromal	JJ	<unknown>
Cells	NNS	cell
and	CC	and
Other	JJ	other
Cellular	NP	Cellular
Therapies	NNS	therapy
:	:	:
A	DT	a
Concise	JJ	concise
Review	NP	Review
Cellular	NP	Cellular
therapies	NNS	therapy
,	,	,
deemed	VBN	deem
live	JJ	live
medicine	NN	medicine
,	,	,
have	VBP	have
brought	VBN	bring
a	DT	a
wave	NN	wave
of	IN	of
new	JJ	new
generation	NN	generation
biological	JJ	biological
therapies	NNS	therapy
to	TO	to
treat	VB	treat
previously	RB	previously
untreatable	JJ	untreatable
diseases	NNS	disease
such	JJ	such
as	IN	as
cancers	NNS	cancer
and	CC	and
degenerative	JJ	degenerative
diseases	NNS	disease
like	IN	like
osteoarthritis	NN	osteoarthritis
.	SENT	.
These	DT	these
cellular	JJ	cellular
therapies	NNS	therapy
have	VBP	have
gained	VBN	gain
significant	JJ	significant
recognition	NN	recognition
in	IN	in
clinical	JJ	clinical
research	NN	research
.	SENT	.
The	DT	the
area	NN	area
has	VBZ	have
been	VBN	be
further	RBR	further
strengthened	VBN	strengthen
with	IN	with
the	DT	the
approval	NN	approval
of	IN	of
Chimeric	JJ	chimeric
Antigen	NN	antigen
Receptor	NN	receptor
added	VBD	add
on	IN	on
T	NN	T
cells	NNS	cell
(	(	(
CAR-T	NP	<unknown>
)	)	)
therapies	NNS	therapy
by	IN	by
the	DT	the
regulatory	JJ	regulatory
authorities	NNS	authority
USA	NP	USA
's	POS	's
Food	NP	Food
and	CC	and
Drugs	NP	Drugs
Administration	NP	Administration
(	(	(
FDA	NP	FDA
)	)	)
,	,	,
European	NP	European
Medical	NP	Medical
Agency	NP	Agency
(	(	(
EMA	NP	EMA
)	)	)
,	,	,
the	DT	the
Australian	JJ	Australian
Therapeutic	JJ	therapeutic
Goods	NP	Goods
Administration	NP	Administration
(	(	(
TGA	NP	TGA
)	)	)
,	,	,
and	CC	and
in	IN	in
many	JJ	many
countries	NNS	country
in	IN	in
2017	CD	@card@
to	TO	to
treat	VB	treat
hematological	JJ	hematological
cancers	NNS	cancer
.	SENT	.
Another	DT	another
milestone	NN	milestone
was	VBD	be
achieved	VBN	achieve
when	WRB	when
allogeneic	JJ	<unknown>
Mesenchymal	JJ	mesenchymal
Stem	NP	Stem
Cell-	NP	<unknown>
(	(	(
MSC-	NP	<unknown>
)	)	)
based	VBN	base
therapy	NN	therapy
was	VBD	be
approved	VBN	approve
by	IN	by
the	DT	the
EMA	NP	EMA
to	TO	to
treat	VB	treat
Chrohn	NP	<unknown>
's	POS	's
disease	NN	disease
in	IN	in
2018	CD	@card@
.	SENT	.
Allogeneic	JJ	<unknown>
donor-derived	JJ	<unknown>
MSC	NP	MSC
therapies	NNS	therapy
in	IN	in
particular	JJ	particular
hold	NN	hold
great	JJ	great
promise	NN	promise
and	CC	and
real	JJ	real
hope	NN	hope
because	IN	because
of	IN	of
their	PP$	their
'	POS	'
off-the	NN	<unknown>
shelf	NN	shelf
'	POS	'
availability	NN	availability
and	CC	and
accessibility	NN	accessibility
for	IN	for
patients	NNS	patient
in	IN	in
need	NN	need
of	IN	of
urgent	JJ	urgent
treatment	NN	treatment
.	SENT	.
So	RB	so
far	RB	far
,	,	,
thousands	NNS	thousand
of	IN	of
clinical	JJ	clinical
trials	NNS	trial
have	VBP	have
explored	VBN	explore
the	DT	the
safety	NN	safety
and	CC	and
efficacy	NN	efficacy
of	IN	of
both	DT	both
autologous	JJ	<unknown>
and	CC	and
allogeneic	JJ	<unknown>
cell	NN	cell
therapies	NNS	therapy
,	,	,
deeming	VBG	deem
them	PP	them
safe	JJ	safe
,	,	,
however	RB	however
with	IN	with
varying	VBG	vary
degrees	NNS	degree
of	IN	of
efficacy	NN	efficacy
.	SENT	.
In	IN	in
the	DT	the
current	JJ	current
pandemic	NN	pandemic
,	,	,
clinical	JJ	clinical
trials	NNS	trial
have	VBP	have
begun	VBN	begin
in	IN	in
many	JJ	many
parts	NNS	part
of	IN	of
the	DT	the
world	NN	world
to	TO	to
treat	VB	treat
severe	JJ	severe
cases	NNS	case
of	IN	of
COVID	NP	<unknown>
with	IN	with
MSCs	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
the	DT	the
risk	NN	risk
of	IN	of
tissue	NN	tissue
rejection	NN	rejection
and	CC	and
the	DT	the
development	NN	development
of	IN	of
undesirable	JJ	undesirable
effects	NNS	effect
due	JJ	due
to	TO	to
alloreactivity	NN	alloreactivity
of	IN	of
allogeneic	JJ	<unknown>
cells	NNS	cell
are	VBP	be
currently	RB	currently
not	RB	not
adequately	RB	adequately
addressed	VBN	address
.	SENT	.
Therefore	RB	therefore
,	,	,
this	DT	this
warrants	NNS	warrant
careful	JJ	careful
investigation	NN	investigation
and	CC	and
detailed	JJ	detailed
reporting	NN	reporting
of	IN	of
such	JJ	such
events	NNS	event
by	IN	by
clinical	JJ	clinical
researchers	NNS	researcher
.	SENT	.
This	DT	this
review	NN	review
aims	VBZ	aim
at	IN	at
discussing	VBG	discuss
the	DT	the
current	JJ	current
landscape	NN	landscape
of	IN	of
approved	VBN	approve
allogeneic	JJ	<unknown>
MSCs	NNS	<unknown>
along	IN	along
with	IN	with
a	DT	a
few	JJ	few
other	JJ	other
cellular	JJ	cellular
therapies	NNS	therapy
.	SENT	.
We	PP	we
explore	VBP	explore
any	DT	any
possible	JJ	possible
reactivity	NN	reactivity
reported	VBD	report
to	TO	to
inform	VB	inform
the	DT	the
readers	NNS	reader
of	IN	of
any	DT	any
safety	NN	safety
concern	NN	concern
and	CC	and
on	IN	on
the	DT	the
efficacy	NN	efficacy
of	IN	of
such	JJ	such
therapies	NNS	therapy
.	SENT	.
33920976/	CD	@card@
The	DT	the
Impact	NN	impact
of	IN	of
Intolerance	NN	intolerance
of	IN	of
Uncertainty	NN	uncertainty
on	IN	on
Negative	JJ	negative
Emotions	NNS	emotion
in	IN	in
COVID-19	NP	<unknown>
:	:	:
Mediation	NP	Mediation
by	IN	by
Pandemic-Focused	NP	<unknown>
Time	NP	Time
and	CC	and
Moderation	NN	moderation
by	IN	by
Perceived	VBN	perceive
Efficacy	NN	efficacy
The	DT	the
COVID-19	NP	<unknown>
global	JJ	global
pandemic	NN	pandemic
has	VBZ	have
resulted	VBN	result
in	IN	in
a	DT	a
large	JJ	large
number	NN	number
of	IN	of
people	NNS	people
suffering	VBG	suffer
from	IN	from
emotional	JJ	emotional
problems	NNS	problem
.	SENT	.
However	RB	however
,	,	,
the	DT	the
mechanisms	NNS	mechanism
by	IN	by
which	WDT	which
intolerance	NN	intolerance
of	IN	of
uncertainty	NN	uncertainty
(	(	(
IU	NP	IU
)	)	)
affects	VBZ	affect
negative	JJ	negative
emotions	NNS	emotion
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
remain	VBP	remain
unclear	JJ	unclear
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
explore	VB	explore
the	DT	the
mediating	VBG	mediate
role	NN	role
of	IN	of
pandemic-focused	JJ	pandemic-focused
time	NN	time
and	CC	and
the	DT	the
moderating	VBG	moderate
role	NN	role
of	IN	of
perceived	VBN	perceive
efficacy	NN	efficacy
in	IN	in
the	DT	the
association	NN	association
between	IN	between
IU	NP	IU
and	CC	and
negative	JJ	negative
emotions	NNS	emotion
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
based	VBN	base
on	IN	on
the	DT	the
uncertainty-time-efficacy-emotion	NN	uncertainty-time-efficacy-emotion
model	NN	model
(	(	(
UTEE	NP	<unknown>
)	)	)
.	SENT	.
1131	CD	@card@
participants	NNS	participant
were	VBD	be
recruited	VBN	recruit
to	TO	to
complete	VB	complete
measures	NNS	measure
of	IN	of
COVID-19	NP	<unknown>
IU	NP	IU
,	,	,
pandemic-focused	JJ	pandemic-focused
time	NN	time
,	,	,
perceived	VBN	perceive
efficacy	NN	efficacy
,	,	,
negative	JJ	negative
emotions	NNS	emotion
and	CC	and
demographic	JJ	demographic
variables	NNS	variable
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
results	NNS	result
showed	VBD	show
that	IN	that
COVID-19	NP	<unknown>
IU	NP	IU
was	VBD	be
significantly	RB	significantly
and	CC	and
positively	RB	positively
associated	VBN	associate
with	IN	with
negative	JJ	negative
emotions	NNS	emotion
,	,	,
and	CC	and
this	DT	this
link	NN	link
could	MD	could
be	VB	be
mediated	VBN	mediate
by	IN	by
pandemic-focused	JJ	pandemic-focused
time	NN	time
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
direct	JJ	direct
effect	NN	effect
of	IN	of
COVID-19	NP	<unknown>
IU	NP	IU
on	IN	on
negative	JJ	negative
emotions	NNS	emotion
was	VBD	be
moderated	VBN	moderate
by	IN	by
perceived	VBN	perceive
efficacy	NN	efficacy
.	SENT	.
Specifically	RB	specifically
,	,	,
the	DT	the
direct	JJ	direct
effect	NN	effect
of	IN	of
COVID-19	NP	<unknown>
IU	NP	IU
on	IN	on
negative	JJ	negative
emotions	NNS	emotion
was	VBD	be
much	RB	much
stronger	JJR	strong
for	IN	for
individuals	NNS	individual
with	IN	with
lower	JJR	low
levels	NNS	level
of	IN	of
perceived	VBN	perceive
efficacy	NN	efficacy
.	SENT	.
The	DT	the
current	JJ	current
study	NN	study
further	RBR	further
extended	VBD	extend
the	DT	the
previous	JJ	previous
integrative	JJ	integrative
uncertainty	NN	uncertainty
tolerance	NN	tolerance
model	NN	model
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
study	NN	study
suggested	VBD	suggest
that	IN	that
policy	NN	policy
makers	NNS	maker
and	CC	and
mental	JJ	mental
health	NN	health
professionals	NNS	professional
should	MD	should
reduce	VB	reduce
the	DT	the
general	JJ	general
public	NN	public
's	POS	's
negative	JJ	negative
emotions	NNS	emotion
during	IN	during
the	DT	the
pandemic	NN	pandemic
through	IN	through
effective	JJ	effective
interventions	NNS	intervention
such	JJ	such
as	IN	as
adjusting	VBG	adjust
COVID-19	NP	<unknown>
IU	NP	IU
,	,	,
shortening	VBG	shorten
pandemic-focused	JJ	pandemic-focused
time	NN	time
and	CC	and
enhancing	VBG	enhance
perceived	VBN	perceive
efficacy	NN	efficacy
.	SENT	.
34630838/	CD	@card@
One	CD	one
year	NN	year
after	IN	after
first	JJ	first
case	NN	case
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Ghana	NP	Ghana
:	:	:
epidemiology	NN	epidemiology
,	,	,
challenges	NNS	challenge
and	CC	and
accomplishments	NNS	accomplishment
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
caused	VBD	cause
by	IN	by
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
has	VBZ	have
affected	VBN	affect
many	JJ	many
lives	NNS	life
,	,	,
health	NN	health
systems	NNS	system
and	CC	and
economies	NNS	economy
across	IN	across
the	DT	the
globe	NN	globe
.	SENT	.
Countries	NNS	country
in	IN	in
both	DT	both
resource-rich	JJ	resource-rich
and	CC	and
poor	JJ	poor
have	VBP	have
equally	RB	equally
been	VBN	be
affected	VBN	affect
.	SENT	.
In	IN	in
Ghana	NP	Ghana
,	,	,
COVID-19	NP	<unknown>
has	VBZ	have
caused	VBN	cause
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
among	IN	among
the	DT	the
populace	NN	populace
.	SENT	.
The	DT	the
first	JJ	first
two	CD	two
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
were	VBD	be
reported	VBN	report
in	IN	in
Ghana	NP	Ghana
in	IN	in
March	NP	March
2020	CD	@card@
.	SENT	.
At	IN	at
the	DT	the
onset	NN	onset
of	IN	of
the	DT	the
pandemic	NN	pandemic
in	IN	in
Ghana	NP	Ghana
,	,	,
there	EX	there
were	VBD	be
challenges	NNS	challenge
in	IN	in
securing	VBG	secure
isolation	NN	isolation
centers	NNS	center
and	CC	and
quarantine	NN	quarantine
facilities	NNS	facility
.	SENT	.
Nonetheless	RB	nonetheless
,	,	,
the	DT	the
government	NN	government
of	IN	of
Ghana	NP	Ghana
put	VBD	put
in	IN	in
place	NN	place
a	DT	a
number	NN	number
of	IN	of
measures	NNS	measure
in	IN	in
line	NN	line
with	IN	with
World	NP	World
Health	NP	Health
Organization	NP	Organization
(	(	(
WHO	WP	who
)	)	)
guidelines	NNS	guideline
,	,	,
to	TO	to
halt	VB	halt
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
virus	NN	virus
.	SENT	.
Some	DT	some
measures	NNS	measure
taken	VBN	take
by	IN	by
the	DT	the
government	NN	government
included	VBD	include
partial	JJ	partial
lockdown	NN	<unknown>
of	IN	of
areas	NNS	area
deemed	VBD	deem
hotspots	NNS	hotspot
for	IN	for
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
virus	NN	virus
.	SENT	.
In	IN	in
April	NP	April
2020	CD	@card@
,	,	,
Ghana	NP	Ghana
was	VBD	be
ranked	VBN	rank
number	NN	number
one	CD	one
among	IN	among
African	JJ	African
countries	NNS	country
in	IN	in
administering	VBG	administer
tests	NNS	test
per	IN	per
million	CD	million
people	NNS	people
,	,	,
because	IN	because
of	IN	of
the	DT	the
effective	JJ	effective
"	``	"
trace	NN	trace
and	CC	and
test	NN	test
"	''	"
approach	NN	approach
.	SENT	.
The	DT	the
government	NN	government
of	IN	of
Ghana	NP	Ghana
also	RB	also
encouraged	VBD	encourage
local	JJ	local
manufacturing	NN	manufacturing
of	IN	of
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
,	,	,
antivirals	NNS	<unknown>
and	CC	and
hand	NN	hand
sanitizers	NNS	<unknown>
to	TO	to
help	VB	help
meet	VB	meet
the	DT	the
demand	NN	demand
of	IN	of
the	DT	the
nation	NN	nation
.	SENT	.
There	EX	there
were	VBD	be
also	RB	also
restrictions	NNS	restriction
on	IN	on
public	JJ	public
gathering	NN	gathering
within	IN	within
the	DT	the
early	JJ	early
parts	NNS	part
of	IN	of
2020	CD	@card@
,	,	,
and	CC	and
these	DT	these
were	VBD	be
eased	VBN	ease
with	IN	with
time	NN	time
.	SENT	.
In	IN	in
February	NP	February
2021	CD	@card@
,	,	,
Ghana	NP	Ghana
became	VBD	become
the	DT	the
first	JJ	first
country	NN	country
to	TO	to
receive	VB	receive
vaccines	NNS	vaccine
through	IN	through
the	DT	the
COVAX	NP	<unknown>
initiative	NN	initiative
with	IN	with
a	DT	a
delivery	NN	delivery
of	IN	of
600,000	CD	@card@
doses	NNS	dose
of	IN	of
Oxford-AstraZeneca	NP	<unknown>
vaccines	NNS	vaccine
.	SENT	.
The	DT	the
efforts	NNS	effort
by	IN	by
Ghana	NP	Ghana
to	TO	to
deal	VB	deal
with	IN	with
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
have	VBP	have
been	VBN	be
commendable	JJ	commendable
.	SENT	.
Not	RB	not
withstanding	VBG	withstand
,	,	,
the	DT	the
adverse	JJ	adverse
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
on	IN	on
public	JJ	public
health	NN	health
in	IN	in
Ghana	NP	Ghana
has	VBZ	have
been	VBN	be
significant	JJ	significant
,	,	,
and	CC	and
there	EX	there
is	VBZ	be
still	RB	still
a	DT	a
lot	NN	lot
to	TO	to
learn	VB	learn
from	IN	from
other	JJ	other
countries	NNS	country
in	IN	in
the	DT	the
sub-region	NN	sub-region
,	,	,
and	CC	and
the	DT	the
world	NN	world
as	IN	as
whole	NN	whole
.	SENT	.
35441967/"Glycans	NP	<unknown>
and	CC	and
Glycosylation	NP	<unknown>
in	IN	in
SARS-COV2	NP	<unknown>
Infection	NN	infection
"	''	"
session	NN	session
at	IN	at
the	DT	the
XVII	NP	XVII
Advanced	NP	Advanced
School	NP	School
in	IN	in
Carbohydrate	NN	carbohydrate
Chemistry	NN	chemistry
,	,	,
Italian	JJ	Italian
Chemical	NP	Chemical
Society	NP	Society
.	SENT	.
July	NP	July
4th	JJ	4th
-7th	NN	<unknown>
2021	CD	@card@
,	,	,
Pontignano	NP	<unknown>
(	(	(
Si	NP	Si
)	)	)
,	,	,
Italy	NP	Italy
34101084/	CD	@card@
Einfluss	JJ	<unknown>
einer	FW	einer
Mund-Nase-Maske	NP	Mund-Nase-Maske
auf	NP	auf
die	VBP	die
objektive	JJ	<unknown>
korperliche	NN	<unknown>
Leistungsfahigkeit	NP	<unknown>
sowie	NP	<unknown>
das	NP	das
subjektive	JJ	<unknown>
Belastungsempfinden	NP	<unknown>
bei	FW	bei
gut-trainierten	NN	<unknown>
,	,	,
gesunden	NP	<unknown>
Jungen	NP	Jungen
Mit	NP	Mit
dieser	NP	<unknown>
Studie	NP	<unknown>
wurden	NN	<unknown>
die	NN	die
Effekte	NP	<unknown>
chirurgischer	NP	chirurgischer
MNS	NP	MNS
auf	NP	auf
die	NN	die
korperliche	NN	<unknown>
Leistungsfahigkeit	NP	<unknown>
sowie	NP	<unknown>
das	NP	das
subjektive	JJ	<unknown>
Belastungsempfinden	NP	<unknown>
bei	FW	bei
trainierten	NN	<unknown>
elfjahrigen	NN	<unknown>
Jungen	NP	Jungen
untersucht	NP	<unknown>
.	SENT	.
Im	NP	Im
aeroben	NP	<unknown>
und	NN	und
aerob-anaeroben	NP	<unknown>
Ubergangsbereich	NP	Ubergangsbereich
fand	NN	<unknown>
sich	NN	<unknown>
keine	NN	<unknown>
Verminderung	NP	<unknown>
der	NP	der
objektiven	NP	<unknown>
Leistungsparameter	NP	Leistungsparameter
.	SENT	.
Allerdings	NP	<unknown>
zeigte	NN	<unknown>
sich	NP	Sich
auf	NP	auf
der	NP	der
maximalen	NP	maximalen
Belastungsstufe	NP	<unknown>
mit	FW	mit
MNS	NP	MNS
eine	NP	Eine
signifikante	NP	<unknown>
Verminderung	NP	<unknown>
der	NP	der
Laufzeit	NP	<unknown>
sowie	NN	<unknown>
eine	NN	<unknown>
signifikante	NN	<unknown>
Erhohung	NP	<unknown>
des	FW	des
subjektiven	NP	<unknown>
Belastungsempfindens	NP	<unknown>
bei	FW	bei
ansonsten	NP	<unknown>
unveranderten	NN	<unknown>
Leistungsparametern	NP	<unknown>
.	SENT	.
Zusammenfassend	NP	<unknown>
beeinflusst	NP	<unknown>
die	VBP	die
Verwendung	NP	<unknown>
chirurgischer	NP	chirurgischer
,,Alltags"-MNS	VBZ	<unknown>
bei	FW	bei
Kindern	NP	<unknown>
die	NN	die
sportlichen	NN	sportlichen
Aktivitaten	NP	<unknown>
nicht	NP	<unknown>
,	,	,
solange	NN	<unknown>
die	NN	die
Belastungen	NP	<unknown>
primar	NP	primar
im	NP	im
aeroben	NP	<unknown>
Intensitatsbereich	NP	Intensitatsbereich
durchgefuhrt	NN	<unknown>
werden	NNS	<unknown>
.	SENT	.
32132521/	CD	@card@
The	NP	The
Effects	NNS	effect
of	IN	of
Social	JJ	social
Support	NN	support
on	IN	on
Sleep	NN	sleep
Quality	NP	Quality
of	IN	of
Medical	NP	Medical
Staff	NP	Staff
Treating	VBG	treat
Patients	NNS	patient
with	IN	with
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
in	IN	in
January	NP	January
and	CC	and
February	NP	February
2020	CD	@card@
in	IN	in
China	NP	China
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
formerly	RB	formerly
known	VBN	know
as	IN	as
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
and	CC	and
2019	CD	@card@
novel	NN	novel
coronavirus	NN	coronavirus
(	(	(
2019-nCoV	NP	<unknown>
)	)	)
,	,	,
was	VBD	be
first	RB	first
identified	VBN	identify
in	IN	in
December	NP	December
2019	CD	@card@
in	IN	in
Wuhan	NP	Wuhan
City	NP	City
,	,	,
China	NP	China
.	SENT	.
Structural	JJ	structural
equation	NN	equation
modeling	NN	modeling
(	(	(
SEM	NP	SEM
)	)	)
is	VBZ	be
a	DT	a
multivariate	JJ	multivariate
analysis	NN	analysis
method	NN	method
to	TO	to
determine	VB	determine
the	DT	the
structural	JJ	structural
relationship	NN	relationship
between	IN	between
measured	JJ	measured
variables	NNS	variable
.	SENT	.
This	DT	this
observational	JJ	observational
study	NN	study
aimed	VBN	aim
to	TO	to
use	VB	use
SEM	NP	SEM
to	TO	to
determine	VB	determine
the	DT	the
effects	NNS	effect
of	IN	of
social	JJ	social
support	NN	support
on	IN	on
sleep	NN	sleep
quality	NN	quality
and	CC	and
function	NN	function
of	IN	of
medical	JJ	medical
staff	NN	staff
who	WP	who
treated	VBD	treat
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
in	IN	in
January	NP	January
and	CC	and
February	NP	February
2020	CD	@card@
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
.	SENT	.
A	DT	a
one-month	JJ	one-month
cross-sectional	JJ	cross-sectional
observational	JJ	observational
study	NN	study
included	VBD	include
180	CD	@card@
medical	JJ	medical
staff	NN	staff
who	WP	who
treated	VBD	treat
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
Levels	NNS	level
of	IN	of
anxiety	NN	anxiety
,	,	,
self-efficacy	NN	self-efficacy
,	,	,
stress	NN	stress
,	,	,
sleep	NN	sleep
quality	NN	quality
,	,	,
and	CC	and
social	JJ	social
support	NN	support
were	VBD	be
measured	VBN	measure
using	VBG	use
the	DT	the
and	CC	and
the	DT	the
Self-Rating	JJ	<unknown>
Anxiety	NN	anxiety
Scale	NP	Scale
(	(	(
SAS	NP	SAS
)	)	)
,	,	,
the	DT	the
General	NP	General
Self-Efficacy	NP	<unknown>
Scale	NP	Scale
(	(	(
GSES	NP	<unknown>
)	)	)
,	,	,
the	DT	the
Stanford	NP	Stanford
Acute	JJ	acute
Stress	NN	stress
Reaction	NN	reaction
(	(	(
SASR	NP	<unknown>
)	)	)
questionnaire	NN	questionnaire
,	,	,
the	DT	the
Pittsburgh	NP	Pittsburgh
Sleep	NN	sleep
Quality	NP	Quality
Index	NP	Index
(	(	(
PSQI	NP	<unknown>
)	)	)
,	,	,
and	CC	and
the	DT	the
Social	NP	Social
Support	NN	support
Rate	NP	Rate
Scale	NP	Scale
(	(	(
SSRS	NP	<unknown>
)	)	)
,	,	,
respectively	RB	respectively
.	SENT	.
Pearson	NP	Pearson
's	POS	's
correlation	NN	correlation
analysis	NN	analysis
and	CC	and
SEM	NP	SEM
identified	VBD	identify
the	DT	the
interactions	NNS	interaction
between	IN	between
these	DT	these
factors	NNS	factor
.	SENT	.
Levels	NNS	level
of	IN	of
social	JJ	social
support	NN	support
for	IN	for
medical	JJ	medical
staff	NN	staff
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
self-efficacy	NN	self-efficacy
and	CC	and
sleep	NN	sleep
quality	NN	quality
and	CC	and
negatively	RB	negatively
associated	VBN	associate
with	IN	with
the	DT	the
degree	NN	degree
of	IN	of
anxiety	NN	anxiety
and	CC	and
stress	NN	stress
.	SENT	.
Levels	NNS	level
of	IN	of
anxiety	NN	anxiety
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
the	DT	the
levels	NNS	level
of	IN	of
stress	NN	stress
,	,	,
which	WDT	which
negatively	RB	negatively
impacted	VBD	impact
self-efficacy	NN	self-efficacy
and	CC	and
sleep	NN	sleep
quality	NN	quality
.	SENT	.
Anxiety	NN	anxiety
,	,	,
stress	NN	stress
,	,	,
and	CC	and
self-efficacy	NN	self-efficacy
were	VBD	be
mediating	VBG	mediate
variables	NNS	variable
associated	VBN	associate
with	IN	with
social	JJ	social
support	NN	support
and	CC	and
sleep	NN	sleep
quality	NN	quality
.	SENT	.
SEM	NP	SEM
showed	VBD	show
that	IN	that
medical	JJ	medical
staff	NN	staff
in	IN	in
China	NP	China
who	WP	who
were	VBD	be
treating	VBG	treat
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
during	IN	during
January	NP	January
and	CC	and
February	NP	February
2020	CD	@card@
had	VBD	have
levels	NNS	level
of	IN	of
anxiety	NN	anxiety
,	,	,
stress	NN	stress
,	,	,
and	CC	and
self-efficacy	NN	self-efficacy
that	WDT	that
were	VBD	be
dependent	JJ	dependent
on	IN	on
sleep	NN	sleep
quality	NN	quality
and	CC	and
social	JJ	social
support	NN	support
.	SENT	.
33418280/	CD	@card@
Comment	NN	comment
on	IN	on
"	``	"
Intoxication	NN	intoxication
by	IN	by
hand	NN	hand
sanitizer	NN	<unknown>
due	JJ	due
to	TO	to
delirium	NN	delirium
after	IN	after
infectious	JJ	infectious
spondylitis	NN	spondylitis
surgery	NN	surgery
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
A	DT	a
case	NN	case
report	NN	report
and	CC	and
literature	NN	literature
review	NN	review
"	``	"
34178332/	CD	@card@
Type	NN	type
1	CD	@card@
diabetic	JJ	diabetic
manifestations	NNS	manifestation
in	IN	in
a	DT	a
young	JJ	young
man	NN	man
triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
COVID-19	NP	<unknown>
could	MD	could
potentially	RB	potentially
lead	VB	lead
to	TO	to
the	DT	the
progression	NN	progression
of	IN	of
the	DT	the
course	NN	course
of	IN	of
undiagnosed	JJ	undiagnosed
type	NN	type
1	CD	@card@
diabetes	NN	diabetes
in	IN	in
an	DT	an
infected	JJ	infected
individuals	NNS	individual
.	SENT	.
COVID-19	NP	<unknown>
could	MD	could
potentially	RB	potentially
lead	VB	lead
to	TO	to
the	DT	the
progression	NN	progression
of	IN	of
the	DT	the
course	NN	course
of	IN	of
undiagnosed	JJ	undiagnosed
type	NN	type
1	CD	@card@
diabetes	NN	diabetes
in	IN	in
an	DT	an
infected	JJ	infected
individuals	NNS	individual
.	SENT	.
33433382/	CD	@card@
The	DT	the
prevalence	NN	prevalence
of	IN	of
post-traumatic	JJ	post-traumatic
stress	NN	stress
disorder	NN	disorder
related	VBN	relate
symptoms	NNS	symptom
in	IN	in
Coronavirus	NP	<unknown>
outbreaks	NNS	outbreak
:	:	:
A	DT	a
systematic-review	NN	systematic-review
and	CC	and
meta-analysis	NN	meta-analysis
Post-Traumatic	JJ	post-traumatic
stress	NN	stress
disorder	NN	disorder
is	VBZ	be
common	JJ	common
in	IN	in
coronavirus	NN	coronavirus
outbreaks	NNS	outbreak
.	SENT	.
Mental	JJ	mental
care	NN	care
is	VBZ	be
important	JJ	important
during	IN	during
the	DT	the
present	JJ	present
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
This	DT	this
study	NN	study
showed	VBD	show
about	RB	about
3	CD	@card@
in	IN	in
every	DT	every
10	CD	@card@
survivors	NNS	survivor
of	IN	of
Coronavirus	NP	<unknown>
had	VBD	have
PTSD	JJ	<unknown>
symptoms	NNS	symptom
.	SENT	.
This	DT	this
study	NN	study
showed	VBD	show
about	RB	about
2	CD	@card@
in	IN	in
every	DT	every
10	CD	@card@
healthcare	NN	<unknown>
workers	NNS	worker
had	VBD	have
PTSD	JJ	<unknown>
symptoms	NNS	symptom
.	SENT	.
:	:	:
Infectious	JJ	infectious
disease	NN	disease
outbreaks	NNS	outbreak
affect	VBP	affect
physical	JJ	physical
and	CC	and
mental	JJ	mental
health	NN	health
of	IN	of
humans	NNS	human
worldwide	RB	worldwide
.	SENT	.
Studies	NNS	study
showed	VBD	show
that	IN	that
the	DT	the
prevalence	NN	prevalence
of	IN	of
post-traumatic	JJ	post-traumatic
stress	NN	stress
disorder	NN	disorder
(	(	(
PTSD	JJ	<unknown>
)	)	)
symptoms	NNS	symptom
increased	VBN	increase
in	IN	in
these	DT	these
conditions	NNS	condition
.	SENT	.
This	DT	this
systematic-review	NN	systematic-review
and	CC	and
meta-analysis	NN	meta-analysis
aimed	VBN	aim
to	TO	to
assess	VB	assess
the	DT	the
prevalence	NN	prevalence
of	IN	of
PTSD	JJ	<unknown>
related	JJ	related
symptoms	NNS	symptom
in	IN	in
coronavirus	NN	coronavirus
outbreaks	NNS	outbreak
.	SENT	.
:	:	:
Systematic	JJ	systematic
search	NN	search
of	IN	of
literature	NN	literature
was	VBD	be
conducted	VBN	conduct
in	IN	in
Scopus	NP	Scopus
,	,	,
Embase	NP	<unknown>
,	,	,
PubMed	NP	<unknown>
,	,	,
and	CC	and
Web	NP	Web
of	IN	of
Science	NP	Science
.	SENT	.
Google	NP	<unknown>
Scholar	NN	scholar
and	CC	and
Grey	NP	Grey
literature	NN	literature
including	VBG	include
conference	NN	conference
proceedings	NNS	proceeding
were	VBD	be
also	RB	also
checked	VBN	check
.	SENT	.
Published	VBN	publish
articles	NNS	article
from	IN	from
November	NP	November
1	CD	@card@
,	,	,
2012	CD	@card@
until	IN	until
May	NP	May
18	CD	@card@
,	,	,
2020	CD	@card@
were	VBD	be
searched	VBN	search
.	SENT	.
Subgroup	NN	subgroup
analysis	NN	analysis
,	,	,
meta-regression	NN	meta-regression
and	CC	and
sensitivity	NN	sensitivity
analysis	NN	analysis
were	VBD	be
also	RB	also
conducted	VBN	conduct
to	TO	to
assess	VB	assess
heterogeneity	NN	heterogeneity
.	SENT	.
:	:	:
We	PP	we
found	VBD	find
38	CD	@card@
articles	NNS	article
with	IN	with
19,428	CD	@card@
individuals	NNS	individual
met	VBD	meet
the	DT	the
eligibility	NN	eligibility
criteria	NNS	criterion
.	SENT	.
Of	IN	of
these	DT	these
papers	NNS	paper
,	,	,
35	CD	@card@
studies	NNS	study
were	VBD	be
included	VBN	include
in	IN	in
meta-analysis	NN	meta-analysis
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
PTSD	JJ	<unknown>
symptoms	NNS	symptom
was	VBD	be
estimated	VBN	estimate
to	TO	to
be	VB	be
about	RB	about
18	CD	@card@
%	NN	%
(	(	(
95%CI	NP	<unknown>
:	:	:
15	CD	@card@
%	NN	%
to	TO	to
20	CD	@card@
%	NN	%
)	)	)
.	SENT	.
These	DT	these
symptoms	NNS	symptom
were	VBD	be
more	RBR	more
frequent	JJ	frequent
in	IN	in
cohort	NN	cohort
studies	NNS	study
(	(	(
29	CD	@card@
%	NN	%
)	)	)
compared	VBN	compare
to	TO	to
cross-sectional	JJ	cross-sectional
(	(	(
15	CD	@card@
%	NN	%
)	)	)
and	CC	and
case-control	NN	case-control
(	(	(
11	CD	@card@
%	NN	%
)	)	)
studies	NNS	study
.	SENT	.
Prevalence	NN	prevalence
rates	NNS	rate
of	IN	of
PTSD	JJ	<unknown>
symptoms	NNS	symptom
in	IN	in
MERS	NP	<unknown>
(	(	(
36	CD	@card@
%	NN	%
)	)	)
outbreaks	NNS	outbreak
were	VBD	be
higher	JJR	high
than	IN	than
SARS	NP	<unknown>
(	(	(
18	CD	@card@
%	NN	%
)	)	)
and	CC	and
COVID-19	NP	<unknown>
(	(	(
9	CD	@card@
%	NN	%
)	)	)
outbreaks	NNS	outbreak
.	SENT	.
Meta-regression	NP	<unknown>
showed	VBD	show
that	IN	that
the	DT	the
geographical	JJ	geographical
location	NN	location
of	IN	of
study	NN	study
was	VBD	be
the	DT	the
source	NN	source
of	IN	of
heterogeneity	NN	heterogeneity
(	(	(
R2	NP	<unknown>
:	:	:
19.8	CD	@card@
%	NN	%
,	,	,
P-value	NP	P-value
:	:	:
0.003	LS	@card@
)	)	)
.	SENT	.
Meta-analysis	NP	Meta-analysis
reported	VBD	report
that	IN	that
about	IN	about
three	CD	three
in	IN	in
every	DT	every
ten	CD	ten
survivors	NNS	survivor
of	IN	of
coronavirus	NN	coronavirus
infection	NN	infection
,	,	,
about	RB	about
two	CD	two
in	IN	in
every	DT	every
ten	CD	ten
healthcare	NN	<unknown>
workers	NNS	worker
,	,	,
and	CC	and
about	RB	about
one	CD	one
in	IN	in
every	DT	every
ten	CD	ten
individuals	NNS	individual
of	IN	of
general	JJ	general
population	NN	population
experienced	VBD	experience
PTSD	JJ	<unknown>
symptoms	NNS	symptom
in	IN	in
outbreaks	NNS	outbreak
.	SENT	.
:	:	:
PTSD	NNS	<unknown>
cannot	MD	can
be	VB	be
objectively	RB	objectively
assessed	VBN	assess
and	CC	and
this	DT	this
can	MD	can
lead	VB	lead
to	TO	to
information	NN	information
bias	NN	bias
of	IN	of
included	VBN	include
studies	NNS	study
.	SENT	.
:	:	:
PTSD	NN	<unknown>
symptoms	NNS	symptom
are	VBP	be
shown	VBN	show
to	TO	to
be	VB	be
common	JJ	common
in	IN	in
coronavirus	NN	coronavirus
outbreaks	NNS	outbreak
.	SENT	.
Mental	JJ	mental
care	NN	care
should	MD	should
be	VB	be
,	,	,
therefore	RB	therefore
,	,	,
considered	VBN	consider
in	IN	in
the	DT	the
present	JJ	present
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
35332270/	CD	@card@
Clotting	VBG	clot
and	CC	and
SARS-CoV-2	JJ	<unknown>
entry	NN	entry
An	DT	an
in	IN	in
vitro	NN	<unknown>
study	NN	study
shows	VBZ	show
that	DT	that
activated	VBN	activate
coagulation	NN	coagulation
factors	NNS	factor
can	MD	can
promote	VB	promote
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
by	IN	by
cleaving	VBG	cleave
spike	NN	spike
.	SENT	.
32708803/	CD	@card@
Deploying	VBG	deploy
Machine	NN	machine
and	CC	and
Deep	JJ	deep
Learning	VBG	learn
Models	NNS	model
for	IN	for
Efficient	JJ	efficient
Data-Augmented	JJ	<unknown>
Detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
Infections	NNS	infection
This	DT	this
generation	NN	generation
faces	VBZ	face
existential	JJ	existential
threats	NNS	threat
because	IN	because
of	IN	of
the	DT	the
global	JJ	global
assault	NN	assault
of	IN	of
the	DT	the
novel	JJ	novel
Corona	NP	Corona
virus	NN	virus
2019	CD	@card@
(	(	(
i.e.	FW	i.e.
,	,	,
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
With	IN	with
more	JJR	more
than	IN	than
thirteen	CD	thirteen
million	CD	million
infected	JJ	infected
and	CC	and
nearly	RB	nearly
600000	CD	@card@
fatalities	NNS	fatality
in	IN	in
188	CD	@card@
countries/regions	NNS	countries/region
,	,	,
COVID-19	NP	<unknown>
is	VBZ	be
the	DT	the
worst	JJS	bad
calamity	NN	calamity
since	IN	since
the	DT	the
World	NP	World
War	NP	War
II	NP	II
.	SENT	.
These	DT	these
misfortunes	NNS	misfortune
are	VBP	be
traced	VBN	trace
to	TO	to
various	JJ	various
reasons	NNS	reason
,	,	,
including	VBG	include
late	JJ	late
detection	NN	detection
of	IN	of
latent	JJ	latent
or	CC	or
asymptomatic	JJ	asymptomatic
carriers	NNS	carrier
,	,	,
migration	NN	migration
,	,	,
and	CC	and
inadequate	JJ	inadequate
isolation	NN	isolation
of	IN	of
infected	JJ	infected
people	NNS	people
.	SENT	.
This	DT	this
makes	VBZ	make
detection	NN	detection
,	,	,
containment	NN	containment
,	,	,
and	CC	and
mitigation	NN	mitigation
global	JJ	global
priorities	NNS	priority
to	TO	to
contain	VB	contain
exposure	NN	exposure
via	IN	via
quarantine	NN	quarantine
,	,	,
lockdowns	NNS	lockdown
,	,	,
work/stay	NN	<unknown>
at	IN	at
home	NN	home
,	,	,
and	CC	and
social	JJ	social
distancing	NN	distancing
that	WDT	that
are	VBP	be
focused	VBN	focus
on	IN	on
"	``	"
flattening	VBG	flatten
the	DT	the
curve	NN	curve
"	''	"
.	SENT	.
While	IN	while
medical	JJ	medical
and	CC	and
healthcare	NN	<unknown>
givers	NNS	giver
are	VBP	be
at	IN	at
the	DT	the
frontline	NN	frontline
in	IN	in
the	DT	the
battle	NN	battle
against	IN	against
COVID-19	NP	<unknown>
,	,	,
it	PP	it
is	VBZ	be
a	DT	a
crusade	NN	crusade
for	IN	for
all	DT	all
of	IN	of
humanity	NN	humanity
.	SENT	.
Meanwhile	RB	meanwhile
,	,	,
machine	NN	machine
and	CC	and
deep	JJ	deep
learning	VBG	learn
models	NNS	model
have	VBP	have
been	VBN	be
revolutionary	JJ	revolutionary
across	IN	across
numerous	JJ	numerous
domains	NNS	domain
and	CC	and
applications	NNS	application
whose	WP$	whose
potency	NN	potency
have	VBP	have
been	VBN	be
exploited	VBN	exploit
to	TO	to
birth	VB	birth
numerous	JJ	numerous
state-of-the-art	JJ	state-of-the-art
technologies	NNS	technology
utilised	VBN	utilise
in	IN	in
disease	NN	disease
detection	NN	detection
,	,	,
diagnoses	NNS	diagnosis
,	,	,
and	CC	and
treatment	NN	treatment
.	SENT	.
Despite	IN	despite
these	DT	these
potentials	NNS	potential
,	,	,
machine	NN	machine
and	CC	and
,	,	,
particularly	RB	particularly
,	,	,
deep	JJ	deep
learning	NN	learning
models	NNS	model
are	VBP	be
data	NNS	datum
sensitive	JJ	sensitive
,	,	,
because	IN	because
their	PP$	their
effectiveness	NN	effectiveness
depends	VBZ	depend
on	IN	on
availability	NN	availability
and	CC	and
reliability	NN	reliability
of	IN	of
data	NNS	datum
.	SENT	.
The	DT	the
unavailability	NN	unavailability
of	IN	of
such	JJ	such
data	NNS	datum
hinders	VBZ	hinder
efforts	NNS	effort
of	IN	of
engineers	NNS	engineer
and	CC	and
computer	NN	computer
scientists	NNS	scientist
to	TO	to
fully	RB	fully
contribute	VB	contribute
to	TO	to
the	DT	the
ongoing	JJ	ongoing
assault	NN	assault
against	IN	against
COVID-19	NP	<unknown>
.	SENT	.
Faced	VBN	face
with	IN	with
a	DT	a
calamity	NN	calamity
on	IN	on
one	CD	one
side	NN	side
and	CC	and
absence	NN	absence
of	IN	of
reliable	JJ	reliable
data	NNS	datum
on	IN	on
the	DT	the
other	JJ	other
,	,	,
this	DT	this
study	NN	study
presents	VBZ	present
two	CD	two
data-augmentation	NN	data-augmentation
models	NNS	model
to	TO	to
enhance	VB	enhance
learnability	NN	learnability
of	IN	of
the	DT	the
Convolutional	JJ	convolutional
Neural	JJ	neural
Network	NP	Network
(	(	(
CNN	NP	CNN
)	)	)
and	CC	and
the	DT	the
Convolutional	JJ	convolutional
Long	NP	Long
Short-Term	JJ	short-term
Memory	NP	Memory
(ConvLSTM)-based	JJ	<unknown>
deep	JJ	deep
learning	NN	learning
models	NNS	model
(	(	(
DADLMs	NP	<unknown>
)	)	)
and	CC	and
,	,	,
by	IN	by
doing	VBG	do
so	RB	so
,	,	,
boost	VB	boost
the	DT	the
accuracy	NN	accuracy
of	IN	of
COVID-19	NP	<unknown>
detection	NN	detection
.	SENT	.
Experimental	JJ	experimental
results	NNS	result
reveal	VBP	reveal
improvement	NN	improvement
in	IN	in
terms	NNS	term
of	IN	of
accuracy	NN	accuracy
of	IN	of
detection	NN	detection
,	,	,
logarithmic	JJ	logarithmic
loss	NN	loss
,	,	,
and	CC	and
testing	VBG	test
time	NN	time
relative	JJ	relative
to	TO	to
DLMs	NP	<unknown>
devoid	JJ	devoid
of	IN	of
such	JJ	such
data	NNS	datum
augmentation	NN	augmentation
.	SENT	.
Furthermore	RB	furthermore
,	,	,
average	JJ	average
increases	NNS	increase
of	IN	of
4	CD	@card@
%	NN	%
to	TO	to
11	CD	@card@
%	NN	%
in	IN	in
COVID-19	NP	<unknown>
detection	NN	detection
accuracy	NN	accuracy
are	VBP	be
reported	VBN	report
in	IN	in
favour	NN	favour
of	IN	of
the	DT	the
proposed	VBN	propose
data-augmented	JJ	data-augmented
deep	JJ	deep
learning	NN	learning
models	NNS	model
relative	JJ	relative
to	TO	to
the	DT	the
machine	NN	machine
learning	VBG	learn
techniques	NNS	technique
.	SENT	.
Therefore	RB	therefore
,	,	,
the	DT	the
proposed	VBN	propose
algorithm	NN	algorithm
is	VBZ	be
effective	JJ	effective
in	IN	in
performing	VBG	perform
a	DT	a
rapid	JJ	rapid
and	CC	and
consistent	JJ	consistent
Corona	NP	Corona
virus	NN	virus
diagnosis	NN	diagnosis
that	WDT	that
is	VBZ	be
primarily	RB	primarily
aimed	VBN	aim
at	IN	at
assisting	VBG	assist
clinicians	NNS	clinician
in	IN	in
making	VBG	make
accurate	JJ	accurate
identification	NN	identification
of	IN	of
the	DT	the
virus	NN	virus
.	SENT	.
34405427/	CD	@card@
Changes	NP	Changes
in	IN	in
antibiotic	NN	antibiotic
prescribing	VBG	prescribe
following	VBG	follow
COVID-19	JJ	<unknown>
restrictions	NNS	restriction
:	:	:
Lessons	NNS	lesson
for	IN	for
post-pandemic	JJ	post-pandemic
antibiotic	JJ	antibiotic
stewardship	NN	stewardship
Public	JJ	public
health	NN	health
responses	NNS	response
to	TO	to
reduce	VB	reduce
SARS-CoV-2	NP	<unknown>
transmission	NN	transmission
have	VBP	have
profoundly	RB	profoundly
affected	VBN	affect
the	DT	the
epidemiology	NN	epidemiology
and	CC	and
management	NN	management
of	IN	of
other	JJ	other
infections	NNS	infection
.	SENT	.
We	PP	we
examined	VBD	examine
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
restrictions	NNS	restriction
on	IN	on
antibiotic	NN	antibiotic
dispensing	VBG	dispense
in	IN	in
Australia	NP	Australia
.	SENT	.
We	PP	we
used	VBD	use
national	JJ	national
claims	NNS	claim
data	NNS	datum
to	TO	to
investigate	VB	investigate
antibiotic	JJ	antibiotic
dispensing	VBG	dispense
trends	NNS	trend
from	IN	from
November	NP	November
2015	CD	@card@
to	TO	to
October	NP	October
2020	CD	@card@
and	CC	and
whether	IN	whether
changes	NNS	change
reflected	VBD	reflect
reductions	NNS	reduction
in	IN	in
primary	JJ	primary
care	NN	care
consultations	NNS	consultation
.	SENT	.
We	PP	we
used	VBD	use
interrupted	JJ	interrupted
time	NN	time
series	NN	series
analysis	NN	analysis
to	TO	to
quantify	VB	quantify
changes	NNS	change
in	IN	in
monthly	JJ	monthly
antibiotic	NN	antibiotic
dispensing	VBG	dispense
and	CC	and
face-to-face	JJ	face-to-face
and	CC	and
telehealth	JJ	<unknown>
GP	NN	GP
consultations	NNS	consultation
and	CC	and
examined	VBN	examine
changes	NNS	change
by	IN	by
recipient	JJ	recipient
age	NN	age
,	,	,
pharmacy	NN	pharmacy
State	NN	state
and	CC	and
prescriber	NN	prescriber
specialty	NN	specialty
.	SENT	.
Over	IN	over
the	DT	the
study	NN	study
period	NN	period
,	,	,
an	DT	an
estimated	VBN	estimate
19	CD	@card@
921	CD	@card@
370	CD	@card@
people	NNS	people
had	VBD	have
125	CD	@card@
495	CD	@card@
137	CD	@card@
antibiotic	JJ	antibiotic
dispensings	NNS	dispensing
,	,	,
71	CD	@card@
%	NN	%
prescribed	VBN	prescribe
by	IN	by
GPs	NNS	GP
.	SENT	.
Following	VBG	follow
COVID-19	NP	<unknown>
restrictions	NNS	restriction
,	,	,
we	PP	we
observed	VBD	observe
a	DT	a
sustained	VBN	sustain
36	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
33-40	CD	@card@
%	NN	%
)	)	)
reduction	NN	reduction
in	IN	in
antibiotic	JJ	antibiotic
dispensings	NNS	dispensing
from	IN	from
April	NP	April
2020	CD	@card@
.	SENT	.
Antibiotics	NNS	antibiotic
recommended	VBN	recommend
for	IN	for
managing	VBG	manage
respiratory	JJ	respiratory
tract	NN	tract
infections	NNS	infection
showed	VBD	show
large	JJ	large
reductions	NNS	reduction
(	(	(
range	NN	range
51-69	CD	@card@
%	NN	%
)	)	)
,	,	,
whereas	IN	whereas
those	DT	those
recommended	VBN	recommend
for	IN	for
non-respiratory	JJ	non-respiratory
infections	NNS	infection
were	VBD	be
unchanged	JJ	unchanged
.	SENT	.
Dispensings	NNS	Dispensing
prescribed	VBN	prescribe
by	IN	by
GPs	NNS	GP
decreased	VBN	decrease
from	IN	from
63.5	CD	@card@
per	IN	per
1000	CD	@card@
population	NN	population
for	IN	for
April-October	NP	April-October
2019	CD	@card@
to	TO	to
37.0	CD	@card@
per	IN	per
1000	CD	@card@
for	IN	for
April-October	NP	April-October
2020	CD	@card@
.	SENT	.
Total	JJ	total
GP	NN	GP
consultation	NN	consultation
rates	NNS	rate
remained	VBD	remain
stable	JJ	stable
,	,	,
but	CC	but
from	IN	from
April	NP	April
2020	CD	@card@
,	,	,
31	CD	@card@
%	NN	%
of	IN	of
consultations	NNS	consultation
were	VBD	be
telehealth	JJ	<unknown>
.	SENT	.
In	IN	in
a	DT	a
setting	NN	setting
with	IN	with
a	DT	a
low	JJ	low
COVID-19	NP	<unknown>
incidence	NN	incidence
,	,	,
restrictions	NNS	restriction
were	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
substantial	JJ	substantial
reduction	NN	reduction
in	IN	in
community	NN	community
dispensings	NNS	dispensing
of	IN	of
antibiotics	NNS	antibiotic
primarily	RB	primarily
used	VBN	use
to	TO	to
treat	VB	treat
respiratory	JJ	respiratory
infections	NNS	infection
,	,	,
coincident	JJ	coincident
with	IN	with
reported	VBN	report
reductions	NNS	reduction
in	IN	in
respiratory	JJ	respiratory
viral	JJ	viral
infections	NNS	infection
.	SENT	.
Our	PP$	our
findings	NNS	finding
are	VBP	be
informative	JJ	informative
for	IN	for
post-pandemic	JJ	post-pandemic
antimicrobial	JJ	antimicrobial
stewardship	NN	stewardship
and	CC	and
highlight	VB	highlight
the	DT	the
potential	NN	potential
to	TO	to
reduce	VB	reduce
inappropriate	JJ	inappropriate
prescribing	VBG	prescribe
by	IN	by
GPs	NNS	GP
and	CC	and
specialists	NNS	specialist
for	IN	for
respiratory	JJ	respiratory
viral	JJ	viral
infections	NNS	infection
.	SENT	.
33768363/	CD	@card@
COVID-19	NP	<unknown>
,	,	,
a	DT	a
critical	JJ	critical
juncture	NN	juncture
in	IN	in
China	NP	China
's	POS	's
wildlife	NN	wildlife
protection	NN	protection
?	SENT	?
The	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
has	VBZ	have
called	VBN	call
into	IN	into
question	NN	question
the	DT	the
utilitarianism-oriented	JJ	utilitarianism-oriented
human-wildlife	NN	human-wildlife
relations	NNS	relation
and	CC	and
the	DT	the
legitimacy	NN	legitimacy
of	IN	of
wildlife	NN	wildlife
protection	NN	protection
regime	NN	regime
in	IN	in
China	NP	China
.	SENT	.
The	DT	the
pandemic	NN	pandemic
has	VBZ	have
triggered	VBN	trigger
significant	JJ	significant
,	,	,
swift	JJ	swift
,	,	,
and	CC	and
encompassing	VBG	encompass
changes	NNS	change
in	IN	in
policies	NNS	policy
.	SENT	.
Drawing	VBG	draw
on	IN	on
insights	NNS	insight
from	IN	from
historical	JJ	historical
institutionalism	NN	institutionalism
,	,	,
we	PP	we
argue	VBP	argue
that	IN	that
COVID-19	NP	<unknown>
constitutes	VBZ	constitute
a	DT	a
critical	JJ	critical
juncture	NN	juncture
in	IN	in
China	NP	China
's	POS	's
wildlife	NN	wildlife
protection	NN	protection
policy	NN	policy
.	SENT	.
32539647/	CD	@card@
Inhaled	VBD	inhale
nitric	JJ	nitric
oxide	NN	oxide
treatment	NN	treatment
in	IN	in
spontaneously	RB	spontaneously
breathing	VBG	breathe
COVID-19	NP	<unknown>
patients	NNS	patient
35145444/	CD	@card@
Socioeconomic	JJ	socioeconomic
and	CC	and
Psychosocial	JJ	psychosocial
Adversities	NNS	adversity
Experienced	VBN	experience
by	IN	by
Freelancers	NNS	freelancer
Working	VBG	work
in	IN	in
the	DT	the
UK	NP	UK
Cultural	JJ	cultural
Sector	NN	sector
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
A	DT	a
Qualitative	JJ	qualitative
Study	NN	study
There	EX	there
are	VBP	be
concerns	NNS	concern
that	IN	that
the	DT	the
socioeconomic	JJ	socioeconomic
consequences	NNS	consequence
of	IN	of
COVID-19	NP	<unknown>
,	,	,
including	VBG	include
unemployment	NN	unemployment
and	CC	and
financial	JJ	financial
insecurity	NN	insecurity
,	,	,
are	VBP	be
having	VBG	have
adverse	JJ	adverse
effects	NNS	effect
on	IN	on
the	DT	the
mental	JJ	mental
wellbeing	NN	wellbeing
of	IN	of
the	DT	the
population	NN	population
.	SENT	.
One	CD	one
group	NN	group
particularly	RB	particularly
vulnerable	JJ	vulnerable
to	TO	to
socioeconomic	JJ	socioeconomic
adversity	NN	adversity
during	IN	during
this	DT	this
period	NN	period
are	VBP	be
those	DT	those
employed	VBN	employ
freelance	NN	freelance
within	IN	within
the	DT	the
cultural	JJ	cultural
industry	NN	industry
.	SENT	.
Many	JJ	many
workers	NNS	worker
in	IN	in
the	DT	the
sector	NN	sector
were	VBD	be
already	RB	already
subject	JJ	subject
to	TO	to
income	NN	income
instability	NN	instability
,	,	,
erratic	JJ	erratic
work	NN	work
schedules	NNS	schedule
and	CC	and
a	DT	a
lack	NN	lack
of	IN	of
economic	JJ	economic
security	NN	security
before	IN	before
the	DT	the
pandemic	NN	pandemic
,	,	,
and	CC	and
it	PP	it
is	VBZ	be
possible	JJ	possible
that	IN	that
COVID-19	NP	<unknown>
may	MD	may
exacerbate	VB	exacerbate
pre-existing	VBG	pre-exist
economic	JJ	economic
precarity	NN	<unknown>
.	SENT	.
Through	IN	through
interviews	NNS	interview
with	IN	with
20	CD	@card@
freelancers	NNS	freelancer
working	VBG	work
within	IN	within
the	DT	the
performing	VBG	perform
arts	NNS	art
,	,	,
visual	JJ	visual
arts	NNS	art
,	,	,
and	CC	and
film	NN	film
and	CC	and
television	NN	television
industries	NNS	industry
,	,	,
this	DT	this
article	NN	article
explores	VBZ	explore
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
their	PP$	their
working	VBG	work
lives	NNS	life
.	SENT	.
Findings	NNS	finding
suggest	VBP	suggest
the	DT	the
pandemic	NN	pandemic
is	VBZ	be
affecting	VBG	affect
the	DT	the
psychological	JJ	psychological
wellbeing	NN	wellbeing
of	IN	of
freelancers	NNS	freelancer
through	IN	through
employment	NN	employment
loss	NN	loss
,	,	,
financial	JJ	financial
instability	NN	instability
and	CC	and
work	NN	work
dissonance	NN	dissonance
,	,	,
and	CC	and
illustrates	VBZ	illustrate
the	DT	the
need	NN	need
for	IN	for
urgent	JJ	urgent
economic	JJ	economic
and	CC	and
psychosocial	JJ	psychosocial
support	NN	support
for	IN	for
those	DT	those
employed	VBN	employ
within	IN	within
the	DT	the
cultural	JJ	cultural
sector	NN	sector
.	SENT	.
34132326/	CD	@card@
On	IN	on
the	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
as	IN	as
a	DT	a
proposed	VBN	propose
instrumental	JJ	instrumental
variable	JJ	variable
Dimitris	NP	<unknown>
and	CC	and
Platt	NP	Platt
(	(	(
Am	NP	Am
J	NP	J
Epidemiol	NP	<unknown>
.	SENT	.
XXXX	NP	xxxx
;	:	;
XXX(XX):XXXX-XXXX)	JJ	<unknown>
take	NN	take
on	IN	on
the	DT	the
challenging	JJ	challenging
topic	NN	topic
of	IN	of
using	VBG	use
"	``	"
shocks	NNS	shock
"	''	"
such	JJ	such
as	IN	as
the	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
as	IN	as
instrumental	JJ	instrumental
variables	NNS	variable
to	TO	to
study	VB	study
the	DT	the
effect	NN	effect
of	IN	of
some	DT	some
exposure	NN	exposure
on	IN	on
some	DT	some
outcome	NN	outcome
.	SENT	.
Evoking	VBG	evoke
our	PP$	our
recent	JJ	recent
lived	VBN	live
experiences	NNS	experience
,	,	,
they	PP	they
conclude	VBP	conclude
that	IN	that
the	DT	the
assumptions	NNS	assumption
necessary	JJ	necessary
for	IN	for
an	DT	an
instrumental	JJ	instrumental
variable	JJ	variable
analysis	NN	analysis
will	MD	will
often	RB	often
be	VB	be
violated	VBN	violate
and	CC	and
therefore	RB	therefore
strongly	RB	strongly
caution	VBP	caution
against	IN	against
such	JJ	such
analyses	NNS	analysis
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
build	VBP	build
upon	IN	upon
this	DT	this
warranted	VBN	warrant
caution	NN	caution
while	IN	while
acknowledging	VBG	acknowledge
that	IN	that
such	JJ	such
analyses	NNS	analysis
may	MD	may
still	RB	still
be	VB	be
pursued	VBN	pursue
and	CC	and
conducted	VBN	conduct
.	SENT	.
We	PP	we
discuss	VBP	discuss
strategies	NNS	strategy
for	IN	for
evaluating	VBG	evaluate
or	CC	or
reasoning	VBG	reason
about	RB	about
when	WRB	when
such	PDT	such
an	DT	an
analysis	NN	analysis
may	MD	may
be	VB	be
clearly	RB	clearly
inappropriate	JJ	inappropriate
for	IN	for
a	DT	a
given	VBN	give
research	NN	research
question	NN	question
,	,	,
as	RB	as
well	RB	well
as	IN	as
strategies	NNS	strategy
for	IN	for
interpreting	VBG	interpret
study	NN	study
findings	NNS	finding
with	IN	with
especial	JJ	especial
attention	NN	attention
to	TO	to
incorporating	VBG	incorporate
plausible	JJ	plausible
sources	NNS	source
of	IN	of
bias	NN	bias
in	IN	in
any	DT	any
conclusions	NNS	conclusion
drawn	VBN	draw
from	IN	from
a	DT	a
given	VBN	give
finding	NN	finding
.	SENT	.
34867130/	CD	@card@
ACE2	NP	<unknown>
Peptide	NN	peptide
Fragment	NN	fragment
Interaction	NP	Interaction
with	IN	with
Different	NP	Different
S1	NP	<unknown>
Protein	NN	protein
Sites	NP	Sites
We	PP	we
study	VBP	study
the	DT	the
effect	NN	effect
of	IN	of
the	DT	the
peptide	NN	peptide
QAKTFLDKFNHEAEDLFYQ	NP	<unknown>
on	IN	on
the	DT	the
kinetics	NN	kinetics
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
spike	NN	spike
protein	NN	protein
S1	NP	<unknown>
binding	VBG	bind
to	TO	to
angiotensin-converting	JJ	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
,	,	,
with	IN	with
the	DT	the
aim	NN	aim
to	TO	to
characterize	VB	characterize
the	DT	the
interaction	NN	interaction
mechanism	NN	mechanism
of	IN	of
the	DT	the
SARS-CoV2	NP	<unknown>
virus	NN	virus
with	IN	with
its	PP$	its
host	NN	host
cell	NN	cell
.	SENT	.
This	DT	this
peptide	NN	peptide
corresponds	VBZ	correspond
to	TO	to
the	DT	the
sequence	NN	sequence
24-42	CD	@card@
of	IN	of
the	DT	the
ACE2	JJ	<unknown>
alpha1	JJ	<unknown>
domain	NN	domain
,	,	,
which	WDT	which
marks	VBZ	mark
the	DT	the
binding	JJ	binding
site	NN	site
for	IN	for
the	DT	the
S1	JJ	<unknown>
protein	NN	protein
.	SENT	.
The	DT	the
kinetics	NN	kinetics
of	IN	of
S1-ACE2	NP	<unknown>
complex	JJ	complex
formation	NN	formation
was	VBD	be
measured	VBN	measure
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
various	JJ	various
concentrations	NNS	concentration
of	IN	of
the	DT	the
peptide	NN	peptide
using	VBG	use
bio-layer	NN	bio-layer
interferometry	NN	interferometry
.	SENT	.
Formation	NN	formation
of	IN	of
the	DT	the
S1-ACE2	NP	<unknown>
complex	NN	complex
was	VBD	be
inhibited	VBN	inhibit
by	IN	by
the	DT	the
peptide	NN	peptide
in	IN	in
cases	NNS	case
where	WRB	where
it	PP	it
was	VBD	be
preincubated	VBN	preincubate
with	IN	with
S1	JJ	<unknown>
protein	NN	protein
before	IN	before
the	DT	the
binding	JJ	binding
experiment	NN	experiment
.	SENT	.
The	DT	the
kinetic	JJ	kinetic
analysis	NN	analysis
of	IN	of
S1-ACE2	NP	<unknown>
complex	JJ	complex
dissociation	NN	dissociation
revealed	VBD	reveal
that	IN	that
preincubation	NN	preincubation
stabilized	VBD	stabilize
this	DT	this
complex	NN	complex
,	,	,
and	CC	and
this	DT	this
effect	NN	effect
was	VBD	be
dependent	JJ	dependent
on	IN	on
the	DT	the
peptide	NN	peptide
concentration	NN	concentration
as	RB	as
well	RB	well
as	IN	as
the	DT	the
preincubation	NN	preincubation
time	NN	time
.	SENT	.
The	DT	the
results	NNS	result
point	VBP	point
to	TO	to
the	DT	the
formation	NN	formation
of	IN	of
the	DT	the
ternary	JJ	ternary
complex	NN	complex
of	IN	of
S1	NP	<unknown>
with	IN	with
ACE2	NP	<unknown>
and	CC	and
the	DT	the
peptide	NN	peptide
.	SENT	.
This	DT	this
is	VBZ	be
possible	JJ	possible
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
another	DT	another
binding	JJ	binding
site	NN	site
for	IN	for
the	DT	the
S1	JJ	<unknown>
protein	NN	protein
beside	IN	beside
the	DT	the
receptor-binding	NN	receptor-binding
domain	NN	domain
for	IN	for
ACE2	NP	<unknown>
,	,	,
which	WDT	which
binds	VBZ	bind
the	DT	the
peptide	NN	peptide
QAKTFLDKFNHEAEDLFYQ	NP	<unknown>
.	SENT	.
Therefore	RB	therefore
,	,	,
we	PP	we
conducted	VBD	conduct
computational	JJ	computational
mapping	NN	mapping
of	IN	of
the	DT	the
S1	NP	<unknown>
protein	NN	protein
surface	NN	surface
,	,	,
revealing	VBG	reveal
two	CD	two
additional	JJ	additional
binding	JJ	binding
sites	NNS	site
located	VBN	locate
at	IN	at
some	DT	some
distance	NN	distance
from	IN	from
the	DT	the
main	JJ	main
receptor-binding	NN	receptor-binding
domain	NN	domain
on	IN	on
S1	NP	<unknown>
.	SENT	.
We	PP	we
suggest	VBP	suggest
the	DT	the
possibility	NN	possibility
to	TO	to
predict	VB	predict
and	CC	and
test	VB	test
the	DT	the
short	JJ	short
protein	NN	protein
derived	VBD	derive
peptides	NNS	peptide
for	IN	for
development	NN	development
of	IN	of
novel	JJ	novel
strategies	NNS	strategy
in	IN	in
inhibiting	VBG	inhibit
virus	NN	virus
infections	NNS	infection
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s10989-021-10324-7	JJ	10.1007/s@card@
.	SENT	.
35010471/	CD	@card@
Comprehensive	JJ	comprehensive
Knowledge	NN	knowledge
and	CC	and
Preparedness	NN	preparedness
among	IN	among
Dental	JJ	dental
Community	NP	Community
to	TO	to
Confront	VB	confront
COVID-19:A	NP	<unknown>
Multicentric	NP	<unknown>
Cross-Sectional	JJ	cross-sectional
Study	NN	study
The	DT	the
healthcare	NN	<unknown>
policy	NN	policy
changes	NNS	change
need	VBP	need
to	TO	to
be	VB	be
updated	VBN	update
for	IN	for
better	JJR	good
management	NN	management
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
;	:	;
hence	RB	hence
,	,	,
there	EX	there
is	VBZ	be
an	DT	an
urgent	JJ	urgent
need	NN	need
to	TO	to
understand	VB	understand
the	DT	the
knowledge	NN	knowledge
and	CC	and
preparedness	NN	preparedness
of	IN	of
healthcare	NN	<unknown>
workers	NNS	worker
regarding	VBG	regard
the	DT	the
infection	NN	infection
control	NN	control
COVID-19	NP	<unknown>
.	SENT	.
Therefore	RB	therefore
,	,	,
the	DT	the
present	JJ	present
study	NN	study
aims	VBZ	aim
to	TO	to
assess	VB	assess
the	DT	the
knowledge	NN	knowledge
and	CC	and
preparedness	NN	preparedness
towards	IN	towards
COVID-19	NP	<unknown>
among	IN	among
dentists	NNS	dentist
,	,	,
undergraduate	JJ	undergraduate
,	,	,
and	CC	and
postgraduates	NNS	postgraduate
in	IN	in
dental	JJ	dental
universities	NNS	university
one	CD	one
year	NN	year
after	IN	after
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
.	SENT	.
The	DT	the
multi-centric	JJ	multi-centric
cross-sectional	JJ	cross-sectional
study	NN	study
was	VBD	be
conducted	VBN	conduct
by	IN	by
evaluating	VBG	evaluate
395	CD	@card@
structured	JJ	structured
,	,	,
pre-coded	JJ	<unknown>
,	,	,
and	CC	and
validated	VBD	validate
questionnaires	NNS	questionnaire
obtained	VBN	obtain
from	IN	from
sample	NN	sample
units	NNS	unit
comprising	VBG	comprise
full-time	JJ	full-time
dental	JJ	dental
students	NNS	student
(	(	(
undergraduates	NNS	undergraduate
,	,	,
interns	VBZ	intern
,	,	,
and	CC	and
postgraduates	NNS	postgraduate
)	)	)
and	CC	and
dentists	NNS	dentist
who	WP	who
were	VBD	be
currently	RB	currently
in	IN	in
practice	NN	practice
and	CC	and
who	WP	who
were	VBD	be
able	JJ	able
to	TO	to
comprehend	VB	comprehend
the	DT	the
languages	NNS	language
English	NP	English
or	CC	or
Arabic	NP	Arabic
.	SENT	.
The	DT	the
first	JJ	first
part	NN	part
of	IN	of
the	DT	the
questionnaire	NN	questionnaire
included	VBD	include
questions	NNS	question
related	VBN	relate
to	TO	to
demographic	JJ	demographic
characteristics	NNS	characteristic
.	SENT	.
The	DT	the
second	JJ	second
part	NN	part
of	IN	of
the	DT	the
survey	NN	survey
consisted	VBN	consist
of	IN	of
questions	NNS	question
that	WDT	that
address	VBP	address
knowledge	NN	knowledge
concerning	VBG	concern
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
third	JJ	third
part	NN	part
of	IN	of
the	DT	the
survey	NN	survey
addressed	VBD	address
questions	NNS	question
based	VBN	base
on	IN	on
the	DT	the
preparedness	NN	preparedness
to	TO	to
fight	VB	fight
against	IN	against
COVID-19	NP	<unknown>
including	VBG	include
sharp	JJ	sharp
injuries	NNS	injury
during	IN	during
this	DT	this
period	NN	period
.	SENT	.
Comparing	VBG	compare
the	DT	the
knowledge	NN	knowledge
scores	NNS	score
of	IN	of
dentists	NNS	dentist
,	,	,
dental	JJ	dental
undergraduates	NNS	undergraduate
,	,	,
and	CC	and
postgraduates	NNS	postgraduate
using	VBG	use
the	DT	the
ANOVA	NP	<unknown>
test	NN	test
,	,	,
dentists	NNS	dentist
have	VBP	have
higher	JJR	high
knowledge	NN	knowledge
and	CC	and
preparedness	NN	preparedness
scores	NNS	score
than	IN	than
postgraduates	NNS	postgraduate
and	CC	and
undergraduates	NNS	undergraduate
(	(	(
p-value	NN	p-value
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
Univariate	JJ	<unknown>
logistic	JJ	logistic
regression	NN	regression
analysis	NN	analysis
demonstrated	VBD	demonstrate
that	IN	that
undergraduates	NNS	undergraduate
and	CC	and
postgraduates	NNS	postgraduate
were	VBD	be
2.567	CD	@card@
and	CC	and
1.352	CD	@card@
times	NNS	time
less	RBR	less
aware	JJ	aware
of	IN	of
the	DT	the
personal	JJ	personal
protective	JJ	protective
measures	NNS	measure
against	IN	against
COVID-19	NP	<unknown>
than	IN	than
dentists	NNS	dentist
,	,	,
respectively	RB	respectively
.	SENT	.
Dentists	NNS	dentist
had	VBD	have
the	DT	the
comparatively	RB	comparatively
better	JJR	good
perception	NN	perception
in	IN	in
knowledge	NN	knowledge
and	CC	and
awareness	NN	awareness
of	IN	of
COVID-19	NP	<unknown>
than	IN	than
undergraduates	NNS	undergraduate
and	CC	and
postgraduates	NNS	postgraduate
.	SENT	.
33352250/	CD	@card@
Substantial	JJ	substantial
reduction	NN	reduction
of	IN	of
healthcare	NN	<unknown>
facility-onset	NN	facility-onset
Clostridioides	NP	<unknown>
difficile	NN	<unknown>
infection	NN	infection
(	(	(
HO-CDI	NP	<unknown>
)	)	)
rates	NNS	rate
after	IN	after
conversion	NN	conversion
of	IN	of
a	DT	a
hospital	NN	hospital
for	IN	for
exclusive	JJ	exclusive
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
Clostridioides	NP	<unknown>
difficile	NN	<unknown>
infection	NN	infection
(	(	(
CDI	NP	CDI
)	)	)
is	VBZ	be
widespread	JJ	widespread
in	IN	in
hospitals	NNS	hospital
.	SENT	.
An	DT	an
important	JJ	important
rate	NN	rate
reduction	NN	reduction
in	IN	in
CDI	NP	CDI
was	VBD	be
noticed	VBN	notice
in	IN	in
a	DT	a
COVID-19	NP	<unknown>
hospital	NN	hospital
.	SENT	.
Better	JJR	good
adherence	NN	adherence
to	TO	to
hand	VB	hand
hygiene	NN	hygiene
and	CC	and
contact	NN	contact
precautions	NNS	precaution
was	VBD	be
noticed	VBN	notice
.	SENT	.
Healthcare	NP	Healthcare
facility-onset	NN	facility-onset
Clostridioides	NP	<unknown>
difficile	JJ	<unknown>
infection	NN	infection
rates	NNS	rate
substantially	RB	substantially
dropped	VBD	drop
in	IN	in
a	DT	a
Mexican	JJ	Mexican
hospital	NN	hospital
after	IN	after
its	PP$	its
conversion	NN	conversion
to	TO	to
a	DT	a
full	JJ	full
COVID-19	NP	<unknown>
setting	NN	setting
,	,	,
despite	IN	despite
heavy	JJ	heavy
contamination	NN	contamination
of	IN	of
the	DT	the
environment	NN	environment
the	DT	the
previous	JJ	previous
year	NN	year
.	SENT	.
Better	JJR	good
adherence	NN	adherence
to	TO	to
hand	VB	hand
hygiene	NN	hygiene
and	CC	and
contact	NN	contact
precautions	NNS	precaution
may	MD	may
help	VB	help
explain	VB	explain
this	DT	this
finding	NN	finding
.	SENT	.
34145087/	CD	@card@
Heterogeneity	NN	heterogeneity
in	IN	in
protocols	NNS	protocol
for	IN	for
bronchoalveolar	JJ	bronchoalveolar
lavage	NN	lavage
&amp	NNS	<unknown>
;	:	;
sub-genomic	JJ	<unknown>
RNA	NP	RNA
evaluation	NN	evaluation
in	IN	in
non-human	NP	non-human
primate	NN	primate
studies	NNS	study
of	IN	of
SARS-CoV-2	NP	<unknown>
vaccine	NN	vaccine
candidates	NNS	candidate
'	POS	'
evaluation	NN	evaluation
34280115/	CD	@card@
Health	NP	Health
Belief	NN	belief
Model	NP	Model
Perspective	NP	Perspective
on	IN	on
the	DT	the
Control	NP	Control
of	IN	of
COVID-19	NP	<unknown>
Vaccine	NN	vaccine
Hesitancy	NN	hesitancy
and	CC	and
the	DT	the
Promotion	NP	Promotion
of	IN	of
Vaccination	NN	vaccination
in	IN	in
China	NP	China
:	:	:
Web-Based	JJ	Web-Based
Cross-sectional	JJ	cross-sectional
Study	NN	study
The	DT	the
control	NN	control
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
and	CC	and
the	DT	the
promotion	NN	promotion
of	IN	of
vaccination	NN	vaccination
are	VBP	be
key	JJ	key
protective	JJ	protective
measures	NNS	measure
against	IN	against
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
study	NN	study
assesses	VBZ	assess
the	DT	the
prevalence	NN	prevalence
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
and	CC	and
the	DT	the
vaccination	NN	vaccination
rate	NN	rate
and	CC	and
examines	VBZ	examine
the	DT	the
association	NN	association
between	IN	between
factors	NNS	factor
of	IN	of
the	DT	the
health	NN	health
belief	NN	belief
model	NN	model
(	(	(
HBM	NN	HBM
)	)	)
and	CC	and
vaccination	NN	vaccination
.	SENT	.
A	DT	a
convenience	NN	convenience
sample	NN	sample
of	IN	of
2531	CD	@card@
valid	JJ	valid
participants	NNS	participant
from	IN	from
31	CD	@card@
provinces	NNS	province
and	CC	and
autonomous	JJ	autonomous
regions	NNS	region
of	IN	of
mainland	JJ	mainland
China	NP	China
were	VBD	be
enrolled	VBN	enroll
in	IN	in
this	DT	this
online	JJ	online
survey	NN	survey
study	NN	study
from	IN	from
January	NP	January
1	CD	@card@
to	TO	to
24	CD	@card@
,	,	,
2021	CD	@card@
.	SENT	.
Multivariable	JJ	Multivariable
logistic	JJ	logistic
regression	NN	regression
was	VBD	be
used	VBN	use
to	TO	to
identify	VB	identify
the	DT	the
associations	NNS	association
of	IN	of
the	DT	the
vaccination	NN	vaccination
rate	NN	rate
and	CC	and
HBM	NN	HBM
factors	NNS	factor
with	IN	with
the	DT	the
prevalence	NN	prevalence
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
after	IN	after
other	JJ	other
covariates	NNS	covariate
were	VBD	be
controlled	VBN	control
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
was	VBD	be
44.3	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
42.3%-46.2	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
the	DT	the
vaccination	NN	vaccination
rate	NN	rate
was	VBD	be
10.4	CD	@card@
%	NN	%
(	(	(
9.2%-11.6	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
factors	NNS	factor
that	WDT	that
directly	RB	directly
promoted	VBD	promote
vaccination	NN	vaccination
behavior	NN	behavior
were	VBD	be
a	DT	a
lack	NN	lack
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
(	(	(
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
OR	CC	or
]	SYM	]
7.75	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
5.03-11.93	CD	@card@
)	)	)
,	,	,
agreement	NN	agreement
with	IN	with
recommendations	NNS	recommendation
from	IN	from
friends	NNS	friend
or	CC	or
family	NN	family
for	IN	for
vaccination	NN	vaccination
(	(	(
OR	CC	or
3.11	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.75-5.52	CD	@card@
)	)	)
,	,	,
and	CC	and
absence	NN	absence
of	IN	of
perceived	VBN	perceive
barriers	NNS	barrier
to	TO	to
COVID-19	NP	<unknown>
vaccination	NN	vaccination
(	(	(
OR	CC	or
0.51	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.35-0.75	CD	@card@
)	)	)
.	SENT	.
The	DT	the
factors	NNS	factor
that	WDT	that
were	VBD	be
directly	RB	directly
associated	VBN	associate
with	IN	with
a	DT	a
higher	JJR	high
vaccine	NN	vaccine
hesitancy	NN	hesitancy
rate	NN	rate
were	VBD	be
a	DT	a
high	JJ	high
level	NN	level
of	IN	of
perceived	VBN	perceive
barriers	NNS	barrier
(	(	(
OR	CC	or
1.63	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.36-1.95	CD	@card@
)	)	)
and	CC	and
perceived	VBN	perceive
benefits	NNS	benefit
(	(	(
OR	CC	or
0.51	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.32-0.79	CD	@card@
)	)	)
.	SENT	.
A	DT	a
mediating	VBG	mediate
effect	NN	effect
of	IN	of
self-efficacy	NN	self-efficacy
,	,	,
influenced	VBN	influence
by	IN	by
perceived	VBN	perceive
barriers	NNS	barrier
(	(	(
standardized	JJ	standardized
structure	NN	structure
coefficient	NN	coefficient
[	SYM	[
SSC]=-0.71	NP	SSC]=@card@
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
,	,	,
perceived	VBN	perceive
benefits	NNS	benefit
(	(	(
SSC=0.58	NP	<unknown>
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
,	,	,
agreement	NN	agreement
with	IN	with
recommendations	NNS	recommendation
from	IN	from
authorities	NNS	authority
(	(	(
SSC=0.27	NP	<unknown>
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
,	,	,
and	CC	and
agreement	NN	agreement
with	IN	with
recommendations	NNS	recommendation
from	IN	from
friends	NNS	friend
or	CC	or
family	NN	family
(	(	(
SSC=0.31	NP	<unknown>
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
,	,	,
was	VBD	be
negatively	RB	negatively
associated	VBN	associate
with	IN	with
vaccination	NN	vaccination
(	(	(
SSC=-0.45	NP	SSC=@card@
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
via	IN	via
vaccine	NN	vaccine
hesitancy	NN	hesitancy
(	(	(
SSC=-0.32	NP	SSC=@card@
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
.	SENT	.
It	PP	it
may	MD	may
be	VB	be
possible	JJ	possible
to	TO	to
increase	VB	increase
the	DT	the
vaccination	NN	vaccination
rate	NN	rate
by	IN	by
reducing	VBG	reduce
vaccine	NN	vaccine
hesitancy	NN	hesitancy
and	CC	and
perceived	VBN	perceive
barriers	NNS	barrier
to	TO	to
vaccination	NN	vaccination
and	CC	and
by	IN	by
encouraging	VBG	encourage
volunteers	NNS	volunteer
to	TO	to
advocate	VB	advocate
for	IN	for
vaccination	NN	vaccination
to	TO	to
their	PP$	their
friends	NNS	friend
and	CC	and
family	NN	family
members	NNS	member
.	SENT	.
It	PP	it
is	VBZ	be
also	RB	also
important	JJ	important
to	TO	to
reduce	VB	reduce
vaccine	NN	vaccine
hesitancy	NN	hesitancy
by	IN	by
enhancing	VBG	enhance
self-efficacy	NN	self-efficacy
for	IN	for
vaccination	NN	vaccination
,	,	,
due	JJ	due
to	TO	to
its	PP$	its
crucial	JJ	crucial
mediating	VBG	mediate
function	NN	function
.	SENT	.
32634111/	CD	@card@
Impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
gaming	NN	gaming
disorder	NN	disorder
:	:	:
Monitoring	NN	monitoring
and	CC	and
prevention	NN	prevention
The	DT	the
global	JJ	global
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
outbreak	NN	outbreak
has	VBZ	have
necessitated	VBN	necessitate
physical	JJ	physical
distancing	NN	distancing
,	,	,
lockdown	NN	<unknown>
,	,	,
contact	NN	contact
tracing	NN	tracing
,	,	,
and	CC	and
self-quarantine	NN	self-quarantine
so	RB	so
as	RB	as
to	TO	to
prevent	VB	prevent
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
Amid	IN	amid
the	DT	the
outbreak	NN	outbreak
,	,	,
gaming	NN	gaming
data	NNS	datum
usage	NN	usage
has	VBZ	have
reportedly	RB	reportedly
increased	VBN	increase
in	IN	in
the	DT	the
United	NP	United
States	NPS	States
,	,	,
and	CC	and
game	NN	game
download	NN	<unknown>
volume	NN	volume
has	VBZ	have
reached	VBN	reach
a	DT	a
record	NN	record
high	JJ	high
in	IN	in
Europe	NP	Europe
.	SENT	.
Because	IN	because
gaming	NN	gaming
can	MD	can
be	VB	be
used	VBN	use
to	TO	to
cope	VB	cope
with	IN	with
the	DT	the
psychological	JJ	psychological
stress	NN	stress
from	IN	from
the	DT	the
outbreak	NN	outbreak
,	,	,
therefore	RB	therefore
mental	JJ	mental
health	NN	health
professionals	NNS	professional
should	MD	should
be	VB	be
aware	JJ	aware
of	IN	of
how	WRB	how
increased	VBN	increase
gaming	NN	gaming
during	IN	during
the	DT	the
pandemic	NN	pandemic
may	MD	may
contribute	VB	contribute
to	TO	to
risk	VB	risk
of	IN	of
gaming	NN	gaming
disorder	NN	disorder
,	,	,
especially	RB	especially
if	IN	if
the	DT	the
pandemic	NN	pandemic
persists	VBZ	persist
.	SENT	.
Mental	JJ	mental
health	NN	health
professionals	NNS	professional
should	MD	should
thus	RB	thus
formulate	VB	formulate
safe	JJ	safe
social	JJ	social
interaction	NN	interaction
alternatives	NNS	alternative
for	IN	for
people	NNS	people
,	,	,
particularly	RB	particularly
adolescents	NNS	adolescent
,	,	,
who	WP	who
have	VBP	have
gaming	NN	gaming
disorder	NN	disorder
risk	NN	risk
.	SENT	.
34790054/	CD	@card@
Cytidine	NN	cytidine
deamination-induced	JJ	<unknown>
perpetual	JJ	perpetual
immunity	NN	immunity
to	TO	to
SAR-CoV-2	NP	<unknown>
infection	NN	infection
is	VBZ	be
a	DT	a
potential	JJ	potential
new	JJ	new
therapeutic	JJ	therapeutic
target	NN	target
As	IN	as
the	DT	the
world	NN	world
is	VBZ	be
racing	VBG	race
to	TO	to
develop	VB	develop
perpetual	JJ	perpetual
immunity	NN	immunity
to	TO	to
the	DT	the
SARS-CoV-2	NP	<unknown>
virus	NN	virus
.	SENT	.
The	DT	the
emergence	NN	emergence
of	IN	of
new	JJ	new
viral	JJ	viral
strains	NNS	strain
,	,	,
together	RB	together
with	IN	with
vaccination	NN	vaccination
and	CC	and
reinfections	NNS	reinfection
,	,	,
are	VBP	be
all	RB	all
contributing	VBG	contribute
to	TO	to
a	DT	a
long-term	JJ	long-term
immunity	NN	immunity
against	IN	against
the	DT	the
deadly	JJ	deadly
virus	NN	virus
that	WDT	that
has	VBZ	have
taken	VBN	take
over	IN	over
the	DT	the
world	NN	world
since	IN	since
its	PP$	its
introduction	NN	introduction
to	TO	to
humans	NNS	human
in	IN	in
late	JJ	late
December	NP	December
2019	CD	@card@
.	SENT	.
The	DT	the
discovery	NN	discovery
that	IN	that
more	JJR	more
than	IN	than
95	CD	@card@
percent	NN	percent
of	IN	of
people	NNS	people
who	WP	who
recovered	VBD	recover
from	IN	from
COVID-19	NP	<unknown>
had	VBD	have
long-lasting	JJ	long-lasting
immunity	NN	immunity
and	CC	and
that	IN	that
asymptomatic	JJ	asymptomatic
people	NNS	people
have	VBP	have
a	DT	a
different	JJ	different
immune	JJ	immune
response	NN	response
to	TO	to
SARS-CoV-2	NP	<unknown>
than	IN	than
symptomatic	JJ	symptomatic
people	NNS	people
has	VBZ	have
shifted	VBN	shift
attention	NN	attention
to	TO	to
how	WRB	how
our	PP$	our
immune	JJ	immune
system	NN	system
initiates	VBZ	initiate
such	JJ	such
diverse	JJ	diverse
responses	NNS	response
.	SENT	.
These	DT	these
findings	NNS	finding
have	VBP	have
provided	VBN	provide
reason	NN	reason
to	TO	to
believe	VB	believe
that	IN	that
SARS-CoV-2	NP	<unknown>
days	NNS	day
are	VBP	be
numbered	VBN	number
.	SENT	.
Hundreds	NNS	hundred
of	IN	of
research	NN	research
papers	NNS	paper
have	VBP	have
been	VBN	be
published	VBN	publish
on	IN	on
the	DT	the
causes	NNS	cause
of	IN	of
long-lasting	JJ	long-lasting
immune	JJ	immune
responses	NNS	response
and	CC	and
variations	NNS	variation
in	IN	in
the	DT	the
numbers	NNS	number
of	IN	of
different	JJ	different
immune	JJ	immune
cell	NN	cell
types	NNS	type
in	IN	in
COVID	NP	<unknown>
19	CD	@card@
survivors	NNS	survivor
,	,	,
but	CC	but
the	DT	the
main	JJ	main
reason	NN	reason
of	IN	of
these	DT	these
differences	NNS	difference
has	VBZ	have
still	RB	still
not	RB	not
been	VBN	be
adequately	RB	adequately
identified	VBN	identify
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
focus	VBP	focus
on	IN	on
the	DT	the
activation-induced	JJ	<unknown>
cytidine	NN	cytidine
deaminase	NN	<unknown>
(	(	(
AID	NN	aid
)	)	)
,	,	,
which	WDT	which
initiates	VBZ	initiate
molecular	JJ	molecular
processes	NNS	process
that	WDT	that
allow	VBP	allow
our	PP$	our
immune	JJ	immune
system	NN	system
to	TO	to
generate	VB	generate
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
.	SENT	.
To	TO	to
establish	VB	establish
lasting	JJ	lasting
immunity	NN	immunity
to	TO	to
SARS-CoV-2	NP	<unknown>
,	,	,
we	PP	we
suggest	VBP	suggest
that	IN	that
AID	NN	aid
could	MD	could
be	VB	be
the	DT	the
key	NN	key
to	TO	to
unlocking	VBG	unlock
it	PP	it
.	SENT	.
35006537/	CD	@card@
Response	NP	Response
to	TO	to
BNT162b2	NP	<unknown>
mRNA	NP	<unknown>
COVID-19	NP	<unknown>
vaccine	NN	vaccine
among	IN	among
healthcare	NN	<unknown>
workers	NNS	worker
in	IN	in
Italy	NP	Italy
:	:	:
a	DT	a
3-month	JJ	<unknown>
follow-up:Reply	NN	<unknown>
32632359/	CD	@card@
Reactive	JJ	reactive
oxygen	NN	oxygen
species	NNS	specie
as	IN	as
an	DT	an
initiator	NN	initiator
of	IN	of
toxic	JJ	toxic
innate	JJ	innate
immune	JJ	immune
responses	NNS	response
in	IN	in
retort	NN	retort
to	TO	to
SARS-CoV-2	NP	<unknown>
in	IN	in
an	DT	an
ageing	VBG	age
population	NN	population
,	,	,
consider	VB	consider
N-acetylcysteine	NN	N-acetylcysteine
as	IN	as
early	JJ	early
therapeutic	JJ	therapeutic
intervention	NN	intervention
Viral	JJ	viral
infections	NNS	infection
cause	VBP	cause
oxidative	JJ	oxidative
stress	NN	stress
which	WDT	which
may	MD	may
be	VB	be
exaggerated	VBN	exaggerate
by	IN	by
inflammaging	NN	inflammaging
.	SENT	.
Oxidative	JJ	oxidative
stress	NN	stress
coping	VBG	cope
mechanisms	NNS	mechanism
can	MD	can
be	VB	be
affected	VBN	affect
by	IN	by
genetic/environmental	JJ	genetic/environmental
factors	NNS	factor
.	SENT	.
SARS-CoV	NP	<unknown>
has	VBZ	have
been	VBN	be
reported	VBN	report
to	TO	to
modulate	VB	modulate
PARP	JJ	<unknown>
function	NN	function
and	CC	and
thereby	RB	thereby
NAD	NN	NAD
+	SYM	+
biosynthesis	NN	biosynthesis
.	SENT	.
Cellular	JJ	cellular
homeostasis	NN	homeostasis
and	CC	and
redox	NN	redox
imbalances	NNS	imbalance
by	IN	by
SARS-CoV2	NP	<unknown>
can	MD	can
cause	VB	cause
stress	NN	stress
responses	NNS	response
.	SENT	.
Antioxidants	NNS	antioxidant
such	JJ	such
as	IN	as
NAC	NP	NAC
could	MD	could
limit	VB	limit
ROS	NP	Ros
mediated	VBN	mediate
tissue	NN	tissue
damage	NN	damage
during	IN	during
COVID-19	NP	<unknown>
.	SENT	.
During	IN	during
the	DT	the
current	JJ	current
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
a	DT	a
need	NN	need
for	IN	for
evaluation	NN	evaluation
of	IN	of
already	RB	already
available	JJ	available
drugs	NNS	drug
for	IN	for
treatment	NN	treatment
of	IN	of
the	DT	the
disease	NN	disease
is	VBZ	be
crucial	JJ	crucial
.	SENT	.
Hereby	RB	hereby
,	,	,
based	VBN	base
on	IN	on
literature	NN	literature
review	NN	review
from	IN	from
the	DT	the
current	JJ	current
pandemic	NN	pandemic
and	CC	and
previous	JJ	previous
outbreaks	NNS	outbreak
with	IN	with
corona	NN	corona
viruses	NNS	virus
we	PP	we
analyze	VBP	analyze
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
virus	NN	virus
infection	NN	infection
on	IN	on
cell	NN	cell
stress	NN	stress
responses	NNS	response
and	CC	and
redox	NN	redox
balance	NN	balance
.	SENT	.
High	JJ	high
levels	NNS	level
of	IN	of
mortality	NN	mortality
are	VBP	be
noticed	VBN	notice
in	IN	in
elderly	JJ	elderly
individuals	NNS	individual
infected	VBN	infect
with	IN	with
SARS-CoV2	NP	<unknown>
and	CC	and
during	IN	during
the	DT	the
previous	JJ	previous
SARS-CoV1	JJ	<unknown>
outbreak	NN	outbreak
.	SENT	.
Elderly	JJ	elderly
individuals	NNS	individual
maintain	VBP	maintain
a	DT	a
chronic	JJ	chronic
low	JJ	low
level	NN	level
of	IN	of
inflammation	NN	inflammation
which	WDT	which
is	VBZ	be
associated	VBN	associate
with	IN	with
oxidative	JJ	oxidative
stress	NN	stress
and	CC	and
inflammatory	JJ	inflammatory
cytokine	NN	<unknown>
production	NN	production
,	,	,
a	DT	a
condition	NN	condition
that	WDT	that
increases	VBZ	increase
the	DT	the
severity	NN	severity
of	IN	of
viral	JJ	viral
infections	NNS	infection
in	IN	in
this	DT	this
population	NN	population
.	SENT	.
Coronavirus	NN	Coronavirus
infections	NNS	infection
can	MD	can
lead	VB	lead
to	TO	to
alterations	NNS	alteration
of	IN	of
redox	NN	redox
balance	NN	balance
in	IN	in
infected	JJ	infected
cells	NNS	cell
through	IN	through
modulation	NN	modulation
of	IN	of
NAD	NN	NAD
+	SYM	+
biosynthesis	NN	biosynthesis
,	,	,
PARP	JJ	<unknown>
function	NN	function
along	IN	along
with	IN	with
altering	VBG	alter
proteasome	JJ	<unknown>
and	CC	and
mitochondrial	JJ	mitochondrial
function	NN	function
in	IN	in
the	DT	the
cell	NN	cell
thereby	RB	thereby
leading	VBG	lead
to	TO	to
enhanced	JJ	enhanced
cell	NN	cell
stress	NN	stress
responses	NNS	response
which	WDT	which
further	VBP	further
exacerbate	VB	exacerbate
inflammation	NN	inflammation
.	SENT	.
ROS	NP	Ros
production	NN	production
can	MD	can
increase	VB	increase
IL-6	NP	<unknown>
production	NN	production
and	CC	and
lipid	NN	lipid
peroxidation	NN	peroxidation
resulting	VBG	result
in	IN	in
cell	NN	cell
damage	NN	damage
.	SENT	.
Therefore	RB	therefore
,	,	,
early	JJ	early
treatment	NN	treatment
with	IN	with
anti-oxidants	NNS	anti-oxidant
such	JJ	such
as	IN	as
NAC	NP	NAC
during	IN	during
COVID-19	NP	<unknown>
can	MD	can
be	VB	be
a	DT	a
way	NN	way
to	TO	to
bypass	VB	bypass
the	DT	the
excessive	JJ	excessive
inflammation	NN	inflammation
and	CC	and
cell	NN	cell
damage	NN	damage
that	WDT	that
lead	VBP	lead
to	TO	to
severe	JJ	severe
infection	NN	infection
,	,	,
thus	RB	thus
early	JJ	early
NAC	NP	NAC
as	IN	as
intervention	NN	intervention
should	MD	should
be	VB	be
evaluated	VBN	evaluate
in	IN	in
a	DT	a
clinical	JJ	clinical
trial	NN	trial
setting	NN	setting
.	SENT	.
33814022/	CD	@card@
Estimating	VBG	estimate
the	DT	the
effects	NNS	effect
of	IN	of
reopening	VBG	reopen
of	IN	of
schools	NNS	school
on	IN	on
the	DT	the
course	NN	course
of	IN	of
the	DT	the
epidemic	NN	epidemic
of	IN	of
COVID-19	NP	<unknown>
In	IN	in
this	DT	this
paper	NN	paper
,	,	,
we	PP	we
present	VBP	present
a	DT	a
method	NN	method
to	TO	to
estimate	VB	estimate
the	DT	the
risk	NN	risk
of	IN	of
reopening	VBG	reopen
of	IN	of
schools	NNS	school
illustrated	VBN	illustrate
with	IN	with
the	DT	the
case	NN	case
of	IN	of
the	DT	the
State	NP	State
of	IN	of
Sao	NP	Sao
Paulo	NP	Paulo
,	,	,
Brazil	NP	Brazil
.	SENT	.
The	DT	the
model	NN	model
showed	VBD	show
that	IN	that
,	,	,
although	IN	although
no	DT	no
death	NN	death
of	IN	of
children	NNS	child
would	MD	would
result	VB	result
from	IN	from
the	DT	the
reopening	VBG	reopen
of	IN	of
the	DT	the
schools	NNS	school
in	IN	in
the	DT	the
three	CD	three
cities	NNS	city
analysed	VBN	analyse
,	,	,
the	DT	the
risk	NN	risk
of	IN	of
asymptomatic	JJ	asymptomatic
and	CC	and
symptomatic	JJ	symptomatic
cases	NNS	case
and	CC	and
secondary	JJ	secondary
cases	NNS	case
among	IN	among
teachers	NNS	teacher
,	,	,
school	NN	school
staff	NN	staff
and	CC	and
relatives	NNS	relative
of	IN	of
the	DT	the
children	NNS	child
is	VBZ	be
not	RB	not
negligible	JJ	negligible
.	SENT	.
Although	IN	although
the	DT	the
epidemic	NN	epidemic
hit	VBD	hit
different	JJ	different
regions	NNS	region
with	IN	with
different	JJ	different
intensities	NNS	intensity
,	,	,
our	PP$	our
model	NN	model
shows	VBZ	show
that	IN	that
,	,	,
for	IN	for
regions	NNS	region
where	WRB	where
the	DT	the
incidence	NN	incidence
profile	NN	profile
is	VBZ	be
similar	JJ	similar
to	TO	to
the	DT	the
cities	NNS	city
analysed	VBD	analyse
,	,	,
the	DT	the
risk	NN	risk
of	IN	of
reopening	VBG	reopen
of	IN	of
schools	NNS	school
is	VBZ	be
still	RB	still
too	RB	too
high	JJ	high
.	SENT	.
This	DT	this
in	IN	in
spite	NN	spite
of	IN	of
the	DT	the
fact	NN	fact
that	IN	that
incidences	NNS	incidence
in	IN	in
these	DT	these
cities	NNS	city
were	VBD	be
declining	VBG	decline
in	IN	in
the	DT	the
period	NN	period
of	IN	of
the	DT	the
time	NN	time
considered	VBD	consider
.	SENT	.
Therefore	RB	therefore
,	,	,
although	IN	although
we	PP	we
cannot	MD	can
extend	VB	extend
the	DT	the
result	NN	result
to	TO	to
the	DT	the
entire	JJ	entire
country	NN	country
,	,	,
the	DT	the
overall	JJ	overall
conclusion	NN	conclusion
is	VBZ	be
valid	JJ	valid
for	IN	for
regions	NNS	region
with	IN	with
a	DT	a
declining	VBG	decline
incidence	NN	incidence
and	CC	and
it	PP	it
is	VBZ	be
even	RB	even
more	RBR	more
valid	JJ	valid
for	IN	for
regions	NNS	region
where	WRB	where
incidence	NN	incidence
is	VBZ	be
increasing	VBG	increase
.	SENT	.
We	PP	we
assumed	VBD	assume
a	DT	a
very	RB	very
conservative	JJ	conservative
level	NN	level
of	IN	of
infection	NN	infection
transmissibility	NN	<unknown>
of	IN	of
children	NNS	child
of	IN	of
just	RB	just
10	CD	@card@
%	NN	%
as	IN	as
that	DT	that
of	IN	of
adults	NNS	adult
.	SENT	.
In	IN	in
spite	NN	spite
of	IN	of
the	DT	the
very	RB	very
low	JJ	low
level	NN	level
of	IN	of
transmissibility	NN	<unknown>
is	VBZ	be
assumed	VBN	assume
,	,	,
the	DT	the
number	NN	number
of	IN	of
secondary	JJ	secondary
cases	NNS	case
caused	VBN	cause
by	IN	by
infected	JJ	infected
children	NNS	child
among	IN	among
teachers	NNS	teacher
,	,	,
school	NN	school
staff	NN	staff
and	CC	and
relatives	NNS	relative
varied	VBN	vary
from	IN	from
2	CD	@card@
to	TO	to
85	CD	@card@
.	SENT	.
It	PP	it
is	VBZ	be
,	,	,
therefore	RB	therefore
,	,	,
too	RB	too
soon	RB	soon
to	TO	to
have	VB	have
any	DT	any
degree	NN	degree
of	IN	of
confidence	NN	confidence
that	IN	that
reopening	VBG	reopen
of	IN	of
schools	NNS	school
before	IN	before
the	DT	the
advent	NN	advent
of	IN	of
a	DT	a
vaccine	NN	vaccine
is	VBZ	be
the	DT	the
right	JJ	right
decision	NN	decision
to	TO	to
take	VB	take
.	SENT	.
The	DT	the
purpose	NN	purpose
of	IN	of
our	PP$	our
model	NN	model
and	CC	and
simulations	NNS	simulation
is	VBZ	be
to	TO	to
provide	VB	provide
a	DT	a
method	NN	method
to	TO	to
estimate	VB	estimate
the	DT	the
risk	NN	risk
of	IN	of
school	NN	school
reopening	VBG	reopen
,	,	,
although	IN	although
we	PP	we
are	VBP	be
sure	JJ	sure
it	PP	it
could	MD	could
be	VB	be
applied	VBN	apply
as	IN	as
a	DT	a
guide	NN	guide
to	TO	to
public	JJ	public
health	NN	health
strategies	NNS	strategy
.	SENT	.
34567255/	CD	@card@
The	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
cancer	NN	cancer
care	NN	care
in	IN	in
the	DT	the
public	JJ	public
health	NN	health
subsector	NN	subsector
,	,	,
province	NN	province
of	IN	of
Santa	NP	Santa
Fe	NP	Fe
,	,	,
Argentina	NP	Argentina
The	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
pandemic	NN	pandemic
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
and	CC	and
the	DT	the
measures	NNS	measure
taken	VBN	take
to	TO	to
lessen	VB	lessen
its	PP$	its
impact	NN	impact
have	VBP	have
had	VBN	have
side	NN	side
effects	NNS	effect
affecting	VBG	affect
timely	JJ	timely
care	NN	care
of	IN	of
other	JJ	other
diseases	NNS	disease
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
paper	NN	paper
is	VBZ	be
to	TO	to
quantify	VB	quantify
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
the	DT	the
cancer	NN	cancer
care	NN	care
line	NN	line
in	IN	in
the	DT	the
province	NN	province
of	IN	of
Santa	NP	Santa
Fe	NP	Fe
,	,	,
Argentina	NP	Argentina
.	SENT	.
It	PP	it
is	VBZ	be
an	DT	an
observational	JJ	observational
cross-sectional	JJ	cross-sectional
study	NN	study
comparing	VBG	compare
the	DT	the
impact	NN	impact
on	IN	on
selected	JJ	selected
variables	NNS	variable
of	IN	of
the	DT	the
pre-pandemic	JJ	pre-pandemic
and	CC	and
intra-pandemic	JJ	intra-pandemic
periods	NNS	period
.	SENT	.
The	DT	the
formula	NN	formula
of	IN	of
percentage	NN	percentage
variation	NN	variation
was	VBD	be
used	VBN	use
to	TO	to
show	VB	show
the	DT	the
differences	NNS	difference
.	SENT	.
The	DT	the
positivity	NN	<unknown>
index	NN	index
was	VBD	be
calculated	VBN	calculate
and	CC	and
expressed	VBN	express
as	IN	as
a	DT	a
percentage	NN	percentage
.	SENT	.
The	DT	the
proportions	NNS	proportion
of	IN	of
both	DT	both
periods	NNS	period
were	VBD	be
compared	VBN	compare
through	IN	through
the	DT	the
chi-squared	JJ	<unknown>
test	NN	test
and	CC	and
its	PP$	its
p-value	NN	p-value
.	SENT	.
Reductions	NNS	reduction
were	VBD	be
observed	VBN	observe
in	IN	in
all	PDT	all
the	DT	the
variables	NNS	variable
under	IN	under
study	NN	study
.	SENT	.
However	RB	however
,	,	,
the	DT	the
deeper	JJR	deep
impact	NN	impact
was	VBD	be
evident	JJ	evident
in	IN	in
screening	NN	screening
,	,	,
with	IN	with
56%-87	CD	@card@
%	NN	%
decreases	NNS	decrease
in	IN	in
the	DT	the
number	NN	number
of	IN	of
procedures	NNS	procedure
carried	VBN	carry
out	RP	out
.	SENT	.
A	DT	a
26	CD	@card@
%	NN	%
reduction	NN	reduction
was	VBD	be
seen	VBN	see
in	IN	in
diagnosis	NN	diagnosis
.	SENT	.
Treatment	NN	treatment
was	VBD	be
the	DT	the
variable	NN	variable
with	IN	with
the	DT	the
least	JJS	least
impact	NN	impact
,	,	,
with	IN	with
a	DT	a
3	CD	@card@
%	NN	%
decrease	NN	decrease
.	SENT	.
COVID-19	NP	<unknown>
as	RB	as
well	RB	well
as	IN	as
the	DT	the
measures	NNS	measure
taken	VBN	take
to	TO	to
reduce	VB	reduce
its	PP$	its
impact	NN	impact
caused	VBD	cause
alterations	NNS	alteration
in	IN	in
the	DT	the
cancer	NN	cancer
care	NN	care
line	NN	line
in	IN	in
the	DT	the
province	NN	province
,	,	,
with	IN	with
clear	JJ	clear
differences	NNS	difference
according	VBG	accord
to	TO	to
the	DT	the
variable	NN	variable
under	IN	under
study	NN	study
.	SENT	.
Measures	NNS	measure
related	VBN	relate
to	TO	to
cancer	NN	cancer
screening	NN	screening
were	VBD	be
displaced	VBN	displace
,	,	,
prioritising	VBG	<unknown>
the	DT	the
care	NN	care
of	IN	of
patients	NNS	patient
already	RB	already
diagnosed	VBN	diagnose
and	CC	and
treated	VBN	treat
.	SENT	.
Considering	VBG	consider
the	DT	the
new	JJ	new
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
COVID-19	NP	<unknown>
cases	NNS	case
,	,	,
it	PP	it
is	VBZ	be
essential	JJ	essential
to	TO	to
adapt	VB	adapt
the	DT	the
healthcare	NN	<unknown>
system	NN	system
,	,	,
and	CC	and
design	VB	design
new	JJ	new
innovative	JJ	innovative
strategies	NNS	strategy
to	TO	to
reduce	VB	reduce
long-term	JJ	long-term
consequences	NNS	consequence
.	SENT	.
32360210/	CD	@card@
Letter	NN	letter
to	TO	to
the	DT	the
Editor	NN	editor
:	:	:
Fasting	VBG	fast
plasma	NN	plasma
glucose	NN	glucose
associated	VBN	associate
with	IN	with
mortality	NN	mortality
rate	NN	rate
in	IN	in
T2DM	NP	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
35584232/	CD	@card@
Evaluation	NN	evaluation
of	IN	of
RT-qPCR	NP	<unknown>
Primer-Probe	NP	<unknown>
Sets	VBZ	set
to	TO	to
Inform	VB	inform
Public	NP	Public
Health	NP	Health
Interventions	NNS	intervention
Based	VBN	base
on	IN	on
COVID-19	NP	<unknown>
Sewage	NN	sewage
Tests	NNS	test
Sewage	NN	sewage
surveillance	NN	surveillance
is	VBZ	be
increasingly	RB	increasingly
employed	VBN	employ
as	IN	as
a	DT	a
supplementary	JJ	supplementary
tool	NN	tool
for	IN	for
COVID-19	NP	<unknown>
control	NN	control
.	SENT	.
Experiences	NNS	experience
learnt	VBN	learn
from	IN	from
large-scale	JJ	large-scale
trials	NNS	trial
could	MD	could
guide	VB	guide
better	JJR	good
interpretation	NN	interpretation
of	IN	of
the	DT	the
sewage	NN	sewage
data	NNS	datum
for	IN	for
public	JJ	public
health	NN	health
interventions	NNS	intervention
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
compared	VBD	compare
the	DT	the
performance	NN	performance
of	IN	of
seven	CD	seven
commonly	RB	commonly
used	VBN	use
primer-probe	NN	primer-probe
sets	NNS	set
in	IN	in
RT-qPCR	NP	<unknown>
and	CC	and
evaluated	VBD	evaluate
the	DT	the
usefulness	NN	usefulness
in	IN	in
the	DT	the
sewage	NN	sewage
surveillance	NN	surveillance
program	NN	program
in	IN	in
Hong	NP	Hong
Kong	NP	Kong
.	SENT	.
All	DT	all
selected	VBN	select
primer-probe	NN	primer-probe
sets	NNS	set
reliably	RB	reliably
detected	VBD	detect
SARS-CoV-2	NP	<unknown>
in	IN	in
pure	JJ	pure
water	NN	water
at	IN	at
7	CD	@card@
copies	NNS	copy
per	IN	per
muL	NN	muL
.	SENT	.
Sewage	NN	sewage
matrix	NN	matrix
did	VBD	do
not	RB	not
influence	VB	influence
RT-qPCR	NP	<unknown>
determination	NN	determination
of	IN	of
SARS-CoV-2	NP	<unknown>
concentrated	VBD	concentrate
from	IN	from
a	DT	a
small-volume	JJ	small-volume
sewage	NN	sewage
(	(	(
30	CD	@card@
mL	NN	mL
)	)	)
but	CC	but
introduced	VBN	introduce
inhibitory	JJ	inhibitory
impacts	NNS	impact
on	IN	on
a	DT	a
large-volume	JJ	large-volume
sewage	NN	sewage
(	(	(
920	CD	@card@
mL	NN	mL
)	)	)
with	IN	with
a	DT	a
DeltaCt	NN	<unknown>
of	IN	of
0.2-10.8	CD	@card@
.	SENT	.
Diagnostic	JJ	diagnostic
performance	NN	performance
evaluation	NN	evaluation
in	IN	in
finding	VBG	find
COVID-19	NP	<unknown>
cases	NNS	case
showed	VBD	show
that	IN	that
N1	NP	<unknown>
was	VBD	be
the	DT	the
best	RBS	well
single	JJ	single
primer-probe	NN	primer-probe
set	NN	set
,	,	,
while	IN	while
the	DT	the
ORF1ab	NP	<unknown>
set	NN	set
is	VBZ	be
not	RB	not
recommended	VBN	recommend
.	SENT	.
Sewage	NN	sewage
surveillance	NN	surveillance
using	VBG	use
the	DT	the
N1	JJ	<unknown>
set	NN	set
for	IN	for
over	RB	over
3200	CD	@card@
samples	NNS	sample
effectively	RB	effectively
caught	VBD	catch
the	DT	the
outbreak	NN	outbreak
trend	NN	trend
and	CC	and
,	,	,
importantly	RB	importantly
,	,	,
had	VBD	have
a	DT	a
56	CD	@card@
%	NN	%
sensitivity	NN	sensitivity
and	CC	and
a	DT	a
96	CD	@card@
%	NN	%
specificity	NN	specificity
in	IN	in
uncovering	VBG	uncover
the	DT	the
signal	NN	signal
sources	NNS	source
from	IN	from
new	JJ	new
cases	NNS	case
and/or	CC	and/or
convalescent	JJ	convalescent
patients	NNS	patient
in	IN	in
the	DT	the
community	NN	community
.	SENT	.
Our	PP$	our
study	NN	study
paves	VBZ	pave
the	DT	the
way	NN	way
for	IN	for
selecting	VBG	select
detection	NN	detection
primer-probe	NN	primer-probe
sets	VBZ	set
in	IN	in
wider	JJR	wide
applications	NNS	application
in	IN	in
responding	VBG	respond
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Diagnostic	JJ	diagnostic
evaluation	NN	evaluation
of	IN	of
different	JJ	different
primer-probe	NN	primer-probe
sets	VBZ	set
enhanced	JJ	enhanced
sewage	NN	sewage
surveillance	NN	surveillance
to	TO	to
inform	VB	inform
public	JJ	public
health	NN	health
interventions	NNS	intervention
for	IN	for
the	DT	the
control	NN	control
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
34822228/	CD	@card@
Nursing	NP	Nursing
and	CC	and
its	PP$	its
Essential	JJ	essential
Role	NN	role
in	IN	in
the	DT	the
Vaccination	NN	vaccination
against	IN	against
COVID-19	NP	<unknown>
:	:	:
New	NP	New
Challenge	NP	Challenge
in	IN	in
a	DT	a
Pandemic	JJ	pandemic
Scenario	NP	Scenario
33660320/	CD	@card@
Virtual	JJ	virtual
COVID	NP	<unknown>
rounds	NNS	round
:	:	:
A	DT	a
curricular	JJ	curricular
enrichment	NN	enrichment
program	NN	program
for	IN	for
pre-clinical	JJ	pre-clinical
medical	JJ	medical
students	NNS	student
32240633/	CD	@card@
Likelihood	NN	likelihood
of	IN	of
survival	NN	survival
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
33631857/	CD	@card@
Managing	NP	Managing
COVID-19	NP	<unknown>
in	IN	in
patients	NNS	patient
with	IN	with
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
:	:	:
navigating	VBG	navigate
unprecedented	JJ	unprecedented
challenges	NNS	challenge
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
demanded	VBN	demand
a	DT	a
rapid	JJ	rapid
adaptation	NN	adaptation
in	IN	in
healthcare	NN	<unknown>
provision	NN	provision
,	,	,
including	VBG	include
patients	NNS	patient
with	IN	with
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
(	(	(
IBD	NN	IBD
)	)	)
.	SENT	.
This	DT	this
viewpoint	NN	viewpoint
discusses	VBZ	discuss
some	DT	some
of	IN	of
the	DT	the
unique	JJ	unique
challenges	NNS	challenge
in	IN	in
managing	VBG	manage
comorbid	JJ	comorbid
IBD	NN	IBD
and	CC	and
COVID-10	NP	<unknown>
experienced	VBD	experience
by	IN	by
our	PP$	our
team	NN	team
at	IN	at
The	DT	the
Royal	NP	Royal
Melbourne	NP	Melbourne
Hospital	NP	Hospital
,	,	,
which	WDT	which
was	VBD	be
at	IN	at
the	DT	the
epicentre	NN	epicentre
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
'	POS	'
second-wave	NN	<unknown>
'	POS	'
surge	NN	surge
in	IN	in
Melbourne	NP	Melbourne
.	SENT	.
32499903/	CD	@card@
2020PMD	JJ	<unknown>
,	,	,
30-years	JJ	<unknown>
of	IN	of
Translational	JJ	translational
Mobility	NN	mobility
Medicine	NN	medicine
at	IN	at
the	DT	the
time	NN	time
of	IN	of
COVID-19	NP	<unknown>
outbreak	NN	outbreak
:	:	:
Last-minute	JJ	last-minute
forewords	NNS	foreword
from	IN	from
the	DT	the
editor	NN	editor
In	IN	in
the	DT	the
autumn	NN	autumn
of	IN	of
2019	CD	@card@
,	,	,
the	DT	the
organizers	NNS	organizer
of	IN	of
the	DT	the
2020	CD	@card@
Padua	NP	Padua
Muscle	NN	muscle
Days	NNS	day
planned	VBD	plan
an	DT	an
intense	JJ	intense
program	NN	program
,	,	,
which	WDT	which
was	VBD	be
to	TO	to
be	VB	be
held	VBN	hold
from	IN	from
March	NP	March
18	CD	@card@
to	TO	to
March	NP	March
21	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
The	DT	the
program	NN	program
included	VBD	include
eight	CD	eight
Scientific	NP	Scientific
Sessions	NP	Sessions
to	TO	to
occur	VB	occur
over	IN	over
three	CD	three
full	JJ	full
days	NNS	day
at	IN	at
either	DT	either
Padova	NP	Padova
University	NP	University
or	CC	or
the	DT	the
Hotel	NP	Hotel
Augustus	NP	Augustus
on	IN	on
Euganei	NP	<unknown>
Hills	NP	Hills
(	(	(
Padova	NP	Padova
)	)	)
,	,	,
Italy	NP	Italy
.	SENT	.
Abruptly	RB	abruptly
,	,	,
however	RB	however
,	,	,
in	IN	in
early	JJ	early
January	NP	January
the	DT	the
Coronavirus	NP	<unknown>
COVID-19	NP	<unknown>
outbreak	NN	outbreak
started	VBD	start
in	IN	in
China	NP	China
and	CC	and
changed	VBD	change
the	DT	the
world	NN	world
perspectives	NNS	perspective
and	CC	and
expectations	NNS	expectation
.	SENT	.
In	IN	in
Italy	NP	Italy
,	,	,
it	PP	it
started	VBD	start
in	IN	in
Lombardy	NP	Lombardy
and	CC	and
Veneto	NP	Veneto
,	,	,
two	CD	two
main	JJ	main
industrial	JJ	industrial
areas	NNS	area
of	IN	of
the	DT	the
country	NN	country
with	IN	with
intense	JJ	intense
connections	NNS	connection
and	CC	and
interchanges	VBZ	interchange
of	IN	of
people	NNS	people
and	CC	and
commercial	JJ	commercial
activities	NNS	activity
with	IN	with
China	NP	China
.	SENT	.
Indeed	RB	indeed
,	,	,
the	DT	the
virus	NN	virus
was	VBD	be
first	RB	first
isolated	VBN	isolate
from	IN	from
a	DT	a
couple	NN	couple
of	IN	of
Chinese	JJ	Chinese
tourists	NNS	tourist
,	,	,
who	WP	who
inadvertently	RB	inadvertently
incubated	VBD	incubate
the	DT	the
infection	NN	infection
during	IN	during
their	PP$	their
visit	NN	visit
to	TO	to
many	JJ	many
towns	NNS	town
in	IN	in
Italy	NP	Italy
.	SENT	.
Within	IN	within
the	DT	the
following	VBG	follow
two	CD	two
weeks	NNS	week
,	,	,
the	DT	the
epidemic	NN	epidemic
had	VBD	have
the	DT	the
first	JJ	first
Italian	JJ	Italian
cases	NNS	case
and	CC	and
victims	NNS	victim
in	IN	in
an	DT	an
area	NN	area
south	NN	south
of	IN	of
Milan	NP	Milan
and	CC	and
in	IN	in
a	DT	a
Village	NP	Village
of	IN	of
the	DT	the
Euganei	NP	<unknown>
Hills	NP	Hills
(	(	(
Vo	NP	Vo
Euganeo	NP	<unknown>
,	,	,
Padova	NP	Padova
)	)	)
.	SENT	.
The	DT	the
village	NN	village
was	VBD	be
immediately	RB	immediately
quarantined	VBN	quarantine
,	,	,
but	CC	but
it	PP	it
was	VBD	be
too	RB	too
late	JJ	late
.	SENT	.
The	DT	the
virus	NN	virus
had	VBD	have
escaped	VBN	escape
the	DT	the
area	NN	area
.	SENT	.
Thus	RB	thus
,	,	,
it	PP	it
was	VBD	be
a	DT	a
mandatory	JJ	mandatory
,	,	,
though	IN	though
difficult	JJ	difficult
decision	NN	decision
(	(	(
made	VBN	make
even	RB	even
before	IN	before
the	DT	the
Italian	JJ	Italian
National	NP	National
Government	NP	Government
posted	VBD	post
rules	NNS	rule
to	TO	to
be	VB	be
followed	VBN	follow
to	TO	to
decrease	VB	decrease
spread	NN	spread
of	IN	of
the	DT	the
infection	NN	infection
)	)	)
,	,	,
to	TO	to
post-pone	NP	<unknown>
the	DT	the
Padua	NP	Padua
Muscle	NN	muscle
Days	NNS	day
meeting	NN	meeting
from	IN	from
18-21	CD	@card@
March	NP	March
,	,	,
2020	CD	@card@
to	TO	to
25-28	CD	@card@
November	NP	November
,	,	,
2020	CD	@card@
.	SENT	.
Luckily	RB	luckily
,	,	,
the	DT	the
vast	JJ	vast
majority	NN	majority
of	IN	of
organizers	NNS	organizer
,	,	,
chairs	NNS	chair
,	,	,
speakers	NNS	speaker
,	,	,
and	CC	and
attendees	NNS	attendee
accepted	VBD	accept
the	DT	the
decision	NN	decision
and	CC	and
have	VBP	have
assured	VBN	assure
their	PP$	their
presence	NN	presence
in	IN	in
late	JJ	late
November	NP	November
,	,	,
despite	IN	despite
the	DT	the
coincidence	NN	coincidence
with	IN	with
the	DT	the
Thanksgiving	NP	Thanksgiving
holiday	NN	holiday
in	IN	in
the	DT	the
US	NP	US
.	SENT	.
Currently	RB	currently
,	,	,
the	DT	the
only	JJ	only
changes	NNS	change
in	IN	in
the	DT	the
program	NN	program
are	VBP	be
the	DT	the
new	JJ	new
dates	NNS	date
;	:	;
however	RB	however
,	,	,
it	PP	it
is	VBZ	be
difficult	JJ	difficult
to	TO	to
forecast	VB	forecast
the	DT	the
future	NN	future
.	SENT	.
Anyhow	RB	anyhow
,	,	,
the	DT	the
rationale	NN	rationale
of	IN	of
the	DT	the
decision	NN	decision
to	TO	to
post-pone	NN	<unknown>
2020PMD	NNS	<unknown>
was	VBD	be
reinforced	VBN	reinforce
by	IN	by
the	DT	the
actions	NNS	action
of	IN	of
many	JJ	many
organizers	NNS	organizer
of	IN	of
international	JJ	international
events	NNS	event
.	SENT	.
One	CD	one
of	IN	of
the	DT	the
most	RBS	most
recent	JJ	recent
examples	NNS	example
is	VBZ	be
the	DT	the
March	NP	March
6	CD	@card@
,	,	,
2020	CD	@card@
decision	NN	decision
of	IN	of
the	DT	the
leaders	NNS	leader
of	IN	of
the	DT	the
Experimental	JJ	experimental
Biology	NN	biology
Host	NN	Host
Societies	NNS	society
to	TO	to
cancel	VB	cancel
Experimental	JJ	experimental
Biology	NN	biology
(	(	(
EB	NP	EB
)	)	)
2020	CD	@card@
,	,	,
set	VBN	set
to	TO	to
take	VB	take
place	NN	place
April	NP	April
4-7	CD	@card@
in	IN	in
San	NP	San
Diego	NP	Diego
,	,	,
California	NP	California
,	,	,
USA	NP	USA
.	SENT	.
All	PDT	all
these	DT	these
active	JJ	active
civil	JJ	civil
responses	NNS	response
to	TO	to
world	NN	world
dangers	NNS	danger
are	VBP	be
mandatory	JJ	mandatory
to	TO	to
avoid	VB	avoid
those	DT	those
military	JJ	military
responses	NNS	response
that	WDT	that
are	VBP	be
easy	JJ	easy
to	TO	to
start	VB	start
,	,	,
but	CC	but
provide	VB	provide
the	DT	the
worst	JJS	bad
results	NNS	result
.	SENT	.
How	WRB	how
do	VBP	do
we	PP	we
not	RB	not
lose	VBP	lose
half	NN	half
of	IN	of
the	DT	the
2020	CD	@card@
year	NN	year
?	SENT	?
The	DT	the
option	NN	option
is	VBZ	be
to	TO	to
try	VB	try
to	TO	to
achieve	VB	achieve
some	DT	some
of	IN	of
the	DT	the
goals	NNS	goal
of	IN	of
the	DT	the
meeting	NN	meeting
by	IN	by
long-distance	JJ	long-distance
communications	NNS	communication
.	SENT	.
Thus	RB	thus
,	,	,
the	DT	the
Collection	NN	collection
of	IN	of
Abstracts	NNS	abstract
will	MD	will
be	VB	be
,	,	,
as	RB	as
originally	RB	originally
planned	VBN	plan
,	,	,
e-published	VBN	e-publish
in	IN	in
this	DT	this
30(1)	JJ	<unknown>
2020	CD	@card@
Issue	NN	issue
of	IN	of
the	DT	the
European	JJ	European
Journal	NN	journal
of	IN	of
Translational	JJ	translational
Myology	NN	myology
(	(	(
EJTM	NP	<unknown>
)	)	)
together	RB	together
with	IN	with
the	DT	the
many	JJ	many
EJTM	NP	<unknown>
Communications	NPS	Communications
submitted	VBD	submit
by	IN	by
speakers	NNS	speaker
and	CC	and
attendees	NNS	attendee
of	IN	of
the	DT	the
2020PMD	JJ	<unknown>
.	SENT	.
We	PP	we
may	MD	may
also	RB	also
start	VB	start
the	DT	the
process	NN	process
that	WDT	that
will	MD	will
implement	VB	implement
EMMA	NP	Emma
,	,	,
the	DT	the
European	JJ	European
Mobility	NN	mobility
Medicine	NP	Medicine
Association	NP	Association
,	,	,
by	IN	by
circulating	VBG	circulate
a	DT	a
proposal	NN	proposal
and	CC	and
inviting	VBG	invite
comments	NNS	comment
.	SENT	.
34673261/	CD	@card@
Caution	NN	caution
in	IN	in
underrepresentation	NN	underrepresentation
of	IN	of
older	JJR	old
adults	NNS	adult
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
on	IN	on
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
We	PP	we
read	VBP	read
with	IN	with
great	JJ	great
interest	NN	interest
the	DT	the
article	NN	article
"	''	"
Underrepresentation	NN	Underrepresentation
of	IN	of
older	JJR	old
adults	NNS	adult
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
on	IN	on
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
:	:	:
A	DT	a
systematic	JJ	systematic
review	NN	review
"	''	"
written	VBN	write
by	IN	by
Nicola	NP	Nicola
Veronese	JJ	Veronese
et	FW	et
al.	FW	al.
This	DT	this
important	JJ	important
work	NN	work
demonstrated	VBD	demonstrate
that	IN	that
medications	NNS	medication
and	CC	and
vaccines	NNS	vaccine
commonly	RB	commonly
used	VBN	use
in	IN	in
older	JJR	old
adults	NNS	adult
have	VBP	have
not	RB	not
been	VBN	be
adequately	RB	adequately
evaluated	VBN	evaluate
.	SENT	.
Concerning	VBG	concern
this	DT	this
systematic	JJ	systematic
review	NN	review
,	,	,
we	PP	we
shall	MD	shall
like	VB	like
to	TO	to
mention	VB	mention
some	DT	some
certain	JJ	certain
points	NNS	point
deserved	VBD	deserve
to	TO	to
be	VB	be
attended	VBN	attend
by	IN	by
the	DT	the
authors	NNS	author
.	SENT	.
34008930/	CD	@card@
Clinical	JJ	clinical
characteristics	NNS	characteristic
and	CC	and
outcomes	NNS	outcome
of	IN	of
1,331	CD	@card@
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
:	:	:
HM	UH	hm
Spanish	JJ	Spanish
Cohort	NN	cohort
Spain	NP	Spain
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
European	JJ	European
countries	NNS	country
most	RBS	most
affected	VBN	affect
by	IN	by
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Epidemiologic	JJ	epidemiologic
studies	NNS	study
are	VBP	be
warranted	VBN	warrant
to	TO	to
improve	VB	improve
the	DT	the
disease	NN	disease
understanding	NN	understanding
,	,	,
evaluate	VB	evaluate
the	DT	the
care	NN	care
procedure	NN	procedure
and	CC	and
prepare	VB	prepare
for	IN	for
futures	NNS	future
waves	NNS	wave
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
the	DT	the
study	NN	study
was	VBD	be
to	TO	to
describe	VB	describe
epidemiologic	JJ	epidemiologic
characteristics	NNS	characteristic
associated	VBN	associate
with	IN	with
hospitalized	VBN	hospitalize
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
real-world	NN	real-world
,	,	,
observational	JJ	observational
,	,	,
multicenter	NN	multicenter
and	CC	and
retrospective	JJ	retrospective
study	NN	study
screened	VBD	screen
all	DT	all
consecutive	JJ	consecutive
patients	NNS	patient
admitted	VBD	admit
to	TO	to
8	CD	@card@
Spanish	JJ	Spanish
private	JJ	private
hospitals	NNS	hospital
.	SENT	.
Inclusion	NN	inclusion
criteria	NNS	criterion
:	:	:
hospitalized	VBN	hospitalize
adults	NNS	adult
(	(	(
age&gt	NN	<unknown>
;	:	;
=18	JJ	=@card@
years	NNS	year
old	JJ	old
)	)	)
with	IN	with
clinically	RB	clinically
and	CC	and
radiologically	RB	radiologically
findings	NNS	finding
compatible	JJ	compatible
with	IN	with
COVID-19	NP	<unknown>
disease	NN	disease
from	IN	from
March	NP	March
1st	JJ	1st
to	TO	to
April	NP	April
5th	JJ	5th
,	,	,
2020	CD	@card@
.	SENT	.
Exclusion	NN	exclusion
criteria	NNS	criterion
:	:	:
patients	NNS	patient
presenting	VBG	present
negative	JJ	negative
PCR	NP	PCR
for	IN	for
SARS-CoV-2	NP	<unknown>
during	IN	during
the	DT	the
first	JJ	first
7	CD	@card@
days	NNS	day
from	IN	from
hospital	NN	hospital
admission	NN	admission
,	,	,
transfer	VB	transfer
to	TO	to
a	DT	a
hospital	NN	hospital
not	RB	not
belonging	VBG	belong
to	TO	to
the	DT	the
HM	UH	hm
consortium	NN	consortium
,	,	,
lack	NN	lack
of	IN	of
data	NNS	datum
and	CC	and
discharge	NN	discharge
against	IN	against
medical	JJ	medical
advice	NN	advice
in	IN	in
emergency	NN	emergency
departments	NNS	department
.	SENT	.
One	CD	one
thousand	CD	thousand
and	CC	and
three	CD	three
hundred	CD	hundred
thirty-one	JJ	Thirty-one
COVID-19	NP	<unknown>
patients	NNS	patient
(	(	(
medium	NN	medium
age	NN	age
66.9	CD	@card@
years	NNS	year
old	JJ	old
;	:	;
males	NNS	male
n=	NN	<unknown>
841	CD	@card@
,	,	,
medium	JJ	medium
length	NN	length
of	IN	of
hospital	NN	hospital
stayed	VBD	stay
8	CD	@card@
days	NNS	day
,	,	,
non-survivors	NNS	non-survivor
n=233	NN	<unknown>
)	)	)
were	VBD	be
analyzed	VBN	analyze
.	SENT	.
One	CD	one
hundred	CD	hundred
and	CC	and
fifteen	CD	fifteen
were	VBD	be
admitted	VBN	admit
to	TO	to
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
medium	JJ	medium
length	NN	length
of	IN	of
stay	NN	stay
16	CD	@card@
days	NNS	day
,	,	,
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
n=	NN	<unknown>
95	CD	@card@
,	,	,
septic	JJ	septic
shock	NN	shock
n=	NN	<unknown>
37	CD	@card@
and	CC	and
renal	JJ	renal
replacement	NN	replacement
therapy	NN	therapy
n=	NP	<unknown>
17	CD	@card@
)	)	)
.	SENT	.
Age	NN	age
,	,	,
male	JJ	male
gender	NN	gender
,	,	,
leukocytes	NNS	<unknown>
,	,	,
platelets	NNS	platelet
,	,	,
oxygen	NN	oxygen
saturation	NN	saturation
,	,	,
chronic	JJ	chronic
therapy	NN	therapy
with	IN	with
steroids	NNS	steroid
and	CC	and
treatment	NN	treatment
with	IN	with
hydroxychloroquine/azithromycin	NN	<unknown>
were	VBD	be
independent	JJ	independent
factors	NNS	factor
associated	VBN	associate
with	IN	with
mortality	NN	mortality
.	SENT	.
The	DT	the
proportion	NN	proportion
of	IN	of
patients	NNS	patient
that	WDT	that
survive	VBP	survive
and	CC	and
received	VBN	receive
tocilizumab	NN	<unknown>
and	CC	and
steroids	NNS	steroid
were	VBD	be
lesser	JJR	lesser
and	CC	and
higher	JJR	high
respectively	RB	respectively
than	IN	than
those	DT	those
that	WDT	that
die	VBP	die
,	,	,
but	CC	but
their	PP$	their
association	NN	association
was	VBD	be
not	RB	not
significant	JJ	significant
.	SENT	.
Overall	JJ	overall
crude	JJ	crude
mortality	NN	mortality
rate	NN	rate
was	VBD	be
17.5	CD	@card@
%	NN	%
,	,	,
rising	VBG	rise
up	RP	up
to	TO	to
36.5	CD	@card@
%	NN	%
in	IN	in
the	DT	the
subgroup	NN	subgroup
of	IN	of
patients	NNS	patient
that	WDT	that
were	VBD	be
admitted	VBN	admit
to	TO	to
the	DT	the
intensive	JJ	intensive
care	NN	care
unit	NN	unit
.	SENT	.
Seven	CD	seven
factors	NNS	factor
impact	NN	impact
in	IN	in
hospital	NN	hospital
mortality	NN	mortality
.	SENT	.
No	DT	no
immunomodulatory	JJ	immunomodulatory
intervention	NN	intervention
were	VBD	be
associated	VBN	associate
with	IN	with
in-hospital	JJ	in-hospital
mortality	NN	mortality
.	SENT	.
32088847/	CD	@card@
18F-FDG	JJ	<unknown>
PET/CT	JJ	<unknown>
findings	NNS	finding
of	IN	of
COVID-19	NP	<unknown>
:	:	:
a	DT	a
series	NN	series
of	IN	of
four	CD	four
highly	RB	highly
suspected	VBN	suspect
cases	NNS	case
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
case	NN	case
series	NN	series
is	VBZ	be
to	TO	to
illustrate	VB	illustrate
the	DT	the
18F-FDG	JJ	<unknown>
PET/CT	NN	<unknown>
findings	NNS	finding
of	IN	of
patients	NNS	patient
with	IN	with
acute	JJ	acute
respiratory	JJ	respiratory
disease	NN	disease
caused	VBN	cause
by	IN	by
COVID-19	NP	<unknown>
in	IN	in
Wuhan	NP	Wuhan
,	,	,
Hubei	NP	Hubei
province	NN	province
of	IN	of
China	NP	China
.	SENT	.
We	PP	we
describe	VBP	describe
the	DT	the
18F-FDG	JJ	<unknown>
PET/CT	NN	<unknown>
results	NNS	result
from	IN	from
four	CD	four
patients	NNS	patient
who	WP	who
were	VBD	be
admitted	VBN	admit
to	TO	to
the	DT	the
hospital	NN	hospital
with	IN	with
respiratory	JJ	respiratory
symptoms	NNS	symptom
and	CC	and
fever	NN	fever
between	IN	between
January	NP	January
13	CD	@card@
and	CC	and
January	NP	January
20	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
when	WRB	when
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
was	VBD	be
still	RB	still
unrecognized	JJ	unrecognized
and	CC	and
the	DT	the
virus	NN	virus
infectivity	NN	infectivity
was	VBD	be
unknown	JJ	unknown
.	SENT	.
A	DT	a
retrospective	JJ	retrospective
review	NN	review
of	IN	of
the	DT	the
patients	NNS	patient
'	POS	'
medical	JJ	medical
history	NN	history
,	,	,
clinical	JJ	clinical
and	CC	and
laboratory	NN	laboratory
data	NNS	datum
,	,	,
as	RB	as
well	RB	well
as	IN	as
imaging	NN	imaging
findings	NNS	finding
strongly	RB	strongly
suggested	VBD	suggest
a	DT	a
diagnosis	NN	diagnosis
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
All	DT	all
patients	NNS	patient
had	VBD	have
peripheral	JJ	peripheral
ground-glass	NN	ground-glass
opacities	NNS	opacity
and/or	CC	and/or
lung	NN	lung
consolidations	NNS	consolidation
in	IN	in
more	JJR	more
than	IN	than
two	CD	two
pulmonary	JJ	pulmonary
lobes	NNS	lobe
.	SENT	.
Lung	NN	lung
lesions	NNS	lesion
were	VBD	be
characterized	VBN	characterize
by	IN	by
a	DT	a
high	JJ	high
18F-FDG	JJ	<unknown>
uptake	NN	uptake
and	CC	and
there	EX	there
was	VBD	be
evidence	NN	evidence
of	IN	of
lymph	NN	lymph
node	NN	node
involvement	NN	involvement
.	SENT	.
Conversely	RB	conversely
,	,	,
disseminated	VBN	disseminate
disease	NN	disease
was	VBD	be
absent	JJ	absent
,	,	,
a	DT	a
finding	NN	finding
suggesting	VBG	suggest
that	IN	that
COVID-19	NP	<unknown>
has	VBZ	have
pulmonary	JJ	pulmonary
tropism	NN	tropism
.	SENT	.
Although	IN	although
18F-FDG	NP	<unknown>
PET/CT	NP	<unknown>
cannot	MD	can
be	VB	be
routinely	RB	routinely
used	VBN	use
in	IN	in
an	DT	an
emergency	NN	emergency
setting	NN	setting
and	CC	and
is	VBZ	be
generally	RB	generally
not	RB	not
recommended	VBN	recommend
for	IN	for
infectious	JJ	infectious
diseases	NNS	disease
,	,	,
our	PP$	our
pilot	NN	pilot
data	NNS	datum
shed	VBD	shed
light	NN	light
on	IN	on
the	DT	the
potential	JJ	potential
clinical	JJ	clinical
utility	NN	utility
of	IN	of
this	DT	this
imaging	NN	imaging
technique	NN	technique
in	IN	in
the	DT	the
differential	JJ	differential
diagnosis	NN	diagnosis
of	IN	of
complex	JJ	complex
cases	NNS	case
.	SENT	.
35313091/	CD	@card@
Assessing	VBG	assess
the	DT	the
Severity	NN	severity
of	IN	of
COVID-19	NP	<unknown>
Lung	NP	Lung
Injury	NP	Injury
in	IN	in
Rheumatic	JJ	rheumatic
Diseases	NNS	disease
versus	IN	versus
the	DT	the
General	NP	General
Population	NP	Population
Using	VBG	use
Deep	JJ	deep
Learning-Derived	JJ	<unknown>
Chest	NN	chest
Radiograph	NN	radiograph
Scores	NNS	score
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
rheumatic	JJ	rheumatic
disease	NN	disease
have	VBP	have
a	DT	a
higher	JJR	high
risk	NN	risk
of	IN	of
mechanical	JJ	mechanical
ventilation	NN	ventilation
than	IN	than
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
We	PP	we
assessed	VBD	assess
lung	NN	lung
involvement	NN	involvement
using	VBG	use
a	DT	a
validated	VBN	validate
deep	JJ	deep
learning	NN	learning
algorithm	NN	algorithm
that	WDT	that
extracts	VBZ	extract
a	DT	a
quantitative	JJ	quantitative
measure	NN	measure
of	IN	of
radiographic	JJ	radiographic
lung	NN	lung
disease	NN	disease
severity	NN	severity
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
comparative	JJ	comparative
cohort	NN	cohort
study	NN	study
of	IN	of
rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
&gt	NP	<unknown>
;	:	;
=1chest	JJ	<unknown>
radiograph	NN	radiograph
within	IN	within
+-2	CD	@card@
weeks	NNS	week
of	IN	of
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
and	CC	and
matched	VBN	match
comparators	NNS	comparator
.	SENT	.
We	PP	we
used	VBD	use
unadjusted	JJ	unadjusted
and	CC	and
adjusted	JJ	adjusted
(	(	(
for	IN	for
age	NN	age
,	,	,
Charlson	NP	Charlson
Comorbidity	NP	<unknown>
Index	NP	Index
,	,	,
and	CC	and
interstitial	JJ	interstitial
lung	NN	lung
disease	NN	disease
)	)	)
quantile	JJ	<unknown>
regression	NN	regression
to	TO	to
compare	VB	compare
the	DT	the
maximum	JJ	maximum
Pulmonary	JJ	pulmonary
X-Ray	NN	x-ray
Severity	NN	severity
(	(	(
PXS	NP	PXS
)	)	)
score	NN	score
at	IN	at
the	DT	the
10th-90th	JJ	<unknown>
percentiles	NNS	percentile
between	IN	between
groups	NNS	group
.	SENT	.
We	PP	we
evaluated	VBD	evaluate
the	DT	the
association	NN	association
of	IN	of
severe	JJ	severe
PXS	NP	PXS
score	NN	score
(	(	(
&gt	NP	<unknown>
;	:	;
9	CD	@card@
)	)	)
with	IN	with
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
death	NN	death
using	VBG	use
Cox	NP	Cox
regression	NN	regression
.	SENT	.
We	PP	we
identified	VBD	identify
70	CD	@card@
patients	NNS	patient
with	IN	with
rheumatic	JJ	rheumatic
disease	NN	disease
and	CC	and
463	CD	@card@
general	JJ	general
population	NN	population
comparators	NNS	comparator
.	SENT	.
Maximum	JJ	maximum
PXS	NP	PXS
scores	NNS	score
were	VBD	be
similar	JJ	similar
in	IN	in
the	DT	the
rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
and	CC	and
comparators	NNS	comparator
at	IN	at
the	DT	the
10th-60th	JJ	<unknown>
percentiles	NNS	percentile
but	CC	but
significantly	RB	significantly
higher	JJR	high
among	IN	among
rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
at	IN	at
the	DT	the
70th-90th	JJ	<unknown>
percentiles	NNS	percentile
(	(	(
90th	NN	<unknown>
percentile	NN	percentile
score	NN	score
of	IN	of
10.2	CD	@card@
vs.	IN	vs.
9.2	CD	@card@
,	,	,
adjusted	VBN	adjust
p=0.03	NN	<unknown>
)	)	)
.	SENT	.
Rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
have	VB	have
a	DT	a
PXS	NP	PXS
score	NN	score
&gt	NN	&gt
;	:	;
9	CD	@card@
(	(	(
20	CD	@card@
%	NN	%
vs.	IN	vs.
11	CD	@card@
%	NN	%
,	,	,
p=0.02	NP	<unknown>
)	)	)
,	,	,
indicating	VBG	indicate
severe	JJ	severe
pulmonary	JJ	pulmonary
disease	NN	disease
.	SENT	.
Rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
with	IN	with
PXS	NP	PXS
scores	NNS	score
&gt	NN	&gt
;	:	;
9	CD	@card@
vs.	NN	vs.
&lt	NN	&lt
;	:	;
=9	NP	<unknown>
had	VBD	have
higher	JJR	high
risk	NN	risk
of	IN	of
mechanical	JJ	mechanical
ventilation	NN	ventilation
(	(	(
HR	NP	HR
24.1	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
6.7	CD	@card@
,	,	,
86.9	CD	@card@
]	SYM	]
)	)	)
and	CC	and
death	NN	death
(	(	(
HR	NP	HR
8.2	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.7	CD	@card@
,	,	,
90.4	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
Rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
had	VBD	have
more	JJR	more
severe	JJ	severe
radiographic	JJ	radiographic
lung	NN	lung
involvement	NN	involvement
than	IN	than
comparators	NNS	comparator
.	SENT	.
Higher	JJR	high
PXS	NP	PXS
scores	NNS	score
were	VBD	be
associated	VBN	associate
with	IN	with
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
will	MD	will
be	VB	be
important	JJ	important
for	IN	for
future	JJ	future
studies	NNS	study
leveraging	VBG	leverage
big	JJ	big
data	NNS	datum
to	TO	to
assess	VB	assess
COVID-19	NP	<unknown>
outcomes	NNS	outcome
in	IN	in
rheumatic	JJ	rheumatic
disease	NN	disease
patients	NNS	patient
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VBN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VBD	reserve
.	SENT	.
33941488/	CD	@card@
Italian	JJ	Italian
association	NN	association
for	IN	for
the	DT	the
study	NN	study
of	IN	of
the	DT	the
liver	NN	liver
position	NN	position
statement	NN	statement
on	IN	on
SARS-CoV2	NP	<unknown>
vaccination	NN	vaccination
The	DT	the
vaccination	NN	vaccination
campaign	NN	campaign
against	IN	against
Sars-CoV-2	NP	<unknown>
commenced	VBD	commence
in	IN	in
Italy	NP	Italy
at	IN	at
the	DT	the
end	NN	end
of	IN	of
December	NP	December
2020	CD	@card@
.	SENT	.
The	DT	the
first	JJ	first
ones	NNS	one
to	TO	to
receive	VB	receive
the	DT	the
immunization	NN	immunization
against	IN	against
the	DT	the
virus	NN	virus
were	VBD	be
the	DT	the
health	NN	health
workers	NNS	worker
and	CC	and
the	DT	the
residents	NNS	resident
of	IN	of
nursing	NN	nursing
homes	NNS	home
,	,	,
following	VBG	follow
which	WDT	which
the	DT	the
vaccine	NN	vaccine
would	MD	would
be	VB	be
available	JJ	available
for	IN	for
the	DT	the
entire	JJ	entire
population	NN	population
,	,	,
beginning	VBG	begin
with	IN	with
the	DT	the
most	RBS	most
vulnerable	JJ	vulnerable
individuals	NNS	individual
.	SENT	.
SARS-CoV2	JJ	<unknown>
vaccines	NNS	vaccine
have	VBP	have
been	VBN	be
demonstrated	VBN	demonstrate
to	TO	to
be	VB	be
safe	JJ	safe
for	IN	for
the	DT	the
general	JJ	general
population	NN	population
,	,	,
although	IN	although
no	DT	no
data	NNS	datum
for	IN	for
patients	NNS	patient
with	IN	with
liver	NN	liver
diseases	NNS	disease
or	CC	or
those	NNS	those
having	VBG	have
undergone	VBN	undergo
liver	JJR	live
transplantation	NN	transplantation
are	VBP	be
available	JJ	available
so	RB	so
far	RB	far
.	SENT	.
The	DT	the
present	JJ	present
position	NN	position
statement	NN	statement
AISF	NP	<unknown>
is	VBZ	be
an	DT	an
attempt	NN	attempt
to	TO	to
suggest	VB	suggest
,	,	,
based	VBN	base
on	IN	on
the	DT	the
published	VBN	publish
data	NNS	datum
on	IN	on
the	DT	the
impact	NN	impact
of	IN	of
Sars-Cov-2	JJ	<unknown>
infection	NN	infection
in	IN	in
patients	NNS	patient
with	IN	with
chronic	JJ	chronic
liver	NN	liver
disease	NN	disease
,	,	,
a	DT	a
possible	JJ	possible
priority	NN	priority
for	IN	for
vaccination	NN	vaccination
for	IN	for
this	DT	this
category	NN	category
of	IN	of
patients	NNS	patient
.	SENT	.
35122732/	CD	@card@
Time-dependent	JJ	time-dependent
bias	NN	bias
when	WRB	when
analysing	VBG	analyse
COVID-19-associated	JJ	COVID-19-associated
pulmonary	JJ	pulmonary
aspergillosis	NN	aspergillosis
33435378/	CD	@card@
Entropy	NN	entropy
Analysis	NN	analysis
of	IN	of
COVID-19	NP	<unknown>
Cardiovascular	NP	Cardiovascular
Signals	VBZ	signal
The	DT	the
world	NN	world
has	VBZ	have
faced	VBN	face
a	DT	a
coronavirus	NN	coronavirus
outbreak	NN	outbreak
,	,	,
which	WDT	which
,	,	,
in	IN	in
addition	NN	addition
to	TO	to
lung	NN	lung
complications	NNS	complication
,	,	,
has	VBZ	have
caused	VBN	cause
other	JJ	other
serious	JJ	serious
problems	NNS	problem
,	,	,
including	VBG	include
cardiovascular	JJ	cardiovascular
.	SENT	.
There	EX	there
is	VBZ	be
still	RB	still
no	DT	no
explanation	NN	explanation
for	IN	for
the	DT	the
mechanisms	NNS	mechanism
of	IN	of
coronavirus	NNS	<unknown>
that	WDT	that
trigger	VBP	trigger
dysfunction	NN	dysfunction
of	IN	of
the	DT	the
cardiac	JJ	cardiac
autonomic	JJ	autonomic
nervous	JJ	nervous
system	NN	system
(	(	(
ANS	NP	Ans
)	)	)
.	SENT	.
We	PP	we
believe	VBP	believe
that	IN	that
the	DT	the
complex	JJ	complex
mechanisms	NNS	mechanism
that	WDT	that
change	VBP	change
the	DT	the
status	NN	status
of	IN	of
ANS	NP	Ans
could	MD	could
only	RB	only
be	VB	be
solved	VBN	solve
by	IN	by
advanced	JJ	advanced
multidimensional	JJ	multidimensional
analysis	NN	analysis
of	IN	of
many	JJ	many
variables	NNS	variable
,	,	,
obtained	VBN	obtain
both	CC	both
from	IN	from
the	DT	the
original	JJ	original
cardiovascular	JJ	cardiovascular
signals	NNS	signal
and	CC	and
from	IN	from
laboratory	NN	laboratory
analysis	NN	analysis
and	CC	and
detailed	JJ	detailed
patient	JJ	patient
history	NN	history
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
paper	NN	paper
is	VBZ	be
to	TO	to
analyze	VB	analyze
different	JJ	different
measures	NNS	measure
of	IN	of
entropy	NN	entropy
as	IN	as
potential	JJ	potential
dimensions	NNS	dimension
of	IN	of
the	DT	the
multidimensional	JJ	multidimensional
space	NN	space
of	IN	of
cardiovascular	JJ	cardiovascular
data	NNS	datum
.	SENT	.
The	DT	the
measures	NNS	measure
were	VBD	be
applied	VBN	apply
to	TO	to
heart	NN	heart
rate	NN	rate
and	CC	and
systolic	JJ	systolic
blood	NN	blood
pressure	NN	pressure
signals	NNS	signal
collected	VBN	collect
from	IN	from
116	CD	@card@
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
77	CD	@card@
healthy	JJ	healthy
controls	NNS	control
.	SENT	.
Methods	NNS	method
that	WDT	that
indicate	VBP	indicate
a	DT	a
statistically	RB	statistically
significant	JJ	significant
difference	NN	difference
between	IN	between
patients	NNS	patient
with	IN	with
different	JJ	different
levels	NNS	level
of	IN	of
infection	NN	infection
and	CC	and
healthy	JJ	healthy
controls	NNS	control
will	MD	will
be	VB	be
used	VBN	use
for	IN	for
further	JJR	further
multivariate	JJ	multivariate
research	NN	research
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
it	PP	it
was	VBD	be
shown	VBN	show
that	IN	that
a	DT	a
statistically	RB	statistically
significant	JJ	significant
difference	NN	difference
between	IN	between
healthy	JJ	healthy
controls	NNS	control
and	CC	and
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
was	VBD	be
shown	VBN	show
by	IN	by
sample	NN	sample
entropy	NN	entropy
applied	VBN	apply
to	TO	to
integrated	JJ	integrated
transformed	VBN	transform
probability	NN	probability
signals	NNS	signal
,	,	,
common	JJ	common
symbolic	JJ	symbolic
dynamics	NNS	dynamics
entropy	NN	entropy
,	,	,
and	CC	and
copula	NN	copula
parameters	NNS	parameter
.	SENT	.
Statistical	JJ	statistical
significance	NN	significance
between	IN	between
serious	JJ	serious
and	CC	and
mild	JJ	mild
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
can	MD	can
only	RB	only
be	VB	be
achieved	VBN	achieve
by	IN	by
cross-entropies	NNS	cross-entropy
of	IN	of
heart	NN	heart
rate	NN	rate
signals	NNS	signal
and	CC	and
systolic	JJ	systolic
pressure	NN	pressure
.	SENT	.
This	DT	this
result	NN	result
contributes	VBZ	contribute
to	TO	to
the	DT	the
hypothesis	NN	hypothesis
that	IN	that
the	DT	the
severity	NN	severity
of	IN	of
COVID-19	NP	<unknown>
disease	NN	disease
is	VBZ	be
associated	VBN	associate
with	IN	with
ANS	NP	Ans
disorder	NN	disorder
and	CC	and
encourages	VBZ	encourage
further	JJR	further
research	NN	research
.	SENT	.
33167115/	CD	@card@
COVID-19	NN	<unknown>
and	CC	and
abortion	NN	abortion
right	RB	right
Induced	VBN	induce
abortion	NN	abortion
has	VBZ	have
always	RB	always
been	VBN	be
a	DT	a
challenging	JJ	challenging
topic	NN	topic
;	:	;
however	RB	however
,	,	,
it	PP	it
needs	VBZ	need
to	TO	to
be	VB	be
discussed	VBN	discuss
during	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
.	SENT	.
35008505/	CD	@card@
Molecular	JJ	molecular
Networking	NN	networking
for	IN	for
Drug	NP	Drug
Toxicities	NNS	toxicity
Studies	NNS	study
:	:	:
The	DT	the
Case	NN	case
of	IN	of
Hydroxychloroquine	NP	Hydroxychloroquine
in	IN	in
COVID-19	NP	<unknown>
Patients	NPS	Patients
Using	VBG	use
drugs	NNS	drug
to	TO	to
treat	VB	treat
COVID-19	NP	<unknown>
symptoms	NNS	symptom
may	MD	may
induce	VB	induce
adverse	JJ	adverse
effects	NNS	effect
and	CC	and
modify	VB	modify
patient	JJ	patient
outcomes	NNS	outcome
.	SENT	.
These	DT	these
adverse	JJ	adverse
events	NNS	event
may	MD	may
be	VB	be
further	RBR	further
aggravated	VBN	aggravate
in	IN	in
obese	JJ	obese
patients	NNS	patient
,	,	,
who	WP	who
often	RB	often
present	VBP	present
different	JJ	different
illnesses	NNS	illness
such	JJ	such
as	IN	as
metabolic-associated	JJ	metabolic-associated
fatty	JJ	fatty
liver	NN	liver
disease	NN	disease
.	SENT	.
In	IN	in
Rennes	NP	Rennes
University	NP	University
Hospital	NP	Hospital
,	,	,
several	JJ	several
drug	NN	drug
such	JJ	such
as	IN	as
hydroxychloroquine	NN	hydroxychloroquine
(	(	(
HCQ	NP	HCQ
)	)	)
have	VBP	have
been	VBN	be
used	VBN	use
in	IN	in
the	DT	the
clinical	JJ	clinical
trial	NN	trial
HARMONICOV	NP	<unknown>
to	TO	to
treat	VB	treat
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
including	VBG	include
obese	JJ	obese
patients	NNS	patient
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
determine	VB	determine
whether	IN	whether
HCQ	NP	HCQ
metabolism	NN	metabolism
and	CC	and
hepatotoxicity	NN	hepatotoxicity
are	VBP	be
worsened	VBN	worsen
in	IN	in
obese	JJ	obese
patients	NNS	patient
using	VBG	use
an	DT	an
in	IN	in
vivo/in	NN	<unknown>
vitro	NN	<unknown>
approach	NN	approach
.	SENT	.
Liquid	JJ	liquid
chromatography	NN	chromatography
high	JJ	high
resolution	NN	resolution
mass	NN	mass
spectrometry	NN	spectrometry
in	IN	in
combination	NN	combination
with	IN	with
untargeted	JJ	untargeted
screening	NN	screening
and	CC	and
molecular	JJ	molecular
networking	NN	networking
were	VBD	be
employed	VBN	employ
to	TO	to
study	VB	study
drug	NN	drug
metabolism	NN	metabolism
in	IN	in
vivo	JJ	vivo
(	(	(
patient	NN	patient
's	POS	's
plasma	NN	plasma
)	)	)
and	CC	and
in	IN	in
vitro	NP	Vitro
(	(	(
HepaRG	NP	<unknown>
cells	NNS	cell
and	CC	and
RPTEC	NP	<unknown>
cells	NNS	cell
)	)	)
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
HepaRG	NP	<unknown>
cells	NNS	cell
model	NN	model
were	VBD	be
used	VBN	use
to	TO	to
reproduce	VB	reproduce
pathophysiological	JJ	pathophysiological
features	NNS	feature
of	IN	of
obese	JJ	obese
patient	JJ	patient
metabolism	NN	metabolism
,	,	,
i.e.	FW	i.e.
,	,	,
in	IN	in
the	DT	the
condition	NN	condition
of	IN	of
hepatic	JJ	hepatic
steatosis	NN	<unknown>
.	SENT	.
The	DT	the
metabolic	JJ	metabolic
signature	NN	signature
of	IN	of
HCQ	NP	HCQ
was	VBD	be
modified	VBN	modify
in	IN	in
HepaRG	NP	<unknown>
cells	NNS	cell
cultured	VBN	culture
under	IN	under
a	DT	a
steatosis	NN	<unknown>
condition	NN	condition
and	CC	and
a	DT	a
new	JJ	new
metabolite	NN	metabolite
was	VBD	be
detected	VBN	detect
(	(	(
carboxychloroquine	NN	carboxychloroquine
)	)	)
.	SENT	.
The	DT	the
RPTEC	NP	<unknown>
model	NN	model
was	VBD	be
found	VBN	find
to	TO	to
produce	VB	produce
only	RB	only
one	CD	one
metabolite	NN	metabolite
.	SENT	.
A	DT	a
higher	JJR	high
cytotoxicity	NN	cytotoxicity
of	IN	of
HCQ	NP	HCQ
was	VBD	be
observed	VBN	observe
in	IN	in
HepaRG	NP	<unknown>
cells	NNS	cell
exposed	VBN	expose
to	TO	to
exogenous	JJ	exogenous
fatty	JJ	fatty
acids	NNS	acid
,	,	,
while	IN	while
neutral	JJ	neutral
lipid	NN	lipid
accumulation	NN	accumulation
(	(	(
steatosis	NN	<unknown>
)	)	)
was	VBD	be
further	RBR	further
enhanced	VBN	enhance
in	IN	in
these	DT	these
cells	NNS	cell
.	SENT	.
These	DT	these
in	IN	in
vitro	NN	<unknown>
data	NNS	datum
were	VBD	be
compared	VBN	compare
with	IN	with
the	DT	the
biological	JJ	biological
parameters	NNS	parameter
of	IN	of
17	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
treated	VBN	treat
with	IN	with
HCQ	NP	HCQ
included	VBD	include
in	IN	in
the	DT	the
HARMONICOV	NP	<unknown>
cohort	NN	cohort
.	SENT	.
Overall	RB	overall
,	,	,
our	PP$	our
data	NNS	datum
suggest	VBP	suggest
that	IN	that
steatosis	NN	<unknown>
may	MD	may
be	VB	be
a	DT	a
risk	NN	risk
factor	NN	factor
for	IN	for
altered	JJ	altered
drug	NN	drug
metabolism	NN	metabolism
and	CC	and
possibly	RB	possibly
toxicity	NN	toxicity
of	IN	of
HCQ	NP	HCQ
.	SENT	.
32234343/	CD	@card@
Monitoring	NN	monitoring
transmissibility	NN	<unknown>
and	CC	and
mortality	NN	mortality
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Europe	NP	Europe
As	IN	as
of	IN	of
March	NP	March
10	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
Italy	NP	Italy
had	VBD	have
reported	VBN	report
9172	CD	@card@
COVID-19	NP	<unknown>
cases	NNS	case
with	IN	with
463	CD	@card@
deaths	NNS	death
.	SENT	.
We	PP	we
report	VBP	report
the	DT	the
real-time	JJ	real-time
reproductive	JJ	reproductive
numbers	NNS	number
(R(t))	NN	<unknown>
and	CC	and
case	NN	case
fatality	NN	fatality
rates	NNS	rate
for	IN	for
selected	JJ	selected
European	JJ	European
countries	NNS	country
(	(	(
Italy	NP	Italy
,	,	,
France	NP	France
,	,	,
Germany	NP	Germany
,	,	,
and	CC	and
Spain	NP	Spain
)	)	)
by	IN	by
March	NP	March
9	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
The	DT	the
R(t)	NP	<unknown>
was	VBD	be
greater	JJR	great
than	IN	than
2	CD	@card@
in	IN	in
the	DT	the
selected	JJ	selected
European	JJ	European
countries	NNS	country
,	,	,
indicating	VBG	indicate
that	IN	that
the	DT	the
outbreak	NN	outbreak
will	MD	will
continue	VB	continue
.	SENT	.
As	IN	as
a	DT	a
global	JJ	global
pandemic	NN	pandemic
is	VBZ	be
inevitable	JJ	inevitable
,	,	,
real-time	JJ	real-time
monitoring	NN	monitoring
of	IN	of
transmission	NN	transmission
is	VBZ	be
vital	JJ	vital
for	IN	for
containing	VBG	contain
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
main	JJ	main
objective	NN	objective
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
report	VB	report
the	DT	the
real-time	JJ	real-time
effective	JJ	effective
reproduction	NN	reproduction
numbers	NNS	number
(R(t))	NN	<unknown>
and	CC	and
case	NN	case
fatality	NN	fatality
rates	NNS	rate
(	(	(
CFR	NP	CFR
)	)	)
in	IN	in
Europe	NP	Europe
.	SENT	.
Data	NNS	datum
for	IN	for
this	DT	this
study	NN	study
were	VBD	be
obtained	VBN	obtain
mainly	RB	mainly
from	IN	from
the	DT	the
World	NP	World
Health	NP	Health
Organization	NP	Organization
website	NN	website
,	,	,
up	RB	up
to	TO	to
March	NP	March
9	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
R(t)	NP	<unknown>
were	VBD	be
estimated	VBN	estimate
by	IN	by
exponential	JJ	exponential
growth	NN	growth
rate	NN	rate
(	(	(
EG	NN	EG
)	)	)
and	CC	and
time-dependent	JJ	time-dependent
(	(	(
TD	NP	TD
)	)	)
methods	NNS	method
.	SENT	.
'	''	'
R0	NP	<unknown>
'	POS	'
package	NN	package
in	IN	in
R	NP	R
was	VBD	be
employed	VBN	employ
to	TO	to
estimate	VB	estimate
R(t)	NP	<unknown>
by	IN	by
fitting	VBG	fit
the	DT	the
existing	JJ	existing
epidemic	NN	epidemic
curve	NN	curve
.	SENT	.
Both	CC	both
the	DT	the
naive	JJ	naive
CFR	NP	CFR
(	(	(
nCFR	NN	<unknown>
)	)	)
and	CC	and
adjusted	VBN	adjust
CFR	NP	CFR
(	(	(
aCFR	NP	<unknown>
)	)	)
were	VBD	be
estimated	VBN	estimate
.	SENT	.
With	IN	with
the	DT	the
EG	NN	EG
method	NN	method
,	,	,
R(t)	NP	<unknown>
was	VBD	be
3.27	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
(	(	(
CI	NP	CI
)	)	)
3.17-3.38	CD	@card@
)	)	)
for	IN	for
Italy	NP	Italy
,	,	,
6.32	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
5.72-6.99	CD	@card@
)	)	)
for	IN	for
France	NP	France
,	,	,
6.07	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
5.51-6.69	CD	@card@
)	)	)
for	IN	for
Germany	NP	Germany
,	,	,
and	CC	and
5.08	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
4.51-5.74	CD	@card@
)	)	)
for	IN	for
Spain	NP	Spain
.	SENT	.
With	IN	with
the	DT	the
TD	NP	TD
method	NN	method
,	,	,
the	DT	the
R	NP	R
value	NN	value
for	IN	for
March	NP	March
9	CD	@card@
was	VBD	be
3.10	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
2.21-4.11	CD	@card@
)	)	)
for	IN	for
Italy	NP	Italy
,	,	,
6.56	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
2.04-12.26	CD	@card@
)	)	)
for	IN	for
France	NP	France
,	,	,
4.43	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
1.83-7.92	CD	@card@
)	)	)
for	IN	for
Germany	NP	Germany
,	,	,
and	CC	and
3.95	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
0-10.19	CD	@card@
)	)	)
for	IN	for
Spain	NP	Spain
.	SENT	.
This	DT	this
study	NN	study
provides	VBZ	provide
important	JJ	important
findings	NNS	finding
on	IN	on
the	DT	the
early	JJ	early
outbreak	NN	outbreak
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Europe	NP	Europe
.	SENT	.
Due	JJ	due
to	TO	to
the	DT	the
recent	JJ	recent
rapid	JJ	rapid
increase	NN	increase
in	IN	in
new	JJ	new
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
,	,	,
real-time	JJ	real-time
monitoring	NN	monitoring
of	IN	of
the	DT	the
transmissibility	NN	<unknown>
and	CC	and
mortality	NN	mortality
in	IN	in
Spain	NP	Spain
and	CC	and
France	NP	France
is	VBZ	be
a	DT	a
priority	NN	priority
.	SENT	.
32495819/	CD	@card@
Effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
Plastic	NP	Plastic
Surgery	NN	surgery
Practices	NP	Practices
and	CC	and
Medi-Spas	NP	<unknown>
in	IN	in
Different	NP	Different
Countries	NPS	Countries
32508391/	CD	@card@
Thoughts	NNS	thought
about	IN	about
Public	NP	Public
Space	NP	Space
During	IN	during
Covid-19	NP	<unknown>
Pandemic	NN	pandemic
33491147/	CD	@card@
Lung	NP	Lung
ultrasound	NN	ultrasound
and	CC	and
computed	VBN	compute
tomography	NN	tomography
to	TO	to
monitor	VB	monitor
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
:	:	:
a	DT	a
two-center	JJ	two-center
prospective	JJ	prospective
cohort	NN	cohort
study	NN	study
Lung	NP	Lung
ultrasound	NN	ultrasound
can	MD	can
adequately	RB	adequately
monitor	VB	monitor
disease	NN	disease
severity	NN	severity
in	IN	in
pneumonia	NN	pneumonia
and	CC	and
acute	JJ	acute
respiratory	JJ	respiratory
distress	NN	distress
syndrome	NN	syndrome
.	SENT	.
We	PP	we
hypothesize	VBP	hypothesize
lung	NN	lung
ultrasound	NN	ultrasound
can	MD	can
adequately	RB	adequately
monitor	VB	monitor
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
.	SENT	.
Adult	NN	adult
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
admitted	VBD	admit
to	TO	to
the	DT	the
intensive	JJ	intensive
care	NN	care
unit	NN	unit
of	IN	of
two	CD	two
academic	JJ	academic
hospitals	NNS	hospital
who	WP	who
underwent	VBD	undergo
a	DT	a
12-zone	JJ	<unknown>
lung	NN	lung
ultrasound	NN	ultrasound
and	CC	and
a	DT	a
chest	NN	chest
CT	NP	CT
examination	NN	examination
were	VBD	be
included	VBN	include
.	SENT	.
Baseline	JJ	baseline
characteristics	NNS	characteristic
,	,	,
and	CC	and
outcomes	NNS	outcome
including	VBG	include
composite	JJ	composite
endpoint	NN	endpoint
death	NN	death
or	CC	or
ICU	NP	ICU
stay	VBP	stay
&gt	NN	&gt
;	:	;
30	CD	@card@
days	NNS	day
were	VBD	be
recorded	VBN	record
.	SENT	.
Lung	NN	lung
ultrasound	NN	ultrasound
and	CC	and
CT	NP	CT
images	NNS	image
were	VBD	be
quantified	VBN	quantify
as	IN	as
a	DT	a
lung	NN	lung
ultrasound	NN	ultrasound
score	NN	score
involvement	NN	involvement
index	NN	index
(	(	(
LUSI	NP	<unknown>
)	)	)
and	CC	and
CT	NP	CT
severity	NN	severity
involvement	NN	involvement
index	NN	index
(	(	(
CTSI	NP	<unknown>
)	)	)
.	SENT	.
Primary	JJ	primary
outcome	NN	outcome
was	VBD	be
the	DT	the
correlation	NN	correlation
,	,	,
agreement	NN	agreement
,	,	,
and	CC	and
concordance	NN	concordance
between	IN	between
LUSI	NP	<unknown>
and	CC	and
CTSI	NP	<unknown>
.	SENT	.
Secondary	JJ	secondary
outcome	NN	outcome
was	VBD	be
the	DT	the
association	NN	association
of	IN	of
LUSI	NP	<unknown>
and	CC	and
CTSI	NP	<unknown>
with	IN	with
the	DT	the
composite	JJ	composite
endpoints	NNS	endpoint
.	SENT	.
We	PP	we
included	VBD	include
55	CD	@card@
ultrasound	NN	ultrasound
examinations	NNS	examination
in	IN	in
34	CD	@card@
patients	NNS	patient
,	,	,
which	WDT	which
were	VBD	be
88	CD	@card@
%	NN	%
were	VBD	be
male	JJ	male
,	,	,
with	IN	with
a	DT	a
mean	JJ	mean
age	NN	age
of	IN	of
63	CD	@card@
years	NNS	year
and	CC	and
mean	VB	mean
P/F	NP	P/F
ratio	NN	ratio
of	IN	of
151	CD	@card@
.	SENT	.
The	DT	the
correlation	NN	correlation
between	IN	between
LUSI	NP	<unknown>
and	CC	and
CTSI	NP	<unknown>
was	VBD	be
strong	JJ	strong
(	(	(
r	LS	r
=	SYM	=
0.795	CD	@card@
)	)	)
,	,	,
with	IN	with
an	DT	an
overall	JJ	overall
15	CD	@card@
%	NN	%
bias	NN	bias
,	,	,
and	CC	and
limits	NNS	limit
of	IN	of
agreement	NN	agreement
ranging	VBG	range
-	NN	<unknown>
40	CD	@card@
to	TO	to
9.7	CD	@card@
.	SENT	.
Concordance	NN	concordance
between	IN	between
changes	NNS	change
in	IN	in
sequentially	RB	sequentially
measured	VBN	measure
LUSI	NP	<unknown>
and	CC	and
CTSI	NP	<unknown>
was	VBD	be
81	CD	@card@
%	NN	%
.	SENT	.
In	IN	in
the	DT	the
univariate	JJ	<unknown>
model	NN	model
,	,	,
high	JJ	high
involvement	NN	involvement
on	IN	on
LUSI	NP	<unknown>
and	CC	and
CTSI	NP	<unknown>
were	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
composite	JJ	composite
endpoint	NN	endpoint
.	SENT	.
In	IN	in
the	DT	the
multivariate	JJ	multivariate
model	NN	model
,	,	,
LUSI	NP	<unknown>
was	VBD	be
the	DT	the
only	RB	only
remaining	VBG	remain
independent	JJ	independent
predictor	NN	predictor
.	SENT	.
Lung	NN	lung
ultrasound	NN	ultrasound
can	MD	can
be	VB	be
used	VBN	use
as	IN	as
an	DT	an
alternative	NN	alternative
for	IN	for
chest	NN	chest
CT	NP	CT
in	IN	in
monitoring	VBG	monitor
COVID-19	JJ	<unknown>
pneumonia	NN	pneumonia
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
as	IN	as
it	PP	it
can	MD	can
quantify	VB	quantify
pulmonary	JJ	pulmonary
involvement	NN	involvement
,	,	,
register	NN	register
changes	NNS	change
over	IN	over
the	DT	the
course	NN	course
of	IN	of
the	DT	the
disease	NN	disease
,	,	,
and	CC	and
predict	VB	predict
death	NN	death
or	CC	or
ICU	NP	ICU
stay	VBP	stay
&gt	NN	&gt
;	:	;
30	CD	@card@
days	NNS	day
.	SENT	.
Trial	NN	trial
registration	NN	registration
:	:	:
NTR	NP	NTR
,	,	,
NL8584	NP	<unknown>
.	SENT	.
Registered	VBN	register
01	CD	@card@
May	NP	May
2020:retrospectively	JJ	<unknown>
registered	JJ	registered
,	,	,
https://www.trialregister.nl/trial/8584	JJ	https://www.trialregister.nl/trial@card@
34427682/	CD	@card@
Safety	NN	safety
and	CC	and
Efficacy	NN	efficacy
of	IN	of
Telehealth	NP	Telehealth
Medication	NN	medication
Abortions	NNS	abortion
in	IN	in
the	DT	the
US	NP	US
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
This	DT	this
cohort	NN	cohort
study	NN	study
examines	VBZ	examine
the	DT	the
safety	NN	safety
and	CC	and
efficacy	NN	efficacy
of	IN	of
fully	RB	fully
remote	JJ	remote
,	,	,
asynchronous	JJ	asynchronous
medication	NN	medication
abortion	NN	abortion
care	NN	care
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
34966387/	CD	@card@
A	NP	A
Potent	JJ	potent
and	CC	and
Protective	JJ	protective
Human	JJ	human
Neutralizing	VBG	neutralize
Antibody	NN	antibody
Against	IN	against
SARS-CoV-2	JJ	<unknown>
Variants	NNS	variant
As	IN	as
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
variants	NNS	variant
continue	VBP	continue
to	TO	to
emerge	VB	emerge
and	CC	and
spread	VB	spread
around	RP	around
the	DT	the
world	NN	world
,	,	,
antibodies	NNS	antibody
and	CC	and
vaccines	NNS	vaccine
to	TO	to
confer	VB	confer
broad	JJ	broad
and	CC	and
potent	JJ	potent
neutralizing	VBG	neutralize
activity	NN	activity
are	VBP	be
urgently	RB	urgently
needed	VBN	need
.	SENT	.
Through	IN	through
the	DT	the
isolation	NN	isolation
and	CC	and
characterization	NN	characterization
of	IN	of
monoclonal	NN	monoclonal
antibodies	NNS	antibody
(	(	(
mAbs	NNS	<unknown>
)	)	)
from	IN	from
individuals	NNS	individual
infected	VBN	infect
with	IN	with
SARS-CoV-2	NP	<unknown>
,	,	,
we	PP	we
identified	VBD	identify
one	CD	one
antibody	NN	antibody
,	,	,
P36-5D2	NP	<unknown>
,	,	,
capable	JJ	capable
of	IN	of
neutralizing	VBG	neutralize
the	DT	the
major	JJ	major
SARS-CoV-2	NP	<unknown>
variants	NNS	variant
of	IN	of
concern	NN	concern
.	SENT	.
Crystal	NN	crystal
and	CC	and
electron	NN	electron
cryo-microscopy	NN	cryo-microscopy
(	(	(
cryo-EM	NN	<unknown>
)	)	)
structure	NN	structure
analyses	NNS	analysis
revealed	VBD	reveal
that	IN	that
P36-5D2	NP	<unknown>
targeted	VBD	target
to	TO	to
a	DT	a
conserved	VBN	conserve
epitope	NN	Epitope
on	IN	on
the	DT	the
receptor-binding	NN	receptor-binding
domain	NN	domain
of	IN	of
the	DT	the
spike	NN	spike
protein	NN	protein
,	,	,
withstanding	VBG	withstand
the	DT	the
three	CD	three
key	JJ	key
mutations:K417N	NN	<unknown>
,	,	,
E484K	NP	<unknown>
,	,	,
and	CC	and
N501Y:found	NN	<unknown>
in	IN	in
the	DT	the
variants	NNS	variant
that	WDT	that
are	VBP	be
responsible	JJ	responsible
for	IN	for
escape	NN	escape
from	IN	from
many	JJ	many
potent	JJ	potent
neutralizing	VBG	neutralize
mAbs	NNS	<unknown>
,	,	,
including	VBG	include
some	DT	some
already	RB	already
approved	VBN	approve
for	IN	for
emergency	NN	emergency
use	NN	use
authorization	NN	authorization
(	(	(
EUA	NP	EUA
)	)	)
.	SENT	.
A	DT	a
single	JJ	single
intraperitoneal	NN	<unknown>
(	(	(
IP	NP	IP
)	)	)
injection	NN	injection
of	IN	of
P36-5D2	NP	<unknown>
as	IN	as
a	DT	a
prophylactic	JJ	prophylactic
treatment	NN	treatment
completely	RB	completely
protected	VBN	protect
animals	NNS	animal
from	IN	from
challenge	NN	challenge
of	IN	of
infectious	JJ	infectious
SARS-CoV-2	NP	<unknown>
Alpha	NP	Alpha
and	CC	and
Beta	NP	Beta
.	SENT	.
Treated	VBN	treat
animals	NNS	animal
manifested	VBD	manifest
normal	JJ	normal
body	NN	body
weight	NN	weight
and	CC	and
were	VBD	be
devoid	JJ	devoid
of	IN	of
infection-associated	JJ	infection-associated
death	NN	death
up	RB	up
to	TO	to
14	CD	@card@
days	NNS	day
.	SENT	.
A	DT	a
substantial	JJ	substantial
decrease	NN	decrease
of	IN	of
the	DT	the
infectious	JJ	infectious
virus	NN	virus
in	IN	in
the	DT	the
lungs	NNS	lung
and	CC	and
brain	NN	brain
,	,	,
as	RB	as
well	RB	well
as	IN	as
reduced	VBN	reduce
lung	NN	lung
pathology	NN	pathology
,	,	,
was	VBD	be
found	VBN	find
in	IN	in
these	DT	these
animals	NNS	animal
compared	VBN	compare
to	TO	to
the	DT	the
controls	NNS	control
.	SENT	.
Thus	RB	thus
,	,	,
P36-5D2	NP	<unknown>
represents	VBZ	represent
a	DT	a
new	JJ	new
and	CC	and
desirable	JJ	desirable
human	JJ	human
antibody	NN	antibody
against	IN	against
the	DT	the
current	JJ	current
and	CC	and
emerging	VBG	emerge
SARS-CoV-2	JJ	<unknown>
variants	NNS	variant
.	SENT	.
35051130/	CD	@card@
Notes	NNS	note
from	IN	from
the	DT	the
Field	NP	Field
:	:	:
Early	JJ	early
Evidence	NN	evidence
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
B.1.1.529	NP	B@card@
(	(	(
Omicron	NN	omicron
)	)	)
Variant	NN	variant
in	IN	in
Community	NP	Community
Wastewater	NP	Wastewater
:	:	:
United	NP	United
States	NPS	States
,	,	,
November-December	NP	November-December
2021	CD	@card@
32346493/	CD	@card@
Clinical	JJ	clinical
presentations	NNS	presentation
and	CC	and
outcomes	NNS	outcome
of	IN	of
SARS-CoV-2	NP	<unknown>
infected	JJ	infected
pneumonia	NN	pneumonia
in	IN	in
pregnant	JJ	pregnant
women	NNS	woman
and	CC	and
health	NN	health
status	NN	status
of	IN	of
their	PP$	their
neonates	NNS	neonate
34903197/	CD	@card@
Children	NNS	child
and	CC	and
parents	NNS	parent
'	POS	'
perspectives	NNS	perspective
of	IN	of
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
Ontario	NP	Ontario
children	NNS	child
's	POS	's
physical	JJ	physical
activity	NN	activity
,	,	,
play	VB	play
,	,	,
and	CC	and
sport	NN	sport
behaviours	NNS	behaviour
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
associated	JJ	associated
public	JJ	public
health	NN	health
measures	NNS	measure
have	VBP	have
resulted	VBN	result
in	IN	in
the	DT	the
closure	NN	closure
of	IN	of
many	JJ	many
physical	JJ	physical
activity-supporting	NN	<unknown>
facilities	NNS	facility
.	SENT	.
This	DT	this
study	NN	study
examined	VBD	examine
Ontario	NP	Ontario
parents	NNS	parent
'	POS	'
and	CC	and
children	NNS	child
's	POS	's
perspectives	NNS	perspective
of	IN	of
COVID-19	NP	<unknown>
's	POS	's
impact	NN	impact
on	IN	on
children	NNS	child
's	POS	's
physical	JJ	physical
activity	NN	activity
behaviours	NNS	behaviour
,	,	,
return	NN	return
to	TO	to
play/sport	NN	play/sport
during	IN	during
COVID-19	NP	<unknown>
,	,	,
as	RB	as
well	RB	well
as	IN	as
barriers/facilitators	NNS	barriers/facilitator
to	TO	to
getting	VBG	get
active	JJ	active
amid	IN	amid
extended	JJ	extended
closures	NNS	closure
of	IN	of
physical	JJ	physical
activity	NN	activity
venues	NNS	venue
.	SENT	.
Parents/guardians	NNS	Parents/guardian
of	IN	of
children	NNS	child
aged	VBN	age
12	CD	@card@
years	NNS	year
and	CC	and
under	IN	under
living	VBG	live
in	IN	in
Ontario	NP	Ontario
,	,	,
Canada	NP	Canada
were	VBD	be
invited	VBN	invite
to	TO	to
participate	VB	participate
in	IN	in
an	DT	an
interview	NN	interview
.	SENT	.
12	CD	@card@
parent/guardian	NN	parent/guardian
and	CC	and
9	CD	@card@
child	NN	child
interviews	NNS	interview
were	VBD	be
conducted	VBN	conduct
via	IN	via
Zoom	NN	zoom
between	IN	between
December	NP	December
2020	CD	@card@
-	NN	<unknown>
January	NP	January
2021	CD	@card@
,	,	,
were	VBD	be
audio-recorded	VBN	audio-record
,	,	,
and	CC	and
transcribed	VBD	transcribe
verbatim	RB	verbatim
.	SENT	.
Thematic	JJ	thematic
content	JJ	content
analysis	NN	analysis
was	VBD	be
undertaken	VBN	undertake
to	TO	to
identify	VB	identify
pronounced	JJ	pronounced
themes	NNS	theme
.	SENT	.
Themes	NNS	theme
for	IN	for
both	DT	both
parent	NN	parent
and	CC	and
child	NN	child
interviews	NNS	interview
fell	VBD	fall
into	IN	into
one	CD	one
of	IN	of
three	CD	three
categories	NNS	category
:	:	:
1	LS	1
)	)	)
barriers	NNS	barrier
and	CC	and
facilitators	NNS	facilitator
for	IN	for
getting	VBG	get
children	NNS	child
active	JJ	active
amid	IN	amid
COVID-19	NP	<unknown>
closures	NNS	closure
of	IN	of
physical	JJ	physical
activity-supporting	NN	<unknown>
facilities	NNS	facility
;	:	;
2	LS	2
)	)	)
changes	NNS	change
in	IN	in
children	NNS	child
's	POS	's
activity	NN	activity
levels	NNS	level
;	:	;
and	CC	and
,	,	,
3	CD	@card@
)	)	)
perspectives	NNS	perspective
on	IN	on
return	NN	return
to	TO	to
play/sport	NN	play/sport
during	IN	during
and	CC	and
post-pandemic	JJ	post-pandemic
.	SENT	.
Various	JJ	various
subthemes	NNS	subtheme
were	VBD	be
identified	VBN	identify
and	CC	and
varied	VBN	vary
between	IN	between
parents	NNS	parent
and	CC	and
children	NNS	child
.	SENT	.
The	DT	the
most	RBS	most
common	JJ	common
facilitator	NN	facilitator
for	IN	for
dealing	VBG	deal
with	IN	with
children	NNS	child
's	POS	's
inactivity	NN	inactivity
voiced	VBN	voice
by	IN	by
parents/guardians	NNS	parents/guardian
was	VBD	be
getting	VBG	get
active	JJ	active
outdoors	RB	outdoors
.	SENT	.
Parents/guardians	NP	<unknown>
noted	VBD	note
their	PP$	their
willingness	NN	willingness
to	TO	to
have	VB	have
their	PP$	their
children	NNS	child
return	VB	return
to	TO	to
play/sport	NN	play/sport
in	IN	in
the	DT	the
community	NN	community
once	RB	once
deemed	VBN	deem
safe	JJ	safe
by	IN	by
public	JJ	public
health	NN	health
guidelines	NNS	guideline
,	,	,
and	CC	and
children	NNS	child
's	POS	's
willingness	NN	willingness
to	TO	to
return	VB	return
stemmed	VBN	stem
primarily	RB	primarily
from	IN	from
missing	VBG	miss
their	PP$	their
friends	NNS	friend
and	CC	and
other	JJ	other
important	JJ	important
authority	NN	authority
figures	NNS	figure
(	(	(
e.g.	FW	e.g.
,	,	,
coaches	NNS	coach
)	)	)
and	CC	and
sporting	NN	sporting
events	NNS	event
(	(	(
e.g.	FW	e.g.
,	,	,
tournaments	NNS	tournament
)	)	)
.	SENT	.
Findings	NNS	finding
from	IN	from
this	DT	this
study	NN	study
could	MD	could
inform	VB	inform
families	NNS	family
of	IN	of
feasible	JJ	feasible
and	CC	and
realistic	JJ	realistic
strategies	NNS	strategy
for	IN	for
increasing	VBG	increase
children	NNS	child
's	POS	's
physical	JJ	physical
activity	NN	activity
during	IN	during
community	NN	community
closures	NNS	closure
,	,	,
while	IN	while
also	RB	also
providing	VBG	provide
public	JJ	public
health	NN	health
experts	NNS	expert
with	IN	with
information	NN	information
regarding	VBG	regard
what	WP	what
supports	VBZ	support
,	,	,
or	CC	or
infrastructure	NN	infrastructure
might	MD	might
be	VB	be
needed	VBN	need
during	IN	during
future	JJ	future
lockdown	NN	<unknown>
periods	NNS	period
and/or	CC	and/or
pandemics	NNS	pandemic
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12889-021-12344-w	JJ	<unknown>
.	SENT	.
35151823/	CD	@card@
Clinical	JJ	clinical
and	CC	and
experimental	JJ	experimental
bacteriophage	NN	bacteriophage
studies	NNS	study
:	:	:
Recommendations	NNS	recommendation
for	IN	for
possible	JJ	possible
approaches	NNS	approach
for	IN	for
standing	NN	standing
against	IN	against
SARS-CoV-2	NP	<unknown>
In	IN	in
2019	CD	@card@
,	,	,
the	DT	the
world	NN	world
faced	VBD	face
a	DT	a
serious	JJ	serious
health	NN	health
challenge	NN	challenge
,	,	,
the	DT	the
rapid	JJ	rapid
spreading	VBG	spread
of	IN	of
a	DT	a
life-threatening	JJ	life-threatening
viral	JJ	viral
pneumonia	NN	pneumonia
,	,	,
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
caused	VBD	cause
by	IN	by
a	DT	a
betacoronavirus	NN	betacoronavirus
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
.	SENT	.
As	RB	as
of	IN	of
January	NP	January
2022	CD	@card@
WHO	WP	who
statistics	NNS	statistic
shows	VBZ	show
more	JJR	more
than	IN	than
5.6	CD	@card@
million	CD	million
death	NN	death
and	CC	and
about	RB	about
350	CD	@card@
million	CD	million
infection	NN	infection
by	IN	by
SARS-CoV-2	NP	<unknown>
.	SENT	.
One	CD	one
of	IN	of
the	DT	the
life	NN	life
threatening	VBG	threaten
aspects	NNS	aspect
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
secondary	JJ	secondary
infections	NNS	infection
and	CC	and
reduced	VBN	reduce
efficacy	NN	efficacy
of	IN	of
antibiotics	NNS	antibiotic
against	IN	against
them	PP	them
.	SENT	.
Since	IN	since
the	DT	the
beginning	NN	beginning
of	IN	of
COVID-19	NP	<unknown>
many	JJ	many
researches	NNS	research
have	VBP	have
been	VBN	be
done	VBN	do
on	IN	on
identification	NN	identification
,	,	,
treatment	NN	treatment
,	,	,
and	CC	and
vaccine	NN	vaccine
development	NN	development
.	SENT	.
Bacterial	JJ	bacterial
viruses	NNS	virus
(	(	(
bacteriophages	NNS	bacteriophage
)	)	)
could	MD	could
offer	VB	offer
novel	NN	novel
approaches	NNS	approach
to	TO	to
detect	VB	detect
,	,	,
treat	VB	treat
and	CC	and
control	VB	control
COVID-19	NP	<unknown>
.	SENT	.
Phage	NN	phage
therapy	NN	therapy
and	CC	and
in	IN	in
particular	JJ	particular
using	VBG	use
phage	NN	phage
cocktails	NNS	cocktail
can	MD	can
be	VB	be
used	VBN	use
to	TO	to
control	VB	control
or	CC	or
eliminate	VB	eliminate
the	DT	the
bacterial	JJ	bacterial
pathogen	NN	pathogen
as	IN	as
an	DT	an
alternative	NN	alternative
or	CC	or
complementary	JJ	complementary
therapeutic	JJ	therapeutic
agent	NN	agent
.	SENT	.
At	IN	at
the	DT	the
same	JJ	same
time	NN	time
,	,	,
phage	NN	phage
interaction	NN	interaction
with	IN	with
the	DT	the
host	NN	host
immune	JJ	immune
system	NN	system
can	MD	can
regulate	VB	regulate
the	DT	the
inflammatory	JJ	inflammatory
response	NN	response
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
phage	NN	phage
display	NN	display
and	CC	and
engineered	JJ	engineered
synthetic	JJ	synthetic
phages	NNS	phage
can	MD	can
be	VB	be
utilized	VBN	utilize
to	TO	to
develop	VB	develop
new	JJ	new
vaccines	NNS	vaccine
and	CC	and
antibodies	NNS	antibody
,	,	,
stimulate	VB	stimulate
the	DT	the
immune	JJ	immune
system	NN	system
,	,	,
and	CC	and
elicit	VB	elicit
a	DT	a
rapid	JJ	rapid
and	CC	and
well-appropriate	JJ	well-appropriate
defense	NN	defense
response	NN	response
.	SENT	.
The	DT	the
emergence	NN	emergence
of	IN	of
SARS-CoV-2	NP	<unknown>
new	JJ	new
variants	NNS	variant
like	IN	like
delta	NN	delta
and	CC	and
omicron	NN	omicron
has	VBZ	have
proved	VBN	prove
the	DT	the
urgent	JJ	urgent
need	NN	need
for	IN	for
precise	JJ	precise
,	,	,
efficient	JJ	efficient
and	CC	and
novel	JJ	novel
approaches	NNS	approach
for	IN	for
vaccine	NN	vaccine
development	NN	development
and	CC	and
virus	NN	virus
detection	NN	detection
techniques	NNS	technique
in	IN	in
which	WDT	which
bacteriophages	NNS	bacteriophage
may	MD	may
be	VB	be
one	CD	one
of	IN	of
the	DT	the
plausible	JJ	plausible
solutions	NNS	solution
.	SENT	.
Therefore	RB	therefore
,	,	,
phages	NNS	phage
with	IN	with
similar	JJ	similar
morphology	NN	morphology
and/or	CC	and/or
genetic	JJ	genetic
content	NN	content
to	TO	to
that	WDT	that
of	IN	of
coronaviruses	NNS	coronavirus
can	MD	can
be	VB	be
used	VBN	use
for	IN	for
ecological	JJ	ecological
and	CC	and
epidemiological	JJ	epidemiological
modeling	NN	modeling
of	IN	of
SARS-CoV-2	NP	<unknown>
behavior	NN	behavior
and	CC	and
future	JJ	future
generations	NNS	generation
of	IN	of
coronavirus	NN	coronavirus
,	,	,
and	CC	and
in	IN	in
general	JJ	general
new	JJ	new
viral	JJ	viral
pathogens	NNS	pathogen
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
a	DT	a
comprehensive	JJ	comprehensive
review/perspective	NN	review/perspective
of	IN	of
potential	JJ	potential
applications	NNS	application
of	IN	of
bacteriophages	NNS	bacteriophage
in	IN	in
the	DT	the
fight	NN	fight
against	IN	against
the	DT	the
present	JJ	present
pandemic	NN	pandemic
and	CC	and
the	DT	the
post-COVID	JJ	<unknown>
era	NN	era
.	SENT	.
34803818/	CD	@card@
How	WRB	how
Mentors	NNS	mentor
Think	VBP	think
About	IN	about
the	DT	the
Attainability	NN	attainability
of	IN	of
Mentoring	VBG	mentore
Goals	NNS	goal
:	:	:
The	DT	the
Impact	NN	impact
of	IN	of
Mentoring	VBG	mentore
Type	NN	type
and	CC	and
Mentoring	VBG	mentore
Context	NN	context
on	IN	on
the	DT	the
Anticipated	JJ	anticipated
Regulatory	NP	Regulatory
Network	NP	Network
and	CC	and
Regulatory	NP	Regulatory
Resources	NPS	Resources
of	IN	of
Potential	JJ	potential
Mentors	NNS	mentor
for	IN	for
School	NP	School
Mentoring	NP	mentoring
Programs	NP	Programs
Research	NP	Research
shows	VBZ	show
that	IN	that
trained	JJ	trained
mentors	NNS	mentor
achieve	VBP	achieve
better	JJR	good
results	NNS	result
than	IN	than
untrained	JJ	untrained
ones	NNS	one
.	SENT	.
Their	PP$	their
training	NN	training
should	MD	should
particularly	RB	particularly
address	VB	address
their	PP$	their
expectations	NNS	expectation
for	IN	for
their	PP$	their
future	JJ	future
mentoring	NN	mentoring
.	SENT	.
Our	PP$	our
study	NN	study
involved	VBD	involve
190	CD	@card@
preservice	NN	preservice
teachers	NNS	teacher
,	,	,
potential	JJ	potential
mentors	NNS	mentor
of	IN	of
ongoing	JJ	ongoing
school	NN	school
mentoring	NN	mentoring
for	IN	for
primary	JJ	primary
and	CC	and
secondary	JJ	secondary
school	NN	school
students	NNS	student
of	IN	of
all	DT	all
grades	NNS	grade
.	SENT	.
They	PP	they
were	VBD	be
randomly	RB	randomly
assigned	VBN	assign
to	TO	to
one	CD	one
of	IN	of
four	CD	four
conditions	NNS	condition
in	IN	in
a	DT	a
2-x-2	JJ	<unknown>
between-subjects	NN	<unknown>
design	NN	design
of	IN	of
mentoring	VBG	mentore
type	NN	type
(	(	(
traditional	JJ	traditional
mentoring	NN	mentoring
versus	IN	versus
e-mentoring	NP	e-mentoring
)	)	)
and	CC	and
mentoring	VBG	mentore
context	NN	context
(	(	(
non-pandemic	JJ	non-pandemic
versus	IN	versus
COVID-19	NP	<unknown>
pandemic	NN	pandemic
)	)	)
.	SENT	.
Participants	NNS	participant
assessed	VBD	assess
mentoring	NN	mentoring
conducted	VBN	conduct
under	IN	under
these	DT	these
four	CD	four
conditions	NNS	condition
in	IN	in
terms	NNS	term
of	IN	of
its	PP$	its
appropriateness	NN	appropriateness
for	IN	for
achieving	VBG	achieve
four	CD	four
mentoring	NN	mentoring
program	NN	program
targets	NNS	target
:	:	:
learning	VBG	learn
,	,	,
key	JJ	key
skills	NNS	skill
,	,	,
social	JJ	social
targets	NNS	target
,	,	,
and	CC	and
problem	NN	problem
coping	NN	coping
.	SENT	.
Participants	NNS	participant
were	VBD	be
also	RB	also
asked	VBN	ask
to	TO	to
assess	VB	assess
the	DT	the
resources	NNS	resource
available	JJ	available
to	TO	to
achieve	VB	achieve
each	DT	each
program	NN	program
target	NN	target
.	SENT	.
Overall	RB	overall
,	,	,
the	DT	the
potential	JJ	potential
mentors	NNS	mentor
considered	VBD	consider
the	DT	the
various	JJ	various
conditions	NNS	condition
to	TO	to
be	VB	be
suitable	JJ	suitable
for	IN	for
achieving	VBG	achieve
the	DT	the
four	CD	four
program	NN	program
targets	NNS	target
.	SENT	.
They	PP	they
were	VBD	be
particularly	RB	particularly
favorable	JJ	favorable
in	IN	in
their	PP$	their
assessment	NN	assessment
of	IN	of
the	DT	the
possibility	NN	possibility
for	IN	for
the	DT	the
realization	NN	realization
of	IN	of
learning	VBG	learn
targets	NNS	target
.	SENT	.
Likewise	RB	likewise
,	,	,
they	PP	they
assumed	VBD	assume
that	IN	that
sufficient	JJ	sufficient
resources	NNS	resource
were	VBD	be
available	JJ	available
to	TO	to
achieve	VB	achieve
the	DT	the
targets	NNS	target
.	SENT	.
However	RB	however
,	,	,
a	DT	a
repeated-measures	NP	repeated-measures
MANOVA	NP	<unknown>
showed	VBD	show
that	IN	that
the	DT	the
potential	JJ	potential
mentors	NNS	mentor
considered	VBN	consider
more	RBR	more
ambitious	JJ	ambitious
targets	NNS	target
to	TO	to
be	VB	be
possible	JJ	possible
in	IN	in
traditional	JJ	traditional
mentoring	NN	mentoring
than	IN	than
in	IN	in
e-mentoring	NP	e-mentoring
and	CC	and
normal	JJ	normal
(	(	(
i.e.	FW	i.e.
,	,	,
pre-pandemic	JJ	pre-pandemic
)	)	)
contextual	JJ	contextual
conditions	NNS	condition
than	IN	than
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
In	IN	in
contrast	NN	contrast
,	,	,
they	PP	they
estimated	VBD	estimate
the	DT	the
resources	NNS	resource
available	JJ	available
to	TO	to
achieve	VB	achieve
the	DT	the
targets	NNS	target
to	TO	to
be	VB	be
about	IN	about
the	DT	the
same	JJ	same
in	IN	in
the	DT	the
four	CD	four
conditions	NNS	condition
.	SENT	.
This	DT	this
indicates	VBZ	indicate
a	DT	a
decoupling	NN	decoupling
of	IN	of
mentoring	VBG	mentore
targets	NNS	target
from	IN	from
the	DT	the
consideration	NN	consideration
of	IN	of
the	DT	the
resources	NNS	resource
needed	VBN	need
to	TO	to
achieve	VB	achieve
them	PP	them
.	SENT	.
This	DT	this
assumption	NN	assumption
was	VBD	be
confirmed	VBN	confirm
in	IN	in
correlation	NN	correlation
analyses	NNS	analysis
and	CC	and
has	VBZ	have
implications	NNS	implication
for	IN	for
mentor	NN	mentor
training	NN	training
.	SENT	.
32337584/	CD	@card@
First	NP	First
reported	VBD	report
nosocomial	JJ	<unknown>
outbreak	NN	outbreak
of	IN	of
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
in	IN	in
a	DT	a
pediatric	JJ	pediatric
dialysis	NN	dialysis
unit	NN	unit
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
life-threatening	JJ	life-threatening
respiratory	JJ	respiratory
condition	NN	condition
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
and	CC	and
was	VBD	be
initially	RB	initially
detected	VBN	detect
in	IN	in
China	NP	China
in	IN	in
December	NP	December
2019	CD	@card@
.	SENT	.
Currently	RB	currently
,	,	,
in	IN	in
Germany	NP	Germany
over	IN	over
140,000	CD	@card@
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
are	VBP	be
confirmed	VBN	confirm
.	SENT	.
Here	RB	here
we	PP	we
report	VBP	report
a	DT	a
nosocomial	JJ	<unknown>
outbreak	NN	outbreak
of	IN	of
SARS-CoV-2	JJ	<unknown>
infections	NNS	infection
in	IN	in
the	DT	the
pediatric	JJ	pediatric
dialysis	NN	dialysis
unit	NN	unit
of	IN	of
the	DT	the
University	NP	University
Hospital	NP	Hospital
of	IN	of
Munster	NP	Munster
(	(	(
UHM	NP	Uhm
)	)	)
.	SENT	.
Single-step	VB	single-step
real-time	JJ	real-time
RT-PCR	NN	<unknown>
from	IN	from
nasopharyngeal	JJ	nasopharyngeal
swaps	NNS	swap
was	VBD	be
used	VBN	use
to	TO	to
diagnose	VB	diagnose
the	DT	the
index	NN	index
patient	NN	patient
and	CC	and
identify	VB	identify
infected	JJ	infected
contacts	NNS	contact
.	SENT	.
Epidemiological	JJ	epidemiological
links	NNS	link
were	VBD	be
analyzed	VBN	analyze
by	IN	by
patient	JJ	patient
interviews	NNS	interview
and	CC	and
chart	NN	chart
reviews	NNS	review
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
each	DT	each
contact	NN	contact
was	VBD	be
assessed	VBN	assess
for	IN	for
exposure	NN	exposure
to	TO	to
the	DT	the
index	NN	index
case	NN	case
and	CC	and
monitored	VBN	monitor
for	IN	for
clinical	JJ	clinical
symptoms	NNS	symptom
.	SENT	.
Threshold	NN	threshold
cycle	NN	cycle
(	(	(
Ct	NP	Ct
)	)	)
values	NNS	value
of	IN	of
all	DT	all
positive	JJ	positive
test	NN	test
results	NNS	result
were	VBD	be
compared	VBN	compare
between	IN	between
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
cases	NNS	case
.	SENT	.
Forty-eight	NP	<unknown>
cases	NNS	case
were	VBD	be
involved	VBN	involve
in	IN	in
this	DT	this
nosocomial	JJ	<unknown>
outbreak	NN	outbreak
.	SENT	.
Nine	CD	nine
contact	NN	contact
cases	NNS	case
developed	VBD	develop
laboratory	NN	laboratory
confirmed	VBD	confirm
COVID-19	NP	<unknown>
infections	NNS	infection
.	SENT	.
Two	CD	two
SARS-CoV-2	JJ	<unknown>
positive	JJ	positive
cases	NNS	case
remained	VBD	remain
clinically	RB	clinically
asymptomatic	JJ	asymptomatic
.	SENT	.
Eleven	NN	eleven
cases	NNS	case
reported	VBD	report
flu-like	JJ	flu-like
symptoms	NNS	symptom
without	IN	without
positive	JJ	positive
results	NNS	result
.	SENT	.
Ct	NP	Ct
values	NNS	value
were	VBD	be
significantly	RB	significantly
lower	JJR	low
in	IN	in
cases	NNS	case
presenting	VBG	present
typical	JJ	typical
COVID-19	NP	<unknown>
symptoms	NNS	symptom
,	,	,
suggesting	VBG	suggest
high	JJ	high
viral	JJ	viral
shedding	NN	shedding
(	(	(
p	NN	p
=0.007	JJ	=@card@
)	)	)
.	SENT	.
Person-to-person	NN	person-to-person
transmission	NN	transmission
was	VBD	be
at	IN	at
the	DT	the
heart	NN	heart
of	IN	of
a	DT	a
hospital	NN	hospital
outbreak	NN	outbreak
of	IN	of
SARS-CoV-2	NP	<unknown>
between	IN	between
healthcare	NN	<unknown>
workers	NNS	worker
(	(	(
HCWs	NP	<unknown>
)	)	)
and	CC	and
patients	NNS	patient
in	IN	in
the	DT	the
pediatric	JJ	pediatric
dialysis	NN	dialysis
unit	NN	unit
at	IN	at
the	DT	the
UHM	NP	Uhm
.	SENT	.
Semi	NN	semi
quantitative	JJ	quantitative
real-time	JJ	real-time
RT-PCR	NP	<unknown>
results	NNS	result
suggest	VBP	suggest
that	IN	that
individuals	NNS	individual
with	IN	with
high	JJ	high
viral	JJ	viral
load	NN	load
pose	VB	pose
a	DT	a
risk	NN	risk
to	TO	to
spread	VB	spread
SARS-CoV-2	NP	<unknown>
in	IN	in
the	DT	the
hospital	NN	hospital
setting	NN	setting
.	SENT	.
Our	PP$	our
epidemiological	JJ	epidemiological
observation	NN	observation
highlights	VBZ	highlight
the	DT	the
need	NN	need
to	TO	to
develop	VB	develop
strategies	NNS	strategy
to	TO	to
trace	VB	trace
and	CC	and
monitor	VB	monitor
SARS-CoV-2	NP	<unknown>
infected	JJ	infected
HCWs	NN	<unknown>
in	IN	in
order	NN	order
to	TO	to
prevent	VB	prevent
COVID-19	NP	<unknown>
outbreaks	NNS	outbreak
in	IN	in
the	DT	the
hospital	NN	hospital
setting	NN	setting
.	SENT	.
32624392/	CD	@card@
Percutaneous	JJ	percutaneous
tracheostomy	NN	tracheostomy
simulation	NN	simulation
training	NN	training
for	IN	for
ENT	NN	Ent
physicians	NNS	physician
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19-positive	JJ	COVID-19-positive
patients	NNS	patient
Tracheostomy	NN	tracheostomy
in	IN	in
COVID-19-related	JJ	COVID-19-related
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
is	VBZ	be
at	IN	at
high	JJ	high
risk	NN	risk
of	IN	of
viral	JJ	viral
dissemination	NN	dissemination
.	SENT	.
The	DT	the
percutaneous	JJ	percutaneous
dilatation	NN	<unknown>
technique	NN	technique
could	MD	could
reduce	VB	reduce
this	DT	this
risk	NN	risk
,	,	,
being	VBG	be
performed	VBN	perform
at	IN	at
the	DT	the
bedside	NN	bedside
and	CC	and
minimising	VBG	minimise
airway	NN	airway
opening	NN	opening
.	SENT	.
In	IN	in
the	DT	the
COVID-19	NP	<unknown>
context	NN	context
,	,	,
however	RB	however
,	,	,
with	IN	with
precarious	JJ	precarious
respiratory	JJ	respiratory
status	NN	status
,	,	,
it	PP	it
requires	VBZ	require
specific	JJ	specific
preparation	NN	preparation
.	SENT	.
We	PP	we
designed	VBD	design
a	DT	a
3-hour	JJ	<unknown>
training	NN	training
module	NN	module
,	,	,
and	CC	and
here	RB	here
provide	VB	provide
a	DT	a
step-by-step	NN	step-by-step
schedule	NN	schedule
,	,	,
including	VBG	include
video	JJ	video
analysis	NN	analysis
,	,	,
a	DT	a
demonstration	NN	demonstration
of	IN	of
the	DT	the
kit	NN	kit
,	,	,
the	DT	the
recommended	JJ	recommended
precautions	NNS	precaution
related	VBN	relate
to	TO	to
COVID-19	NP	<unknown>
,	,	,
and	CC	and
several	JJ	several
simulation	NN	simulation
scenarios	NNS	scenario
of	IN	of
increasing	VBG	increase
difficulty	NN	difficulty
,	,	,
using	VBG	use
a	DT	a
high-tech	JJ	high-tech
mannequin	NN	mannequin
.	SENT	.
A	DT	a
low-tech	NN	low-tech
procedural	JJ	procedural
simulator	NN	simulator
was	VBD	be
also	RB	also
developed	VBN	develop
for	IN	for
practicing	VBG	practice
the	DT	the
steps	NNS	step
of	IN	of
the	DT	the
procedure	NN	procedure
.	SENT	.
Our	PP$	our
experience	NN	experience
(	(	(
3	CD	@card@
sessions	NNS	session
with	IN	with
14	CD	@card@
participants	NNS	participant
)	)	)
highlighted	VBD	highlight
the	DT	the
difficult	JJ	difficult
points	NNS	point
of	IN	of
the	DT	the
procedure	NN	procedure
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
context	NN	context
,	,	,
and	CC	and
defined	VBD	define
a	DT	a
checklist	NN	checklist
for	IN	for
clinical	JJ	clinical
practice	NN	practice
and	CC	and
an	DT	an
assessment	NN	assessment
grid	NN	grid
.	SENT	.
This	DT	this
type	NN	type
of	IN	of
simulation	NN	simulation
helps	VBZ	help
to	TO	to
prepare	VB	prepare
teams	NNS	team
for	IN	for
a	DT	a
potentially	RB	potentially
delicate	JJ	delicate
technical	JJ	technical
act	NN	act
.	SENT	.
33706836/	CD	@card@
Povidone-iodine	NP	<unknown>
preprocedural	JJ	preprocedural
rinse:An	NN	<unknown>
evidence-based	JJ	<unknown>
,	,	,
second-line	NN	second-line
defense	NN	defense
against	IN	against
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
coronavirus	NN	coronavirus
virus	NN	virus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
in	IN	in
dental	JJ	dental
healthcare	NN	<unknown>
34697001/	CD	@card@
Consequences	NNS	consequence
of	IN	of
COVID-19	NP	<unknown>
pandemic	NN	pandemic
over	IN	over
acute	JJ	acute
bronchiolitis	NN	<unknown>
hospitalizations	NNS	hospitalization
in	IN	in
the	DT	the
center	NN	center
and	CC	and
east	JJ	east
of	IN	of
Spain	NP	Spain
Non-pharmaceutical	JJ	non-pharmaceutical
interventions	NNS	intervention
that	WDT	that
have	VBP	have
been	VBN	be
implemented	VBN	implement
in	IN	in
southern	JJ	southern
hemisphere	NN	hemisphere
countries	NNS	country
because	IN	because
of	IN	of
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
declaration	NN	declaration
in	IN	in
March	NP	March
2020	CD	@card@
,	,	,
have	VBP	have
evidenced	VBN	evidence
some	DT	some
unexpected	JJ	unexpected
changes	NNS	change
in	IN	in
the	DT	the
way	NN	way
of	IN	of
spreading	VBG	spread
of	IN	of
many	JJ	many
other	JJ	other
viruses	NNS	virus
.	SENT	.
This	DT	this
study	NN	study
as	IN	as
a	DT	a
part	NN	part
of	IN	of
ECEALHBA	NP	<unknown>
's	POS	's
Project	NP	Project
,	,	,
reports	VBZ	report
the	DT	the
consequences	NNS	consequence
of	IN	of
COVID-19	NP	<unknown>
pandemic	NN	pandemic
over	IN	over
2020-2021	CD	@card@
bronchiolitis	NN	<unknown>
epidemic	NN	epidemic
period	NN	period
in	IN	in
the	DT	the
Central	NP	Central
and	CC	and
Eastern	NP	Eastern
regions	NNS	region
of	IN	of
Spain	NP	Spain
.	SENT	.
Multicenter	NN	multicenter
,	,	,
observational	JJ	observational
,	,	,
descriptive	JJ	descriptive
and	CC	and
ambispective	JJ	<unknown>
study	NN	study
of	IN	of
admitted	VBN	admit
infants	NNS	infant
with	IN	with
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
bronchiolitis	NN	<unknown>
in	IN	in
16	CD	@card@
Spanish	JJ	Spanish
hospitals	NNS	hospital
involved	VBN	involve
in	IN	in
the	DT	the
investigation	NN	investigation
project	NN	project
.	SENT	.
Five	CD	five
epidemic	JJ	epidemic
periods	NNS	period
previous	JJ	previous
to	TO	to
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
from	IN	from
2015	CD	@card@
to	TO	to
2020	CD	@card@
,	,	,
were	VBD	be
compared	VBN	compare
with	IN	with
the	DT	the
current	JJ	current
one	CD	one
,	,	,
2020-2021	CD	@card@
,	,	,
in	IN	in
both	CC	both
a	DT	a
qualitative	JJ	qualitative
and	CC	and
quantitative	JJ	quantitative
manner	NN	manner
.	SENT	.
Total	JJ	total
of	IN	of
4643	CD	@card@
infants	NNS	infant
were	VBD	be
admitted	VBN	admit
to	TO	to
the	DT	the
participating	VBG	participate
hospitals	NNS	hospital
along	IN	along
the	DT	the
study	NN	study
period	NN	period
.	SENT	.
Pandemic	JJ	pandemic
season	NN	season
hospital	NN	hospital
admissions	NNS	admission
for	IN	for
bronchiolitis	NN	<unknown>
were	VBD	be
94.1	CD	@card@
%	NN	%
lower	JJR	low
than	IN	than
in	IN	in
pre-pandemic	JJ	pre-pandemic
period	NN	period
.	SENT	.
December	NP	December
and	CC	and
January	NP	January
were	VBD	be
peak	NN	peak
months	NNS	month
for	IN	for
bronchiolitis	NN	<unknown>
admissions	NNS	admission
during	IN	during
pre-pandemic	JJ	pre-pandemic
period	NN	period
,	,	,
but	CC	but
September	NP	September
was	VBD	be
the	DT	the
peak	JJ	peak
month	NN	month
during	IN	during
pandemic	JJ	pandemic
year	NN	year
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
progressive	JJ	progressive
decrease	NN	decrease
of	IN	of
admissions	NNS	admission
from	IN	from
this	DT	this
moment	NN	moment
until	IN	until
the	DT	the
end	NN	end
of	IN	of
the	DT	the
follow-up	NN	follow-up
,	,	,
in	IN	in
April	NP	April
2021	CD	@card@
.	SENT	.
Rhinovirus	NP	<unknown>
has	VBZ	have
been	VBN	be
the	DT	the
commonest	JJS	common
etiology	NN	etiology
for	IN	for
bronchiolitis	NN	<unknown>
in	IN	in
2020-2021	CD	@card@
epidemic	NN	epidemic
period	NN	period
of	IN	of
bronchiolitis	NN	<unknown>
.	SENT	.
Some	DT	some
of	IN	of
the	DT	the
non-pharmaceutical	JJ	non-pharmaceutical
interventions	NNS	intervention
initiated	VBN	initiate
because	IN	because
of	IN	of
COVID-19	NP	<unknown>
pandemic	NN	pandemic
are	VBP	be
probably	RB	probably
related	VBN	relate
to	TO	to
the	DT	the
dramatic	JJ	dramatic
decrease	NN	decrease
of	IN	of
bronchiolitis	NN	<unknown>
cases	NNS	case
in	IN	in
2020-2021	CD	@card@
season	NN	season
.	SENT	.
It	PP	it
would	MD	would
be	VB	be
rewarding	JJ	rewarding
to	TO	to
purpose	NN	purpose
novel	NN	novel
research	NN	research
to	TO	to
clarify	VB	clarify
how	WRB	how
these	DT	these
simple	JJ	simple
interventions	NNS	intervention
can	MD	can
be	VB	be
useful	JJ	useful
,	,	,
close	JJ	close
to	TO	to
vaccines	NNS	vaccine
and	CC	and
antiviral	JJ	antiviral
drugs	NNS	drug
,	,	,
to	TO	to
achieve	VB	achieve
the	DT	the
goal	NN	goal
of	IN	of
avoiding	VBG	avoid
the	DT	the
spread	NN	spread
of	IN	of
respiratory	JJ	respiratory
viruses	NNS	virus
in	IN	in
pediatric	JJ	pediatric
population	NN	population
.	SENT	.
32354772/	CD	@card@
Recovery	NN	recovery
from	IN	from
COVID-19	NP	<unknown>
in	IN	in
a	DT	a
patient	NN	patient
with	IN	with
spondyloarthritis	NNS	<unknown>
treated	VBN	treat
with	IN	with
TNF-alpha	NP	TNF-alpha
inhibitor	NN	inhibitor
etanercept	NN	<unknown>
35195025/	CD	@card@
Digital	NP	Digital
habits	NNS	habit
of	IN	of
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
service-users	NNS	service-user
following	VBG	follow
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
We	PP	we
previously	RB	previously
demonstrated	VBD	demonstrate
low	JJ	low
levels	NNS	level
of	IN	of
digital	JJ	digital
literacy	NN	literacy
amongst	IN	amongst
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
service-users	NNS	service-user
prior	RB	prior
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
identify	VB	identify
whether	IN	whether
the	DT	the
pandemic	NN	pandemic
accelerated	VBD	accelerate
digital	JJ	digital
literacy	NN	literacy
in	IN	in
this	DT	this
population	NN	population
,	,	,
resulting	VBG	result
in	IN	in
greater	JJR	great
acceptance	NN	acceptance
of	IN	of
remote	JJ	remote
web-based	JJ	<unknown>
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
programme	NN	programme
models	NNS	model
.	SENT	.
We	PP	we
surveyed	VBD	survey
digital	JJ	digital
access	NN	access
and	CC	and
behaviours	NNS	behaviour
and	CC	and
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
delivery	NN	delivery
preferences	NNS	preference
of	IN	of
service-users	NNS	service-user
referred	VBN	refer
to	TO	to
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
in	IN	in
2021	CD	@card@
(	(	(
cohort	NN	cohort
2021	CD	@card@
)	)	)
and	CC	and
propensity	NN	propensity
score-matched	VBD	score-match
them	PP	them
to	TO	to
a	DT	a
cohort	NN	cohort
who	WP	who
completed	VBD	complete
the	DT	the
survey	NN	survey
in	IN	in
2020	CD	@card@
(	(	(
cohort	NN	cohort
2020	CD	@card@
)	)	)
.	SENT	.
There	EX	there
were	VBD	be
indicators	NNS	indicator
that	IN	that
digital	JJ	digital
access	NN	access
and	CC	and
confidence	NN	confidence
were	VBD	be
better	JJR	good
amongst	IN	amongst
the	DT	the
Cohort	NN	cohort
2021	CD	@card@
but	CC	but
no	DT	no
difference	NN	difference
was	VBD	be
seen	VBN	see
in	IN	in
the	DT	the
proportion	NN	proportion
of	IN	of
patients	NNS	patient
choosing	VBG	choose
remote	JJ	remote
web-based	JJ	<unknown>
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
as	IN	as
an	DT	an
acceptable	JJ	acceptable
method	NN	method
of	IN	of
receiving	VBG	receive
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
.	SENT	.
In	IN	in
an	DT	an
unselected	JJ	unselected
cohort	NN	cohort
of	IN	of
service-users	NNS	service-user
,	,	,
remote	JJ	remote
web-based	JJ	<unknown>
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
was	VBD	be
considered	VBN	consider
acceptable	JJ	acceptable
in	IN	in
only	RB	only
a	DT	a
minority	NN	minority
of	IN	of
patients	NNS	patient
which	WDT	which
has	VBZ	have
implications	NNS	implication
on	IN	on
healthcare	NN	<unknown>
commissioning	VBG	commission
and	CC	and
delivery	NN	delivery
of	IN	of
pulmonary	JJ	pulmonary
rehabilitation	NN	rehabilitation
.	SENT	.
33141912/	CD	@card@
Tribute	NN	tribute
to	TO	to
All	DT	all
Covid-19	NP	<unknown>
Fighters	NNS	fighter
in	IN	in
Healthcare	NP	Healthcare
32985745/	CD	@card@
Evaluation	NN	evaluation
of	IN	of
Skin	NN	skin
Problems	NP	Problems
and	CC	and
Dermatology	NN	dermatology
Life	NP	Life
Quality	NP	Quality
Index	NP	Index
in	IN	in
Health	NP	Health
Care	NP	Care
Workers	NPS	Workers
Who	WP	who
Use	NP	Use
Personal	NP	Personal
Protection	NP	Protection
Measures	NP	Measures
during	IN	during
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
evaluate	VB	evaluate
the	DT	the
skin	NN	skin
problems	NNS	problem
and	CC	and
dermatological	JJ	dermatological
life	NN	life
quality	NN	quality
of	IN	of
the	DT	the
health	NN	health
care	NN	care
workers	NNS	worker
(	(	(
HCWs	JJ	<unknown>
)	)	)
due	JJ	due
to	TO	to
personal	JJ	personal
protection	NN	protection
equipment	NN	equipment
(	(	(
PPE	NP	PPE
)	)	)
use	NN	use
,	,	,
who	WP	who
are	VBP	be
at	IN	at
high	JJ	high
risk	NN	risk
for	IN	for
Covid-19	NP	<unknown>
infection	NN	infection
.	SENT	.
A	DT	a
questionnaire	NN	questionnaire
about	IN	about
HCWs	NP	<unknown>
'	POS	'
PPE	NP	PPE
use	NN	use
,	,	,
their	PP$	their
skin	NN	skin
symptoms	NNS	symptom
,	,	,
and	CC	and
prevention	NN	prevention
,	,	,
management	NN	management
methods	NNS	method
and	CC	and
Dermatology	NN	dermatology
Life	NP	Life
Quality	NP	Quality
Index	NP	Index
(	(	(
DLQI	NP	<unknown>
)	)	)
was	VBD	be
fulfilled	VBN	fulfill
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
of	IN	of
440	CD	@card@
participants	NNS	participant
was	VBD	be
33.5	CD	@card@
(	(	(
21.0-65.0	CD	@card@
)	)	)
years	NNS	year
old	JJ	old
.	SENT	.
Skin	NN	skin
problems	NNS	problem
were	VBD	be
found	VBN	find
to	TO	to
be	VB	be
90.2	CD	@card@
%	NN	%
,	,	,
the	DT	the
most	RBS	most
common	JJ	common
were	VBD	be
dryness	NN	dryness
,	,	,
itching	VBG	itch
,	,	,
cracking	VBG	crack
,	,	,
burning	NN	burning
,	,	,
flaking	VBG	flake
,	,	,
peeling	NN	peeling
and	CC	and
lichenification	NN	lichenification
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
skin	NN	skin
problems	NNS	problem
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
was	VBD	be
higher	JJR	high
in	IN	in
those	DT	those
who	WP	who
did	VBD	do
not	RB	not
use	VB	use
moisturizers	NNS	moisturizer
.	SENT	.
Of	IN	of
all	DT	all
,	,	,
22.3	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
98	CD	@card@
)	)	)
stated	VBD	state
that	IN	that
the	DT	the
use	NN	use
of	IN	of
PPE	NP	PPE
increased	VBD	increase
the	DT	the
severity	NN	severity
of	IN	of
their	PP$	their
previously	RB	previously
diagnosed	VBN	diagnose
skin	NN	skin
diseases	NNS	disease
and	CC	and
allergies	NNS	allergy
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
Only	RB	only
28.0	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
123	CD	@card@
)	)	)
stated	VBD	state
that	IN	that
they	PP	they
know	VBP	know
the	DT	the
skin	NN	skin
symptoms	NNS	symptom
that	WDT	that
may	MD	may
develop	VB	develop
by	IN	by
using	VBG	use
PPE	NP	PPE
.	SENT	.
The	DT	the
proper	JJ	proper
hand	NN	hand
washing	NN	washing
rate	NN	rate
was	VBD	be
higher	JJR	high
as	IN	as
education	NN	education
level	NN	level
increased	VBN	increase
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Skin	NN	skin
problems	NNS	problem
were	VBD	be
higher	JJR	high
in	IN	in
those	DT	those
using	VBG	use
mask	NN	mask
with	IN	with
metal	NN	metal
nose	NN	nose
bridge	NN	bridge
(	(	(
p:0.02	JJ	p@card@
;	:	;
p:0.003	NN	<unknown>
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
As	IN	as
the	DT	the
mask	NN	mask
using	VBG	use
period	NN	period
prolonged	JJ	prolonged
,	,	,
acne	NN	acne
was	VBD	be
more	JJR	more
common	JJ	common
(	(	(
p:0.02	NN	<unknown>
)	)	)
.	SENT	.
DLQI	NP	<unknown>
was	VBD	be
significantly	RB	significantly
affected	VBN	affect
in	IN	in
women	NNS	woman
(	(	(
P	NN	P
=	SYM	=
0.003	CD	@card@
)	)	)
,	,	,
and	CC	and
with	IN	with
increased	VBN	increase
skin	NN	skin
problems	NNS	problem
related	VBN	relate
to	TO	to
PPE	NP	PPE
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001).It	NN	<unknown>
is	VBZ	be
important	JJ	important
to	TO	to
organize	VB	organize
trainings	NNS	training
on	IN	on
prevention	NN	prevention
and	CC	and
management	NN	management
of	IN	of
possible	JJ	possible
skin	NN	skin
symptoms	NNS	symptom
due	JJ	due
to	TO	to
PPE	NP	PPE
use	NN	use
according	VBG	accord
to	TO	to
guidelines	NNS	guideline
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VBN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VBD	reserve
.	SENT	.
34326985/'Erring	JJ	<unknown>
on	IN	on
the	DT	the
side	NN	side
of	IN	of
rare	JJ	rare
events	NNS	event
'	POS	'
?	SENT	?
A	DT	a
behavioural	JJ	<unknown>
explanation	NN	explanation
for	IN	for
COVID-19	NP	<unknown>
vaccine	NN	vaccine
regulatory	JJ	regulatory
misalignment	NN	misalignment
35175442/	CD	@card@
Clinical	JJ	clinical
outcome	NN	outcome
of	IN	of
neurological	JJ	neurological
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
:	:	:
the	DT	the
impact	NN	impact
of	IN	of
healthcare	NN	<unknown>
organization	NN	organization
improvement	NN	improvement
between	IN	between
waves	NNS	wave
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
evaluate	VB	evaluate
the	DT	the
differences	NNS	difference
in	IN	in
clinical	JJ	clinical
presentations	NNS	presentation
and	CC	and
the	DT	the
impact	NN	impact
of	IN	of
healthcare	NN	<unknown>
organization	NN	organization
on	IN	on
outcomes	NNS	outcome
of	IN	of
neurological	JJ	neurological
COVID-19	NP	<unknown>
patients	NNS	patient
admitted	VBD	admit
during	IN	during
the	DT	the
first	JJ	first
and	CC	and
second	JJ	second
pandemic	JJ	pandemic
waves	NNS	wave
.	SENT	.
In	IN	in
this	DT	this
single-center	NN	single-center
cohort	NN	cohort
study	NN	study
,	,	,
we	PP	we
included	VBD	include
all	DT	all
patients	NNS	patient
with	IN	with
SARS-CoV-2	NP	<unknown>
infection	NN	infection
admitted	VBD	admit
to	TO	to
a	DT	a
Neuro-COVID	NP	<unknown>
Unit	NP	Unit
.	SENT	.
Demographic	JJ	demographic
,	,	,
clinical	JJ	clinical
,	,	,
and	CC	and
laboratory	NN	laboratory
data	NNS	datum
were	VBD	be
compared	VBN	compare
between	IN	between
patients	NNS	patient
admitted	VBN	admit
during	IN	during
the	DT	the
first	JJ	first
and	CC	and
second	JJ	second
waves	NNS	wave
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Two	CD	two
hundred	CD	hundred
twenty-three	NN	twenty-three
patients	NNS	patient
were	VBD	be
included	VBN	include
,	,	,
of	IN	of
whom	WP	whom
112	CD	@card@
and	CC	and
111	CD	@card@
were	VBD	be
hospitalized	VBN	hospitalize
during	IN	during
the	DT	the
first	JJ	first
and	CC	and
second	JJ	second
pandemic	JJ	pandemic
waves	NNS	wave
,	,	,
respectively	RB	respectively
.	SENT	.
Patients	NNS	patient
admitted	VBN	admit
during	IN	during
the	DT	the
second	JJ	second
wave	NN	wave
were	VBD	be
younger	JJR	young
and	CC	and
exhibited	VBD	exhibit
pulmonary	JJ	pulmonary
COVID-19	NP	<unknown>
severity	NN	severity
,	,	,
resulting	VBG	result
in	IN	in
less	JJR	less
oxygen	NN	oxygen
support	NN	support
(	(	(
n	NN	n
=	SYM	=
41	CD	@card@
,	,	,
36.9	CD	@card@
%	NN	%
vs	NP	vs
n	NN	n
=	SYM	=
79	CD	@card@
,	,	,
70.5	CD	@card@
%	NN	%
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
lower	JJR	low
mortality	NN	mortality
rates	NNS	rate
(	(	(
14.4	CD	@card@
%	NN	%
vs	NP	vs
31.3	CD	@card@
%	NN	%
,	,	,
p	NN	p
=	SYM	=
0.004	CD	@card@
)	)	)
.	SENT	.
The	DT	the
different	JJ	different
healthcare	NN	<unknown>
strategies	NNS	strategy
and	CC	and
early	JJ	early
steroid	NN	steroid
treatment	NN	treatment
emerged	VBD	emerge
as	IN	as
significant	JJ	significant
predictors	NNS	predictor
of	IN	of
mortality	NN	mortality
independently	RB	independently
from	IN	from
age	NN	age
,	,	,
pre-morbid	NN	<unknown>
conditions	NNS	condition
and	CC	and
COVID-19	JJ	<unknown>
severity	NN	severity
in	IN	in
Cox	NP	Cox
regression	NN	regression
analyses	NNS	analysis
.	SENT	.
Differences	NNS	difference
in	IN	in
healthcare	NN	<unknown>
strategies	NNS	strategy
during	IN	during
the	DT	the
second	JJ	second
phase	NN	phase
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
probably	RB	probably
explain	VB	explain
the	DT	the
differences	NNS	difference
in	IN	in
clinical	JJ	clinical
outcomes	NNS	outcome
independently	RB	independently
of	IN	of
disease	NN	disease
severity	NN	severity
,	,	,
underlying	VBG	underlie
the	DT	the
importance	NN	importance
of	IN	of
standardized	JJ	standardized
early	JJ	early
management	NN	management
of	IN	of
neurological	JJ	neurological
patients	NNS	patient
with	IN	with
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s10072-022-05946-8	JJ	10.1007/s@card@
.	SENT	.
32007643/	CD	@card@
Preliminary	JJ	preliminary
estimation	NN	estimation
of	IN	of
the	DT	the
basic	JJ	basic
reproduction	NN	reproduction
number	NN	number
of	IN	of
novel	NN	novel
coronavirus	NN	coronavirus
(	(	(
2019-nCoV	JJ	<unknown>
)	)	)
in	IN	in
China	NP	China
,	,	,
from	IN	from
2019	CD	@card@
to	TO	to
2020	CD	@card@
:	:	:
A	DT	a
data-driven	JJ	data-driven
analysis	NN	analysis
in	IN	in
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
outbreak	NN	outbreak
The	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
(	(	(
2019-nCoV	JJ	<unknown>
)	)	)
pneumonia	NN	pneumonia
has	VBZ	have
caused	VBN	cause
2033	CD	@card@
confirmed	JJ	confirmed
cases	NNS	case
,	,	,
including	VBG	include
56	CD	@card@
deaths	NNS	death
in	IN	in
mainland	JJ	mainland
China	NP	China
,	,	,
by	IN	by
2020-01-26	CD	@card@
17:06	CD	@card@
.	SENT	.
We	PP	we
aim	VBP	aim
to	TO	to
estimate	VB	estimate
the	DT	the
basic	JJ	basic
reproduction	NN	reproduction
number	NN	number
of	IN	of
2019-nCoV	NP	<unknown>
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
using	VBG	use
the	DT	the
exponential	JJ	exponential
growth	NN	growth
model	NN	model
method	NN	method
.	SENT	.
We	PP	we
estimated	VBD	estimate
that	IN	that
the	DT	the
mean	JJ	mean
R	NN	R
0	CD	@card@
ranges	NNS	range
from	IN	from
2.24	CD	@card@
to	TO	to
3.58	CD	@card@
with	IN	with
an	DT	an
8-fold	NN	<unknown>
to	TO	to
2-fold	JJ	<unknown>
increase	NN	increase
in	IN	in
the	DT	the
reporting	VBG	report
rate	NN	rate
.	SENT	.
Changes	NNS	change
in	IN	in
reporting	VBG	report
likely	JJ	likely
occurred	VBN	occur
and	CC	and
should	MD	should
be	VB	be
taken	VBN	take
into	IN	into
account	NN	account
in	IN	in
the	DT	the
estimation	NN	estimation
of	IN	of
R	NP	R
0	CD	@card@
.	SENT	.
An	DT	an
ongoing	JJ	ongoing
outbreak	NN	outbreak
of	IN	of
a	DT	a
novel	NN	novel
coronavirus	NN	coronavirus
(	(	(
2019-nCoV	JJ	<unknown>
)	)	)
pneumonia	NN	pneumonia
hit	VBD	hit
a	DT	a
major	JJ	major
city	NN	city
in	IN	in
China	NP	China
,	,	,
Wuhan	NP	Wuhan
,	,	,
December	NP	December
2019	CD	@card@
and	CC	and
subsequently	RB	subsequently
reached	VBN	reach
other	JJ	other
provinces/regions	NNS	provinces/region
of	IN	of
China	NP	China
and	CC	and
other	JJ	other
countries	NNS	country
.	SENT	.
We	PP	we
present	VBP	present
estimates	NNS	estimate
of	IN	of
the	DT	the
basic	JJ	basic
reproduction	NN	reproduction
number	NN	number
,	,	,
R0	NP	<unknown>
,	,	,
of	IN	of
2019-nCoV	NP	<unknown>
in	IN	in
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
outbreak	NN	outbreak
.	SENT	.
Accounting	NN	accounting
for	IN	for
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
variations	NNS	variation
in	IN	in
disease	NN	disease
reporting	VBG	report
rate	NN	rate
,	,	,
we	PP	we
modelled	VBD	model
the	DT	the
epidemic	JJ	epidemic
curve	NN	curve
of	IN	of
2019-nCoV	JJ	<unknown>
cases	NNS	case
time	NN	time
series	NN	series
,	,	,
in	IN	in
mainland	JJ	mainland
China	NP	China
from	IN	from
January	NP	January
10	CD	@card@
to	TO	to
January	NP	January
24	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
through	IN	through
the	DT	the
exponential	JJ	exponential
growth	NN	growth
.	SENT	.
With	IN	with
the	DT	the
estimated	JJ	estimated
intrinsic	JJ	intrinsic
growth	NN	growth
rate	NN	rate
(	(	(
gamma	NN	gamma
)	)	)
,	,	,
we	PP	we
estimated	VBD	estimate
R0	NP	<unknown>
by	IN	by
using	VBG	use
the	DT	the
serial	JJ	serial
intervals	NNS	interval
(	(	(
SI	NP	SI
)	)	)
of	IN	of
two	CD	two
other	JJ	other
well-known	JJ	well-known
coronavirus	NN	coronavirus
diseases	NNS	disease
,	,	,
MERS	NP	<unknown>
and	CC	and
SARS	NP	<unknown>
,	,	,
as	IN	as
approximations	NNS	approximation
for	IN	for
the	DT	the
true	JJ	true
unknown	JJ	unknown
SI	NP	SI
.	SENT	.
The	DT	the
early	JJ	early
outbreak	NN	outbreak
data	NNS	datum
largely	RB	largely
follows	VBZ	follow
the	DT	the
exponential	JJ	exponential
growth	NN	growth
.	SENT	.
We	PP	we
estimated	VBD	estimate
that	IN	that
the	DT	the
mean	JJ	mean
R0	NP	<unknown>
ranges	NNS	range
from	IN	from
2.24	CD	@card@
(	(	(
95%CI	NP	<unknown>
:	:	:
1.96-2.55	LS	@card@
)	)	)
to	TO	to
3.58	CD	@card@
(	(	(
95%CI	NP	<unknown>
:	:	:
2.89-4.39	LS	@card@
)	)	)
associated	VBN	associate
with	IN	with
8-fold	NN	<unknown>
to	TO	to
2-fold	JJ	<unknown>
increase	NN	increase
in	IN	in
the	DT	the
reporting	VBG	report
rate	NN	rate
.	SENT	.
We	PP	we
demonstrated	VBD	demonstrate
that	IN	that
changes	NNS	change
in	IN	in
reporting	VBG	report
rate	NN	rate
substantially	RB	substantially
affect	VB	affect
estimates	NNS	estimate
of	IN	of
R0	NP	<unknown>
.	SENT	.
The	DT	the
mean	JJ	mean
estimate	NN	estimate
of	IN	of
R0	NP	<unknown>
for	IN	for
the	DT	the
2019-nCoV	JJ	<unknown>
ranges	NNS	range
from	IN	from
2.24	CD	@card@
to	TO	to
3.58	CD	@card@
,	,	,
and	CC	and
is	VBZ	be
significantly	RB	significantly
larger	JJR	large
than	IN	than
1	CD	@card@
.	SENT	.
Our	PP$	our
findings	NNS	finding
indicate	VBP	indicate
the	DT	the
potential	NN	potential
of	IN	of
2019-nCoV	NP	<unknown>
to	TO	to
cause	VB	cause
outbreaks	NNS	outbreak
.	SENT	.
33822099/	CD	@card@
A	DT	a
cluster	NN	cluster
of	IN	of
differentiation	NN	differentiation
14	CD	@card@
(	(	(
CD14	NP	<unknown>
)	)	)
polymorphism	NN	polymorphism
(	(	(
C-159T	NP	<unknown>
rs2569190	NN	<unknown>
)	)	)
is	VBZ	be
associated	VBN	associate
with	IN	with
SARS-CoV-2	NP	<unknown>
infection	NN	infection
and	CC	and
mortality	NN	mortality
in	IN	in
the	DT	the
European	JJ	European
population	NN	population
35597776/	CD	@card@
Heterogeneous	JJ	heterogeneous
SARS-CoV-2	NP	<unknown>
humoral	JJ	humoral
response	NN	response
after	IN	after
COVID-19	NP	<unknown>
vaccination	NN	vaccination
and/or	CC	and/or
infection	NN	infection
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
Assessment	NP	Assessment
of	IN	of
the	DT	the
intensity	NN	intensity
,	,	,
dynamics	NNS	dynamics
and	CC	and
determinants	NNS	determinant
of	IN	of
the	DT	the
antibody	NN	antibody
response	NN	response
after	IN	after
SARS-CoV-2	NP	<unknown>
infection	NN	infection
or	CC	or
vaccination	NN	vaccination
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
is	VBZ	be
critical	JJ	critical
to	TO	to
guide	VB	guide
vaccination	NN	vaccination
policies	NNS	policy
.	SENT	.
This	DT	this
study	NN	study
characterized	VBD	characterize
the	DT	the
anti-spike	NP	anti-spike
IgG	NP	IgG
titers	NNS	titer
in	IN	in
13,971	CD	@card@
participants	NNS	participant
included	VBN	include
in	IN	in
a	DT	a
French	JJ	French
multicohort	NN	multicohort
population-based	JJ	<unknown>
serological	JJ	serological
survey	NN	survey
on	IN	on
COVID-19	NP	<unknown>
between	IN	between
April	NP	April
and	CC	and
October	NP	October
2020	CD	@card@
and	CC	and
followed-up	JJ	<unknown>
with	IN	with
serological	JJ	serological
testing	NN	testing
between	IN	between
May	NP	May
and	CC	and
October	NP	October
2021	CD	@card@
.	SENT	.
Eight	CD	eight
follow-up	NN	follow-up
profiles	NNS	profile
were	VBD	be
defined	VBN	define
depending	VBG	depend
on	IN	on
SARS-CoV-2	NP	<unknown>
infection	NN	infection
(	(	(
0	CD	@card@
,	,	,
1	CD	@card@
or	CC	or
2	CD	@card@
)	)	)
and	CC	and
COVID-19	NP	<unknown>
vaccination	NN	vaccination
(	(	(
0	CD	@card@
,	,	,
1	CD	@card@
,	,	,
2	CD	@card@
or	CC	or
3	CD	@card@
)	)	)
.	SENT	.
The	DT	the
anti-spike	NN	anti-spike
titer	NN	titer
was	VBD	be
lower	JJR	low
in	IN	in
adults	NNS	adult
with	IN	with
no	DT	no
vaccination	NN	vaccination
even	RB	even
in	IN	in
case	NN	case
of	IN	of
infection	NN	infection
or	CC	or
reinfection	NN	reinfection
,	,	,
while	IN	while
it	PP	it
was	VBD	be
higher	RBR	higher
in	IN	in
adults	NNS	adult
with	IN	with
infection	NN	infection
followed	VBN	follow
by	IN	by
vaccination	NN	vaccination
.	SENT	.
The	DT	the
anti-spike	NN	anti-spike
titer	NN	titer
was	VBD	be
negatively	RB	negatively
correlated	VBN	correlate
with	IN	with
age	NN	age
in	IN	in
vaccinated	VBN	vaccinate
but	CC	but
uninfected	JJ	uninfected
adults	NNS	adult
,	,	,
whereas	IN	whereas
it	PP	it
was	VBD	be
positively	RB	positively
correlated	VBN	correlate
with	IN	with
age	NN	age
in	IN	in
unvaccinated	JJ	unvaccinated
but	CC	but
infected	JJ	infected
adults	NNS	adult
.	SENT	.
In	IN	in
adults	NNS	adult
with	IN	with
2	CD	@card@
vaccine	NN	vaccine
injections	NNS	injection
and	CC	and
no	DT	no
infection	NN	infection
,	,	,
the	DT	the
vaccine	NN	vaccine
protocol	NN	protocol
,	,	,
age	NN	age
,	,	,
gender	NN	gender
,	,	,
and	CC	and
time	NN	time
since	IN	since
the	DT	the
last	JJ	last
vaccine	NN	vaccine
injection	NN	injection
were	VBD	be
independently	RB	independently
associated	VBN	associate
with	IN	with
the	DT	the
anti-spike	NN	anti-spike
titer	NN	titer
.	SENT	.
The	DT	the
decrease	NN	decrease
in	IN	in
anti-spike	NN	anti-spike
titer	NN	titer
was	VBD	be
much	RB	much
more	RBR	more
rapid	JJ	rapid
in	IN	in
vaccinated	VBN	vaccinate
than	IN	than
in	IN	in
infected	JJ	infected
subjects	NNS	subject
.	SENT	.
These	DT	these
results	NNS	result
highlight	VB	highlight
the	DT	the
strong	JJ	strong
heterogeneity	NN	heterogeneity
of	IN	of
the	DT	the
antibody	NN	antibody
response	NN	response
against	IN	against
SARS-CoV-2	NP	<unknown>
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
depending	VBG	depend
on	IN	on
previous	JJ	previous
infection	NN	infection
and	CC	and
vaccination	NN	vaccination
.	SENT	.
33452734/	CD	@card@
Exploring	VBG	explore
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
with	IN	with
Yinqiao	NP	<unknown>
powder	NN	powder
based	VBN	base
on	IN	on
network	NN	network
pharmacology	NN	pharmacology
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
.	SENT	.
In	IN	in
China	NP	China
,	,	,
Yinqiao	NP	<unknown>
powder	NN	powder
is	VBZ	be
widely	RB	widely
used	VBN	use
to	TO	to
prevent	VB	prevent
and	CC	and
treat	VB	treat
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
Weifen	NP	<unknown>
syndrome	NN	syndrome
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
the	DT	the
screening	NN	screening
and	CC	and
verification	NN	verification
of	IN	of
active	JJ	active
ingredients	NNS	ingredient
,	,	,
target	NN	target
selection	NN	selection
and	CC	and
DisGeNET	NP	<unknown>
scoring	VBG	score
,	,	,
drug-ingredient-gene	JJ	<unknown>
network	NN	network
construction	NN	construction
,	,	,
protein-protein	NN	protein-protein
interaction	NN	interaction
network	NN	network
construction	NN	construction
,	,	,
molecular	JJ	molecular
docking	VBG	dock
and	CC	and
surface	NN	surface
plasmon	NN	plasmon
resonance	NN	resonance
(	(	(
SPR	NP	Spr
)	)	)
analysis	NN	analysis
,	,	,
gene	NN	gene
ontology	NN	ontology
(	(	(
GO	VB	go
)	)	)
functional	JJ	functional
analysis	NN	analysis
,	,	,
gene	NN	gene
tissue	NN	tissue
analysis	NN	analysis
,	,	,
and	CC	and
kyoto	NN	<unknown>
encyclopedia	NN	encyclopedia
of	IN	of
genes	NNS	gene
and	CC	and
genomes	NNS	genome
(	(	(
KEGG	NP	Kegg
)	)	)
pathway	NN	pathway
analysis	NN	analysis
were	VBD	be
used	VBN	use
to	TO	to
explore	VB	explore
the	DT	the
active	JJ	active
ingredients	NNS	ingredient
,	,	,
targets	NNS	target
,	,	,
and	CC	and
potential	JJ	potential
mechanisms	NNS	mechanism
of	IN	of
Yinqiao	NP	<unknown>
powder	NN	powder
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
also	RB	also
predicted	VBD	predict
the	DT	the
therapeutic	JJ	therapeutic
effect	NN	effect
of	IN	of
Yinqiao	NP	<unknown>
powder	NN	powder
using	VBG	use
TCM	NP	TCM
anti-COVID-19	NP	<unknown>
(	(	(
TCMATCOV	NP	<unknown>
)	)	)
.	SENT	.
Yinqiao	NP	<unknown>
powder	NN	powder
has	VBZ	have
a	DT	a
certain	JJ	certain
therapeutic	JJ	therapeutic
effect	NN	effect
on	IN	on
COVID-19	NP	<unknown>
,	,	,
with	IN	with
an	DT	an
intervention	NN	intervention
score	NN	score
of	IN	of
20.16	CD	@card@
.	SENT	.
Hesperetin	NP	<unknown>
,	,	,
eriodictyol	NN	<unknown>
,	,	,
luteolin	NN	luteolin
,	,	,
quercetin	NN	quercetin
,	,	,
and	CC	and
naringenin	NN	<unknown>
were	VBD	be
the	DT	the
potentially	RB	potentially
effective	JJ	effective
active	JJ	active
ingredients	NNS	ingredient
against	IN	against
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
hub-proteins	NNS	hub-protein
were	VBD	be
interleukin-6	JJ	<unknown>
(	(	(
IL-6	NP	<unknown>
)	)	)
,	,	,
mitogen-activated	JJ	<unknown>
protein	NN	protein
kinase	NN	kinase
3	CD	@card@
(	(	(
MAPK3	NP	<unknown>
)	)	)
,	,	,
tumor	NN	tumor
necrosis	NN	necrosis
factor	NN	factor
(	(	(
TNF	NP	TNF
)	)	)
,	,	,
and	CC	and
tumor	NN	tumor
protein	NN	protein
P53	NN	p53
(	(	(
TP53	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
potential	JJ	potential
mechanisms	NNS	mechanism
of	IN	of
Yinqiao	NP	<unknown>
powder	NN	powder
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
are	VBP	be
the	DT	the
TNF	NP	TNF
signaling	VBG	signal
pathway	NN	pathway
,	,	,
T-cell	NN	T-cell
receptor	NN	receptor
signaling	VBG	signal
pathway	NN	pathway
,	,	,
Toll-like	JJ	<unknown>
receptor	NN	receptor
signaling	VBG	signal
pathway	NN	pathway
,	,	,
and	CC	and
MAPK	NP	<unknown>
signaling	VBG	signal
pathway	NN	pathway
.	SENT	.
This	DT	this
study	NN	study
provides	VBZ	provide
a	DT	a
new	JJ	new
perspective	NN	perspective
for	IN	for
discovering	VBG	discover
potential	JJ	potential
drugs	NNS	drug
and	CC	and
mechanisms	NNS	mechanism
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
35340778/	CD	@card@
Spontaneous	JJ	spontaneous
ilio-psoas	NNS	<unknown>
hematoma	NN	hematoma
in	IN	in
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
:	:	:
A	DT	a
rising	VBG	rise
catastrophic	JJ	catastrophic
complication	NN	complication
32458459/	CD	@card@
Neutrophil	NN	neutrophil
to	TO	to
lymphocyte	NN	lymphocyte
ratio	NN	ratio
as	IN	as
prognostic	JJ	prognostic
and	CC	and
predictive	JJ	predictive
factor	NN	factor
in	IN	in
patients	NNS	patient
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
:	:	:
A	DT	a
retrospective	JJ	retrospective
cross-sectional	JJ	cross-sectional
study	NN	study
This	DT	this
retrospective	JJ	retrospective
study	NN	study
was	VBD	be
designed	VBN	design
to	TO	to
explore	VB	explore
whether	IN	whether
neutrophil	NN	neutrophil
to	TO	to
lymphocyte	NN	lymphocyte
ratio	NN	ratio
(	(	(
NLR	NP	NLR
)	)	)
is	VBZ	be
a	DT	a
prognostic	JJ	prognostic
factor	NN	factor
in	IN	in
patients	NNS	patient
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
A	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
admitted	VBD	admit
to	TO	to
the	DT	the
Tongren	NP	Tongren
Hospital	NP	Hospital
of	IN	of
Wuhan	NP	Wuhan
University	NP	University
from	IN	from
11	CD	@card@
January	NP	January
2020	CD	@card@
to	TO	to
3	CD	@card@
March	NP	March
2020	CD	@card@
was	VBD	be
retrospectively	RB	retrospectively
analyzed	VBN	analyze
.	SENT	.
Patients	NNS	patient
with	IN	with
hematologic	JJ	hematologic
malignancy	NN	malignancy
were	VBD	be
excluded	VBN	exclude
.	SENT	.
The	DT	the
NLR	NP	NLR
was	VBD	be
calculated	VBN	calculate
by	IN	by
dividing	VBG	divide
the	DT	the
neutrophil	JJ	neutrophil
count	NN	count
by	IN	by
the	DT	the
lymphocyte	NN	lymphocyte
count	NN	count
.	SENT	.
NLR	NP	NLR
values	NNS	value
were	VBD	be
measured	VBN	measure
at	IN	at
the	DT	the
time	NN	time
of	IN	of
admission	NN	admission
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
was	VBD	be
all-cause	JJ	<unknown>
in-hospital	JJ	in-hospital
mortality	NN	mortality
.	SENT	.
A	DT	a
multivariate	JJ	multivariate
logistic	JJ	logistic
analysis	NN	analysis
was	VBD	be
performed	VBN	perform
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
1004	CD	@card@
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
study	NN	study
.	SENT	.
The	DT	the
mortality	NN	mortality
rate	NN	rate
was	VBD	be
4.0	CD	@card@
%	NN	%
(	(	(
40	CD	@card@
cases	NNS	case
)	)	)
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
of	IN	of
nonsurvivors	NNS	nonsurvivor
(	(	(
68	CD	@card@
years	NNS	year
)	)	)
was	VBD	be
significantly	RB	significantly
older	JJR	old
than	IN	than
survivors	NNS	survivor
(	(	(
62	CD	@card@
years	NNS	year
)	)	)
.	SENT	.
Male	JJ	male
sex	NN	sex
was	VBD	be
more	RBR	more
predominant	JJ	predominant
in	IN	in
nonsurvival	JJ	<unknown>
group	NN	group
(	(	(
27	CD	@card@
;	:	;
67.5	CD	@card@
%	NN	%
)	)	)
than	IN	than
in	IN	in
the	DT	the
survival	NN	survival
group	NN	group
(	(	(
466	CD	@card@
;	:	;
48.3	CD	@card@
%	NN	%
)	)	)
.	SENT	.
NLR	NN	NLR
value	NN	value
of	IN	of
nonsurvival	JJ	<unknown>
group	NN	group
(	(	(
median	JJ	median
:	:	:
49.06	CD	@card@
;	:	;
interquartile	JJ	<unknown>
range	NN	range
[	SYM	[
IQR	NP	IQR
]	SYM	]
:	:	:
25.71-69.70	LS	@card@
)	)	)
was	VBD	be
higher	JJR	high
than	IN	than
that	IN	that
of	IN	of
survival	NN	survival
group	NN	group
(	(	(
median	JJ	median
:	:	:
4.11	CD	@card@
;	:	;
IQR	NP	IQR
:	:	:
2.44-8.12	CD	@card@
;	:	;
P	NN	P
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
.	SENT	.
In	IN	in
multivariate	JJ	multivariate
logistic	JJ	logistic
regression	NN	regression
analysis	NN	analysis
,	,	,
after	IN	after
adjusting	VBG	adjust
for	IN	for
confounding	VBG	confound
factors	NNS	factor
,	,	,
NLR	NN	NLR
more	JJR	more
than	IN	than
11.75	CD	@card@
was	VBD	be
significantly	RB	significantly
correlated	VBN	correlate
with	IN	with
all-cause	JJ	<unknown>
in-hospital	JJ	in-hospital
mortality	NN	mortality
(	(	(
odds	NNS	odd
ratio	NN	ratio
=	SYM	=
44.351	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
=	SYM	=
4.627-425.088	CD	@card@
)	)	)
.	SENT	.
These	DT	these
results	NNS	result
suggest	VBP	suggest
that	IN	that
the	DT	the
NLR	NP	NLR
at	IN	at
hospital	NN	hospital
admission	NN	admission
is	VBZ	be
associated	VBN	associate
with	IN	with
in-hospital	JJ	in-hospital
mortality	NN	mortality
among	IN	among
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Therefore	RB	therefore
,	,	,
the	DT	the
NLR	NP	NLR
appears	VBZ	appear
to	TO	to
be	VB	be
a	DT	a
significant	JJ	significant
prognostic	JJ	prognostic
biomarker	NN	biomarker
of	IN	of
outcomes	NNS	outcome
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
further	JJR	further
investigation	NN	investigation
is	VBZ	be
needed	VBN	need
to	TO	to
validate	VB	validate
this	DT	this
relationship	NN	relationship
with	IN	with
data	NNS	datum
collected	VBN	collect
prospectively	RB	prospectively
.	SENT	.
NLR	NP	NLR
is	VBZ	be
a	DT	a
significant	JJ	significant
prognostic	JJ	prognostic
biomarker	NN	biomarker
of	IN	of
outcomes	NNS	outcome
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
COVID-19	NP	<unknown>
is	VBZ	be
more	RBR	more
likely	JJ	likely
to	TO	to
infected	VBN	infect
those	DT	those
elder	JJR	elder
men	NNS	man
with	IN	with
chronic	JJ	chronic
comorbidities	NNS	comorbidity
.	SENT	.
NLR	NP	NLR
may	MD	may
also	RB	also
help	VB	help
in	IN	in
the	DT	the
early	JJ	early
identification	NN	identification
of	IN	of
older	JJR	old
patients	NNS	patient
at	IN	at
higher	JJR	high
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
Close	JJ	close
monitoring	NN	monitoring
and	CC	and
timely	JJ	timely
intervention	NN	intervention
are	VBP	be
needed	VBN	need
for	IN	for
elderly	JJ	elderly
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
35169259/	CD	@card@
Lessons	NNS	lesson
from	IN	from
Long	NP	Long
COVID	NP	<unknown>
:	:	:
working	VBG	work
with	IN	with
patients	NNS	patient
to	TO	to
design	VB	design
better	JJR	good
research	NN	research
The	DT	the
perspectives	NNS	perspective
of	IN	of
people	NNS	people
with	IN	with
lived	VBN	live
experience	NN	experience
of	IN	of
any	DT	any
condition	NN	condition
being	VBG	be
researched	VBN	research
must	MD	must
actively	RB	actively
inform	VB	inform
the	DT	the
research	NN	research
questions	NNS	question
asked	VBD	ask
and	CC	and
the	DT	the
way	NN	way
in	IN	in
which	WDT	which
we	PP	we
go	VBP	go
about	RB	about
answering	VBG	answer
them	PP	them
.	SENT	.
The	DT	the
experience	NN	experience
of	IN	of
Long	NP	Long
Covid	NP	<unknown>
gives	VBZ	give
a	DT	a
contemporary	JJ	contemporary
example	NN	example
of	IN	of
how	WRB	how
working	VBG	work
together	RB	together
with	IN	with
patients	NNS	patient
is	VBZ	be
integral	JJ	integral
to	TO	to
medical	JJ	medical
research	NN	research
.	SENT	.
In	IN	in
this	DT	this
Comment	NP	Comment
article	NN	article
,	,	,
Nisreen	NP	<unknown>
Alwan	NP	Alwan
discusses	VBZ	discuss
what	WP	what
her	PP$	her
experience	NN	experience
as	IN	as
both	CC	both
a	DT	a
public	JJ	public
health	NN	health
academic	NN	academic
and	CC	and
a	DT	a
person	NN	person
living	NN	living
with	IN	with
Long	NP	Long
COVID	NP	<unknown>
has	VBZ	have
taught	VBN	teach
her	PP	her
about	IN	about
the	DT	the
importance	NN	importance
of	IN	of
including	VBG	include
those	DT	those
with	IN	with
lived	VBN	live
experience	NN	experience
of	IN	of
a	DT	a
condition	NN	condition
in	IN	in
setting	VBG	set
the	DT	the
research	NN	research
agenda	NN	agenda
.	SENT	.
33114356/	CD	@card@
New	NP	New
Insights	NNS	insight
on	IN	on
the	DT	the
Mobility	NN	mobility
of	IN	of
Viral	JJ	viral
and	CC	and
Host	NP	Host
Non-Coding	NP	<unknown>
RNAs	NP	<unknown>
Reveal	NP	Reveal
Extracellular	JJ	extracellular
Vesicles	NNS	vesicle
as	IN	as
Intriguing	JJ	intriguing
Candidate	NN	candidate
Antiviral	JJ	antiviral
Targets	NNS	target
Intercellular	JJ	intercellular
communication	NN	communication
occurring	VBG	occur
by	IN	by
cell-to-cell	NN	cell-to-cell
contacts	NNS	contact
and	CC	and
via	IN	via
secreted	VBN	secrete
messengers	NNS	messenger
trafficked	VBN	traffic
through	IN	through
extracellular	JJ	extracellular
vehicles	NNS	vehicle
is	VBZ	be
critical	JJ	critical
for	IN	for
regulating	VBG	regulate
biological	JJ	biological
functions	NNS	function
of	IN	of
multicellular	JJ	multicellular
organisms	NNS	organism
.	SENT	.
Recent	JJ	Recent
research	NN	research
has	VBZ	have
revealed	VBN	reveal
that	IN	that
non-coding	JJ	<unknown>
RNAs	NP	<unknown>
can	MD	can
be	VB	be
found	VBN	find
in	IN	in
extracellular	JJ	extracellular
vesicles	NNS	vesicle
consistent	JJ	consistent
with	IN	with
a	DT	a
functional	JJ	functional
importance	NN	importance
of	IN	of
these	DT	these
molecular	JJ	molecular
vehicles	NNS	vehicle
in	IN	in
virus	NN	virus
propagation	NN	propagation
and	CC	and
suggesting	VBG	suggest
that	IN	that
these	DT	these
essential	JJ	essential
membrane-bound	JJ	membrane-bound
bodies	NNS	body
can	MD	can
be	VB	be
highjacked	VBN	highjack
by	IN	by
viruses	NNS	virus
to	TO	to
promote	VB	promote
disease	NN	disease
pathogenesis	NN	pathogenesis
.	SENT	.
Newly	RB	newly
emerging	VBG	emerge
evidence	NN	evidence
that	IN	that
coronaviruses	NNS	coronavirus
generate	VB	generate
non-coding	JJ	<unknown>
RNAs	NP	<unknown>
and	CC	and
use	VB	use
extracellular	JJ	extracellular
vesicles	NNS	vesicle
to	TO	to
facilitate	VB	facilitate
viral	JJ	viral
pathogenicity	NN	<unknown>
may	MD	may
have	VB	have
important	JJ	important
implications	NNS	implication
for	IN	for
the	DT	the
development	NN	development
of	IN	of
effective	JJ	effective
strategies	NNS	strategy
to	TO	to
combat	VB	combat
COVID-19	NP	<unknown>
,	,	,
a	DT	a
disease	NN	disease
caused	VBN	cause
by	IN	by
infection	NN	infection
with	IN	with
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
SARS-CoV-2	NP	<unknown>
.	SENT	.
This	DT	this
article	NN	article
provides	VBZ	provide
a	DT	a
short	JJ	short
overview	NN	overview
of	IN	of
our	PP$	our
current	JJ	current
understanding	NN	understanding
of	IN	of
the	DT	the
interactions	NNS	interaction
between	IN	between
non-coding	JJ	<unknown>
RNAs	NP	<unknown>
and	CC	and
extracellular	JJ	extracellular
vesicles	NNS	vesicle
and	CC	and
highlights	VBZ	highlight
recent	JJ	recent
research	NN	research
which	WDT	which
supports	VBZ	support
these	DT	these
interactions	NNS	interaction
as	IN	as
potential	JJ	potential
therapeutic	JJ	therapeutic
targets	NNS	target
in	IN	in
the	DT	the
development	NN	development
of	IN	of
novel	JJ	novel
antiviral	JJ	antiviral
therapies	NNS	therapy
.	SENT	.
34188432/	CD	@card@
Modeling	VBG	model
the	DT	the
impact	NN	impact
of	IN	of
SARS-CoV-2	NP	<unknown>
variants	NNS	variant
and	CC	and
vaccines	NNS	vaccine
on	IN	on
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
The	DT	the
continuous	JJ	continuous
mutation	NN	mutation
of	IN	of
SARS-CoV-2	NP	<unknown>
opens	VBZ	open
the	DT	the
possibility	NN	possibility
of	IN	of
the	DT	the
appearance	NN	appearance
of	IN	of
new	JJ	new
variants	NNS	variant
of	IN	of
the	DT	the
virus	NN	virus
with	IN	with
important	JJ	important
differences	NNS	difference
in	IN	in
its	PP$	its
spreading	VBG	spread
characteristics	NNS	characteristic
,	,	,
mortality	NN	mortality
rates	NNS	rate
,	,	,
etc.	FW	etc.
On	IN	on
14	CD	@card@
December	NP	December
2020	CD	@card@
,	,	,
the	DT	the
United	NP	United
Kingdom	NP	Kingdom
reported	VBD	report
a	DT	a
potentially	RB	potentially
more	RBR	more
contagious	JJ	contagious
coronavirus	NN	coronavirus
variant	NN	variant
,	,	,
present	JJ	present
in	IN	in
that	DT	that
country	NN	country
,	,	,
which	WDT	which
is	VBZ	be
referred	VBN	refer
to	TO	to
as	IN	as
VOC	NP	VOC
202012/01	CD	@card@
.	SENT	.
On	IN	on
18	CD	@card@
December	NP	December
2020	CD	@card@
,	,	,
the	DT	the
South	JJ	South
African	JJ	African
government	NN	government
also	RB	also
announced	VBD	announce
the	DT	the
emergence	NN	emergence
of	IN	of
a	DT	a
new	JJ	new
variant	NN	variant
in	IN	in
a	DT	a
scenario	NN	scenario
similar	JJ	similar
to	TO	to
that	DT	that
of	IN	of
the	DT	the
UK	NP	UK
,	,	,
which	WDT	which
is	VBZ	be
referred	VBN	refer
to	TO	to
as	RB	as
variant	JJ	variant
501.V2	NN	<unknown>
.	SENT	.
Another	DT	another
important	JJ	important
milestone	NN	milestone
regarding	VBG	regard
this	DT	this
pandemic	NN	pandemic
was	VBD	be
the	DT	the
beginning	NN	beginning
,	,	,
in	IN	in
December	NP	December
2020	CD	@card@
,	,	,
of	IN	of
vaccination	NN	vaccination
campaigns	NNS	campaign
in	IN	in
several	JJ	several
countries	NNS	country
.	SENT	.
There	EX	there
are	VBP	be
several	JJ	several
vaccines	NNS	vaccine
,	,	,
with	IN	with
different	JJ	different
characteristics	NNS	characteristic
,	,	,
developed	VBN	develop
by	IN	by
various	JJ	various
laboratories	NNS	laboratory
and	CC	and
research	NN	research
centers	NNS	center
.	SENT	.
A	DT	a
natural	JJ	natural
question	NN	question
arises	VBZ	arise
:	:	:
what	WP	what
could	MD	could
be	VB	be
the	DT	the
impact	NN	impact
of	IN	of
these	DT	these
variants	NNS	variant
and	CC	and
vaccines	NNS	vaccine
on	IN	on
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
?	SENT	?
Many	JJ	many
models	NNS	model
have	VBP	have
been	VBN	be
proposed	VBN	propose
to	TO	to
simulate	VB	simulate
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
but	CC	but
,	,	,
to	TO	to
the	DT	the
best	JJS	good
of	IN	of
our	PP$	our
knowledge	NN	knowledge
,	,	,
none	NN	none
of	IN	of
them	PP	them
incorporates	VBZ	incorporate
the	DT	the
effects	NNS	effect
of	IN	of
potential	JJ	potential
SARS-CoV-2	NP	<unknown>
variants	NNS	variant
together	RB	together
with	IN	with
the	DT	the
vaccines	NNS	vaccine
in	IN	in
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
develop	VBP	develop
here	RB	here
a	DT	a
-SVEIHQRD	NN	<unknown>
mathematical	JJ	mathematical
model	NN	model
able	JJ	able
to	TO	to
simulate	VB	simulate
the	DT	the
possible	JJ	possible
impact	NN	impact
of	IN	of
this	DT	this
type	NN	type
of	IN	of
variants	NNS	variant
and	CC	and
of	IN	of
the	DT	the
vaccines	NNS	vaccine
,	,	,
together	RB	together
with	IN	with
the	DT	the
main	JJ	main
mechanisms	NNS	mechanism
influencing	VBG	influence
the	DT	the
disease	NN	disease
spread	NN	spread
.	SENT	.
The	DT	the
model	NN	model
may	MD	may
be	VB	be
of	IN	of
interest	NN	interest
for	IN	for
policy	NN	policy
makers	NNS	maker
,	,	,
as	IN	as
a	DT	a
tool	NN	tool
to	TO	to
evaluate	VB	evaluate
different	JJ	different
possible	JJ	possible
future	JJ	future
scenarios	NNS	scenario
.	SENT	.
We	PP	we
apply	VBP	apply
the	DT	the
model	NN	model
to	TO	to
the	DT	the
particular	JJ	particular
case	NN	case
of	IN	of
Italy	NP	Italy
(	(	(
as	IN	as
an	DT	an
example	NN	example
of	IN	of
study	NN	study
case	NN	case
)	)	)
,	,	,
showing	VBG	show
different	JJ	different
outcomes	NNS	outcome
.	SENT	.
We	PP	we
observe	VBP	observe
that	IN	that
the	DT	the
vaccines	NNS	vaccine
may	MD	may
reduce	VB	reduce
the	DT	the
infections	NNS	infection
,	,	,
but	CC	but
they	PP	they
might	MD	might
not	RB	not
be	VB	be
enough	JJ	enough
for	IN	for
avoiding	VBG	avoid
a	DT	a
new	JJ	new
wave	NN	wave
,	,	,
with	IN	with
the	DT	the
current	JJ	current
expected	VBN	expect
vaccination	NN	vaccination
rates	NNS	rate
in	IN	in
that	DT	that
country	NN	country
,	,	,
if	IN	if
the	DT	the
control	NN	control
measures	NNS	measure
are	VBP	be
relaxed	VBN	relax
.	SENT	.
Furthermore	RB	furthermore
,	,	,
a	DT	a
more	RBR	more
contagious	JJ	contagious
variant	NN	variant
could	MD	could
increase	VB	increase
significantly	RB	significantly
the	DT	the
cases	NNS	case
,	,	,
becoming	VBG	become
the	DT	the
most	RBS	most
common	JJ	common
way	NN	way
of	IN	of
infection	NN	infection
.	SENT	.
We	PP	we
show	VBP	show
how	WRB	how
,	,	,
even	RB	even
with	IN	with
the	DT	the
pandemic	JJ	pandemic
cases	NNS	case
slowing	VBG	slow
down	IN	down
(	(	(
with	IN	with
an	DT	an
effective	JJ	effective
reproduction	NN	reproduction
number	NN	number
less	JJR	less
than	IN	than
1	CD	@card@
)	)	)
and	CC	and
the	DT	the
disease	NN	disease
seeming	JJ	seeming
to	TO	to
be	VB	be
under	IN	under
control	NN	control
,	,	,
the	DT	the
effective	JJ	effective
reproduction	NN	reproduction
number	NN	number
of	IN	of
just	RB	just
the	DT	the
new	JJ	new
variant	NN	variant
may	MD	may
be	VB	be
greater	JJR	great
than	IN	than
1	CD	@card@
and	CC	and
,	,	,
eventually	RB	eventually
,	,	,
the	DT	the
number	NN	number
of	IN	of
infections	NNS	infection
would	MD	would
increase	VB	increase
towards	IN	towards
a	DT	a
new	JJ	new
disease	NN	disease
wave	NN	wave
.	SENT	.
Therefore	RB	therefore
,	,	,
a	DT	a
rigorous	JJ	rigorous
follow-up	NN	follow-up
of	IN	of
the	DT	the
evolution	NN	evolution
of	IN	of
the	DT	the
number	NN	number
of	IN	of
infections	NNS	infection
with	IN	with
any	DT	any
potentially	RB	potentially
more	RBR	more
dangerous	JJ	dangerous
new	JJ	new
variant	NN	variant
is	VBZ	be
of	IN	of
paramount	JJ	paramount
importance	NN	importance
at	IN	at
any	DT	any
stage	NN	stage
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
33409040/	CD	@card@
Raiders	NNS	raider
of	IN	of
the	DT	the
Lost	VBN	lose
Correlation	NN	correlation
:	:	:
A	DT	a
Guide	NP	Guide
on	IN	on
Using	VBG	use
Pearson	NP	Pearson
and	CC	and
Spearman	NP	Spearman
Coefficients	NNS	coefficient
to	TO	to
Detect	VB	detect
Hidden	NP	Hidden
Correlations	NNS	correlation
in	IN	in
Medical	NP	Medical
Sciences	NPS	Sciences
Pearson	NP	Pearson
and	CC	and
Spearman	NP	Spearman
correlations	NNS	correlation
are	VBP	be
important	JJ	important
tools	NNS	tool
for	IN	for
all	DT	all
scientific	JJ	scientific
fields	NNS	field
and	CC	and
are	VBP	be
widely	RB	widely
used	VBN	use
in	IN	in
medical	JJ	medical
sciences	NNS	science
,	,	,
especially	RB	especially
during	IN	during
the	DT	the
current	JJ	current
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
emergency	NN	emergency
.	SENT	.
This	DT	this
technical	JJ	technical
report	NN	report
has	VBZ	have
shown	VBN	show
that	IN	that
conventional	JJ	conventional
criteria	NNS	criterion
for	IN	for
evaluating	VBG	evaluate
the	DT	the
adoption	NN	adoption
of	IN	of
these	DT	these
coefficients	NNS	coefficient
can	MD	can
conceal	VB	conceal
substantial	JJ	substantial
scientific	JJ	scientific
information	NN	information
regarding	VBG	regard
correlations	NNS	correlation
that	WDT	that
occur	VBP	occur
above	IN	above
or	CC	or
below	IN	below
a	DT	a
certain	JJ	certain
threshold	NN	threshold
.	SENT	.
In	IN	in
particular	JJ	particular
,	,	,
the	DT	the
Pearson	NP	Pearson
coefficient	NN	coefficient
can	MD	can
reveal	VB	reveal
hidden	JJ	hidden
correlations	NNS	correlation
even	RB	even
when	WRB	when
data	NNS	datum
are	VBP	be
not	RB	not
normally	RB	normally
distributed	VBN	distribute
.	SENT	.
Finally	RB	finally
,	,	,
an	DT	an
optimized	VBN	optimize
operational	JJ	operational
guide	NN	guide
to	TO	to
reveal	VB	reveal
any	DT	any
hidden	JJ	hidden
correlation	NN	correlation
is	VBZ	be
reported	VBN	report
.	SENT	.
33908897/	CD	@card@
Protection	NP	Protection
against	IN	against
SARS-CoV-2	NP	<unknown>
infection	NN	infection
by	IN	by
a	DT	a
mucosal	JJ	mucosal
vaccine	NN	vaccine
in	IN	in
rhesus	NN	rhesus
macaques	NNS	macaque
Effective	JJ	effective
SARS-CoV-2	NP	<unknown>
vaccines	NNS	vaccine
are	VBP	be
urgently	RB	urgently
needed	VBN	need
.	SENT	.
Although	IN	although
most	JJS	most
vaccine	NN	vaccine
strategies	NNS	strategy
have	VBP	have
focused	VBN	focus
on	IN	on
systemic	JJ	systemic
immunization	NN	immunization
,	,	,
here	RB	here
we	PP	we
compared	VBD	compare
the	DT	the
protective	JJ	protective
efficacy	NN	efficacy
of	IN	of
2	CD	@card@
adjuvanted	JJ	<unknown>
subunit	NN	subunit
vaccines	NNS	vaccine
with	IN	with
spike	NN	spike
protein	NN	protein
S1	NP	<unknown>
:	:	:
an	DT	an
intramuscularly	RB	intramuscularly
primed/boosted	JJ	<unknown>
vaccine	NN	vaccine
and	CC	and
an	DT	an
intramuscularly	RB	intramuscularly
primed/intranasally	RB	primed/intranasally
boosted	VBN	boost
mucosal	JJ	mucosal
vaccine	NN	vaccine
in	IN	in
rhesus	NN	rhesus
macaques	NNS	macaque
.	SENT	.
The	DT	the
intramuscular-alum-only	JJ	<unknown>
vaccine	NN	vaccine
induced	VBD	induce
robust	JJ	robust
binding	VBG	bind
and	CC	and
neutralizing	VBG	neutralize
antibody	NN	antibody
and	CC	and
persistent	JJ	persistent
cellular	JJ	cellular
immunity	NN	immunity
systemically	RB	systemically
and	CC	and
mucosally	RB	<unknown>
,	,	,
whereas	IN	whereas
intranasal	JJ	intranasal
boosting	VBG	boost
with	IN	with
nanoparticles	NNS	nanoparticle
,	,	,
including	VBG	include
IL-15	NP	<unknown>
and	CC	and
TLR	NP	TLR
agonists	NNS	agonist
,	,	,
elicited	VBD	elicit
weaker	JJR	weak
T	NN	T
cell	NN	cell
and	CC	and
Ab	NP	Ab
responses	NNS	response
but	CC	but
higher	JJR	high
dimeric	JJ	<unknown>
IgA	NP	IgA
and	CC	and
IFN-alpha	NP	IFN-alpha
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
following	VBG	follow
SARS-CoV-2	NP	<unknown>
challenge	NN	challenge
,	,	,
neither	DT	neither
group	NN	group
showed	VBD	show
detectable	JJ	detectable
subgenomic	JJ	<unknown>
RNA	NP	RNA
in	IN	in
upper	JJ	upper
or	CC	or
lower	JJR	low
respiratory	JJ	respiratory
tracts	NNS	tract
versus	IN	versus
naive	JJ	naive
controls	NNS	control
,	,	,
indicating	VBG	indicate
full	JJ	full
protection	NN	protection
against	IN	against
viral	JJ	viral
replication	NN	replication
.	SENT	.
Although	IN	although
mucosal	JJ	mucosal
and	CC	and
systemic	JJ	systemic
protective	JJ	protective
mechanisms	NNS	mechanism
may	MD	may
differ	VB	differ
,	,	,
results	NNS	result
demonstrate	VBP	demonstrate
both	DT	both
vaccines	NNS	vaccine
can	MD	can
protect	VB	protect
against	IN	against
respiratory	JJ	respiratory
SARS-CoV-2	NP	<unknown>
exposure	NN	exposure
.	SENT	.
In	IN	in
summary	NN	summary
,	,	,
we	PP	we
have	VBP	have
demonstrated	VBN	demonstrate
that	IN	that
the	DT	the
mucosal	JJ	mucosal
vaccine	NN	vaccine
was	VBD	be
safe	JJ	safe
after	IN	after
multiple	JJ	multiple
doses	NNS	dose
and	CC	and
cleared	VBD	clear
the	DT	the
input	NN	input
virus	NN	virus
more	RBR	more
efficiently	RB	efficiently
in	IN	in
the	DT	the
nasal	JJ	nasal
cavity	NN	cavity
and	CC	and
thus	RB	thus
may	MD	may
act	VB	act
as	IN	as
a	DT	a
potent	JJ	potent
complementary	JJ	complementary
reinforcing	VBG	reinforce
boost	NN	boost
for	IN	for
conventional	JJ	conventional
systemic	JJ	systemic
vaccines	NNS	vaccine
to	TO	to
provide	VB	provide
overall	JJ	overall
better	JJR	good
protection	NN	protection
.	SENT	.
33501506/	CD	@card@
18F-FDG	JJ	<unknown>
brain	NN	brain
PET	NN	pet
hypometabolism	NN	hypometabolism
in	IN	in
patients	NNS	patient
with	IN	with
long	JJ	long
COVID	NN	<unknown>
In	IN	in
the	DT	the
context	NN	context
of	IN	of
the	DT	the
worldwide	JJ	worldwide
outbreak	NN	outbreak
of	IN	of
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
some	DT	some
patients	NNS	patient
report	VBP	report
functional	JJ	functional
complaints	NNS	complaint
after	IN	after
apparent	JJ	apparent
recovery	NN	recovery
from	IN	from
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
clinical	JJ	clinical
presentation	NN	presentation
has	VBZ	have
been	VBN	be
referred	VBN	refer
as	IN	as
"	``	"
long	JJ	long
COVID	NN	<unknown>
.	SENT	.
"	``	"
We	PP	we
here	RB	here
present	VB	present
a	DT	a
retrospective	JJ	retrospective
analysis	NN	analysis
of	IN	of
18F-FDG	JJ	<unknown>
brain	NN	brain
PET	NN	pet
of	IN	of
long	JJ	long
COVID	NP	<unknown>
patients	NNS	patient
from	IN	from
the	DT	the
same	JJ	same
center	NN	center
with	IN	with
a	DT	a
biologically	RB	biologically
confirmed	VBN	confirm
diagnosis	NN	diagnosis
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
and	CC	and
persistent	JJ	persistent
functional	JJ	functional
complaints	NNS	complaint
at	IN	at
least	JJS	least
3	CD	@card@
weeks	NNS	week
after	IN	after
the	DT	the
initial	JJ	initial
infection	NN	infection
.	SENT	.
PET	JJ	pet
scans	NNS	scan
of	IN	of
35	CD	@card@
patients	NNS	patient
with	IN	with
long	JJ	long
COVID	NP	<unknown>
were	VBD	be
compared	VBN	compare
using	VBG	use
whole-brain	NN	whole-brain
voxel-based	JJ	<unknown>
analysis	NN	analysis
to	TO	to
a	DT	a
local	JJ	local
database	NN	database
of	IN	of
44	CD	@card@
healthy	JJ	healthy
subjects	NNS	subject
controlled	VBN	control
for	IN	for
age	NN	age
and	CC	and
sex	NN	sex
to	TO	to
characterize	VB	characterize
cerebral	JJ	cerebral
hypometabolism	NN	hypometabolism
.	SENT	.
The	DT	the
individual	JJ	individual
relevance	NN	relevance
of	IN	of
this	DT	this
metabolic	JJ	metabolic
profile	NN	profile
was	VBD	be
evaluated	VBN	evaluate
to	TO	to
classify	VB	classify
patients	NNS	patient
and	CC	and
healthy	JJ	healthy
subjects	NNS	subject
.	SENT	.
Finally	RB	finally
,	,	,
the	DT	the
PET	JJ	pet
abnormalities	NNS	abnormality
were	VBD	be
exploratory	JJ	exploratory
compared	VBN	compare
with	IN	with
the	DT	the
patients	NNS	patient
'	POS	'
characteristics	NNS	characteristic
and	CC	and
functional	JJ	functional
complaints	NNS	complaint
.	SENT	.
In	IN	in
comparison	NN	comparison
to	TO	to
healthy	JJ	healthy
subjects	NNS	subject
,	,	,
patients	NNS	patient
with	IN	with
long	JJ	long
COVID	NP	<unknown>
exhibited	VBD	exhibit
bilateral	JJ	bilateral
hypometabolism	NN	hypometabolism
in	IN	in
the	DT	the
bilateral	JJ	bilateral
rectal/orbital	JJ	rectal/orbital
gyrus	NN	gyrus
,	,	,
including	VBG	include
the	DT	the
olfactory	JJ	olfactory
gyrus	NN	gyrus
;	:	;
the	DT	the
right	JJ	right
temporal	JJ	temporal
lobe	NN	lobe
,	,	,
including	VBG	include
the	DT	the
amygdala	NN	amygdala
and	CC	and
the	DT	the
hippocampus	NN	hippocampus
,	,	,
extending	VBG	extend
to	TO	to
the	DT	the
right	JJ	right
thalamus	NN	thalamus
;	:	;
the	DT	the
bilateral	JJ	bilateral
pons/medulla	NN	pons/medulla
brainstem	NN	<unknown>
;	:	;
the	DT	the
bilateral	JJ	bilateral
cerebellum	NN	cerebellum
(	(	(
p-voxel	NN	<unknown>
&lt	NN	&lt
;	:	;
0.001	CD	@card@
uncorrected	JJ	uncorrected
,	,	,
p-cluster	JJ	<unknown>
&lt	NN	&lt
;	:	;
0.05	CD	@card@
FWE-corrected	NN	<unknown>
)	)	)
.	SENT	.
These	DT	these
metabolic	JJ	metabolic
clusters	NNS	cluster
were	VBD	be
highly	RB	highly
discriminant	NN	discriminant
to	TO	to
distinguish	VB	distinguish
patients	NNS	patient
and	CC	and
healthy	JJ	healthy
subjects	NNS	subject
(	(	(
100	CD	@card@
%	NN	%
correct	JJ	correct
classification	NN	classification
)	)	)
.	SENT	.
These	DT	these
clusters	NNS	cluster
of	IN	of
hypometabolism	NN	hypometabolism
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
more	JJR	more
numerous	JJ	numerous
functional	JJ	functional
complaints	NNS	complaint
(	(	(
brainstem	NN	<unknown>
and	CC	and
cerebellar	JJ	cerebellar
clusters	NNS	cluster
)	)	)
,	,	,
and	CC	and
all	RB	all
associated	VBN	associate
with	IN	with
the	DT	the
occurrence	NN	occurrence
of	IN	of
certain	JJ	certain
symptoms	NNS	symptom
(	(	(
hyposmia/anosmia	NP	<unknown>
,	,	,
memory/cognitive	JJ	memory/cognitive
impairment	NN	impairment
,	,	,
pain	NN	pain
and	CC	and
insomnia	NN	insomnia
)	)	)
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
In	IN	in
a	DT	a
more	RBR	more
preliminary	JJ	preliminary
analysis	NN	analysis
,	,	,
the	DT	the
metabolism	NN	metabolism
of	IN	of
the	DT	the
frontal	JJ	frontal
cluster	NN	cluster
which	WDT	which
included	VBD	include
the	DT	the
olfactory	JJ	olfactory
gyrus	NN	gyrus
was	VBD	be
worse	JJR	bad
in	IN	in
the	DT	the
7	CD	@card@
patients	NNS	patient
treated	VBN	treat
by	IN	by
ACE	NN	ace
drugs	NNS	drug
for	IN	for
high	JJ	high
blood	NN	blood
pressure	NN	pressure
(	(	(
p	NN	p
=	SYM	=
0.032	CD	@card@
)	)	)
,	,	,
and	CC	and
better	JJR	good
in	IN	in
the	DT	the
3	CD	@card@
patients	NNS	patient
that	WDT	that
had	VBD	have
used	VBN	use
nasal	JJ	nasal
decongestant	JJ	decongestant
spray	NN	spray
at	IN	at
the	DT	the
infectious	JJ	infectious
stage	NN	stage
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
This	DT	this
study	NN	study
demonstrates	VBZ	demonstrate
a	DT	a
profile	NN	profile
of	IN	of
brain	NN	brain
PET	NN	pet
hypometabolism	NN	hypometabolism
in	IN	in
long	JJ	long
COVID	NP	<unknown>
patients	NNS	patient
with	IN	with
biologically	RB	biologically
confirmed	VBN	confirm
SARS-CoV-2	NP	<unknown>
and	CC	and
persistent	JJ	persistent
functional	JJ	functional
complaints	NNS	complaint
more	JJR	more
than	IN	than
3	CD	@card@
weeks	NNS	week
after	IN	after
the	DT	the
initial	JJ	initial
infection	NN	infection
symptoms	NNS	symptom
,	,	,
involving	VBG	involve
the	DT	the
olfactory	JJ	olfactory
gyrus	NN	gyrus
and	CC	and
connected	JJ	connected
limbic/paralimbic	JJ	limbic/paralimbic
regions	NNS	region
,	,	,
extended	VBD	extend
to	TO	to
the	DT	the
brainstem	NN	<unknown>
and	CC	and
the	DT	the
cerebellum	NN	cerebellum
.	SENT	.
These	DT	these
hypometabolisms	NNS	hypometabolism
are	VBP	be
associated	VBN	associate
with	IN	with
patients	NNS	patient
'	POS	'
symptoms	NNS	symptom
,	,	,
with	IN	with
a	DT	a
biomarker	NN	biomarker
value	NN	value
to	TO	to
identify	VB	identify
and	CC	and
potentially	RB	potentially
follow	VB	follow
these	DT	these
patients	NNS	patient
.	SENT	.
The	DT	the
hypometabolism	NN	hypometabolism
of	IN	of
the	DT	the
frontal	JJ	frontal
cluster	NN	cluster
,	,	,
which	WDT	which
included	VBD	include
the	DT	the
olfactory	JJ	olfactory
gyrus	NN	gyrus
,	,	,
seems	VBZ	seem
to	TO	to
be	VB	be
linked	VBN	link
to	TO	to
ACE	NN	ace
drugs	NNS	drug
in	IN	in
patients	NNS	patient
with	IN	with
high	JJ	high
blood	NN	blood
pressure	NN	pressure
,	,	,
with	IN	with
also	RB	also
a	DT	a
better	JJR	good
metabolism	NN	metabolism
of	IN	of
this	DT	this
olfactory	JJ	olfactory
region	NN	region
in	IN	in
patients	NNS	patient
using	VBG	use
nasal	JJ	nasal
decongestant	JJ	decongestant
spray	NN	spray
,	,	,
suggesting	VBG	suggest
a	DT	a
possible	JJ	possible
role	NN	role
of	IN	of
ACE	NN	ace
receptors	NNS	receptor
as	IN	as
an	DT	an
olfactory	JJ	olfactory
gateway	NN	gateway
for	IN	for
this	DT	this
neurotropism	NN	neurotropism
.	SENT	.
34904088/	CD	@card@
Did	VBD	do
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome-coronavirus	NN	syndrome-coronavirus
2	CD	@card@
pandemic	NN	pandemic
cause	VBP	cause
an	DT	an
endemic	JJ	endemic
Clostridium	NN	clostridium
difficile	NN	<unknown>
infection	NN	infection
?	SENT	?
Clostridium	NN	clostridium
difficile	NN	<unknown>
infection	NN	infection
(	(	(
CDI	NP	CDI
)	)	)
has	VBZ	have
increased	VBN	increase
in	IN	in
prevalence	NN	prevalence
during	IN	during
the	DT	the
last	JJ	last
years	NNS	year
.	SENT	.
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
has	VBZ	have
negatively	RB	negatively
influenced	VBN	influence
patient	JJ	patient
outcomes	NNS	outcome
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome-coronavirus	NN	syndrome-coronavirus
2	CD	@card@
(SARS-CoV-2)-infected	JJ	(SARS-CoV-2)-infected
patients	NNS	patient
received	VBD	receive
antibiotics	NNS	antibiotic
during	IN	during
hospitalization	NN	hospitalization
.	SENT	.
To	TO	to
analyze	VB	analyze
the	DT	the
factors	NNS	factor
that	WDT	that
influenced	VBD	influence
CDI	NP	CDI
development	NN	development
after	IN	after
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
Between	IN	between
March	NP	March
2020	CD	@card@
to	TO	to
December	NP	December
2020	CD	@card@
,	,	,
we	PP	we
performed	VBD	perform
a	DT	a
prospective	JJ	prospective
observational	JJ	observational
study	NN	study
including	VBG	include
447	CD	@card@
patients	NNS	patient
diagnosed	VBN	diagnose
with	IN	with
CDI	NP	CDI
who	WP	who
were	VBD	be
admitted	VBN	admit
to	TO	to
our	PP$	our
tertiary	JJ	tertiary
referral	NN	referral
university	NN	university
hospital	NN	hospital
.	SENT	.
The	DT	the
diagnosis	NN	diagnosis
of	IN	of
CDI	NP	CDI
was	VBD	be
based	VBN	base
on	IN	on
the	DT	the
presence	NN	presence
of	IN	of
diarrhea	NN	diarrhea
(	(	(
&gt	NN	&gt
;	:	;
=	SYM	=
3	CD	@card@
watery	JJ	watery
stools	NNS	stool
within	IN	within
24	CD	@card@
h	NN	h
)	)	)
associated	VBN	associate
with	IN	with
Clostridium	NN	clostridium
difficile	NN	<unknown>
toxins	NNS	toxin
A	NP	A
or	CC	or
B.	NP	B.
We	PP	we
excluded	VBD	exclude
patients	NNS	patient
with	IN	with
other	JJ	other
etiology	NN	etiology
of	IN	of
acute	JJ	acute
diarrhea	NN	diarrhea
.	SENT	.
Among	IN	among
the	DT	the
total	NN	total
447	CD	@card@
(	(	(
12.5	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
with	IN	with
CDI	NP	CDI
,	,	,
most	JJS	most
were	VBD	be
male	JJ	male
(	(	(
54.3	CD	@card@
%	NN	%
)	)	)
and	CC	and
mean	JJ	mean
age	NN	age
was	VBD	be
59.7	CD	@card@
+-	NN	<unknown>
10.8	CD	@card@
years	NNS	year
.	SENT	.
Seventy-six	NP	<unknown>
(	(	(
17.0	CD	@card@
%	NN	%
)	)	)
had	VBD	have
history	NN	history
of	IN	of
COVID-19	NP	<unknown>
,	,	,
most	RBS	most
being	JJ	being
elderly	JJ	elderly
(	(	(
COVID-19	NP	<unknown>
:	:	:
62.6	CD	@card@
+-	NN	<unknown>
14.6	CD	@card@
years	NNS	year
vs	NP	vs
non-COVID-19	NP	<unknown>
:	:	:
56.8	CD	@card@
+-	NN	<unknown>
17.6	CD	@card@
years	NNS	year
,	,	,
P	NN	P
=	SYM	=
0.007	CD	@card@
)	)	)
,	,	,
with	IN	with
history	NN	history
of	IN	of
alcohol	NN	alcohol
consumption	NN	consumption
(	(	(
43.4	CD	@card@
%	NN	%
vs	NP	vs
29.4	CD	@card@
%	NN	%
,	,	,
P	NN	P
=	SYM	=
0.017	CD	@card@
)	)	)
,	,	,
previous	JJ	previous
hospitalizations	NNS	hospitalization
(	(	(
81.6	CD	@card@
%	NN	%
vs	NP	vs
54.9	CD	@card@
%	NN	%
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
antibiotic	JJ	antibiotic
treatments	NNS	treatment
(	(	(
60.5	CD	@card@
%	NN	%
vs	NP	vs
35.5	CD	@card@
%	NN	%
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
requiring	VBG	require
higher	JJR	high
doses	NNS	dose
of	IN	of
vancomycin	NP	vancomycin
and	CC	and
prone	JJ	prone
to	TO	to
recurrent	JJ	recurrent
disease	NN	disease
(	(	(
25.0	CD	@card@
%	NN	%
vs	NP	vs
13.1	CD	@card@
%	NN	%
,	,	,
P	NN	P
=	SYM	=
0.011	CD	@card@
)	)	)
.	SENT	.
Age	NN	age
over	IN	over
60	CD	@card@
years	NNS	year
[	SYM	[
odds	NNS	odd
ratio	NN	ratio
(	(	(
OR	CC	or
)	)	)
:	:	:
2.591	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
(	(	(
CI	NP	CI
)	)	)
:	:	:
1.452-4.624	LS	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
]	SYM	]
,	,	,
urban	JJ	urban
residence	NN	residence
(	(	(
OR	CC	or
:	:	:
2.330	LS	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
1.286-4.221	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.005	CD	@card@
)	)	)
,	,	,
previous	JJ	previous
antibiotic	JJ	antibiotic
treatments	NNS	treatment
(	(	(
OR	CC	or
:	:	:
1.909	LS	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
1.083-3.365	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.025	CD	@card@
)	)	)
,	,	,
previous	JJ	previous
hospitalizations	NNS	hospitalization
(	(	(
OR	CC	or
:	:	:
2.509	LS	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
1.263-4.986	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.009	CD	@card@
)	)	)
and	CC	and
alcohol	NN	alcohol
consumption	NN	consumption
(	(	(
OR	CC	or
:	:	:
2.550	LS	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
1.459-4.459	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
)	)	)
were	VBD	be
risk	NN	risk
factors	NNS	factor
of	IN	of
CDI	NP	CDI
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
CDI	NP	CDI
risk	NN	risk
is	VBZ	be
unrelated	JJ	unrelated
to	TO	to
history	NN	history
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
However	RB	however
,	,	,
previous	JJ	previous
COVID-19	NP	<unknown>
may	MD	may
necessitate	VB	necessitate
higher	JJR	high
doses	NNS	dose
of	IN	of
vancomycin	NP	vancomycin
for	IN	for
CDI	NP	CDI
.	SENT	.
32502597/	CD	@card@
The	NP	The
War	NP	War
We	PP	we
Call	NP	Call
COVID-19	NP	<unknown>
:	:	:
A	DT	a
Letter	NN	letter
From	IN	from
the	DT	the
Front	NP	Front
in	IN	in
New	NP	New
York	NP	York
34736354/	CD	@card@
Waning	VBG	wane
antibodies	NNS	antibody
from	IN	from
inactivated	VBN	inactivate
SARS-CoV-2	NP	<unknown>
vaccination	NN	vaccination
offer	NN	offer
protection	NN	protection
against	IN	against
infection	NN	infection
without	IN	without
antibody-enhanced	JJ	antibody-enhanced
immunopathology	NN	Immunopathology
in	IN	in
rhesus	NN	rhesus
macaque	NN	macaque
pneumonia	NN	pneumonia
models	NNS	model
Inactivated	VBD	inactivate
coronaviruses	NNS	coronavirus
,	,	,
including	VBG	include
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
1	CD	@card@
(	(	(
SARS-CoV-1	NP	<unknown>
)	)	)
and	CC	and
Middle	NP	Middle
East	NP	East
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
(	(	(
MERS-CoV	NP	<unknown>
)	)	)
,	,	,
as	IN	as
potential	JJ	potential
vaccines	NNS	vaccine
have	VBP	have
been	VBN	be
reported	VBN	report
to	TO	to
result	VB	result
in	IN	in
enhanced	JJ	enhanced
respiratory	JJ	respiratory
diseases	NNS	disease
(	(	(
ERDs	NP	<unknown>
)	)	)
in	IN	in
murine	NN	murine
and	CC	and
nonhuman	NN	nonhuman
primate	NN	primate
(	(	(
NHP	NP	NHP
)	)	)
pneumonia	NN	pneumonia
models	NNS	model
after	IN	after
virus	NN	virus
challenge	NN	challenge
,	,	,
which	WDT	which
poses	VBZ	pose
great	JJ	great
safety	NN	safety
concerns	NNS	concern
of	IN	of
antibody-dependent	JJ	antibody-dependent
enhancement	NN	enhancement
(	(	(
ADE	NP	Ade
)	)	)
for	IN	for
the	DT	the
rapid	JJ	rapid
wide	JJ	wide
application	NN	application
of	IN	of
inactivated	VBN	inactivate
SARS-CoV-2	JJ	<unknown>
vaccines	NNS	vaccine
in	IN	in
humans	NNS	human
,	,	,
especially	RB	especially
when	WRB	when
the	DT	the
neutralizing	VBG	neutralize
antibody	NN	antibody
levels	NNS	level
induced	VBN	induce
by	IN	by
vaccination	NN	vaccination
or	CC	or
initial	JJ	initial
infection	NN	infection
quickly	RB	quickly
wane	VBP	wane
to	TO	to
nonneutralizing	JJ	<unknown>
or	CC	or
subneutralizing	VBG	subneutralize
levels	NNS	level
over	IN	over
the	DT	the
time	NN	time
.	SENT	.
With	IN	with
passive	JJ	passive
transfer	NN	transfer
of	IN	of
diluted	JJ	diluted
postvaccination	NN	postvaccination
polyclonal	JJ	polyclonal
antibodies	NNS	antibody
to	TO	to
mimic	VB	mimic
the	DT	the
waning	VBG	wane
antibody	NN	antibody
responses	NNS	response
after	IN	after
vaccination	NN	vaccination
,	,	,
we	PP	we
found	VBD	find
that	IN	that
in	IN	in
the	DT	the
absence	NN	absence
of	IN	of
cellular	JJ	cellular
immunity	NN	immunity
,	,	,
passive	JJ	passive
infusion	NN	infusion
of	IN	of
subneutralizing	VBG	subneutralize
or	CC	or
nonneutralizing	VBG	nonneutralize
anti-SARS-CoV-2	JJ	<unknown>
antibodies	NNS	antibody
could	MD	could
still	RB	still
provide	VB	provide
some	DT	some
level	NN	level
of	IN	of
protection	NN	protection
against	IN	against
infection	NN	infection
upon	IN	upon
challenge	NN	challenge
,	,	,
and	CC	and
no	DT	no
low-level	JJ	low-level
antibody-enhanced	JJ	antibody-enhanced
infection	NN	infection
was	VBD	be
observed	VBN	observe
.	SENT	.
The	DT	the
anti-SARS-CoV-2	JJ	<unknown>
IgG-infused	NP	<unknown>
group	NN	group
and	CC	and
control	NN	control
group	NN	group
showed	VBD	show
similar	JJ	similar
,	,	,
mild	JJ	mild
to	TO	to
moderate	VB	moderate
pulmonary	JJ	pulmonary
immunopathology	NN	Immunopathology
during	IN	during
the	DT	the
acute	JJ	acute
phase	NN	phase
of	IN	of
virus	NN	virus
infection	NN	infection
,	,	,
and	CC	and
no	DT	no
evidence	NN	evidence
of	IN	of
vaccine-related	JJ	vaccine-related
pulmonary	JJ	pulmonary
immunopathology	NN	Immunopathology
enhancement	NN	enhancement
was	VBD	be
found	VBN	find
.	SENT	.
Typical	JJ	typical
immunopathology	NN	Immunopathology
included	VBD	include
elevated	JJ	elevated
MCP-1	NP	<unknown>
,	,	,
IL-8	NP	<unknown>
and	CC	and
IL-33	NP	<unknown>
in	IN	in
bronchoalveolar	JJ	bronchoalveolar
lavage	NN	lavage
fluid	NN	fluid
;	:	;
alveolar	JJ	alveolar
epithelial	JJ	epithelial
hyperplasia	NN	hyperplasia
;	:	;
and	CC	and
exfoliated	VBN	exfoliate
cells	NNS	cell
and	CC	and
mucus	NN	mucus
in	IN	in
bronchioles	NNS	bronchiole
.	SENT	.
Our	PP$	our
results	NNS	result
corresponded	VBN	correspond
with	IN	with
the	DT	the
recent	JJ	recent
observations	NNS	observation
that	IN	that
no	DT	no
pulmonary	JJ	pulmonary
immunology	NN	immunology
was	VBD	be
detected	VBN	detect
in	IN	in
preclinical	JJ	preclinical
studies	NNS	study
of	IN	of
inactivated	VBN	inactivate
SARS-CoV-2	JJ	<unknown>
vaccines	NNS	vaccine
in	IN	in
either	DT	either
murine	JJ	murine
or	CC	or
NHP	JJ	<unknown>
pneumonia	NN	pneumonia
models	NNS	model
or	CC	or
in	IN	in
large	JJ	large
clinical	JJ	clinical
trials	NNS	trial
and	CC	and
further	RBR	further
supported	VBD	support
the	DT	the
safety	NN	safety
of	IN	of
inactivated	VBN	inactivate
SARS-CoV-2	JJ	<unknown>
vaccines	NNS	vaccine
.	SENT	.
34641391/	CD	@card@
An	NP	An
Insight	NP	Insight
into	IN	into
FDA	NP	FDA
Approved	VBN	approve
Antibody-Drug	NN	<unknown>
Conjugates	VBZ	conjugate
for	IN	for
Cancer	NP	Cancer
Therapy	NN	therapy
The	DT	the
large	JJ	large
number	NN	number
of	IN	of
emerging	VBG	emerge
antibody-drug	NN	<unknown>
conjugates	VBZ	conjugate
(	(	(
ADCs	NP	<unknown>
)	)	)
for	IN	for
cancer	NN	cancer
therapy	NN	therapy
has	VBZ	have
resulted	VBN	result
in	IN	in
a	DT	a
significant	JJ	significant
market	NN	market
'	POS	'
boom	NN	boom
'	''	'
,	,	,
garnering	VBG	garner
worldwide	JJ	worldwide
attention	NN	attention
.	SENT	.
Despite	IN	despite
ADCs	NP	<unknown>
presenting	VBG	present
huge	JJ	huge
challenges	NNS	challenge
to	TO	to
researchers	NNS	researcher
,	,	,
particularly	RB	particularly
regarding	VBG	regard
the	DT	the
identification	NN	identification
of	IN	of
a	DT	a
suitable	JJ	suitable
combination	NN	combination
of	IN	of
antibody	NN	antibody
,	,	,
linker	NN	linker
,	,	,
and	CC	and
payload	NN	payload
,	,	,
as	RB	as
of	IN	of
September	NP	September
2021	CD	@card@
,	,	,
11	CD	@card@
ADCs	NNS	<unknown>
have	VBP	have
been	VBN	be
granted	VBN	grant
FDA	NP	FDA
approval	NN	approval
,	,	,
with	IN	with
eight	CD	eight
of	IN	of
these	DT	these
approved	VBN	approve
since	IN	since
2017	CD	@card@
alone	RB	alone
.	SENT	.
Optimism	NN	optimism
for	IN	for
this	DT	this
therapeutic	JJ	therapeutic
approach	NN	approach
is	VBZ	be
clear	JJ	clear
,	,	,
despite	IN	despite
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
2020	CD	@card@
was	VBD	be
a	DT	a
landmark	JJ	landmark
year	NN	year
for	IN	for
deals	NNS	deal
and	CC	and
partnerships	NNS	partnership
in	IN	in
the	DT	the
ADC	NP	ADC
arena	NN	arena
,	,	,
suggesting	VBG	suggest
that	IN	that
there	EX	there
remains	VBZ	remain
significant	JJ	significant
interest	NN	interest
from	IN	from
Big	NP	Big
Pharma	NP	Pharma
.	SENT	.
Herein	RB	herein
we	PP	we
review	VB	review
the	DT	the
enthusiasm	NN	enthusiasm
for	IN	for
ADCs	NP	<unknown>
by	IN	by
focusing	VBG	focus
on	IN	on
the	DT	the
features	NNS	feature
of	IN	of
those	DT	those
approved	VBN	approve
by	IN	by
the	DT	the
FDA	NP	FDA
,	,	,
and	CC	and
offer	VB	offer
some	DT	some
thoughts	NNS	thought
as	IN	as
to	TO	to
where	WRB	where
the	DT	the
field	NN	field
is	VBZ	be
headed	VBN	head
.	SENT	.
32239515/	CD	@card@
Fecal	JJ	fecal
transmission	NN	transmission
in	IN	in
COVID-19	NP	<unknown>
:	:	:
A	DT	a
potential	JJ	potential
shedding	NN	shedding
route	NN	route
32753072/"It	JJ	<unknown>
's	VBZ	be
like	IN	like
fighting	VBG	fight
a	DT	a
war	NN	war
with	IN	with
rocks	NNS	rock
"	''	"
:	:	:
Nursing	VBG	nurse
home	NN	home
healthcare	NN	<unknown>
workers	NNS	worker
'	POS	'
experiences	NNS	experience
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
35503234/	CD	@card@
Healthcare	NP	Healthcare
Providers	NNS	provider
'	POS	'
Perspectives	NNS	perspective
Toward	IN	toward
the	DT	the
Integration	NP	Integration
of	IN	of
over	IN	over
the	DT	the
Counter	NP	Counter
Supplements	NNS	supplement
During	IN	during
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
A	DT	a
Cross-Sectional	JJ	cross-sectional
Study	NN	study
from	IN	from
Jordan	NP	Jordan
Objective	NN	objective
:	:	:
During	IN	during
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
healthcare	NN	<unknown>
providers	NNS	provider
(	(	(
HCPs	NP	<unknown>
)	)	)
have	VBP	have
been	VBN	be
inundated	VBN	inundate
with	IN	with
consultations	NNS	consultation
related	VBN	relate
to	TO	to
over	IN	over
the	DT	the
counter	NN	counter
(	(	(
OTC	NP	OTC
)	)	)
dietary	JJ	dietary
supplements	NNS	supplement
'	POS	'
protective	JJ	protective
role	NN	role
.	SENT	.
Thus	RB	thus
,	,	,
the	DT	the
present	JJ	present
study	NN	study
focused	VBN	focus
on	IN	on
assessing	VBG	assess
HCPs	NP	<unknown>
perceptions	NNS	perception
toward	IN	toward
OTC	NP	OTC
products	NNS	product
integration	NN	integration
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
.	SENT	.
Methods	NNS	method
:	:	:
Pertinent	JJ	pertinent
data	NNS	datum
was	VBD	be
collected	VBN	collect
using	VBG	use
validated-online	NN	<unknown>
survey	NN	survey
comprising	VBG	comprise
four	CD	four
sections	NNS	section
:	:	:
demographics	NNS	demographic
,	,	,
OTC	NP	OTC
supplementation	NN	supplementation
perceptions	NNS	perception
,	,	,
awareness	NN	awareness
related	VBN	relate
to	TO	to
safety	NN	safety
of	IN	of
OTC	NP	OTC
supplements	NNS	supplement
,	,	,
confidence	NN	confidence
in	IN	in
recommending	VBG	recommend
dosage	NN	dosage
and	CC	and
counseling	VBG	counsel
to	TO	to
patients	NNS	patient
regarding	VBG	regard
OTC	NP	OTC
supplements	NNS	supplement
'	POS	'
safety	NN	safety
,	,	,
and	CC	and
some	DT	some
health-related	JJ	health-related
behaviors	NNS	behavior
.	SENT	.
Quantified	VBN	quantify
perception	NN	perception
score	NN	score
represented	VBN	represent
by	IN	by
corrected	JJ	corrected
confidence-concern	NN	confidence-concern
ratio	NN	ratio
was	VBD	be
used	VBN	use
in	IN	in
assessing	VBG	assess
perceptions	NNS	perception
,	,	,
and	CC	and
associations	NNS	association
between	IN	between
demographics	NNS	demographic
with	IN	with
perception	NN	perception
and	CC	and
awareness	NN	awareness
were	VBD	be
explored	VBN	explore
.	SENT	.
Results	NNS	result
:	:	:
A	DT	a
total	NN	total
of	IN	of
600	CD	@card@
responses	NNS	response
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
final	JJ	final
analysis	NN	analysis
.	SENT	.
Vitamin	NN	vitamin
C	NP	C
,	,	,
zinc	NN	zinc
,	,	,
and	CC	and
vitamin	NN	vitamin
D	NN	D
were	VBD	be
the	DT	the
most	RBS	most
popularly	RB	popularly
recommended	VBN	recommend
OTC	NP	OTC
supplements	NNS	supplement
.	SENT	.
Most	JJS	most
respondents	NNS	respondent
indicated	VBD	indicate
positive	JJ	positive
perceptions	NNS	perception
toward	IN	toward
dietary	JJ	dietary
supplementation	NN	supplementation
while	IN	while
around	RB	around
60	CD	@card@
%	NN	%
of	IN	of
respondents	NNS	respondent
reported	VBD	report
reluctance	NN	reluctance
about	IN	about
the	DT	the
protective	JJ	protective
role	NN	role
of	IN	of
COVID-19	NP	<unknown>
vaccination	NN	vaccination
.	SENT	.
Bachelor	NN	bachelor
's	POS	's
degree	NN	degree
holders	NNS	holder
(	(	(
AOR	NP	AOR
=	SYM	=
4.39	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
2.25-10.33	CD	@card@
)	)	)
,	,	,
pharmacists	NNS	pharmacist
(	(	(
AOR	NP	AOR
=	SYM	=
2.17	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
1.5-9.5	CD	@card@
)	)	)
,	,	,
and	CC	and
junior	JJ	junior
HCPs	NP	<unknown>
(	(	(
&lt	NP	&lt
;	:	;
1	CD	@card@
year	NN	year
experience	NN	experience
)	)	)
had	VBD	have
improved	VBN	improve
perceptions	NNS	perception
compared	VBN	compare
to	TO	to
college	NN	college
graduates	NNS	graduate
,	,	,
physicians	NNS	physician
,	,	,
and	CC	and
senior	JJ	senior
practitioners	NNS	practitioner
(	(	(
AOR	NP	AOR
=	SYM	=
.17	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
.04-.78	CD	@card@
and	CC	and
AOR	NP	AOR
=	SYM	=
.15	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
.02-.93	CD	@card@
)	)	)
,	,	,
respectively	RB	respectively
.	SENT	.
Conclusion	NN	conclusion
:	:	:
Suboptimal	JJ	suboptimal
knowledge	NN	knowledge
among	IN	among
HCPs	NP	<unknown>
toward	IN	toward
the	DT	the
safety	NN	safety
and	CC	and
hazards	NNS	hazard
associated	VBN	associate
with	IN	with
integration	NN	integration
of	IN	of
different	JJ	different
OTC	NP	OTC
supplements	NNS	supplement
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
dictates	VBZ	dictate
further	JJR	further
education	NN	education
to	TO	to
ensure	VB	ensure
the	DT	the
safe	JJ	safe
integration	NN	integration
of	IN	of
OTC	NP	OTC
supplements	NNS	supplement
.	SENT	.
32381441/	CD	@card@
Effect	NN	effect
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
Hip	NN	hip
and	CC	and
Knee	NP	Knee
Arthroplasty	NP	<unknown>
Surgical	JJ	surgical
Volume	NN	volume
in	IN	in
the	DT	the
United	NP	United
States	NPS	States
In	IN	in
an	DT	an
effort	NN	effort
to	TO	to
help	VB	help
combat	VB	combat
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
preserve	VB	preserve
essential	JJ	essential
health	NN	health
care	NN	care
resources	NNS	resource
,	,	,
starting	VBG	start
in	IN	in
mid-March	NP	mid-March
2020	CD	@card@
,	,	,
surgeons	NNS	surgeon
have	VBP	have
been	VBN	be
instructed	VBN	instruct
to	TO	to
only	RB	only
perform	VB	perform
essential	JJ	essential
surgical	JJ	surgical
procedures	NNS	procedure
.	SENT	.
The	DT	the
vast	JJ	vast
majority	NN	majority
of	IN	of
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
surgery	NN	surgery
does	VBZ	do
not	RB	not
meet	VB	meet
the	DT	the
definition	NN	definition
of	IN	of
essential	JJ	essential
surgery	NN	surgery
.	SENT	.
This	DT	this
study	NN	study
estimated	VBD	estimate
the	DT	the
number	NN	number
of	IN	of
arthroplasty	JJ	<unknown>
procedures	NNS	procedure
that	WDT	that
would	MD	would
be	VB	be
canceled	VBN	cancel
because	IN	because
of	IN	of
these	DT	these
important	JJ	important
restrictions	NNS	restriction
.	SENT	.
The	DT	the
US	NP	US
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
procedure	NN	procedure
volume	NN	volume
projections	NNS	projection
for	IN	for
2020	CD	@card@
were	VBD	be
estimated	VBN	estimate
from	IN	from
four	CD	four
recently	RB	recently
published	VBN	publish
studies	NNS	study
.	SENT	.
Data	NNS	datum
from	IN	from
the	DT	the
American	NP	American
Joint	NP	Joint
Replacement	NN	replacement
Registry	NN	registry
were	VBD	be
utilized	VBN	utilize
to	TO	to
determine	VB	determine
what	WP	what
percentage	NN	percentage
of	IN	of
these	DT	these
cases	NNS	case
would	MD	would
be	VB	be
considered	VBN	consider
nonessential	JJ	nonessential
surgery	NN	surgery
.	SENT	.
Monthly	JJ	monthly
and	CC	and
weekly	JJ	weekly
estimates	NNS	estimate
of	IN	of
nonessential	JJ	nonessential
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
procedures	NNS	procedure
that	WDT	that
would	MD	would
have	VB	have
occurred	VBN	occur
had	VBD	have
there	RB	there
not	RB	not
been	VBN	be
any	DT	any
restrictions	NNS	restriction
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
were	VBD	be
calculated	VBN	calculate
.	SENT	.
After	IN	after
excluding	VBG	exclude
essential	JJ	essential
procedures	NNS	procedure
,	,	,
it	PP	it
was	VBD	be
estimated	VBN	estimate
that	IN	that
approximately	RB	approximately
30,000	CD	@card@
primary	NN	primary
and	CC	and
3000	CD	@card@
revision	NN	revision
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
procedures	NNS	procedure
will	MD	will
be	VB	be
canceled	VBN	cancel
each	DT	each
week	NN	week
while	IN	while
COVID-19	NP	<unknown>
restrictions	NNS	restriction
regarding	VBG	regard
nonessential	JJ	nonessential
surgery	NN	surgery
are	VBP	be
in	IN	in
place	NN	place
.	SENT	.
If	IN	if
only	RB	only
50	CD	@card@
%	NN	%
of	IN	of
nonessential	JJ	nonessential
cases	NNS	case
were	VBD	be
actually	RB	actually
canceled	VBN	cancel
across	IN	across
the	DT	the
United	NP	United
States	NPS	States
,	,	,
that	WDT	that
would	MD	would
still	RB	still
result	VB	result
in	IN	in
the	DT	the
cancellation	NN	cancellation
of	IN	of
15,001	CD	@card@
primary	NN	primary
and	CC	and
1435	CD	@card@
revision	NN	revision
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
procedures	NNS	procedure
per	IN	per
week	NN	week
while	IN	while
restrictions	NNS	restriction
are	VBP	be
in	IN	in
place	NN	place
.	SENT	.
This	DT	this
study	NN	study
highlights	VBZ	highlight
the	DT	the
profound	JJ	profound
impact	NN	impact
COVID-19	NP	<unknown>
is	VBZ	be
having	VBG	have
on	IN	on
our	PP$	our
current	JJ	current
hip	NN	hip
and	CC	and
knee	NN	knee
arthroplasty	NN	<unknown>
volume	NN	volume
.	SENT	.
The	DT	the
large	JJ	large
number	NN	number
of	IN	of
cases	NNS	case
canceled	VBN	cancel
because	IN	because
of	IN	of
COVID-19	NP	<unknown>
translates	VBZ	translate
into	IN	into
major	JJ	major
financial	JJ	financial
losses	NNS	loss
for	IN	for
health	NN	health
care	NN	care
institutions	NNS	institution
and	CC	and
may	MD	may
have	VB	have
a	DT	a
profound	JJ	profound
impact	NN	impact
on	IN	on
our	PP$	our
patients	NNS	patient
.	SENT	.
32710774/	CD	@card@
Dynamic	JJ	dynamic
pharmacy	NN	pharmacy
leadership	NN	leadership
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
:	:	:
Optimizing	VBG	optimize
patient	JJ	patient
care	NN	care
through	IN	through
formulary	NN	formulary
and	CC	and
drug	NN	drug
shortage	NN	shortage
management	NN	management
In	IN	in
an	DT	an
effort	NN	effort
to	TO	to
expedite	VB	expedite
the	DT	the
publication	NN	publication
of	IN	of
articles	NNS	article
related	VBN	relate
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
AJHP	NP	<unknown>
is	VBZ	be
posting	VBG	post
these	DT	these
manuscripts	NNS	manuscript
online	JJ	online
as	IN	as
soon	RB	soon
as	RB	as
possible	JJ	possible
after	IN	after
acceptance	NN	acceptance
.	SENT	.
Accepted	JJ	accepted
manuscripts	NNS	manuscript
have	VBP	have
been	VBN	be
peer-reviewed	VBN	peer-review
and	CC	and
copyedited	VBN	copyedit
,	,	,
but	CC	but
are	VBP	be
posted	VBN	post
online	JJ	online
before	IN	before
technical	JJ	technical
formatting	VBG	format
and	CC	and
author	NN	author
proofing	VBG	proof
.	SENT	.
These	DT	these
manuscripts	NNS	manuscript
are	VBP	be
not	RB	not
the	DT	the
final	JJ	final
version	NN	version
of	IN	of
record	NN	record
and	CC	and
will	MD	will
be	VB	be
replaced	VBN	replace
with	IN	with
the	DT	the
final	JJ	final
article	NN	article
(	(	(
formatted	VBN	format
per	IN	per
AJHP	NP	<unknown>
style	NN	style
and	CC	and
proofed	VBN	proof
by	IN	by
the	DT	the
authors	NNS	author
)	)	)
at	IN	at
a	DT	a
later	JJR	late
time	NN	time
.	SENT	.
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
has	VBZ	have
created	VBN	create
unprecedented	JJ	unprecedented
challenges	NNS	challenge
for	IN	for
health	NN	health
systems	NNS	system
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
We	PP	we
describe	VBP	describe
our	PP$	our
approach	NN	approach
to	TO	to
adapting	VBG	adapt
the	DT	the
pharmacy	NN	pharmacy
leadership	NN	leadership
structure	NN	structure
to	TO	to
address	VB	address
critical	JJ	critical
medication	NN	medication
shortages	NNS	shortage
through	IN	through
innovative	JJ	innovative
data	NNS	datum
analysis	NN	analysis
,	,	,
procurement	NN	procurement
strategies	NNS	strategy
,	,	,
and	CC	and
rapid	JJ	rapid
implementation	NN	implementation
of	IN	of
medication	NN	medication
policy	NN	policy
.	SENT	.
Yale	NP	Yale
New	NP	New
Haven	NP	Haven
Health	NP	Health
deployed	VBD	deploy
a	DT	a
system	NN	system
incident	NN	incident
management	NN	management
command	NN	command
structure	NN	structure
to	TO	to
effectively	RB	effectively
respond	VB	respond
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
.	SENT	.
System	NN	system
pharmacy	NN	pharmacy
services	NNS	service
adopted	VBD	adopt
a	DT	a
similar	JJ	similar
framework	NN	framework
to	TO	to
enable	VB	enable
efficient	JJ	efficient
communication	NN	communication
and	CC	and
quick	JJ	quick
decision-making	NN	decision-making
in	IN	in
key	JJ	key
domains	NNS	domain
,	,	,
including	VBG	include
drug	NN	drug
procurement	NN	procurement
and	CC	and
policy	NN	policy
.	SENT	.
By	IN	by
refining	VBG	refine
a	DT	a
model	NN	model
to	TO	to
project	VB	project
health-system	NN	health-system
medication	NN	medication
needs	VBZ	need
,	,	,
we	PP	we
were	VBD	be
able	JJ	able
to	TO	to
anticipate	VB	anticipate
challenges	NNS	challenge
and	CC	and
devise	VB	devise
alternative	JJ	alternative
treatment	NN	treatment
algorithms	NNS	algorithm
.	SENT	.
By	IN	by
leveraging	VBG	leverage
big	JJ	big
data	NNS	datum
and	CC	and
creating	VBG	create
a	DT	a
system	NN	system
knowledge	NN	knowledge
base	NN	base
,	,	,
we	PP	we
were	VBD	be
able	JJ	able
to	TO	to
consolidate	VB	consolidate
reporting	NN	reporting
and	CC	and
coordinate	VB	coordinate
efforts	NNS	effort
to	TO	to
ensure	VB	ensure
system	NN	system
success	NN	success
.	SENT	.
Various	JJ	various
procurement	NN	procurement
strategies	NNS	strategy
were	VBD	be
employed	VBN	employ
to	TO	to
ensure	VB	ensure
adequate	JJ	adequate
supply	NN	supply
,	,	,
including	VBG	include
frequent	JJ	frequent
communication	NN	communication
with	IN	with
our	PP$	our
wholesaler	NN	wholesaler
,	,	,
sourcing	VBG	source
direct	JJ	direct
from	IN	from
suppliers	NNS	supplier
,	,	,
outsourcing	VBG	outsource
of	IN	of
sterile	JJ	sterile
products	NNS	product
compounding	VBG	compound
to	TO	to
registered	JJ	registered
503B	JJ	<unknown>
outsourcing	NN	outsourcing
facilities	NNS	facility
,	,	,
and	CC	and
acquisition	NN	acquisition
of	IN	of
active	JJ	active
pharmaceutical	JJ	pharmaceutical
ingredients	NNS	ingredient
for	IN	for
compounding	NN	compounding
of	IN	of
essential	JJ	essential
medications	NNS	medication
.	SENT	.
Strategic	JJ	strategic
positioning	NN	positioning
of	IN	of
pharmacists	NNS	pharmacist
within	IN	within
the	DT	the
health	NN	health
system	NN	system
's	POS	's
incident	NN	incident
command	NN	command
response	NN	response
teams	NNS	team
and	CC	and
rapid	JJ	rapid
adaption	NN	adaption
of	IN	of
drug	NN	drug
use	NN	use
policy	NN	policy
governance	NN	governance
fueled	VBD	fuel
accelerated	VBN	accelerate
response	NN	response
and	CC	and
nimble	JJ	nimble
implementation	NN	implementation
.	SENT	.
Communication	NP	Communication
was	VBD	be
streamlined	VBN	streamline
and	CC	and
executed	VBN	execute
via	IN	via
multiple	JJ	multiple
outlets	NNS	outlet
to	TO	to
reach	VB	reach
a	DT	a
broad	JJ	broad
audience	NN	audience
across	IN	across
the	DT	the
health	NN	health
system	NN	system
.	SENT	.
With	IN	with
medication	NN	medication
shortages	NNS	shortage
posing	VBG	pose
a	DT	a
threat	NN	threat
to	TO	to
patient	JJ	patient
care	NN	care
,	,	,
dynamic	JJ	dynamic
pharmacy	NN	pharmacy
leadership	NN	leadership
proved	VBD	prove
essential	JJ	essential
to	TO	to
providing	VBG	provide
patient	JJ	patient
care	NN	care
at	IN	at
the	DT	the
height	NN	height
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
System	NN	system
alignment	NN	alignment
and	CC	and
the	DT	the
rapid	JJ	rapid
adaption	NN	adaption
of	IN	of
the	DT	the
existing	JJ	existing
framework	NN	framework
for	IN	for
drug	NN	drug
shortage	NN	shortage
management	NN	management
and	CC	and
medication	NN	medication
use	NN	use
policy	NN	policy
were	VBD	be
crucial	JJ	crucial
to	TO	to
success	NN	success
in	IN	in
crisis	NN	crisis
response	NN	response
.	SENT	.
35048011/	CD	@card@
Changes	NP	Changes
in	IN	in
Oral	NP	Oral
Health	NP	Health
Policies	NNS	policy
and	CC	and
Guidelines	NNS	guideline
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
describe	VB	describe
the	DT	the
changes	NNS	change
in	IN	in
oral	JJ	oral
health	NN	health
policies	NNS	policy
and	CC	and
guidelines	NNS	guideline
in	IN	in
response	NN	response
to	TO	to
the	DT	the
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
in	IN	in
different	JJ	different
countries	NNS	country
and	CC	and
regions	NNS	region
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
Information	NN	information
on	IN	on
oral	JJ	oral
health	NN	health
policies	NNS	policy
and	CC	and
guidelines	NNS	guideline
from	IN	from
9	CD	@card@
countries	NNS	country
(	(	(
Canada	NP	Canada
,	,	,
China	NP	China
including	VBG	include
Hong	NP	Hong
Kong	NP	Kong
,	,	,
Egypt	NP	Egypt
,	,	,
India	NP	India
,	,	,
Japan	NP	Japan
,	,	,
New	NP	New
Zealand	NP	Zealand
,	,	,
Nigeria	NP	Nigeria
,	,	,
Switzerland	NP	Switzerland
,	,	,
and	CC	and
Thailand	NP	Thailand
)	)	)
were	VBD	be
summarized	VBN	summarize
,	,	,
and	CC	and
sources	NNS	source
of	IN	of
the	DT	the
information	NN	information
were	VBD	be
mostly	RB	mostly
the	DT	the
national	JJ	national
or	CC	or
regional	JJ	regional
health	NN	health
authorities	NNS	authority
and/or	CC	and/or
dental	JJ	dental
council/associations	NNS	council/association
.	SENT	.
The	DT	the
changes	NNS	change
made	VBD	make
to	TO	to
the	DT	the
oral	JJ	oral
health	NN	health
guidelines	NNS	guideline
depended	VBN	depend
on	IN	on
the	DT	the
severity	NN	severity
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
This	DT	this
included	VBN	include
suspension	NN	suspension
of	IN	of
non-emergency	NN	non-emergency
dental	JJ	dental
care	NN	care
services	NNS	service
at	IN	at
the	DT	the
peak	NN	peak
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
,	,	,
and	CC	and
easing	VBG	ease
the	DT	the
restrictions	NNS	restriction
on	IN	on
non-essential	JJ	non-essential
and	CC	and
elective	JJ	elective
dental	JJ	dental
care	NN	care
when	WRB	when
the	DT	the
pandemic	NN	pandemic
became	VBD	become
under	IN	under
control	NN	control
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
risk	NN	risk
mitigation	NN	mitigation
strategies	NNS	strategy
include	VBP	include
strict	JJ	strict
adherence	NN	adherence
to	TO	to
infection	NN	infection
control	NN	control
practices	NNS	practice
(	(	(
use	NN	use
of	IN	of
hand	NN	hand
sanitizers	NNS	<unknown>
,	,	,
facemask	NN	<unknown>
and	CC	and
maintaining	VBG	maintain
social	JJ	social
distancing	NN	distancing
)	)	)
,	,	,
reducing	VBG	reduce
the	DT	the
amount	NN	amount
of	IN	of
aerosol	NN	aerosol
production	NN	production
in	IN	in
the	DT	the
dental	JJ	dental
setting	NN	setting
,	,	,
and	CC	and
managing	VBG	manage
the	DT	the
quality	NN	quality
of	IN	of
air	NN	air
in	IN	in
the	DT	the
dental	JJ	dental
treatment	NN	treatment
rooms	NNS	room
by	IN	by
reducing	VBG	reduce
the	DT	the
use	NN	use
of	IN	of
air	NN	air
conditioners	NNS	conditioner
and	CC	and
improving	VBG	improve
air	NN	air
exchange	NN	exchange
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
shown	VBN	show
a	DT	a
major	JJ	major
impact	NN	impact
on	IN	on
dental	JJ	dental
practice	NN	practice
.	SENT	.
Dental	JJ	dental
professionals	NNS	professional
are	VBP	be
trying	VBG	try
to	TO	to
adapt	VB	adapt
to	TO	to
the	DT	the
new	JJ	new
norms	NNS	norm
,	,	,
while	IN	while
the	DT	the
medium	NN	medium
to	TO	to
long-term	JJ	long-term
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
dentistry	NN	dentistry
needs	VBZ	need
further	JJR	further
investigation	NN	investigation
.	SENT	.
33558097/	CD	@card@
A	DT	a
breath	NN	breath
of	IN	of
fresh	JJ	fresh
air	NN	air
:	:	:
The	DT	the
role	NN	role
of	IN	of
incentive	NN	incentive
spirometry	NN	spirometry
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
33675696/	CD	@card@
Multisystem	NP	Multisystem
inflammatory	JJ	inflammatory
syndrome	NN	syndrome
in	IN	in
a	DT	a
neonate	NN	neonate
,	,	,
temporally	RB	temporally
associated	VBN	associate
with	IN	with
prenatal	JJ	prenatal
exposure	NN	exposure
to	TO	to
SARS-CoV-2	NP	<unknown>
:	:	:
a	DT	a
case	NN	case
report	NN	report
34757734/	CD	@card@
SARS-CoV-2-Impedimetric	NP	<unknown>
Biosensor	NP	biosensor
:	:	:
Virus-Imprinted	NP	<unknown>
Chips	NPS	Chips
for	IN	for
Early	NP	Early
and	CC	and
Rapid	NP	Rapid
Diagnosis	NN	diagnosis
Due	JJ	due
to	TO	to
the	DT	the
current	JJ	current
global	JJ	global
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
,	,	,
rapid	JJ	rapid
and	CC	and
accurate	JJ	accurate
diagnostic	JJ	diagnostic
tools	NNS	tool
are	VBP	be
needed	VBN	need
to	TO	to
prevent	VB	prevent
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
across	IN	across
the	DT	the
globe	NN	globe
.	SENT	.
An	DT	an
electrochemical	JJ	electrochemical
sensing	VBG	sense
platform	NN	platform
was	VBD	be
constructed	VBN	construct
using	VBG	use
CNTs/WO3-screen	NP	CNTs/WO3-screen
printed	VBN	print
electrodes	NNS	electrode
for	IN	for
imprinting	VBG	imprint
the	DT	the
complete	JJ	complete
virus	NN	virus
particles	NNS	particle
(	(	(
SARS-CoV-2	NP	<unknown>
particles	NNS	particle
)	)	)
within	IN	within
the	DT	the
polymeric	JJ	polymeric
matrix	NN	matrix
to	TO	to
create	VB	create
viral	JJ	viral
complementary	JJ	complementary
binding	JJ	binding
sites	NNS	site
.	SENT	.
The	DT	the
sensor	NN	sensor
provided	VBD	provide
high	JJ	high
selectivity	NN	selectivity
toward	IN	toward
the	DT	the
target	NN	target
virus	NN	virus
over	IN	over
other	JJ	other
tested	VBN	test
human	JJ	human
corona	NN	corona
and	CC	and
influenza	NN	influenza
respiratory	JJ	respiratory
interference	NN	interference
viruses	NNS	virus
.	SENT	.
The	DT	the
sensitivity	NN	sensitivity
performance	NN	performance
of	IN	of
the	DT	the
sensor	NN	sensor
chips	NNS	chip
was	VBD	be
evaluated	VBN	evaluate
using	VBG	use
different	JJ	different
viral	JJ	viral
concentrations	NNS	concentration
,	,	,
while	IN	while
the	DT	the
limits	NNS	limit
of	IN	of
detection	NN	detection
and	CC	and
quantification	NN	quantification
were	VBD	be
57	CD	@card@
and	CC	and
175	CD	@card@
pg/mL	NN	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
Reaching	VBG	reach
this	DT	this
satisfied	JJ	satisfied
low	JJ	low
detection	NN	detection
limit	NN	limit
(	(	(
almost	RB	almost
27-fold	JJ	<unknown>
more	JJR	more
sensitive	JJ	sensitive
than	IN	than
the	DT	the
RT-PCR	NP	<unknown>
)	)	)
,	,	,
the	DT	the
sensor	NN	sensor
was	VBD	be
applied	VBN	apply
in	IN	in
clinical	JJ	clinical
specimens	NNS	specimen
obtained	VBN	obtain
from	IN	from
SARS-CoV-2	NP	<unknown>
suspected	JJ	suspected
cases	NNS	case
.	SENT	.
Thus	RB	thus
,	,	,
dealing	VBG	deal
directly	RB	directly
with	IN	with
clinical	JJ	clinical
samples	NNS	sample
on	IN	on
the	DT	the
chip	NN	chip
could	MD	could
be	VB	be
provided	VBN	provide
as	IN	as
a	DT	a
portable	JJ	portable
device	NN	device
for	IN	for
instantaneous	JJ	instantaneous
and	CC	and
simple	JJ	simple
point	NN	point
of	IN	of
care	NN	care
in	IN	in
hospitals	NNS	hospital
,	,	,
airports	NNS	airport
,	,	,
and	CC	and
hotspots	NNS	hotspot
.	SENT	.
35492426/	CD	@card@
COVID-19	NP	<unknown>
,	,	,
marriage	NN	marriage
,	,	,
and	CC	and
divorce	NN	divorce
in	IN	in
Japan	NP	Japan
Using	VBG	use
monthly	JJ	monthly
panel	NN	panel
dataset	NN	<unknown>
of	IN	of
prefectures	NNS	prefecture
in	IN	in
Japan	NP	Japan
,	,	,
this	DT	this
study	NN	study
explored	VBD	explore
the	DT	the
effects	NNS	effect
of	IN	of
stay-at-home	JJ	stay-at-home
policies	NNS	policy
on	IN	on
the	DT	the
flows	NNS	flow
into	IN	into
and	CC	and
out	IN	out
of	IN	of
marriage	NN	marriage
.	SENT	.
It	PP	it
was	VBD	be
found	VBN	find
that	IN	that
these	DT	these
policies	NNS	policy
significantly	RB	significantly
reduced	VBD	reduce
both	DT	both
outcomes	NNS	outcome
.	SENT	.
According	VBG	accord
to	TO	to
our	PP$	our
estimates	NNS	estimate
,	,	,
a	DT	a
nationwide	JJ	nationwide
state	NN	state
of	IN	of
emergency	NN	emergency
reduced	VBD	reduce
the	DT	the
number	NN	number
of	IN	of
marriages	NNS	marriage
per	IN	per
1000	CD	@card@
population	NN	population
by	IN	by
10.4	CD	@card@
%	NN	%
,	,	,
while	IN	while
that	IN	that
of	IN	of
divorces	NNS	divorce
was	VBD	be
reduced	VBN	reduce
by	IN	by
27.0	CD	@card@
%	NN	%
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
prefectures	NNS	prefecture
designated	VBN	designate
as	IN	as
the	DT	the
special-precautions	NNS	special-precaution
area	NN	area
suffered	VBD	suffer
additional	JJ	additional
reductions	NNS	reduction
with	IN	with
6.1	CD	@card@
%	NN	%
and	CC	and
8.9	CD	@card@
%	NN	%
for	IN	for
those	DT	those
of	IN	of
marriage	NN	marriage
and	CC	and
divorce	NN	divorce
,	,	,
respectively	RB	respectively
.	SENT	.
32304928/	CD	@card@
When	WRB	when
basic	JJ	basic
supplies	NNS	supply
are	VBP	be
missing	VBG	miss
,	,	,
what	WP	what
to	TO	to
do	VB	do
?	SENT	?
Specific	JJ	specific
demands	NNS	demand
of	IN	of
the	DT	the
local	JJ	local
street	NN	street
population	NN	population
in	IN	in
times	NNS	time
of	IN	of
coronavirus	NN	coronavirus
-	NN	<unknown>
a	DT	a
concern	NN	concern
of	IN	of
social	JJ	social
psychiatry	NN	psychiatry
Homeless	JJ	homeless
experts	NNS	expert
and	CC	and
some	DT	some
federal	JJ	federal
housing	NN	housing
officials	NNS	official
are	VBP	be
sounding	VBG	sound
the	DT	the
alarm	NN	alarm
that	IN	that
the	DT	the
patchwork	NN	patchwork
of	IN	of
government	NN	government
efforts	NNS	effort
to	TO	to
address	VB	address
the	DT	the
coronavirus	NN	coronavirus
outbreak	NN	outbreak
risks	NNS	risk
leaving	VBG	leave
out	RP	out
one	CD	one
group	NN	group
of	IN	of
acutely	RB	acutely
vulnerable	JJ	vulnerable
people	NNS	people
:	:	:
the	DT	the
homeless	NN	homeless
.	SENT	.
In	IN	in
terms	NNS	term
of	IN	of
isolation	NN	isolation
,	,	,
it	PP	it
is	VBZ	be
too	RB	too
unclear	JJ	unclear
what	WP	what
that	DT	that
looks	NNS	look
like	VBP	like
if	IN	if
you	PP	you
normally	RB	normally
sleep	VBP	sleep
on	IN	on
the	DT	the
streets	NNS	street
.	SENT	.
In	IN	in
this	DT	this
tough	JJ	tough
moment	NN	moment
,	,	,
when	WRB	when
people	NNS	people
should	MD	should
be	VB	be
turned	VBN	turn
away	RP	away
,	,	,
not	RB	not
only	RB	only
it	PP	it
feels	VBZ	feel
inhumane	JJ	inhumane
,	,	,
but	CC	but
it	PP	it
is	VBZ	be
also	RB	also
a	DT	a
big	JJ	big
public	JJ	public
health	NN	health
risk	NN	risk
,	,	,
because	IN	because
where	WRB	where
are	VBP	be
they	PP	they
going	VBG	go
to	TO	to
go	VB	go
?	SENT	?
With	IN	with
more	JJR	more
cities	NNS	city
suspecting	VBG	suspect
community	NN	community
transmission	NN	transmission
of	IN	of
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
people	NNS	people
who	WP	who
sleep	VBP	sleep
in	IN	in
shelters	NNS	shelter
or	CC	or
hunker	NN	<unknown>
down	RB	down
outside	RB	outside
already	RB	already
have	VB	have
a	DT	a
lower	JJR	low
life	NN	life
expectancy	NN	expectancy
and	CC	and
often	RB	often
have	VB	have
underlying	JJ	underlying
health	NN	health
conditions	NNS	condition
that	WDT	that
put	VBP	put
them	PP	them
at	IN	at
greater	JJR	great
risk	NN	risk
if	IN	if
they	PP	they
develop	VBP	develop
COVID-19	NP	<unknown>
.	SENT	.
A	DT	a
large	JJ	large
population	NN	population
of	IN	of
homeless	JJ	homeless
people	NNS	people
experience	VBP	experience
their	PP$	their
pain	NN	pain
and	CC	and
psychological	JJ	psychological
distress	NN	distress
intermittently	RB	intermittently
.	SENT	.
For	IN	for
low-income	JJ	low-income
patients	NNS	patient
,	,	,
the	DT	the
various	JJ	various
borderline	JJ	borderline
situations	NNS	situation
related	VBN	relate
to	TO	to
health/illness	NN	health/illness
involve	VB	involve
growing	VBG	grow
expectations	NNS	expectation
regarding	VBG	regard
the	DT	the
basic	JJ	basic
needs	NNS	need
.	SENT	.
This	DT	this
is	VBZ	be
a	DT	a
serious	JJ	serious
concern	NN	concern
when	WRB	when
linked	VBN	link
to	TO	to
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Homeless	JJ	homeless
experts	NNS	expert
and	CC	and
some	DT	some
federal	JJ	federal
housing	NN	housing
officials	NNS	official
are	VBP	be
sounding	VBG	sound
the	DT	the
alarm	NN	alarm
that	IN	that
the	DT	the
patchwork	NN	patchwork
of	IN	of
government	NN	government
efforts	NNS	effort
to	TO	to
address	VB	address
the	DT	the
coronavirus	NN	coronavirus
outbreak	NN	outbreak
risks	NNS	risk
leaving	VBG	leave
out	RP	out
one	CD	one
group	NN	group
of	IN	of
acutely	RB	acutely
vulnerable	JJ	vulnerable
people	NNS	people
:	:	:
the	DT	the
homeless	NN	homeless
.	SENT	.
In	IN	in
terms	NNS	term
of	IN	of
isolation	NN	isolation
,	,	,
it	PP	it
is	VBZ	be
too	RB	too
unclear	JJ	unclear
what	WP	what
that	DT	that
looks	NNS	look
like	VBP	like
if	IN	if
you	PP	you
normally	RB	normally
sleep	VBP	sleep
on	IN	on
the	DT	the
streets	NNS	street
.	SENT	.
In	IN	in
this	DT	this
tough	JJ	tough
moment	NN	moment
,	,	,
when	WRB	when
people	NNS	people
should	MD	should
be	VB	be
turned	VBN	turn
away	RP	away
,	,	,
not	RB	not
only	RB	only
it	PP	it
feels	VBZ	feel
inhumane	JJ	inhumane
,	,	,
but	CC	but
it	PP	it
is	VBZ	be
also	RB	also
a	DT	a
big	JJ	big
public	JJ	public
health	NN	health
risk	NN	risk
,	,	,
because	IN	because
where	WRB	where
are	VBP	be
they	PP	they
going	VBG	go
to	TO	to
go	VB	go
?	SENT	?
The	DT	the
studies	NNS	study
were	VBD	be
identified	VBN	identify
using	VBG	use
large-sized	JJ	large-sized
newspapers	NNS	newspaper
with	IN	with
international	JJ	international
circulation	NN	circulation
With	IN	with
more	JJR	more
cities	NNS	city
suspecting	VBG	suspect
community	NN	community
transmission	NN	transmission
of	IN	of
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
people	NNS	people
who	WP	who
sleep	VBP	sleep
in	IN	in
shelters	NNS	shelter
or	CC	or
hunker	NN	<unknown>
down	RB	down
outside	RB	outside
already	RB	already
have	VB	have
a	DT	a
lower	JJR	low
life	NN	life
expectancy	NN	expectancy
and	CC	and
often	RB	often
have	VB	have
underlying	JJ	underlying
health	NN	health
conditions	NNS	condition
that	WDT	that
put	VBP	put
them	PP	them
at	IN	at
greater	JJR	great
risk	NN	risk
if	IN	if
they	PP	they
develop	VBP	develop
COVID-19	NP	<unknown>
(	(	(
Global	NP	Global
News	NP	News
,	,	,
2020	CD	@card@
)	)	)
.	SENT	.
These	DT	these
people	NNS	people
face	VBP	face
lack	NN	lack
of	IN	of
sleep	NN	sleep
,	,	,
malnutrition	NN	malnutrition
,	,	,
and	CC	and
"	``	"
extreme	JJ	extreme
stress	NN	stress
levels	NNS	level
just	RB	just
to	TO	to
meet	VB	meet
their	PP$	their
daily	JJ	daily
needs	NNS	need
"	''	"
,	,	,
all	DT	all
of	IN	of
which	WDT	which
weakens	VBZ	weaken
the	DT	the
immune	JJ	immune
system	NN	system
.	SENT	.
Along	IN	along
with	IN	with
mental	JJ	mental
illness	NN	illness
or	CC	or
substance	NN	substance
abuse	NN	abuse
disorders	NNS	disorder
,	,	,
they	PP	they
are	VBP	be
"	``	"
incredibly	RB	incredibly
vulnerable	JJ	vulnerable
to	TO	to
this	DT	this
virus	NN	virus
"	''	"
.	SENT	.
Health	NN	health
organizations	NNS	organization
are	VBP	be
well	RB	well
aware	JJ	aware
of	IN	of
the	DT	the
risks	NNS	risk
involved	VBN	involve
in	IN	in
mental	JJ	mental
health	NN	health
.	SENT	.
A	DT	a
large	JJ	large
population	NN	population
of	IN	of
homeless	JJ	homeless
people	NNS	people
experience	VBP	experience
their	PP$	their
pain	NN	pain
and	CC	and
psychological	JJ	psychological
distress	NN	distress
intermittently	RB	intermittently
.	SENT	.
For	IN	for
low-income	JJ	low-income
patients	NNS	patient
,	,	,
the	DT	the
various	JJ	various
borderline	JJ	borderline
situations	NNS	situation
related	VBN	relate
to	TO	to
health/illness	NN	health/illness
involve	VB	involve
growing	VBG	grow
expectations	NNS	expectation
regarding	VBG	regard
the	DT	the
basic	JJ	basic
needs	NNS	need
.	SENT	.
This	DT	this
is	VBZ	be
a	DT	a
serious	JJ	serious
concern	NN	concern
when	WRB	when
linked	VBN	link
to	TO	to
the	DT	the
pandemic	NN	pandemic
.	SENT	.
34667785/	CD	@card@
Performance	NN	performance
evaluation	NN	evaluation
of	IN	of
selected	JJ	selected
machine	NN	machine
learning	VBG	learn
algorithms	NNS	algorithm
for	IN	for
COVID-19	NP	<unknown>
prediction	NN	prediction
using	VBG	use
routine	JJ	routine
clinical	JJ	clinical
data	NNS	datum
:	:	:
With	IN	with
versus	CC	versus
Without	IN	without
CT	NP	CT
scan	NN	scan
features	VBZ	feature
Given	VBN	give
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
's	POS	's
)	)	)
unknown	JJ	unknown
nature	NN	nature
,	,	,
diagnosis	NN	diagnosis
,	,	,
and	CC	and
treatment	NN	treatment
is	VBZ	be
very	RB	very
complex	JJ	complex
up	RB	up
to	TO	to
the	DT	the
present	JJ	present
time	NN	time
.	SENT	.
Thus	RB	thus
,	,	,
it	PP	it
is	VBZ	be
essential	JJ	essential
to	TO	to
have	VB	have
a	DT	a
framework	NN	framework
for	IN	for
an	DT	an
early	JJ	early
prediction	NN	prediction
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
In	IN	in
this	DT	this
regard	NN	regard
,	,	,
machines	NNS	machine
learning	NN	learning
(	(	(
ML	NP	ML
)	)	)
could	MD	could
be	VB	be
crucial	JJ	crucial
to	TO	to
extract	VB	extract
concealed	VBN	conceal
patterns	NNS	pattern
from	IN	from
mining	NN	mining
of	IN	of
huge	JJ	huge
raw	JJ	raw
datasets	NNS	<unknown>
then	RB	then
it	PP	it
establishes	VBZ	establish
high-quality	JJ	high-quality
predictive	JJ	predictive
models	NNS	model
.	SENT	.
At	IN	at
this	DT	this
juncture	NN	juncture
,	,	,
we	PP	we
aimed	VBD	aim
to	TO	to
apply	VB	apply
different	JJ	different
ML	NP	ML
techniques	NNS	technique
to	TO	to
develop	VB	develop
clinical	JJ	clinical
predictive	JJ	predictive
models	NNS	model
and	CC	and
select	VB	select
the	DT	the
best	JJS	good
performance	NN	performance
of	IN	of
them	PP	them
.	SENT	.
The	DT	the
dataset	NN	<unknown>
of	IN	of
Ayatollah	NP	Ayatollah
Talleghani	NP	Talleghani
hospital	NN	hospital
,	,	,
COVID-19	NP	<unknown>
focal	JJ	focal
center	NN	center
affiliated	VBN	affiliate
to	TO	to
Abadan	NP	<unknown>
University	NP	University
of	IN	of
Medical	NP	Medical
Sciences	NPS	Sciences
have	VBP	have
been	VBN	be
taken	VBN	take
into	IN	into
consideration	NN	consideration
.	SENT	.
The	DT	the
dataset	NN	<unknown>
used	VBN	use
in	IN	in
this	DT	this
study	NN	study
consists	VBZ	consist
of	IN	of
501	CD	@card@
case	NN	case
records	NNS	record
with	IN	with
two	CD	two
classes	NNS	class
(	(	(
COVID-19	NP	<unknown>
and	CC	and
non	JJ	non
COVID-19	NN	<unknown>
)	)	)
and	CC	and
32	CD	@card@
columns	NNS	column
for	IN	for
the	DT	the
diagnostic	JJ	diagnostic
features	NNS	feature
.	SENT	.
ML	NP	ML
algorithms	NNS	algorithm
such	JJ	such
as	IN	as
Naive	JJ	naive
Bayesian	NP	<unknown>
,	,	,
Bayesian	NP	<unknown>
Net	NP	Net
,	,	,
random	JJ	random
forest	NN	forest
(	(	(
RF	NP	RF
)	)	)
,	,	,
multilayer	JJ	multilayer
perceptron	NN	<unknown>
,	,	,
K-star	NP	<unknown>
,	,	,
C4.5	NP	<unknown>
,	,	,
and	CC	and
support	NN	support
vector	NN	vector
machine	NN	machine
were	VBD	be
developed	VBN	develop
.	SENT	.
Then	RB	then
,	,	,
the	DT	the
recital	NN	recital
of	IN	of
selected	JJ	selected
ML	NP	ML
models	NNS	model
was	VBD	be
assessed	VBN	assess
by	IN	by
the	DT	the
comparison	NN	comparison
of	IN	of
some	DT	some
performance	NN	performance
indices	NN	indices
such	JJ	such
as	IN	as
accuracy	NN	accuracy
,	,	,
sensitivity	NN	sensitivity
,	,	,
specificity	NN	specificity
,	,	,
precision	NN	precision
,	,	,
F-score	NP	F-score
,	,	,
and	CC	and
receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
(	(	(
ROC	NN	roc
)	)	)
.	SENT	.
The	DT	the
experimental	JJ	experimental
results	NNS	result
indicate	VBP	indicate
that	IN	that
RF	NP	RF
algorithm	NN	algorithm
with	IN	with
the	DT	the
accuracy	NN	accuracy
of	IN	of
92.42	CD	@card@
%	NN	%
,	,	,
specificity	NN	specificity
of	IN	of
75.70	CD	@card@
%	NN	%
,	,	,
precision	NN	precision
of	IN	of
92.30	CD	@card@
%	NN	%
,	,	,
sensitivity	NN	sensitivity
of	IN	of
92.40	CD	@card@
%	NN	%
,	,	,
F-measure	NP	<unknown>
of	IN	of
92.00	CD	@card@
%	NN	%
,	,	,
and	CC	and
ROC	NN	roc
of	IN	of
97.15	CD	@card@
%	NN	%
has	VBZ	have
the	DT	the
best	JJS	good
capability	NN	capability
for	IN	for
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
and	CC	and
screening	NN	screening
.	SENT	.
The	DT	the
empirical	JJ	empirical
results	NNS	result
reveal	VBP	reveal
that	IN	that
RF	NP	RF
model	NN	model
yielded	VBD	yield
higher	JJR	high
performance	NN	performance
as	IN	as
compared	VBN	compare
to	TO	to
other	JJ	other
six	CD	six
classification	NN	classification
models	NNS	model
.	SENT	.
It	PP	it
is	VBZ	be
promising	VBG	promise
to	TO	to
the	DT	the
implementation	NN	implementation
of	IN	of
RF	NP	RF
model	NN	model
in	IN	in
the	DT	the
health-care	JJ	health-care
settings	NNS	setting
to	TO	to
increase	VB	increase
the	DT	the
accuracy	NN	accuracy
and	CC	and
speed	NN	speed
of	IN	of
disease	NN	disease
diagnosis	NN	diagnosis
for	IN	for
primary	JJ	primary
prevention	NN	prevention
,	,	,
screening	NN	screening
,	,	,
surveillance	NN	surveillance
,	,	,
and	CC	and
early	JJ	early
treatment	NN	treatment
.	SENT	.
32360231/	CD	@card@
Arbidol	NN	<unknown>
:	:	:
A	DT	a
potential	JJ	potential
antiviral	JJ	antiviral
drug	NN	drug
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
SARS-CoV-2	NP	<unknown>
by	IN	by
blocking	VBG	block
trimerization	NN	<unknown>
of	IN	of
the	DT	the
spike	NN	spike
glycoprotein	NN	glycoprotein
The	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
a	DT	a
global	JJ	global
emergency	NN	emergency
,	,	,
and	CC	and
new	JJ	new
therapeutics	NNS	therapeutics
are	VBP	be
needed	VBN	need
.	SENT	.
Molecular	JJ	molecular
dynamics	NNS	dynamics
and	CC	and
structure-guided	JJ	<unknown>
drug-binding	NN	drug-binding
analysis	NN	analysis
suggest	VBP	suggest
that	IN	that
Arbidol	NP	<unknown>
may	MD	may
have	VB	have
potential	JJ	potential
to	TO	to
treat	VB	treat
COVID-19	NP	<unknown>
.	SENT	.
Arbidol	NP	<unknown>
impedes	VBZ	impede
trimerization	NN	<unknown>
of	IN	of
SARS-CoV-2	NP	<unknown>
spike	NN	spike
glycoprotein	NN	glycoprotein
and	CC	and
inhibits	VBZ	inhibit
host	NN	host
cell	NN	cell
adhesion	NN	adhesion
.	SENT	.
The	DT	the
binding	JJ	binding
mode	NN	mode
of	IN	of
Arbidol	NP	<unknown>
to	TO	to
SARS-CoV-2	NP	<unknown>
spike	NN	spike
glycoprotein	NN	glycoprotein
is	VBZ	be
similar	JJ	similar
to	TO	to
that	DT	that
of	IN	of
influenza	NN	influenza
virus	NN	virus
haemagglutinin	NN	haemagglutinin
.	SENT	.
The	DT	the
key	JJ	key
residues	NNS	residue
of	IN	of
SARS-CoV-2	NP	<unknown>
spike	NN	spike
glycoprotein	NN	glycoprotein
involved	VBN	involve
in	IN	in
Arbidol	NP	<unknown>
binding	JJ	binding
guide	NN	guide
the	DT	the
development	NN	development
of	IN	of
new	JJ	new
therapeutics	NNS	therapeutics
.	SENT	.
The	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus-2	NN	<unknown>
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
pandemic	NN	pandemic
is	VBZ	be
a	DT	a
global	JJ	global
public	JJ	public
health	NN	health
emergency	NN	emergency
,	,	,
and	CC	and
new	JJ	new
therapeutics	NNS	therapeutics
are	VBP	be
needed	VBN	need
.	SENT	.
This	DT	this
article	NN	article
reports	VBZ	report
the	DT	the
potential	JJ	potential
drug	NN	drug
target	NN	target
and	CC	and
mechanism	NN	mechanism
of	IN	of
action	NN	action
of	IN	of
Arbidol	NP	<unknown>
(	(	(
umifenovir	NN	<unknown>
)	)	)
to	TO	to
treat	VB	treat
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
Molecular	JJ	molecular
dynamics	NNS	dynamics
and	CC	and
structural	JJ	structural
analysis	NN	analysis
were	VBD	be
used	VBN	use
to	TO	to
show	VB	show
how	WRB	how
Arbidol	NP	<unknown>
targets	VBZ	target
the	DT	the
SARS-CoV-2	NP	<unknown>
spike	NN	spike
glycoprotein	NN	glycoprotein
and	CC	and
impedes	VBZ	impede
its	PP$	its
trimerization	NN	<unknown>
,	,	,
which	WDT	which
is	VBZ	be
key	JJ	key
for	IN	for
host	NN	host
cell	NN	cell
adhesion	NN	adhesion
and	CC	and
hijacking	VBG	hijack
,	,	,
indicating	VBG	indicate
the	DT	the
potential	NN	potential
of	IN	of
Arbidol	NP	<unknown>
to	TO	to
treat	VB	treat
COVID-19	NP	<unknown>
.	SENT	.
It	PP	it
is	VBZ	be
hoped	VBN	hope
that	IN	that
knowledge	NN	knowledge
of	IN	of
the	DT	the
potential	JJ	potential
drug	NN	drug
target	NN	target
and	CC	and
mechanism	NN	mechanism
of	IN	of
action	NN	action
of	IN	of
Arbidol	NP	<unknown>
will	MD	will
help	VB	help
in	IN	in
the	DT	the
development	NN	development
of	IN	of
new	JJ	new
therapeutics	NNS	therapeutics
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
34803106/	CD	@card@
Successful	JJ	successful
Use	NN	use
of	IN	of
Certolizumab	NP	<unknown>
Pegol	NP	<unknown>
for	IN	for
Refractory	JJ	refractory
Psoriatic	JJ	psoriatic
Arthritis	NN	arthritis
Triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
Infection	NN	infection
Recently	RB	recently
,	,	,
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
,	,	,
has	VBZ	have
spread	VBN	spread
worldwide	RB	worldwide
.	SENT	.
Although	IN	although
nearly	RB	nearly
all	DT	all
patients	NNS	patient
incur	VBP	incur
mild-to-moderate	JJ	mild-to-moderate
disease	NN	disease
from	IN	from
this	DT	this
viral	JJ	viral
infection	NN	infection
,	,	,
some	DT	some
develop	VBP	develop
severe	JJ	severe
manifestations	NNS	manifestation
with	IN	with
a	DT	a
poor	JJ	poor
prognosis	NN	prognosis
.	SENT	.
COVID-19	NP	<unknown>
can	MD	can
also	RB	also
induce	VB	induce
autoimmune	JJ	autoimmune
disease	NN	disease
;	:	;
several	JJ	several
cases	NNS	case
of	IN	of
arthritis	NN	arthritis
following	VBG	follow
COVID-19	NP	<unknown>
have	VBP	have
been	VBN	be
documented	VBN	document
in	IN	in
the	DT	the
literature	NN	literature
,	,	,
such	JJ	such
as	IN	as
reactive	JJ	reactive
arthritis	NN	arthritis
and	CC	and
chronic	JJ	chronic
arthritis	NN	arthritis
.	SENT	.
We	PP	we
herein	RB	herein
report	VB	report
a	DT	a
case	NN	case
of	IN	of
psoriatic	JJ	psoriatic
arthritis	NN	arthritis
triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
.	SENT	.
Although	IN	although
the	DT	the
arthritis	NN	arthritis
had	VBD	have
been	VBN	be
refractory	JJ	refractory
to	TO	to
glucocorticoids	NNS	glucocorticoid
and	CC	and
methotrexate	NN	methotrexate
,	,	,
certolizumab	NN	<unknown>
pegol	NN	<unknown>
subsequently	RB	subsequently
led	VBN	lead
to	TO	to
remission	NN	remission
.	SENT	.
33680350/	CD	@card@
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
Can	MD	can
zinc	NN	zinc
supplementation	NN	supplementation
provide	VB	provide
an	DT	an
additional	JJ	additional
shield	NN	shield
against	IN	against
the	DT	the
infection	NN	infection
?	SENT	?
Coronavirus	NP	<unknown>
disease-19	NN	<unknown>
(COVID-19)-induced	VBD	(COVID-19)-induce
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
is	VBZ	be
a	DT	a
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
As	IN	as
a	DT	a
preventive	JJ	preventive
measure	NN	measure
,	,	,
human	JJ	human
movement	NN	movement
is	VBZ	be
restricted	VBN	restrict
in	IN	in
most	JJS	most
of	IN	of
the	DT	the
world	NN	world
.	SENT	.
The	DT	the
Centers	NPS	Centers
for	IN	for
Disease	NP	Disease
Control	NP	Control
and	CC	and
Prevention	NN	prevention
(	(	(
CDC	NP	CDC
)	)	)
,	,	,
the	DT	the
National	NP	National
Institutes	NPS	Institutes
of	IN	of
Health	NP	Health
(	(	(
NIH	NP	NIH
)	)	)
,	,	,
along	RB	along
with	IN	with
the	DT	the
WHO	WP	who
have	VBP	have
laid	VBN	lay
out	RP	out
some	DT	some
therapeutic	JJ	therapeutic
guidelines	NNS	guideline
for	IN	for
the	DT	the
infected	JJ	infected
patients	NNS	patient
.	SENT	.
However	RB	however
,	,	,
other	JJ	other
than	IN	than
handwashing	NN	handwashing
and	CC	and
vigilance	NN	vigilance
surrounding	VBG	surround
commonly	RB	commonly
encountered	VBN	encounter
oronasal	JJ	oronasal
symptoms	NNS	symptom
and	CC	and
fever	NN	fever
,	,	,
no	DT	no
useful	JJ	useful
prophylactic	JJ	prophylactic
measure	NN	measure
has	VBZ	have
yet	RB	yet
been	VBN	be
established	VBN	establish
.	SENT	.
In	IN	in
a	DT	a
pandemic	NN	pandemic
,	,	,
the	DT	the
accessibility	NN	accessibility
of	IN	of
a	DT	a
prophylactic	NN	prophylactic
biologically	RB	biologically
active	JJ	active
substance	NN	substance
is	VBZ	be
crucial	JJ	crucial
.	SENT	.
Ideally	RB	ideally
,	,	,
it	PP	it
would	MD	would
be	VB	be
something	NN	something
readily	RB	readily
available	JJ	available
at	IN	at
a	DT	a
low	JJ	low
price	NN	price
to	TO	to
a	DT	a
larger	JJR	large
percentage	NN	percentage
of	IN	of
the	DT	the
population	NN	population
with	IN	with
minimal	JJ	minimal
risk	NN	risk
.	SENT	.
Studies	NNS	study
have	VBP	have
demonstrated	VBN	demonstrate
that	IN	that
zinc	NN	zinc
may	MD	may
reduce	VB	reduce
viral	JJ	viral
replication	NN	replication
and	CC	and
increase	VB	increase
immune	JJ	immune
responses	NNS	response
.	SENT	.
For	IN	for
example	NN	example
,	,	,
in	IN	in
some	DT	some
studies	NNS	study
,	,	,
zinc	NN	zinc
supplementation	NN	supplementation
used	VBN	use
against	IN	against
the	DT	the
influenza	NN	influenza
virus	NN	virus
has	VBZ	have
been	VBN	be
shown	VBN	show
to	TO	to
yield	VB	yield
clinical	JJ	clinical
benefits	NNS	benefit
with	IN	with
reduced	VBN	reduce
disease	NN	disease
burden	NN	burden
.	SENT	.
While	IN	while
consuming	NN	consuming
zinc	NN	zinc
(	(	(
within	IN	within
the	DT	the
recommended	JJ	recommended
upper	JJ	upper
safety	NN	safety
limits	NNS	limit
)	)	)
,	,	,
as	IN	as
a	DT	a
prophylactic	NN	prophylactic
might	MD	might
provide	VB	provide
an	DT	an
additional	JJ	additional
shield	NN	shield
against	IN	against
the	DT	the
initiation	NN	initiation
and	CC	and
progression	NN	progression
of	IN	of
COVID-19	NP	<unknown>
would	MD	would
need	VB	need
clinical	JJ	clinical
studies	NNS	study
,	,	,
the	DT	the
potential	NN	potential
clearly	RB	clearly
exists	VBZ	exist
.	SENT	.
33840053/	CD	@card@
Proton	NN	proton
pump	NN	pump
inhibitor	NN	inhibitor
on	IN	on
susceptibility	NN	susceptibility
to	TO	to
COVID-19	NP	<unknown>
and	CC	and
its	PP$	its
severity	NN	severity
:	:	:
a	DT	a
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
The	DT	the
negative	JJ	negative
impacts	NNS	impact
of	IN	of
proton	NN	proton
pump	NN	pump
inhibitor	NN	inhibitor
(	(	(
PPI	NP	PPI
)	)	)
,	,	,
including	VBG	include
the	DT	the
risk	NN	risk
of	IN	of
pneumonia	NN	pneumonia
and	CC	and
mortality	NN	mortality
,	,	,
have	VBP	have
been	VBN	be
reported	VBN	report
previously	RB	previously
.	SENT	.
This	DT	this
meta-analysis	NN	meta-analysis
aimed	VBN	aim
to	TO	to
address	VB	address
the	DT	the
current	JJ	current
interest	NN	interest
of	IN	of
whether	IN	whether
the	DT	the
administration	NN	administration
of	IN	of
PPI	NP	PPI
could	MD	could
increase	VB	increase
the	DT	the
susceptibility	NN	susceptibility
and	CC	and
risk	NN	risk
of	IN	of
poor	JJ	poor
outcome	NN	outcome
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
systematic	JJ	systematic
literature	NN	literature
search	NN	search
from	IN	from
PubMed	NP	<unknown>
,	,	,
Embase	NP	<unknown>
,	,	,
EBSCOhost	NP	<unknown>
,	,	,
and	CC	and
EuropePMC	NN	<unknown>
databases	NNS	database
up	RB	up
until	IN	until
3	CD	@card@
December	NP	December
2020	CD	@card@
.	SENT	.
The	DT	the
main	JJ	main
outcome	NN	outcome
was	VBD	be
composite	JJ	composite
poor	JJ	poor
outcome	NN	outcome
which	WDT	which
comprised	VBD	comprise
of	IN	of
mortality	NN	mortality
and	CC	and
severe	JJ	severe
COVID-19	NP	<unknown>
.	SENT	.
Severe	JJ	severe
COVID-19	NN	<unknown>
in	IN	in
this	DT	this
study	NN	study
was	VBD	be
defined	VBN	define
as	IN	as
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
that	WDT	that
fulfill	VBP	fulfill
the	DT	the
criteria	NNS	criterion
for	IN	for
severe	JJ	severe
CAP	NN	cap
,	,	,
including	VBG	include
the	DT	the
need	NN	need
for	IN	for
intensive	JJ	intensive
unit	NN	unit
care	NN	care
or	CC	or
mechanical	JJ	mechanical
ventilation	NN	ventilation
.	SENT	.
The	DT	the
secondary	JJ	secondary
outcome	NN	outcome
was	VBD	be
susceptibility	NN	susceptibility
,	,	,
based	VBN	base
on	IN	on
cohort	NN	cohort
comparing	VBG	compare
COVID-19	NP	<unknown>
positive	JJ	positive
and	CC	and
COVID-19	JJ	<unknown>
negative	JJ	negative
participants	NNS	participant
.	SENT	.
There	EX	there
were	VBD	be
a	DT	a
total	NN	total
of	IN	of
290,455	CD	@card@
patients	NNS	patient
from	IN	from
12	CD	@card@
studies	NNS	study
in	IN	in
this	DT	this
meta-analysis	NN	meta-analysis
.	SENT	.
PPI	NP	PPI
use	NN	use
was	VBD	be
associated	VBN	associate
with	IN	with
increased	VBN	increase
composite	JJ	composite
poor	JJ	poor
outcome	NN	outcome
(	(	(
OR	CC	or
1.85	CD	@card@
[	SYM	[
1.13	CD	@card@
,	,	,
3.03	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.014	CD	@card@
;	:	;
I2	NP	<unknown>
90.26	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Meta-regression	NN	Meta-regression
analysis	NN	analysis
indicate	VBP	indicate
that	IN	that
the	DT	the
association	NN	association
does	VBZ	do
not	RB	not
vary	VB	vary
by	IN	by
age	NN	age
(	(	(
OR	CC	or
0.97	CD	@card@
[	SYM	[
0.92	CD	@card@
,	,	,
1.02	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.244	CD	@card@
)	)	)
,	,	,
male	NN	male
(	(	(
OR	CC	or
1.05	CD	@card@
[	SYM	[
0.99	CD	@card@
,	,	,
1.11	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.091	CD	@card@
)	)	)
,	,	,
hypertension	NN	hypertension
(	(	(
OR	CC	or
9.98	CD	@card@
[	SYM	[
0.95	CD	@card@
,	,	,
1.02	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.317	CD	@card@
)	)	)
,	,	,
diabetes	NN	diabetes
(	(	(
OR	CC	or
0.99	CD	@card@
[	SYM	[
0.93	CD	@card@
,	,	,
1.05	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.699	CD	@card@
)	)	)
,	,	,
chronic	JJ	chronic
kidney	NN	kidney
disease	NN	disease
(	(	(
OR	CC	or
1.01	CD	@card@
[	SYM	[
0.93	CD	@card@
,	,	,
1.10	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.756	CD	@card@
)	)	)
,	,	,
non-steroidal	NN	non-steroidal
anti-inflammatory	JJ	anti-inflammatory
drug	NN	drug
use	NN	use
(	(	(
OR	CC	or
1.02	CD	@card@
[	SYM	[
0.96	CD	@card@
,	,	,
1.09	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.499	CD	@card@
)	)	)
,	,	,
and	CC	and
pre-admission/in-hospital	JJ	pre-admission/in-hospital
PPI	NP	PPI
use	NN	use
(	(	(
OR	CC	or
0.77	CD	@card@
[	SYM	[
0.26	CD	@card@
,	,	,
2.31	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.644	CD	@card@
)	)	)
.	SENT	.
PPI	NP	PPI
use	NN	use
was	VBD	be
not	RB	not
associated	VBN	associate
with	IN	with
the	DT	the
susceptibility	NN	susceptibility
to	TO	to
COVID-19	NP	<unknown>
(	(	(
OR	CC	or
1.56	CD	@card@
[	SYM	[
0.48	CD	@card@
,	,	,
5.05	CD	@card@
]	SYM	]
,	,	,
p	NN	p
=	SYM	=
0.46	CD	@card@
;	:	;
I2	NP	<unknown>
99.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
This	DT	this
meta-analysis	NN	meta-analysis
showed	VBD	show
a	DT	a
potential	JJ	potential
association	NN	association
between	IN	between
PPI	NP	PPI
use	NN	use
and	CC	and
composite	JJ	composite
poor	JJ	poor
outcome	NN	outcome
,	,	,
but	CC	but
not	RB	not
susceptibility	NN	susceptibility
.	SENT	.
PROSPERO	NN	<unknown>
ID	NN	id
:	:	:
CRD42020224286	NN	<unknown>
.	SENT	.
34545952/	CD	@card@
Low	NP	Low
seropositivity	NN	<unknown>
and	CC	and
suboptimal	JJ	suboptimal
neutralisation	NN	neutralisation
rates	NNS	rate
in	IN	in
patients	NNS	patient
fully	RB	fully
vaccinated	VBN	vaccinate
against	IN	against
COVID-19	NP	<unknown>
with	IN	with
B-cell	NN	B-cell
malignancies	NNS	malignancy
35081177/	CD	@card@
Adding	VBG	add
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
Educational	NP	Educational
Script	NN	script
35206434/	CD	@card@
Changes	NP	Changes
in	IN	in
Physical	JJ	physical
Activity	NN	activity
Patterns	NNS	pattern
Due	JJ	due
to	TO	to
the	DT	the
Covid-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
A	DT	a
Systematic	JJ	systematic
Review	NP	Review
and	CC	and
Meta-Analysis	NP	Meta-Analysis
With	IN	with
the	DT	the
outbreak	NN	outbreak
of	IN	of
the	DT	the
Corona	NP	Corona
Virus	NN	virus
Disease	NP	Disease
19	CD	@card@
(	(	(
Covid-19	NP	<unknown>
)	)	)
in	IN	in
late	JJ	late
2019	CD	@card@
,	,	,
governments	NNS	government
increasingly	RB	increasingly
imposed	VBN	impose
containment	NN	containment
strategies	NNS	strategy
,	,	,
including	VBG	include
social	JJ	social
distancing	NN	distancing
as	RB	as
well	RB	well
as	IN	as
restricted	JJ	restricted
population	NN	population
movement	NN	movement
,	,	,
potentially	RB	potentially
having	VBG	have
negative	JJ	negative
impacts	NNS	impact
on	IN	on
mental	JJ	mental
and	CC	and
physical	JJ	physical
health	NN	health
.	SENT	.
A	DT	a
growing	VBG	grow
number	NN	number
of	IN	of
studies	NNS	study
have	VBP	have
examined	VBN	examine
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
different	JJ	different
facets	NNS	facet
of	IN	of
physical	JJ	physical
activity	NN	activity
(	(	(
PA	NN	pa
)	)	)
;	:	;
an	DT	an
overview	NN	overview
combining	VBG	combine
these	DT	these
(	(	(
mixed	JJ	mixed
)	)	)
results	NNS	result
,	,	,
however	RB	however
,	,	,
is	VBZ	be
missing	VBG	miss
.	SENT	.
Thus	RB	thus
,	,	,
the	DT	the
objective	NN	objective
of	IN	of
this	DT	this
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
was	VBD	be
to	TO	to
investigate	VB	investigate
whether	IN	whether
and	CC	and
to	TO	to
which	WDT	which
extent	NN	extent
PA	NN	pa
changed	VBN	change
from	IN	from
before	IN	before
to	TO	to
during	IN	during
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
taking	VBG	take
age	NN	age
,	,	,
gender	NN	gender
,	,	,
and	CC	and
measurement	NN	measurement
method	NN	method
into	IN	into
account	NN	account
.	SENT	.
The	DT	the
literature	NN	literature
search	NN	search
was	VBD	be
conducted	VBN	conduct
using	VBG	use
PubMed	NP	<unknown>
,	,	,
Web	NP	Web
of	IN	of
Science	NP	Science
,	,	,
and	CC	and
Scopus	NP	Scopus
.	SENT	.
Results	NNS	result
of	IN	of
the	DT	the
main	JJ	main
characteristics	NNS	characteristic
were	VBD	be
descriptively	RB	descriptively
synthesized	VBN	synthesize
and	CC	and
analyzed	VBN	analyze
in	IN	in
a	DT	a
meta-analysis	NN	meta-analysis
quantifying	VBG	quantify
effects	NNS	effect
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
PA	NN	pa
divided	VBN	divide
by	IN	by
age	NN	age
groups	NNS	group
,	,	,
with	IN	with
additional	JJ	additional
subgroup	NN	subgroup
analyses	NNS	analysis
of	IN	of
the	DT	the
characteristics	NNS	characteristic
age	NN	age
,	,	,
gender	NN	gender
,	,	,
and	CC	and
measurement	NN	measurement
method	NN	method
being	VBG	be
narratively	RB	narratively
synthesized	VBN	synthesize
.	SENT	.
Overall	RB	overall
,	,	,
57	CD	@card@
studies	NNS	study
with	IN	with
a	DT	a
total	JJ	total
sample	NN	sample
size	NN	size
of	IN	of
119,094	CD	@card@
participants	NNS	participant
(	(	(
N	NP	N
between	IN	between
10	CD	@card@
and	CC	and
60,560	CD	@card@
subjects	NNS	subject
)	)	)
from	IN	from
14	CD	@card@
countries	NNS	country
worldwide	RB	worldwide
with	IN	with
participants	NNS	participant
aged	VBN	age
between	IN	between
four	CD	four
and	CC	and
93	CD	@card@
years	NNS	year
were	VBD	be
included	VBN	include
.	SENT	.
Thirty-two	NP	<unknown>
studies	NNS	study
revealed	VBD	reveal
a	DT	a
significant	JJ	significant
decline	NN	decline
in	IN	in
PA	NN	pa
,	,	,
whereas	IN	whereas
only	RB	only
five	CD	five
studies	NNS	study
found	VBD	find
a	DT	a
significant	JJ	significant
increase	NN	increase
in	IN	in
PA	NN	pa
during	IN	during
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Fourteen	NN	fourteen
studies	NNS	study
revealed	VBD	reveal
mixed	JJ	mixed
results	NNS	result
.	SENT	.
PA	NN	pa
decreased	VBD	decrease
in	IN	in
all	DT	all
age	NN	age
groups	NNS	group
,	,	,
independent	JJ	independent
of	IN	of
gender	NN	gender
.	SENT	.
Most	RBS	most
self-reported	JJ	self-reported
and	CC	and
all	DT	all
device-based	JJ	<unknown>
measurement	NN	measurement
methods	NNS	method
showed	VBD	show
a	DT	a
reduction	NN	reduction
in	IN	in
PA	NN	pa
.	SENT	.
However	RB	however
,	,	,
effects	NNS	effect
were	VBD	be
not	RB	not
found	VBN	find
to	TO	to
be	VB	be
significant	JJ	significant
in	IN	in
all	DT	all
age	NN	age
groups	NNS	group
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
the	DT	the
declining	VBG	decline
trend	NN	trend
should	MD	should
be	VB	be
noted	VBN	note
and	CC	and
governments	NNS	government
should	MD	should
strive	VB	strive
to	TO	to
enable	VB	enable
PA	NN	pa
within	IN	within
periods	NNS	period
of	IN	of
pandemic	JJ	pandemic
restrictions	NNS	restriction
,	,	,
or	CC	or
promote	VB	promote
alternatives	NNS	alternative
such	JJ	such
as	IN	as
digital	JJ	digital
training	NN	training
to	TO	to
avoid	VB	avoid
negative	JJ	negative
health	NN	health
consequences	NNS	consequence
within	IN	within
the	DT	the
population	NN	population
.	SENT	.
35051664/	CD	@card@
Retinal	JJ	retinal
findings	NNS	finding
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
using	VBG	use
Ocular	JJ	ocular
coherence	NN	coherence
tomography	NN	tomography
angiography	NN	angiography
two	CD	two
to	TO	to
three	CD	three
months	NNS	month
after	IN	after
infection	NN	infection
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
evaluate	VB	evaluate
the	DT	the
ocular	JJ	ocular
disorders	NNS	disorder
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
two	CD	two
to	TO	to
three	CD	three
months	NNS	month
after	IN	after
infection	NN	infection
.	SENT	.
In	IN	in
this	DT	this
cross-sectional	JJ	cross-sectional
,	,	,
historically	RB	historically
controlled	VBN	control
study	NN	study
,	,	,
fifty-one	NP	<unknown>
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
compared	VBN	compare
with	IN	with
thirty-seven	VBN	thirty-seven
age	NN	age
,	,	,
and	CC	and
gender-matched	JJ	<unknown>
healthy	JJ	healthy
individuals	NNS	individual
.	SENT	.
After	IN	after
complete	JJ	complete
ophthalmological	JJ	ophthalmological
examination	NN	examination
,	,	,
all	DT	all
participants	NNS	participant
underwent	VBD	undergo
peripapillary	JJ	peripapillary
and	CC	and
macular	JJ	macular
optical	JJ	optical
coherence	NN	coherence
tomography	NN	tomography
,	,	,
and	CC	and
optical	JJ	optical
coherence	NN	coherence
tomography	NN	tomography
angiography	NN	angiography
(	(	(
OCTA	NP	<unknown>
)	)	)
measurements	NNS	measurement
(	(	(
OptoVue	NP	<unknown>
Inc	NP	Inc
,	,	,
Freemont	NP	Freemont
,	,	,
CA	MD	ca
,	,	,
USA	NP	USA
)	)	)
.	SENT	.
The	DT	the
time	NN	time
between	IN	between
the	DT	the
initial	JJ	initial
onset	NN	onset
of	IN	of
symptoms	NNS	symptom
,	,	,
and	CC	and
ophthalmologic	JJ	<unknown>
examination	NN	examination
was	VBD	be
63.31+-15.21	CD	@card@
(	(	(
40-95	CD	@card@
days	NNS	day
)	)	)
.	SENT	.
Ophthalmic	JJ	ophthalmic
examination	NN	examination
of	IN	of
all	PDT	all
the	DT	the
recovered	VBN	recover
COVID-19	NP	<unknown>
patients	NNS	patient
was	VBD	be
within	IN	within
normal	JJ	normal
range	NN	range
.	SENT	.
None	NN	none
of	IN	of
the	DT	the
peripapillary	JJ	peripapillary
and	CC	and
macular	JJ	macular
OCTA	NP	<unknown>
parameters	NNS	parameter
were	VBD	be
significantly	RB	significantly
different	JJ	different
between	IN	between
the	DT	the
two	CD	two
groups	NNS	group
with	IN	with
pairwise	JJ	<unknown>
comparisons	NNS	comparison
,	,	,
but	CC	but
after	IN	after
adjusting	VBG	adjust
for	IN	for
age	NN	age
,	,	,
gender	NN	gender
,	,	,
axial	JJ	axial
length	NN	length
,	,	,
and	CC	and
signal	NN	signal
strength	NN	strength
index	NN	index
(	(	(
SSI	NP	SSI
)	)	)
,	,	,
recovered	VBD	recover
COVID-19	NP	<unknown>
eyes	NNS	eye
showed	VBD	show
a	DT	a
significant	JJ	significant
increase	NN	increase
in	IN	in
peripapillary	JJ	peripapillary
retinal	JJ	retinal
nerve	NN	nerve
fiber	NN	fiber
(	(	(
RNFL	NP	<unknown>
)	)	)
thickness	NN	thickness
,	,	,
superficial	JJ	superficial
,	,	,
and	CC	and
deep	JJ	deep
macular	JJ	macular
vessel	NN	vessel
densities	NNS	density
in	IN	in
parafoveal	NN	<unknown>
and	CC	and
perifoveal	JJ	perifoveal
regions	NNS	region
compared	VBN	compare
with	IN	with
healthy	JJ	healthy
control	NN	control
eyes	NNS	eye
(	(	(
p&lt	NN	<unknown>
;	:	;
=	SYM	=
0.05	CD	@card@
)	)	)
.	SENT	.
Inner	JJ	inner
retinal	JJ	retinal
thickness	NN	thickness
overall	NN	overall
is	VBZ	be
higher	JJR	high
in	IN	in
recovered	VBN	recover
COVID-19	JJ	<unknown>
eyes	NNS	eye
compared	VBN	compare
to	TO	to
healthy	JJ	healthy
eyes	NNS	eye
after	IN	after
adjustment	NN	adjustment
.	SENT	.
Patients	NNS	patient
with	IN	with
moderate-intensity	NN	moderate-intensity
SARS-CoV-2	NP	<unknown>
pneumonia	NN	pneumonia
had	VBD	have
altered	VBN	alter
peripapillary	JJ	peripapillary
and	CC	and
macular	JJ	macular
vessel	NN	vessel
density	NN	density
compared	VBN	compare
to	TO	to
healthy	JJ	healthy
subjects	NNS	subject
.	SENT	.
Further	JJR	further
investigation	NN	investigation
is	VBZ	be
warranted	VBN	warrant
to	TO	to
analyze	VB	analyze
the	DT	the
correlation	NN	correlation
of	IN	of
these	DT	these
changes	NNS	change
with	IN	with
disease	NN	disease
severity	NN	severity
as	RB	as
well	RB	well
as	IN	as
evolution	NN	evolution
of	IN	of
these	DT	these
changes	NNS	change
over	IN	over
time	NN	time
.	SENT	.
32495372/	CD	@card@
Terminal	NN	terminal
complement	NN	complement
inhibition	NN	inhibition
dampens	VBZ	dampen
the	DT	the
inflammation	NN	inflammation
during	IN	during
COVID-19	NP	<unknown>
Emerging	NP	Emerging
evidence	NN	evidence
suggests	VBZ	suggest
that	DT	that
activation	NN	activation
of	IN	of
the	DT	the
complement	NN	complement
system	NN	system
is	VBZ	be
critical	JJ	critical
in	IN	in
the	DT	the
pathogenesis	NN	pathogenesis
of	IN	of
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
SARS-CoV-2	NP	<unknown>
,	,	,
the	DT	the
causative	JJ	causative
agent	NN	agent
of	IN	of
COVID-19	NP	<unknown>
related	JJ	related
lung	NN	lung
injury	NN	injury
.	SENT	.
Inhibition	NN	inhibition
of	IN	of
the	DT	the
terminal	JJ	terminal
complement	NN	complement
pathway	NN	pathway
by	IN	by
targeting	VBG	target
complement	NN	complement
protein	NN	protein
5	CD	@card@
(	(	(
C5	NP	<unknown>
)	)	)
may	MD	may
be	VB	be
an	DT	an
effective	JJ	effective
therapeutic	JJ	therapeutic
intervention	NN	intervention
in	IN	in
CoV-mediated	JJ	<unknown>
disease.1	JJ	<unknown>
Paroxysmal	JJ	paroxysmal
nocturnal	JJ	nocturnal
haemoglobinuria	NN	haemoglobinuria
(	(	(
PNH	NP	PNH
)	)	)
is	VBZ	be
a	DT	a
rare	JJ	rare
,	,	,
acquired	JJ	acquired
hematopoietic	JJ	hematopoietic
stem	NN	stem
cell	NN	cell
(	(	(
HSC	NP	HSC
)	)	)
disease	NN	disease
characterized	VBN	characterize
by	IN	by
intravascular	JJ	intravascular
haemolysis	NN	haemolysis
,	,	,
increased	VBD	increase
thromboembolic	JJ	thromboembolic
risk	NN	risk
and	CC	and
bone	NN	bone
marrow	NN	marrow
failure.2	JJ	<unknown>
34958526/	CD	@card@
Low	NP	Low
Immunoglobulin	NN	immunoglobulin
G	NP	G
Antibody	NN	antibody
Levels	NP	Levels
Against	IN	against
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Disease	NN	disease
Coronavirus	NP	<unknown>
2	CD	@card@
After	IN	after
2-Dose	JJ	<unknown>
Vaccination	NN	vaccination
Among	IN	among
Liver	JJR	live
Transplantation	NN	transplantation
Recipients	NNS	recipient
32327321/	JJ	@card@
Development	NP	Development
of	IN	of
a	DT	a
telehealth	JJ	<unknown>
geriatric	JJ	geriatric
assessment	NN	assessment
model	NN	model
in	IN	in
response	NN	response
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
35283488/	CD	@card@
Les	NP	Les
suites	NNS	suite
de	NP	de
la	NP	la
pandemie	NP	<unknown>
COVID-19	NP	<unknown>
une	NN	une
occasion	NN	occasion
de	NP	de
reformer	JJ	reformer
la	NP	la
sante	NN	<unknown>
35078495/	CD	@card@
Effects	NNS	effect
of	IN	of
prone	JJ	prone
and	CC	and
lateral	JJ	lateral
positioning	NN	positioning
alternate	NN	alternate
in	IN	in
high-flow	JJ	<unknown>
nasal	JJ	nasal
cannula	NN	cannula
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
32653855/	CD	@card@
Maternal	JJ	maternal
mental	JJ	mental
health	NN	health
in	IN	in
Nepal	NP	Nepal
and	CC	and
its	PP$	its
prioritization	NN	prioritization
during	IN	during
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
Missing	VBG	miss
the	DT	the
obvious	JJ	obvious
33647988/	CD	@card@
In	IN	in
Reply	NN	reply
:	:	:
Thrombotic	JJ	thrombotic
Neurovascular	JJ	neurovascular
Disease	NN	disease
in	IN	in
COVID-19	NP	<unknown>
Patients	NPS	Patients
34591874/	CD	@card@
The	DT	the
cost-effectiveness	NN	cost-effectiveness
of	IN	of
common	JJ	common
strategies	NNS	strategy
for	IN	for
the	DT	the
prevention	NN	prevention
of	IN	of
transmission	NN	transmission
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
universities	NNS	university
Most	JJS	most
universities	NNS	university
that	IN	that
re-open	NNS	<unknown>
in	IN	in
the	DT	the
United	NP	United
States	NPS	States
(	(	(
US	NP	US
)	)	)
for	IN	for
in-person	NN	in-person
instruction	NN	instruction
have	VBP	have
implemented	VBN	implement
the	DT	the
Centers	NPS	Centers
for	IN	for
Disease	NP	Disease
Prevention	NN	prevention
and	CC	and
Control	NP	Control
(	(	(
CDC	NP	CDC
)	)	)
guidelines	NNS	guideline
.	SENT	.
The	DT	the
value	NN	value
of	IN	of
additional	JJ	additional
interventions	NNS	intervention
to	TO	to
prevent	VB	prevent
the	DT	the
transmission	NN	transmission
of	IN	of
SARS-CoV-2	NP	<unknown>
is	VBZ	be
unclear	JJ	unclear
.	SENT	.
We	PP	we
calculated	VBD	calculate
the	DT	the
cost-effectiveness	NN	cost-effectiveness
and	CC	and
cases	NNS	case
averted	VBN	avert
of	IN	of
each	DT	each
intervention	NN	intervention
in	IN	in
combination	NN	combination
with	IN	with
implementing	VBG	implement
the	DT	the
CDC	NP	CDC
guidelines	NNS	guideline
.	SENT	.
We	PP	we
built	VBD	build
a	DT	a
decision-analytic	JJ	decision-analytic
model	NN	model
to	TO	to
examine	VB	examine
the	DT	the
cost-effectiveness	NN	cost-effectiveness
of	IN	of
interventions	NNS	intervention
to	TO	to
re-open	JJ	<unknown>
universities	NNS	university
.	SENT	.
The	DT	the
interventions	NNS	intervention
included	VBD	include
implementing	VBG	implement
the	DT	the
CDC	NP	CDC
guidelines	NNS	guideline
alone	RB	alone
and	CC	and
in	IN	in
combination	NN	combination
with	IN	with
1	CD	@card@
)	)	)
a	DT	a
symptom-checking	JJ	<unknown>
mobile	JJ	mobile
application	NN	application
,	,	,
2	LS	2
)	)	)
university-provided	VBN	university-provide
standardized	JJ	standardized
,	,	,
high	JJ	high
filtration	NN	filtration
masks	NNS	mask
,	,	,
3	LS	3
)	)	)
thermal	JJ	thermal
cameras	NNS	camera
for	IN	for
temperature	NN	temperature
screening	NN	screening
,	,	,
4	LS	4
)	)	)
one-time	JJ	one-time
entry	NN	entry
(	(	(
'	POS	'
gateway	NN	gateway
'	''	'
)	)	)
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
testing	NN	testing
,	,	,
and	CC	and
5	LS	5
)	)	)
weekly	JJ	weekly
PCR	NP	PCR
testing	NN	testing
.	SENT	.
We	PP	we
also	RB	also
modeled	VBD	model
a	DT	a
package	NN	package
of	IN	of
interventions	NNS	intervention
(	(	(
'	POS	'
package	NN	package
intervention	NN	intervention
'	''	'
)	)	)
that	WDT	that
combines	VBZ	combine
the	DT	the
CDC	NP	CDC
guidelines	NNS	guideline
with	IN	with
using	VBG	use
the	DT	the
symptom-checking	JJ	<unknown>
mobile	JJ	mobile
application	NN	application
,	,	,
standardized	JJ	standardized
masks	NNS	mask
,	,	,
gateway	NN	gateway
PCR	NP	PCR
testing	NN	testing
,	,	,
and	CC	and
weekly	JJ	weekly
PCR	NP	PCR
testing	NN	testing
.	SENT	.
The	DT	the
direct	JJ	direct
and	CC	and
indirect	JJ	indirect
costs	NNS	cost
were	VBD	be
calculated	VBN	calculate
in	IN	in
2020	CD	@card@
US	NP	US
dollars	NNS	dollar
.	SENT	.
We	PP	we
also	RB	also
provided	VBD	provide
an	DT	an
online	JJ	online
interface	NN	interface
that	WDT	that
allows	VBZ	allow
the	DT	the
user	NN	user
to	TO	to
change	VB	change
model	NN	model
parameters	NNS	parameter
.	SENT	.
All	DT	all
interventions	NNS	intervention
averted	VBD	avert
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
When	WRB	when
the	DT	the
prevalence	NN	prevalence
of	IN	of
actively	RB	actively
infectious	JJ	infectious
cases	NNS	case
reached	VBD	reach
0.1	CD	@card@
%	NN	%
,	,	,
providing	VBG	provide
standardized	JJ	standardized
,	,	,
high	JJ	high
filtration	NN	filtration
masks	NNS	mask
saved	VBD	save
money	NN	money
and	CC	and
improved	VBN	improve
health	NN	health
relative	JJ	relative
to	TO	to
implementing	VBG	implement
the	DT	the
CDC	NP	CDC
guidelines	NNS	guideline
alone	RB	alone
and	CC	and
in	IN	in
combination	NN	combination
with	IN	with
using	VBG	use
the	DT	the
symptom-checking	JJ	<unknown>
mobile	JJ	mobile
application	NN	application
,	,	,
thermal	JJ	thermal
cameras	NNS	camera
,	,	,
and	CC	and
gateway	NN	gateway
testing	NN	testing
.	SENT	.
Compared	VBN	compare
with	IN	with
standardized	JJ	standardized
masks	NNS	mask
,	,	,
weekly	JJ	weekly
PCR	NP	PCR
testing	NN	testing
cost	NN	cost
$9.27	JJ	<unknown>
million	CD	million
(	(	(
95	CD	@card@
%	NN	%
Credible	JJ	credible
Interval	NN	interval
[	SYM	[
CrI	NP	Cri
]	SYM	]
:	:	:
cost-saving-$77.36	JJ	cost-saving-$@card@
million)/QALY	NN	<unknown>
gained	VBD	gain
.	SENT	.
Compared	VBN	compare
with	IN	with
weekly	JJ	weekly
PCR	NP	PCR
testing	NN	testing
,	,	,
the	NP	the
'	POS	'
package	NN	package
'	POS	'
intervention	NN	intervention
cost	VBD	cost
$137,877	JJ	$@card@
(	(	(
95	CD	@card@
%	NN	%
CrI	NP	Cri
:	:	:
$3,108-$19.11	JJ	$3,108-$@card@
million)/QALY	NN	<unknown>
gained	VBD	gain
.	SENT	.
At	IN	at
both	CC	both
a	DT	a
prevalence	NN	prevalence
of	IN	of
1	CD	@card@
%	NN	%
and	CC	and
2	CD	@card@
%	NN	%
,	,	,
the	NP	the
'	POS	'
package	NN	package
'	POS	'
intervention	NN	intervention
saved	VBD	save
money	NN	money
and	CC	and
improved	VBN	improve
health	NN	health
compared	VBN	compare
to	TO	to
all	PDT	all
the	DT	the
other	JJ	other
interventions	NNS	intervention
.	SENT	.
All	DT	all
interventions	NNS	intervention
were	VBD	be
effective	JJ	effective
at	IN	at
averting	VBG	avert
infection	NN	infection
from	IN	from
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
when	WRB	when
the	DT	the
prevalence	NN	prevalence
of	IN	of
actively	RB	actively
infectious	JJ	infectious
cases	NNS	case
in	IN	in
the	DT	the
community	NN	community
was	VBD	be
low	JJ	low
,	,	,
only	RB	only
standardized	JJ	standardized
,	,	,
high	JJ	high
filtration	NN	filtration
masks	NNS	mask
clearly	RB	clearly
provided	VBN	provide
value	NN	value
.	SENT	.
32376401/	CD	@card@
Fatal	JJ	fatal
COVID-19	NP	<unknown>
infections	NNS	infection
:	:	:
Is	VBZ	be
NK	JJ	<unknown>
cell	NN	cell
dysfunction	NN	dysfunction
a	DT	a
link	NN	link
with	IN	with
autoimmune	JJ	autoimmune
HLH	NP	HLH
?	SENT	?
33509849/	CD	@card@
How	WRB	how
big	JJ	big
is	VBZ	be
your	PP$	your
bubble	NN	bubble
?	SENT	?
Characteristics	NNS	characteristic
of	IN	of
self-isolating	VBG	self-isolate
household	NN	household
units	NNS	unit
(	(	(
'	POS	'
bubbles	NNS	bubble
'	''	'
)	)	)
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
Alert	NP	Alert
Level	NP	Level
4	CD	@card@
period	NN	period
in	IN	in
New	NP	New
Zealand	NP	Zealand
:	:	:
a	DT	a
cross-sectional	JJ	cross-sectional
survey	NN	survey
To	TO	to
characterise	VB	characterise
the	DT	the
self-isolating	JJ	self-isolating
household	NN	household
units	NNS	unit
(	(	(
bubbles	NNS	bubble
)	)	)
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
Alert	NP	Alert
Level	NP	Level
4	CD	@card@
lockdown	NN	<unknown>
in	IN	in
New	NP	New
Zealand	NP	Zealand
.	SENT	.
In	IN	in
this	DT	this
cross-sectional	JJ	cross-sectional
study	NN	study
,	,	,
an	DT	an
online	JJ	online
survey	NN	survey
was	VBD	be
distributed	VBN	distribute
to	TO	to
a	DT	a
convenience	NN	convenience
sample	NN	sample
via	IN	via
Facebook	NP	<unknown>
advertising	NN	advertising
and	CC	and
the	DT	the
Medical	NP	Medical
Research	NP	Research
Institute	NP	Institute
of	IN	of
New	NP	New
Zealand	NP	Zealand
's	POS	's
social	JJ	social
media	NN	media
platforms	NNS	platform
and	CC	and
mailing	NN	mailing
list	NN	list
.	SENT	.
Respondents	NNS	respondent
were	VBD	be
able	JJ	able
to	TO	to
share	VB	share
a	DT	a
link	NN	link
to	TO	to
the	DT	the
survey	NN	survey
via	IN	via
their	PP$	their
own	JJ	own
social	JJ	social
media	NNS	medium
platforms	NNS	platform
and	CC	and
by	IN	by
email	NN	<unknown>
.	SENT	.
Results	NNS	result
were	VBD	be
collected	VBN	collect
over	IN	over
6	CD	@card@
days	NNS	day
during	IN	during
Alert	NP	Alert
Level	NP	Level
4	CD	@card@
from	IN	from
respondents	NNS	respondent
living	VBG	live
in	IN	in
New	NP	New
Zealand	NP	Zealand
,	,	,
aged	VBN	age
16	CD	@card@
years	NNS	year
and	CC	and
over	IN	over
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
was	VBD	be
the	DT	the
mean	JJ	mean
size	NN	size
of	IN	of
a	DT	a
self-isolating	JJ	self-isolating
household	NN	household
unit	NN	unit
or	CC	or
bubble	NN	bubble
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
included	VBD	include
the	DT	the
mean	JJ	mean
number	NN	number
of	IN	of
households	NNS	household
in	IN	in
each	DT	each
bubble	NN	bubble
,	,	,
the	DT	the
proportion	NN	proportion
of	IN	of
bubbles	NNS	bubble
containing	VBG	contain
essential	JJ	essential
workers	NNS	worker
and/or	CC	and/or
vulnerable	JJ	vulnerable
people	NNS	people
,	,	,
and	CC	and
the	DT	the
mean	JJ	mean
number	NN	number
of	IN	of
times	NNS	time
the	DT	the
home	NN	home
was	VBD	be
left	VBN	leave
each	DT	each
week	NN	week
.	SENT	.
14	CD	@card@
876	CD	@card@
surveys	NNS	survey
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
analysis	NN	analysis
.	SENT	.
The	DT	the
mean	JJ	mean
(	(	(
SD	NP	SD
)	)	)
bubble	NN	bubble
size	NN	size
was	VBD	be
3.58	CD	@card@
(	(	(
4.63	CD	@card@
)	)	)
people	NNS	people
,	,	,
with	IN	with
mean	JJ	mean
(	(	(
SD	NP	SD
)	)	)
number	NN	number
of	IN	of
households	NNS	household
1.26	CD	@card@
(	(	(
0.77	CD	@card@
)	)	)
.	SENT	.
The	DT	the
proportion	NN	proportion
of	IN	of
bubbles	NNS	bubble
containing	VBG	contain
one	CD	one
or	CC	or
more	JJR	more
essential	JJ	essential
workers	NNS	worker
,	,	,
or	CC	or
one	CD	one
or	CC	or
more	JJR	more
vulnerable	JJ	vulnerable
persons	NNS	person
was	VBD	be
45.3	CD	@card@
%	NN	%
and	CC	and
42.1	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
mean	JJ	mean
number	NN	number
of	IN	of
times	NNS	time
individual	JJ	individual
bubble	NN	bubble
members	NNS	member
left	VBD	leave
their	PP$	their
home	NN	home
in	IN	in
the	DT	the
previous	JJ	previous
week	NN	week
was	VBD	be
12.9	CD	@card@
(	(	(
12.4	CD	@card@
)	)	)
.	SENT	.
Bubbles	NNS	bubble
that	WDT	that
contained	VBD	contain
at	IN	at
least	JJS	least
one	CD	one
vulnerable	JJ	vulnerable
individual	NN	individual
had	VBD	have
fewer	JJR	few
outings	NNS	outing
over	IN	over
the	DT	the
previous	JJ	previous
week	NN	week
compared	VBN	compare
with	IN	with
bubbles	NNS	bubble
that	WDT	that
did	VBD	do
not	RB	not
contain	VB	contain
a	DT	a
vulnerable	JJ	vulnerable
person	NN	person
.	SENT	.
The	DT	the
bubble	NN	bubble
sizes	NNS	size
were	VBD	be
similar	JJ	similar
by	IN	by
respondent	JJ	respondent
ethnicity	NN	ethnicity
.	SENT	.
In	IN	in
this	DT	this
New	NP	New
Zealand	NP	Zealand
convenience	NN	convenience
sample	NN	sample
,	,	,
bubble	NN	bubble
sizes	NNS	size
were	VBD	be
small	JJ	small
,	,	,
mostly	RB	mostly
limited	VBN	limit
to	TO	to
one	CD	one
household	NN	household
,	,	,
and	CC	and
a	DT	a
high	JJ	high
proportion	NN	proportion
contained	VBD	contain
essential	JJ	essential
workers	NNS	worker
and/or	CC	and/or
vulnerable	JJ	vulnerable
people	NNS	people
.	SENT	.
Understanding	VBG	understand
these	DT	these
characteristics	NNS	characteristic
from	IN	from
a	DT	a
country	NN	country
which	WDT	which
achieved	VBD	achieve
a	DT	a
low	JJ	low
COVID-19	NP	<unknown>
infection	NN	infection
rate	NN	rate
may	MD	may
help	VB	help
inform	VB	inform
public	JJ	public
health	NN	health
interventions	NNS	intervention
during	IN	during
this	DT	this
and	CC	and
future	JJ	future
pandemics	NNS	pandemic
.	SENT	.
35220656/	CD	@card@
Scientific	JJ	scientific
method	NN	method
and	CC	and
the	DT	the
COVID	NP	<unknown>
pandemic	NN	pandemic
33114654/	CD	@card@
Protecting	VBG	protect
the	DT	the
Herd	NP	Herd
:	:	:
Why	WRB	why
Pharmacists	NNS	pharmacist
Matter	NP	Matter
in	IN	in
Mass	NP	Mass
Vaccination	NN	vaccination
Background	NN	background
:	:	:
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
ongoing	JJ	ongoing
.	SENT	.
The	DT	the
unprecedented	JJ	unprecedented
challenges	NNS	challenge
worldwide	RB	worldwide
implore	VBP	implore
the	DT	the
urgent	JJ	urgent
development	NN	development
of	IN	of
a	DT	a
safe	JJ	safe
and	CC	and
effective	JJ	effective
COVID-19	NP	<unknown>
vaccine	NN	vaccine
.	SENT	.
Globally	RB	globally
,	,	,
pharmacists	NNS	pharmacist
have	VBP	have
been	VBN	be
delivering	VBG	deliver
important	JJ	important
public	JJ	public
health	NN	health
services	NNS	service
as	IN	as
part	NN	part
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
response	NN	response
.	SENT	.
It	PP	it
remains	VBZ	remain
to	TO	to
be	VB	be
seen	VBN	see
what	WDT	what
role	NN	role
they	PP	they
will	MD	will
play	VB	play
once	RB	once
a	DT	a
vaccine	NN	vaccine
is	VBZ	be
available	JJ	available
.	SENT	.
This	DT	this
review	NN	review
examines	VBZ	examine
herd	NN	herd
immunity	NN	immunity
and	CC	and
the	DT	the
potential	JJ	potential
role	NN	role
of	IN	of
the	DT	the
pharmacy	NN	pharmacy
profession	NN	profession
in	IN	in
mass	JJ	mass
vaccination	NN	vaccination
against	IN	against
COVID-19	NP	<unknown>
,	,	,
particularly	RB	particularly
within	IN	within
the	DT	the
Australian	JJ	Australian
context	NN	context
.	SENT	.
Aim	NN	aim
:	:	:
A	DT	a
literature	NN	literature
review	NN	review
was	VBD	be
conducted	VBN	conduct
to	TO	to
review	VB	review
the	DT	the
global	JJ	global
development	NN	development
of	IN	of
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
,	,	,
and	CC	and
the	DT	the
Australian	JJ	Australian
healthcare	NN	<unknown>
workforce	NN	workforce
capability	NN	capability
and	CC	and
existing	VBG	exist
policy	NN	policy
for	IN	for
mass	JJ	mass
vaccination	NN	vaccination
and	CC	and
the	DT	the
potential	JJ	potential
role	NN	role
of	IN	of
the	DT	the
pharmacist	NN	pharmacist
.	SENT	.
Method	NN	method
:	:	:
ScienceDirect	NP	ScienceDirect
,	,	,
Scopus	NP	Scopus
,	,	,
The	DT	the
National	NP	National
Centre	NP	Centre
for	IN	for
Biotechnology	NP	Biotechnology
Information	NP	Information
(	(	(
NCBI	NP	<unknown>
)	)	)
,	,	,
Wiley	NP	Wiley
Online	JJ	online
Library	NP	Library
,	,	,
PubMed	NP	<unknown>
,	,	,
and	CC	and
Google	NP	<unknown>
Scholar	NN	scholar
were	VBD	be
used	VBN	use
to	TO	to
search	VB	search
for	IN	for
relevant	JJ	relevant
literature	NN	literature
using	VBG	use
keywords	NNS	keyword
COVID-19	NP	<unknown>
,	,	,
vaccines	NNS	vaccine
,	,	,
immunisation	NN	immunisation
,	,	,
herd	NN	herd
immunity	NN	immunity
,	,	,
pandemic	NN	pandemic
,	,	,
pharmacist	NN	pharmacist
and	CC	and
Australian	JJ	Australian
healthcare	NN	<unknown>
.	SENT	.
Results	NNS	result
:	:	:
A	DT	a
large	JJ	large
portion	NN	portion
of	IN	of
the	DT	the
literature	NN	literature
was	VBD	be
journal	NN	journal
articles	NNS	article
,	,	,
and	CC	and
information	NN	information
from	IN	from
governmental	JJ	governmental
and	CC	and
international	JJ	international
bodies	NNS	body
such	JJ	such
as	IN	as
the	DT	the
World	NP	World
Health	NP	Health
Organisation	NP	Organisation
were	VBD	be
often	RB	often
referenced	VBN	reference
.	SENT	.
Over	IN	over
20	CD	@card@
million	CD	million
Australians	NNS	Australian
need	VBP	need
to	TO	to
be	VB	be
immunised	VBN	immunise
through	IN	through
vaccination	NN	vaccination
or	CC	or
acquire	VB	acquire
immunity	NN	immunity
through	IN	through
natural	JJ	natural
infection	NN	infection
for	IN	for
the	DT	the
country	NN	country
to	TO	to
achieve	VB	achieve
herd	NN	herd
immunity	NN	immunity
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
When	WRB	when
examining	VBG	examine
state	NN	state
and	CC	and
territory	NN	territory
pandemic	NN	pandemic
plans	NNS	plan
,	,	,
pharmacists	NNS	pharmacist
are	VBP	be
underutilised	VBN	underutilise
.	SENT	.
Modifying	VBG	modify
legislation	NN	legislation
to	TO	to
allow	VB	allow
pharmacists	NNS	pharmacist
to	TO	to
administer	VB	administer
approved	JJ	approved
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
will	MD	will
enable	VB	enable
a	DT	a
trained	JJ	trained
and	CC	and
skilled	JJ	skilled
workforce	NN	workforce
to	TO	to
be	VB	be
deployed	VBN	deploy
to	TO	to
increase	VB	increase
the	DT	the
rate	NN	rate
of	IN	of
mass	JJ	mass
vaccination	NN	vaccination
.	SENT	.
Conclusion	NN	conclusion
:	:	:
In	IN	in
preparation	NN	preparation
for	IN	for
a	DT	a
successful	JJ	successful
COVID-19	NP	<unknown>
vaccine	NN	vaccine
,	,	,
the	DT	the
Australian	JJ	Australian
Government	NN	government
must	MD	must
consider	VB	consider
various	JJ	various
elements	NNS	element
in	IN	in
their	PP$	their
vaccination	NN	vaccination
policy	NN	policy
.	SENT	.
This	DT	this
includes	VBZ	include
the	DT	the
estimated	JJ	estimated
herd	NN	herd
immunity	NN	immunity
threshold	NN	threshold
,	,	,
methods	NNS	method
of	IN	of
vaccine	NN	vaccine
delivery	NN	delivery
,	,	,
vaccine	NN	vaccine
clinic	NN	clinic
locations	NNS	location
,	,	,
staffing	VBG	staff
arrangements	NNS	arrangement
and	CC	and
training	NN	training
,	,	,
and	CC	and
strategies	NNS	strategy
for	IN	for
vaccine	NN	vaccine
prioritisation	NN	<unknown>
.	SENT	.
Pharmacists	NNS	pharmacist
can	MD	can
and	CC	and
should	MD	should
play	VB	play
a	DT	a
key	JJ	key
role	NN	role
in	IN	in
the	DT	the
roll	NN	roll
out	RP	out
of	IN	of
mass	JJ	mass
COVID-19	NP	<unknown>
vaccination	NN	vaccination
.	SENT	.
32673509/	CD	@card@
Effects	NNS	effect
of	IN	of
Renin-Angiotensin	NP	<unknown>
Inhibition	NN	inhibition
on	IN	on
ACE2	NP	<unknown>
(	(	(
Angiotensin-Converting	NP	<unknown>
Enzyme	NN	enzyme
2	CD	@card@
)	)	)
and	CC	and
TMPRSS2	NP	<unknown>
(	(	(
Transmembrane	NP	<unknown>
Protease	NN	protease
Serine	NN	serine
2	CD	@card@
)	)	)
Expression	NN	expression
34436248/	CD	@card@
The	DT	the
Anti-Viral	JJ	anti-viral
Applications	NP	Applications
of	IN	of
Marine	NP	Marine
Resources	NPS	Resources
for	IN	for
COVID-19	NP	<unknown>
Treatment	NP	Treatment
:	:	:
An	DT	an
Overview	NN	overview
The	DT	the
ongoing	JJ	ongoing
pandemic	NN	pandemic
has	VBZ	have
led	VBN	lead
to	TO	to
an	DT	an
urgent	JJ	urgent
need	NN	need
for	IN	for
novel	JJ	novel
drug	NN	drug
discovery	NN	discovery
and	CC	and
potential	JJ	potential
therapeutics	NNS	therapeutics
for	IN	for
Sars-CoV-2	JJ	<unknown>
infected	JJ	infected
patients	NNS	patient
.	SENT	.
Although	IN	although
Remdesivir	NP	<unknown>
and	CC	and
the	DT	the
anti-inflammatory	JJ	anti-inflammatory
agent	NN	agent
dexamethasone	NN	<unknown>
are	VBP	be
currently	RB	currently
on	IN	on
the	DT	the
market	NN	market
for	IN	for
treatment	NN	treatment
,	,	,
Remdesivir	NP	<unknown>
lacks	VBZ	lack
full	JJ	full
efficacy	NN	efficacy
and	CC	and
thus	RB	thus
,	,	,
more	JJR	more
drugs	NNS	drug
are	VBP	be
needed	VBN	need
.	SENT	.
This	DT	this
review	NN	review
was	VBD	be
conducted	VBN	conduct
through	IN	through
literature	NN	literature
search	NN	search
of	IN	of
PubMed	NP	<unknown>
,	,	,
MDPI	NP	<unknown>
,	,	,
Google	NP	<unknown>
Scholar	NN	scholar
and	CC	and
Scopus	NP	Scopus
.	SENT	.
Upon	IN	upon
review	NN	review
of	IN	of
existing	VBG	exist
literature	NN	literature
,	,	,
it	PP	it
is	VBZ	be
evident	JJ	evident
that	IN	that
marine	JJ	marine
organisms	NNS	organism
harbor	VBP	harbor
numerous	JJ	numerous
active	JJ	active
metabolites	NNS	metabolite
with	IN	with
anti-viral	JJ	anti-viral
properties	NNS	property
that	WDT	that
serve	VBP	serve
as	IN	as
potential	JJ	potential
leads	NNS	lead
for	IN	for
COVID-19	NP	<unknown>
therapy	NN	therapy
.	SENT	.
Inorganic	JJ	inorganic
polyphosphates	NNS	polyphosphate
(	(	(
polyP	NN	polyp
)	)	)
naturally	RB	naturally
found	VBD	find
in	IN	in
marine	JJ	marine
bacteria	NNS	bacterium
and	CC	and
sponges	VBZ	sponge
have	VB	have
been	VBN	be
shown	VBN	show
to	TO	to
prevent	VB	prevent
viral	JJ	viral
entry	NN	entry
,	,	,
induce	VB	induce
the	DT	the
innate	JJ	innate
immune	JJ	immune
response	NN	response
,	,	,
and	CC	and
downregulate	JJ	<unknown>
human	JJ	human
ACE-2	NN	<unknown>
.	SENT	.
Furthermore	RB	furthermore
,	,	,
several	JJ	several
marine	JJ	marine
metabolites	NNS	metabolite
isolated	VBN	isolate
from	IN	from
diverse	JJ	diverse
sponges	VBZ	sponge
and	CC	and
algae	NN	algae
have	VBP	have
been	VBN	be
shown	VBN	show
to	TO	to
inhibit	VB	inhibit
main	JJ	main
protease	NN	protease
(	(	(
Mpro	NP	<unknown>
)	)	)
,	,	,
a	DT	a
crucial	JJ	crucial
protein	NN	protein
required	VBN	require
for	IN	for
the	DT	the
viral	JJ	viral
life	NN	life
cycle	NN	cycle
.	SENT	.
Sulfated	JJ	Sulfated
polysaccharides	NNS	polysaccharide
have	VBP	have
also	RB	also
been	VBN	be
shown	VBN	show
to	TO	to
have	VB	have
potent	JJ	potent
anti-viral	JJ	anti-viral
effects	NNS	effect
due	JJ	due
to	TO	to
their	PP$	their
anionic	JJ	anionic
properties	NNS	property
and	CC	and
high	JJ	high
molecular	JJ	molecular
weight	NN	weight
.	SENT	.
Likewise	RB	likewise
,	,	,
select	JJ	select
marine	NN	marine
sponges	VBZ	sponge
produce	VB	produce
bromotyrosines	NNS	bromotyrosine
which	WDT	which
have	VBP	have
been	VBN	be
shown	VBN	show
to	TO	to
prevent	VB	prevent
viral	JJ	viral
entry	NN	entry
,	,	,
replication	NN	replication
and	CC	and
protein	NN	protein
synthesis	NN	synthesis
.	SENT	.
The	DT	the
numerous	JJ	numerous
compounds	NNS	compound
isolated	VBN	isolate
from	IN	from
marine	JJ	marine
resources	NNS	resource
demonstrate	VBP	demonstrate
significant	JJ	significant
potential	NN	potential
against	IN	against
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
present	JJ	present
review	NN	review
for	IN	for
the	DT	the
first	JJ	first
time	NN	time
highlights	VBZ	highlight
marine	JJ	marine
bioactive	JJ	bioactive
compounds	NNS	compound
,	,	,
their	PP$	their
sources	NNS	source
,	,	,
and	CC	and
their	PP$	their
anti-viral	JJ	anti-viral
mechanisms	NNS	mechanism
of	IN	of
action	NN	action
,	,	,
with	IN	with
a	DT	a
focus	NN	focus
on	IN	on
potential	JJ	potential
COVID-19	NP	<unknown>
treatment	NN	treatment
.	SENT	.
32446801/	CD	@card@
SARS-CoV-2	NN	<unknown>
and	CC	and
diabetes	NN	diabetes
:	:	:
New	JJ	new
challenges	NNS	challenge
for	IN	for
the	DT	the
disease	NN	disease
A	DT	a
novel	NN	novel
small	JJ	small
enveloped	VBN	envelop
RNA	NP	RNA
virus	NN	virus
with	IN	with
the	DT	the
typical	JJ	typical
characteristic	NN	characteristic
of	IN	of
the	DT	the
family	NN	family
to	TO	to
which	WDT	which
it	PP	it
belongs	VBZ	belong
,	,	,
a	DT	a
crown	NN	crown
,	,	,
hence	RB	hence
the	DT	the
name	NN	name
coronavirus	NN	coronavirus
,	,	,
appeared	VBD	appear
in	IN	in
December	NP	December
2019	CD	@card@
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
,	,	,
and	CC	and
subdued	VBD	subdue
the	DT	the
world	NN	world
to	TO	to
its	PP$	its
influence	NN	influence
.	SENT	.
The	DT	the
particular	JJ	particular
severity	NN	severity
of	IN	of
the	DT	the
disease	NN	disease
and	CC	and
higher	JJR	high
mortality	NN	mortality
rates	NNS	rate
in	IN	in
patients	NNS	patient
with	IN	with
associated	JJ	associated
morbidities	NNS	morbidity
,	,	,
including	VBG	include
hypertension	NN	hypertension
,	,	,
obesity	NN	obesity
and	CC	and
diabetes	NN	diabetes
,	,	,
increases	VBZ	increase
the	DT	the
concern	NN	concern
over	IN	over
the	DT	the
consequences	NNS	consequence
of	IN	of
this	DT	this
pandemic	NN	pandemic
.	SENT	.
In	IN	in
this	DT	this
review	NN	review
,	,	,
the	DT	the
features	NNS	feature
of	IN	of
SARS-CoV-2	NP	<unknown>
will	MD	will
be	VB	be
addressed	VBN	address
,	,	,
as	RB	as
well	RB	well
as	IN	as
the	DT	the
reasons	NNS	reason
why	WRB	why
it	PP	it
poses	VBZ	pose
a	DT	a
particular	JJ	particular
challenge	NN	challenge
to	TO	to
diabetic	JJ	diabetic
patients	NNS	patient
.	SENT	.
We	PP	we
will	MD	will
also	RB	also
highlight	VB	highlight
the	DT	the
recent	JJ	recent
treatment	NN	treatment
strategies	NNS	strategy
being	VBG	be
explored	VBN	explore
to	TO	to
control	VB	control
this	DT	this
pandemic	NN	pandemic
.	SENT	.
Emerging	VBG	emerge
evidence	NN	evidence
demonstrates	VBZ	demonstrate
that	IN	that
the	DT	the
correct	JJ	correct
management	NN	management
of	IN	of
diabetes	NN	diabetes
in	IN	in
those	DT	those
patients	NNS	patient
infected	VBN	infect
with	IN	with
SARS-CoV-2	NP	<unknown>
is	VBZ	be
of	IN	of
utmost	JJ	utmost
importance	NN	importance
for	IN	for
the	DT	the
viral	JJ	viral
disease	NN	disease
progression	NN	progression
,	,	,
therefore	RB	therefore
,	,	,
the	DT	the
importance	NN	importance
of	IN	of
blood	NN	blood
glucose	NN	glucose
control	NN	control
will	MD	will
also	RB	also
be	VB	be
addressed	VBN	address
.	SENT	.
35309721/	CD	@card@
Factors	NNS	factor
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
vaccine	NN	vaccine
acceptance	NN	acceptance
and	CC	and
hesitancy	NN	hesitancy
among	IN	among
residents	NNS	resident
of	IN	of
Northern	NP	Northern
California	NP	California
jails	VBZ	jail
Vaccine	NN	vaccine
uptake	NN	uptake
was	VBD	be
low	JJ	low
among	IN	among
jail	NN	jail
residents	NNS	resident
but	CC	but
increased	VBN	increase
with	IN	with
repeated	JJ	repeated
offers	NNS	offer
.	SENT	.
Concerns	NNS	concern
around	IN	around
side	NN	side
effects	NNS	effect
and	CC	and
efficacy	NN	efficacy
were	VBD	be
major	JJ	major
reasons	NNS	reason
for	IN	for
vaccine	NN	vaccine
hesitancy	NN	hesitancy
.	SENT	.
Jail	NN	jail
residents	NNS	resident
trusted	VBD	trust
jail	NN	jail
health	NN	health
staff	NN	staff
less	JJR	less
than	IN	than
their	PP$	their
doctor	NN	doctor
outside	IN	outside
jail	NN	jail
.	SENT	.
Trust	NN	trust
in	IN	in
medical	JJ	medical
personnel	NNS	personnel
was	VBD	be
associated	VBN	associate
with	IN	with
greater	JJR	great
vaccine	NN	vaccine
acceptance	NN	acceptance
.	SENT	.
Friends/family	NP	Friends/family
were	VBD	be
the	DT	the
most	RBS	most
trusted	VBN	trust
source	NN	source
for	IN	for
COVID-19	NP	<unknown>
information	NN	information
.	SENT	.
Carceral	JJ	<unknown>
facilities	NNS	facility
are	VBP	be
high-risk	JJ	high-risk
settings	NNS	setting
for	IN	for
COVID-19	NP	<unknown>
transmission	NN	transmission
.	SENT	.
Factors	NNS	factor
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
vaccine	NN	vaccine
acceptance	NN	acceptance
and	CC	and
hesitancy	NN	hesitancy
among	IN	among
incarcerated	VBN	incarcerate
individuals	NNS	individual
are	VBP	be
poorly	RB	poorly
understood	VBN	understand
,	,	,
especially	RB	especially
among	IN	among
jail	NN	jail
residents	NNS	resident
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
conducted	VBD	conduct
a	DT	a
retrospective	JJ	retrospective
review	NN	review
of	IN	of
electronic	JJ	electronic
health	NN	health
record	NN	record
(	(	(
EHR	NP	EHR
)	)	)
data	NNS	datum
on	IN	on
COVID-19	NP	<unknown>
vaccine	NN	vaccine
uptake	NN	uptake
in	IN	in
custody	NN	custody
and	CC	and
additionally	RB	additionally
administered	VBN	administer
a	DT	a
survey	NN	survey
to	TO	to
assess	VB	assess
reasons	NNS	reason
for	IN	for
vaccine	NN	vaccine
hesitancy	NN	hesitancy
,	,	,
sources	NNS	source
of	IN	of
COVID-19	NP	<unknown>
information	NN	information
,	,	,
and	CC	and
medical	JJ	medical
mistrust	NN	mistrust
among	IN	among
residents	NNS	resident
of	IN	of
four	CD	four
Northern	NP	Northern
California	NP	California
jails	VBZ	jail
.	SENT	.
We	PP	we
performed	VBD	perform
multivariate	JJ	multivariate
logistic	JJ	logistic
regression	NN	regression
to	TO	to
determine	VB	determine
associations	NNS	association
with	IN	with
vaccine	NN	vaccine
acceptance	NN	acceptance
.	SENT	.
Of	IN	of
2,564	CD	@card@
jail	NN	jail
residents	NNS	resident
offered	VBD	offer
a	DT	a
COVID-19	NP	<unknown>
vaccine	NN	vaccine
between	IN	between
March	NP	March
19	CD	@card@
,	,	,
2021	CD	@card@
and	CC	and
June	NP	June
30	CD	@card@
,	,	,
2021	CD	@card@
,	,	,
1,441	CD	@card@
(	(	(
56.2	CD	@card@
%	NN	%
)	)	)
accepted	VBN	accept
at	IN	at
least	JJS	least
one	CD	one
dose	NN	dose
.	SENT	.
Among	IN	among
vaccinated	VBN	vaccinate
residents	NNS	resident
,	,	,
497	CD	@card@
(	(	(
34.5	CD	@card@
%	NN	%
)	)	)
had	VBD	have
initially	RB	initially
refused	VBN	refuse
.	SENT	.
Vaccine	NN	vaccine
uptake	NN	uptake
was	VBD	be
higher	JJR	high
among	IN	among
older	JJR	old
individuals	NNS	individual
,	,	,
women	NNS	woman
,	,	,
those	DT	those
with	IN	with
recent	JJ	recent
flu	NN	flu
vaccination	NN	vaccination
,	,	,
and	CC	and
those	DT	those
living	NN	living
in	IN	in
shared	JJ	shared
housing	NN	housing
.	SENT	.
Among	IN	among
509	CD	@card@
survey	NN	survey
respondents	NNS	respondent
,	,	,
leading	VBG	lead
reasons	NNS	reason
for	IN	for
vaccine	NN	vaccine
hesitancy	NN	hesitancy
were	VBD	be
concerns	NNS	concern
around	IN	around
side	NN	side
effects	NNS	effect
and	CC	and
suboptimal	JJ	suboptimal
efficacy	NN	efficacy
,	,	,
with	IN	with
cost	NN	cost
and	CC	and
the	DT	the
need	NN	need
for	IN	for
an	DT	an
annual	JJ	annual
booster	NN	booster
being	VBG	be
other	JJ	other
hypothetical	JJ	hypothetical
deterrents	NNS	deterrent
to	TO	to
vaccination	NN	vaccination
.	SENT	.
Vaccine	NN	vaccine
hesitancy	NN	hesitancy
was	VBD	be
also	RB	also
associated	VBN	associate
with	IN	with
mistrust	NN	mistrust
of	IN	of
medical	JJ	medical
personnel	NNS	personnel
in	IN	in
and	CC	and
out	IN	out
of	IN	of
jail	NN	jail
,	,	,
although	IN	although
this	DT	this
association	NN	association
varied	VBN	vary
by	IN	by
race/ethnicity	NN	race/ethnicity
.	SENT	.
Television	NN	television
and	CC	and
friends/family	NN	friends/family
were	VBD	be
the	DT	the
most	RBS	most
common	JJ	common
and	CC	and
most	RBS	most
trusted	VBN	trust
sources	NNS	source
of	IN	of
COVID-19	NP	<unknown>
information	NN	information
,	,	,
respectively	RB	respectively
.	SENT	.
Overall	RB	overall
,	,	,
vaccine	NN	vaccine
acceptance	NN	acceptance
was	VBD	be
much	RB	much
lower	JJR	low
among	IN	among
jail	NN	jail
residents	NNS	resident
than	IN	than
the	DT	the
local	JJ	local
and	CC	and
national	JJ	national
general	JJ	general
population	NN	population
.	SENT	.
Interventions	NNS	intervention
to	TO	to
increase	VB	increase
vaccination	NN	vaccination
rates	NNS	rate
in	IN	in
this	DT	this
setting	NN	setting
should	MD	should
utilize	VB	utilize
accessible	JJ	accessible
and	CC	and
trusted	VBN	trust
sources	NNS	source
of	IN	of
information	NN	information
to	TO	to
address	VB	address
concerns	NNS	concern
about	IN	about
side	NN	side
effects	NNS	effect
and	CC	and
efficacy	NN	efficacy
,	,	,
while	IN	while
working	VBG	work
to	TO	to
mitigate	VB	mitigate
medical	JJ	medical
and	CC	and
institutional	JJ	institutional
mistrust	NN	mistrust
among	IN	among
residents	NNS	resident
.	SENT	.
35321490/	CD	@card@
Analyzing	VBG	analyze
the	DT	the
Morality	NN	morality
of	IN	of
Owning	VBG	own
and	CC	and
Suspending	VBG	suspend
Patent	NP	Patent
Rights	NPS	Rights
for	IN	for
COVID-19	NP	<unknown>
Vaccines	NNS	vaccine
in	IN	in
the	DT	the
Light	NP	Light
of	IN	of
Catholic	NP	Catholic
Social	NP	Social
Teaching	NN	teaching
Using	VBG	use
the	DT	the
Roman	NP	Roman
Catholic	NP	Catholic
Church	NP	Church
's	POS	's
set	NN	set
of	IN	of
moral	JJ	moral
principles	NNS	principle
on	IN	on
social	JJ	social
concerns	NNS	concern
called	VBD	call
Catholic	JJ	Catholic
social	JJ	social
teaching	NN	teaching
(	(	(
CST	NP	CST
)	)	)
and	CC	and
utilizing	VBG	utilize
some	DT	some
secondary	JJ	secondary
data	NNS	datum
and	CC	and
scientific	JJ	scientific
research	NN	research
literature	NN	literature
,	,	,
this	DT	this
article	NN	article
examines	VBZ	examine
the	DT	the
morality	NN	morality
of	IN	of
India	NP	India
and	CC	and
South	NP	South
Africa	NP	Africa
's	POS	's
request	NN	request
to	TO	to
the	DT	the
World	NP	World
Trade	NP	Trade
Organization	NP	Organization
(	(	(
WTO	NP	WTO
)	)	)
to	TO	to
temporarily	RB	temporarily
suspend	VB	suspend
the	DT	the
property	NN	property
rights	NNS	right
and	CC	and
patents	NNS	patent
of	IN	of
top	JJ	top
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
to	TO	to
their	PP$	their
vaccines	NNS	vaccine
to	TO	to
allow	VB	allow
low-income	JJ	low-income
countries	NNS	country
to	TO	to
locally	RB	locally
manufacture	VB	manufacture
them	PP	them
to	TO	to
save	VB	save
the	DT	the
lives	NNS	life
of	IN	of
the	DT	the
poor	JJ	poor
during	IN	during
this	DT	this
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Applying	VBG	apply
the	DT	the
theological	JJ	theological
method	NN	method
of	IN	of
"	``	"
See-Judge-and-Act	NP	<unknown>
,	,	,
"	''	"
this	DT	this
article	NN	article
argues	VBZ	argue
that	IN	that
the	DT	the
suspension	NN	suspension
of	IN	of
patents	NNS	patent
for	IN	for
COVID	NP	<unknown>
vaccines	NNS	vaccine
is	VBZ	be
morally	RB	morally
justifiable	JJ	justifiable
in	IN	in
the	DT	the
light	NN	light
of	IN	of
CST	NP	CST
's	POS	's
principles	NNS	principle
on	IN	on
the	DT	the
universal	JJ	universal
destination	NN	destination
of	IN	of
earth	NN	earth
's	POS	's
goods	NNS	good
,	,	,
the	DT	the
common	JJ	common
good	NN	good
,	,	,
and	CC	and
preferential	JJ	preferential
option	NN	option
for	IN	for
the	DT	the
poor	JJ	poor
.	SENT	.
The	DT	the
top	JJ	top
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
cannot	MD	can
claim	VB	claim
absolute	JJ	absolute
ownership	NN	ownership
to	TO	to
their	PP$	their
vaccines	NNS	vaccine
as	IN	as
they	PP	they
do	VBP	do
not	RB	not
totally	RB	totally
own	VB	own
and	CC	and
fund	VB	fund
the	DT	the
entire	JJ	entire
development	NN	development
and	CC	and
production	NN	production
process	NN	process
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
right	NN	right
to	TO	to
private	JJ	private
ownership	NN	ownership
and	CC	and
patents	NNS	patent
has	VBZ	have
a	DT	a
social	JJ	social
dimension	NN	dimension
and	CC	and
must	MD	must
serve	VB	serve
the	DT	the
common	JJ	common
good	NN	good
and	CC	and
welfare	NN	welfare
of	IN	of
the	DT	the
poor	JJ	poor
,	,	,
especially	RB	especially
in	IN	in
times	NNS	time
of	IN	of
global	JJ	global
emergency	NN	emergency
such	JJ	such
as	IN	as
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Patent	NN	patent
holders	NNS	holder
have	VBP	have
a	DT	a
moral	JJ	moral
obligation	NN	obligation
to	TO	to
promote	VB	promote
the	DT	the
common	JJ	common
good	JJ	good
and	CC	and
save	VB	save
the	DT	the
lives	NNS	life
of	IN	of
the	DT	the
poor	NN	poor
which	WDT	which
must	MD	must
prevail	VB	prevail
over	RP	over
their	PP$	their
capitalist	JJ	capitalist
quest	NN	quest
for	IN	for
profit	NN	profit
.	SENT	.
This	DT	this
article	NN	article
recommends	VBZ	recommend
that	DT	that
Catholics	NPS	Catholics
and	CC	and
Christians	NPS	Christian
must	MD	must
join	VB	join
this	DT	this
crusade	NN	crusade
for	IN	for
the	DT	the
suspension	NN	suspension
of	IN	of
patents	NNS	patent
as	IN	as
part	NN	part
of	IN	of
their	PP$	their
spirituality	NN	spirituality
of	IN	of
social	JJ	social
transformation	NN	transformation
.	SENT	.
Summary	NN	summary
:	:	:
Applying	VBG	apply
the	DT	the
Roman	NP	Roman
Catholic	NP	Catholic
Church	NP	Church
's	POS	's
set	NN	set
of	IN	of
moral	JJ	moral
principles	NNS	principle
on	IN	on
social	JJ	social
concerns	NNS	concern
called	VBD	call
CST	NP	CST
and	CC	and
utilizing	VBG	utilize
some	DT	some
secondary	JJ	secondary
data	NNS	datum
and	CC	and
scientific	JJ	scientific
research	NN	research
literature	NN	literature
,	,	,
this	DT	this
article	NN	article
examines	VBZ	examine
the	DT	the
morality	NN	morality
of	IN	of
India	NP	India
and	CC	and
South	NP	South
Africa	NP	Africa
's	POS	's
request	NN	request
to	TO	to
the	DT	the
World	NP	World
Trade	NP	Trade
Organization	NP	Organization
to	TO	to
temporarily	RB	temporarily
suspend	VB	suspend
the	DT	the
property	NN	property
rights	NNS	right
and	CC	and
patents	NNS	patent
of	IN	of
top	JJ	top
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
to	TO	to
their	PP$	their
vaccines	NNS	vaccine
to	TO	to
allow	VB	allow
low-income	JJ	low-income
countries	NNS	country
to	TO	to
locally	RB	locally
manufacture	VB	manufacture
them	PP	them
to	TO	to
save	VB	save
the	DT	the
lives	NNS	life
of	IN	of
the	DT	the
poor	JJ	poor
during	IN	during
the	DT	the
current	JJ	current
pandemic	NN	pandemic
.	SENT	.
Applying	VBG	apply
the	DT	the
theological	JJ	theological
method	NN	method
of	IN	of
"	``	"
See-Judge-and-Act	NP	<unknown>
,	,	,
"	''	"
this	DT	this
article	NN	article
argues	VBZ	argue
that	IN	that
the	DT	the
suspension	NN	suspension
of	IN	of
patents	NNS	patent
for	IN	for
COVID	NP	<unknown>
vaccines	NNS	vaccine
is	VBZ	be
morally	RB	morally
justifiable	JJ	justifiable
in	IN	in
the	DT	the
light	NN	light
of	IN	of
CST	NP	CST
's	POS	's
principles	NNS	principle
on	IN	on
the	DT	the
universal	JJ	universal
destination	NN	destination
of	IN	of
earth	NN	earth
goods	NNS	good
,	,	,
the	DT	the
common	JJ	common
good	NN	good
,	,	,
and	CC	and
preferential	JJ	preferential
option	NN	option
for	IN	for
the	DT	the
poor	JJ	poor
.	SENT	.
It	PP	it
recommends	VBZ	recommend
that	IN	that
Catholics	NPS	Catholics
and	CC	and
Christians	NPS	Christian
must	MD	must
join	VB	join
this	DT	this
crusade	NN	crusade
for	IN	for
the	DT	the
suspension	NN	suspension
of	IN	of
patents	NNS	patent
as	IN	as
part	NN	part
of	IN	of
their	PP$	their
spirituality	NN	spirituality
of	IN	of
social	JJ	social
transformation	NN	transformation
.	SENT	.
Short	JJ	short
Summary	NN	summary
:	:	:
This	DT	this
article	NN	article
argues	VBZ	argue
that	IN	that
patents	NNS	patent
of	IN	of
the	DT	the
top	JJ	top
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
to	TO	to
their	PP$	their
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
must	MD	must
be	VB	be
suspended	VBN	suspend
as	IN	as
requested	VBN	request
by	IN	by
India	NP	India
and	CC	and
South	NP	South
Africa	NP	Africa
in	IN	in
the	DT	the
WTO	NP	WTO
in	IN	in
the	DT	the
light	NN	light
of	IN	of
CST	NP	CST
's	POS	's
moral	JJ	moral
principles	NNS	principle
on	IN	on
the	DT	the
universal	JJ	universal
destination	NN	destination
of	IN	of
earth	NN	earth
's	POS	's
goods	NNS	good
,	,	,
the	DT	the
common	JJ	common
good	NN	good
,	,	,
and	CC	and
preferential	JJ	preferential
option	NN	option
for	IN	for
the	DT	the
poor	JJ	poor
.	SENT	.
32493494/	CD	@card@
Controlled	JJ	controlled
,	,	,
double-blind	JJ	double-blind
,	,	,
randomized	VBD	randomize
trial	NN	trial
to	TO	to
assess	VB	assess
the	DT	the
efficacy	NN	efficacy
and	CC	and
safety	NN	safety
of	IN	of
hydroxychloroquine	JJ	<unknown>
chemoprophylaxis	NN	chemoprophylaxis
in	IN	in
SARS	NP	<unknown>
CoV2	NP	<unknown>
infection	NN	infection
in	IN	in
healthcare	NN	<unknown>
personnel	NNS	personnel
in	IN	in
the	DT	the
hospital	NN	hospital
setting	NN	setting
:	:	:
A	DT	a
structured	JJ	structured
summary	NN	summary
of	IN	of
a	DT	a
study	NN	study
protocol	NN	protocol
for	IN	for
a	DT	a
randomised	VBN	randomise
controlled	JJ	controlled
trial	NN	trial
SARS-CoV-2	NP	<unknown>
infection	NN	infection
presents	VBZ	present
a	DT	a
high	JJ	high
transmission	NN	transmission
in	IN	in
the	DT	the
group	NN	group
of	IN	of
health	NN	health
professionals	NNS	professional
in	IN	in
Spain	NP	Spain
(	(	(
12-15	CD	@card@
%	NN	%
infected	VBN	infect
)	)	)
.	SENT	.
Currently	RB	currently
there	EX	there
is	VBZ	be
no	DT	no
accepted	JJ	accepted
chemoprophylaxis	NN	chemoprophylaxis
but	CC	but
hydroxychloroquine	NN	hydroxychloroquine
(	(	(
HDQ	NP	HDQ
)	)	)
is	VBZ	be
known	VBN	know
to	TO	to
inhibit	VB	inhibit
the	DT	the
coronavirus	NN	coronavirus
in	IN	in
vitro	NN	<unknown>
.	SENT	.
Our	PP$	our
hypothesis	NN	hypothesis
is	VBZ	be
that	IN	that
oral	JJ	oral
administration	NN	administration
of	IN	of
hydroxychloroquine	NN	hydroxychloroquine
to	TO	to
healthcare	NN	<unknown>
professionals	NNS	professional
can	MD	can
reduce	VB	reduce
the	DT	the
incidence	NN	incidence
and	CC	and
prevalence	NN	prevalence
of	IN	of
infection	NN	infection
as	RB	as
well	RB	well
as	IN	as
its	PP$	its
severity	NN	severity
in	IN	in
this	DT	this
group	NN	group
.	SENT	.
Design	NN	design
:	:	:
Prospective	JJ	prospective
,	,	,
single	JJ	single
center	NN	center
,	,	,
double	RB	double
blind	JJ	blind
,	,	,
randomised	VBN	randomise
,	,	,
controlled	VBN	control
trial	NN	trial
(	(	(
RCT	NP	RCT
)	)	)
.	SENT	.
Participants	NNS	participant
:	:	:
Adult	JJ	adult
health-care	JJ	health-care
professionals	NNS	professional
(	(	(
18-65	CD	@card@
years	NNS	year
)	)	)
working	VBG	work
in	IN	in
areas	NNS	area
of	IN	of
high	JJ	high
exposure	NN	exposure
and	CC	and
high	JJ	high
risk	NN	risk
of	IN	of
transmission	NN	transmission
of	IN	of
SARS-COV-2	NP	<unknown>
(	(	(
COVID	NP	<unknown>
areas	NNS	area
,	,	,
Intensive	JJ	intensive
Care	NP	Care
Unit	NP	Unit
-ICUs-	NN	<unknown>
,	,	,
Emergency	NP	Emergency
,	,	,
Anesthesia	NN	anesthesia
and	CC	and
all	PDT	all
those	DT	those
performing	VBG	perform
aerosol-generating	NN	aerosol-generating
procedures	NNS	procedure
)	)	)
will	MD	will
be	VB	be
included	VBN	include
.	SENT	.
Exclusion	NN	exclusion
criteria	NNS	criterion
include	VBP	include
previous	JJ	previous
infection	NN	infection
with	IN	with
SARS	NP	<unknown>
CoV2	NP	<unknown>
(	(	(
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
PCR	NP	PCR
or	CC	or
IgG	NP	IgG
serology	NN	serology
)	)	)
,	,	,
pregnancy	NN	pregnancy
or	CC	or
lactation	NN	lactation
,	,	,
any	DT	any
contraindication	NN	contraindication
to	TO	to
hydroxychloroquine	NN	hydroxychloroquine
or	CC	or
evidence	NN	evidence
of	IN	of
unstable	JJ	unstable
or	CC	or
clinically	RB	clinically
significant	JJ	significant
systemic	JJ	systemic
disease	NN	disease
.	SENT	.
Patients	NNS	patient
will	MD	will
be	VB	be
randomized	VBN	randomize
(	(	(
1:1	CD	@card@
)	)	)
to	TO	to
receive	VB	receive
once-daily	RB	once-daily
oral	JJ	oral
Hydroxychloroquine	NP	Hydroxychloroquine
200mg	JJ	<unknown>
for	IN	for
two	CD	two
months	NNS	month
(	(	(
HC	NP	HC
group	NN	group
)	)	)
or	CC	or
placebo	NN	placebo
(	(	(
P	NN	P
group	NN	group
)	)	)
in	IN	in
addition	NN	addition
to	TO	to
the	DT	the
protective	JJ	protective
measures	NNS	measure
appropriate	JJ	appropriate
to	TO	to
the	DT	the
level	NN	level
of	IN	of
exposure	NN	exposure
established	VBN	establish
by	IN	by
the	DT	the
hospital	NN	hospital
.	SENT	.
A	DT	a
serological	JJ	serological
evaluation	NN	evaluation
will	MD	will
be	VB	be
carried	VBN	carry
out	IN	out
every	DT	every
15	CD	@card@
days	NNS	day
with	IN	with
PCR	NP	PCR
in	IN	in
case	NN	case
of	IN	of
seroconversion	NN	seroconversion
,	,	,
symptoms	NNS	symptom
or	CC	or
risk	NN	risk
exposure	NN	exposure
.	SENT	.
Primary	JJ	primary
outcome	NN	outcome
is	VBZ	be
the	DT	the
percentage	NN	percentage
of	IN	of
subjects	NNS	subject
presenting	VBG	present
infection	NN	infection
(	(	(
seroconversion	NN	seroconversion
and/or	CC	and/or
PCR	NP	PCR
+ve	NN	+ve
)	)	)
by	IN	by
the	DT	the
SARS-Cov-2	NP	<unknown>
virus	NN	virus
during	IN	during
the	DT	the
observation	NN	observation
period	NN	period
.	SENT	.
Additionally	RB	additionally
,	,	,
both	CC	both
the	DT	the
percentage	NN	percentage
of	IN	of
subjects	NNS	subject
in	IN	in
each	DT	each
group	NN	group
presenting	VBG	present
Pneumonia	NN	pneumonia
with	IN	with
severity	NN	severity
criteria	NNS	criterion
(	(	(
Curb	NP	Curb
65	CD	@card@
&gt	NN	&gt
;	:	;
=2	NP	<unknown>
)	)	)
and	CC	and
that	IN	that
of	IN	of
subjects	NNS	subject
requiring	VBG	require
admission	NN	admission
to	TO	to
ICU	NP	ICU
will	MD	will
be	VB	be
determined	VBN	determine
.	SENT	.
While	IN	while
awaiting	VBG	await
a	DT	a
vaccine	NN	vaccine
,	,	,
hygiene	NN	hygiene
measures	NNS	measure
,	,	,
social	JJ	social
distancing	NN	distancing
and	CC	and
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
are	VBP	be
the	DT	the
only	JJ	only
primary	JJ	primary
prophylaxis	NN	prophylaxis
measures	NNS	measure
against	IN	against
SARS-CoV-2	NP	<unknown>
,	,	,
but	CC	but
they	PP	they
have	VBP	have
not	RB	not
been	VBN	be
sufficient	JJ	sufficient
to	TO	to
protect	VB	protect
our	PP$	our
healthcare	NN	<unknown>
professionals	NNS	professional
.	SENT	.
Some	DT	some
evidence	NN	evidence
of	IN	of
the	DT	the
in	IN	in
vitro	NN	<unknown>
efficacy	NN	efficacy
of	IN	of
hydroxychloroquine	NN	hydroxychloroquine
against	IN	against
this	DT	this
virus	NN	virus
is	VBZ	be
known	VBN	know
,	,	,
along	RB	along
with	IN	with
some	DT	some
clinical	JJ	clinical
data	NNS	datum
that	WDT	that
would	MD	would
support	VB	support
the	DT	the
study	NN	study
of	IN	of
this	DT	this
drug	NN	drug
in	IN	in
the	DT	the
chemoprophylaxis	NN	chemoprophylaxis
of	IN	of
infection	NN	infection
.	SENT	.
However	RB	however
,	,	,
there	EX	there
are	VBP	be
still	RB	still
no	DT	no
data	NNS	datum
from	IN	from
controlled	VBN	control
clinical	JJ	clinical
trials	NNS	trial
in	IN	in
this	DT	this
regard	NN	regard
.	SENT	.
If	IN	if
our	PP$	our
hypothesis	NN	hypothesis
is	VBZ	be
confirmed	VBN	confirm
,	,	,
hydroxychloroquine	NN	hydroxychloroquine
can	MD	can
help	VB	help
professionals	NNS	professional
fight	VB	fight
this	DT	this
infection	NN	infection
with	IN	with
more	JJR	more
guarantees	NNS	guarantee
.	SENT	.
This	DT	this
is	VBZ	be
a	DT	a
single-center	NN	single-center
study	NN	study
that	WDT	that
will	MD	will
be	VB	be
carried	VBN	carry
out	RP	out
at	IN	at
the	DT	the
Marques	NP	Marques
de	NP	de
Valdecilla	NP	Valdecilla
University	NP	University
Hospital	NP	Hospital
.	SENT	.
450	CD	@card@
health	NN	health
professionals	NNS	professional
working	VBG	work
at	IN	at
the	DT	the
Hospital	NP	Hospital
Universitario	NP	<unknown>
Marques	NP	Marques
de	NP	de
Valdecilla	NP	Valdecilla
in	IN	in
areas	NNS	area
of	IN	of
high	JJ	high
exposure	NN	exposure
and	CC	and
high	JJ	high
risk	NN	risk
of	IN	of
transmission	NN	transmission
of	IN	of
SARS	NP	<unknown>
COV2	NP	<unknown>
(	(	(
COVID	NP	<unknown>
hospital	NN	hospital
areas	NNS	area
,	,	,
Intensive	JJ	intensive
Care	NP	Care
Unit	NP	Unit
,	,	,
Emergency	NP	Emergency
,	,	,
Anesthesia	NN	anesthesia
and	CC	and
all	PDT	all
those	DT	those
performing	VBG	perform
aerosol-generating	NN	aerosol-generating
procedures	NNS	procedure
)	)	)
will	MD	will
be	VB	be
included	VBN	include
.	SENT	.
Inclusion	NN	inclusion
criteria	NNS	criterion
:	:	:
1	LS	1
)	)	)
Health	NP	Health
professionals	NNS	professional
aged	VBN	age
between	IN	between
18	CD	@card@
and	CC	and
65	CD	@card@
years	NNS	year
(	(	(
inclusive	JJ	inclusive
)	)	)
at	IN	at
the	DT	the
time	NN	time
of	IN	of
the	DT	the
first	JJ	first
screening	NN	screening
visit	NN	visit
;	:	;
2	LS	2
)	)	)
They	PP	they
must	MD	must
provide	VB	provide
signed	VBN	sign
written	JJ	written
informed	JJ	informed
consent	NN	consent
and	CC	and
agree	VBP	agree
to	TO	to
comply	VB	comply
with	IN	with
the	DT	the
study	NN	study
protocol	NN	protocol
;	:	;
3	LS	3
)	)	)
Active	JJ	active
work	NN	work
in	IN	in
high	JJ	high
exposure	NN	exposure
areas	NNS	area
during	IN	during
the	DT	the
last	JJ	last
two	CD	two
weeks	NNS	week
and	CC	and
during	IN	during
the	DT	the
following	VBG	follow
weeks	NNS	week
.	SENT	.
Exclusion	NN	exclusion
criteria	NNS	criterion
:	:	:
1	LS	1
)	)	)
Previous	JJ	previous
infection	NN	infection
with	IN	with
SARS	NP	<unknown>
CoV2	NP	<unknown>
(	(	(
positive	JJ	positive
coronavirus	NN	coronavirus
PCR	NP	PCR
or	CC	or
positive	JJ	positive
serology	NN	serology
with	IN	with
SARS	NP	<unknown>
Cov2	NP	<unknown>
negative	JJ	negative
PCR	NP	PCR
and	CC	and
absence	NN	absence
of	IN	of
symptoms	NNS	symptom
)	)	)
;	:	;
2	LS	2
)	)	)
Current	JJ	current
treatment	NN	treatment
with	IN	with
hydroxychloroquine	NN	hydroxychloroquine
or	CC	or
chloroquine	NN	chloroquine
;	:	;
3	LS	3
)	)	)
Hypersensitivity	NN	hypersensitivity
,	,	,
allergy	NN	allergy
or	CC	or
any	DT	any
contraindication	NN	contraindication
for	IN	for
taking	VBG	take
hydroxychloroquine	NN	hydroxychloroquine
,	,	,
in	IN	in
the	DT	the
technical	JJ	technical
sheet	NN	sheet
;	:	;
4	LS	4
)	)	)
Previous	JJ	previous
or	CC	or
current	JJ	current
treatment	NN	treatment
with	IN	with
tamoxifen	NP	tamoxifen
or	CC	or
raloxifene	NP	<unknown>
;	:	;
5	LS	5
)	)	)
Previous	JJ	previous
eye	NN	eye
disease	NN	disease
,	,	,
especially	RB	especially
maculopathy	NN	<unknown>
;	:	;
6	CD	@card@
)	)	)
Known	VBN	know
heart	NN	heart
failure	NN	failure
(	(	(
Grade	NP	Grade
III	NP	III
to	TO	to
IV	NP	IV
of	IN	of
the	DT	the
New	NP	New
York	NP	York
Heart	NP	Heart
Association	NP	Association
classification	NN	classification
)	)	)
or	CC	or
prolonged	JJ	prolonged
QTc	NP	QTc
;	:	;
7	CD	@card@
)	)	)
Any	DT	any
type	NN	type
of	IN	of
cancer	NN	cancer
(	(	(
except	IN	except
basal	JJ	basal
cell	NN	cell
)	)	)
in	IN	in
the	DT	the
last	JJ	last
5	CD	@card@
years	NNS	year
;	:	;
6	CD	@card@
)	)	)
Refusal	NN	refusal
to	TO	to
give	VB	give
informed	JJ	informed
consent	NN	consent
;	:	;
8	CD	@card@
)	)	)
Evidence	NN	evidence
of	IN	of
any	DT	any
other	JJ	other
unstable	JJ	unstable
or	CC	or
clinically	RB	clinically
significant	JJ	significant
untreated	JJ	untreated
immune	JJ	immune
,	,	,
endocrine	JJ	endocrine
,	,	,
hematological	JJ	hematological
,	,	,
gastrointestinal	JJ	gastrointestinal
,	,	,
neurological	JJ	neurological
,	,	,
neoplastic	JJ	neoplastic
or	CC	or
psychiatric	JJ	psychiatric
illness	NN	illness
;	:	;
9	CD	@card@
)	)	)
Antibodies	NNS	antibody
positive	JJ	positive
for	IN	for
the	DT	the
human	JJ	human
immunodeficiency	NN	immunodeficiency
virus	NN	virus
;	:	;
10	LS	@card@
)	)	)
Significant	JJ	significant
kidney	NN	kidney
or	CC	or
liver	NN	liver
disease	NN	disease
;	:	;
11	LS	@card@
)	)	)
Pregnancy	NN	pregnancy
or	CC	or
lactation	NN	lactation
.	SENT	.
Intervention	NN	intervention
:	:	:
(	(	(
n	NN	n
=	SYM	=
225	CD	@card@
)	)	)
:	:	:
One	CD	one
200	CD	@card@
mg	NN	mg
hydroxychloroquine	NN	hydroxychloroquine
sulfate	NN	sulfate
coated	JJ	coated
tablet	NN	tablet
once	RB	once
daily	JJ	daily
for	IN	for
two	CD	two
months	NNS	month
.	SENT	.
Comparator	NN	comparator
(	(	(
control	NN	control
group	NN	group
)	)	)
(	(	(
n	NN	n
=	SYM	=
225	CD	@card@
)	)	)
:	:	:
One	CD	one
hydroxychloroquine	NN	hydroxychloroquine
placebo	NN	placebo
tablet	NN	tablet
(	(	(
identical	JJ	identical
to	TO	to
that	DT	that
of	IN	of
the	DT	the
drug	NN	drug
)	)	)
once	RB	once
daily	JJ	daily
for	IN	for
two	CD	two
months	NNS	month
Two	CD	two
groups	NNS	group
will	MD	will
be	VB	be
analyzed	VBN	analyze
with	IN	with
a	DT	a
1	CD	@card@
:	:	:
1	CD	@card@
randomization	NN	randomization
rate	NN	rate
.	SENT	.
number	NN	number
and	CC	and
percentage	NN	percentage
of	IN	of
healthcare	NN	<unknown>
personnel	NNS	personnel
presenting	VBG	present
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
infection	NN	infection
(	(	(
see	VB	see
"	``	"
Diagnosis	NN	diagnosis
of	IN	of
SARS	NP	<unknown>
CoV2	NP	<unknown>
infection	NN	infection
"	''	"
below	IN	below
)	)	)
by	IN	by
the	DT	the
SARS-Cov2	NP	<unknown>
virus	NN	virus
during	IN	during
the	DT	the
study	NN	study
observation	NN	observation
period	NN	period
(	(	(
8	CD	@card@
weeks	NNS	week
)	)	)
in	IN	in
both	DT	both
treatment	NN	treatment
arms	NNS	arm
;	:	;
number	NN	number
and	CC	and
percentage	NN	percentage
of	IN	of
healthcare	NN	<unknown>
personnel	NNS	personnel
in	IN	in
each	DT	each
group	NN	group
presenting	VBG	present
with	IN	with
Pneumonia	NN	pneumonia
with	IN	with
severity	NN	severity
criteria	NNS	criterion
(	(	(
Curb	NP	Curb
65	CD	@card@
&gt	NN	&gt
;	:	;
=2	NP	<unknown>
)	)	)
and	CC	and
number	NN	number
and	CC	and
percentage	NN	percentage
of	IN	of
healthcare	NN	<unknown>
personnel	NNS	personnel
requiring	VBG	require
admission	NN	admission
to	TO	to
the	DT	the
Intensive	JJ	intensive
Care	NP	Care
Unit	NP	Unit
(	(	(
ICU	NP	ICU
)	)	)
in	IN	in
both	DT	both
treatment	NN	treatment
arms	NNS	arm
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
of	IN	of
this	DT	this
study	NN	study
will	MD	will
be	VB	be
to	TO	to
evaluate	VB	evaluate
:	:	:
Determination	NN	determination
of	IN	of
IgA	NP	IgA
,	,	,
IgM	NP	Igm
and	CC	and
IgG	NP	IgG
type	NN	type
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
using	VBG	use
the	DT	the
Anti-SARS-CoV-2	JJ	<unknown>
ELISA	NP	Elisa
kit	NN	kit
(	(	(
EUROIMMUN	NP	<unknown>
Medizinische	NP	<unknown>
Labordiagnostika	NP	Labordiagnostika
AG	NP	AG
,	,	,
Germany	NP	Germany
)	)	)
every	DT	every
two	CD	two
weeks	NNS	week
.	SENT	.
In	IN	in
cases	NNS	case
of	IN	of
seroconversion	NN	seroconversion
,	,	,
a	DT	a
SARS-CoV-2	NP	<unknown>
PCR	NP	PCR
will	MD	will
be	VB	be
performed	VBN	perform
to	TO	to
rule	VB	rule
out	RP	out
/	SYM	/
confirm	VB	confirm
an	DT	an
active	JJ	active
infection	NN	infection
(	(	(
RT-PCR	NP	<unknown>
in	IN	in
One	CD	one
Step	NN	step
:	:	:
RT	NP	RT
performed	VBD	perform
with	IN	with
mastermix	NN	<unknown>
(	(	(
Takara	NP	Takara
)	)	)
and	CC	and
IDT	NP	Idt
probes	NNS	probe
,	,	,
following	VBG	follow
protocol	NN	protocol
published	VBN	publish
and	CC	and
validated	VBN	validate
by	IN	by
the	DT	the
CDC	NP	CDC
Evaluation	NN	evaluation
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
case	NN	case
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
Participants	NNS	participant
will	MD	will
be	VB	be
allocated	VBN	allocate
to	TO	to
intervention	NN	intervention
and	CC	and
comparator	NN	comparator
groups	NNS	group
according	VBG	accord
to	TO	to
a	DT	a
balanced	JJ	balanced
randomization	NN	randomization
scheme	NN	scheme
(	(	(
1	CD	@card@
:	:	:
1	LS	1
)	)	)
.	SENT	.
The	DT	the
assignment	NN	assignment
will	MD	will
be	VB	be
made	VBN	make
through	IN	through
a	DT	a
computer-generated	JJ	computer-generated
numeric	JJ	numeric
sequence	NN	sequence
for	IN	for
all	DT	all
participants	NNS	participant
Both	CC	both
participants	NNS	participant
and	CC	and
investigators	NNS	investigator
responsible	JJ	responsible
for	IN	for
recruiting	VBG	recruit
and	CC	and
monitoring	VBG	monitor
participants	NNS	participant
will	MD	will
be	VB	be
blind	JJ	blind
to	TO	to
the	DT	the
assigned	JJ	assigned
arm	NN	arm
.	SENT	.
Taking	VBG	take
into	IN	into
account	NN	account
the	DT	the
current	JJ	current
high	JJ	high
prevalence	NN	prevalence
of	IN	of
infection	NN	infection
in	IN	in
healthcare	NN	<unknown>
personnel	NNS	personnel
in	IN	in
Spain	NP	Spain
(	(	(
up	RB	up
to	TO	to
15	CD	@card@
%	NN	%
)	)	)
,	,	,
to	TO	to
detect	VB	detect
a	DT	a
difference	NN	difference
equal	JJ	equal
to	TO	to
or	CC	or
greater	JJR	great
than	IN	than
8	CD	@card@
%	NN	%
in	IN	in
the	DT	the
percentage	NN	percentage
estimates	VBZ	estimate
through	IN	through
a	DT	a
two-tailed	JJ	<unknown>
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
with	IN	with
a	DT	a
statistical	JJ	statistical
power	NN	power
of	IN	of
80	CD	@card@
%	NN	%
and	CC	and
a	DT	a
dropout	NN	dropout
rate	NN	rate
of	IN	of
5	CD	@card@
%	NN	%
,	,	,
a	DT	a
total	NN	total
of	IN	of
450	CD	@card@
participants	NNS	participant
will	MD	will
need	VB	need
to	TO	to
be	VB	be
included	JJ	included
(	(	(
250	CD	@card@
in	IN	in
each	DT	each
arm	NN	arm
)	)	)
.	SENT	.
The	DT	the
protocol	NN	protocol
approved	VBN	approve
by	IN	by
the	DT	the
health	NN	health
authorities	NNS	authority
in	IN	in
Spain	NP	Spain
(	(	(
Spanish	NP	Spanish
Agency	NP	Agency
for	IN	for
Medicines	NNS	medicine
and	CC	and
Health	NP	Health
Products	NP	Products
"	``	"
AEMPS	NP	<unknown>
"	''	"
)	)	)
and	CC	and
the	DT	the
Ethics	NP	Ethics
and	CC	and
Research	NP	Research
Committee	NP	Committee
of	IN	of
Cantabria	NP	<unknown>
(	(	(
CEIm	NP	<unknown>
Cantabria	NP	<unknown>
)	)	)
corresponds	VBZ	correspond
to	TO	to
version	NN	version
1.1	CD	@card@
of	IN	of
April	NP	April
2	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
Currently	RB	currently
,	,	,
recruitment	NN	recruitment
has	VBZ	have
not	RB	not
yet	RB	yet
started	VBN	start
,	,	,
with	IN	with
the	DT	the
start	NN	start
scheduled	VBN	schedule
for	IN	for
the	DT	the
second	JJ	second
week	NN	week
of	IN	of
May	NP	May
2020	CD	@card@
.	SENT	.
Eudra	NP	<unknown>
CT	NP	CT
number	NN	number
:	:	:
2020-001704-42	NP	@card@
(	(	(
Registered	NP	Registered
on	IN	on
29	CD	@card@
March	NP	March
2020	CD	@card@
)	)	)
The	DT	the
full	JJ	full
protocol	NN	protocol
is	VBZ	be
attached	VBN	attach
as	IN	as
an	DT	an
additional	JJ	additional
file	NN	file
,	,	,
accessible	JJ	accessible
from	IN	from
the	DT	the
Trials	NNS	trial
website	NN	website
(	(	(
Additional	JJ	additional
file	NN	file
1	CD	@card@
)	)	)
.	SENT	.
In	IN	in
the	DT	the
interest	NN	interest
in	IN	in
expediting	VBG	expedite
dissemination	NN	dissemination
of	IN	of
this	DT	this
material	NN	material
,	,	,
the	DT	the
familiar	JJ	familiar
formatting	VBG	format
has	VBZ	have
been	VBN	be
eliminated	VBN	eliminate
;	:	;
this	DT	this
Letter	NN	letter
serves	VBZ	serve
as	IN	as
a	DT	a
summary	NN	summary
of	IN	of
the	DT	the
key	JJ	key
elements	NNS	element
of	IN	of
the	DT	the
full	JJ	full
protocol	NN	protocol
.	SENT	.
The	DT	the
study	NN	study
protocol	NN	protocol
has	VBZ	have
been	VBN	be
reported	VBN	report
in	IN	in
accordance	NN	accordance
with	IN	with
the	DT	the
Standard	NP	Standard
Protocol	NP	Protocol
Items	NNS	item
:	:	:
Recommendations	NNS	recommendation
for	IN	for
Clinical	JJ	clinical
Interventional	JJ	interventional
Trials	NNS	trial
(	(	(
SPIRIT	NN	spirit
)	)	)
guidelines	NNS	guideline
(	(	(
Additional	JJ	additional
file	NN	file
2	CD	@card@
)	)	)
.	SENT	.
32330531/	CD	@card@
Managing	VBG	manage
Urology	NN	urology
Consultations	NNS	consultation
During	IN	during
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
Application	NN	application
of	IN	of
a	DT	a
Structured	JJ	structured
Care	NP	Care
Pathway	NN	pathway
To	TO	to
describe	VB	describe
and	CC	and
evaluate	VB	evaluate
a	DT	a
risk-stratified	JJ	<unknown>
triage	NN	triage
pathway	NN	pathway
for	IN	for
inpatient	NN	inpatient
urology	NN	urology
consultations	NNS	consultation
during	IN	during
the	DT	the
SARS-CoV-2	NP	<unknown>
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
.	SENT	.
This	DT	this
pathway	NN	pathway
seeks	VBZ	seek
to	TO	to
outline	VB	outline
a	DT	a
urology	NN	urology
patient	NN	patient
care	NN	care
strategy	NN	strategy
that	WDT	that
reduces	VBZ	reduce
the	DT	the
transmission	NN	transmission
risk	NN	risk
to	TO	to
both	DT	both
healthcare	NN	<unknown>
providers	NNS	provider
and	CC	and
patients	NNS	patient
,	,	,
reduces	VBZ	reduce
the	DT	the
healthcare	NN	<unknown>
burden	NN	burden
,	,	,
and	CC	and
maintains	VBZ	maintain
appropriate	JJ	appropriate
patient	JJ	patient
care	NN	care
.	SENT	.
Consultations	NNS	consultation
to	TO	to
the	DT	the
urology	NN	urology
service	NN	service
during	IN	during
a	DT	a
3-week	JJ	<unknown>
period	NN	period
(	(	(
March	NP	March
16	CD	@card@
to	TO	to
April	NP	April
2	CD	@card@
,	,	,
2020	CD	@card@
)	)	)
were	VBD	be
triaged	VBN	<unknown>
and	CC	and
managed	VBN	manage
via	IN	via
one	CD	one
of	IN	of
3	CD	@card@
pathways	NNS	pathway
:	:	:
Standard	NP	Standard
,	,	,
Telemedicine	NP	Telemedicine
,	,	,
or	CC	or
High-Risk	JJ	high-risk
.	SENT	.
Standard	NP	Standard
consults	VBZ	consult
were	VBD	be
in-person	NN	in-person
consults	VBZ	consult
with	IN	with
non	JJ	non
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
High-Risk	JJ	high-risk
consults	VBZ	consult
were	VBD	be
in-person	NN	in-person
consults	VBZ	consult
with	IN	with
COVID-19	NP	<unknown>
positive/suspected	JJ	positive/suspected
patients	NNS	patient
,	,	,
and	CC	and
Telemedicine	NP	Telemedicine
consults	VBZ	consult
were	VBD	be
telephonic	JJ	telephonic
consults	VBZ	consult
for	IN	for
low-acuity	NN	low-acuity
urologic	JJ	urologic
issues	NNS	issue
in	IN	in
either	DT	either
group	NN	group
of	IN	of
patients	NNS	patient
.	SENT	.
Patient	JJ	patient
demographics	NNS	demographic
,	,	,
consultation	NN	consultation
parameters	NNS	parameter
and	CC	and
consultation	NN	consultation
outcomes	NNS	outcome
were	VBD	be
compared	VBN	compare
to	TO	to
consultations	NNS	consultation
from	IN	from
the	DT	the
month	NN	month
of	IN	of
March	NP	March
2019	CD	@card@
.	SENT	.
Categorical	JJ	categorical
variables	NNS	variable
were	VBD	be
compared	VBN	compare
using	VBG	use
Chi-square	NP	Chi-square
test	NN	test
and	CC	and
continuous	JJ	continuous
variables	NNS	variable
using	VBG	use
Mann-Whitney	NP	Mann-Whitney
U	NP	U
test	NN	test
.	SENT	.
A	DT	a
P	NN	P
value	NN	value
&lt	NN	&lt
;	:	;
.05	CD	@card@
was	VBD	be
considered	VBN	consider
significant	JJ	significant
.	SENT	.
Between	IN	between
March	NP	March
16	CD	@card@
and	CC	and
April	NP	April
2	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
53	CD	@card@
inpatient	NN	inpatient
consultations	NNS	consultation
were	VBD	be
performed	VBN	perform
.	SENT	.
By	IN	by
following	VBG	follow
our	PP$	our
triage	NN	triage
pathway	NN	pathway
,	,	,
a	DT	a
total	NN	total
of	IN	of
19/53	CD	@card@
consultations	NNS	consultation
(	(	(
35.8	CD	@card@
%	NN	%
)	)	)
were	VBD	be
performed	VBN	perform
via	IN	via
Telemedicine	NP	Telemedicine
with	IN	with
no	DT	no
in-person	NN	in-person
exposure	NN	exposure
,	,	,
10/53	CD	@card@
consultations	NNS	consultation
(	(	(
18.9	CD	@card@
%	NN	%
)	)	)
were	VBD	be
High-Risk	JJ	high-risk
,	,	,
in	IN	in
which	WDT	which
we	PP	we
strictly	RB	strictly
controlled	VBD	control
the	DT	the
urology	NN	urology
team	NN	team
member	NN	member
in-person	NN	in-person
contact	NN	contact
,	,	,
and	CC	and
the	DT	the
remainder	NN	remainder
,	,	,
24/53	CD	@card@
consultations	NNS	consultation
(	(	(
45.2	CD	@card@
%	NN	%
)	)	)
,	,	,
were	VBD	be
performed	VBN	perform
as	IN	as
Standard	NP	Standard
in-person	NN	in-person
encounters	NNS	encounter
.	SENT	.
COVID-19	JJ	<unknown>
associated	JJ	associated
consultations	NNS	consultation
represented	VBD	represent
18/53	CD	@card@
(	(	(
34.0	CD	@card@
%	NN	%
)	)	)
of	IN	of
all	DT	all
consultations	NNS	consultation
during	IN	during
this	DT	this
period	NN	period
,	,	,
and	CC	and
of	IN	of
these	DT	these
,	,	,
8/18	CD	@card@
(	(	(
44.4	CD	@card@
%	NN	%
)	)	)
were	VBD	be
managed	VBN	manage
successfully	RB	successfully
via	IN	via
Telemedicine	NP	Telemedicine
alone	RB	alone
.	SENT	.
No	DT	no
team	NN	team
member	NN	member
developed	VBN	develop
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
most	JJS	most
urology	NN	urology
consultations	NNS	consultation
can	MD	can
be	VB	be
managed	VBN	manage
in	IN	in
a	DT	a
patient	NN	patient
and	CC	and
physician	NN	physician
safety-conscious	JJ	safety-conscious
manner	NN	manner
,	,	,
by	IN	by
implementing	VBG	implement
a	DT	a
novel	JJ	novel
triage	NN	triage
pathway	NN	pathway
.	SENT	.
35586079/	CD	@card@
Knowledge	NN	knowledge
,	,	,
Attitudes	NNS	attitude
,	,	,
and	CC	and
Misconceptions	NNS	misconception
About	IN	about
COVID-19	NP	<unknown>
Prevention	NN	prevention
Practices	NP	Practices
Among	IN	among
High	NP	High
and	CC	and
Preparatory	JJ	preparatory
School	NP	School
Students	NNS	student
in	IN	in
Dessie	NP	Dessie
City	NP	City
,	,	,
Ethiopia	NP	Ethiopia
Knowledge	NP	Knowledge
,	,	,
attitudes	NNS	attitude
,	,	,
and	CC	and
misconceptions	NNS	misconception
of	IN	of
students	NNS	student
about	IN	about
COVID-19	NP	<unknown>
(	(	(
coronavirus	NN	coronavirus
disease	NN	disease
)	)	)
prevention	NN	prevention
have	VBP	have
been	VBN	be
examined	VBN	examine
in	IN	in
relatively	RB	relatively
few	JJ	few
studies	NNS	study
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
assess	VB	assess
the	DT	the
knowledge	NN	knowledge
,	,	,
attitudes	NNS	attitude
and	CC	and
misconceptions	NNS	misconception
about	IN	about
COVID-19	NP	<unknown>
prevention	NN	prevention
practices	NNS	practice
among	IN	among
high	JJ	high
and	CC	and
preparatory	JJ	preparatory
school	NN	school
(	(	(
grades	NNS	grade
9	CD	@card@
to	TO	to
12	CD	@card@
)	)	)
students	NNS	student
in	IN	in
Dessie	NP	Dessie
City	NP	City
,	,	,
Ethiopia	NP	Ethiopia
.	SENT	.
This	DT	this
school-based	JJ	school-based
cross-sectional	JJ	cross-sectional
study	NN	study
used	VBD	use
a	DT	a
pre-tested	JJ	<unknown>
structured	JJ	structured
questionnaire	NN	questionnaire
and	CC	and
direct	JJ	direct
observations	NNS	observation
from	IN	from
March	NP	March
1	CD	@card@
to	TO	to
30	CD	@card@
,	,	,
2021	CD	@card@
in	IN	in
5	CD	@card@
high	JJ	high
and	CC	and
preparatory	JJ	preparatory
school	NN	school
students	NNS	student
in	IN	in
Dessie	NP	Dessie
City	NP	City
,	,	,
Ethiopia	NP	Ethiopia
.	SENT	.
The	DT	the
sample	NN	sample
size	NN	size
was	VBD	be
proportionally	RB	proportionally
allocated	VBN	allocate
in	IN	in
each	DT	each
school	NN	school
based	VBN	base
on	IN	on
the	DT	the
number	NN	number
of	IN	of
students	NNS	student
registered	VBN	register
in	IN	in
the	DT	the
first	JJ	first
semester	NN	semester
,	,	,
stratified	VBN	stratify
by	IN	by
grade	NN	grade
level	NN	level
,	,	,
and	CC	and
section	NN	section
.	SENT	.
Data	NP	Data
analysis	NN	analysis
employed	VBN	employ
3	CD	@card@
binary	JJ	binary
logistic	JJ	logistic
regression	NN	regression
models	NNS	model
(	(	(
Models	NPS	Models
I	NP	I
,	,	,
II	NP	II
and	CC	and
III	NP	III
)	)	)
with	IN	with
95	CD	@card@
%	NN	%
CI	NP	CI
(	(	(
confidence	NN	confidence
interval	NN	interval
)	)	)
.	SENT	.
Bivariate	JJ	<unknown>
analysis	NN	analysis
(	(	(
crude	JJ	crude
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
COR	NP	Cor
]	SYM	]
)	)	)
and	CC	and
multivariable	JJ	multivariable
analysis	NN	analysis
(	(	(
adjusted	JJ	adjusted
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
AOR	NP	AOR
]	SYM	]
)	)	)
were	VBD	be
used	VBN	use
.	SENT	.
Variables	NNS	variable
with	IN	with
P-values	NP	<unknown>
&lt	NP	&lt
;	:	;
0.3	CD	@card@
in	IN	in
the	DT	the
bivariate	JJ	<unknown>
analysis	NN	analysis
were	VBD	be
retained	VBN	retain
in	IN	in
the	DT	the
multivariable	JJ	multivariable
logistic	JJ	logistic
regression	NN	regression
analysis	NN	analysis
for	IN	for
each	DT	each
model	NN	model
.	SENT	.
Variables	NNS	variable
with	IN	with
significance	NN	significance
levels	NNS	level
P&lt	JJ	<unknown>
;	:	;
0.05	CD	@card@
in	IN	in
the	DT	the
multivariable	JJ	multivariable
analysis	NN	analysis
of	IN	of
each	DT	each
model	NN	model
was	VBD	be
identified	VBN	identify
as	IN	as
significant	JJ	significant
factors	NNS	factor
.	SENT	.
The	DT	the
levels	NNS	level
of	IN	of
good	JJ	good
knowledge	NN	knowledge
,	,	,
positive	JJ	positive
attitudes	NNS	attitude
,	,	,
and	CC	and
low	JJ	low
misconceptions	NNS	misconception
were	VBD	be
74.8	CD	@card@
%	NN	%
,	,	,
60.2	CD	@card@
%	NN	%
,	,	,
and	CC	and
56.1	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
After	IN	after
adjusting	VBG	adjust
for	IN	for
the	DT	the
covariates	NNS	covariate
,	,	,
grade	NN	grade
12	CD	@card@
,	,	,
positive	JJ	positive
attitude	NN	attitude
and	CC	and
living	NN	living
in	IN	in
households	NNS	household
with	IN	with
more	JJR	more
than	IN	than
5	CD	@card@
members	NNS	member
were	VBD	be
identified	VBN	identify
as	IN	as
factors	NNS	factor
significantly	RB	significantly
associated	VBN	associate
with	IN	with
good	JJ	good
knowledge	NN	knowledge
about	IN	about
COVID-19	NP	<unknown>
prevention	NN	prevention
practices	NNS	practice
.	SENT	.
Good	JJ	good
knowledge	NN	knowledge
of	IN	of
COVID-19	NP	<unknown>
prevention	NN	prevention
practices	NNS	practice
,	,	,
household	NN	household
size	NN	size
&gt	NN	&gt
;	:	;
5	LS	5
,	,	,
infection	NN	infection
prevention	NN	prevention
and	CC	and
control	NN	control
(	(	(
IPC	NP	IPC
)	)	)
training	NN	training
,	,	,
and	CC	and
low	JJ	low
level	NN	level
of	IN	of
misconceptions	NNS	misconception
were	VBD	be
factors	NNS	factor
significantly	RB	significantly
associated	VBN	associate
with	IN	with
positive	JJ	positive
attitudes	NNS	attitude
,	,	,
whereas	IN	whereas
students	NNS	student
age	NN	age
&gt	NN	&gt
;	:	;
=18	JJ	=@card@
years	NNS	year
,	,	,
positive	JJ	positive
attitude	NN	attitude
,	,	,
and	CC	and
IPC	NP	IPC
training	NN	training
were	VBD	be
factors	NNS	factor
significantly	RB	significantly
associated	VBN	associate
with	IN	with
less	JJR	less
misconceptions	NNS	misconception
about	IN	about
COVID-19	NP	<unknown>
prevention	NN	prevention
measures	NNS	measure
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
good	JJ	good
knowledge	NN	knowledge
,	,	,
positive	JJ	positive
attitude	NN	attitude
,	,	,
and	CC	and
low	JJ	low
level	NN	level
of	IN	of
misconceptions	NNS	misconception
of	IN	of
prevention	NN	prevention
practices	NNS	practice
for	IN	for
COVID-19	NP	<unknown>
among	IN	among
students	NNS	student
was	VBD	be
relatively	RB	relatively
low	JJ	low
.	SENT	.
Therefore	RB	therefore
,	,	,
Dessie	NP	Dessie
City	NP	City
Health	NP	Health
and	CC	and
Education	NP	Education
Department	NP	Department
and	CC	and
each	DT	each
high	JJ	high
and	CC	and
preparatory	JJ	preparatory
school	NN	school
should	MD	should
implement	VB	implement
continuous	JJ	continuous
monitoring	NN	monitoring
programs	NNS	program
to	TO	to
ensure	VB	ensure
high	JJ	high
prevention	NN	prevention
awareness	NN	awareness
and	CC	and
promote	VB	promote
preventive	JJ	preventive
behavior	NN	behavior
towards	IN	towards
COVID-19	NP	<unknown>
.	SENT	.
33591938/	CD	@card@
Model	NP	Model
Prediction	NN	prediction
for	IN	for
In-Hospital	JJ	in-hospital
Mortality	NN	mortality
in	IN	in
Patients	NPS	Patients
with	IN	with
COVID-19	NP	<unknown>
:	:	:
A	DT	a
Case-Control	NP	Case-Control
Study	NP	Study
in	IN	in
Isfahan	NP	Isfahan
,	,	,
Iran	NP	Iran
The	NP	The
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
now	RB	now
imposed	VBN	impose
an	DT	an
enormous	JJ	enormous
global	JJ	global
burden	NN	burden
as	RB	as
well	RB	well
as	IN	as
a	DT	a
large	JJ	large
mortality	NN	mortality
in	IN	in
a	DT	a
short	JJ	short
time	NN	time
period	NN	period
.	SENT	.
Although	IN	although
there	EX	there
is	VBZ	be
no	DT	no
promising	JJ	promising
treatment	NN	treatment
,	,	,
identification	NN	identification
of	IN	of
early	JJ	early
predictors	NNS	predictor
of	IN	of
in-hospital	JJ	in-hospital
mortality	NN	mortality
would	MD	would
be	VB	be
critically	RB	critically
important	JJ	important
in	IN	in
reducing	VBG	reduce
its	PP$	its
worldwide	JJ	worldwide
mortality	NN	mortality
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
suggest	VB	suggest
a	DT	a
prediction	NN	prediction
model	NN	model
for	IN	for
in-hospital	JJ	in-hospital
mortality	NN	mortality
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
this	DT	this
case-control	NN	case-control
study	NN	study
,	,	,
we	PP	we
recruited	VBD	recruit
513	CD	@card@
confirmed	VBN	confirm
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
from	IN	from
February	NP	February
18	CD	@card@
to	TO	to
March	NP	March
26	CD	@card@
,	,	,
2020	CD	@card@
from	IN	from
Isfahan	NP	Isfahan
COVID-19	NP	<unknown>
registry	NN	registry
.	SENT	.
Based	VBN	base
on	IN	on
extracted	VBN	extract
laboratory	NN	laboratory
,	,	,
clinical	JJ	clinical
,	,	,
and	CC	and
demographic	JJ	demographic
data	NNS	datum
,	,	,
we	PP	we
created	VBD	create
an	DT	an
in-hospital	JJ	in-hospital
mortality	NN	mortality
predictive	JJ	predictive
model	NN	model
using	VBG	use
gradient	JJ	gradient
boosting	VBG	boost
.	SENT	.
We	PP	we
also	RB	also
determined	VBD	determine
the	DT	the
diagnostic	JJ	diagnostic
performance	NN	performance
of	IN	of
the	DT	the
proposed	VBN	propose
model	NN	model
including	VBG	include
sensitivity	NN	sensitivity
,	,	,
specificity	NN	specificity
,	,	,
and	CC	and
area	NN	area
under	IN	under
the	DT	the
curve	NN	curve
(	(	(
AUC	NP	AUC
)	)	)
as	RB	as
well	RB	well
as	IN	as
their	PP$	their
95	CD	@card@
%	NN	%
CIs	NP	CI
.	SENT	.
Of	IN	of
513	CD	@card@
patients	NNS	patient
,	,	,
there	EX	there
were	VBD	be
60	CD	@card@
(	(	(
11.7	CD	@card@
%	NN	%
)	)	)
in-hospital	JJ	in-hospital
deaths	NNS	death
during	IN	during
the	DT	the
study	NN	study
period	NN	period
.	SENT	.
The	DT	the
diagnostic	JJ	diagnostic
values	NNS	value
of	IN	of
the	DT	the
suggested	JJ	suggested
model	NN	model
based	VBN	base
on	IN	on
the	DT	the
gradient	JJ	gradient
boosting	VBG	boost
method	NN	method
with	IN	with
oversampling	VBN	oversample
techniques	NNS	technique
using	VBG	use
all	DT	all
of	IN	of
the	DT	the
original	JJ	original
data	NNS	datum
were	VBD	be
specificity	NN	specificity
of	IN	of
98.5	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
96.8-99.4	LS	@card@
)	)	)
,	,	,
sensitivity	NN	sensitivity
of	IN	of
100	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
94-100	LS	@card@
)	)	)
,	,	,
negative	JJ	negative
predictive	JJ	predictive
value	NN	value
of	IN	of
100	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
99.2-100	LS	@card@
)	)	)
,	,	,
positive	JJ	positive
predictive	JJ	predictive
value	NN	value
of	IN	of
89.6	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
79.7-95.7	LS	@card@
)	)	)
,	,	,
and	CC	and
an	DT	an
AUC	NP	AUC
of	IN	of
98.6	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
suggested	VBN	suggest
model	NN	model
may	MD	may
be	VB	be
useful	JJ	useful
in	IN	in
making	VBG	make
decision	NN	decision
to	TO	to
patient	NN	patient
's	POS	's
hospitalization	NN	hospitalization
where	WRB	where
the	DT	the
probability	NN	probability
of	IN	of
mortality	NN	mortality
may	MD	may
be	VB	be
more	RBR	more
obvious	JJ	obvious
based	VBN	base
on	IN	on
the	DT	the
final	JJ	final
variable	NN	variable
.	SENT	.
However	RB	however
,	,	,
moderate	JJ	moderate
gaps	NNS	gap
in	IN	in
our	PP$	our
knowledge	NN	knowledge
of	IN	of
the	DT	the
predictors	NNS	predictor
of	IN	of
in-hospital	JJ	in-hospital
mortality	NN	mortality
suggest	VBP	suggest
further	JJR	further
studies	NNS	study
aiming	VBG	aim
at	IN	at
predicting	VBG	predict
models	NNS	model
for	IN	for
in-hospital	JJ	in-hospital
mortality	NN	mortality
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
33682315/	CD	@card@
The	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
of	IN	of
older	JJR	old
adults	NNS	adult
receiving	VBG	receive
community-based	JJ	community-based
aged	VBN	age
care	NN	care
To	TO	to
investigate	VB	investigate
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
and	CC	and
social	JJ	social
networks	NNS	network
of	IN	of
older	JJR	old
adults	NNS	adult
receiving	VBG	receive
community	NN	community
care	NN	care
services	NNS	service
.	SENT	.
Quality	NN	quality
of	IN	of
life	NN	life
and	CC	and
social	JJ	social
network	NN	network
questionnaires	NNS	questionnaire
were	VBD	be
completed	VBN	complete
by	IN	by
older	JJR	old
adults	NNS	adult
(	(	(
n	NN	n
=	SYM	=
21	CD	@card@
)	)	)
receiving	VBG	receive
home	NN	home
care	NN	care
services	NNS	service
at	IN	at
three	CD	three
time	NN	time
points	NNS	point
(	(	(
2018	CD	@card@
,	,	,
2019	CD	@card@
,	,	,
and	CC	and
during	IN	during
the	DT	the
first	JJ	first
Australian	JJ	Australian
COVID-19	NP	<unknown>
lockdown	NN	<unknown>
in	IN	in
2020	CD	@card@
)	)	)
.	SENT	.
Additional	JJ	additional
questions	NNS	question
about	IN	about
technology	NN	technology
use	NN	use
were	VBD	be
included	VBN	include
in	IN	in
2020	CD	@card@
.	SENT	.
Older	JJR	old
adults	NNS	adult
'	POS	'
quality	NN	quality
of	IN	of
life	NN	life
significantly	RB	significantly
decreased	VBD	decrease
during	IN	during
the	DT	the
pandemic	NN	pandemic
compared	VBN	compare
to	TO	to
the	DT	the
prior	JJ	prior
year	NN	year
.	SENT	.
During	IN	during
the	DT	the
pandemic	NN	pandemic
,	,	,
over	IN	over
80	CD	@card@
%	NN	%
used	VBN	use
technology	NN	technology
to	TO	to
maintain	VB	maintain
contact	NN	contact
with	IN	with
family	NN	family
and	CC	and
friends	NNS	friend
,	,	,
and	CC	and
social	JJ	social
networks	NNS	network
did	VBD	do
not	RB	not
change	VB	change
.	SENT	.
Government	NN	government
messages	NNS	message
and	CC	and
support	NN	support
initiatives	NNS	initiative
directed	VBN	direct
towards	IN	towards
technology	NN	technology
adoption	NN	adoption
among	IN	among
older	JJR	old
adults	NNS	adult
receiving	VBG	receive
home	NN	home
care	NN	care
may	MD	may
assist	VB	assist
with	IN	with
maintaining	VBG	maintain
social	JJ	social
connection	NN	connection
during	IN	during
COVID-19	NP	<unknown>
.	SENT	.
Our	PP$	our
findings	NNS	finding
add	VBP	add
to	TO	to
the	DT	the
relatively	RB	relatively
limited	JJ	limited
understanding	NN	understanding
of	IN	of
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
the	DT	the
socio-emotional	JJ	socio-emotional
well-being	NN	well-being
of	IN	of
older	JJR	old
people	NNS	people
.	SENT	.
34790223/	CD	@card@
Remote	JJ	remote
Delivery	NN	delivery
of	IN	of
Motor	NP	Motor
Function	NN	function
Assessment	NP	Assessment
and	CC	and
Training	NP	Training
for	IN	for
Clinical	JJ	clinical
Trials	NNS	trial
in	IN	in
Neuromuscular	JJ	neuromuscular
Disease	NN	disease
:	:	:
A	DT	a
Response	NP	Response
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
Global	NP	Global
Pandemic	JJ	pandemic
Clinical	JJ	clinical
outcome	NN	outcome
assessments	NNS	assessment
of	IN	of
function	NN	function
or	CC	or
strength	NN	strength
,	,	,
assessed	VBN	assess
by	IN	by
physical	JJ	physical
therapists	NNS	therapist
,	,	,
are	VBP	be
commonly	RB	commonly
used	VBN	use
as	IN	as
primary	JJ	primary
endpoints	NNS	endpoint
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
,	,	,
natural	JJ	natural
history	NN	history
studies	NNS	study
and	CC	and
within	IN	within
clinics	NNS	clinic
for	IN	for
individuals	NNS	individual
with	IN	with
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
.	SENT	.
These	DT	these
evaluations	NNS	evaluation
not	RB	not
only	RB	only
inform	VB	inform
the	DT	the
efficacy	NN	efficacy
of	IN	of
investigational	JJ	investigational
agents	NNS	agent
in	IN	in
clinical	JJ	clinical
trials	NNS	trial
,	,	,
but	CC	but
also	RB	also
importantly	RB	importantly
track	VB	track
disease	NN	disease
trajectory	NN	trajectory
to	TO	to
prospectively	RB	prospectively
advise	VB	advise
need	NN	need
for	IN	for
equipment	NN	equipment
,	,	,
home	NN	home
and	CC	and
work	NN	work
modifications	NNS	modification
,	,	,
and	CC	and
other	JJ	other
assistive	JJ	<unknown>
devices	NNS	device
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
had	VBD	have
a	DT	a
global	JJ	global
impact	NN	impact
on	IN	on
the	DT	the
safety	NN	safety
and	CC	and
feasibility	NN	feasibility
of	IN	of
in-person	NN	in-person
visits	NNS	visit
and	CC	and
assessments	NNS	assessment
,	,	,
necessitating	VBG	necessitate
rapid	JJ	rapid
development	NN	development
of	IN	of
mitigation	NN	mitigation
strategies	NNS	strategy
to	TO	to
ensure	VB	ensure
ongoing	JJ	ongoing
collection	NN	collection
of	IN	of
key	JJ	key
clinical	JJ	clinical
trial	NN	trial
endpoints	NNS	endpoint
and	CC	and
access	NN	access
to	TO	to
expert	JJ	expert
clinical	JJ	clinical
care	NN	care
despite	IN	despite
travel	NN	travel
restrictions	NNS	restriction
.	SENT	.
Physical	JJ	physical
therapists	NNS	therapist
who	WP	who
are	VBP	be
expert	JJ	expert
in	IN	in
neuromuscular	JJ	neuromuscular
disorders	NNS	disorder
working	VBG	work
across	IN	across
clinics	NNS	clinic
,	,	,
countries	NNS	country
,	,	,
and	CC	and
clinical	JJ	clinical
trials	NNS	trial
developed	VBD	develop
initial	JJ	initial
guidelines	NNS	guideline
and	CC	and
methods	NNS	method
for	IN	for
the	DT	the
suitability	NN	suitability
and	CC	and
feasibility	NN	feasibility
of	IN	of
performing	VBG	perform
remote	JJ	remote
evaluations	NNS	evaluation
.	SENT	.
A	DT	a
number	NN	number
of	IN	of
Sponsors	NNS	sponsor
introduced	VBD	introduce
amendments	NNS	amendment
to	TO	to
their	PP$	their
study	NN	study
protocols	NNS	protocol
to	TO	to
enable	VB	enable
remote	JJ	remote
evaluations	NNS	evaluation
,	,	,
supported	VBN	support
by	IN	by
live	JJ	live
video	NN	video
streaming	VBG	stream
of	IN	of
the	DT	the
assessment	NN	assessment
to	TO	to
their	PP$	their
local	JJ	local
clinical	JJ	clinical
evaluators	NNS	evaluator
.	SENT	.
Similarly	RB	similarly
,	,	,
application	NN	application
of	IN	of
these	DT	these
techniques	NNS	technique
to	TO	to
clinical	JJ	clinical
telemedicine	NN	telemedicine
enabled	VBD	enable
objective	JJ	objective
evaluations	NNS	evaluation
for	IN	for
use	NN	use
in	IN	in
payer	NN	payer
discussions	NNS	discussion
,	,	,
equipment	NN	equipment
procurement	NN	procurement
,	,	,
and	CC	and
general	JJ	general
access	NN	access
to	TO	to
expert	JJ	expert
physical	JJ	physical
therapy	NN	therapy
services	NNS	service
.	SENT	.
Here	RB	here
we	PP	we
report	VBP	report
on	IN	on
our	PP$	our
methodology	NN	methodology
for	IN	for
adapting	VBG	adapt
current	JJ	current
practices	NNS	practice
to	TO	to
remote	JJ	remote
testing	NN	testing
and	CC	and
considerations	NNS	consideration
for	IN	for
remote	JJ	remote
evaluations	NNS	evaluation
.	SENT	.
34568168/	CD	@card@
Why	WRB	why
the	DT	the
COVID-19	NP	<unknown>
Is	VBZ	be
Not	RB	not
Significantly	RB	significantly
Reduced	VBN	reduce
in	IN	in
Iran	NP	Iran
?	SENT	?
Severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
was	VBD	be
transported	VBN	transport
from	IN	from
China	NP	China
to	TO	to
Iran	NP	Iran
via	IN	via
passengers	NNS	passenger
.	SENT	.
The	DT	the
virus	NN	virus
is	VBZ	be
transmitted	VBN	transmit
through	IN	through
droplets	NNS	droplet
from	IN	from
coughing	VBG	cough
,	,	,
sneezing	VBG	sneeze
,	,	,
talking	VBG	talk
and	CC	and
contact	NN	contact
with	IN	with
infected	JJ	infected
surfaces	NNS	surface
.	SENT	.
Due	JJ	due
to	TO	to
high	JJ	high
transmissibility	NN	<unknown>
in	IN	in
places	NNS	place
such	JJ	such
as	IN	as
clinics	NNS	clinic
,	,	,
medical	JJ	medical
offices	NNS	office
,	,	,
buses	NNS	bus
and	CC	and
offices	NNS	office
where	WRB	where
there	EX	there
are	VBP	be
large	JJ	large
crowds	NNS	crowd
,	,	,
it	PP	it
spread	VBD	spread
rapidly	RB	rapidly
in	IN	in
Iran	NP	Iran
and	CC	and
caused	VBD	cause
the	DT	the
mortality	NN	mortality
of	IN	of
a	DT	a
significant	JJ	significant
number	NN	number
of	IN	of
people	NNS	people
,	,	,
especially	RB	especially
the	DT	the
elderly	JJ	elderly
with	IN	with
underlying	VBG	underlie
disease	NN	disease
.	SENT	.
Preventing	VBG	prevent
travel	NN	travel
and	CC	and
gatherings	NNS	gathering
,	,	,
as	RB	as
well	RB	well
as	IN	as
applying	VBG	apply
house	NN	house
quarantine	NN	quarantine
in	IN	in
Apr	NP	Apr
2020	CD	@card@
,	,	,
reduced	VBN	reduce
COVID-19	NP	<unknown>
somewhat	RB	somewhat
but	CC	but
then	RB	then
due	JJ	due
to	TO	to
lack	NN	lack
of	IN	of
attention	NN	attention
to	TO	to
social	JJ	social
distancing	NN	distancing
,	,	,
reducing	VBG	reduce
the	DT	the
use	NN	use
of	IN	of
masks	NNS	mask
by	IN	by
the	DT	the
people	NNS	people
and	CC	and
inappropriate	JJ	inappropriate
decisions	NNS	decision
by	IN	by
the	DT	the
national	JJ	national
committee	NN	committee
on	IN	on
combating	VBG	combat
coronavirus	NN	coronavirus
(	(	(
NCCC	NP	<unknown>
)	)	)
,	,	,
including	VBG	include
reducing	VBG	reduce
the	DT	the
working	VBG	work
hours	NNS	hour
of	IN	of
public	JJ	public
offices	NNS	office
and	CC	and
shops	NNS	shop
,	,	,
reducing	VBG	reduce
the	DT	the
staff	NN	staff
of	IN	of
government	NN	government
offices	NNS	office
,	,	,
monopoly	NN	monopoly
on	IN	on
the	DT	the
distribution	NN	distribution
of	IN	of
essential	JJ	essential
materials	NNS	material
and	CC	and
supplies	NNS	supply
,	,	,
the	DT	the
presence	NN	presence
of	IN	of
overcrowding	NN	overcrowding
in	IN	in
clinics	NNS	clinic
of	IN	of
medical	JJ	medical
centers	NNS	center
,	,	,
hospitals	NNS	hospital
,	,	,
and	CC	and
private	JJ	private
clinics	NNS	clinic
caused	VBD	cause
the	DT	the
decline	NN	decline
of	IN	of
the	DT	the
disease	NN	disease
in	IN	in
the	DT	the
country	NN	country
to	TO	to
decrease	VB	decrease
.	SENT	.
Measures	NNS	measure
can	MD	can
be	VB	be
taken	VBN	take
to	TO	to
prevent	VB	prevent
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
virus	NN	virus
as	IN	as
much	RB	much
as	RB	as
possible	JJ	possible
,	,	,
including	VBG	include
:	:	:
rapid	JJ	rapid
detection	NN	detection
of	IN	of
infected	JJ	infected
people	NNS	people
,	,	,
their	PP$	their
isolation	NN	isolation
,	,	,
contact	NN	contact
tracing	NN	tracing
,	,	,
quarantine	NN	quarantine
of	IN	of
people	NNS	people
over	IN	over
65	CD	@card@
and	CC	and
under	IN	under
15	CD	@card@
,	,	,
protection	NN	protection
of	IN	of
the	DT	the
elderly	JJ	elderly
,	,	,
prevention	NN	prevention
of	IN	of
gatherings	NNS	gathering
,	,	,
forcing	VBG	force
the	DT	the
use	NN	use
of	IN	of
protective	JJ	protective
equipment	NN	equipment
in	IN	in
possible	JJ	possible
gatherings	NNS	gathering
,	,	,
and	CC	and
electronicizing	VBG	<unknown>
public	JJ	public
services	NNS	service
.	SENT	.
35284994/	CD	@card@
COVID-19	NP	<unknown>
Outcomes	NNS	outcome
and	CC	and
Vaccination	NN	vaccination
in	IN	in
People	NNS	people
with	IN	with
Relapsing	VBG	relapse
Multiple	JJ	multiple
Sclerosis	NN	sclerosis
Treated	VBN	treat
with	IN	with
Ofatumumab	NP	<unknown>
The	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
necessitated	VBD	necessitate
better	JJR	good
understanding	NN	understanding
of	IN	of
the	DT	the
impact	NN	impact
of	IN	of
disease-modifying	VBG	disease-modify
therapies	NNS	therapy
on	IN	on
COVID-19	NP	<unknown>
outcomes	NNS	outcome
and	CC	and
vaccination	NN	vaccination
.	SENT	.
We	PP	we
report	VBP	report
characteristics	NNS	characteristic
of	IN	of
COVID-19	NP	<unknown>
cases	NNS	case
and	CC	and
vaccination	NN	vaccination
status	NN	status
in	IN	in
ofatumumab-treated	JJ	<unknown>
relapsing	VBG	relapse
multiple	NN	multiple
sclerosis	NN	sclerosis
(	(	(
RMS	NP	RMS
)	)	)
patients	NNS	patient
.	SENT	.
COVID-19	NP	<unknown>
data	NNS	datum
analyzed	VBD	analyze
were	VBD	be
from	IN	from
the	DT	the
ongoing	JJ	ongoing
,	,	,
open-label	NN	open-label
,	,	,
long-term	JJ	long-term
extension	NN	extension
phase	NN	phase
3b	JJ	<unknown>
ALITHIOS	NP	<unknown>
study	NN	study
from	IN	from
December	NP	December
2019	CD	@card@
(	(	(
pandemic	NN	pandemic
start	NN	start
)	)	)
and	CC	and
post-marketing	NN	post-marketing
cases	NNS	case
from	IN	from
August	NP	August
2020	CD	@card@
(	(	(
ofatumumab	NN	<unknown>
first	JJ	first
approval	NN	approval
)	)	)
up	IN	up
to	TO	to
25	CD	@card@
September	NP	September
2021	CD	@card@
.	SENT	.
COVID-19	NN	<unknown>
cases	NNS	case
,	,	,
severity	NN	severity
,	,	,
seriousness	NN	seriousness
,	,	,
outcomes	NNS	outcome
,	,	,
vaccination	NN	vaccination
status	NN	status
,	,	,
and	CC	and
breakthrough	NN	breakthrough
infection	NN	infection
were	VBD	be
evaluated	VBN	evaluate
.	SENT	.
As	RB	as
of	IN	of
25	CD	@card@
September	NP	September
2021	CD	@card@
,	,	,
245	CD	@card@
of	IN	of
1703	CD	@card@
patients	NNS	patient
(	(	(
14.3	CD	@card@
%	NN	%
)	)	)
enrolled	VBN	enroll
in	IN	in
ALITHIOS	NP	<unknown>
receiving	VBG	receive
ofatumumab	NN	<unknown>
(	(	(
median	JJ	median
exposure	NN	exposure
:	:	:
2.45	CD	@card@
years	NNS	year
)	)	)
reported	VBN	report
COVID-19	NP	<unknown>
(	(	(
confirmed	VBD	confirm
:	:	:
210	CD	@card@
;	:	;
suspected	VBN	suspect
:	:	:
35	LS	@card@
)	)	)
.	SENT	.
Most	JJS	most
COVID-19	NN	<unknown>
was	VBD	be
of	IN	of
mild	JJ	mild
(	(	(
44.1	CD	@card@
%	NN	%
)	)	)
or	CC	or
moderate	JJ	moderate
(	(	(
46.5	CD	@card@
%	NN	%
)	)	)
severity	NN	severity
,	,	,
but	CC	but
9	CD	@card@
%	NN	%
had	VBD	have
severe/life-threatening	JJ	severe/life-threatening
COVID-19	NP	<unknown>
.	SENT	.
There	EX	there
were	VBD	be
24	CD	@card@
serious	JJ	serious
cases	NNS	case
(	(	(
9.8	CD	@card@
%	NN	%
)	)	)
with	IN	with
23	CD	@card@
patients	NNS	patient
were	VBD	be
hospitalized	VBN	hospitalize
;	:	;
22	LS	@card@
recovered	VBN	recover
and	CC	and
2	CD	@card@
died	VBD	die
.	SENT	.
At	IN	at
study	NN	study
cut-off	NN	cut-off
,	,	,
241	CD	@card@
patients	NNS	patient
(	(	(
98.4	CD	@card@
%	NN	%
)	)	)
had	VBD	have
recovered	VBN	recover
or	CC	or
were	VBD	be
recovering	VBG	recover
or	CC	or
had	VBD	have
recovered	VBN	recover
with	IN	with
sequelae	NNS	sequela
and	CC	and
2	CD	@card@
(	(	(
0.8	CD	@card@
%	NN	%
)	)	)
had	VBD	have
not	RB	not
recovered	VBN	recover
.	SENT	.
Ofatumumab	NP	<unknown>
was	VBD	be
temporarily	RB	temporarily
interrupted	VBN	interrupt
in	IN	in
39	CD	@card@
(	(	(
15.9	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
.	SENT	.
Before	IN	before
COVID-19	NP	<unknown>
onset	NN	onset
,	,	,
IgG	NP	IgG
levels	NNS	level
were	VBD	be
within	IN	within
the	DT	the
normal	JJ	normal
range	NN	range
in	IN	in
all	DT	all
COVID-19-affected	JJ	COVID-19-affected
patients	NNS	patient
,	,	,
while	IN	while
IgM	NP	Igm
was	VBD	be
&lt	JJ	<unknown>
;	:	;
0.4	CD	@card@
g/l	NN	g/l
in	IN	in
23	CD	@card@
(	(	(
9.4	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
.	SENT	.
No	DT	no
patient	NN	patient
had	VBD	have
a	DT	a
reinfection	NN	reinfection
.	SENT	.
Overall	RB	overall
,	,	,
559	CD	@card@
patients	NNS	patient
were	VBD	be
vaccinated	VBN	vaccinate
(	(	(
full	JJ	full
,	,	,
476	CD	@card@
;	:	;
partial	JJ	partial
,	,	,
74	CD	@card@
;	:	;
unspecified	JJ	unspecified
,	,	,
9	CD	@card@
)	)	)
.	SENT	.
Breakthrough	NN	breakthrough
infection	NN	infection
was	VBD	be
reported	VBN	report
in	IN	in
1.5	CD	@card@
%	NN	%
(	(	(
7/476	CD	@card@
)	)	)
patients	NNS	patient
,	,	,
and	CC	and
11	CD	@card@
reported	VBD	report
COVID-19	NP	<unknown>
after	IN	after
partial	JJ	partial
vaccination	NN	vaccination
.	SENT	.
As	RB	as
of	IN	of
25	CD	@card@
September	NP	September
2021	CD	@card@
,	,	,
the	DT	the
Novartis	NP	Novartis
Safety	NP	Safety
Database	NP	Database
(	(	(
~	SYM	~
4713	CD	@card@
patient-treatment	NN	patient-treatment
years	NNS	year
)	)	)
recorded	VBD	record
90	CD	@card@
confirmed	JJ	confirmed
COVID-19	NP	<unknown>
cases	NNS	case
receiving	VBG	receive
ofatumumab	NN	<unknown>
.	SENT	.
Most	JJS	most
cases	NNS	case
were	VBD	be
non-serious	JJ	non-serious
(	(	(
n	NN	n
=	SYM	=
80	CD	@card@
)	)	)
,	,	,
and	CC	and
ten	CD	ten
were	VBD	be
serious	JJ	serious
(	(	(
1	CD	@card@
medically	RB	medically
significant	JJ	significant
,	,	,
9	CD	@card@
hospitalized	VBD	hospitalize
,	,	,
0	CD	@card@
deaths	NNS	death
)	)	)
.	SENT	.
Among	IN	among
36	CD	@card@
of	IN	of
90	CD	@card@
cases	NNS	case
with	IN	with
outcomes	NNS	outcome
reported	VBD	report
,	,	,
30	CD	@card@
recovered	VBD	recover
and	CC	and
6	CD	@card@
did	VBD	do
not	RB	not
recover	VB	recover
.	SENT	.
COVID-19	NP	<unknown>
in	IN	in
RMS	NP	RMS
patients	NNS	patient
on	IN	on
ofatumumab	NN	<unknown>
was	VBD	be
primarily	RB	primarily
of	IN	of
mild/moderate	JJ	mild/moderate
severity	NN	severity
and	CC	and
non-serious	JJ	non-serious
in	IN	in
these	DT	these
observational	JJ	observational
data	NNS	datum
.	SENT	.
Most	RBS	most
recovered	VBN	recover
from	IN	from
COVID-19	NP	<unknown>
without	IN	without
treatment	NN	treatment
interruption	NN	interruption
.	SENT	.
Two	CD	two
people	NNS	people
died	VBN	die
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Breakthrough	NN	breakthrough
COVID-19	NP	<unknown>
despite	IN	despite
being	VBG	be
fully/partially	RB	fully/partially
vaccinated	VBN	vaccinate
was	VBD	be
uncommon	JJ	uncommon
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s40120-022-00341-z	NP	<unknown>
.	SENT	.
32730222/	CD	@card@
Use	NN	use
of	IN	of
the	DT	the
HoloLens2	NP	<unknown>
Mixed	JJ	mixed
Reality	NN	reality
Headset	NN	headset
for	IN	for
Protecting	VBG	protect
Health	NP	Health
Care	NP	Care
Workers	NPS	Workers
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
Prospective	JJ	prospective
,	,	,
Observational	JJ	observational
Evaluation	NN	evaluation
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
has	VBZ	have
led	VBN	lead
to	TO	to
rapid	JJ	rapid
acceleration	NN	acceleration
in	IN	in
the	DT	the
deployment	NN	deployment
of	IN	of
new	JJ	new
digital	JJ	digital
technologies	NNS	technology
to	TO	to
improve	VB	improve
both	DT	both
accessibility	NN	accessibility
to	TO	to
and	CC	and
quality	NN	quality
of	IN	of
care	NN	care
,	,	,
and	CC	and
to	TO	to
protect	VB	protect
staff	NN	staff
.	SENT	.
Mixed-reality	NP	<unknown>
(	(	(
MR	NP	Mr
)	)	)
technology	NN	technology
is	VBZ	be
the	DT	the
latest	JJS	late
iteration	NN	iteration
of	IN	of
telemedicine	NN	telemedicine
innovation	NN	innovation
;	:	;
it	PP	it
is	VBZ	be
a	DT	a
logical	JJ	logical
next	JJ	next
step	NN	step
in	IN	in
the	DT	the
move	NN	move
toward	IN	toward
the	DT	the
provision	NN	provision
of	IN	of
digitally	RB	digitally
supported	VBN	support
clinical	JJ	clinical
care	NN	care
and	CC	and
medical	JJ	medical
education	NN	education
.	SENT	.
This	DT	this
technology	NN	technology
has	VBZ	have
the	DT	the
potential	NN	potential
to	TO	to
revolutionize	VB	revolutionize
care	NN	care
both	CC	both
during	IN	during
and	CC	and
after	IN	after
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
This	DT	this
pilot	NN	pilot
project	NN	project
sought	VBD	seek
to	TO	to
deploy	VB	deploy
the	DT	the
HoloLens2	NP	<unknown>
MR	NP	Mr
device	NN	device
to	TO	to
support	VB	support
the	DT	the
delivery	NN	delivery
of	IN	of
remote	JJ	remote
care	NN	care
in	IN	in
COVID-19	NP	<unknown>
hospital	NN	hospital
environments	NNS	environment
.	SENT	.
A	DT	a
prospective	JJ	prospective
,	,	,
observational	JJ	observational
,	,	,
nested	VBD	nest
cohort	NN	cohort
evaluation	NN	evaluation
of	IN	of
the	DT	the
HoloLens2	NP	<unknown>
was	VBD	be
undertaken	VBN	undertake
across	IN	across
three	CD	three
distinct	JJ	distinct
clinical	JJ	clinical
clusters	NNS	cluster
in	IN	in
a	DT	a
teaching	NN	teaching
hospital	NN	hospital
in	IN	in
the	DT	the
United	NP	United
Kingdom	NP	Kingdom
.	SENT	.
Data	NNS	datum
pertaining	VBG	pertain
to	TO	to
staff	VB	staff
exposure	NN	exposure
to	TO	to
high-risk	JJ	high-risk
COVID-19	NP	<unknown>
environments	NNS	environment
and	CC	and
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
(	(	(
PPE	NP	PPE
)	)	)
use	NN	use
by	IN	by
clinical	JJ	clinical
staff	NN	staff
(	(	(
N=28	NP	<unknown>
)	)	)
were	VBD	be
collected	VBN	collect
,	,	,
and	CC	and
assessments	NNS	assessment
of	IN	of
acceptability	NN	acceptability
and	CC	and
feasibility	NN	feasibility
were	VBD	be
conducted	VBN	conduct
.	SENT	.
The	DT	the
deployment	NN	deployment
of	IN	of
the	DT	the
HoloLens2	NP	<unknown>
led	VBD	lead
to	TO	to
a	DT	a
51.5	CD	@card@
%	NN	%
reduction	NN	reduction
in	IN	in
time	NN	time
exposed	VBN	expose
to	TO	to
harm	VB	harm
for	IN	for
staff	NN	staff
looking	VBG	look
after	IN	after
COVID-19	NP	<unknown>
patients	NNS	patient
(	(	(
3.32	CD	@card@
vs	NP	vs
1.63	CD	@card@
hours/day/staff	NN	hours/day/staff
member	NN	member
;	:	;
P=.002	NP	<unknown>
)	)	)
,	,	,
and	CC	and
an	DT	an
83.1	CD	@card@
%	NN	%
reduction	NN	reduction
in	IN	in
the	DT	the
amount	NN	amount
of	IN	of
PPE	NP	PPE
used	VBD	use
(	(	(
178	CD	@card@
vs	NP	vs
30	CD	@card@
items/round/day	NN	<unknown>
;	:	;
P=.02	NP	<unknown>
)	)	)
.	SENT	.
This	DT	this
represents	VBZ	represent
222.98	CD	@card@
hours	NNS	hour
of	IN	of
reduced	VBN	reduce
staff	NN	staff
exposure	NN	exposure
to	TO	to
COVID-19	NP	<unknown>
,	,	,
and	CC	and
3100	CD	@card@
fewer	JJR	few
PPE	NP	PPE
items	NNS	item
used	VBD	use
each	DT	each
week	NN	week
across	IN	across
the	DT	the
three	CD	three
clusters	NNS	cluster
evaluated	VBD	evaluate
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
staff	NN	staff
using	VBG	use
the	DT	the
device	NN	device
agreed	VBD	agree
it	PP	it
was	VBD	be
easy	JJ	easy
to	TO	to
set	VB	set
up	RP	up
and	CC	and
comfortable	JJ	comfortable
to	TO	to
wear	VB	wear
,	,	,
improved	VBD	improve
the	DT	the
quality	NN	quality
of	IN	of
care	NN	care
and	CC	and
decision	NN	decision
making	NN	making
,	,	,
and	CC	and
led	VBD	lead
to	TO	to
better	JJR	good
teamwork	NN	teamwork
and	CC	and
communication	NN	communication
.	SENT	.
In	IN	in
total	NN	total
,	,	,
89.3	CD	@card@
%	NN	%
(	(	(
25/28	CD	@card@
)	)	)
of	IN	of
users	NNS	user
felt	VBD	feel
that	IN	that
their	PP$	their
clinical	JJ	clinical
team	NN	team
was	VBD	be
safer	JJR	safe
when	WRB	when
using	VBG	use
the	DT	the
HoloLens2	NP	<unknown>
.	SENT	.
New	JJ	new
technologies	NNS	technology
have	VBP	have
a	DT	a
role	NN	role
in	IN	in
minimizing	VBG	minimize
exposure	NN	exposure
to	TO	to
nosocomial	JJ	<unknown>
infection	NN	infection
,	,	,
optimizing	VBG	optimize
the	DT	the
use	NN	use
of	IN	of
PPE	NP	PPE
,	,	,
and	CC	and
enhancing	VBG	enhance
aspects	NNS	aspect
of	IN	of
care	NN	care
.	SENT	.
Deploying	VBG	deploy
such	JJ	such
technologies	NNS	technology
at	IN	at
pace	NN	pace
requires	VBZ	require
context-specific	JJ	context-specific
information	NN	information
security	NN	security
,	,	,
infection	NN	infection
control	NN	control
,	,	,
user	NN	user
experience	NN	experience
,	,	,
and	CC	and
workflow	NN	<unknown>
integration	NN	integration
to	TO	to
be	VB	be
addressed	VBN	address
at	IN	at
the	DT	the
outset	NN	outset
and	CC	and
led	VBN	lead
by	IN	by
clinical	JJ	clinical
end-users	NNS	end-user
.	SENT	.
The	DT	the
deployment	NN	deployment
of	IN	of
new	JJ	new
telemedicine	NN	telemedicine
technology	NN	technology
must	MD	must
be	VB	be
supported	VBN	support
with	IN	with
objective	JJ	objective
evidence	NN	evidence
for	IN	for
its	PP$	its
safety	NN	safety
and	CC	and
effectiveness	NN	effectiveness
to	TO	to
ensure	VB	ensure
maximum	JJ	maximum
impact	NN	impact
.	SENT	.
32673494/	CD	@card@
COVID-19	NP	<unknown>
Associated	NP	Associated
Stress	NN	stress
(	(	(
Takotsubo	NP	<unknown>
)	)	)
Cardiomyopathy	NP	<unknown>
33720028/	CD	@card@
HOPES	NNS	hope
:	:	:
An	DT	an
Integrative	JJ	integrative
Digital	NP	Digital
Phenotyping	NP	<unknown>
Platform	NN	platform
for	IN	for
Data	NP	Data
Collection	NP	Collection
,	,	,
Monitoring	NN	monitoring
,	,	,
and	CC	and
Machine	NP	Machine
Learning	NP	Learning
The	DT	the
collection	NN	collection
of	IN	of
data	NNS	datum
from	IN	from
a	DT	a
personal	JJ	personal
digital	JJ	digital
device	NN	device
to	TO	to
characterize	VB	characterize
current	JJ	current
health	NN	health
conditions	NNS	condition
and	CC	and
behaviors	NNS	behavior
that	WDT	that
determine	VBP	determine
how	WRB	how
an	DT	an
individual	NN	individual
's	POS	's
health	NN	health
will	MD	will
evolve	VB	evolve
has	VBZ	have
been	VBN	be
called	VBN	call
digital	JJ	digital
phenotyping	NN	<unknown>
.	SENT	.
In	IN	in
this	DT	this
paper	NN	paper
,	,	,
we	PP	we
describe	VBP	describe
the	DT	the
development	NN	development
of	IN	of
and	CC	and
early	JJ	early
experiences	NNS	experience
with	IN	with
a	DT	a
comprehensive	JJ	comprehensive
digital	JJ	digital
phenotyping	NN	<unknown>
platform	NN	platform
:	:	:
Health	NN	health
Outcomes	NNS	outcome
through	IN	through
Positive	JJ	positive
Engagement	NN	engagement
and	CC	and
Self-Empowerment	NN	<unknown>
(	(	(
HOPES	NNS	hope
)	)	)
.	SENT	.
HOPES	VBZ	hope
is	VBZ	be
based	VBN	base
on	IN	on
the	DT	the
open-source	NN	open-source
Beiwe	NP	<unknown>
platform	NN	platform
but	CC	but
adds	VBZ	add
a	DT	a
wider	JJR	wide
range	NN	range
of	IN	of
data	NN	data
collection	NN	collection
,	,	,
including	VBG	include
the	DT	the
integration	NN	integration
of	IN	of
wearable	JJ	wearable
devices	NNS	device
and	CC	and
further	JJR	further
sensor	NN	sensor
collection	NN	collection
from	IN	from
smartphones	NNS	smartphone
.	SENT	.
Requirements	NNS	requirement
were	VBD	be
partly	RB	partly
derived	VBN	derive
from	IN	from
a	DT	a
concurrent	JJ	concurrent
clinical	JJ	clinical
trial	NN	trial
for	IN	for
schizophrenia	NN	schizophrenia
that	WDT	that
required	VBD	require
the	DT	the
development	NN	development
of	IN	of
significant	JJ	significant
capabilities	NNS	capability
in	IN	in
HOPES	NNS	hope
for	IN	for
security	NN	security
,	,	,
privacy	NN	privacy
,	,	,
ease	NN	ease
of	IN	of
use	NN	use
,	,	,
and	CC	and
scalability	NN	scalability
,	,	,
based	VBN	base
on	IN	on
a	DT	a
careful	JJ	careful
combination	NN	combination
of	IN	of
public	JJ	public
cloud	NN	cloud
and	CC	and
on-premises	NP	on-premises
operation	NN	operation
.	SENT	.
We	PP	we
describe	VBP	describe
new	JJ	new
data	NNS	datum
pipelines	NNS	pipeline
to	TO	to
clean	VB	clean
,	,	,
process	NN	process
,	,	,
present	JJ	present
,	,	,
and	CC	and
analyze	VB	analyze
data	NNS	datum
.	SENT	.
This	DT	this
includes	VBZ	include
a	DT	a
set	NN	set
of	IN	of
dashboards	NNS	dashboard
customized	VBN	customize
to	TO	to
the	DT	the
needs	NNS	need
of	IN	of
research	NN	research
study	NN	study
operations	NNS	operation
and	CC	and
clinical	JJ	clinical
care	NN	care
.	SENT	.
A	DT	a
test	NN	test
use	NN	use
case	NN	case
for	IN	for
HOPES	NNS	hope
was	VBD	be
described	VBN	describe
by	IN	by
analyzing	VBG	analyze
the	DT	the
digital	JJ	digital
behavior	NN	behavior
of	IN	of
22	CD	@card@
participants	NNS	participant
during	IN	during
the	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
33435808/	CD	@card@
Immune	NP	Immune
memory	NN	memory
:	:	:
an	DT	an
evolutionary	JJ	evolutionary
perspective	NN	perspective
The	DT	the
innate	JJ	innate
immune	JJ	immune
system	NN	system
,	,	,
through	IN	through
pattern	NN	pattern
recognition	NN	recognition
receptors	NNS	receptor
,	,	,
intercepts	VBZ	intercept
any	DT	any
kind	NN	kind
of	IN	of
pathogen	NN	pathogen
and	CC	and
reacts	VBZ	react
through	IN	through
chemotactic	JJ	chemotactic
,	,	,
phagocyting	NN	<unknown>
,	,	,
cytokines-secreting	NN	<unknown>
and	CC	and
cell-killing	NN	cell-killing
mechanisms	NNS	mechanism
in	IN	in
a	DT	a
very	RB	very
quick	JJ	quick
and	CC	and
effective	JJ	effective
way	NN	way
.	SENT	.
Meanwhile	RB	meanwhile
,	,	,
the	DT	the
adaptive	JJ	adaptive
immunity	NN	immunity
arm	NN	arm
,	,	,
through	IN	through
dendritic	JJ	dendritic
and	CC	and
T	NN	T
and	CC	and
B	NN	B
cells	NNS	cell
memory	NN	memory
activation	NN	activation
,	,	,
is	VBZ	be
alerted	VBN	alert
and	CC	and
starts	NNS	start
,	,	,
more	RBR	more
slowly	RB	slowly
,	,	,
to	TO	to
produce	VB	produce
antibodies	NNS	antibody
,	,	,
seen	VBN	see
thanks	NNS	thanks
to	TO	to
the	DT	the
progress	NN	progress
of	IN	of
immunological	JJ	immunological
investigations	NNS	investigation
in	IN	in
comparative	JJ	comparative
vertebrates	NNS	vertebrate
,	,	,
invertebrates	NNS	invertebrate
,	,	,
and	CC	and
vegetal	JJ	vegetal
models	NNS	model
.	SENT	.
However	RB	however
,	,	,
it	PP	it
has	VBZ	have
been	VBN	be
stated	VBN	state
that	IN	that
the	DT	the
innate	JJ	innate
immune	JJ	immune
system	NN	system
also	RB	also
displays	VBZ	display
adaptive	JJ	adaptive
potential	NN	potential
in	IN	in
terms	NNS	term
of	IN	of
reinfection	NN	reinfection
resistance	NN	resistance
through	IN	through
immune	JJ	immune
memory	NN	memory
,	,	,
in	IN	in
addition	NN	addition
to	TO	to
the	DT	the
modulation	NN	modulation
of	IN	of
responses	NNS	response
against	IN	against
repeated	JJ	repeated
low	JJ	low
doses	NNS	dose
of	IN	of
lipopolysaccharides	NNS	lipopolysaccharide
(	(	(
Lps	NP	Lps
)	)	)
or	CC	or
cross-immunization	NN	cross-immunization
,	,	,
starting	VBG	start
from	IN	from
one	CD	one
pathogenic	JJ	pathogenic
species	NNS	specie
and	CC	and
extending	VBG	extend
to	TO	to
others	NNS	other
.	SENT	.
34193877/	CD	@card@
Increased	VBN	increase
risk	NN	risk
of	IN	of
acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
patients	NNS	patient
with	IN	with
renin-angiotensin-aldosterone-system	NN	renin-angiotensin-aldosterone-system
blockade	NN	blockade
use	NN	use
:	:	:
a	DT	a
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
Acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
(	(	(
AKI	NP	Aki
)	)	)
is	VBZ	be
a	DT	a
severe	JJ	severe
complication	NN	complication
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
that	WDT	that
negatively	RB	negatively
affects	VBZ	affect
its	PP$	its
outcome	NN	outcome
.	SENT	.
Concern	NN	concern
had	VBD	have
been	VBN	be
raised	VBN	raise
about	IN	about
the	DT	the
potential	JJ	potential
effect	NN	effect
of	IN	of
renin-angiotensin-aldosterone	NN	renin-angiotensin-aldosterone
system	NN	system
(	(	(
RAAS	NP	<unknown>
)	)	)
blockades	NNS	blockade
on	IN	on
renal	JJ	renal
outcomes	NNS	outcome
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
However	RB	however
,	,	,
the	DT	the
association	NN	association
between	IN	between
RAAS	NP	<unknown>
blockade	NN	blockade
use	NN	use
and	CC	and
incident	NN	incident
AKI	NP	Aki
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
has	VBZ	have
not	RB	not
been	VBN	be
fully	RB	fully
understood	VBN	understand
.	SENT	.
We	PP	we
investigated	VBD	investigate
the	DT	the
association	NN	association
between	IN	between
RAAS	NP	<unknown>
blockade	NN	blockade
exposure	NN	exposure
and	CC	and
COVID-19-related	JJ	COVID-19-related
AKI	NP	Aki
in	IN	in
hospitalized	VBN	hospitalize
patients	NNS	patient
through	IN	through
meta-analysis	NN	meta-analysis
.	SENT	.
Electronic	JJ	electronic
databases	NNS	database
were	VBD	be
searched	VBN	search
up	RP	up
to	TO	to
24th	JJ	24th
December	NP	December
2020	CD	@card@
.	SENT	.
Summary	NN	summary
estimates	NNS	estimate
of	IN	of
pooled	JJ	pooled
odds	NNS	odd
ratio	NN	ratio
(	(	(
OR	CC	or
)	)	)
of	IN	of
COVID-19-related	JJ	COVID-19-related
AKI	NP	Aki
depending	VBG	depend
on	IN	on
RAAS	NP	<unknown>
blockade	NN	blockade
exposure	NN	exposure
were	VBD	be
obtained	VBN	obtain
through	IN	through
random-effects	JJ	<unknown>
model	NN	model
.	SENT	.
The	DT	the
random-effect	JJ	<unknown>
meta-analysis	NN	meta-analysis
on	IN	on
fourteen	NN	fourteen
studies	NNS	study
(	(	(
17,876	CD	@card@
patients	NNS	patient
)	)	)
showed	VBD	show
that	IN	that
RAAS	NP	<unknown>
blockade	NN	blockade
use	NN	use
was	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
increased	VBN	increase
risk	NN	risk
of	IN	of
incident	NN	incident
AKI	NP	Aki
in	IN	in
hospitalized	VBN	hospitalize
COVID-19	JJ	<unknown>
patients	NNS	patient
(	(	(
OR	CC	or
1.68	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
1.19-2.36	CD	@card@
)	)	)
.	SENT	.
Additional	JJ	additional
analysis	NN	analysis
showed	VBD	show
that	IN	that
the	DT	the
association	NN	association
of	IN	of
RAAS	NP	<unknown>
blockade	NN	blockade
use	NN	use
on	IN	on
COVID-19-related	NP	COVID-19-related
AKI	NP	Aki
remains	VBZ	remain
significant	JJ	significant
even	RB	even
after	IN	after
stratification	NN	stratification
by	IN	by
drug	NN	drug
class	NN	class
and	CC	and
AKI	NP	Aki
severity	NN	severity
.	SENT	.
RAAS	NP	<unknown>
blockade	NN	blockade
use	NN	use
is	VBZ	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
the	DT	the
incident	NN	incident
AKI	NP	Aki
in	IN	in
hospitalized	VBN	hospitalize
COVID-19	JJ	<unknown>
patients	NNS	patient
.	SENT	.
Therefore	RB	therefore
,	,	,
careful	JJ	careful
monitoring	NN	monitoring
of	IN	of
renal	JJ	renal
complications	NNS	complication
is	VBZ	be
recommended	VBN	recommend
for	IN	for
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
recent	JJ	recent
RAAS	NP	<unknown>
blockade	NN	blockade
use	NN	use
due	JJ	due
to	TO	to
the	DT	the
potential	JJ	potential
risk	NN	risk
of	IN	of
AKI	NP	Aki
.	SENT	.
34627082/	CD	@card@
Immunogenic	JJ	immunogenic
T	NN	T
cell	NN	cell
epitopes	NNS	epitope
of	IN	of
SARS-CoV-2	NP	<unknown>
are	VBP	be
recognized	VBN	recognize
by	IN	by
circulating	VBG	circulate
memory	NN	memory
and	CC	and
naive	JJ	naive
CD8	NP	<unknown>
T	NN	T
cells	NNS	cell
of	IN	of
unexposed	JJ	unexposed
individuals	NNS	individual
Recent	JJ	Recent
studies	NNS	study
have	VBP	have
provided	VBN	provide
evidence	NN	evidence
of	IN	of
T	NN	T
cell	NN	cell
reactivity	NN	reactivity
to	TO	to
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Syndrome	NN	syndrome
Coronavirus	NP	<unknown>
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
in	IN	in
significant	JJ	significant
numbers	NNS	number
of	IN	of
non-infected	JJ	non-infected
individuals	NNS	individual
,	,	,
which	WDT	which
has	VBZ	have
been	VBN	be
attributed	VBN	attribute
to	TO	to
cross-reactive	JJ	cross-reactive
CD4	NP	<unknown>
memory	NN	memory
T	NN	T
cells	NNS	cell
from	IN	from
previous	JJ	previous
exposure	NN	exposure
to	TO	to
seasonal	JJ	seasonal
coronaviruses	NNS	coronavirus
.	SENT	.
Less	JJR	less
evidence	NN	evidence
of	IN	of
cross-reactive	JJ	cross-reactive
memory	NN	memory
CD8	NP	<unknown>
T	NN	T
cells	NNS	cell
has	VBZ	have
been	VBN	be
documented	VBN	document
to	TO	to
date	NN	date
.	SENT	.
We	PP	we
used	VBD	use
the	DT	the
NetCTLPan	NP	<unknown>
neural	JJ	neural
network	NN	network
of	IN	of
the	DT	the
Epitope	NP	Epitope
Database	NP	Database
and	CC	and
Analysis	NP	Analysis
Resource	NP	Resource
to	TO	to
select	VB	select
a	DT	a
series	NN	series
of	IN	of
27	CD	@card@
HLA-A*02:01	JJ	HLA-A*@card@
epitopes	NNS	epitope
derived	VBN	derive
from	IN	from
the	DT	the
proteome	NN	<unknown>
of	IN	of
SARS-CoV-2	NP	<unknown>
.	SENT	.
Their	PP$	their
binding	JJ	binding
capacity	NN	capacity
was	VBD	be
assessed	VBN	assess
by	IN	by
a	DT	a
HLA-A*02:01	NP	HLA-A*@card@
stabilization	NN	stabilization
assay	NN	assay
and	CC	and
by	IN	by
quantifying	VBG	quantify
their	PP$	their
binding	NN	binding
to	TO	to
HLA-A*02:01	JJ	HLA-A*@card@
monomers	NNS	monomer
for	IN	for
the	DT	the
generation	NN	generation
of	IN	of
tetramers	NNS	<unknown>
.	SENT	.
Their	PP$	their
ability	NN	ability
to	TO	to
stimulate	VB	stimulate
and	CC	and
induce	VB	induce
expansion	NN	expansion
of	IN	of
SARS-CoV-2	NP	<unknown>
reactive	JJ	reactive
CD8	NP	<unknown>
T	NN	T
cells	NNS	cell
was	VBD	be
measured	VBN	measure
by	IN	by
flow	NN	flow
cytometry	NN	<unknown>
.	SENT	.
The	DT	the
TCR	NP	TCR
repertoire	NN	repertoire
of	IN	of
COVID	NP	<unknown>
convalescent	JJ	convalescent
and	CC	and
healthy	JJ	healthy
unexposed	JJ	unexposed
donors	NNS	donor
was	VBD	be
analysed	VBN	analyse
using	VBG	use
the	DT	the
MIRA	NP	Mira
database	NN	database
.	SENT	.
The	DT	the
HLA-A*02:01	JJ	HLA-A*@card@
epitopes	NNS	epitope
tested	VBN	test
were	VBD	be
able	JJ	able
to	TO	to
stabilise	VB	stabilise
HLA	NP	HLA
molecules	NNS	molecule
and	CC	and
induce	VB	induce
activation	NN	activation
of	IN	of
CD8	NP	<unknown>
T	NN	T
cells	NNS	cell
of	IN	of
healthy	JJ	healthy
unexposed	JJ	unexposed
donors	NNS	donor
.	SENT	.
Our	PP$	our
results	NNS	result
,	,	,
based	VBN	base
on	IN	on
specific	JJ	specific
tetramer	NN	<unknown>
binding	VBG	bind
,	,	,
provide	VB	provide
evidence	NN	evidence
supporting	VBG	support
the	DT	the
presence	NN	presence
of	IN	of
frequent	JJ	frequent
cross-reactive	JJ	cross-reactive
CD8	NP	<unknown>
T	NN	T
cells	NNS	cell
to	TO	to
SARS-CoV-2	NP	<unknown>
antigens	NNS	antigen
in	IN	in
non-exposed	JJ	non-exposed
individuals	NNS	individual
.	SENT	.
Interestingly	RB	interestingly
,	,	,
the	DT	the
reactive	JJ	reactive
cells	NNS	cell
were	VBD	be
distributed	VBN	distribute
into	IN	into
naive	JJ	naive
,	,	,
memory	NN	memory
and	CC	and
effector	NN	effector
subsets	NNS	subset
.	SENT	.
Our	PP$	our
data	NNS	datum
are	VBP	be
consistent	JJ	consistent
with	IN	with
a	DT	a
significant	JJ	significant
proportion	NN	proportion
of	IN	of
the	DT	the
reactive	JJ	reactive
CD8	NP	<unknown>
T	NN	T
clones	NNS	clone
belonging	VBG	belong
to	TO	to
the	DT	the
public	JJ	public
shared	JJ	shared
repertoire	NN	repertoire
,	,	,
readily	RB	readily
available	JJ	available
in	IN	in
absence	NN	absence
of	IN	of
previous	JJ	previous
contact	NN	contact
with	IN	with
closely	RB	closely
related	VBN	relate
coronaviruses	NNS	coronavirus
.	SENT	.
Furthermore	RB	furthermore
,	,	,
we	PP	we
demonstrate	VBP	demonstrate
the	DT	the
immunogenic	JJ	immunogenic
capacity	NN	capacity
of	IN	of
long	JJ	long
peptides	NNS	peptide
carrying	VBG	carry
T	NN	T
cell	NN	cell
epitopes	NNS	epitope
,	,	,
which	WDT	which
can	MD	can
serve	VB	serve
to	TO	to
isolate	VB	isolate
virus-specific	JJ	virus-specific
T	NN	T
cell	NN	cell
receptors	NNS	receptor
among	IN	among
the	DT	the
ample	JJ	ample
repertoire	NN	repertoire
of	IN	of
healthy	JJ	healthy
unexposed	JJ	unexposed
subjects	NNS	subject
and	CC	and
could	MD	could
have	VB	have
application	NN	application
in	IN	in
COVID-19	NP	<unknown>
immunotherapy	NN	immunotherapy
.	SENT	.
Limitations	NNS	limitation
of	IN	of
our	PP$	our
study	NN	study
are	VBP	be
that	IN	that
it	PP	it
concentrated	VBD	concentrate
on	IN	on
one	CD	one
MHC	NP	MHC
I	NP	I
allele	NN	allele
(	(	(
HLA-A*02:01	NP	HLA-A*@card@
)	)	)
and	CC	and
the	DT	the
low	JJ	low
numbers	NNS	number
of	IN	of
samples	NNS	sample
and	CC	and
epitopes	NNS	epitope
tested	VBD	test
.	SENT	.
34256928/	CD	@card@
Retraction	NN	retraction
notice	NN	notice
to	TO	to
"	``	"
Impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
on	IN	on
Stroke	NN	stroke
Epidemiology	NN	epidemiology
and	CC	and
Clinical	JJ	clinical
Stroke	NN	stroke
Practice	NN	practice
in	IN	in
the	DT	the
US	NP	US
"	''	"
[	SYM	[
Journal	NP	Journal
of	IN	of
Stroke	NN	stroke
and	CC	and
Cerebrovascular	JJ	cerebrovascular
Diseases	NNS	disease
,	,	,
Vol.	NP	Volume
30	CD	@card@
,	,	,
No.	NN	No.
4	CD	@card@
(	(	(
April	NP	April
)	)	)
,	,	,
2021	CD	@card@
:	:	:
105639	CD	@card@
]	SYM	]
32343996/	CD	@card@
Rising	VBG	rise
Concern	NN	concern
on	IN	on
Damaged	JJ	damaged
Testis	NN	testis
of	IN	of
COVID-19	NP	<unknown>
Patients	NPS	Patients
32387409/	CD	@card@
Early	JJ	early
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
hydroxychloroquine	NN	hydroxychloroquine
and	CC	and
azithromycin	NN	<unknown>
:	:	:
A	DT	a
retrospective	JJ	retrospective
analysis	NN	analysis
of	IN	of
1061	CD	@card@
cases	NNS	case
in	IN	in
Marseille	NP	Marseille
,	,	,
France	NP	France
In	IN	in
France	NP	France
,	,	,
the	DT	the
combination	NN	combination
hydroxychloroquine	NN	hydroxychloroquine
(	(	(
HCQ	NP	HCQ
)	)	)
and	CC	and
azithromycin	NP	<unknown>
(	(	(
AZ	NP	AZ
)	)	)
is	VBZ	be
used	VBN	use
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
retrospectively	RB	retrospectively
report	VBP	report
on	IN	on
1061	CD	@card@
SARS-CoV-2	NN	<unknown>
positive	JJ	positive
tested	VBN	test
patients	NNS	patient
treated	VBN	treat
for	IN	for
at	IN	at
least	JJS	least
three	CD	three
days	NNS	day
with	IN	with
the	DT	the
following	VBG	follow
regimen	NN	regimen
:	:	:
HCQ	NP	HCQ
(	(	(
200	CD	@card@
mg	NN	mg
three	CD	three
times	NNS	time
daily	JJ	daily
for	IN	for
ten	CD	ten
days	NNS	day
)	)	)
+	SYM	+
AZ	NP	AZ
(	(	(
500	CD	@card@
mg	NN	mg
on	IN	on
day	NN	day
1	CD	@card@
followed	VBN	follow
by	IN	by
250	CD	@card@
mg	NN	mg
daily	JJ	daily
for	IN	for
the	DT	the
next	JJ	next
four	CD	four
days	NNS	day
)	)	)
.	SENT	.
Outcomes	NNS	outcome
were	VBD	be
death	NN	death
,	,	,
clinical	JJ	clinical
worsening	NN	worsening
(	(	(
transfer	NN	transfer
to	TO	to
ICU	NP	ICU
,	,	,
and	CC	and
&gt	NN	&gt
;	:	;
10	CD	@card@
day	NN	day
hospitalization	NN	hospitalization
)	)	)
and	CC	and
viral	JJ	viral
shedding	VBG	shed
persistence	NN	persistence
(	(	(
&gt	NP	<unknown>
;	:	;
10	CD	@card@
days	NNS	day
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
1061	CD	@card@
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
analysis	NN	analysis
(	(	(
46.4	CD	@card@
%	NN	%
male	JJ	male
,	,	,
mean	JJ	mean
age	NN	age
43.6	CD	@card@
years	NNS	year
-	NN	<unknown>
range	NN	range
14-95	CD	@card@
years	NNS	year
)	)	)
.	SENT	.
Good	JJ	good
clinical	JJ	clinical
outcome	NN	outcome
and	CC	and
virological	JJ	virological
cure	NN	cure
were	VBD	be
obtained	VBN	obtain
in	IN	in
973	CD	@card@
patients	NNS	patient
within	IN	within
10	CD	@card@
days	NNS	day
(	(	(
91.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Prolonged	JJ	prolonged
viral	JJ	viral
carriage	NN	carriage
was	VBD	be
observed	VBN	observe
in	IN	in
47	CD	@card@
patients	NNS	patient
(	(	(
4.4	CD	@card@
%	NN	%
)	)	)
and	CC	and
was	VBD	be
associated	VBN	associate
to	TO	to
a	DT	a
higher	JJR	high
viral	JJ	viral
load	NN	load
at	IN	at
diagnosis	NN	diagnosis
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
but	CC	but
viral	JJ	viral
culture	NN	culture
was	VBD	be
negative	JJ	negative
at	IN	at
day	NN	day
10	CD	@card@
.	SENT	.
All	DT	all
but	CC	but
one	CD	one
,	,	,
were	VBD	be
PCR-cleared	JJ	PCR-cleared
at	IN	at
day	NN	day
15	CD	@card@
.	SENT	.
A	DT	a
poor	JJ	poor
clinical	JJ	clinical
outcome	NN	outcome
(	(	(
PClinO	NP	<unknown>
)	)	)
was	VBD	be
observed	VBN	observe
for	IN	for
46	CD	@card@
patients	NNS	patient
(	(	(
4.3	CD	@card@
%	NN	%
)	)	)
and	CC	and
8	CD	@card@
died	VBD	die
(	(	(
0.75	CD	@card@
%	NN	%
)	)	)
(	(	(
74-95	CD	@card@
years	NNS	year
old	JJ	old
)	)	)
.	SENT	.
All	DT	all
deaths	NNS	death
resulted	VBN	result
from	IN	from
respiratory	JJ	respiratory
failure	NN	failure
and	CC	and
not	RB	not
from	IN	from
cardiac	JJ	cardiac
toxicity	NN	toxicity
.	SENT	.
Five	CD	five
patients	NNS	patient
are	VBP	be
still	RB	still
hospitalized	VBN	hospitalize
(	(	(
98.7	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
cured	VBN	cure
so	RB	so
far	RB	far
)	)	)
.	SENT	.
PClinO	NP	<unknown>
was	VBD	be
associated	VBN	associate
with	IN	with
older	JJR	old
age	NN	age
(	(	(
OR	CC	or
1.11	CD	@card@
)	)	)
,	,	,
severity	NN	severity
of	IN	of
illness	NN	illness
at	IN	at
admission	NN	admission
(	(	(
OR	CC	or
10.05	CD	@card@
)	)	)
and	CC	and
low	JJ	low
HCQ	NP	HCQ
serum	NN	serum
concentration	NN	concentration
.	SENT	.
PClinO	NP	<unknown>
was	VBD	be
independently	RB	independently
associated	VBN	associate
with	IN	with
the	DT	the
use	NN	use
of	IN	of
selective	JJ	selective
beta-blocking	NN	<unknown>
agents	NNS	agent
and	CC	and
angiotensin	NP	angiotensin
II	NP	II
receptor	NN	receptor
blockers	NNS	blocker
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
.05	LS	@card@
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
2.3	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
reported	VBD	report
mild	JJ	mild
adverse	JJ	adverse
events	NNS	event
(	(	(
gastrointestinal	JJ	gastrointestinal
or	CC	or
skin	NN	skin
symptoms	NNS	symptom
,	,	,
headache	NN	headache
,	,	,
insomnia	NN	insomnia
and	CC	and
transient	JJ	transient
blurred	VBN	blur
vision	NN	vision
)	)	)
.	SENT	.
Administration	NN	administration
of	IN	of
the	DT	the
HCQ+AZ	NP	<unknown>
combination	NN	combination
before	IN	before
COVID-19	NP	<unknown>
complications	NNS	complication
occur	VBP	occur
is	VBZ	be
safe	JJ	safe
and	CC	and
associated	VBN	associate
with	IN	with
a	DT	a
very	RB	very
low	JJ	low
fatality	NN	fatality
rate	NN	rate
in	IN	in
patients	NNS	patient
.	SENT	.
34237727/	CD	@card@
Reduction	NN	reduction
in	IN	in
Acute	JJ	acute
Stroke	NN	stroke
Admissions	NNS	admission
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
Data	NNS	datum
from	IN	from
a	DT	a
National	NP	National
Stroke	NN	stroke
Registry	NN	registry
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
overwhelmed	VBD	overwhelm
health-care	JJ	health-care
systems	NNS	system
worldwide	RB	worldwide
,	,	,
and	CC	and
medical	JJ	medical
care	NN	care
for	IN	for
other	JJ	other
acute	JJ	acute
diseases	NNS	disease
was	VBD	be
negatively	RB	negatively
impacted	VBN	impact
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
investigate	VB	investigate
the	DT	the
effect	NN	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
on	IN	on
admission	NN	admission
rates	NNS	rate
and	CC	and
in-hospital	JJ	in-hospital
care	NN	care
for	IN	for
acute	JJ	acute
stroke	NN	stroke
and	CC	and
transient	JJ	transient
ischemic	JJ	ischemic
attack	NN	attack
(	(	(
TIA	NP	Tia
)	)	)
in	IN	in
Israel	NP	Israel
,	,	,
shortly	RB	shortly
after	IN	after
the	DT	the
start	NN	start
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
retrospective	JJ	retrospective
observational	JJ	observational
study	NN	study
,	,	,
based	VBN	base
on	IN	on
data	NNS	datum
reported	VBD	report
to	TO	to
the	DT	the
Israeli	JJ	Israeli
National	NP	National
Stroke	NN	stroke
Registry	NN	registry
from	IN	from
7	CD	@card@
tertiary	JJ	tertiary
hospitals	NNS	hospital
.	SENT	.
All	DT	all
hospital	NN	hospital
admissions	NNS	admission
for	IN	for
acute	JJ	acute
stroke	NN	stroke
or	CC	or
TIA	NP	Tia
that	WDT	that
occurred	VBD	occur
between	IN	between
January	NP	January
1	CD	@card@
and	CC	and
April	NP	April
30	CD	@card@
,	,	,
2020	CD	@card@
were	VBD	be
included	VBN	include
.	SENT	.
Data	NNS	datum
were	VBD	be
stratified	VBN	stratify
into	IN	into
2	CD	@card@
periods	NNS	period
according	VBG	accord
to	TO	to
the	DT	the
timing	NN	timing
of	IN	of
COVID-19	NP	<unknown>
restrictions	NNS	restriction
as	RB	as
follows	VBZ	follow
:	:	:
(	(	(
1	LS	1
)	)	)
"	``	"
pre-pandemic	JJ	pre-pandemic
"	''	"
-	NN	<unknown>
January	NP	January
1	CD	@card@
to	TO	to
March	NP	March
7	CD	@card@
,	,	,
2020	CD	@card@
and	CC	and
(	(	(
2	LS	2
)	)	)
"	``	"
pandemic	JJ	pandemic
"	''	"
-	NN	<unknown>
March	NP	March
8	CD	@card@
to	TO	to
April	NP	April
30	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
We	PP	we
compared	VBD	compare
the	DT	the
weekly	JJ	weekly
counts	NNS	count
of	IN	of
hospitalizations	NNS	hospitalization
between	IN	between
the	DT	the
2	CD	@card@
periods	NNS	period
.	SENT	.
We	PP	we
further	RBR	further
investigated	VBD	investigate
changes	NNS	change
in	IN	in
demographic	JJ	demographic
characteristics	NNS	characteristic
and	CC	and
in	IN	in
some	DT	some
key	JJ	key
parameters	NNS	parameter
of	IN	of
stroke	NN	stroke
care	NN	care
,	,	,
including	VBG	include
the	DT	the
percentage	NN	percentage
of	IN	of
reperfusion	NN	reperfusion
therapies	NNS	therapy
performed	VBD	perform
,	,	,
time	NN	time
from	IN	from
hospital	NN	hospital
arrival	NN	arrival
to	TO	to
brain	NN	brain
imaging	NN	imaging
and	CC	and
to	TO	to
thrombolysis	NN	thrombolysis
,	,	,
length	NN	length
of	IN	of
hospital	NN	hospital
stay	NN	stay
,	,	,
and	CC	and
in-hospital	JJ	in-hospital
mortality	NN	mortality
.	SENT	.
2,260	CD	@card@
cases	NNS	case
were	VBD	be
included	VBN	include
:	:	:
1,469	CD	@card@
in	IN	in
the	DT	the
pre-COVID-19	JJ	<unknown>
period	NN	period
and	CC	and
791	CD	@card@
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
period	NN	period
.	SENT	.
Hospital	NN	hospital
admissions	NNS	admission
significantly	RB	significantly
declined	VBD	decline
between	IN	between
the	DT	the
2	CD	@card@
periods	NNS	period
,	,	,
by	IN	by
48	CD	@card@
%	NN	%
for	IN	for
TIA	NP	Tia
(	(	(
rate	NN	rate
ratio	NN	ratio
[	SYM	[
RR	NP	RR
]	SYM	]
=	SYM	=
0.52	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.43-0.64	CD	@card@
)	)	)
and	CC	and
by	IN	by
29	CD	@card@
%	NN	%
for	IN	for
stroke	NN	stroke
(	(	(
RR	NP	RR
=	SYM	=
0.71	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.64-0.78	CD	@card@
)	)	)
.	SENT	.
No	DT	no
significant	JJ	significant
changes	NNS	change
were	VBD	be
detected	VBN	detect
in	IN	in
demographic	JJ	demographic
characteristics	NNS	characteristic
and	CC	and
in	IN	in
most	JJS	most
parameters	NNS	parameter
of	IN	of
stroke	NN	stroke
management	NN	management
.	SENT	.
While	IN	while
the	DT	the
percentage	NN	percentage
of	IN	of
reperfusion	NN	reperfusion
therapies	NNS	therapy
performed	VBN	perform
remained	VBD	remain
unchanged	JJ	unchanged
,	,	,
the	DT	the
absolute	JJ	absolute
number	NN	number
of	IN	of
patients	NNS	patient
treated	VBN	treat
with	IN	with
reperfusion	NN	reperfusion
therapies	NNS	therapy
seemed	VBD	seem
to	TO	to
decrease	VB	decrease
.	SENT	.
Higher	JJR	high
in-hospital	JJ	in-hospital
mortality	NN	mortality
was	VBD	be
observed	VBN	observe
only	RB	only
for	IN	for
hemorrhagic	JJ	hemorrhagic
stroke	NN	stroke
.	SENT	.
The	DT	the
marked	JJ	marked
decrease	NN	decrease
in	IN	in
admissions	NNS	admission
for	IN	for
acute	JJ	acute
stroke	NN	stroke
and	CC	and
TIA	NP	Tia
,	,	,
occurring	VBG	occur
at	IN	at
a	DT	a
time	NN	time
of	IN	of
a	DT	a
relatively	RB	relatively
low	JJ	low
burden	NN	burden
of	IN	of
COVID-19	NP	<unknown>
,	,	,
is	VBZ	be
of	IN	of
great	JJ	great
concern	NN	concern
.	SENT	.
Public	JJ	public
awareness	NN	awareness
campaigns	NNS	campaign
are	VBP	be
needed	VBN	need
as	IN	as
patients	NNS	patient
reluctant	JJ	reluctant
to	TO	to
seek	VB	seek
urgent	JJ	urgent
stroke	NN	stroke
care	NN	care
are	VBP	be
deprived	VBN	deprive
of	IN	of
lifesaving	JJ	lifesaving
procedures	NNS	procedure
and	CC	and
secondary	JJ	secondary
prevention	NN	prevention
treatments	NNS	treatment
.	SENT	.
34845183/	CD	@card@
Thrombocytosis	NN	<unknown>
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
without	IN	without
myeloproliferative	JJ	myeloproliferative
neoplasms	NNS	neoplasm
is	VBZ	be
associated	VBN	associate
with	IN	with
better	JJR	good
prognosis	NN	prognosis
but	CC	but
higher	JJR	high
rate	NN	rate
of	IN	of
venous	JJ	venous
thromboembolism	NN	thromboembolism
33855698/	CD	@card@
Immune	NP	Immune
thrombocytopenia	NN	<unknown>
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
34870100/	CD	@card@
Effect	NN	effect
of	IN	of
ABO	NP	ABO
blood	NN	blood
groups	NNS	group
on	IN	on
length	NN	length
of	IN	of
hospital	NN	hospital
stay	VBP	stay
according	VBG	accord
to	TO	to
age	NN	age
in	IN	in
Covid-19	NP	<unknown>
patients	NNS	patient
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
novel	JJ	novel
viral	JJ	viral
disease	NN	disease
with	IN	with
person-to-person	NN	person-to-person
transmission	NN	transmission
that	WDT	that
has	VBZ	have
spread	VBN	spread
to	TO	to
many	JJ	many
countries	NNS	country
since	IN	since
the	DT	the
end	NN	end
of	IN	of
2019	CD	@card@
.	SENT	.
Although	IN	although
many	JJ	many
unknowns	NNS	unknown
were	VBD	be
resolved	VBN	resolve
within	IN	within
a	DT	a
year	NN	year
and	CC	and
the	DT	the
vaccine	NN	vaccine
is	VBZ	be
available	JJ	available
,	,	,
it	PP	it
is	VBZ	be
still	RB	still
a	DT	a
major	JJ	major
global	JJ	global
health	NN	health
problem	NN	problem
.	SENT	.
COVID-19	JJ	<unknown>
infection	NN	infection
may	MD	may
present	VB	present
with	IN	with
a	DT	a
considerably	RB	considerably
wide	JJ	wide
spectrum	NN	spectrum
of	IN	of
severity	NN	severity
and	CC	and
host	NN	host
factors	NNS	factor
play	VBP	play
a	DT	a
significant	JJ	significant
role	NN	role
in	IN	in
determining	VBG	determine
the	DT	the
course	NN	course
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
One	CD	one
of	IN	of
these	DT	these
factors	NNS	factor
is	VBZ	be
blood	NN	blood
groups	NNS	group
.	SENT	.
Based	VBN	base
on	IN	on
previous	JJ	previous
experience	NN	experience
,	,	,
it	PP	it
is	VBZ	be
believed	VBN	believe
that	IN	that
the	DT	the
ABO	NP	ABO
blood	NN	blood
group	NN	group
type	NN	type
affects	VBZ	affect
prognosis	NN	prognosis
,	,	,
treatment	NN	treatment
response	NN	response
and	CC	and
length	NN	length
of	IN	of
stay	NN	stay
in	IN	in
the	DT	the
hospital	NN	hospital
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
our	PP$	our
aim	NN	aim
was	VBD	be
to	TO	to
evaluate	VB	evaluate
whether	IN	whether
the	DT	the
blood	NN	blood
group	NN	group
had	VBD	have
an	DT	an
effect	NN	effect
on	IN	on
the	DT	the
length	NN	length
of	IN	of
the	DT	the
hospital	NN	hospital
stay	NN	stay
.	SENT	.
To	TO	to
the	DT	the
best	JJS	good
of	IN	of
our	PP$	our
knowledge	NN	knowledge
,	,	,
no	DT	no
previous	JJ	previous
studies	NNS	study
have	VBP	have
assessed	VBN	assess
the	DT	the
effect	NN	effect
of	IN	of
ABO	NP	ABO
blood	NN	blood
groups	NNS	group
,	,	,
as	RB	as
well	RB	well
as	IN	as
age	NN	age
,	,	,
on	IN	on
the	DT	the
length	NN	length
of	IN	of
the	DT	the
hospital	NN	hospital
stay	NN	stay
in	IN	in
these	DT	these
settings	NNS	setting
.	SENT	.
In	IN	in
this	DT	this
retrospective	JJ	retrospective
cohort	NN	cohort
study	NN	study
,	,	,
969	CD	@card@
patients	NNS	patient
admitted	VBN	admit
to	TO	to
our	PP$	our
hospital	NN	hospital
between	IN	between
March	NP	March
15	CD	@card@
,	,	,
2020	CD	@card@
and	CC	and
May	NP	May
15	CD	@card@
,	,	,
2020	CD	@card@
were	VBD	be
evaluated	VBN	evaluate
.	SENT	.
The	DT	the
patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
4	CD	@card@
groups	NNS	group
according	VBG	accord
to	TO	to
ABO	NP	ABO
blood	NN	blood
groups	NNS	group
.	SENT	.
The	DT	the
effect	NN	effect
of	IN	of
the	DT	the
ABO	NP	ABO
blood	NN	blood
group	NN	group
by	IN	by
age	NN	age
on	IN	on
the	DT	the
course	NN	course
of	IN	of
the	DT	the
disease	NN	disease
,	,	,
need	NN	need
for	IN	for
intensive	JJ	intensive
care	NN	care
,	,	,
duration	NN	duration
of	IN	of
hospitalization	NN	hospitalization
and	CC	and
mortality	NN	mortality
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
,	,	,
especially	RB	especially
in	IN	in
geriatric	JJ	geriatric
patients	NNS	patient
,	,	,
was	VBD	be
evaluated	VBN	evaluate
.	SENT	.
Of	IN	of
all	PDT	all
the	DT	the
patients	NNS	patient
,	,	,
9.1	CD	@card@
%	NN	%
required	JJ	required
admission	NN	admission
to	TO	to
the	DT	the
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
,	,	,
of	IN	of
whom	WP	whom
83	CD	@card@
%	NN	%
died	VBD	die
.	SENT	.
The	DT	the
average	JJ	average
length	NN	length
of	IN	of
ICU	NP	ICU
stay	NN	stay
was	VBD	be
11	CD	@card@
days	NNS	day
(	(	(
0	CD	@card@
-	NN	<unknown>
59	CD	@card@
)	)	)
.	SENT	.
The	DT	the
observed	JJ	observed
mortality	NN	mortality
rates	NNS	rate
in	IN	in
blood	NN	blood
groups	NNS	group
A	NP	A
,	,	,
B	NP	B
,	,	,
AB	NP	AB
and	CC	and
0	CD	@card@
were	VBD	be
86.4	CD	@card@
%	NN	%
,	,	,
93.3	CD	@card@
%	NN	%
,	,	,
80.0	CD	@card@
%	NN	%
and	CC	and
70.8	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
,	,	,
indicating	VBG	indicate
similar	JJ	similar
death	NN	death
rates	NNS	rate
in	IN	in
all	DT	all
ABO	NP	ABO
blood	NN	blood
types	NNS	type
.	SENT	.
When	WRB	when
the	DT	the
Rh	NP	Rh
phenotype	NN	phenotype
was	VBD	be
taken	VBN	take
into	IN	into
consideration	NN	consideration
,	,	,
no	DT	no
significant	JJ	significant
changes	NNS	change
in	IN	in
results	NNS	result
were	VBD	be
seen	VBN	see
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
we	PP	we
could	MD	could
not	RB	not
observe	VB	observe
a	DT	a
significant	JJ	significant
relationship	NN	relationship
between	IN	between
blood	NN	blood
groups	NNS	group
and	CC	and
clinical	JJ	clinical
outcomes	NNS	outcome
in	IN	in
this	DT	this
study	NN	study
,	,	,
which	WDT	which
included	VBD	include
a	DT	a
sample	NN	sample
of	IN	of
Turkish	JJ	Turkish
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
35310793/	CD	@card@
Combining	VBG	combine
Non-invasive	JJ	non-invasive
Ventilation	NN	ventilation
with	IN	with
timed	VBN	time
position	NN	position
change	NN	change
in	IN	in
the	DT	the
Emergency	NP	Emergency
Department	NP	Department
to	TO	to
improve	VB	improve
oxygenation	NN	oxygenation
and	CC	and
outcomes	NNS	outcome
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
:	:	:
A	DT	a
prospective	JJ	prospective
analysis	NN	analysis
from	IN	from
a	DT	a
low	JJ	low
resource	NN	resource
setup	NN	setup
Moving	VBG	move
away	RB	away
from	IN	from
invasive	JJ	invasive
ventilation	NN	ventilation
towards	IN	towards
timed	VBN	time
position	NN	position
change	NN	change
and	CC	and
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
is	VBZ	be
especially	RB	especially
of	IN	of
benefit	NN	benefit
in	IN	in
low	JJ	low
and	CC	and
middle	JJ	middle
income	NN	income
countries	NNS	country
,	,	,
where	WRB	where
judicious	JJ	judicious
use	NN	use
of	IN	of
the	DT	the
available	JJ	available
healthcare	NN	<unknown>
resources	NNS	resource
is	VBZ	be
the	DT	the
need	NN	need
of	IN	of
the	DT	the
day	NN	day
.	SENT	.
Our	PP$	our
study	NN	study
was	VBD	be
conducted	VBN	conduct
prospectively	RB	prospectively
to	TO	to
develop	VB	develop
strategies	NNS	strategy
for	IN	for
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
in	IN	in
combination	NN	combination
with	IN	with
timed	VBN	time
position	NN	position
change	NN	change
of	IN	of
patients	NNS	patient
to	TO	to
see	VB	see
its	PP$	its
impact	NN	impact
on	IN	on
their	PP$	their
outcome	NN	outcome
.	SENT	.
Non-invasive	JJ	non-invasive
ventilation	NN	ventilation
has	VBZ	have
proven	VBN	prove
to	TO	to
be	VB	be
of	IN	of
benefit	NN	benefit
in	IN	in
COVID-19	NP	<unknown>
related	JJ	related
acute	JJ	acute
lung	NN	lung
injury	NN	injury
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
prospective	JJ	prospective
,	,	,
cross	VBP	cross
sectional	JJ	sectional
study	NN	study
was	VBD	be
to	TO	to
develop	VB	develop
a	DT	a
protocol	NN	protocol
for	IN	for
the	DT	the
use	NN	use
of	IN	of
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
with	IN	with
timed	VBN	time
position	NN	position
change	NN	change
to	TO	to
improve	VB	improve
COVID-19	NP	<unknown>
patients	NNS	patient
'	POS	'
outcomes	NNS	outcome
in	IN	in
the	DT	the
Emergency	NP	Emergency
Department	NP	Department
(	(	(
ED	NN	editor
)	)	)
.	SENT	.
All	DT	all
patients	NNS	patient
presenting	VBG	present
with	IN	with
confirmed	VBN	confirm
or	CC	or
suspected	VBN	suspect
COVID-19	NP	<unknown>
were	VBD	be
enrolled	VBN	enroll
in	IN	in
the	DT	the
study	NN	study
from	IN	from
March	NP	March
2020	CD	@card@
to	TO	to
October	NP	October
2020	CD	@card@
.	SENT	.
Data	NNS	datum
was	VBD	be
collected	VBN	collect
to	TO	to
see	VB	see
the	DT	the
effect	NN	effect
of	IN	of
timed	VBN	time
position	NN	position
change	NN	change
and	CC	and
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
on	IN	on
these	DT	these
patients	NNS	patient
and	CC	and
its	PP$	its
effect	NN	effect
on	IN	on
delaying	VBG	delay
or	CC	or
avoiding	VBG	avoid
invasive	JJ	invasive
ventilation	NN	ventilation
.	SENT	.
Of	IN	of
the	DT	the
207	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
presenting	VBG	present
to	TO	to
the	DT	the
IHHN	NP	<unknown>
ED	NN	editor
,	,	,
109(52.7%)	NP	<unknown>
had	VBD	have
oxygen	NN	oxygen
saturation	NN	saturation
in	IN	in
the	DT	the
nineties	NNS	ninety
in	IN	in
supine	JJ	supine
position	NN	position
followed	VBN	follow
by	IN	by
right	JJ	right
lateral	NN	lateral
in	IN	in
37(17.9%)	JJ	<unknown>
,	,	,
sitting	VBG	sit
up	RP	up
in	IN	in
30(14.5%)	JJ	<unknown>
,	,	,
left	JJ	left
lateral	NN	lateral
in	IN	in
29(14%)	JJ	<unknown>
and	CC	and
prone	JJ	prone
position	NN	position
in	IN	in
2(1	JJ	<unknown>
%	NN	%
)	)	)
.	SENT	.
Maximal	JJ	maximal
oxygenation	NN	oxygenation
was	VBD	be
achieved	VBN	achieve
with	IN	with
non	JJ	non
rebreather	NN	rebreather
mask	NN	mask
(	(	(
NRM	NP	NRM
)	)	)
and	CC	and
nasal	JJ	nasal
prongs	NNS	prong
in	IN	in
87(42%)	JJ	<unknown>
of	IN	of
the	DT	the
patients	NNS	patient
,	,	,
followed	VBN	follow
by	IN	by
the	DT	the
use	NN	use
of	IN	of
continuous	JJ	continuous
positive	JJ	positive
airway	NN	airway
pressure	NN	pressure
(	(	(
CPAP	NP	<unknown>
)	)	)
in	IN	in
29(14	JJ	<unknown>
%	NN	%
)	)	)
.	SENT	.
Most	JJS	most
of	IN	of
the	DT	the
patients	NNS	patient
preferred	VBD	prefer
to	TO	to
stay	VB	stay
in	IN	in
the	DT	the
supine	JJ	supine
position	NN	position
and	CC	and
described	VBD	describe
it	PP	it
as	IN	as
the	DT	the
position	NN	position
of	IN	of
comfort	NN	comfort
.	SENT	.
When	WRB	when
used	VBN	use
in	IN	in
combination	NN	combination
supine	JJ	supine
position	NN	position
,	,	,
patients	NNS	patient
on	IN	on
NRM	NP	NRM
with	IN	with
nasal	JJ	nasal
prongs	NNS	prong
and	CC	and
on	IN	on
CPAP	NP	<unknown>
,	,	,
had	VBD	have
oxygen	NN	oxygen
saturation	NN	saturation
in	IN	in
the	DT	the
nineties	NNS	ninety
.	SENT	.
Central	JJ	central
obesity	NN	obesity
was	VBD	be
found	VBN	find
to	TO	to
be	VB	be
the	DT	the
prime	JJ	prime
reason	NN	reason
for	IN	for
the	DT	the
inability	NN	inability
to	TO	to
prone	JJ	prone
our	PP$	our
patients	NNS	patient
.	SENT	.
This	DT	this
needs	VBZ	need
to	TO	to
be	VB	be
followed	VBN	follow
up	RP	up
in	IN	in
the	DT	the
current	JJ	current
fourth	JJ	fourth
wave	NN	wave
of	IN	of
COVID-19	NP	<unknown>
to	TO	to
see	VB	see
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
the	DT	the
said	VBN	say
modalities	NNS	modality
.	SENT	.
34682939/	CD	@card@
The	NP	The
COVID-19	NP	<unknown>
Global	NP	Global
Pandemic	NN	pandemic
and	CC	and
Its	PP$	its
Impact	NN	impact
on	IN	on
the	DT	the
Mental	JJ	mental
Health	NN	health
of	IN	of
Nurses	NNS	nurse
in	IN	in
Malaysia	NP	Malaysia
The	DT	the
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
global	JJ	global
pandemic	NN	pandemic
since	IN	since
its	PP$	its
onset	NN	onset
has	VBZ	have
had	VBN	have
a	DT	a
dramatic	JJ	dramatic
and	CC	and
often	RB	often
devastating	JJ	devastating
impact	NN	impact
,	,	,
both	CC	both
physical	JJ	physical
and	CC	and
psychological	JJ	psychological
,	,	,
on	IN	on
all	DT	all
healthcare	NN	<unknown>
workers	NNS	worker
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
assess	VB	assess
the	DT	the
impact	NN	impact
of	IN	of
psychological	JJ	psychological
distress	NN	distress
that	IN	that
COVID-19	NP	<unknown>
has	VBZ	have
on	IN	on
nurses	NNS	nurse
,	,	,
as	RB	as
well	RB	well
as	IN	as
the	DT	the
coping	VBG	cope
strategies	NNS	strategy
that	IN	that
they	PP	they
employed	VBD	employ
.	SENT	.
This	DT	this
is	VBZ	be
a	DT	a
cross-sectional	JJ	cross-sectional
national	JJ	national
online	JJ	online
survey	NN	survey
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
859	CD	@card@
nurses	NNS	nurse
actively	RB	actively
involved	VBN	involve
in	IN	in
caring	VBG	care
for	IN	for
patients	NNS	patient
with	IN	with
suspected	VBN	suspect
or	CC	or
confirmed	VBN	confirm
COVID-19	NP	<unknown>
in	IN	in
Malaysia	NP	Malaysia
participated	VBD	participate
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
More	JJR	more
than	IN	than
three-quarters	NNS	three-quarter
of	IN	of
the	DT	the
nurses	NNS	nurse
experienced	VBD	experience
stress	NN	stress
(	(	(
77.2	CD	@card@
%	NN	%
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
88.7	CD	@card@
%	NN	%
and	CC	and
7.2	CD	@card@
%	NN	%
of	IN	of
nurses	NNS	nurse
revealed	VBD	reveal
a	DT	a
moderate	JJ	moderate
and	CC	and
high	JJ	high
stress	NN	stress
level	NN	level
,	,	,
respectively	RB	respectively
.	SENT	.
Approximately	RB	approximately
one	CD	one
in	IN	in
eight	CD	eight
(	(	(
12.1	CD	@card@
%	NN	%
)	)	)
nurses	NNS	nurse
reported	VBD	report
feeling	VBG	feel
depressed	JJ	depressed
.	SENT	.
Nurses	NNS	nurse
working	VBG	work
in	IN	in
the	DT	the
outpatient	NN	outpatient
departments	NNS	department
reported	VBD	report
significantly	RB	significantly
higher	JJR	high
stress	NN	stress
levels	NNS	level
than	IN	than
nurses	NNS	nurse
working	VBG	work
in	IN	in
inpatient	NN	inpatient
care	NN	care
departments	NNS	department
.	SENT	.
Nurses	NNS	nurse
having	VBG	have
chronic	JJ	chronic
health	NN	health
problems	NNS	problem
reported	VBD	report
significantly	RB	significantly
higher	JJR	high
depression	NN	depression
levels	NNS	level
than	IN	than
nurses	NNS	nurse
with	IN	with
no	DT	no
chronic	JJ	chronic
health	NN	health
problem	NN	problem
.	SENT	.
Highly	RB	highly
stressed	VBN	stress
or	CC	or
depressed	VBN	depress
nurses	NNS	nurse
tend	VBP	tend
to	TO	to
adopt	VB	adopt
avoidance	NN	avoidance
coping	VBG	cope
strategies	NNS	strategy
while	IN	while
religion	NN	religion
and	CC	and
emotional	JJ	emotional
support	NN	support
were	VBD	be
used	VBN	use
regardless	RB	regardless
of	IN	of
the	DT	the
stress	NN	stress
or	CC	or
depression	NN	depression
levels	NNS	level
experienced	VBD	experience
.	SENT	.
The	DT	the
findings	NNS	finding
of	IN	of
the	DT	the
study	NN	study
provide	VB	provide
insight	NN	insight
into	IN	into
the	DT	the
mental	JJ	mental
health	NN	health
and	CC	and
coping	VBG	cope
strategies	NNS	strategy
of	IN	of
nurses	NNS	nurse
actively	RB	actively
involved	VBN	involve
in	IN	in
caring	VBG	care
for	IN	for
patients	NNS	patient
with	IN	with
suspected	VBN	suspect
or	CC	or
confirmed	VBN	confirm
COVID-19	NP	<unknown>
in	IN	in
Malaysia	NP	Malaysia
.	SENT	.
This	DT	this
would	MD	would
be	VB	be
of	IN	of
tremendous	JJ	tremendous
help	NN	help
to	TO	to
nursing	NN	nursing
administrators	NNS	administrator
in	IN	in
implementing	VBG	implement
mental	JJ	mental
health	NN	health
services	NNS	service
for	IN	for
nurses	NNS	nurse
during	IN	during
and	CC	and
following	VBG	follow
the	DT	the
COVID-19	NP	<unknown>
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
35013191/	CD	@card@
Dynamics	NPS	Dynamics
of	IN	of
spike-and	NN	<unknown>
nucleocapsid	NN	nucleocapsid
specific	JJ	specific
immunity	NN	immunity
during	IN	during
long-term	JJ	long-term
follow-up	NN	follow-up
and	CC	and
vaccination	NN	vaccination
of	IN	of
SARS-CoV-2	NP	<unknown>
convalescents	NNS	convalescent
Anti-viral	JJ	anti-viral
immunity	NN	immunity
continuously	RB	continuously
declines	VBZ	decline
over	IN	over
time	NN	time
after	IN	after
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
characterize	VBP	characterize
the	DT	the
dynamics	NNS	dynamics
of	IN	of
anti-viral	JJ	anti-viral
immunity	NN	immunity
during	IN	during
long-term	JJ	long-term
follow-up	NN	follow-up
and	CC	and
after	IN	after
BNT162b2	JJ	<unknown>
mRNA-vaccination	NN	mRNA-vaccination
in	IN	in
convalescents	NNS	convalescent
after	IN	after
asymptomatic	JJ	asymptomatic
or	CC	or
mild	JJ	mild
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
.	SENT	.
Virus-specific	JJ	Virus-specific
and	CC	and
virus-neutralizing	JJ	<unknown>
antibody	NN	antibody
titers	NNS	titer
rapidly	RB	rapidly
declined	VBD	decline
in	IN	in
convalescents	NNS	convalescent
over	IN	over
9	CD	@card@
months	NNS	month
after	IN	after
infection	NN	infection
,	,	,
whereas	IN	whereas
virus-specific	JJ	virus-specific
cytokine-producing	NN	cytokine-producing
polyfunctional	JJ	polyfunctional
T	NN	T
cells	NNS	cell
persisted	VBD	persist
,	,	,
among	IN	among
which	WDT	which
IL-2-producing	JJ	IL-2-producing
T	NN	T
cells	NNS	cell
correlated	VBN	correlate
with	IN	with
virus-neutralizing	JJ	<unknown>
antibody	NN	antibody
titers	NNS	titer
.	SENT	.
Among	IN	among
convalescents	NNS	convalescent
,	,	,
5	CD	@card@
%	NN	%
of	IN	of
individuals	NNS	individual
failed	VBN	fail
to	TO	to
mount	VB	mount
long-lasting	JJ	long-lasting
immunity	NN	immunity
after	IN	after
infection	NN	infection
and	CC	and
showed	VBD	show
a	DT	a
delayed	JJ	delayed
response	NN	response
to	TO	to
vaccination	NN	vaccination
compared	VBN	compare
to	TO	to
1	CD	@card@
%	NN	%
of	IN	of
naive	JJ	naive
vaccinees	NNS	<unknown>
,	,	,
but	CC	but
successfully	RB	successfully
responded	VBD	respond
to	TO	to
prime/boost	NN	prime/boost
vaccination	NN	vaccination
.	SENT	.
During	IN	during
the	DT	the
follow-up	NN	follow-up
period	NN	period
,	,	,
8	CD	@card@
%	NN	%
of	IN	of
convalescents	NNS	convalescent
showed	VBD	show
a	DT	a
selective	JJ	selective
increase	NN	increase
in	IN	in
virus-neutralizing	JJ	<unknown>
antibody	NN	antibody
titers	NNS	titer
without	IN	without
accompanying	VBG	accompany
increased	VBN	increase
frequencies	NNS	frequency
of	IN	of
circulating	VBG	circulate
SARS-CoV-2-specific	JJ	SARS-CoV-2-specific
T	NN	T
cells	NNS	cell
.	SENT	.
The	DT	the
same	JJ	same
convalescents	NNS	convalescent
,	,	,
however	RB	however
,	,	,
responded	VBD	respond
to	TO	to
vaccination	NN	vaccination
with	IN	with
simultaneous	JJ	simultaneous
increase	NN	increase
in	IN	in
antibody	NN	antibody
and	CC	and
T	NN	T
cell	NN	cell
immunity	NN	immunity
revealing	VBG	reveal
the	DT	the
strength	NN	strength
of	IN	of
mRNA-vaccination	NN	mRNA-vaccination
to	TO	to
increase	VB	increase
virus-specific	JJ	virus-specific
immunity	NN	immunity
in	IN	in
convalescents	NNS	convalescent
.	SENT	.
Waning	VBG	wane
immunity	NN	immunity
to	TO	to
SARS-CoV-2	NP	<unknown>
is	VBZ	be
of	IN	of
concern	NN	concern
.	SENT	.
Here	RB	here
the	DT	the
authors	NNS	author
follow	VBP	follow
spike-	NN	<unknown>
and	CC	and
nucleocapsid	JJ	<unknown>
specific	JJ	specific
immunity	NN	immunity
in	IN	in
convalescent	JJ	convalescent
individuals	NNS	individual
for	IN	for
9	CD	@card@
months	NNS	month
observing	VBG	observe
a	DT	a
decline	NN	decline
in	IN	in
antibody	NN	antibody
levels	NNS	level
but	CC	but
persisting	VBG	persist
T	NN	T
cell	NN	cell
response	NN	response
.	SENT	.
Vaccination	NN	vaccination
approximately	RB	approximately
11	CD	@card@
months	NNS	month
after	IN	after
infection	NN	infection
boosts	NNS	boost
antibody	NN	antibody
and	CC	and
T	NN	T
cell	NN	cell
immunity	NN	immunity
.	SENT	.
35165656/	CD	@card@
Short	JJ	short
term	NN	term
safety	NN	safety
of	IN	of
booster	NN	booster
immunization	NN	immunization
with	IN	with
BNT162b2	NP	<unknown>
mRNA	NP	<unknown>
COVID-19	NP	<unknown>
vaccine	NN	vaccine
in	IN	in
healthcare	NN	<unknown>
workers	NNS	worker
This	DT	this
study	NN	study
demonstrated	VBD	demonstrate
good	JJ	good
short-term	JJ	short-term
safety	NN	safety
profile	NN	profile
after	IN	after
a	DT	a
third	JJ	third
dose	NN	dose
of	IN	of
BNT162b2	NP	<unknown>
vaccine	NN	vaccine
among	IN	among
HCWs	NP	<unknown>
.	SENT	.
There	EX	there
were	VBD	be
more	JJR	more
frequent	JJ	frequent
local	JJ	local
reactions	NNS	reaction
and	CC	and
less	JJR	less
systemic	JJ	systemic
reactions	NNS	reaction
compared	VBN	compare
to	TO	to
the	DT	the
second	JJ	second
dose	NN	dose
.	SENT	.
HCW	NN	HCW
's	VBZ	be
who	WP	who
reported	VBD	report
reactions	NNS	reaction
had	VBD	have
higher	JJR	high
pre-booster	NN	pre-booster
titer	NN	titer
of	IN	of
anti-S1	JJ	<unknown>
antibodies	NNS	antibody
compared	VBN	compare
to	TO	to
those	DT	those
reported	VBD	report
no	DT	no
reactions	NNS	reaction
.	SENT	.
35312380/	CD	@card@
Inherited	JJ	inherited
Thrombophilias	NNS	<unknown>
Are	VBP	be
Associated	NP	Associated
With	IN	with
a	DT	a
Higher	JJR	high
Risk	NN	risk
of	IN	of
COVID-19-Associated	JJ	<unknown>
Venous	JJ	venous
Thromboembolism	NN	thromboembolism
:	:	:
A	DT	a
Prospective	JJ	prospective
Population-Based	JJ	<unknown>
Cohort	NN	cohort
Study	NN	study
34415401/	CD	@card@
Effects	NNS	effect
of	IN	of
a	DT	a
disposable	JJ	disposable
home	NN	home
electro-stimulation	NN	electro-stimulation
device	NN	device
(	(	(
Pelviva	NP	<unknown>
)	)	)
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
female	JJ	female
urinary	JJ	urinary
incontinence	NN	incontinence
:	:	:
a	DT	a
randomised	VBN	randomise
controlled	JJ	controlled
trial	NN	trial
To	TO	to
compare	VB	compare
current	JJ	current
General	NP	General
Medical	NP	Medical
Practitioner	NN	practitioner
treatment	NN	treatment
as	IN	as
usual	JJ	usual
(	(	(
TAU	NN	tau
)	)	)
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
female	JJ	female
urinary	JJ	urinary
incontinence	NN	incontinence
with	IN	with
a	DT	a
novel	JJ	novel
disposable	JJ	disposable
home	NN	home
electro-stimulation	NN	electro-stimulation
device	NN	device
(	(	(
Pelviva	NP	<unknown>
)	)	)
.	SENT	.
Open	JJ	open
label	NN	label
,	,	,
Primary	JJ	primary
Care	NP	Care
post-market	NN	post-market
evaluation	NN	evaluation
.	SENT	.
86	CD	@card@
women	NNS	woman
with	IN	with
urinary	JJ	urinary
incontinence	NN	incontinence
were	VBD	be
randomly	RB	randomly
assigned	VBN	assign
to	TO	to
one	CD	one
of	IN	of
two	CD	two
12-week	JJ	<unknown>
treatments	NNS	treatment
:	:	:
TAU	NN	tau
or	CC	or
Pelviva	NP	<unknown>
for	IN	for
30	CD	@card@
min	NN	min
every	DT	every
other	JJ	other
day	NN	day
plus	CC	plus
TAU	NN	tau
.	SENT	.
Outcome	NN	outcome
measures	NNS	measure
included	VBN	include
ICIQ-UI	NP	<unknown>
(	(	(
primary	JJ	primary
)	)	)
,	,	,
PISQ-IR	NP	<unknown>
,	,	,
PGI-S	NP	<unknown>
/	SYM	/
PGI-I	NP	<unknown>
and	CC	and
FSFI	NP	<unknown>
(	(	(
secondary	JJ	secondary
)	)	)
at	IN	at
recruitment	NN	recruitment
and	CC	and
immediately	RB	immediately
after	IN	after
intervention	NN	intervention
,	,	,
1-h	NP	1-h
pad	NN	pad
test	NN	test
at	IN	at
recruitment	NN	recruitment
and	CC	and
usage	NN	usage
diaries	NNS	diary
throughout	IN	throughout
.	SENT	.
Pelviva	NN	<unknown>
plus	CC	plus
TAU	NN	tau
produced	VBD	produce
significantly	RB	significantly
better	JJR	good
outcome	NN	outcome
than	IN	than
TAU	NN	tau
alone	RB	alone
:	:	:
3	CD	@card@
versus	IN	versus
1	CD	@card@
point	NN	point
for	IN	for
ICIQ-UI	NP	<unknown>
(	(	(
Difference	NN	difference
-	NN	<unknown>
1.8	CD	@card@
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
-	NN	<unknown>
3.5	CD	@card@
to	TO	to
-	NN	<unknown>
0.1	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.033	CD	@card@
)	)	)
.	SENT	.
Significant	JJ	significant
differences	NNS	difference
were	VBD	be
also	RB	also
observed	VBN	observe
for	IN	for
PGI-I	NP	<unknown>
at	IN	at
both	DT	both
6	CD	@card@
weeks	NNS	week
(	(	(
P	NN	P
=	SYM	=
0.001	CD	@card@
)	)	)
and	CC	and
12	CD	@card@
weeks	NNS	week
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
In	IN	in
the	DT	the
Pelviva	NP	<unknown>
group	NN	group
,	,	,
17	CD	@card@
%	NN	%
of	IN	of
women	NNS	woman
described	VBD	describe
themselves	PP	themselves
as	IN	as
feeling	VBG	feel
very	RB	very
much	RB	much
better	JJR	good
and	CC	and
54	CD	@card@
%	NN	%
a	DT	a
little	JJ	little
or	CC	or
much	RB	much
better	RBR	well
compared	VBN	compare
to	TO	to
0	CD	@card@
%	NN	%
and	CC	and
15	CD	@card@
%	NN	%
in	IN	in
the	DT	the
TAU	NN	tau
.	SENT	.
Overall	JJ	overall
PISQ-IR	NP	<unknown>
score	NN	score
reached	VBD	reach
statistical	JJ	statistical
significance	NN	significance
(	(	(
P	NN	P
=	SYM	=
0.032	CD	@card@
)	)	)
seemingly	RB	seemingly
related	VBN	relate
to	TO	to
impact	VB	impact
(	(	(
P	NN	P
=	SYM	=
0.027	CD	@card@
)	)	)
.	SENT	.
No	DT	no
other	JJ	other
outcome	NN	outcome
measures	NNS	measure
reached	VBD	reach
statistical	JJ	statistical
significance	NN	significance
.	SENT	.
Premature	JJ	premature
termination	NN	termination
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
meant	VBD	mean
only	RB	only
86	CD	@card@
women	NNS	woman
were	VBD	be
recruited	VBN	recruit
from	IN	from
a	DT	a
sample	NN	sample
size	NN	size
of	IN	of
264	CD	@card@
.	SENT	.
TAU	NN	tau
did	VBD	do
not	RB	not
reflect	VB	reflect
NICE	JJ	nice
guidelines	NNS	guideline
.	SENT	.
This	DT	this
study	NN	study
suggests	VBZ	suggest
Pelviva	NP	<unknown>
is	VBZ	be
more	RBR	more
successful	JJ	successful
than	IN	than
TAU	NN	tau
in	IN	in
treating	VBG	treat
urinary	JJ	urinary
incontinence	NN	incontinence
in	IN	in
Primary	JJ	primary
Care	NP	Care
.	SENT	.
The	DT	the
study	NN	study
had	VBD	have
reduced	VBN	reduce
power	NN	power
due	JJ	due
to	TO	to
early	JJ	early
termination	NN	termination
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
and	CC	and
suggests	VBZ	suggest
TAU	NN	tau
does	VBZ	do
not	RB	not
follow	VB	follow
NICE	JJ	nice
guidelines	NNS	guideline
.	SENT	.
33330343/	CD	@card@
Covid-19	NP	<unknown>
Mortality	NN	mortality
:	:	:
A	DT	a
Matter	NP	Matter
of	IN	of
Vulnerability	NN	vulnerability
Among	IN	among
Nations	NPS	Nations
Facing	VBG	face
Limited	JJ	limited
Margins	NNS	margin
of	IN	of
Adaptation	NN	adaptation
Context	NN	context
:	:	:
The	DT	the
human	JJ	human
development	NN	development
territories	NNS	territory
have	VBP	have
been	VBN	be
severely	RB	severely
constrained	VBN	constrain
under	IN	under
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
A	DT	a
common	JJ	common
dynamics	NNS	dynamics
has	VBZ	have
been	VBN	be
observed	VBN	observe
,	,	,
but	CC	but
its	PP$	its
propagation	NN	propagation
has	VBZ	have
not	RB	not
been	VBN	be
homogeneous	JJ	homogeneous
over	IN	over
each	DT	each
continent	NN	continent
.	SENT	.
We	PP	we
aimed	VBD	aim
at	IN	at
characterizing	VBG	characterize
the	DT	the
non-viral	JJ	non-viral
parameters	NNS	parameter
that	WDT	that
were	VBD	be
most	RBS	most
associated	VBN	associate
with	IN	with
death	NN	death
rate	NN	rate
.	SENT	.
Methods	NNS	method
:	:	:
We	PP	we
tested	VBD	test
major	JJ	major
indices	NN	indices
from	IN	from
five	CD	five
domains	NNS	domain
(	(	(
demography	NN	demography
,	,	,
public	JJ	public
health	NN	health
,	,	,
economy	NN	economy
,	,	,
politics	NNS	politics
,	,	,
environment	NN	environment
)	)	)
and	CC	and
their	PP$	their
potential	JJ	potential
associations	NNS	association
with	IN	with
Covid-19	NP	<unknown>
mortality	NN	mortality
during	IN	during
the	DT	the
first	JJ	first
8	CD	@card@
months	NNS	month
of	IN	of
2020	CD	@card@
,	,	,
through	IN	through
a	DT	a
Principal	NN	principal
Component	NN	component
Analysis	NN	analysis
and	CC	and
a	DT	a
correlation	NN	correlation
matrix	NN	matrix
with	IN	with
a	DT	a
Pearson	NP	Pearson
correlation	NN	correlation
test	NN	test
.	SENT	.
Data	NNS	datum
of	IN	of
all	DT	all
countries	NNS	country
,	,	,
or	CC	or
states	NNS	state
in	IN	in
federal	JJ	federal
countries	NNS	country
,	,	,
showing	VBG	show
at	IN	at
least	JJS	least
10	CD	@card@
fatality	NN	fatality
cases	NNS	case
,	,	,
were	VBD	be
retrieved	VBN	retrieve
from	IN	from
official	JJ	official
public	JJ	public
sites	NNS	site
.	SENT	.
For	IN	for
countries	NNS	country
that	WDT	that
have	VBP	have
not	RB	not
yet	RB	yet
finished	VBD	finish
the	DT	the
first	JJ	first
epidemic	NN	epidemic
phase	NN	phase
,	,	,
a	DT	a
prospective	JJ	prospective
model	NN	model
has	VBZ	have
been	VBN	be
computed	VBN	compute
to	TO	to
provide	VB	provide
options	NNS	option
of	IN	of
death	NN	death
rates	NNS	rate
evolution	NN	evolution
.	SENT	.
Results	NNS	result
:	:	:
Higher	JJR	high
Covid	NP	<unknown>
death	NN	death
rates	NNS	rate
are	VBP	be
observed	VBN	observe
in	IN	in
the	NP	the
[	SYM	[
25/65	CD	@card@
]	SYM	]
latitude	NN	latitude
and	CC	and
in	IN	in
the	NP	the
[	SYM	[
-35/-125	CD	@card@
]	SYM	]
longitude	NN	longitude
ranges	NNS	range
.	SENT	.
The	DT	the
national	JJ	national
criteria	NNS	criterion
most	RBS	most
associated	VBN	associate
with	IN	with
death	NN	death
rate	NN	rate
are	VBP	be
life	NN	life
expectancy	NN	expectancy
and	CC	and
its	PP$	its
slowdown	NN	slowdown
,	,	,
public	JJ	public
health	NN	health
context	NN	context
(	(	(
metabolic	JJ	metabolic
and	CC	and
non-communicable	JJ	non-communicable
diseases	NNS	disease
(	(	(
NCD	JJ	<unknown>
)	)	)
burden	NN	burden
vs.	IN	vs.
infectious	JJ	infectious
diseases	NNS	disease
prevalence	NN	prevalence
)	)	)
,	,	,
economy	NN	economy
(	(	(
growth	NN	growth
national	JJ	national
product	NN	product
,	,	,
financial	JJ	financial
support	NN	support
)	)	)
,	,	,
and	CC	and
environment	NN	environment
(	(	(
temperature	NN	temperature
,	,	,
ultra-violet	NN	ultra-violet
index	NN	index
)	)	)
.	SENT	.
Stringency	NN	stringency
of	IN	of
the	DT	the
measures	NNS	measure
settled	VBD	settle
to	TO	to
fight	VB	fight
pandemia	NN	<unknown>
,	,	,
including	VBG	include
lockdown	NN	<unknown>
,	,	,
did	VBD	do
not	RB	not
appear	VB	appear
to	TO	to
be	VB	be
linked	VBN	link
with	IN	with
death	NN	death
rate	NN	rate
.	SENT	.
Conclusion	NN	conclusion
:	:	:
Countries	NNS	country
that	WDT	that
already	RB	already
experienced	VBD	experience
a	DT	a
stagnation	NN	stagnation
or	CC	or
regression	NN	regression
of	IN	of
life	NN	life
expectancy	NN	expectancy
,	,	,
with	IN	with
high	JJ	high
income	NN	income
and	CC	and
NCD	JJ	<unknown>
rates	NNS	rate
,	,	,
had	VBD	have
the	DT	the
highest	JJS	high
price	NN	price
to	TO	to
pay	VB	pay
.	SENT	.
This	DT	this
burden	NN	burden
was	VBD	be
not	RB	not
alleviated	VBN	alleviate
by	IN	by
more	JJR	more
stringent	JJ	stringent
public	JJ	public
decisions	NNS	decision
.	SENT	.
Inherent	JJ	inherent
factors	NNS	factor
have	VBP	have
predetermined	VBN	predetermine
the	DT	the
Covid-19	NP	<unknown>
mortality	NN	mortality
:	:	:
understanding	VBG	understand
them	PP	them
may	MD	may
improve	VB	improve
prevention	NN	prevention
strategies	NNS	strategy
by	IN	by
increasing	VBG	increase
population	NN	population
resilience	NN	resilience
through	IN	through
better	JJR	good
physical	JJ	physical
fitness	NN	fitness
and	CC	and
immunity	NN	immunity
.	SENT	.
35233780/'Learning	JJ	<unknown>
in	IN	in
and	CC	and
out	IN	out
of	IN	of
lockdown	NN	<unknown>
'	''	'
:	:	:
A	DT	a
comparison	NN	comparison
of	IN	of
two	CD	two
groups	NNS	group
of	IN	of
undergraduate	JJ	undergraduate
occupational	JJ	occupational
therapy	NN	therapy
students	NNS	student
'	POS	'
engagement	NN	engagement
in	IN	in
online-only	JJ	<unknown>
and	CC	and
blended	VBN	blend
education	NN	education
approaches	NNS	approach
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
In	IN	in
many	JJ	many
countries	NNS	country
,	,	,
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
resulted	VBD	result
in	IN	in
sudden	JJ	sudden
changes	NNS	change
to	TO	to
the	DT	the
delivery	NN	delivery
of	IN	of
health	NN	health
professions	NNS	profession
education	NN	education
in	IN	in
response	NN	response
to	TO	to
local	JJ	local
and	CC	and
national	JJ	national
lockdowns	NNS	lockdown
.	SENT	.
Within	IN	within
occupational	JJ	occupational
therapy	NN	therapy
,	,	,
university	NN	university
education	NN	education
programs	NNS	program
traditionally	RB	traditionally
delivered	VBN	deliver
in	IN	in
face-to-face	JJ	face-to-face
classroom	NN	classroom
,	,	,
and	CC	and
clinical	JJ	clinical
settings	NNS	setting
,	,	,
the	DT	the
transition	NN	transition
to	TO	to
online	JJ	online
learning	NN	learning
presented	VBD	present
unique	JJ	unique
issues	NNS	issue
and	CC	and
challenges	NNS	challenge
for	IN	for
faculty	NN	faculty
and	CC	and
students	NNS	student
.	SENT	.
This	DT	this
study	NN	study
compared	VBN	compare
the	DT	the
experiences	NNS	experience
and	CC	and
perceptions	NNS	perception
of	IN	of
learning	VBG	learn
in	IN	in
two	CD	two
groups	NNS	group
of	IN	of
occupational	JJ	occupational
therapy	NN	therapy
students	NNS	student
during	IN	during
the	DT	the
pandemic	NN	pandemic
:	:	:
one	CD	one
group	NN	group
converted	VBN	convert
to	TO	to
online	JJ	online
learning	VBG	learn
only	RB	only
and	CC	and
the	DT	the
other	NN	other
had	VBD	have
a	DT	a
blended	VBN	blend
approach	NN	approach
that	IN	that
combined	JJ	combined
face-to-face	JJ	face-to-face
on-campus	NN	on-campus
learning	VBG	learn
with	IN	with
some	DT	some
online	JJ	online
lecture	NN	lecture
content	NN	content
delivery	NN	delivery
.	SENT	.
Two	CD	two
hundred	CD	hundred
and	CC	and
eight	CD	eight
(	(	(
n	NN	n
=	SYM	=
208	CD	@card@
)	)	)
undergraduate	JJ	undergraduate
occupational	JJ	occupational
therapy	NN	therapy
students	NNS	student
from	IN	from
three	CD	three
Australian	JJ	Australian
universities	NNS	university
completed	VBD	complete
an	DT	an
online	JJ	online
self-report	NN	self-report
demographic	JJ	demographic
questionnaire	NN	questionnaire
and	CC	and
two	CD	two
standardised	VBN	standardise
instruments	NNS	instrument
:	:	:
the	DT	the
Student	NN	student
Engagement	NN	engagement
in	IN	in
the	DT	the
e-Learning	NP	e-Learning
Environment	NP	Environment
Scale	NP	Scale
and	CC	and
the	DT	the
Distance	NP	Distance
Education	NP	Education
Learning	NP	Learning
Environment	NP	Environment
Scale	NP	Scale
.	SENT	.
An	DT	an
independent-samples	NNS	independent-sample
t	NN	t
test	NN	test
with	IN	with
bootstrapping	NN	<unknown>
was	VBD	be
completed	VBN	complete
to	TO	to
examine	VB	examine
differences	NNS	difference
in	IN	in
students	NNS	student
'	POS	'
scores	NNS	score
.	SENT	.
Statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
were	VBD	be
observed	VBN	observe
between	IN	between
the	DT	the
online	JJ	online
and	CC	and
blended	VBN	blend
learning	VBG	learn
groups	NNS	group
across	IN	across
a	DT	a
range	NN	range
of	IN	of
the	DT	the
SELES	NP	<unknown>
and	CC	and
DELES	NNS	dele
subscales	NNS	subscale
.	SENT	.
The	DT	the
strongest	JJS	strong
findings	NNS	finding
related	VBN	relate
to	TO	to
psychological	JJ	psychological
motivation	NN	motivation
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
,	,	,
personal	JJ	personal
relevance	NN	relevance
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
,	,	,
interactions	NNS	interaction
with	IN	with
instructors	NNS	instructor
(	(	(
p	NN	p
=	SYM	=
0.002	CD	@card@
)	)	)
,	,	,
instructor	NN	instructor
support	NN	support
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
,	,	,
student	NN	student
interaction	NN	interaction
&amp	NN	<unknown>
;	:	;
collaboration	NN	collaboration
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
,	,	,
and	CC	and
cognitive	JJ	cognitive
problem	NN	problem
solving	VBG	solve
(	(	(
p	NN	p
=	SYM	=
0.001	CD	@card@
)	)	)
.	SENT	.
Occupational	JJ	occupational
therapy	NN	therapy
students	NNS	student
who	WP	who
transitioned	VBD	<unknown>
to	TO	to
online-only	JJ	<unknown>
learning	NN	learning
experienced	VBD	experience
higher	JJR	high
levels	NNS	level
of	IN	of
motivation	NN	motivation
,	,	,
interactions	NNS	interaction
with	IN	with
instructors	NNS	instructor
and	CC	and
peers	NNS	peer
,	,	,
and	CC	and
self-directed	JJ	self-directed
learning	NN	learning
than	IN	than
students	NNS	student
who	WP	who
experienced	VBD	experience
a	DT	a
blended	VBN	blend
education	NN	education
delivery	NN	delivery
approach	NN	approach
of	IN	of
face-to-face	JJ	face-to-face
and	CC	and
online	JJ	online
learning	NN	learning
.	SENT	.
The	DT	the
findings	NNS	finding
extend	VBP	extend
educators	NNS	educator
'	POS	'
understanding	NN	understanding
of	IN	of
the	DT	the
matrix	NN	matrix
of	IN	of
factors	NNS	factor
that	WDT	that
have	VBP	have
impacted	VBN	impact
students	NNS	student
'	POS	'
education	NN	education
during	IN	during
COVID-19	NP	<unknown>
and	CC	and
support	VB	support
the	DT	the
development	NN	development
of	IN	of
contemporary	JJ	contemporary
and	CC	and
pedagogically	RB	<unknown>
sound	VB	sound
online	JJ	online
and	CC	and
traditional	JJ	traditional
modes	NNS	mode
of	IN	of
occupational	JJ	occupational
therapy	NN	therapy
instruction	NN	instruction
.	SENT	.
The	DT	the
results	NNS	result
provide	VBP	provide
evidence	NN	evidence
of	IN	of
the	DT	the
importance	NN	importance
of	IN	of
well-structured	JJ	well-structured
programs	NNS	program
that	WDT	that
facilitate	VBP	facilitate
active	JJ	active
and	CC	and
flexible	JJ	flexible
learning	VBG	learn
,	,	,
provide	VB	provide
meaningful	JJ	meaningful
and	CC	and
positive	JJ	positive
experiences	NNS	experience
,	,	,
and	CC	and
promote	VB	promote
initiatives	NNS	initiative
safeguarding	VBG	safeguard
social	JJ	social
and	CC	and
personal	JJ	personal
well-being	NN	well-being
.	SENT	.
Further	JJR	further
research	NN	research
in	IN	in
this	DT	this
area	NN	area
is	VBZ	be
recommended	VBN	recommend
.	SENT	.
34013051/	CD	@card@
Telemedicine	NN	Telemedicine
in	IN	in
routine	JJ	routine
gastroenterology	NN	gastroenterology
practice	NN	practice
:	:	:
A	DT	a
boost	NN	boost
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
32252855/	CD	@card@
Alert	NP	Alert
for	IN	for
SARS-CoV-2	NP	<unknown>
infection	NN	infection
caused	VBN	cause
by	IN	by
fecal	JJ	fecal
aerosols	NNS	aerosol
in	IN	in
rural	JJ	rural
areas	NNS	area
in	IN	in
China	NP	China
32339218/	CD	@card@
Working	NP	Working
schedule	NN	schedule
,	,	,
sleep	NN	sleep
quality	NN	quality
and	CC	and
susceptibility	NN	susceptibility
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
healthcare	NN	<unknown>
workers	NNS	worker
34782790/	CD	@card@
Dexamethasone	NN	<unknown>
modulates	VBZ	modulate
immature	JJ	immature
neutrophils	NNS	neutrophil
and	CC	and
interferon	NN	interferon
programming	NN	programming
in	IN	in
severe	JJ	severe
COVID-19	NN	<unknown>
Although	IN	although
critical	JJ	critical
for	IN	for
host	NN	host
defense	NN	defense
,	,	,
innate	JJ	innate
immune	JJ	immune
cells	NNS	cell
are	VBP	be
also	RB	also
pathologic	JJ	pathologic
drivers	NNS	driver
of	IN	of
acute	JJ	acute
respiratory	JJ	respiratory
distress	NN	distress
syndrome	NN	syndrome
(	(	(
ARDS	NN	<unknown>
)	)	)
.	SENT	.
Innate	JJ	innate
immune	JJ	immune
dynamics	NNS	dynamics
during	IN	during
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
ARDS	NP	<unknown>
,	,	,
compared	VBN	compare
to	TO	to
ARDS	NNS	<unknown>
from	IN	from
other	JJ	other
respiratory	JJ	respiratory
pathogens	NNS	pathogen
,	,	,
is	VBZ	be
unclear	JJ	unclear
.	SENT	.
Moreover	RB	moreover
,	,	,
mechanisms	NNS	mechanism
underlying	VBG	underlie
the	DT	the
beneficial	JJ	beneficial
effects	NNS	effect
of	IN	of
dexamethasone	NN	<unknown>
during	IN	during
severe	JJ	severe
COVID-19	NP	<unknown>
remain	VBP	remain
elusive	JJ	elusive
.	SENT	.
Using	VBG	use
single-cell	NN	single-cell
RNA	NP	RNA
sequencing	NP	sequencing
and	CC	and
plasma	NN	plasma
proteomics	NNS	<unknown>
,	,	,
we	PP	we
discovered	VBD	discover
that	IN	that
,	,	,
compared	VBN	compare
to	TO	to
bacterial	JJ	bacterial
ARDS	NN	<unknown>
,	,	,
COVID-19	NP	<unknown>
was	VBD	be
associated	VBN	associate
with	IN	with
expansion	NN	expansion
of	IN	of
distinct	JJ	distinct
neutrophil	JJ	neutrophil
states	NNS	state
characterized	VBN	characterize
by	IN	by
interferon	NN	interferon
(	(	(
IFN	NP	IFN
)	)	)
and	CC	and
prostaglandin	NN	prostaglandin
signaling	VBG	signal
.	SENT	.
Dexamethasone	NN	<unknown>
during	IN	during
severe	JJ	severe
COVID-19	NP	<unknown>
affected	VBD	affect
circulating	VBG	circulate
neutrophils	NNS	neutrophil
,	,	,
altered	VBN	alter
IFNactive	JJ	IFNactive
neutrophils	NNS	neutrophil
,	,	,
downregulated	JJ	downregulated
interferon-stimulated	JJ	interferon-stimulated
genes	NNS	gene
and	CC	and
activated	VBN	activate
IL-1R2+	JJ	<unknown>
neutrophils	NNS	neutrophil
.	SENT	.
Dexamethasone	NP	<unknown>
also	RB	also
expanded	VBD	expand
immunosuppressive	JJ	immunosuppressive
immature	JJ	immature
neutrophils	NNS	neutrophil
and	CC	and
remodeled	VBN	remodel
cellular	JJ	cellular
interactions	NNS	interaction
by	IN	by
changing	VBG	change
neutrophils	NNS	neutrophil
from	IN	from
information	NN	information
receivers	NNS	receiver
into	IN	into
information	NN	information
providers	NNS	provider
.	SENT	.
Male	JJ	male
patients	NNS	patient
had	VBD	have
higher	JJR	high
proportions	NNS	proportion
of	IN	of
IFNactive	JJ	IFNactive
neutrophils	NNS	neutrophil
and	CC	and
preferential	JJ	preferential
steroid-induced	JJ	<unknown>
immature	JJ	immature
neutrophil	JJ	neutrophil
expansion	NN	expansion
,	,	,
potentially	RB	potentially
affecting	VBG	affect
outcomes	NNS	outcome
.	SENT	.
Our	PP$	our
single-cell	NN	single-cell
atlas	NN	atlas
(	(	(
see	NN	see
'	POS	'
Data	NP	Data
availability	NN	availability
'	POS	'
section	NN	section
)	)	)
defines	VBZ	define
COVID-19-enriched	JJ	<unknown>
neutrophil	JJ	neutrophil
states	NNS	state
and	CC	and
molecular	JJ	molecular
mechanisms	NNS	mechanism
of	IN	of
dexamethasone	NN	<unknown>
action	NN	action
to	TO	to
develop	VB	develop
targeted	JJ	targeted
immunotherapies	NNS	immunotherapy
for	IN	for
severe	JJ	severe
COVID-19	NP	<unknown>
.	SENT	.
New	JJ	new
results	NNS	result
shed	VBD	shed
light	NN	light
on	IN	on
the	DT	the
molecular	JJ	molecular
mechanisms	NNS	mechanism
of	IN	of
dexamethasone	NN	<unknown>
action	NN	action
,	,	,
underlying	VBG	underlie
its	PP$	its
therapeutic	JJ	therapeutic
benefit	NN	benefit
in	IN	in
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
.	SENT	.
32580924/	CD	@card@
COVID-19	NP	<unknown>
:	:	:
What	WP	what
We	PP	we
Have	VBP	have
Learned	NP	Learned
So	IN	so
Far	NP	Far
32776354/	CD	@card@
The	DT	the
hidden	JJ	hidden
role	NN	role
of	IN	of
NLRP3	JJ	<unknown>
inflammasome	NN	<unknown>
in	IN	in
obesity-related	JJ	obesity-related
COVID-19	NP	<unknown>
exacerbations	NNS	exacerbation
:	:	:
lessons	NNS	lesson
for	IN	for
drug	NN	drug
repurposing	VBG	repurpose
COVID-19	NP	<unknown>
,	,	,
the	DT	the
illness	NN	illness
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
,	,	,
has	VBZ	have
a	DT	a
wide-ranging	JJ	wide-ranging
clinical	JJ	clinical
spectrum	NN	spectrum
that	IN	that
,	,	,
in	IN	in
the	DT	the
worst-case	JJ	worst-case
scenario	NN	scenario
,	,	,
involves	VBZ	involve
a	DT	a
rapid	JJ	rapid
progression	NN	progression
to	TO	to
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
and	CC	and
even	RB	even
death	NN	death
.	SENT	.
Epidemiological	JJ	epidemiological
data	NNS	datum
show	VBP	show
that	IN	that
obesity	NN	obesity
and	CC	and
diabetes	NN	diabetes
are	VBP	be
among	IN	among
the	DT	the
main	JJ	main
risk	NN	risk
factors	NNS	factor
associated	VBN	associate
with	IN	with
high	JJ	high
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
.	SENT	.
The	DT	the
increased	VBN	increase
susceptibility	NN	susceptibility
to	TO	to
SARS-CoV-2	NP	<unknown>
infection	NN	infection
documented	VBN	document
in	IN	in
obesity-related	JJ	obesity-related
metabolic	JJ	metabolic
derangements	NNS	derangement
argues	VBZ	argue
for	IN	for
initial	JJ	initial
defects	NNS	defect
in	IN	in
defense	NN	defense
mechanisms	NNS	mechanism
,	,	,
most	RBS	most
likely	RB	likely
due	JJ	due
to	TO	to
an	DT	an
elevated	JJ	elevated
systemic	JJ	systemic
metabolic	JJ	metabolic
inflammation	NN	inflammation
(	(	(
"	``	"
metaflammation	NN	<unknown>
"	''	"
)	)	)
.	SENT	.
The	DT	the
NLRP3	NP	<unknown>
inflammasome	NN	<unknown>
is	VBZ	be
a	DT	a
master	NN	master
regulator	NN	regulator
of	IN	of
metaflammation	NN	<unknown>
and	CC	and
has	VBZ	have
a	DT	a
pivotal	JJ	pivotal
role	NN	role
in	IN	in
the	DT	the
pathophysiology	NN	pathophysiology
of	IN	of
either	DT	either
obesity	NN	obesity
and	CC	and
diabetes	NN	diabetes
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
discuss	VBP	discuss
the	DT	the
most	RBS	most
recent	JJ	recent
findings	NNS	finding
suggesting	VBG	suggest
contribution	NN	contribution
of	IN	of
NLRP3	NP	<unknown>
inflammasome	JJ	<unknown>
to	TO	to
the	DT	the
increase	NN	increase
in	IN	in
complications	NNS	complication
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
diabesity	NN	<unknown>
.	SENT	.
We	PP	we
also	RB	also
review	VB	review
current	JJ	current
pharmacological	JJ	pharmacological
strategies	NNS	strategy
for	IN	for
COVID-19	NP	<unknown>
,	,	,
focusing	VBG	focus
on	IN	on
treatments	NNS	treatment
whose	WP$	whose
efficacy	NN	efficacy
could	MD	could
be	VB	be
due	JJ	due
,	,	,
at	IN	at
least	JJS	least
in	IN	in
part	NN	part
,	,	,
to	TO	to
interference	NN	interference
with	IN	with
the	DT	the
activation	NN	activation
of	IN	of
the	DT	the
NLRP3	NP	<unknown>
inflammasome	NN	<unknown>
.	SENT	.
33461841/	CD	@card@
A	DT	a
cross-sectional	JJ	cross-sectional
seroprevalence	NN	seroprevalence
for	IN	for
COVID-19	NP	<unknown>
among	IN	among
healthcare	NN	<unknown>
workers	NNS	worker
in	IN	in
a	DT	a
tertially	JJ	<unknown>
care	NN	care
hospital	NN	hospital
in	IN	in
Taiwan	NP	Taiwan
Healthcare	NP	Healthcare
workers	NNS	worker
(	(	(
HCWs	NP	<unknown>
)	)	)
are	VBP	be
at	IN	at
the	DT	the
frontline	NN	frontline
during	IN	during
the	DT	the
pandemic	NN	pandemic
of	IN	of
COVID-19	NP	<unknown>
globally	RB	globally
.	SENT	.
According	VBG	accord
to	TO	to
the	DT	the
WHO	WP	who
situation	NN	situation
report	NN	report
at	IN	at
April	NP	April
17	CD	@card@
,	,	,
there	EX	there
were	VBD	be
22	CD	@card@
,	,	,
073	CD	@card@
HCWs	NNS	<unknown>
contracted	VBD	contract
the	DT	the
infection	NN	infection
.	SENT	.
Whether	IN	whether
the	DT	the
infection	NN	infection
control	NN	control
policy	NN	policy
and	CC	and
practice	NN	practice
in	IN	in
the	DT	the
hospital	NN	hospital
setting	NN	setting
can	MD	can
protect	VB	protect
the	DT	the
HCWs	NN	<unknown>
is	VBZ	be
an	DT	an
important	JJ	important
issue	NN	issue
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
cross-sectional	JJ	cross-sectional
serology	NN	serology
study	NN	study
in	IN	in
a	DT	a
tertiary	JJ	tertiary
care	NN	care
hospital	NN	hospital
in	IN	in
Taiwan	NP	Taiwan
to	TO	to
explore	VB	explore
the	DT	the
sero-prevalence	NN	sero-prevalence
rate	NN	rate
among	IN	among
HCWs	NP	<unknown>
.	SENT	.
The	DT	the
participants	NNS	participant
are	VBP	be
enrolled	VBN	enroll
on	IN	on
a	DT	a
voluntary	JJ	voluntary
basis	NN	basis
.	SENT	.
A	DT	a
structured	JJ	structured
questionnaire	NN	questionnaire
was	VBD	be
collected	VBN	collect
to	TO	to
gather	VB	gather
the	DT	the
epidemiology	NN	epidemiology
character	NN	character
and	CC	and
risk	NN	risk
factors	NNS	factor
for	IN	for
potential	JJ	potential
exposure	NN	exposure
.	SENT	.
ELISA	NP	Elisa
tests	NNS	test
as	IN	as
Architect	NN	architect
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
(	(	(
Abbott	NP	Abbott
)	)	)
and	CC	and
Elecsys	NP	<unknown>
Anti-SARS-CoV-2	JJ	<unknown>
assay	NN	assay
(	(	(
Roche	NP	Roche
)	)	)
were	VBD	be
used	VBN	use
to	TO	to
detect	VB	detect
antibody	NN	antibody
responses	NNS	response
.	SENT	.
If	IN	if
any	DT	any
of	IN	of
the	DT	the
tests	NNS	test
was	VBD	be
positive	JJ	positive
,	,	,
a	DT	a
western	JJ	western
blot	NN	blot
assay	NN	assay
was	VBD	be
used	VBN	use
for	IN	for
confirmation	NN	confirmation
.	SENT	.
There	EX	there
were	VBD	be
194	CD	@card@
HCWs	NNS	<unknown>
participated	VBN	participate
during	IN	during
July	NP	July
1	CD	@card@
to	TO	to
Aug.	NP	Aug.
31	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
The	DT	the
mean	JJ	mean
age	NN	age
was	VBD	be
36.3	CD	@card@
+-	NN	<unknown>
10.4	CD	@card@
.	SENT	.
More	JJR	more
than	IN	than
half	NN	half
of	IN	of
the	DT	the
participants	NNS	participant
had	VBD	have
possible	JJ	possible
hospital	NN	hospital
associated	VBN	associate
risk	NN	risk
for	IN	for
COVID-19	NP	<unknown>
exposure	NN	exposure
(	(	(
110/192	CD	@card@
,	,	,
57.3	CD	@card@
%	NN	%
)	)	)
and	CC	and
64	NP	@card@
had	VBD	have
possible	JJ	possible
community	NN	community
risk	NN	risk
for	IN	for
COVID-19	NP	<unknown>
exposure	NN	exposure
(	(	(
64/194	CD	@card@
,	,	,
33.0	CD	@card@
%	NN	%
)	)	)
.	SENT	.
There	EX	there
was	VBD	be
only	RB	only
one	CD	one
participant	NN	participant
had	VBD	have
positive	JJ	positive
test	NN	test
by	IN	by
Architect	NN	architect
IgG	NP	IgG
test	NN	test
and	CC	and
confirmed	VBD	confirm
to	TO	to
be	VB	be
negative	JJ	negative
for	IN	for
seasonal	JJ	seasonal
coronavirus	NN	coronavirus
and	CC	and
SARS-CoV-2	JJ	<unknown>
antibody	NN	antibody
.	SENT	.
(	(	(
Mikrogen	NP	<unknown>
Diagnostik	NP	<unknown>
,	,	,
Germany	NP	Germany
)	)	)
.	SENT	.
The	DT	the
cross-sectional	JJ	cross-sectional
serology	NN	serology
study	NN	study
in	IN	in
a	DT	a
tertiary	JJ	tertiary
care	NN	care
hospital	NN	hospital
in	IN	in
Taiwan	NP	Taiwan
revealed	VBD	reveal
no	DT	no
HCWs	NN	<unknown>
had	VBD	have
positive	JJ	positive
serology	NN	serology
response	NN	response
to	TO	to
SARS-CoV-2	NP	<unknown>
.	SENT	.
We	PP	we
believe	VBP	believe
that	IN	that
the	DT	the
infection	NN	infection
control	NN	control
policy	NN	policy
and	CC	and
practice	NN	practice
in	IN	in
the	DT	the
hospital	NN	hospital
and	CC	and
in	IN	in
the	DT	the
community	NN	community
are	VBP	be
both	CC	both
important	JJ	important
to	TO	to
prevent	VB	prevent
the	DT	the
disease	NN	disease
transmission	NN	transmission
.	SENT	.
34256781/	CD	@card@
The	DT	the
negative	JJ	negative
effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
national	JJ	national
lockdown	NN	<unknown>
on	IN	on
emergency	NN	emergency
surgery	NN	surgery
morbidity	NN	morbidity
due	JJ	due
to	TO	to
delayed	JJ	delayed
access	NN	access
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
retrospective	JJ	retrospective
comparative	JJ	comparative
study	NN	study
was	VBD	be
to	TO	to
assess	VB	assess
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
delayed	JJ	delayed
emergency	NN	emergency
department	NN	department
access	NN	access
on	IN	on
emergency	NN	emergency
surgery	NN	surgery
outcomes	NNS	outcome
,	,	,
by	IN	by
comparing	VBG	compare
the	DT	the
main	JJ	main
clinical	JJ	clinical
outcomes	NNS	outcome
in	IN	in
the	DT	the
period	NN	period
March-May	NP	March-May
2019	CD	@card@
(	(	(
group	NN	group
1	CD	@card@
)	)	)
with	IN	with
the	DT	the
same	JJ	same
period	NN	period
during	IN	during
the	DT	the
national	JJ	national
COVID-19	NP	<unknown>
lockdown	NN	<unknown>
in	IN	in
Italy	NP	Italy
(	(	(
March-May	NP	March-May
2020	CD	@card@
,	,	,
group	NN	group
2	CD	@card@
)	)	)
.	SENT	.
A	DT	a
comparison	NN	comparison
(	(	(
groups	NNS	group
1	CD	@card@
versus	CC	versus
2	CD	@card@
)	)	)
and	CC	and
subgroup	NN	subgroup
analysis	NN	analysis
were	VBD	be
performed	VBN	perform
between	IN	between
patients	NNS	patient
'	POS	'
demographic	JJ	demographic
,	,	,
medical	JJ	medical
history	NN	history
,	,	,
surgical	JJ	surgical
,	,	,
clinical	JJ	clinical
and	CC	and
management	NN	management
characteristics	NNS	characteristic
.	SENT	.
Two-hundred	JJ	<unknown>
forty-six	NN	<unknown>
patients	NNS	patient
were	VBD	be
included	VBN	include
,	,	,
137	CD	@card@
in	IN	in
group	NN	group
1	CD	@card@
and	CC	and
109	CD	@card@
in	IN	in
group	NN	group
2	CD	@card@
(	(	(
p	NN	p
=	SYM	=
0.03	CD	@card@
)	)	)
.	SENT	.
No	DT	no
significant	JJ	significant
differences	NNS	difference
were	VBD	be
observed	VBN	observe
in	IN	in
the	DT	the
peri-operative	JJ	peri-operative
characteristics	NNS	characteristic
of	IN	of
the	DT	the
two	CD	two
groups	NNS	group
.	SENT	.
A	DT	a
declared	VBN	declare
delay	NN	delay
in	IN	in
access	NN	access
to	TO	to
hospital	NN	hospital
and	CC	and
preoperative	JJ	preoperative
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
rates	NNS	rate
were	VBD	be
15.5	CD	@card@
%	NN	%
and	CC	and
5.8	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
in	IN	in
group	NN	group
2	CD	@card@
.	SENT	.
The	DT	the
overall	JJ	overall
morbidity	NN	morbidity
(	(	(
OR	CC	or
=	SYM	=
2.22	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.08-4.55	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.03	CD	@card@
)	)	)
and	CC	and
30-day	JJ	30-day
mortality	NN	mortality
(	(	(
OR	CC	or
=	SYM	=
1.34	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.33-5.50	CD	@card@
,	,	,
=0.68	NP	<unknown>
)	)	)
were	VBD	be
significantly	RB	significantly
higher	JJR	high
in	IN	in
group	NN	group
2	CD	@card@
.	SENT	.
The	DT	the
delayed	JJ	delayed
access	NN	access
cohort	NN	cohort
showed	VBD	show
a	DT	a
close	JJ	close
correlation	NN	correlation
with	IN	with
increased	VBN	increase
morbidity	NN	morbidity
(	(	(
OR	CC	or
=	SYM	=
3.19	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.89-11.44	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.07	CD	@card@
)	)	)
,	,	,
blood	NN	blood
transfusion	NN	transfusion
(	(	(
OR	CC	or
=	SYM	=
5.13	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.05-25.15	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.04	CD	@card@
)	)	)
and	CC	and
30-day	JJ	30-day
mortality	NN	mortality
risk	NN	risk
(	(	(
OR	CC	or
=	SYM	=
8.00	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.01-63.23	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.05	CD	@card@
)	)	)
.	SENT	.
SARS-CoV-2-positive	JJ	SARS-CoV-2-positive
patients	NNS	patient
had	VBD	have
higher	JJR	high
risk	NN	risk
of	IN	of
blood	NN	blood
transfusion	NN	transfusion
(	(	(
20	CD	@card@
%	NN	%
vs	NP	vs
7.8	CD	@card@
%	NN	%
,	,	,
p	NN	p
=	SYM	=
0.37	CD	@card@
)	)	)
and	CC	and
ICU	NP	ICU
admissions	NNS	admission
(	(	(
20	CD	@card@
%	NN	%
vs	NP	vs
2.6	CD	@card@
%	NN	%
,	,	,
p	NN	p
=	SYM	=
0.17	CD	@card@
)	)	)
and	CC	and
a	DT	a
longer	RBR	longer
median	JJ	median
LOS	NP	los
(	(	(
9	CD	@card@
days	NNS	day
vs	NP	vs
4	CD	@card@
days	NNS	day
,	,	,
p	NN	p
=	SYM	=
0.11	CD	@card@
)	)	)
.	SENT	.
This	DT	this
article	NN	article
provides	VBZ	provide
enhanced	JJ	enhanced
understanding	NN	understanding
of	IN	of
the	DT	the
effects	NNS	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
patient	JJ	patient
access	NN	access
to	TO	to
emergency	NN	emergency
surgical	JJ	surgical
care	NN	care
.	SENT	.
Our	PP$	our
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
COVID-19	NP	<unknown>
changed	VBD	change
the	DT	the
quality	NN	quality
of	IN	of
surgical	JJ	surgical
care	NN	care
with	IN	with
poorer	JJR	poor
prognosis	NN	prognosis
and	CC	and
higher	JJR	high
morbidity	NN	morbidity
rates	NNS	rate
.	SENT	.
Delayed	JJ	delayed
emergency	NN	emergency
department	NN	department
access	NN	access
and	CC	and
a	DT	a
"	``	"
filter	NN	filter
effect	NN	effect
"	''	"
induced	VBN	induce
by	IN	by
a	DT	a
fear	NN	fear
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
in	IN	in
the	DT	the
population	NN	population
resulted	VBD	result
in	IN	in
only	RB	only
the	DT	the
most	RBS	most
severe	JJ	severe
cases	NNS	case
reaching	VBG	reach
the	DT	the
emergency	NN	emergency
department	NN	department
in	IN	in
time	NN	time
.	SENT	.
32780757/	CD	@card@
Correction	NN	correction
:	:	:
Ultraviolet	NN	ultraviolet
A	DT	a
light	NN	light
effectively	RB	effectively
reduces	VBZ	reduce
bacteria	NNS	bacterium
and	CC	and
viruses	NNS	virus
including	VBG	include
coronavirus	JJ	<unknown>
34281994/	CD	@card@
What	WP	what
do	VBP	do
users	NNS	user
think	VBP	think
of	IN	of
the	DT	the
UK	NP	UK
's	POS	's
three	CD	three
COVID-19	NP	<unknown>
contact-tracing	NN	contact-tracing
apps	NNS	<unknown>
?	SENT	?
A	DT	a
comparative	JJ	comparative
analysis	NN	analysis
Our	PP$	our
goal	NN	goal
was	VBD	be
to	TO	to
gain	VB	gain
insights	NNS	insight
into	IN	into
the	DT	the
user	NN	user
reviews	VBZ	review
of	IN	of
the	DT	the
three	CD	three
COVID-19	NP	<unknown>
contact-tracing	NN	contact-tracing
mobile	JJ	mobile
apps	NNS	<unknown>
,	,	,
developed	VBN	develop
for	IN	for
the	DT	the
different	JJ	different
regions	NNS	region
of	IN	of
the	DT	the
UK	NP	UK
:	:	:
'	POS	'
NHS	NN	NHS
COVID-19	NN	<unknown>
'	''	'
for	IN	for
England	NP	England
and	CC	and
Wales	NP	Wales
,	,	,
'	''	'
StopCOVID	NP	<unknown>
NI	NP	NI
'	POS	'
for	IN	for
Northern	NP	Northern
Ireland	NP	Ireland
and	NP	and
'	POS	'
Protect	VB	protect
Scotland	NP	Scotland
'	POS	'
for	IN	for
Scotland	NP	Scotland
.	SENT	.
Our	PP$	our
two	CD	two
research	NN	research
questions	NNS	question
are	VBP	be
(	(	(
1	LS	1
)	)	)
what	WP	what
are	VBP	be
the	DT	the
users	NNS	user
'	POS	'
experience	NN	experience
and	CC	and
satisfaction	NN	satisfaction
levels	NNS	level
with	IN	with
the	DT	the
three	CD	three
apps	NNS	<unknown>
?	SENT	?
and	CC	and
(	(	(
2	LS	2
)	)	)
what	WP	what
are	VBP	be
the	DT	the
main	JJ	main
issues	NNS	issue
(	(	(
problems	NNS	problem
)	)	)
that	IN	that
users	NNS	user
have	VBP	have
reported	VBN	report
about	IN	about
the	DT	the
apps	NNS	<unknown>
?	SENT	?
We	PP	we
assess	VBP	assess
the	DT	the
popularity	NN	popularity
of	IN	of
the	DT	the
apps	NNS	<unknown>
and	CC	and
end	NN	end
users	NNS	user
'	POS	'
perceptions	NNS	perception
based	VBN	base
on	IN	on
user	NN	user
reviews	NNS	review
in	IN	in
app	NP	App
stores	NNS	store
.	SENT	.
We	PP	we
conduct	VBP	conduct
three	CD	three
types	NNS	type
of	IN	of
analysis	NN	analysis
(	(	(
data	NNS	datum
mining	NN	mining
,	,	,
sentiment	NN	sentiment
analysis	NN	analysis
and	CC	and
topic	NN	topic
modelling	VBG	model
)	)	)
to	TO	to
derive	VB	derive
insights	NNS	insight
from	IN	from
the	DT	the
combined	JJ	combined
set	NN	set
of	IN	of
25	CD	@card@
583	CD	@card@
user	NN	user
reviews	NNS	review
of	IN	of
the	DT	the
aforementioned	JJ	aforementioned
three	CD	three
apps	NNS	<unknown>
(	(	(
submitted	VBN	submit
by	IN	by
users	NNS	user
until	IN	until
the	DT	the
end	NN	end
of	IN	of
2020	CD	@card@
)	)	)
.	SENT	.
Results	NNS	result
show	VBP	show
that	IN	that
end	NN	end
users	NNS	user
have	VBP	have
been	VBN	be
generally	RB	generally
dissatisfied	VBN	dissatisfy
with	IN	with
the	DT	the
apps	NNS	<unknown>
under	IN	under
study	NN	study
,	,	,
except	IN	except
the	DT	the
Scottish	NP	Scottish
app	NP	App
.	SENT	.
Some	DT	some
of	IN	of
the	DT	the
major	JJ	major
issues	NNS	issue
that	IN	that
users	NNS	user
have	VBP	have
reported	VBN	report
are	VBP	be
high	JJ	high
battery	NN	battery
drainage	NN	drainage
and	CC	and
doubts	VBZ	doubt
on	IN	on
whether	IN	whether
apps	NNS	<unknown>
are	VBP	be
really	RB	really
working	VBG	work
.	SENT	.
Towards	IN	towards
the	DT	the
end	NN	end
of	IN	of
2020	CD	@card@
,	,	,
the	DT	the
much-awaited	VBN	much-await
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
started	VBD	start
to	TO	to
be	VB	be
available	JJ	available
,	,	,
but	CC	but
still	RB	still
,	,	,
analysing	VBG	analyse
the	DT	the
users	NNS	user
'	POS	'
feedback	NN	feedback
and	CC	and
technical	JJ	technical
issues	NNS	issue
of	IN	of
these	DT	these
apps	NNS	<unknown>
,	,	,
in	IN	in
retrospective	NN	retrospective
,	,	,
is	VBZ	be
valuable	JJ	valuable
to	TO	to
learn	VB	learn
the	DT	the
right	JJ	right
lessons	NNS	lesson
to	TO	to
be	VB	be
ready	JJ	ready
for	IN	for
similar	JJ	similar
circumstances	NNS	circumstance
in	IN	in
future	NN	future
.	SENT	.
Our	PP$	our
results	NNS	result
show	VBP	show
that	IN	that
more	JJR	more
work	NN	work
is	VBZ	be
needed	VBN	need
by	IN	by
the	DT	the
stakeholders	NNS	stakeholder
behind	IN	behind
the	DT	the
apps	NNS	<unknown>
(	(	(
eg	NN	eg
,	,	,
apps	NNS	<unknown>
'	POS	'
software	NN	software
engineering	NN	engineering
teams	NNS	team
,	,	,
public-health	NN	public-health
experts	NNS	expert
and	CC	and
decision	NN	decision
makers	NNS	maker
)	)	)
to	TO	to
improve	VB	improve
the	DT	the
software	NN	software
quality	NN	quality
and	CC	and
,	,	,
as	IN	as
a	DT	a
result	NN	result
,	,	,
the	DT	the
public	JJ	public
adoption	NN	adoption
of	IN	of
these	DT	these
apps	NNS	<unknown>
.	SENT	.
For	IN	for
example	NN	example
,	,	,
they	PP	they
should	MD	should
be	VB	be
designed	VBN	design
to	TO	to
be	VB	be
as	RB	as
simple	JJ	simple
as	IN	as
possible	JJ	possible
to	TO	to
operate	VB	operate
(	(	(
need	NN	need
for	IN	for
usability	NN	usability
)	)	)
.	SENT	.
34101494/	CD	@card@
Access	NP	Access
to	TO	to
Harm	NP	Harm
Reduction	NP	Reduction
Treatment	NP	Treatment
Among	IN	among
Formerly	RB	formerly
Incarcerated	VBN	incarcerate
Individuals	NNS	individual
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Era	NP	Era
33462438/	CD	@card@
Publisher	NN	publisher
Correction	NN	correction
:	:	:
Genomic	JJ	<unknown>
epidemiology	NN	epidemiology
reveals	VBZ	reveal
multiple	JJ	multiple
introductions	NNS	introduction
of	IN	of
SARS-CoV-2	NP	<unknown>
from	IN	from
mainland	JJ	mainland
Europe	NP	Europe
into	IN	into
Scotland	NP	Scotland
32840829/	CD	@card@
Gambling	NN	gambling
with	IN	with
COVID-19	NP	<unknown>
Makes	VBZ	make
More	JJR	more
Sense	NN	sense
:	:	:
Ethical	JJ	ethical
and	CC	and
Practical	JJ	practical
Challenges	NNS	challenge
in	IN	in
COVID-19	NP	<unknown>
Responses	NNS	response
in	IN	in
Communalistic	JJ	communalistic
Resource-Limited	NP	Resource-Limited
Africa	NP	Africa
Informed	VBD	inform
by	IN	by
evidence	NN	evidence
from	IN	from
past	JJ	past
studies	NNS	study
and	CC	and
experiences	NNS	experience
with	IN	with
epidemics	NNS	epidemic
,	,	,
an	DT	an
intervention	NN	intervention
combining	VBG	combine
quarantine	NN	quarantine
,	,	,
lockdowns	NNS	lockdown
,	,	,
curfews	NNS	curfew
,	,	,
social	JJ	social
distancing	NN	distancing
,	,	,
and	CC	and
washing	VBG	wash
of	IN	of
hands	NNS	hand
has	VBZ	have
been	VBN	be
adopted	VBN	adopt
as	IN	as
"	``	"
international	JJ	international
best	JJS	good
practice	NN	practice
"	''	"
in	IN	in
COVID-19	NP	<unknown>
response	NN	response
.	SENT	.
With	IN	with
massive	JJ	massive
total	JJ	total
lockdowns	NNS	lockdown
complemented	VBN	complement
by	IN	by
electronic	JJ	electronic
surveillance	NN	surveillance
,	,	,
China	NP	China
successfully	RB	successfully
controlled	VBD	control
the	DT	the
pandemic	NN	pandemic
in	IN	in
country	NN	country
within	IN	within
a	DT	a
few	JJ	few
months	NNS	month
.	SENT	.
But	CC	but
would	MD	would
this	DT	this
work	NN	work
for	IN	for
Africa	NP	Africa
and	CC	and
other	JJ	other
communalistic	JJ	communalistic
resource-poor	NN	<unknown>
settings	NNS	setting
where	WRB	where
social	JJ	social
togetherness	NN	togetherness
translates	VBZ	translate
to	TO	to
effective	JJ	effective
sharing	NN	sharing
of	IN	of
basic	JJ	basic
needs	NNS	need
?	SENT	?
What	WP	what
ethical	JJ	ethical
and	CC	and
practical	JJ	practical
challenges	NNS	challenge
would	MD	would
this	RB	this
pose	VB	pose
?	SENT	?
How	WRB	how
would	MD	would
communalism	NN	communalism
be	VB	be
translated	VBN	translate
in	IN	in
special	JJ	special
contexts	NNS	context
to	TO	to
be	VB	be
useful	JJ	useful
in	IN	in
contributing	VBG	contribute
to	TO	to
the	DT	the
ultimate	JJ	ultimate
common	JJ	common
good	NN	good
?	SENT	?
This	DT	this
paper	NN	paper
uses	VBZ	use
examples	NNS	example
from	IN	from
the	DT	the
current	JJ	current
situation	NN	situation
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Kenya	NP	Kenya
to	TO	to
address	VB	address
these	DT	these
questions	NNS	question
.	SENT	.
34077572/	CD	@card@
Immune	NP	Immune
thrombocytopenic	JJ	thrombocytopenic
purpura	NN	purpura
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
Pfizer-BioNTech	NP	<unknown>
BNT16B2b2	NP	<unknown>
mRNA	NP	<unknown>
vaccine	NN	vaccine
34975646/	CD	@card@
Students	NNS	student
'	POS	'
Attitudes	NNS	attitude
Toward	IN	toward
Online	JJ	online
Music	NP	Music
Education	NP	Education
During	IN	during
the	DT	the
COVID	NP	<unknown>
19	CD	@card@
Lockdown	NP	<unknown>
Given	VBN	give
the	DT	the
current	JJ	current
pandemic	JJ	pandemic
context	NN	context
generated	VBN	generate
by	IN	by
COVID	NP	<unknown>
19	CD	@card@
,	,	,
important	JJ	important
changes	NNS	change
in	IN	in
the	DT	the
way	NN	way
specific	JJ	specific
subjects	NNS	subject
to	TO	to
music	NN	music
education	NN	education
are	VBP	be
taught	VBN	teach
emerged	VBN	emerge
,	,	,
affecting	VBG	affect
not	RB	not
only	RB	only
the	DT	the
particularities	NNS	particularity
of	IN	of
learning	VBG	learn
and	CC	and
teaching	VBG	teach
in	IN	in
individual	JJ	individual
courses	NNS	course
,	,	,
but	CC	but
also	RB	also
the	DT	the
other	JJ	other
courses	NNS	course
regarding	VBG	regard
group	NN	group
learning	NN	learning
or	CC	or
theoretical	JJ	theoretical
subjects	NNS	subject
.	SENT	.
In	IN	in
this	DT	this
time	NN	time
,	,	,
emergency	NN	emergency
remote	JJ	remote
teaching	NN	teaching
and	CC	and
learning	NN	learning
requires	VBZ	require
cross-collaboration	NN	cross-collaboration
between	IN	between
instructional	JJ	instructional
,	,	,
content	JJ	content
,	,	,
and	CC	and
technological	JJ	technological
teams	NNS	team
.	SENT	.
Our	PP$	our
research	NN	research
examines	VBZ	examine
the	DT	the
students	NNS	student
'	POS	'
attitudes	NNS	attitude
toward	IN	toward
online	JJ	online
education	NN	education
,	,	,
also	RB	also
presenting	VBG	present
proposals	NNS	proposal
for	IN	for
optimization	NN	optimization
and	CC	and
efficiency	NN	efficiency
.	SENT	.
The	DT	the
research	NN	research
was	VBD	be
undertaken	VBN	undertake
after	IN	after
an	DT	an
experience	NN	experience
of	IN	of
a	DT	a
University	NP	University
semester	NN	semester
in	IN	in
a	DT	a
lockdown	JJ	<unknown>
context	NN	context
,	,	,
and	CC	and
it	PP	it
aimed	VBD	aim
at	IN	at
undergraduate	NN	undergraduate
and	CC	and
master	NN	master
's	POS	's
degree	NN	degree
students	NNS	student
from	IN	from
music	NN	music
faculties	NNS	faculty
in	IN	in
Romania	NP	Romania
.	SENT	.
An	DT	an
important	JJ	important
result	NN	result
was	VBD	be
the	DT	the
mediating	VBG	mediate
role	NN	role
of	IN	of
perceived	VBN	perceive
utility	NN	utility
of	IN	of
e-learning	NP	e-learning
methods	NNS	method
,	,	,
perceived	VBN	perceive
utility	NN	utility
mediated	VBD	mediate
the	DT	the
associations	NNS	association
between	IN	between
compatibility	NN	compatibility
of	IN	of
online	JJ	online
methods	NNS	method
and	CC	and
satisfaction	NN	satisfaction
toward	IN	toward
the	DT	the
use	NN	use
of	IN	of
e-learning	NP	e-learning
methods	NNS	method
.	SENT	.
The	DT	the
perceived	VBN	perceive
compatibility	NN	compatibility
of	IN	of
e-Learning	NP	e-Learning
methods	NNS	method
with	IN	with
online	JJ	online
music	NN	music
education	NN	education
led	VBD	lead
to	TO	to
a	DT	a
higher	JJR	high
perceived	VBN	perceive
utility	NN	utility
which	WDT	which
,	,	,
in	IN	in
turn	NN	turn
,	,	,
predicted	VBD	predict
a	DT	a
higher	JJR	high
satisfaction	NN	satisfaction
toward	IN	toward
e-Learning	NP	e-Learning
Although	IN	although
this	DT	this
period	NN	period
accentuated	VBD	accentuate
the	DT	the
fear	NN	fear
of	IN	of
interaction	NN	interaction
with	IN	with
others	NNS	other
,	,	,
the	DT	the
anxiety	NN	anxiety
related	VBN	relate
to	TO	to
the	DT	the
unknown	NN	unknown
,	,	,
the	DT	the
intolerance	NN	intolerance
of	IN	of
uncertainty	NN	uncertainty
did	VBD	do
not	RB	not
predict	VB	predict
the	DT	the
satisfaction	NN	satisfaction
toward	IN	toward
the	DT	the
use	NN	use
of	IN	of
e-learning	NP	e-learning
platforms	NNS	platform
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
more	JJR	more
educational	JJ	educational
initiatives	NNS	initiative
are	VBP	be
needed	VBN	need
to	TO	to
promote	VB	promote
remote	JJ	remote
teaching	NN	teaching
methods	NNS	method
in	IN	in
music	NN	music
education	NN	education
.	SENT	.
In	IN	in
the	DT	the
absence	NN	absence
of	IN	of
similar	JJ	similar
research	NN	research
in	IN	in
our	PP$	our
country	NN	country
,	,	,
we	PP	we
considered	VBD	consider
that	IN	that
future	JJ	future
research	NN	research
on	IN	on
this	DT	this
topic	NN	topic
is	VBZ	be
needed	VBN	need
.	SENT	.
33177848/	CD	@card@
Multiple	JJ	multiple
Expression	NN	expression
Assessments	NNS	assessment
of	IN	of
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
SARS-CoV-2	NP	<unknown>
Entry	NN	entry
Molecules	NNS	molecule
in	IN	in
the	DT	the
Urinary	JJ	urinary
Tract	NN	tract
and	CC	and
Their	PP$	their
Associations	NNS	association
with	IN	with
Clinical	JJ	clinical
Manifestations	NNS	manifestation
of	IN	of
COVID-19	NP	<unknown>
Since	IN	since
December	NP	December
2019	CD	@card@
,	,	,
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
first	RB	first
spread	VBN	spread
quickly	RB	quickly
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
,	,	,
then	RB	then
globally	RB	globally
.	SENT	.
Based	VBN	base
on	IN	on
previously	RB	previously
published	VBN	publish
evidence	NN	evidence
,	,	,
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
are	VBP	be
both	DT	both
pivotal	JJ	pivotal
entry	NN	entry
molecules	NNS	molecule
that	WDT	that
enable	VBP	enable
cellular	JJ	cellular
infection	NN	infection
by	IN	by
SARS-CoV-2	NP	<unknown>
.	SENT	.
Also	RB	also
,	,	,
increased	VBD	increase
expression	NN	expression
of	IN	of
pro-inflammatory	JJ	pro-inflammatory
cytokines	NNS	cytokine
,	,	,
or	CC	or
a	DT	a
"	``	"
cytokine	NN	<unknown>
storm	NN	storm
,	,	,
"	''	"
is	VBZ	be
associated	VBN	associate
with	IN	with
multiple	JJ	multiple
organ	NN	organ
dysfunction	NN	dysfunction
syndrome	NN	syndrome
often	RB	often
observed	VBD	observe
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
.	SENT	.
We	PP	we
investigated	VBD	investigate
the	DT	the
expression	NN	expression
pattern	NN	pattern
of	IN	of
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
in	IN	in
major	JJ	major
organs	NNS	organ
in	IN	in
the	DT	the
human	JJ	human
body	NN	body
,	,	,
especially	RB	especially
in	IN	in
specific	JJ	specific
disease	NN	disease
conditions	NNS	condition
.	SENT	.
Multiple	JJ	multiple
sequence	NN	sequence
alignment	NN	alignment
of	IN	of
ACE2	NP	<unknown>
in	IN	in
different	JJ	different
species	NNS	specie
was	VBD	be
used	VBN	use
to	TO	to
explain	VB	explain
animal	JJ	animal
susceptibility	NN	susceptibility
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
cell-specific	JJ	cell-specific
expression	NN	expression
patterns	NNS	pattern
of	IN	of
ACE2	NP	<unknown>
and	CC	and
cytokine	JJ	<unknown>
receptors	NNS	receptor
in	IN	in
the	DT	the
urinary	JJ	urinary
tract	NN	tract
were	VBD	be
assessed	VBN	assess
using	VBG	use
single-cell	NN	single-cell
RNA	NP	RNA
sequencing	NP	sequencing
(	(	(
scRNA-seq	NP	<unknown>
)	)	)
.	SENT	.
Additional	JJ	additional
biological	JJ	biological
relevance	NN	relevance
was	VBD	be
determined	VBN	determine
through	IN	through
Gene	NP	Gene
Set	VBD	set
Enrichment	NN	enrichment
Analysis	NP	Analysis
(	(	(
GSEA	NP	<unknown>
)	)	)
using	VBG	use
an	DT	an
ACE2-specific	JJ	ACE2-specific
signature	NN	signature
.	SENT	.
Our	PP$	our
results	NNS	result
revealed	VBD	reveal
that	IN	that
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
were	VBD	be
highly	RB	highly
expressed	VBN	express
in	IN	in
genitourinary	JJ	genitourinary
organs	NNS	organ
.	SENT	.
ACE2	NP	<unknown>
was	VBD	be
highly	RB	highly
and	CC	and
significantly	RB	significantly
expressed	VBN	express
in	IN	in
the	DT	the
kidney	NN	kidney
among	IN	among
individuals	NNS	individual
with	IN	with
chronic	JJ	chronic
kidney	NN	kidney
diseases	NNS	disease
or	CC	or
diabetic	JJ	diabetic
nephropathy	NN	<unknown>
.	SENT	.
In	IN	in
single	JJ	single
cells	NNS	cell
,	,	,
ACE2	NP	<unknown>
was	VBD	be
primarily	RB	primarily
enriched	VBN	enrich
in	IN	in
gametocytes	NNS	gametocyte
in	IN	in
the	DT	the
testis	NN	testis
and	CC	and
renal	JJ	renal
proximal	JJ	proximal
tubules	NNS	tubule
.	SENT	.
The	DT	the
receptors	NNS	receptor
for	IN	for
pro-inflammatory	JJ	pro-inflammatory
cytokines	NNS	cytokine
,	,	,
especially	RB	especially
IL6ST	NP	<unknown>
,	,	,
were	VBD	be
notably	RB	notably
concentrated	VBN	concentrate
in	IN	in
endothelial	JJ	endothelial
cells	NNS	cell
,	,	,
macrophages	NNS	macrophage
,	,	,
spermatogonial	JJ	spermatogonial
stem	NN	stem
cells	NNS	cell
in	IN	in
the	DT	the
testis	NN	testis
,	,	,
and	CC	and
renal	JJ	renal
endothelial	JJ	endothelial
cells	NNS	cell
,	,	,
which	WDT	which
suggested	VBD	suggest
the	DT	the
occurrence	NN	occurrence
of	IN	of
alternative	JJ	alternative
damaging	JJ	damaging
autoimmune	JJ	autoimmune
mechanisms	NNS	mechanism
.	SENT	.
This	DT	this
study	NN	study
provided	VBD	provide
new	JJ	new
insights	NNS	insight
into	IN	into
the	DT	the
pathogenic	JJ	pathogenic
mechanisms	NNS	mechanism
of	IN	of
SARS-CoV-2	NP	<unknown>
that	WDT	that
underlie	VBP	underlie
the	DT	the
clinical	JJ	clinical
manifestations	NNS	manifestation
observed	VBN	observe
in	IN	in
the	DT	the
human	JJ	human
testis	NN	testis
and	CC	and
kidney	NN	kidney
.	SENT	.
These	DT	these
observations	NNS	observation
might	MD	might
substantially	RB	substantially
facilitate	VB	facilitate
the	DT	the
development	NN	development
of	IN	of
effective	JJ	effective
treatments	NNS	treatment
for	IN	for
this	DT	this
rapidly	RB	rapidly
spreading	VBG	spread
disease	NN	disease
.	SENT	.
32652368/	CD	@card@
Looking	VBG	look
at	IN	at
intra-hospital	JJ	<unknown>
non	JJ	non
COVID-19	NP	<unknown>
mortality	NN	mortality
among	IN	among
elderly	JJ	elderly
patients	NNS	patient
during	IN	during
COVID-19	NP	<unknown>
pandemic	NN	pandemic
33754150/	CD	@card@
Using	VBG	use
Technology	NN	technology
to	TO	to
Measure	NN	measure
Older	JJR	old
Adults	NNS	adult
'	POS	'
Social	NP	Social
Networks	NPS	Networks
for	IN	for
Health	NP	Health
and	CC	and
Well-Being	NN	well-being
:	:	:
A	DT	a
Scoping	NP	<unknown>
Review	NP	Review
Social	NP	Social
networks	NNS	network
impact	VBP	impact
the	DT	the
health	NN	health
and	CC	and
well-being	NN	well-being
of	IN	of
older	JJR	old
adults	NNS	adult
.	SENT	.
Advancements	NNS	advancement
in	IN	in
technology	NN	technology
(	(	(
e.g.	FW	e.g.
,	,	,
digital	JJ	digital
devices	NNS	device
and	CC	and
mHealth	NN	mhealth
)	)	)
enrich	VBP	enrich
our	PP$	our
ability	NN	ability
to	TO	to
collect	VB	collect
social	JJ	social
networks	NNS	network
and	CC	and
health	NN	health
data	NNS	datum
.	SENT	.
The	DT	the
purpose	NN	purpose
of	IN	of
this	DT	this
scoping	JJ	<unknown>
review	NN	review
was	VBD	be
to	TO	to
identify	VB	identify
and	CC	and
map	VB	map
the	DT	the
use	NN	use
of	IN	of
technology	NN	technology
in	IN	in
measuring	VBG	measure
older	JJR	old
adults	NNS	adult
'	POS	'
social	JJ	social
networks	NNS	network
for	IN	for
health	NN	health
and	CC	and
social	JJ	social
care	NN	care
.	SENT	.
Joanna	NP	Joanna
Briggs	NP	Briggs
Institute	NP	Institute
methodology	NN	methodology
was	VBD	be
followed	VBN	follow
.	SENT	.
PubMed	NP	<unknown>
(	(	(
MEDLINE	NP	<unknown>
)	)	)
,	,	,
Sociological	JJ	sociological
Abstracts	NNS	abstract
,	,	,
SocINDEX	NP	<unknown>
,	,	,
CINAHL	NP	<unknown>
,	,	,
and	CC	and
Web	NP	Web
of	IN	of
Science	NP	Science
were	VBD	be
searched	VBN	search
for	IN	for
relevant	JJ	relevant
articles	NNS	article
.	SENT	.
Conference	NN	conference
abstracts	NNS	abstract
and	CC	and
proceedings	NNS	proceeding
were	VBD	be
searched	VBN	search
via	IN	via
Conference	NP	Conference
Papers	NP	Papers
Index	NP	Index
,	,	,
the	DT	the
American	JJ	American
Sociological	JJ	sociological
Society	NP	Society
,	,	,
and	CC	and
The	DT	the
Gerontological	JJ	gerontological
Society	NP	Society
of	IN	of
America	NP	America
.	SENT	.
Studies	NNS	study
published	VBN	publish
in	IN	in
English	NP	English
from	IN	from
January	NP	January
2004	CD	@card@
to	TO	to
March	NP	March
2020	CD	@card@
that	WDT	that
aimed	VBD	aim
to	TO	to
improve	VB	improve
health	NN	health
or	CC	or
social	JJ	social
care	NN	care
for	IN	for
older	JJR	old
adults	NNS	adult
and	CC	and
used	VBN	use
technology	NN	technology
to	TO	to
measure	VB	measure
social	JJ	social
networks	NNS	network
were	VBD	be
included	VBN	include
.	SENT	.
Data	NNS	datum
were	VBD	be
extracted	VBN	extract
by	IN	by
two	CD	two
independent	JJ	independent
reviewers	NNS	reviewer
using	VBG	use
an	DT	an
a	DT	a
priori	NN	priori
extraction	NN	extraction
tool	NN	tool
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
the	DT	the
18	CD	@card@
reviewed	VBN	review
studies	NNS	study
were	VBD	be
pilot	NN	pilot
or	CC	or
simulation	NN	simulation
research	NN	research
conducted	VBN	conduct
in	IN	in
Europe	NP	Europe
that	WDT	that
focused	VBD	focus
on	IN	on
older	JJR	old
adults	NNS	adult
living	VBG	live
in	IN	in
the	DT	the
community	NN	community
.	SENT	.
The	DT	the
various	JJ	various
types	NNS	type
of	IN	of
technologies	NNS	technology
used	VBN	use
can	MD	can
be	VB	be
categorized	VBN	categorize
as	IN	as
environment-based	JJ	<unknown>
,	,	,
person-based	JJ	<unknown>
,	,	,
and	CC	and
data-based	JJ	<unknown>
.	SENT	.
Technology	NP	Technology
facilitates	VBZ	facilitate
objective	JJ	objective
and	CC	and
longitudinal	JJ	longitudinal
data	NNS	datum
collection	NN	collection
on	IN	on
the	DT	the
social	JJ	social
interactions	NNS	interaction
and	CC	and
activities	NNS	activity
of	IN	of
older	JJR	old
adults	NNS	adult
.	SENT	.
The	DT	the
use	NN	use
of	IN	of
technology	NN	technology
to	TO	to
measure	VB	measure
older	JJR	old
adults	NNS	adult
'	POS	'
social	JJ	social
networks	NNS	network
,	,	,
however	RB	however
,	,	,
is	VBZ	be
primarily	RB	primarily
in	IN	in
an	DT	an
exploratory	JJ	exploratory
phase	NN	phase
.	SENT	.
Multidisciplinary	JJ	multidisciplinary
collaborations	NNS	collaboration
are	VBP	be
needed	VBN	need
to	TO	to
overcome	VB	overcome
operational	JJ	operational
,	,	,
analytical	JJ	analytical
,	,	,
and	CC	and
implementation	NN	implementation
challenges	NNS	challenge
.	SENT	.
Future	JJ	future
studies	NNS	study
should	MD	should
leverage	VB	leverage
technologies	NNS	technology
for	IN	for
addressing	VBG	address
social	JJ	social
isolation	NN	isolation
and	CC	and
care	NN	care
for	IN	for
older	JJR	old
adults	NNS	adult
,	,	,
especially	RB	especially
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
34568249/	CD	@card@
Operationalizing	NP	<unknown>
Cooperative	JJ	cooperative
Research	NN	research
for	IN	for
Infectious	JJ	infectious
Disease	NP	Disease
Surveillance	NN	surveillance
:	:	:
Lessons	NNS	lesson
Learned	NP	Learned
and	CC	and
Ways	NP	Ways
Forward	NP	Forward
The	DT	the
current	JJ	current
COVID-19	NP	<unknown>
pandemic	NN	pandemic
demonstrates	VBZ	demonstrate
the	DT	the
need	NN	need
for	IN	for
urgent	JJ	urgent
and	CC	and
on-demand	NN	on-demand
solutions	NNS	solution
to	TO	to
provide	VB	provide
diagnostics	NNS	diagnostic
,	,	,
treatment	NN	treatment
and	CC	and
preventative	JJ	preventative
measures	NNS	measure
for	IN	for
infectious	JJ	infectious
disease	NN	disease
outbreaks	NNS	outbreak
.	SENT	.
Once	RB	once
solutions	NNS	solution
are	VBP	be
developed	VBN	develop
,	,	,
meeting	NN	meeting
capacities	NNS	capacity
depends	VBZ	depend
on	IN	on
the	DT	the
ability	NN	ability
to	TO	to
mitigate	VB	mitigate
technical	JJ	technical
,	,	,
logistical	JJ	logistical
and	CC	and
production	NN	production
issues	NNS	issue
.	SENT	.
While	IN	while
it	PP	it
is	VBZ	be
difficult	JJ	difficult
to	TO	to
predict	VB	predict
the	DT	the
next	JJ	next
outbreak	NN	outbreak
,	,	,
augmenting	VBG	augment
investments	NNS	investment
in	IN	in
preparedness	NN	preparedness
,	,	,
such	JJ	such
as	IN	as
infectious	JJ	infectious
disease	NN	disease
surveillance	NN	surveillance
,	,	,
is	VBZ	be
far	RB	far
more	RBR	more
effective	JJ	effective
than	IN	than
mustering	VBG	muster
last-minute	JJ	last-minute
response	NN	response
funds	NNS	fund
.	SENT	.
Bringing	VBG	bring
research	NN	research
outputs	NNS	output
into	IN	into
practice	NN	practice
sooner	RBR	sooner
rather	RB	rather
than	IN	than
later	RBR	later
is	VBZ	be
part	NN	part
of	IN	of
an	DT	an
agile	JJ	agile
approach	NN	approach
to	TO	to
pivot	VB	pivot
and	CC	and
deliver	VB	deliver
solutions	NNS	solution
.	SENT	.
Cooperative	JJ	cooperative
multi-	NN	<unknown>
country	NN	country
research	NN	research
programs	NNS	program
,	,	,
especially	RB	especially
those	DT	those
funded	VBN	fund
by	IN	by
global	JJ	global
biosecurity	NN	biosecurity
programs	NNS	program
,	,	,
develop	VB	develop
capacity	NN	capacity
that	WDT	that
can	MD	can
be	VB	be
applied	VBN	apply
to	TO	to
infectious	JJ	infectious
disease	NN	disease
surveillance	NN	surveillance
and	CC	and
research	NN	research
that	WDT	that
enhances	VBZ	enhance
detection	NN	detection
,	,	,
identification	NN	identification
,	,	,
and	CC	and
response	NN	response
to	TO	to
emerging	VBG	emerge
and	CC	and
re-emerging	VBG	re-emerge
pathogens	NNS	pathogen
with	IN	with
epidemic	NN	epidemic
or	CC	or
pandemic	JJ	pandemic
potential	NN	potential
.	SENT	.
Moreover	RB	moreover
,	,	,
these	DT	these
programs	NNS	program
enhance	VB	enhance
trust	NN	trust
building	NN	building
among	IN	among
partners	NNS	partner
,	,	,
which	WDT	which
is	VBZ	be
essential	JJ	essential
because	IN	because
setting	VBG	set
expectation	NN	expectation
and	CC	and
commitment	NN	commitment
are	VBP	be
required	VBN	require
for	IN	for
successful	JJ	successful
research	NN	research
and	CC	and
training	NN	training
.	SENT	.
Measuring	VBG	measure
research	NN	research
outputs	NNS	output
,	,	,
evaluating	VBG	evaluate
outcomes	NNS	outcome
and	CC	and
justifying	VBG	justify
continual	JJ	continual
investments	NNS	investment
are	VBP	be
essential	JJ	essential
but	CC	but
not	RB	not
straightforward	JJ	straightforward
.	SENT	.
Lessons	NNS	lesson
learned	VBD	learn
include	VB	include
those	DT	those
related	VBN	relate
to	TO	to
reducing	VBG	reduce
biological	JJ	biological
threats	NNS	threat
and	CC	and
maturing	VBG	mature
capabilities	NNS	capability
for	IN	for
national	JJ	national
laboratory	NN	laboratory
diagnostics	NNS	diagnostic
strategy	NN	strategy
and	CC	and
related	JJ	related
health	NN	health
systems	NNS	system
.	SENT	.
Challenges	NNS	challenge
,	,	,
such	JJ	such
as	IN	as
growing	VBG	grow
networks	NNS	network
,	,	,
promoting	VBG	promote
scientific	JJ	scientific
transparency	NN	transparency
,	,	,
data	NNS	datum
and	CC	and
material	NN	material
sharing	NN	sharing
,	,	,
sustaining	VBG	sustain
funds	NNS	fund
and	CC	and
developing	VBG	develop
research	NN	research
strategies	NNS	strategy
remain	VBP	remain
to	TO	to
be	VB	be
fully	RB	fully
resolved	VBN	resolve
.	SENT	.
Here	RB	here
,	,	,
experiences	NNS	experience
from	IN	from
several	JJ	several
programs	NNS	program
highlight	VB	highlight
successful	JJ	successful
partnerships	NNS	partnership
that	WDT	that
provide	VBP	provide
ways	NNS	way
forward	RB	forward
to	TO	to
address	VB	address
the	DT	the
next	JJ	next
outbreak	NN	outbreak
.	SENT	.
34665318/	CD	@card@
Behind	IN	behind
the	DT	the
mask	NN	mask
:	:	:
extended	JJ	extended
use	NN	use
of	IN	of
surgical	JJ	surgical
masks	NNS	mask
is	VBZ	be
not	RB	not
associated	VBN	associate
with	IN	with
increased	VBN	increase
risk	NN	risk
of	IN	of
surgical	JJ	surgical
site	NN	site
infection	NN	infection
COVID-19	NP	<unknown>
has	VBZ	have
prompted	VBN	prompt
significant	JJ	significant
policy	NN	policy
change	NN	change
,	,	,
with	IN	with
critical	JJ	critical
attention	NN	attention
to	TO	to
the	DT	the
conservation	NN	conservation
of	IN	of
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
(	(	(
PPE	NP	PPE
)	)	)
.	SENT	.
An	DT	an
extended	JJ	extended
surgical	JJ	surgical
mask	NN	mask
use	NN	use
policy	NN	policy
was	VBD	be
implemented	VBN	implement
at	IN	at
our	PP$	our
institution	NN	institution
,	,	,
allowing	VBG	allow
use	NN	use
of	IN	of
one	CD	one
disposable	JJ	disposable
mask	NN	mask
per	IN	per
each	DT	each
individual	NN	individual
,	,	,
per	IN	per
day	NN	day
,	,	,
for	IN	for
all	PDT	all
the	DT	the
cases	NNS	case
.	SENT	.
We	PP	we
investigate	VBP	investigate
the	DT	the
clinical	JJ	clinical
impact	NN	impact
of	IN	of
this	DT	this
policy	NN	policy
change	NN	change
and	CC	and
its	PP$	its
effect	NN	effect
on	IN	on
the	DT	the
rate	NN	rate
of	IN	of
30-day	JJ	30-day
surgical	JJ	surgical
site	NN	site
infection	NN	infection
(	(	(
SSI	NP	SSI
)	)	)
.	SENT	.
A	DT	a
single-institution	NN	single-institution
retrospective	NN	retrospective
review	NN	review
was	VBD	be
performed	VBN	perform
for	IN	for
all	PDT	all
the	DT	the
elective	JJ	elective
pediatric	JJ	pediatric
general	JJ	general
surgery	NN	surgery
cases	NNS	case
performed	VBD	perform
pre-COVID	NN	<unknown>
from	IN	from
August	NP	August
2019	CD	@card@
to	TO	to
October	NP	October
2019	CD	@card@
and	CC	and
under	IN	under
the	DT	the
extended	JJ	extended
mask	NN	mask
use	NN	use
policy	NN	policy
from	IN	from
August	NP	August
2020	CD	@card@
to	TO	to
October	NP	October
2020	CD	@card@
.	SENT	.
Procedure	NN	procedure
type	NN	type
,	,	,
SSI	NP	SSI
within	IN	within
30	CD	@card@
days	NNS	day
,	,	,
and	CC	and
postoperative	JJ	postoperative
interventions	NNS	intervention
were	VBD	be
recorded	VBN	record
.	SENT	.
Four	CD	four
hundred	CD	hundred
and	CC	and
eighty-eight	NN	eighty-eight
cases	NNS	case
were	VBD	be
reviewed	VBN	review
:	:	:
240	CD	@card@
in	IN	in
the	DT	the
pre-COVID-19	JJ	<unknown>
cohort	NN	cohort
and	CC	and
248	CD	@card@
in	IN	in
the	DT	the
extended	JJ	extended
surgical	JJ	surgical
mask	NN	mask
use	NN	use
cohort	NN	cohort
.	SENT	.
Three	NP	Three
SSIs	NP	<unknown>
were	VBD	be
identified	VBN	identify
in	IN	in
the	DT	the
2019	CD	@card@
cohort	NN	cohort
,	,	,
and	CC	and
two	CD	two
in	IN	in
the	DT	the
2020	CD	@card@
cohort	NN	cohort
.	SENT	.
All	DT	all
postoperative	JJ	postoperative
infections	NNS	infection
were	VBD	be
superficial	JJ	superficial
and	CC	and
resolved	VBN	resolve
within	IN	within
1	CD	@card@
month	NN	month
of	IN	of
diagnosis	NN	diagnosis
with	IN	with
oral	JJ	oral
antibiotics	NNS	antibiotic
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
deep	JJ	deep
space	NN	space
infections	NNS	infection
,	,	,
readmissions	NNS	readmission
,	,	,
or	CC	or
infections	NNS	infection
requiring	VBG	require
re-operation	NN	re-operation
.	SENT	.
Extended	VBN	extend
surgical	JJ	surgical
mask	NN	mask
use	NN	use
was	VBD	be
not	RB	not
associated	VBN	associate
with	IN	with
increased	VBN	increase
SSI	NP	SSI
in	IN	in
this	DT	this
series	NN	series
of	IN	of
pediatric	JJ	pediatric
general	JJ	general
surgery	NN	surgery
cases	NNS	case
and	CC	and
may	MD	may
be	VB	be
considered	VBN	consider
an	DT	an
effective	JJ	effective
and	CC	and
safe	JJ	safe
strategy	NN	strategy
for	IN	for
resource	NN	resource
conservation	NN	conservation
with	IN	with
minimal	JJ	minimal
clinical	JJ	clinical
impact	NN	impact
.	SENT	.
32429009/	CD	@card@
Safe	NP	Safe
Colorectal	JJ	colorectal
Surgery	NN	surgery
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
Era	NP	Era
-	NN	<unknown>
A	DT	a
Singapore	NP	Singapore
Experience	NN	experience
35170714/	CD	@card@
Pulmonary	JJ	pulmonary
hemorrhage	NN	hemorrhage
in	IN	in
dengue	NN	dengue
:	:	:
differential	JJ	differential
diagnosis	NN	diagnosis
with	IN	with
acute	JJ	acute
viral	JJ	viral
respiratory	JJ	respiratory
syndromes	NNS	syndrome
including	VBG	include
COVID-19	NP	<unknown>
Clinical	JJ	clinical
similarities	NNS	similarity
among	IN	among
viral	JJ	viral
diseases	NNS	disease
become	VBN	become
even	RB	even
more	RBR	more
relevant	JJ	relevant
considering	VBG	consider
the	DT	the
current	JJ	current
scenario	NN	scenario
,	,	,
especially	RB	especially
in	IN	in
Brazil	NP	Brazil
,	,	,
where	WRB	where
there	EX	there
is	VBZ	be
a	DT	a
high	JJ	high
incidence	NN	incidence
of	IN	of
these	DT	these
diseases	NNS	disease
and	CC	and
overlapping	JJ	overlapping
seasonality	NN	seasonality
.	SENT	.
We	PP	we
report	VBP	report
the	DT	the
case	NN	case
of	IN	of
a	DT	a
patient	NN	patient
with	IN	with
acute	JJ	acute
clinical	JJ	clinical
manifestations	NNS	manifestation
composed	VBN	compose
of	IN	of
predominant	JJ	predominant
respiratory	JJ	respiratory
symptoms	NNS	symptom
and	CC	and
alveolar	JJ	alveolar
hemorrhage	NN	hemorrhage
in	IN	in
which	WDT	which
three	CD	three
etiologies	NNS	etiology
(	(	(
dengue	NN	dengue
,	,	,
influenza	NN	influenza
and	CC	and
COVID-19	NP	<unknown>
)	)	)
were	VBD	be
investigated	VBN	investigate
concomitantly	RB	concomitantly
.	SENT	.
Only	RB	only
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
dengue	NN	dengue
was	VBD	be
confirmed	VBN	confirm
.	SENT	.
Then	RB	then
,	,	,
the	DT	the
patient	NN	patient
's	POS	's
immunological	JJ	immunological
profile	NN	profile
in	IN	in
response	NN	response
to	TO	to
stimulation	NN	stimulation
of	IN	of
mononuclear	JJ	mononuclear
cells	NNS	cell
with	IN	with
dengue	NN	dengue
virus	NN	virus
antigen	NN	antigen
was	VBD	be
analyzed	VBN	analyze
in	IN	in
an	DT	an
attempt	NN	attempt
to	TO	to
identify	VB	identify
specific	JJ	specific
characteristics	NNS	characteristic
that	WDT	that
could	MD	could
be	VB	be
associated	VBN	associate
with	IN	with
the	DT	the
clinical	JJ	clinical
manifestation	NN	manifestation
.	SENT	.
32541708/	CD	@card@
Loss	NN	loss
of	IN	of
taste	NN	taste
and	CC	and
smell	VBP	smell
35123395/	CD	@card@
Coresidence	NP	<unknown>
increases	NNS	increase
the	DT	the
risk	NN	risk
of	IN	of
testing	VBG	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
among	IN	among
older	JJR	old
Brazilians	NNS	Brazilian
Brazil	NP	Brazil
is	VBZ	be
among	IN	among
the	DT	the
countries	NNS	country
hit	VBD	hit
hardest	JJS	hard
by	IN	by
COVID-19	NP	<unknown>
,	,	,
and	CC	and
older	JJR	old
adults	NNS	adult
are	VBP	be
among	IN	among
the	DT	the
vulnerable	JJ	vulnerable
groups	NNS	group
.	SENT	.
Intergenerational	JJ	intergenerational
coresidence	NN	coresidence
and	CC	and
interdependence	NN	interdependence
among	IN	among
family	NN	family
members	NNS	member
,	,	,
both	CC	both
prevalent	JJ	prevalent
in	IN	in
Brazil	NP	Brazil
,	,	,
likely	JJ	likely
increase	NN	increase
social	JJ	social
and	CC	and
physical	JJ	physical
contact	NN	contact
and	CC	and
thus	RB	thus
potential	JJ	potential
infection	NN	infection
.	SENT	.
Using	VBG	use
nationally	RB	nationally
representative	JJ	representative
data	NNS	datum
from	IN	from
the	DT	the
COVID-19	NP	<unknown>
module	NN	module
of	IN	of
the	DT	the
Brazilian	JJ	Brazilian
National	NP	National
Household	NN	household
Sample	NP	Sample
Survey	NP	Survey
(	(	(
Pesquisa	NP	<unknown>
Nacional	NP	Nacional
por	NP	por
Amostra	NP	<unknown>
de	NP	de
Domicilios	NP	<unknown>
)	)	)
,	,	,
collected	VBN	collect
between	IN	between
July	NP	July
and	CC	and
November	NP	November
of	IN	of
2020	CD	@card@
,	,	,
we	PP	we
examined	VBD	examine
the	DT	the
association	NN	association
between	IN	between
living	VBG	live
arrangements	NNS	arrangement
and	CC	and
exposure	NN	exposure
to	TO	to
and	CC	and
testing	VBG	test
for	IN	for
COVID-19	NP	<unknown>
among	IN	among
63,816	CD	@card@
Brazilians	NNS	Brazilian
aged	VBN	age
60	CD	@card@
years	NNS	year
and	CC	and
older	JJR	old
.	SENT	.
We	PP	we
examine	VBP	examine
whether	IN	whether
living	NN	living
arrangements	NNS	arrangement
influence	VBP	influence
self-reported	JJ	self-reported
COVID-19	NP	<unknown>
symptoms	NNS	symptom
as	IN	as
an	DT	an
indicator	NN	indicator
of	IN	of
subjective	JJ	subjective
health	NN	health
assessment	NN	assessment
,	,	,
testing	VBG	test
as	IN	as
an	DT	an
indicator	NN	indicator
of	IN	of
health	NN	health
care	NN	care
service	NN	service
use	NN	use
,	,	,
and	CC	and
a	DT	a
positive	JJ	positive
COVID-19	NP	<unknown>
test	NN	test
result	NN	result
as	IN	as
an	DT	an
objective	JJ	objective
indicator	NN	indicator
of	IN	of
exposure	NN	exposure
to	TO	to
the	DT	the
disease	NN	disease
.	SENT	.
Living	NN	living
arrangements	NNS	arrangement
shape	VBP	shape
older	JJR	old
adults	NNS	adult
'	POS	'
vulnerabilities	NNS	vulnerability
to	TO	to
COVID-19	NP	<unknown>
exposure	NN	exposure
and	CC	and
testing	NN	testing
.	SENT	.
Specifically	RB	specifically
,	,	,
those	DT	those
living	NN	living
alone	RB	alone
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
report	VB	report
having	VBG	have
symptoms	NNS	symptom
and	CC	and
having	VBG	have
had	VBD	have
a	DT	a
test	NN	test
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
older	JJR	old
adults	NNS	adult
in	IN	in
multigenerational	JJ	multigenerational
and	CC	and
skipped	VBN	skip
generation	NN	generation
households	NNS	household
were	VBD	be
more	RBR	more
likely	JJ	likely
than	IN	than
solo-dwellers	NNS	solo-dweller
to	TO	to
test	VB	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
Those	DT	those
with	IN	with
symptoms	NNS	symptom
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
test	VB	test
,	,	,
regardless	RB	regardless
of	IN	of
their	PP$	their
living	NN	living
arrangement	NN	arrangement
.	SENT	.
Among	IN	among
older	JJR	old
adults	NNS	adult
without	IN	without
symptoms	NNS	symptom
,	,	,
those	DT	those
living	NN	living
alone	RB	alone
had	VBD	have
a	DT	a
higher	JJR	high
probability	NN	probability
of	IN	of
testing	NN	testing
than	IN	than
those	DT	those
living	NN	living
in	IN	in
multigenerational	JJ	multigenerational
or	CC	or
skipped-generation	NN	skipped-generation
households	NNS	household
.	SENT	.
Overall	RB	overall
,	,	,
our	PP$	our
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
coresidence	NN	coresidence
with	IN	with
younger	JJR	young
family	NN	family
members	NNS	member
puts	VBZ	put
older	JJR	old
adults	NNS	adult
'	POS	'
health	NN	health
at	IN	at
risk	NN	risk
in	IN	in
the	DT	the
context	NN	context
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
As	IN	as
younger	JJR	young
Brazilians	NNS	Brazilian
are	VBP	be
increasingly	RB	increasingly
vulnerable	JJ	vulnerable
to	TO	to
COVID-19	NP	<unknown>
and	CC	and
experiencing	VBG	experience
severe	JJ	severe
outcomes	NNS	outcome
,	,	,
policy	NN	policy
makers	NNS	maker
need	VBP	need
to	TO	to
be	VB	be
more	RBR	more
attentive	JJ	attentive
to	TO	to
the	DT	the
health	NN	health
needs	VBZ	need
of	IN	of
households	NNS	household
that	WDT	that
comprise	VBP	comprise
older	JJR	old
and	CC	and
younger	JJR	young
cohorts	NNS	cohort
,	,	,
which	WDT	which
are	VBP	be
also	RB	also
more	RBR	more
prevalent	JJ	prevalent
in	IN	in
poor	JJ	poor
and	CC	and
marginalized	VBN	marginalize
segments	NNS	segment
of	IN	of
the	DT	the
population	NN	population
.	SENT	.
34444648/	CD	@card@
Food	NP	Food
Preferences	NNS	preference
and	CC	and
Food	NN	food
Choice	NN	choice
Determinants	NNS	determinant
in	IN	in
a	DT	a
Polish	JJ	Polish
Adolescents	NNS	adolescent
'	POS	'
COVID-19	NP	<unknown>
Experience	NN	experience
(	(	(
PLACE-19	NP	<unknown>
)	)	)
Study	NP	Study
Food	NP	Food
preferences	NNS	preference
are	VBP	be
within	IN	within
the	DT	the
most	RBS	most
important	JJ	important
determinants	NNS	determinant
of	IN	of
food	NN	food
choices	NNS	choice
;	:	;
however	RB	however
,	,	,
little	RB	little
is	VBZ	be
known	VBN	know
about	IN	about
their	PP$	their
complex	JJ	complex
associations	NNS	association
,	,	,
and	CC	and
no	DT	no
studies	NNS	study
were	VBD	be
conducted	VBN	conduct
in	IN	in
the	DT	the
period	NN	period
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
the	DT	the
study	NN	study
was	VBD	be
to	TO	to
analyze	VB	analyze
the	DT	the
association	NN	association
between	IN	between
food	NN	food
preferences	NNS	preference
and	CC	and
food	NN	food
choice	NN	choice
determinants	NNS	determinant
in	IN	in
adolescents	NNS	adolescent
aged	VBN	age
15-20	CD	@card@
years	NNS	year
within	IN	within
the	DT	the
Polish	JJ	Polish
Adolescents	NNS	adolescent
'	POS	'
COVID-19	NP	<unknown>
Experience	NN	experience
(	(	(
PLACE-19	NP	<unknown>
)	)	)
Study	NP	Study
.	SENT	.
The	DT	the
PLACE-19	NP	<unknown>
Study	NP	Study
included	VBD	include
a	DT	a
random	JJ	random
quota	NN	quota
sampling	NN	sampling
conducted	VBN	conduct
in	IN	in
the	DT	the
whole	NN	whole
of	IN	of
Poland	NP	Poland
and	CC	and
covered	VBD	cover
a	DT	a
population-based	JJ	<unknown>
sample	NN	sample
of	IN	of
2448	CD	@card@
secondary	JJ	secondary
school	NN	school
students	NNS	student
.	SENT	.
The	DT	the
food	NN	food
preferences	NNS	preference
were	VBD	be
assessed	VBN	assess
using	VBG	use
a	DT	a
validated	VBN	validate
Food	NN	food
Preference	NN	preference
Questionnaire	NN	questionnaire
(	(	(
FPQ	NP	FPQ
)	)	)
,	,	,
and	CC	and
the	DT	the
food	NN	food
choices	NNS	choice
were	VBD	be
assessed	VBN	assess
using	VBG	use
a	DT	a
validated	VBN	validate
Food	NN	food
Choice	NN	choice
Questionnaire	NN	questionnaire
(	(	(
FCQ	NP	FCQ
)	)	)
.	SENT	.
The	DT	the
statistical	JJ	statistical
analysis	NN	analysis
comprised	VBN	comprise
k-means	NNS	k-mean
clustering	VBG	cluster
and	CC	and
linear	JJ	linear
regression	NN	regression
adjusted	VBN	adjust
for	IN	for
sex	NN	sex
and	CC	and
age	NN	age
.	SENT	.
Four	CD	four
homogenous	JJ	homogenous
clusters	NNS	cluster
of	IN	of
respondents	NNS	respondent
were	VBD	be
defined	VBN	define
based	VBN	base
on	IN	on
the	DT	the
food	NN	food
choice	NN	choice
motives:"healthy	JJ	motives:"healthy
eaters	NNS	eater
"	''	"
(	(	(
health	NN	health
as	IN	as
the	DT	the
most	RBS	most
important	JJ	important
determinant	NN	determinant
of	IN	of
food	NN	food
choices	NNS	choice
)	)	)
,	,	,
"	``	"
hedonists	NNS	hedonist
"	''	"
(	(	(
convenience	NN	convenience
,	,	,
sensory	JJ	sensory
appeal	NN	appeal
,	,	,
and	CC	and
price	NN	price
as	IN	as
the	DT	the
most	RBS	most
important	JJ	important
determinants	NNS	determinant
)	)	)
,	,	,
"	``	"
indifferent	JJ	indifferent
consumers	NNS	consumer
"	''	"
(	(	(
low	JJ	low
significance	NN	significance
for	IN	for
all	DT	all
determinants	NNS	determinant
)	)	)
,	,	,
and	CC	and
"	``	"
demanding	JJ	demanding
consumers	NNS	consumer
"	''	"
(	(	(
high	JJ	high
significance	NN	significance
for	IN	for
all	DT	all
determinants	NNS	determinant
)	)	)
.	SENT	.
The	DT	the
preferences	NNS	preference
for	IN	for
all	DT	all
food	NN	food
categories	NNS	category
differed	VBD	differ
when	WRB	when
comparing	VBG	compare
between	IN	between
clusters	NNS	cluster
presenting	VBG	present
various	JJ	various
food	NN	food
choice	NN	choice
determinants	NNS	determinant
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
"	``	"
healthy	JJ	healthy
eaters	NNS	eater
"	``	"
were	VBD	be
characterized	VBN	characterize
by	IN	by
the	DT	the
highest	JJS	high
preference	NN	preference
for	IN	for
vegetables	NNS	vegetable
;	:	;
the	DT	the
"	``	"
hedonists	NNS	hedonist
"	''	"
preferred	JJ	preferred
meat/fish	NNS	<unknown>
,	,	,
dairy	NN	dairy
,	,	,
and	CC	and
snacks	NNS	snack
;	:	;
the	DT	the
"	``	"
demanding	JJ	demanding
consumers	NNS	consumer
"	''	"
had	VBD	have
a	DT	a
high	JJ	high
preference	NN	preference
for	IN	for
all	DT	all
food	NN	food
categories	NNS	category
,	,	,
while	IN	while
"	``	"
indifferent	JJ	indifferent
consumers	NNS	consumer
"	''	"
had	VBD	have
a	DT	a
low	JJ	low
preference	NN	preference
for	IN	for
all	DT	all
food	NN	food
categories	NNS	category
.	SENT	.
All	DT	all
preference	NN	preference
scores	NNS	score
were	VBD	be
positively	RB	positively
associated	VBN	associate
with	IN	with
mood	NN	mood
,	,	,
convenience	NN	convenience
,	,	,
sensory	JJ	sensory
appeal	NN	appeal
,	,	,
natural	JJ	natural
content	NN	content
,	,	,
and	CC	and
price	NN	price
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
The	DT	the
results	NNS	result
confirmed	VBD	confirm
the	DT	the
association	NN	association
between	IN	between
food	NN	food
preferences	NNS	preference
and	CC	and
food	NN	food
choice	NN	choice
determinants	NNS	determinant
in	IN	in
adolescents	NNS	adolescent
,	,	,
as	RB	as
well	RB	well
as	IN	as
allowed	VBN	allow
adolescents	NNS	adolescent
to	TO	to
be	VB	be
clustered	VBN	cluster
into	IN	into
segments	NNS	segment
to	TO	to
define	VB	define
various	JJ	various
needs	NNS	need
and	CC	and
motives	NNS	motive
among	IN	among
the	DT	the
identified	VBN	identify
segments	NNS	segment
.	SENT	.
For	IN	for
public	JJ	public
health	NN	health
purposes	NNS	purpose
,	,	,
it	PP	it
may	MD	may
be	VB	be
crucial	JJ	crucial
to	TO	to
educate	VB	educate
"	``	"
hedonists	NNS	hedonist
,	,	,
"	''	"
with	IN	with
a	DT	a
high	JJ	high
preference	NN	preference
for	IN	for
meat/fish	NN	<unknown>
,	,	,
dairy	NN	dairy
and	CC	and
snacks	NNS	snack
,	,	,
accompanied	VBN	accompany
by	IN	by
convenience	NN	convenience
,	,	,
sensory	JJ	sensory
appeal	NN	appeal
,	,	,
and	CC	and
price	NN	price
as	IN	as
the	DT	the
most	RBS	most
important	JJ	important
determinants	NNS	determinant
of	IN	of
their	PP$	their
food	NN	food
choices	NNS	choice
.	SENT	.
33058235/	CD	@card@
Background	NN	background
immunity	NN	immunity
:	:	:
How	WRB	how
important	JJ	important
is	VBZ	be
it	PP	it
for	IN	for
SARS-CoV-2	NP	<unknown>
?	SENT	?
33400475/	CD	@card@
Core	NP	Core
Outcome	NN	outcome
Measures	NNS	measure
for	IN	for
Trials	NNS	trial
in	IN	in
People	NNS	people
With	IN	with
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
:	:	:
Respiratory	JJ	respiratory
Failure	NN	failure
,	,	,
Multiorgan	NP	Multiorgan
Failure	NN	failure
,	,	,
Shortness	NN	shortness
of	IN	of
Breath	NN	breath
,	,	,
and	CC	and
Recovery	NP	Recovery
Supplemental	NP	Supplemental
Digital	NP	Digital
Content	NN	content
is	VBZ	be
available	JJ	available
in	IN	in
the	DT	the
text	NN	text
.	SENT	.
Respiratory	JJ	respiratory
failure	NN	failure
,	,	,
multiple	JJ	multiple
organ	NN	organ
failure	NN	failure
,	,	,
shortness	NN	shortness
of	IN	of
breath	NN	breath
,	,	,
recovery	NN	recovery
,	,	,
and	CC	and
mortality	NN	mortality
have	VBP	have
been	VBN	be
identified	VBN	identify
as	IN	as
critically	RB	critically
important	JJ	important
core	NN	core
outcomes	NNS	outcome
by	IN	by
more	JJR	more
than	IN	than
9300	CD	@card@
patients	NNS	patient
,	,	,
health	NN	health
professionals	NNS	professional
,	,	,
and	CC	and
the	DT	the
public	NN	public
from	IN	from
111	CD	@card@
countries	NNS	country
in	IN	in
the	DT	the
global	JJ	global
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
core	NN	core
outcome	NN	outcome
set	NN	set
initiative	NN	initiative
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
project	NN	project
was	VBD	be
to	TO	to
establish	VB	establish
the	DT	the
core	JJ	core
outcome	NN	outcome
measures	NNS	measure
for	IN	for
these	DT	these
domains	NNS	domain
for	IN	for
trials	NNS	trial
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
.	SENT	.
Three	CD	three
online	JJ	online
consensus	NN	consensus
workshops	NNS	workshop
were	VBD	be
convened	VBN	convene
to	TO	to
establish	VB	establish
outcome	NN	outcome
measures	NNS	measure
for	IN	for
the	DT	the
four	CD	four
core	JJ	core
domains	NNS	domain
of	IN	of
respiratory	JJ	respiratory
failure	NN	failure
,	,	,
multiple	JJ	multiple
organ	NN	organ
failure	NN	failure
,	,	,
shortness	NN	shortness
of	IN	of
breath	NN	breath
,	,	,
and	CC	and
recovery	NN	recovery
.	SENT	.
International	NP	International
.	SENT	.
About	RB	about
130	CD	@card@
participants	NNS	participant
(	(	(
patients	NNS	patient
,	,	,
public	JJ	public
,	,	,
and	CC	and
health	NN	health
professionals	NNS	professional
)	)	)
from	IN	from
17	CD	@card@
countries	NNS	country
attended	VBD	attend
the	DT	the
three	CD	three
workshops	NNS	workshop
.	SENT	.
None	NN	none
.	SENT	.
Respiratory	JJ	respiratory
failure	NN	failure
,	,	,
assessed	VBN	assess
by	IN	by
the	DT	the
need	NN	need
for	IN	for
respiratory	JJ	respiratory
support	NN	support
based	VBN	base
on	IN	on
the	DT	the
World	NP	World
Health	NP	Health
Organization	NP	Organization
Clinical	JJ	clinical
Progression	NN	progression
Scale	NP	Scale
,	,	,
was	VBD	be
considered	VBN	consider
pragmatic	JJ	pragmatic
,	,	,
objective	JJ	objective
,	,	,
and	CC	and
with	IN	with
broad	JJ	broad
applicability	NN	applicability
to	TO	to
various	JJ	various
clinical	JJ	clinical
scenarios	NNS	scenario
.	SENT	.
The	DT	the
Sequential	JJ	sequential
Organ	NP	Organ
Failure	NN	failure
Assessment	NP	Assessment
was	VBD	be
recommended	VBN	recommend
for	IN	for
multiple	JJ	multiple
organ	NN	organ
failure	NN	failure
,	,	,
because	IN	because
it	PP	it
was	VBD	be
routinely	RB	routinely
used	VBN	use
in	IN	in
trials	NNS	trial
and	CC	and
clinical	JJ	clinical
care	NN	care
,	,	,
well	RB	well
validated	VBN	validate
,	,	,
and	CC	and
feasible	JJ	feasible
.	SENT	.
The	DT	the
Modified	JJ	modified
Medical	NP	Medical
Research	NP	Research
Council	NP	Council
measure	NN	measure
for	IN	for
shortness	NN	shortness
of	IN	of
breath	NN	breath
,	,	,
with	IN	with
minor	JJ	minor
adaptations	NNS	adaptation
(	(	(
recall	NN	recall
period	NN	period
of	IN	of
24	CD	@card@
hr	NN	hr
to	TO	to
capture	VB	capture
daily	JJ	daily
fluctuations	NNS	fluctuation
and	CC	and
inclusion	NN	inclusion
of	IN	of
activities	NNS	activity
to	TO	to
ensure	VB	ensure
relevance	NN	relevance
and	CC	and
to	TO	to
capture	VB	capture
the	DT	the
extreme	JJ	extreme
severity	NN	severity
of	IN	of
shortness	NN	shortness
of	IN	of
breath	NN	breath
in	IN	in
people	NNS	people
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
)	)	)
,	,	,
was	VBD	be
regarded	VBN	regard
as	IN	as
fit	NN	fit
for	IN	for
purpose	NN	purpose
for	IN	for
this	DT	this
indication	NN	indication
.	SENT	.
The	DT	the
recovery	NN	recovery
measure	NN	measure
was	VBD	be
developed	VBN	develop
de	NP	de
novo	NP	Novo
and	CC	and
defined	VBN	define
as	IN	as
the	DT	the
absence	NN	absence
of	IN	of
symptoms	NNS	symptom
,	,	,
resumption	NN	resumption
of	IN	of
usual	JJ	usual
daily	JJ	daily
activities	NNS	activity
,	,	,
and	CC	and
return	VB	return
to	TO	to
the	DT	the
previous	JJ	previous
state	NN	state
of	IN	of
health	NN	health
prior	RB	prior
to	TO	to
the	DT	the
illness	NN	illness
,	,	,
using	VBG	use
a	DT	a
5-point	JJ	<unknown>
Likert	NP	Likert
scale	NN	scale
,	,	,
and	CC	and
was	VBD	be
endorsed	VBN	endorse
.	SENT	.
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
core	NN	core
outcome	NN	outcome
set	VBD	set
recommended	JJ	recommended
core	JJ	core
outcome	NN	outcome
measures	NNS	measure
have	VBP	have
content	JJ	content
validity	NN	validity
and	CC	and
are	VBP	be
considered	VBN	consider
the	DT	the
most	RBS	most
feasible	JJ	feasible
and	CC	and
acceptable	JJ	acceptable
among	IN	among
existing	VBG	exist
measures	NNS	measure
.	SENT	.
Implementation	NN	implementation
of	IN	of
the	DT	the
core	JJ	core
outcome	NN	outcome
measures	NNS	measure
in	IN	in
trials	NNS	trial
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
will	MD	will
ensure	VB	ensure
consistency	NN	consistency
and	CC	and
relevance	NN	relevance
of	IN	of
the	DT	the
evidence	NN	evidence
to	TO	to
inform	VB	inform
decision-making	NN	decision-making
and	CC	and
care	NN	care
of	IN	of
patients	NNS	patient
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
.	SENT	.
34758422/	CD	@card@
Results	NNS	result
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
mental	JJ	mental
health	NN	health
international	JJ	international
for	IN	for
the	DT	the
general	JJ	general
population	NN	population
(	(	(
COMET-G	NP	<unknown>
)	)	)
study	NN	study
There	EX	there
are	VBP	be
few	JJ	few
published	VBN	publish
empirical	JJ	empirical
data	NNS	datum
on	IN	on
the	DT	the
effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
mental	JJ	mental
health	NN	health
,	,	,
and	CC	and
until	IN	until
now	RB	now
,	,	,
there	EX	there
is	VBZ	be
no	DT	no
large	JJ	large
international	JJ	international
study	NN	study
.	SENT	.
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
an	DT	an
online	JJ	online
questionnaire	NN	questionnaire
gathered	VBD	gather
data	NNS	datum
from	IN	from
55,589	CD	@card@
participants	NNS	participant
from	IN	from
40	CD	@card@
countries	NNS	country
(	(	(
64.85	CD	@card@
%	NN	%
females	NNS	female
aged	VBN	age
35.80	CD	@card@
+-	NN	<unknown>
13.61	CD	@card@
;	:	;
34.05	CD	@card@
%	NN	%
males	NNS	male
aged	VBN	age
34.90+-13.29	CD	@card@
and	CC	and
1.10	CD	@card@
%	NN	%
other	JJ	other
aged	NN	aged
31.64+-13.15	CD	@card@
)	)	)
.	SENT	.
Distress	NN	distress
and	CC	and
probable	JJ	probable
depression	NN	depression
were	VBD	be
identified	VBN	identify
with	IN	with
the	DT	the
use	NN	use
of	IN	of
a	DT	a
previously	RB	previously
developed	VBN	develop
cut-off	NN	cut-off
and	CC	and
algorithm	NN	algorithm
respectively	RB	respectively
.	SENT	.
Descriptive	JJ	descriptive
statistics	NNS	statistic
were	VBD	be
calculated	VBN	calculate
.	SENT	.
Chi-square	NN	Chi-square
tests	NNS	test
,	,	,
multiple	JJ	multiple
forward	RB	forward
stepwise	RB	stepwise
linear	JJ	linear
regression	NN	regression
analyses	NNS	analysis
and	CC	and
Factorial	JJ	factorial
Analysis	NN	analysis
of	IN	of
Variance	NN	variance
(	(	(
ANOVA	NP	<unknown>
)	)	)
tested	VBD	test
relations	NNS	relation
among	IN	among
variables	NNS	variable
.	SENT	.
Probable	JJ	probable
depression	NN	depression
was	VBD	be
detected	VBN	detect
in	IN	in
17.80	CD	@card@
%	NN	%
and	CC	and
distress	NN	distress
in	IN	in
16.71	CD	@card@
%	NN	%
.	SENT	.
A	DT	a
significant	JJ	significant
percentage	NN	percentage
reported	VBD	report
a	DT	a
deterioration	NN	deterioration
in	IN	in
mental	JJ	mental
state	NN	state
,	,	,
family	NN	family
dynamics	NNS	dynamics
and	CC	and
everyday	JJ	everyday
lifestyle	NN	lifestyle
.	SENT	.
Persons	NNS	person
with	IN	with
a	DT	a
history	NN	history
of	IN	of
mental	JJ	mental
disorders	NNS	disorder
had	VBD	have
higher	JJR	high
rates	NNS	rate
of	IN	of
current	JJ	current
depression	NN	depression
(	(	(
31.82	CD	@card@
%	NN	%
vs.	IN	vs.
13.07	CD	@card@
%	NN	%
)	)	)
.	SENT	.
At	IN	at
least	JJS	least
half	NN	half
of	IN	of
participants	NNS	participant
were	VBD	be
accepting	VBG	accept
(	(	(
at	IN	at
least	JJS	least
to	TO	to
a	DT	a
moderate	JJ	moderate
degree	NN	degree
)	)	)
a	DT	a
non-bizarre	JJ	non-bizarre
conspiracy	NN	conspiracy
.	SENT	.
The	DT	the
highest	JJS	high
Relative	JJ	relative
Risk	NN	risk
(	(	(
RR	NP	RR
)	)	)
to	TO	to
develop	VB	develop
depression	NN	depression
was	VBD	be
associated	VBN	associate
with	IN	with
history	NN	history
of	IN	of
Bipolar	JJ	bipolar
disorder	NN	disorder
and	CC	and
self-harm/attempts	NNS	self-harm/attempt
(	(	(
RR	NP	RR
=	SYM	=
5.88	CD	@card@
)	)	)
.	SENT	.
Suicidality	NN	<unknown>
was	VBD	be
not	RB	not
increased	VBN	increase
in	IN	in
persons	NNS	person
without	IN	without
a	DT	a
history	NN	history
of	IN	of
any	DT	any
mental	JJ	mental
disorder	NN	disorder
.	SENT	.
Based	VBN	base
on	IN	on
these	DT	these
results	NNS	result
a	DT	a
model	NN	model
was	VBD	be
developed	VBN	develop
.	SENT	.
The	DT	the
final	JJ	final
model	NN	model
revealed	VBD	reveal
multiple	JJ	multiple
vulnerabilities	NNS	vulnerability
and	CC	and
an	DT	an
interplay	NN	interplay
leading	VBG	lead
from	IN	from
simple	JJ	simple
anxiety	NN	anxiety
to	TO	to
probable	JJ	probable
depression	NN	depression
and	CC	and
suicidality	NN	<unknown>
through	IN	through
distress	NN	distress
.	SENT	.
This	DT	this
could	MD	could
be	VB	be
of	IN	of
practical	JJ	practical
utility	NN	utility
since	IN	since
many	JJ	many
of	IN	of
these	DT	these
factors	NNS	factor
are	VBP	be
modifiable	JJ	modifiable
.	SENT	.
Future	JJ	future
research	NN	research
and	CC	and
interventions	NNS	intervention
should	MD	should
specifically	RB	specifically
focus	VB	focus
on	IN	on
them	PP	them
.	SENT	.
35291048/	CD	@card@
The	DT	the
impact	NN	impact
of	IN	of
asynchronous	JJ	asynchronous
online	JJ	online
anatomy	NN	anatomy
teaching	NN	teaching
and	CC	and
smaller	JJR	small
learning	VBG	learn
groups	NNS	group
in	IN	in
the	DT	the
anatomy	NN	anatomy
laboratory	NN	laboratory
on	IN	on
medical	JJ	medical
students	NNS	student
'	POS	'
performance	NN	performance
during	IN	during
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
Due	JJ	due
to	TO	to
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
National	NP	National
Taiwan	NP	Taiwan
University	NP	University
anatomy	NN	anatomy
teachers	NNS	teacher
adopted	VBD	adopt
asynchronous	JJ	asynchronous
online	JJ	online
video	NN	video
teaching	NN	teaching
and	CC	and
reduced	VBD	reduce
the	DT	the
size	NN	size
of	IN	of
anatomy	NN	anatomy
laboratory	NN	laboratory
groups	NNS	group
in	IN	in
April	NP	April
2020	CD	@card@
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
the	DT	the
impact	NN	impact
of	IN	of
these	DT	these
changes	NNS	change
on	IN	on
medical	JJ	medical
students	NNS	student
'	POS	'
learning	NN	learning
.	SENT	.
Before	IN	before
Covid-19	NP	<unknown>
,	,	,
the	DT	the
performance	NN	performance
of	IN	of
the	DT	the
2019-2020	CD	@card@
cohort	NN	cohort
was	VBD	be
significantly	RB	significantly
better	JJR	good
than	IN	than
that	DT	that
of	IN	of
the	DT	the
2018-2019	CD	@card@
cohort	NN	cohort
.	SENT	.
However	RB	however
,	,	,
the	DT	the
implementation	NN	implementation
of	IN	of
modified	JJ	modified
teaching	NN	teaching
strategies	NNS	strategy
significantly	RB	significantly
lowered	VBD	lower
the	DT	the
laboratory	NN	laboratory
midterm	NN	midterm
score	NN	score
of	IN	of
the	DT	the
2019-2020	CD	@card@
cohort	NN	cohort
in	IN	in
the	DT	the
second	JJ	second
semester	NN	semester
.	SENT	.
Conversely	RB	conversely
,	,	,
the	DT	the
final	JJ	final
laboratory	NN	laboratory
examination	NN	examination
score	NN	score
of	IN	of
the	DT	the
2019-2020	CD	@card@
cohort	NN	cohort
was	VBD	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
that	DT	that
of	IN	of
the	DT	the
2018-2019	CD	@card@
cohort	NN	cohort
.	SENT	.
Through	IN	through
correlation	NN	correlation
analysis	NN	analysis
,	,	,
lecture	NN	lecture
and	CC	and
laboratory	NN	laboratory
examination	NN	examination
scores	NNS	score
were	VBD	be
highly	RB	highly
correlated	VBN	correlate
.	SENT	.
Additionally	RB	additionally
,	,	,
the	DT	the
difference	NN	difference
in	IN	in
lecture	NN	lecture
and	CC	and
laboratory	NN	laboratory
z-scores	NNS	z-score
between	IN	between
two	CD	two
cohorts	NNS	cohort
,	,	,
the	DT	the
Likert	NP	Likert
scale	NN	scale
survey	NN	survey
and	CC	and
free-text	NN	<unknown>
feedback	NN	feedback
of	IN	of
the	DT	the
2019-2020	CD	@card@
cohort	NN	cohort
,	,	,
were	VBD	be
conducted	VBN	conduct
to	TO	to
show	VB	show
the	DT	the
impact	NN	impact
of	IN	of
modified	JJ	modified
teaching	NN	teaching
strategies	NNS	strategy
.	SENT	.
There	EX	there
were	VBD	be
several	JJ	several
important	JJ	important
findings	NNS	finding
in	IN	in
this	DT	this
study	NN	study
.	SENT	.
First	RB	first
,	,	,
the	DT	the
change	NN	change
in	IN	in
teaching	NN	teaching
strategies	NNS	strategy
may	MD	may
temporarily	RB	temporarily
negatively	RB	negatively
influence	VB	influence
medical	JJ	medical
students	NNS	student
to	TO	to
learn	VB	learn
anatomy	NN	anatomy
.	SENT	.
Besides	RB	besides
,	,	,
analyzing	VBG	analyze
the	DT	the
performance	NN	performance
of	IN	of
laboratory	NN	laboratory
assessments	NNS	assessment
could	MD	could
be	VB	be
a	DT	a
complementary	JJ	complementary
strategy	NN	strategy
to	TO	to
evaluate	VB	evaluate
online	JJ	online
assessments	NNS	assessment
.	SENT	.
Applying	VBG	apply
lecture	NN	lecture
examination	NN	examination
scores	NNS	score
to	TO	to
predict	VB	predict
laboratory	NN	laboratory
performance	NN	performance
was	VBD	be
a	DT	a
feasible	JJ	feasible
way	NN	way
to	TO	to
identify	VB	identify
students	NNS	student
who	WP	who
may	MD	may
have	VB	have
difficulty	NN	difficulty
in	IN	in
learning	VBG	learn
practical	JJ	practical
dissection	NN	dissection
.	SENT	.
Finally	RB	finally
,	,	,
reducing	VBG	reduce
group	NN	group
size	NN	size
together	RB	together
with	IN	with
reduced	VBN	reduce
peer	NN	peer
discussion	NN	discussion
may	MD	may
have	VB	have
a	DT	a
negative	JJ	negative
effect	NN	effect
on	IN	on
learning	VBG	learn
cadaver	NN	cadaver
dissection	NN	dissection
for	IN	for
students	NNS	student
with	IN	with
low	JJ	low
academic	JJ	academic
performance	NN	performance
.	SENT	.
These	DT	these
findings	NNS	finding
should	MD	should
be	VB	be
taken	VBN	take
into	IN	into
consideration	NN	consideration
when	WRB	when
anatomy	NN	anatomy
teachers	NNS	teacher
apply	VBP	apply
new	JJ	new
teaching	NN	teaching
strategies	NNS	strategy
in	IN	in
anatomy	NN	anatomy
courses	NNS	course
.	SENT	.
34393592/	CD	@card@
Public	JJ	public
Sphere	NN	sphere
in	IN	in
Crisis	NN	crisis
Mode	NP	Mode
:	:	:
How	WRB	how
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
Influenced	NP	Influenced
Public	NP	Public
Discourse	NP	Discourse
and	CC	and
User	NP	User
Behaviour	NN	behaviour
in	IN	in
the	DT	the
Swiss	JJ	Swiss
Twitter-sphere	NN	Twitter-sphere
In	IN	in
modern	JJ	modern
democracies	NNS	democracy
,	,	,
large	JJ	large
societal	JJ	societal
crises	NNS	crisis
like	IN	like
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
are	VBP	be
accompanied	VBN	accompany
by	IN	by
intensified	JJ	intensified
public	JJ	public
discourse	NN	discourse
about	IN	about
which	WDT	which
policies	NNS	policy
and	CC	and
strategies	NNS	strategy
are	VBP	be
adequate	JJ	adequate
to	TO	to
fight	VB	fight
the	DT	the
crisis	NN	crisis
.	SENT	.
In	IN	in
such	JJ	such
times	NNS	time
,	,	,
the	DT	the
public	JJ	public
sphere	NN	sphere
switches	NNS	switch
to	TO	to
crisis	NN	crisis
mode	NN	mode
with	IN	with
fundamentally	RB	fundamentally
different	JJ	different
communicative	JJ	communicative
dynamics	NNS	dynamics
compared	VBN	compare
to	TO	to
routinised	JJ	<unknown>
periods	NNS	period
.	SENT	.
Data	NNS	datum
from	IN	from
social	JJ	social
media	NNS	medium
platforms	NNS	platform
like	IN	like
Twitter	NN	twitter
offers	VBZ	offer
new	JJ	new
possibilities	NNS	possibility
to	TO	to
study	VB	study
such	JJ	such
dynamics	NNS	dynamics
.	SENT	.
However	RB	however
,	,	,
comprehensive	JJ	comprehensive
studies	NNS	study
on	IN	on
how	WRB	how
crises	NNS	crisis
affect	VBP	affect
discourse	NN	discourse
in	IN	in
distinct	JJ	distinct
national	JJ	national
publics	NNS	public
are	VBP	be
missing	VBG	miss
up	RP	up
to	TO	to
now	RB	now
.	SENT	.
Based	VBN	base
on	IN	on
1,762,262	CD	@card@
tweets	VBZ	tweet
referring	VBG	refer
to	TO	to
COVID-19	NP	<unknown>
written	VBN	write
between	IN	between
1	CD	@card@
January	NP	January
and	CC	and
30	CD	@card@
April	NP	April
2020	CD	@card@
by	IN	by
56,418	CD	@card@
validated	VBD	validate
Swiss	JJ	Swiss
users	NNS	user
,	,	,
we	PP	we
illustrate	VBP	illustrate
how	WRB	how
the	DT	the
lockdown	NN	<unknown>
of	IN	of
public	JJ	public
life	NN	life
in	IN	in
Switzerland	NP	Switzerland
affected	VBD	affect
the	DT	the
discourse	NN	discourse
in	IN	in
the	DT	the
Swiss	JJ	Swiss
Twitter-sphere	NN	Twitter-sphere
.	SENT	.
Based	VBN	base
on	IN	on
public	JJ	public
sphere	NN	sphere
theories	NNS	theory
,	,	,
we	PP	we
identify	VBP	identify
four	CD	four
crisis-related	JJ	crisis-related
dimensions	NNS	dimension
for	IN	for
our	PP$	our
analysis	NN	analysis
.	SENT	.
We	PP	we
show	VBP	show
that	IN	that
the	DT	the
pandemic	NN	pandemic
led	VBD	lead
to	TO	to
a	DT	a
narrowing	NN	narrowing
of	IN	of
the	DT	the
topic	NN	topic
agenda	NN	agenda
and	CC	and
to	TO	to
a	DT	a
more	RBR	more
inwardly	RB	inwardly
oriented	VBN	orient
public	JJ	public
sphere	NN	sphere
with	IN	with
increased	VBN	increase
Twitter	NN	twitter
activity	NN	activity
by	IN	by
experts	NNS	expert
.	SENT	.
Furthermore	RB	furthermore
,	,	,
actors	NNS	actor
from	IN	from
the	DT	the
social	JJ	social
periphery	NN	periphery
were	VBD	be
able	JJ	able
to	TO	to
reach	VB	reach
the	DT	the
centre	NN	centre
of	IN	of
public	JJ	public
discourse	NN	discourse
with	IN	with
their	PP$	their
tweets	VBZ	tweet
.	SENT	.
Overall	RB	overall
our	PP$	our
study	NN	study
shows	VBZ	show
how	WRB	how
methodological	JJ	methodological
innovation	NN	innovation
allows	VBZ	allow
us	PP	us
to	TO	to
better	RBR	well
connect	VB	connect
an	DT	an
empirical	JJ	empirical
analysis	NN	analysis
with	IN	with
the	DT	the
concept	NN	concept
of	IN	of
a	DT	a
public	JJ	public
sphere	NN	sphere
as	IN	as
a	DT	a
communication	NN	communication
network	NN	network
.	SENT	.
32222253/	CD	@card@
COVID-19	NN	<unknown>
:	:	:
lessons	NNS	lesson
from	IN	from
the	DT	the
Italian	JJ	Italian
reproductive	JJ	reproductive
medical	JJ	medical
experience	NN	experience
35149232/	CD	@card@
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
:	:	:
Considering	VBG	consider
sex	NN	sex
differences	NNS	difference
in	IN	in
efficacy	NN	efficacy
and	CC	and
safety	VB	safety
The	DT	the
development	NN	development
of	IN	of
SARS-CoV-2	NP	<unknown>
vaccines	NNS	vaccine
represents	VBZ	represent
a	DT	a
significant	JJ	significant
breakthrough	NN	breakthrough
for	IN	for
managing	VBG	manage
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
however	RB	however
their	PP$	their
approval	NN	approval
process	NN	process
has	VBZ	have
exposed	VBN	expose
a	DT	a
crucial	JJ	crucial
limitation	NN	limitation
in	IN	in
clinical	JJ	clinical
trial	NN	trial
reports:that	NN	<unknown>
is	VBZ	be
,	,	,
a	DT	a
disregard	NN	disregard
for	IN	for
sex	NN	sex
differences	NNS	difference
in	IN	in
response	NN	response
to	TO	to
vaccines	NNS	vaccine
.	SENT	.
Historically	RB	historically
,	,	,
males	NNS	male
and	CC	and
females	NNS	female
have	VBP	have
shown	VBN	show
different	JJ	different
reactions	NNS	reaction
to	TO	to
vaccines	NNS	vaccine
of	IN	of
many	JJ	many
kinds	NNS	kind
,	,	,
which	WDT	which
have	VBP	have
become	VBN	become
apparent	JJ	apparent
with	IN	with
the	DT	the
arrival	NN	arrival
of	IN	of
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
in	IN	in
late-2020	NN	<unknown>
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
review	VBP	review
both	DT	both
regulatory	JJ	regulatory
data	NNS	datum
from	IN	from
Phase	NN	phase
III	NP	III
vaccine	NN	vaccine
trials	NNS	trial
as	RB	as
well	RB	well
as	IN	as
peer-reviewed	JJ	peer-reviewed
reports	NNS	report
from	IN	from
vaccines	NNS	vaccine
administered	VBN	administer
to	TO	to
the	DT	the
general	JJ	general
population	NN	population
,	,	,
many	JJ	many
of	IN	of
which	WDT	which
failed	VBD	fail
to	TO	to
stratify	VB	stratify
results	NNS	result
by	IN	by
sex	NN	sex
.	SENT	.
We	PP	we
also	RB	also
discuss	VB	discuss
the	DT	the
exclusion	NN	exclusion
of	IN	of
pregnant	JJ	pregnant
and	CC	and
lactating	VBG	lactate
women	NNS	woman
in	IN	in
drug	NN	drug
development	NN	development
and	CC	and
the	DT	the
regulatory	JJ	regulatory
guidelines	NNS	guideline
for	IN	for
use	NN	use
of	IN	of
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
in	IN	in
such	JJ	such
populations	NNS	population
.	SENT	.
We	PP	we
conclude	VBP	conclude
by	IN	by
proposing	VBG	propose
some	DT	some
questions	NNS	question
to	TO	to
stimulate	VB	stimulate
discussion	NN	discussion
with	IN	with
the	DT	the
intent	NN	intent
to	TO	to
advance	VB	advance
the	DT	the
field	NN	field
toward	IN	toward
one	CD	one
of	IN	of
precision	NN	precision
medicine	NN	medicine
.	SENT	.
33253073/	CD	@card@
Mentoring	NN	mentoring
in	IN	in
the	DT	the
time	NN	time
of	IN	of
Coronavirus	NP	<unknown>
34864190/	CD	@card@
The	DT	the
2021	CD	@card@
Neurosurgery	NN	neurosurgery
Match	NN	match
:	:	:
An	DT	an
Analysis	NN	analysis
of	IN	of
the	DT	the
Impact	NN	impact
of	IN	of
Virtual	JJ	virtual
Interviewing	VBG	interview
and	CC	and
Other	JJ	other
COVID-19-Related	JJ	COVID-19-related
Changes	NP	Changes
Given	VBN	give
the	DT	the
safety	NN	safety
concerns	NNS	concern
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
(	(	(
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
)	)	)
pandemic	NN	pandemic
,	,	,
residency	NN	residency
programs	NNS	program
suspended	VBD	suspend
away	RP	away
rotations	NNS	rotation
in	IN	in
2021	CD	@card@
,	,	,
and	CC	and
the	DT	the
interview	NN	interview
process	NN	process
was	VBD	be
transitioned	VBN	<unknown>
to	TO	to
a	DT	a
virtual	JJ	virtual
video	NN	video
format	NN	format
.	SENT	.
In	IN	in
the	DT	the
present	JJ	present
study	NN	study
,	,	,
we	PP	we
assessed	VBD	assess
the	DT	the
extent	NN	extent
to	TO	to
which	WDT	which
these	DT	these
changes	NNS	change
had	VBD	have
affected	VBN	affect
match	NN	match
outcomes	NNS	outcome
and	CC	and
whether	IN	whether
medical	JJ	medical
school	NN	school
ranking	NN	ranking
,	,	,
international	JJ	international
graduate	JJ	graduate
status	NN	status
,	,	,
or	CC	or
affiliation	NN	affiliation
with	IN	with
a	DT	a
home	NN	home
neurosurgery	NN	neurosurgery
program	NN	program
had	VBD	have
affected	VBN	affect
these	DT	these
outcomes	NNS	outcome
.	SENT	.
A	DT	a
cross-sectional	JJ	cross-sectional
analysis	NN	analysis
of	IN	of
neurosurgery	NN	neurosurgery
match	NN	match
data	NNS	datum
from	IN	from
2016	CD	@card@
to	TO	to
2021	CD	@card@
was	VBD	be
performed	VBN	perform
,	,	,
and	CC	and
the	DT	the
match	NN	match
outcomes	NNS	outcome
were	VBD	be
assessed	VBN	assess
by	IN	by
matched	VBN	match
program	NN	program
geography	NN	geography
and	CC	and
program	NN	program
research	NN	research
ranking	NN	ranking
.	SENT	.
chi2	JJ	<unknown>
tests	NNS	test
were	VBD	be
performed	VBN	perform
to	TO	to
identify	VB	identify
significant	JJ	significant
differences	NNS	difference
between	IN	between
the	DT	the
2021	CD	@card@
and	CC	and
2016-2020	CD	@card@
match	NN	match
results	NNS	result
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
1324	CD	@card@
confirmed	VBD	confirm
matched	VBN	match
neurosurgery	NN	neurosurgery
residents	NNS	resident
were	VBD	be
identified	VBN	identify
from	IN	from
2016	CD	@card@
to	TO	to
2021	CD	@card@
(	(	(
2016-2020	CD	@card@
,	,	,
n	NN	n
=	SYM	=
1113	CD	@card@
;	:	;
2021	CD	@card@
,	,	,
n	NN	n
=	SYM	=
211	CD	@card@
)	)	)
.	SENT	.
No	DT	no
statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
were	VBD	be
found	VBN	find
in	IN	in
the	DT	the
rates	NNS	rate
of	IN	of
matching	VBG	match
at	IN	at
a	DT	a
home	NN	home
program	NN	program
,	,	,
within	IN	within
state	NN	state
,	,	,
or	CC	or
within	IN	within
region	NN	region
between	IN	between
2021	CD	@card@
and	CC	and
2016-2020	CD	@card@
in	IN	in
the	DT	the
overall	JJ	overall
cohort	NN	cohort
.	SENT	.
The	DT	the
proportions	NNS	proportion
of	IN	of
international	JJ	international
graduates	NNS	graduate
and	CC	and
students	NNS	student
without	IN	without
home	NN	home
programs	NNS	program
among	IN	among
the	DT	the
matched	VBN	match
applicants	NNS	applicant
were	VBD	be
unchanged	JJ	unchanged
in	IN	in
2021	CD	@card@
.	SENT	.
In	IN	in
2021	CD	@card@
,	,	,
students	NNS	student
from	IN	from
the	DT	the
top	JJ	top
25	CD	@card@
medical	JJ	medical
schools	NNS	school
were	VBD	be
less	RBR	less
likely	JJ	likely
to	TO	to
match	VB	match
within	IN	within
their	PP$	their
state	NN	state
or	CC	or
region	NN	region
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
Our	PP$	our
findings	NNS	finding
might	MD	might
reflect	VB	reflect
enhanced	JJ	enhanced
weighting	NN	weighting
given	VBN	give
by	IN	by
programs	NNS	program
to	TO	to
applicants	NNS	applicant
from	IN	from
top	JJ	top
medical	JJ	medical
schools	NNS	school
in	IN	in
the	DT	the
absence	NN	absence
of	IN	of
data	NNS	datum
from	IN	from
in-person	NN	in-person
rotations	NNS	rotation
and	CC	and
interviews	NNS	interview
.	SENT	.
These	DT	these
findings	NNS	finding
,	,	,
coupled	VBN	couple
with	IN	with
the	DT	the
potential	JJ	potential
benefits	NNS	benefit
of	IN	of
an	DT	an
increasingly	RB	increasingly
virtual	JJ	virtual
application	NN	application
process	NN	process
in	IN	in
improving	VBG	improve
equity	NN	equity
and	CC	and
diversity	NN	diversity
among	IN	among
candidates	NNS	candidate
from	IN	from
underrepresented	VBN	underrepresent
communities	NNS	community
,	,	,
should	MD	should
be	VB	be
considered	VBN	consider
when	WRB	when
determining	VBG	determine
permanent	JJ	permanent
modifications	NNS	modification
to	TO	to
future	JJ	future
residency	NN	residency
application	NN	application
cycles	NNS	cycle
.	SENT	.
33883315/	CD	@card@
Challenges	NNS	challenge
in	IN	in
Chronic	JJ	chronic
Genetic	JJ	genetic
Disorders	NNS	disorder
:	:	:
Lessons	NNS	lesson
From	IN	from
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
To	TO	to
examine	VB	examine
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
we	PP	we
interviewed	VBD	interview
26	CD	@card@
patients	NNS	patient
with	IN	with
lysosomal	JJ	lysosomal
storage	NN	storage
disorders	NNS	disorder
receiving	VBG	receive
enzyme	NN	enzyme
replacement	NN	replacement
therapy	NN	therapy
.	SENT	.
20	CD	@card@
(	(	(
77	CD	@card@
%	NN	%
)	)	)
had	VBD	have
significant	JJ	significant
interruption	NN	interruption
in	IN	in
their	PP$	their
treatment	NN	treatment
,	,	,
with	IN	with
an	DT	an
average	NN	average
of	IN	of
8	CD	@card@
(	(	(
range	NN	range
2-28	CD	@card@
)	)	)
missed	VBN	miss
doses	NNS	dose
.	SENT	.
Alternate	JJ	alternate
methods	NNS	method
of	IN	of
delivering	VBG	deliver
uninterrupted	JJ	uninterrupted
care	NN	care
including	VBG	include
home	NN	home
therapy	NN	therapy
were	VBD	be
used	VBN	use
.	SENT	.
Vulnerable	JJ	vulnerable
patients	NNS	patient
with	IN	with
chronic	JJ	chronic
genetic	JJ	genetic
disorders	NNS	disorder
require	VBP	require
organization	NN	organization
for	IN	for
their	PP$	their
multidisciplinary	JJ	multidisciplinary
needs	NNS	need
of	IN	of
care	NN	care
.	SENT	.
33503002/	CD	@card@
Digital	NP	Digital
Pathology	NN	pathology
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Outbreak	NN	outbreak
in	IN	in
Italy	NP	Italy
:	:	:
Survey	NP	Survey
Study	NP	Study
Transition	NN	transition
to	TO	to
digital	JJ	digital
pathology	NN	pathology
usually	RB	usually
takes	VBZ	take
months	NNS	month
or	CC	or
years	NNS	year
to	TO	to
be	VB	be
completed	VBN	complete
.	SENT	.
We	PP	we
were	VBD	be
familiarizing	VBG	familiarize
ourselves	PP	ourselves
with	IN	with
digital	JJ	digital
pathology	NN	pathology
solutions	NNS	solution
at	IN	at
the	DT	the
time	NN	time
when	WRB	when
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
forced	VBD	force
us	PP	us
to	TO	to
embark	VB	embark
on	IN	on
an	DT	an
abrupt	JJ	abrupt
transition	NN	transition
to	TO	to
digital	JJ	digital
pathology	NN	pathology
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
quantitatively	RB	quantitatively
describe	VB	describe
how	WRB	how
the	DT	the
abrupt	JJ	abrupt
transition	NN	transition
to	TO	to
digital	JJ	digital
pathology	NN	pathology
might	MD	might
affect	VB	affect
the	DT	the
quality	NN	quality
of	IN	of
diagnoses	NNS	diagnosis
,	,	,
model	JJ	model
possible	JJ	possible
causes	NNS	cause
by	IN	by
probabilistic	JJ	probabilistic
modeling	NN	modeling
,	,	,
and	CC	and
qualitatively	RB	qualitatively
gauge	VB	gauge
the	DT	the
perception	NN	perception
of	IN	of
this	DT	this
abrupt	JJ	abrupt
transition	NN	transition
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
17	CD	@card@
pathologists	NNS	pathologist
and	CC	and
residents	NNS	resident
participated	VBD	participate
in	IN	in
this	DT	this
study	NN	study
;	:	;
these	DT	these
participants	NNS	participant
reviewed	VBD	review
25	CD	@card@
additional	JJ	additional
test	NN	test
cases	NNS	case
from	IN	from
the	DT	the
archives	NN	archives
and	CC	and
completed	VBD	complete
a	DT	a
final	JJ	final
psychologic	JJ	<unknown>
survey	NN	survey
.	SENT	.
For	IN	for
each	DT	each
case	NN	case
,	,	,
participants	NNS	participant
performed	VBD	perform
several	JJ	several
different	JJ	different
diagnostic	JJ	diagnostic
tasks	NNS	task
,	,	,
and	CC	and
their	PP$	their
results	NNS	result
were	VBD	be
recorded	VBN	record
and	CC	and
compared	VBN	compare
with	IN	with
the	DT	the
original	JJ	original
diagnoses	NNS	diagnosis
performed	VBD	perform
using	VBG	use
the	DT	the
gold	JJ	gold
standard	JJ	standard
method	NN	method
(	(	(
ie	NP	Ie
,	,	,
conventional	JJ	conventional
microscopy	NN	microscopy
)	)	)
.	SENT	.
We	PP	we
performed	VBD	perform
Bayesian	NP	<unknown>
data	NNS	datum
analysis	NN	analysis
with	IN	with
probabilistic	JJ	probabilistic
modeling	NN	modeling
.	SENT	.
The	DT	the
overall	JJ	overall
analysis	NN	analysis
,	,	,
comprising	VBG	comprise
1345	CD	@card@
different	JJ	different
items	NNS	item
,	,	,
resulted	VBN	result
in	IN	in
a	DT	a
9	CD	@card@
%	NN	%
(	(	(
117/1345	CD	@card@
)	)	)
error	NN	error
rate	NN	rate
in	IN	in
using	VBG	use
digital	JJ	digital
slides	NNS	slide
.	SENT	.
The	DT	the
task	NN	task
of	IN	of
differentiating	VBG	differentiate
a	DT	a
neoplastic	JJ	neoplastic
process	NN	process
from	IN	from
a	DT	a
nonneoplastic	JJ	nonneoplastic
one	CD	one
accounted	VBD	account
for	IN	for
an	DT	an
error	NN	error
rate	NN	rate
of	IN	of
10.7	CD	@card@
%	NN	%
(	(	(
42/392	CD	@card@
)	)	)
,	,	,
whereas	IN	whereas
the	DT	the
distinction	NN	distinction
of	IN	of
a	DT	a
malignant	JJ	malignant
process	NN	process
from	IN	from
a	DT	a
benign	JJ	benign
one	CD	one
accounted	VBD	account
for	IN	for
an	DT	an
error	NN	error
rate	NN	rate
of	IN	of
4.2	CD	@card@
%	NN	%
(	(	(
11/258	CD	@card@
)	)	)
.	SENT	.
Apart	RB	apart
from	IN	from
residents	NNS	resident
,	,	,
senior	JJ	senior
pathologists	NNS	pathologist
generated	VBD	generate
most	RBS	most
discrepancies	NNS	discrepancy
(	(	(
7.9	CD	@card@
%	NN	%
,	,	,
13/164	CD	@card@
)	)	)
.	SENT	.
Our	PP$	our
model	NN	model
showed	VBD	show
that	IN	that
these	DT	these
differences	NNS	difference
among	IN	among
career	NN	career
levels	NNS	level
persisted	VBD	persist
even	RB	even
after	IN	after
adjusting	VBG	adjust
for	IN	for
other	JJ	other
factors	NNS	factor
.	SENT	.
Our	PP$	our
findings	NNS	finding
are	VBP	be
in	IN	in
line	NN	line
with	IN	with
previous	JJ	previous
findings	NNS	finding
,	,	,
emphasizing	VBG	emphasize
that	IN	that
the	DT	the
duration	NN	duration
of	IN	of
transition	NN	transition
(	(	(
ie	NP	Ie
,	,	,
lengthy	JJ	lengthy
or	CC	or
abrupt	JJ	abrupt
)	)	)
might	MD	might
not	RB	not
influence	VB	influence
the	DT	the
diagnostic	JJ	diagnostic
performance	NN	performance
.	SENT	.
Moreover	RB	moreover
,	,	,
our	PP$	our
findings	NNS	finding
highlight	VB	highlight
that	IN	that
senior	JJ	senior
pathologists	NNS	pathologist
may	MD	may
be	VB	be
limited	VBN	limit
by	IN	by
a	DT	a
digital	JJ	digital
gap	NN	gap
,	,	,
which	WDT	which
may	MD	may
negatively	RB	negatively
affect	VB	affect
their	PP$	their
performance	NN	performance
with	IN	with
digital	JJ	digital
pathology	NN	pathology
.	SENT	.
These	DT	these
results	NNS	result
can	MD	can
guide	VB	guide
the	DT	the
process	NN	process
of	IN	of
digital	JJ	digital
transition	NN	transition
in	IN	in
the	DT	the
field	NN	field
of	IN	of
pathology	NN	pathology
.	SENT	.
32578210/	CD	@card@
Remote	JJ	remote
management	NN	management
of	IN	of
hidradenitis	NN	hidradenitis
suppurativa	NN	<unknown>
in	IN	in
a	DT	a
pandemic	JJ	pandemic
era	NN	era
of	IN	of
COVID-19	NP	<unknown>
35453906/	CD	@card@
Systemic	JJ	systemic
Inflammatory	JJ	inflammatory
Predictors	NNS	predictor
of	IN	of
In-Hospital	JJ	in-hospital
Mortality	NN	mortality
in	IN	in
COVID-19	NP	<unknown>
Patients	NPS	Patients
:	:	:
A	DT	a
Retrospective	JJ	retrospective
Study	NN	study
The	DT	the
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
whether	IN	whether
routine	JJ	routine
blood	NN	blood
tests	NNS	test
and	CC	and
clinical	JJ	clinical
characteristics	NNS	characteristic
can	MD	can
predict	VB	predict
in-hospital	JJ	in-hospital
mortality	NN	mortality
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
Clinical	JJ	clinical
data	NNS	datum
of	IN	of
285	CD	@card@
patients	NNS	patient
aged	VBN	age
59.7	CD	@card@
+-	NN	<unknown>
10.3	CD	@card@
yrs	NNS	<unknown>
.	SENT	.
(	(	(
males	NNS	male
n	NN	n
=	SYM	=
189	CD	@card@
,	,	,
females	NNS	female
n	NN	n
=	SYM	=
96	CD	@card@
)	)	)
were	VBD	be
retrospectively	RB	retrospectively
collected	VBN	collect
from	IN	from
December	NP	December
2020	CD	@card@
to	TO	to
June	NP	June
2021	CD	@card@
.	SENT	.
Routine	JJ	routine
blood	NN	blood
tests	NNS	test
were	VBD	be
recorded	VBN	record
within	IN	within
the	DT	the
1st	JJ	1st
hour	NN	hour
of	IN	of
admission	NN	admission
to	TO	to
hospital	NN	hospital
.	SENT	.
The	DT	the
inflammatory	JJ	inflammatory
variables	NNS	variable
,	,	,
such	JJ	such
as	IN	as
C-reactive	JJ	C-reactive
protein	NN	protein
(	(	(
CRP	NP	<unknown>
)	)	)
,	,	,
procalcitonin	NP	<unknown>
(	(	(
PCT	NP	PCT
)	)	)
,	,	,
neutrophils-lymphocyte	NN	neutrophils-lymphocyte
ratio	NN	ratio
(	(	(
NLR	NP	NLR
)	)	)
and	CC	and
the	DT	the
systemic	JJ	systemic
inflammatory	JJ	inflammatory
index	NN	index
(	(	(
SII	NP	SII
)	)	)
,	,	,
exceeded	VBD	exceed
the	DT	the
reference	NN	reference
values	VBZ	value
in	IN	in
all	DT	all
patients	NNS	patient
and	CC	and
were	VBD	be
significantly	RB	significantly
higher	JJR	high
in	IN	in
deceased	JJ	deceased
patients	NNS	patient
(	(	(
n	NN	n
=	SYM	=
108	LS	@card@
)	)	)
compared	VBN	compare
to	TO	to
survivors	NNS	survivor
(	(	(
n	NN	n
=	SYM	=
177	CD	@card@
)	)	)
.	SENT	.
The	DT	the
log-rank	NN	<unknown>
test	NN	test
for	IN	for
comparing	VBG	compare
two	CD	two
survival	NN	survival
curves	NNS	curve
showed	VBD	show
that	IN	that
patients	NNS	patient
aged	VBN	age
&gt	NN	&gt
;	:	;
=60.5	JJ	<unknown>
years	NNS	year
,	,	,
with	IN	with
PCT	NN	PCT
&gt	NN	&gt
;	:	;
=	SYM	=
0.188	CD	@card@
ng/mL	NNS	<unknown>
or	CC	or
NLR	NP	NLR
&gt	NN	&gt
;	:	;
=	SYM	=
11.57	CD	@card@
103/microL	NN	<unknown>
were	VBD	be
at	IN	at
a	DT	a
greater	JJR	great
risk	NN	risk
of	IN	of
death	NN	death
.	SENT	.
NLR	NP	NLR
demonstrated	VBD	demonstrate
a	DT	a
high	JJ	high
impact	NN	impact
on	IN	on
the	DT	the
COVID-19	NP	<unknown>
mortality	NN	mortality
(	(	(
HR	NP	HR
1.317	CD	@card@
;	:	;
95%CI	NP	<unknown>
1.004-1.728	CD	@card@
;	:	;
p	NN	p
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
,	,	,
whereas	IN	whereas
CRP	NP	<unknown>
and	CC	and
SII	NP	SII
showed	VBD	show
no	DT	no
effect	NN	effect
(	(	(
HR	NP	HR
1.000	CD	@card@
;	:	;
95%CI	NP	<unknown>
1.000-1.004	CD	@card@
;	:	;
p	NN	p
=	SYM	=
0.085	CD	@card@
and	CC	and
HR	NP	HR
1.078	CD	@card@
;	:	;
95%CI	NP	<unknown>
0.865-1.344	CD	@card@
;	:	;
p	NN	p
=	SYM	=
0.503	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
In	IN	in
the	DT	the
first	JJ	first
Polish	JJ	Polish
study	NN	study
including	VBG	include
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
we	PP	we
demonstrated	VBD	demonstrate
that	DT	that
age	NN	age
in	IN	in
relation	NN	relation
to	TO	to
simple	JJ	simple
parameters	NNS	parameter
derived	VBN	derive
from	IN	from
complete	JJ	complete
blood	NN	blood
cell	NN	cell
count	NN	count
has	VBZ	have
prognostic	JJ	prognostic
implications	NNS	implication
in	IN	in
the	DT	the
course	NN	course
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
can	MD	can
identify	VB	identify
the	DT	the
patients	NNS	patient
at	IN	at
a	DT	a
higher	JJR	high
risk	NN	risk
of	IN	of
in-hospital	JJ	in-hospital
mortality	NN	mortality
.	SENT	.
35124470/	CD	@card@
Home	NP	Home
parenteral	JJ	parenteral
nutrition	NN	nutrition
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
Experience	NN	experience
in	IN	in
a	DT	a
tertiary	JJ	tertiary
referral	NN	referral
hospital	NN	hospital
in	IN	in
Malaysia	NP	Malaysia
34714362/	CD	@card@
Snake	NN	snake
venom	NN	venom
phospholipase	NN	phospholipase
A2s	NP	A2s
exhibit	NN	exhibit
strong	JJ	strong
virucidal	JJ	<unknown>
activity	NN	activity
against	IN	against
SARS-CoV-2	NP	<unknown>
and	CC	and
inhibit	VB	inhibit
the	DT	the
viral	JJ	viral
spike	NN	spike
glycoprotein	NN	glycoprotein
interaction	NN	interaction
with	IN	with
ACE2	NP	<unknown>
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
requires	VBZ	require
new	JJ	new
treatments	NNS	treatment
both	CC	both
to	TO	to
alleviate	VB	alleviate
the	DT	the
symptoms	NNS	symptom
and	CC	and
to	TO	to
prevent	VB	prevent
the	DT	the
spread	NN	spread
of	IN	of
this	DT	this
disease	NN	disease
.	SENT	.
Previous	JJ	previous
studies	NNS	study
demonstrated	VBD	demonstrate
good	JJ	good
antiviral	JJ	antiviral
and	CC	and
virucidal	JJ	<unknown>
activity	NN	activity
of	IN	of
phospholipase	NN	phospholipase
A2s	NP	A2s
(	(	(
PLA2s	NP	<unknown>
)	)	)
from	IN	from
snake	NN	snake
venoms	NNS	venom
against	IN	against
viruses	NNS	virus
from	IN	from
different	JJ	different
families	NNS	family
but	CC	but
there	EX	there
was	VBD	be
no	DT	no
data	NNS	datum
for	IN	for
coronaviruses	NNS	coronavirus
.	SENT	.
Here	RB	here
we	PP	we
show	VBP	show
that	IN	that
PLA2s	NNS	<unknown>
from	IN	from
snake	NN	snake
venoms	NNS	venom
protect	VBP	protect
Vero	NP	Vero
E6	NP	<unknown>
cells	NNS	cell
against	IN	against
SARS-CoV-2	JJ	<unknown>
cytopathic	JJ	<unknown>
effects	NNS	effect
.	SENT	.
PLA2s	NP	<unknown>
showed	VBD	show
low	JJ	low
cytotoxicity	NN	cytotoxicity
to	TO	to
Vero	NP	Vero
E6	NP	<unknown>
cells	NNS	cell
with	IN	with
some	DT	some
activity	NN	activity
at	IN	at
micromolar	JJ	micromolar
concentrations	NNS	concentration
,	,	,
but	CC	but
strong	JJ	strong
antiviral	JJ	antiviral
activity	NN	activity
at	IN	at
nanomolar	NN	nanomolar
concentrations	NNS	concentration
.	SENT	.
Dimeric	NP	<unknown>
PLA2	NP	<unknown>
from	IN	from
the	DT	the
viper	NN	viper
Vipera	NP	<unknown>
nikolskii	NP	<unknown>
and	CC	and
its	PP$	its
subunits	NN	subunits
manifested	VBD	manifest
especially	RB	especially
potent	JJ	potent
virucidal	JJ	<unknown>
effects	NNS	effect
,	,	,
which	WDT	which
were	VBD	be
related	VBN	relate
to	TO	to
their	PP$	their
phospholipolytic	JJ	phospholipolytic
activity	NN	activity
,	,	,
and	CC	and
inhibited	VBD	inhibit
cell-cell	NN	<unknown>
fusion	NN	fusion
mediated	VBN	mediate
by	IN	by
the	DT	the
SARS-CoV-2	NP	<unknown>
spike	NN	spike
glycoprotein	NN	glycoprotein
.	SENT	.
Moreover	RB	moreover
,	,	,
PLA2s	NP	<unknown>
interfered	VBD	interfere
with	IN	with
binding	VBG	bind
both	DT	both
of	IN	of
an	DT	an
antibody	NN	antibody
against	IN	against
ACE2	NP	<unknown>
and	CC	and
of	IN	of
the	DT	the
receptor-binding	NN	receptor-binding
domain	NN	domain
of	IN	of
the	DT	the
glycoprotein	NN	glycoprotein
S	NN	S
to	TO	to
293T/ACE2	JJ	<unknown>
cells	NNS	cell
.	SENT	.
This	DT	this
is	VBZ	be
the	DT	the
first	JJ	first
demonstration	NN	demonstration
of	IN	of
a	DT	a
detrimental	JJ	detrimental
effect	NN	effect
of	IN	of
PLA2s	NP	<unknown>
on	IN	on
beta-coronaviruses	NNS	beta-coronavirus
.	SENT	.
Thus	RB	thus
,	,	,
snake	NN	snake
PLA2s	NNS	<unknown>
are	VBP	be
promising	VBG	promise
for	IN	for
the	DT	the
development	NN	development
of	IN	of
antiviral	JJ	antiviral
drugs	NNS	drug
that	WDT	that
target	VBP	target
the	DT	the
viral	JJ	viral
envelope	NN	envelope
,	,	,
and	CC	and
could	MD	could
also	RB	also
prove	VB	prove
to	TO	to
be	VB	be
useful	JJ	useful
tools	NNS	tool
to	TO	to
study	VB	study
the	DT	the
interaction	NN	interaction
of	IN	of
viruses	NNS	virus
with	IN	with
host	NN	host
cells	NNS	cell
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s00018-021-03985-6	JJ	10.1007/s@card@
.	SENT	.
35578330/	CD	@card@
Public	NP	Public
health	NN	health
and	CC	and
social	JJ	social
measures	NNS	measure
to	TO	to
mitigate	VB	mitigate
the	DT	the
health	NN	health
and	CC	and
economic	JJ	economic
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Turkey	NP	Turkey
,	,	,
Egypt	NP	Egypt
,	,	,
Ukraine	NP	Ukraine
,	,	,
Kazakhstan	NP	Kazakhstan
,	,	,
and	CC	and
Poland	NP	Poland
during	IN	during
2020-2021	CD	@card@
:	:	:
situational	JJ	situational
analysis	NN	analysis
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
had	VBD	have
a	DT	a
colossal	JJ	colossal
impact	NN	impact
on	IN	on
human	JJ	human
society	NN	society
globally	RB	globally
.	SENT	.
There	EX	there
were	VBD	be
similarities	NNS	similarity
and	CC	and
differences	NNS	difference
in	IN	in
the	DT	the
public	JJ	public
health	NN	health
and	CC	and
social	JJ	social
measures	NNS	measure
taken	VBN	take
by	IN	by
countries	NNS	country
,	,	,
and	CC	and
comparative	JJ	comparative
analysis	NN	analysis
facilitates	VBZ	facilitate
cross-country	JJ	cross-country
learning	NN	learning
of	IN	of
contextual	JJ	contextual
practices	NNS	practice
and	CC	and
sharing	VBG	share
lessons	NNS	lesson
to	TO	to
mitigate	VB	mitigate
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
impact	NN	impact
.	SENT	.
Our	PP$	our
aim	NN	aim
is	VBZ	be
to	TO	to
conduct	VB	conduct
a	DT	a
situational	JJ	situational
analysis	NN	analysis
of	IN	of
the	DT	the
public	JJ	public
health	NN	health
and	CC	and
social	JJ	social
measures	NNS	measure
to	TO	to
mitigate	VB	mitigate
the	DT	the
health	NN	health
and	CC	and
economic	JJ	economic
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Turkey	NP	Turkey
,	,	,
Egypt	NP	Egypt
,	,	,
Ukraine	NP	Ukraine
,	,	,
Kazakhstan	NP	Kazakhstan
,	,	,
and	CC	and
Poland	NP	Poland
during	IN	during
2020-2021	CD	@card@
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
situational	JJ	situational
analysis	NN	analysis
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
response	NN	response
in	IN	in
Turkey	NP	Turkey
,	,	,
Egypt	NP	Egypt
,	,	,
Ukraine	NP	Ukraine
,	,	,
Kazakhstan	NP	Kazakhstan
,	,	,
and	CC	and
Poland	NP	Poland
from	IN	from
the	DT	the
perspectives	NNS	perspective
of	IN	of
the	DT	the
health	NN	health
system	NN	system
and	CC	and
health	NN	health
finance	NN	finance
,	,	,
national	JJ	national
coordination	NN	coordination
,	,	,
surveillance	NN	surveillance
,	,	,
testing	VBG	test
capacity	NN	capacity
,	,	,
health	NN	health
infrastructure	NN	infrastructure
,	,	,
healthcare	NN	<unknown>
workforce	NN	workforce
,	,	,
medical	JJ	medical
supply	NN	supply
,	,	,
physical	JJ	physical
distancing	NN	distancing
and	CC	and
non-pharmaceutical	JJ	non-pharmaceutical
interventions	NNS	intervention
,	,	,
health	NN	health
communication	NN	communication
,	,	,
impact	NN	impact
on	IN	on
non-COVID-19	JJ	<unknown>
health	NN	health
services	NNS	service
,	,	,
impact	NN	impact
on	IN	on
the	DT	the
economy	NN	economy
,	,	,
education	NN	education
,	,	,
gender	NN	gender
and	CC	and
civil	JJ	civil
liberties	NNS	liberty
,	,	,
and	CC	and
COVID-19	NP	<unknown>
vaccination	NN	vaccination
.	SENT	.
Since	IN	since
the	DT	the
onset	NN	onset
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
Turkey	NP	Turkey
,	,	,
Egypt	NP	Egypt
,	,	,
Ukraine	NP	Ukraine
,	,	,
Kazakhstan	NP	Kazakhstan
,	,	,
and	CC	and
Poland	NP	Poland
have	VBP	have
expanded	VBN	expand
COVID-19	NP	<unknown>
testing	NN	testing
and	CC	and
treatment	NN	treatment
capacity	NN	capacity
over	IN	over
time	NN	time
.	SENT	.
However	RB	however
,	,	,
they	PP	they
faced	VBD	face
a	DT	a
shortage	NN	shortage
of	IN	of
healthcare	NN	<unknown>
workforce	NN	workforce
and	CC	and
medical	JJ	medical
supplies	NNS	supply
.	SENT	.
They	PP	they
took	VBD	take
population-based	JJ	<unknown>
quarantine	NN	quarantine
measures	NNS	measure
rather	RB	rather
than	IN	than
individual-based	JJ	<unknown>
isolation	NN	isolation
measures	NNS	measure
,	,	,
which	WDT	which
significantly	RB	significantly
burdened	VBD	burden
their	PP$	their
economies	NNS	economy
and	CC	and
disrupted	VBN	disrupt
education	NN	education
.	SENT	.
The	DT	the
unemployment	NN	unemployment
rate	NN	rate
increased	VBD	increase
,	,	,
and	CC	and
economic	JJ	economic
growth	NN	growth
stagnated	VBD	stagnate
.	SENT	.
Economic	JJ	economic
stimulus	NN	stimulus
policy	NN	policy
was	VBD	be
accompanied	VBN	accompany
by	IN	by
high	JJ	high
inflation	NN	inflation
.	SENT	.
Despite	IN	despite
the	DT	the
effort	NN	effort
to	TO	to
sustain	VB	sustain
essential	JJ	essential
health	NN	health
services	NNS	service
,	,	,
healthcare	NN	<unknown>
access	NN	access
declined	VBD	decline
.	SENT	.
Schools	NNS	school
were	VBD	be
closed	VBN	close
for	IN	for
5-11	CD	@card@
months	NNS	month
.	SENT	.
Gender	NN	gender
inequality	NN	inequality
was	VBD	be
aggravated	VBN	aggravate
in	IN	in
Turkey	NP	Turkey
and	CC	and
Ukraine	NP	Ukraine
,	,	,
and	CC	and
an	DT	an
issue	NN	issue
was	VBD	be
raised	VBN	raise
for	IN	for
balancing	VBG	balance
public	JJ	public
health	NN	health
measures	NNS	measure
and	CC	and
civil	JJ	civil
liberties	NNS	liberty
in	IN	in
Egypt	NP	Egypt
and	CC	and
Poland	NP	Poland
.	SENT	.
Digital	NP	Digital
technologies	NNS	technology
played	VBD	play
an	DT	an
important	JJ	important
role	NN	role
in	IN	in
maintaining	VBG	maintain
routine	JJ	routine
healthcare	NN	<unknown>
,	,	,
education	NN	education
,	,	,
and	CC	and
public	JJ	public
health	NN	health
communication	NN	communication
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
exposed	VBN	expose
weaknesses	NNS	weakness
in	IN	in
healthcare	NN	<unknown>
systems	NNS	system
in	IN	in
the	DT	the
emerging	VBG	emerge
economies	NNS	economy
of	IN	of
Turkey	NP	Turkey
,	,	,
Egypt	NP	Egypt
,	,	,
Ukraine	NP	Ukraine
,	,	,
Kazakhstan	NP	Kazakhstan
,	,	,
and	CC	and
Poland	NP	Poland
,	,	,
and	CC	and
highlighted	VBD	highlight
the	DT	the
intricate	JJ	intricate
link	NN	link
between	IN	between
health	NN	health
and	CC	and
economy	NN	economy
.	SENT	.
Individual-level	JJ	Individual-level
testing	NN	testing
,	,	,
isolation	NN	isolation
,	,	,
and	CC	and
contact	NN	contact
tracing	NN	tracing
are	VBP	be
effective	JJ	effective
public	JJ	public
health	NN	health
interventions	NNS	intervention
in	IN	in
mitigating	VBG	mitigate
the	DT	the
health	NN	health
and	CC	and
economic	JJ	economic
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
comparison	NN	comparison
to	TO	to
population-level	JJ	population-level
measures	NNS	measure
of	IN	of
lockdowns	NNS	lockdown
.	SENT	.
Smart	JJ	smart
investments	NNS	investment
in	IN	in
public	JJ	public
health	NN	health
,	,	,
including	VBG	include
digital	JJ	digital
health	NN	health
and	CC	and
linking	VBG	link
health	NN	health
security	NN	security
with	IN	with
sustainable	JJ	sustainable
development	NN	development
,	,	,
are	VBP	be
key	JJ	key
for	IN	for
economic	JJ	economic
gain	NN	gain
,	,	,
social	JJ	social
stability	NN	stability
,	,	,
and	CC	and
more	RBR	more
equitable	JJ	equitable
and	CC	and
sustainable	JJ	sustainable
development	NN	development
.	SENT	.
34017205/	CD	@card@
Perceived	VBN	perceive
Stress	NN	stress
Among	IN	among
Chinese	JJ	Chinese
Medical	NP	Medical
Students	NNS	student
Engaging	VBG	engage
in	IN	in
Online	JJ	online
Learning	NP	Learning
in	IN	in
Light	NP	Light
of	IN	of
COVID-19	NP	<unknown>
After	IN	after
a	DT	a
year	NN	year
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
countries	NNS	country
have	VBP	have
repeatedly	RB	repeatedly
imposed	VBN	impose
strict	JJ	strict
quarantine	NN	quarantine
regimes	NNS	regime
as	IN	as
the	DT	the
virus	NN	virus
mutates	VBZ	mutate
and	CC	and
becomes	VBZ	become
more	RBR	more
contagious	JJ	contagious
.	SENT	.
Medical	JJ	medical
undergraduate	JJ	undergraduate
education	NN	education
has	VBZ	have
been	VBN	be
disrupted	VBN	disrupt
and	CC	and
transformed	VBN	transform
into	IN	into
prolonged	JJ	prolonged
home	NN	home
isolation	NN	isolation
and	CC	and
online	JJ	online
learning	NN	learning
.	SENT	.
Although	IN	although
studies	NNS	study
have	VBP	have
reported	VBN	report
that	IN	that
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
tends	VBZ	tend
to	TO	to
increase	VB	increase
perceived	VBN	perceive
stress	NN	stress
(	(	(
PS	NP	PS
)	)	)
and	CC	and
affect	VB	affect
the	DT	the
mental	JJ	mental
health	NN	health
of	IN	of
medical	JJ	medical
students	NNS	student
,	,	,
the	DT	the
influencing	VBG	influence
factors	NNS	factor
are	VBP	be
unclear	JJ	unclear
.	SENT	.
Therefore	RB	therefore
,	,	,
based	VBN	base
on	IN	on
the	DT	the
stress	NN	stress
process	NN	process
model	NN	model
,	,	,
this	DT	this
study	NN	study
will	MD	will
comprehensively	RB	comprehensively
evaluate	VB	evaluate
the	DT	the
distribution	NN	distribution
of	IN	of
stressors	NNS	<unknown>
of	IN	of
medical	JJ	medical
students	NNS	student
and	CC	and
explore	VB	explore
the	DT	the
personal	JJ	personal
and	CC	and
environmental	JJ	environmental
predictors	NNS	predictor
of	IN	of
PS	NP	PS
during	IN	during
the	DT	the
epidemic	NN	epidemic
.	SENT	.
An	DT	an
online	JJ	online
survey	NN	survey
was	VBD	be
conducted	VBN	conduct
among	IN	among
medical	JJ	medical
students	NNS	student
(	(	(
n=369	NN	<unknown>
)	)	)
from	IN	from
three	CD	three
medical	JJ	medical
universities	NNS	university
in	IN	in
western	JJ	western
China	NP	China
who	WP	who
engaged	VBD	engage
in	IN	in
online	JJ	online
learning	NN	learning
.	SENT	.
A	DT	a
stress	NN	stress
process	NN	process
conceptual	JJ	conceptual
framework	NN	framework
was	VBD	be
formed	VBN	form
to	TO	to
explore	VB	explore
the	DT	the
influencing	VBG	influence
factors	NNS	factor
of	IN	of
PS	NP	PS
.	SENT	.
The	DT	the
survey	NN	survey
items	NNS	item
contained	VBD	contain
four	CD	four
sections	NNS	section
:	:	:
(	(	(
a	DT	a
)	)	)
the	DT	the
potential	JJ	potential
stressors	NNS	<unknown>
derived	VBN	derive
from	IN	from
academic	JJ	academic
,	,	,
psychosocial	JJ	psychosocial
and	CC	and
health-related	JJ	health-related
demands	NNS	demand
;	:	;
coping	VBG	cope
resources	NNS	resource
such	JJ	such
as	IN	as
(	(	(
b	LS	b
)	)	)
online	JJ	online
learning	VBG	learn
environment	NN	environment
support	NN	support
and	CC	and
(	(	(
c	LS	c
)	)	)
personal	JJ	personal
resilience	NN	resilience
,	,	,
including	VBG	include
online	JJ	online
learning	VBG	learn
behavior	NN	behavior
and	CC	and
individual	JJ	individual
characteristics	NNS	characteristic
;	:	;
and	CC	and
(	(	(
d	LS	d
)	)	)
PS	NP	PS
,	,	,
perception	NN	perception
of	IN	of
imbalanced	JJ	imbalanced
demands	NNS	demand
and	CC	and
coping	VBG	cope
resources	NNS	resource
.	SENT	.
The	DT	the
mean	JJ	mean
PS	NP	PS
score	NN	score
was	VBD	be
17.39	CD	@card@
(	(	(
SD=4.58	NP	<unknown>
)	)	)
,	,	,
and	CC	and
over	IN	over
four-fifths	NNS	four-fifth
(	(	(
82.3	CD	@card@
%	NN	%
)	)	)
of	IN	of
the	DT	the
students	NNS	student
had	VBD	have
moderate	JJ	moderate
to	TO	to
high	JJ	high
levels	NNS	level
of	IN	of
stress	NN	stress
.	SENT	.
The	DT	the
average	JJ	average
item	NN	item
scores	NNS	score
of	IN	of
academic	JJ	academic
,	,	,
psychosocial	JJ	psychosocial
and	CC	and
health-related	JJ	health-related
stressors	NNS	<unknown>
were	VBD	be
2.72	CD	@card@
(	(	(
SD=0.55	NP	<unknown>
)	)	)
,	,	,
2.31	NP	@card@
(	(	(
SD=0.55	NP	<unknown>
)	)	)
and	CC	and
2.07	CD	@card@
(	(	(
SD=0.50	NP	<unknown>
)	)	)
,	,	,
respectively	RB	respectively
.	SENT	.
Gender	NN	gender
,	,	,
grade	NN	grade
,	,	,
psychosocial	JJ	psychosocial
stressors	NNS	<unknown>
,	,	,
health-related	JJ	health-related
stressors	NNS	<unknown>
,	,	,
specific	JJ	specific
online	JJ	online
learning	NN	learning
behavior	NN	behavior
(	(	(
persistence	NN	persistence
,	,	,
attitude	NN	attitude
and	CC	and
flexibility	NN	flexibility
)	)	)
,	,	,
and	CC	and
the	DT	the
online	JJ	online
learning	NN	learning
environment	NN	environment
(	(	(
teaching	NN	teaching
,	,	,
social	JJ	social
and	CC	and
cognitive	JJ	cognitive
presence	NN	presence
)	)	)
were	VBD	be
predictors	NNS	predictor
of	IN	of
PS	NP	PS
.	SENT	.
Our	PP$	our
results	NNS	result
specify	VB	specify
that	IN	that
a	DT	a
reduction	NN	reduction
in	IN	in
psychological	JJ	psychological
and	CC	and
health-related	JJ	health-related
stressor	NN	<unknown>
stimulation	NN	stimulation
,	,	,
specific	JJ	specific
online	JJ	online
learning	NN	learning
behavior	NN	behavior
promotion	NN	promotion
,	,	,
and	CC	and
well-established	JJ	well-established
online	JJ	online
learning	NN	learning
environment	NN	environment
support	NN	support
could	MD	could
be	VB	be
considered	VBN	consider
essential	JJ	essential
for	IN	for
alleviating	VBG	alleviate
the	DT	the
negative	JJ	negative
impacts	NNS	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
the	DT	the
psychosocial	JJ	psychosocial
health	NN	health
of	IN	of
medical	JJ	medical
undergraduates	NNS	undergraduate
.	SENT	.
32589348/	CD	@card@
COVID-19	NP	<unknown>
Screening	NN	screening
with	IN	with
Chest	NN	chest
CT	NP	CT
in	IN	in
Acute	JJ	acute
Stroke	NN	stroke
Imaging	NP	Imaging
:	:	:
A	DT	a
Clinical	JJ	clinical
Decision	NP	Decision
Model	NP	Model
Acute	JJ	acute
stroke	NN	stroke
patients	NNS	patient
may	MD	may
have	VB	have
undiagnosed	JJ	undiagnosed
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
infection	NN	infection
,	,	,
transmissible	JJ	transmissible
to	TO	to
medical	JJ	medical
professionals	NNS	professional
involved	VBN	involve
in	IN	in
their	PP$	their
care	NN	care
.	SENT	.
Our	PP$	our
aim	NN	aim
was	VBD	be
to	TO	to
determine	VB	determine
the	DT	the
value	NN	value
of	IN	of
incorporating	VBG	incorporate
a	DT	a
chest	NN	chest
computed	VBD	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
scan	NN	scan
during	IN	during
acute	JJ	acute
stroke	NN	stroke
imaging	NN	imaging
,	,	,
and	CC	and
the	DT	the
factors	NNS	factor
that	WDT	that
influence	VBP	influence
this	DT	this
decision	NN	decision
.	SENT	.
We	PP	we
constructed	VBD	construct
a	DT	a
probabilistic	JJ	probabilistic
decision	NN	decision
tree	NN	tree
of	IN	of
the	DT	the
value	NN	value
of	IN	of
acquiring	VBG	acquire
a	DT	a
chest	NN	chest
CT	NP	CT
scan	NN	scan
or	CC	or
not	RB	not
,	,	,
expressed	VBN	express
in	IN	in
quality-adjusted	NN	quality-adjusted
life	NN	life
months	NNS	month
(	(	(
QALM	NP	<unknown>
)	)	)
of	IN	of
patients	NNS	patient
and	CC	and
medical	JJ	medical
professionals	NNS	professional
.	SENT	.
The	DT	the
model	NN	model
was	VBD	be
based	VBN	base
on	IN	on
the	DT	the
chance	NN	chance
of	IN	of
detecting	VBG	detect
infection	NN	infection
by	IN	by
chest	NN	chest
CT	NP	CT
scan	NN	scan
,	,	,
the	DT	the
case	NN	case
fatality	NN	fatality
rates	NNS	rate
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
,	,	,
the	DT	the
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
after	IN	after
exposure	NN	exposure
,	,	,
the	DT	the
expected	VBN	expect
proportion	NN	proportion
of	IN	of
medical	JJ	medical
professionals	NNS	professional
exposed	VBN	expose
,	,	,
and	CC	and
the	DT	the
exposure	NN	exposure
reduction	NN	reduction
derived	VBN	derive
from	IN	from
early	JJ	early
disease	NN	disease
detection	NN	detection
.	SENT	.
The	DT	the
decision	NN	decision
to	TO	to
incorporate	VB	incorporate
the	DT	the
chest	NN	chest
CT	NP	CT
scan	NN	scan
was	VBD	be
superior	JJ	superior
to	TO	to
not	RB	not
doing	VBG	do
so	IN	so
(	(	(
12.00	CD	@card@
QALM	NP	<unknown>
vs	NP	vs
11.99	NP	@card@
QALM	NP	<unknown>
,	,	,
respectively	RB	respectively
)	)	)
,	,	,
when	WRB	when
the	DT	the
probability	NN	probability
of	IN	of
patients	NNS	patient
having	VBG	have
undetected	JJ	undetected
COVID-19	NP	<unknown>
infection	NN	infection
is	VBZ	be
3.5	CD	@card@
%	NN	%
,	,	,
potentially	RB	potentially
exposing	VBG	expose
100	CD	@card@
%	NN	%
of	IN	of
medical	JJ	medical
professionals	NNS	professional
,	,	,
and	CC	and
if	IN	if
early	JJ	early
detection	NN	detection
reduces	VBZ	reduce
exposure	NN	exposure
by	IN	by
50	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
risk	NN	risk
of	IN	of
developing	VBG	develop
symptomatic	JJ	symptomatic
COVID-19	NP	<unknown>
infection	NN	infection
following	VBG	follow
exposure	NN	exposure
casts	VBZ	cast
uncertainty	NN	uncertainty
on	IN	on
the	DT	the
results	NNS	result
,	,	,
but	CC	but
this	DT	this
is	VBZ	be
offset	VBN	offset
by	IN	by
the	DT	the
potential	NN	potential
for	IN	for
reducing	VBG	reduce
exposure	NN	exposure
.	SENT	.
We	PP	we
identified	VBD	identify
a	DT	a
measurable	JJ	measurable
benefit	NN	benefit
of	IN	of
incorporating	VBG	incorporate
a	DT	a
chest	NN	chest
CT	NP	CT
into	IN	into
the	DT	the
urgent	JJ	urgent
imaging	NN	imaging
protocol	NN	protocol
of	IN	of
acute	JJ	acute
stroke	NN	stroke
patients	NNS	patient
in	IN	in
reducing	VBG	reduce
exposure	NN	exposure
of	IN	of
medical	JJ	medical
professionals	NNS	professional
without	IN	without
appropriate	JJ	appropriate
precautions	NNS	precaution
.	SENT	.
The	DT	the
clinical	JJ	clinical
impact	NN	impact
of	IN	of
this	DT	this
benefit	NN	benefit
,	,	,
however	RB	however
,	,	,
may	MD	may
not	RB	not
be	VB	be
materially	RB	materially
significant	JJ	significant
.	SENT	.
34142877/	CD	@card@
Switching	NP	Switching
from	IN	from
face-to-face	RB	face-to-face
to	TO	to
an	DT	an
online	JJ	online
teaching	NN	teaching
strategy	NN	strategy
:	:	:
how	WRB	how
anatomy	NN	anatomy
and	CC	and
physiology	NN	physiology
teaching	NN	teaching
transformed	VBD	transform
post-COVID-19	NN	<unknown>
for	IN	for
a	DT	a
university	NN	university
preprofessional	JJ	preprofessional
program	NN	program
The	DT	the
College	NP	College
of	IN	of
Science	NP	Science
and	CC	and
Health	NP	Health
Professions	NNS	profession
offers	VBZ	offer
a	DT	a
university	NN	university
preprofessional	JJ	preprofessional
program	NN	program
.	SENT	.
Like	IN	like
most	JJS	most
medical	JJ	medical
schools	NNS	school
in	IN	in
Saudi	NP	Saudi
Arabia	NP	Arabia
,	,	,
the	DT	the
teaching	NN	teaching
delivery	NN	delivery
strategy	NN	strategy
in	IN	in
the	DT	the
university	NN	university
preprofessional	JJ	preprofessional
program	NN	program
is	VBZ	be
on	IN	on
campus	NN	campus
and	CC	and
face-to-face	JJ	face-to-face
.	SENT	.
During	IN	during
the	DT	the
month	NN	month
of	IN	of
March	NP	March
2020	CD	@card@
,	,	,
teaching	VBG	teach
activities	NNS	activity
of	IN	of
the	DT	the
spring	NN	spring
semester	NN	semester
were	VBD	be
proceeding	VBG	proceed
as	RB	as
normal	JJ	normal
;	:	;
however	RB	however
,	,	,
the	DT	the
sudden	JJ	sudden
emergence	NN	emergence
of	IN	of
COVID-19	NP	<unknown>
disturbed	VBD	disturb
routine	JJ	routine
activities	NNS	activity
and	CC	and
compelled	VBN	compel
authorities	NNS	authority
to	TO	to
switch	VB	switch
all	DT	all
teaching	NN	teaching
activities	NNS	activity
from	IN	from
face-to-face	JJ	face-to-face
to	TO	to
online	JJ	online
.	SENT	.
Training	NN	training
sessions	NNS	session
and	CC	and
workshops	NNS	workshop
for	IN	for
all	DT	all
stakeholders	NNS	stakeholder
on	IN	on
online	JJ	online
delivery	NN	delivery
methods	NNS	method
were	VBD	be
arranged	VBN	arrange
.	SENT	.
Blackboard	NN	blackboard
and	CC	and
other	JJ	other
online	JJ	online
facilities	NNS	facility
were	VBD	be
utilized	VBN	utilize
.	SENT	.
All	DT	all
teaching	NN	teaching
materials	NNS	material
,	,	,
including	VBG	include
newly	RB	newly
made	VBN	make
video	JJ	video
clips	NNS	clip
for	IN	for
anatomy	NN	anatomy
and	CC	and
physiology	NN	physiology
practicals	NNS	practical
,	,	,
were	VBD	be
uploaded	VBN	upload
on	IN	on
Blackboard	NN	blackboard
and	CC	and
discussed	VBD	discuss
online	JJ	online
with	IN	with
students	NNS	student
.	SENT	.
Students	NNS	student
'	POS	'
anxiety	NN	anxiety
related	VBN	relate
to	TO	to
the	DT	the
exam	NN	exam
was	VBD	be
reassured	VBN	reassure
by	IN	by
giving	VBG	give
them	PP	them
the	DT	the
option	NN	option
of	IN	of
open	JJ	open
book	NN	book
quizzes	NNS	quiz
during	IN	during
summative	JJ	<unknown>
continuous	JJ	continuous
assessment	NN	assessment
.	SENT	.
All	DT	all
scheduled	VBN	schedule
teaching	NN	teaching
sessions	NNS	session
,	,	,
lectures	NNS	lecture
,	,	,
and	CC	and
practicals	NNS	practical
were	VBD	be
conducted	VBN	conduct
proficiently	RB	proficiently
.	SENT	.
Revision	NN	revision
sessions	NNS	session
and	CC	and
assessment	NN	assessment
quizzes	NNS	quiz
were	VBD	be
conducted	VBN	conduct
with	IN	with
students	NNS	student
'	POS	'
satisfaction	NN	satisfaction
.	SENT	.
At	IN	at
the	DT	the
end	NN	end
of	IN	of
the	DT	the
semester	NN	semester
,	,	,
a	DT	a
final	JJ	final
exam	NN	exam
was	VBD	be
conducted	VBN	conduct
online	JJ	online
as	IN	as
an	DT	an
open	JJ	open
book	NN	book
exam	NN	exam
.	SENT	.
Students	NNS	student
with	IN	with
technical	JJ	technical
issues	NNS	issue
while	IN	while
attempting	VBG	attempt
the	DT	the
exam	NN	exam
were	VBD	be
given	VBN	give
an	DT	an
opportunity	NN	opportunity
to	TO	to
make	VB	make
up	RP	up
for	IN	for
it	PP	it
.	SENT	.
After	IN	after
a	DT	a
successful	JJ	successful
final	JJ	final
exam	NN	exam
,	,	,
the	DT	the
cumulative	JJ	cumulative
block	NN	block
grades	NNS	grade
showed	VBD	show
students	NNS	student
secured	VBD	secure
higher	JJR	high
grades	NNS	grade
in	IN	in
the	DT	the
open	JJ	open
book	NN	book
exam	NN	exam
.	SENT	.
Following	VBG	follow
that	IN	that
,	,	,
the	DT	the
King	NP	King
Saud	NP	Saud
bin	NN	bin
Abdulaziz	NP	Abdulaziz
University	NP	University
for	IN	for
Health	NP	Health
Sciences	NPS	Sciences
has	VBZ	have
managed	VBN	manage
to	TO	to
conduct	VB	conduct
on-campus	NP	on-campus
close	JJ	close
book	NN	book
exams	NNS	exam
that	WDT	that
abide	VBP	abide
by	IN	by
self-distancing	NN	self-distancing
and	CC	and
standard	JJ	standard
operating	VBG	operate
procedure	NN	procedure
policies	NNS	policy
.	SENT	.
34795818/	CD	@card@
Frequency	NN	frequency
and	CC	and
factors	NNS	factor
associated	VBN	associate
with	IN	with
proteinuria	NN	proteinuria
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
:	:	:
a	DT	a
cross-sectional	JJ	cross-sectional
study	NN	study
Proteinuria	NN	proteinuria
is	VBZ	be
a	DT	a
marker	NN	marker
of	IN	of
severity	NN	severity
and	CC	and
poor	JJ	poor
outcome	NN	outcome
of	IN	of
patients	NNS	patient
in	IN	in
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
determine	VB	determine
the	DT	the
frequency	NN	frequency
of	IN	of
proteinuria	NN	proteinuria
and	CC	and
the	DT	the
risk	NN	risk
factors	NNS	factor
associated	VBN	associate
with	IN	with
proteinuria	NN	proteinuria
in	IN	in
Congolese	JJ	Congolese
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
The	DT	the
present	JJ	present
cross	NN	cross
sectional	JJ	sectional
study	NN	study
of	IN	of
proteinuria	NN	proteinuria
status	NN	status
is	VBZ	be
a	DT	a
post	NN	post
hoc	FW	hoc
analysis	NN	analysis
of	IN	of
data	NNS	datum
from	IN	from
80	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
admitted	VBN	admit
at	IN	at
Kinshasa	NP	Kinshasa
Medical	NP	Medical
Center	NP	Center
(	(	(
KMC	NP	KMC
)	)	)
from	IN	from
March	NP	March
10th	JJ	10th
to	TO	to
July	NP	July
10th	JJ	10th
,	,	,
2020	CD	@card@
.	SENT	.
The	DT	the
population	NN	population
under	IN	under
study	NN	study
came	VBD	come
from	IN	from
all	DT	all
adult	JJ	adult
inpatients	NNS	inpatient
(	(	(
&gt	NP	<unknown>
;	:	;
=18	JJ	=@card@
years	NNS	year
old	JJ	old
)	)	)
with	IN	with
a	DT	a
laboratory	NN	laboratory
diagnosis	NN	diagnosis
by	IN	by
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
of	IN	of
COVID-19	NP	<unknown>
were	VBD	be
selected	VBN	select
and	CC	and
divided	VBN	divide
into	IN	into
two	CD	two
groups	NNS	group
(	(	(
positive	JJ	positive
proteinuria	NN	proteinuria
and	CC	and
negative	JJ	negative
proteinuria	NN	proteinuria
group	NN	group
)	)	)
.	SENT	.
Logistic	JJ	logistic
regression	NN	regression
models	NNS	model
helped	VBD	help
to	TO	to
identify	VB	identify
the	DT	the
factors	NNS	factor
associated	VBN	associate
with	IN	with
proteinuria	NN	proteinuria
.	SENT	.
The	DT	the
P	NN	P
value	NN	value
significance	NN	significance
level	NN	level
was	VBD	be
0.05	CD	@card@
.	SENT	.
Among	IN	among
80	CD	@card@
patients	NNS	patient
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
SARS-CoV-2	NP	<unknown>
RT-PCR	NP	<unknown>
,	,	,
55	CD	@card@
%	NN	%
had	VBD	have
proteinuria	NN	proteinuria
.	SENT	.
The	DT	the
mean	JJ	mean
age	NN	age
was	VBD	be
55.2	CD	@card@
+-	NN	<unknown>
12.8	CD	@card@
years	NNS	year
.	SENT	.
Fourty-seven	JJ	<unknown>
patients	NNS	patient
(	(	(
58.8	CD	@card@
%	NN	%
)	)	)
had	VBD	have
history	NN	history
of	IN	of
hypertension	NN	hypertension
and	CC	and
26	CD	@card@
patients	NNS	patient
(	(	(
32.5	CD	@card@
%	NN	%
)	)	)
diabetes	NN	diabetes
.	SENT	.
Multivariable	JJ	Multivariable
analysis	NN	analysis
showed	VBD	show
age	NN	age
&gt	NN	&gt
;	:	;
=	SYM	=
65	CD	@card@
years	NNS	year
(	(	(
aOR	NN	aOR
5,04	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
1.51-16.78	LS	@card@
)	)	)
,	,	,
diabetes	NN	diabetes
(	(	(
aOR	NN	aOR
3,15	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
1.14-8.72	LS	@card@
)	)	)
,	,	,
ASAT	NP	ASAT
&gt	NP	<unknown>
;	:	;
40	CD	@card@
UI/L	NN	<unknown>
(	(	(
aOR	NN	aOR
7,08	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
2.40-20.87	LS	@card@
)	)	)
,	,	,
ferritin	NN	ferritin
&gt	NN	&gt
;	:	;
300	CD	@card@
(	(	(
aOR	NN	aOR
13,47	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
1.56-26.25	LS	@card@
)	)	)
as	IN	as
factors	NNS	factor
independently	RB	independently
associated	VBN	associate
with	IN	with
proteinuria	NN	proteinuria
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
Proteinuria	NN	proteinuria
is	VBZ	be
common	JJ	common
in	IN	in
Congolese	JJ	Congolese
COVID-19	NP	<unknown>
patients	NNS	patient
and	CC	and
is	VBZ	be
associated	VBN	associate
with	IN	with
age	NN	age
,	,	,
diabetes	NN	diabetes
,	,	,
ferritin	NN	ferritin
and	CC	and
aspartate	NN	<unknown>
aminotransferase	NN	aminotransferase
(	(	(
ASAT	NP	ASAT
)	)	)
.	SENT	.
35272613/	CD	@card@
xsGastrointestinal	JJ	xsGastrointestinal
symptoms	NNS	symptom
are	VBP	be
associated	VBN	associate
with	IN	with
a	DT	a
lower	JJR	low
risk	NN	risk
of	IN	of
hospitalization	NN	hospitalization
and	CC	and
mortality	NN	mortality
and	CC	and
Outcomes	NNS	outcome
in	IN	in
COVID-19	NP	<unknown>
We	PP	we
aimed	VBD	aim
to	TO	to
find	VB	find
the	DT	the
association	NN	association
between	IN	between
gastrointestinal	JJ	gastrointestinal
(	(	(
GI	NP	GI
)	)	)
and	CC	and
respiratory	JJ	respiratory
symptoms	NNS	symptom
with	IN	with
mortality	NN	mortality
and	CC	and
hospitalization	NN	hospitalization
among	IN	among
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
We	PP	we
analyzed	VBD	analyze
the	DT	the
registered	JJ	registered
data	NNS	datum
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
from	IN	from
February	NP	February
20	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
to	TO	to
March	NP	March
10	CD	@card@
,	,	,
2021	CD	@card@
.	SENT	.
Depending	VBG	depend
on	IN	on
the	DT	the
patients	NNS	patient
'	POS	'
disease	NN	disease
symptoms	NNS	symptom
,	,	,
four	CD	four
categories	NNS	category
were	VBD	be
defined	VBN	define
:	:	:
patients	NNS	patient
with	IN	with
only	JJ	only
GI	JJ	GI
symptoms	NNS	symptom
,	,	,
patients	NNS	patient
with	IN	with
only	JJ	only
respiratory	JJ	respiratory
symptoms	NNS	symptom
,	,	,
patients	NNS	patient
with	IN	with
both	DT	both
symptoms	NNS	symptom
,	,	,
and	CC	and
patients	NNS	patient
with	IN	with
other	JJ	other
symptoms	NNS	symptom
.	SENT	.
Logistic	JJ	logistic
regression	NN	regression
analysis	NN	analysis
was	VBD	be
used	VBN	use
to	TO	to
assess	VB	assess
the	DT	the
association	NN	association
of	IN	of
groups	NNS	group
with	IN	with
outcomes	NNS	outcome
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
42,964	CD	@card@
patients	NNS	patient
from	IN	from
23	CD	@card@
hospitals	NNS	hospital
were	VBD	be
included	VBN	include
,	,	,
of	IN	of
which	WDT	which
26.5	CD	@card@
%	NN	%
patients	NNS	patient
had	VBD	have
at	IN	at
least	JJS	least
one	CD	one
or	CC	or
more	JJR	more
GI	JJ	GI
symptoms	NNS	symptom
.	SENT	.
Of	IN	of
total	JJ	total
patients	NNS	patient
,	,	,
51.58	CD	@card@
%	NN	%
patients	NNS	patient
were	VBD	be
hospitalized	VBN	hospitalize
among	IN	among
which	WDT	which
22.8	CD	@card@
%	NN	%
had	VBN	have
at	IN	at
least	JJS	least
one	CD	one
or	CC	or
more	JJR	more
GI	JJ	GI
symptoms	NNS	symptom
.	SENT	.
GI	NP	GI
symptoms	NNS	symptom
significantly	RB	significantly
decreased	VBD	decrease
the	DT	the
odds	NNS	odd
of	IN	of
mortality	NN	mortality
(	(	(
OR	CC	or
0.72	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.56-0.92	CD	@card@
)	)	)
,	,	,
but	CC	but
respiratory	JJ	respiratory
symptoms	NNS	symptom
increased	VBD	increase
the	DT	the
odds	NNS	odd
for	IN	for
mortality	NN	mortality
(	(	(
1.36	CD	@card@
:	:	:
1.24-1.50	LS	@card@
)	)	)
,	,	,
compared	VBN	compare
with	IN	with
patients	NNS	patient
with	IN	with
other	JJ	other
symptoms	NNS	symptom
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
odds	NNS	odd
ratio	NN	ratio
of	IN	of
patients	NNS	patient
who	WP	who
had	VBD	have
both	DT	both
respiratory	JJ	respiratory
and	CC	and
GI	JJ	GI
symptoms	NNS	symptom
increased	VBN	increase
(	(	(
1.52	LS	@card@
:	:	:
1.31-1.78	LS	@card@
)	)	)
compared	VBN	compare
with	IN	with
patients	NNS	patient
with	IN	with
other	JJ	other
symptoms	NNS	symptom
.	SENT	.
The	DT	the
same	JJ	same
results	NNS	result
were	VBD	be
observed	VBN	observe
for	IN	for
hospitalization	NN	hospitalization
as	IN	as
the	DT	the
outcome	NN	outcome
.	SENT	.
Our	PP$	our
study	NN	study
showed	VBD	show
that	IN	that
the	DT	the
presence	NN	presence
of	IN	of
GI	JJ	GI
symptoms	NNS	symptom
in	IN	in
COVID-19	NP	<unknown>
at	IN	at
the	DT	the
time	NN	time
of	IN	of
admission	NN	admission
was	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
lower	JJR	low
odds	NNS	odd
of	IN	of
hospitalization	NN	hospitalization
and	CC	and
mortality	NN	mortality
;	:	;
however	RB	however
,	,	,
this	DT	this
association	NN	association
had	VBD	have
higher	JJR	high
odds	NNS	odd
for	IN	for
respiratory	JJ	respiratory
symptoms	NNS	symptom
.	SENT	.
32463093/	CD	@card@
COVID-19	NP	<unknown>
Immunity	NN	immunity
Passport	NN	passport
to	TO	to
Ease	VB	ease
Travel	NP	Travel
Restrictions	NNS	restriction
?	SENT	?
33190222/	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
intensive	JJ	intensive
care	NN	care
develop	VB	develop
predominantly	RB	predominantly
oliguric	JJ	<unknown>
acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
Acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
(	(	(
AKI	NP	Aki
)	)	)
is	VBZ	be
a	DT	a
syndrome	NN	syndrome
of	IN	of
reduced	VBN	reduce
glomerular	JJ	glomerular
filtration	NN	filtration
rate	NN	rate
and/or	CC	and/or
reduced	VBN	reduce
urine	NN	urine
flow	NN	flow
associated	VBN	associate
with	IN	with
mortality	NN	mortality
in	IN	in
corona	NN	corona
virus	NN	virus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
AKI	NP	Aki
is	VBZ	be
often	RB	often
associated	VBN	associate
with	IN	with
renal	JJ	renal
tissue	NN	tissue
damage	NN	damage
,	,	,
which	WDT	which
may	MD	may
lead	VB	lead
to	TO	to
chronic	JJ	chronic
kidney	NN	kidney
disease	NN	disease
.	SENT	.
Biomarkers	NNS	Biomarker
of	IN	of
tissue	NN	tissue
damage	NN	damage
may	MD	may
identify	VB	identify
patients	NNS	patient
of	IN	of
particular	JJ	particular
risk	NN	risk
.	SENT	.
In	IN	in
a	DT	a
prospective	JJ	prospective
observational	JJ	observational
study	NN	study
of	IN	of
57	CD	@card@
patients	NNS	patient
admitted	VBN	admit
to	TO	to
intensive	JJ	intensive
care	NN	care
,	,	,
AKI	NP	Aki
incidence	NN	incidence
and	CC	and
characteristics	NNS	characteristic
was	VBD	be
evaluated	VBN	evaluate
according	VBG	accord
to	TO	to
KDIGO	NP	<unknown>
criteria	NNS	criterion
and	CC	and
related	VBN	relate
to	TO	to
days	NNS	day
after	IN	after
admission	NN	admission
.	SENT	.
Urinary	JJ	urinary
albumin	NN	albumin
,	,	,
Neutrophil	JJ	neutrophil
Gelatinase-Associated	NP	Gelatinase-Associated
Lipocalin	NP	Lipocalin
(	(	(
NGAL	NP	<unknown>
)	)	)
,	,	,
Kidney	NP	Kidney
Injury	NP	Injury
Molecule	NN	molecule
1	CD	@card@
(	(	(
KIM-1	NP	<unknown>
)	)	)
and	CC	and
Plasma	NN	plasma
Tissue	NN	tissue
Inhibitor	NN	inhibitor
of	IN	of
MetalloProteinase	NP	<unknown>
2	CD	@card@
(	(	(
TIMP-2	NP	<unknown>
)	)	)
were	VBD	be
analysed	VBN	analyse
in	IN	in
52	CD	@card@
patients	NNS	patient
at	IN	at
admission	NN	admission
.	SENT	.
The	DT	the
majority	NN	majority
(	(	(
n	NN	n
=	SYM	=
51	CD	@card@
,	,	,
89	CD	@card@
%	NN	%
)	)	)
of	IN	of
patients	NNS	patient
developed	VBN	develop
AKI	NP	Aki
,	,	,
and	CC	and
27	CD	@card@
(	(	(
47	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
had	VBD	have
predominantly	RB	predominantly
oliguric	JJ	<unknown>
AKI	NP	Aki
where	WRB	where
oliguria	NN	oliguria
was	VBD	be
more	RBR	more
severe	JJ	severe
than	IN	than
plasma	NN	plasma
Creatinine	NN	creatinine
increase	NN	increase
.	SENT	.
Severe	JJ	severe
oliguria	NN	oliguria
within	IN	within
first	JJ	first
2	CD	@card@
days	NNS	day
after	IN	after
admission	NN	admission
was	VBD	be
common	JJ	common
(	(	(
n	NN	n
=	SYM	=
37	CD	@card@
,	,	,
65	CD	@card@
%	NN	%
)	)	)
,	,	,
whereas	IN	whereas
stage	NN	stage
2	CD	@card@
and	CC	and
3	CD	@card@
AKI	NP	Aki
due	JJ	due
to	TO	to
Creatinine	NN	creatinine
occurred	VBD	occur
later	RBR	later
than	IN	than
day	NN	day
2	CD	@card@
in	IN	in
67	CD	@card@
%	NN	%
(	(	(
12/18	CD	@card@
)	)	)
of	IN	of
cases	NNS	case
.	SENT	.
Renal	JJ	renal
replacement	NN	replacement
therapy	NN	therapy
was	VBD	be
started	VBN	start
in	IN	in
9	CD	@card@
(	(	(
16	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
,	,	,
and	CC	and
30-day	JJ	30-day
mortality	NN	mortality
was	VBD	be
28	CD	@card@
%	NN	%
.	SENT	.
Urinary	JJ	urinary
biomarkers	NNS	biomarker
were	VBD	be
increased	VBN	increase
in	IN	in
a	DT	a
majority	NN	majority
of	IN	of
patients	NNS	patient
,	,	,
but	CC	but
did	VBD	do
not	RB	not
robustly	RB	robustly
predict	VB	predict
KDIGO	NP	<unknown>
stage	NN	stage
.	SENT	.
Most	JJS	most
patients	NNS	patient
had	VBD	have
microalbuminuria	NN	microalbuminuria
,	,	,
and	CC	and
severe	JJ	severe
albuminuria	NN	albuminuria
(	(	(
albumin	NN	albumin
Creatinine	NN	creatinine
ratio	NN	ratio
&gt	NN	&gt
;	:	;
30	CD	@card@
mg/mmol	NN	<unknown>
)	)	)
was	VBD	be
found	VBN	find
in	IN	in
n	NN	n
=	SYM	=
9	CD	@card@
(	(	(
17	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
.	SENT	.
A	DT	a
majority	NN	majority
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
admitted	VBD	admit
to	TO	to
the	DT	the
ICU	NP	ICU
develop	VB	develop
AKI	NP	Aki
.	SENT	.
The	DT	the
functional	JJ	functional
deficit	NN	deficit
is	VBZ	be
often	RB	often
low	JJ	low
urinary	JJ	urinary
volume	NN	volume
,	,	,
and	CC	and
initial	JJ	initial
levels	NNS	level
of	IN	of
biomarkers	NNS	biomarker
are	VBP	be
generally	RB	generally
increased	VBN	increase
without	IN	without
clear	JJ	clear
relation	NN	relation
to	TO	to
final	JJ	final
AKI	NP	Aki
stage	NN	stage
.	SENT	.
32997560/	CD	@card@
Detection	NN	detection
Methods	NNS	method
of	IN	of
COVID-19	NP	<unknown>
Since	IN	since
being	VBG	be
first	RB	first
detected	VBN	detect
in	IN	in
China	NP	China
,	,	,
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
spread	VBN	spread
rapidly	RB	rapidly
across	IN	across
the	DT	the
world	NN	world
,	,	,
triggering	VBG	trigger
a	DT	a
global	JJ	global
pandemic	NN	pandemic
with	IN	with
no	DT	no
viable	JJ	viable
cure	NN	cure
in	IN	in
sight	NN	sight
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
national	JJ	national
responses	NNS	response
have	VBP	have
focused	VBN	focus
on	IN	on
the	DT	the
effective	JJ	effective
minimization	NN	minimization
of	IN	of
the	DT	the
spread	NN	spread
.	SENT	.
Border	NN	border
control	NN	control
measures	NNS	measure
and	CC	and
travel	NN	travel
restrictions	NNS	restriction
have	VBP	have
been	VBN	be
implemented	VBN	implement
in	IN	in
a	DT	a
number	NN	number
of	IN	of
countries	NNS	country
to	TO	to
limit	VB	limit
the	DT	the
import	NN	import
and	CC	and
export	NN	export
of	IN	of
the	DT	the
virus	NN	virus
.	SENT	.
The	DT	the
detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
a	DT	a
key	JJ	key
task	NN	task
for	IN	for
physicians	NNS	physician
.	SENT	.
The	DT	the
erroneous	JJ	erroneous
results	NNS	result
of	IN	of
early	JJ	early
laboratory	NN	laboratory
tests	NNS	test
and	CC	and
their	PP$	their
delays	NNS	delay
led	VBD	lead
researchers	NNS	researcher
to	TO	to
focus	VB	focus
on	IN	on
different	JJ	different
options	NNS	option
.	SENT	.
Information	NN	information
obtained	VBD	obtain
from	IN	from
computed	VBN	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
and	CC	and
radiological	JJ	radiological
images	NNS	image
is	VBZ	be
important	JJ	important
for	IN	for
clinical	JJ	clinical
diagnosis	NN	diagnosis
.	SENT	.
Therefore	RB	therefore
,	,	,
it	PP	it
is	VBZ	be
worth	JJ	worth
developing	VBG	develop
a	DT	a
rapid	JJ	rapid
method	NN	method
of	IN	of
detection	NN	detection
of	IN	of
viral	JJ	viral
diseases	NNS	disease
through	IN	through
the	DT	the
analysis	NN	analysis
of	IN	of
radiographic	JJ	radiographic
images	NNS	image
.	SENT	.
We	PP	we
propose	VBP	propose
a	DT	a
novel	JJ	novel
method	NN	method
of	IN	of
detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
purpose	NN	purpose
is	VBZ	be
to	TO	to
provide	VB	provide
clinical	JJ	clinical
decision	NN	decision
support	NN	support
to	TO	to
healthcare	NN	<unknown>
workers	NNS	worker
and	CC	and
researchers	NNS	researcher
.	SENT	.
The	DT	the
article	NN	article
is	VBZ	be
to	TO	to
support	VB	support
researchers	NNS	researcher
working	VBG	work
on	IN	on
early	JJ	early
detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
as	RB	as
well	RB	well
as	IN	as
similar	JJ	similar
viral	JJ	viral
diseases	NNS	disease
.	SENT	.
35421155/	CD	@card@
Fear	NN	fear
of	IN	of
an	DT	an
unprecedented	JJ	unprecedented
,	,	,
invisible	JJ	invisible
enemy	NN	enemy
:	:	:
Difficulties	NNS	difficulty
experienced	VBN	experience
in	IN	in
establishing	VBG	establish
criteria	NNS	criterion
for	IN	for
the	DT	the
release	NN	release
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
from	IN	from
isolation	NN	isolation
in	IN	in
a	DT	a
Japanese	JJ	Japanese
University	NP	University
Hospital	NP	Hospital
The	DT	the
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
emerged	VBN	emerge
as	IN	as
a	DT	a
global	JJ	global
pandemic	NN	pandemic
,	,	,
and	CC	and
the	DT	the
United	NP	United
States	NPS	States
and	CC	and
European	NP	European
authorities	NNS	authority
established	VBD	establish
criteria	NNS	criterion
for	IN	for
the	DT	the
release	NN	release
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
from	IN	from
isolation	NN	isolation
in	IN	in
October	NP	October
2020	CD	@card@
.	SENT	.
However	RB	however
,	,	,
a	DT	a
huge	JJ	huge
discrepancy	NN	discrepancy
exists	VBZ	exist
between	IN	between
the	DT	the
hospital-discharge	JJ	<unknown>
protocol	NN	protocol
for	IN	for
COVID-19	NP	<unknown>
patients	NNS	patient
and	CC	and
the	DT	the
release	NN	release
of	IN	of
patients	NNS	patient
from	IN	from
in-hospital	JJ	in-hospital
isolation	NN	isolation
.	SENT	.
Our	PP$	our
initially	RB	initially
proposed	VBN	propose
criteria	NNS	criterion
for	IN	for
in-hospital	JJ	in-hospital
release	NN	release
from	IN	from
isolation	NN	isolation
was	VBD	be
not	RB	not
adhered	VBN	adhere
to	TO	to
by	IN	by
healthcare	NN	<unknown>
workers	NNS	worker
(	(	(
HCWs	JJ	<unknown>
)	)	)
due	JJ	due
to	TO	to
prevailing	JJ	prevailing
concerns	NNS	concern
regarding	VBG	regard
disease	NN	disease
infectivity	NN	infectivity
.	SENT	.
Herein	RB	herein
,	,	,
we	PP	we
report	VBP	report
difficulties	NNS	difficulty
encountered	VBN	encounter
in	IN	in
attempting	VBG	attempt
to	TO	to
establish	VB	establish
a	DT	a
common	JJ	common
understanding	NN	understanding
of	IN	of
the	DT	the
management	NN	management
of	IN	of
emerging	VBG	emerge
infections	NNS	infection
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
Google	NP	<unknown>
Form-based	JJ	<unknown>
questionnaire	NN	questionnaire
survey	NN	survey
targeting	VBG	target
HCWs	NP	<unknown>
from	IN	from
Okayama	NP	Okayama
University	NP	University
Hospital	NP	Hospital
,	,	,
Japan	NP	Japan
,	,	,
via	IN	via
e-mail	NP	<unknown>
on	IN	on
January	NP	January
21-28	CD	@card@
,	,	,
2021	CD	@card@
.	SENT	.
The	DT	the
anonymous	JJ	anonymous
investigation	NN	investigation
required	VBD	require
respondents	NNS	respondent
to	TO	to
provide	VB	provide
information	NN	information
regarding	VBG	regard
their	PP$	their
background	NN	background
as	RB	as
well	RB	well
as	IN	as
perceptions	NNS	perception
regarding	VBG	regard
the	DT	the
requirement	NN	requirement
,	,	,
level	NN	level
of	IN	of
understanding	NN	understanding
,	,	,
and	CC	and
readiness	NN	readiness
for	IN	for
developing	VBG	develop
release	NN	release
criteria	NNS	criterion
.	SENT	.
We	PP	we
obtained	VBD	obtain
150	CD	@card@
eligible	JJ	eligible
responses	NNS	response
,	,	,
including	VBG	include
57	CD	@card@
(	(	(
38.0	CD	@card@
%	NN	%
)	)	)
from	IN	from
medical	JJ	medical
doctors	NNS	doctor
and	CC	and
53	CD	@card@
(	(	(
35.3	CD	@card@
%	NN	%
)	)	)
from	IN	from
nurses	NNS	nurse
.	SENT	.
Most	JJS	most
HCWs	NNS	<unknown>
managing	VBG	manage
COVID-19	NP	<unknown>
patients	NNS	patient
advocated	VBN	advocate
for	IN	for
the	DT	the
implementation	NN	implementation
of	IN	of
the	DT	the
criteria	NNS	criterion
,	,	,
whereas	IN	whereas
those	DT	those
not	RB	not
working	VBG	work
in	IN	in
that	DT	that
capacity	NN	capacity
did	VBD	do
not	RB	not
(	(	(
p&lt	VB	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Over	IN	over
half	NN	half
of	IN	of
the	DT	the
HCWs	JJ	<unknown>
indicated	JJ	indicated
discomfort	NN	discomfort
at	IN	at
seeing	VBG	see
COVID-19	NP	<unknown>
patients	NNS	patient
transitioning	VBG	<unknown>
to	TO	to
general	JJ	general
management	NN	management
even	RB	even
after	IN	after
meeting	VBG	meet
the	DT	the
criteria	NNS	criterion
.	SENT	.
It	PP	it
was	VBD	be
challenging	VBG	challenge
to	TO	to
establish	VB	establish
a	DT	a
common	JJ	common
understanding	NN	understanding
regarding	VBG	regard
the	DT	the
ideal	JJ	ideal
criteria	NNS	criterion
for	IN	for
in-hospital	JJ	in-hospital
release	NN	release
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
from	IN	from
isolation	NN	isolation
in	IN	in
our	PP$	our
hospital	NN	hospital
.	SENT	.
The	DT	the
dissemination	NN	dissemination
of	IN	of
our	PP$	our
experiences	NNS	experience
and	CC	and
multifaceted	JJ	multifaceted
discussions	NNS	discussion
with	IN	with
HCWs	NNS	<unknown>
would	MD	would
be	VB	be
of	IN	of
great	JJ	great
value	NN	value
as	IN	as
a	DT	a
countermeasure	NN	countermeasure
against	IN	against
the	DT	the
emergent	JJ	emergent
pandemic	NN	pandemic
.	SENT	.
33224626/	CD	@card@
CME	NP	CME
in	IN	in
the	DT	the
Time	NP	Time
of	IN	of
COVID-19	NP	<unknown>
:	:	:
Educating	VBG	educate
Healthcare	NP	Healthcare
Professionals	NNS	professional
at	IN	at
the	DT	the
Point-of-care	NN	<unknown>
and	CC	and
Improving	VBG	improve
Performance	NN	performance
Outcomes	NNS	outcome
UpToDate	NN	<unknown>
is	VBZ	be
a	DT	a
point-of-care	NN	<unknown>
clinical	JJ	clinical
resource	NN	resource
used	VBN	use
by	IN	by
nearly	RB	nearly
2	CD	@card@
million	CD	million
clinicians	NNS	clinician
worldwide	RB	worldwide
.	SENT	.
Users	NNS	user
in	IN	in
the	DT	the
USA	NP	USA
and	CC	and
other	JJ	other
regions	NNS	region
can	MD	can
obtain	VB	obtain
continuing	VBG	continue
education	NN	education
credits	NNS	credit
after	IN	after
researching	VBG	research
clinical	JJ	clinical
questions	NNS	question
at	IN	at
the	DT	the
point-of-care	NN	<unknown>
.	SENT	.
As	IN	as
part	NN	part
of	IN	of
the	DT	the
CME	NP	CME
credit	NN	credit
redemption	NN	redemption
process	NN	process
,	,	,
participants	NNS	participant
provide	VBP	provide
feedback	NN	feedback
on	IN	on
the	DT	the
information	NN	information
researched	VBN	research
during	IN	during
the	DT	the
UpToDate	JJ	<unknown>
learning	NN	learning
activity	NN	activity
.	SENT	.
We	PP	we
examined	VBD	examine
the	DT	the
impact	NN	impact
of	IN	of
UpToDate	JJ	<unknown>
searches	NNS	search
on	IN	on
clinical	JJ	clinical
decision-making	NN	decision-making
related	VBN	relate
to	TO	to
COVID-19	NP	<unknown>
.	SENT	.
Between	IN	between
January	NP	January
1	CD	@card@
and	CC	and
31	CD	@card@
August	NP	August
2020	CD	@card@
,	,	,
UpToDate	NP	<unknown>
added	VBD	add
more	JJR	more
than	IN	than
40	CD	@card@
topic	NN	topic
reviews	NNS	review
on	IN	on
various	JJ	various
aspects	NNS	aspect
of	IN	of
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
and	CC	and
management	NN	management
,	,	,
and	CC	and
developed	VBD	develop
new	JJ	new
methods	NNS	method
for	IN	for
delivering	VBG	deliver
COVID-19	NP	<unknown>
content	NN	content
to	TO	to
our	PP$	our
learners	NNS	learner
.	SENT	.
During	IN	during
the	DT	the
observation	NN	observation
period	NN	period
,	,	,
participants	NNS	participant
accessed	VBD	access
COVID-19-related	JJ	COVID-19-related
topic	NN	topic
reviews	NNS	review
over	IN	over
7.5	CD	@card@
million	CD	million
times	NNS	time
.	SENT	.
Data	NNS	datum
collected	VBN	collect
from	IN	from
CME	NP	CME
activity	NN	activity
evaluations	NNS	evaluation
and	CC	and
user	NN	user
feedback	NN	feedback
suggested	VBD	suggest
that	IN	that
the	DT	the
learning	VBG	learn
activity	NN	activity
had	VBD	have
a	DT	a
significant	JJ	significant
impact	NN	impact
on	IN	on
clinical	JJ	clinical
decision-making	NN	decision-making
.	SENT	.
Over	IN	over
94	CD	@card@
%	NN	%
reported	VBD	report
that	IN	that
they	PP	they
modified	VBD	modify
their	PP$	their
management	NN	management
strategies	NNS	strategy
as	IN	as
a	DT	a
result	NN	result
of	IN	of
using	VBG	use
UpToDate	NN	<unknown>
,	,	,
and	CC	and
97	CD	@card@
%	NN	%
reported	VBD	report
that	DT	that
use	NN	use
of	IN	of
UpToDate	NNS	<unknown>
led	VBN	lead
to	TO	to
improvement	NN	improvement
in	IN	in
care	NN	care
.	SENT	.
These	DT	these
findings	NNS	finding
support	VBP	support
the	DT	the
benefit	NN	benefit
of	IN	of
self-directed	JJ	self-directed
,	,	,
point-of-care	JJ	<unknown>
learning	VBG	learn
activities	NNS	activity
on	IN	on
the	DT	the
clinical	JJ	clinical
management	NN	management
of	IN	of
patients	NNS	patient
during	IN	during
a	DT	a
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
32945597/	CD	@card@
Changes	NP	Changes
in	IN	in
alcohol	NN	alcohol
consumption	NN	consumption
associated	VBN	associate
with	IN	with
social	JJ	social
distancing	NN	distancing
and	CC	and
self-isolation	NN	self-isolation
policies	NNS	policy
triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
in	IN	in
South	NP	South
Australia	NP	Australia
:	:	:
a	DT	a
wastewater	NN	wastewater
analysis	NN	analysis
study	NN	study
To	TO	to
assess	VB	assess
the	DT	the
effects	NNS	effect
of	IN	of
social	JJ	social
distancing	NN	distancing
and	CC	and
social	JJ	social
isolation	NN	isolation
policies	NNS	policy
triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
on	IN	on
alcohol	NN	alcohol
consumption	NN	consumption
using	VBG	use
wastewater	NN	wastewater
analysis	NN	analysis
in	IN	in
Adelaide	NP	Adelaide
,	,	,
South	NP	South
Australia	NP	Australia
.	SENT	.
Longitudinal	JJ	longitudinal
quantitative	JJ	quantitative
analysis	NN	analysis
of	IN	of
influent	JJ	influent
wastewater	NN	wastewater
data	NNS	datum
for	IN	for
alcohol	NN	alcohol
concentration	NN	concentration
.	SENT	.
Adelaide	NP	Adelaide
,	,	,
South	NP	South
Australia	NP	Australia
.	SENT	.
Wastewater	NP	Wastewater
catchment	NN	catchment
area	NN	area
representative	NN	representative
of	IN	of
1.1	CD	@card@
million	CD	million
inhabitants	NNS	inhabitant
.	SENT	.
Twenty-four	NP	Twenty-four
hour	NN	hour
composite	JJ	composite
influent	JJ	influent
wastewater	NN	wastewater
samples	NNS	sample
were	VBD	be
collected	VBN	collect
from	IN	from
four	CD	four
wastewater	NN	wastewater
treatment	NN	treatment
plants	NNS	plant
in	IN	in
Adelaide	NP	Adelaide
,	,	,
South	NP	South
Australia	NP	Australia
for	IN	for
7	CD	@card@
consecutive	JJ	consecutive
days	NNS	day
(	(	(
Wednesday-Tuesday	NP	Wednesday-Tuesday
)	)	)
every	DT	every
2	CD	@card@
months	NNS	month
from	IN	from
April	NP	April
2016-April	NP	2016-April
2020	CD	@card@
.	SENT	.
The	DT	the
alcohol	NN	alcohol
metabolite	NN	metabolite
ethyl	NN	ethyl
sulfate	NN	sulfate
was	VBD	be
measured	VBN	measure
in	IN	in
samples	NNS	sample
using	VBG	use
chromatography-tandem	NN	chromatography-tandem
mass	NN	mass
spectrometry	NN	spectrometry
.	SENT	.
Data	NNS	datum
were	VBD	be
population-weighted	VBN	population-weight
adjusted	VBN	adjust
with	IN	with
consumption	NN	consumption
expressed	VBN	express
as	IN	as
standard	JJ	standard
drinks/day/1000	NN	<unknown>
people	NNS	people
.	SENT	.
Weekly	JJ	weekly
consumption	NN	consumption
and	CC	and
weekend	NN	weekend
to	TO	to
mid-week	NN	mid-week
consumption	NN	consumption
ratios	NNS	ratio
were	VBD	be
analysed	VBN	analyse
to	TO	to
identify	VB	identify
changes	NNS	change
in	IN	in
weekday	NN	weekday
alcohol	NN	alcohol
use	NN	use
pattern	NN	pattern
.	SENT	.
Estimated	JJ	estimated
weekend	NN	weekend
alcohol	NN	alcohol
consumption	NN	consumption
was	VBD	be
significantly	RB	significantly
lower	JJR	low
(	(	(
698	CD	@card@
standard	JJ	standard
drinks/day/1000	NN	<unknown>
people	NNS	people
)	)	)
after	IN	after
self-isolation	NN	self-isolation
measures	NNS	measure
were	VBD	be
enforced	VBN	enforce
in	IN	in
April	NP	April
2020	CD	@card@
compared	VBN	compare
with	IN	with
the	DT	the
preceding	JJ	preceding
sampling	NN	sampling
period	NN	period
in	IN	in
February	NP	February
2020	CD	@card@
(	(	(
1047	CD	@card@
standard	JJ	standard
drinks/day/1000	NN	<unknown>
people	NNS	people
)	)	)
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.05	CD	@card@
.	SENT	.
Weekend	NN	weekend
to	TO	to
midweek	JJ	midweek
consumption	NN	consumption
ratio	NN	ratio
was	VBD	be
12	CD	@card@
%	NN	%
lower	JJR	low
than	IN	than
the	DT	the
average	JJ	average
ratio	NN	ratio
compared	VBN	compare
with	IN	with
all	DT	all
previous	JJ	previous
sampling	NN	sampling
periods	NNS	period
.	SENT	.
April	NP	April
2020	CD	@card@
recorded	VBD	record
the	DT	the
lowest	JJS	low
alcohol	NN	alcohol
consumption	NN	consumption
relative	JJ	relative
to	TO	to
April	NP	April
in	IN	in
previous	JJ	previous
years	NNS	year
,	,	,
dating	VBG	date
back	RB	back
to	TO	to
2016	CD	@card@
.	SENT	.
Wastewater	NN	wastewater
analysis	NN	analysis
suggests	VBZ	suggest
that	DT	that
introduction	NN	introduction
of	IN	of
social	JJ	social
distancing	NN	distancing
and	CC	and
isolation	NN	isolation
policies	NNS	policy
triggered	VBN	trigger
by	IN	by
COVID-19	NP	<unknown>
in	IN	in
Adelaide	NP	Adelaide
,	,	,
South	NP	South
Australia	NP	Australia
,	,	,
was	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
decrease	NN	decrease
in	IN	in
population-level	JJ	population-level
weekend	NN	weekend
alcohol	NN	alcohol
consumption	NN	consumption
.	SENT	.
32988978/	CD	@card@
Takotsubo	NP	<unknown>
cardiomyopathy	NN	<unknown>
in	IN	in
early	JJ	early
term	NN	term
pregnancy	NN	pregnancy
:	:	:
a	DT	a
rare	JJ	rare
cardiac	JJ	cardiac
complication	NN	complication
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
34207721/	CD	@card@
Participatory	NN	participatory
Action	NP	Action
Research	NP	Research
on	IN	on
the	DT	the
Impact	NN	impact
of	IN	of
Community	NP	Community
Gardening	NN	gardening
in	IN	in
the	DT	the
Context	NN	context
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
Investigating	VBG	investigate
the	DT	the
Seeding	VBG	seed
Plan	NN	plan
in	IN	in
Shanghai	NP	Shanghai
,	,	,
China	NP	China
This	DT	this
study	NN	study
aims	VBZ	aim
to	TO	to
examine	VB	examine
the	DT	the
impacts	NNS	impact
of	IN	of
community	NN	community
gardening	NN	gardening
on	IN	on
the	DT	the
daily	JJ	daily
life	NN	life
of	IN	of
residents	NNS	resident
and	CC	and
the	DT	the
management	NN	management
organisation	NN	organisation
of	IN	of
pandemic	JJ	pandemic
prevention	NN	prevention
in	IN	in
the	DT	the
context	NN	context
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
a	DT	a
major	JJ	major
public	JJ	public
health	NN	health
scourge	NN	scourge
in	IN	in
2020	CD	@card@
.	SENT	.
The	DT	the
research	NN	research
team	NN	team
applied	VBD	apply
a	DT	a
participatory	NN	participatory
action	NN	action
research	NN	research
approach	NN	approach
to	TO	to
work	VB	work
with	IN	with
residents	NNS	resident
to	TO	to
design	VB	design
and	CC	and
implement	VB	implement
the	DT	the
Seeding	VBG	seed
Plan	NP	Plan
,	,	,
a	DT	a
contactless	JJ	contactless
community	NN	community
gardening	NN	gardening
program	NN	program
.	SENT	.
The	DT	the
authors	NNS	author
carried	VBD	carry
out	RP	out
a	DT	a
study	NN	study
to	TO	to
compare	VB	compare
the	DT	the
everyday	JJ	everyday
conditions	NNS	condition
reflecting	VBG	reflect
residents	NNS	resident
'	POS	'
mental	JJ	mental
health	NN	health
of	IN	of
the	DT	the
three	CD	three
subject	JJ	subject
groups	NNS	group
during	IN	during
the	DT	the
pandemic	NN	pandemic
:	:	:
the	DT	the
participants	NNS	participant
of	IN	of
the	DT	the
Seeding	VBG	seed
Plan	NP	Plan
(	(	(
Group	NP	Group
A	NP	A
)	)	)
,	,	,
the	DT	the
non-participants	NNS	non-participant
living	VBG	live
in	IN	in
the	DT	the
same	JJ	same
communities	NNS	community
that	WDT	that
had	VBD	have
implemented	VBN	implement
the	DT	the
Seeding	VBG	seed
Plan	NP	Plan
(	(	(
Group	NP	Group
B	NP	B
)	)	)
,	,	,
and	CC	and
the	DT	the
non-participants	NNS	non-participant
in	IN	in
other	JJ	other
communities	NNS	community
(	(	(
Group	NP	Group
C	NP	C
)	)	)
.	SENT	.
According	VBG	accord
to	TO	to
the	DT	the
results	NNS	result
,	,	,
group	NN	group
A	NP	A
showed	VBD	show
the	DT	the
best	RBS	well
mental	JJ	mental
health	NN	health
among	IN	among
the	DT	the
three	CD	three
;	:	;
Group	NP	Group
B	NP	B
,	,	,
positively	RB	positively
influenced	VBN	influence
by	IN	by
seeding	VBG	seed
activities	NNS	activity
,	,	,
was	VBD	be
better	JJR	good
than	IN	than
Group	NP	Group
C.	NP	C.
The	DT	the
interview	NN	interview
results	NNS	result
also	RB	also
confirmed	VBD	confirm
that	IN	that
the	DT	the
community	NN	community
connections	NNS	connection
established	VBN	establish
through	IN	through
gardening	NN	gardening
activities	NNS	activity
have	VBP	have
a	DT	a
significant	JJ	significant
impact	NN	impact
on	IN	on
maintaining	VBG	maintain
a	DT	a
positive	JJ	positive
social	JJ	social
mentality	NN	mentality
under	IN	under
extraordinary	JJ	extraordinary
circumstances	NNS	circumstance
.	SENT	.
From	IN	from
this	DT	this
,	,	,
the	DT	the
study	NN	study
concluded	VBD	conclude
that	IN	that
gardening	NN	gardening
activities	NNS	activity
can	MD	can
improve	VB	improve
people	NNS	people
's	POS	's
mental	JJ	mental
health	NN	health
,	,	,
effectively	RB	effectively
resist	VB	resist
negative	JJ	negative
impacts	NNS	impact
,	,	,
and	CC	and
it	PP	it
is	VBZ	be
a	DT	a
convenient	JJ	convenient
tool	NN	tool
with	IN	with
spreading	VBG	spread
influence	NN	influence
on	IN	on
the	DT	the
entire	JJ	entire
community	NN	community
,	,	,
so	RB	so
as	RB	as
to	TO	to
support	VB	support
the	DT	the
collective	JJ	collective
response	NN	response
to	TO	to
public	JJ	public
health	NN	health
emergencies	NNS	emergency
in	IN	in
a	DT	a
bottom-up	JJ	bottom-up
direction	NN	direction
by	IN	by
the	DT	the
community	NN	community
.	SENT	.
34769806/	CD	@card@
Reduction	NN	reduction
in	IN	in
Absolute	JJ	absolute
Neutrophil	JJ	neutrophil
Counts	NP	Counts
in	IN	in
Patient	NP	Patient
on	IN	on
Clozapine	NP	clozapine
Infected	VBN	infect
with	IN	with
COVID-19	NP	<unknown>
Despite	IN	despite
its	PP$	its
severe	JJ	severe
adverse	JJ	adverse
effects	NNS	effect
,	,	,
such	JJ	such
as	IN	as
agranulocytosis	NN	agranulocytosis
,	,	,
clozapine	NP	clozapine
is	VBZ	be
the	DT	the
primary	JJ	primary
treatment	NN	treatment
for	IN	for
treatment-resistant	JJ	treatment-resistant
schizophrenia	NN	schizophrenia
.	SENT	.
The	DT	the
established	JJ	established
clozapine	NN	clozapine
monitoring	NN	monitoring
system	NN	system
has	VBZ	have
contributed	VBN	contribute
to	TO	to
reducing	VBG	reduce
agranulocytosis	NN	agranulocytosis
incidence	NN	incidence
and	CC	and
mortality	NN	mortality
rates	NNS	rate
.	SENT	.
However	RB	however
,	,	,
the	DT	the
pandemic	JJ	pandemic
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
caused	VBN	cause
changes	NNS	change
in	IN	in
the	DT	the
monitoring	NN	monitoring
system	NN	system
.	SENT	.
This	DT	this
review	NN	review
aimed	VBN	aim
to	TO	to
assess	VB	assess
the	DT	the
current	JJ	current
evidence	NN	evidence
on	IN	on
the	DT	the
neutrophil	JJ	neutrophil
changes	NNS	change
in	IN	in
the	DT	the
patient	NN	patient
on	IN	on
clozapine	NP	clozapine
treatment	NN	treatment
and	CC	and
infected	VBN	infect
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Individual	JJ	individual
cases	NNS	case
reported	VBD	report
various	JJ	various
absolute	JJ	absolute
neutrophil	JJ	neutrophil
count	NN	count
(	(	(
ANC	NP	ANC
)	)	)
levels	NNS	level
,	,	,
normal	JJ	normal
,	,	,
reduced	VBN	reduce
,	,	,
or	CC	or
elevated	VBD	elevate
.	SENT	.
No	DT	no
agranulocytosis	NN	agranulocytosis
case	NN	case
was	VBD	be
reported	VBN	report
.	SENT	.
One	CD	one
case	NN	case
had	VBD	have
a	DT	a
borderline	JJ	borderline
moderate-severe	NN	<unknown>
ANC	NP	ANC
level	NN	level
,	,	,
but	CC	but
the	DT	the
patient	NN	patient
was	VBD	be
in	IN	in
the	DT	the
18-week	JJ	<unknown>
period	NN	period
of	IN	of
clozapine	NN	clozapine
treatment	NN	treatment
.	SENT	.
A	DT	a
cumulative	JJ	cumulative
analysis	NN	analysis
of	IN	of
case	NN	case
the	DT	the
series	NN	series
initially	RB	initially
reported	VBD	report
inconclusive	JJ	inconclusive
results	NNS	result
.	SENT	.
However	RB	however
,	,	,
a	DT	a
more	RBR	more
recent	JJ	recent
study	NN	study
with	IN	with
a	DT	a
larger	JJR	large
sample	NN	sample
size	NN	size
reported	VBD	report
a	DT	a
significant	JJ	significant
reduction	NN	reduction
in	IN	in
the	DT	the
ANC	NP	ANC
during	IN	during
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
Nevertheless	RB	nevertheless
,	,	,
this	DT	this
effect	NN	effect
is	VBZ	be
transient	JJ	transient
as	IN	as
no	DT	no
significant	JJ	significant
difference	NN	difference
was	VBD	be
found	VBN	find
between	IN	between
the	DT	the
baseline	NN	baseline
and	CC	and
the	DT	the
post-infection	NN	post-infection
period	NN	period
in	IN	in
ANC	NP	ANC
levels	NNS	level
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
COVID-19	NP	<unknown>
is	VBZ	be
associated	VBN	associate
with	IN	with
a	DT	a
temporary	JJ	temporary
reduction	NN	reduction
in	IN	in
ANC	NP	ANC
levels	NNS	level
.	SENT	.
The	DT	the
results	NNS	result
supported	VBD	support
the	DT	the
recommendation	NN	recommendation
to	TO	to
reduce	VB	reduce
the	DT	the
frequency	NN	frequency
of	IN	of
clozapine	NN	clozapine
monitoring	NN	monitoring
in	IN	in
the	DT	the
eligible	JJ	eligible
candidates	NNS	candidate
.	SENT	.
However	RB	however
,	,	,
more	JJR	more
data	NNS	datum
are	VBP	be
required	VBN	require
to	TO	to
confirm	VB	confirm
the	DT	the
current	JJ	current
findings	NNS	finding
given	VBN	give
the	DT	the
limitations	NNS	limitation
,	,	,
including	VBG	include
study	NN	study
design	NN	design
,	,	,
sample	NN	sample
size	NN	size
,	,	,
and	CC	and
statistical	JJ	statistical
analysis	NN	analysis
.	SENT	.
34908708/	CD	@card@
COVID-19	NP	<unknown>
moral	JJ	moral
dilemmas	NNS	dilemma
viewed	VBN	view
through	IN	through
Eastern	NP	Eastern
and	CC	and
Western	NP	Western
philosophy	NN	philosophy
COVID-19	NP	<unknown>
has	VBZ	have
been	VBN	be
a	DT	a
considerable	JJ	considerable
major	JJ	major
stress	NN	stress
factor	NN	factor
and	CC	and
has	VBZ	have
led	VBN	lead
to	TO	to
a	DT	a
great	JJ	great
increase	NN	increase
in	IN	in
psychological	JJ	psychological
illnesses	NNS	illness
.	SENT	.
Literature	NN	literature
related	VBN	relate
to	TO	to
spirituality	NN	spirituality
and	CC	and
philosophy	NN	philosophy
can	MD	can
provide	VB	provide
solace	NN	solace
in	IN	in
times	NNS	time
like	IN	like
these	DT	these
.	SENT	.
We	PP	we
have	VBP	have
taken	VBN	take
excerpts	NNS	excerpt
from	IN	from
Bhagwad	NP	<unknown>
Gita	NP	Gita
which	WDT	which
is	VBZ	be
a	DT	a
spiritual	JJ	spiritual
and	CC	and
philosophical	JJ	philosophical
scripture	NN	scripture
,	,	,
existential	JJ	existential
philosopher	NN	philosopher
Albert	NP	Albert
Camus	NP	Camus
's	POS	's
La	NP	La
Peste	NP	<unknown>
and	CC	and
the	DT	the
myth	NN	myth
of	IN	of
Sisyphus	NN	Sisyphus
and	CC	and
writings	NNS	writing
of	IN	of
the	DT	the
philosopher	NN	philosopher
Immanule	NN	<unknown>
Kant	NP	Kant
.	SENT	.
These	DT	these
literary	JJ	literary
masterpieces	NNS	masterpiece
can	MD	can
provide	VB	provide
a	DT	a
wealth	NN	wealth
of	IN	of
guidance	NN	guidance
and	CC	and
solace	NN	solace
to	TO	to
both	CC	both
the	DT	the
medical	JJ	medical
fraternity	NN	fraternity
and	CC	and
affected	JJ	affected
people	NNS	people
and	CC	and
their	PP$	their
caregivers	NNS	caregiver
.	SENT	.
"	``	"
We	PP	we
tell	VBP	tell
ourselves	PP	ourselves
that	IN	that
pestilence	NN	pestilence
is	VBZ	be
a	DT	a
mere	JJ	mere
bogy	NN	bogy
of	IN	of
the	DT	the
mind	NN	mind
,	,	,
a	DT	a
bad	JJ	bad
dream	NN	dream
that	WDT	that
will	MD	will
pass	VB	pass
away	RB	away
.	SENT	.
But	CC	but
it	PP	it
does	VBZ	do
n't	RB	n't
always	RB	always
pass	VB	pass
away	RB	away
and	CC	and
from	IN	from
one	CD	one
bad	JJ	bad
dream	NN	dream
to	TO	to
another	DT	another
,	,	,
it	PP	it
is	VBZ	be
men	NNS	man
who	WP	who
pass	VBP	pass
away	RB	away
.	SENT	.
"	''	"
-Albert	NP	-Albert
Camus	NP	Camus
34882720/	CD	@card@
Patterns	NNS	pattern
and	CC	and
predictors	NNS	predictor
of	IN	of
sick	JJ	sick
leave	NN	leave
among	IN	among
Swedish	JJ	Swedish
non-hospitalized	JJ	<unknown>
healthcare	NN	<unknown>
and	CC	and
residential	JJ	residential
care	NN	care
workers	NNS	worker
with	IN	with
Covid-19	NP	<unknown>
during	IN	during
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
pandemic	JJ	pandemic
Healthcare	NP	Healthcare
and	CC	and
residential	JJ	residential
care	NN	care
workers	NNS	worker
represent	VBP	represent
two	CD	two
occupational	JJ	occupational
groups	NNS	group
that	WDT	that
have	VBP	have
,	,	,
in	IN	in
particular	JJ	particular
,	,	,
been	VBN	be
at	IN	at
risk	NN	risk
of	IN	of
Covid-19	NP	<unknown>
,	,	,
its	PP$	its
long-term	JJ	long-term
consequences	NNS	consequence
,	,	,
and	CC	and
related	JJ	related
sick	JJ	sick
leave	NN	leave
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
investigated	VBD	investigate
the	DT	the
predictors	NNS	predictor
of	IN	of
prolonged	JJ	prolonged
sick	JJ	sick
leave	NN	leave
among	IN	among
healthcare	NN	<unknown>
and	CC	and
residential	JJ	residential
workers	NNS	worker
due	JJ	due
to	TO	to
non-hospitalized	JJ	<unknown>
Covid-19	NP	<unknown>
in	IN	in
the	DT	the
early	JJ	early
period	NN	period
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
This	DT	this
study	NN	study
is	VBZ	be
based	VBN	base
on	IN	on
a	DT	a
patient	JJ	patient
register	NN	register
(	(	(
n	NN	n
=	SYM	=
3209	CD	@card@
)	)	)
and	CC	and
included	VBD	include
non-hospitalized	JJ	<unknown>
healthcare	NN	<unknown>
or	CC	or
residential	JJ	residential
care	NN	care
service	NN	service
workers	NNS	worker
with	IN	with
a	DT	a
positive	JJ	positive
RT-	NP	<unknown>
PCR	NP	PCR
for	IN	for
SARS-CoV-2	NP	<unknown>
(	(	(
n	NN	n
=	SYM	=
433	CD	@card@
)	)	)
between	IN	between
March	NP	March
and	CC	and
August	NP	August
2020	CD	@card@
.	SENT	.
Data	NNS	datum
such	JJ	such
as	IN	as
socio-demographics	NNS	socio-demographic
,	,	,
clinical	JJ	clinical
characteristics	NNS	characteristic
,	,	,
and	CC	and
the	DT	the
length	NN	length
of	IN	of
sick	JJ	sick
leave	NN	leave
because	IN	because
of	IN	of
Covid-19	NP	<unknown>
and	CC	and
prior	RB	prior
to	TO	to
the	DT	the
pandemic	NN	pandemic
were	VBD	be
extracted	VBN	extract
from	IN	from
the	DT	the
patient	NN	patient
's	POS	's
electronic	JJ	electronic
health	NN	health
records	NNS	record
.	SENT	.
Prolonged	JJ	prolonged
sick	JJ	sick
leave	NN	leave
was	VBD	be
defined	VBN	define
as	IN	as
sick	JJ	sick
leave	NN	leave
&gt	NN	&gt
;	:	;
=	SYM	=
3	CD	@card@
weeks	NNS	week
,	,	,
based	VBN	base
on	IN	on
the	DT	the
Swedish	JJ	Swedish
pandemic	JJ	pandemic
policy	NN	policy
.	SENT	.
A	DT	a
generalized	VBN	generalize
linear	JJ	linear
model	NN	model
was	VBD	be
used	VBN	use
with	IN	with
a	DT	a
binary	JJ	binary
distribution	NN	distribution
,	,	,
adjusted	VBN	adjust
for	IN	for
age	NN	age
,	,	,
gender	NN	gender
,	,	,
and	CC	and
comorbidity	NN	comorbidity
in	IN	in
order	NN	order
to	TO	to
predict	VB	predict
prolonged	JJ	prolonged
sick	JJ	sick
leave	NN	leave
.	SENT	.
Of	IN	of
433	CD	@card@
(	(	(
77	CD	@card@
%	NN	%
women	NNS	woman
)	)	)
healthcare	NN	<unknown>
and	CC	and
residential	JJ	residential
care	NN	care
workers	NNS	worker
included	VBD	include
in	IN	in
this	DT	this
study	NN	study
,	,	,
14.8	CD	@card@
%	NN	%
needed	VBN	need
longer	RBR	longer
sick	JJ	sick
leave	NN	leave
(	(	(
&gt	NP	<unknown>
;	:	;
3	CD	@card@
weeks	NNS	week
)	)	)
due	JJ	due
to	TO	to
Covid-19	NP	<unknown>
.	SENT	.
Only	RB	only
1.4	CD	@card@
%	NN	%
of	IN	of
the	DT	the
subjects	NNS	subject
were	VBD	be
on	IN	on
sick	JJ	sick
leave	NN	leave
because	IN	because
of	IN	of
long	JJ	long
Covid	NP	<unknown>
.	SENT	.
The	DT	the
risk	NN	risk
of	IN	of
sick	JJ	sick
leave	NN	leave
was	VBD	be
increased	VBN	increase
two-fold	NN	two-fold
among	IN	among
residential	JJ	residential
care	NN	care
workers	NNS	worker
(	(	(
adjusted	VBN	adjust
RR	NP	RR
2.14	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.31-3.51	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
Depression/anxiety	NP	<unknown>
(	(	(
adjusted	VBN	adjust
RR	NP	RR
2.09	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.31-3.34	CD	@card@
]	SYM	]
)	)	)
,	,	,
obesity	NN	obesity
(	(	(
adjusted	VBN	adjust
RR	NP	RR
1.96	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.01-3.81	CD	@card@
]	SYM	]
)	)	)
and	CC	and
dyspnea	NN	dyspnea
at	IN	at
symptom	NN	symptom
onset	NN	onset
(	(	(
adjusted	VBN	adjust
RR	NP	RR
2.47	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.55-3.92	CD	@card@
]	SYM	]
)	)	)
,	,	,
sick	JJ	sick
leave	VBP	leave
prior	RB	prior
to	TO	to
the	DT	the
pandemic	JJ	pandemic
(	(	(
3-12	CD	@card@
weeks	NNS	week
)	)	)
(	(	(
adjusted	VBN	adjust
RR	NP	RR
2.23	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.21-4.10	CD	@card@
]	SYM	]
)	)	)
were	VBD	be
associated	VBN	associate
with	IN	with
longer	RBR	longer
sick	JJ	sick
leave	NN	leave
.	SENT	.
From	IN	from
a	DT	a
public	JJ	public
health	NN	health
perspective	NN	perspective
,	,	,
considering	VBG	consider
occupational	JJ	occupational
category	NN	category
,	,	,
comorbidity	NN	comorbidity
,	,	,
symptoms	NNS	symptom
at	IN	at
onset	NN	onset
,	,	,
and	CC	and
sick	JJ	sick
leave	VBP	leave
prior	RB	prior
to	TO	to
the	DT	the
pandemic	NN	pandemic
as	IN	as
potential	JJ	potential
predictors	NNS	predictor
of	IN	of
sick	JJ	sick
leave	NN	leave
in	IN	in
healthcare	NN	<unknown>
may	MD	may
help	VB	help
prevent	VB	prevent
staff	NN	staff
shortage	NN	shortage
.	SENT	.
35224217/	CD	@card@
Impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
routine	JJ	routine
vaccination	NN	vaccination
coverage	NN	coverage
of	IN	of
children	NNS	child
and	CC	and
adolescents	NNS	adolescent
:	:	:
A	DT	a
systematic	JJ	systematic
review	NN	review
Scientists	NNS	scientist
and	CC	and
healthcare	NN	<unknown>
workers	NNS	worker
have	VBP	have
expressed	VBN	express
their	PP$	their
concerns	NNS	concern
on	IN	on
the	DT	the
impacts	NNS	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
vaccination	NN	vaccination
coverage	NN	coverage
in	IN	in
children	NNS	child
and	CC	and
adolescents	NNS	adolescent
.	SENT	.
Therefore	RB	therefore
,	,	,
we	PP	we
aimed	VBD	aim
to	TO	to
systematically	RB	systematically
review	VB	review
the	DT	the
studies	NNS	study
addressing	VBG	address
this	DT	this
issue	NN	issue
worldwide	RB	worldwide
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
systematic	JJ	systematic
search	NN	search
of	IN	of
relevant	JJ	relevant
studies	NNS	study
using	VBG	use
the	DT	the
keywords	NNS	keyword
on	IN	on
databases	NNS	database
of	IN	of
PubMed	NP	<unknown>
,	,	,
Web	NP	Web
of	IN	of
Science	NP	Science
,	,	,
and	CC	and
Cochrane	NP	Cochrane
on	IN	on
May	NP	May
22	CD	@card@
,	,	,
2021	CD	@card@
.	SENT	.
The	DT	the
identified	VBN	identify
records	NNS	record
were	VBD	be
imported	VBN	import
into	IN	into
EndNote	NP	<unknown>
software	NN	software
and	CC	and
underwent	VBD	undergo
a	DT	a
two-phase	JJ	two-phase
screening	NN	screening
process	NN	process
consisting	VBG	consist
of	IN	of
title/abstract	NN	title/abstract
and	CC	and
full-text	NN	<unknown>
screenings	NNS	screenings
against	IN	against
inclusion	NN	inclusion
criteria	NNS	criterion
.	SENT	.
The	DT	the
data	NNS	datum
of	IN	of
the	DT	the
included	VBN	include
studies	NNS	study
were	VBD	be
summarized	VBN	summarize
into	IN	into
a	DT	a
table	NN	table
and	CC	and
the	DT	the
findings	NNS	finding
were	VBD	be
analyzed	VBN	analyze
in	IN	in
a	DT	a
systematic	JJ	systematic
approach	NN	approach
.	SENT	.
From	IN	from
26	CD	@card@
eligible	JJ	eligible
studies	NNS	study
,	,	,
21	CD	@card@
studies	NNS	study
demonstrated	VBN	demonstrate
decreased	VBD	decrease
vaccination	NN	vaccination
rates	NNS	rate
in	IN	in
the	DT	the
children	NNS	child
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
while	IN	while
three	CD	three
studies	NNS	study
found	VBD	find
increased	VBN	increase
or	CC	or
no	DT	no
significant	JJ	significant
changes	NNS	change
only	RB	only
in	IN	in
influenza	NN	influenza
vaccination	NN	vaccination
.	SENT	.
The	DT	the
two	CD	two
remaining	VBG	remain
studies	NNS	study
from	IN	from
Brazil	NP	Brazil
and	CC	and
Sweden	NP	Sweden
also	RB	also
showed	VBD	show
no	DT	no
significant	JJ	significant
changes	NNS	change
in	IN	in
vaccination	NN	vaccination
rates	NNS	rate
in	IN	in
the	DT	the
children	NNS	child
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Most	JJS	most
of	IN	of
the	DT	the
reports	NNS	report
worldwide	RB	worldwide
reported	VBD	report
a	DT	a
decline	NN	decline
or	CC	or
delay	NN	delay
in	IN	in
vaccination	NN	vaccination
at	IN	at
the	DT	the
time	NN	time
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
A	DT	a
sustained	JJ	sustained
catch-up	NN	catch-up
program	NN	program
seems	VBZ	seem
to	TO	to
be	VB	be
necessary	JJ	necessary
,	,	,
especially	RB	especially
in	IN	in
low-income	JJ	low-income
countries	NNS	country
,	,	,
to	TO	to
avoid	VB	avoid
any	DT	any
vaccine	NN	vaccine
dose	NN	dose
missing	VBG	miss
.	SENT	.
Facilitating	VBG	facilitate
the	DT	the
vaccination	NN	vaccination
process	NN	process
is	VBZ	be
recommended	JJ	recommended
,	,	,
such	JJ	such
as	IN	as
decreasing	VBG	decrease
the	DT	the
waiting	VBG	wait
time	NN	time
for	IN	for
vaccination	NN	vaccination
at	IN	at
the	DT	the
health	NN	health
center	NN	center
,	,	,
addressing	VBG	address
the	DT	the
fear	NN	fear
and	CC	and
concerns	NNS	concern
related	VBN	relate
to	TO	to
COVID	NP	<unknown>
infection	NN	infection
for	IN	for
parents	NNS	parent
,	,	,
and	CC	and
enhancing	VBG	enhance
vaccine	NN	vaccine
availability	NN	availability
,	,	,
and	CC	and
promoting	VBG	promote
access	NN	access
in	IN	in
remote	JJ	remote
areas	NNS	area
.	SENT	.
Countries	NNS	country
should	MD	should
ensure	VB	ensure
proper	JJ	proper
vaccination	NN	vaccination
to	TO	to
prevent	VB	prevent
future	JJ	future
pandemics	NNS	pandemic
related	VBN	relate
to	TO	to
vaccine-preventable	JJ	vaccine-preventable
diseases	NNS	disease
.	SENT	.
32382746/	CD	@card@
Clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
in	IN	in
Japan	NP	Japan
:	:	:
a	DT	a
single-center	NN	single-center
case	NN	case
series	NN	series
We	PP	we
report	VBP	report
a	DT	a
case	NN	case
series	NN	series
of	IN	of
6	CD	@card@
patients	NNS	patient
with	IN	with
confirmed	VBN	confirm
COVID-19	NP	<unknown>
in	IN	in
Wakayama	NP	Wakayama
prefecture	NN	prefecture
,	,	,
Japan	NP	Japan
.	SENT	.
All	DT	all
6	CD	@card@
of	IN	of
the	DT	the
patients	NNS	patient
tested	VBD	test
positive	JJ	positive
in	IN	in
pharyngeal	JJ	pharyngeal
swab	NN	swab
PCR	NP	PCR
tests	NNS	test
,	,	,
and	CC	and
2	CD	@card@
of	IN	of
the	DT	the
6	CD	@card@
were	VBD	be
still	RB	still
positive	JJ	positive
at	IN	at
3	CD	@card@
weeks	NNS	week
after	IN	after
onset	NN	onset
.	SENT	.
All	DT	all
of	IN	of
the	DT	the
patients	NNS	patient
exhibited	VBD	exhibit
bilateral	JJ	bilateral
ground	NN	ground
glass	NN	glass
opacities	NNS	opacity
(	(	(
GGO	NP	GGO
)	)	)
on	IN	on
computed	VBN	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
.	SENT	.
This	DT	this
paper	NN	paper
also	RB	also
reports	VBZ	report
narrative	JJ	narrative
information	NN	information
on	IN	on
the	DT	the
spectrum	NN	spectrum
of	IN	of
symptoms	NNS	symptom
collected	VBN	collect
directly	RB	directly
from	IN	from
the	DT	the
patients	NNS	patient
.	SENT	.
It	PP	it
would	MD	would
be	VB	be
difficult	JJ	difficult
to	TO	to
triage	NN	triage
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
based	VBN	base
on	IN	on
the	DT	the
typical	JJ	typical
symptoms	NNS	symptom
of	IN	of
fever	NN	fever
and/or	CC	and/or
cough	NN	cough
,	,	,
although	IN	although
PCR	NP	PCR
and	CC	and
CT	NP	CT
are	VBP	be
definitive	JJ	definitive
in	IN	in
diagnosis	NN	diagnosis
.	SENT	.
34991778/	CD	@card@
Impact	NN	impact
of	IN	of
booster	NN	booster
vaccination	NN	vaccination
on	IN	on
the	DT	the
control	NN	control
of	IN	of
COVID-19	NP	<unknown>
Delta	NP	Delta
wave	NN	wave
in	IN	in
the	DT	the
context	NN	context
of	IN	of
waning	VBG	wane
immunity	NN	immunity
:	:	:
application	NN	application
to	TO	to
France	NP	France
in	IN	in
the	DT	the
winter	NN	winter
2021/22	CD	@card@
Europe	NP	Europe
has	VBZ	have
experienced	VBN	experience
a	DT	a
large	JJ	large
COVID-19	NP	<unknown>
wave	NN	wave
caused	VBD	cause
by	IN	by
the	DT	the
Delta	NP	Delta
variant	NN	variant
in	IN	in
winter	NN	winter
2021/22	CD	@card@
.	SENT	.
Using	VBG	use
mathematical	JJ	mathematical
models	NNS	model
applied	VBN	apply
to	TO	to
Metropolitan	NP	Metropolitan
France	NP	France
,	,	,
we	PP	we
find	VBP	find
that	IN	that
boosters	NNS	booster
administered	VBN	administer
to	TO	to
&gt	NN	&gt
;	:	;
=	SYM	=
65	CD	@card@
,	,	,
&gt	NN	&gt
;	:	;
=	SYM	=
50	CD	@card@
or	CC	or
&gt	NN	&gt
;	:	;
=	SYM	=
18	CD	@card@
year-olds	NNS	<unknown>
may	MD	may
reduce	VB	reduce
the	DT	the
hospitalisation	NN	hospitalisation
peak	NN	peak
by	IN	by
25	CD	@card@
%	NN	%
,	,	,
36	CD	@card@
%	NN	%
and	CC	and
43	CD	@card@
%	NN	%
respectively	RB	respectively
,	,	,
with	IN	with
a	DT	a
delay	NN	delay
of	IN	of
5	CD	@card@
months	NNS	month
between	IN	between
second	JJ	second
and	CC	and
third	JJ	third
dose	NN	dose
.	SENT	.
A	DT	a
10	CD	@card@
%	NN	%
reduction	NN	reduction
in	IN	in
transmission	NN	transmission
rates	NNS	rate
might	MD	might
further	RBR	further
reduce	VB	reduce
it	PP	it
by	IN	by
41	CD	@card@
%	NN	%
,	,	,
indicating	VBG	indicate
that	IN	that
even	RB	even
small	JJ	small
increases	NNS	increase
in	IN	in
protective	JJ	protective
behaviours	NNS	behaviour
may	MD	may
be	VB	be
critical	JJ	critical
to	TO	to
mitigate	VB	mitigate
the	DT	the
wave	NN	wave
.	SENT	.
32407564/	CD	@card@
Cutaneous	JJ	cutaneous
manifestations	NNS	manifestation
in	IN	in
COVID-19	NP	<unknown>
:	:	:
Family	NN	family
cluster	NN	cluster
of	IN	of
Urticarial	JJ	urticarial
Rash	NP	Rash
Coronavirus	NP	<unknown>
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
rapidly	RB	rapidly
spread	VBN	spread
across	IN	across
the	DT	the
world	NN	world
.	SENT	.
Many	JJ	many
clinical	JJ	clinical
manifestations	NNS	manifestation
of	IN	of
the	DT	the
virus	NN	virus
are	VBP	be
described	VBN	describe
,	,	,
and	CC	and
new	JJ	new
symptoms	NNS	symptom
are	VBP	be
emerging	VBG	emerge
,	,	,
only	RB	only
few	JJ	few
cases	NNS	case
of	IN	of
patients	NNS	patient
with	IN	with
skin	NN	skin
manifestation	NN	manifestation
were	VBD	be
described	VBN	describe
since	IN	since
the	DT	the
pandemic	NN	pandemic
was	VBD	be
announced	VBN	announce
by	IN	by
the	DT	the
WHO	WP	who
on	IN	on
March	NP	March
.	SENT	.
Common	JJ	common
clinical	JJ	clinical
features	NNS	feature
of	IN	of
COVID-19	NP	<unknown>
reported	VBD	report
include	VB	include
fever	NN	fever
,	,	,
cough	NN	cough
,	,	,
myalgia	NN	myalgia
,	,	,
fatigue	NN	fatigue
,	,	,
headache	NN	headache
,	,	,
shortness	NN	shortness
of	IN	of
breath	NN	breath
and	CC	and
diarrhea	NN	diarrhea
.	SENT	.
35128391/	CD	@card@
Inequalities	NNS	inequality
through	IN	through
the	DT	the
lens	NN	lens
of	IN	of
science	NN	science
Inequalities	NNS	inequality
are	VBP	be
ubiquitous	JJ	ubiquitous
in	IN	in
every	DT	every
society	NN	society
on	IN	on
Earth	NP	Earth
,	,	,
and	CC	and
the	DT	the
COVID-2019	NP	COVID@card@
pandemic	NN	pandemic
has	VBZ	have
exposed	VBN	expose
the	DT	the
marginalized	VBN	marginalize
communities	NNS	community
that	WDT	that
suffer	VBP	suffer
the	DT	the
most	JJS	most
.	SENT	.
A	DT	a
warming	NN	warming
planet	NN	planet
will	MD	will
only	RB	only
magnify	VB	magnify
this	DT	this
gap	NN	gap
.	SENT	.
On	IN	on
the	DT	the
eve	NN	eve
of	IN	of
the	DT	the
26th	JJ	26th
session	NN	session
of	IN	of
the	DT	the
Conference	NN	conference
of	IN	of
the	DT	the
Parties	NNS	party
to	TO	to
the	DT	the
UNFCCC	NP	<unknown>
,	,	,
this	DT	this
Voices	NNS	voice
asks	VBZ	ask
:	:	:
how	WRB	how
can	MD	can
science	NN	science
inform	VB	inform
and	CC	and
address	VB	address
inequalities	NNS	inequality
?	SENT	?
35316929/	CD	@card@
Single-fraction	NN	Single-fraction
stereotactic	JJ	stereotactic
ablative	JJ	ablative
body	NN	body
radiation	NN	radiation
therapy	NN	therapy
for	IN	for
primary	JJ	primary
and	CC	and
metastasic	JJ	<unknown>
lung	NN	lung
tumor	NN	tumor
:	:	:
A	DT	a
new	JJ	new
paradigm	NN	paradigm
?	SENT	?
Stereotactic	JJ	stereotactic
ablative	JJ	ablative
body	NN	body
radiotherapy	NN	radiotherapy
(	(	(
SABR	NP	<unknown>
)	)	)
is	VBZ	be
an	DT	an
effective	JJ	effective
technique	NN	technique
comparable	JJ	comparable
to	TO	to
surgery	NN	surgery
in	IN	in
terms	NNS	term
of	IN	of
local	JJ	local
control	NN	control
and	CC	and
efficacy	NN	efficacy
in	IN	in
early	JJ	early
stages	NNS	stage
of	IN	of
non-small	NN	non-small
cell	NN	cell
lung	NN	lung
cancer	NN	cancer
(	(	(
NSCLC	NP	<unknown>
)	)	)
and	CC	and
pulmonary	JJ	pulmonary
metastasis	NN	metastasis
.	SENT	.
Several	JJ	several
fractionation	NN	fractionation
schemes	NNS	scheme
have	VBP	have
proven	VBN	prove
to	TO	to
be	VB	be
safe	JJ	safe
and	CC	and
effective	JJ	effective
,	,	,
including	VBG	include
the	DT	the
single	JJ	single
fraction	NN	fraction
(	(	(
SF	NP	SF
)	)	)
scheme	NN	scheme
.	SENT	.
SF	NP	SF
is	VBZ	be
an	DT	an
option	NN	option
cost-effectiveness	NN	cost-effectiveness
,	,	,
more	JJR	more
convenience	NN	convenience
and	CC	and
comfortable	JJ	comfortable
for	IN	for
the	DT	the
patient	NN	patient
and	CC	and
flexible	JJ	flexible
in	IN	in
terms	NNS	term
of	IN	of
its	PP$	its
management	NN	management
combined	VBN	combine
with	IN	with
systemic	JJ	systemic
treatments	NNS	treatment
.	SENT	.
The	DT	the
outbreak	NN	outbreak
of	IN	of
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
pandemic	NN	pandemic
has	VBZ	have
driven	VBN	drive
this	DT	this
not	RB	not
new	JJ	new
but	CC	but
underutilized	VBN	underutilize
paradigm	NN	paradigm
,	,	,
recommending	VBG	recommend
this	DT	this
option	NN	option
to	TO	to
minimize	VB	minimize
patients	NNS	patient
'	POS	'
visits	NNS	visit
to	TO	to
hospital	NN	hospital
.	SENT	.
SF	NP	SF
SABR	NP	<unknown>
already	RB	already
has	VBZ	have
a	DT	a
long	JJ	long
experience	NN	experience
,	,	,
strong	JJ	strong
evidence	NN	evidence
and	CC	and
sufficient	JJ	sufficient
maturity	NN	maturity
to	TO	to
reliably	RB	reliably
evaluate	VB	evaluate
outcomes	NNS	outcome
in	IN	in
peripheral	JJ	peripheral
primary	JJ	primary
NSCLC	NN	<unknown>
and	CC	and
there	EX	there
are	VBP	be
promising	JJ	promising
outcomes	NNS	outcome
in	IN	in
pulmonary	JJ	pulmonary
metastases	NNS	metastasis
,	,	,
making	VBG	make
it	PP	it
a	DT	a
valid	JJ	valid
treatment	NN	treatment
option	NN	option
;	:	;
although	IN	although
its	PP$	its
use	NN	use
in	IN	in
central	JJ	central
locations	NNS	location
,	,	,
synchronous	JJ	synchronous
and	CC	and
recurrencies	NNS	recurrency
tumors	NNS	tumor
requires	VBZ	require
more	RBR	more
prospective	JJ	prospective
safety	NN	safety
and	CC	and
efficacy	NN	efficacy
studies	NNS	study
.	SENT	.
The	DT	the
SABR	NP	<unknown>
radiobiology	NN	radiobiology
study	NN	study
,	,	,
together	RB	together
with	IN	with
the	DT	the
combination	NN	combination
with	IN	with
systemic	JJ	systemic
therapies	NNS	therapy
,	,	,
(	(	(
targeted	JJ	targeted
therapies	NNS	therapy
and	CC	and
immunotherapy	NN	immunotherapy
)	)	)
is	VBZ	be
a	DT	a
direction	NN	direction
of	IN	of
research	NN	research
in	IN	in
both	DT	both
advanced	JJ	advanced
disease	NN	disease
and	CC	and
early	JJ	early
stages	NNS	stage
whose	WP$	whose
future	NN	future
includes	VBZ	include
SF	NP	SF
.	SENT	.
32533432/	CD	@card@
COVID-19	NP	<unknown>
and	CC	and
Asian	NP	Asian
American	NP	American
Pacific	NP	Pacific
Islanders	NNS	islander
32820721/	CD	@card@
Differential	JJ	differential
occupational	JJ	occupational
risks	NNS	risk
to	TO	to
healthcare	NN	<unknown>
workers	NNS	worker
from	IN	from
SARS-CoV-2	NP	<unknown>
observed	VBD	observe
during	IN	during
a	DT	a
prospective	JJ	prospective
observational	JJ	observational
study	NN	study
We	PP	we
conducted	VBD	conduct
voluntary	JJ	voluntary
Covid-19	NP	<unknown>
testing	NN	testing
programmes	NNS	programme
for	IN	for
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
staff	NN	staff
at	IN	at
a	DT	a
UK	NP	UK
teaching	NN	teaching
hospital	NN	hospital
using	VBG	use
naso-/oro-pharyngeal	JJ	naso-/oro-pharyngeal
PCR	NP	PCR
testing	NN	testing
and	CC	and
immunoassays	NNS	immunoassay
for	IN	for
IgG	NP	IgG
antibodies	NNS	antibody
.	SENT	.
1128/10,034	CD	@card@
(	(	(
11.2	CD	@card@
%	NN	%
)	)	)
staff	NN	staff
had	VBD	have
evidence	NN	evidence
of	IN	of
Covid-19	NP	<unknown>
at	IN	at
some	DT	some
time	NN	time
.	SENT	.
Using	VBG	use
questionnaire	NN	questionnaire
data	NNS	datum
provided	VBN	provide
on	IN	on
potential	JJ	potential
risk-factors	NNS	risk-factor
,	,	,
staff	NN	staff
with	IN	with
a	DT	a
confirmed	VBN	confirm
household	NN	household
contact	NN	contact
were	VBD	be
at	IN	at
greatest	JJS	great
risk	NN	risk
(	(	(
adjusted	JJ	adjusted
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
aOR	NN	aOR
]	SYM	]
4.82	CD	@card@
[	SYM	[
95%CI	NP	<unknown>
3.45-6.72	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
Higher	JJR	high
rates	NNS	rate
of	IN	of
Covid-19	NP	<unknown>
were	VBD	be
seen	VBN	see
in	IN	in
staff	NN	staff
working	VBG	work
in	IN	in
Covid-19-facing	NN	Covid-19-facing
areas	NNS	area
(	(	(
22.6	CD	@card@
%	NN	%
vs.	IN	vs.
8.6	CD	@card@
%	NN	%
elsewhere	NN	elsewhere
)	)	)
(	(	(
aOR	NP	aOR
2.47	CD	@card@
[	SYM	[
1.99-3.08	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
Controlling	VBG	control
for	IN	for
Covid-19-facing	NN	Covid-19-facing
status	NN	status
,	,	,
risks	NNS	risk
were	VBD	be
heterogenous	JJ	heterogenous
across	IN	across
the	DT	the
hospital	NN	hospital
,	,	,
with	IN	with
higher	JJR	high
rates	NNS	rate
in	IN	in
acute	JJ	acute
medicine	NN	medicine
(	(	(
1.52	CD	@card@
[	SYM	[
1.07-2.16	CD	@card@
]	SYM	]
)	)	)
and	CC	and
sporadic	JJ	sporadic
outbreaks	NNS	outbreak
in	IN	in
areas	NNS	area
with	IN	with
few	JJ	few
or	CC	or
no	DT	no
Covid-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
Covid-19	JJ	<unknown>
intensive	JJ	intensive
care	NN	care
unit	NN	unit
staff	NN	staff
were	VBD	be
relatively	RB	relatively
protected	JJ	protected
(	(	(
0.44	CD	@card@
[	SYM	[
0.28-0.69	CD	@card@
]	SYM	]
)	)	)
,	,	,
likely	RB	likely
by	IN	by
a	DT	a
bundle	NN	bundle
of	IN	of
PPE-related	JJ	PPE-related
measures	NNS	measure
.	SENT	.
Positive	JJ	positive
results	NNS	result
were	VBD	be
more	RBR	more
likely	JJ	likely
in	IN	in
Black	NP	Black
(	(	(
1.66	CD	@card@
[	SYM	[
1.25-2.21	CD	@card@
]	SYM	]
)	)	)
and	CC	and
Asian	JJ	Asian
(	(	(
1.51	CD	@card@
[	SYM	[
1.28-1.77	CD	@card@
]	SYM	]
)	)	)
staff	NN	staff
,	,	,
independent	JJ	independent
of	IN	of
role	NN	role
or	CC	or
working	VBG	work
location	NN	location
,	,	,
and	CC	and
in	IN	in
porters	NNS	porter
and	CC	and
cleaners	NNS	cleaner
(	(	(
2.06	CD	@card@
[	SYM	[
1.34-3.15	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
34394024/	CD	@card@
Profiling	VBG	profil
of	IN	of
Oral	NP	Oral
Microbiota	NP	<unknown>
and	CC	and
Cytokines	NP	Cytokines
in	IN	in
COVID-19	NP	<unknown>
Patients	NPS	Patients
The	DT	the
presence	NN	presence
of	IN	of
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
has	VBZ	have
been	VBN	be
recently	RB	recently
demonstrated	VBN	demonstrate
in	IN	in
the	DT	the
sputum	NN	sputum
or	CC	or
saliva	NN	saliva
,	,	,
suggesting	VBG	suggest
how	WRB	how
the	DT	the
shedding	NN	shedding
of	IN	of
viral	JJ	viral
RNA	NP	RNA
outlasts	VBZ	outlast
the	DT	the
end	NN	end
of	IN	of
symptoms	NNS	symptom
.	SENT	.
Recent	JJ	Recent
data	NNS	datum
from	IN	from
transcriptome	NN	<unknown>
analysis	NN	analysis
show	VBP	show
that	IN	that
the	DT	the
oral	JJ	oral
cavity	NN	cavity
mucosa	NN	mucosa
harbors	VBZ	harbor
high	JJ	high
levels	NNS	level
of	IN	of
angiotensin-converting	JJ	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
and	CC	and
transmembrane	NN	transmembrane
protease	NN	protease
,	,	,
serine	NN	serine
2	CD	@card@
(	(	(
TMPRSS2	NP	<unknown>
)	)	)
,	,	,
highlighting	VBG	highlight
its	PP$	its
role	NN	role
as	IN	as
a	DT	a
double-edged	JJ	double-edged
sword	NN	sword
for	IN	for
SARS-CoV-2	NP	<unknown>
body	NN	body
entrance	NN	entrance
or	CC	or
interpersonal	JJ	interpersonal
transmission	NN	transmission
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
studied	VBD	study
the	DT	the
oral	JJ	oral
microbiota	NN	microbiota
structure	NN	structure
and	CC	and
inflammatory	JJ	inflammatory
profile	NN	profile
of	IN	of
26	CD	@card@
naive	JJ	naive
severe	JJ	severe
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
patients	NNS	patient
and	CC	and
15	CD	@card@
controls	NNS	control
by	IN	by
16S	NP	16S
rRNA	NP	<unknown>
V2	NP	<unknown>
automated	VBD	automate
targeted	VBN	target
sequencing	VBG	sequence
and	CC	and
magnetic	JJ	magnetic
bead-based	JJ	<unknown>
multiplex	JJ	multiplex
immunoassays	NNS	immunoassay
,	,	,
respectively	RB	respectively
.	SENT	.
A	DT	a
significant	JJ	significant
diminution	NN	diminution
in	IN	in
species	NN	species
richness	NN	richness
was	VBD	be
observed	VBN	observe
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
along	RB	along
with	IN	with
a	DT	a
marked	JJ	marked
difference	NN	difference
in	IN	in
beta-diversity	NN	beta-diversity
.	SENT	.
Species	NNS	specie
such	JJ	such
as	IN	as
Prevotella	NP	<unknown>
salivae	NP	<unknown>
and	CC	and
Veillonella	NP	Veillonella
infantium	NN	<unknown>
were	VBD	be
distinctive	JJ	distinctive
for	IN	for
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
while	IN	while
Neisseria	NP	<unknown>
perflava	NP	<unknown>
and	CC	and
Rothia	NP	<unknown>
mucilaginosa	NN	<unknown>
were	VBD	be
predominant	JJ	predominant
in	IN	in
controls	NNS	control
.	SENT	.
Interestingly	RB	interestingly
,	,	,
these	DT	these
two	CD	two
groups	NNS	group
of	IN	of
oral	JJ	oral
species	NNS	specie
oppositely	RB	oppositely
clustered	VBN	cluster
within	IN	within
the	DT	the
bacterial	JJ	bacterial
network	NN	network
,	,	,
defining	VBG	define
two	CD	two
distinct	JJ	distinct
Species	NP	Species
Interacting	VBG	interact
Groups	NNS	group
(	(	(
SIGs	NP	<unknown>
)	)	)
.	SENT	.
COVID-19-related	JJ	COVID-19-related
pro-inflammatory	JJ	pro-inflammatory
cytokines	NNS	cytokine
were	VBD	be
found	VBN	find
in	IN	in
both	DT	both
oral	JJ	oral
and	CC	and
serum	NN	serum
samples	NNS	sample
,	,	,
along	RB	along
with	IN	with
a	DT	a
specific	JJ	specific
bacterial	JJ	bacterial
consortium	NN	consortium
able	JJ	able
to	TO	to
counteract	VB	counteract
them	PP	them
.	SENT	.
We	PP	we
introduced	VBD	introduce
a	DT	a
new	JJ	new
parameter	NN	parameter
,	,	,
named	VBN	name
CytoCOV	NP	<unknown>
,	,	,
able	JJ	able
to	TO	to
predict	VB	predict
COVID-19	NP	<unknown>
susceptibility	NN	susceptibility
for	IN	for
an	DT	an
unknown	JJ	unknown
subject	NN	subject
at	IN	at
71	CD	@card@
%	NN	%
of	IN	of
power	NN	power
with	IN	with
an	DT	an
Area	NN	area
Under	IN	under
Curve	NN	curve
(	(	(
AUC	NP	AUC
)	)	)
equal	JJ	equal
to	TO	to
0.995	CD	@card@
.	SENT	.
This	DT	this
pilot	NN	pilot
study	NN	study
evidenced	VBD	evidence
a	DT	a
distinctive	JJ	distinctive
oral	JJ	oral
microbiota	NN	microbiota
composition	NN	composition
in	IN	in
COVID-19	NP	<unknown>
subjects	NNS	subject
,	,	,
with	IN	with
a	DT	a
definite	JJ	definite
structural	JJ	structural
network	NN	network
in	IN	in
relation	NN	relation
to	TO	to
secreted	VBN	secrete
cytokines	NNS	cytokine
.	SENT	.
Our	PP$	our
results	NNS	result
would	MD	would
be	VB	be
usable	JJ	usable
in	IN	in
clinics	NNS	clinic
against	IN	against
COVID-19	NP	<unknown>
,	,	,
using	VBG	use
bacterial	JJ	bacterial
consortia	NN	consortia
as	IN	as
biomarkers	NNS	biomarker
or	CC	or
to	TO	to
reduce	VB	reduce
local	JJ	local
inflammation	NN	inflammation
.	SENT	.
35568022/	CD	@card@
Monitoring	VBG	monitor
cerebral	JJ	cerebral
hemodynamics	NNS	hemodynamics
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
the	DT	the
prone	JJ	prone
position	NN	position
32527466/	CD	@card@
SARS-CoV-2	NN	<unknown>
as	IN	as
a	DT	a
protective	JJ	protective
factor	NN	factor
for	IN	for
cardiovascular	JJ	cardiovascular
mortality	NN	mortality
?	SENT	?
32494062/	CD	@card@
Author	NN	author
Correction	NN	correction
:	:	:
Caring	VBG	care
for	IN	for
patients	NNS	patient
with	IN	with
cancer	NN	cancer
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
era	NN	era
35199310/	CD	@card@
Virtually	RB	virtually
Normal	JJ	normal
:	:	:
on	IN	on
Becoming	VBG	become
a	DT	a
Psychiatrist	NN	psychiatrist
in	IN	in
the	DT	the
Era	NN	era
of	IN	of
COVID-19	NP	<unknown>
35518554/	CD	@card@
Improving	NN	improving
staff	NN	staff
confidence	NN	confidence
and	CC	and
morale	NN	morale
through	IN	through
rapid	JJ	rapid
,	,	,
structured	JJ	structured
trust-wide	JJ	<unknown>
technology-enhanced	JJ	technology-enhanced
training	NN	training
in	IN	in
the	DT	the
use	NN	use
of	IN	of
COVID-19	NP	<unknown>
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
at	IN	at
Oxford	NP	Oxford
University	NP	University
Hospitals	NPS	Hospitals
33152182/	CD	@card@
Investigacion	NN	<unknown>
cientifica	NN	<unknown>
prioritaria	NN	<unknown>
en	IN	en
Latinoamerica	NP	Latinoamerica
para	NNS	para
orientar	JJ	<unknown>
la	NP	la
prevencion	NN	<unknown>
y	NN	y
el	NN	el
control	VBP	control
de	FW	de
la	FW	la
COVID-19	NP	<unknown>
32590691/	CD	@card@
Reply	NN	reply
to	TO	to
Radermacher	NP	Radermacher
et	FW	et
al.	FW	al.
on	IN	on
"	``	"
Serum	NP	Serum
Hydrogen	NN	hydrogen
Sulfide	NN	sulfide
and	CC	and
Outcome	NN	outcome
Association	NN	association
in	IN	in
Pneumonia	NN	pneumonia
by	IN	by
the	DT	the
SARS-CoV-2	NP	<unknown>
Coronavirus	NP	<unknown>
"	''	"
33547814/	CD	@card@
Impact	NN	impact
of	IN	of
both	DT	both
socioeconomic	JJ	socioeconomic
level	NN	level
and	CC	and
occupation	NN	occupation
on	IN	on
antibody	NN	antibody
prevalence	NN	prevalence
to	TO	to
SARS-CoV-2	NP	<unknown>
in	IN	in
an	DT	an
Egyptian	JJ	Egyptian
cohort	NN	cohort
:	:	:
The	DT	the
first	JJ	first
episode	NN	episode
We	PP	we
studied	VBD	study
the	DT	the
impact	NN	impact
of	IN	of
socioeconomic	JJ	socioeconomic
level	NN	level
on	IN	on
the	DT	the
anti-SARS-CoV-2-antibodies	NNS	anti-SARS-CoV-2-antibody
prevalence	NN	prevalence
in	IN	in
an	DT	an
Egyptian	JJ	Egyptian
cohort	NN	cohort
.	SENT	.
The	DT	the
low	JJ	low
socioeconomic	JJ	socioeconomic
standard	JJ	standard
group	NN	group
(	(	(
LSS	NP	LSS
)	)	)
included	VBD	include
51	CD	@card@
humans	NNS	human
,	,	,
30	CD	@card@
females	NNS	female
(	(	(
F	NN	F
)	)	)
and	CC	and
21	CD	@card@
males	NNS	male
(	(	(
M	NP	M
)	)	)
.	SENT	.
The	DT	the
high	JJ	high
socioeconomic	JJ	socioeconomic
standard	JJ	standard
group	NN	group
(	(	(
HSS	NP	HSS
)	)	)
included	VBD	include
55	CD	@card@
subjects	NNS	subject
,	,	,
24	CD	@card@
F	NN	F
and	CC	and
31	CD	@card@
M.	NP	M.
Of	IN	of
the	DT	the
30	CD	@card@
LSSF	NP	<unknown>
,	,	,
6	CD	@card@
were	VBD	be
immunoglobulin	NN	immunoglobulin
M	NP	M
(	(	(
IgM	NP	Igm
)	)	)
,	,	,
21	CD	@card@
immunoglobulin	NN	immunoglobulin
G	NP	G
(	(	(
IgG	NP	IgG
)	)	)
,	,	,
and	CC	and
6	CD	@card@
double	RB	double
positive	JJ	positive
.	SENT	.
Of	IN	of
the	DT	the
21	CD	@card@
LSSM	NN	<unknown>
,	,	,
5	CD	@card@
were	VBD	be
IgM	NP	Igm
,	,	,
12	CD	@card@
IgG	NP	IgG
,	,	,
and	CC	and
5	CD	@card@
double	RB	double
positive	JJ	positive
.	SENT	.
Of	IN	of
the	DT	the
24	CD	@card@
HSSF	NP	<unknown>
,	,	,
6	CD	@card@
were	VBD	be
IgM	NP	Igm
,	,	,
11	CD	@card@
IgG	NP	IgG
,	,	,
and	CC	and
5	CD	@card@
double	RB	double
positive	JJ	positive
.	SENT	.
Of	IN	of
the	DT	the
31	CD	@card@
HSSM	NN	<unknown>
,	,	,
6	CD	@card@
were	VBD	be
IgM	NP	Igm
,	,	,
14	CD	@card@
IgG	NP	IgG
,	,	,
and	CC	and
4	CD	@card@
double	RB	double
positive	JJ	positive
.	SENT	.
Of	IN	of
the	DT	the
51	CD	@card@
LSS	NP	LSS
humans	NNS	human
,	,	,
26	CD	@card@
were	VBD	be
symptomatic	JJ	symptomatic
(	(	(
S	NP	S
)	)	)
and	CC	and
25	CD	@card@
asymptomatic	JJ	asymptomatic
(	(	(
AS	NP	AS
)	)	)
.	SENT	.
Of	IN	of
the	DT	the
26	CD	@card@
S	NP	S
,	,	,
20	CD	@card@
were	VBD	be
IgG	NP	IgG
and	CC	and
8	CD	@card@
IgM/IgG	NP	<unknown>
double	JJ	double
positive	NN	positive
.	SENT	.
Of	IN	of
the	DT	the
25	CD	@card@
AS	NP	AS
,	,	,
13	CD	@card@
were	VBD	be
IgG	NP	IgG
and	CC	and
3	CD	@card@
IgM/IgG	NP	<unknown>
double	JJ	double
positive	NN	positive
.	SENT	.
Of	IN	of
the	DT	the
55	CD	@card@
HSS	NP	HSS
humans	NNS	human
,	,	,
38	CD	@card@
were	VBD	be
S	NP	S
and	CC	and
17	NP	@card@
AS	NP	AS
.	SENT	.
Of	IN	of
the	DT	the
38S	JJ	<unknown>
,	,	,
24	CD	@card@
were	VBD	be
IgG	NP	IgG
and	CC	and
11	CD	@card@
IgM	NP	Igm
positive	JJ	positive
of	IN	of
whom	WP	whom
,	,	,
9	CD	@card@
were	VBD	be
double	RB	double
positive	JJ	positive
.	SENT	.
Of	IN	of
the	DT	the
17	CD	@card@
AS	NP	AS
,	,	,
one	PP	one
was	VBD	be
IgG	NP	IgG
and	CC	and
one	CD	one
IgM	NP	Igm
positive	NN	positive
.	SENT	.
The	DT	the
IgM	NP	Igm
prevalence	NN	prevalence
was	VBD	be
higher	JJR	high
among	IN	among
the	DT	the
HSS	NP	HSS
humans	NNS	human
.	SENT	.
The	DT	the
IgG	NP	IgG
prevalence	NN	prevalence
was	VBD	be
significantly	RB	significantly
higher	JJR	high
among	IN	among
the	DT	the
LSS	NP	LSS
humans	NNS	human
.	SENT	.
In	IN	in
the	DT	the
two	CD	two
different	JJ	different
socioeconomic	JJ	socioeconomic
standards	NNS	standard
,	,	,
the	DT	the
prevalence	NN	prevalence
of	IN	of
either	DT	either
IgM	NP	Igm
or	CC	or
IgG	NP	IgG
was	VBD	be
higher	JJR	high
among	IN	among
F.	NP	F.
An	DT	an
inverse	JJ	inverse
correlation	NN	correlation
was	VBD	be
observed	VBN	observe
between	IN	between
age	NN	age
and	CC	and
the	DT	the
anti-SARS-CoV-2-antibodies	NNS	anti-SARS-CoV-2-antibody
prevalence	NN	prevalence
except	IN	except
for	IN	for
LSSF-IgG	NP	<unknown>
and	CC	and
LSSM-IgM	NP	<unknown>
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
socioeconomic	JJ	socioeconomic
standard	NN	standard
,	,	,
gender	NN	gender
,	,	,
and	CC	and
age	NN	age
impact	NN	impact
humoral	JJ	humoral
responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
with	IN	with
a	DT	a
clear	JJ	clear
heterogeneity	NN	heterogeneity
in	IN	in
individualized	VBN	individualize
responses	NNS	response
to	TO	to
the	DT	the
infection	NN	infection
in	IN	in
terms	NNS	term
of	IN	of
symptoms	NNS	symptom
.	SENT	.
Socioeconomic	JJ	socioeconomic
standard	NN	standard
,	,	,
gender	NN	gender
,	,	,
and	CC	and
age	NN	age
impact	NN	impact
humoral	JJ	humoral
responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
with	IN	with
a	DT	a
clear	JJ	clear
heterogeneity	NN	heterogeneity
in	IN	in
individualized	VBN	individualize
responses	NNS	response
to	TO	to
the	DT	the
infection	NN	infection
in	IN	in
terms	NNS	term
of	IN	of
symptoms	NNS	symptom
.	SENT	.
34491565/	RB	@card@
Why	WRB	why
Does	VBZ	do
the	DT	the
Precautionary	JJ	precautionary
Principle	NN	principle
Suffice	VB	suffice
for	IN	for
Blood	NP	Blood
Regulation	NP	Regulation
?	SENT	?
Traditional	JJ	traditional
approaches	NNS	approach
to	TO	to
blood	NN	blood
regulation	NN	regulation
emphasise	VBP	emphasise
the	DT	the
precautionary	JJ	precautionary
principle	NN	principle
and	CC	and
pursue	VB	pursue
zero-risk	NN	zero-risk
for	IN	for
viral	JJ	viral
transmission	NN	transmission
;	:	;
these	DT	these
traditional	JJ	traditional
approaches	NNS	approach
have	VBP	have
usually	RB	usually
followed	VBN	follow
tragedy	NN	tragedy
,	,	,
such	JJ	such
as	IN	as
the	DT	the
HIV	NP	HIV
and	CC	and
hepatitis	NP	hepatitis
C	NP	C
infections	NNS	infection
that	WDT	that
followed	VBD	follow
the	DT	the
use	NN	use
of	IN	of
factor	NN	factor
VIII	CD	@card@
concentrates	NNS	concentrate
.	SENT	.
However	RB	however
,	,	,
a	DT	a
much	RB	much
more	RBR	more
haphazard	JJ	haphazard
haemovigilance	NN	haemovigilance
system	NN	system
operates	VBZ	operate
for	IN	for
general	JJ	general
adverse	JJ	adverse
events	NNS	event
.	SENT	.
Such	JJ	such
imprecise	JJ	imprecise
assessment	NN	assessment
of	IN	of
hazards	NNS	hazard
prevents	VBZ	prevent
sound	JJ	sound
benefit-risk	NN	<unknown>
assessment	NN	assessment
,	,	,
and	CC	and
for	IN	for
blood	NN	blood
products	NNS	product
this	DT	this
is	VBZ	be
further	RBR	further
confounded	VBN	confound
by	IN	by
the	DT	the
fact	NN	fact
that	IN	that
their	PP$	their
efficacy	NN	efficacy
has	VBZ	have
attracted	VBN	attract
little	JJ	little
systematic	JJ	systematic
study	NN	study
.	SENT	.
The	DT	the
ongoing	JJ	ongoing
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
now	RB	now
prompted	VBN	prompt
the	DT	the
proposal	NN	proposal
of	IN	of
a	DT	a
convalescent	JJ	convalescent
plasma	NN	plasma
(	(	(
CP	NP	CP
)	)	)
blood	NN	blood
product	NN	product
.	SENT	.
Clearly	RB	clearly
,	,	,
mere	JJ	mere
freedom	NN	freedom
from	IN	from
infectious	JJ	infectious
agents	NNS	agent
will	MD	will
not	RB	not
suffice	VB	suffice
in	IN	in
assessing	VBG	assess
CP	NP	CP
,	,	,
and	CC	and
an	DT	an
objective	JJ	objective
measure	NN	measure
of	IN	of
efficacy	NN	efficacy
,	,	,
so	RB	so
as	RB	as
to	TO	to
permit	VB	permit
formal	JJ	formal
benefit-risk	NN	<unknown>
analysis	NN	analysis
,	,	,
is	VBZ	be
essential	JJ	essential
.	SENT	.
This	DT	this
is	VBZ	be
both	DT	both
a	DT	a
scientific	JJ	scientific
and	CC	and
an	DT	an
ethical	JJ	ethical
demand	NN	demand
,	,	,
as	RB	as
has	VBZ	have
been	VBN	be
the	DT	the
case	NN	case
for	IN	for
other	JJ	other
experimental	JJ	experimental
COVID-19	NP	<unknown>
treatments	NNS	treatment
.	SENT	.
With	IN	with
special	JJ	special
reference	NN	reference
to	TO	to
COVID-19	NP	<unknown>
CP	NP	CP
,	,	,
the	DT	the
well-recognized	JJ	well-recognized
adverse	JJ	adverse
events	NNS	event
of	IN	of
transfusion-associated	JJ	transfusion-associated
lung	NN	lung
injury	NN	injury
(	(	(
TRALI	NP	<unknown>
)	)	)
and	CC	and
transfusion-associated	JJ	transfusion-associated
circulatory	JJ	circulatory
overload	NN	overload
(	(	(
TACO	NN	taco
)	)	)
will	MD	will
be	VB	be
important	JJ	important
.	SENT	.
Furthermore	RB	furthermore
,	,	,
not	RB	not
only	JJ	only
efficacy	NN	efficacy
but	CC	but
also	RB	also
product	NN	product
quality	NN	quality
attributes	VBZ	attribute
(	(	(
e.g.	FW	e.g.
,	,	,
antibody	NN	antibody
titre	NN	titre
)	)	)
will	MD	will
have	VB	have
to	TO	to
be	VB	be
defined	VBN	define
.	SENT	.
Both	CC	both
of	IN	of
these	DT	these
are	VBP	be
outside	IN	outside
the	DT	the
traditional	JJ	traditional
regulatory	JJ	regulatory
philosophy	NN	philosophy
for	IN	for
blood	NN	blood
products	NNS	product
and	CC	and
are	VBP	be
needed	VBN	need
to	TO	to
truly	RB	truly
assess	VB	assess
the	DT	the
benefit-risk	NN	<unknown>
of	IN	of
this	DT	this
putative	JJ	putative
therapeutic	JJ	therapeutic
product	NN	product
.	SENT	.
34230210/	CD	@card@
Kynurenic	NP	<unknown>
acid	NN	acid
may	MD	may
underlie	VB	underlie
sex-specific	JJ	sex-specific
immune	JJ	immune
responses	NNS	response
to	TO	to
COVID-19	NP	<unknown>
Compared	VBN	compare
to	TO	to
females	NNS	female
,	,	,
male	JJ	male
COVID-19	NP	<unknown>
patients	NNS	patient
have	VBP	have
more	RBR	more
kynurenic	JJ	<unknown>
acid	NN	acid
,	,	,
which	WDT	which
may	MD	may
underlie	VB	underlie
their	PP$	their
poorer	JJR	poor
immune	JJ	immune
response	NN	response
.	SENT	.
Males	NNS	male
and	CC	and
females	NNS	female
have	VBP	have
different	JJ	different
immune	JJ	immune
responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
infection	NN	infection
,	,	,
with	IN	with
male	JJ	male
sex	NN	sex
being	VBG	be
a	DT	a
risk	NN	risk
factor	NN	factor
for	IN	for
mortality	NN	mortality
,	,	,
particularly	RB	particularly
among	IN	among
older	JJR	old
individuals	NNS	individual
.	SENT	.
Cai	NP	Cai
et	FW	et
al.	FW	al.
performed	VBN	perform
metabolomics	NN	<unknown>
analysis	NN	analysis
of	IN	of
serum	NN	serum
from	IN	from
COVID-19	NP	<unknown>
patients	NNS	patient
and	CC	and
uninfected	JJ	uninfected
health	NN	health
care	NN	care
workers	NNS	worker
and	CC	and
identified	VBN	identify
17	CD	@card@
metabolites	NNS	metabolite
that	WDT	that
were	VBD	be
associated	VBN	associate
with	IN	with
the	DT	the
disease	NN	disease
.	SENT	.
However	RB	however
,	,	,
in	IN	in
male	JJ	male
COVID-19	NP	<unknown>
patients	NNS	patient
only	RB	only
,	,	,
the	DT	the
amount	NN	amount
of	IN	of
the	DT	the
tryptophan	NN	tryptophan
metabolite	NN	metabolite
kynurenic	JJ	<unknown>
acid	NN	acid
(	(	(
KA	NP	KA
)	)	)
correlated	VBD	correlate
with	IN	with
age	NN	age
,	,	,
inflammation	NN	inflammation
,	,	,
and	CC	and
disease	NN	disease
outcome	NN	outcome
.	SENT	.
KA	NP	KA
inhibits	VBZ	inhibit
glutamate	NN	glutamate
release	NN	release
,	,	,
and	CC	and
glutamate	NN	glutamate
abundance	NN	abundance
was	VBD	be
reduced	VBN	reduce
in	IN	in
patients	NNS	patient
who	WP	who
deteriorated	VBD	deteriorate
.	SENT	.
Together	RB	together
,	,	,
these	DT	these
findings	NNS	finding
indicate	VBP	indicate
that	IN	that
KA	NP	KA
is	VBZ	be
associated	VBN	associate
with	IN	with
sex-specific	JJ	sex-specific
differences	NNS	difference
in	IN	in
immune	JJ	immune
responses	NNS	response
to	TO	to
COVID-19	NP	<unknown>
,	,	,
suggesting	VBG	suggest
that	IN	that
it	PP	it
might	MD	might
be	VB	be
targeted	VBN	target
in	IN	in
male	JJ	male
patients	NNS	patient
.	SENT	.
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
poorer	JJR	poor
clinical	JJ	clinical
outcomes	NNS	outcome
in	IN	in
males	NNS	male
than	IN	than
in	IN	in
females	NNS	female
,	,	,
and	CC	and
immune	JJ	immune
responses	NNS	response
underlie	VBP	underlie
these	DT	these
sex-related	JJ	sex-related
differences	NNS	difference
.	SENT	.
Because	IN	because
immune	JJ	immune
responses	NNS	response
are	VBP	be
,	,	,
in	IN	in
part	NN	part
,	,	,
regulated	VBN	regulate
by	IN	by
metabolites	NNS	metabolite
,	,	,
we	PP	we
examined	VBD	examine
the	DT	the
serum	NN	serum
metabolomes	NNS	<unknown>
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
In	IN	in
male	JJ	male
patients	NNS	patient
,	,	,
kynurenic	JJ	<unknown>
acid	NN	acid
(	(	(
KA	NP	KA
)	)	)
and	CC	and
a	DT	a
high	JJ	high
KA-to-kynurenine	NP	<unknown>
(	(	(
K	NP	K
)	)	)
ratio	NN	ratio
(	(	(
KA:K	NP	<unknown>
)	)	)
positively	RB	positively
correlated	VBD	correlate
with	IN	with
age	NN	age
and	CC	and
with	IN	with
inflammatory	JJ	inflammatory
cytokines	NNS	cytokine
and	CC	and
chemokines	NNS	chemokine
and	CC	and
negatively	RB	negatively
correlated	VBN	correlate
with	IN	with
T	NN	T
cell	NN	cell
responses	NNS	response
.	SENT	.
Males	NNS	male
that	WDT	that
clinically	RB	clinically
deteriorated	VBD	deteriorate
had	VBD	have
a	DT	a
higher	JJR	high
KA:K	NP	<unknown>
than	IN	than
those	DT	those
that	WDT	that
stabilized	VBD	stabilize
.	SENT	.
KA	NP	KA
inhibits	VBZ	inhibit
glutamate	NN	glutamate
release	NN	release
,	,	,
and	CC	and
glutamate	NN	glutamate
abundance	NN	abundance
was	VBD	be
lower	JJR	low
in	IN	in
patients	NNS	patient
that	IN	that
clinically	RB	clinically
deteriorated	VBN	deteriorate
and	CC	and
correlated	VBN	correlate
with	IN	with
immune	JJ	immune
responses	NNS	response
.	SENT	.
Analysis	NN	analysis
of	IN	of
data	NNS	datum
from	IN	from
the	DT	the
Genotype-Tissue	NP	Genotype-Tissue
Expression	NN	expression
(	(	(
GTEx	NP	<unknown>
)	)	)
project	NN	project
revealed	VBD	reveal
that	IN	that
the	DT	the
expression	NN	expression
of	IN	of
the	DT	the
gene	NN	gene
encoding	VBG	encode
the	DT	the
enzyme	NN	enzyme
that	WDT	that
produces	VBZ	produce
KA	NP	KA
,	,	,
kynurenine	NN	<unknown>
aminotransferase	NN	aminotransferase
,	,	,
correlated	VBN	correlate
with	IN	with
cytokine	NN	<unknown>
abundance	NN	abundance
and	CC	and
activation	NN	activation
of	IN	of
immune	JJ	immune
responses	NNS	response
in	IN	in
older	JJR	old
males	NNS	male
.	SENT	.
This	DT	this
study	NN	study
reveals	VBZ	reveal
that	IN	that
KA	NP	KA
has	VBZ	have
a	DT	a
sex-specific	JJ	sex-specific
link	NN	link
to	TO	to
immune	JJ	immune
responses	NNS	response
and	CC	and
clinical	JJ	clinical
outcomes	NNS	outcome
in	IN	in
COVID-19	NP	<unknown>
,	,	,
suggesting	VBG	suggest
a	DT	a
positive	JJ	positive
feedback	NN	feedback
between	IN	between
metabolites	NNS	metabolite
and	CC	and
immune	JJ	immune
responses	NNS	response
in	IN	in
males	NNS	male
.	SENT	.
33448086/	CD	@card@
Beyond	IN	beyond
COVID-19	NP	<unknown>
:	:	:
Consumers	NNS	consumer
call	VBP	call
for	IN	for
greater	JJR	great
focus	NN	focus
on	IN	on
health	NN	health
equity	NN	equity
34110314/	CD	@card@
The	DT	the
Effect	NN	effect
of	IN	of
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
on	IN	on
Plastic	NP	Plastic
Surgery	NN	surgery
Practice	NN	practice
in	IN	in
a	DT	a
Tertiary	JJ	Tertiary
Health	NP	Health
Care	NP	Care
Center	NP	Center
in	IN	in
Egypt	NP	Egypt
34535859/	CD	@card@
COVID-19	NP	<unknown>
and	CC	and
increasing	VBG	increase
demand	NN	demand
for	IN	for
medical	JJ	medical
oxygen	NN	oxygen
:	:	:
can	MD	can
impurity	NN	impurity
be	VB	be
a	DT	a
problem	NN	problem
?	SENT	?
34412446/	CD	@card@
Herd	NP	Herd
immunity	NN	immunity
:	:	:
challenges	NNS	challenge
and	CC	and
the	DT	the
way	NN	way
forward	RB	forward
in	IN	in
Korea	NP	Korea
Vaccination	NN	vaccination
is	VBZ	be
considered	VBN	consider
to	TO	to
be	VB	be
the	DT	the
most	RBS	most
effective	JJ	effective
measure	NN	measure
for	IN	for
preventing	VBG	prevent
the	DT	the
spread	NN	spread
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
Many	JJ	many
countries	NNS	country
,	,	,
including	VBG	include
of	IN	of
Korea	NP	Korea
,	,	,
are	VBP	be
focusing	VBG	focus
on	IN	on
achieving	VBG	achieve
herd	NN	herd
immunity	NN	immunity
with	IN	with
the	DT	the
goal	NN	goal
of	IN	of
reaching	VBG	reach
a	DT	a
vaccination	NN	vaccination
rate	NN	rate
of	IN	of
70-80	CD	@card@
%	NN	%
.	SENT	.
However	RB	however
,	,	,
achieving	VBG	achieve
herd	NN	herd
immunity	NN	immunity
does	VBZ	do
not	RB	not
mean	VB	mean
eradicating	VBG	eradicate
COVID-19	NP	<unknown>
,	,	,
and	CC	and
the	DT	the
following	VBG	follow
challenges	NNS	challenge
can	MD	can
occur	VB	occur
in	IN	in
the	DT	the
process	NN	process
of	IN	of
achieving	VBG	achieve
herd	NN	herd
immunity	NN	immunity
.	SENT	.
First	RB	first
,	,	,
as	IN	as
the	DT	the
vaccination	NN	vaccination
rate	NN	rate
is	VBZ	be
likely	JJ	likely
to	TO	to
slow	VB	slow
down	RP	down
over	IN	over
time	NN	time
,	,	,
it	PP	it
is	VBZ	be
necessary	JJ	necessary
to	TO	to
promote	VB	promote
the	DT	the
benefits	NNS	benefit
of	IN	of
vaccination	NN	vaccination
through	IN	through
risk	NN	risk
communication	NN	communication
strategies	NNS	strategy
and	CC	and
provide	VB	provide
incentives	NNS	incentive
for	IN	for
those	DT	those
who	WP	who
have	VBP	have
been	VBN	be
vaccinated	VBN	vaccinate
.	SENT	.
Second	RB	second
,	,	,
a	DT	a
booster	NN	booster
dose	NN	dose
may	MD	may
be	VB	be
required	VBN	require
depending	VBG	depend
on	IN	on
future	JJ	future
studies	NNS	study
on	IN	on
vaccine-induced	JJ	<unknown>
immunity	NN	immunity
.	SENT	.
Third	JJ	third
,	,	,
since	IN	since
variants	NNS	variant
capable	JJ	capable
of	IN	of
evading	VBG	evade
immunity	NN	immunity
and	CC	and
with	IN	with
higher	JJR	high
transmissibility	NN	<unknown>
can	MD	can
emerge	VB	emerge
,	,	,
rapid	JJ	rapid
contract	NN	contract
tracing	NN	tracing
and	CC	and
regular	JJ	regular
community	NN	community
genomic	JJ	<unknown>
surveillance	NN	surveillance
could	MD	could
help	VB	help
mitigate	VB	mitigate
the	DT	the
impact	NN	impact
of	IN	of
new	JJ	new
variants	NNS	variant
.	SENT	.
When	WRB	when
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
controlled	VBN	control
to	TO	to
the	DT	the
level	NN	level
of	IN	of
seasonal	JJ	seasonal
influenza	NN	influenza
,	,	,
the	DT	the
current	JJ	current
public	JJ	public
health	NN	health
measures	NNS	measure
that	WDT	that
have	VBP	have
been	VBN	be
strictly	RB	strictly
imposed	VBN	impose
on	IN	on
society	NN	society
since	IN	since
the	DT	the
beginning	NN	beginning
of	IN	of
the	DT	the
pandemic	NN	pandemic
will	MD	will
no	RB	no
longer	RBR	longer
be	VB	be
needed	VBN	need
.	SENT	.
The	DT	the
overall	JJ	overall
response	NN	response
strategy	NN	strategy
to	TO	to
COVID-19	NP	<unknown>
will	MD	will
need	VB	need
to	TO	to
change	VB	change
accordingly	RB	accordingly
,	,	,
based	VBN	base
on	IN	on
evaluations	NNS	evaluation
of	IN	of
the	DT	the
level	NN	level
of	IN	of
population	NN	population
immunity	NN	immunity
.	SENT	.
These	DT	these
changes	NNS	change
will	MD	will
include	VB	include
more	RBR	more
efficient	JJ	efficient
and	CC	and
targeted	JJ	targeted
contact	NN	contact
tracing	NN	tracing
and	CC	and
eased	VBD	ease
quarantine	NN	quarantine
measures	NNS	measure
for	IN	for
vaccinated	VBN	vaccinate
close	JJ	close
contacts	NNS	contact
and	CC	and
travelers	NNS	traveler
.	SENT	.
Mask	NN	mask
wearing	VBG	wear
and	CC	and
a	DT	a
minimum	NN	minimum
of	IN	of
social	JJ	social
distancing	NN	distancing
will	MD	will
still	RB	still
be	VB	be
required	VBN	require
in	IN	in
the	DT	the
journey	NN	journey
towards	IN	towards
the	DT	the
end	NN	end
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
will	MD	will
end	VB	end
,	,	,
but	CC	but
the	DT	the
virus	NN	virus
will	MD	will
not	RB	not
disappear	VB	disappear
.	SENT	.
34703462/	CD	@card@
Weight	NP	Weight
gain	NN	gain
and	CC	and
physical	JJ	physical
inactivity	NN	inactivity
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
32776538/	CD	@card@
COVID-19	NP	<unknown>
related	JJ	related
immune	JJ	immune
hemolysis	NNS	hemolysi
and	CC	and
thrombocytopenia	NN	<unknown>
The	DT	the
current	JJ	current
pandemic	NN	pandemic
due	JJ	due
to	TO	to
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
posed	VBN	pose
an	DT	an
unprecedented	JJ	unprecedented
challenge	NN	challenge
for	IN	for
the	DT	the
medical	JJ	medical
communities	NNS	community
,	,	,
various	JJ	various
countries	NNS	country
worldwide	RB	worldwide
,	,	,
and	CC	and
their	PP$	their
citizens	NNS	citizen
.	SENT	.
Severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
has	VBZ	have
been	VBN	be
studied	VBN	study
for	IN	for
its	PP$	its
various	JJ	various
pathophysiological	JJ	pathophysiological
pathways	NNS	pathway
and	CC	and
mechanisms	NNS	mechanism
through	IN	through
which	WDT	which
it	PP	it
causes	VBZ	cause
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
discussed	VBD	discuss
the	DT	the
immunological	JJ	immunological
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
the	DT	the
hematological	JJ	hematological
system	NN	system
,	,	,
platelets	NNS	platelet
,	,	,
and	CC	and
red	JJ	red
blood	NN	blood
cells	NNS	cell
.	SENT	.
32680626/	CD	@card@
A	DT	a
survey	NN	survey
and	CC	and
panel	NN	panel
discussion	NN	discussion
of	IN	of
the	DT	the
effects	NNS	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
paediatric	JJ	paediatric
urological	JJ	urological
productivity	NN	productivity
,	,	,
guideline	NN	guideline
adherence	NN	adherence
and	CC	and
provider	NN	provider
stress	VBP	stress
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
led	VBN	lead
to	TO	to
an	DT	an
unprecedented	JJ	unprecedented
need	NN	need
to	TO	to
re-organise	VB	re-organise
and	CC	and
re-align	NN	<unknown>
priorities	NNS	priority
for	IN	for
all	DT	all
surgical	JJ	surgical
specialties	NNS	specialty
.	SENT	.
Despite	IN	despite
the	DT	the
current	JJ	current
declining	VBG	decline
numbers	NNS	number
globally	RB	globally
,	,	,
the	DT	the
direct	JJ	direct
effects	NNS	effect
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
institutional	JJ	institutional
practices	NNS	practice
and	CC	and
on	IN	on
personal	JJ	personal
stress	NN	stress
and	CC	and
coping	VBG	cope
mechanisms	NNS	mechanism
remains	VBZ	remain
unknown	JJ	unknown
.	SENT	.
The	DT	the
aims	VBZ	aim
of	IN	of
this	DT	this
study	NN	study
were	VBD	be
to	TO	to
assess	VB	assess
the	DT	the
effect	NN	effect
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
daily	JJ	daily
scheduling	NN	scheduling
and	CC	and
work	NN	work
balances	NNS	balance
,	,	,
its	PP$	its
effects	NNS	effect
on	IN	on
stress	NN	stress
,	,	,
and	CC	and
to	TO	to
determine	VB	determine
compliance	NN	compliance
with	IN	with
guidelines	NNS	guideline
and	CC	and
to	TO	to
assess	VB	assess
whether	IN	whether
quarantining	VBG	quarantine
has	VBZ	have
led	VBN	lead
to	TO	to
other	JJ	other
areas	NNS	area
of	IN	of
increased	VBN	increase
productivity	NN	productivity
.	SENT	.
A	DT	a
trans-Atlantic	JJ	trans-Atlantic
convenience	NN	convenience
sample	NN	sample
of	IN	of
paediatric	JJ	paediatric
urologists	NNS	urologist
was	VBD	be
created	VBN	create
in	IN	in
which	WDT	which
panellists	NNS	panellist
(	(	(
Zoom	NN	zoom
)	)	)
discussed	VBD	discuss
the	DT	the
direct	JJ	direct
effects	NNS	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
individual	JJ	individual
units	NNS	unit
,	,	,
as	RB	as
well	RB	well
as	IN	as
creating	VBG	create
a	DT	a
questionnaire	NN	questionnaire
using	VBG	use
a	DT	a
mini-Delphi	NN	<unknown>
method	NN	method
to	TO	to
provide	VB	provide
current	JJ	current
semi-quantitative	JJ	semi-quantitative
data	NNS	datum
regarding	VBG	regard
practice	NN	practice
,	,	,
and	CC	and
adherence	NN	adherence
levels	NNS	level
to	TO	to
recently	RB	recently
published	VBN	publish
risk	NN	risk
stratification	NN	stratification
guidelines	NNS	guideline
.	SENT	.
They	PP	they
also	RB	also
filled	VBD	fill
out	RP	out
a	DT	a
Perceived	VBN	perceive
Stress	NN	stress
Scale	NP	Scale
(	(	(
PSS	NP	PSS
)	)	)
questionnaire	NN	questionnaire
to	TO	to
assess	VB	assess
contemporary	JJ	contemporary
pandemic	JJ	pandemic
stress	NN	stress
levels	NNS	level
.	SENT	.
There	EX	there
was	VBD	be
an	DT	an
86	CD	@card@
%	NN	%
response	NN	response
rate	NN	rate
from	IN	from
paediatric	JJ	paediatric
urologists	NNS	urologist
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
respondents	NNS	respondent
reported	VBN	report
near	IN	near
complete	JJ	complete
disruption	NN	disruption
to	TO	to
planned	JJ	planned
operations	NNS	operation
(	(	(
70	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
trainee	NN	trainee
education	NN	education
(	(	(
70	CD	@card@
%	NN	%
)	)	)
.	SENT	.
They	PP	they
were	VBD	be
also	RB	also
worried	VBN	worry
about	IN	about
the	DT	the
effects	NNS	effect
of	IN	of
altered	JJ	altered
home-lives	NNS	home-life
on	IN	on
productivity	NN	productivity
(	(	(
&lt	NP	&lt
;	:	;
=90	JJ	=@card@
%	NN	%
)	)	)
,	,	,
as	RB	as
well	RB	well
as	IN	as
a	DT	a
lack	NN	lack
of	IN	of
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
(	(	(
57	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
baseline	JJ	baseline
stress	NN	stress
rate	NN	rate
was	VBD	be
measured	VBN	measure
at	IN	at
a	DT	a
very	RB	very
high	JJ	high
level	NN	level
(	(	(
PSS	NP	PSS
)	)	)
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Adherence	NN	adherence
to	TO	to
recent	JJ	recent
operative	JJ	operative
guidelines	NNS	guideline
for	IN	for
urgent	JJ	urgent
cases	NNS	case
was	VBD	be
100	CD	@card@
%	NN	%
.	SENT	.
Geographic	JJ	geographic
heatmap	NN	<unknown>
demonstrating	VBG	demonstrate
Transatlantic	JJ	transatlantic
international	JJ	international
discussion	NN	discussion
of	IN	of
the	DT	the
effects	NNS	effect
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
paediatric	JJ	paediatric
urological	JJ	urological
practice	NN	practice
.	SENT	.
This	DT	this
study	NN	study
represents	VBZ	represent
a	DT	a
panel	NN	panel
discussion	NN	discussion
of	IN	of
a	DT	a
number	NN	number
of	IN	of
practical	JJ	practical
implications	NNS	implication
for	IN	for
paediatric	JJ	paediatric
urologists	NNS	urologist
,	,	,
and	CC	and
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
few	JJ	few
papers	NNS	paper
to	TO	to
assess	VB	assess
more	JJR	more
pragmatic	JJ	pragmatic
effects	NNS	effect
and	CC	and
combines	NNS	combine
opinions	NNS	opinion
from	IN	from
both	DT	both
sides	NNS	side
of	IN	of
the	DT	the
Atlantic	NP	Atlantic
.	SENT	.
The	DT	the
impact	NN	impact
of	IN	of
the	DT	the
pandemic	NN	pandemic
has	VBZ	have
been	VBN	be
very	RB	very
significant	JJ	significant
for	IN	for
paediatric	JJ	paediatric
urologists	NNS	urologist
and	CC	and
includes	VBZ	include
a	DT	a
decrease	NN	decrease
in	IN	in
the	DT	the
number	NN	number
of	IN	of
patients	NNS	patient
seen	VBN	see
and	CC	and
operated	VBN	operate
on	IN	on
,	,	,
decreased	VBD	decrease
salary	NN	salary
,	,	,
increased	VBD	increase
self-reported	JJ	self-reported
stress	NN	stress
levels	NNS	level
,	,	,
substantially	RB	substantially
increased	VBN	increase
telemedicine	NN	telemedicine
usage	NN	usage
,	,	,
increased	VBD	increase
free	JJ	free
time	NN	time
for	IN	for
various	JJ	various
activities	NNS	activity
,	,	,
and	CC	and
good	JJ	good
compliance	NN	compliance
with	IN	with
guidelines	NNS	guideline
and	CC	and
hospital	NN	hospital
management	NN	management
decisions	NNS	decision
.	SENT	.
34177926/	CD	@card@
Antibody	NN	antibody
Responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
Following	VBG	follow
an	DT	an
Outbreak	NN	outbreak
Among	IN	among
Marine	NP	Marine
Recruits	NNS	recruit
With	IN	with
Asymptomatic	JJ	asymptomatic
or	CC	or
Mild	JJ	mild
Infection	NN	infection
We	PP	we
investigated	VBD	investigate
serological	JJ	serological
responses	NNS	response
following	VBG	follow
a	DT	a
SARS-CoV-2	JJ	<unknown>
outbreak	NN	outbreak
in	IN	in
spring	NN	spring
2020	CD	@card@
on	IN	on
a	DT	a
US	NP	US
Marine	NP	Marine
recruit	NN	recruit
training	NN	training
base	NN	base
.	SENT	.
147	CD	@card@
participants	NNS	participant
that	WDT	that
were	VBD	be
isolated	VBN	isolate
during	IN	during
an	DT	an
outbreak	NN	outbreak
of	IN	of
respiratory	JJ	respiratory
illness	NN	illness
were	VBD	be
enrolled	VBN	enroll
in	IN	in
this	DT	this
study	NN	study
,	,	,
with	IN	with
visits	NNS	visit
approximately	RB	approximately
6	CD	@card@
and	CC	and
10	CD	@card@
weeks	NNS	week
post-outbreak	NN	post-outbreak
(	(	(
PO	NN	po
)	)	)
.	SENT	.
This	DT	this
cohort	NN	cohort
is	VBZ	be
comprised	VBN	comprise
of	IN	of
young	JJ	young
healthy	JJ	healthy
adults	NNS	adult
,	,	,
ages	NNS	age
18-26	CD	@card@
,	,	,
with	IN	with
a	DT	a
high	JJ	high
rate	NN	rate
of	IN	of
asymptomatic	JJ	asymptomatic
infection	NN	infection
or	CC	or
mild	JJ	mild
symptoms	NNS	symptom
,	,	,
and	CC	and
therefore	RB	therefore
differs	VBZ	differ
from	IN	from
previously	RB	previously
reported	VBN	report
longitudinal	JJ	longitudinal
studies	NNS	study
on	IN	on
humoral	JJ	humoral
responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
,	,	,
which	WDT	which
often	RB	often
focus	VBP	focus
on	IN	on
more	JJR	more
diverse	JJ	diverse
age	NN	age
populations	NNS	population
and	CC	and
worse	JJR	bad
clinical	JJ	clinical
presentation	NN	presentation
.	SENT	.
80.9	CD	@card@
%	NN	%
(	(	(
119/147	CD	@card@
)	)	)
of	IN	of
the	DT	the
participants	NNS	participant
presented	VBN	present
with	IN	with
circulating	VBG	circulate
IgG	NP	IgG
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
spike	NN	spike
(	(	(
S	NP	S
)	)	)
receptor-binding	NN	receptor-binding
domain	NN	domain
(	(	(
RBD	NN	RBD
)	)	)
at	IN	at
6	CD	@card@
weeks	NNS	week
PO	NN	po
,	,	,
of	IN	of
whom	WP	whom
97.3	CD	@card@
%	NN	%
(	(	(
111/114	CD	@card@
)	)	)
remained	VBD	remain
positive	JJ	positive
,	,	,
with	IN	with
significantly	RB	significantly
decreased	VBN	decrease
levels	NNS	level
,	,	,
at	IN	at
10	CD	@card@
weeks	NNS	week
PO	NN	po
.	SENT	.
Neutralizing	VBG	neutralize
activity	NN	activity
was	VBD	be
detected	VBN	detect
in	IN	in
all	DT	all
sera	NN	sera
from	IN	from
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
positive	JJ	positive
participants	NNS	participant
tested	VBN	test
(	(	(
n=38	NN	<unknown>
)	)	)
at	IN	at
6	CD	@card@
and	CC	and
10	CD	@card@
weeks	NNS	week
PO	NN	po
,	,	,
without	IN	without
significant	JJ	significant
loss	NN	loss
between	IN	between
time	NN	time
points	NNS	point
.	SENT	.
IgG	NP	IgG
and	CC	and
IgA	NP	IgA
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
RBD	NP	RBD
,	,	,
S1	NP	<unknown>
,	,	,
S2	NP	<unknown>
,	,	,
and	CC	and
the	DT	the
nucleocapsid	NN	nucleocapsid
(	(	(
N	NP	N
)	)	)
protein	NN	protein
,	,	,
as	IN	as
well	RB	well
neutralization	NN	neutralization
activity	NN	activity
,	,	,
were	VBD	be
generally	RB	generally
comparable	JJ	comparable
between	IN	between
those	DT	those
participants	NNS	participant
that	WDT	that
had	VBD	have
asymptomatic	JJ	asymptomatic
infection	NN	infection
or	CC	or
mild	JJ	mild
disease	NN	disease
.	SENT	.
A	DT	a
multiplex	JJ	multiplex
assay	NN	assay
including	VBG	include
S	NP	S
proteins	NNS	protein
from	IN	from
SARS-CoV-2	NP	<unknown>
and	CC	and
related	JJ	related
zoonotic	JJ	<unknown>
and	CC	and
human	JJ	human
endemic	JJ	endemic
betacoronaviruses	NNS	betacoronavirus
revealed	VBD	reveal
a	DT	a
positive	JJ	positive
correlation	NN	correlation
for	IN	for
polyclonal	JJ	polyclonal
cross-reactivity	NN	cross-reactivity
to	TO	to
S	NP	S
after	IN	after
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
Overall	RB	overall
,	,	,
young	JJ	young
adults	NNS	adult
that	WDT	that
experienced	VBD	experience
asymptomatic	JJ	asymptomatic
or	CC	or
mild	JJ	mild
SARS-CoV-2	NP	<unknown>
infection	NN	infection
developed	VBD	develop
comparable	JJ	comparable
humoral	JJ	humoral
responses	NNS	response
,	,	,
with	IN	with
no	DT	no
decrease	NN	decrease
in	IN	in
neutralizing	VBG	neutralize
activity	NN	activity
at	IN	at
least	JJS	least
up	RB	up
to	TO	to
10	CD	@card@
weeks	NNS	week
after	IN	after
infection	NN	infection
.	SENT	.
34777896/	CD	@card@
Nanomaterial	NP	<unknown>
Based	VBN	base
Biosensors	NNS	Biosensor
for	IN	for
Detection	NN	detection
of	IN	of
Viruses	NNS	virus
Including	VBG	include
SARS-CoV-2	NP	<unknown>
:	:	:
A	DT	a
Review	NP	Review
The	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
led	VBD	lead
to	TO	to
an	DT	an
uncontrollable	JJ	uncontrollable
situation	NN	situation
and	CC	and
was	VBD	be
later	RBR	later
declared	VBN	declare
a	DT	a
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
RT-PCR	NP	<unknown>
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
reliable	JJ	reliable
methods	NNS	method
for	IN	for
the	DT	the
detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
,	,	,
but	CC	but
it	PP	it
requires	VBZ	require
transporting	VBG	transport
samples	NNS	sample
to	TO	to
sophisticated	JJ	sophisticated
laboratories	NNS	laboratory
and	CC	and
takes	VBZ	take
a	DT	a
significant	JJ	significant
amount	NN	amount
of	IN	of
time	NN	time
to	TO	to
amplify	VB	amplify
the	DT	the
viral	JJ	viral
genome	NN	genome
.	SENT	.
Therefore	RB	therefore
,	,	,
there	EX	there
is	VBZ	be
an	DT	an
urgent	JJ	urgent
need	NN	need
for	IN	for
a	DT	a
large-scale	JJ	large-scale
,	,	,
rapid	JJ	rapid
,	,	,
specific	JJ	specific
,	,	,
and	CC	and
portable	JJ	portable
detection	NN	detection
kit	NN	kit
.	SENT	.
Nowadays	RB	nowadays
nanomaterials-based	JJ	<unknown>
detection	NN	detection
technology	NN	technology
has	VBZ	have
been	VBN	be
developed	VBN	develop
and	CC	and
it	PP	it
showed	VBD	show
advancement	NN	advancement
over	IN	over
the	DT	the
conventional	JJ	conventional
methods	NNS	method
in	IN	in
selectivity	NN	selectivity
and	CC	and
sensitivity	NN	sensitivity
.	SENT	.
This	DT	this
review	NN	review
aims	VBZ	aim
at	IN	at
summarising	VBG	summarise
some	DT	some
of	IN	of
the	DT	the
most	RBS	most
promising	JJ	promising
nanomaterial-based	JJ	<unknown>
sensing	VBG	sense
technologies	NNS	technology
for	IN	for
detecting	VBG	detect
SARS-CoV-2	NP	<unknown>
.	SENT	.
Nanomaterials	NNS	Nanomaterial
possess	VBP	possess
unique	JJ	unique
physical	JJ	physical
,	,	,
chemical	JJ	chemical
,	,	,
electrical	JJ	electrical
and	CC	and
optical	JJ	optical
properties	NNS	property
,	,	,
which	WDT	which
can	MD	can
be	VB	be
exploited	VBN	exploit
for	IN	for
the	DT	the
application	NN	application
in	IN	in
biosensors	NNS	biosensor
.	SENT	.
Furthermore	RB	furthermore
,	,	,
nanomaterials	NNS	nanomaterial
work	VBP	work
on	IN	on
the	DT	the
same	JJ	same
scale	NN	scale
as	IN	as
biological	JJ	biological
processes	NNS	process
and	CC	and
can	MD	can
be	VB	be
easily	RB	easily
functionalized	VBN	<unknown>
with	IN	with
substrates	NNS	substrate
of	IN	of
interest	NN	interest
.	SENT	.
These	DT	these
devices	NNS	device
do	VBP	do
not	RB	not
require	VB	require
extraordinary	JJ	extraordinary
sophistication	NN	sophistication
and	CC	and
are	VBP	be
suitable	JJ	suitable
for	IN	for
use	NN	use
by	IN	by
common	JJ	common
individuals	NNS	individual
without	IN	without
high-tech	JJ	high-tech
laboratories	NNS	laboratory
.	SENT	.
Electrochemical	JJ	electrochemical
and	CC	and
colorimetric	JJ	colorimetric
methods	NNS	method
similar	JJ	similar
to	TO	to
glucometer	NN	glucometer
and	CC	and
pregnancy	NN	pregnancy
test	NN	test
kits	NNS	kit
are	VBP	be
discussed	VBN	discuss
and	CC	and
reviewed	VBN	review
as	IN	as
potential	JJ	potential
diagnostic	JJ	diagnostic
devices	NNS	device
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
Other	JJ	other
devices	NNS	device
working	VBG	work
on	IN	on
the	DT	the
principle	NN	principle
of	IN	of
immune	JJ	immune
response	NN	response
and	CC	and
microarrays	NNS	microarray
are	VBP	be
also	RB	also
discussed	VBN	discuss
as	IN	as
possible	JJ	possible
candidates	NNS	candidate
.	SENT	.
Nanomaterials	NNS	Nanomaterial
such	JJ	such
as	IN	as
metal	NN	metal
nanoparticles	NNS	nanoparticle
,	,	,
graphene	NN	<unknown>
,	,	,
quantum	NN	quantum
dots	NNS	dot
,	,	,
and	CC	and
CNTs	NP	<unknown>
enhance	VB	enhance
the	DT	the
limit	NN	limit
of	IN	of
detection	NN	detection
and	CC	and
accuracy	NN	accuracy
of	IN	of
the	DT	the
biosensors	NNS	biosensor
to	TO	to
give	VB	give
spontaneous	JJ	spontaneous
results	NNS	result
.	SENT	.
The	DT	the
challenges	NNS	challenge
of	IN	of
industrial-scale	JJ	<unknown>
production	NN	production
of	IN	of
these	DT	these
devices	NNS	device
are	VBP	be
also	RB	also
discussed	VBN	discuss
.	SENT	.
If	IN	if
mass	JJ	mass
production	NN	production
is	VBZ	be
successfully	RB	successfully
developed	VBN	develop
,	,	,
these	DT	these
sensors	NNS	sensor
can	MD	can
ramp	VB	ramp
up	RP	up
the	DT	the
testing	NN	testing
to	TO	to
provide	VB	provide
the	DT	the
accurate	JJ	accurate
number	NN	number
of	IN	of
people	NNS	people
affected	VBN	affect
by	IN	by
the	DT	the
virus	NN	virus
,	,	,
which	WDT	which
is	VBZ	be
extremely	RB	extremely
critical	JJ	critical
in	IN	in
today	NN	today
's	POS	's
scenario	NN	scenario
.	SENT	.
32100024/	CD	@card@
De-isolating	NP	<unknown>
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
Suspected	VBN	suspect
Cases	NNS	case
:	:	:
A	DT	a
Continuing	VBG	continue
Challenge	NP	Challenge
34867122/	CD	@card@
COVID-19	NP	<unknown>
Fear	NN	fear
Among	IN	among
Pakistanis	NNS	Pakistani
:	:	:
Psychometric	JJ	psychometric
Evaluation	NN	evaluation
of	IN	of
the	DT	the
Fear	NN	fear
of	IN	of
COVID-19	NP	<unknown>
Scale	NP	Scale
Using	VBG	use
Item	NN	item
Response	NP	Response
Theory	NN	theory
and	CC	and
Confirmatory	JJ	confirmatory
Factor	NP	Factor
Analysis	NP	Analysis
The	DT	the
Fear	NN	fear
of	IN	of
COVID-19	NP	<unknown>
Scale	NP	Scale
(	(	(
FCV-19S	NP	<unknown>
)	)	)
assesses	VBZ	assess
the	DT	the
fear	NN	fear
of	IN	of
the	DT	the
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
and	CC	and
has	VBZ	have
been	VBN	be
translated	VBN	translate
and	CC	and
validated	VBN	validate
into	IN	into
over	IN	over
20	CD	@card@
languages	NNS	language
.	SENT	.
The	DT	the
present	JJ	present
study	NN	study
conducted	VBN	conduct
confirmatory	JJ	confirmatory
factor	NN	factor
analysis	NN	analysis
(	(	(
CFA	NP	CFA
)	)	)
and	CC	and
item	NN	item
response	NN	response
theory	NN	theory
(	(	(
IRT	NP	IRT
)	)	)
analyses	NNS	analysis
on	IN	on
the	DT	the
FCV-19S	NP	<unknown>
among	IN	among
a	DT	a
sample	NN	sample
of	IN	of
937	CD	@card@
Pakistani	JJ	Pakistani
adults	NNS	adult
(	(	(
mean	NN	mean
[	SYM	[
SD	NP	SD
]	SYM	]
age	NN	age
of	IN	of
25.83	CD	@card@
[	SYM	[
11.80	CD	@card@
]	SYM	]
years	NNS	year
;	:	;
537	CD	@card@
[	SYM	[
57.3	CD	@card@
%	NN	%
]	SYM	]
females	NNS	female
)	)	)
.	SENT	.
The	DT	the
CFA	NP	CFA
and	CC	and
IRT	NP	IRT
confirmed	VBD	confirm
the	DT	the
unidimensionality	NN	unidimensionality
of	IN	of
the	DT	the
FCV-19S	NP	<unknown>
.	SENT	.
The	DT	the
Likert-type	NP	<unknown>
scale	NN	scale
used	VBN	use
in	IN	in
the	DT	the
FCV-19S	NP	<unknown>
was	VBD	be
supported	VBN	support
by	IN	by
the	DT	the
proper	JJ	proper
threshold	NN	threshold
orderings	NNS	ordering
.	SENT	.
Additionally	RB	additionally
,	,	,
no	DT	no
DIF	NP	DIF
contrast	NN	contrast
had	VBD	have
an	DT	an
absolute	JJ	absolute
value	NN	value
larger	JJR	large
than	IN	than
0.5	CD	@card@
regarding	VBG	regard
the	DT	the
participants	NNS	participant
'	POS	'
characteristics	NNS	characteristic
of	IN	of
gender	NN	gender
,	,	,
age	NN	age
,	,	,
living	VBG	live
status	NN	status
,	,	,
and	CC	and
education	NN	education
in	IN	in
the	DT	the
IRT	NP	IRT
findings	NNS	finding
.	SENT	.
The	DT	the
FCV-19S	NP	<unknown>
was	VBD	be
found	VBN	find
to	TO	to
be	VB	be
valid	JJ	valid
and	CC	and
reliable	JJ	reliable
with	IN	with
strong	JJ	strong
psychometric	JJ	psychometric
properties	NNS	property
among	IN	among
the	DT	the
Pakistani	JJ	Pakistani
adult	NN	adult
population	NN	population
.	SENT	.
35066705/	CD	@card@
Ocular	JJ	ocular
transmissibility	NN	<unknown>
of	IN	of
COVID-19	NP	<unknown>
:	:	:
possibilities	NNS	possibility
and	CC	and
perspectives	NNS	perspective
Since	IN	since
the	DT	the
initial	JJ	initial
outbreak	NN	outbreak
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
extensive	JJ	extensive
research	NN	research
has	VBZ	have
emerged	VBN	emerge
from	IN	from
across	IN	across
the	DT	the
globe	NN	globe
to	TO	to
understand	VB	understand
the	DT	the
pathophysiology	NN	pathophysiology
of	IN	of
this	DT	this
novel	NN	novel
coronavirus	NN	coronavirus
.	SENT	.
Transmission	NN	transmission
of	IN	of
this	DT	this
virus	NN	virus
is	VBZ	be
a	DT	a
subject	NN	subject
of	IN	of
particular	JJ	particular
interest	NN	interest
as	IN	as
researchers	NNS	researcher
work	VBP	work
to	TO	to
understand	VB	understand
which	WDT	which
protective	JJ	protective
and	CC	and
preventative	JJ	preventative
measures	NNS	measure
are	VBP	be
most	RBS	most
effective	JJ	effective
.	SENT	.
Despite	IN	despite
the	DT	the
well	RB	well
understood	VBN	understand
model	NN	model
of	IN	of
aerosol-respiratory	JJ	aerosol-respiratory
mediated	VBN	mediate
transmission	NN	transmission
,	,	,
the	DT	the
exact	JJ	exact
mechanism	NN	mechanism
underlying	VBG	underlie
the	DT	the
inoculation	NN	inoculation
,	,	,
infection	NN	infection
and	CC	and
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
currently	RB	currently
unknown	JJ	unknown
.	SENT	.
Given	VBN	give
anatomical	JJ	anatomical
positioning	NN	positioning
and	CC	and
near	JJ	near
constant	JJ	constant
exposure	NN	exposure
to	TO	to
aerosolized	JJ	<unknown>
pathogens	NNS	pathogen
,	,	,
the	DT	the
eye	NN	eye
may	MD	may
be	VB	be
a	DT	a
possible	JJ	possible
gateway	NN	gateway
for	IN	for
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
This	DT	this
critical	JJ	critical
review	NN	review
explores	VBZ	explore
the	DT	the
possibility	NN	possibility
of	IN	of
an	DT	an
ocular-systemic	JJ	ocular-systemic
or	CC	or
ocular-nasal-pulmonic	JJ	ocular-nasal-pulmonic
pathway	NN	pathway
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
and	CC	and
includes	VBZ	include
novel	NN	novel
insights	NNS	insight
into	IN	into
the	DT	the
possible	JJ	possible
immunological	JJ	immunological
mechanisms	NNS	mechanism
leading	VBG	lead
to	TO	to
cytokine	NN	<unknown>
surge	NN	surge
.	SENT	.
35382039/	CD	@card@
Online	JJ	online
administration	NN	administration
of	IN	of
a	DT	a
pilot	JJ	pilot
mindfulness-based	JJ	<unknown>
intervention	NN	intervention
for	IN	for
adolescents	NNS	adolescent
:	:	:
Feasibility	NN	feasibility
,	,	,
treatment	NN	treatment
perception	NN	perception
and	CC	and
satisfaction	NN	satisfaction
Adolescents	NNS	adolescent
may	MD	may
be	VB	be
more	RBR	more
vulnerable	JJ	vulnerable
to	TO	to
COVID-19-related	JJ	COVID-19-related
impacts	NNS	impact
and	CC	and
require	VB	require
long-term	JJ	long-term
mental	JJ	mental
health	NN	health
care	NN	care
.	SENT	.
Services	NNS	service
that	WDT	that
bolster	VB	bolster
emotion	NN	emotion
regulation	NN	regulation
,	,	,
such	JJ	such
as	IN	as
mindfulness-based	JJ	<unknown>
interventions	NNS	intervention
(	(	(
MBIs	NP	<unknown>
)	)	)
promote	VB	promote
positive	JJ	positive
impacts	NNS	impact
on	IN	on
psychosocial	JJ	psychosocial
outcomes	NNS	outcome
and	CC	and
have	VBP	have
high	JJ	high
acceptability	NN	acceptability
.	SENT	.
No	DT	no
studies	NNS	study
have	VBP	have
assessed	VBN	assess
feasibility	NN	feasibility
,	,	,
treatment	NN	treatment
perceptions	NNS	perception
and	CC	and
satisfaction	NN	satisfaction
of	IN	of
online	JJ	online
MBIs	NNS	<unknown>
with	IN	with
adolescents	NNS	adolescent
.	SENT	.
56	CD	@card@
moderate-	NN	<unknown>
and	CC	and
high-risk	JJ	high-risk
adolescent	NN	adolescent
(	(	(
m	NN	m
=	SYM	=
14.5	CD	@card@
years	NNS	year
,	,	,
66.1	CD	@card@
%	NN	%
female	NN	female
,	,	,
26.8	CD	@card@
%	NN	%
LatinX	NN	<unknown>
)	)	)
participants	NNS	participant
tested	VBD	test
the	DT	the
feasibility	NN	feasibility
,	,	,
treatment	NN	treatment
perceptions	NNS	perception
and	CC	and
satisfaction	NN	satisfaction
of	IN	of
an	DT	an
8-session	JJ	<unknown>
online	JJ	online
MBI	NP	MBI
focused	VBD	focus
on	IN	on
observing	VBG	observe
non-judgmentally	RB	non-judgmentally
,	,	,
attending	VBG	attend
to	TO	to
positivity	NN	<unknown>
,	,	,
and	CC	and
self-soothing	NN	self-soothing
.	SENT	.
The	DT	the
study	NN	study
achieved	VBD	achieve
acceptable	JJ	acceptable
feasibility	NN	feasibility
with	IN	with
high	JJ	high
attendance	NN	attendance
(	(	(
m	NN	m
=	SYM	=
5.75	CD	@card@
)	)	)
and	CC	and
retention	NN	retention
rates	NNS	rate
(	(	(
87.5	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
moderate-	NN	<unknown>
vs.	IN	vs.
high-risk	JJ	high-risk
group	NN	group
reported	VBD	report
significantly	RB	significantly
higher	JJR	high
ratings	NNS	rating
of	IN	of
treatment	NN	treatment
perceptions	NNS	perception
(	(	(
t	NN	t
=	SYM	=
2.03	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
.05	CD	@card@
,	,	,
d	LS	d
=	SYM	=
0.60	CD	@card@
)	)	)
.	SENT	.
Significant	JJ	significant
associations	NNS	association
were	VBD	be
found	VBN	find
between	IN	between
increased	VBN	increase
pre-test	JJ	pre-test
depression	NN	depression
and	CC	and
anxiety	NN	anxiety
symptomology	NN	symptomology
and	CC	and
reduced	VBN	reduce
intervention	NN	intervention
utility	NN	utility
(	(	(
rs	NNS	<unknown>
=	SYM	=
-0.34	CD	@card@
and	CC	and
-0.32	CD	@card@
,	,	,
ps	JJ	<unknown>
&lt	NN	&lt
;	:	;
.05	LS	@card@
)	)	)
.	SENT	.
This	DT	this
study	NN	study
demonstrated	VBD	demonstrate
feasibility	NN	feasibility
,	,	,
treatment	NN	treatment
perceptions	NNS	perception
and	CC	and
satisfaction	NN	satisfaction
of	IN	of
an	DT	an
online	JJ	online
MBI	NP	MBI
for	IN	for
adolescents	NNS	adolescent
presenting	VBG	present
with	IN	with
two	CD	two
risk	NN	risk
levels	NNS	level
.	SENT	.
Higher-risk	NN	higher-risk
adolescents	NNS	adolescent
may	MD	may
need	VB	need
a	DT	a
higher-touch	NN	higher-touch
intervention	NN	intervention
than	IN	than
moderate-risk	NN	<unknown>
,	,	,
who	WP	who
may	MD	may
be	VB	be
more	RBR	more
likely	JJ	likely
to	TO	to
find	VB	find
online	JJ	online
MBIs	NNS	<unknown>
acceptable	JJ	acceptable
.	SENT	.
The	DT	the
impact	NN	impact
of	IN	of
adjunctive	JJ	adjunctive
MBIs	NNS	<unknown>
for	IN	for
adolescents	NNS	adolescent
on	IN	on
treatment	NN	treatment
attendance	NN	attendance
and	CC	and
mental	JJ	mental
health	NN	health
outcomes	NNS	outcome
over	IN	over
longer	JJR	long
periods	NNS	period
is	VBZ	be
necessary	JJ	necessary
to	TO	to
understand	VB	understand
patterns	NNS	pattern
in	IN	in
effective	JJ	effective
adolescent	JJ	adolescent
treatment	NN	treatment
options	NNS	option
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s12144-022-03025-x	NP	<unknown>
.	SENT	.
34986676/	CD	@card@
Measurement	NN	measurement
of	IN	of
antibody	NN	antibody
levels	NNS	level
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
over	IN	over
time	NN	time
by	IN	by
immunofluorescence	NN	immunofluorescence
assay	NN	assay
:	:	:
a	DT	a
longitudinal	JJ	longitudinal
observational	JJ	observational
study	NN	study
During	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
,	,	,
antibody	NN	antibody
screening	NN	screening
is	VBZ	be
a	DT	a
critical	JJ	critical
tool	NN	tool
to	TO	to
assess	VB	assess
anti-severe	JJ	anti-severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
immunity	NN	immunity
.	SENT	.
We	PP	we
examined	VBD	examine
variation	NN	variation
in	IN	in
antibody	NN	antibody
titers	NNS	titer
associated	VBN	associate
with	IN	with
age	NN	age
and	CC	and
sex	NN	sex
among	IN	among
patients	NNS	patient
with	IN	with
confirmed	VBN	confirm
COVID-19	NP	<unknown>
.	SENT	.
Blood	NP	Blood
IgG	NP	IgG
levels	NNS	level
were	VBD	be
tested	VBN	test
in	IN	in
1081	CD	@card@
patients	NNS	patient
with	IN	with
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
quantitative	JJ	quantitative
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
RT-qPCR	NP	<unknown>
)	)	)
tests	NNS	test
between	IN	between
1	CD	@card@
September	NP	September
and	CC	and
31	CD	@card@
December	NP	December
2020	CD	@card@
.	SENT	.
Patients	NNS	patient
who	WP	who
did	VBD	do
not	RB	not
experience	NN	experience
reinfection	NN	reinfection
were	VBD	be
identified	VBN	identify
.	SENT	.
Serum	NP	Serum
IgG	NP	IgG
levels	NNS	level
were	VBD	be
measured	VBN	measure
by	IN	by
immunofluorescence	NN	immunofluorescence
assay	NN	assay
.	SENT	.
Antibody	NN	antibody
positivity	NN	<unknown>
and	CC	and
antibody	NN	antibody
titers	NNS	titer
were	VBD	be
analyzed	VBN	analyze
according	VBG	accord
to	TO	to
time	NN	time
since	IN	since
infection	NN	infection
,	,	,
sex	NN	sex
,	,	,
and	CC	and
age	NN	age
.	SENT	.
The	DT	the
mean	JJ	mean
(	(	(
standard	JJ	standard
deviation	NN	deviation
)	)	)
age	NN	age
was	VBD	be
41.2	CD	@card@
(	(	(
14.2	CD	@card@
)	)	)
years	NNS	year
and	CC	and
41.2	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
were	VBD	be
women	NNS	woman
.	SENT	.
The	DT	the
lowest	JJS	low
antibody	NN	antibody
positivity	NN	<unknown>
rate	NN	rate
between	IN	between
the	DT	the
first	JJ	first
and	CC	and
ninth	JJ	ninth
month	NN	month
post-infection	NN	post-infection
was	VBD	be
detected	VBN	detect
in	IN	in
the	DT	the
sixth	JJ	sixth
month	NN	month
.	SENT	.
The	DT	the
lowest	JJS	low
antibody	NN	antibody
titers	NNS	titer
among	IN	among
patients	NNS	patient
aged	VBN	age
20	CD	@card@
to	TO	to
80	CD	@card@
years	NNS	year
occurred	VBN	occur
in	IN	in
those	DT	those
aged	VBN	age
30	CD	@card@
to	TO	to
39	CD	@card@
years	NNS	year
.	SENT	.
The	DT	the
IgG	NP	IgG
titer	NN	titer
was	VBD	be
positively	RB	positively
correlated	VBN	correlate
with	IN	with
age	NN	age
in	IN	in
years	NNS	year
(	(	(
r	LS	r
=	SYM	=
0.125	CD	@card@
)	)	)
and	CC	and
decades	NNS	decade
(	(	(
r	LS	r
=	SYM	=
0.126	CD	@card@
)	)	)
.	SENT	.
Six	CD	six
months	NNS	month
after	IN	after
infection	NN	infection
,	,	,
anti-SARS-CoV-2	JJ	<unknown>
antibody	NN	antibody
titers	NNS	titer
increased	VBD	increase
.	SENT	.
Anti-SARS-CoV-2	JJ	<unknown>
antibody	NN	antibody
titers	NNS	titer
also	RB	also
increased	VBN	increase
with	IN	with
age	NN	age
.	SENT	.
Immunity	NN	immunity
and	CC	and
pathogenicity	NN	<unknown>
should	MD	should
be	VB	be
investigated	VBN	investigate
in	IN	in
addition	NN	addition
to	TO	to
antibody	NN	antibody
positivity	NN	<unknown>
rates	NNS	rate
and	CC	and
antibody	NN	antibody
titers	NNS	titer
.	SENT	.
32421878/	CD	@card@
Efficacy	NN	efficacy
of	IN	of
hydrogel	NN	<unknown>
patches	NNS	patch
in	IN	in
preventing	VBG	prevent
facial	JJ	facial
skin	NN	skin
damage	NN	damage
caused	VBN	cause
by	IN	by
mask	NN	mask
compression	NN	compression
in	IN	in
fighting	VBG	fight
against	IN	against
coronavirus	NN	coronavirus
disease-2019	NN	<unknown>
:	:	:
a	DT	a
short-term	JJ	short-term
,	,	,
self-controlled	JJ	self-controlled
study	NN	study
During	IN	during
the	DT	the
recent	JJ	recent
ongoing	JJ	ongoing
coronavirus	NN	coronavirus
disease-2019	NN	<unknown>
(	(	(
COVID-19	NP	<unknown>
)	)	)
outbreak	NN	outbreak
,	,	,
healthcare	NN	<unknown>
workers	NNS	worker
around	IN	around
the	DT	the
world	NN	world
are	VBP	be
fighting	VBG	fight
at	IN	at
the	DT	the
front	JJ	front
lines	NNS	line
of	IN	of
this	DT	this
epidemic	NN	epidemic
,	,	,
as	RB	as
well	RB	well
as	IN	as
the	DT	the
dermatologists	NNS	dermatologist
.	SENT	.
Our	PP$	our
previous	JJ	previous
research	NN	research
revealed	VBD	reveal
that	IN	that
long-term	JJ	long-term
wearing	VBG	wear
of	IN	of
N95	JJ	N@card@
masks	NNS	mask
could	MD	could
lead	VB	lead
to	TO	to
various	JJ	various
facial	JJ	facial
skin	NN	skin
lesions	NNS	lesion
,	,	,
which	WDT	which
might	MD	might
affect	VB	affect
their	PP$	their
routine	JJ	routine
work	NN	work
and	CC	and
mental	JJ	mental
health	NN	health
.	SENT	.
More	RBR	more
importantly	RB	importantly
,	,	,
severe	JJ	severe
skin	NN	skin
lesions	NNS	lesion
(	(	(
e.g.	FW	e.g.
ulcers	NNS	ulcer
)	)	)
might	MD	might
put	VB	put
them	PP	them
in	IN	in
danger	NN	danger
of	IN	of
being	VBG	be
infected	VBN	infect
.	SENT	.
Generally	RB	generally
,	,	,
hydrogels	NNS	<unknown>
have	VBP	have
been	VBN	be
used	VBN	use
to	TO	to
treat	VB	treat
patients	NNS	patient
with	IN	with
pressure	NN	pressure
ulcers	NNS	ulcer
.	SENT	.
34906234/	CD	@card@
An	DT	an
important	JJ	important
new	JJ	new
health	NN	health
policy	NN	policy
voice	NN	voice
In	IN	in
the	DT	the
10	CD	@card@
years	NNS	year
since	IN	since
its	PP$	its
founding	NN	founding
,	,	,
the	DT	the
Israel	NP	Israel
Journal	NP	Journal
of	IN	of
Health	NP	Health
Policy	NP	Policy
Research	NP	Research
has	VBZ	have
established	VBN	establish
itself	PP	itself
as	IN	as
an	DT	an
important	JJ	important
voice	NN	voice
in	IN	in
Israeli	JJ	Israeli
and	CC	and
international	JJ	international
health	NN	health
policy	NN	policy
.	SENT	.
The	DT	the
Journal	NP	Journal
's	POS	's
ability	NN	ability
to	TO	to
combine	VB	combine
national	JJ	national
and	CC	and
international	JJ	international
perspectives	NNS	perspective
on	IN	on
key	JJ	key
issues	NNS	issue
in	IN	in
health	NN	health
services	NNS	service
delivery	NN	delivery
and	CC	and
health	NN	health
systems	NNS	system
analysis	NN	analysis
has	VBZ	have
developed	VBN	develop
a	DT	a
valuable	JJ	valuable
new	JJ	new
arena	NN	arena
for	IN	for
academic	JJ	academic
research	NN	research
about	IN	about
the	DT	the
increasingly	RB	increasingly
complex	JJ	complex
post-COVID	JJ	<unknown>
future	NN	future
of	IN	of
health	NN	health
care	NN	care
systems	NNS	system
.	SENT	.
33999135/	CD	@card@
Anakinra	NP	<unknown>
in	IN	in
hospitalized	VBN	hospitalize
non-intubated	JJ	<unknown>
patients	NNS	patient
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
:	:	:
a	DT	a
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
Acute	JJ	acute
respiratory	JJ	respiratory
distress	NN	distress
syndrome	NN	syndrome
and	CC	and
cytokine	NN	<unknown>
release	NN	release
syndrome	NN	syndrome
are	VBP	be
the	DT	the
major	JJ	major
complications	NNS	complication
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NN	<unknown>
)	)	)
associated	VBN	associate
with	IN	with
increased	VBN	increase
mortality	NN	mortality
risk	NN	risk
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
meta-analysis	NN	meta-analysis
to	TO	to
assess	VB	assess
the	DT	the
efficacy	NN	efficacy
and	CC	and
safety	NN	safety
of	IN	of
anakinra	NN	<unknown>
in	IN	in
adult	NN	adult
hospitalized	VBN	hospitalize
non-intubated	JJ	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Relevant	JJ	relevant
trials	NNS	trial
were	VBD	be
identified	VBN	identify
by	IN	by
searching	VBG	search
literature	NN	literature
until	IN	until
24	CD	@card@
April	NP	April
2021	CD	@card@
using	VBG	use
the	DT	the
following	VBG	follow
terms	NNS	term
:	:	:
anakinra	NP	<unknown>
,	,	,
interleukin	NN	interleukin
1	CD	@card@
,	,	,
coronavirus	NN	coronavirus
,	,	,
COVID-19	NP	<unknown>
,	,	,
SARS-CoV-2	NP	<unknown>
.	SENT	.
Trials	NNS	trial
evaluating	VBG	evaluate
the	DT	the
effect	NN	effect
of	IN	of
anakinra	NN	<unknown>
on	IN	on
the	DT	the
need	NN	need
for	IN	for
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
mortality	NN	mortality
in	IN	in
hospitalized	VBN	hospitalize
non-intubated	JJ	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Nine	CD	nine
studies	NNS	study
(	(	(
n	NN	n
=	SYM	=
1,119	CD	@card@
)	)	)
were	VBD	be
eligible	JJ	eligible
for	IN	for
inclusion	NN	inclusion
in	IN	in
the	DT	the
present	JJ	present
meta-analysis	NN	meta-analysis
.	SENT	.
Their	PP$	their
bias	NN	bias
risk	NN	risk
with	IN	with
reference	NN	reference
to	TO	to
the	DT	the
assessed	VBN	assess
parameters	NNS	parameter
was	VBD	be
high	JJ	high
.	SENT	.
In	IN	in
pooled	JJ	pooled
analyses	NNS	analysis
,	,	,
anakinra	NNS	<unknown>
reduced	VBD	reduce
the	DT	the
need	NN	need
for	IN	for
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
(	(	(
odds	NNS	odd
ratio	NN	ratio
,	,	,
OR	CC	or
:	:	:
0	CD	@card@
38	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
,	,	,
CI	NP	CI
:	:	:
0	CD	@card@
17-0	CD	@card@
85	CD	@card@
,	,	,
p=	NP	<unknown>
0.02	CD	@card@
,	,	,
I2=67	JJ	<unknown>
%	NN	%
;	:	;
6	CD	@card@
studies	NNS	study
,	,	,
n	NN	n
=	SYM	=
587	CD	@card@
)	)	)
and	CC	and
mortality	NN	mortality
risk	NN	risk
(	(	(
OR	CC	or
:	:	:
0	CD	@card@
32	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0	CD	@card@
23-0	CD	@card@
45	CD	@card@
,	,	,
p&lt	NP	<unknown>
;	:	;
0	CD	@card@
00001	CD	@card@
,	,	,
I2=0	NP	<unknown>
%	NN	%
;	:	;
9	CD	@card@
studies	NNS	study
,	,	,
n	NN	n
=	SYM	=
1,119	LS	@card@
)	)	)
compared	VBN	compare
with	IN	with
standard	NN	standard
of	IN	of
care	NN	care
therapy	NN	therapy
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
differences	NNS	difference
regarding	VBG	regard
the	DT	the
risk	NN	risk
of	IN	of
adverse	JJ	adverse
events	NNS	event
,	,	,
including	VBG	include
liver	JJR	live
dysfunction	NN	dysfunction
(	(	(
OR	CC	or
:	:	:
0	CD	@card@
75	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0	CD	@card@
48-1	CD	@card@
16	CD	@card@
,	,	,
p&gt	NP	<unknown>
;	:	;
0	CD	@card@
05	CD	@card@
,	,	,
I2=28	NP	<unknown>
%	NN	%
;	:	;
5	CD	@card@
studies	NNS	study
,	,	,
n	NN	n
=	SYM	=
591	CD	@card@
)	)	)
and	CC	and
bacteremia	NN	bacteremia
(	(	(
OR	CC	or
:	:	:
1	CD	@card@
07	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0	CD	@card@
42-2	CD	@card@
73	CD	@card@
,	,	,
p&gt	NP	<unknown>
;	:	;
0	CD	@card@
05	CD	@card@
,	,	,
I2=71	JJ	<unknown>
%	NN	%
;	:	;
6	CD	@card@
studies	NNS	study
,	,	,
n	NN	n
=	SYM	=
727	CD	@card@
)	)	)
.	SENT	.
Available	JJ	available
evidence	NN	evidence
shows	VBZ	show
that	DT	that
treatment	NN	treatment
with	IN	with
anakinra	NN	<unknown>
reduces	VBZ	reduce
both	CC	both
the	DT	the
need	NN	need
for	IN	for
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
mortality	NN	mortality
risk	NN	risk
of	IN	of
hospitalized	VBN	hospitalize
non-intubated	JJ	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
without	IN	without
increasing	VBG	increase
the	DT	the
risk	NN	risk
of	IN	of
adverse	JJ	adverse
events	NNS	event
.	SENT	.
Confirmation	NN	confirmation
of	IN	of
efficacy	NN	efficacy
and	CC	and
safety	NN	safety
requires	VBZ	require
randomized	VBD	randomize
placebo-controlled	VBN	placebo-control
trials	NNS	trial
.	SENT	.
32635695/	CD	@card@
Stroke	NN	stroke
in	IN	in
the	DT	the
Time	NP	Time
of	IN	of
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
:	:	:
Experience	NN	experience
of	IN	of
Two	CD	two
University	NP	University
Stroke	NN	stroke
Centers	VBZ	center
in	IN	in
Egypt	NP	Egypt
33590152/	CD	@card@
Solidarity	NP	Solidarity
as	IN	as
a	DT	a
companion	JJ	companion
virtue	NN	virtue
in	IN	in
response	NN	response
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
This	DT	this
paper	NN	paper
establishes	VBZ	establish
that	IN	that
there	EX	there
is	VBZ	be
a	DT	a
need	NN	need
to	TO	to
turn	VB	turn
to	TO	to
virtue	NN	virtue
ethics	NNS	ethic
in	IN	in
dealing	VBG	deal
with	IN	with
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
It	PP	it
argues	VBZ	argue
that	IN	that
the	DT	the
virtue	NN	virtue
of	IN	of
solidarity	NN	solidarity
can	MD	can
be	VB	be
a	DT	a
companion	JJ	companion
virtue	NN	virtue
to	TO	to
compassion	NN	compassion
for	IN	for
medical	JJ	medical
frontline	NN	frontline
workers	NNS	worker
and	CC	and
other	JJ	other
individuals	NNS	individual
involved	VBN	involve
.	SENT	.
Like	IN	like
compassion	NN	compassion
,	,	,
the	DT	the
virtue	NN	virtue
of	IN	of
solidarity	NN	solidarity
is	VBZ	be
a	DT	a
reminder	NN	reminder
that	IN	that
everyone	NN	everyone
is	VBZ	be
in	IN	in
this	DT	this
crisis	NN	crisis
together	RB	together
and	CC	and
that	IN	that
each	DT	each
is	VBZ	be
responsible	JJ	responsible
for	IN	for
all	DT	all
.	SENT	.
33988134/	CD	@card@
Is	VBZ	be
2020	CD	@card@
the	DT	the
golden	JJ	golden
year	NN	year
of	IN	of
Otolaryngology	NN	otolaryngology
research	NN	research
?	SENT	?
The	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
the	DT	the
Italian	JJ	Italian
academic	JJ	academic
production	NN	production
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
research	NN	research
was	VBD	be
to	TO	to
review	VB	review
the	DT	the
articles	NNS	article
published	VBN	publish
by	IN	by
the	DT	the
Ear	NP	Ear
,	,	,
Nose	NP	Nose
and	CC	and
Throat	NN	throat
(	(	(
ENT	NP	Ent
)	)	)
departments	NNS	department
of	IN	of
the	DT	the
Italian	JJ	Italian
University	NP	University
Hospitals	NNS	hospital
in	IN	in
2019	CD	@card@
and	CC	and
in	IN	in
2020	CD	@card@
to	TO	to
analyze	VB	analyze
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
the	DT	the
academic	JJ	academic
production	NN	production
.	SENT	.
PubMed	NP	<unknown>
and	CC	and
Scopus	NP	Scopus
were	VBD	be
searched	VBN	search
for	IN	for
the	DT	the
articles	NNS	article
published	VBN	publish
by	IN	by
the	DT	the
ENT	NP	Ent
departments	NNS	department
of	IN	of
the	DT	the
Italian	JJ	Italian
Universities	NNS	university
in	IN	in
2019	CD	@card@
and	CC	and
in	IN	in
2020	CD	@card@
.	SENT	.
The	DT	the
main	JJ	main
eligibility	NN	eligibility
criteria	NNS	criterion
were	VBD	be
English-language	JJ	English-language
articles	NNS	article
,	,	,
while	IN	while
there	EX	there
were	VBD	be
no	DT	no
exclusion	NN	exclusion
criteria	NNS	criterion
related	VBN	relate
to	TO	to
topic	NN	topic
.	SENT	.
The	DT	the
articles	NNS	article
were	VBD	be
classified	VBN	classify
into	IN	into
seven	CD	seven
domains	NNS	domain
corresponding	JJ	corresponding
to	TO	to
the	DT	the
main	JJ	main
ENT	NN	Ent
subspecialties	NNS	subspecialty
.	SENT	.
There	EX	there
was	VBD	be
an	DT	an
overall	JJ	overall
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
articles	NNS	article
by	IN	by
the	DT	the
42.2	CD	@card@
%	NN	%
in	IN	in
2020	CD	@card@
.	SENT	.
Publications	NNS	publication
pertaining	VBG	pertain
Rhinology	NN	rhinology
and	CC	and
Laryngology	NN	laryngology
increased	VBN	increase
more	RBR	more
significantly	RB	significantly
in	IN	in
2020	CD	@card@
,	,	,
respectively	RB	respectively
by	IN	by
the	DT	the
50.5	CD	@card@
%	NN	%
and	CC	and
72.2	CD	@card@
%	NN	%
.	SENT	.
Additionally	RB	additionally
,	,	,
there	EX	there
was	VBD	be
an	DT	an
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
articles	NNS	article
concerning	VBG	concern
topics	NNS	topic
of	IN	of
general	JJ	general
interest	NN	interest
,	,	,
by	IN	by
the	DT	the
95.2	CD	@card@
%	NN	%
in	IN	in
2020	CD	@card@
.	SENT	.
Also	RB	also
,	,	,
the	DT	the
citation	NN	citation
trends	NNS	trend
of	IN	of
the	DT	the
articles	NNS	article
published	VBN	publish
by	IN	by
the	DT	the
Italian	JJ	Italian
University	NP	University
Hospitals	NPS	Hospitals
increased	VBD	increase
remarkably	RB	remarkably
in	IN	in
2020	CD	@card@
.	SENT	.
These	DT	these
results	NNS	result
evidenced	VBD	evidence
an	DT	an
overall	JJ	overall
increase	NN	increase
in	IN	in
the	DT	the
number	NN	number
of	IN	of
ENT	NN	Ent
articles	NNS	article
.	SENT	.
Although	IN	although
2020	CD	@card@
is	VBZ	be
going	VBG	go
to	TO	to
be	VB	be
remembered	VBN	remember
as	IN	as
a	DT	a
year	NN	year
to	TO	to
forget	VB	forget
,	,	,
it	PP	it
should	MD	should
be	VB	be
acknowledged	VBN	acknowledge
for	IN	for
being	VBG	be
the	DT	the
"	``	"
golden	JJ	golden
year	NN	year
of	IN	of
research	NN	research
"	''	"
.	SENT	.
However	RB	however
,	,	,
the	DT	the
scientific	JJ	scientific
community	NN	community
needs	VBZ	need
quality	NN	quality
more	RBR	more
than	IN	than
quantity	NN	quantity
and	CC	and
it	PP	it
is	VBZ	be
now	RB	now
more	RBR	more
important	JJ	important
than	IN	than
ever	RB	ever
to	TO	to
provide	VB	provide
optimal	JJ	optimal
medical	JJ	medical
indications	NNS	indication
and	CC	and
clear	JJ	clear
answers	NNS	answer
to	TO	to
patients	NNS	patient
'	POS	'
questions	NNS	question
.	SENT	.
32294078/	CD	@card@
Comparison	NN	comparison
of	IN	of
the	DT	the
Indicators	NNS	indicator
of	IN	of
Psychological	JJ	psychological
Stress	NN	stress
in	IN	in
the	DT	the
Population	NN	population
of	IN	of
Hubei	NP	Hubei
Province	NP	Province
and	CC	and
Non-Endemic	NP	<unknown>
Provinces	NP	Provinces
in	IN	in
China	NP	China
During	IN	during
Two	CD	two
Weeks	NP	Weeks
During	IN	during
the	DT	the
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
Outbreak	NN	outbreak
in	IN	in
February	NP	February
2020	CD	@card@
During	IN	during
February	NP	February
2020	CD	@card@
,	,	,
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
epidemic	NN	epidemic
in	IN	in
Hubei	NP	Hubei
Province	NP	Province
,	,	,
China	NP	China
,	,	,
was	VBD	be
at	IN	at
its	PP$	its
height	NN	height
,	,	,
requiring	VBG	require
isolation	NN	isolation
of	IN	of
the	DT	the
population	NN	population
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
compare	VB	compare
the	DT	the
emotional	JJ	emotional
state	NN	state
,	,	,
somatic	JJ	somatic
responses	NNS	response
,	,	,
sleep	NN	sleep
quality	NN	quality
,	,	,
and	CC	and
behavior	NN	behavior
of	IN	of
people	NNS	people
in	IN	in
Hubei	NP	Hubei
Province	NP	Province
with	IN	with
non-endemic	JJ	non-endemic
provinces	NNS	province
in	IN	in
China	NP	China
during	IN	during
two	CD	two
weeks	NNS	week
in	IN	in
February	NP	February
2020	CD	@card@
.	SENT	.
Questionnaires	NNS	questionnaire
were	VBD	be
completed	VBN	complete
by	IN	by
939	CD	@card@
individuals	NNS	individual
(	(	(
357	CD	@card@
men	NNS	man
;	:	;
582	CD	@card@
women	NNS	woman
)	)	)
,	,	,
including	VBG	include
33	CD	@card@
from	IN	from
Hubei	NP	Hubei
and	CC	and
906	CD	@card@
from	IN	from
non-endemic	JJ	non-endemic
provinces	NNS	province
.	SENT	.
The	DT	the
Stress	NN	stress
Response	NP	Response
Questionnaire	NN	questionnaire
(	(	(
SRQ	NP	SRQ
)	)	)
determined	VBD	determine
the	DT	the
emotional	JJ	emotional
state	NN	state
,	,	,
somatic	JJ	somatic
responses	NNS	response
,	,	,
and	CC	and
behavior	NN	behavior
.	SENT	.
The	DT	the
Pittsburgh	NP	Pittsburgh
Sleep	NN	sleep
Quality	NP	Quality
Index	NP	Index
(	(	(
PSQI	NP	<unknown>
)	)	)
was	VBD	be
used	VBN	use
to	TO	to
measure	VB	measure
the	DT	the
duration	NN	duration
of	IN	of
sleep	NN	sleep
and	CC	and
sleep	NN	sleep
quality	NN	quality
.	SENT	.
There	EX	there
were	VBD	be
939	CD	@card@
study	NN	study
participants	NNS	participant
,	,	,
aged	VBN	age
18-24	CD	@card@
years	NNS	year
(	(	(
35.89	CD	@card@
%	NN	%
)	)	)
and	CC	and
25-39	CD	@card@
years	NNS	year
(	(	(
35.57	CD	@card@
%	NN	%
)	)	)
;	:	;
65.92	CD	@card@
%	NN	%
were	VBD	be
university	NN	university
students	NNS	student
.	SENT	.
During	IN	during
a	DT	a
two	CD	two
week	NN	week
period	NN	period
in	IN	in
February	NP	February
2020	CD	@card@
,	,	,
the	DT	the
emotional	JJ	emotional
state	NN	state
and	CC	and
behavior	NN	behavior
of	IN	of
participants	NNS	participant
in	IN	in
Hubei	NP	Hubei
improved	VBD	improve
,	,	,
but	CC	but
the	DT	the
quality	NN	quality
of	IN	of
sleep	NN	sleep
did	VBD	do
not	RB	not
.	SENT	.
Health	NN	health
workers	NNS	worker
and	CC	and
business	NN	business
people	NNS	people
became	VBD	become
increasingly	RB	increasingly
anxious	JJ	anxious
,	,	,
but	CC	but
other	JJ	other
professionals	NNS	professional
became	VBD	become
less	RBR	less
anxious	JJ	anxious
.	SENT	.
The	DT	the
data	NNS	datum
showed	VBD	show
that	IN	that
most	JJS	most
people	NNS	people
in	IN	in
Hubei	NP	Hubei
Province	NP	Province
developed	VBD	develop
a	DT	a
more	RBR	more
positive	JJ	positive
attitude	NN	attitude
regarding	VBG	regard
their	PP$	their
risk	NN	risk
of	IN	of
infection	NN	infection
and	CC	and
the	DT	the
chances	NNS	chance
of	IN	of
surviving	VBG	survive
the	DT	the
COVID-19	NP	<unknown>
epidemic	NN	epidemic
.	SENT	.
During	IN	during
a	DT	a
two-week	JJ	two-week
period	NN	period
,	,	,
front-line	NN	front-line
health	NN	health
workers	NNS	worker
and	CC	and
people	NNS	people
in	IN	in
Hubei	NP	Hubei
Province	NP	Province
became	VBD	become
less	RBR	less
anxious	JJ	anxious
about	IN	about
the	DT	the
COVID-19	NP	<unknown>
epidemic	NN	epidemic
,	,	,
but	CC	but
sleep	NN	sleep
quality	NN	quality
did	VBD	do
not	RB	not
improve	VB	improve
.	SENT	.
Despite	IN	despite
public	JJ	public
awareness	NN	awareness
,	,	,
levels	NNS	level
of	IN	of
anxiety	NN	anxiety
exist	VBP	exist
that	RB	that
affect	VB	affect
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
during	IN	during
epidemics	NNS	epidemic
,	,	,
including	VBG	include
periods	NNS	period
of	IN	of
population	NN	population
quarantine	NN	quarantine
.	SENT	.
Therefore	RB	therefore
,	,	,
health	NN	health
education	NN	education
should	MD	should
be	VB	be
combined	VBN	combine
with	IN	with
psychological	JJ	psychological
counseling	NN	counseling
for	IN	for
vulnerable	JJ	vulnerable
individuals	NNS	individual
.	SENT	.
34413324/	CD	@card@
Machine	NN	machine
learning	VBG	learn
approach	NN	approach
to	TO	to
dynamic	JJ	dynamic
risk	NN	risk
modeling	NN	modeling
of	IN	of
mortality	NN	mortality
in	IN	in
COVID-19	NP	<unknown>
:	:	:
a	DT	a
UK	NP	UK
Biobank	NP	<unknown>
study	VB	study
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
created	VBN	create
an	DT	an
urgent	JJ	urgent
need	NN	need
for	IN	for
robust	JJ	robust
,	,	,
scalable	JJ	scalable
monitoring	NN	monitoring
tools	NNS	tool
supporting	VBG	support
stratification	NN	stratification
of	IN	of
high-risk	JJ	high-risk
patients	NNS	patient
.	SENT	.
This	DT	this
research	NN	research
aims	VBZ	aim
to	TO	to
develop	VB	develop
and	CC	and
validate	VB	validate
prediction	NN	prediction
models	NNS	model
,	,	,
using	VBG	use
the	DT	the
UK	NP	UK
Biobank	NP	<unknown>
,	,	,
to	TO	to
estimate	VB	estimate
COVID-19	NP	<unknown>
mortality	NN	mortality
risk	NN	risk
in	IN	in
confirmed	VBN	confirm
cases	NNS	case
.	SENT	.
From	IN	from
the	DT	the
11,245	CD	@card@
participants	NNS	participant
testing	VBG	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
,	,	,
we	PP	we
develop	VBP	develop
a	DT	a
data-driven	JJ	data-driven
random	JJ	random
forest	NN	forest
classification	NN	classification
model	NN	model
with	IN	with
excellent	JJ	excellent
performance	NN	performance
(	(	(
AUC	NP	AUC
:	:	:
0.91	LS	@card@
)	)	)
,	,	,
using	VBG	use
baseline	JJ	baseline
characteristics	NNS	characteristic
,	,	,
pre-existing	VBG	pre-exist
conditions	NNS	condition
,	,	,
symptoms	NNS	symptom
,	,	,
and	CC	and
vital	JJ	vital
signs	NNS	sign
,	,	,
such	JJ	such
that	IN	that
the	DT	the
score	NN	score
could	MD	could
dynamically	RB	dynamically
assess	VB	assess
mortality	NN	mortality
risk	NN	risk
with	IN	with
disease	NN	disease
deterioration	NN	deterioration
.	SENT	.
We	PP	we
also	RB	also
identify	VBP	identify
several	JJ	several
significant	JJ	significant
novel	NN	novel
predictors	NNS	predictor
of	IN	of
COVID-19	NP	<unknown>
mortality	NN	mortality
with	IN	with
equivalent	NN	equivalent
or	CC	or
greater	JJR	great
predictive	JJ	predictive
value	NN	value
than	IN	than
established	JJ	established
high-risk	JJ	high-risk
comorbidities	NNS	comorbidity
,	,	,
such	JJ	such
as	IN	as
detailed	JJ	detailed
anthropometrics	NNS	anthropometric
and	CC	and
prior	JJ	prior
acute	JJ	acute
kidney	NN	kidney
failure	NN	failure
,	,	,
urinary	JJ	urinary
tract	NN	tract
infection	NN	infection
,	,	,
and	CC	and
pneumonias	NNS	pneumonia
.	SENT	.
The	DT	the
model	NN	model
design	NN	design
and	CC	and
feature	NN	feature
selection	NN	selection
enables	VBZ	enable
utility	NN	utility
in	IN	in
outpatient	NN	outpatient
settings	NNS	setting
.	SENT	.
Possible	JJ	possible
applications	NNS	application
include	VBP	include
supporting	VBG	support
individual-level	JJ	individual-level
risk	NN	risk
profiling	VBG	profil
and	CC	and
monitoring	VBG	monitor
disease	NN	disease
progression	NN	progression
across	IN	across
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
at-scale	NN	at-scale
,	,	,
especially	RB	especially
in	IN	in
hospital-at-home	NN	hospital-at-home
settings	NNS	setting
.	SENT	.
34383756/	CD	@card@
Using	VBG	use
mobility	NN	mobility
data	NNS	datum
in	IN	in
the	DT	the
design	NN	design
of	IN	of
optimal	JJ	optimal
lockdown	NN	<unknown>
strategies	NNS	strategy
for	IN	for
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
A	DT	a
mathematical	JJ	mathematical
model	NN	model
for	IN	for
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
spread	NN	spread
,	,	,
which	WDT	which
integrates	VBZ	integrate
age-structured	JJ	age-structured
Susceptible-Exposed-Infected-Recovered-Deceased	JJ	<unknown>
dynamics	NNS	dynamics
with	IN	with
real	JJ	real
mobile	JJ	mobile
phone	NN	phone
data	NNS	datum
accounting	VBG	account
for	IN	for
the	DT	the
population	NN	population
mobility	NN	mobility
,	,	,
is	VBZ	be
presented	VBN	present
.	SENT	.
The	DT	the
dynamical	JJ	dynamical
model	NN	model
adjustment	NN	adjustment
is	VBZ	be
performed	VBN	perform
via	IN	via
Approximate	JJ	approximate
Bayesian	NP	<unknown>
Computation	NN	computation
.	SENT	.
Optimal	JJ	optimal
lockdown	NN	<unknown>
and	CC	and
exit	NN	exit
strategies	NNS	strategy
are	VBP	be
determined	VBN	determine
based	VBN	base
on	IN	on
nonlinear	JJ	nonlinear
model	NN	model
predictive	JJ	predictive
control	NN	control
,	,	,
constrained	VBN	constrain
to	TO	to
public-health	NN	public-health
and	CC	and
socio-economic	JJ	socio-economic
factors	NNS	factor
.	SENT	.
Through	IN	through
an	DT	an
extensive	JJ	extensive
computational	JJ	computational
validation	NN	validation
of	IN	of
the	DT	the
methodology	NN	methodology
,	,	,
it	PP	it
is	VBZ	be
shown	VBN	show
that	IN	that
it	PP	it
is	VBZ	be
possible	JJ	possible
to	TO	to
compute	VB	compute
robust	JJ	robust
exit	NN	exit
strategies	NNS	strategy
with	IN	with
realistic	JJ	realistic
reduced	VBN	reduce
mobility	NN	mobility
values	NNS	value
to	TO	to
inform	VB	inform
public	JJ	public
policy	NN	policy
making	VBG	make
,	,	,
and	CC	and
we	PP	we
exemplify	VBP	exemplify
the	DT	the
applicability	NN	applicability
of	IN	of
the	DT	the
methodology	NN	methodology
using	VBG	use
datasets	NNS	<unknown>
from	IN	from
England	NP	England
and	CC	and
France	NP	France
.	SENT	.
In	IN	in
many	JJ	many
countries	NNS	country
,	,	,
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
revealed	VBN	reveal
a	DT	a
gap	NN	gap
between	IN	between
public	JJ	public
policy	NN	policy
making	VBG	make
and	CC	and
the	DT	the
use	NN	use
of	IN	of
advanced	JJ	advanced
technological	JJ	technological
tools	NNS	tool
to	TO	to
inform	VB	inform
such	PDT	such
a	DT	a
process	NN	process
.	SENT	.
In	IN	in
the	DT	the
big	JJ	big
data	NN	data
era	NN	era
,	,	,
decisions	NNS	decision
concerning	VBG	concern
the	DT	the
implementation	NN	implementation
of	IN	of
quarantines	NNS	quarantine
and	CC	and
travel	NN	travel
restrictions	NNS	restriction
are	VBP	be
still	RB	still
being	VBG	be
taken	VBN	take
based	VBN	base
on	IN	on
incomplete	JJ	incomplete
public	JJ	public
health	NN	health
data	NNS	datum
,	,	,
despite	IN	despite
the	DT	the
myriad	NN	myriad
of	IN	of
information	NN	information
our	PP$	our
society	NN	society
provides	VBZ	provide
in	IN	in
real	JJ	real
time	NN	time
,	,	,
such	JJ	such
as	IN	as
mobility	NN	mobility
data	NNS	datum
,	,	,
commuting	VBG	commute
network	NN	network
structures	NNS	structure
,	,	,
and	CC	and
financial	JJ	financial
patterns	NNS	pattern
,	,	,
to	TO	to
name	VB	name
a	DT	a
few	JJ	few
.	SENT	.
To	TO	to
advance	VB	advance
towards	IN	towards
an	DT	an
effective	JJ	effective
data-driven	NN	<unknown>
,	,	,
quantitative	JJ	quantitative
policy	NN	policy
making	VBG	make
,	,	,
we	PP	we
propose	VBP	propose
a	DT	a
computational	JJ	computational
framework	NN	framework
where	WRB	where
a	DT	a
predictive	JJ	predictive
epidemiological	JJ	epidemiological
model	NN	model
is	VBZ	be
fitted	VBN	fit
by	IN	by
feeding	VBG	feed
both	DT	both
public	JJ	public
health	NN	health
and	CC	and
Google	NP	<unknown>
mobility	NN	mobility
data	NNS	datum
.	SENT	.
The	DT	the
resulting	VBG	result
model	NN	model
is	VBZ	be
then	RB	then
used	VBN	use
as	IN	as
a	DT	a
basis	NN	basis
for	IN	for
designing	VBG	design
mobility	NN	mobility
reduction	NN	reduction
strategies	NNS	strategy
which	WDT	which
are	VBP	be
optimised	VBN	optimise
taking	VBG	take
into	IN	into
account	NN	account
both	CC	both
the	DT	the
healthcare	NN	<unknown>
system	NN	system
capacity	NN	capacity
,	,	,
and	CC	and
the	DT	the
economic	JJ	economic
impact	NN	impact
of	IN	of
an	DT	an
extended	JJ	extended
lockdown	NN	<unknown>
.	SENT	.
For	IN	for
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
England	NP	England
and	CC	and
France	NP	France
,	,	,
we	PP	we
show	VBP	show
that	IN	that
it	PP	it
is	VBZ	be
possible	JJ	possible
to	TO	to
design	VB	design
lockdown	NN	<unknown>
policies	NNS	policy
allowing	VBG	allow
a	DT	a
partial	JJ	partial
return	NN	return
to	TO	to
workplaces	NNS	workplace
and	CC	and
schools	NNS	school
,	,	,
while	IN	while
maintaining	VBG	maintain
the	DT	the
epidemic	NN	epidemic
under	IN	under
control	NN	control
.	SENT	.
32675000/	CD	@card@
Concordance	NN	concordance
between	IN	between
two	CD	two
rapid	JJ	rapid
diagnostic	JJ	diagnostic
tests	NNS	test
for	IN	for
the	DT	the
detection	NN	detection
of	IN	of
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
To	TO	to
assess	VB	assess
the	DT	the
agreement	NN	agreement
between	IN	between
two	CD	two
rapid	JJ	rapid
detection	NN	detection
tests	NNS	test
(	(	(
RDT	NP	<unknown>
)	)	)
for	IN	for
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
This	DT	this
was	VBD	be
a	DT	a
cross-sectional	JJ	cross-sectional
study	NN	study
that	WDT	that
used	VBD	use
a	DT	a
random	JJ	random
sample	NN	sample
of	IN	of
non-hospitalized	JJ	<unknown>
patients	NNS	patient
from	IN	from
the	DT	the
primary	JJ	primary
care	NN	care
management	NN	management
division	NN	division
of	IN	of
the	DT	the
Healthcare	NP	Healthcare
Area	NP	Area
of	IN	of
Leon	NP	Leon
(	(	(
58	CD	@card@
RT-PCR-positive	NP	<unknown>
cases	NNS	case
and	CC	and
52	CD	@card@
RT-PCR-negative	JJ	RT-PCR-negative
cases	NNS	case
)	)	)
.	SENT	.
Information	NN	information
regarding	VBG	regard
symptoms	NNS	symptom
was	VBD	be
collected	VBN	collect
and	CC	and
all	DT	all
patients	NNS	patient
were	VBD	be
simultaneously	RB	simultaneously
tested	VBN	test
using	VBG	use
two	CD	two
RDTs	NNS	<unknown>
(	(	(
Combined	VBN	combine
-	NN	<unknown>
cRDT	NNS	<unknown>
and	CC	and
Differentiated	VBN	differentiate
-	NN	<unknown>
dRDT	NNS	<unknown>
)	)	)
.	SENT	.
The	DT	the
results	NNS	result
of	IN	of
both	DT	both
tests	NNS	test
were	VBD	be
evaluated	VBN	evaluate
using	VBG	use
the	DT	the
chi-square	NN	chi-square
test	NN	test
and	CC	and
,	,	,
for	IN	for
degree	NN	degree
of	IN	of
agreement	NN	agreement
,	,	,
the	DT	the
kappa	NN	kappa
coefficient	NN	coefficient
.	SENT	.
About	RB	about
52	CD	@card@
%	NN	%
of	IN	of
the	DT	the
participants	NNS	participant
were	VBD	be
women	NNS	woman
(	(	(
mean	JJ	mean
age	NN	age
:	:	:
48.2	CD	@card@
+-	NN	<unknown>
11.0	CD	@card@
years	NNS	year
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
58.2	CD	@card@
%	NN	%
were	VBD	be
positive	JJ	positive
for	IN	for
d-RDT	NP	<unknown>
and	CC	and
41.2	CD	@card@
%	NN	%
were	VBD	be
positive	JJ	positive
for	IN	for
c-RDT	NP	<unknown>
.	SENT	.
In	IN	in
the	DT	the
subjects	NNS	subject
who	WP	who
were	VBD	be
RT-PCR-positive	JJ	RT-PCR-positive
,	,	,
d-RDT	NP	<unknown>
was	VBD	be
positive	JJ	positive
in	IN	in
72.4	CD	@card@
%	NN	%
and	CC	and
c-RDT	NP	<unknown>
in	IN	in
55.2	CD	@card@
%	NN	%
;	:	;
in	IN	in
those	DT	those
who	WP	who
were	VBD	be
RT-PCR-negative	JJ	RT-PCR-negative
,	,	,
the	DT	the
percentages	NNS	percentage
were	VBD	be
42.3	CD	@card@
%	NN	%
and	CC	and
26.9	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
kappa	NN	kappa
coefficient	NN	coefficient
observed	VBD	observe
between	IN	between
the	DT	the
two	CD	two
RDTs	NP	<unknown>
was	VBD	be
0.644	CD	@card@
,	,	,
and	CC	and
was	VBD	be
higher	JJR	high
in	IN	in
patients	NNS	patient
without	IN	without
a	DT	a
fever	NN	fever
or	CC	or
anosmia	NN	anosmia
(	(	(
0.725	CD	@card@
)	)	)
and	CC	and
lower	JJR	low
in	IN	in
those	DT	those
with	IN	with
a	DT	a
fever	NN	fever
or	CC	or
anosmia	NN	anosmia
(	(	(
0.524	CD	@card@
)	)	)
.	SENT	.
There	EX	there
is	VBZ	be
good	JJ	good
agreement	NN	agreement
between	IN	between
the	DT	the
tests	NNS	test
used	VBN	use
in	IN	in
this	DT	this
study	NN	study
.	SENT	.
Given	VBN	give
the	DT	the
sensitivity	NN	sensitivity
observed	VBD	observe
,	,	,
they	PP	they
can	MD	can
be	VB	be
very	RB	very
useful	JJ	useful
as	IN	as
a	DT	a
complement	NN	complement
to	TO	to
RT-PCR	NP	<unknown>
.	SENT	.
34289965/	CD	@card@
Head	NP	Head
home	NN	home
:	:	:
implementation	NN	implementation
during	IN	during
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
Recent	JJ	Recent
research	NN	research
suggests	VBZ	suggest
that	IN	that
between	IN	between
20	CD	@card@
%	NN	%
and	CC	and
50	CD	@card@
%	NN	%
of	IN	of
paediatric	JJ	paediatric
head	NN	head
injuries	NNS	injury
attending	VBG	attend
our	PP$	our
emergency	NN	emergency
department	NN	department
(	(	(
ED	NN	editor
)	)	)
could	MD	could
be	VB	be
safely	RB	safely
discharged	VBN	discharge
soon	RB	soon
after	IN	after
triage	NN	triage
,	,	,
without	IN	without
the	DT	the
need	NN	need
for	IN	for
medical	JJ	medical
review	NN	review
,	,	,
using	VBG	use
a	DT	a
'	''	'
Head	NP	Head
Injury	NP	Injury
Discharge	NN	discharge
At	IN	at
Triage	NN	triage
'	POS	'
tool	NN	tool
(	(	(
HIDAT	NP	<unknown>
)	)	)
.	SENT	.
We	PP	we
sought	VBD	seek
to	TO	to
implement	VB	implement
this	DT	this
into	IN	into
clinical	JJ	clinical
practice	NN	practice
.	SENT	.
Paediatric	JJ	paediatric
ED	NN	editor
triage	NN	triage
staff	NN	staff
underwent	VBD	undergo
competency-based	JJ	<unknown>
assessments	NNS	assessment
for	IN	for
HIDAT	NP	<unknown>
with	IN	with
all	DT	all
head	NN	head
injury	NN	injury
presentations	NNS	presentation
1	CD	@card@
May	NP	May
to	TO	to
31	CD	@card@
October	NP	October
2020	CD	@card@
included	VBD	include
in	IN	in
analysis	NN	analysis
.	SENT	.
We	PP	we
determined	VBD	determine
which	WDT	which
patients	NNS	patient
were	VBD	be
discharged	VBN	discharge
using	VBG	use
the	DT	the
tool	NN	tool
,	,	,
which	WDT	which
underwent	VBD	undergo
CT	NP	CT
of	IN	of
the	DT	the
brain	NN	brain
and	CC	and
whether	IN	whether
there	EX	there
was	VBD	be
a	DT	a
clinically	RB	clinically
important	JJ	important
traumatic	JJ	traumatic
brain	NN	brain
injury	NN	injury
or	CC	or
representation	NN	representation
to	TO	to
the	DT	the
ED	NN	editor
.	SENT	.
Of	IN	of
the	DT	the
1429	CD	@card@
patients	NNS	patient
screened	VBD	screen
;	:	;
610	CD	@card@
(	(	(
43	CD	@card@
%	NN	%
)	)	)
screened	VBD	screen
negative	JJ	negative
with	IN	with
250	CD	@card@
(	(	(
18	CD	@card@
%	NN	%
)	)	)
discharged	VBN	discharge
by	IN	by
nursing	NN	nursing
staff	NN	staff
.	SENT	.
Of	IN	of
the	DT	the
entire	JJ	entire
cohort	NN	cohort
,	,	,
32	CD	@card@
CTs	NNS	<unknown>
were	VBD	be
performed	VBN	perform
for	IN	for
head	NN	head
injury	NN	injury
concerns	NNS	concern
(	(	(
6	CD	@card@
abnormal	JJ	abnormal
)	)	)
with	IN	with
1	CD	@card@
CT	NP	CT
performed	VBN	perform
in	IN	in
the	DT	the
HIDAT	NP	<unknown>
negative	JJ	negative
group	NN	group
(	(	(
normal	JJ	normal
)	)	)
.	SENT	.
Of	IN	of
those	DT	those
discharged	VBN	discharge
using	VBG	use
HIDAT	NP	<unknown>
,	,	,
four	CD	four
reattended	JJ	<unknown>
,	,	,
two	CD	two
with	IN	with
vomiting	NN	vomiting
(	(	(
no	DT	no
imaging	NN	imaging
or	CC	or
admission	NN	admission
)	)	)
and	CC	and
two	CD	two
with	IN	with
minor	JJ	minor
scalp	NN	scalp
wound	NN	wound
infections	NNS	infection
.	SENT	.
Two	CD	two
patients	NNS	patient
who	WP	who
screened	VBD	screen
negative	JJ	negative
declined	VBD	decline
discharge	NN	discharge
under	IN	under
the	DT	the
policy	NN	policy
with	IN	with
later	RBR	later
medical	JJ	medical
discharge	NN	discharge
(	(	(
no	DT	no
imaging	NN	imaging
or	CC	or
admission	NN	admission
)	)	)
.	SENT	.
Paediatric	JJ	paediatric
ED	NN	editor
attendances	NNS	attendance
were	VBD	be
29	CD	@card@
%	NN	%
lower	JJR	low
than	IN	than
in	IN	in
2018	CD	@card@
.	SENT	.
We	PP	we
have	VBP	have
successfully	RB	successfully
implemented	VBN	implement
HIDAT	NP	<unknown>
into	IN	into
local	JJ	local
clinical	JJ	clinical
practice	NN	practice
.	SENT	.
The	DT	the
number	NN	number
discharged	VBN	discharge
(	(	(
18	CD	@card@
%	NN	%
)	)	)
is	VBZ	be
lower	JJR	low
than	IN	than
originally	RB	originally
described	VBN	describe
;	:	;
this	DT	this
is	VBZ	be
likely	RB	likely
multifactorial	JJ	multifactorial
.	SENT	.
The	DT	the
relationship	NN	relationship
between	IN	between
COVID-19	NP	<unknown>
and	CC	and
paediatric	JJ	paediatric
ED	NN	editor
attendances	NNS	attendance
is	VBZ	be
unclear	JJ	unclear
but	CC	but
decreased	VBN	decrease
attendances	NNS	attendance
suggest	VBP	suggest
those	DT	those
for	IN	for
whom	WP	whom
the	DT	the
tool	NN	tool
was	VBD	be
originally	RB	originally
designed	VBN	design
are	VBP	be
not	RB	not
attending	VBG	attend
ED	NN	editor
and	CC	and
may	MD	may
be	VB	be
accessing	VBG	access
other	JJ	other
medical/non-medical	JJ	medical/non-medical
resources	NNS	resource
33902480/	CD	@card@
Epidemiology	NN	epidemiology
,	,	,
clinical	JJ	clinical
characteristics	NNS	characteristic
,	,	,
and	CC	and
treatment	NN	treatment
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
at	IN	at
Thailand	NP	Thailand
's	POS	's
university-based	JJ	university-based
referral	NN	referral
hospital	NN	hospital
The	DT	the
epidemiology	NN	epidemiology
and	CC	and
outcomes	NNS	outcome
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
Thailand	NP	Thailand
are	VBP	be
scarce	JJ	scarce
.	SENT	.
This	DT	this
retrospective	JJ	retrospective
cohort	NN	cohort
study	NN	study
included	VBD	include
adult	JJ	adult
hospitalized	VBN	hospitalize
patients	NNS	patient
who	WP	who
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
at	IN	at
Siriraj	NP	<unknown>
Hospital	NP	Hospital
during	IN	during
February	NP	February
2020	CD	@card@
to	TO	to
April	NP	April
2020	CD	@card@
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
COVID-19	NP	<unknown>
was	VBD	be
7.5	CD	@card@
%	NN	%
(	(	(
107	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
)	)	)
among	IN	among
1409	CD	@card@
patients	NNS	patient
who	WP	who
underwent	VBD	undergo
RT-PCR	NP	<unknown>
for	IN	for
SARS-CoV-2	NP	<unknown>
detection	NN	detection
at	IN	at
our	PP$	our
hospital	NN	hospital
during	IN	during
the	DT	the
outbreak	NN	outbreak
period	NN	period
.	SENT	.
Patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
presented	VBD	present
with	IN	with
symptoms	NNS	symptom
in	IN	in
94.4	CD	@card@
%	NN	%
.	SENT	.
Among	IN	among
the	DT	the
104	CD	@card@
patients	NNS	patient
who	WP	who
were	VBD	be
treated	VBN	treat
with	IN	with
antiviral	JJ	antiviral
medications	NNS	medication
,	,	,
78	CD	@card@
(	(	(
75	CD	@card@
%	NN	%
)	)	)
received	VBD	receive
2-drug	JJ	<unknown>
regimen	NN	regimen
(	(	(
lopinavir/ritonavir	NN	<unknown>
or	CC	or
darunavir/ritonavir	NN	<unknown>
plus	CC	plus
chloroquine	NN	chloroquine
or	CC	or
hydroxychloroquine	NN	hydroxychloroquine
)	)	)
,	,	,
and	CC	and
26	CD	@card@
(	(	(
25	CD	@card@
%	NN	%
)	)	)
received	VBD	receive
a	DT	a
3-drug	JJ	<unknown>
regimen	NN	regimen
with	IN	with
favipiravir	NN	<unknown>
added	VBD	add
to	TO	to
the	DT	the
2-drug	JJ	<unknown>
regimen	NN	regimen
.	SENT	.
Disease	NN	disease
progression	NN	progression
was	VBD	be
observed	VBN	observe
in	IN	in
18	CD	@card@
patients	NNS	patient
(	(	(
16.8	CD	@card@
%	NN	%
)	)	)
.	SENT	.
All	DT	all
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
were	VBD	be
discharged	VBN	discharge
alive	JJ	alive
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
COVID-19	NP	<unknown>
was	VBD	be
7.5	CD	@card@
%	NN	%
among	IN	among
patients	NNS	patient
who	WP	who
underwent	VBD	undergo
RT-PCR	NP	<unknown>
testing	NN	testing
,	,	,
and	CC	and
10	CD	@card@
%	NN	%
among	IN	among
those	DT	those
having	VBG	have
risk	NN	risk
factors	NNS	factor
for	IN	for
COVID-19	NP	<unknown>
acquisition	NN	acquisition
.	SENT	.
Combination	NN	combination
antiviral	JJ	antiviral
therapies	NNS	therapy
for	IN	for
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
well-tolerated	VBN	well-tolerate
and	CC	and
produced	VBN	produce
a	DT	a
favorable	JJ	favorable
outcome	NN	outcome
.	SENT	.
34873885/	CD	@card@
Development	NP	Development
of	IN	of
the	DT	the
Stress	NN	stress
and	CC	and
Anxiety	NN	anxiety
to	TO	to
Viral	JJ	viral
Epidemics-9	NP	<unknown>
(	(	(
SAVE-9	NP	<unknown>
)	)	)
Scale	NP	Scale
for	IN	for
Assessing	VBG	assess
Work-related	JJ	work-related
Stress	NN	stress
and	CC	and
Anxiety	NN	anxiety
in	IN	in
Healthcare	NP	Healthcare
Workers	NPS	Workers
in	IN	in
Response	NP	Response
to	TO	to
Viral	JJ	viral
Epidemics	NNS	epidemic
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
,	,	,
or	CC	or
COVID-19	NP	<unknown>
,	,	,
has	VBZ	have
had	VBN	have
a	DT	a
major	JJ	major
psychological	JJ	psychological
impact	NN	impact
on	IN	on
healthcare	NN	<unknown>
workers	NNS	worker
.	SENT	.
However	RB	however
,	,	,
very	RB	very
few	JJ	few
scales	NNS	scale
are	VBP	be
available	JJ	available
to	TO	to
specifically	RB	specifically
assess	VB	assess
work-related	JJ	work-related
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
in	IN	in
healthcare	NN	<unknown>
workers	NNS	worker
responding	VBG	respond
to	TO	to
a	DT	a
viral	JJ	viral
epidemic	NN	epidemic
.	SENT	.
This	DT	this
study	NN	study
developed	VBD	develop
a	DT	a
new	JJ	new
assessment	NN	assessment
tool	NN	tool
,	,	,
the	DT	the
Stress	NN	stress
and	CC	and
Anxiety	NN	anxiety
to	TO	to
Viral	JJ	viral
Epidemics-9	NP	<unknown>
(	(	(
SAVE-9	NP	<unknown>
)	)	)
and	CC	and
aimed	VBN	aim
to	TO	to
validate	VB	validate
it	PP	it
among	IN	among
healthcare	NN	<unknown>
workers	NNS	worker
directly	RB	directly
affected	VBN	affect
by	IN	by
COVID-19	NP	<unknown>
in	IN	in
Korea	NP	Korea
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
1,019	CD	@card@
healthcare	NN	<unknown>
workers	NNS	worker
responded	VBD	respond
through	IN	through
anonymous	JJ	anonymous
questionnaires	NNS	questionnaire
during	IN	during
April	NP	April
20-30	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
Exploratory	JJ	exploratory
factor	NN	factor
analysis	NN	analysis
(	(	(
EFA	NP	EFA
)	)	)
was	VBD	be
conducted	VBN	conduct
to	TO	to
explore	VB	explore
the	DT	the
construct	NN	construct
validity	NN	validity
,	,	,
and	CC	and
the	DT	the
reliability	NN	reliability
was	VBD	be
assessed	VBN	assess
using	VBG	use
internal	JJ	internal
consistency	NN	consistency
measures	NNS	measure
of	IN	of
Cronbach	NP	<unknown>
's	POS	's
alpha	NN	alpha
coefficients	NNS	coefficient
.	SENT	.
Receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
analysis	NN	analysis
was	VBD	be
conducted	VBN	conduct
to	TO	to
define	VB	define
the	DT	the
most	RBS	most
appropriate	JJ	appropriate
cut-off	NN	cut-off
point	NN	point
of	IN	of
SAVE-9	NP	<unknown>
using	VBG	use
the	DT	the
Generalized	VBN	generalize
Anxiety	NN	anxiety
Disorder-7	JJ	<unknown>
scale	NN	scale
(	(	(
GAD-7	JJ	<unknown>
;	:	;
&gt	NN	&gt
;	:	;
=	SYM	=
5	CD	@card@
)	)	)
.	SENT	.
Second	RB	second
,	,	,
Spearman	NP	Spearman
's	POS	's
rank	JJ	rank
correlation	NN	correlation
coefficient	NN	coefficient
was	VBD	be
used	VBN	use
to	TO	to
establish	VB	establish
convergent	JJ	convergent
validity	NN	validity
for	IN	for
the	DT	the
SAVE-9	NP	<unknown>
questionnaire	NN	questionnaire
with	IN	with
GAD-7	JJ	<unknown>
and	CC	and
the	DT	the
Patient	NP	Patient
Health	NP	Health
Questionnaire-9	NP	<unknown>
.	SENT	.
The	DT	the
nine-item	NN	<unknown>
scale	NN	scale
had	VBD	have
satisfactory	JJ	satisfactory
internal	JJ	internal
consistency	NN	consistency
(	(	(
Cronbach	NP	<unknown>
's	POS	's
alpha	NN	alpha
=	SYM	=
0.795	CD	@card@
)	)	)
.	SENT	.
It	PP	it
adopted	VBD	adopt
a	DT	a
two-factor	NN	two-factor
structure	NN	structure
:	:	:
1	LS	1
)	)	)
anxiety	NN	anxiety
regarding	VBG	regard
viral	JJ	viral
epidemics	NNS	epidemic
and	CC	and
2	LS	2
)	)	)
work-related	JJ	work-related
stress	NN	stress
associated	VBN	associate
with	IN	with
viral	JJ	viral
epidemics	NNS	epidemic
.	SENT	.
A	DT	a
cut-off	NN	cut-off
score	NN	score
of	IN	of
22	CD	@card@
for	IN	for
the	DT	the
SAVE-9	NP	<unknown>
ascertained	VBD	ascertain
levels	NNS	level
of	IN	of
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
in	IN	in
response	NN	response
to	TO	to
a	DT	a
viral	JJ	viral
epidemic	NN	epidemic
in	IN	in
healthcare	NN	<unknown>
workers	NNS	worker
that	WDT	that
warranted	VBD	warrant
clinical	JJ	clinical
attention	NN	attention
.	SENT	.
Correlations	NNS	correlation
between	IN	between
the	DT	the
SAVE-9	NP	<unknown>
and	CC	and
the	DT	the
other	JJ	other
scales	NNS	scale
were	VBD	be
statistically	RB	statistically
significant	JJ	significant
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
The	DT	the
results	NNS	result
suggest	VBP	suggest
that	IN	that
the	DT	the
SAVE-9	NP	<unknown>
is	VBZ	be
a	DT	a
useful	JJ	useful
,	,	,
reliable	JJ	reliable
,	,	,
and	CC	and
valid	JJ	valid
tool	NN	tool
to	TO	to
evaluate	VB	evaluate
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
responses	NNS	response
in	IN	in
healthcare	NN	<unknown>
workers	NNS	worker
during	IN	during
viral	JJ	viral
epidemics	NNS	epidemic
.	SENT	.
33626376/	CD	@card@
Predictions	NNS	prediction
of	IN	of
cancer	NN	cancer
mortality	NN	mortality
in	IN	in
Europe	NP	Europe
in	IN	in
2021	CD	@card@
:	:	:
room	NN	room
for	IN	for
hope	NN	hope
in	IN	in
the	DT	the
shadow	NN	shadow
of	IN	of
COVID-19	NP	<unknown>
?	SENT	?
34403943/	CD	@card@
Face	NP	Face
mask:A	NP	<unknown>
potential	JJ	potential
source	NN	source
of	IN	of
phthalate	JJ	phthalate
exposure	NN	exposure
for	IN	for
human	JJ	human
Face	NP	Face
masks	NNS	mask
are	VBP	be
necessary	JJ	necessary
for	IN	for
fighting	VBG	fight
against	IN	against
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
As	IN	as
the	DT	the
face	NN	face
mask	NN	mask
is	VBZ	be
usually	RB	usually
made	VBN	make
from	IN	from
polymers	NNS	polymer
and	CC	and
phthalates	NNS	<unknown>
are	VBP	be
widely-used	JJ	<unknown>
additives	NNS	additive
into	IN	into
the	DT	the
polymers	NNS	polymer
,	,	,
the	DT	the
face	NN	face
mask	NN	mask
could	MD	could
be	VB	be
a	DT	a
potential	JJ	potential
source	NN	source
of	IN	of
phthalate	JJ	phthalate
exposure	NN	exposure
to	TO	to
humans	NNS	human
.	SENT	.
However	RB	however
,	,	,
limited	JJ	limited
knowledge	NN	knowledge
is	VBZ	be
available	JJ	available
on	IN	on
the	DT	the
occurrence	NN	occurrence
and	CC	and
risks	NNS	risk
of	IN	of
the	DT	the
phthalates	NNS	<unknown>
from	IN	from
the	DT	the
face	NN	face
mask	NN	mask
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
twelve	NN	twelve
phthalates	NNS	<unknown>
were	VBD	be
determined	VBN	determine
in	IN	in
56	CD	@card@
mask	NN	mask
samples	NNS	sample
collected	VBN	collect
from	IN	from
different	JJ	different
countries	NNS	country
.	SENT	.
The	DT	the
phthalates	NNS	<unknown>
were	VBD	be
detected	VBN	detect
in	IN	in
all	PDT	all
the	DT	the
samples	NNS	sample
with	IN	with
total	JJ	total
levels	NNS	level
ranging	VBG	range
from	IN	from
115	CD	@card@
ng/g	NNS	<unknown>
to	TO	to
37,700	CD	@card@
ng/g	NNS	<unknown>
.	SENT	.
Estimated	VBN	estimate
daily	JJ	daily
intakes	NNS	intake
(	(	(
EDIs	NP	<unknown>
)	)	)
of	IN	of
the	DT	the
phthalates	NNS	<unknown>
from	IN	from
the	DT	the
masks	NNS	mask
ranged	VBN	range
from	IN	from
3.71	CD	@card@
to	TO	to
639	CD	@card@
ng/kg-bw/day	NNS	<unknown>
,	,	,
and	CC	and
the	DT	the
EDIs	NP	<unknown>
of	IN	of
the	DT	the
phthalates	NNS	<unknown>
from	IN	from
masks	NNS	mask
for	IN	for
toddlers	NNS	toddler
were	VBD	be
approximately	RB	approximately
4-5	CD	@card@
times	NNS	time
higher	JJR	high
than	IN	than
those	DT	those
for	IN	for
adults	NNS	adult
.	SENT	.
Non-carcinogenic	JJ	Non-carcinogenic
risks	NNS	risk
in	IN	in
relation	NN	relation
to	TO	to
the	DT	the
phthalates	NNS	<unknown>
in	IN	in
masks	NNS	mask
were	VBD	be
found	VBN	find
to	TO	to
be	VB	be
within	IN	within
safe	JJ	safe
levels	NNS	level
,	,	,
yet	RB	yet
89.3	CD	@card@
%	NN	%
of	IN	of
the	DT	the
mask	NN	mask
samples	NNS	sample
exhibited	VBD	exhibit
potential	JJ	potential
carcinogenic	JJ	carcinogenic
effects	NNS	effect
to	TO	to
humans	NNS	human
.	SENT	.
The	DT	the
extent	NN	extent
of	IN	of
the	DT	the
risks	NNS	risk
for	IN	for
wearing	VBG	wear
masks	NNS	mask
located	VBN	locate
at	IN	at
a	DT	a
moderate	JJ	moderate
level	NN	level
comparing	VBG	compare
with	IN	with
other	JJ	other
skin-contacted	JJ	<unknown>
products	NNS	product
.	SENT	.
This	DT	this
study	NN	study
unveiled	VBD	unveil
a	DT	a
potential	JJ	potential
source	NN	source
of	IN	of
phthalate	JJ	phthalate
exposure	NN	exposure
to	TO	to
human	JJ	human
,	,	,
and	CC	and
indicated	VBD	indicate
necessity	NN	necessity
of	IN	of
managing	VBG	manage
types	NNS	type
and	CC	and
levels	NNS	level
of	IN	of
additives	NNS	additive
in	IN	in
the	DT	the
face	NN	face
masks	NNS	mask
.	SENT	.
34629857/	CD	@card@
Abordaje	NP	<unknown>
del	NP	del
duelo	NP	<unknown>
y	NP	y
de	FW	de
la	FW	la
muerte	NP	<unknown>
en	FW	en
familiares	NP	<unknown>
de	FW	de
pacientes	NP	<unknown>
con	NN	con
COVID-19	NP	<unknown>
:	:	:
revision	NN	revision
narrativa	NN	<unknown>
Realizar	NP	<unknown>
una	NP	Una
sintesis	NN	<unknown>
de	NP	de
la	NP	la
evidencia	NP	<unknown>
disponible	JJ	<unknown>
para	NN	para
establecer	NN	<unknown>
recomendaciones	NNS	<unknown>
sobre	NN	<unknown>
el	NN	el
abordaje	NP	<unknown>
del	FW	del
duelo	NP	<unknown>
y	NP	y
la	FW	la
muerte	NP	<unknown>
en	FW	en
familiares	NP	<unknown>
de	FW	de
pacientes	NP	<unknown>
con	NN	con
COVID-19	NP	<unknown>
,	,	,
asi	NP	Asi
como	NP	Como
ofrecer	NN	<unknown>
recursos	NNS	<unknown>
sustitutivos	NNS	<unknown>
de	NP	de
los	NP	los
rituales	NP	<unknown>
y	NP	y
procedimientos	NNS	<unknown>
necesarios	NNS	<unknown>
con	NN	con
el	NN	el
fin	NN	fin
de	NP	de
favorecer	NP	<unknown>
duelos	NP	<unknown>
funcionales	NP	<unknown>
y	NP	y
prevenir	NN	<unknown>
duelos	NN	<unknown>
complicados	NNS	<unknown>
.	SENT	.
Se	NP	Se
realizo	NP	<unknown>
busqueda	NN	<unknown>
bibliografica	NN	<unknown>
en	IN	en
bases	NNS	base
de	NP	de
datos	NNS	dato
MEDLINE	NP	<unknown>
,	,	,
EMBASE	NP	<unknown>
,	,	,
SCIENCEDIRECT	NP	<unknown>
,	,	,
WOS	NNS	wo
,	,	,
CINAHL	NP	<unknown>
y	NP	y
CUIDEN	NP	<unknown>
,	,	,
utilizando	NN	<unknown>
terminos	NNS	<unknown>
MeSH	NN	mesh
(	(	(
family	NN	family
,	,	,
patient	NN	patient
,	,	,
isolation	NN	isolation
hospitals	NNS	hospital
,	,	,
grief	NN	grief
,	,	,
death	NN	death
,	,	,
ceremonial	JJ	ceremonial
behavior	NN	behavior
,	,	,
self	NN	self
care	NN	care
,	,	,
affects	VBZ	affect
y	NP	y
social	JJ	social
networking	NN	networking
)	)	)
con	NN	con
su	NN	su
ecuacion	NN	<unknown>
booleana	NN	<unknown>
correspondiente	NN	<unknown>
.	SENT	.
Los	NP	Los
articulos	NP	<unknown>
seleccionados	NP	<unknown>
se	FW	se
sometieron	NN	<unknown>
a	DT	a
una	NN	una
lectura	NN	<unknown>
critica	NN	<unknown>
a	DT	a
traves	NNS	trave
del	DT	del
Critical	JJ	critical
Apraisal	NP	<unknown>
Skill	NP	Skill
Programme	NN	programme
en	IN	en
espanol	NN	<unknown>
.	SENT	.
Se	FW	se
encontraron	NN	<unknown>
560	CD	@card@
articulos	NP	<unknown>
atingentes	NNS	atingent
;	:	;
tras	NNS	<unknown>
aplicar	NN	<unknown>
los	NP	los
criterios	NP	<unknown>
de	NP	de
seleccion	NN	<unknown>
13	NP	@card@
estudios	NP	Estudios
se	FW	se
incluyeron	NP	<unknown>
en	FW	en
el	NN	el
analisis	NN	<unknown>
,	,	,
de	NP	de
los	NP	los
cuales	VBZ	<unknown>
8	CD	@card@
eran	JJ	<unknown>
revisiones	NNS	<unknown>
sistematicas	NNS	<unknown>
,	,	,
3	CD	@card@
estudios	NNS	estudio
cualitativos	NNS	<unknown>
,	,	,
un	VBG	<unknown>
estudio	NP	<unknown>
piloto	NP	<unknown>
prospectivo	NP	<unknown>
transversal	JJ	transversal
y	NP	y
una	NN	una
guia	NN	<unknown>
clinica	NN	<unknown>
,	,	,
que	NP	que
permitieron	NP	<unknown>
identificar	NN	<unknown>
estrategias	NNS	<unknown>
para	NN	para
el	NN	el
abordaje	NP	<unknown>
del	FW	del
duelo	NP	<unknown>
y	NP	y
la	NP	la
muerte	NN	<unknown>
atendiendo	NN	<unknown>
a	DT	a
este	NN	<unknown>
momento	NP	momento
de	FW	de
excepcionalidad	NP	<unknown>
de	FW	de
la	FW	la
COVID-19	NP	<unknown>
,	,	,
incidiendo	NN	<unknown>
en	IN	en
el	NN	el
manejo	NN	<unknown>
competencial	JJ	<unknown>
de	NP	de
los	NP	los
profesionales	NNS	<unknown>
sanitarios	NNS	<unknown>
en	IN	en
apoyo	NN	<unknown>
emocional	JJ	<unknown>
y	NN	y
en	IN	en
el	NN	el
acompanamiento	NN	<unknown>
,	,	,
asi	NN	asi
como	NN	<unknown>
en	IN	en
el	NN	el
seguimiento	NN	<unknown>
durante	NN	<unknown>
todo	NN	<unknown>
el	NN	el
proceso	NN	<unknown>
y	NP	y
en	FW	en
la	FW	la
comunicacion	NN	<unknown>
con	JJ	con
la	NP	la
familia	NN	<unknown>
.	SENT	.
En	IN	en
el	NN	el
proceso	NN	<unknown>
final	JJ	final
de	NP	de
la	FW	la
vida	NP	Vida
en	FW	en
tiempos	NP	<unknown>
de	FW	de
la	FW	la
COVID-19	NP	<unknown>
los	NP	los
profesionales	NP	<unknown>
sanitarios	NP	<unknown>
deben	NP	<unknown>
trabajar	JJ	<unknown>
despedidas	NNS	<unknown>
,	,	,
los	NP	los
ritos	NP	<unknown>
funebres	NNS	<unknown>
alternativos	NNS	<unknown>
,	,	,
la	DT	la
atencion	NN	<unknown>
espiritual	JJ	espiritual
y	NP	y
el	NN	el
afrontamiento	NN	<unknown>
precoz	NP	<unknown>
que	NP	que
permitiran	VBD	<unknown>
a	DT	a
su	NN	su
vez	NP	vez
la	FW	la
prevencion	NP	<unknown>
del	FW	del
duelo	NP	<unknown>
complicado	NP	<unknown>
.	SENT	.
34682492/	CD	@card@
Leveraging	VBG	leverage
HIV	NP	HIV
Care	NP	Care
Infrastructures	NNS	infrastructure
for	IN	for
Integrated	NP	Integrated
Chronic	JJ	chronic
Disease	NN	disease
and	CC	and
Pandemic	JJ	pandemic
Management	NN	management
in	IN	in
Sub-Saharan	NP	Sub-Saharan
Africa	NP	Africa
In	IN	in
Sub-Saharan	NP	Sub-Saharan
Africa	NP	Africa
,	,	,
communicable	JJ	communicable
and	CC	and
other	JJ	other
tropical	JJ	tropical
infectious	JJ	infectious
diseases	NNS	disease
remain	VBP	remain
major	JJ	major
challenges	NNS	challenge
apart	RB	apart
from	IN	from
the	DT	the
continuing	JJ	continuing
HIV/AIDS	NP	<unknown>
epidemic	NN	epidemic
.	SENT	.
Recognition	NN	recognition
and	CC	and
prevalence	NN	prevalence
of	IN	of
non-communicable	JJ	non-communicable
diseases	NNS	disease
have	VBP	have
risen	VBN	rise
throughout	IN	throughout
Africa	NP	Africa
,	,	,
and	CC	and
the	DT	the
reimagining	NN	<unknown>
of	IN	of
healthcare	NN	<unknown>
delivery	NN	delivery
is	VBZ	be
needed	VBN	need
to	TO	to
support	VB	support
communities	NNS	community
coping	VBG	cope
with	IN	with
not	RB	not
only	RB	only
with	IN	with
HIV	NP	HIV
,	,	,
tuberculosis	NN	tuberculosis
,	,	,
and	CC	and
COVID-19	NP	<unknown>
,	,	,
but	CC	but
also	RB	also
cancer	NN	cancer
,	,	,
cardiovascular	JJ	cardiovascular
disease	NN	disease
,	,	,
diabetes	NN	diabetes
,	,	,
and	CC	and
depression	NN	depression
.	SENT	.
Many	JJ	many
non-communicable	JJ	non-communicable
diseases	NNS	disease
can	MD	can
be	VB	be
prevented	VBN	prevent
or	CC	or
treated	VBN	treat
with	IN	with
low-cost	JJ	low-cost
interventions	NNS	intervention
,	,	,
yet	RB	yet
implementation	NN	implementation
of	IN	of
such	JJ	such
care	NN	care
has	VBZ	have
been	VBN	be
limited	VBN	limit
in	IN	in
the	DT	the
region	NN	region
.	SENT	.
In	IN	in
this	DT	this
Perspective	NP	Perspective
piece	NN	piece
,	,	,
we	PP	we
argue	VBP	argue
that	DT	that
deployment	NN	deployment
of	IN	of
an	DT	an
integrated	JJ	integrated
service	NN	service
delivery	NN	delivery
model	NN	model
is	VBZ	be
an	DT	an
urgent	JJ	urgent
next	JJ	next
step	NN	step
,	,	,
propose	VBP	propose
a	DT	a
South	JJ	South
African	JJ	African
model	NN	model
for	IN	for
integration	NN	integration
,	,	,
and	CC	and
conclude	VB	conclude
with	IN	with
recommendations	NNS	recommendation
for	IN	for
next	JJ	next
steps	NNS	step
in	IN	in
research	NN	research
and	CC	and
implementation	NN	implementation
.	SENT	.
An	DT	an
approach	NN	approach
that	WDT	that
is	VBZ	be
inspired	VBN	inspire
by	IN	by
South	JJ	South
African	JJ	African
experience	NN	experience
would	MD	would
build	VB	build
on	IN	on
existing	VBG	exist
HIV-focused	JJ	HIV-focused
infrastructure	NN	infrastructure
that	WDT	that
has	VBZ	have
been	VBN	be
developed	VBN	develop
by	IN	by
Ministries	NNS	ministry
of	IN	of
Health	NP	Health
with	IN	with
strong	JJ	strong
support	NN	support
from	IN	from
the	DT	the
U.S.	NP	U.S.
President	NP	President
's	POS	's
Emergency	NP	Emergency
Response	NP	Response
for	IN	for
AIDS	NP	AIDS
Relief	NP	Relief
(	(	(
PEPFAR	NP	<unknown>
)	)	)
and	CC	and
the	DT	the
Global	NP	Global
Fund	NP	Fund
to	TO	to
Fight	VB	fight
AIDS	NP	AIDS
,	,	,
Tuberculosis	NN	tuberculosis
and	CC	and
Malaria	NN	malaria
.	SENT	.
An	DT	an
integrated	JJ	integrated
chronic	JJ	chronic
healthcare	NN	<unknown>
model	NN	model
holds	VBZ	hold
promise	NN	promise
to	TO	to
sustainably	RB	<unknown>
deliver	VB	deliver
infectious	JJ	infectious
disease	NN	disease
and	CC	and
non-communicable	JJ	non-communicable
disease	NN	disease
care	NN	care
.	SENT	.
Integrated	JJ	integrated
care	NN	care
will	MD	will
be	VB	be
especially	RB	especially
critical	JJ	critical
as	IN	as
health	NN	health
systems	NNS	system
seek	VBP	seek
to	TO	to
cope	VB	cope
with	IN	with
the	DT	the
unprecedented	JJ	unprecedented
challenges	NNS	challenge
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
future	JJ	future
pandemic	JJ	pandemic
threats	NNS	threat
.	SENT	.
35399336/	CD	@card@
Evidence-Based	JJ	<unknown>
Policymaking	VBG	policymak
in	IN	in
Times	NP	Times
of	IN	of
Acute	JJ	acute
Crisis	NN	crisis
:	:	:
Comparing	VBG	compare
the	DT	the
Use	NN	use
of	IN	of
Scientific	NP	Scientific
Knowledge	NP	Knowledge
in	IN	in
Germany	NP	Germany
,	,	,
Switzerland	NP	Switzerland
,	,	,
and	CC	and
Italy	NP	Italy
This	DT	this
article	NN	article
studies	VBZ	study
how	WRB	how
different	JJ	different
systems	NNS	system
of	IN	of
policy	NN	policy
advice	NN	advice
are	VBP	be
suited	VBN	suit
to	TO	to
provide	VB	provide
relevant	JJ	relevant
knowledge	NN	knowledge
in	IN	in
times	NNS	time
of	IN	of
acute	JJ	acute
crisis	NN	crisis
.	SENT	.
The	DT	the
notion	NN	notion
of	IN	of
evidence-based	JJ	<unknown>
policymaking	VBG	policymak
(	(	(
EBP	NP	EBP
)	)	)
originated	VBP	originated
in	IN	in
the	DT	the
successful	JJ	successful
1997	CD	@card@
New	NP	New
Labour	NP	Labour
program	NN	program
in	IN	in
the	DT	the
United	NP	United
Kingdom	NP	Kingdom
to	TO	to
formulate	VB	formulate
policy	NN	policy
based	VBN	base
not	RB	not
on	IN	on
ideology	NN	ideology
but	CC	but
on	IN	on
sound	JJ	sound
empirical	JJ	empirical
evidence	NN	evidence
.	SENT	.
We	PP	we
provide	VBP	provide
a	DT	a
brief	JJ	brief
overview	NN	overview
of	IN	of
the	DT	the
history	NN	history
of	IN	of
the	DT	the
concept	NN	concept
and	CC	and
the	DT	the
current	JJ	current
debates	NNS	debate
around	IN	around
it	PP	it
.	SENT	.
We	PP	we
then	RB	then
outline	VB	outline
the	DT	the
main	JJ	main
characteristics	NNS	characteristic
of	IN	of
the	DT	the
policy	NN	policy
advisory	JJ	advisory
systems	NNS	system
in	IN	in
Germany	NP	Germany
,	,	,
Switzerland	NP	Switzerland
,	,	,
and	CC	and
Italy	NP	Italy
through	IN	through
which	WDT	which
scientific	JJ	scientific
knowledge:in	NN	<unknown>
the	DT	the
form	NN	form
of	IN	of
either	DT	either
person-bound	JJ	person-bound
expertise	NN	expertise
or	CC	or
evidence	NN	evidence
generated	VBN	generate
through	IN	through
standard	JJ	standard
scientific	JJ	scientific
processes:was	NNS	<unknown>
fed	VBN	feed
into	IN	into
policy	NN	policy
formulation	NN	formulation
processes	VBZ	process
before	IN	before
the	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
.	SENT	.
Whereas	IN	whereas
EBP	NP	EBP
takes	VBZ	take
place	NN	place
in	IN	in
the	DT	the
form	NN	form
of	IN	of
institutionalized	VBN	institutionalize
advisory	JJ	advisory
bodies	NNS	body
and	CC	and
draws	NNS	draw
on	IN	on
expertise	NN	expertise
rather	RB	rather
than	IN	than
on	IN	on
evidence	NN	evidence
in	IN	in
Germany	NP	Germany
,	,	,
the	DT	the
system	NN	system
in	IN	in
Switzerland	NP	Switzerland
focuses	VBZ	focus
more	RBR	more
on	IN	on
the	DT	the
use	NN	use
of	IN	of
evidence	NN	evidence
provided	VBN	provide
through	IN	through
external	JJ	external
mandates	NNS	mandate
.	SENT	.
Italy	NP	Italy
has	VBZ	have
a	DT	a
hybrid	JJ	hybrid
politicized	JJ	politicized
expert	NN	expert
system	NN	system
.	SENT	.
The	DT	the
article	NN	article
then	RB	then
analyzes	VBZ	analyze
how	WRB	how
this	DT	this
different	JJ	different
prioritization	NN	prioritization
of	IN	of
expertise	NN	expertise
vs.	CC	vs.
evidence	NN	evidence
in	IN	in
the	DT	the
three	CD	three
countries	NNS	country
affects	VBZ	affect
policymakers	NNS	policymaker
'	POS	'
capacity	NN	capacity
to	TO	to
include	VB	include
scientific	JJ	scientific
knowledge	NN	knowledge
in	IN	in
policy	NN	policy
decisions	NNS	decision
in	IN	in
times	NNS	time
of	IN	of
acute	JJ	acute
crisis	NN	crisis
.	SENT	.
The	DT	the
comparison	NN	comparison
of	IN	of
the	DT	the
three	CD	three
countries	NNS	country
implies	VBZ	imply
that	IN	that
countries	NNS	country
with	IN	with
policy	NN	policy
advisory	NN	advisory
systems	NNS	system
designed	VBN	design
to	TO	to
use	NN	use
expertise	NN	expertise
are	VBP	be
better	RBR	well
placed	VBN	place
to	TO	to
incorporate	VB	incorporate
scientific	JJ	scientific
knowledge	NN	knowledge
into	IN	into
their	PP$	their
decisions	NNS	decision
in	IN	in
times	NNS	time
of	IN	of
acute	JJ	acute
crisis	NN	crisis
than	IN	than
are	VBP	be
countries	NNS	country
with	IN	with
policy	NN	policy
advisory	JJ	advisory
systems	NNS	system
that	WDT	that
relied	VBD	rely
primarily	RB	primarily
on	IN	on
evidence	NN	evidence
before	IN	before
the	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
of	IN	of
this	DT	this
article	NN	article
(	(	(
10.1007/s11615-022-00382-x	NP	<unknown>
)	)	)
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
,	,	,
which	WDT	which
is	VBZ	be
available	JJ	available
to	TO	to
authorized	JJ	authorized
users	NNS	user
.	SENT	.
33461516/	CD	@card@
Quality	JJ	Quality
and	CC	and
readability	NN	readability
of	IN	of
web-based	JJ	<unknown>
Arabic	JJ	Arabic
health	NN	health
information	NN	information
on	IN	on
COVID-19	NP	<unknown>
:	:	:
an	DT	an
infodemiological	JJ	infodemiological
study	NN	study
This	DT	this
study	NN	study
sought	VBD	seek
to	TO	to
assess	VB	assess
the	DT	the
quality	NN	quality
and	CC	and
readability	NN	readability
of	IN	of
web-based	JJ	<unknown>
Arabic	JJ	Arabic
health	NN	health
information	NN	information
on	IN	on
COVID-19	NP	<unknown>
.	SENT	.
Three	CD	three
search	NN	search
engines	NNS	engine
were	VBD	be
searched	VBN	search
on	IN	on
13	CD	@card@
April	NP	April
2020	CD	@card@
for	IN	for
specific	JJ	specific
Arabic	JJ	Arabic
terms	NNS	term
on	IN	on
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
first	JJ	first
100	CD	@card@
consecutive	JJ	consecutive
websites	NNS	website
from	IN	from
each	DT	each
engine	NN	engine
were	VBD	be
analyzed	VBN	analyze
for	IN	for
eligibility	NN	eligibility
,	,	,
which	WDT	which
resulted	VBD	result
in	IN	in
a	DT	a
sample	NN	sample
of	IN	of
36	CD	@card@
websites	NNS	website
.	SENT	.
These	DT	these
websites	NNS	website
were	VBD	be
subjected	VBN	subject
to	TO	to
quality	NN	quality
assessments	NNS	assessment
using	VBG	use
the	DT	the
Journal	NP	Journal
of	IN	of
the	DT	the
American	NP	American
Medical	NP	Medical
Association	NP	Association
(	(	(
JAMA	NP	JAMA
)	)	)
benchmarks	NNS	benchmark
tool	NN	tool
,	,	,
the	DT	the
DISCERN	VBP	discern
tool	NN	tool
,	,	,
and	CC	and
Health	NP	Health
on	IN	on
the	DT	the
Net	JJ	net
Foundation	NP	Foundation
Code	NP	Code
of	IN	of
Conduct	NP	Conduct
(	(	(
HONcode	NP	<unknown>
)	)	)
certification	NN	certification
.	SENT	.
The	DT	the
readability	NN	readability
of	IN	of
the	DT	the
websites	NNS	website
was	VBD	be
assessed	VBN	assess
using	VBG	use
an	DT	an
online	JJ	online
readability	NN	readability
calculator	NN	calculator
.	SENT	.
Among	IN	among
the	DT	the
36	CD	@card@
eligible	JJ	eligible
websites	NNS	website
,	,	,
only	RB	only
one	CD	one
(	(	(
2.7	CD	@card@
%	NN	%
)	)	)
was	VBD	be
HONcode	RB	<unknown>
certified	VBN	certify
.	SENT	.
No	DT	no
website	NN	website
attained	VBD	attain
a	DT	a
high	JJ	high
score	NN	score
based	VBN	base
on	IN	on
the	DT	the
criteria	NNS	criterion
of	IN	of
the	DT	the
DISCERN	VBP	discern
tool	NN	tool
;	:	;
the	DT	the
mean	JJ	mean
score	NN	score
of	IN	of
all	DT	all
websites	NNS	website
was	VBD	be
31.5	CD	@card@
+-	NN	<unknown>
12.55	CD	@card@
.	SENT	.
As	RB	as
regards	VBZ	regard
the	DT	the
JAMA	NP	JAMA
benchmarks	NNS	benchmark
results	NNS	result
,	,	,
a	DT	a
mean	JJ	mean
score	NN	score
of	IN	of
2.08	CD	@card@
+-	NN	<unknown>
1.05	CD	@card@
was	VBD	be
achieved	VBN	achieve
by	IN	by
the	DT	the
websites	NNS	website
;	:	;
however	RB	however
,	,	,
only	RB	only
four	CD	four
(	(	(
11.1	CD	@card@
%	NN	%
)	)	)
met	VBD	meet
all	PDT	all
the	DT	the
JAMA	NP	JAMA
criteria	NNS	criterion
.	SENT	.
The	DT	the
average	JJ	average
grade	NN	grade
levels	NNS	level
for	IN	for
readability	NN	readability
were	VBD	be
7.2	CD	@card@
+-	NN	<unknown>
7.5	CD	@card@
,	,	,
3.3	CD	@card@
+-	NN	<unknown>
0.6	CD	@card@
and	CC	and
93.5	CD	@card@
+-	NN	<unknown>
19.4	CD	@card@
for	IN	for
the	DT	the
Flesch	NP	Flesch
Kincaid	NP	Kincaid
Grade	NP	Grade
Level	NP	Level
,	,	,
Simple	JJ	simple
Measure	NN	measure
of	IN	of
Gobbledygook	NN	gobbledygook
,	,	,
and	CC	and
Flesch	NP	Flesch
Reading	NP	Reading
Ease	NN	ease
scales	NNS	scale
,	,	,
respectively	RB	respectively
.	SENT	.
Almost	RB	almost
all	RB	all
of	IN	of
the	DT	the
most	RBS	most
easily	RB	easily
accessible	JJ	accessible
web-based	JJ	<unknown>
Arabic	JJ	Arabic
health	NN	health
information	NN	information
on	IN	on
COVID-19	NP	<unknown>
does	VBZ	do
not	RB	not
meet	VB	meet
recognized	VBN	recognize
quality	NN	quality
standards	NNS	standard
regardless	RB	regardless
of	IN	of
the	DT	the
level	NN	level
of	IN	of
readability	NN	readability
and	CC	and
ability	NN	ability
to	TO	to
be	VB	be
understood	VBN	understand
by	IN	by
the	DT	the
general	JJ	general
population	NN	population
of	IN	of
Arabic	JJ	Arabic
speakers	NNS	speaker
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12889-021-10218-9	JJ	10.1186/s@card@
.	SENT	.
32358765/	CD	@card@
In	IN	in
reply	NN	reply
:	:	:
Regional	JJ	regional
anesthesia	NN	anesthesia
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
a	DT	a
time	NN	time
to	TO	to
reconsider	VB	reconsider
practices	NNS	practice
?	SENT	?
(	(	(
Letters	NNS	letter
#1	JJ	<unknown>
and	CC	and
#2	JJ	<unknown>
)	)	)
35095602/	CD	@card@
Risk	NN	risk
of	IN	of
Depression	NP	Depression
,	,	,
Anxiety	NN	anxiety
,	,	,
and	CC	and
Stress	NN	stress
During	IN	during
the	DT	the
Second	NP	Second
Wave	NP	Wave
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Slovenia	NP	Slovenia
The	DT	the
spread	NN	spread
of	IN	of
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Syndrome	NN	syndrome
Coronavirus	NP	<unknown>
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
causing	VBG	cause
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
has	VBZ	have
led	VBN	lead
to	TO	to
numerous	JJ	numerous
negative	JJ	negative
consequences	NNS	consequence
on	IN	on
the	DT	the
mental	JJ	mental
health	NN	health
of	IN	of
the	DT	the
population	NN	population
throughout	IN	throughout
the	DT	the
world	NN	world
.	SENT	.
The	DT	the
main	JJ	main
aim	NN	aim
of	IN	of
our	PP$	our
study	NN	study
was	VBD	be
to	TO	to
compare	VB	compare
the	DT	the
risk	NN	risk
for	IN	for
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
during	IN	during
the	DT	the
second	JJ	second
wave	NN	wave
of	IN	of
the	DT	the
pandemic	NN	pandemic
in	IN	in
Slovenia	NP	Slovenia
.	SENT	.
An	DT	an
additional	JJ	additional
goal	NN	goal
was	VBD	be
to	TO	to
analyze	VB	analyze
the	DT	the
association	NN	association
of	IN	of
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
,	,	,
with	IN	with
the	DT	the
most	RBS	most
relevant	JJ	relevant
subjective	JJ	subjective
factors	NNS	factor
that	WDT	that
define	VBP	define
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
.	SENT	.
Furthermore	RB	furthermore
,	,	,
we	PP	we
aimed	VBD	aim
at	IN	at
determining	VBG	determine
whether	IN	whether
health	NN	health
workers	NNS	worker
have	VBP	have
a	DT	a
higher	JJR	high
risk	NN	risk
for	IN	for
depression	NN	depression
following	VBG	follow
the	DT	the
course	NN	course
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
study	NN	study
was	VBD	be
conducted	VBN	conduct
on	IN	on
the	DT	the
general	JJ	general
population	NN	population
,	,	,
between	IN	between
July	NP	July
2020	CD	@card@
and	CC	and
January	NP	January
2021	CD	@card@
through	IN	through
an	DT	an
online	JJ	online
survey	NN	survey
.	SENT	.
The	DT	the
data	NNS	datum
of	IN	of
1,728	CD	@card@
respondents	NNS	respondent
in	IN	in
two	CD	two
samples	NNS	sample
of	IN	of
respondents	NNS	respondent
(	(	(
782	CD	@card@
at	IN	at
baseline	JJ	baseline
-	NN	<unknown>
first	JJ	first
measurement	NN	measurement
point	NN	point
and	CC	and
946	CD	@card@
during	IN	during
the	DT	the
second	JJ	second
measurement	NN	measurement
point	NN	point
)	)	)
of	IN	of
the	DT	the
second	JJ	second
wave	NN	wave
were	VBD	be
analyzed	VBN	analyze
using	VBG	use
zero-inflated	JJ	zero-inflated
negative	JJ	negative
binomial	JJ	binomial
regression	NN	regression
and	CC	and
Mann-Whitney	NP	Mann-Whitney
U-test	NN	<unknown>
.	SENT	.
The	DT	the
findings	NNS	finding
of	IN	of
this	DT	this
study	NN	study
show	VBP	show
that	IN	that
the	DT	the
rise	NN	rise
the	DT	the
second	JJ	second
wave	NN	wave
was	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
higher	JJR	high
risk	NN	risk
for	IN	for
depression	NN	depression
,	,	,
anxiety	NN	anxiety
and	CC	and
stress	NN	stress
.	SENT	.
The	DT	the
risk	NN	risk
for	IN	for
all	DT	all
three	CD	three
was	VBD	be
higher	JJR	high
for	IN	for
younger	JJR	young
participants	NNS	participant
.	SENT	.
Women	NNS	woman
showed	VBD	show
a	DT	a
higher	JJR	high
risk	NN	risk
for	IN	for
anxiety	NN	anxiety
and	CC	and
stress	NN	stress
.	SENT	.
Finances	NNS	finance
,	,	,
relationships	NNS	relationship
,	,	,
and	CC	and
housing	NN	housing
dissatisfaction	NN	dissatisfaction
were	VBD	be
relevant	JJ	relevant
predictors	NNS	predictor
for	IN	for
depression	NN	depression
,	,	,
anxiety	NN	anxiety
and	CC	and
stress	NN	stress
.	SENT	.
Health	NN	health
workers	NNS	worker
in	IN	in
our	PP$	our
sample	NN	sample
showed	VBD	show
a	DT	a
higher	JJR	high
risk	NN	risk
for	IN	for
stress	NN	stress
,	,	,
but	CC	but
not	RB	not
for	IN	for
depression	NN	depression
or	CC	or
anxiety	NN	anxiety
,	,	,
than	IN	than
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
Our	PP$	our
findings	NNS	finding
highlight	VB	highlight
the	DT	the
urgent	JJ	urgent
need	NN	need
for	IN	for
coordinating	VBG	coordinate
and	CC	and
developing	VBG	develop
mental	JJ	mental
health	NN	health
services	NNS	service
and	CC	and
tailored	JJ	tailored
interventions	NNS	intervention
to	TO	to
reduce	VB	reduce
the	DT	the
mental	JJ	mental
health	NN	health
burden	NN	burden
,	,	,
especially	RB	especially
in	IN	in
the	DT	the
younger	JJR	young
.	SENT	.
34897635/	CD	@card@
COVID-19	NP	<unknown>
are	VBP	be
dangerous	JJ	dangerous
to	TO	to
the	DT	the
kidneys	NNS	kidney
in	IN	in
any	DT	any
situation	NN	situation
,	,	,
not	RB	not
only	RB	only
in	IN	in
a	DT	a
pandemic	NN	pandemic
:	:	:
LONG-COVID-19	NN	<unknown>
and	CC	and
kidney	NN	kidney
disease	NN	disease
33797339/	CD	@card@
COVID19-inhibitory	NN	<unknown>
activity	NN	activity
of	IN	of
withanolides	NNS	<unknown>
involves	VBZ	involve
targeting	VBG	target
of	IN	of
the	DT	the
host	NN	host
cell	NN	cell
surface	NN	surface
receptor	NN	receptor
ACE2	NP	<unknown>
:	:	:
insights	NNS	insight
from	IN	from
computational	JJ	computational
and	CC	and
biochemical	JJ	biochemical
assays	NNS	assay
SARS-CoV-2	JJ	<unknown>
outbreak	NN	outbreak
in	IN	in
China	NP	China
in	IN	in
December	NP	December
2019	CD	@card@
and	CC	and
its	PP$	its
spread	NN	spread
as	IN	as
worldwide	JJ	worldwide
pandemic	NN	pandemic
has	VBZ	have
been	VBN	be
a	DT	a
major	JJ	major
global	JJ	global
health	NN	health
crisis	NN	crisis
.	SENT	.
Extremely	RB	extremely
high	JJ	high
infection	NN	infection
and	CC	and
mortality	NN	mortality
rate	NN	rate
has	VBZ	have
severely	RB	severely
affected	VBN	affect
all	DT	all
sectors	NNS	sector
of	IN	of
life	NN	life
and	CC	and
derailed	VBD	derail
the	DT	the
global	JJ	global
economy	NN	economy
.	SENT	.
While	IN	while
drug	NN	drug
and	CC	and
vaccine	NN	vaccine
development	NN	development
have	VBP	have
been	VBN	be
prioritized	JJ	<unknown>
and	CC	and
have	VBP	have
made	VBN	make
significant	JJ	significant
progression	NN	progression
,	,	,
use	NN	use
of	IN	of
phytochemicals	NNS	phytochemical
and	CC	and
herbal	JJ	herbal
constituents	NNS	constituent
is	VBZ	be
deemed	VBN	deem
as	IN	as
a	DT	a
low-cost	JJ	low-cost
,	,	,
safer	JJR	safe
and	CC	and
readily	RB	readily
available	JJ	available
alternative	NN	alternative
.	SENT	.
We	PP	we
investigated	VBD	investigate
therapeutic	JJ	therapeutic
efficacy	NN	efficacy
of	IN	of
eight	CD	eight
withanolides	NNS	<unknown>
(	(	(
derived	VBN	derive
from	IN	from
Ashwagandha	NP	<unknown>
)	)	)
against	IN	against
the	DT	the
angiotensin-converting	JJ	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
proteins	NNS	protein
,	,	,
a	DT	a
target	NN	target
cell	NN	cell
surface	NN	surface
receptor	NN	receptor
for	IN	for
SARS-CoV-2	NP	<unknown>
and	CC	and
report	VB	report
results	NNS	result
on	IN	on
the	DT	the
(	(	(
i	NP	i
)	)	)
computational	JJ	computational
analyses	NNS	analysis
including	VBG	include
binding	JJ	binding
affinity	NN	affinity
and	CC	and
stable	JJ	stable
interactions	NNS	interaction
with	IN	with
ACE2	NP	<unknown>
,	,	,
occupancy	NN	occupancy
of	IN	of
ACE2	JJ	<unknown>
residues	NNS	residue
in	IN	in
making	VBG	make
polar	JJ	polar
and	CC	and
nonpolar	JJ	nonpolar
interactions	NNS	interaction
with	IN	with
different	JJ	different
withanolides/ligands	NNS	withanolides/ligand
and	CC	and
(	(	(
2	LS	2
)	)	)
in	IN	in
vitro	NN	<unknown>
mRNA	NN	<unknown>
and	CC	and
protein	NN	protein
analyses	NNS	analysis
using	VBG	use
human	JJ	human
cancer	NN	cancer
(	(	(
A549	NP	<unknown>
,	,	,
MCF7	JJ	<unknown>
and	CC	and
HSC3	JJ	<unknown>
)	)	)
cells	NNS	cell
.	SENT	.
We	PP	we
found	VBD	find
that	IN	that
among	IN	among
all	DT	all
withanolides	NNS	<unknown>
,	,	,
Withaferin-A	NP	<unknown>
,	,	,
Withanone	NP	<unknown>
,	,	,
Withanoside-IV	NP	<unknown>
and	CC	and
Withanoside-V	NP	<unknown>
significantly	RB	significantly
inhibited	VBD	inhibit
the	DT	the
ACE2	JJ	<unknown>
expression	NN	expression
.	SENT	.
Analysis	NN	analysis
of	IN	of
withanolides-rich	JJ	<unknown>
aqueous	JJ	aqueous
extracts	VBZ	extract
derived	VBN	derive
from	IN	from
Ashwagandha	NP	<unknown>
leaves	NNS	leaf
and	CC	and
stem	NN	stem
showed	VBD	show
a	DT	a
higher	JJR	high
ACE2	NP	<unknown>
inhibitory	JJ	inhibitory
potency	NN	potency
of	IN	of
stem-derived	NN	<unknown>
extracts	VBZ	extract
.	SENT	.
Taken	VBN	take
together	RB	together
,	,	,
we	PP	we
demonstrated	VBD	demonstrate
the	DT	the
inhibitory	JJ	inhibitory
potency	NN	potency
of	IN	of
Ashwagandha	NP	<unknown>
withanolides	NNS	<unknown>
and	CC	and
its	PP$	its
aqueous	JJ	aqueous
extracts	VBZ	extract
against	IN	against
ACE2	NP	<unknown>
.	SENT	.
Communicated	VBN	communicate
by	IN	by
Ramaswamy	NP	Ramaswamy
H.	NP	H.
Sarma	NP	Sarma
35194549/	CD	@card@
Obsessive	JJ	obsessive
compulsive	JJ	compulsive
disorder	NN	disorder
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
A	DT	a
brief	JJ	brief
review	NN	review
of	IN	of
course	NN	course
,	,	,
psychological	JJ	psychological
assessment	NN	assessment
and	CC	and
treatment	NN	treatment
considerations	NNS	consideration
Obsessive-compulsive	JJ	obsessive-compulsive
disorder	NN	disorder
(	(	(
OCD	NN	OCD
)	)	)
is	VBZ	be
an	DT	an
impairing	VBG	impair
mental	JJ	mental
health	NN	health
condition	NN	condition
defined	VBN	define
by	IN	by
intense	JJ	intense
distress	NN	distress
in	IN	in
the	DT	the
presence	NN	presence
of	IN	of
unwanted	JJ	unwanted
,	,	,
recurrent	JJ	recurrent
thoughts	NNS	thought
,	,	,
images	NNS	image
,	,	,
or	CC	or
impulses	NNS	impulse
which	WDT	which
are	VBP	be
accompanied	VBN	accompany
by	IN	by
compulsions	NNS	compulsion
and	CC	and
avoidance	NN	avoidance
performed	VBN	perform
to	TO	to
reduce	VB	reduce
distress	NN	distress
.	SENT	.
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
OCD	NP	OCD
has	VBZ	have
continued	VBN	continue
to	TO	to
be	VB	be
an	DT	an
impairing	VBG	impair
mental	JJ	mental
health	NN	health
condition	NN	condition
regardless	RB	regardless
of	IN	of
symptom	NN	symptom
dimensionality	NN	dimensionality
(	(	(
e.g.	FW	e.g.
,	,	,
contamination	NN	contamination
,	,	,
harm	NN	harm
,	,	,
etc.	FW	etc.
)	)	)
with	IN	with
varying	VBG	vary
reports	NNS	report
of	IN	of
the	DT	the
overall	JJ	overall
clinical	JJ	clinical
course	NN	course
.	SENT	.
However	RB	however
,	,	,
changes	NNS	change
in	IN	in
the	DT	the
assessment	NN	assessment
,	,	,
treatment	NN	treatment
,	,	,
and	CC	and
diagnosis	NN	diagnosis
of	IN	of
OCD	NNS	<unknown>
have	VBP	have
occurred	VBN	occur
to	TO	to
personalize	VB	personalize
care	NN	care
and	CC	and
be	VB	be
aligned	VBN	align
with	IN	with
public	JJ	public
health	NN	health
guidelines	NNS	guideline
.	SENT	.
Exposure	NN	exposure
and	CC	and
response	NN	response
prevention	NN	prevention
and	CC	and
pharmacotherapy	NN	pharmacotherapy
remain	VBP	remain
the	DT	the
treatment	NN	treatment
of	IN	of
choice	NN	choice
,	,	,
even	RB	even
though	IN	though
the	DT	the
setting	NN	setting
in	IN	in
which	WDT	which
treatment	NN	treatment
is	VBZ	be
conducted	VBN	conduct
may	MD	may
have	VB	have
shifted	VBN	shift
.	SENT	.
Telehealth	NN	Telehealth
in	IN	in
particular	JJ	particular
has	VBZ	have
been	VBN	be
a	DT	a
'	''	'
game-changer	NN	game-changer
'	''	'
for	IN	for
clinicians	NNS	clinician
and	CC	and
patients	NNS	patient
alike	RB	alike
.	SENT	.
Given	VBN	give
the	DT	the
continued	JJ	continued
health	NN	health
risk	NN	risk
posed	VBN	pose
by	IN	by
the	DT	the
pandemic	NN	pandemic
,	,	,
treatment	NN	treatment
personalization	NN	personalization
should	MD	should
still	RB	still
be	VB	be
made	VBN	make
to	TO	to
ensure	VB	ensure
safety	NN	safety
for	IN	for
both	DT	both
patients	NNS	patient
and	CC	and
providers	NNS	provider
while	IN	while
balancing	VBG	balance
efficacy	NN	efficacy
and	CC	and
patient	NN	patient
preferences	NNS	preference
.	SENT	.
34696346/	CD	@card@
Identification	NN	identification
,	,	,
Mechanism	NN	mechanism
,	,	,
and	CC	and
Treatment	NP	Treatment
of	IN	of
Skin	NN	skin
Lesions	NNS	lesion
in	IN	in
COVID-19	NP	<unknown>
:	:	:
A	DT	a
Review	NP	Review
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
multisystem	NN	multisystem
disease	NN	disease
caused	VBN	cause
by	IN	by
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Syndrome	NN	syndrome
Coronavirus	NP	<unknown>
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
that	WDT	that
primarily	RB	primarily
causes	VBZ	cause
respiratory	JJ	respiratory
symptoms	NNS	symptom
.	SENT	.
However	RB	however
,	,	,
an	DT	an
increasing	VBG	increase
number	NN	number
of	IN	of
cutaneous	JJ	cutaneous
manifestations	NNS	manifestation
associated	VBN	associate
with	IN	with
this	DT	this
disease	NN	disease
have	VBP	have
been	VBN	be
reported	VBN	report
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
analyze	VB	analyze
the	DT	the
scientific	JJ	scientific
literature	NN	literature
on	IN	on
cutaneous	JJ	cutaneous
manifestations	NNS	manifestation
associated	VBN	associate
with	IN	with
SARS-CoV-2	NP	<unknown>
by	IN	by
means	NNS	mean
of	IN	of
a	DT	a
narrative	JJ	narrative
literature	NN	literature
review	NN	review
until	IN	until
June	NP	June
2021	CD	@card@
.	SENT	.
The	DT	the
search	NN	search
was	VBD	be
conducted	VBN	conduct
in	IN	in
the	DT	the
following	VBG	follow
electronic	JJ	electronic
databases	NNS	database
:	:	:
Medline	NP	<unknown>
(	(	(
PubMed	NP	<unknown>
)	)	)
,	,	,
SciELO	NP	<unknown>
,	,	,
and	CC	and
Cochrane	NP	Cochrane
Library	NP	Library
Plus	NP	Plus
.	SENT	.
The	DT	the
most	RBS	most
common	JJ	common
cutaneous	JJ	cutaneous
manifestations	NNS	manifestation
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
are	VBP	be
vesicular	JJ	vesicular
eruptions	NNS	eruption
,	,	,
petechial/purpuric	JJ	<unknown>
rashes	NNS	rash
,	,	,
acral	JJ	<unknown>
lesions	NNS	lesion
,	,	,
liveoid	JJ	<unknown>
lesions	NNS	lesion
,	,	,
urticarial	JJ	urticarial
rash	NN	rash
,	,	,
and	CC	and
maculopapular-erythematous	JJ	maculopapular-erythematous
rash	NN	rash
.	SENT	.
These	DT	these
manifestations	NNS	manifestation
may	MD	may
be	VB	be
the	DT	the
first	JJ	first
presenting	VBG	present
symptoms	NNS	symptom
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
,	,	,
as	IN	as
is	VBZ	be
the	DT	the
case	NN	case
with	IN	with
acral	JJ	<unknown>
lesions	NNS	lesion
,	,	,
vesicular	JJ	vesicular
eruptions	NNS	eruption
,	,	,
and	CC	and
urticaria	NN	urticaria
.	SENT	.
In	IN	in
relation	NN	relation
to	TO	to
severity	NN	severity
,	,	,
the	DT	the
presence	NN	presence
of	IN	of
liveoid	JJ	<unknown>
lesions	NNS	lesion
may	MD	may
be	VB	be
associated	VBN	associate
with	IN	with
a	DT	a
more	RBR	more
severe	JJ	severe
course	NN	course
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
Treatment	NN	treatment
used	VBN	use
for	IN	for
dermatological	JJ	dermatological
lesions	NNS	lesion
includes	VBZ	include
therapy	NN	therapy
with	IN	with
anticoagulants	NNS	anticoagulant
,	,	,
corticosteroids	NNS	corticosteroid
,	,	,
and	CC	and
antihistamines	NNS	antihistamine
.	SENT	.
Knowledge	NN	knowledge
of	IN	of
the	DT	the
dermatologic	JJ	<unknown>
manifestations	NNS	manifestation
associated	VBN	associate
with	IN	with
SARS-CoV-2	NP	<unknown>
contributes	VBZ	contribute
to	TO	to
the	DT	the
diagnosis	NN	diagnosis
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
patients	NNS	patient
with	IN	with
skin	NN	skin
lesions	NNS	lesion
associated	VBN	associate
with	IN	with
respiratory	JJ	respiratory
symptoms	NNS	symptom
or	CC	or
in	IN	in
asymptomatic	JJ	asymptomatic
patients	NNS	patient
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
understanding	VBG	understand
the	DT	the
dermatologic	JJ	<unknown>
lesions	NNS	lesion
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
could	MD	could
be	VB	be
useful	JJ	useful
to	TO	to
establish	VB	establish
a	DT	a
personalized	JJ	personalized
care	NN	care
plan	NN	plan
.	SENT	.
32500431/	CD	@card@
Continuing	VBG	continue
our	PP$	our
work	NN	work
:	:	:
transplant	NN	transplant
surgery	NN	surgery
and	CC	and
surgical	JJ	surgical
oncology	NN	oncology
in	IN	in
a	DT	a
tertiary	JJ	tertiary
referral	NN	referral
COVID-19	NP	<unknown>
center	NN	center
COVID-19	NP	<unknown>
is	VBZ	be
rapidly	RB	rapidly
spreading	VBG	spread
worldwide	RB	worldwide
.	SENT	.
Healthcare	NP	Healthcare
systems	NNS	system
are	VBP	be
struggling	VBG	struggle
to	TO	to
properly	RB	properly
allocate	VB	allocate
resources	NNS	resource
while	IN	while
ensuring	VBG	ensure
cure	NN	cure
for	IN	for
diseases	NNS	disease
outside	JJ	outside
of	IN	of
the	DT	the
infection	NN	infection
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
demonstrate	VB	demonstrate
how	WRB	how
surgical	JJ	surgical
activity	NN	activity
was	VBD	be
affected	VBN	affect
by	IN	by
the	DT	the
virus	NN	virus
outbreak	NN	outbreak
and	CC	and
show	VB	show
the	DT	the
changes	NNS	change
in	IN	in
practice	NN	practice
in	IN	in
a	DT	a
tertiary	JJ	tertiary
referral	NN	referral
COVID-19	NP	<unknown>
center	NN	center
.	SENT	.
The	DT	the
official	JJ	official
bulletins	NNS	bulletin
of	IN	of
the	DT	the
Italian	JJ	Italian
National	NP	National
Institute	NP	Institute
for	IN	for
the	DT	the
Infectious	JJ	infectious
Diseases	NNS	disease
"	''	"
L.	NP	L.
Spallanzani	NP	<unknown>
"	''	"
were	VBD	be
reviewed	VBN	review
to	TO	to
retrieve	VB	retrieve
the	DT	the
number	NN	number
of	IN	of
daily	JJ	daily
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
Records	NNS	record
of	IN	of
consecutive	JJ	consecutive
oncological	JJ	oncological
and	CC	and
transplant	NN	transplant
procedures	NNS	procedure
performed	VBN	perform
during	IN	during
the	DT	the
outbreak	NN	outbreak
were	VBD	be
reviewed	VBN	review
.	SENT	.
Patients	NNS	patient
with	IN	with
a	DT	a
high	JJ	high
probability	NN	probability
of	IN	of
postoperative	JJ	postoperative
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
admission	NN	admission
were	VBD	be
considered	VBN	consider
as	IN	as
high	JJ	high
risk	NN	risk
and	CC	and
defined	VBN	define
by	IN	by
an	DT	an
ASA	NP	ASA
score	NN	score
&gt	NN	&gt
;	:	;
=	SYM	=
III	NP	III
and/or	CC	and/or
a	DT	a
Charlson	NP	Charlson
Comorbidity	NP	<unknown>
Index	NP	Index
(	(	(
CCI	NP	CCI
)	)	)
&gt	NN	&gt
;	:	;
=	SYM	=
6	CD	@card@
and/or	CC	and/or
a	DT	a
Revised	VBN	revise
Cardiac	JJ	cardiac
Risk	NP	Risk
Index	NP	Index
for	IN	for
Preoperative	NP	<unknown>
Risk	NP	Risk
(	(	(
RCRI	NP	<unknown>
)	)	)
&gt	NN	&gt
;	:	;
=	SYM	=
3	CD	@card@
.	SENT	.
72	CD	@card@
patients	NNS	patient
were	VBD	be
operated	VBN	operate
,	,	,
including	VBG	include
12	CD	@card@
(	(	(
16.6	CD	@card@
%	NN	%
)	)	)
liver	NN	liver
and	CC	and
kidney	NN	kidney
transplantations	NNS	transplantation
.	SENT	.
Patients	NNS	patient
had	VBD	have
few	JJ	few
comorbidities	NNS	comorbidity
(	(	(
26.3	CD	@card@
%	NN	%
)	)	)
,	,	,
low	JJ	low
ASA	NP	ASA
score	NN	score
(	(	(
1.9	CD	@card@
+-	NN	<unknown>
0.5	CD	@card@
)	)	)
,	,	,
CCI	NP	CCI
(	(	(
3.7	CD	@card@
+-	NN	<unknown>
1.3	CD	@card@
)	)	)
,	,	,
and	CC	and
RCRI	NP	<unknown>
(	(	(
1.2	CD	@card@
+-	NN	<unknown>
0.6	CD	@card@
)	)	)
and	CC	and
had	VBD	have
overall	RB	overall
a	DT	a
low	JJ	low
risk	NN	risk
of	IN	of
postoperative	JJ	postoperative
ICU	NP	ICU
admission	NN	admission
.	SENT	.
Few	JJ	few
patients	NNS	patient
had	VBD	have
liver	JJR	live
cirrhosis	NN	cirrhosis
(	(	(
12.5	CD	@card@
%	NN	%
)	)	)
or	CC	or
received	VBD	receive
preoperative	JJ	preoperative
systemic	JJ	systemic
therapy	NN	therapy
(	(	(
16.6	CD	@card@
%	NN	%
)	)	)
.	SENT	.
36	CD	@card@
(	(	(
50	CD	@card@
%	NN	%
)	)	)
high-risk	JJ	high-risk
surgical	JJ	surgical
procedures	NNS	procedure
were	VBD	be
performed	VBN	perform
,	,	,
including	VBG	include
major	JJ	major
hepatectomies	NNS	<unknown>
,	,	,
pancreaticoduodenectomies	NNS	<unknown>
,	,	,
total	JJ	total
gastrectomies	NNS	gastrectomy
,	,	,
multivisceral	JJ	multivisceral
resections	NNS	resection
,	,	,
and	CC	and
transplantations	NNS	transplantation
.	SENT	.
Despite	IN	despite
this	DT	this
,	,	,
only	RB	only
15	CD	@card@
patients	NNS	patient
(	(	(
20.8	CD	@card@
%	NN	%
)	)	)
were	VBD	be
admitted	VBN	admit
to	TO	to
the	DT	the
ICU	NP	ICU
.	SENT	.
Only	JJ	only
oncologic	JJ	<unknown>
cases	NNS	case
and	CC	and
transplantations	NNS	transplantation
were	VBD	be
performed	VBN	perform
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
.	SENT	.
Careful	JJ	careful
selection	NN	selection
of	IN	of
patients	NNS	patient
allowed	VBN	allow
to	TO	to
perform	VB	perform
major	JJ	major
cancer	NN	cancer
surgeries	NNS	surgery
and	CC	and
transplantations	NNS	transplantation
without	IN	without
further	JJR	further
stressing	VBG	stress
hospital	NN	hospital
resources	NNS	resource
,	,	,
meanwhile	RB	meanwhile
minimizing	VBG	minimize
collateral	NN	collateral
damage	NN	damage
to	TO	to
patients	NNS	patient
.	SENT	.
34819524/	CD	@card@
Segmentation	NN	segmentation
of	IN	of
infected	JJ	infected
region	NN	region
in	IN	in
CT	NP	CT
images	NNS	image
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
based	VBN	base
on	IN	on
QC-HC	NP	<unknown>
U-net	NP	<unknown>
Since	IN	since
the	DT	the
outbreak	NN	outbreak
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
2019	CD	@card@
,	,	,
the	DT	the
rapid	JJ	rapid
spread	NN	spread
of	IN	of
the	DT	the
epidemic	NN	epidemic
has	VBZ	have
brought	VBN	bring
huge	JJ	huge
challenges	NNS	challenge
to	TO	to
medical	JJ	medical
institutions	NNS	institution
.	SENT	.
If	IN	if
the	DT	the
pathological	JJ	pathological
region	NN	region
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
CT	NP	CT
image	NN	image
can	MD	can
be	VB	be
automatically	RB	automatically
segmented	VBN	segment
,	,	,
it	PP	it
will	MD	will
help	VB	help
doctors	NNS	doctor
quickly	RB	quickly
determine	VBP	determine
the	DT	the
patient	NN	patient
's	POS	's
infection	NN	infection
,	,	,
thereby	RB	thereby
speeding	VBG	speed
up	RP	up
the	DT	the
diagnosis	NN	diagnosis
process	NN	process
.	SENT	.
To	TO	to
be	VB	be
able	JJ	able
to	TO	to
automatically	RB	automatically
segment	VB	segment
the	DT	the
infected	JJ	infected
area	NN	area
,	,	,
we	PP	we
proposed	VBD	propose
a	DT	a
new	JJ	new
network	NN	network
structure	NN	structure
and	CC	and
named	VBD	name
QC-HC	NP	<unknown>
U-Net	NP	<unknown>
.	SENT	.
First	RB	first
,	,	,
we	PP	we
combine	VBP	combine
residual	JJ	residual
connection	NN	connection
and	CC	and
dense	JJ	dense
connection	NN	connection
to	TO	to
form	VB	form
a	DT	a
new	JJ	new
connection	NN	connection
method	NN	method
and	CC	and
apply	VB	apply
it	PP	it
to	TO	to
the	DT	the
encoder	NN	encoder
and	CC	and
the	DT	the
decoder	NN	decoder
.	SENT	.
Second	RB	second
,	,	,
we	PP	we
choose	VBP	choose
to	TO	to
add	VB	add
Hypercolumns	NNS	Hypercolumn
in	IN	in
the	DT	the
decoder	NN	decoder
section	NN	section
.	SENT	.
Compared	VBN	compare
with	IN	with
the	DT	the
benchmark	JJ	benchmark
3D	JJ	3D
U-Net	NN	<unknown>
,	,	,
the	DT	the
improved	VBN	improve
network	NN	network
can	MD	can
effectively	RB	effectively
avoid	VB	avoid
vanishing	VBG	vanish
gradient	JJ	gradient
while	IN	while
extracting	VBG	extract
more	JJR	more
features	NNS	feature
.	SENT	.
To	TO	to
improve	VB	improve
the	DT	the
situation	NN	situation
of	IN	of
insufficient	JJ	insufficient
data	NNS	datum
,	,	,
resampling	NN	resampling
and	CC	and
data	NN	data
enhancement	NN	enhancement
methods	NNS	method
are	VBP	be
selected	VBN	select
in	IN	in
this	DT	this
paper	NN	paper
to	TO	to
expand	VB	expand
the	DT	the
datasets	NNS	<unknown>
.	SENT	.
We	PP	we
used	VBD	use
63	CD	@card@
cases	NNS	case
of	IN	of
MSD	NP	MSD
lung	NN	lung
tumor	NN	tumor
data	NNS	datum
for	IN	for
training	NN	training
and	CC	and
testing	NN	testing
,	,	,
continuously	RB	continuously
verified	VBN	verify
to	TO	to
ensure	VB	ensure
the	DT	the
training	NN	training
effect	NN	effect
of	IN	of
this	DT	this
model	NN	model
,	,	,
and	CC	and
then	RB	then
selected	VBN	select
20	CD	@card@
cases	NNS	case
of	IN	of
public	JJ	public
COVID-19	NP	<unknown>
data	NNS	datum
for	IN	for
training	NN	training
and	CC	and
testing	NN	testing
.	SENT	.
Experimental	JJ	experimental
results	NNS	result
showed	VBD	show
that	IN	that
in	IN	in
the	DT	the
segmentation	NN	segmentation
of	IN	of
COVID-19	NP	<unknown>
,	,	,
the	DT	the
specificity	NN	specificity
and	CC	and
sensitivity	NN	sensitivity
were	VBD	be
85.3	CD	@card@
%	NN	%
and	CC	and
83.6	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
,	,	,
and	CC	and
in	IN	in
the	DT	the
segmentation	NN	segmentation
of	IN	of
MSD	NP	MSD
lung	NN	lung
tumors	NNS	tumor
,	,	,
the	DT	the
specificity	NN	specificity
and	CC	and
sensitivity	NN	sensitivity
were	VBD	be
81.45	CD	@card@
%	NN	%
and	CC	and
80.93	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
,	,	,
without	IN	without
any	DT	any
fitting	NN	fitting
.	SENT	.
32834192/	CD	@card@
The	DT	the
anesthesiologist	NN	anesthesiologist
and	CC	and
COVID-19	NP	<unknown>
33614055/	CD	@card@
Adapting	NN	adapting
Nephrology	NP	<unknown>
Training	NP	Training
Curriculum	NN	curriculum
in	IN	in
the	DT	the
Era	NN	era
of	IN	of
COVID-19	NP	<unknown>
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
widespread	JJ	widespread
implications	NNS	implication
not	RB	not
only	RB	only
for	IN	for
clinical	JJ	clinical
practice	NN	practice
but	CC	but
also	RB	also
for	IN	for
academic	JJ	academic
medicine	NN	medicine
and	CC	and
postgraduate	NN	postgraduate
training	NN	training
.	SENT	.
The	DT	the
need	NN	need
to	TO	to
promote	VB	promote
physical	JJ	physical
distancing	NN	distancing
and	CC	and
flexibility	NN	flexibility
within	IN	within
our	PP$	our
department	NN	department
has	VBZ	have
generated	VBN	generate
important	JJ	important
revisions	NNS	revision
to	TO	to
the	DT	the
core	JJ	core
curriculum	NN	curriculum
for	IN	for
the	DT	the
Adult	NN	adult
Nephrology	NN	Nephrology
Training	NP	Training
Program	NP	Program
in	IN	in
Vancouver	NP	Vancouver
,	,	,
Canada	NP	Canada
.	SENT	.
We	PP	we
reviewed	VBD	review
available	JJ	available
educational	JJ	educational
resources	NNS	resource
and	CC	and
objectives	NNS	objective
to	TO	to
develop	VB	develop
curricular	JJ	curricular
adaptations	NNS	adaptation
informed	VBN	inform
by	IN	by
staff	NN	staff
and	CC	and
trainee	NN	trainee
feedback	NN	feedback
.	SENT	.
Many	JJ	many
facets	NNS	facet
of	IN	of
the	DT	the
program	NN	program
including	VBG	include
clinical	JJ	clinical
rotations	NNS	rotation
,	,	,
scholarly	JJ	scholarly
activities	NNS	activity
,	,	,
evaluation	NN	evaluation
,	,	,
and	CC	and
wellness	NN	wellness
have	VBP	have
been	VBN	be
impacted	VBN	impact
,	,	,
and	CC	and
thus	RB	thus
revised	VBN	revise
for	IN	for
online	JJ	online
delivery	NN	delivery
where	WRB	where
possible	JJ	possible
.	SENT	.
Trainees	NNS	trainee
have	VBP	have
personalized	VBN	personalize
a	DT	a
learning	VBG	learn
plan	NN	plan
based	VBN	base
on	IN	on
individual	JJ	individual
goals	NNS	goal
and	CC	and
supplemented	VBN	supplement
by	IN	by
a	DT	a
list	NN	list
of	IN	of
internet-based	JJ	<unknown>
resources	NNS	resource
for	IN	for
independent	JJ	independent
review	NN	review
.	SENT	.
Changes	NNS	change
in	IN	in
learning	VBG	learn
objectives	NNS	objective
and	CC	and
methods	NNS	method
for	IN	for
specific	JJ	specific
rotations	NNS	rotation
have	VBP	have
occurred	VBN	occur
and	CC	and
are	VBP	be
described	VBN	describe
.	SENT	.
Ongoing	JJ	ongoing
evaluation	NN	evaluation
will	MD	will
be	VB	be
undertaken	VBN	undertake
.	SENT	.
Curriculum	NN	curriculum
adaptation	NN	adaptation
in	IN	in
the	DT	the
era	NN	era
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
necessary	JJ	necessary
to	TO	to
ensure	VB	ensure
ongoing	JJ	ongoing
high-quality	JJ	high-quality
education	NN	education
for	IN	for
future	JJ	future
nephrologists	NNS	nephrologist
.	SENT	.
We	PP	we
describe	VBP	describe
existing	VBG	exist
changes	NNS	change
to	TO	to
formal	JJ	formal
training	NN	training
in	IN	in
British	NP	British
Columbia	NP	Columbia
(	(	(
BC	NP	BC
)	)	)
,	,	,
which	WDT	which
will	MD	will
be	VB	be
tailored	VBN	tailor
as	IN	as
the	DT	the
pandemic	NN	pandemic
evolves	VBZ	evolve
,	,	,
and	CC	and
anticipate	VB	anticipate
them	PP	them
to	TO	to
have	VB	have
lasting	JJ	lasting
impact	NN	impact
on	IN	on
the	DT	the
way	NN	way
we	PP	we
structure	VBP	structure
training	NN	training
programs	NNS	program
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
Standardization	NN	standardization
and	CC	and
harmonization	NN	harmonization
of	IN	of
modified	JJ	modified
curriculum	NN	curriculum
may	MD	may
be	VB	be
possible	JJ	possible
across	IN	across
Canada	NP	Canada
with	IN	with
sharing	VBG	share
of	IN	of
these	DT	these
learnings	NNS	learning
.	SENT	.
Formal	JJ	formal
evaluation	NN	evaluation
of	IN	of
these	DT	these
changes	NNS	change
in	IN	in
terms	NNS	term
of	IN	of
knowledge	NN	knowledge
acquisition	NN	acquisition
and	CC	and
examination	NN	examination
performance	NN	performance
has	VBZ	have
not	RB	not
yet	RB	yet
been	VBN	be
undertaken	VBN	undertake
.	SENT	.
Next	JJ	next
steps	NNS	step
will	MD	will
include	VB	include
assessing	VBG	assess
and	CC	and
documenting	VBG	document
the	DT	the
impact	NN	impact
of	IN	of
this	DT	this
curricular	JJ	curricular
transformation	NN	transformation
to	TO	to
further	RBR	further
optimize	VB	optimize
scheduling	NN	scheduling
,	,	,
educational	JJ	educational
yield	NN	yield
,	,	,
and	CC	and
trainee	NN	trainee
wellness	NN	wellness
.	SENT	.
32425288/	CD	@card@
Clinical	JJ	clinical
and	CC	and
biochemical	JJ	biochemical
characteristics	NNS	characteristic
of	IN	of
patients	NNS	patient
admitted	VBN	admit
to	TO	to
ICU	NP	ICU
with	IN	with
SARS-CoV-2	NP	<unknown>
34824253/	CD	@card@
Spike	NP	Spike
residue	NN	residue
403	CD	@card@
affects	VBZ	affect
binding	VBG	bind
of	IN	of
coronavirus	NN	coronavirus
spikes	NNS	spike
to	TO	to
human	JJ	human
ACE2	NP	<unknown>
The	DT	the
bat	NN	bat
sarbecovirus	NN	sarbecovirus
RaTG13	NP	<unknown>
is	VBZ	be
a	DT	a
close	JJ	close
relative	NN	relative
of	IN	of
SARS-CoV-2	NP	<unknown>
,	,	,
the	DT	the
cause	NN	cause
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
However	RB	however
,	,	,
this	DT	this
bat	NN	bat
virus	NN	virus
was	VBD	be
most	RBS	most
likely	RB	likely
unable	JJ	unable
to	TO	to
directly	RB	directly
infect	VB	infect
humans	NNS	human
since	IN	since
its	PP$	its
Spike	NP	Spike
(	(	(
S	NP	S
)	)	)
protein	NN	protein
does	VBZ	do
not	RB	not
interact	VB	interact
efficiently	RB	efficiently
with	IN	with
the	DT	the
human	JJ	human
ACE2	JJ	<unknown>
receptor	NN	receptor
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
show	VBP	show
that	IN	that
a	DT	a
single	JJ	single
T403R	NP	<unknown>
mutation	NN	mutation
increases	NNS	increase
binding	VBG	bind
of	IN	of
RaTG13	NP	<unknown>
S	NP	S
to	TO	to
human	JJ	human
ACE2	NN	<unknown>
and	CC	and
allows	VBZ	allow
VSV	NP	<unknown>
pseudoparticle	NN	pseudoparticle
infection	NN	infection
of	IN	of
human	JJ	human
lung	NN	lung
cells	NNS	cell
and	CC	and
intestinal	JJ	intestinal
organoids	NNS	organoid
.	SENT	.
Conversely	RB	conversely
,	,	,
mutation	NN	mutation
of	IN	of
R403T	NP	<unknown>
in	IN	in
the	DT	the
SARS-CoV-2	NP	<unknown>
S	NP	S
reduces	VBZ	reduce
pseudoparticle	NN	pseudoparticle
infection	NN	infection
and	CC	and
viral	JJ	viral
replication	NN	replication
.	SENT	.
The	DT	the
T403R	NP	<unknown>
RaTG13	NP	<unknown>
S	NP	S
is	VBZ	be
neutralized	VBN	neutralize
by	IN	by
sera	NN	sera
from	IN	from
individuals	NNS	individual
vaccinated	VBN	vaccinate
against	IN	against
COVID-19	NP	<unknown>
indicating	VBG	indicate
that	DT	that
vaccination	NN	vaccination
might	MD	might
protect	VB	protect
against	IN	against
future	JJ	future
zoonoses	NNS	zoonosis
.	SENT	.
Our	PP$	our
data	NNS	datum
suggest	VBP	suggest
that	IN	that
a	DT	a
positively	RB	positively
charged	VBN	charge
amino	NN	amino
acid	NN	acid
at	IN	at
position	NN	position
403	CD	@card@
in	IN	in
the	DT	the
S	NP	S
protein	NN	protein
is	VBZ	be
critical	JJ	critical
for	IN	for
efficient	JJ	efficient
utilization	NN	utilization
of	IN	of
human	JJ	human
ACE2	NP	<unknown>
by	IN	by
S	NP	S
proteins	NNS	protein
of	IN	of
bat	NN	bat
coronaviruses	NNS	coronavirus
.	SENT	.
This	DT	this
finding	NN	finding
could	MD	could
help	VB	help
to	TO	to
better	RBR	well
predict	VB	predict
the	DT	the
zoonotic	JJ	<unknown>
potential	NN	potential
of	IN	of
animal	JJ	animal
coronaviruses	NNS	coronavirus
.	SENT	.
The	DT	the
bat	NN	bat
sarbecovirus	NN	sarbecovirus
RaTG13	NP	<unknown>
is	VBZ	be
a	DT	a
close	JJ	close
relative	NN	relative
of	IN	of
SARS-CoV-2	NP	<unknown>
,	,	,
but	CC	but
its	PP$	its
spike	NN	spike
protein	NN	protein
does	VBZ	do
n't	RB	n't
efficiently	RB	efficiently
bind	VB	bind
human	JJ	human
ACE2	NP	<unknown>
.	SENT	.
Here	RB	here
,	,	,
the	DT	the
authors	NNS	author
show	VBP	show
that	IN	that
exchange	NN	exchange
of	IN	of
spike	NN	spike
residue	NN	residue
403	CD	@card@
between	IN	between
RaTG13	NP	<unknown>
and	CC	and
SARS-CoV-2	NP	<unknown>
spike	NN	spike
proteins	NNS	protein
affects	VBZ	affect
binding	VBG	bind
to	TO	to
human	JJ	human
ACE2	NN	<unknown>
and	CC	and
entry	NN	entry
of	IN	of
pseudotyped	JJ	<unknown>
viruses	NNS	virus
.	SENT	.
32582329/	CD	@card@
How	WRB	how
Nutrition	NN	nutrition
can	MD	can
help	VB	help
to	TO	to
fight	VB	fight
against	IN	against
COVID-19	NP	<unknown>
Pandemic	JJ	pandemic
Currently	NP	Currently
Covid-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
a	DT	a
leading	VBG	lead
challenge	NN	challenge
across	IN	across
the	DT	the
globe	NN	globe
.	SENT	.
It	PP	it
is	VBZ	be
mandatory	JJ	mandatory
to	TO	to
attain	VB	attain
and	CC	and
maintain	VB	maintain
good	JJ	good
nutritional	JJ	nutritional
status	NN	status
to	TO	to
fight	VB	fight
against	IN	against
virus	NN	virus
.	SENT	.
Nutritional	JJ	nutritional
status	NN	status
of	IN	of
individual	NN	individual
is	VBZ	be
affected	VBN	affect
by	IN	by
several	JJ	several
factors	NNS	factor
such	JJ	such
as	IN	as
age	NN	age
,	,	,
sex	NN	sex
,	,	,
health	NN	health
status	NN	status
,	,	,
life	NN	life
style	NN	style
and	CC	and
medications	NNS	medication
.	SENT	.
Nutritional	JJ	nutritional
status	NN	status
of	IN	of
individuals	NNS	individual
has	VBZ	have
been	VBN	be
used	VBN	use
as	IN	as
resilience	NN	resilience
towards	IN	towards
destabilization	NN	destabilization
during	IN	during
this	DT	this
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Optimal	JJ	optimal
nutrition	NN	nutrition
and	CC	and
dietary	JJ	dietary
nutrient	JJ	nutrient
intake	NN	intake
impact	NN	impact
the	DT	the
immune	JJ	immune
system	NN	system
,	,	,
therefore	RB	therefore
the	DT	the
only	JJ	only
sustainable	JJ	sustainable
way	NN	way
to	TO	to
survive	VB	survive
in	IN	in
current	JJ	current
context	NN	context
is	VBZ	be
to	TO	to
strengthen	VB	strengthen
the	DT	the
immune	JJ	immune
system	NN	system
.	SENT	.
There	EX	there
is	VBZ	be
no	DT	no
evidence	NN	evidence
found	VBD	find
that	IN	that
supplement	NN	supplement
can	MD	can
cure	VB	cure
the	DT	the
immune	JJ	immune
system	NN	system
except	IN	except
Vit	NP	<unknown>
C	NP	C
,	,	,
which	WDT	which
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
best	JJS	good
way	NN	way
to	TO	to
improve	VB	improve
immune	JJ	immune
system	NN	system
.	SENT	.
A	DT	a
proper	JJ	proper
diet	NN	diet
can	MD	can
ensure	VB	ensure
that	IN	that
the	DT	the
body	NN	body
is	VBZ	be
in	IN	in
proper	JJ	proper
state	NN	state
to	TO	to
defeat	VB	defeat
the	DT	the
virus	NN	virus
.	SENT	.
However	RB	however
along	RB	along
with	IN	with
the	DT	the
dietary	JJ	dietary
management	NN	management
guidelines	NNS	guideline
the	DT	the
food	NN	food
safety	NN	safety
management	NN	management
and	CC	and
good	JJ	good
food	NN	food
practices	NNS	practice
is	VBZ	be
compulsory	JJ	compulsory
.	SENT	.
This	DT	this
article	NN	article
explores	VBZ	explore
the	DT	the
importance	NN	importance
of	IN	of
nutrition	NN	nutrition
to	TO	to
boost	VB	boost
immunity	NN	immunity
and	CC	and
gives	VBZ	give
some	DT	some
professional	JJ	professional
and	CC	and
authentic	JJ	authentic
dietary	JJ	dietary
guidelines	NNS	guideline
about	IN	about
nutrition	NN	nutrition
and	CC	and
food	NN	food
safety	NN	safety
to	TO	to
withstand	VB	withstand
COVID-19	NP	<unknown>
.	SENT	.
34649268/	CD	@card@
Genomic	JJ	<unknown>
reconstruction	NN	reconstruction
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
epidemic	NN	epidemic
in	IN	in
England	NP	England
The	DT	the
evolution	NN	evolution
of	IN	of
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
virus	NN	virus
leads	VBZ	lead
to	TO	to
new	JJ	new
variants	NNS	variant
that	WDT	that
warrant	VBP	warrant
timely	JJ	timely
epidemiological	JJ	epidemiological
characterization	NN	characterization
.	SENT	.
Here	RB	here
we	PP	we
use	VBP	use
the	DT	the
dense	JJ	dense
genomic	JJ	<unknown>
surveillance	NN	surveillance
data	NNS	datum
generated	VBN	generate
by	IN	by
the	DT	the
COVID-19	NP	<unknown>
Genomics	NP	<unknown>
UK	NP	UK
Consortium	NP	Consortium
to	TO	to
reconstruct	VB	reconstruct
the	DT	the
dynamics	NNS	dynamics
of	IN	of
71	CD	@card@
different	JJ	different
lineages	NNS	lineage
in	IN	in
each	DT	each
of	IN	of
315	CD	@card@
English	JJ	English
local	JJ	local
authorities	NNS	authority
between	IN	between
September	NP	September
2020	CD	@card@
and	CC	and
June	NP	June
2021	CD	@card@
.	SENT	.
This	DT	this
analysis	NN	analysis
reveals	VBZ	reveal
a	DT	a
series	NN	series
of	IN	of
subepidemics	NNS	subepidemic
that	WDT	that
peaked	VBD	peak
in	IN	in
early	JJ	early
autumn	NN	autumn
2020	CD	@card@
,	,	,
followed	VBN	follow
by	IN	by
a	DT	a
jump	NN	jump
in	IN	in
transmissibility	NN	<unknown>
of	IN	of
the	DT	the
B.1.1.7/Alpha	NP	B.1.1.7/Alpha
lineage	NN	lineage
.	SENT	.
The	DT	the
Alpha	NP	Alpha
variant	NN	variant
grew	VBD	grow
when	WRB	when
other	JJ	other
lineages	NNS	lineage
declined	VBD	decline
during	IN	during
the	DT	the
second	JJ	second
national	JJ	national
lockdown	NN	<unknown>
and	CC	and
regionally	RB	regionally
tiered	VBD	tier
restrictions	NNS	restriction
between	IN	between
November	NP	November
and	CC	and
December	NP	December
2020	CD	@card@
.	SENT	.
A	DT	a
third	JJ	third
more	JJR	more
stringent	JJ	stringent
national	JJ	national
lockdown	NN	<unknown>
suppressed	VBD	suppress
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
and	CC	and
eliminated	VBD	eliminate
nearly	RB	nearly
all	DT	all
other	JJ	other
lineages	NNS	lineage
in	IN	in
early	JJ	early
2021	CD	@card@
.	SENT	.
Yet	RB	yet
a	DT	a
series	NN	series
of	IN	of
variants	NNS	variant
(	(	(
most	JJS	most
of	IN	of
which	WDT	which
contained	VBD	contain
the	DT	the
spike	NN	spike
E484K	NN	<unknown>
mutation	NN	mutation
)	)	)
defied	VBD	defy
these	DT	these
trends	NNS	trend
and	CC	and
persisted	VBD	persist
at	IN	at
moderately	RB	moderately
increasing	VBG	increase
proportions	NNS	proportion
.	SENT	.
However	RB	however
,	,	,
by	IN	by
accounting	NN	accounting
for	IN	for
sustained	JJ	sustained
introductions	NNS	introduction
,	,	,
we	PP	we
found	VBD	find
that	IN	that
the	DT	the
transmissibility	NN	<unknown>
of	IN	of
these	DT	these
variants	NNS	variant
is	VBZ	be
unlikely	JJ	unlikely
to	TO	to
have	VB	have
exceeded	VBN	exceed
the	DT	the
transmissibility	NN	<unknown>
of	IN	of
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
.	SENT	.
Finally	RB	finally
,	,	,
B.1.617.2/Delta	NP	B.1.617.2/Delta
was	VBD	be
repeatedly	RB	repeatedly
introduced	VBN	introduce
in	IN	in
England	NP	England
and	CC	and
grew	VBD	grow
rapidly	RB	rapidly
in	IN	in
early	JJ	early
summer	NN	summer
2021	CD	@card@
,	,	,
constituting	VBG	constitute
approximately	RB	approximately
98	CD	@card@
%	NN	%
of	IN	of
sampled	VBN	sample
SARS-CoV-2	JJ	<unknown>
genomes	NNS	genome
on	IN	on
26	CD	@card@
June	NP	June
2021	CD	@card@
.	SENT	.
A	DT	a
study	NN	study
of	IN	of
the	DT	the
evolution	NN	evolution
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
virus	NN	virus
in	IN	in
England	NP	England
between	IN	between
September	NP	September
2020	CD	@card@
and	CC	and
June	NP	June
2021	NP	@card@
finds	VBZ	find
that	IN	that
interventions	NNS	intervention
capable	JJ	capable
of	IN	of
containing	VBG	contain
previous	JJ	previous
variants	NNS	variant
were	VBD	be
insufficient	JJ	insufficient
to	TO	to
stop	VB	stop
the	DT	the
more	RBR	more
transmissible	JJ	transmissible
Alpha	NP	Alpha
and	CC	and
Delta	NP	Delta
variants	NNS	variant
.	SENT	.
33104178/	CD	@card@
Reply	NN	reply
to	TO	to
Cimolai	NP	Cimolai
:	:	:
Even	RB	even
With	IN	with
Variable	JJ	variable
Viral	JJ	viral
Culture	NP	Culture
Methods	NNS	method
,	,	,
Culturing	VBG	culture
SARS-CoV-2	NP	<unknown>
After	IN	after
10	CD	@card@
Days	NNS	day
Appears	VBZ	appear
to	TO	to
be	VB	be
Rare	JJ	rare
and	CC	and
Has	VBZ	have
Unclear	JJ	unclear
Implications	NNS	implication
for	IN	for
Transmission	NP	Transmission
34868831/	CD	@card@
Effect	NN	effect
of	IN	of
vaccination	NN	vaccination
on	IN	on
the	DT	the
transmission	NN	transmission
dynamics	NNS	dynamics
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Ethiopia	NP	Ethiopia
Governments	NNS	government
and	CC	and
health	NN	health
officials	NNS	official
are	VBP	be
eager	JJ	eager
to	TO	to
gain	VB	gain
a	DT	a
thorough	JJ	thorough
understanding	NN	understanding
of	IN	of
the	DT	the
dynamics	NNS	dynamics
of	IN	of
COVID-19	NP	<unknown>
transmission	NN	transmission
in	IN	in
order	NN	order
to	TO	to
devise	VB	devise
strategies	NNS	strategy
to	TO	to
mitigate	VB	mitigate
the	DT	the
pandemic	NN	pandemic
's	POS	's
negative	JJ	negative
effects	NNS	effect
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
we	PP	we
created	VBD	create
a	DT	a
new	JJ	new
fractional	JJ	fractional
order	NN	order
mathematical	JJ	mathematical
model	NN	model
to	TO	to
investigate	VB	investigate
the	DT	the
dynamics	NNS	dynamics
of	IN	of
Covid-19	NP	<unknown>
vaccine	NN	vaccine
transmission	NN	transmission
in	IN	in
Ethiopia	NP	Ethiopia
.	SENT	.
The	DT	the
nonlinear	JJ	nonlinear
system	NN	system
of	IN	of
differential	JJ	differential
equations	NNS	equation
for	IN	for
the	DT	the
model	NN	model
is	VBZ	be
represented	VBN	represent
using	VBG	use
Atangana-Baleanu	NP	<unknown>
fractional	JJ	fractional
derivative	NN	derivative
in	IN	in
Caputo	NP	Caputo
sense	NN	sense
and	CC	and
the	DT	the
Jacobi	NP	Jacobi
spectral	JJ	spectral
collocation	NN	collocation
method	NN	method
is	VBZ	be
used	VBN	use
to	TO	to
convert	VB	convert
this	DT	this
system	NN	system
into	IN	into
an	DT	an
algebraic	JJ	algebraic
system	NN	system
of	IN	of
equations	NNS	equation
,	,	,
which	WDT	which
is	VBZ	be
then	RB	then
solved	VBN	solve
using	VBG	use
inexact	JJ	inexact
Newton	NP	Newton
's	POS	's
method	NN	method
.	SENT	.
The	DT	the
fundamental	JJ	fundamental
reproduction	NN	reproduction
number	NN	number
,	,	,
for	IN	for
the	DT	the
proposed	VBN	propose
model	NN	model
is	VBZ	be
determined	VBN	determine
using	VBG	use
the	DT	the
next	JJ	next
generation	NN	generation
matrix	NN	matrix
approach	NN	approach
.	SENT	.
32502119/	CD	@card@
Hospital	NN	hospital
visiting	VBG	visit
policies	NNS	policy
in	IN	in
the	DT	the
time	NN	time
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
:	:	:
A	DT	a
nationwide	JJ	nationwide
website	NN	website
survey	NN	survey
in	IN	in
Taiwan	NP	Taiwan
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
a	DT	a
novel	JJ	novel
infectious	JJ	infectious
coronavirus	NN	coronavirus
disease	NN	disease
,	,	,
has	VBZ	have
become	VBN	become
a	DT	a
worldwide	JJ	worldwide
pandemic	NN	pandemic
.	SENT	.
Infection	NN	infection
control	NN	control
precautions	NNS	precaution
for	IN	for
hospital	NN	hospital
visitors	NNS	visitor
are	VBP	be
needed	VBN	need
to	TO	to
avoid	VB	avoid
cluster	NN	cluster
outbreaks	NNS	outbreak
,	,	,
so	RB	so
this	DT	this
study	NN	study
investigated	VBD	investigate
the	DT	the
visiting	VBG	visit
policies	NNS	policy
of	IN	of
all	PDT	all
the	DT	the
hospitals	NNS	hospital
in	IN	in
Taiwan	NP	Taiwan
in	IN	in
the	DT	the
time	NN	time
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
From	IN	from
March	NP	March
15	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
to	TO	to
March	NP	March
18	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
we	PP	we
searched	VBD	search
the	DT	the
official	JJ	official
websites	NNS	website
of	IN	of
all	DT	all
472	CD	@card@
National	NP	National
Health	NP	Health
Insurance-contracted	NP	<unknown>
hospitals	NNS	hospital
to	TO	to
determine	VB	determine
their	PP$	their
visiting	VBG	visit
policies	NNS	policy
.	SENT	.
For	IN	for
those	DT	those
hospitals	NNS	hospital
that	WDT	that
had	VBD	have
posted	VBN	post
new	JJ	new
visiting	VBG	visit
policies	NNS	policy
and	CC	and
still	RB	still
allowed	VBN	allow
visits	NNS	visit
to	TO	to
ordinary	JJ	ordinary
wards	NNS	ward
,	,	,
we	PP	we
recorded	VBD	record
the	DT	the
relevant	JJ	relevant
details	NNS	detail
shown	VBN	show
on	IN	on
their	PP$	their
websites	NNS	website
,	,	,
including	VBG	include
the	DT	the
number	NN	number
of	IN	of
visitors	NNS	visitor
allowed	VBN	allow
at	IN	at
one	CD	one
time	NN	time
,	,	,
the	DT	the
number	NN	number
of	IN	of
visiting	VBG	visit
slots	NNS	slot
per	IN	per
day	NN	day
,	,	,
the	DT	the
total	JJ	total
visiting	VBG	visit
hours	NNS	hour
per	IN	per
day	NN	day
,	,	,
and	CC	and
the	DT	the
rules	NNS	rule
provided	VBN	provide
to	TO	to
visitors	NNS	visitor
before	IN	before
visiting	VBG	visit
.	SENT	.
During	IN	during
the	DT	the
study	NN	study
period	NN	period
,	,	,
276	CD	@card@
(	(	(
58.5	CD	@card@
%	NN	%
)	)	)
hospitals	NNS	hospital
had	VBD	have
posted	VBN	post
new	JJ	new
visiting	VBG	visit
policies	NNS	policy
on	IN	on
their	PP$	their
websites	NNS	website
,	,	,
with	IN	with
higher	JJR	high
proportions	NNS	proportion
of	IN	of
academic	JJ	academic
medical	JJ	medical
centers	NNS	center
(	(	(
92.0	CD	@card@
%	NN	%
,	,	,
23/25	CD	@card@
)	)	)
and	CC	and
metropolitan	JJ	metropolitan
hospitals	NNS	hospital
(	(	(
91.5	CD	@card@
%	NN	%
,	,	,
75/82	CD	@card@
)	)	)
than	IN	than
local	JJ	local
community	NN	community
hospitals	NNS	hospital
(	(	(
48.8	CD	@card@
%	NN	%
,	,	,
178/365	CD	@card@
)	)	)
doing	VBG	do
so	RB	so
.	SENT	.
Visits	NNS	visit
to	TO	to
ordinary	JJ	ordinary
wards	NNS	ward
were	VBD	be
forbidden	VBN	forbid
in	IN	in
83	CD	@card@
hospitals	NNS	hospital
among	IN	among
those	DT	those
.	SENT	.
Among	IN	among
the	DT	the
193	CD	@card@
hospitals	NNS	hospital
that	WDT	that
had	VBD	have
new	JJ	new
visiting	VBG	visit
policies	NNS	policy
and	CC	and
still	RB	still
allowed	VBN	allow
visits	NNS	visit
to	TO	to
ordinary	JJ	ordinary
wards	NNS	ward
,	,	,
73.1	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
141	LS	@card@
)	)	)
restricted	VBN	restrict
visitors	NNS	visitor
to	TO	to
two	CD	two
at	IN	at
a	DT	a
time	NN	time
and	CC	and
54.9	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
106	LS	@card@
)	)	)
restricted	VBN	restrict
visits	NNS	visit
to	TO	to
two	CD	two
visiting	VBG	visit
slots	NNS	slot
per	IN	per
day	NN	day
.	SENT	.
Furthermore	RB	furthermore
,	,	,
history	NN	history
taking	VBG	take
regarding	VBG	regard
travel	NN	travel
,	,	,
occupation	NN	occupation
,	,	,
contacts	NNS	contact
,	,	,
and	CC	and
cluster	NN	cluster
information	NN	information
was	VBD	be
mentioned	VBN	mention
by	IN	by
82.4	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
159	CD	@card@
)	)	)
of	IN	of
these	DT	these
193	CD	@card@
hospitals	NNS	hospital
,	,	,
body	NN	body
temperature	NN	temperature
monitoring	NN	monitoring
by	IN	by
78.2	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
151	CD	@card@
)	)	)
,	,	,
hand	NN	hand
hygiene	NN	hygiene
by	IN	by
63.2	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
122	CD	@card@
)	)	)
,	,	,
and	CC	and
identity	NN	identity
checks	NNS	check
by	IN	by
51.8	CD	@card@
%	NN	%
(	(	(
n	NN	n
=	SYM	=
100	CD	@card@
)	)	)
.	SENT	.
In	IN	in
the	DT	the
time	NN	time
of	IN	of
COVID-19	NP	<unknown>
covered	VBN	cover
by	IN	by
this	DT	this
study	NN	study
,	,	,
about	IN	about
three-fifths	NNS	three-fifth
of	IN	of
the	DT	the
hospitals	NNS	hospital
in	IN	in
Taiwan	NP	Taiwan
had	VBD	have
posted	VBN	post
their	PP$	their
visiting	VBG	visit
policies	NNS	policy
for	IN	for
ordinary	JJ	ordinary
wards	NNS	ward
on	IN	on
their	PP$	their
websites	NNS	website
.	SENT	.
Furthermore	RB	furthermore
,	,	,
the	DT	the
thoroughness	NN	thoroughness
with	IN	with
which	WDT	which
such	JJ	such
visiting	VBG	visit
policies	NNS	policy
have	VBP	have
been	VBN	be
enforced	VBN	enforce
also	RB	also
requires	VBZ	require
investigation	NN	investigation
.	SENT	.
32596482/	CD	@card@
Vaping	NN	<unknown>
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
NOT	RB	not
GOOD	JJ	good
!	SENT	!
!	SENT	!
Vaping	VBG	Vape
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
NOT	RB	not
GOOD	JJ	good
!	SENT	!
35263375/	CD	@card@
Attitude	NN	attitude
of	IN	of
health	NN	health
professionals	NNS	professional
towards	IN	towards
COVID-19	NP	<unknown>
vaccination	NN	vaccination
and	CC	and
associated	VBN	associate
factors	NNS	factor
among	IN	among
health	NN	health
professionals	NNS	professional
,	,	,
Western	NP	Western
Ethiopia	NP	Ethiopia
:	:	:
A	DT	a
cross-sectional	JJ	cross-sectional
survey	NN	survey
Even	RB	even
though	IN	though
people	NNS	people
of	IN	of
the	DT	the
world	NN	world
were	VBD	be
eagerly	RB	eagerly
waiting	VBG	wait
for	IN	for
the	DT	the
hope	NN	hope
of	IN	of
vaccine	NN	vaccine
development	NN	development
,	,	,
vaccine	NN	vaccine
hesitancy	NN	hesitancy
is	VBZ	be
becoming	VBG	become
the	DT	the
top	JJ	top
concern	NN	concern
in	IN	in
both	DT	both
developed	JJ	developed
and	CC	and
developing	VBG	develop
countries	NNS	country
.	SENT	.
However	RB	however
,	,	,
there	EX	there
is	VBZ	be
no	DT	no
adequate	JJ	adequate
evidence	NN	evidence
regarding	VBG	regard
the	DT	the
attitude	NN	attitude
and	CC	and
perception	NN	perception
of	IN	of
health	NN	health
professionals	NNS	professional
towards	IN	towards
the	DT	the
COVID	NP	<unknown>
19	CD	@card@
vaccine	NN	vaccine
in	IN	in
resource-limited	JJ	resource-limited
settings	NNS	setting
like	IN	like
Ethiopia	NP	Ethiopia
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
assess	VB	assess
health	NN	health
professionals	NNS	professional
'	POS	'
attitudes	NNS	attitude
and	CC	and
perceptions	NNS	perception
towards	IN	towards
COVID	NP	<unknown>
19	CD	@card@
vaccine	NN	vaccine
in	IN	in
Western	NP	Western
Ethiopia	NP	Ethiopia
.	SENT	.
An	DT	an
institution-based	JJ	<unknown>
cross-sectional	JJ	cross-sectional
study	NN	study
was	VBD	be
conducted	VBN	conduct
among	IN	among
health	NN	health
care	NN	care
workers	NNS	worker
found	VBN	find
in	IN	in
Nekemte	NP	<unknown>
town	NN	town
from	IN	from
April	NP	April
14-21	CD	@card@
,	,	,
2021	CD	@card@
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
439	CD	@card@
health	NN	health
professionals	NNS	professional
present	JJ	present
on	IN	on
duty	NN	duty
during	IN	during
the	DT	the
study	NN	study
period	NN	period
was	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
The	DT	the
data	NNS	datum
were	VBD	be
collected	VBN	collect
by	IN	by
using	VBG	use
self-administered	VBN	self-administer
questionnaire	NN	questionnaire
.	SENT	.
Epidata	NP	<unknown>
version	NN	version
3.2	CD	@card@
was	VBD	be
used	VBN	use
for	IN	for
data	NNS	datum
entry	NN	entry
,	,	,
and	CC	and
STATA	NP	Stata
version	NN	version
14	CD	@card@
was	VBD	be
used	VBN	use
for	IN	for
data	NN	data
analysis	NN	analysis
.	SENT	.
The	DT	the
binary	JJ	binary
logistic	JJ	logistic
regression	NN	regression
model	NN	model
was	VBD	be
employed	VBN	employ
to	TO	to
determine	VB	determine
factors	NNS	factor
associated	VBN	associate
with	IN	with
the	DT	the
attitude	NN	attitude
towards	IN	towards
COVID-19	NP	<unknown>
vaccination	NN	vaccination
.	SENT	.
Adjusted	JJ	adjusted
Odds	NNS	odd
Ratio	NN	ratio
(	(	(
AOR	NP	AOR
)	)	)
with	IN	with
95	CD	@card@
%	NN	%
confidence	NN	confidence
intervals	NNS	interval
was	VBD	be
computed	VBN	compute
and	CC	and
statistical	JJ	statistical
significance	NN	significance
was	VBD	be
declared	VBN	declare
at	IN	at
a	DT	a
5	CD	@card@
%	NN	%
level	NN	level
(	(	(
p-value	NN	p-value
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
431	CD	@card@
health	NN	health
professionals	NNS	professional
participated	VBD	participate
in	IN	in
the	DT	the
study	NN	study
yielding	VBG	yield
a	DT	a
response	NN	response
rate	NN	rate
of	IN	of
98.1	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
results	NNS	result
indicated	VBD	indicate
that	IN	that
51.28	CD	@card@
%	NN	%
(	(	(
95%CI	NP	<unknown>
:	:	:
45.12	CD	@card@
%	NN	%
,	,	,
57.34	CD	@card@
%	NN	%
)	)	)
of	IN	of
health	NN	health
professionals	NNS	professional
had	VBD	have
a	DT	a
favorable	JJ	favorable
attitude	NN	attitude
towards	IN	towards
COVID-19	NP	<unknown>
vaccination	NN	vaccination
.	SENT	.
Having	VBG	have
good	JJ	good
knowledge	NN	knowledge
about	IN	about
the	DT	the
COVID-19	NP	<unknown>
vaccine	NN	vaccine
(	(	(
AOR	NP	AOR
=	SYM	=
0.38	CD	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
0.22	CD	@card@
,	,	,
0.64	CD	@card@
,	,	,
P-value	NP	P-value
&lt	NP	&lt
;	:	;
0.001	LS	@card@
)	)	)
was	VBD	be
negatively	RB	negatively
associated	VBN	associate
with	IN	with
unfavorable	JJ	unfavorable
attitude	NN	attitude
towards	IN	towards
COVID-19	NP	<unknown>
vaccine	NN	vaccine
,	,	,
whereas	IN	whereas
age	NN	age
less	JJR	less
than	IN	than
30	CD	@card@
years	NNS	year
(	(	(
AOR	NP	AOR
=	SYM	=
2.14	CD	@card@
,	,	,
95%CI:1.25,3.67	JJ	95%CI@card@
,	,	,
P-value	NP	P-value
&lt	NP	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
working	VBG	work
in	IN	in
a	DT	a
private	JJ	private
clinic	NN	clinic
(	(	(
AOR	NP	AOR
=	SYM	=
7.77	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
2.19	CD	@card@
,	,	,
27.58	CD	@card@
,	,	,
P-value	NP	P-value
&lt	NP	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
health	NN	health
center	NN	center
(	(	(
AOR	NP	AOR
=	SYM	=
2.45	CD	@card@
,	,	,
95%CI	NP	<unknown>
:	:	:
1.01	CD	@card@
,	,	,
5.92	CD	@card@
,	,	,
P-value	NP	P-value
=	SYM	=
0.045	CD	@card@
)	)	)
were	VBD	be
positively	RB	positively
associated	VBN	associate
with	IN	with
unfavorable	JJ	unfavorable
attitude	NN	attitude
towards	IN	towards
COVID-19	NP	<unknown>
vaccine	NN	vaccine
.	SENT	.
In	IN	in
general	NN	general
,	,	,
the	DT	the
attitude	NN	attitude
and	CC	and
perception	NN	perception
of	IN	of
health	NN	health
care	NN	care
professionals	NNS	professional
toward	IN	toward
the	DT	the
COVID-19	NP	<unknown>
vaccine	NN	vaccine
in	IN	in
the	DT	the
study	NN	study
area	NN	area
were	VBD	be
unsatisfactory	JJ	unsatisfactory
.	SENT	.
Knowledge	NN	knowledge
about	IN	about
the	DT	the
COVID-19	NP	<unknown>
vaccine	NN	vaccine
,	,	,
age	NN	age
of	IN	of
health	NN	health
care	NN	care
workers	NNS	worker
,	,	,
and	CC	and
place	NN	place
of	IN	of
work	NN	work
are	VBP	be
the	DT	the
factors	NNS	factor
which	WDT	which
affects	VBZ	affect
attitude	NN	attitude
towards	IN	towards
COVID-19	NP	<unknown>
vaccine	NN	vaccine
.	SENT	.
Thus	RB	thus
,	,	,
we	PP	we
recommend	VBP	recommend
the	DT	the
media	NNS	medium
outlets	NNS	outlet
and	CC	and
concerned	JJ	concerned
bodies	NNS	body
to	TO	to
work	VB	work
to	TO	to
develop	VB	develop
trust	NN	trust
among	IN	among
the	DT	the
public	NN	public
by	IN	by
disseminating	VBG	disseminate
accurate	JJ	accurate
and	CC	and
consistent	JJ	consistent
information	NN	information
about	IN	about
the	DT	the
vaccine	NN	vaccine
.	SENT	.
35592326/	CD	@card@
Pandemic	NN	pandemic
,	,	,
Epidemic	NN	epidemic
,	,	,
Endemic	NN	endemic
:	:	:
B	SYM	b
Cell	NN	cell
Repertoire	NN	repertoire
Analysis	NN	analysis
Reveals	VBZ	reveal
Unique	JJ	unique
Anti-Viral	JJ	anti-viral
Responses	NNS	response
to	TO	to
SARS-CoV-2	NP	<unknown>
,	,	,
Ebola	NP	<unknown>
and	CC	and
Respiratory	JJ	respiratory
Syncytial	JJ	syncytial
Virus	NN	virus
Immunoglobulin	NN	immunoglobulin
gene	NN	gene
heterogeneity	NN	heterogeneity
reflects	VBZ	reflect
the	DT	the
diversity	NN	diversity
and	CC	and
focus	NN	focus
of	IN	of
the	DT	the
humoral	JJ	humoral
immune	JJ	immune
response	NN	response
towards	IN	towards
different	JJ	different
infections	NNS	infection
,	,	,
enabling	VBG	enable
inference	NN	inference
of	IN	of
B	NP	B
cell	NN	cell
development	NN	development
processes	NNS	process
.	SENT	.
Detailed	JJ	detailed
compositional	JJ	compositional
and	CC	and
lineage	NN	lineage
analysis	NN	analysis
of	IN	of
long	RB	long
read	VBN	read
IGH	JJ	<unknown>
repertoire	NN	repertoire
sequencing	VBG	sequence
,	,	,
combining	VBG	combine
examples	NNS	example
of	IN	of
pandemic	JJ	pandemic
,	,	,
epidemic	JJ	epidemic
and	CC	and
endemic	JJ	endemic
viral	JJ	viral
infections	NNS	infection
with	IN	with
control	NN	control
and	CC	and
vaccination	NN	vaccination
samples	NNS	sample
,	,	,
demonstrates	VBZ	demonstrate
general	JJ	general
responses	NNS	response
including	VBG	include
increased	VBN	increase
use	NN	use
of	IN	of
IGHV4-39	NP	<unknown>
in	IN	in
both	DT	both
Zaire	NP	Zaire
Ebolavirus	NP	<unknown>
(	(	(
EBOV	NP	<unknown>
)	)	)
and	CC	and
COVID-19	NP	<unknown>
patient	NN	patient
cohorts	NNS	cohort
.	SENT	.
We	PP	we
also	RB	also
show	VBP	show
unique	JJ	unique
characteristics	NNS	characteristic
absent	JJ	absent
in	IN	in
Respiratory	JJ	respiratory
Syncytial	JJ	syncytial
Virus	NN	virus
or	CC	or
yellow	JJ	yellow
fever	NN	fever
vaccine	NN	vaccine
samples	NNS	sample
:	:	:
EBOV	NP	<unknown>
survivors	NNS	survivor
show	VBP	show
unprecedented	JJ	unprecedented
high	JJ	high
levels	NNS	level
of	IN	of
class	NN	class
switching	VBG	switch
events	NNS	event
while	IN	while
COVID-19	NP	<unknown>
repertoires	NNS	repertoire
from	IN	from
acute	JJ	acute
disease	NN	disease
appear	VBP	appear
underdeveloped	JJ	underdeveloped
.	SENT	.
Despite	IN	despite
the	DT	the
high	JJ	high
levels	NNS	level
of	IN	of
clonal	JJ	clonal
expansion	NN	expansion
in	IN	in
COVID-19	NP	<unknown>
IgG1	NP	<unknown>
repertoires	NNS	repertoire
there	EX	there
is	VBZ	be
a	DT	a
striking	JJ	striking
lack	NN	lack
of	IN	of
evidence	NN	evidence
of	IN	of
germinal	JJ	germinal
centre	NN	centre
mutation	NN	mutation
and	CC	and
selection	NN	selection
.	SENT	.
Given	VBN	give
the	DT	the
differences	NNS	difference
in	IN	in
COVID-19	NP	<unknown>
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
with	IN	with
age	NN	age
,	,	,
it	PP	it
is	VBZ	be
also	RB	also
pertinent	JJ	pertinent
that	IN	that
we	PP	we
find	VBP	find
significant	JJ	significant
differences	NNS	difference
in	IN	in
repertoire	NN	repertoire
characteristics	NNS	characteristic
between	IN	between
young	JJ	young
and	CC	and
old	JJ	old
patients	NNS	patient
.	SENT	.
Our	PP$	our
data	NN	data
supports	VBZ	support
the	DT	the
hypothesis	NN	hypothesis
that	IN	that
a	DT	a
primary	JJ	primary
viral	JJ	viral
challenge	NN	challenge
can	MD	can
result	VB	result
in	IN	in
a	DT	a
strong	JJ	strong
but	CC	but
immature	JJ	immature
humoral	JJ	humoral
response	NN	response
where	WRB	where
failures	NNS	failure
in	IN	in
selection	NN	selection
of	IN	of
the	DT	the
repertoire	NN	repertoire
risk	NN	risk
off-target	NN	off-target
effects	NNS	effect
.	SENT	.
34747367/	CD	@card@
Chitinase	NN	<unknown>
3-like-1	JJ	<unknown>
is	VBZ	be
a	DT	a
therapeutic	JJ	therapeutic
target	NN	target
that	WDT	that
mediates	VBZ	mediate
the	DT	the
effects	NNS	effect
of	IN	of
aging	VBG	age
in	IN	in
COVID-19	NP	<unknown>
COVID-19	NP	<unknown>
is	VBZ	be
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
(	(	(
SC2	NP	<unknown>
)	)	)
and	CC	and
is	VBZ	be
more	RBR	more
prevalent	JJ	prevalent
and	CC	and
severe	JJ	severe
in	IN	in
elderly	JJ	elderly
and	CC	and
patients	NNS	patient
with	IN	with
comorbid	JJ	comorbid
diseases	NNS	disease
(	(	(
CM	NP	CM
)	)	)
.	SENT	.
Because	IN	because
chitinase	NN	<unknown>
3-like-1	JJ	<unknown>
(	(	(
CHI3L1	NP	<unknown>
)	)	)
is	VBZ	be
induced	VBN	induce
during	IN	during
aging	VBG	age
and	CC	and
CM	NP	CM
,	,	,
the	DT	the
relationships	NNS	relationship
between	IN	between
CHI3L1	NP	<unknown>
and	CC	and
SC2	NP	<unknown>
were	VBD	be
investigated	VBN	investigate
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
demonstrate	VBP	demonstrate
that	IN	that
CHI3L1	NP	<unknown>
is	VBZ	be
a	DT	a
potent	JJ	potent
stimulator	NN	stimulator
of	IN	of
the	DT	the
SC2	NP	<unknown>
receptor	NN	receptor
angiotensin	NP	angiotensin
converting	VBG	convert
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
and	CC	and
viral	JJ	viral
spike	NN	spike
protein	NN	protein
priming	NN	priming
proteases	NNS	protease
(	(	(
SPP	NP	SPP
)	)	)
,	,	,
that	IN	that
ACE2	NP	<unknown>
and	CC	and
SPP	NP	SPP
are	VBP	be
induced	VBN	induce
during	IN	during
aging	VBG	age
,	,	,
and	CC	and
that	DT	that
anti-CHI3L1	NN	<unknown>
,	,	,
kasugamycin	NN	<unknown>
,	,	,
and	CC	and
inhibitors	NNS	inhibitor
of	IN	of
phosphorylation	NN	<unknown>
abrogate	VBP	abrogate
these	DT	these
ACE2-	NP	<unknown>
and	CC	and
SPP-inductive	NP	<unknown>
events	NNS	event
.	SENT	.
Human	JJ	human
studies	NNS	study
also	RB	also
demonstrate	VBP	demonstrate
that	IN	that
the	DT	the
levels	NNS	level
of	IN	of
circulating	VBG	circulate
CHI3L1	NP	<unknown>
are	VBP	be
increased	VBN	increase
in	IN	in
the	DT	the
elderly	JJ	elderly
and	CC	and
patients	NNS	patient
with	IN	with
CM	NP	CM
,	,	,
where	WRB	where
they	PP	they
correlate	VBP	correlate
with	IN	with
COVID-19	NP	<unknown>
severity	NN	severity
.	SENT	.
These	DT	these
studies	NNS	study
demonstrate	VBP	demonstrate
that	IN	that
CHI3L1	NP	<unknown>
is	VBZ	be
a	DT	a
potent	JJ	potent
stimulator	NN	stimulator
of	IN	of
ACE2	NP	<unknown>
and	CC	and
SPP	NP	SPP
,	,	,
that	IN	that
this	DT	this
induction	NN	induction
is	VBZ	be
a	DT	a
major	JJ	major
mechanism	NN	mechanism
contributing	VBG	contribute
to	TO	to
the	DT	the
effects	NNS	effect
of	IN	of
aging	VBG	age
during	IN	during
SC2	NP	<unknown>
infection	NN	infection
,	,	,
and	CC	and
that	IN	that
CHI3L1	NP	<unknown>
co-opts	VBZ	co-opt
the	DT	the
CHI3L1	JJ	<unknown>
axis	NN	axis
to	TO	to
augment	VB	augment
SC2	NP	<unknown>
infection	NN	infection
.	SENT	.
CHI3L1	NP	<unknown>
plays	VBZ	play
a	DT	a
critical	JJ	critical
role	NN	role
in	IN	in
the	DT	the
pathogenesis	NN	pathogenesis
of	IN	of
and	CC	and
is	VBZ	be
an	DT	an
attractive	JJ	attractive
therapeutic	JJ	therapeutic
target	NN	target
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
33793460/	CD	@card@
Interim	JJ	interim
Estimates	NNS	estimate
of	IN	of
Vaccine	NN	vaccine
Effectiveness	NN	effectiveness
of	IN	of
BNT162b2	NP	<unknown>
and	CC	and
mRNA-1273	NP	mRNA@card@
COVID-19	NP	<unknown>
Vaccines	NNS	vaccine
in	IN	in
Preventing	VBG	prevent
SARS-CoV-2	JJ	<unknown>
Infection	NN	infection
Among	IN	among
Health	NP	Health
Care	NP	Care
Personnel	NP	Personnel
,	,	,
First	NP	First
Responders	NNS	responder
,	,	,
and	CC	and
Other	JJ	other
Essential	JJ	essential
and	CC	and
Frontline	NP	Frontline
Workers	NPS	Workers
:	:	:
Eight	CD	eight
U.S.	NP	U.S.
Locations	NNS	location
,	,	,
December	NP	December
2020-March	JJ	<unknown>
2021	CD	@card@
35358722/	CD	@card@
Role	NN	role
of	IN	of
procalcitonin	NN	procalcitonin
as	IN	as
a	DT	a
predictor	NN	predictor
of	IN	of
clinical	JJ	clinical
outcomes	NNS	outcome
in	IN	in
hospitalized	VBN	hospitalize
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
aimed	VBD	aim
to	TO	to
determine	VB	determine
the	DT	the
correlation	NN	correlation
between	IN	between
procalcitonin	NP	<unknown>
(	(	(
PCT	NP	PCT
)	)	)
levels	NNS	level
and	CC	and
clinical	JJ	clinical
outcomes	NNS	outcome
including	VBG	include
in-hospital	JJ	in-hospital
mortality	NN	mortality
,	,	,
ICU	NP	ICU
length	NN	length
of	IN	of
stay	NN	stay
,	,	,
and	CC	and
hospital	NN	hospital
length	NN	length
of	IN	of
stay	NN	stay
in	IN	in
patients	NNS	patient
hospitalized	VBN	hospitalize
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Clinical	JJ	clinical
,	,	,
laboratory	NN	laboratory
,	,	,
and	CC	and
demographic	JJ	demographic
data	NNS	datum
of	IN	of
223	CD	@card@
patients	NNS	patient
who	WP	who
met	VBD	meet
inclusion	NN	inclusion
criteria	NNS	criterion
were	VBD	be
analyzed	VBN	analyze
.	SENT	.
PCT	NP	PCT
measurements	NNS	measurement
of	IN	of
0.25	CD	@card@
ng/mL	NNS	<unknown>
and	CC	and
0.50	CD	@card@
ng/mL	NNS	<unknown>
were	VBD	be
used	VBN	use
to	TO	to
stratify	VB	stratify
patients	NNS	patient
into	IN	into
two	CD	two
mutually	RB	mutually
exclusive	JJ	exclusive
groups	NNS	group
Patients	NNS	patient
with	IN	with
PCT	NN	PCT
above	IN	above
0.25	CD	@card@
ng/mL	NNS	<unknown>
on	IN	on
admission	NN	admission
had	VBD	have
significantly	RB	significantly
elevated	VBN	elevate
APACHE	NN	apache
II	CD	@card@
scores	NNS	score
(	(	(
9	CD	@card@
vs.	IN	vs.
8	CD	@card@
;	:	;
P	NN	P
=	SYM	=
0.042	CD	@card@
)	)	)
and	CC	and
CRP	NP	<unknown>
levels	NNS	level
(	(	(
111	CD	@card@
mug/mL	NN	<unknown>
vs.	IN	vs.
79	CD	@card@
mug/mL	NN	<unknown>
;	:	;
P	NN	P
=	SYM	=
0.007	CD	@card@
)	)	)
.	SENT	.
A	DT	a
multivariable	JJ	multivariable
binary	JJ	binary
logistic	JJ	logistic
regression	NN	regression
model	NN	model
demonstrated	VBD	demonstrate
no	DT	no
relationship	NN	relationship
between	IN	between
PCT	NN	PCT
and	CC	and
mortality	NN	mortality
(	(	(
OR	CC	or
=	SYM	=
1.00	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
Cl	NP	Cl
:	:	:
0.97	CD	@card@
to	TO	to
1.02	CD	@card@
;	:	;
P	NN	P
=	SYM	=
0.713	CD	@card@
)	)	)
.	SENT	.
Kaplan-Meier	NP	Kaplan-Meier
analysis	NN	analysis
revealed	VBD	reveal
no	DT	no
statistical	JJ	statistical
evidence	NN	evidence
of	IN	of
a	DT	a
difference	NN	difference
between	IN	between
PCT	NN	PCT
groups	NNS	group
and	CC	and
hospital	NN	hospital
length	NN	length
of	IN	of
stay	NN	stay
(	(	(
P	NN	P
=	SYM	=
0.144	CD	@card@
for	IN	for
0.25	CD	@card@
ng/mL	NNS	<unknown>
,	,	,
P	NN	P
=	SYM	=
0.368	CD	@card@
for	IN	for
0.50	CD	@card@
ng/mL	NNS	<unknown>
)	)	)
or	CC	or
intensive	JJ	intensive
care	NN	care
unit	NN	unit
length	NN	length
of	IN	of
stay	NN	stay
(	(	(
P	NN	P
=	SYM	=
0.986	CD	@card@
for	IN	for
0.25	CD	@card@
ng/mL	NNS	<unknown>
,	,	,
P	NN	P
=	SYM	=
0.771	CD	@card@
for	IN	for
0.50	CD	@card@
ng/mL	NNS	<unknown>
)	)	)
.	SENT	.
Elevated	JJ	elevated
PCT	NN	PCT
levels	NNS	level
were	VBD	be
associated	VBN	associate
with	IN	with
severity	NN	severity
of	IN	of
illness	NN	illness
but	CC	but
did	VBD	do
not	RB	not
correlate	VB	correlate
with	IN	with
in-hospital	JJ	in-hospital
mortality	NN	mortality
,	,	,
hospital	NN	hospital
length	NN	length
of	IN	of
stay	NN	stay
,	,	,
or	CC	or
ICU	NP	ICU
length	NN	length
of	IN	of
stay	NN	stay
.	SENT	.
32328576/	CD	@card@
Can	NN	can
early	JJ	early
and	CC	and
high	JJ	high
intravenous	JJ	intravenous
dose	NN	dose
of	IN	of
vitamin	NN	vitamin
C	NN	C
prevent	VB	prevent
and	CC	and
treat	VB	treat
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
?	SENT	?
34075622/	CD	@card@
Rapid	JJ	rapid
Transition	NN	transition
to	TO	to
Telehealth	NP	Telehealth
and	CC	and
the	DT	the
Digital	NP	Digital
Divide	NP	Divide
:	:	:
Implications	NNS	implication
for	IN	for
Primary	JJ	primary
Care	NP	Care
Access	NP	Access
and	CC	and
Equity	NP	Equity
in	IN	in
a	DT	a
Post-COVID	NP	<unknown>
Era	NP	Era
Telehealth	NP	Telehealth
has	VBZ	have
many	JJ	many
potential	JJ	potential
advantages	NNS	advantage
during	IN	during
an	DT	an
infectious	JJ	infectious
disease	NN	disease
outbreak	NN	outbreak
such	JJ	such
as	IN	as
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
and	CC	and
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
accelerated	VBN	accelerate
the	DT	the
shift	NN	shift
to	TO	to
telehealth	NN	telehealth
as	IN	as
a	DT	a
prominent	JJ	prominent
care	NN	care
delivery	NN	delivery
mode	NN	mode
.	SENT	.
Not	RB	not
all	DT	all
health	NN	health
care	NN	care
providers	NNS	provider
and	CC	and
patients	NNS	patient
are	VBP	be
equally	RB	equally
ready	JJ	ready
to	TO	to
take	VB	take
part	NN	part
in	IN	in
the	DT	the
telehealth	NN	telehealth
revolution	NN	revolution
,	,	,
which	WDT	which
raises	VBZ	raise
concerns	NNS	concern
for	IN	for
health	NN	health
equity	NN	equity
during	IN	during
and	CC	and
after	IN	after
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Without	IN	without
proactive	JJ	proactive
efforts	NNS	effort
to	TO	to
address	VB	address
both	DT	both
patient-	NN	<unknown>
and	CC	and
provider-related	JJ	provider-related
digital	JJ	digital
barriers	NNS	barrier
associated	VBN	associate
with	IN	with
socioeconomic	JJ	socioeconomic
status	NN	status
,	,	,
the	DT	the
wide-scale	JJ	wide-scale
implementation	NN	implementation
of	IN	of
telehealth	NN	telehealth
amid	IN	amid
COVID-19	NP	<unknown>
may	MD	may
reinforce	VB	reinforce
disparities	NNS	disparity
in	IN	in
health	NN	health
access	NN	access
in	IN	in
already	RB	already
marginalized	VBN	marginalize
and	CC	and
underserved	VBN	underserv
communities	NNS	community
.	SENT	.
To	TO	to
ensure	VB	ensure
greater	JJR	great
telehealth	NN	telehealth
equity	NN	equity
,	,	,
policy	NN	policy
changes	NNS	change
should	MD	should
address	VB	address
barriers	NNS	barrier
faced	VBN	face
overwhelmingly	RB	overwhelmingly
by	IN	by
marginalized	VBN	marginalize
patient	NN	patient
populations	NNS	population
and	CC	and
those	DT	those
who	WP	who
serve	VBP	serve
them	PP	them
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
catalyzed	VBN	catalyze
fundamental	JJ	fundamental
shifts	NNS	shift
across	IN	across
the	DT	the
US	NP	US
health	NN	health
care	NN	care
delivery	NN	delivery
system	NN	system
,	,	,
including	VBG	include
a	DT	a
rapid	JJ	rapid
transition	NN	transition
to	TO	to
telehealth	NN	telehealth
.	SENT	.
Telehealth	NP	Telehealth
has	VBZ	have
many	JJ	many
potential	JJ	potential
advantages	NNS	advantage
,	,	,
including	VBG	include
maintaining	VBG	maintain
critical	JJ	critical
access	NN	access
to	TO	to
care	VB	care
while	IN	while
keeping	VBG	keep
both	DT	both
patients	NNS	patient
and	CC	and
providers	NNS	provider
safe	JJ	safe
from	IN	from
unnecessary	JJ	unnecessary
exposure	NN	exposure
to	TO	to
the	DT	the
coronavirus	NN	coronavirus
.	SENT	.
However	RB	however
,	,	,
not	RB	not
all	DT	all
health	NN	health
care	NN	care
providers	NNS	provider
and	CC	and
patients	NNS	patient
are	VBP	be
equally	RB	equally
ready	JJ	ready
to	TO	to
take	VB	take
part	NN	part
in	IN	in
this	DT	this
digital	JJ	digital
revolution	NN	revolution
,	,	,
which	WDT	which
raises	VBZ	raise
concerns	NNS	concern
for	IN	for
health	NN	health
equity	NN	equity
during	IN	during
and	CC	and
after	IN	after
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
study	NN	study
analyzed	VBD	analyze
data	NNS	datum
about	IN	about
small	JJ	small
primary	JJ	primary
care	NN	care
practices	NNS	practice
'	POS	'
telehealth	NN	telehealth
use	NN	use
and	CC	and
barriers	NNS	barrier
to	TO	to
telehealth	NN	telehealth
use	NN	use
collected	VBN	collect
from	IN	from
rapid-response	NN	rapid-response
surveys	NNS	survey
administered	VBN	administer
by	IN	by
the	DT	the
New	NP	New
York	NP	York
City	NP	City
Department	NP	Department
of	IN	of
Health	NP	Health
and	CC	and
Mental	JJ	mental
Hygiene	NN	hygiene
's	POS	's
Bureau	NP	Bureau
of	IN	of
Equitable	NP	Equitable
Health	NP	Health
Systems	NPS	Systems
and	CC	and
New	NP	New
York	NP	York
University	NP	University
from	IN	from
mid-April	NP	mid-April
through	IN	through
mid-June	NP	mid-June
2020	CD	@card@
as	IN	as
part	NN	part
of	IN	of
the	DT	the
city	NN	city
's	POS	's
efforts	NNS	effort
to	TO	to
understand	VB	understand
how	WRB	how
primary	JJ	primary
care	NN	care
practices	NNS	practice
were	VBD	be
responding	VBG	respond
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
following	VBG	follow
New	NP	New
York	NP	York
State	NP	State
's	POS	's
stay-at-home	JJ	stay-at-home
order	NN	order
on	IN	on
March	NP	March
22	CD	@card@
.	SENT	.
We	PP	we
focused	VBD	focus
on	IN	on
small	JJ	small
primary	JJ	primary
care	NN	care
practices	NNS	practice
because	IN	because
they	PP	they
represent	VBP	represent
40	CD	@card@
%	NN	%
of	IN	of
primary	JJ	primary
care	NN	care
providers	NNS	provider
and	CC	and
are	VBP	be
disproportionately	RB	disproportionately
located	VBN	locate
in	IN	in
low-income	JJ	low-income
,	,	,
minority	NN	minority
or	CC	or
immigrant	NN	immigrant
areas	NNS	area
that	WDT	that
were	VBD	be
more	JJR	more
severely	RB	severely
impacted	VBN	impact
by	IN	by
COVID-19	NP	<unknown>
.	SENT	.
To	TO	to
examine	VB	examine
whether	IN	whether
telehealth	NN	telehealth
use	NN	use
and	CC	and
barriers	NNS	barrier
differed	VBD	differ
based	VBN	base
on	IN	on
the	DT	the
socioeconomic	JJ	socioeconomic
characteristics	NNS	characteristic
of	IN	of
the	DT	the
communities	NNS	community
served	VBN	serve
by	IN	by
these	DT	these
practices	NNS	practice
,	,	,
we	PP	we
used	VBD	use
the	DT	the
Centers	NPS	Centers
for	IN	for
Disease	NP	Disease
Control	NP	Control
and	CC	and
Prevention	NN	prevention
Social	NP	Social
Vulnerability	NN	vulnerability
Index	NP	Index
(	(	(
SVI	NP	SVI
)	)	)
to	TO	to
stratify	VB	stratify
respondents	NNS	respondent
as	IN	as
being	VBG	be
in	IN	in
high-SVI	NN	<unknown>
or	CC	or
low-SVI	NN	<unknown>
areas	NNS	area
.	SENT	.
We	PP	we
then	RB	then
characterized	VBD	characterize
respondents	NNS	respondent
'	POS	'
telehealth	NN	telehealth
use	NN	use
and	CC	and
barriers	NNS	barrier
to	TO	to
adoption	NN	adoption
by	IN	by
using	VBG	use
means	NNS	mean
and	CC	and
proportions	NNS	proportion
with	IN	with
95	CD	@card@
%	NN	%
confidence	NN	confidence
intervals	NNS	interval
.	SENT	.
In	IN	in
addition	NN	addition
to	TO	to
a	DT	a
primary	JJ	primary
analysis	NN	analysis
using	VBG	use
pooled	JJ	pooled
data	NNS	datum
across	IN	across
the	DT	the
five	CD	five
waves	NNS	wave
of	IN	of
the	DT	the
survey	NN	survey
,	,	,
we	PP	we
performed	VBD	perform
sensitivity	NN	sensitivity
analyses	NNS	analysis
using	VBG	use
data	NNS	datum
from	IN	from
respondents	NNS	respondent
who	WP	who
only	RB	only
took	VBD	take
one	CD	one
survey	NN	survey
,	,	,
first	JJ	first
wave	NN	wave
only	RB	only
,	,	,
and	CC	and
the	DT	the
last	JJ	last
two	CD	two
waves	NNS	wave
only	RB	only
.	SENT	.
While	IN	while
all	DT	all
providers	NNS	provider
rapidly	RB	rapidly
shifted	VBN	shift
to	TO	to
telehealth	NN	telehealth
,	,	,
there	EX	there
were	VBD	be
differences	NNS	difference
based	VBN	base
on	IN	on
community	NN	community
characteristics	NNS	characteristic
in	IN	in
both	CC	both
the	DT	the
primary	JJ	primary
mode	NN	mode
of	IN	of
telehealth	NN	telehealth
used	VBN	use
and	CC	and
the	DT	the
types	NNS	type
of	IN	of
barriers	NNS	barrier
experienced	VBN	experience
by	IN	by
providers	NNS	provider
.	SENT	.
Providers	NNS	provider
in	IN	in
high-SVI	NN	<unknown>
areas	NNS	area
were	VBD	be
almost	RB	almost
twice	RB	twice
as	RB	as
likely	JJ	likely
as	IN	as
providers	NNS	provider
in	IN	in
low-SVI	NN	<unknown>
areas	NNS	area
to	TO	to
use	VB	use
telephones	NNS	telephone
as	IN	as
their	PP$	their
primary	JJ	primary
telehealth	NN	telehealth
modality	NN	modality
(	(	(
41.7	CD	@card@
%	NN	%
vs	NP	vs
23.8	CD	@card@
%	NN	%
;	:	;
P	NN	P
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
opposite	NN	opposite
was	VBD	be
true	JJ	true
for	IN	for
video	NN	video
,	,	,
which	WDT	which
was	VBD	be
used	VBN	use
as	IN	as
the	DT	the
primary	JJ	primary
telehealth	NN	telehealth
modality	NN	modality
by	IN	by
18.7	CD	@card@
%	NN	%
of	IN	of
providers	NNS	provider
in	IN	in
high-SVI	NN	<unknown>
areas	NNS	area
and	CC	and
33.7	CD	@card@
%	NN	%
of	IN	of
providers	NNS	provider
in	IN	in
low-SVI	NN	<unknown>
areas	NNS	area
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Providers	NNS	provider
in	IN	in
high-SVI	NN	<unknown>
areas	NNS	area
also	RB	also
faced	VBD	face
more	JJR	more
patient-related	JJ	patient-related
barriers	NNS	barrier
and	CC	and
fewer	JJR	few
provider-related	JJ	provider-related
barriers	NNS	barrier
than	IN	than
those	DT	those
in	IN	in
low-SVI	NP	<unknown>
areas	NNS	area
.	SENT	.
Between	IN	between
April	NP	April
and	CC	and
June	NP	June
2020	CD	@card@
,	,	,
telehealth	NN	telehealth
became	VBD	become
a	DT	a
prominent	JJ	prominent
mode	NN	mode
of	IN	of
primary	JJ	primary
care	NN	care
delivery	NN	delivery
in	IN	in
New	NP	New
York	NP	York
City	NP	City
.	SENT	.
However	RB	however
,	,	,
the	DT	the
transition	NN	transition
to	TO	to
telehealth	NN	telehealth
did	VBD	do
not	RB	not
unfold	VB	unfold
in	IN	in
the	DT	the
same	JJ	same
manner	NN	manner
across	IN	across
communities	NNS	community
.	SENT	.
To	TO	to
ensure	VB	ensure
greater	JJR	great
telehealth	NN	telehealth
equity	NN	equity
,	,	,
policy	NN	policy
changes	NNS	change
should	MD	should
address	VB	address
barriers	NNS	barrier
faced	VBN	face
overwhelmingly	RB	overwhelmingly
by	IN	by
marginalized	VBN	marginalize
patient	NN	patient
populations	NNS	population
and	CC	and
those	DT	those
who	WP	who
serve	VBP	serve
them	PP	them
.	SENT	.
35380101/	CD	@card@
The	DT	the
prominent	JJ	prominent
role	NN	role
of	IN	of
a	DT	a
CDR1	JJ	<unknown>
somatic	JJ	somatic
hypermutation	NN	hypermutation
for	IN	for
convergent	JJ	convergent
IGHV3-53/3-66	NP	IGHV@card@
antibodies	NNS	antibody
in	IN	in
binding	VBG	bind
to	TO	to
SARS-CoV-2	NP	<unknown>
In	IN	in
the	DT	the
fight	NN	fight
against	IN	against
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus-2	NN	<unknown>
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
monoclonal	NN	monoclonal
antibodies	NNS	antibody
(	(	(
mAbs	NNS	<unknown>
)	)	)
serve	VBP	serve
as	IN	as
key	JJ	key
strategies	NNS	strategy
for	IN	for
the	DT	the
rapid	JJ	rapid
prevention	NN	prevention
and	CC	and
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
analysis	NN	analysis
to	TO	to
fully	RB	fully
characterize	VB	characterize
functional	JJ	functional
SARS-CoV-2	NP	<unknown>
mAbs	NNS	<unknown>
is	VBZ	be
still	RB	still
needed	VBN	need
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
by	IN	by
interrogating	VBG	interrogate
1,695	CD	@card@
published	VBN	publish
or	CC	or
patented	VBN	patent
mAbs	NNS	<unknown>
of	IN	of
human	JJ	human
origin	NN	origin
and	CC	and
validated	VBD	validate
SARS-CoV-2-binding	NP	<unknown>
potency	NN	potency
,	,	,
we	PP	we
found	VBD	find
a	DT	a
highly	RB	highly
preferential	JJ	preferential
usage	NN	usage
of	IN	of
IGHV3-53/3-66	NP	IGHV@card@
germline	NN	<unknown>
genes	NNS	gene
that	WDT	that
was	VBD	be
then	RB	then
revealed	VBN	reveal
as	IN	as
a	DT	a
distinct	JJ	distinct
selectivity	NN	selectivity
of	IN	of
SARS-CoV-2-induced	JJ	<unknown>
humoral	JJ	humoral
immunity	NN	immunity
across	IN	across
other	JJ	other
coronaviruses	NNS	coronavirus
.	SENT	.
Moreover	RB	moreover
,	,	,
among	IN	among
the	DT	the
rare	JJ	rare
somatic	JJ	somatic
hypermutations	NNS	hypermutation
,	,	,
we	PP	we
identified	VBD	identify
a	DT	a
novel	JJ	novel
mutation	NN	mutation
signature	NN	signature
of	IN	of
F27	JJ	F@card@
to	TO	to
I	PP	I
,	,	,
L	NP	L
,	,	,
or	CC	or
V	CD	@card@
with	IN	with
high	JJ	high
frequency	NN	frequency
,	,	,
which	WDT	which
was	VBD	be
located	VBN	locate
in	IN	in
the	DT	the
CDR1	JJ	<unknown>
region	NN	region
of	IN	of
the	DT	the
heavy	JJ	heavy
chain	NN	chain
among	IN	among
IGHV3-53/3-66-encoded	JJ	<unknown>
antibodies	NNS	antibody
.	SENT	.
This	DT	this
convergent	JJ	convergent
mutation	NN	mutation
contributed	VBD	contribute
to	TO	to
improving	VBG	improve
SARS-CoV-2	JJ	<unknown>
binding	JJ	binding
affinity	NN	affinity
and	CC	and
may	MD	may
advance	VB	advance
our	PP$	our
knowledge	NN	knowledge
of	IN	of
the	DT	the
humoral	JJ	humoral
immunity	NN	immunity
to	TO	to
SARS-CoV-2	NP	<unknown>
.	SENT	.
32590073/	CD	@card@
Transforming	VBG	transform
laparoendoscopic	JJ	laparoendoscopic
surgical	JJ	surgical
protocols	NNS	protocol
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
;	:	;
big	JJ	big
data	NNS	datum
analytics	NNS	<unknown>
,	,	,
resource	NN	resource
allocation	NN	allocation
and	CC	and
operational	JJ	operational
considerations	NNS	consideration
The	DT	the
current	JJ	current
dreadful	JJ	dreadful
pandemic	NN	pandemic
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
playing	VBG	play
havoc	NN	havoc
with	IN	with
humanity	NN	humanity
,	,	,
socio-communal	JJ	socio-communal
systems	NNS	system
and	CC	and
economic	JJ	economic
reserves	NNS	reserve
worldwide	RB	worldwide
.	SENT	.
Certain	JJ	certain
countries	NNS	country
have	VBP	have
managed	VBN	manage
to	TO	to
curtail	VB	curtail
COVID-19	NP	<unknown>
crisis	NN	crisis
to	TO	to
some	DT	some
extent	NN	extent
,	,	,
however	RB	however
,	,	,
a	DT	a
great	JJ	great
majority	NN	majority
still	RB	still
remains	VBZ	remain
helpless	JJ	helpless
in	IN	in
containing	VBG	contain
this	DT	this
outbreak	NN	outbreak
.	SENT	.
Rapidly	RB	rapidly
evolving	VBG	evolve
disease	NN	disease
patterns	NNS	pattern
and	CC	and
complex	JJ	complex
epidemiology	NN	epidemiology
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
necessitate	VB	necessitate
a	DT	a
tailored	JJ	tailored
approach	NN	approach
by	IN	by
medical	JJ	medical
experts	NNS	expert
in	IN	in
dealing	VBG	deal
with	IN	with
this	DT	this
devastating	JJ	devastating
outbreak	NN	outbreak
.	SENT	.
Similar	JJ	similar
to	TO	to
other	JJ	other
medical	JJ	medical
disciplines	NNS	discipline
,	,	,
surgical	JJ	surgical
associations	NNS	association
and	CC	and
societies	NNS	society
have	VBP	have
developed	VBN	develop
a	DT	a
tailored	JJ	tailored
approach	NN	approach
of	IN	of
patients	NNS	patient
'	POS	'
selection	NN	selection
and	CC	and
management	NN	management
plans	NNS	plan
with	IN	with
improvised	VBN	improvise
endolaparoscopic	JJ	<unknown>
practice	NN	practice
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Non-essential	JJ	non-essential
and	CC	and
non-urgent	JJ	non-urgent
surgical	JJ	surgical
procedures	NNS	procedure
are	VBP	be
deferred	VBN	defer
till	IN	till
this	DT	this
outbreak	NN	outbreak
is	VBZ	be
abated	VBN	abate
.	SENT	.
Benefits	NNS	benefit
of	IN	of
delaying	VBG	delay
elective	JJ	elective
and	CC	and
non-urgent	JJ	non-urgent
surgery	NN	surgery
outweighs	VBZ	outweigh
the	DT	the
risk	NN	risk
of	IN	of
performing	VBG	perform
surgical	JJ	surgical
procedures	NNS	procedure
on	IN	on
patients	NNS	patient
with	IN	with
asymptomatic	JJ	asymptomatic
or	CC	or
active	JJ	active
COVID-19	NP	<unknown>
disease	NN	disease
.	SENT	.
Laparoendoscopic	JJ	Laparoendoscopic
procedures	NNS	procedure
increase	VBP	increase
the	DT	the
risk	NN	risk
of	IN	of
aerosol	NN	aerosol
exposure	NN	exposure
,	,	,
disease	NN	disease
transmission	NN	transmission
and	CC	and
contamination	NN	contamination
.	SENT	.
Limiting	VBG	limit
the	DT	the
number	NN	number
of	IN	of
operating	VBG	operate
room	NN	room
personnel	NNS	personnel
,	,	,
use	NN	use
of	IN	of
disposable	JJ	disposable
instruments	NNS	instrument
,	,	,
small	JJ	small
trocar	NN	trocar
incisions	NNS	incision
,	,	,
negative	JJ	negative
pressure	NN	pressure
environment	NN	environment
,	,	,
and	CC	and
setting	VBG	set
energy	NN	energy
devices	NNS	device
at	IN	at
low	JJ	low
modes	NNS	mode
can	MD	can
help	VB	help
reduce	VB	reduce
disease	NN	disease
transmission	NN	transmission
during	IN	during
laparoendocsopic	JJ	<unknown>
procedures	NNS	procedure
.	SENT	.
This	DT	this
write	NN	write
up	RB	up
sheds	VBZ	shed
lights	NNS	light
on	IN	on
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
,	,	,
big	JJ	big
data	NNS	datum
analytics	NNS	<unknown>
of	IN	of
response	NN	response
of	IN	of
medical	JJ	medical
personnel	NNS	personnel
in	IN	in
understanding	VBG	understand
and	CC	and
curtailing	VBG	curtail
the	DT	the
disease	NN	disease
process	NN	process
and	CC	and
the	DT	the
consensus	NN	consensus
guidelines	NNS	guideline
for	IN	for
carrying	VBG	carry
out	RP	out
laparoscoendoscopic	JJ	laparoscoendoscopic
procedures	NNS	procedure
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
spreading	VBG	spread
with	IN	with
escalating	VBG	escalate
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
worldwide	RB	worldwide
.	SENT	.
Big	JJ	big
data	NNS	datum
analytics	NN	<unknown>
has	VBZ	have
reflected	VBN	reflect
enormous	JJ	enormous
proliferation	NN	proliferation
of	IN	of
research	NN	research
and	CC	and
publications	NNS	publication
about	IN	about
COVID-19	NP	<unknown>
during	IN	during
2020	CD	@card@
.	SENT	.
Surgical	JJ	surgical
practice	NN	practice
is	VBZ	be
rapidly	RB	rapidly
evolving	VBG	evolve
according	VBG	accord
to	TO	to
the	DT	the
needs	NNS	need
analysis	NN	analysis
and	CC	and
disease	NN	disease
burden	NN	burden
across	IN	across
regions	NNS	region
.	SENT	.
Laparoendocsopic	JJ	<unknown>
surgery	NN	surgery
should	MD	should
be	VB	be
postponed	VBN	postpone
for	IN	for
non-essential	JJ	non-essential
and	CC	and
non-urgent	JJ	non-urgent
surgical	JJ	surgical
cases	NNS	case
.	SENT	.
Laparoendoscopic	JJ	Laparoendoscopic
procedures	NNS	procedure
have	VBP	have
potentially	RB	potentially
increased	VBN	increase
risk	NN	risk
of	IN	of
disease	NN	disease
transmission	NN	transmission
by	IN	by
aerosol	NN	aerosol
exposure	NN	exposure
and	CC	and
contamination	NN	contamination
.	SENT	.
Limit	VB	limit
the	DT	the
number	NN	number
of	IN	of
operating	VBG	operate
room	NN	room
personnel	NNS	personnel
,	,	,
use	NN	use
of	IN	of
disposable	JJ	disposable
instruments	NNS	instrument
,	,	,
negative	JJ	negative
pressure	NN	pressure
air	NN	air
flow	NN	flow
,	,	,
and	CC	and
electrocautery	NN	electrocautery
energy	NN	energy
devices	NNS	device
at	IN	at
low	JJ	low
modes	NNS	mode
.	SENT	.
32476305/	CD	@card@
The	NP	The
Burden	NP	Burden
of	IN	of
Disease	NP	Disease
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
Korea	NP	Korea
Using	VBG	use
Disability-Adjusted	NP	<unknown>
Life	NP	Life
Years	NPS	Years
The	DT	the
world	NN	world
is	VBZ	be
currently	RB	currently
experiencing	VBG	experience
a	DT	a
pandemic	NN	pandemic
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
In	IN	in
Korea	NP	Korea
,	,	,
as	RB	as
in	IN	in
other	JJ	other
countries	NNS	country
,	,	,
the	DT	the
number	NN	number
of	IN	of
confirmed	VBN	confirm
cases	NNS	case
and	CC	and
deaths	NNS	death
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
have	VBP	have
been	VBN	be
rising	VBG	rise
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
calculate	VB	calculate
the	DT	the
burden	NN	burden
of	IN	of
disease	NN	disease
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
Korea	NP	Korea
.	SENT	.
We	PP	we
used	VBD	use
data	NNS	datum
on	IN	on
confirmed	VBN	confirm
cases	NNS	case
and	CC	and
deaths	NNS	death
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
between	IN	between
January	NP	January
20	CD	@card@
and	CC	and
April	NP	April
24	CD	@card@
,	,	,
2020	CD	@card@
provided	VBN	provide
by	IN	by
the	DT	the
Korea	NP	Korea
Centers	NPS	Centers
for	IN	for
Disease	NP	Disease
Control	NP	Control
and	CC	and
Prevention	NN	prevention
,	,	,
the	DT	the
local	JJ	local
governments	NNS	government
and	CC	and
the	DT	the
public	JJ	public
media	NNS	medium
to	TO	to
determine	VB	determine
disability-adjusted	JJ	disability-adjusted
life	NN	life
years	NNS	year
(	(	(
DALYs	NP	<unknown>
)	)	)
by	IN	by
sex	NN	sex
and	CC	and
age	NN	age
.	SENT	.
Morbidity	NN	morbidity
was	VBD	be
estimated	VBN	estimate
directly	RB	directly
among	IN	among
the	DT	the
confirmed	VBN	confirm
,	,	,
cured	VBN	cure
,	,	,
and	CC	and
fatal	JJ	fatal
cases	NNS	case
.	SENT	.
Disability	NN	disability
weights	NNS	weight
were	VBD	be
adopted	VBN	adopt
from	IN	from
previous	JJ	previous
similar	JJ	similar
causes	NNS	cause
on	IN	on
the	DT	the
severity	NN	severity
of	IN	of
COVID-19	NP	<unknown>
for	IN	for
the	DT	the
years	NNS	year
of	IN	of
life	NN	life
lived	VBN	live
with	IN	with
disability	NN	disability
(	(	(
YLDs	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
years	NNS	year
of	IN	of
life	NN	life
lost	VBN	lose
(	(	(
YLLs	NP	<unknown>
)	)	)
were	VBD	be
calculated	VBN	calculate
using	VBG	use
the	DT	the
standard	JJ	standard
life	NN	life
expectancy	NN	expectancy
from	IN	from
the	DT	the
2018	CD	@card@
life	NN	life
tables	NNS	table
for	IN	for
each	DT	each
sex	NN	sex
and	CC	and
age	NN	age
.	SENT	.
The	DT	the
YLDs	NP	<unknown>
were	VBD	be
higher	JJR	high
in	IN	in
females	NNS	female
(	(	(
155.2	CD	@card@
)	)	)
than	IN	than
in	IN	in
males	NNS	male
(	(	(
105.1	CD	@card@
)	)	)
,	,	,
but	CC	but
the	DT	the
YLLs	NNS	<unknown>
were	VBD	be
higher	JJR	high
in	IN	in
males	NNS	male
(	(	(
1,274.3	CD	@card@
)	)	)
than	IN	than
in	IN	in
females	NNS	female
(	(	(
996.4	CD	@card@
)	)	)
.	SENT	.
The	DT	the
total	JJ	total
disease	NN	disease
burden	NN	burden
attributable	JJ	attributable
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
Korea	NP	Korea
during	IN	during
the	DT	the
study	NN	study
period	NN	period
,	,	,
was	VBD	be
estimated	VBN	estimate
to	TO	to
be	VB	be
2,531.0	CD	@card@
DALYs	NP	<unknown>
,	,	,
and	CC	and
4.930	CD	@card@
DALYs	NP	<unknown>
per	IN	per
100,000	CD	@card@
population	NN	population
.	SENT	.
The	DT	the
YLDs	NP	<unknown>
and	CC	and
the	DT	the
YLLs	NP	<unknown>
constituted	VBD	constitute
10.3	CD	@card@
%	NN	%
and	CC	and
89.7	CD	@card@
%	NN	%
of	IN	of
the	DT	the
total	JJ	total
DALYs	NP	<unknown>
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
DALYs	NP	<unknown>
per	IN	per
100,000	CD	@card@
population	NN	population
were	VBD	be
highest	RBS	highest
in	IN	in
people	NNS	people
aged	VBN	age
&gt	NN	&gt
;	:	;
=	SYM	=
80	CD	@card@
years	NNS	year
,	,	,
followed	VBN	follow
by	IN	by
those	DT	those
aged	VBN	age
70-79	CD	@card@
,	,	,
60-69	CD	@card@
,	,	,
and	CC	and
50-59	CD	@card@
years	NNS	year
,	,	,
but	CC	but
the	DT	the
incidence	NN	incidence
was	VBD	be
the	DT	the
highest	JJS	high
in	IN	in
individuals	NNS	individual
aged	VBN	age
20-29	CD	@card@
years	NNS	year
.	SENT	.
This	DT	this
study	NN	study
provided	VBD	provide
the	DT	the
estimates	NNS	estimate
of	IN	of
DALYs	NP	<unknown>
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
Korea	NP	Korea
.	SENT	.
Most	JJS	most
of	IN	of
the	DT	the
disease	NN	disease
burden	NN	burden
from	IN	from
COVID-19	NP	<unknown>
was	VBD	be
derived	VBN	derive
from	IN	from
YLL	NP	YLL
;	:	;
this	DT	this
indicates	VBZ	indicate
that	IN	that
decision-makers	NNS	decision-maker
should	MD	should
focus	VB	focus
and	CC	and
make	VB	make
an	DT	an
effort	NN	effort
on	IN	on
reducing	VBG	reduce
fatality	NN	fatality
for	IN	for
preparing	VBG	prepare
the	DT	the
second	JJ	second
wave	NN	wave
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
34716614/	CD	@card@
Human	NP	Human
semen	NN	semen
quality	NN	quality
as	IN	as
affected	VBN	affect
by	IN	by
SARS-CoV-2	NP	<unknown>
infection	NN	infection
:	:	:
An	DT	an
up-to-date	JJ	up-to-date
review	NN	review
Revealing	VBG	reveal
the	DT	the
effect	NN	effect
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
on	IN	on
semen	NN	semen
quality	NN	quality
is	VBZ	be
a	DT	a
dynamic	JJ	dynamic
priority	NN	priority
for	IN	for
many	JJ	many
healthcare	NN	<unknown>
providers	NNS	provider
in	IN	in
the	DT	the
field	NN	field
as	RB	as
well	RB	well
as	IN	as
subfertile	JJ	subfertile
patients	NNS	patient
.	SENT	.
Therefore	RB	therefore
,	,	,
the	DT	the
collective	JJ	collective
summary	NN	summary
in	IN	in
this	DT	this
research	NN	research
approach	NN	approach
is	VBZ	be
still	RB	still
highly	RB	highly
needed	VBN	need
,	,	,
especially	RB	especially
with	IN	with
the	DT	the
continuous	JJ	continuous
increase	NN	increase
in	IN	in
original	JJ	original
publications	NNS	publication
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
provide	VBP	provide
an	DT	an
up-to-date	JJ	up-to-date
review	NN	review
and	CC	and
discussion	NN	discussion
to	TO	to
collectively	RB	collectively
reveal	VB	reveal
the	DT	the
effect	NN	effect
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
on	IN	on
human	JJ	human
semen	NN	semen
quality	NN	quality
.	SENT	.
To	TO	to
do	VB	do
this	DT	this
,	,	,
we	PP	we
reviewed	VBD	review
all	DT	all
articles	NNS	article
and	CC	and
abstracts	NNS	abstract
published	VBN	publish
in	IN	in
Scopus	NP	Scopus
and	CC	and
PubMed	NP	<unknown>
using	VBG	use
the	DT	the
keywords	NNS	keyword
'	POS	'
SARS-CoV-2	NP	<unknown>
'	POS	'
and	NP	and
'	POS	'
COVID	NP	<unknown>
'	POS	'
versus	FW	versus
'	POS	'
sperm	NN	sperm
'	''	'
and	CC	and
'	POS	'
semen	NN	semen
'	''	'
.	SENT	.
In	IN	in
summary	NN	summary
,	,	,
it	PP	it
can	MD	can
be	VB	be
revealed	VBN	reveal
that	IN	that
,	,	,
at	IN	at
both	DT	both
symptomatic	JJ	symptomatic
and	CC	and
recovery	NN	recovery
stages	NNS	stage
of	IN	of
infection	NN	infection
,	,	,
no	DT	no
investigational	JJ	investigational
evidence	NN	evidence
of	IN	of
SARS-CoV-2	NP	<unknown>
shedding	VBG	shed
in	IN	in
human	JJ	human
semen	NN	semen
.	SENT	.
Also	RB	also
,	,	,
the	DT	the
mainstream	NN	mainstream
of	IN	of
the	DT	the
up-to-date	JJ	up-to-date
published	JJ	published
work	NN	work
reveals	VBZ	reveal
a	DT	a
negative	JJ	negative
impact	NN	impact
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
on	IN	on
semen	NN	semen
quality	NN	quality
parameters	NNS	parameter
,	,	,
particularly	RB	particularly
sperm	NN	sperm
count	NN	count
and	CC	and
motility	NN	motility
.	SENT	.
However	RB	however
,	,	,
long-term	JJ	long-term
post-recovery	JJ	<unknown>
comparative	JJ	comparative
studies	NNS	study
seem	VBP	seem
very	RB	very
important	JJ	important
in	IN	in
this	DT	this
particular	JJ	particular
setting	NN	setting
.	SENT	.
35440094/	CD	@card@
An	DT	an
unusual	JJ	unusual
clinical	JJ	clinical
manifestation	NN	manifestation
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
in	IN	in
a	DT	a
woman	NN	woman
with	IN	with
twin	JJ	twin
pregnancy	NN	pregnancy
:	:	:
a	DT	a
case	NN	case
report	NN	report
Although	IN	although
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
affects	VBZ	affect
mainly	RB	mainly
the	DT	the
respiratory	JJ	respiratory
system	NN	system
,	,	,
as	IN	as
time	NN	time
passes	NNS	pass
and	CC	and
our	PP$	our
understanding	NN	understanding
of	IN	of
the	DT	the
disease	NN	disease
improves	VBZ	improve
,	,	,
many	JJ	many
nonrespiratory	JJ	nonrespiratory
clinical	JJ	clinical
manifestations	NNS	manifestation
such	JJ	such
as	IN	as
thromboembolic	JJ	thromboembolic
events	NNS	event
have	VBP	have
been	VBN	be
shown	VBN	show
to	TO	to
occur	VB	occur
with	IN	with
or	CC	or
without	IN	without
respiratory	JJ	respiratory
tract	NN	tract
involvement	NN	involvement
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
case	NN	case
of	IN	of
a	DT	a
21-year-old	JJ	21-year-old
gravid	JJ	gravid
3	CD	@card@
,	,	,
live	RB	live
1	CD	@card@
,	,	,
abortion	NN	abortion
1	CD	@card@
Iranian	JJ	Iranian
woman	NN	woman
pregnant	JJ	pregnant
with	IN	with
twins	NNS	twin
in	IN	in
her	PP$	her
early	JJ	early
first	JJ	first
trimester	NN	trimester
.	SENT	.
Her	PP$	her
initial	JJ	initial
chief	JJ	chief
complaint	NN	complaint
was	VBD	be
headache	NN	headache
that	IN	that
gradually	RB	gradually
increased	VBN	increase
in	IN	in
intensity	NN	intensity
.	SENT	.
Eventually	RB	eventually
,	,	,
cerebral	JJ	cerebral
vein	NN	vein
thrombosis	NN	thrombosis
was	VBD	be
confirmed	VBN	confirm
.	SENT	.
Although	IN	although
the	DT	the
patient	NN	patient
first	RB	first
manifested	VBN	manifest
with	IN	with
neurological	JJ	neurological
involvement	NN	involvement
,	,	,
she	PP	she
developed	VBD	develop
upper	JJ	upper
respiratory	JJ	respiratory
symptoms	NNS	symptom
soon	RB	soon
after	RB	after
,	,	,
and	CC	and
then	RB	then
nasopharyngeal	JJ	nasopharyngeal
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
test	NN	test
returned	VBD	return
positive	JJ	positive
.	SENT	.
Any	DT	any
neurological	JJ	neurological
complaints	NNS	complaint
in	IN	in
pregnant	JJ	pregnant
women	NNS	woman
during	IN	during
the	DT	the
current	JJ	current
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
pandemic	NN	pandemic
should	MD	should
raise	VB	raise
suspicion	NN	suspicion
for	IN	for
the	DT	the
presence	NN	presence
of	IN	of
significant	JJ	significant
cerebral	JJ	cerebral
thrombotic	JJ	thrombotic
or	CC	or
ischemic	JJ	ischemic
events	NNS	event
,	,	,
even	RB	even
if	IN	if
the	DT	the
patient	NN	patient
has	VBZ	have
no	DT	no
complaint	NN	complaint
of	IN	of
respiratory	JJ	respiratory
tract	NN	tract
involvement	NN	involvement
and/or	CC	and/or
when	WRB	when
an	DT	an
initial	JJ	initial
nasopharyngeal	JJ	nasopharyngeal
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
test	NN	test
is	VBZ	be
negative	JJ	negative
.	SENT	.
33071434/	CD	@card@
The	DT	the
market-reach	NN	market-reach
of	IN	of
pandemics	NNS	pandemic
:	:	:
Evidence	NN	evidence
from	IN	from
female	JJ	female
workers	NNS	worker
in	IN	in
Ethiopia	NP	Ethiopia
's	POS	's
ready-made	JJ	ready-made
garment	NN	garment
industry	NN	industry
The	DT	the
employment	NN	employment
of	IN	of
female	JJ	female
workers	NNS	worker
in	IN	in
Ethiopia	NP	Ethiopia
's	POS	's
garment	NN	garment
industry	NN	industry
has	VBZ	have
changed	VBN	change
dramatically	RB	dramatically
due	JJ	due
to	TO	to
a	DT	a
sharp	JJ	sharp
drop	NN	drop
in	IN	in
demand	NN	demand
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
In	IN	in
our	PP$	our
sample	NN	sample
,	,	,
41	CD	@card@
percent	NN	percent
of	IN	of
respondents	NNS	respondent
employed	VBN	employ
in	IN	in
January	NP	January
2020	CD	@card@
were	VBD	be
put	VBN	put
on	IN	on
leave	NN	leave
or	CC	or
terminated	VBN	terminate
by	IN	by
the	DT	the
time	NN	time
of	IN	of
our	PP$	our
survey	NN	survey
a	DT	a
few	JJ	few
months	NNS	month
later	RBR	later
.	SENT	.
Migration	NN	migration
appears	VBZ	appear
to	TO	to
be	VB	be
a	DT	a
major	JJ	major
coping	VBG	cope
mechanism	NN	mechanism
,	,	,
but	CC	but
many	JJ	many
respondents	NNS	respondent
report	NN	report
barriers	NNS	barrier
.	SENT	.
Most	RBS	most
who	WP	who
have	VBP	have
left	VBN	leave
the	DT	the
city	NN	city
desire	NN	desire
to	TO	to
return	VB	return
if	IN	if
possible	JJ	possible
.	SENT	.
Levels	NNS	level
of	IN	of
food	NN	food
insecurity	NN	insecurity
are	VBP	be
high	JJ	high
;	:	;
rates	NNS	rate
are	VBP	be
higher	JJR	high
for	IN	for
those	DT	those
currently	RB	currently
still	RB	still
in	IN	in
the	DT	the
city	NN	city
where	WRB	where
garment	NN	garment
industry	NN	industry
jobs	NNS	job
are	VBP	be
located	VBN	locate
.	SENT	.
Respondents	NNS	respondent
are	VBP	be
well	RB	well
informed	VBN	inform
about	IN	about
COVID-19	NP	<unknown>
;	:	;
false	JJ	false
beliefs	NNS	belief
or	CC	or
myths	NNS	myth
appear	VBP	appear
to	TO	to
be	VB	be
extremely	RB	extremely
uncommon	JJ	uncommon
.	SENT	.
In	IN	in
a	DT	a
globalized	VBN	globalize
world	NN	world
,	,	,
pandemics	NNS	pandemic
transmit	VBP	transmit
impacts	NNS	impact
through	IN	through
markets	NNS	market
.	SENT	.
We	PP	we
document	VBP	document
employment	NN	employment
changes	NNS	change
,	,	,
coping	VBG	cope
strategies	NNS	strategy
,	,	,
and	CC	and
welfare	NN	welfare
of	IN	of
garment	NN	garment
factory	NN	factory
workers	NNS	worker
in	IN	in
Ethiopia	NP	Ethiopia
's	POS	's
largest	JJS	large
industrial	JJ	industrial
park	NN	park
during	IN	during
the	DT	the
early	JJ	early
stages	NNS	stage
of	IN	of
the	DT	the
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
pandemic	NN	pandemic
.	SENT	.
We	PP	we
field	VBP	field
a	DT	a
phone	NN	phone
survey	NN	survey
of	IN	of
female	JJ	female
workers	NNS	worker
during	IN	during
a	DT	a
two	CD	two
month	NN	month
period	NN	period
in	IN	in
which	WDT	which
cases	NNS	case
are	VBP	be
rapidly	RB	rapidly
rising	VBG	rise
globally	RB	globally
,	,	,
but	CC	but
not	RB	not
locally	RB	locally
.	SENT	.
Our	PP$	our
data	NNS	datum
suggest	VBP	suggest
significant	JJ	significant
changes	NNS	change
in	IN	in
employment	NN	employment
,	,	,
high	JJ	high
levels	NNS	level
of	IN	of
migration	NN	migration
away	RB	away
from	IN	from
urban	JJ	urban
areas	NNS	area
to	TO	to
rural	JJ	rural
areas	NNS	area
if	IN	if
women	NNS	woman
are	VBP	be
no	RB	no
longer	RBR	longer
working	JJ	working
,	,	,
and	CC	and
high	JJ	high
levels	NNS	level
of	IN	of
food	NN	food
insecurity	NN	insecurity
.	SENT	.
These	DT	these
findings	NNS	finding
compel	VBP	compel
a	DT	a
research	NN	research
and	CC	and
policy	NN	policy
focus	NN	focus
on	IN	on
documenting	VBG	document
and	CC	and
mitigating	VBG	mitigate
the	DT	the
market-reach	NN	market-reach
of	IN	of
pandemics	NNS	pandemic
on	IN	on
low-income	JJ	low-income
workers	NNS	worker
at	IN	at
the	DT	the
margins	NNS	margin
.	SENT	.
33779211/	CD	@card@
Effectively	RB	effectively
confronting	VBG	confront
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
Critical	JJ	critical
lessons	NNS	lesson
from	IN	from
HIV	NP	HIV
prevention	NN	prevention
,	,	,
care	NN	care
,	,	,
and	CC	and
treatment	NN	treatment
and	CC	and
innovative	JJ	innovative
strategies	NNS	strategy
to	TO	to
conduct	VB	conduct
community-based	JJ	community-based
and	CC	and
community-engaged	JJ	community-engaged
research	NN	research
safely	RB	safely
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
a	DT	a
new	JJ	new
infectious	JJ	infectious
disease	NN	disease
caused	VBN	cause
by	IN	by
the	DT	the
novel	JJ	novel
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
profoundly	RB	profoundly
altered	VBN	alter
the	DT	the
ways	NNS	way
in	IN	in
which	WDT	which
members	NNS	member
of	IN	of
communities	NNS	community
live	VBP	live
,	,	,
learn	VB	learn
,	,	,
work	VB	work
,	,	,
and	CC	and
play	NN	play
.	SENT	.
Similarly	RB	similarly
,	,	,
the	DT	the
pandemic	NN	pandemic
has	VBZ	have
affected	VBN	affect
the	DT	the
conduct	NN	conduct
of	IN	of
community-based	JJ	community-based
and	CC	and
community-engaged	JJ	community-engaged
research	NN	research
,	,	,
which	WDT	which
are	VBP	be
essential	JJ	essential
research	NN	research
approaches	VBZ	approach
to	TO	to
promoting	VBG	promote
health	NN	health
equity	NN	equity
,	,	,
reducing	VBG	reduce
health	NN	health
disparities	NNS	disparity
,	,	,
and	CC	and
improving	VBG	improve
community	NN	community
and	CC	and
population	NN	population
health	NN	health
.	SENT	.
In	IN	in
this	DT	this
commentary	NN	commentary
,	,	,
we	PP	we
outline	VBP	outline
nine	CD	nine
lessons	NNS	lesson
from	IN	from
HIV	NP	HIV
prevention	NN	prevention
,	,	,
care	NN	care
,	,	,
and	CC	and
treatment	NN	treatment
that	WDT	that
are	VBP	be
particularly	RB	particularly
relevant	JJ	relevant
to	TO	to
reducing	VBG	reduce
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
We	PP	we
also	RB	also
identify	VBP	identify
ten	CD	ten
innovative	JJ	innovative
strategies	NNS	strategy
to	TO	to
reduce	VB	reduce
exposure	NN	exposure
to	TO	to
SARS-CoV-2	NP	<unknown>
among	IN	among
teams	NNS	team
and	CC	and
community	NN	community
members	NNS	member
conducting	VBG	conduct
community-based	JJ	community-based
and	CC	and
community-engaged	JJ	community-engaged
research	NN	research
.	SENT	.
Implementation	NN	implementation
of	IN	of
these	DT	these
strategies	NNS	strategy
will	MD	will
help	VB	help
to	TO	to
ensure	VB	ensure
these	DT	these
research	NN	research
approaches	NNS	approach
can	MD	can
safely	RB	safely
continue	VB	continue
during	IN	during
the	DT	the
pandemic	NN	pandemic
and	CC	and
that	IN	that
communities	NNS	community
and	CC	and
populations	NNS	population
continue	VBP	continue
to	TO	to
benefit	VB	benefit
from	IN	from
research	NN	research
designed	VBN	design
to	TO	to
promote	VB	promote
equity	NN	equity
,	,	,
reduce	VB	reduce
disparities	NNS	disparity
,	,	,
and	CC	and
improve	VB	improve
health	NN	health
.	SENT	.
34253291/	CD	@card@
Lives	NNS	life
saved	VBN	save
with	IN	with
vaccination	NN	vaccination
for	IN	for
10	CD	@card@
pathogens	NNS	pathogen
across	IN	across
112	CD	@card@
countries	NNS	country
in	IN	in
a	DT	a
pre-COVID-19	JJ	<unknown>
world	NN	world
Vaccination	NN	vaccination
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
most	RBS	most
effective	JJ	effective
public	JJ	public
health	NN	health
interventions	NNS	intervention
.	SENT	.
We	PP	we
investigate	VBP	investigate
the	DT	the
impact	NN	impact
of	IN	of
vaccination	NN	vaccination
activities	NNS	activity
for	IN	for
Haemophilus	NP	<unknown>
influenzae	NP	influenzae
type	NN	type
b	NN	b
,	,	,
hepatitis	NP	hepatitis
B	NP	B
,	,	,
human	JJ	human
papillomavirus	NN	papillomavirus
,	,	,
Japanese	JJ	Japanese
encephalitis	NN	encephalitis
,	,	,
measles	NN	measles
,	,	,
Neisseria	NP	<unknown>
meningitidis	NP	<unknown>
serogroup	NP	serogroup
A	NP	A
,	,	,
rotavirus	NN	rotavirus
,	,	,
rubella	NN	rubella
,	,	,
Streptococcus	NN	streptococcus
pneumoniae	NNS	<unknown>
,	,	,
and	CC	and
yellow	JJ	yellow
fever	NN	fever
over	IN	over
the	DT	the
years	NNS	year
2000-2030	CD	@card@
across	IN	across
112	CD	@card@
countries	NNS	country
.	SENT	.
Twenty-one	NN	twenty-one
mathematical	JJ	mathematical
models	NNS	model
estimated	VBD	estimate
disease	NN	disease
burden	NN	burden
using	VBG	use
standardised	VBN	standardise
demographic	JJ	demographic
and	CC	and
immunisation	NN	immunisation
data	NNS	datum
.	SENT	.
Impact	NN	impact
was	VBD	be
attributed	VBN	attribute
to	TO	to
the	DT	the
year	NN	year
of	IN	of
vaccination	NN	vaccination
through	IN	through
vaccine-activity-stratified	JJ	<unknown>
impact	NN	impact
ratios	NNS	ratio
.	SENT	.
We	PP	we
estimate	VBP	estimate
97	NP	@card@
(	(	(
95%CrI[80	NP	<unknown>
,	,	,
120	CD	@card@
]	SYM	]
)	)	)
million	CD	million
deaths	NNS	death
would	MD	would
be	VB	be
averted	VBN	avert
due	RB	due
to	TO	to
vaccination	NN	vaccination
activities	NNS	activity
over	IN	over
2000-2030	CD	@card@
,	,	,
with	IN	with
50	CD	@card@
(	(	(
95%CrI[41	NN	<unknown>
,	,	,
62	CD	@card@
]	SYM	]
)	)	)
million	CD	million
deaths	NNS	death
averted	VBN	avert
by	IN	by
activities	NNS	activity
between	IN	between
2000	CD	@card@
and	CC	and
2019	CD	@card@
.	SENT	.
For	IN	for
children	NNS	child
under-5	NN	<unknown>
born	VBN	bear
between	IN	between
2000	CD	@card@
and	CC	and
2030	CD	@card@
,	,	,
we	PP	we
estimate	VBP	estimate
52	CD	@card@
(	(	(
95%CrI[41	NN	<unknown>
,	,	,
69	CD	@card@
]	SYM	]
)	)	)
million	CD	million
more	JJR	more
deaths	NNS	death
would	MD	would
occur	VB	occur
over	RP	over
their	PP$	their
lifetimes	NNS	lifetime
without	IN	without
vaccination	NN	vaccination
against	IN	against
these	DT	these
diseases	NNS	disease
.	SENT	.
This	DT	this
study	NN	study
represents	VBZ	represent
the	DT	the
largest	JJS	large
assessment	NN	assessment
of	IN	of
vaccine	NN	vaccine
impact	NN	impact
before	IN	before
COVID-19-related	JJ	COVID-19-related
disruptions	NNS	disruption
and	CC	and
provides	VBZ	provide
motivation	NN	motivation
for	IN	for
sustaining	VBG	sustain
and	CC	and
improving	VBG	improve
global	JJ	global
vaccination	NN	vaccination
coverage	NN	coverage
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
VIMC	NP	<unknown>
is	VBZ	be
jointly	RB	jointly
funded	VBN	fund
by	IN	by
Gavi	NP	<unknown>
,	,	,
the	DT	the
Vaccine	NN	vaccine
Alliance	NP	Alliance
,	,	,
and	CC	and
the	DT	the
Bill	NP	Bill
and	CC	and
Melinda	NP	Melinda
Gates	NP	Gates
Foundation	NP	Foundation
(	(	(
BMGF	NP	<unknown>
)	)	)
(	(	(
BMGF	NP	<unknown>
grant	NN	grant
number	NN	number
:	:	:
OPP1157270	NP	OPP@card@
/	SYM	/
INV-009125	NN	<unknown>
)	)	)
.	SENT	.
Funding	NN	funding
from	IN	from
Gavi	NP	<unknown>
is	VBZ	be
channelled	VBN	channel
via	IN	via
VIMC	NP	<unknown>
to	TO	to
the	DT	the
Consortium	NP	Consortium
's	POS	's
modelling	VBG	model
groups	NNS	group
(	(	(
VIMC-funded	JJ	VIMC-funded
institutions	NNS	institution
represented	VBN	represent
in	IN	in
this	DT	this
paper	NN	paper
:	:	:
Imperial	NP	Imperial
College	NP	College
London	NP	London
,	,	,
London	NP	London
School	NP	School
of	IN	of
Hygiene	NN	hygiene
and	CC	and
Tropical	JJ	tropical
Medicine	NN	medicine
,	,	,
Oxford	NP	Oxford
University	NP	University
Clinical	JJ	clinical
Research	NP	Research
Unit	NP	Unit
,	,	,
Public	NP	Public
Health	NP	Health
England	NP	England
,	,	,
Johns	NP	Johns
Hopkins	NP	Hopkins
University	NP	University
,	,	,
The	DT	the
Pennsylvania	NP	Pennsylvania
State	NP	State
University	NP	University
,	,	,
Center	NP	Center
for	IN	for
Disease	NP	Disease
Analysis	NP	Analysis
Foundation	NP	Foundation
,	,	,
Kaiser	NP	Kaiser
Permanente	NP	Permanente
Washington	NP	Washington
,	,	,
University	NP	University
of	IN	of
Cambridge	NP	Cambridge
,	,	,
University	NP	University
of	IN	of
Notre	NP	Notre
Dame	NP	Dame
,	,	,
Harvard	NP	Harvard
University	NP	University
,	,	,
Conservatoire	NN	conservatoire
National	NP	National
des	FW	des
Arts	NP	Arts
et	FW	et
Metiers	NP	<unknown>
,	,	,
Emory	NP	Emory
University	NP	University
,	,	,
National	NP	National
University	NP	University
of	IN	of
Singapore	NP	Singapore
)	)	)
.	SENT	.
Funding	NN	funding
from	IN	from
BMGF	NP	<unknown>
was	VBD	be
used	VBN	use
for	IN	for
salaries	NNS	salary
of	IN	of
the	DT	the
Consortium	NP	Consortium
secretariat	NN	secretariat
(	(	(
authors	NNS	author
represented	VBN	represent
here	RB	here
:	:	:
TBH	NP	TBH
,	,	,
MJ	NP	MJ
,	,	,
XL	NP	XL
,	,	,
SE-L	NP	<unknown>
,	,	,
JT	NP	JT
,	,	,
KW	NP	KW
,	,	,
NMF	NP	NMF
,	,	,
KAMG	NP	<unknown>
)	)	)
;	:	;
and	CC	and
channelled	VBN	channel
via	IN	via
VIMC	NP	<unknown>
for	IN	for
travel	NN	travel
and	CC	and
subsistence	NN	subsistence
costs	NNS	cost
of	IN	of
all	DT	all
Consortium	NP	Consortium
members	NNS	member
(	(	(
all	DT	all
authors	NNS	author
)	)	)
.	SENT	.
We	PP	we
also	RB	also
acknowledge	VBP	acknowledge
funding	NN	funding
from	IN	from
the	DT	the
UK	NP	UK
Medical	NP	Medical
Research	NP	Research
Council	NP	Council
and	CC	and
Department	NP	Department
for	IN	for
International	NP	International
Development	NP	Development
,	,	,
which	WDT	which
supported	VBD	support
aspects	NNS	aspect
of	IN	of
VIMC	NP	<unknown>
's	POS	's
work	NN	work
(	(	(
MRC	NP	MRC
grant	NN	grant
number	NN	number
:	:	:
MR/R015600/1	NP	MR/R@card@
)	)	)
.	SENT	.
JHH	NP	JHH
acknowledges	VBZ	acknowledge
funding	NN	funding
from	IN	from
National	NP	National
Science	NP	Science
Foundation	NP	Foundation
Graduate	NP	Graduate
Research	NP	Research
Fellowship	NN	fellowship
;	:	;
Richard	NP	Richard
and	CC	and
Peggy	NP	Peggy
Notebaert	NP	<unknown>
Premier	NP	Premier
Fellowship	NN	fellowship
from	IN	from
the	DT	the
University	NP	University
of	IN	of
Notre	NP	Notre
Dame	NP	Dame
.	SENT	.
BAL	NP	Bal
acknowledges	VBZ	acknowledge
funding	NN	funding
from	IN	from
NIH/NIGMS	NP	<unknown>
(	(	(
grant	NN	grant
number	NN	number
R01	NP	R@card@
GM124280	NP	GM@card@
)	)	)
and	CC	and
NIH/NIAID	NP	NIH/NIAID
(	(	(
grant	NN	grant
number	NN	number
R01	NP	R@card@
AI112970	NP	AI@card@
)	)	)
.	SENT	.
The	DT	the
Lives	NNS	life
Saved	VBN	save
Tool	NP	Tool
(	(	(
LiST	NN	list
)	)	)
receives	VBZ	receive
funding	NN	funding
support	NN	support
from	IN	from
the	DT	the
Bill	NP	Bill
and	CC	and
Melinda	NP	Melinda
Gates	NP	Gates
Foundation	NP	Foundation
.	SENT	.
This	DT	this
paper	NN	paper
was	VBD	be
compiled	VBN	compile
by	IN	by
all	DT	all
coauthors	NNS	coauthor
,	,	,
including	VBG	include
two	CD	two
coauthors	NNS	coauthor
from	IN	from
Gavi	NP	<unknown>
.	SENT	.
Other	JJ	other
funders	NNS	funder
had	VBD	have
no	DT	no
role	NN	role
in	IN	in
study	NN	study
design	NN	design
,	,	,
data	NNS	datum
collection	NN	collection
,	,	,
data	NNS	datum
analysis	NN	analysis
,	,	,
data	NNS	datum
interpretation	NN	interpretation
,	,	,
or	CC	or
writing	VBG	write
of	IN	of
the	DT	the
report	NN	report
.	SENT	.
All	DT	all
authors	NNS	author
had	VBD	have
full	JJ	full
access	NN	access
to	TO	to
all	DT	all
the	DT	the
data	NNS	datum
in	IN	in
the	DT	the
study	NN	study
and	CC	and
had	VBD	have
final	JJ	final
responsibility	NN	responsibility
for	IN	for
the	DT	the
decision	NN	decision
to	TO	to
submit	VB	submit
for	IN	for
publication	NN	publication
.	SENT	.
34274539/	CD	@card@
The	DT	the
mechanism	NN	mechanism
behind	IN	behind
flaring/triggering	VBG	flaring/trigger
of	IN	of
autoimmunity	NN	autoimmunity
disorders	NNS	disorder
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
33955567/	CD	@card@
The	DT	the
BNT162b2	NN	<unknown>
vaccine	NN	vaccine
is	VBZ	be
associated	VBN	associate
with	IN	with
lower	JJR	low
new	JJ	new
COVID-19	NP	<unknown>
cases	NNS	case
in	IN	in
nursing	VBG	nurse
home	NN	home
residents	NNS	resident
and	CC	and
staff	VB	staff
The	DT	the
effectiveness	NN	effectiveness
of	IN	of
the	DT	the
BNT162b2	NP	<unknown>
vaccine	NN	vaccine
on	IN	on
preventing	VBG	prevent
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
deaths	NNS	death
in	IN	in
nursing	NN	nursing
homes	NNS	home
(	(	(
NH	NP	NH
)	)	)
is	VBZ	be
unknown	JJ	unknown
.	SENT	.
We	PP	we
used	VBD	use
zero-inflated	JJ	zero-inflated
negative	JJ	negative
binomial	JJ	binomial
mixed	JJ	mixed
effects	NNS	effect
regressions	NNS	regression
to	TO	to
model	VB	model
the	DT	the
associations	NNS	association
of	IN	of
time	NN	time
since	IN	since
the	DT	the
vaccine	NN	vaccine
clinic	NN	clinic
ending	VBG	end
the	DT	the
week	NN	week
of	IN	of
December	NP	December
27	CD	@card@
,	,	,
2020	CD	@card@
(	(	(
cohort	NN	cohort
1	CD	@card@
)	)	)
,	,	,
January	NP	January
3	CD	@card@
,	,	,
2021	CD	@card@
(	(	(
cohort	NN	cohort
2	CD	@card@
)	)	)
,	,	,
or	CC	or
January	NP	January
10	CD	@card@
,	,	,
2021	CD	@card@
(	(	(
cohort	NN	cohort
3	CD	@card@
)	)	)
controlling	VBG	control
for	IN	for
county	NN	county
rate	NN	rate
of	IN	of
COVID-19	NP	<unknown>
,	,	,
bed	NN	bed
size	NN	size
,	,	,
urban	JJ	urban
location	NN	location
,	,	,
racial	JJ	racial
and	CC	and
ethnic	JJ	ethnic
census	NN	census
,	,	,
and	CC	and
level	NN	level
of	IN	of
registered	JJ	registered
nurses	NNS	nurse
with	IN	with
resident	JJ	resident
cases	NNS	case
and	CC	and
deaths	NNS	death
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
staff	NN	staff
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
All	DT	all
2501	CD	@card@
NHs	NPS	<unknown>
who	WP	who
held	VBD	hold
a	DT	a
vaccine	NN	vaccine
clinic	NN	clinic
from	IN	from
the	DT	the
first	JJ	first
17	CD	@card@
states	NNS	state
to	TO	to
initiate	VB	initiate
clinics	NNS	clinic
as	IN	as
part	NN	part
of	IN	of
the	DT	the
Pharmacy	NP	Pharmacy
Partnership	NP	Partnership
for	IN	for
Long-Term	NP	Long-Term
Care	NP	Care
Program	NP	Program
.	SENT	.
Adjusted	JJ	adjusted
Incidence	NN	incidence
Rate	NN	rate
Ratio	NN	ratio
(	(	(
IRR	NP	IRR
)	)	)
for	IN	for
time	NN	time
in	IN	in
3	CD	@card@
,	,	,
4	CD	@card@
,	,	,
5	CD	@card@
,	,	,
and	CC	and
6	CD	@card@
weeks	NNS	week
after	IN	after
the	DT	the
first	JJ	first
vaccine	NN	vaccine
clinic	NN	clinic
for	IN	for
resident	JJ	resident
cases	NNS	case
and	CC	and
deaths	NNS	death
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
staff	NN	staff
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
Resident	NN	resident
and	CC	and
staff	NN	staff
cases	NNS	case
trended	VBD	trend
downward	RB	downward
in	IN	in
all	DT	all
three	CD	three
cohorts	NNS	cohort
following	VBG	follow
the	DT	the
vaccine	NN	vaccine
clinics	NNS	clinic
.	SENT	.
Time	NN	time
following	VBG	follow
the	DT	the
first	JJ	first
clinic	NN	clinic
at	IN	at
5	CD	@card@
and	CC	and
6	CD	@card@
weeks	NNS	week
was	VBD	be
consistently	RB	consistently
associated	VBN	associate
with	IN	with
fewer	JJR	few
resident	JJ	resident
cases	NNS	case
(	(	(
IRR	NP	IRR
:	:	:
0.68	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.54-0.84	CD	@card@
]	SYM	]
,	,	,
IRR	NP	IRR
:	:	:
0.64	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.48-0.86	CD	@card@
]	SYM	]
,	,	,
respectively	RB	respectively
)	)	)
;	:	;
resident	JJ	resident
deaths	NNS	death
(	(	(
IRR	NP	IRR
:	:	:
0.59	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.45-0.77	CD	@card@
]	SYM	]
,	,	,
IRR	NP	IRR
:	:	:
0.45	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.31-0.65	CD	@card@
]	SYM	]
,	,	,
respectively	RB	respectively
)	)	)
;	:	;
and	CC	and
staff	NN	staff
cases	NNS	case
(	(	(
IRR	NP	IRR
:	:	:
0.64	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.56-0.73	CD	@card@
]	SYM	]
,	,	,
IRR	NP	IRR
:	:	:
0.51	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.42-0.62	CD	@card@
]	SYM	]
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
Other	JJ	other
factors	NNS	factor
associated	VBN	associate
with	IN	with
fewer	JJR	few
resident	NN	resident
and	CC	and
staff	NN	staff
cases	NNS	case
included	VBD	include
facilities	NNS	facility
with	IN	with
less	JJR	less
than	IN	than
50	CD	@card@
certified	JJ	certified
beds	NNS	bed
and	CC	and
high	JJ	high
nurse	NN	nurse
staffing	NN	staffing
per	IN	per
resident	JJ	resident
day	NN	day
(	(	(
&gt	NP	<unknown>
;	:	;
0.987	LS	@card@
)	)	)
.	SENT	.
Contrary	JJ	contrary
to	TO	to
prior	JJ	prior
research	NN	research
,	,	,
higher	JJR	high
Hispanic	JJ	Hispanic
non-white	JJ	non-white
resident	NN	resident
census	NN	census
was	VBD	be
associated	VBN	associate
with	IN	with
fewer	JJR	few
resident	JJ	resident
cases	NNS	case
(	(	(
IRR	NP	IRR
:	:	:
0.42	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.31-0.56	LS	@card@
)	)	)
and	CC	and
deaths	NNS	death
(	(	(
IRR	NP	IRR
:	:	:
0.18	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.12-0.27	LS	@card@
)	)	)
.	SENT	.
The	DT	the
BNT162b2	NP	<unknown>
vaccine	NN	vaccine
is	VBZ	be
associated	VBN	associate
with	IN	with
decreased	VBN	decrease
spread	NN	spread
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
both	DT	both
residents	NNS	resident
and	CC	and
staff	NN	staff
as	RB	as
well	RB	well
as	IN	as
decreased	VBN	decrease
deaths	NNS	death
among	IN	among
residents	NNS	resident
.	SENT	.
See	VB	see
related	JJ	related
editorial	NN	editorial
by	IN	by
Ouslander	NP	Ouslander
et	CC	et
al	NP	al
and	CC	and
related	JJ	related
articles	NNS	article
by	IN	by
Mor	NP	Mor
et	NP	et
al	NP	al
,	,	,
Moore	NP	Moore
et	CC	et
al	NP	al
,	,	,
and	CC	and
Rudolph	NP	Rudolph
et	FW	et
al.	FW	al.
32776524/	CD	@card@
A	DT	a
survey	NN	survey
on	IN	on
burnout	NNS	burnout
and	CC	and
depression	NN	depression
risk	NN	risk
among	IN	among
anaesthetists	NNS	anaesthetist
during	IN	during
COVID-19	NP	<unknown>
:	:	:
the	DT	the
tip	NN	tip
of	IN	of
an	DT	an
iceberg	NN	iceberg
?	SENT	?
34812845/	CD	@card@
Seroprevalence	NN	Seroprevalence
of	IN	of
SARS-CoV-2	JJ	<unknown>
Antibodies	NNS	antibody
Among	IN	among
Children	NNS	child
in	IN	in
School	NP	School
and	CC	and
Day	NP	Day
Care	NP	Care
in	IN	in
Montreal	NP	Montreal
,	,	,
Canada	NP	Canada
What	WP	what
is	VBZ	be
the	DT	the
seroprevalence	NN	seroprevalence
of	IN	of
SARS-CoV-2	JJ	<unknown>
antibodies	NNS	antibody
in	IN	in
a	DT	a
convenience	NN	convenience
sample	NN	sample
of	IN	of
children	NNS	child
aged	VBN	age
2	CD	@card@
to	TO	to
17	CD	@card@
years	NNS	year
in	IN	in
Montreal	NP	Montreal
,	,	,
Canada	NP	Canada
,	,	,
enrolled	VBN	enroll
between	IN	between
October	NP	October
2020	CD	@card@
and	CC	and
March	NP	March
2021	CD	@card@
?	SENT	?
In	IN	in
this	DT	this
cohort	NN	cohort
study	NN	study
of	IN	of
1632	CD	@card@
participants	NNS	participant
,	,	,
the	DT	the
mean	JJ	mean
baseline	NN	baseline
seroprevalence	NN	seroprevalence
of	IN	of
SARS-CoV-2	NP	<unknown>
was	VBD	be
5.8	CD	@card@
%	NN	%
.	SENT	.
Of	IN	of
the	DT	the
95	CD	@card@
participants	NNS	participant
who	WP	who
were	VBD	be
seropositive	JJ	seropositive
for	IN	for
SARS-CoV-2	NP	<unknown>
antibodies	NNS	antibody
,	,	,
82	CD	@card@
%	NN	%
were	VBD	be
not	RB	not
tested	VBN	test
or	CC	or
tested	VBN	test
negative	JJ	negative
,	,	,
and	CC	and
all	DT	all
experienced	JJ	experienced
either	CC	either
mild	JJ	mild
or	CC	or
no	DT	no
clinical	JJ	clinical
symptoms	NNS	symptom
.	SENT	.
The	DT	the
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
there	EX	there
was	VBD	be
more	JJR	more
transmission	NN	transmission
occurring	VBG	occur
in	IN	in
children	NNS	child
compared	VBN	compare
with	IN	with
what	WP	what
was	VBD	be
being	VBG	be
detected	VBN	detect
,	,	,
although	IN	although
children	NNS	child
experienced	VBN	experience
few	JJ	few
or	CC	or
mild	JJ	mild
symptoms	NNS	symptom
.	SENT	.
This	DT	this
cohort	NN	cohort
study	NN	study
estimates	VBZ	estimate
the	DT	the
seroprevalence	NN	seroprevalence
of	IN	of
SARS-CoV-2	JJ	<unknown>
antibodies	NNS	antibody
in	IN	in
children	NNS	child
and	CC	and
teenagers	NNS	teenager
in	IN	in
4	CD	@card@
neighborhoods	NNS	neighborhood
of	IN	of
Montreal	NP	Montreal
,	,	,
Canada	NP	Canada
.	SENT	.
Quebec	NP	Quebec
prioritized	JJ	<unknown>
in-person	NN	in-person
learning	VBG	learn
after	IN	after
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
with	IN	with
school	NN	school
closures	NNS	closure
being	VBG	be
implemented	VBN	implement
temporarily	RB	temporarily
in	IN	in
selected	JJ	selected
schools	NNS	school
or	CC	or
in	IN	in
hot-spot	NN	<unknown>
areas	NNS	area
.	SENT	.
Quebec	NP	Quebec
's	POS	's
decision	NN	decision
to	TO	to
keep	VB	keep
most	JJS	most
schools	NNS	school
open	RB	open
was	VBD	be
controversial	JJ	controversial
,	,	,
especially	RB	especially
in	IN	in
Montreal	NP	Montreal
,	,	,
which	WDT	which
was	VBD	be
the	DT	the
epicenter	NN	epicenter
of	IN	of
Canada	NP	Canada
's	POS	's
first	JJ	first
and	CC	and
second	JJ	second
waves	NNS	wave
;	:	;
therefore	RB	therefore
,	,	,
understanding	VBG	understand
the	DT	the
extent	NN	extent
to	TO	to
which	WDT	which
children	NNS	child
were	VBD	be
infected	VBN	infect
with	IN	with
SARS-CoV-2	NP	<unknown>
provides	VBZ	provide
important	JJ	important
information	NN	information
for	IN	for
decisions	NNS	decision
about	IN	about
school	NN	school
closures	NNS	closure
.	SENT	.
To	TO	to
estimate	VB	estimate
the	DT	the
seroprevalence	NN	seroprevalence
of	IN	of
SARS-CoV-2	JJ	<unknown>
antibodies	NNS	antibody
in	IN	in
children	NNS	child
and	CC	and
teenagers	NNS	teenager
in	IN	in
4	CD	@card@
neighborhoods	NNS	neighborhood
of	IN	of
Montreal	NP	Montreal
,	,	,
Canada	NP	Canada
.	SENT	.
This	DT	this
cohort	NN	cohort
study	NN	study
(	(	(
the	DT	the
Enfants	NP	Enfants
et	NP	et
COVID-19	NP	<unknown>
:	:	:
Etude	NP	<unknown>
de	NP	de
seroprevalence	NP	seroprevalence
[	SYM	[
EnCORE	NN	encore
]	SYM	]
study	NN	study
)	)	)
enrolled	VBD	enroll
a	DT	a
convenience	NN	convenience
sample	NN	sample
of	IN	of
children	NNS	child
aged	VBN	age
2	CD	@card@
to	TO	to
17	CD	@card@
years	NNS	year
between	IN	between
October	NP	October
22	CD	@card@
,	,	,
2020	CD	@card@
,	,	,
and	CC	and
March	NP	March
22	CD	@card@
,	,	,
2021	CD	@card@
,	,	,
in	IN	in
Montreal	NP	Montreal
,	,	,
Canada	NP	Canada
.	SENT	.
Potential	JJ	potential
exposure	NN	exposure
to	TO	to
SARS-CoV-2	NP	<unknown>
.	SENT	.
The	DT	the
main	JJ	main
outcome	NN	outcome
was	VBD	be
seroprevalence	NN	seroprevalence
of	IN	of
SARS-CoV-2	NP	<unknown>
antibodies	NNS	antibody
,	,	,
collected	VBD	collect
using	VBG	use
dried	VBN	dry
blood	NN	blood
spots	NNS	spot
(	(	(
DBSs	NP	<unknown>
)	)	)
and	CC	and
analyzed	VBD	analyze
with	IN	with
a	DT	a
research-based	JJ	research-based
enzyme-linked	JJ	enzyme-linked
immunosorbent	JJ	immunosorbent
assay	NN	assay
(	(	(
ELISA	NP	Elisa
)	)	)
.	SENT	.
Parents	NNS	parent
also	RB	also
completed	VBD	complete
an	DT	an
online	JJ	online
questionnaire	NN	questionnaire
that	WDT	that
included	VBD	include
questions	NNS	question
on	IN	on
self-reported	JJ	self-reported
COVID-19	NP	<unknown>
symptoms	NNS	symptom
and	CC	and
tests	NNS	test
,	,	,
along	RB	along
with	IN	with
sociodemographic	JJ	sociodemographic
questions	NNS	question
.	SENT	.
This	DT	this
study	NN	study
included	VBD	include
1632	CD	@card@
participants	NNS	participant
who	WP	who
provided	VBD	provide
a	DT	a
DBS	NP	DBS
sample	NN	sample
from	IN	from
30	CD	@card@
day	NN	day
cares	VBZ	care
,	,	,
22	CD	@card@
primary	JJ	primary
schools	NNS	school
,	,	,
and	CC	and
11	CD	@card@
secondary	JJ	secondary
schools	NNS	school
.	SENT	.
The	DT	the
mean	JJ	mean
(	(	(
SD	NP	SD
)	)	)
age	NN	age
of	IN	of
the	DT	the
children	NNS	child
who	WP	who
provided	VBD	provide
a	DT	a
DBS	NP	DBS
sample	NN	sample
was	VBD	be
9.0	CD	@card@
(	(	(
4.4	CD	@card@
)	)	)
years	NNS	year
;	:	;
801	CD	@card@
(	(	(
49	CD	@card@
%	NN	%
)	)	)
were	VBD	be
female	JJ	female
individuals	NNS	individual
,	,	,
with	IN	with
354	CD	@card@
participants	NNS	participant
(	(	(
22	CD	@card@
%	NN	%
)	)	)
from	IN	from
day	NN	day
cares	VBZ	care
,	,	,
725	CD	@card@
(	(	(
44	CD	@card@
%	NN	%
)	)	)
from	IN	from
primary	JJ	primary
schools	NNS	school
,	,	,
and	CC	and
553	CD	@card@
(	(	(
34	CD	@card@
%	NN	%
)	)	)
from	IN	from
secondary	JJ	secondary
schools	NNS	school
.	SENT	.
Most	JJS	most
parents	NNS	parent
had	VBD	have
at	IN	at
least	JJS	least
a	DT	a
bachelor	NN	bachelor
's	POS	's
degree	NN	degree
(	(	(
1228	CD	@card@
[	SYM	[
75	CD	@card@
%	NN	%
]	SYM	]
)	)	)
,	,	,
and	CC	and
210	CD	@card@
(	(	(
13	CD	@card@
%	NN	%
)	)	)
self-identified	VBN	self-identify
as	IN	as
being	VBG	be
a	DT	a
racial	JJ	racial
or	CC	or
ethnic	JJ	ethnic
minority	NN	minority
.	SENT	.
The	DT	the
mean	JJ	mean
seroprevalence	NN	seroprevalence
was	VBD	be
5.8	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
4.6%-7.0	CD	@card@
%	NN	%
)	)	)
but	CC	but
increased	VBN	increase
over	IN	over
time	NN	time
from	IN	from
3.2	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.7%-5.8	CD	@card@
%	NN	%
)	)	)
in	IN	in
October	NP	October
to	TO	to
November	NP	November
2020	CD	@card@
to	TO	to
8.4	CD	@card@
%	NN	%
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
4.4%-12.4	CD	@card@
%	NN	%
)	)	)
in	IN	in
March	NP	March
to	TO	to
April	NP	April
2021	CD	@card@
.	SENT	.
Of	IN	of
the	DT	the
95	CD	@card@
children	NNS	child
with	IN	with
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
antibody	NN	antibody
results	NNS	result
,	,	,
78	CD	@card@
(	(	(
82	CD	@card@
%	NN	%
)	)	)
were	VBD	be
not	RB	not
tested	VBN	test
or	CC	or
tested	VBN	test
negative	JJ	negative
with	IN	with
reverse	JJ	reverse
transcription-polymerase	NN	transcription-polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
RT-PCR	NP	<unknown>
)	)	)
testing	NN	testing
,	,	,
and	CC	and
all	DT	all
experienced	JJ	experienced
mild	JJ	mild
(	(	(
49	CD	@card@
[	SYM	[
52	CD	@card@
%	NN	%
]	SYM	]
)	)	)
or	CC	or
no	DT	no
clinical	JJ	clinical
symptoms	NNS	symptom
(	(	(
46	CD	@card@
[	SYM	[
48	CD	@card@
%	NN	%
]	SYM	]
)	)	)
.	SENT	.
The	DT	the
children	NNS	child
of	IN	of
parents	NNS	parent
who	WP	who
self-identified	VBD	self-identify
as	IN	as
belonging	VBG	belong
to	TO	to
a	DT	a
racial	JJ	racial
and	CC	and
ethnic	JJ	ethnic
minority	NN	minority
group	NN	group
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
be	VB	be
seropositive	JJ	seropositive
compared	VBN	compare
with	IN	with
children	NNS	child
of	IN	of
White	NP	White
parents	NNS	parent
(	(	(
adjusted	VBN	adjust
seroprevalence	NN	seroprevalence
ratio	NN	ratio
,	,	,
1.9	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
1.1-2.6	CD	@card@
)	)	)
.	SENT	.
These	DT	these
results	NNS	result
provide	VBP	provide
a	DT	a
benchmark	NN	benchmark
of	IN	of
the	DT	the
seroprevalence	NN	seroprevalence
status	NN	status
in	IN	in
Canadian	JJ	Canadian
children	NNS	child
.	SENT	.
The	DT	the
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
there	EX	there
was	VBD	be
more	JJR	more
transmission	NN	transmission
occurring	VBG	occur
in	IN	in
children	NNS	child
compared	VBN	compare
with	IN	with
what	WP	what
was	VBD	be
being	VBG	be
detected	VBN	detect
by	IN	by
RT-PCR	NP	<unknown>
,	,	,
although	IN	although
children	NNS	child
experienced	VBN	experience
few	JJ	few
or	CC	or
mild	JJ	mild
symptoms	NNS	symptom
.	SENT	.
It	PP	it
will	MD	will
be	VB	be
important	JJ	important
to	TO	to
continue	VB	continue
monitoring	VBG	monitor
the	DT	the
serological	JJ	serological
status	NN	status
of	IN	of
children	NNS	child
,	,	,
particularly	RB	particularly
in	IN	in
the	DT	the
context	NN	context
of	IN	of
new	JJ	new
COVID-19	NP	<unknown>
variants	NNS	variant
of	IN	of
concern	NN	concern
and	CC	and
in	IN	in
the	DT	the
absence	NN	absence
of	IN	of
mass	JJ	mass
vaccination	NN	vaccination
campaigns	NNS	campaign
targeting	VBG	target
young	JJ	young
children	NNS	child
.	SENT	.
32762083/	CD	@card@
Neuropathologic	JJ	Neuropathologic
features	NNS	feature
of	IN	of
four	CD	four
autopsied	JJ	<unknown>
COVID-19	NP	<unknown>
patients	NNS	patient
Published	VBN	publish
descriptions	NNS	description
of	IN	of
the	DT	the
neuropathological	JJ	neuropathological
features	NNS	feature
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
have	VBP	have
been	VBN	be
controversial	JJ	controversial
,	,	,
ranging	VBG	range
from	IN	from
only	RB	only
modest	JJ	modest
or	CC	or
no	DT	no
pathology	NN	pathology
to	TO	to
severe	JJ	severe
hypoxic	JJ	hypoxic
and	CC	and
hemorrhagic	JJ	hemorrhagic
phenotypes	NNS	phenotype
,	,	,
thrombotic	JJ	thrombotic
complications	NNS	complication
,	,	,
acute	JJ	acute
disseminated	VBN	disseminate
encephalomyelitis-like	JJ	<unknown>
changes	NNS	change
,	,	,
and	CC	and
encephalitis	NN	encephalitis
and	CC	and
meningitis	NN	meningitis
.	SENT	.
Here	RB	here
we	PP	we
describe	VBP	describe
the	DT	the
neuropathological	JJ	neuropathological
findings	NNS	finding
of	IN	of
four	CD	four
COVID-19-positive	JJ	COVID-19-positive
patients	NNS	patient
autopsied	VBN	<unknown>
at	IN	at
the	DT	the
Helsinki	NP	Helsinki
University	NP	University
Hospital	NP	Hospital
during	IN	during
the	DT	the
spring	NN	spring
of	IN	of
2020	CD	@card@
.	SENT	.
While	IN	while
three	CD	three
of	IN	of
the	DT	the
patients	NNS	patient
(	(	(
age	NN	age
range	NN	range
63-90	CD	@card@
)	)	)
exhibited	VBD	exhibit
merely	RB	merely
mild	JJ	mild
to	TO	to
moderate	VB	moderate
hypoxia-associated	JJ	hypoxia-associated
changes	NNS	change
,	,	,
one	CD	one
38-year-old	JJ	38-year-old
subject	NN	subject
with	IN	with
obesity	NN	obesity
,	,	,
diabetes	NN	diabetes
(	(	(
type	NN	type
2	CD	@card@
)	)	)
,	,	,
Parkinson	NP	Parkinson
's	POS	's
disease	NN	disease
,	,	,
and	CC	and
a	DT	a
very	RB	very
severe	JJ	severe
clinical	JJ	clinical
course	NN	course
was	VBD	be
found	VBN	find
to	TO	to
have	VB	have
severe	JJ	severe
ischemic	JJ	ischemic
injury	NN	injury
,	,	,
abundant	JJ	abundant
microhemorrhages	NNS	microhemorrhage
and	CC	and
enlarged	JJ	enlarged
perivascular	JJ	perivascular
spaces	NNS	space
most	RBS	most
pronounced	VBN	pronounce
in	IN	in
the	DT	the
white	JJ	white
matter	NN	matter
and	CC	and
deep	JJ	deep
gray	JJ	gray
matter	NN	matter
.	SENT	.
The	DT	the
pattern	NN	pattern
of	IN	of
ischemic	JJ	ischemic
changes	NNS	change
suggested	VBD	suggest
a	DT	a
defect	NN	defect
in	IN	in
microcirculation	NN	microcirculation
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
a	DT	a
few	JJ	few
small	JJ	small
perivascular	JJ	perivascular
white	JJ	white
matter	NN	matter
lesions	NNS	lesion
,	,	,
with	IN	with
macrophages	NNS	macrophage
engulfing	VBG	engulf
myelin	NN	myelin
,	,	,
were	VBD	be
found	VBN	find
.	SENT	.
No	DT	no
signs	NNS	sign
of	IN	of
encephalitis	NN	encephalitis
or	CC	or
meningitis	NN	meningitis
were	VBD	be
detected	VBN	detect
in	IN	in
any	DT	any
of	IN	of
the	DT	the
patients	NNS	patient
.	SENT	.
When	WRB	when
conducting	VBG	conduct
RT-PCR	NP	<unknown>
and	CC	and
immunohistochemical	JJ	immunohistochemical
analyses	NNS	analysis
of	IN	of
brain	NN	brain
tissue	NN	tissue
we	PP	we
could	MD	could
not	RB	not
demonstrate	VB	demonstrate
in	IN	in
any	DT	any
of	IN	of
the	DT	the
patients	NNS	patient
marked	VBD	mark
injury	NN	injury
or	CC	or
presence	NN	presence
of	IN	of
SARS-CoV2	NP	<unknown>
in	IN	in
the	DT	the
olfactory	JJ	olfactory
epithelium	NN	epithelium
,	,	,
olfactory	JJ	olfactory
bulbs	NNS	bulb
,	,	,
or	CC	or
brain	NN	brain
areas	NNS	area
responsible	JJ	responsible
for	IN	for
respiratory	JJ	respiratory
control	NN	control
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
our	PP$	our
small	JJ	small
autopsy	NN	autopsy
series	NN	series
demonstrates	VBZ	demonstrate
various	JJ	various
hypoxia-associated	JJ	hypoxia-associated
neuropathological	JJ	neuropathological
features	NNS	feature
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
but	CC	but
no	DT	no
evidence	NN	evidence
of	IN	of
neurotropism	NN	neurotropism
or	CC	or
meningitis/encephalitis	NN	meningitis/encephalitis
.	SENT	.
34706299/	CD	@card@
Exhaustive	JJ	exhaustive
assessment	NN	assessment
of	IN	of
Reunion	NP	Reunion
Island	NP	Island
inpatients	NNS	inpatient
with	IN	with
COVID-19	NP	<unknown>
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
35073855/	CD	@card@
Bronchiolitis	NP	<unknown>
,	,	,
epidemiological	JJ	epidemiological
changes	NNS	change
during	IN	during
the	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
Bronchiolitis	NP	<unknown>
is	VBZ	be
the	DT	the
most	RBS	most
common	JJ	common
viral	JJ	viral
infection	NN	infection
of	IN	of
the	DT	the
lower	JJR	low
respiratory	JJ	respiratory
tract	NN	tract
in	IN	in
infants	NNS	infant
under	IN	under
2	CD	@card@
years	NNS	year
of	IN	of
age	NN	age
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
analyze	VB	analyze
and	CC	and
compare	VB	compare
the	DT	the
seasonal	JJ	seasonal
bronchiolitis	NN	<unknown>
peaks	NNS	peak
before	IN	before
and	CC	and
during	IN	during
the	DT	the
SARS-CoV-2	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Descriptive	JJ	descriptive
,	,	,
prospective	JJ	prospective
,	,	,
and	CC	and
observational	JJ	observational
study	NN	study
.	SENT	.
Patients	NNS	patient
with	IN	with
severe	JJ	severe
bronchiolitis	NN	<unknown>
admitted	VBD	admit
to	TO	to
the	DT	the
Pediatric	JJ	pediatric
Intensive	JJ	intensive
Care	NP	Care
Unit	NP	Unit
(	(	(
PICU	NP	<unknown>
)	)	)
of	IN	of
a	DT	a
referral	NN	referral
tertiary	JJ	tertiary
hospital	NN	hospital
between	IN	between
September	NP	September
2010	CD	@card@
and	CC	and
June	NP	June
2021	CD	@card@
were	VBD	be
included	VBN	include
.	SENT	.
Demographic	JJ	demographic
data	NNS	datum
were	VBD	be
collected	VBN	collect
.	SENT	.
Viral	JJ	viral
laboratory-confirmation	NN	laboratory-confirmation
was	VBD	be
carried	VBN	carry
out	RP	out
.	SENT	.
Each	DT	each
season	NN	season
was	VBD	be
analyzed	VBN	analyze
and	CC	and
compared	VBN	compare
.	SENT	.
The	DT	the
daily	JJ	daily
average	JJ	average
temperature	NN	temperature
was	VBD	be
collected	VBN	collect
.	SENT	.
1116	CD	@card@
patients	NNS	patient
were	VBD	be
recruited	VBN	recruit
,	,	,
58.2	CD	@card@
%	NN	%
of	IN	of
them	PP	them
males	NNS	male
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
was	VBD	be
49	CD	@card@
days	NNS	day
.	SENT	.
Respiratory	JJ	respiratory
syncytial	JJ	syncytial
virus	NN	virus
(	(	(
RSV	NP	RSV
)	)	)
was	VBD	be
isolated	VBN	isolate
in	IN	in
782	CD	@card@
cases	NNS	case
(	(	(
70.1	CD	@card@
%	NN	%
)	)	)
.	SENT	.
In	IN	in
April	NP	April
2021	CD	@card@
,	,	,
the	DT	the
first	JJ	first
and	CC	and
only	JJ	only
case	NN	case
of	IN	of
bronchiolitis	NNS	<unknown>
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
was	VBD	be
identified	VBN	identify
.	SENT	.
The	DT	the
pre-	NN	pre-
and	CC	and
post-pandemic	JJ	post-pandemic
periods	NNS	period
were	VBD	be
compared	VBN	compare
.	SENT	.
There	EX	there
were	VBD	be
statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
regarding	VBG	regard
:	:	:
age	NN	age
,	,	,
47	CD	@card@
vs.	CC	vs.
73	CD	@card@
days	NNS	day
(	(	(
p	NN	p
=	SYM	=
0.006	CD	@card@
)	)	)
,	,	,
PICU	NP	<unknown>
and	CC	and
hospital	NN	hospital
length	NN	length
of	IN	of
stay	NN	stay
(	(	(
p	NN	p
=	SYM	=
0.024	CD	@card@
and	CC	and
p	NN	p
=	SYM	=
0.001	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
,	,	,
and	CC	and
etiology	NN	etiology
(	(	(
p	NN	p
=	SYM	=
0.031	CD	@card@
)	)	)
.	SENT	.
The	DT	the
peak	NN	peak
for	IN	for
bronchiolitis	NN	<unknown>
in	IN	in
2020	CD	@card@
was	VBD	be
non-existent	JJ	non-existent
before	IN	before
week	NN	week
52	CD	@card@
.	SENT	.
A	DT	a
delayed	JJ	delayed
peak	NN	peak
was	VBD	be
seen	VBN	see
around	IN	around
week	NN	week
26/2021	CD	@card@
.	SENT	.
The	DT	the
mean	JJ	mean
temperature	NN	temperature
during	IN	during
the	DT	the
epidemic	JJ	epidemic
peak	NN	peak
was	VBD	be
10oC	JJ	<unknown>
for	IN	for
the	DT	the
years	NNS	year
of	IN	of
the	DT	the
last	JJ	last
decade	NN	decade
and	CC	and
is	VBZ	be
23oC	JJ	<unknown>
for	IN	for
the	DT	the
present	JJ	present
season	NN	season
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
outbreak	NN	outbreak
has	VBZ	have
led	VBN	lead
to	TO	to
a	DT	a
clearly	RB	clearly
observable	JJ	observable
epidemiological	JJ	epidemiological
change	NN	change
regarding	VBG	regard
acute	JJ	acute
bronchiolitis	NN	<unknown>
,	,	,
which	WDT	which
should	MD	should
be	VB	be
studied	VBN	study
in	IN	in
detail	NN	detail
.	SENT	.
The	DT	the
influence	NN	influence
of	IN	of
the	DT	the
environmental	JJ	environmental
temperature	NN	temperature
does	VBZ	do
not	RB	not
seem	VB	seem
to	TO	to
determine	VB	determine
the	DT	the
viral	JJ	viral
circulation	NN	circulation
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12879-022-07041-x	NP	<unknown>
.	SENT	.
33489409/	CD	@card@
A	NP	A
Rare	JJ	rare
Presentation	NP	Presentation
of	IN	of
Renal	JJ	renal
Papillary	JJ	papillary
Necrosis	NN	necrosis
in	IN	in
a	DT	a
COVID-19-Positive	NP	<unknown>
Patient	NP	Patient
In	IN	in
this	DT	this
case	NN	case
report	NN	report
we	PP	we
describe	VBP	describe
an	DT	an
unusual	JJ	unusual
presentation	NN	presentation
of	IN	of
severe	JJ	severe
acute	JJ	acute
papillary	JJ	papillary
necrosis	NN	necrosis
in	IN	in
a	DT	a
COVID-19-positive	JJ	COVID-19-positive
patient	NN	patient
.	SENT	.
An	DT	an
emergency	NN	emergency
flexible	JJ	flexible
ureteroscopy	NN	<unknown>
greatly	RB	greatly
helped	VBD	help
in	IN	in
the	DT	the
establishment	NN	establishment
of	IN	of
the	DT	the
diagnosis	NN	diagnosis
.	SENT	.
In	IN	in
the	DT	the
international	JJ	international
literature	NN	literature
,	,	,
there	EX	there
is	VBZ	be
a	DT	a
paucity	NN	paucity
of	IN	of
intraoperative	JJ	intraoperative
endoscopic	JJ	endoscopic
images	NNS	image
representing	VBG	represent
severe	JJ	severe
renal	JJ	renal
papillary	JJ	papillary
necrosis	NN	necrosis
.	SENT	.
We	PP	we
present	VBP	present
a	DT	a
case	NN	case
of	IN	of
severe	JJ	severe
acute	JJ	acute
renal	JJ	renal
papillary	JJ	papillary
necrosis	NN	necrosis
in	IN	in
a	DT	a
49-year-old	JJ	49-year-old
south-Asian	NN	south-Asian
,	,	,
COVID-19-positive	JJ	COVID-19-positive
male	JJ	male
patient	NN	patient
who	WP	who
needed	VBD	need
emergency	NN	emergency
urological	JJ	urological
intervention	NN	intervention
for	IN	for
macroscopic	JJ	macroscopic
hematuria	NN	hematuria
and	CC	and
urinary	JJ	urinary
retention	NN	retention
due	JJ	due
to	TO	to
clot	VB	clot
formation	NN	formation
in	IN	in
the	DT	the
urinary	JJ	urinary
bladder	NN	bladder
.	SENT	.
The	DT	the
patient	NN	patient
underwent	VBD	undergo
emergency	NN	emergency
cystoscopy	NN	cystoscopy
,	,	,
clot	NN	clot
evacuation	NN	evacuation
,	,	,
and	CC	and
by	IN	by
rigid	JJ	rigid
and	CC	and
flexible	JJ	flexible
ureteroscopy	NN	<unknown>
.	SENT	.
The	DT	the
diagnosis	NN	diagnosis
was	VBD	be
only	RB	only
confirmed	VBN	confirm
in	IN	in
the	DT	the
postoperative	JJ	postoperative
period	NN	period
,	,	,
retrospectively	RB	retrospectively
.	SENT	.
Finally	RB	finally
,	,	,
the	DT	the
patient	NN	patient
fully	RB	fully
recovered	VBD	recover
due	JJ	due
to	TO	to
the	DT	the
multidisciplinary	JJ	multidisciplinary
management	NN	management
.	SENT	.
Diagnosis	NN	diagnosis
of	IN	of
rare	JJ	rare
clinical	JJ	clinical
entities	NNS	entity
can	MD	can
be	VB	be
sometimes	RB	sometimes
challenging	JJ	challenging
in	IN	in
the	DT	the
everyday	JJ	everyday
routine	JJ	routine
practice	NN	practice
.	SENT	.
Having	VBG	have
atypical	JJ	atypical
clinical	JJ	clinical
course	NN	course
,	,	,
the	DT	the
surgeon	NN	surgeon
should	MD	should
be	VB	be
prepared	VBN	prepare
and	CC	and
sometimes	RB	sometimes
must	MD	must
take	VB	take
responsible	JJ	responsible
decisions	NNS	decision
promptly	RB	promptly
,	,	,
even	RB	even
if	IN	if
needed	VBN	need
intraoperatively	RB	intraoperatively
,	,	,
to	TO	to
manage	VB	manage
unexpected	JJ	unexpected
findings	NNS	finding
in	IN	in
order	NN	order
to	TO	to
get	VB	get
the	DT	the
right	JJ	right
diagnosis	NN	diagnosis
without	IN	without
compromising	VBG	compromise
the	DT	the
patient	NN	patient
's	POS	's
safety	NN	safety
.	SENT	.
34072087/	CD	@card@
Identification	NN	identification
of	IN	of
SARS-CoV-2	NP	<unknown>
Receptor	NN	receptor
Binding	VBG	bind
Inhibitors	NNS	inhibitor
by	IN	by
In	IN	in
Vitro	NP	Vitro
Screening	NN	screening
of	IN	of
Drug	NP	Drug
Libraries	NNS	library
Severe	NP	Severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
responsible	JJ	responsible
for	IN	for
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
The	DT	the
first	JJ	first
step	NN	step
of	IN	of
viral	JJ	viral
infection	NN	infection
is	VBZ	be
cell	NN	cell
attachment	NN	attachment
,	,	,
which	WDT	which
is	VBZ	be
mediated	VBN	mediate
by	IN	by
the	DT	the
binding	NN	binding
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
receptor	NN	receptor
binding	VBG	bind
domain	NN	domain
(	(	(
RBD	NP	RBD
)	)	)
,	,	,
part	NN	part
of	IN	of
the	DT	the
virus	NN	virus
spike	NN	spike
protein	NN	protein
,	,	,
to	TO	to
human	JJ	human
angiotensin-converting	NN	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
.	SENT	.
Therefore	RB	therefore
,	,	,
drug	NN	drug
repurposing	NN	<unknown>
to	TO	to
discover	VB	discover
RBD-ACE2	JJ	<unknown>
binding	JJ	binding
inhibitors	NNS	inhibitor
may	MD	may
provide	VB	provide
a	DT	a
rapid	JJ	rapid
and	CC	and
safe	JJ	safe
approach	NN	approach
for	IN	for
COVID-19	NP	<unknown>
therapy	NN	therapy
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
describe	VBP	describe
the	DT	the
development	NN	development
of	IN	of
an	DT	an
in	IN	in
vitro	NP	Vitro
RBD-ACE2	NP	<unknown>
binding	JJ	binding
assay	NN	assay
and	CC	and
its	PP$	its
application	NN	application
to	TO	to
identify	VB	identify
inhibitors	NNS	inhibitor
of	IN	of
the	DT	the
interaction	NN	interaction
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
RBD	NP	RBD
to	TO	to
ACE2	NP	<unknown>
by	IN	by
the	DT	the
high-throughput	NN	high-throughput
screening	NN	screening
of	IN	of
two	CD	two
compound	JJ	compound
libraries	NNS	library
(	(	(
LOPAC	NP	<unknown>
1280	CD	@card@
and	CC	and
DiscoveryProbeTM	NP	<unknown>
)	)	)
.	SENT	.
Three	CD	three
compounds	NNS	compound
,	,	,
heparin	NN	heparin
sodium	NN	sodium
,	,	,
aurintricarboxylic	JJ	<unknown>
acid	NN	acid
(	(	(
ATA	NP	ATA
)	)	)
,	,	,
and	CC	and
ellagic	JJ	<unknown>
acid	NN	acid
,	,	,
were	VBD	be
found	VBN	find
to	TO	to
exert	VB	exert
an	DT	an
effective	JJ	effective
binding	JJ	binding
inhibition	NN	inhibition
,	,	,
with	IN	with
IC50	NP	<unknown>
values	NNS	value
ranging	VBG	range
from	IN	from
0.6	CD	@card@
to	TO	to
5.5	CD	@card@
microg/mL	NN	<unknown>
.	SENT	.
A	DT	a
plaque	NN	plaque
reduction	NN	reduction
assay	NN	assay
in	IN	in
Vero	NP	Vero
E6	NP	<unknown>
cells	NNS	cell
infected	VBN	infect
with	IN	with
a	DT	a
SARS-CoV-2	NP	<unknown>
surrogate	NN	surrogate
virus	NN	virus
confirmed	VBD	confirm
the	DT	the
inhibition	NN	inhibition
efficacy	NN	efficacy
of	IN	of
heparin	NN	heparin
sodium	NN	sodium
and	CC	and
ATA	NP	ATA
.	SENT	.
Molecular	JJ	molecular
docking	VBG	dock
analysis	NN	analysis
located	VBN	locate
potential	JJ	potential
binding	JJ	binding
sites	NNS	site
of	IN	of
these	DT	these
compounds	NNS	compound
in	IN	in
the	DT	the
RBD	NN	RBD
.	SENT	.
In	IN	in
light	NN	light
of	IN	of
these	DT	these
findings	NNS	finding
,	,	,
the	DT	the
screening	NN	screening
system	NN	system
described	VBN	describe
herein	RB	herein
can	MD	can
be	VB	be
applied	VBN	apply
to	TO	to
other	JJ	other
drug	NN	drug
libraries	NNS	library
to	TO	to
discover	VB	discover
potent	JJ	potent
SARS-CoV-2	NP	<unknown>
inhibitors	NNS	inhibitor
.	SENT	.
35135773/	CD	@card@
Descriptive	JJ	descriptive
comparison	NN	comparison
of	IN	of
admission	NN	admission
characteristics	NNS	characteristic
between	IN	between
pandemic	JJ	pandemic
waves	NNS	wave
and	CC	and
multivariable	JJ	multivariable
analysis	NN	analysis
of	IN	of
the	DT	the
association	NN	association
of	IN	of
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
(	(	(
B.1.1.7	JJ	B@card@
lineage	NN	lineage
)	)	)
of	IN	of
SARS-CoV-2	NP	<unknown>
with	IN	with
disease	NN	disease
severity	NN	severity
in	IN	in
inner	JJ	inner
London	NP	London
The	DT	the
Alpha	NP	Alpha
variant	NN	variant
(	(	(
B.1.1.7	JJ	B@card@
lineage	NN	lineage
)	)	)
of	IN	of
SARS-CoV-2	NP	<unknown>
emerged	VBD	emerge
and	CC	and
became	VBD	become
the	DT	the
dominant	JJ	dominant
circulating	VBG	circulate
variant	NN	variant
in	IN	in
the	DT	the
UK	NP	UK
in	IN	in
late	RB	late
2020	CD	@card@
.	SENT	.
Current	JJ	current
literature	NN	literature
is	VBZ	be
unclear	JJ	unclear
on	IN	on
whether	IN	whether
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
is	VBZ	be
associated	VBN	associate
with	IN	with
increased	VBN	increase
severity	NN	severity
.	SENT	.
We	PP	we
linked	VBD	link
clinical	JJ	clinical
data	NNS	datum
with	IN	with
viral	JJ	viral
genome	NN	genome
sequence	NN	sequence
data	NNS	datum
to	TO	to
compare	VB	compare
admitted	VBN	admit
cases	NNS	case
between	IN	between
SARS-CoV-2	JJ	<unknown>
waves	NNS	wave
in	IN	in
London	NP	London
and	CC	and
to	TO	to
investigate	VB	investigate
the	DT	the
association	NN	association
between	IN	between
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
and	CC	and
the	DT	the
severity	NN	severity
of	IN	of
disease	NN	disease
.	SENT	.
Clinical	JJ	clinical
,	,	,
demographic	JJ	demographic
,	,	,
laboratory	NN	laboratory
and	CC	and
viral	JJ	viral
sequence	NN	sequence
data	NNS	datum
from	IN	from
electronic	JJ	electronic
health	NN	health
record	NN	record
systems	NNS	system
were	VBD	be
collected	VBN	collect
for	IN	for
all	DT	all
cases	NNS	case
with	IN	with
a	DT	a
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
RNA	NP	RNA
test	NN	test
between	IN	between
13	CD	@card@
March	NP	March
2020	CD	@card@
and	CC	and
17	CD	@card@
February	NP	February
2021	CD	@card@
in	IN	in
a	DT	a
multisite	JJ	multisite
London	NP	London
healthcare	NN	<unknown>
institution	NN	institution
.	SENT	.
Multivariate	JJ	multivariate
analysis	NN	analysis
using	VBG	use
logistic	JJ	logistic
regression	NN	regression
assessed	VBD	assess
risk	NN	risk
factors	NNS	factor
for	IN	for
severity	NN	severity
as	IN	as
defined	VBN	define
by	IN	by
hypoxia	NN	hypoxia
at	IN	at
admission	NN	admission
.	SENT	.
There	EX	there
were	VBD	be
5810	CD	@card@
SARS-CoV-2	JJ	<unknown>
RNA-positive	JJ	RNA-positive
cases	NNS	case
of	IN	of
which	WDT	which
2341	CD	@card@
were	VBD	be
admitted	VBN	admit
(	(	(
838	CD	@card@
in	IN	in
wave	NN	wave
1	CD	@card@
and	CC	and
1503	CD	@card@
in	IN	in
wave	NN	wave
2	CD	@card@
)	)	)
.	SENT	.
Both	DT	both
waves	NNS	wave
had	VBD	have
a	DT	a
temporally	RB	temporally
aligned	VBN	align
rise	NN	rise
in	IN	in
nosocomial	JJ	<unknown>
cases	NNS	case
(	(	(
96	CD	@card@
in	IN	in
wave	NN	wave
1	CD	@card@
and	CC	and
137	CD	@card@
in	IN	in
wave	NN	wave
2	CD	@card@
)	)	)
.	SENT	.
The	DT	the
Alpha	NP	Alpha
variant	NN	variant
was	VBD	be
first	RB	first
identified	VBN	identify
on	IN	on
15	CD	@card@
November	NP	November
2020	CD	@card@
and	CC	and
increased	VBD	increase
rapidly	RB	rapidly
to	TO	to
comprise	VB	comprise
400/472	CD	@card@
(	(	(
85	CD	@card@
%	NN	%
)	)	)
of	IN	of
sequenced	JJ	<unknown>
isolates	NNS	isolate
from	IN	from
admitted	VBN	admit
cases	NNS	case
in	IN	in
wave	NN	wave
2	CD	@card@
.	SENT	.
A	DT	a
multivariate	JJ	multivariate
analysis	NN	analysis
identified	VBN	identify
risk	NN	risk
factors	NNS	factor
for	IN	for
severity	NN	severity
on	IN	on
admission	NN	admission
,	,	,
such	JJ	such
as	IN	as
age	NN	age
(	(	(
OR	CC	or
1.02	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.01	CD	@card@
to	TO	to
1.03	CD	@card@
,	,	,
for	IN	for
every	DT	every
year	NN	year
older	JJR	old
;	:	;
p&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
obesity	NN	obesity
(	(	(
OR	CC	or
1.70	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.28	CD	@card@
to	TO	to
2.26	CD	@card@
;	:	;
p&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
infection	NN	infection
with	IN	with
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
(	(	(
OR	CC	or
1.68	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
1.26	CD	@card@
to	TO	to
2.24	CD	@card@
;	:	;
p&lt	NN	<unknown>
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Our	PP$	our
analysis	NN	analysis
is	VBZ	be
the	DT	the
first	JJ	first
in	IN	in
hospitalised	VBN	hospitalise
cohorts	NNS	cohort
to	TO	to
show	VB	show
increased	VBN	increase
severity	NN	severity
of	IN	of
disease	NN	disease
associated	VBN	associate
with	IN	with
the	DT	the
Alpha	NP	Alpha
variant	NN	variant
.	SENT	.
The	DT	the
number	NN	number
of	IN	of
nosocomial	JJ	<unknown>
cases	NNS	case
was	VBD	be
similar	JJ	similar
in	IN	in
both	DT	both
waves	NNS	wave
despite	IN	despite
the	DT	the
introduction	NN	introduction
of	IN	of
many	JJ	many
infection	NN	infection
control	NN	control
interventions	NNS	intervention
before	IN	before
wave	NN	wave
2	CD	@card@
.	SENT	.
34159155/	CD	@card@
Retrospective	JJ	retrospective
and	CC	and
prospective	JJ	prospective
monitoring	NN	monitoring
in	IN	in
post	JJ	post
COVID-19	NP	<unknown>
complications	NNS	complication
and	CC	and
an	DT	an
approach	NN	approach
for	IN	for
vigilance	NN	vigilance
in	IN	in
Post-recovery	NP	Post-recovery
period	NN	period
COVID-19	NP	<unknown>
is	VBZ	be
a	DT	a
Severe	NP	Severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
.	SENT	.
It	PP	it
threatened	VBD	threaten
the	DT	the
whole	JJ	whole
world	NN	world
and	CC	and
considered	VBN	consider
as	IN	as
pandemic	NN	pandemic
recently	RB	recently
,	,	,
emergencies	NNS	emergency
and	CC	and
quarantine	NN	quarantine
has	VBZ	have
been	VBN	be
declared	VBN	declare
all	RB	all
over	IN	over
the	DT	the
world	NN	world
.	SENT	.
Many	JJ	many
published	JJ	published
reviews	NNS	review
and	CC	and
research	NN	research
articles	NNS	article
,	,	,
discussed	VBN	discuss
analysis	NN	analysis
,	,	,
symptoms	NNS	symptom
,	,	,
diagnosis	NN	diagnosis
,	,	,
and	CC	and
possible	JJ	possible
ways	NNS	way
of	IN	of
treatments	NNS	treatment
.	SENT	.
However	RB	however
,	,	,
nowadays	RB	nowadays
,	,	,
more	JJR	more
focus	NN	focus
is	VBZ	be
inclined	VBN	incline
on	IN	on
recovered	VBN	recover
patients	NNS	patient
and	CC	and
the	DT	the
possible	JJ	possible
events	NNS	event
faced	VBN	face
by	IN	by
these	DT	these
patients	NNS	patient
in	IN	in
postrecovery	NN	postrecovery
period	NN	period
.	SENT	.
Specialists	NNS	specialist
,	,	,
medical	JJ	medical
care	NN	care
workers	NNS	worker
are	VBP	be
looking	VBG	look
for	IN	for
unmistakable	JJ	unmistakable
approaches	NNS	approach
to	TO	to
defend	VB	defend
their	PP$	their
life	NN	life
later	RBR	later
on	RB	on
.	SENT	.
It	PP	it
is	VBZ	be
important	JJ	important
to	TO	to
have	VB	have
a	DT	a
full	JJ	full
background	NN	background
on	IN	on
their	PP$	their
physical	JJ	physical
and	CC	and
psychological	JJ	psychological
status	NN	status
after	IN	after
their	PP$	their
recovery	NN	recovery
with	IN	with
certain	JJ	certain
guidelines	NNS	guideline
to	TO	to
follow-up	NN	follow-up
.	SENT	.
There	EX	there
is	VBZ	be
more	JJR	more
concern	NN	concern
,	,	,
care	NN	care
for	IN	for
family	NN	family
and	CC	and
society	NN	society
as	IN	as
they	PP	they
might	MD	might
suffer	VB	suffer
from	IN	from
stress	NN	stress
,	,	,
depression	NN	depression
,	,	,
and	CC	and
stigmatization	NN	stigmatization
from	IN	from
society	NN	society
.	SENT	.
Awareness	NN	awareness
programs	NNS	program
and	CC	and
counseling	NN	counseling
should	MD	should
be	VB	be
recommended	VBN	recommend
to	TO	to
bring	VB	bring
the	DT	the
recovered	VBN	recover
patients	NNS	patient
to	TO	to
their	PP$	their
normalcy	NN	normalcy
.	SENT	.
Surveys	NNS	survey
and	CC	and
cohort	NN	cohort
studies	NNS	study
will	MD	will
be	VB	be
helpful	JJ	helpful
for	IN	for
prognosis	NN	prognosis
of	IN	of
the	DT	the
disease	NN	disease
as	IN	as
well	RB	well
as	RB	as
to	TO	to
be	VB	be
ready	JJ	ready
to	TO	to
face	VB	face
the	DT	the
second	JJ	second
stage	NN	stage
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
article	NN	article
will	MD	will
focus	VB	focus
on	IN	on
recovered	VBN	recover
COVID-19	JJ	<unknown>
patients	NNS	patient
,	,	,
their	PP$	their
complications	NNS	complication
,	,	,
precautionary	JJ	precautionary
methods	NNS	method
,	,	,
and	CC	and
post	NN	post
care	NN	care
.	SENT	.
35572180/	CD	@card@
Perceived	VBN	perceive
stress	NN	stress
and	CC	and
wellbeing	NN	wellbeing
in	IN	in
Romanian	JJ	Romanian
teachers	NNS	teacher
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
The	DT	the
intervening	VBG	intervene
effects	NNS	effect
of	IN	of
job	NN	job
crafting	VBG	craft
and	CC	and
problem-focused	JJ	problem-focused
coping	VBG	cope
This	DT	this
study	NN	study
examines	VBZ	examine
the	DT	the
relationship	NN	relationship
between	IN	between
teacher	NN	teacher
perceived	VBN	perceive
stress	NN	stress
during	IN	during
the	DT	the
online	JJ	online
period	NN	period
of	IN	of
schooling	NN	schooling
in	IN	in
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
pandemic	NN	pandemic
,	,	,
and	CC	and
their	PP$	their
wellbeing	NN	wellbeing
,	,	,
with	IN	with
job	NN	job
crafting	VBG	craft
as	IN	as
a	DT	a
mediator	NN	mediator
,	,	,
The	DT	the
study	NN	study
also	RB	also
examines	VBZ	examine
the	DT	the
role	NN	role
of	IN	of
problem-focused	JJ	problem-focused
coping	NN	coping
as	IN	as
a	DT	a
moderator	NN	moderator
in	IN	in
the	DT	the
stress-job	NN	<unknown>
crafting	VBG	craft
relationship	NN	relationship
.	SENT	.
A	DT	a
sample	NN	sample
of	IN	of
360	CD	@card@
teachers	NNS	teacher
,	,	,
347	CD	@card@
females	NNS	female
,	,	,
and	CC	and
13	CD	@card@
males	NNS	male
,	,	,
aged	VBN	age
21-63	CD	@card@
years	NNS	year
answered	VBN	answer
to	TO	to
an	DT	an
online	JJ	online
survey	NN	survey
from	IN	from
October	NP	October
to	TO	to
December	NP	December
2020	CD	@card@
.	SENT	.
Regression	NN	regression
analyses	NNS	analysis
were	VBD	be
employed	VBN	employ
to	TO	to
the	DT	the
data	NNS	datum
.	SENT	.
The	DT	the
results	NNS	result
show	VBP	show
that	IN	that
the	DT	the
conditional	JJ	conditional
indirect	JJ	indirect
effects	NNS	effect
of	IN	of
stress	NN	stress
on	IN	on
wellbeing	NN	wellbeing
are	VBP	be
statistically	RB	statistically
significant	JJ	significant
for	IN	for
low	JJ	low
problem-focused	JJ	problem-focused
coping	NN	coping
(	(	(
beta	NN	beta
=	SYM	=
-.06	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.02	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
,	,	,
whereas	IN	whereas
for	IN	for
high	JJ	high
problem-focused	NNS	<unknown>
coping	VBG	cope
the	DT	the
effects	NNS	effect
are	VBP	be
not	RB	not
statistically	RB	statistically
significant	JJ	significant
(	(	(
beta	NN	beta
=	SYM	=
.01	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.01	CD	@card@
,	,	,
p	NN	p
&gt	NN	&gt
;	:	;
.05	LS	@card@
)	)	)
.	SENT	.
The	DT	the
effects	NNS	effect
of	IN	of
stress	NN	stress
on	IN	on
wellbeing	NN	wellbeing
are	VBP	be
mediated	VBN	mediate
by	IN	by
job	NN	job
crafting	VBG	craft
for	IN	for
teachers	NNS	teacher
who	WP	who
score	VBP	score
low	JJ	low
on	IN	on
problem-focused	JJ	problem-focused
coping	NN	coping
.	SENT	.
During	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
pandemics	NNS	pandemic
,	,	,
only	RB	only
a	DT	a
small	JJ	small
number	NN	number
of	IN	of
teachers	NNS	teacher
have	VBP	have
used	VBN	use
problem-focused	JJ	problem-focused
coping	NN	coping
.	SENT	.
For	IN	for
teachers	NNS	teacher
who	WP	who
are	VBP	be
low	JJ	low
on	IN	on
problem-focused	JJ	problem-focused
coping	NN	coping
,	,	,
job	NN	job
crafting	VBG	craft
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
ways	NNS	way
through	IN	through
which	WDT	which
they	PP	they
develop	VBP	develop
well-being	NN	well-being
under	IN	under
stress	NN	stress
conditions	NNS	condition
.	SENT	.
Using	VBG	use
low	JJ	low
problem-focused	JJ	problem-focused
coping	NN	coping
was	VBD	be
helpful	JJ	helpful
for	IN	for
teachers	NNS	teacher
because	IN	because
they	PP	they
had	VBD	have
no	DT	no
means	VBZ	mean
to	TO	to
change	VB	change
the	DT	the
situation	NN	situation
and	CC	and
all	RB	all
they	PP	they
could	MD	could
do	VB	do
was	VBD	be
adapt	VB	adapt
to	TO	to
preserve	VB	preserve
their	PP$	their
mental	JJ	mental
health	NN	health
status	NN	status
.	SENT	.
33627160/	CD	@card@
Computed	VBN	compute
tomography	NN	tomography
assessment	NN	assessment
of	IN	of
PEEP-induced	JJ	<unknown>
alveolar	JJ	alveolar
recruitment	NN	recruitment
in	IN	in
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	JJ	<unknown>
pneumonia	NN	pneumonia
There	EX	there
is	VBZ	be
a	DT	a
paucity	NN	paucity
of	IN	of
data	NNS	datum
concerning	VBG	concern
the	DT	the
optimal	JJ	optimal
ventilator	NN	ventilator
management	NN	management
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
;	:	;
particularly	RB	particularly
,	,	,
the	DT	the
optimal	JJ	optimal
levels	NNS	level
of	IN	of
positive-end	JJ	<unknown>
expiratory	JJ	expiratory
pressure	NN	pressure
(	(	(
PEEP	NN	peep
)	)	)
are	VBP	be
unknown	JJ	unknown
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
investigate	VB	investigate
the	DT	the
effects	NNS	effect
of	IN	of
two	CD	two
levels	NNS	level
of	IN	of
PEEP	NN	peep
on	IN	on
alveolar	JJ	alveolar
recruitment	NN	recruitment
in	IN	in
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
.	SENT	.
A	DT	a
single-center	NN	single-center
cohort	NN	cohort
study	NN	study
was	VBD	be
conducted	VBN	conduct
in	IN	in
a	DT	a
39-bed	JJ	<unknown>
intensive	JJ	intensive
care	NN	care
unit	NN	unit
at	IN	at
a	DT	a
university-affiliated	JJ	university-affiliated
hospital	NN	hospital
in	IN	in
Genoa	NP	Genoa
,	,	,
Italy	NP	Italy
.	SENT	.
Chest	NN	chest
computed	VBD	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
was	VBD	be
performed	VBN	perform
to	TO	to
quantify	VB	quantify
aeration	NN	aeration
at	IN	at
8	CD	@card@
and	CC	and
16	CD	@card@
cmH2O	NN	<unknown>
PEEP	NN	peep
.	SENT	.
The	DT	the
primary	JJ	primary
endpoint	NN	endpoint
was	VBD	be
the	DT	the
amount	NN	amount
of	IN	of
alveolar	JJ	alveolar
recruitment	NN	recruitment
,	,	,
defined	VBN	define
as	IN	as
the	DT	the
change	NN	change
in	IN	in
the	DT	the
non-aerated	JJ	<unknown>
compartment	NN	compartment
at	IN	at
the	DT	the
two	CD	two
PEEP	NN	peep
levels	NNS	level
on	IN	on
CT	NP	CT
scan	NN	scan
.	SENT	.
Forty-two	NP	Forty-two
patients	NNS	patient
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
analysis	NN	analysis
.	SENT	.
Alveolar	JJ	alveolar
recruitment	NN	recruitment
was	VBD	be
median	NN	median
[	SYM	[
interquartile	JJ	<unknown>
range	NN	range
]	SYM	]
2.7	CD	@card@
[	SYM	[
0.7-4.5	CD	@card@
]	SYM	]
%	NN	%
of	IN	of
lung	NN	lung
weight	NN	weight
and	CC	and
was	VBD	be
not	RB	not
associated	VBN	associate
with	IN	with
excess	JJ	excess
lung	NN	lung
weight	NN	weight
,	,	,
PaO2/FiO2	NP	<unknown>
ratio	NN	ratio
,	,	,
respiratory	JJ	respiratory
system	NN	system
compliance	NN	compliance
,	,	,
inflammatory	JJ	inflammatory
and	CC	and
thrombophilia	NN	<unknown>
markers	NNS	marker
.	SENT	.
Patients	NNS	patient
in	IN	in
the	DT	the
upper	JJ	upper
quartile	NN	quartile
of	IN	of
recruitment	NN	recruitment
(	(	(
recruiters	NNS	recruiter
)	)	)
,	,	,
compared	VBN	compare
to	TO	to
non-recruiters	NNS	non-recruiter
,	,	,
had	VBD	have
comparable	JJ	comparable
clinical	JJ	clinical
characteristics	NNS	characteristic
,	,	,
lung	NN	lung
weight	NN	weight
and	CC	and
gas	NN	gas
volume	NN	volume
.	SENT	.
Alveolar	JJ	alveolar
recruitment	NN	recruitment
was	VBD	be
not	RB	not
different	JJ	different
in	IN	in
patients	NNS	patient
with	IN	with
lower	JJR	low
versus	CC	versus
higher	JJR	high
respiratory	JJ	respiratory
system	NN	system
compliance	NN	compliance
.	SENT	.
In	IN	in
a	DT	a
subgroup	NN	subgroup
of	IN	of
20	CD	@card@
patients	NNS	patient
with	IN	with
available	JJ	available
gas	NN	gas
exchange	NN	exchange
data	NNS	datum
,	,	,
increasing	VBG	increase
PEEP	NN	peep
decreased	VBD	decrease
respiratory	JJ	respiratory
system	NN	system
compliance	NN	compliance
(	(	(
median	JJ	median
difference	NN	difference
,	,	,
MD	NP	Md
-	NN	<unknown>
9	CD	@card@
ml/cmH2O	NN	<unknown>
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
from	IN	from
-	NN	<unknown>
12	CD	@card@
to	TO	to
-	NN	<unknown>
6	CD	@card@
ml/cmH2O	NN	<unknown>
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
the	DT	the
ventilatory	JJ	ventilatory
ratio	NN	ratio
(	(	(
MD	NP	Md
-	NP	<unknown>
0.1	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
from	IN	from
-	NN	<unknown>
0.3	CD	@card@
to	TO	to
-	NN	<unknown>
0.1	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.003	CD	@card@
)	)	)
,	,	,
increased	VBD	increase
PaO2	NP	<unknown>
with	IN	with
FiO2	NP	<unknown>
=	SYM	=
0.5	CD	@card@
(	(	(
MD	NP	Md
24	CD	@card@
mmHg	NN	<unknown>
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
from	IN	from
12	CD	@card@
to	TO	to
51	CD	@card@
mmHg	NN	<unknown>
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
but	CC	but
did	VBD	do
not	RB	not
change	VB	change
PaO2	NP	<unknown>
with	IN	with
FiO2	NP	<unknown>
=	SYM	=
1.0	CD	@card@
(	(	(
MD	NP	Md
7	CD	@card@
mmHg	NN	<unknown>
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
from	IN	from
-	NN	<unknown>
12	CD	@card@
to	TO	to
49	CD	@card@
mmHg	NN	<unknown>
,	,	,
p	NN	p
=	SYM	=
0.313	CD	@card@
)	)	)
.	SENT	.
Moreover	RB	moreover
,	,	,
alveolar	JJ	alveolar
recruitment	NN	recruitment
was	VBD	be
not	RB	not
correlated	VBN	correlate
with	IN	with
improvement	NN	improvement
of	IN	of
oxygenation	NN	oxygenation
or	CC	or
venous	JJ	venous
admixture	NN	admixture
.	SENT	.
In	IN	in
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
,	,	,
higher	JJR	high
PEEP	NN	peep
resulted	VBN	result
in	IN	in
limited	JJ	limited
alveolar	JJ	alveolar
recruitment	NN	recruitment
.	SENT	.
These	DT	these
findings	NNS	finding
suggest	VBP	suggest
limiting	VBG	limit
PEEP	NN	peep
strictly	RB	strictly
to	TO	to
the	DT	the
values	NNS	value
necessary	JJ	necessary
to	TO	to
maintain	VB	maintain
oxygenation	NN	oxygenation
,	,	,
thus	RB	thus
avoiding	VBG	avoid
the	DT	the
use	NN	use
of	IN	of
higher	JJR	high
PEEP	NN	peep
levels	NNS	level
.	SENT	.
34056576/	CD	@card@
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
and	CC	and
Psychiatric	JJ	psychiatric
Sequelae	NNS	sequela
in	IN	in
South	NP	South
Africa	NP	Africa
:	:	:
Anxiety	NN	anxiety
and	CC	and
Beyond	IN	beyond
The	DT	the
2019	CD	@card@
coronavirus	NN	coronavirus
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
has	VBZ	have
brought	VBN	bring
unprecedented	JJ	unprecedented
challenges	NNS	challenge
to	TO	to
the	DT	the
health	NN	health
sector	NN	sector
nationwide	RB	nationwide
and	CC	and
internationally	RB	internationally
.	SENT	.
Across	IN	across
all	DT	all
disciplines	NNS	discipline
,	,	,
unique	JJ	unique
and	CC	and
novel	JJ	novel
modes	NNS	mode
of	IN	of
presentation	NN	presentation
with	IN	with
substantial	JJ	substantial
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
are	VBP	be
being	VBG	be
encountered	VBN	encounter
,	,	,
and	CC	and
growing	VBG	grow
evidence	NN	evidence
suggests	VBZ	suggest
that	IN	that
psychiatric	JJ	psychiatric
comorbidity	NN	comorbidity
is	VBZ	be
likely	JJ	likely
among	IN	among
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
This	DT	this
article	NN	article
aims	VBZ	aim
to	TO	to
broaden	VB	broaden
the	DT	the
current	JJ	current
discussion	NN	discussion
on	IN	on
the	DT	the
psychiatric	JJ	psychiatric
sequalae	NNS	<unknown>
of	IN	of
COVID-19	NP	<unknown>
,	,	,
which	WDT	which
has	VBZ	have
largely	RB	largely
focused	VBN	focus
on	IN	on
anxiety	NN	anxiety
,	,	,
and	CC	and
examine	VB	examine
the	DT	the
recently	RB	recently
documented	VBN	document
psychiatric	JJ	psychiatric
sequelae	NNS	sequela
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
,	,	,
the	DT	the
secondary	JJ	secondary
effects	NNS	effect
of	IN	of
the	DT	the
pandemic	NN	pandemic
on	IN	on
public	JJ	public
mental	JJ	mental
health	NN	health
,	,	,
and	CC	and
future	JJ	future
psychiatric	JJ	psychiatric
conditions	NNS	condition
that	WDT	that
may	MD	may
arise	VB	arise
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
conducted	VBD	conduct
an	DT	an
in-depth	JJ	in-depth
review	NN	review
of	IN	of
the	DT	the
current	JJ	current
global	JJ	global
psychiatric	JJ	psychiatric
literature	NN	literature
and	CC	and
describe	VB	describe
the	DT	the
wide	JJ	wide
range	NN	range
of	IN	of
psychopathological	JJ	psychopathological
presentations	NNS	presentation
reported	VBN	report
among	IN	among
past	JJ	past
COVID-19	NP	<unknown>
patients	NNS	patient
worldwide	RB	worldwide
and	CC	and
those	DT	those
that	WDT	that
are	VBP	be
expected	VBN	expect
to	TO	to
emerge	VB	emerge
.	SENT	.
Current	JJ	current
discussions	NNS	discussion
in	IN	in
the	DT	the
psychiatric	JJ	psychiatric
literature	NN	literature
on	IN	on
COVID-19	NP	<unknown>
report	NN	report
anxiety	NN	anxiety
and	CC	and
anxiety	NN	anxiety
disorders	NNS	disorder
as	IN	as
a	DT	a
predominant	JJ	predominant
set	NN	set
of	IN	of
clinical	JJ	clinical
presentations	NNS	presentation
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
impacts	NNS	impact
of	IN	of
direct	JJ	direct
COVID-19	NP	<unknown>
infection	NN	infection
,	,	,
associated	VBN	associate
psychopathological	JJ	psychopathological
sequelae	NNS	sequela
,	,	,
and	CC	and
drastic	JJ	drastic
lifestyle	NN	lifestyle
changes	NNS	change
due	JJ	due
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
South	NP	South
Africa	NP	Africa
,	,	,
are	VBP	be
associated	VBN	associate
with	IN	with
a	DT	a
broad	JJ	broad
range	NN	range
of	IN	of
psychopathologies	NNS	psychopathology
and	CC	and
other	JJ	other
neuropsychiatric	JJ	neuropsychiatric
presentations	NNS	presentation
.	SENT	.
Pre-existing	VBG	pre-exist
societal	JJ	societal
conditions	NNS	condition
and	CC	and
burdens	NNS	burden
on	IN	on
the	DT	the
health	NN	health
system	NN	system
in	IN	in
South	NP	South
Africa	NP	Africa
prompt	JJ	prompt
healthcare	NN	<unknown>
providers	NNS	provider
and	CC	and
public	JJ	public
health	NN	health
planners	NNS	planner
to	TO	to
accordingly	RB	accordingly
prepare	VB	prepare
for	IN	for
the	DT	the
expected	VBN	expect
rise	NN	rise
in	IN	in
new	JJ	new
psychiatric	JJ	psychiatric
presentations	NNS	presentation
.	SENT	.
Greater	JJR	great
awareness	NN	awareness
of	IN	of
the	DT	the
various	JJ	various
psychiatric	JJ	psychiatric
conditions	NNS	condition
attributed	VBD	attribute
to	TO	to
COVID-19	NP	<unknown>
infection	NN	infection
may	MD	may
allow	VB	allow
for	IN	for
earlier	JJR	early
screening	NN	screening
,	,	,
more	RBR	more
effective	JJ	effective
treatment	NN	treatment
,	,	,
and	CC	and
greater	JJR	great
positive	JJ	positive
health	NN	health
outcomes	NNS	outcome
and	CC	and
better	JJR	good
prepare	VBP	prepare
health	NN	health
systems	NNS	system
to	TO	to
address	VB	address
the	DT	the
growing	VBG	grow
pandemic	NN	pandemic
in	IN	in
South	NP	South
Africa	NP	Africa
.	SENT	.
34939428/	CD	@card@
Restoration	NN	restoration
of	IN	of
elective	JJ	elective
spine	NN	spine
surgery	NN	surgery
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
COVID-19	NP	<unknown>
With	IN	with
resumption	NN	resumption
of	IN	of
elective	JJ	elective
spine	NN	spine
surgery	NN	surgery
services	NNS	service
in	IN	in
the	DT	the
UK	NP	UK
following	VBG	follow
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
we	PP	we
conducted	VBD	conduct
a	DT	a
multicentre	NN	multicentre
British	NP	British
Association	NP	Association
of	IN	of
Spine	NP	Spine
Surgeons	NNS	surgeon
(	(	(
BASS	NN	bass
)	)	)
collaborative	JJ	collaborative
study	NN	study
to	TO	to
examine	VB	examine
the	DT	the
complications	NNS	complication
and	CC	and
deaths	NNS	death
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
at	IN	at
the	DT	the
recovery	NN	recovery
phase	NN	phase
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
aim	NN	aim
was	VBD	be
to	TO	to
analyze	VB	analyze
the	DT	the
safety	NN	safety
of	IN	of
elective	JJ	elective
spinal	JJ	spinal
surgery	NN	surgery
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
A	DT	a
prospective	JJ	prospective
observational	JJ	observational
study	NN	study
was	VBD	be
conducted	VBN	conduct
from	IN	from
eight	CD	eight
spinal	JJ	spinal
centres	NNS	centre
for	IN	for
the	DT	the
first	JJ	first
month	NN	month
of	IN	of
operating	VBG	operate
following	VBG	follow
restoration	NN	restoration
of	IN	of
elective	JJ	elective
spine	NN	spine
surgery	NN	surgery
in	IN	in
each	DT	each
individual	JJ	individual
unit	NN	unit
.	SENT	.
Primary	JJ	primary
outcome	NN	outcome
measure	NN	measure
was	VBD	be
the	DT	the
30-day	JJ	30-day
postoperative	JJ	postoperative
COVID-19	NP	<unknown>
infection	NN	infection
rate	NN	rate
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
analyzed	VBD	analyze
were	VBD	be
the	DT	the
30-day	JJ	30-day
mortality	NN	mortality
rate	NN	rate
,	,	,
surgical	JJ	surgical
adverse	JJ	adverse
events	NNS	event
,	,	,
medical	JJ	medical
complications	NNS	complication
,	,	,
and	CC	and
length	NN	length
of	IN	of
inpatient	NN	inpatient
stay	NN	stay
.	SENT	.
In	IN	in
all	DT	all
,	,	,
257	CD	@card@
patients	NNS	patient
(	(	(
128	CD	@card@
males	NNS	male
)	)	)
with	IN	with
a	DT	a
median	JJ	median
age	NN	age
of	IN	of
54	CD	@card@
years	NNS	year
(	(	(
2	CD	@card@
to	TO	to
88	CD	@card@
)	)	)
formed	VBD	form
the	DT	the
study	NN	study
cohort	NN	cohort
.	SENT	.
The	DT	the
mean	JJ	mean
number	NN	number
of	IN	of
procedures	NNS	procedure
performed	VBN	perform
from	IN	from
each	DT	each
unit	NN	unit
was	VBD	be
32	CD	@card@
(	(	(
16	CD	@card@
to	TO	to
101	CD	@card@
)	)	)
,	,	,
with	IN	with
118	CD	@card@
procedures	NNS	procedure
(	(	(
46	CD	@card@
%	NN	%
)	)	)
done	VBN	do
as	IN	as
category	NN	category
three	CD	three
prioritization	NN	prioritization
level	NN	level
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
patients	NNS	patient
(	(	(
87	CD	@card@
%	NN	%
)	)	)
were	VBD	be
low-medium	JJ	low-medium
"	``	"
risk	NN	risk
stratification	NN	stratification
"	''	"
category	NN	category
and	CC	and
the	DT	the
mean	JJ	mean
length	NN	length
of	IN	of
hospital	NN	hospital
stay	NN	stay
was	VBD	be
5.2	CD	@card@
days	NNS	day
.	SENT	.
None	NN	none
of	IN	of
the	DT	the
patients	NNS	patient
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
,	,	,
nor	CC	nor
was	VBD	be
there	RB	there
any	DT	any
mortality	NN	mortality
related	VBN	relate
to	TO	to
COVID-19	NP	<unknown>
during	IN	during
the	DT	the
30-day	JJ	30-day
follow-up	NN	follow-up
period	NN	period
,	,	,
with	IN	with
25	CD	@card@
patients	NNS	patient
(	(	(
10	CD	@card@
%	NN	%
)	)	)
having	VBG	have
been	VBN	be
tested	VBN	test
for	IN	for
symptoms	NNS	symptom
.	SENT	.
Overall	RB	overall
,	,	,
32	CD	@card@
patients	NNS	patient
(	(	(
12	CD	@card@
%	NN	%
)	)	)
developed	VBD	develop
a	DT	a
total	NN	total
of	IN	of
34	CD	@card@
complications	NNS	complication
,	,	,
with	IN	with
the	DT	the
majority	NN	majority
(	(	(
19/34	CD	@card@
)	)	)
being	VBG	be
grade	NN	grade
1	CD	@card@
to	TO	to
2	CD	@card@
Clavien-Dindo	NP	<unknown>
classification	NN	classification
of	IN	of
surgical	JJ	surgical
complications	NNS	complication
.	SENT	.
No	DT	no
patient	NN	patient
required	VBD	require
postoperative	JJ	postoperative
care	NN	care
in	IN	in
an	DT	an
intensive	JJ	intensive
care	NN	care
setting	VBG	set
for	IN	for
any	DT	any
unexpected	JJ	unexpected
complication	NN	complication
.	SENT	.
This	DT	this
study	NN	study
shows	VBZ	show
that	IN	that
safe	JJ	safe
and	CC	and
effective	JJ	effective
planned	JJ	planned
spinal	JJ	spinal
surgical	JJ	surgical
services	NNS	service
can	MD	can
be	VB	be
restored	VBN	restore
avoiding	VBG	avoid
viral	JJ	viral
transmission	NN	transmission
,	,	,
with	IN	with
diligent	JJ	diligent
adherence	NN	adherence
to	TO	to
national	JJ	national
guidelines	NNS	guideline
and	CC	and
COVID-19-secure	NN	<unknown>
pathways	NNS	pathway
tailored	VBD	tailor
according	VBG	accord
to	TO	to
the	DT	the
resources	NNS	resource
of	IN	of
the	DT	the
individual	JJ	individual
spinal	JJ	spinal
units	NNS	unit
.	SENT	.
Cite	VB	cite
this	DT	this
article	NN	article
:	:	:
Bone	NP	Bone
Jt	NP	<unknown>
Open	NP	Open
2021	CD	@card@
;	:	;
2(12):1096-1101	JJ	2(12)@card@
.	SENT	.
33686389/	CD	@card@
Early	RB	early
cardiac	JJ	cardiac
involvement	NN	involvement
in	IN	in
patients	NNS	patient
with	IN	with
acute	JJ	acute
COVID-19	NP	<unknown>
infection	NN	infection
identified	VBN	identify
by	IN	by
multiparametric	JJ	multiparametric
cardiovascular	JJ	cardiovascular
magnetic	JJ	magnetic
resonance	NN	resonance
imaging	NN	imaging
In	IN	in
order	NN	order
to	TO	to
determine	VB	determine
acute	JJ	acute
cardiac	JJ	cardiac
involvement	NN	involvement
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
,	,	,
we	PP	we
quantitatively	RB	quantitatively
evaluated	VBD	evaluate
tissue	NN	tissue
characteristics	NNS	characteristic
and	CC	and
mechanics	NNS	mechanic
by	IN	by
non-invasive	JJ	non-invasive
cardiac	JJ	cardiac
magnetic	JJ	magnetic
resonance	NN	resonance
(	(	(
CMR	NP	CMR
)	)	)
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
within	IN	within
the	DT	the
first	JJ	first
10	CD	@card@
days	NNS	day
of	IN	of
the	DT	the
onset	NN	onset
of	IN	of
COVID	NP	<unknown>
symptoms	NNS	symptom
.	SENT	.
Twenty-five	JJ	<unknown>
patients	NNS	patient
with	IN	with
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
confirmed	VBD	confirm
COVID-19	NP	<unknown>
and	CC	and
at	IN	at
least	JJS	least
one	CD	one
marker	NN	marker
of	IN	of
cardiac	JJ	cardiac
involvement	NN	involvement
[	SYM	[
cardiac	JJ	cardiac
symptoms	NNS	symptom
,	,	,
abnormal	JJ	abnormal
electrocardiograph	NN	electrocardiograph
(	(	(
ECG	NP	ECG
)	)	)
,	,	,
or	CC	or
abnormal	JJ	abnormal
cardiac	JJ	cardiac
biomarkers	NNS	biomarker
]	SYM	]
and	CC	and
25	CD	@card@
healthy	JJ	healthy
age-	NN	<unknown>
and	CC	and
gender-matched	JJ	<unknown>
control	NN	control
subjects	NNS	subject
were	VBD	be
recruited	VBN	recruit
to	TO	to
the	DT	the
study	NN	study
.	SENT	.
Patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
those	DT	those
with	IN	with
elevated	JJ	elevated
(	(	(
n	NN	n
=	SYM	=
8	CD	@card@
)	)	)
or	CC	or
normal	JJ	normal
TnI	NP	Tni
(	(	(
n	NN	n
=	SYM	=
17	CD	@card@
)	)	)
.	SENT	.
There	EX	there
were	VBD	be
significant	JJ	significant
differences	NNS	difference
in	IN	in
global	JJ	global
longitudinal	JJ	longitudinal
strain	NN	strain
among	IN	among
patients	NNS	patient
who	WP	who
were	VBD	be
positive	JJ	positive
and	CC	and
negative	JJ	negative
for	IN	for
hs-TnI	NNS	<unknown>
,	,	,
and	CC	and
controls	NNS	control
[	SYM	[
-12.3	CD	@card@
(	(	(
-13.3	CD	@card@
,	,	,
-11.5	CD	@card@
)	)	)
%	NN	%
,	,	,
-13.1	CD	@card@
(	(	(
-14.2	CD	@card@
,	,	,
-9.8	CD	@card@
)	)	)
%	NN	%
,	,	,
and	CC	and
-15.7	CD	@card@
(	(	(
-18.3	CD	@card@
,	,	,
-12.7	CD	@card@
)	)	)
%	NN	%
,	,	,
P	NN	P
=	SYM	=
0.004	CD	@card@
]	SYM	]
.	SENT	.
Native	JJ	native
myocardial	JJ	myocardial
T1	JJ	<unknown>
relaxation	NN	relaxation
times	NNS	time
in	IN	in
patients	NNS	patient
with	IN	with
positive	JJ	positive
and	CC	and
negative	JJ	negative
hs-TnI	NN	<unknown>
manifestation	NN	manifestation
(	(	(
1169.8	CD	@card@
+-	NN	<unknown>
12.9	CD	@card@
and	CC	and
1113.2	CD	@card@
+-	NN	<unknown>
31.2	CD	@card@
ms	NNS	<unknown>
)	)	)
were	VBD	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
the	DT	the
normal	JJ	normal
(	(	(
1065	CD	@card@
+-	NN	<unknown>
57	CD	@card@
ms	NN	Ms
)	)	)
subjects	NNS	subject
,	,	,
respectively	RB	respectively
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
extracellular	JJ	extracellular
volume	NN	volume
(	(	(
ECV	NP	ECV
)	)	)
of	IN	of
patients	NNS	patient
who	WP	who
were	VBD	be
positive	JJ	positive
and	CC	and
negative	JJ	negative
for	IN	for
hs-TnI	NNS	<unknown>
was	VBD	be
higher	JJR	high
than	IN	than
that	DT	that
of	IN	of
the	DT	the
normal	JJ	normal
controls	NNS	control
[	SYM	[
32	CD	@card@
(	(	(
31	CD	@card@
,	,	,
33	CD	@card@
)	)	)
%	NN	%
,	,	,
29	CD	@card@
(	(	(
27	CD	@card@
,	,	,
30	CD	@card@
)	)	)
%	NN	%
,	,	,
and	CC	and
26	CD	@card@
(	(	(
24	CD	@card@
,	,	,
27.5	CD	@card@
)	)	)
%	NN	%
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.001	CD	@card@
]	SYM	]
.	SENT	.
In	IN	in
our	PP$	our
study	NN	study
,	,	,
quantitative	JJ	quantitative
T2	JJ	<unknown>
mapping	NN	mapping
in	IN	in
patients	NNS	patient
who	WP	who
were	VBD	be
positive	JJ	positive
and	CC	and
negative	JJ	negative
for	IN	for
hs-TnI	NP	<unknown>
[	SYM	[
51	CD	@card@
(	(	(
47.9	CD	@card@
,	,	,
52.8	CD	@card@
)	)	)
and	CC	and
48	CD	@card@
(	(	(
47	CD	@card@
,	,	,
49.4	CD	@card@
)	)	)
ms	NN	Ms
]	SYM	]
was	VBD	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
the	DT	the
normal	NN	normal
[	SYM	[
42	CD	@card@
(	(	(
41	CD	@card@
,	,	,
45.2	CD	@card@
)	)	)
ms	RB	<unknown>
]	SYM	]
subjects	VBZ	subject
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
In	IN	in
patients	NNS	patient
with	IN	with
early-stage	NN	early-stage
COVID-19	NP	<unknown>
,	,	,
myocardial	JJ	myocardial
oedema	NN	oedema
,	,	,
and	CC	and
functional	JJ	functional
abnormalities	NNS	abnormality
are	VBP	be
a	DT	a
frequent	JJ	frequent
finding	NN	finding
,	,	,
while	IN	while
irreversible	JJ	irreversible
regional	JJ	regional
injury	NN	injury
such	JJ	such
as	IN	as
necrosis	NN	necrosis
may	MD	may
be	VB	be
infrequent	JJ	infrequent
.	SENT	.
35578593/	CD	@card@
Force	NP	Force
application	NN	application
of	IN	of
laparoscopic	JJ	<unknown>
surgeons	NNS	surgeon
under	IN	under
the	DT	the
impact	NN	impact
of	IN	of
heavy	JJ	heavy
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
Surgeons	NNS	surgeon
are	VBP	be
required	VBN	require
to	TO	to
wear	VB	wear
heavy	JJ	heavy
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
while	IN	while
delivering	VBG	deliver
cares	VBZ	care
to	TO	to
patients	NNS	patient
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
We	PP	we
examined	VBD	examine
the	DT	the
impact	NN	impact
of	IN	of
wearing	VBG	wear
double	JJ	double
gloves	NNS	glove
on	IN	on
surgeons	NNS	surgeon
'	POS	'
performance	NN	performance
in	IN	in
laparoscopic	JJ	<unknown>
surgery	NN	surgery
.	SENT	.
Eleven	NN	eleven
surgeons-in-training	NN	surgeons-in-training
were	VBD	be
recruited	VBN	recruit
to	TO	to
perform	VB	perform
laparoscopic	JJ	<unknown>
cutting	VBG	cut
tasks	NNS	task
in	IN	in
simulation	NN	simulation
while	IN	while
wearing	VBG	wear
none	NN	none
,	,	,
one	CD	one
pair	NN	pair
,	,	,
and	CC	and
two	CD	two
pairs	NNS	pair
of	IN	of
surgical	JJ	surgical
gloves	NNS	glove
.	SENT	.
Forces	NNS	force
applied	VBN	apply
to	TO	to
laparoscopic	JJ	<unknown>
instruments	NNS	instrument
were	VBD	be
measured	VBN	measure
.	SENT	.
Wearing	VBG	wear
gloves	NNS	glove
prolonged	JJ	prolonged
task	NN	task
times	NNS	time
(	(	(
one	CD	one
pair	NN	pair
of	IN	of
gloves	NNS	glove
:	:	:
301.6	CD	@card@
+-	NN	<unknown>
61.7	CD	@card@
s	NNS	<unknown>
;	:	;
two	CD	two
pairs	NNS	pair
of	IN	of
gloves	NNS	glove
:	:	:
295.8	CD	@card@
+-	NN	<unknown>
65.3	CD	@card@
s	NNS	<unknown>
)	)	)
compared	VBN	compare
with	IN	with
no	DT	no
gloves	NNS	glove
(	(	(
241.7	CD	@card@
+-	NN	<unknown>
46.9	CD	@card@
s	NNS	<unknown>
;	:	;
p	NN	p
=	SYM	=
0.043	CD	@card@
)	)	)
.	SENT	.
Wearing	VBG	wear
double	JJ	double
gloves	NNS	glove
increased	VBD	increase
cutting	VBG	cut
errors	NNS	error
(	(	(
20.4	CD	@card@
+-	NN	<unknown>
5.1	CD	@card@
mm2	NN	<unknown>
)	)	)
compared	VBN	compare
with	IN	with
wearing	VBG	wear
one	CD	one
pair	NN	pair
of	IN	of
gloves	NNS	glove
(	(	(
16.9	CD	@card@
+-	NN	<unknown>
5.5	CD	@card@
mm2	NN	<unknown>
)	)	)
and	CC	and
no	DT	no
gloves	NNS	glove
(	(	(
14.4	CD	@card@
+-	NN	<unknown>
4.6	CD	@card@
mm2	NN	<unknown>
;	:	;
p	NN	p
=	SYM	=
0.030	CD	@card@
)	)	)
.	SENT	.
Wearing	VBG	wear
gloves	NNS	glove
reduced	VBD	reduce
the	DT	the
peak	NN	peak
force	NN	force
(	(	(
one	CD	one
pair	NN	pair
of	IN	of
gloves	NNS	glove
:	:	:
2.4	CD	@card@
+-	NN	<unknown>
0.7	CD	@card@
N	NN	N
;	:	;
two	CD	two
pairs	NNS	pair
of	IN	of
gloves	NNS	glove
:	:	:
2.7	CD	@card@
+-	NN	<unknown>
0.6	CD	@card@
N	NN	N
;	:	;
no	DT	no
gloves	NNS	glove
:	:	:
3.4	CD	@card@
+-	NN	<unknown>
1.4	CD	@card@
N	NN	N
;	:	;
p	NN	p
=	SYM	=
0.049	CD	@card@
)	)	)
,	,	,
and	CC	and
the	DT	the
total	JJ	total
force	NN	force
(	(	(
one	CD	one
pair	NN	pair
of	IN	of
gloves	NNS	glove
:	:	:
10.1	CD	@card@
+-	NN	<unknown>
2.8	CD	@card@
N	NN	N
;	:	;
two	CD	two
pairs	NNS	pair
of	IN	of
gloves	NNS	glove
:	:	:
10.3	CD	@card@
+-	NN	<unknown>
2.6	CD	@card@
N	NN	N
;	:	;
no	DT	no
glove	NN	glove
:	:	:
12.6	CD	@card@
+-	NN	<unknown>
1.9	CD	@card@
N	NN	N
;	:	;
p	NN	p
=	SYM	=
0.048	LS	@card@
)	)	)
delivered	VBN	deliver
onto	IN	onto
laparoscopic	JJ	<unknown>
scissors	NN	scissors
compared	VBN	compare
with	IN	with
wearing	VBG	wear
no	DT	no
glove	NN	glove
.	SENT	.
Combined	JJ	combined
effects	NNS	effect
of	IN	of
wearing	VBG	wear
heavy	JJ	heavy
gloves	NNS	glove
and	CC	and
using	VBG	use
tools	NNS	tool
reduced	VBD	reduce
touching	JJ	touching
sensation	NN	sensation
,	,	,
which	WDT	which
limited	VBD	limit
the	DT	the
surgeons	NNS	surgeon
'	POS	'
confidence	NN	confidence
in	IN	in
performing	VBG	perform
surgical	JJ	surgical
tasks	NNS	task
.	SENT	.
Increasing	VBG	increase
practice	NN	practice
in	IN	in
simulation	NN	simulation
is	VBZ	be
suggested	VBN	suggest
to	TO	to
allow	VB	allow
surgeons	NNS	surgeon
for	IN	for
overcome	VBN	overcome
difficulties	NNS	difficulty
brought	VBN	bring
by	IN	by
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
.	SENT	.
35142233/	CD	@card@
What	WP	what
Affected	VBD	affect
Primary	JJ	primary
Care	NP	Care
Patients	NPS	Patients
'	POS	'
Decisions	NNS	decision
to	TO	to
Receive	VB	receive
the	DT	the
Seasonal	JJ	seasonal
Influenza	NN	influenza
Vaccine	NN	vaccine
in	IN	in
the	DT	the
2020	CD	@card@
to	TO	to
2021	CD	@card@
Season	NP	Season
?	SENT	?
A	DT	a
primary	JJ	primary
care	NN	care
patient	NN	patient
's	POS	's
decision	NN	decision
to	TO	to
undergo	VB	undergo
seasonal	JJ	seasonal
influenza	NN	influenza
vaccination	NN	vaccination
may	MD	may
have	VB	have
been	VBN	be
different	JJ	different
during	IN	during
the	DT	the
global	JJ	global
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
the	DT	the
2020	CD	@card@
to	TO	to
2021	CD	@card@
season	NN	season
.	SENT	.
The	DT	the
purpose	NN	purpose
of	IN	of
this	DT	this
study	NN	study
is	VBZ	be
to	TO	to
investigate	VB	investigate
what	WP	what
affected	VBD	affect
primary	JJ	primary
care	NN	care
patients	NNS	patient
'	POS	'
decisions	NNS	decision
to	TO	to
undergo	VB	undergo
seasonal	JJ	seasonal
influenza	NN	influenza
vaccination	NN	vaccination
in	IN	in
the	DT	the
2020	CD	@card@
to	TO	to
2021	CD	@card@
season	NN	season
.	SENT	.
Semi-structured	JJ	semi-structured
interviews	NNS	interview
were	VBD	be
conducted	VBN	conduct
in	IN	in
a	DT	a
primary	JJ	primary
care	NN	care
clinic	NN	clinic
in	IN	in
Ibaraki	NP	Ibaraki
,	,	,
Japan	NP	Japan
.	SENT	.
We	PP	we
used	VBD	use
a	DT	a
purposive	JJ	purposive
sampling	NN	sampling
strategy	NN	strategy
to	TO	to
reach	VB	reach
individuals	NNS	individual
aged	VBN	age
20	CD	@card@
years	NNS	year
or	CC	or
older	JJR	old
who	WP	who
underwent	VBD	undergo
influenza	NN	influenza
vaccination	NN	vaccination
.	SENT	.
The	DT	the
transcripts	NNS	transcript
were	VBD	be
analyzed	VBN	analyze
using	VBG	use
thematic	JJ	thematic
analysis	NN	analysis
.	SENT	.
Twenty-one	NN	twenty-one
patients	NNS	patient
completed	VBD	complete
the	DT	the
interview	NN	interview
.	SENT	.
Two	CD	two
main	JJ	main
themes	NNS	theme
emerged	VBD	emerge
:	:	:
the	DT	the
desire	NN	desire
to	TO	to
avoid	VB	avoid
risks	NNS	risk
to	TO	to
one	CD	one
's	POS	's
health	NN	health
and	CC	and
being	VBG	be
a	DT	a
part	NN	part
a	DT	a
community	NN	community
in	IN	in
coexistence	NN	coexistence
with	IN	with
others	NNS	other
.	SENT	.
The	DT	the
first	JJ	first
theme	NN	theme
included	VBD	include
desire	NN	desire
to	TO	to
avoid	VB	avoid
influenza	NN	influenza
and	CC	and
expectations	NNS	expectation
that	IN	that
vaccination	NN	vaccination
will	MD	will
prevent	VB	prevent
severe	JJ	severe
disease	NN	disease
.	SENT	.
The	DT	the
second	JJ	second
theme	NN	theme
included	VBD	include
concerns	NNS	concern
about	IN	about
the	DT	the
consequences	NNS	consequence
of	IN	of
one	CD	one
's	POS	's
own	JJ	own
influenza	NN	influenza
infection	NN	infection
on	IN	on
others	NNS	other
in	IN	in
the	DT	the
community	NN	community
and	CC	and
necessity	NN	necessity
of	IN	of
vaccination	NN	vaccination
based	VBN	base
on	IN	on
the	DT	the
surroundings	NNS	surroundings
and	CC	and
others	NNS	other
.	SENT	.
Raising	VBG	raise
awareness	NN	awareness
of	IN	of
risk	NN	risk
factors	NNS	factor
such	JJ	such
as	IN	as
older	JJR	old
age	NN	age
and	CC	and
comorbidities	NNS	comorbidity
,	,	,
and	CC	and
the	DT	the
expectations	NNS	expectation
of	IN	of
community	NN	community
members	NNS	member
might	MD	might
be	VB	be
effective	JJ	effective
in	IN	in
promoting	VBG	promote
influenza	NN	influenza
vaccination	NN	vaccination
.	SENT	.
34974674/	CD	@card@
SARS-CoV-2	NP	<unknown>
vaccination	NN	vaccination
for	IN	for
adult	JJ	adult
patients	NNS	patient
with	IN	with
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
:	:	:
expert	NN	expert
consensus	NN	consensus
statement	NN	statement
by	IN	by
KASID	NP	<unknown>
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
caused	VBN	cause
by	IN	by
the	DT	the
novel	NN	novel
coronavirus	NN	coronavirus
,	,	,
is	VBZ	be
threatening	VBG	threaten
global	JJ	global
health	NN	health
worldwide	RB	worldwide
with	IN	with
unprecedented	JJ	unprecedented
contagiousness	NN	contagiousness
and	CC	and
severity	NN	severity
.	SENT	.
The	DT	the
best	JJS	good
strategy	NN	strategy
to	TO	to
overcome	VB	overcome
COVID-19	NP	<unknown>
is	VBZ	be
a	DT	a
vaccine	NN	vaccine
.	SENT	.
Various	JJ	various
vaccines	NNS	vaccine
are	VBP	be
currently	RB	currently
being	VBG	be
developed	VBN	develop
,	,	,
and	CC	and
mass	JJ	mass
vaccination	NN	vaccination
is	VBZ	be
in	IN	in
progress	NN	progress
.	SENT	.
Despite	IN	despite
the	DT	the
very	RB	very
encouraging	JJ	encouraging
clinical	JJ	clinical
trial	NN	trial
results	NNS	result
of	IN	of
these	DT	these
vaccines	NNS	vaccine
,	,	,
there	EX	there
is	VBZ	be
insufficient	JJ	insufficient
information	NN	information
on	IN	on
the	DT	the
safety	NN	safety
and	CC	and
efficacy	NN	efficacy
of	IN	of
vaccines	NNS	vaccine
for	IN	for
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
(	(	(
IBD	JJ	<unknown>
)	)	)
patients	NNS	patient
facing	VBG	face
various	JJ	various
issues	NNS	issue
.	SENT	.
After	IN	after
reviewing	VBG	review
current	JJ	current
evidence	NN	evidence
and	CC	and
international	JJ	international
guidelines	NNS	guideline
,	,	,
the	DT	the
Korean	JJ	Korean
Association	NN	association
for	IN	for
the	DT	the
Study	NN	study
of	IN	of
Intestinal	JJ	intestinal
Diseases	NNS	disease
developed	VBD	develop
an	DT	an
expert	JJ	expert
consensus	NN	consensus
statement	NN	statement
on	IN	on
COVID-19	NP	<unknown>
vaccination	NN	vaccination
issues	NNS	issue
for	IN	for
Korean	JJ	Korean
IBD	JJ	<unknown>
patients	NNS	patient
.	SENT	.
This	DT	this
expert	NN	expert
consensus	NN	consensus
statement	NN	statement
emphasizes	VBZ	emphasize
that	IN	that
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
vaccination	NN	vaccination
be	VB	be
strongly	RB	strongly
recommended	VBN	recommend
for	IN	for
IBD	JJ	<unknown>
patients	NNS	patient
,	,	,
and	CC	and
it	PP	it
is	VBZ	be
safe	JJ	safe
for	IN	for
IBD	JJ	<unknown>
patients	NNS	patient
receiving	VBG	receive
immunomodulatory	JJ	immunomodulatory
therapy	NN	therapy
.	SENT	.
34465068/	CD	@card@
Neurointervention	NN	Neurointervention
in	IN	in
the	DT	the
Era	NN	era
of	IN	of
COVID-19	NP	<unknown>
:	:	:
Korean	NP	Korean
Nationwide	NP	Nationwide
Survey	NP	Survey
,	,	,
Literature	NN	literature
Review	NP	Review
,	,	,
and	CC	and
Recommendations	NNS	recommendation
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
has	VBZ	have
had	VBN	have
a	DT	a
tremendous	JJ	tremendous
impact	NN	impact
on	IN	on
healthcare	NN	<unknown>
systems	NNS	system
worldwide	RB	worldwide
.	SENT	.
Although	IN	although
the	DT	the
most	RBS	most
common	JJ	common
presentation	NN	presentation
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
respiratory	JJ	respiratory
illness	NN	illness
,	,	,
neurologic	JJ	neurologic
manifestations	NNS	manifestation
are	VBP	be
increasing	VBG	increase
and	CC	and
the	DT	the
pandemic	NN	pandemic
may	MD	may
have	VB	have
consequential	JJ	consequential
effects	NNS	effect
on	IN	on
urgent	JJ	urgent
conditions	NNS	condition
such	JJ	such
as	IN	as
acute	JJ	acute
ischemic	JJ	ischemic
stroke	NN	stroke
.	SENT	.
In	IN	in
this	DT	this
document	NN	document
,	,	,
we	PP	we
describe	VBP	describe
the	DT	the
current	JJ	current
status	NN	status
of	IN	of
neurointervention	NN	neurointervention
in	IN	in
Korea	NP	Korea
affected	VBN	affect
by	IN	by
COVID-19	NP	<unknown>
based	VBN	base
on	IN	on
a	DT	a
nationwide	JJ	nationwide
survey	NN	survey
and	CC	and
review	VB	review
relevant	JJ	relevant
literature	NN	literature
from	IN	from
other	JJ	other
countries	NNS	country
and	CC	and
professional	JJ	professional
societies	NNS	society
.	SENT	.
34316049/	CD	@card@
Paranoia	NN	paranoia
and	CC	and
belief	NN	belief
updating	VBG	update
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
crisis	NN	crisis
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
made	VBN	make
the	DT	the
world	NN	world
seem	VBP	seem
less	RBR	less
predictable	JJ	predictable
.	SENT	.
Such	JJ	such
crises	NNS	crisis
can	MD	can
lead	VB	lead
people	NNS	people
to	TO	to
feel	VB	feel
that	IN	that
others	NNS	other
are	VBP	be
a	DT	a
threat	NN	threat
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
show	VBP	show
that	IN	that
the	DT	the
initial	JJ	initial
phase	NN	phase
of	IN	of
the	DT	the
pandemic	NN	pandemic
in	IN	in
2020	CD	@card@
increased	VBN	increase
individuals	NNS	individual
'	POS	'
paranoia	NN	paranoia
and	CC	and
rendered	VBD	render
their	PP$	their
belief	NN	belief
updating	VBG	update
more	RBR	more
erratic	JJ	erratic
.	SENT	.
A	DT	a
proactive	JJ	proactive
lockdown	NN	<unknown>
rendered	VBD	render
people	NNS	people
's	POS	's
belief	NN	belief
updating	VBG	update
less	RBR	less
capricious	JJ	capricious
.	SENT	.
However	RB	however
,	,	,
state-mandated	VBN	state-mandate
mask	NN	mask
wearing	VBG	wear
increased	VBN	increase
paranoia	NN	paranoia
and	CC	and
induced	VBD	induce
more	JJR	more
erratic	JJ	erratic
behaviour	NN	behaviour
.	SENT	.
This	DT	this
was	VBD	be
most	RBS	most
evident	JJ	evident
in	IN	in
states	NNS	state
where	WRB	where
adherence	NN	adherence
to	TO	to
mask	VB	mask
wearing	VBG	wear
rules	NNS	rule
was	VBD	be
poor	JJ	poor
but	CC	but
where	WRB	where
rule	NN	rule
following	NN	following
is	VBZ	be
typically	RB	typically
more	RBR	more
common	JJ	common
.	SENT	.
Computational	JJ	computational
analyses	NNS	analysis
of	IN	of
participant	NN	participant
behaviour	NN	behaviour
suggested	VBD	suggest
that	IN	that
people	NNS	people
with	IN	with
higher	JJR	high
paranoia	NN	paranoia
expected	VBD	expect
the	DT	the
task	NN	task
to	TO	to
be	VB	be
more	RBR	more
unstable	JJ	unstable
.	SENT	.
People	NNS	people
who	WP	who
were	VBD	be
more	JJR	more
paranoid	JJ	paranoid
endorsed	VBN	endorse
conspiracies	NNS	conspiracy
about	IN	about
mask-wearing	NN	mask-wearing
and	CC	and
potential	JJ	potential
vaccines	NNS	vaccine
,	,	,
as	RB	as
well	RB	well
as	IN	as
the	DT	the
QAnon	NP	<unknown>
conspiracy	NN	conspiracy
theory	NN	theory
.	SENT	.
These	DT	these
beliefs	NNS	belief
were	VBD	be
associated	VBN	associate
with	IN	with
erratic	JJ	erratic
task	NN	task
behaviour	NN	behaviour
and	CC	and
changed	JJ	changed
priors	NNS	prior
.	SENT	.
Taken	VBN	take
together	RB	together
,	,	,
we	PP	we
find	VBP	find
that	IN	that
real-world	NN	real-world
uncertainty	NN	uncertainty
increases	VBZ	increase
paranoia	NN	paranoia
and	CC	and
influences	VBZ	influence
laboratory	NN	laboratory
task	NN	task
behaviour	NN	behaviour
.	SENT	.
32762346/	CD	@card@
Diabetes	NN	diabetes
in	IN	in
the	DT	the
Time	NP	Time
of	IN	of
COVID-19	NP	<unknown>
:	:	:
A	DT	a
Twitter-Based	JJ	<unknown>
Sentiment	NN	sentiment
Analysis	NP	Analysis
34594139/	CD	@card@
Regular	JJ	regular
COVID-19	NP	<unknown>
Pandemic	JJ	pandemic
Containment	NN	containment
in	IN	in
Communities	NNS	community
:	:	:
A	DT	a
Risk	NN	risk
Governance	NN	governance
Perspective	NP	Perspective
Post	NP	Post
COVID-19	NP	<unknown>
,	,	,
differentiated	VBD	differentiate
regular	JJ	regular
management	NN	management
in	IN	in
place	NN	place
of	IN	of
strict	JJ	strict
lockdowns	NNS	lockdown
is	VBZ	be
more	RBR	more
favored	VBN	favor
as	IN	as
a	DT	a
feasible	JJ	feasible
option	NN	option
for	IN	for
balancing	VBG	balance
economic	JJ	economic
resumption	NN	resumption
and	CC	and
pandemic	JJ	pandemic
control	NN	control
.	SENT	.
China	NP	China
's	POS	's
transition	NN	transition
experience	NN	experience
shows	VBZ	show
that	IN	that
this	DT	this
stage	NN	stage
came	VBD	come
not	RB	not
easily	RB	easily
,	,	,
during	IN	during
which	WDT	which
regional	JJ	regional
sporadic	JJ	sporadic
outbreaks	NNS	outbreak
could	MD	could
re-emerge	VB	re-emerge
.	SENT	.
Actually	RB	actually
,	,	,
it	PP	it
is	VBZ	be
an	DT	an
ongoing	JJ	ongoing
process	NN	process
of	IN	of
identifying	VBG	identify
loopholes	NNS	loophole
and	CC	and
refining	VBG	refine
the	DT	the
management	NN	management
.	SENT	.
Based	VBN	base
on	IN	on
the	DT	the
IRGC	NP	<unknown>
risk	NN	risk
governance	NN	governance
framework	NN	framework
,	,	,
this	DT	this
article	NN	article
analyzes	VBZ	analyze
these	DT	these
challenges	NNS	challenge
in	IN	in
community	NN	community
involvement	NN	involvement
posed	VBN	pose
by	IN	by
the	DT	the
transition	NN	transition
.	SENT	.
The	DT	the
systematic	JJ	systematic
examination	NN	examination
of	IN	of
the	DT	the
whole	JJ	whole
risk	NN	risk
chain	NN	chain
would	MD	would
be	VB	be
conducive	JJ	conducive
to	TO	to
contain	VB	contain
the	DT	the
virus	NN	virus
spread	NN	spread
,	,	,
lessen	VB	lessen
the	DT	the
pressure	NN	pressure
of	IN	of
communities	NNS	community
for	IN	for
the	DT	the
battle	NN	battle
and	CC	and
enhance	VB	enhance
future	JJ	future
responses	NNS	response
for	IN	for
a	DT	a
possible	JJ	possible
resurgence	NN	resurgence
.	SENT	.
Unlike	IN	unlike
the	DT	the
emergency	NN	emergency
mode	NN	mode
with	IN	with
mass	RB	mass
mobilized	VBN	mobilize
,	,	,
during	IN	during
regular	JJ	regular
control	NN	control
periods	NNS	period
,	,	,
community	NN	community
becomes	VBZ	become
the	DT	the
critical	JJ	critical
frontline	NN	frontline
for	IN	for
suppressing	VBG	suppress
COVID-19	NP	<unknown>
but	CC	but
with	IN	with
limited	JJ	limited
manpower	NN	manpower
and	CC	and
resources	NNS	resource
.	SENT	.
Still	RB	still
,	,	,
it	PP	it
can	MD	can
serve	VB	serve
as	IN	as
a	DT	a
transformation	NN	transformation
platform	NN	platform
to	TO	to
motivate	VB	motivate
atomized	VBN	atomize
residents	NNS	resident
to	TO	to
take	VB	take
responsibility	NN	responsibility
or	CC	or
contribute	VB	contribute
.	SENT	.
Notably	RB	notably
,	,	,
the	DT	the
health	NN	health
governance	NN	governance
of	IN	of
all	DT	all
people	NNS	people
never	RB	never
ends	VBZ	end
.	SENT	.
With	IN	with
the	DT	the
increased	VBN	increase
knowledge	NN	knowledge
of	IN	of
COVID-19	NP	<unknown>
,	,	,
the	DT	the
progress	NN	progress
of	IN	of
pandemic	JJ	pandemic
control	NN	control
,	,	,
and	CC	and
the	DT	the
needed	VBN	need
adjustments	NNS	adjustment
for	IN	for
behavioral	JJ	behavioral
responses	NNS	response
,	,	,
different	JJ	different
communities	NNS	community
should	MD	should
come	VB	come
up	RP	up
with	IN	with
more	JJR	more
suitable	JJ	suitable
options	NNS	option
instead	RB	instead
of	IN	of
rigid	JJ	rigid
management	NN	management
back	RB	back
to	TO	to
the	DT	the
old	JJ	old
days	NNS	day
.	SENT	.
35043033/	CD	@card@
Saliva-based	JJ	<unknown>
COVID-19	NP	<unknown>
detection	NN	detection
:	:	:
A	DT	a
rapid	JJ	rapid
antigen	NN	antigen
test	NN	test
of	IN	of
SARS-CoV-2	NP	<unknown>
nucleocapsid	JJ	<unknown>
protein	NN	protein
using	VBG	use
an	DT	an
electrical-double-layer	NN	electrical-double-layer
gated	VBD	gate
field-effect	JJ	<unknown>
transistor-based	JJ	<unknown>
biosensing	NN	<unknown>
system	NN	system
Facing	VBG	face
the	DT	the
unstopped	JJ	unstopped
surges	NNS	surge
of	IN	of
COVID-19	NP	<unknown>
,	,	,
an	DT	an
insufficient	JJ	insufficient
capacity	NN	capacity
of	IN	of
diagnostic	JJ	diagnostic
testing	NN	testing
jeopardizes	VBZ	jeopardize
the	DT	the
control	NN	control
of	IN	of
disease	NN	disease
spread	NN	spread
.	SENT	.
Due	JJ	due
to	TO	to
a	DT	a
centralized	JJ	centralized
setting	NN	setting
and	CC	and
a	DT	a
long	JJ	long
turnaround	NN	turnaround
,	,	,
real-time	JJ	real-time
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
real-time	JJ	real-time
RT-PCR	NN	<unknown>
)	)	)
,	,	,
the	DT	the
gold	JJ	gold
standard	NN	standard
of	IN	of
viral	JJ	viral
detection	NN	detection
,	,	,
has	VBZ	have
fallen	VBN	fall
short	RB	short
in	IN	in
timely	JJ	timely
reflecting	VBG	reflect
the	DT	the
epidemic	NN	epidemic
status	FW	status
quo	FW	quo
during	IN	during
an	DT	an
urgent	JJ	urgent
outbreak	NN	outbreak
.	SENT	.
As	IN	as
such	JJ	such
,	,	,
a	DT	a
rapid	JJ	rapid
screening	NN	screening
tool	NN	tool
is	VBZ	be
necessitated	VBN	necessitate
to	TO	to
help	VB	help
contain	VB	contain
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
amid	IN	amid
the	DT	the
countries	NNS	country
where	WRB	where
the	DT	the
vaccine	NN	vaccine
implementations	NNS	implementation
have	VBP	have
not	RB	not
been	VBN	be
widely	RB	widely
deployed	VBN	deploy
.	SENT	.
In	IN	in
this	DT	this
work	NN	work
,	,	,
we	PP	we
propose	VBP	propose
a	DT	a
saliva-based	JJ	<unknown>
COVID-19	NP	<unknown>
antigen	NN	antigen
test	NN	test
using	VBG	use
the	DT	the
electrical	JJ	electrical
double	JJ	double
layer	NN	layer
(EDL)-gated	JJ	<unknown>
field-effect	NNS	<unknown>
transistor-based	JJ	<unknown>
biosensor	NP	biosensor
(	(	(
BioFET	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
detection	NN	detection
of	IN	of
SARS-CoV-2	NP	<unknown>
nucleocapsid	NP	<unknown>
(	(	(
N	NP	N
)	)	)
protein	NN	protein
is	VBZ	be
validated	VBN	validate
with	IN	with
limits	NNS	limit
of	IN	of
detection	NN	detection
(	(	(
LoDs	NP	<unknown>
)	)	)
of	IN	of
0.34	CD	@card@
ng/mL	NNS	<unknown>
(	(	(
7.44	CD	@card@
pM	NN	pm
)	)	)
and	CC	and
0.14	CD	@card@
ng/mL	NNS	<unknown>
(	(	(
2.96	CD	@card@
pM	NN	pm
)	)	)
in	IN	in
1x	NP	1x
PBS	NP	PBS
and	CC	and
artificial	JJ	artificial
saliva	NN	saliva
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
specificity	NN	specificity
is	VBZ	be
inspected	VBN	inspect
with	IN	with
types	NNS	type
of	IN	of
antigens	NNS	antigen
,	,	,
exhibiting	VBG	exhibit
low	JJ	low
cross-reactivity	NN	cross-reactivity
among	IN	among
MERS-CoV	NP	<unknown>
,	,	,
Influenza	NN	influenza
A	DT	a
virus	NN	virus
,	,	,
and	CC	and
Influenza	NN	influenza
B	NN	B
virus	NN	virus
.	SENT	.
This	DT	this
portable	JJ	portable
system	NN	system
is	VBZ	be
embedded	VBN	embed
with	IN	with
Bluetooth	NP	<unknown>
communication	NN	communication
and	CC	and
user-friendly	JJ	user-friendly
interfaces	NNS	interface
that	WDT	that
are	VBP	be
fully	RB	fully
compatible	JJ	compatible
with	IN	with
digital	JJ	digital
health	NN	health
,	,	,
feasibly	RB	feasibly
leading	VBG	lead
to	TO	to
an	DT	an
on-site	JJ	on-site
turnaround	NN	turnaround
,	,	,
an	DT	an
effective	JJ	effective
management	NN	management
,	,	,
and	CC	and
a	DT	a
proactive	JJ	proactive
response	NN	response
taken	VBN	take
by	IN	by
medical	JJ	medical
providers	NNS	provider
and	CC	and
frontline	NN	frontline
health	NN	health
workers	NNS	worker
.	SENT	.
34721912/	CD	@card@
Endometriosis	NN	endometriosis
Surgery	NN	surgery
during	IN	during
the	DT	the
First	NP	First
Wave	NP	Wave
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
A	DT	a
Brazilian	JJ	Brazilian
Single	NP	Single
Institution	NP	Institution
Experience	NN	experience
Introduction	NN	introduction
.	SENT	.
Early	RB	early
in	IN	in
the	DT	the
2020	CD	@card@
Coronavirus	NP	<unknown>
pandemic	JJ	pandemic
stay-at-home	JJ	stay-at-home
guidelines	NNS	guideline
,	,	,
there	EX	there
were	VBD	be
public	JJ	public
health	NN	health
orders	NNS	order
that	IN	that
elective	JJ	elective
surgeries	NNS	surgery
be	VB	be
deferred	VBN	defer
to	TO	to
prioritize	VB	<unknown>
hospital	NN	hospital
beds	NNS	bed
for	IN	for
critically	RB	critically
ill	JJ	ill
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
Besides	RB	besides
,	,	,
several	JJ	several
reasons	NNS	reason
led	VBN	lead
to	TO	to
the	DT	the
postponement	NN	postponement
of	IN	of
consultations	NNS	consultation
,	,	,
diagnostic	JJ	diagnostic
tests	NNS	test
,	,	,
and	CC	and
elective	JJ	elective
therapeutic	JJ	therapeutic
procedures	NNS	procedure
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
some	DT	some
women	NNS	woman
with	IN	with
endometriosis	NN	endometriosis
faced	VBN	face
chronification	NN	chronification
of	IN	of
their	PP$	their
pain	NN	pain
and	CC	and
decreased	VBD	decrease
prospects	NNS	prospect
for	IN	for
pregnancy	NN	pregnancy
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
describe	VB	describe
individual	JJ	individual
responses	NNS	response
to	TO	to
minimally	RB	minimally
invasive	JJ	invasive
complete	JJ	complete
excision	NN	excision
of	IN	of
endometriosis	NN	endometriosis
through	IN	through
40	CD	@card@
days	NNS	day
of	IN	of
follow-up	NN	follow-up
of	IN	of
women	NNS	woman
whose	WP$	whose
endometriosis	NN	endometriosis
was	VBD	be
considered	VBN	consider
severe	JJ	severe
enough	RB	enough
to	TO	to
proceed	VB	proceed
with	IN	with
surgery	NN	surgery
during	IN	during
the	DT	the
fourth	JJ	fourth
,	,	,
fifth	JJ	fifth
,	,	,
and	CC	and
sixth	JJ	sixth
months	NNS	month
of	IN	of
constraints	NNS	constraint
imposed	VBN	impose
by	IN	by
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Preventive	JJ	preventive
strategies	NNS	strategy
and	CC	and
safety	NN	safety
measures	NNS	measure
employed	VBN	employ
to	TO	to
protect	VB	protect
patients	NNS	patient
and	CC	and
staff	NN	staff
from	IN	from
acquiring	VBG	acquire
or	CC	or
transmitting	VBG	transmit
Coronavirus	NP	<unknown>
infection	NN	infection
are	VBP	be
presented	VBN	present
.	SENT	.
Case	NP	Case
Presentation	NP	Presentation
.	SENT	.
This	DT	this
case	NN	case
series	NN	series
report	NN	report
enrolled	VBD	enroll
11	CD	@card@
consecutive	JJ	consecutive
Brazilian	JJ	Brazilian
women	NNS	woman
(	(	(
ages	NNS	age
22	CD	@card@
to	TO	to
47	CD	@card@
y	NN	y
)	)	)
who	WP	who
underwent	VBD	undergo
minimally	RB	minimally
invasive	JJ	invasive
surgical	JJ	surgical
treatment	NN	treatment
of	IN	of
endometriosis	NN	endometriosis
between	IN	between
June	NP	June
26	CD	@card@
and	CC	and
August	NP	August
17	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
Cases	NNS	case
of	IN	of
endometriosis	NN	endometriosis
requiring	VBG	require
more	RBR	more
urgent	JJ	urgent
surgery	NN	surgery
were	VBD	be
promptly	RB	promptly
identified	VBN	identify
and	CC	and
considered	VBN	consider
individually	RB	individually
.	SENT	.
The	DT	the
strict	JJ	strict
safety	NN	safety
measures	NNS	measure
were	VBD	be
well	RB	well
accepted	VBN	accept
by	IN	by
patients	NNS	patient
.	SENT	.
No	DT	no
women	NNS	woman
developed	VBD	develop
any	DT	any
flu-like	JJ	flu-like
or	CC	or
COVID-19-related	JJ	COVID-19-related
symptoms	NNS	symptom
(	(	(
cough	NN	cough
,	,	,
dyspnea	NN	dyspnea
,	,	,
fever	NN	fever
,	,	,
or	CC	or
anosmia	NN	anosmia
)	)	)
in	IN	in
the	DT	the
40	CD	@card@
days	NNS	day
of	IN	of
postoperative	JJ	postoperative
follow-up	NN	follow-up
.	SENT	.
One	CD	one
of	IN	of
the	DT	the
most	RBS	most
praised	VBN	praise
measures	NNS	measure
reported	VBN	report
by	IN	by
patients	NNS	patient
was	VBD	be
the	DT	the
routine	JJ	routine
testing	NN	testing
of	IN	of
the	DT	the
patient	NN	patient
,	,	,
the	DT	the
person	NN	person
who	WP	who
would	MD	would
accompany	VB	accompany
her	PP	her
in	IN	in
the	DT	the
hospital	NN	hospital
,	,	,
and	CC	and
all	DT	all
medical	JJ	medical
staff	NN	staff
and	CC	and
employees	NNS	employee
.	SENT	.
Discussion	NN	discussion
.	SENT	.
It	PP	it
is	VBZ	be
feasible	JJ	feasible
to	TO	to
safely	RB	safely
perform	VB	perform
elective	JJ	elective
endometriosis	NN	endometriosis
surgery	NN	surgery
in	IN	in
selected	JJ	selected
cases	NNS	case
during	IN	during
a	DT	a
pandemic	NN	pandemic
.	SENT	.
34610907/	CD	@card@
A	DT	a
pragmatic	JJ	pragmatic
approach	NN	approach
to	TO	to
COVID-19	NP	<unknown>
vaccine	NN	vaccine
passport	NN	passport
35222989/	CD	@card@
Students	NNS	student
'	POS	'
perception	NN	perception
of	IN	of
online	JJ	online
learning	NN	learning
amidst	IN	amidst
the	DT	the
Covid-19	NP	<unknown>
pandemic	NN	pandemic
:	:	:
A	DT	a
study	NN	study
of	IN	of
junior	JJ	junior
,	,	,
senior	JJ	senior
high	JJ	high
school	NN	school
and	CC	and
college	NN	college
students	NNS	student
in	IN	in
a	DT	a
remote	JJ	remote
area	NN	area
Background	NN	background
:	:	:
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
brought	VBN	bring
about	IN	about
many	JJ	many
changes	NNS	change
in	IN	in
all	DT	all
sectors	NNS	sector
of	IN	of
life	NN	life
,	,	,
especially	RB	especially
in	IN	in
the	DT	the
field	NN	field
of	IN	of
education	NN	education
.	SENT	.
These	DT	these
changes	NNS	change
aim	VBP	aim
to	TO	to
make	VB	make
the	DT	the
learning	VBG	learn
process	NN	process
more	RBR	more
effective	JJ	effective
in	IN	in
the	DT	the
pandemic	JJ	pandemic
environment	NN	environment
.	SENT	.
However	RB	however
,	,	,
it	PP	it
can	MD	can
be	VB	be
challenging	VBG	challenge
,	,	,
as	IN	as
some	DT	some
students	NNS	student
do	VBP	do
not	RB	not
give	VB	give
positive	JJ	positive
responses	NNS	response
to	TO	to
these	DT	these
changes	NNS	change
,	,	,
especially	RB	especially
those	DT	those
in	IN	in
remote	JJ	remote
areas	NNS	area
.	SENT	.
This	DT	this
article	NN	article
aims	VBZ	aim
to	TO	to
identify	VB	identify
and	CC	and
report	VB	report
students	NNS	student
'	POS	'
perceptions	NNS	perception
about	IN	about
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
online	JJ	online
learning	NN	learning
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
the	DT	the
remote	JJ	remote
North	NP	North
Tapanuli	NP	Tapanuli
region	NN	region
of	IN	of
Indonesia	NP	Indonesia
.	SENT	.
Methods	NNS	method
:	:	:
In	IN	in
this	DT	this
study	NN	study
,	,	,
data	NNS	datum
were	VBD	be
obtained	VBN	obtain
using	VBG	use
an	DT	an
online	JJ	online
survey	NN	survey
involving	VBG	involve
30	CD	@card@
students	NNS	student
from	IN	from
three	CD	three
levels	NNS	level
of	IN	of
education	NN	education
,	,	,
namely	RB	namely
junior	JJ	junior
high	JJ	high
school	NN	school
,	,	,
senior	JJ	senior
high	JJ	high
school	NN	school
,	,	,
and	CC	and
college	NN	college
.	SENT	.
They	PP	they
are	VBP	be
students	NNS	student
who	WP	who
the	DT	the
teacher	NN	teacher
appoints	VBZ	appoint
as	IN	as
class	NN	class
administrators	NNS	administrator
;	:	;
through	IN	through
them	PP	them
,	,	,
the	DT	the
teacher	NN	teacher
communicates	VBZ	communicate
about	IN	about
everything:learning	VBG	everything:learn
activities	NNS	activity
.	SENT	.
So	RB	so
compared	VBN	compare
to	TO	to
his	PP$	his
other	JJ	other
friends	NNS	friend
,	,	,
they	PP	they
know	VBP	know
more	JJR	more
about	IN	about
the	DT	the
implementation	NN	implementation
of	IN	of
online	JJ	online
learning	NN	learning
during	IN	during
the	DT	the
covid	JJ	<unknown>
19	CD	@card@
pandemic	NN	pandemic
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
schools	NNS	school
in	IN	in
remote	JJ	remote
areas	NNS	area
have	VBP	have
fewer	JJR	few
students	NNS	student
than	IN	than
schools	NNS	school
in	IN	in
big	JJ	big
cities	NNS	city
.	SENT	.
So	RB	so
we	PP	we
conclude	VBP	conclude
that	IN	that
this	DT	this
research	NN	research
is	VBZ	be
considered	VBN	consider
representative	NN	representative
with	IN	with
thirty	CD	thirty
students	NNS	student
as	IN	as
the	DT	the
sample	NN	sample
.	SENT	.
The	DT	the
data	NNS	datum
gathered	VBN	gather
from	IN	from
the	DT	the
survey	NN	survey
were	VBD	be
analyzed	VBN	analyze
using	VBG	use
quantitative	JJ	quantitative
descriptive	JJ	descriptive
methods	NNS	method
.	SENT	.
Results	NNS	result
:	:	:
Results	NNS	result
show	VBP	show
that	IN	that
online	JJ	online
learning	NN	learning
is	VBZ	be
considered	VBN	consider
less	RBR	less
effective	JJ	effective
by	IN	by
students	NNS	student
in	IN	in
remote	JJ	remote
areas	NNS	area
;	:	;
this	DT	this
happens	VBZ	happen
because	IN	because
communication	NN	communication
networks	NNS	network
and	CC	and
infrastructure	NN	infrastructure
do	VBP	do
not	RB	not
adequately	RB	adequately
support	VB	support
them	PP	them
to	TO	to
follow	VB	follow
online	JJ	online
learning	NN	learning
.	SENT	.
Conclusion	NN	conclusion
:	:	:
Teachers	NNS	teacher
need	VBP	need
to	TO	to
evaluate	VB	evaluate
how	WRB	how
to	TO	to
teach	VB	teach
as	RB	as
well	RB	well
as	IN	as
re-design	NN	re-design
models	NNS	model
and	CC	and
approaches	VBZ	approach
to	TO	to
be	VB	be
applied	VBN	apply
in	IN	in
learning	VBG	learn
.	SENT	.
This	DT	this
can	MD	can
be	VB	be
achieved	VBN	achieve
by	IN	by
adjusting	VBG	adjust
to	TO	to
the	DT	the
student	NN	student
's	POS	's
current	JJ	current
situation	NN	situation
to	TO	to
generate	VB	generate
interest	NN	interest
and	CC	and
willingness	NN	willingness
to	TO	to
learn	VB	learn
online	JJ	online
.	SENT	.
32553562/	CD	@card@
The	DT	the
diagnostic	JJ	diagnostic
value	NN	value
of	IN	of
detecting	VBG	detect
sudden	JJ	sudden
smell	NN	smell
loss	NN	loss
among	IN	among
asymptomatic	JJ	asymptomatic
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
early	JJ	early
stage	NN	stage
:	:	:
The	DT	the
possible	JJ	possible
early	JJ	early
sign	NN	sign
of	IN	of
COVID-19	NP	<unknown>
The	NP	The
newly	RB	newly
emerged	VBD	emerge
coronavirus	NN	coronavirus
disease	NN	disease
19	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
is	VBZ	be
threatening	VBG	threaten
the	DT	the
world	NN	world
.	SENT	.
Olfactory	JJ	olfactory
or	CC	or
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
is	VBZ	be
reported	VBN	report
as	IN	as
one	CD	one
of	IN	of
the	DT	the
symptoms	NNS	symptom
worldwide	RB	worldwide
.	SENT	.
As	RB	as
reported	VBN	report
so	RB	so
far	RB	far
,	,	,
different	JJ	different
clinical	JJ	clinical
features	NNS	feature
have	VBP	have
been	VBN	be
reported	VBN	report
according	VBG	accord
to	TO	to
outbreak	NN	outbreak
sites	NNS	site
and	CC	and
gender	VB	gender
;	:	;
most	JJS	most
of	IN	of
the	DT	the
patients	NNS	patient
,	,	,
who	WP	who
complained	VBD	complain
of	IN	of
anosmia	NN	anosmia
or	CC	or
hyposmia	NN	<unknown>
,	,	,
were	VBD	be
Europeans	NNS	European
.	SENT	.
We	PP	we
had	VBD	have
a	DT	a
fast	JJ	fast
review	NN	review
for	IN	for
novel	JJ	novel
articles	NNS	article
about	IN	about
COVID-19	NP	<unknown>
infection	NN	infection
and	CC	and
olfactory	JJ	olfactory
function	NN	function
.	SENT	.
Rapid	JJ	rapid
reviews	NNS	review
for	IN	for
COVID-19	NP	<unknown>
or	CC	or
other	JJ	other
viral	JJ	viral
infection	NN	infection
and	CC	and
olfactory	JJ	olfactory
and/or	CC	and/or
gustatory	JJ	gustatory
dysfunctions	NNS	dysfunction
were	VBD	be
done	VBN	do
in	IN	in
this	DT	this
review	NN	review
.	SENT	.
Up	RB	up
to	TO	to
date	NN	date
,	,	,
a	DT	a
lot	NN	lot
of	IN	of
reports	NNS	report
have	VBP	have
shown	VBN	show
that	IN	that
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
is	VBZ	be
related	VBN	relate
to	TO	to
viral	JJ	viral
infections	NNS	infection
but	CC	but
no	DT	no
exact	JJ	exact
mechanism	NN	mechanism
,	,	,
clinical	JJ	clinical
course	NN	course
,	,	,
and	CC	and
definite	JJ	definite
treatment	NN	treatment
have	VBP	have
been	VBN	be
discovered	VBN	discover
,	,	,
which	WDT	which
is	VBZ	be
also	RB	also
same	JJ	same
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
general	JJ	general
,	,	,
intranasal	JJ	intranasal
steroid	NN	steroid
(	(	(
INS	NP	INS
)	)	)
and	CC	and
oral	JJ	oral
steroid	NN	steroid
for	IN	for
short	JJ	short
time	NN	time
help	NN	help
improve	VB	improve
the	DT	the
recovery	NN	recovery
of	IN	of
the	DT	the
olfactory	JJ	olfactory
function	NN	function
in	IN	in
case	NN	case
of	IN	of
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
after	IN	after
virus	NN	virus
infection	NN	infection
.	SENT	.
Considering	VBG	consider
severe	JJ	severe
respiratory	JJ	respiratory
complications	NNS	complication
and	CC	and
immunocompromised	JJ	immunocompromised
state	NN	state
of	IN	of
COVID-19	NP	<unknown>
,	,	,
the	DT	the
use	NN	use
of	IN	of
steroid	NN	steroid
should	MD	should
be	VB	be
limited	JJ	limited
and	CC	and
cautious	JJ	cautious
because	IN	because
we	PP	we
do	VBP	do
not	RB	not
have	VB	have
enough	JJ	enough
data	NNS	datum
to	TO	to
support	VB	support
the	DT	the
usage	NN	usage
of	IN	of
steroid	NN	steroid
to	TO	to
treat	VB	treat
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
in	IN	in
the	DT	the
clinical	JJ	clinical
course	NN	course
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
the	DT	the
days	NNS	day
of	IN	of
pandemic	JJ	pandemic
COVID-19	NP	<unknown>
,	,	,
we	PP	we
should	MD	should
keep	VB	keep
in	IN	in
mind	NN	mind
that	IN	that
olfactory	JJ	olfactory
dysfunctions	NNS	dysfunction
,	,	,
even	RB	even
without	IN	without
other	JJ	other
upper	JJ	upper
respiratory	JJ	respiratory
infection	NN	infection
or	CC	or
otolaryngologic	JJ	otolaryngologic
symptoms	NNS	symptom
,	,	,
might	MD	might
be	VB	be
the	DT	the
early	JJ	early
signs	NNS	sign
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
35128537/	CD	@card@
Epidemiology	NN	epidemiology
of	IN	of
Pediatric	JJ	pediatric
Foreign	JJ	foreign
Body	NN	body
Ingestions	NNS	ingestion
Amidst	IN	amidst
the	DT	the
Coronavirus	NP	<unknown>
2019	CD	@card@
Pandemic	NN	pandemic
at	IN	at
a	DT	a
Tertiary	JJ	Tertiary
Care	NP	Care
Children	NP	Children
's	POS	's
Hospital	NP	Hospital
Supplemental	NP	Supplemental
Digital	NP	Digital
Content	NN	content
is	VBZ	be
available	JJ	available
in	IN	in
the	DT	the
text	NN	text
.	SENT	.
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID	NN	<unknown>
)	)	)
2019	CD	@card@
pandemic	NN	pandemic
and	CC	and
resultant	JJ	resultant
stay-at-home	JJ	stay-at-home
orders	NNS	order
altered	VBD	alter
caregivers	NNS	caregiver
'	POS	'
responsibilities	NNS	responsibility
and	CC	and
children	NNS	child
's	POS	's
daily	JJ	daily
environments	NNS	environment
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
compare	VB	compare
the	DT	the
epidemiology	NN	epidemiology
and	CC	and
morbidity	NN	morbidity
of	IN	of
foreign	JJ	foreign
body	NN	body
ingestions	NNS	ingestion
(	(	(
FBIs	NP	<unknown>
)	)	)
during	IN	during
the	DT	the
COVID	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
the	DT	the
prior	JJ	prior
year	NN	year
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
retrospective	JJ	retrospective
review	NN	review
of	IN	of
children	NNS	child
cared	VBN	care
for	IN	for
at	IN	at
our	PP$	our
tertiary	JJ	tertiary
care	NN	care
children	NNS	child
's	POS	's
hospital	NN	hospital
for	IN	for
FBI	NP	FBI
from	IN	from
March	NP	March
to	TO	to
July	NP	July
2019	CD	@card@
(	(	(
pre-COVID	NN	<unknown>
)	)	)
and	CC	and
March	NP	March
to	TO	to
July	NP	July
2020	CD	@card@
(	(	(
COVID	NP	<unknown>
)	)	)
.	SENT	.
Cases	NNS	case
were	VBD	be
identified	VBN	identify
via	IN	via
a	DT	a
search	NN	search
of	IN	of
all	DT	all
diagnoses	NNS	diagnosis
of	IN	of
foreign	JJ	foreign
bodies	NNS	body
(	(	(
FBs	NP	FB
)	)	)
in	IN	in
the	DT	the
alimentary	JJ	alimentary
tract	NN	tract
.	SENT	.
Charts	NNS	chart
were	VBD	be
reviewed	VBN	review
to	TO	to
determine	VB	determine
the	DT	the
types	NNS	type
of	IN	of
FBs	NP	FB
ingested	VBD	ingest
and	CC	and
the	DT	the
patients	NNS	patient
'	POS	'
clinical	JJ	clinical
courses	NNS	course
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
71	CD	@card@
encounters	NNS	encounter
were	VBD	be
identified	VBN	identify
.	SENT	.
Thirty	CD	thirty
ingestions	NNS	ingestion
occurred	VBN	occur
in	IN	in
the	DT	the
pre-COVID	JJ	<unknown>
cohort	NN	cohort
and	CC	and
42	CD	@card@
in	IN	in
the	DT	the
COVID	NP	<unknown>
cohort	NN	cohort
.	SENT	.
One	CD	one
patient	NN	patient
ingested	VBD	ingest
2	CD	@card@
different	JJ	different
FBs	NP	FB
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
significantly	RB	significantly
higher	JJR	high
rate	NN	rate
of	IN	of
FBIs	NP	<unknown>
per	IN	per
day	NN	day
in	IN	in
May	NP	May
2020	CD	@card@
(	(	(
COVID	NN	<unknown>
)	)	)
compared	VBN	compare
with	IN	with
May	NP	May
2019	CD	@card@
(	(	(
pre-COVID	NN	<unknown>
;	:	;
0.387	CD	@card@
versus	IN	versus
0.161	CD	@card@
;	:	;
P	NN	P
=	SYM	=
0.046	CD	@card@
)	)	)
.	SENT	.
The	DT	the
median	JJ	median
age	NN	age
at	IN	at
presentation	NN	presentation
was	VBD	be
not	RB	not
significantly	RB	significantly
different	JJ	different
between	IN	between
the	DT	the
two	CD	two
groups	NNS	group
(	(	(
pre-COVID	NP	<unknown>
,	,	,
63.8	CD	@card@
months	NNS	month
;	:	;
COVID	NP	<unknown>
,	,	,
62.5	CD	@card@
months	NNS	month
;	:	;
P	NN	P
=	SYM	=
0.78	CD	@card@
)	)	)
.	SENT	.
FBs	NNS	<unknown>
were	VBD	be
located	VBN	locate
in	IN	in
the	DT	the
esophagus	NN	esophagus
less	RBR	less
frequently	RB	frequently
in	IN	in
the	DT	the
COVID	NP	<unknown>
cohort	NN	cohort
than	IN	than
in	IN	in
the	DT	the
pre-COVID	JJ	<unknown>
cohort	NN	cohort
(	(	(
P	NN	P
&lt	NN	&lt
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
Endoscopies	NNS	endoscopy
were	VBD	be
less	JJR	less
frequently	RB	frequently
performed	VBN	perform
in	IN	in
the	DT	the
COVID	NP	<unknown>
cohort	NN	cohort
(	(	(
52.4	CD	@card@
%	NN	%
versus	IN	versus
70.0	CD	@card@
%	NN	%
;	:	;
odds	NNS	odd
ratio	NN	ratio
,	,	,
0.47	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.15-1.40	CD	@card@
)	)	)
.	SENT	.
The	DT	the
frequency	NN	frequency
of	IN	of
FBIs	NP	<unknown>
trended	VBD	trend
higher	JJR	high
in	IN	in
the	DT	the
COVID	NP	<unknown>
cohort	NN	cohort
,	,	,
with	IN	with
significantly	RB	significantly
more	JJR	more
FBIs	NP	<unknown>
in	IN	in
May	NP	May
2020	CD	@card@
when	WRB	when
compared	VBN	compare
with	IN	with
May	NP	May
2019	CD	@card@
.	SENT	.
Patients	NNS	patient
in	IN	in
the	DT	the
COVID	NP	<unknown>
cohort	NN	cohort
more	RBR	more
frequently	RB	frequently
had	VBD	have
FBs	NP	FB
located	VBN	locate
beyond	IN	beyond
the	DT	the
esophagus	NN	esophagus
,	,	,
indicating	VBG	indicate
later	JJR	late
presentation	NN	presentation
and	CC	and
a	DT	a
lesser	JJR	lesser
need	NN	need
for	IN	for
urgent	JJ	urgent
endoscopic	JJ	endoscopic
removal	NN	removal
.	SENT	.
33165674/	CD	@card@
Chest	NN	chest
CT	NP	CT
in	IN	in
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
:	:	:
what	WP	what
are	VBP	be
the	DT	the
findings	NNS	finding
in	IN	in
mid-term	NN	mid-term
follow-up	NN	follow-up
?	SENT	?
The	DT	the
purposes	NNS	purpose
of	IN	of
this	DT	this
study	NN	study
are	VBP	be
to	TO	to
investigate	VB	investigate
mid-term	NN	mid-term
chest	NN	chest
computed	VBD	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
findings	NNS	finding
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pneumonia	NN	pneumonia
,	,	,
assess	VB	assess
the	DT	the
rate	NN	rate
of	IN	of
complete	JJ	complete
resolution	NN	resolution
,	,	,
and	CC	and
determine	VB	determine
the	DT	the
individuals	NNS	individual
at	IN	at
risk	NN	risk
for	IN	for
residual	JJ	residual
abnormalities	NNS	abnormality
.	SENT	.
Fifty-two	NN	<unknown>
cases	NNS	case
of	IN	of
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
with	IN	with
at	IN	at
least	JJS	least
two	CD	two
chest	NN	chest
CTs	NN	CTs
and	CC	and
mean	VB	mean
3-month	JJ	<unknown>
interval	NN	interval
between	IN	between
the	DT	the
initial	JJ	initial
and	CC	and
follow-up	NN	follow-up
CT	NP	CT
were	VBD	be
enrolled	VBN	enroll
in	IN	in
this	DT	this
retrospective	JJ	retrospective
study	NN	study
.	SENT	.
Patients	NNS	patient
were	VBD	be
categorized	VBN	categorize
into	IN	into
two	CD	two
groups	NNS	group
:	:	:
complete	JJ	complete
resolution	NN	resolution
and	CC	and
residual	JJ	residual
disease	NN	disease
on	IN	on
follow-up	NN	follow-up
CT	NP	CT
.	SENT	.
Demographic	JJ	demographic
,	,	,
clinical	JJ	clinical
,	,	,
laboratory	NN	laboratory
,	,	,
and	CC	and
therapeutic	JJ	therapeutic
data	NNS	datum
as	RB	as
well	RB	well
as	IN	as
initial	JJ	initial
and	CC	and
follow-up	NN	follow-up
chest	NN	chest
CT	NP	CT
scans	NNS	scan
were	VBD	be
compared	VBN	compare
and	CC	and
analyzed	VBN	analyze
.	SENT	.
Thirty	CD	thirty
patients	NNS	patient
(	(	(
57.7	CD	@card@
%	NN	%
)	)	)
demonstrate	VBP	demonstrate
complete	JJ	complete
resolution	NN	resolution
of	IN	of
pulmonary	JJ	pulmonary
findings	NNS	finding
,	,	,
and	CC	and
22	CD	@card@
patients	NNS	patient
(	(	(
42.3	CD	@card@
%	NN	%
)	)	)
had	VBD	have
residual	JJ	residual
disease	NN	disease
on	IN	on
follow-up	NN	follow-up
CT	NP	CT
.	SENT	.
The	DT	the
mean	JJ	mean
time	NN	time
interval	NN	interval
between	IN	between
initial	JJ	initial
and	CC	and
follow-up	NN	follow-up
CT	NP	CT
was	VBD	be
91.3	CD	@card@
+-	NN	<unknown>
17.2	CD	@card@
and	CC	and
90.6	CD	@card@
+-	NN	<unknown>
14.3	CD	@card@
days	NNS	day
in	IN	in
the	DT	the
complete	JJ	complete
resolution	NN	resolution
and	CC	and
residual	JJ	residual
groups	NNS	group
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
most	RBS	most
common	JJ	common
radiologic	JJ	<unknown>
pattern	NN	pattern
in	IN	in
residual	JJ	residual
disease	NN	disease
was	VBD	be
ground-glass	NN	ground-glass
opacities	NNS	opacity
(	(	(
54.5	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
mixed	JJ	mixed
ground-glass	NN	ground-glass
and	CC	and
subpleural	JJ	subpleural
parenchymal	JJ	<unknown>
bands	NNS	band
(	(	(
31.8	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
pure	JJ	pure
parenchymal	JJ	<unknown>
bands	NNS	band
(	(	(
13.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Compared	VBN	compare
to	TO	to
complete	VB	complete
resolution	NN	resolution
group	NN	group
,	,	,
patients	NNS	patient
with	IN	with
residual	JJ	residual
disease	NN	disease
had	VBD	have
higher	JJR	high
CT	NP	CT
severity	NN	severity
score	NN	score
on	IN	on
initial	JJ	initial
exam	NN	exam
(	(	(
10.3	CD	@card@
+-	NN	<unknown>
5.4	CD	@card@
vs.	CC	vs.
7.3	CD	@card@
+-	NN	<unknown>
4.6	CD	@card@
,	,	,
P	NN	P
value	NN	value
=	SYM	=
0.036	CD	@card@
)	)	)
,	,	,
longer	JJR	long
duration	NN	duration
of	IN	of
hospitalization	NN	hospitalization
,	,	,
higher	JJR	high
rate	NN	rate
of	IN	of
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
admission	NN	admission
,	,	,
more	RBR	more
underlying	VBG	underlie
medical	JJ	medical
conditions	NNS	condition
,	,	,
higher	JJR	high
initial	JJ	initial
WBC	NP	WBC
count	NN	count
,	,	,
and	CC	and
higher	JJR	high
occurrence	NN	occurrence
rate	NN	rate
of	IN	of
leukocytosis	NN	<unknown>
in	IN	in
the	DT	the
hospitalization	NN	hospitalization
time	NN	time
period	NN	period
(	(	(
all	DT	all
P	NN	P
values	VBZ	value
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
Extensive	JJ	extensive
lung	NN	lung
involvement	NN	involvement
on	IN	on
initial	JJ	initial
CT	NP	CT
,	,	,
ICU	NP	ICU
admission	NN	admission
,	,	,
long	JJ	long
duration	NN	duration
of	IN	of
hospitalization	NN	hospitalization
,	,	,
presence	NN	presence
of	IN	of
underlying	VBG	underlie
medical	JJ	medical
conditions	NNS	condition
,	,	,
high	JJ	high
initial	JJ	initial
WBC	NP	WBC
count	NN	count
,	,	,
and	CC	and
development	NN	development
of	IN	of
leukocytosis	NN	<unknown>
during	IN	during
the	DT	the
course	NN	course
of	IN	of
disease	NN	disease
are	VBP	be
associated	VBN	associate
with	IN	with
more	JJR	more
prevalence	NN	prevalence
of	IN	of
chronic	JJ	chronic
lung	NN	lung
sequela	NN	sequela
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
32873261/	CD	@card@
Publisher	NN	publisher
Correction	NN	correction
to	TO	to
:	:	:
Protocol	NN	protocol
of	IN	of
a	DT	a
population-based	JJ	<unknown>
prospective	JJ	prospective
COVID-19	NP	<unknown>
cohort	NN	cohort
study	NN	study
Munich	NP	Munich
,	,	,
Germany	NP	Germany
(	(	(
KoCo19	NP	<unknown>
)	)	)
32693101/	NP	@card@
Triaging	NP	<unknown>
Access	NP	Access
to	TO	to
Critical	JJ	critical
Care	NP	Care
Resources	NPS	Resources
in	IN	in
Patients	NPS	Patients
With	IN	with
Chronic	JJ	chronic
Respiratory	JJ	respiratory
Diseases	NNS	disease
in	IN	in
the	DT	the
Event	NN	event
of	IN	of
a	DT	a
Major	NP	Major
COVID-19	NP	<unknown>
Surge	NN	surge
32512187/	CD	@card@
Using	VBG	use
GRADE	NN	grade
in	IN	in
situations	NNS	situation
of	IN	of
emergencies	NNS	emergency
and	CC	and
urgencies	NNS	urgency
:	:	:
certainty	NN	certainty
in	IN	in
evidence	NN	evidence
and	CC	and
recommendations	NNS	recommendation
matters	NNS	matter
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
now	RB	now
more	JJR	more
than	IN	than
ever	RB	ever
and	CC	and
no	RB	no
matter	VB	matter
what	WP	what
The	DT	the
public	NN	public
,	,	,
policy	NN	policy
makers	NNS	maker
,	,	,
and	CC	and
science	NN	science
communities	NNS	community
are	VBP	be
subject	JJ	subject
to	TO	to
many	JJ	many
false	JJ	false
,	,	,
uninformed	JJ	uninformed
,	,	,
overly	RB	overly
optimistic	JJ	optimistic
,	,	,
premature	JJ	premature
,	,	,
or	CC	or
simply	RB	simply
ridiculous	JJ	ridiculous
health	NN	health
claims	NNS	claim
.	SENT	.
The	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
and	CC	and
its	PP$	its
context	NN	context
is	VBZ	be
a	DT	a
paramount	JJ	paramount
example	NN	example
for	IN	for
such	JJ	such
claims	NNS	claim
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
describe	VBP	describe
why	WRB	why
expressing	VBG	express
the	DT	the
certainty	NN	certainty
in	IN	in
evidence	NN	evidence
to	TO	to
support	VB	support
a	DT	a
decision	NN	decision
is	VBZ	be
critical	JJ	critical
and	CC	and
why	WRB	why
the	DT	the
Grading	NP	Grading
of	IN	of
Recommendations	NNS	recommendation
Assessment	NP	Assessment
,	,	,
Development	NP	Development
and	CC	and
Evaluation	NN	evaluation
(	(	(
GRADE	NN	grade
)	)	)
approach	NN	approach
matters	NNS	matter
now	RB	now
,	,	,
perhaps	RB	perhaps
more	JJR	more
than	IN	than
ever	RB	ever
and	CC	and
no	RB	no
matter	VB	matter
what	WP	what
the	DT	the
specific	JJ	specific
topic	NN	topic
is	VBZ	be
in	IN	in
relation	NN	relation
to	TO	to
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
finally	RB	finally
also	RB	also
offer	VB	offer
suggestions	NNS	suggestion
for	IN	for
how	WRB	how
it	PP	it
can	MD	can
be	VB	be
used	VBN	use
appropriately	RB	appropriately
to	TO	to
support	VB	support
decision-making	NN	decision-making
at	IN	at
global	JJ	global
,	,	,
national	JJ	national
,	,	,
and	CC	and
local	JJ	local
level	NN	level
when	WRB	when
emergency	NN	emergency
,	,	,
urgent	JJ	urgent
or	CC	or
rapid	JJ	rapid
responses	NNS	response
are	VBP	be
needed	VBN	need
.	SENT	.
This	DT	this
is	VBZ	be
an	DT	an
invited	VBN	invite
commentary	NN	commentary
to	TO	to
address	VB	address
the	DT	the
objectives	NNS	objective
above	IN	above
building	NN	building
on	IN	on
examples	NNS	example
from	IN	from
the	DT	the
recent	JJ	recent
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
This	DT	this
includes	VBZ	include
an	DT	an
iterative	JJ	iterative
discussion	NN	discussion
of	IN	of
examples	NNS	example
and	CC	and
development	NN	development
of	IN	of
guidance	NN	guidance
.	SENT	.
The	DT	the
GRADE	NN	grade
approach	NN	approach
is	VBZ	be
a	DT	a
transparent	JJ	transparent
and	CC	and
structured	JJ	structured
method	NN	method
for	IN	for
assessing	VBG	assess
the	DT	the
certainty	NN	certainty
of	IN	of
evidence	NN	evidence
and	CC	and
when	WRB	when
developing	VBG	develop
recommendations	NNS	recommendation
that	WDT	that
requires	VBZ	require
little	JJ	little
additional	JJ	additional
time	NN	time
.	SENT	.
We	PP	we
describe	VBP	describe
why	WRB	why
emergency	NN	emergency
,	,	,
urgent	JJ	urgent
,	,	,
or	CC	or
rapid	JJ	rapid
responses	NNS	response
do	VBP	do
not	RB	not
justify	VB	justify
omitting	VBG	omit
this	DT	this
critical	JJ	critical
assessment	NN	assessment
of	IN	of
the	DT	the
evidence	NN	evidence
.	SENT	.
In	IN	in
situations	NNS	situation
of	IN	of
emergencies	NNS	emergency
and	CC	and
urgencies	NNS	urgency
,	,	,
such	JJ	such
as	IN	as
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
GRADE	NN	grade
can	MD	can
similarly	RB	similarly
be	VB	be
used	VBN	use
to	TO	to
express	VB	express
and	CC	and
convey	VB	convey
certainty	NN	certainty
in	IN	in
intervention	NN	intervention
effects	NNS	effect
,	,	,
test	NN	test
accuracy	NN	accuracy
,	,	,
risk	NN	risk
and	CC	and
prognostic	JJ	prognostic
factors	NNS	factor
,	,	,
consequences	NNS	consequence
of	IN	of
public	JJ	public
health	NN	health
measures	NNS	measure
,	,	,
and	CC	and
qualitative	JJ	qualitative
bodies	NNS	body
of	IN	of
evidence	NN	evidence
.	SENT	.
Assessing	VBG	assess
and	CC	and
communicating	VBG	communicate
the	DT	the
certainty	NN	certainty
of	IN	of
evidence	NN	evidence
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
critical	JJ	critical
.	SENT	.
Those	DT	those
offering	NN	offering
evidence	NN	evidence
synthesis	NN	synthesis
or	CC	or
making	VBG	make
recommendations	NNS	recommendation
should	MD	should
use	VB	use
transparent	JJ	transparent
ratings	NNS	rating
of	IN	of
the	DT	the
body	NN	body
of	IN	of
evidence	NN	evidence
supporting	VBG	support
a	DT	a
claim	NN	claim
regardless	RB	regardless
of	IN	of
time	NN	time
that	WDT	that
is	VBZ	be
available	JJ	available
or	CC	or
needed	VBN	need
to	TO	to
provide	VB	provide
this	DT	this
response	NN	response
.	SENT	.
GRADEing	VBG	<unknown>
the	DT	the
certainty	NN	certainty
of	IN	of
the	DT	the
available	JJ	available
evidence	NN	evidence
is	VBZ	be
more	RBR	more
important	JJ	important
than	IN	than
ever	RB	ever
because	IN	because
of	IN	of
the	DT	the
unprecedented	JJ	unprecedented
pressure	NN	pressure
for	IN	for
action	NN	action
and	CC	and
the	DT	the
large	JJ	large
number	NN	number
of	IN	of
people	NNS	people
affected	VBN	affect
by	IN	by
decisions	NNS	decision
.	SENT	.
The	DT	the
GRADE	NN	grade
approach	NN	approach
is	VBZ	be
a	DT	a
transparent	JJ	transparent
and	CC	and
structured	JJ	structured
method	NN	method
for	IN	for
assessing	VBG	assess
the	DT	the
certainty	NN	certainty
of	IN	of
evidence	NN	evidence
and	CC	and
when	WRB	when
developing	VBG	develop
recommendations	NNS	recommendation
that	WDT	that
requires	VBZ	require
little	JJ	little
additional	JJ	additional
time	NN	time
.	SENT	.
In	IN	in
situations	NNS	situation
of	IN	of
emergencies	NNS	emergency
and	CC	and
urgencies	NNS	urgency
,	,	,
such	JJ	such
as	IN	as
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
GRADE	NN	grade
can	MD	can
similarly	RB	similarly
be	VB	be
used	VBN	use
to	TO	to
express	VB	express
and	CC	and
convey	VB	convey
certainty	NN	certainty
in	IN	in
intervention	NN	intervention
effects	NNS	effect
,	,	,
test	NN	test
accuracy	NN	accuracy
,	,	,
risk	NN	risk
and	CC	and
prognostic	JJ	prognostic
factors	NNS	factor
,	,	,
consequences	NNS	consequence
of	IN	of
public	JJ	public
health	NN	health
measures	NNS	measure
,	,	,
and	CC	and
qualitative	JJ	qualitative
bodies	NNS	body
of	IN	of
evidence	NN	evidence
.	SENT	.
Requirements	NNS	requirement
for	IN	for
emergency	NN	emergency
,	,	,
urgency	NN	urgency
,	,	,
rapid	JJ	rapid
,	,	,
and	CC	and
routine	JJ	routine
GRADE	NN	grade
assessment	NN	assessment
may	MD	may
differ	VB	differ
but	CC	but
should	MD	should
transition	NN	transition
from	IN	from
one	CD	one
to	TO	to
another	DT	another
.	SENT	.
34268819/	CD	@card@
Self-infection	NN	Self-infection
with	IN	with
speech	NN	speech
aerosol	NN	aerosol
may	MD	may
contribute	VB	contribute
to	TO	to
COVID-19	NP	<unknown>
severity	NN	severity
34430514/	CD	@card@
Caring	NN	caring
for	IN	for
Cancer	NP	Cancer
Patients	NPS	Patients
during	IN	during
Corona	NP	Corona
Pandemic:(COVID-19):A	NP	<unknown>
Narrative	JJ	narrative
Review	NP	Review
Background	NN	background
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
,	,	,
the	DT	the
third	JJ	third
pandemic	NN	pandemic
of	IN	of
21st	JJ	21st
century	NN	century
which	WDT	which
has	VBZ	have
brought	VBN	bring
the	DT	the
whole	JJ	whole
world	NN	world
under	IN	under
panic	NN	panic
,	,	,
is	VBZ	be
caused	VBN	cause
by	IN	by
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
a	DT	a
zoonotic	JJ	<unknown>
beta	JJ	beta
coronavirus	NN	coronavirus
sharing	VBG	share
phylogenetic	JJ	phylogenetic
,	,	,
genomic	JJ	<unknown>
similarities	NNS	similarity
with	IN	with
SARS	NP	<unknown>
virus	NN	virus
and	CC	and
Middle	JJ	middle
East	JJ	East
Respiratory	JJ	respiratory
Syndrome	NN	syndrome
virus	NN	virus
.	SENT	.
Specific	JJ	specific
Concerns	NNS	concern
Cancer	NP	Cancer
patients	NNS	patient
are	VBP	be
at	IN	at
double	RB	double
the	DT	the
risk	NN	risk
than	IN	than
normal	JJ	normal
patients	NNS	patient
since	IN	since
these	DT	these
patients	NNS	patient
are	VBP	be
at	IN	at
immunocompromised	JJ	immunocompromised
state	NN	state
.	SENT	.
WHO	WP	who
guidelines	NNS	guideline
advice	NN	advice
the	DT	the
patients	NNS	patient
to	TO	to
plan	VB	plan
only	JJ	only
emergency	NN	emergency
hospital	NN	hospital
visits	VBZ	visit
only	RB	only
till	IN	till
the	DT	the
pandemic	NN	pandemic
persists	VBZ	persist
.	SENT	.
Should	MD	should
meet	VB	meet
patient/visitors	NNS	patient/visitor
in	IN	in
a	DT	a
well-ventilated	JJ	well-ventilated
room	NN	room
or	CC	or
outdoors	RB	outdoors
and	CC	and
maintain	VB	maintain
at	IN	at
least	JJS	least
2	CD	@card@
m	NN	m
distance	NN	distance
between	IN	between
the	DT	the
visitor/patients	NNS	visitor/patient
.	SENT	.
It	PP	it
also	RB	also
encourages	VBZ	encourage
the	DT	the
patient	NN	patient
to	TO	to
refill	VB	refill
the	DT	the
prescribed	JJ	prescribed
medications	NNS	medication
in	IN	in
well	RB	well
advance	NN	advance
and	CC	and
to	TO	to
stay	VB	stay
physically	RB	physically
active	JJ	active
,	,	,
if	IN	if
possible	JJ	possible
.	SENT	.
Discussion	NN	discussion
The	DT	the
World	NP	World
Health	NP	Health
Organizations	NP	Organizations
'	POS	'
isolate	NN	isolate
,	,	,
trace	NN	trace
,	,	,
test	NN	test
,	,	,
treat	NN	treat
policy	NN	policy
needs	VBZ	need
to	TO	to
be	VB	be
followed	VBN	follow
to	TO	to
protect	VB	protect
these	DT	these
high-risk	JJ	high-risk
patients	NNS	patient
from	IN	from
this	DT	this
global	JJ	global
pandemic	NN	pandemic
.	SENT	.
]	SYM	]
33772419/	CD	@card@
Risk	NN	risk
Factors	NNS	factor
for	IN	for
Hospitalization	NN	hospitalization
Among	IN	among
Patients	NPS	Patients
with	IN	with
COVID-19	NP	<unknown>
at	IN	at
a	DT	a
Community	NP	Community
Ambulatory	JJ	ambulatory
Clinic	NP	Clinic
in	IN	in
Massachusetts	NP	Massachusetts
During	IN	during
the	DT	the
Initial	JJ	initial
Pandemic	JJ	pandemic
Surge	NN	surge
Among	IN	among
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
evaluated	VBD	evaluate
in	IN	in
outpatient	NN	outpatient
settings	NNS	setting
,	,	,
factors	NNS	factor
associated	VBN	associate
with	IN	with
hospitalization	NN	hospitalization
remain	VBP	remain
poorly	RB	poorly
understood	VBN	understand
.	SENT	.
Multivariable	JJ	Multivariable
regressions	NNS	regression
were	VBD	be
used	VBN	use
to	TO	to
assess	VB	assess
sociodemographic	JJ	sociodemographic
and	CC	and
clinical	JJ	clinical
factors	NNS	factor
associated	VBN	associate
with	IN	with
increased	VBN	increase
odds	NNS	odd
of	IN	of
hospitalization	NN	hospitalization
among	IN	among
patients	NNS	patient
with	IN	with
confirmed	VBN	confirm
COVID-19	NP	<unknown>
between	IN	between
March	NP	March
18	CD	@card@
,	,	,
2020	CD	@card@
through	IN	through
April	NP	April
25	CD	@card@
,	,	,
2020	CD	@card@
at	IN	at
a	DT	a
community-based	JJ	community-based
outpatient	NN	outpatient
clinic	NN	clinic
in	IN	in
Massachusetts	NP	Massachusetts
.	SENT	.
Older	JJR	old
age	NN	age
,	,	,
BMI	NP	BMI
&gt	NN	&gt
;	:	;
=	SYM	=
25	CD	@card@
,	,	,
self-reported	JJ	self-reported
dizziness/lightheadedness	NN	dizziness/lightheadedness
,	,	,
temperature	NN	temperature
&gt	NN	&gt
;	:	;
=	SYM	=
99.5	CD	@card@
F	NN	F
,	,	,
tachycardia	NN	tachycardia
,	,	,
and	CC	and
oxygen	NN	oxygen
saturation	NN	saturation
&lt	NN	&lt
;	:	;
95	CD	@card@
%	NN	%
were	VBD	be
associated	VBN	associate
with	IN	with
increased	VBN	increase
odds	NNS	odd
of	IN	of
hospitalization	NN	hospitalization
after	IN	after
adjustment	NN	adjustment
for	IN	for
age	NN	age
,	,	,
sex	NN	sex
,	,	,
and	CC	and
BMI	NP	BMI
.	SENT	.
There	EX	there
was	VBD	be
also	RB	also
an	DT	an
association	NN	association
between	IN	between
speaking	VBG	speak
Spanish	JJ	Spanish
as	IN	as
primary	JJ	primary
language	NN	language
and	CC	and
increased	VBN	increase
odds	NNS	odd
of	IN	of
hospitalization	NN	hospitalization
(	(	(
compared	VBN	compare
to	TO	to
English	NP	English
,	,	,
adjusted	VBN	adjust
OR	CC	or
=	SYM	=
2.99	CD	@card@
[	SYM	[
95	CD	@card@
%	NN	%
CI	NP	CI
1.39	CD	@card@
,	,	,
6.39	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
Speaking	VBG	speak
Portuguese	JJ	Portuguese
as	IN	as
primary	JJ	primary
language	NN	language
was	VBD	be
not	RB	not
associated	VBN	associate
with	IN	with
increased	VBN	increase
odds	NNS	odd
of	IN	of
hospitalization	NN	hospitalization
(	(	(
compared	VBN	compare
to	TO	to
English	NP	English
,	,	,
adjusted	VBN	adjust
OR	CC	or
=	SYM	=
1.83	CD	@card@
[	SYM	[
0.78	CD	@card@
,	,	,
4.28	CD	@card@
]	SYM	]
)	)	)
.	SENT	.
In	IN	in
addition	NN	addition
to	TO	to
several	JJ	several
clinical	JJ	clinical
risk	NN	risk
factors	NNS	factor
established	VBN	establish
among	IN	among
inpatients	NNS	inpatient
,	,	,
our	PP$	our
study	NN	study
found	VBD	find
that	IN	that
primarily	RB	primarily
speaking	VBG	speak
Spanish	JJ	Spanish
,	,	,
but	CC	but
not	RB	not
Portuguese	JJ	Portuguese
,	,	,
was	VBD	be
a	DT	a
marker	NN	marker
of	IN	of
hospitalization	NN	hospitalization
risk	NN	risk
among	IN	among
a	DT	a
diverse	JJ	diverse
outpatient	NN	outpatient
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
33634042/	CD	@card@
Inequities	NNS	inequity
as	IN	as
a	DT	a
social	JJ	social
determinant	NN	determinant
of	IN	of
health	NN	health
:	:	:
Responsibility	NN	responsibility
in	IN	in
paying	VBG	pay
attention	NN	attention
to	TO	to
the	DT	the
poor	JJ	poor
and	CC	and
vulnerable	JJ	vulnerable
at	IN	at
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
The	DT	the
social	JJ	social
nature	NN	nature
of	IN	of
COVID-19	NP	<unknown>
disease	NN	disease
requires	VBZ	require
that	IN	that
all	DT	all
social	JJ	social
capacities	NNS	capacity
,	,	,
including	VBG	include
prevention	NN	prevention
and	CC	and
socio-economic	JJ	socio-economic
policies	NNS	policy
,	,	,
be	VB	be
used	VBN	use
to	TO	to
prevent	VB	prevent
and	CC	and
control	VB	control
it	PP	it
as	IN	as
much	RB	much
as	RB	as
possible	JJ	possible
in	IN	in
order	NN	order
to	TO	to
reimburse	VB	reimburse
and	CC	and
compensate	VB	compensate
the	DT	the
lost	VBN	lose
income	NN	income
of	IN	of
the	DT	the
affected	JJ	affected
strata	NNS	stratum
in	IN	in
the	DT	the
form	NN	form
of	IN	of
financial	JJ	financial
and	CC	and
livelihood	NN	livelihood
assistance	NN	assistance
.	SENT	.
35280451/	CD	@card@
Trauma-Informed	NP	<unknown>
Care	NP	Care
for	IN	for
Hospitalized	VBN	hospitalize
Adolescents	NNS	adolescent
Exposure	NN	exposure
to	TO	to
trauma	NN	trauma
accelerates	VBZ	accelerate
during	IN	during
the	DT	the
adolescence	NN	adolescence
,	,	,
and	CC	and
due	JJ	due
to	TO	to
increased	VBN	increase
behavioral	JJ	behavioral
and	CC	and
psychiatric	JJ	psychiatric
vulnerability	NN	vulnerability
during	IN	during
this	DT	this
developmental	JJ	developmental
period	NN	period
,	,	,
traumatic	JJ	traumatic
events	NNS	event
during	IN	during
this	DT	this
time	NN	time
are	VBP	be
more	RBR	more
likely	JJ	likely
to	TO	to
cause	VB	cause
a	DT	a
lasting	JJ	lasting
impact	NN	impact
.	SENT	.
In	IN	in
this	DT	this
article	NN	article
,	,	,
we	PP	we
use	VBP	use
three	CD	three
case	NN	case
studies	NNS	study
of	IN	of
hospitalized	VBN	hospitalize
adolescents	NNS	adolescent
to	TO	to
illustrate	VB	illustrate
the	DT	the
application	NN	application
of	IN	of
trauma-informed	JJ	trauma-informed
principles	NNS	principle
of	IN	of
care	NN	care
with	IN	with
this	DT	this
unique	JJ	unique
population	NN	population
.	SENT	.
Adolescents	NNS	adolescent
today	NN	today
are	VBP	be
caught	VBN	catch
in	IN	in
the	DT	the
crosshairs	NNS	crosshair
of	IN	of
two	CD	two
syndemics:racism	NN	syndemics:racism
and	CC	and
other	JJ	other
structural	JJ	structural
inequities	NNS	inequity
and	CC	and
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Increased	VBN	increase
hospitalizations	NNS	hospitalization
and	CC	and
mental	JJ	mental
health	NN	health
diagnoses	NNS	diagnosis
during	IN	during
the	DT	the
past	JJ	past
two	CD	two
years	NNS	year
signal	VBP	signal
toxic	JJ	toxic
levels	NNS	level
of	IN	of
stress	NN	stress
affecting	VBG	affect
this	DT	this
group	NN	group
.	SENT	.
Trauma-informed	JJ	Trauma-informed
care	NN	care
promotes	VBZ	promote
health	NN	health
,	,	,
healing	NN	healing
,	,	,
and	CC	and
equity	NN	equity
.	SENT	.
This	DT	this
concept	NN	concept
of	IN	of
the	DT	the
"	``	"
trauma-informed	JJ	trauma-informed
approach	NN	approach
"	''	"
is	VBZ	be
still	RB	still
novel	JJ	novel
;	:	;
through	IN	through
examples	NNS	example
and	CC	and
practice	NN	practice
,	,	,
providers	NNS	provider
can	MD	can
learn	VB	learn
to	TO	to
universally	RB	universally
apply	VB	apply
the	DT	the
trauma-informed	JJ	trauma-informed
care	NN	care
framework	NN	framework
to	TO	to
every	DT	every
patient	JJ	patient
encounter	NN	encounter
to	TO	to
address	VB	address
the	DT	the
harmful	JJ	harmful
effects	NNS	effect
of	IN	of
trauma	NN	trauma
and	CC	and
promote	VB	promote
recovery	NN	recovery
and	CC	and
resilience	NN	resilience
.	SENT	.
33505949/	CD	@card@
Clinical	JJ	clinical
Characteristics	NNS	characteristic
and	CC	and
Diagnostic	JJ	diagnostic
Challenges	NNS	challenge
of	IN	of
COVID-19	NP	<unknown>
:	:	:
An	DT	an
Update	NN	update
From	IN	from
the	DT	the
Global	NP	Global
Perspective	NP	Perspective
Clinical	JJ	clinical
characteristics	NNS	characteristic
are	VBP	be
essential	JJ	essential
for	IN	for
the	DT	the
correct	JJ	correct
diagnosis	NN	diagnosis
of	IN	of
diseases	NNS	disease
.	SENT	.
The	DT	the
current	JJ	current
review	NN	review
aimed	VBN	aim
to	TO	to
summarize	VB	summarize
the	DT	the
global	JJ	global
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
patients	NNS	patient
systematically	RB	systematically
and	CC	and
identify	VB	identify
their	PP$	their
diagnostic	JJ	diagnostic
challenges	NNS	challenge
to	TO	to
help	VB	help
the	DT	the
medical	JJ	medical
practitioners	NNS	practitioner
properly	RB	properly
diagnose	VBP	diagnose
and	CC	and
for	IN	for
better	JJR	good
management	NN	management
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
systematic	JJ	systematic
search	NN	search
in	IN	in
PubMed	NP	<unknown>
,	,	,
Web	NP	Web
of	IN	of
Science	NP	Science
,	,	,
Scopus	NP	Scopus
,	,	,
Science	NP	Science
Direct	NP	Direct
,	,	,
and	CC	and
Google	NP	<unknown>
Scholar	NN	scholar
databases	NNS	database
for	IN	for
original	JJ	original
articles	NNS	article
containing	VBG	contain
clinical	JJ	clinical
information	NN	information
of	IN	of
COVID-19	NP	<unknown>
published	VBD	publish
up	RP	up
to	TO	to
7th	JJ	7th
May	NP	May
2020	CD	@card@
.	SENT	.
Two	CD	two
researchers	NNS	researcher
independently	RB	independently
searched	VBD	search
the	DT	the
databases	NNS	database
to	TO	to
extract	VB	extract
eligible	JJ	eligible
articles	NNS	article
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
34	CD	@card@
studies	NNS	study
from	IN	from
8	CD	@card@
different	JJ	different
countries	NNS	country
with	IN	with
10889	CD	@card@
case-patients	NNS	case-patient
were	VBD	be
included	VBN	include
for	IN	for
clinical	JJ	clinical
characteristics	NNS	characteristic
.	SENT	.
The	DT	the
most	RBS	most
common	JJ	common
clinical	JJ	clinical
symptoms	NNS	symptom
were	VBD	be
cough	NN	cough
59.6	CD	@card@
,	,	,
fever	NN	fever
46.9	CD	@card@
,	,	,
fatigue	NN	fatigue
27.8	CD	@card@
,	,	,
and	CC	and
dyspnea	NN	dyspnea
20.23	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
prominent	JJ	prominent
laboratory	NN	laboratory
findings	NNS	finding
were	VBD	be
lymphocytopenia	NP	<unknown>
55.9	CD	@card@
,	,	,
elevated	JJ	elevated
levels	NNS	level
of	IN	of
CRP	NP	<unknown>
61.9	CD	@card@
,	,	,
aspartate	NN	<unknown>
aminotransferase	NN	aminotransferase
53.3	CD	@card@
,	,	,
LDH	NP	LDH
40.8	CD	@card@
,	,	,
ESR	NP	ESR
72.99	CD	@card@
,	,	,
serum	NN	serum
ferritin	NN	ferritin
63	CD	@card@
,	,	,
IL-6	NP	<unknown>
52	CD	@card@
,	,	,
and	CC	and
prothrombin	NN	prothrombin
time	NN	time
35.47	CD	@card@
%	NN	%
,	,	,
and	CC	and
decreased	VBD	decrease
levels	NNS	level
of	IN	of
platelets	NNS	platelet
17.26	CD	@card@
,	,	,
eosinophils	NNS	eosinophil
59.0	CD	@card@
,	,	,
hemoglobin	NN	hemoglobin
29	CD	@card@
,	,	,
and	CC	and
albumin	NN	albumin
38.4	CD	@card@
%	NN	%
.	SENT	.
CT	NP	CT
scan	NN	scan
of	IN	of
the	DT	the
chest	NN	chest
showed	VBD	show
an	DT	an
abnormality	NN	abnormality
in	IN	in
93.50	CD	@card@
%	NN	%
cases	NNS	case
with	IN	with
bilateral	JJ	bilateral
lungs	NNS	lung
71.1	CD	@card@
%	NN	%
,	,	,
ground-glass	NN	ground-glass
opacity	NN	opacity
48	CD	@card@
%	NN	%
,	,	,
lesion	NN	lesion
in	IN	in
lungs	NNS	lung
78.3	CD	@card@
%	NN	%
,	,	,
and	CC	and
enlargement	NN	enlargement
of	IN	of
lymph	NN	lymph
node	NN	node
50.7	CD	@card@
%	NN	%
.	SENT	.
Common	JJ	common
comorbidities	NNS	comorbidity
were	VBD	be
hypertension	NN	hypertension
,	,	,
diabetes	NN	diabetes
,	,	,
obesity	NN	obesity
,	,	,
and	CC	and
cardiovascular	JJ	cardiovascular
diseases	NNS	disease
.	SENT	.
The	DT	the
estimated	JJ	estimated
median	JJ	median
incubation	NN	incubation
period	NN	period
was	VBD	be
5.36	CD	@card@
days	NNS	day
,	,	,
and	CC	and
the	DT	the
overall	JJ	overall
case	NN	case
fatality	NN	fatality
rate	NN	rate
was	VBD	be
16.9	CD	@card@
%	NN	%
(	(	(
Global	JJ	global
case	NN	case
fatality	NN	fatality
outside	IN	outside
China	NP	China
was	VBD	be
22.24	CD	@card@
%	NN	%
:	:	:
USA	NP	USA
21.24	CD	@card@
%	NN	%
,	,	,
Italy	NP	Italy
25.61	CD	@card@
%	NN	%
,	,	,
and	CC	and
others	NNS	other
0	CD	@card@
%	NN	%
;	:	;
whereas	IN	whereas
the	DT	the
case	NN	case
fatality	NN	fatality
inside	IN	inside
the	DT	the
Hubei	NP	Hubei
Province	NP	Province
of	IN	of
China	NP	China
was	VBD	be
found	VBN	find
to	TO	to
be	VB	be
11.71	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Global	JJ	global
features	NNS	feature
on	IN	on
the	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
COVID-19	NP	<unknown>
obtained	VBD	obtain
from	IN	from
laboratory	NN	laboratory
tests	NNS	test
and	CC	and
CT	NP	CT
scan	NN	scan
results	NNS	result
will	MD	will
provide	VB	provide
useful	JJ	useful
information	NN	information
to	TO	to
the	DT	the
physicians	NNS	physician
to	TO	to
diagnose	VB	diagnose
the	DT	the
disease	NN	disease
and	CC	and
for	IN	for
better	JJR	good
management	NN	management
of	IN	of
the	DT	the
patients	NNS	patient
as	IN	as
well	RB	well
as	RB	as
to	TO	to
address	VB	address
the	DT	the
diagnostic	JJ	diagnostic
challenges	NNS	challenge
to	TO	to
control	VB	control
the	DT	the
infection	NN	infection
.	SENT	.
34817214/	CD	@card@
Whole-Genome	NP	<unknown>
Sequences	NNS	sequence
of	IN	of
SARS-CoV-2	NP	<unknown>
Isolates	VBZ	isolate
from	IN	from
the	DT	the
Dominican	NP	Dominican
Republic	NP	Republic
Here	RB	here
,	,	,
we	PP	we
report	VBP	report
the	DT	the
genome	NN	genome
sequences	NNS	sequence
of	IN	of
five	CD	five
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
strains	NNS	strain
that	WDT	that
were	VBD	be
obtained	VBN	obtain
from	IN	from
symptomatic	JJ	symptomatic
individuals	NNS	individual
with	IN	with
travel	NN	travel
histories	NNS	history
during	IN	during
community	NN	community
surveillance	NN	surveillance
in	IN	in
the	DT	the
Dominican	NP	Dominican
Republic	NP	Republic
in	IN	in
2020	CD	@card@
.	SENT	.
These	DT	these
sequences	NNS	sequence
provide	VBP	provide
a	DT	a
starting	VBG	start
point	NN	point
for	IN	for
further	JJR	further
genomic	JJ	<unknown>
studies	NNS	study
of	IN	of
gene	NN	gene
flow	NN	flow
and	CC	and
molecular	JJ	molecular
diversity	NN	diversity
in	IN	in
the	DT	the
Caribbean	JJ	Caribbean
nation	NN	nation
.	SENT	.
Phylogenetic	JJ	phylogenetic
analysis	NN	analysis
suggests	VBZ	suggest
that	IN	that
all	DT	all
genomes	NNS	genome
correspond	VBP	correspond
to	TO	to
the	DT	the
B.1	JJ	B@card@
variant	NN	variant
.	SENT	.
34252379/	CD	@card@
Azithromycin	NP	<unknown>
:	:	:
can	MD	can
its	PP$	its
benefit	NN	benefit
be	VB	be
ruled	VBN	rule
out	RP	out
in	IN	in
mild	JJ	mild
COVID-19	NP	<unknown>
?	SENT	?
33619245/	CD	@card@
Genome	NN	genome
and	CC	and
epigenome	JJ	<unknown>
editing	VBG	edit
identify	VB	identify
CCR9	NP	<unknown>
and	CC	and
SLC6A20	NP	<unknown>
as	IN	as
target	NN	target
genes	NNS	gene
at	IN	at
the	DT	the
3p21.31	JJ	3p@card@
locus	NN	locus
associated	VBN	associate
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
33644905/	CD	@card@
Nursing	NP	Nursing
care	NN	care
management	NN	management
based	VBN	base
on	IN	on
the	DT	the
Omaha	NP	Omaha
system	NN	system
for	IN	for
inpatients	NNS	inpatient
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
:	:	:
An	DT	an
electronic	JJ	electronic
health	NN	health
record	NN	record
study	NN	study
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
identify	VB	identify
the	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
of	IN	of
patients	NNS	patient
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
the	DT	the
existing	JJ	existing
nursing	NN	nursing
problems	NNS	problem
based	VBN	base
on	IN	on
the	DT	the
Omaha	NP	Omaha
System	NP	System
,	,	,
and	CC	and
to	TO	to
establish	VB	establish
a	DT	a
comprehensive	JJ	comprehensive
nursing	NN	nursing
care	NN	care
management	NN	management
plan	NN	plan
by	IN	by
determining	VBG	determine
the	DT	the
nursing	NN	nursing
interventions	NNS	intervention
and	CC	and
care	NN	care
outcomes	NNS	outcome
.	SENT	.
This	DT	this
study	NN	study
used	VBD	use
a	DT	a
descriptive	JJ	descriptive
cross-sectional	JJ	cross-sectional
design	NN	design
.	SENT	.
This	DT	this
study	NN	study
was	VBD	be
conducted	VBN	conduct
in	IN	in
a	DT	a
training	NN	training
and	CC	and
research	NN	research
hospital	NN	hospital
with	IN	with
25	CD	@card@
non-intubated	JJ	<unknown>
COVID-19	NP	<unknown>
inpatients	NNS	inpatient
between	IN	between
6	CD	@card@
April	NP	April
and	CC	and
13	CD	@card@
May	NP	May
2020	CD	@card@
in	IN	in
Turkey	NP	Turkey
.	SENT	.
Data	NNS	datum
were	VBD	be
collected	VBN	collect
using	VBG	use
a	DT	a
Socio-demographic	JJ	Socio-demographic
and	CC	and
Clinical	JJ	clinical
Characteristics	NNS	characteristic
Form	NN	form
,	,	,
the	DT	the
COVID-19	NP	<unknown>
Response	NP	Response
Separate	JJ	separate
Guidelines	NNS	guideline
and	CC	and
the	DT	the
Omaha	NP	Omaha
System	NP	System
and	CC	and
Nightingale	NP	Nightingale
Notes	NPS	Notes
software	NN	software
.	SENT	.
Data	NNS	datum
were	VBD	be
analysed	VBN	analyse
using	VBG	use
descriptive	JJ	descriptive
statistical	JJ	statistical
tests	NNS	test
and	CC	and
the	DT	the
chi-square	NN	chi-square
method	NN	method
.	SENT	.
Using	VBG	use
the	DT	the
Omaha	NP	Omaha
System	NP	System
,	,	,
it	PP	it
was	VBD	be
shown	VBN	show
that	IN	that
the	DT	the
patients	NNS	patient
'	POS	'
most	RBS	most
common	JJ	common
problems	NNS	problem
were	VBD	be
communicable/infectious	JJ	communicable/infectious
condition	NN	condition
,	,	,
respiration	NN	respiration
,	,	,
circulation	NN	circulation
,	,	,
pain	NN	pain
,	,	,
nutrition	NN	nutrition
,	,	,
personal	JJ	personal
care	NN	care
and	CC	and
substance	NN	substance
use	NN	use
respectively	RB	respectively
.	SENT	.
The	DT	the
most	RBS	most
common	JJ	common
signs	NNS	sign
and	CC	and
symptoms	NNS	symptom
were	VBD	be
signs	NNS	sign
of	IN	of
infection	NN	infection
,	,	,
fever	NN	fever
,	,	,
cough	NN	cough
,	,	,
respiratory	JJ	respiratory
distress	NN	distress
and	CC	and
pain	NN	pain
.	SENT	.
The	DT	the
interventions	NNS	intervention
that	WDT	that
were	VBD	be
performed	VBN	perform
most	RBS	most
frequently	RB	frequently
to	TO	to
the	DT	the
patients	NNS	patient
included	VBD	include
infection	NN	infection
precautions	NNS	precaution
,	,	,
medication	NN	medication
action/side	NN	<unknown>
effects	NNS	effect
,	,	,
signs/symptoms-physical	JJ	signs/symptoms-physical
,	,	,
dietary	JJ	dietary
management	NN	management
and	CC	and
nursing	NN	nursing
care	NN	care
targets	NNS	target
for	IN	for
intervention	NN	intervention
.	SENT	.
These	DT	these
interventions	NNS	intervention
were	VBD	be
applied	VBN	apply
using	VBG	use
the	DT	the
category	NN	category
of	IN	of
teaching	NN	teaching
,	,	,
guidance	NN	guidance
and	CC	and
counselling	VBG	counsel
.	SENT	.
A	DT	a
significant	JJ	significant
improvement	NN	improvement
was	VBD	be
observed	VBN	observe
in	IN	in
the	DT	the
patients	NNS	patient
'	POS	'
pre-	NN	pre-
and	CC	and
post-intervention	NN	post-intervention
knowledge	NN	knowledge
,	,	,
behaviour	NN	behaviour
and	CC	and
status	NN	status
scores	NNS	score
.	SENT	.
The	DT	the
results	NNS	result
showed	VBD	show
that	IN	that
the	DT	the
Omaha	NP	Omaha
System	NP	System
provided	VBD	provide
effective	JJ	effective
guidelines	NNS	guideline
for	IN	for
diagnosing	VBG	diagnose
the	DT	the
problems	NNS	problem
,	,	,
planning	VBG	plan
and	CC	and
implementing	VBG	implement
appropriate	JJ	appropriate
interventions	NNS	intervention
for	IN	for
the	DT	the
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
Therefore	RB	therefore
,	,	,
it	PP	it
is	VBZ	be
recommended	VBN	recommend
to	TO	to
use	VB	use
the	DT	the
Omaha	NP	Omaha
System	NP	System
in	IN	in
nursing	VBG	nurse
care	NN	care
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
This	DT	this
is	VBZ	be
the	DT	the
first	JJ	first
study	NN	study
to	TO	to
identify	VB	identify
the	DT	the
nursing	NN	nursing
problems	NNS	problem
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
and	CC	and
to	TO	to
evaluate	VB	evaluate
the	DT	the
outcomes	NNS	outcome
of	IN	of
nursing	NN	nursing
interventions	NNS	intervention
and	CC	and
care	NN	care
using	VBG	use
an	DT	an
international	JJ	international
taxonomy	NN	taxonomy
along	IN	along
with	IN	with
electronic	JJ	electronic
health	NN	health
record	NN	record
software	NN	software
.	SENT	.
The	DT	the
findings	NNS	finding
of	IN	of
this	DT	this
study	NN	study
can	MD	can
provide	VB	provide
evidence-based	JJ	<unknown>
guidelines	NNS	guideline
addressing	VBG	address
the	DT	the
nursing	NN	nursing
problems	NNS	problem
,	,	,
interventions	NNS	intervention
and	CC	and
outcomes	NNS	outcome
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
33626155/	CD	@card@
Factors	NNS	factor
influencing	VBG	influence
decision	NN	decision
making	VBG	make
for	IN	for
implementing	VBG	implement
e-health	NP	e-health
in	IN	in
light	NN	light
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
in	IN	in
Gulf	NP	Gulf
Cooperation	NP	Cooperation
Council	NP	Council
countries	NNS	country
Electronic	JJ	electronic
health	NN	health
(	(	(
e-health	NP	e-health
)	)	)
approaches	VBZ	approach
such	JJ	such
as	IN	as
telemedicine	NN	telemedicine
,	,	,
mobile	JJ	mobile
health	NN	health
,	,	,
virtual	JJ	virtual
healthcare	NN	<unknown>
and	CC	and
electronic	JJ	electronic
health	NN	health
records	NNS	record
are	VBP	be
considered	VBN	consider
to	TO	to
be	VB	be
effective	JJ	effective
in	IN	in
increasing	VBG	increase
access	NN	access
to	TO	to
healthcare	NN	<unknown>
services	NNS	service
,	,	,
reducing	VBG	reduce
operational	JJ	operational
costs	NNS	cost
and	CC	and
improving	VBG	improve
the	DT	the
quality	NN	quality
of	IN	of
healthcare	NN	<unknown>
services	NNS	service
during	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
outbreak	NN	outbreak
,	,	,
a	DT	a
pandemic	NN	pandemic
resulting	VBG	result
from	IN	from
the	DT	the
spread	NN	spread
of	IN	of
a	DT	a
novel	NN	novel
coronavirus	NN	coronavirus
discovered	VBN	discover
in	IN	in
December	NP	December
2019	CD	@card@
.	SENT	.
In	IN	in
this	DT	this
context	NN	context
,	,	,
the	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
identify	VB	identify
the	DT	the
most	RBS	most
important	JJ	important
factors	NNS	factor
influencing	VBG	influence
decision	NN	decision
making	VBG	make
on	IN	on
the	DT	the
implementation	NN	implementation
of	IN	of
e-health	NP	e-health
in	IN	in
Gulf	NP	Gulf
Cooperation	NP	Cooperation
Council	NP	Council
(	(	(
GCC	NP	GCC
)	)	)
member	NN	member
states	NNS	state
(	(	(
Bahrain	NP	Bahrain
,	,	,
Kuwait	NP	Kuwait
,	,	,
Oman	NP	Oman
,	,	,
Qatar	NP	Qatar
,	,	,
Saudi	NP	Saudi
Arabia	NP	Arabia
and	CC	and
the	DT	the
United	NP	United
Arab	NP	Arab
Emirates	NP	Emirates
)	)	)
,	,	,
which	WDT	which
are	VBP	be
in	IN	in
the	DT	the
process	NN	process
of	IN	of
digitizing	VBG	digitize
healthcare	NN	<unknown>
services	NNS	service
.	SENT	.
This	DT	this
study	NN	study
reviewed	VBD	review
the	DT	the
literature	NN	literature
to	TO	to
identify	VB	identify
the	DT	the
important	JJ	important
factors	NNS	factor
influencing	VBG	influence
decision	NN	decision
making	VBG	make
on	IN	on
e-health	NP	e-health
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
a	DT	a
questionnaire-based	JJ	<unknown>
survey	NN	survey
was	VBD	be
conducted	VBN	conduct
in	IN	in
order	NN	order
to	TO	to
identify	VB	identify
the	DT	the
most	RBS	most
important	JJ	important
criteria	NNS	criterion
to	TO	to
be	VB	be
considered	VBN	consider
in	IN	in
decision	NN	decision
making	VBG	make
on	IN	on
e-health	NP	e-health
.	SENT	.
The	DT	the
survey	NN	survey
link	NN	link
was	VBD	be
forwarded	VBN	forward
to	TO	to
978	CD	@card@
healthcare	NN	<unknown>
practitioners	NNS	practitioner
and	CC	and
42	CD	@card@
experts	NNS	expert
(	(	(
purposive	JJ	purposive
sampling	NN	sampling
)	)	)
,	,	,
from	IN	from
which	WDT	which
a	DT	a
final	JJ	final
sample	NN	sample
of	IN	of
892	CD	@card@
(	(	(
864	CD	@card@
practitioners	NNS	practitioner
and	CC	and
28	CD	@card@
experts	NNS	expert
)	)	)
was	VBD	be
achieved	VBN	achieve
,	,	,
reflecting	VBG	reflect
a	DT	a
response	NN	response
rate	NN	rate
of	IN	of
87.45	CD	@card@
%	NN	%
.	SENT	.
Of	IN	of
the	DT	the
44	CD	@card@
factors	NNS	factor
identified	VBN	identify
under	IN	under
seven	CD	seven
themes	NNS	theme
(	(	(
strategic	JJ	strategic
,	,	,
quality	NN	quality
,	,	,
management	NN	management
,	,	,
technology	NN	technology
,	,	,
function	NN	function
characteristics	NNS	characteristic
,	,	,
economic	JJ	economic
,	,	,
sociocultural	JJ	sociocultural
and	CC	and
demographic	JJ	demographic
factors	NNS	factor
)	)	)
,	,	,
22	CD	@card@
factors	NNS	factor
were	VBD	be
identified	VBN	identify
to	TO	to
be	VB	be
the	DT	the
most	RBS	most
important	JJ	important
criteria	NNS	criterion
.	SENT	.
Findings	NNS	finding
from	IN	from
this	DT	this
study	NN	study
suggest	VBP	suggest
that	IN	that
decision	NN	decision
making	VBG	make
in	IN	in
relation	NN	relation
to	TO	to
e-health	NP	e-health
is	VBZ	be
a	DT	a
complex	JJ	complex
process	NN	process
that	WDT	that
requires	VBZ	require
consideration	NN	consideration
of	IN	of
various	JJ	various
factors	NNS	factor
.	SENT	.
It	PP	it
was	VBD	be
also	RB	also
found	VBN	find
that	IN	that
attention	NN	attention
should	MD	should
be	VB	be
paid	VBN	pay
to	TO	to
sociocultural	JJ	sociocultural
and	CC	and
demographic	JJ	demographic
factors	NNS	factor
,	,	,
which	WDT	which
may	MD	may
need	VB	need
to	TO	to
be	VB	be
considered	VBN	consider
in	IN	in
increasing	VBG	increase
healthcare	NN	<unknown>
access	NN	access
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
.	SENT	.
33225308/	CD	@card@
Camostat	NP	<unknown>
Mesylate	NP	<unknown>
May	MD	may
Reduce	VB	reduce
Severity	NN	severity
of	IN	of
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
Sepsis	NN	sepsis
:	:	:
A	DT	a
First	NP	First
Observation	NN	observation
Severe	NP	Severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
cell	NN	cell
entry	NN	entry
depends	VBZ	depend
on	IN	on
angiotensin-converting	NN	<unknown>
enzyme	NN	enzyme
2	CD	@card@
and	CC	and
transmembrane	JJ	<unknown>
serine	NN	serine
protease	NN	protease
2	CD	@card@
and	CC	and
is	VBZ	be
blocked	VBN	block
in	IN	in
cell	NN	cell
culture	NN	culture
by	IN	by
camostat	NN	<unknown>
mesylate	NN	<unknown>
,	,	,
a	DT	a
clinically	RB	clinically
proven	JJ	proven
protease	NN	protease
inhibitor	NN	inhibitor
.	SENT	.
Whether	IN	whether
camostat	NN	<unknown>
mesylate	NN	<unknown>
is	VBZ	be
able	JJ	able
to	TO	to
lower	JJR	low
disease	NN	disease
burden	NN	burden
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
sepsis	NN	sepsis
is	VBZ	be
currently	RB	currently
unknown	JJ	unknown
.	SENT	.
Retrospective	JJ	retrospective
observational	JJ	observational
case	NN	case
series	NN	series
.	SENT	.
Patient	NN	patient
treated	VBN	treat
in	IN	in
ICU	NP	ICU
of	IN	of
University	NP	University
hospital	NN	hospital
Gottingen	NP	Gottingen
,	,	,
Germany	NP	Germany
.	SENT	.
Eleven	NN	eleven
critical	JJ	critical
ill	JJ	ill
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
patients	NNS	patient
with	IN	with
organ	NN	organ
failure	NN	failure
were	VBD	be
treated	VBN	treat
in	IN	in
ICU	NP	ICU
.	SENT	.
Compassionate	JJ	compassionate
use	NN	use
of	IN	of
camostat	NN	<unknown>
mesylate	NN	<unknown>
(	(	(
six	CD	six
patients	NNS	patient
,	,	,
camostat	NN	<unknown>
group	NN	group
)	)	)
or	CC	or
hydroxychloroquine	JJ	<unknown>
(	(	(
five	CD	five
patients	NNS	patient
,	,	,
hydroxychloroquine	NN	hydroxychloroquine
group	NN	group
)	)	)
.	SENT	.
Clinical	JJ	clinical
courses	NNS	course
were	VBD	be
assessed	VBN	assess
by	IN	by
Sepsis-related	JJ	Sepsis-related
Organ	NP	Organ
Failure	NN	failure
Assessment	NP	Assessment
score	NN	score
at	IN	at
days	NNS	day
1	CD	@card@
,	,	,
3	CD	@card@
,	,	,
and	CC	and
8	CD	@card@
.	SENT	.
Further	RBR	further
,	,	,
viral	JJ	viral
load	NN	load
,	,	,
oxygenation	NN	oxygenation
,	,	,
and	CC	and
inflammatory	JJ	inflammatory
markers	NNS	marker
were	VBD	be
determined	VBN	determine
.	SENT	.
Sepsis-related	JJ	Sepsis-related
Organ	NP	Organ
Failure	NN	failure
Assessment	NP	Assessment
score	NN	score
was	VBD	be
comparable	JJ	comparable
between	IN	between
camostat	NN	<unknown>
and	CC	and
hydroxychloroquine	NN	hydroxychloroquine
groups	NNS	group
upon	IN	upon
ICU	NP	ICU
admission	NN	admission
.	SENT	.
During	IN	during
observation	NN	observation
,	,	,
the	DT	the
Sepsis-related	JJ	Sepsis-related
Organ	NP	Organ
Failure	NN	failure
Assessment	NP	Assessment
score	NN	score
decreased	VBD	decrease
in	IN	in
the	DT	the
camostat	NN	<unknown>
group	NN	group
but	CC	but
remained	VBD	remain
elevated	JJ	elevated
in	IN	in
the	DT	the
hydroxychloroquine	NN	hydroxychloroquine
group	NN	group
.	SENT	.
The	DT	the
decline	NN	decline
in	IN	in
disease	NN	disease
severity	NN	severity
in	IN	in
camostat	NN	<unknown>
mesylate	JJ	<unknown>
treated	VBN	treat
patients	NNS	patient
was	VBD	be
paralleled	VBN	parallel
by	IN	by
a	DT	a
decline	NN	decline
in	IN	in
inflammatory	JJ	inflammatory
markers	NNS	marker
and	CC	and
improvement	NN	improvement
of	IN	of
oxygenation	NN	oxygenation
.	SENT	.
The	DT	the
severity	NN	severity
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
decreased	VBN	decrease
upon	IN	upon
camostat	NN	<unknown>
mesylate	JJ	<unknown>
treatment	NN	treatment
within	IN	within
a	DT	a
period	NN	period
of	IN	of
8	CD	@card@
days	NNS	day
and	CC	and
a	DT	a
similar	JJ	similar
effect	NN	effect
was	VBD	be
not	RB	not
observed	VBN	observe
in	IN	in
patients	NNS	patient
receiving	VBG	receive
hydroxychloroquine	NN	hydroxychloroquine
.	SENT	.
Camostat	NN	<unknown>
mesylate	NN	<unknown>
thus	RB	thus
warrants	VBZ	warrant
further	JJR	further
evaluation	NN	evaluation
within	IN	within
randomized	VBN	randomize
clinical	JJ	clinical
trials	NNS	trial
.	SENT	.
35493416/	CD	@card@
Diagnosing	VBG	diagnose
and	CC	and
differentiating	VBG	differentiate
viral	JJ	viral
pneumonia	NN	pneumonia
and	CC	and
COVID-19	JJ	<unknown>
using	VBG	use
X-ray	NN	X-ray
images	NNS	image
Coronavirus-caused	NP	<unknown>
diseases	NNS	disease
are	VBP	be
common	JJ	common
worldwide	RB	worldwide
and	CC	and
might	MD	might
worsen	VB	worsen
both	DT	both
human	JJ	human
health	NN	health
and	CC	and
the	DT	the
world	NN	world
economy	NN	economy
.	SENT	.
Most	JJS	most
people	NNS	people
may	MD	may
instantly	RB	instantly
encounter	VB	encounter
coronavirus	NN	coronavirus
in	IN	in
their	PP$	their
life	NN	life
and	CC	and
may	MD	may
result	VB	result
in	IN	in
pneumonia	NN	pneumonia
.	SENT	.
Nowadays	RB	nowadays
,	,	,
the	DT	the
world	NN	world
is	VBZ	be
fighting	VBG	fight
against	IN	against
the	DT	the
new	JJ	new
coronavirus	NN	coronavirus
:	:	:
COVID-19	NN	<unknown>
.	SENT	.
The	DT	the
rate	NN	rate
of	IN	of
increase	NN	increase
is	VBZ	be
high	JJ	high
,	,	,
and	CC	and
the	DT	the
world	NN	world
got	VBD	get
caught	VBN	catch
the	DT	the
disease	NN	disease
unprepared	JJ	unprepared
.	SENT	.
In	IN	in
most	JJS	most
regions	NNS	region
of	IN	of
the	DT	the
world	NN	world
,	,	,
COVID-19	NP	<unknown>
test	NN	test
is	VBZ	be
not	RB	not
possible	JJ	possible
due	RB	due
to	TO	to
the	DT	the
absence	NN	absence
of	IN	of
the	DT	the
diagnostic	JJ	diagnostic
kit	NN	kit
,	,	,
even	RB	even
if	IN	if
the	DT	the
kit	NN	kit
exists	VBZ	exist
,	,	,
its	PP$	its
false-negative	JJ	false-negative
(	(	(
giving	VBG	give
a	DT	a
negative	JJ	negative
result	NN	result
for	IN	for
a	DT	a
person	NN	person
infected	VBN	infect
with	IN	with
COVID-19	NP	<unknown>
)	)	)
rate	NN	rate
is	VBZ	be
high	JJ	high
.	SENT	.
Also	RB	also
,	,	,
early	JJ	early
detection	NN	detection
of	IN	of
COVID-19	NP	<unknown>
is	VBZ	be
crucial	JJ	crucial
to	TO	to
keep	VB	keep
its	PP$	its
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
rates	NNS	rate
low	JJ	low
.	SENT	.
The	DT	the
symptoms	NNS	symptom
of	IN	of
pneumonia	NN	pneumonia
are	VBP	be
alike	RB	alike
,	,	,
and	CC	and
COVID-19	NP	<unknown>
is	VBZ	be
no	DT	no
exception	NN	exception
.	SENT	.
The	DT	the
chest	NN	chest
X-ray	NN	X-ray
is	VBZ	be
the	DT	the
main	JJ	main
reference	NN	reference
in	IN	in
diagnosing	VBG	diagnose
pneumonia	NN	pneumonia
.	SENT	.
Thus	RB	thus
,	,	,
the	DT	the
need	NN	need
for	IN	for
radiologists	NNS	radiologist
has	VBZ	have
been	VBN	be
increased	VBN	increase
considerably	RB	considerably
not	RB	not
only	RB	only
to	TO	to
detect	VB	detect
COVID-19	NP	<unknown>
but	CC	but
also	RB	also
to	TO	to
identify	VB	identify
other	JJ	other
abnormalities	NNS	abnormality
it	PP	it
caused	VBD	cause
.	SENT	.
Herein	RB	herein
,	,	,
a	DT	a
transfer	NN	transfer
learning-based	JJ	<unknown>
multi-class	JJ	<unknown>
convolutional	JJ	convolutional
neural	JJ	neural
network	NN	network
model	NN	model
was	VBD	be
proposed	VBN	propose
for	IN	for
the	DT	the
automatic	JJ	automatic
detection	NN	detection
of	IN	of
pneumonia	NN	pneumonia
and	CC	and
also	RB	also
for	IN	for
differentiating	VBG	differentiate
non-COVID-19	JJ	<unknown>
pneumonia	NN	pneumonia
and	CC	and
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
model	NN	model
that	IN	that
inputs	NNS	input
chest	NN	chest
X-ray	NN	X-ray
images	NNS	image
is	VBZ	be
capable	JJ	capable
of	IN	of
extracting	VBG	extract
radiographic	JJ	radiographic
patterns	NNS	pattern
on	IN	on
chest	NN	chest
X-ray	NN	X-ray
images	NNS	image
to	TO	to
turn	VB	turn
into	IN	into
valuable	JJ	valuable
information	NN	information
and	CC	and
monitor	VB	monitor
structural	JJ	structural
differences	NNS	difference
in	IN	in
the	DT	the
lungs	NNS	lung
caused	VBN	cause
by	IN	by
the	DT	the
diseases	NNS	disease
.	SENT	.
The	DT	the
model	NN	model
was	VBD	be
developed	VBN	develop
by	IN	by
two	CD	two
public	JJ	public
datasets	NNS	<unknown>
:	:	:
Cohen	NP	Cohen
dataset	NP	<unknown>
and	CC	and
Kermany	NP	<unknown>
dataset	NN	<unknown>
.	SENT	.
The	DT	the
model	NN	model
achieves	VBZ	achieve
an	DT	an
average	JJ	average
training	NN	training
accuracy	NN	accuracy
of	IN	of
0.9886	CD	@card@
,	,	,
an	DT	an
average	JJ	average
training	NN	training
recall	NN	recall
of	IN	of
0.9829	CD	@card@
,	,	,
and	CC	and
an	DT	an
average	JJ	average
training	NN	training
precision	NN	precision
of	IN	of
0.9837	CD	@card@
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
average	JJ	average
training	NN	training
false-positive	NN	false-positive
and	CC	and
false-negative	JJ	false-negative
rates	NNS	rate
are	VBP	be
0.0085	CD	@card@
and	CC	and
0.0171	CD	@card@
,	,	,
respectively	RB	respectively
.	SENT	.
Conversely	RB	conversely
,	,	,
the	DT	the
model	NN	model
's	POS	's
test	NN	test
set	NN	set
metrics	NNS	metric
such	JJ	such
as	IN	as
average	JJ	average
accuracy	NN	accuracy
,	,	,
average	JJ	average
recall	NN	recall
,	,	,
and	CC	and
average	JJ	average
precision	NN	precision
are	VBP	be
97.78	CD	@card@
%	NN	%
,	,	,
96.67	CD	@card@
%	NN	%
,	,	,
and	CC	and
96.67	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
According	VBG	accord
to	TO	to
the	DT	the
simulation	NN	simulation
results	NNS	result
,	,	,
the	DT	the
proposed	VBN	propose
model	NN	model
is	VBZ	be
promising	JJ	promising
,	,	,
can	MD	can
quickly	RB	quickly
and	CC	and
accurately	RB	accurately
classify	VB	classify
chest	NN	chest
images	NNS	image
,	,	,
and	CC	and
helps	VBZ	help
doctors	NNS	doctor
as	IN	as
the	DT	the
second	JJ	second
reader	NN	reader
in	IN	in
their	PP$	their
final	JJ	final
decision	NN	decision
.	SENT	.
32516844/	CD	@card@
Comment	NN	comment
on	IN	on
Han	NP	Han
et	CC	et
al	NP	al
:	:	:
Analysis	NN	analysis
of	IN	of
heart	NN	heart
injury	NN	injury
laboratory	NN	laboratory
parameters	NNS	parameter
in	IN	in
273	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
one	CD	one
hospital	NN	hospital
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
34184314/	CD	@card@
Incremental	JJ	incremental
prognostic	JJ	prognostic
value	NN	value
of	IN	of
biventricular	JJ	biventricular
longitudinal	JJ	longitudinal
strain	NN	strain
and	CC	and
high-sensitivity	NN	high-sensitivity
troponin	NN	<unknown>
I	PP	I
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
Whether	IN	whether
the	DT	the
combination	NN	combination
of	IN	of
ventricular	JJ	ventricular
strain	NN	strain
with	IN	with
high-sensitivity	NN	high-sensitivity
troponin	NN	<unknown>
I	PP	I
(	(	(
hs-TNI	NN	<unknown>
)	)	)
has	VBZ	have
an	DT	an
incremental	JJ	incremental
prognostic	JJ	prognostic
value	NN	value
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
patients	NNS	patient
has	VBZ	have
not	RB	not
been	VBN	be
evaluated	VBN	evaluate
.	SENT	.
The	DT	the
study	NN	study
aimed	VBN	aim
to	TO	to
evaluate	VB	evaluate
the	DT	the
prognostic	JJ	prognostic
value	NN	value
of	IN	of
biventricular	JJ	biventricular
longitudinal	JJ	longitudinal
strain	NN	strain
and	CC	and
its	PP$	its
combination	NN	combination
with	IN	with
hs-TNI	NNS	<unknown>
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
160	CD	@card@
COVID-19	NP	<unknown>
patients	NNS	patient
who	WP	who
underwent	VBD	undergo
both	DT	both
echocardiography	NN	echocardiography
and	CC	and
hs-TNI	NN	<unknown>
testing	NN	testing
were	VBD	be
enrolled	VBN	enroll
in	IN	in
our	PP$	our
study	NN	study
.	SENT	.
COVID-19	NP	<unknown>
patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
two	CD	two
groups	NNS	group
(	(	(
critical	JJ	critical
and	CC	and
non-critical	JJ	non-critical
)	)	)
according	VBG	accord
to	TO	to
severity-of-illness	NN	severity-of-illness
.	SENT	.
The	DT	the
clinical	JJ	clinical
characteristics	NNS	characteristic
,	,	,
cardiac	JJ	cardiac
structure	NN	structure
and	CC	and
function	NN	function
were	VBD	be
compared	VBN	compare
between	IN	between
the	DT	the
two	CD	two
groups	NNS	group
.	SENT	.
The	DT	the
prognostic	JJ	prognostic
value	NN	value
of	IN	of
biventricular	JJ	biventricular
longitudinal	JJ	longitudinal
strain	NN	strain
and	CC	and
its	PP$	its
combination	NN	combination
with	IN	with
hs-TNI	NNS	<unknown>
were	VBD	be
evaluated	VBN	evaluate
by	IN	by
logistic	JJ	logistic
regression	NN	regression
analyses	NNS	analysis
and	CC	and
receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
curves	NNS	curve
.	SENT	.
Left	VBN	leave
ventricular	JJ	ventricular
longitudinal	JJ	longitudinal
strain	NN	strain
(	(	(
LV	NP	<unknown>
LS	NP	LS
)	)	)
and	CC	and
right	JJ	right
ventricular	JJ	ventricular
free	JJ	free
wall	NN	wall
longitudinal	JJ	longitudinal
strain	NN	strain
(	(	(
RVFWLS	NP	<unknown>
)	)	)
were	VBD	be
determined	VBN	determine
by	IN	by
2D	JJ	<unknown>
speckle-tracking	NN	speckle-tracking
echocardiography	NN	echocardiography
.	SENT	.
The	DT	the
LV	NP	<unknown>
LS	NP	LS
and	CC	and
RVFWLS	NP	<unknown>
both	CC	both
were	VBD	be
significantly	RB	significantly
lower	JJR	low
in	IN	in
critical	JJ	critical
patients	NNS	patient
than	IN	than
non-critical	JJ	non-critical
patients	NNS	patient
(	(	(
LV	NP	<unknown>
LS	NP	LS
:	:	:
-16.6+-2.4	CD	@card@
vs	NP	vs
-17.9+-3.0	CD	@card@
,	,	,
P	NN	P
=	SYM	=
.003	CD	@card@
;	:	;
RVFWLS	NP	<unknown>
:-18.8+-3.6	CD	@card@
vs	NP	vs
-23.9+-4.4	CD	@card@
,	,	,
P&lt	NP	<unknown>
;	:	;
.001	LS	@card@
)	)	)
.	SENT	.
During	IN	during
a	DT	a
median	JJ	median
follow-up	NN	follow-up
of	IN	of
60	CD	@card@
days	NNS	day
,	,	,
23	CD	@card@
(	(	(
14.4	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
died	VBD	die
.	SENT	.
The	DT	the
multivariant	JJ	multivariant
analysis	NN	analysis
revealed	VBD	reveal
that	IN	that
LV	NP	<unknown>
LS	NP	LS
and	CC	and
RVFWLS	NNS	<unknown>
[	SYM	[
Odd	JJ	odd
ratio	NN	ratio
(	(	(
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
)	)	)
:	:	:
1.533	CD	@card@
(	(	(
1.131-2.079	CD	@card@
)	)	)
,	,	,
P	NN	P
=	SYM	=
.006	CD	@card@
;	:	;
1.267	CD	@card@
(	(	(
1.036-1.551	CD	@card@
)	)	)
,	,	,
P	NN	P
=	SYM	=
.021	CD	@card@
,	,	,
respectively	RB	respectively
]	SYM	]
were	VBD	be
the	DT	the
independent	JJ	independent
predictors	NNS	predictor
of	IN	of
higher	JJR	high
mortality	NN	mortality
.	SENT	.
Further	RBR	further
,	,	,
receiver-operating	VBG	receiver-operate
characteristic	JJ	characteristic
analysis	NN	analysis
revealed	VBD	reveal
that	IN	that
the	DT	the
accuracy	NN	accuracy
for	IN	for
predicting	VBG	predict
death	NN	death
was	VBD	be
greater	JJR	great
for	IN	for
the	DT	the
combination	NN	combination
of	IN	of
hs-TNI	NN	<unknown>
levels	NNS	level
with	IN	with
LV	NP	<unknown>
LS	NP	LS
than	IN	than
separate	JJ	separate
LV	NP	<unknown>
LS	NP	LS
(	(	(
AUC	NP	AUC
:	:	:
.91	CD	@card@
vs	NP	vs
.77	CD	@card@
,	,	,
P	NN	P
=	SYM	=
.001	CD	@card@
)	)	)
,	,	,
and	CC	and
the	DT	the
combination	NN	combination
of	IN	of
hs-TNI	NN	<unknown>
levels	NNS	level
with	IN	with
RVFWLS	NP	<unknown>
than	IN	than
RVFWLS	NP	<unknown>
alone	RB	alone
(	(	(
AUC	NP	AUC
:	:	:
.89	CD	@card@
vs	NP	vs
.83	CD	@card@
,	,	,
P	NN	P
=	SYM	=
.041	CD	@card@
)	)	)
.	SENT	.
Our	PP$	our
study	NN	study
highlights	VBZ	highlight
that	IN	that
the	DT	the
combination	NN	combination
of	IN	of
ventricular	JJ	ventricular
longitudinal	JJ	longitudinal
strain	NN	strain
with	IN	with
hs-TNI	NNS	<unknown>
can	MD	can
provide	VB	provide
higher	JJR	high
accuracy	NN	accuracy
for	IN	for
predicting	VBG	predict
mortality	NN	mortality
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
which	WDT	which
may	MD	may
enhance	VB	enhance
risk	NN	risk
stratification	NN	stratification
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
34683149/	CD	@card@
Domain-Adaptive	JJ	Domain-adaptive
Artificial	JJ	artificial
Intelligence-Based	JJ	<unknown>
Model	NP	Model
for	IN	for
Personalized	JJ	personalized
Diagnosis	NN	diagnosis
of	IN	of
Trivial	JJ	trivial
Lesions	NNS	lesion
Related	VBN	relate
to	TO	to
COVID-19	NP	<unknown>
in	IN	in
Chest	NN	chest
Computed	VBD	compute
Tomography	NN	tomography
Scans	NNS	scan
Background	NN	background
:	:	:
Early	JJ	early
and	CC	and
accurate	JJ	accurate
detection	NN	detection
of	IN	of
COVID-19-related	JJ	COVID-19-related
findings	NNS	finding
(	(	(
such	JJ	such
as	IN	as
well-aerated	JJ	<unknown>
regions	NNS	region
,	,	,
ground-glass	NN	ground-glass
opacity	NN	opacity
,	,	,
crazy	JJ	crazy
paving	NN	paving
and	CC	and
linear	JJ	linear
opacities	NNS	opacity
,	,	,
and	CC	and
consolidation	NN	consolidation
in	IN	in
lung	NN	lung
computed	VBN	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
scan	NN	scan
)	)	)
is	VBZ	be
crucial	JJ	crucial
for	IN	for
preventive	JJ	preventive
measures	NNS	measure
and	CC	and
treatment	NN	treatment
.	SENT	.
However	RB	however
,	,	,
the	DT	the
visual	JJ	visual
assessment	NN	assessment
of	IN	of
lung	NN	lung
CT	NP	CT
scans	VBZ	scan
is	VBZ	be
a	DT	a
time-consuming	JJ	time-consuming
process	NN	process
particularly	RB	particularly
in	IN	in
case	NN	case
of	IN	of
trivial	JJ	trivial
lesions	NNS	lesion
and	CC	and
requires	VBZ	require
medical	JJ	medical
specialists	NNS	specialist
.	SENT	.
Method	NN	method
:	:	:
A	DT	a
recent	JJ	recent
breakthrough	NN	breakthrough
in	IN	in
deep	JJ	deep
learning	VBG	learn
methods	NNS	method
has	VBZ	have
boosted	VBN	boost
the	DT	the
diagnostic	JJ	diagnostic
capability	NN	capability
of	IN	of
computer-aided	JJ	computer-aided
diagnosis	NN	diagnosis
(	(	(
CAD	NN	cad
)	)	)
systems	NNS	system
and	CC	and
further	RBR	further
aided	VBN	aid
health	NN	health
professionals	NNS	professional
in	IN	in
making	VBG	make
effective	JJ	effective
diagnostic	JJ	diagnostic
decisions	NNS	decision
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
propose	VBP	propose
a	DT	a
domain-adaptive	JJ	domain-adaptive
CAD	NN	cad
framework	NN	framework
,	,	,
namely	RB	namely
the	DT	the
dilated	VBN	dilate
aggregation-based	JJ	<unknown>
lightweight	JJ	lightweight
network	NN	network
(	(	(
DAL-Net	NP	<unknown>
)	)	)
,	,	,
for	IN	for
effective	JJ	effective
recognition	NN	recognition
of	IN	of
trivial	JJ	trivial
COVID-19	NP	<unknown>
lesions	NNS	lesion
in	IN	in
CT	NP	CT
scans	VBZ	scan
.	SENT	.
Our	PP$	our
network	NN	network
design	NN	design
achieves	VBZ	achieve
a	DT	a
fast	JJ	fast
execution	NN	execution
speed	NN	speed
(	(	(
inference	NN	inference
time	NN	time
is	VBZ	be
43	CD	@card@
ms	NN	Ms
on	IN	on
a	DT	a
single	JJ	single
image	NN	image
)	)	)
with	IN	with
optimal	JJ	optimal
memory	NN	memory
consumption	NN	consumption
(	(	(
almost	RB	almost
9	CD	@card@
MB	NP	MB
)	)	)
.	SENT	.
To	TO	to
evaluate	VB	evaluate
the	DT	the
performances	NNS	performance
of	IN	of
the	DT	the
proposed	VBN	propose
and	CC	and
state-of-the-art	JJ	state-of-the-art
models	NNS	model
,	,	,
we	PP	we
considered	VBD	consider
two	CD	two
publicly	RB	publicly
accessible	JJ	accessible
datasets	NNS	<unknown>
,	,	,
namely	RB	namely
COVID-19-CT-Seg	NP	<unknown>
(	(	(
comprising	VBG	comprise
a	DT	a
total	NN	total
of	IN	of
3520	CD	@card@
images	NNS	image
of	IN	of
20	CD	@card@
different	JJ	different
patients	NNS	patient
)	)	)
and	CC	and
MosMed	NP	<unknown>
(	(	(
including	VBG	include
a	DT	a
total	NN	total
of	IN	of
2049	CD	@card@
images	NNS	image
of	IN	of
50	CD	@card@
different	JJ	different
patients	NNS	patient
)	)	)
.	SENT	.
Results	NNS	result
:	:	:
Our	PP$	our
method	NN	method
exhibits	VBZ	exhibit
average	JJ	average
area	NN	area
under	IN	under
the	DT	the
curve	NN	curve
(	(	(
AUC	NP	AUC
)	)	)
up	IN	up
to	TO	to
98.84	CD	@card@
%	NN	%
,	,	,
98.47	CD	@card@
%	NN	%
,	,	,
and	CC	and
95.51	CD	@card@
%	NN	%
for	IN	for
COVID-19-CT-Seg	NP	<unknown>
,	,	,
MosMed	NP	<unknown>
,	,	,
and	CC	and
cross-dataset	NN	<unknown>
,	,	,
respectively	RB	respectively
,	,	,
and	CC	and
outperforms	VBZ	outperform
various	JJ	various
state-of-the-art	JJ	state-of-the-art
methods	NNS	method
.	SENT	.
Conclusions	NNS	conclusion
:	:	:
These	DT	these
results	NNS	result
demonstrate	VBP	demonstrate
that	IN	that
deep	JJ	deep
learning-based	JJ	<unknown>
models	NNS	model
are	VBP	be
an	DT	an
effective	JJ	effective
tool	NN	tool
for	IN	for
building	VBG	build
a	DT	a
robust	JJ	robust
CAD	NN	cad
solution	NN	solution
based	VBN	base
on	IN	on
CT	NP	CT
data	NNS	datum
in	IN	in
response	NN	response
to	TO	to
present	VB	present
disaster	NN	disaster
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
35142693/	CD	@card@
Ruxolitinib	NP	<unknown>
attenuates	VBZ	attenuate
secondary	JJ	secondary
injury	NN	injury
after	IN	after
traumatic	JJ	traumatic
spinal	JJ	spinal
cord	NN	cord
injury	NN	injury
Excessive	JJ	excessive
inflammation	NN	inflammation
post-traumatic	JJ	post-traumatic
spinal	JJ	spinal
cord	NN	cord
injury	NN	injury
(	(	(
SCI	NP	SCI
)	)	)
induces	VBZ	induce
microglial	JJ	<unknown>
activation	NN	activation
,	,	,
which	WDT	which
leads	VBZ	lead
to	TO	to
prolonged	JJ	prolonged
neurological	JJ	neurological
dysfunction	NN	dysfunction
.	SENT	.
However	RB	however
,	,	,
the	DT	the
mechanism	NN	mechanism
underlying	VBG	underlie
microglial	JJ	<unknown>
activation-induced	JJ	<unknown>
neuroinflammation	NN	neuroinflammation
remains	VBZ	remain
poorly	RB	poorly
understood	VBN	understand
.	SENT	.
Ruxolitinib	NP	<unknown>
(	(	(
RUX	NP	Rux
)	)	)
,	,	,
a	DT	a
selective	JJ	selective
inhibitor	NN	inhibitor
of	IN	of
JAK1/2	NP	<unknown>
,	,	,
was	VBD	be
recently	RB	recently
reported	VBN	report
to	TO	to
inhibit	VB	inhibit
inflammatory	JJ	inflammatory
storms	NNS	storm
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
in	IN	in
the	DT	the
lung	NN	lung
.	SENT	.
However	RB	however
,	,	,
its	PP$	its
role	NN	role
in	IN	in
disrupting	VBG	disrupt
inflammation	NN	inflammation
post-SCI	NN	<unknown>
has	VBZ	have
not	RB	not
been	VBN	be
confirmed	VBN	confirm
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
microglia	NN	<unknown>
were	VBD	be
treated	VBN	treat
with	IN	with
RUX	NP	Rux
for	IN	for
24	CD	@card@
hours	NNS	hour
and	CC	and
then	RB	then
activated	VBN	activate
with	IN	with
interferon-gamma	NNS	<unknown>
for	IN	for
6	CD	@card@
hours	NNS	hour
.	SENT	.
The	DT	the
results	NNS	result
showed	VBD	show
that	IN	that
interferon-gamma-induced	JJ	<unknown>
phosphorylation	NN	<unknown>
of	IN	of
JAK	NP	Jak
and	CC	and
STAT	NN	stat
in	IN	in
microglia	NN	<unknown>
was	VBD	be
inhibited	VBN	inhibit
,	,	,
and	CC	and
the	DT	the
mRNA	NN	<unknown>
expression	NN	expression
levels	NNS	level
of	IN	of
pro-inflammatory	JJ	pro-inflammatory
cytokines	NNS	cytokine
tumor	NN	tumor
necrosis	NN	necrosis
factor-alpha	NN	factor-alpha
,	,	,
interleukin-1beta	NP	<unknown>
,	,	,
interleukin-6	NN	<unknown>
,	,	,
and	CC	and
cell	NN	cell
proliferation	NN	proliferation
marker	NN	marker
Ki67	NP	<unknown>
were	VBD	be
reduced	VBN	reduce
.	SENT	.
In	IN	in
further	JJR	further
in	IN	in
vivo	JJ	vivo
experiments	NNS	experiment
,	,	,
a	DT	a
mouse	NN	mouse
model	NN	model
of	IN	of
spinal	JJ	spinal
cord	NN	cord
injury	NN	injury
was	VBD	be
treated	VBN	treat
intragastrically	RB	<unknown>
with	IN	with
RUX	NP	Rux
for	IN	for
3	CD	@card@
successive	JJ	successive
days	NNS	day
,	,	,
and	CC	and
the	DT	the
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
RUX	NP	Rux
can	MD	can
inhibit	VB	inhibit
microglial	JJ	<unknown>
proliferation	NN	proliferation
by	IN	by
inhibiting	VBG	inhibit
the	DT	the
interferon-gamma/JAK/STAT	NN	<unknown>
pathway	NN	pathway
.	SENT	.
Moreover	RB	moreover
,	,	,
microglia	NNS	<unknown>
treated	VBN	treat
with	IN	with
RUX	NP	Rux
centripetally	RB	centripetally
migrated	VBD	migrate
toward	IN	toward
injured	JJ	injured
foci	NNS	focus
,	,	,
remaining	VBG	remain
limited	JJ	limited
and	CC	and
compacted	VBN	compact
within	IN	within
the	DT	the
glial	NN	<unknown>
scar	NN	scar
,	,	,
which	WDT	which
resulted	VBD	result
in	IN	in
axon	NN	axon
preservation	NN	preservation
and	CC	and
less	JJR	less
demyelination	NN	demyelination
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
protein	NN	protein
expression	NN	expression
levels	NNS	level
of	IN	of
tumor	NN	tumor
necrosis	NN	necrosis
factor-alpha	NN	factor-alpha
,	,	,
interleukin-1beta	NN	<unknown>
,	,	,
and	CC	and
interleukin-6	NN	<unknown>
were	VBD	be
reduced	VBN	reduce
.	SENT	.
The	DT	the
neuromotor	NN	neuromotor
function	NN	function
of	IN	of
SCI	NP	SCI
mice	NNS	mouse
also	RB	also
recovered	VBD	recover
.	SENT	.
These	DT	these
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
RUX	NP	Rux
can	MD	can
inhibit	VB	inhibit
neuroinflammation	NN	neuroinflammation
through	IN	through
inhibiting	VBG	inhibit
the	DT	the
interferon-gamma/JAK/STAT	NN	<unknown>
pathway	NN	pathway
,	,	,
thereby	RB	thereby
reducing	VBG	reduce
secondary	JJ	secondary
injury	NN	injury
after	IN	after
SCI	NP	SCI
and	CC	and
producing	VBG	produce
neuroprotective	JJ	neuroprotective
effects	NNS	effect
.	SENT	.
32646505/	CD	@card@
SARS-CoV-2	NP	<unknown>
prevalence	NN	prevalence
in	IN	in
an	DT	an
asymptomatic	JJ	asymptomatic
cancer	NN	cancer
cohort	NN	cohort
-	NN	<unknown>
results	NNS	result
and	CC	and
consequences	NNS	consequence
for	IN	for
clinical	JJ	clinical
routine	NN	routine
Starting	VBG	start
in	IN	in
December	NP	December
2019	CD	@card@
,	,	,
the	DT	the
current	JJ	current
pandemic	NN	pandemic
caused	VBN	cause
by	IN	by
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
confronts	VBZ	confront
the	DT	the
world	NN	world
with	IN	with
an	DT	an
unprecedented	JJ	unprecedented
challenge	NN	challenge
.	SENT	.
With	IN	with
no	DT	no
vaccine	NN	vaccine
or	CC	or
drug	NN	drug
being	VBG	be
currently	RB	currently
available	JJ	available
to	TO	to
control	VB	control
the	DT	the
pandemic	JJ	pandemic
spread	NN	spread
,	,	,
prevention	NN	prevention
and	CC	and
PCR	NP	PCR
(	(	(
Polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
)	)	)
testing	NN	testing
becomes	VBZ	become
a	DT	a
crucial	JJ	crucial
pillar	NN	pillar
of	IN	of
medical	JJ	medical
systems	NNS	system
.	SENT	.
Aim	NN	aim
of	IN	of
the	DT	the
present	JJ	present
study	NN	study
was	VBD	be
to	TO	to
report	VB	report
on	IN	on
the	DT	the
first	JJ	first
results	NNS	result
of	IN	of
the	DT	the
measures	NNS	measure
taken	VBN	take
in	IN	in
a	DT	a
large	JJ	large
German	JJ	German
Department	NN	department
of	IN	of
Radiation	NN	radiation
Oncology	NN	oncology
,	,	,
including	VBG	include
PCR	NP	PCR
testing	NN	testing
of	IN	of
asymptomatic	JJ	asymptomatic
cancer	NN	cancer
patients	NNS	patient
.	SENT	.
Pandemic-adapted	JJ	<unknown>
hygiene	NN	hygiene
regulations	NNS	regulation
and	CC	and
prevention	NN	prevention
measures	NNS	measure
for	IN	for
patients	NNS	patient
and	CC	and
staff	NN	staff
were	VBD	be
implemented	VBN	implement
.	SENT	.
A	DT	a
visiting	VBG	visit
ban	NN	ban
on	IN	on
both	DT	both
wards	NNS	ward
was	VBD	be
implemented	VBN	implement
from	IN	from
the	DT	the
beginning	NN	beginning
and	CC	and
medical	JJ	medical
staff	NN	staff
and	CC	and
patients	NNS	patient
were	VBD	be
required	VBN	require
to	TO	to
wear	VB	wear
face	NN	face
masks	NNS	mask
at	IN	at
all	DT	all
times	NNS	time
.	SENT	.
The	DT	the
waiting	VBG	wait
rooms	NNS	room
were	VBD	be
rearranged	VBN	rearrange
to	TO	to
ensure	VB	ensure
distance	NN	distance
between	IN	between
patients	NNS	patient
of	IN	of
at	IN	at
least	JJS	least
1.5	CD	@card@
m.	JJ	<unknown>
Clinical	JJ	clinical
follow	NN	follow
up	RB	up
was	VBD	be
mainly	RB	mainly
done	VBN	do
by	IN	by
telephone	NN	telephone
and	CC	and
all	DT	all
patients	NNS	patient
had	VBD	have
to	TO	to
complete	VB	complete
a	DT	a
questionnaire	NN	questionnaire
regarding	VBG	regard
symptoms	NNS	symptom
and	CC	and
contacts	NNS	contact
with	IN	with
COVID-19	NP	<unknown>
patients	NNS	patient
before	IN	before
entering	VBG	enter
our	PP$	our
department	NN	department
.	SENT	.
Educational	JJ	educational
documents	NNS	document
were	VBD	be
created	VBN	create
for	IN	for
patients	NNS	patient
to	TO	to
raise	VB	raise
awareness	NN	awareness
of	IN	of
symptoms	NNS	symptom
and	CC	and
avoidance	NN	avoidance
strategies	NNS	strategy
for	IN	for
interactions	NNS	interaction
with	IN	with
other	JJ	other
people	NNS	people
.	SENT	.
Indications	NNS	indication
for	IN	for
therapy	NN	therapy
and	CC	and
fractionation	NN	fractionation
schemes	NNS	scheme
were	VBD	be
adapted	VBN	adapt
when	WRB	when
possible	JJ	possible
.	SENT	.
In	IN	in
a	DT	a
subsequent	JJ	subsequent
step	NN	step
,	,	,
all	DT	all
new	JJ	new
asymptomatic	JJ	asymptomatic
patients	NNS	patient
were	VBD	be
tested	VBN	test
via	IN	via
nasopharyngeal	JJ	nasopharyngeal
swab	NN	swab
at	IN	at
our	PP$	our
screening	NN	screening
station	NN	station
shortly	RB	shortly
before	IN	before
their	PP$	their
simulation	NN	simulation
CT	NP	CT
.	SENT	.
All	PDT	all
these	DT	these
measures	NNS	measure
and	CC	and
implementations	NNS	implementation
have	VBP	have
been	VBN	be
well	RB	well
accepted	VBN	accept
semiquantitatively	RB	semiquantitatively
measured	VBN	measure
by	IN	by
the	DT	the
consent	NN	consent
received	VBN	receive
from	IN	from
patients	NNS	patient
and	CC	and
staff	NN	staff
.	SENT	.
Regarding	VBG	regard
the	DT	the
PCR	NP	PCR
testing	NN	testing
,	,	,
only	RB	only
1	CD	@card@
out	IN	out
of	IN	of
139	CD	@card@
asymptomatic	JJ	asymptomatic
patients	NNS	patient
of	IN	of
our	PP$	our
cohort	NN	cohort
so	RB	so
far	RB	far
tested	VBN	test
positive	JJ	positive
for	IN	for
SARS-CoV-2	NP	<unknown>
,	,	,
reflecting	VBG	reflect
a	DT	a
prevalence	NN	prevalence
of	IN	of
0.72	CD	@card@
%	NN	%
in	IN	in
this	DT	this
cancer	NN	cancer
patient	NN	patient
population	NN	population
.	SENT	.
Up	RB	up
to	TO	to
this	DT	this
point	NN	point
no	DT	no
staff	NN	staff
members	NNS	member
was	VBD	be
tested	VBN	test
positive	JJ	positive
.	SENT	.
The	DT	the
start	NN	start
of	IN	of
the	DT	the
treatment	NN	treatment
for	IN	for
the	DT	the
PCR-positive	JJ	PCR-positive
patient	NN	patient
was	VBD	be
deferred	VBN	defer
for	IN	for
2	CD	@card@
weeks	NNS	week
.	SENT	.
Due	JJ	due
to	TO	to
the	DT	the
pandemic-adapted	JJ	<unknown>
implementations	NNS	implementation
,	,	,
our	PP$	our
department	NN	department
seems	VBZ	seem
well	RB	well
prepared	VBN	prepare
during	IN	during
this	DT	this
crisis	NN	crisis
.	SENT	.
The	DT	the
initial	JJ	initial
screening	NN	screening
helps	VBZ	help
to	TO	to
identify	VB	identify
asymptomatic	JJ	asymptomatic
COVID-19	NP	<unknown>
patients	NNS	patient
in	IN	in
order	NN	order
to	TO	to
protect	VB	protect
other	JJ	other
patients	NNS	patient
and	CC	and
our	PP$	our
staff	NN	staff
from	IN	from
infection	NN	infection
and	CC	and
the	DT	the
observed	JJ	observed
PCR	NP	PCR
prevalence	NN	prevalence
is	VBZ	be
in	IN	in
line	NN	line
with	IN	with
comparable	JJ	comparable
studies	NNS	study
.	SENT	.
A	DT	a
regular	JJ	regular
PCR	NP	PCR
testing	NN	testing
(	(	(
e.g.	FW	e.g.
twice	RB	twice
a	DT	a
week	NN	week
)	)	)
of	IN	of
all	DT	all
patients	NNS	patient
and	CC	and
staff	NN	staff
would	MD	would
in	IN	in
principle	NN	principle
be	VB	be
desirable	JJ	desirable
but	CC	but
is	VBZ	be
limited	VBN	limit
due	RB	due
to	TO	to
testing	NN	testing
capacities	NNS	capacity
at	IN	at
present	NN	present
.	SENT	.
34149003/	CD	@card@
Prospective	JJ	prospective
Clinical	JJ	clinical
,	,	,
Virologic	NP	Virologic
,	,	,
and	CC	and
Immunologic	JJ	immunologic
Assessment	NP	Assessment
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
Transplant	NN	transplant
Recipients	NNS	recipient
Supplemental	NP	Supplemental
Digital	NP	Digital
Content	NN	content
is	VBZ	be
available	JJ	available
in	IN	in
the	DT	the
text	NN	text
.	SENT	.
Several	JJ	several
studies	NNS	study
have	VBP	have
described	VBN	describe
the	DT	the
clinical	JJ	clinical
features	NNS	feature
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
solid-organ	NP	solid-organ
transplant	NN	transplant
recipients	NNS	recipient
.	SENT	.
However	RB	however
,	,	,
many	RB	many
have	VBP	have
been	VBN	be
retrospective	JJ	retrospective
or	CC	or
limited	JJ	limited
to	TO	to
more	JJR	more
severe	JJ	severe
cases	NNS	case
(	(	(
hospitalized	VBN	hospitalize
)	)	)
and	CC	and
have	VBP	have
not	RB	not
routinely	RB	routinely
included	VBD	include
serial	JJ	serial
virological	JJ	virological
sampling	NN	sampling
(	(	(
especially	RB	especially
in	IN	in
outpatients	NNS	outpatient
)	)	)
and	CC	and
immunologic	JJ	immunologic
assessment	NN	assessment
.	SENT	.
Transplant	NN	transplant
patients	NNS	patient
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
based	VBN	base
on	IN	on
a	DT	a
respiratory	JJ	respiratory
sample	NN	sample
PCR	NP	PCR
were	VBD	be
prospectively	RB	prospectively
followed	VBN	follow
up	RP	up
to	TO	to
90	CD	@card@
d.	NN	<unknown>
Patients	NNS	patient
provided	VBD	provide
consent	NN	consent
for	IN	for
convalescent	JJ	convalescent
serum	NN	serum
samples	NNS	sample
and	CC	and
serial	JJ	serial
nasopharyngeal	JJ	nasopharyngeal
swabs	NNS	swab
for	IN	for
SARS-CoV-2	NP	<unknown>
antibody	NN	antibody
(	(	(
antinucleoprotein	NN	antinucleoprotein
and	CC	and
anti-RBD	NN	<unknown>
)	)	)
and	CC	and
viral	JJ	viral
load	NN	load
,	,	,
respectively	RB	respectively
.	SENT	.
In	IN	in
the	DT	the
161	CD	@card@
SOT	NN	sot
recipients	NNS	recipient
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
,	,	,
the	DT	the
spectrum	NN	spectrum
of	IN	of
disease	NN	disease
ranged	VBN	range
from	IN	from
asymptomatic	JJ	asymptomatic
infection	NN	infection
(	(	(
4.3	CD	@card@
%	NN	%
)	)	)
to	TO	to
hospitalization	NN	hospitalization
(	(	(
60.6	CD	@card@
%	NN	%
)	)	)
,	,	,
supplemental	JJ	supplemental
oxygen	NN	oxygen
requirement	NN	requirement
(	(	(
43.1	CD	@card@
%	NN	%
)	)	)
,	,	,
mechanical	JJ	mechanical
ventilation	NN	ventilation
(	(	(
22.7	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
death	NN	death
(	(	(
15.6	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Increasing	VBG	increase
age	NN	age
(	(	(
OR	CC	or
,	,	,
1.031	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
1.001-1.062	CD	@card@
;	:	;
P	NN	P
=	SYM	=
0.046	CD	@card@
)	)	)
and	CC	and
&gt	NN	&gt
;	:	;
=2	JJ	<unknown>
comorbid	JJ	comorbid
conditions	NNS	condition
(	(	(
OR	CC	or
,	,	,
3.690	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
1.418-9.615	CD	@card@
;	:	;
P	NN	P
=	SYM	=
0.007	CD	@card@
)	)	)
were	VBD	be
associated	VBN	associate
with	IN	with
the	DT	the
need	NN	need
for	IN	for
supplemental	JJ	supplemental
oxygen	NN	oxygen
.	SENT	.
Allograft	NP	Allograft
rejection	NN	rejection
was	VBD	be
uncommon	JJ	uncommon
(	(	(
3.7	CD	@card@
%	NN	%
)	)	)
despite	IN	despite
immunosuppression	NN	immunosuppression
modification	NN	modification
.	SENT	.
Antibody	NN	antibody
response	NN	response
at	IN	at
&gt	NN	&gt
;	:	;
=14	JJ	=@card@
d	NN	d
postsymptoms	NNS	postsymptom
onset	NN	onset
was	VBD	be
present	JJ	present
in	IN	in
90	CD	@card@
%	NN	%
(	(	(
anti-RBD	NN	<unknown>
)	)	)
and	CC	and
76.7	CD	@card@
%	NN	%
(	(	(
anti-NP	NN	<unknown>
)	)	)
with	IN	with
waning	VBG	wane
of	IN	of
anti-NP	NN	<unknown>
titers	NNS	titer
and	CC	and
stability	NN	stability
of	IN	of
anti-RBD	NN	<unknown>
over	IN	over
time	NN	time
.	SENT	.
Median	JJ	Median
duration	NN	duration
of	IN	of
nasopharyngeal	JJ	nasopharyngeal
positivity	NN	<unknown>
was	VBD	be
10.0	CD	@card@
d	NN	d
(	(	(
IQR	NP	IQR
,	,	,
5.5-18.0	CD	@card@
)	)	)
and	CC	and
shedding	VBG	shed
beyond	IN	beyond
30	CD	@card@
d	NN	d
was	VBD	be
observed	VBN	observe
in	IN	in
6.7	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
.	SENT	.
The	DT	the
development	NN	development
of	IN	of
antibody	NN	antibody
did	VBD	do
not	RB	not
have	VB	have
an	DT	an
impact	NN	impact
on	IN	on
viral	JJ	viral
shedding	NN	shedding
.	SENT	.
This	DT	this
study	NN	study
demonstrates	VBZ	demonstrate
the	DT	the
spectrum	NN	spectrum
of	IN	of
COVID-19	NP	<unknown>
illness	NN	illness
in	IN	in
transplant	NN	transplant
patients	NNS	patient
.	SENT	.
Risk	NN	risk
factors	NNS	factor
for	IN	for
severe	JJ	severe
disease	NN	disease
are	VBP	be
identified	VBN	identify
.	SENT	.
The	DT	the
majority	NN	majority
form	NN	form
antibody	NN	antibody
by	IN	by
2	CD	@card@
wk	NN	wk
with	IN	with
differential	JJ	differential
stability	NN	stability
over	IN	over
time	NN	time
.	SENT	.
Prolonged	JJ	prolonged
viral	JJ	viral
shedding	NN	shedding
was	VBD	be
observed	VBN	observe
in	IN	in
a	DT	a
minority	NN	minority
of	IN	of
patients	NNS	patient
.	SENT	.
Reduction	NN	reduction
of	IN	of
immunosuppression	NN	immunosuppression
was	VBD	be
a	DT	a
safe	JJ	safe
strategy	NN	strategy
.	SENT	.
34091005/	CD	@card@
Colloidal	JJ	colloidal
gold	JJ	gold
immunochromatographic	JJ	immunochromatographic
assay	NN	assay
(	(	(
GICA	NP	Gica
)	)	)
is	VBZ	be
an	DT	an
effective	JJ	effective
screening	NN	screening
method	NN	method
for	IN	for
identifying	VBG	identify
detectable	JJ	detectable
anti-SARS-CoV-2	NN	<unknown>
neutralizing	VBG	neutralize
antibodies	NNS	antibody
A	DT	a
large	JJ	large
number	NN	number
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
are	VBP	be
in	IN	in
recovery	NN	recovery
and	CC	and
millions	NNS	million
of	IN	of
people	NNS	people
are	VBP	be
vaccinated	VBN	vaccinate
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
globally	RB	globally
daily	RB	daily
.	SENT	.
This	DT	this
calls	NNS	call
for	IN	for
a	DT	a
rapid	JJ	rapid
screening	NN	screening
strategy	NN	strategy
of	IN	of
SARS-CoV-2	NP	<unknown>
protective	JJ	protective
antibodies	NNS	antibody
generated	VBN	generate
in	IN	in
rehabilitators	NNS	rehabilitator
and	CC	and
vaccinated	VBN	vaccinate
populations	NNS	population
.	SENT	.
Serum	NN	serum
samples	NNS	sample
collected	VBN	collect
over	IN	over
a	DT	a
follow-up	NN	follow-up
period	NN	period
of	IN	of
6	CD	@card@
months	NNS	month
from	IN	from
306	CD	@card@
COVID-19	NP	<unknown>
cases	NNS	case
discharged	VBN	discharge
from	IN	from
Wuhan	NP	Wuhan
Tongji	NP	<unknown>
Hospital	NP	Hospital
were	VBD	be
analyzed	VBN	analyze
.	SENT	.
Anti-S	NP	<unknown>
Abs	NP	Abs
were	VBD	be
detected	VBN	detect
by	IN	by
colloidal	JJ	colloidal
gold	JJ	gold
immunochromatographic	JJ	immunochromatographic
assay	NN	assay
(	(	(
GICA	NP	Gica
)	)	)
and	CC	and
neutralizing	VBG	neutralize
antibodies	NNS	antibody
(	(	(
nAbs	NNS	<unknown>
)	)	)
were	VBD	be
detected	VBN	detect
by	IN	by
chemiluminescent	JJ	chemiluminescent
microparticle	NN	microparticle
immunoassay	NN	immunoassay
(	(	(
CMIA	NP	<unknown>
)	)	)
.	SENT	.
Most	JJS	most
COVID-19	NP	<unknown>
survivors	NNS	survivor
tested	VBD	test
positive	JJ	positive
for	IN	for
anti-S	NP	<unknown>
Abs	NP	Abs
(	(	(
83.7	CD	@card@
%	NN	%
)	)	)
and	CC	and
nAbs	NNS	<unknown>
(	(	(
98.0	CD	@card@
%	NN	%
)	)	)
6	CD	@card@
months	NNS	month
after	IN	after
being	VBG	be
discharged	VBN	discharge
from	IN	from
the	DT	the
hospital	NN	hospital
,	,	,
and	CC	and
the	DT	the
levels	NNS	level
of	IN	of
anti-S	NP	<unknown>
Abs	NP	Abs
in	IN	in
the	DT	the
blood	NN	blood
were	VBD	be
highly	RB	highly
positively	RB	positively
correlated	VBN	correlate
with	IN	with
nAbs	NNS	<unknown>
(	(	(
r	LS	r
=	SYM	=
0.652	CD	@card@
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.0001	LS	@card@
)	)	)
.	SENT	.
The	DT	the
positivity	NN	<unknown>
rate	NN	rate
of	IN	of
nAbs	NNS	<unknown>
for	IN	for
patients	NNS	patient
with	IN	with
anti-S	NP	<unknown>
Abs	NP	Abs
positive	NN	positive
was	VBD	be
100	CD	@card@
%	NN	%
.	SENT	.
There	EX	there
is	VBZ	be
a	DT	a
good	JJ	good
agreement	NN	agreement
between	IN	between
anti-S	NP	<unknown>
Abs	NP	Abs
detected	VBD	detect
by	IN	by
GICA	NP	Gica
and	CC	and
nAbs	NNS	<unknown>
detected	VBN	detect
by	IN	by
CMIA	NP	<unknown>
.	SENT	.
It	PP	it
indicates	VBZ	indicate
that	IN	that
anti-S	NP	<unknown>
Abs	NP	Abs
detected	VBD	detect
by	IN	by
GICA	NP	Gica
may	MD	may
be	VB	be
used	VBN	use
as	IN	as
a	DT	a
cheaper	JJR	cheap
screening	NN	screening
strategy	NN	strategy
for	IN	for
detectable	JJ	detectable
SARS-CoV-2	NP	<unknown>
nAbs	NNS	<unknown>
in	IN	in
COVID-19	NP	<unknown>
convalescent	JJ	convalescent
individuals	NNS	individual
.	SENT	.
34958181/	CD	@card@
Detection	NN	detection
of	IN	of
SARS-CoV-2	NP	<unknown>
B.1.617.2	NP	B@card@
(	(	(
Delta	NP	Delta
)	)	)
variant	NN	variant
in	IN	in
three	CD	three
cats	NNS	cat
owned	VBN	own
by	IN	by
a	DT	a
confirmed	VBN	confirm
COVID-19	NP	<unknown>
patient	NN	patient
in	IN	in
Harbin	NP	Harbin
,	,	,
China	NP	China
35289365/	CD	@card@
Effect	NN	effect
of	IN	of
a	DT	a
prioritization	NN	prioritization
score	NN	score
on	IN	on
the	DT	the
inter-hospital	JJ	<unknown>
transfer	NN	transfer
time	NN	time
management	NN	management
of	IN	of
severe	JJ	severe
COVID-19	NP	<unknown>
patients	NNS	patient
:	:	:
a	DT	a
quasi-experimental	JJ	quasi-experimental
intervention	NN	intervention
study	NN	study
The	DT	the
overburdening	VBG	overburden
of	IN	of
the	DT	the
healthcare	NN	<unknown>
system	NN	system
during	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
19	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
is	VBZ	be
driving	VBG	drive
the	DT	the
need	NN	need
to	TO	to
create	VB	create
new	JJ	new
tools	NNS	tool
to	TO	to
improve	VB	improve
the	DT	the
management	NN	management
of	IN	of
inter-hospital	JJ	<unknown>
transport	NN	transport
for	IN	for
patients	NNS	patient
with	IN	with
a	DT	a
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
analyse	VB	analyse
the	DT	the
usefulness	NN	usefulness
of	IN	of
the	DT	the
application	NN	application
of	IN	of
a	DT	a
prioritization	NN	prioritization
score	NN	score
(	(	(
IHTCOVID-19	NP	<unknown>
)	)	)
for	IN	for
inter-hospital	JJ	<unknown>
transfer	NN	transfer
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
The	DT	the
study	NN	study
has	VBZ	have
a	DT	a
quasi-experimental	JJ	quasi-experimental
design	NN	design
and	CC	and
was	VBD	be
conducted	VBN	conduct
on	IN	on
the	DT	the
Medical	NP	Medical
Emergency	NP	Emergency
System	NP	System
,	,	,
the	DT	the
pre-hospital	JJ	<unknown>
emergency	NN	emergency
department	NN	department
of	IN	of
the	DT	the
public	JJ	public
company	NN	company
belonging	VBG	belong
to	TO	to
the	DT	the
Autonomous	JJ	autonomous
Government	NN	government
of	IN	of
Catalonia	NP	Catalonia
that	WDT	that
manages	VBZ	manage
urgent	JJ	urgent
healthcare	NN	<unknown>
in	IN	in
the	DT	the
region	NN	region
.	SENT	.
Patients	NNS	patient
with	IN	with
a	DT	a
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
requiring	VBG	require
inter-hospital	JJ	<unknown>
transport	NN	transport
were	VBD	be
consecutively	RB	consecutively
included	VBN	include
.	SENT	.
The	DT	the
pre-intervention	NN	pre-intervention
period	NN	period
was	VBD	be
from	IN	from
1	CD	@card@
to	TO	to
31	CD	@card@
March	NP	March
2020	CD	@card@
,	,	,
and	CC	and
the	DT	the
intervention	NN	intervention
period	NN	period
with	IN	with
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
was	VBD	be
from	IN	from
1	CD	@card@
to	TO	to
30	CD	@card@
April	NP	April
2020	CD	@card@
(	(	(
from	IN	from
8	CD	@card@
am	VBP	be
to	TO	to
8	CD	@card@
pm	NN	pm
)	)	)
.	SENT	.
The	DT	the
prioritization	NN	prioritization
score	NN	score
comprises	VBZ	comprise
four	CD	four
priority	NN	priority
categories	NNS	category
,	,	,
with	IN	with
Priority	NP	Priority
0	CD	@card@
being	VBG	be
the	DT	the
highest	JJS	high
and	CC	and
Priority	NP	Priority
3	CD	@card@
being	VBG	be
the	DT	the
lowest	JJS	low
.	SENT	.
Inter-hospital	JJ	<unknown>
transfer	NN	transfer
(	(	(
IHT	NN	IHT
)	)	)
management	NN	management
times	NNS	time
(	(	(
alert-assignment	NN	alert-assignment
time	NN	time
,	,	,
resource	NN	resource
management	NN	management
time	NN	time
and	CC	and
total	JJ	total
central	JJ	central
management	NN	management
time	NN	time
)	)	)
and	CC	and
their	PP$	their
variability	NN	variability
were	VBD	be
evaluated	VBN	evaluate
according	VBG	accord
to	TO	to
whether	IN	whether
or	CC	or
not	RB	not
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
was	VBD	be
applied	VBN	apply
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
344	CD	@card@
IHTs	NNS	<unknown>
were	VBD	be
included	VBN	include
:	:	:
189	CD	@card@
(	(	(
54.9	CD	@card@
%	NN	%
)	)	)
in	IN	in
the	DT	the
pre-intervention	NN	pre-intervention
period	NN	period
and	CC	and
155	CD	@card@
(	(	(
45.1	CD	@card@
%	NN	%
)	)	)
in	IN	in
the	DT	the
post-intervention	NN	post-intervention
period	NN	period
.	SENT	.
The	DT	the
majority	NN	majority
of	IN	of
patients	NNS	patient
were	VBD	be
male	JJ	male
and	CC	and
the	DT	the
most	RBS	most
frequent	JJ	frequent
age	NN	age
range	NN	range
was	VBD	be
between	IN	between
50	CD	@card@
and	CC	and
70	CD	@card@
years	NNS	year
.	SENT	.
According	VBG	accord
to	TO	to
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
,	,	,
12	CD	@card@
(	(	(
3.5	CD	@card@
%	NN	%
)	)	)
transfers	NNS	transfer
were	VBD	be
classified	VBN	classify
as	IN	as
Priority	NP	Priority
0	CD	@card@
,	,	,
66	CD	@card@
(	(	(
19.4	CD	@card@
%	NN	%
)	)	)
as	IN	as
Priority	NP	Priority
1	CD	@card@
,	,	,
247	CD	@card@
(	(	(
71.8	CD	@card@
%	NN	%
)	)	)
as	IN	as
Priority	NP	Priority
2	CD	@card@
and	CC	and
19	CD	@card@
(	(	(
5.6	CD	@card@
%	NN	%
)	)	)
as	IN	as
Priority	NP	Priority
3	CD	@card@
.	SENT	.
Overall	RB	overall
,	,	,
with	IN	with
the	DT	the
application	NN	application
of	IN	of
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
,	,	,
there	EX	there
was	VBD	be
a	DT	a
significant	JJ	significant
reduction	NN	reduction
in	IN	in
total	JJ	total
central	JJ	central
management	NN	management
time	NN	time
[	SYM	[
from	IN	from
112.4	CD	@card@
(	(	(
inter-quartile	NN	inter-quartile
range	NN	range
(	(	(
IQR	NP	IQR
)	)	)
281.3	CD	@card@
)	)	)
to	TO	to
89.8	CD	@card@
min	NN	min
(	(	(
IQR	NP	IQR
154.9	CD	@card@
)	)	)
;	:	;
P	NN	P
=	SYM	=
0.012	CD	@card@
]	SYM	]
.	SENT	.
This	DT	this
significant	JJ	significant
reduction	NN	reduction
was	VBD	be
observed	VBN	observe
in	IN	in
Priority	NP	Priority
0	CD	@card@
patients	NNS	patient
[	SYM	[
286.2	CD	@card@
(	(	(
IQR	NP	IQR
218.5	CD	@card@
)	)	)
to	TO	to
42.0	CD	@card@
min	NN	min
(	(	(
IQR	NP	IQR
58	CD	@card@
)	)	)
;	:	;
P	NN	P
=	SYM	=
0.018	CD	@card@
]	SYM	]
and	CC	and
Priority	NP	Priority
1	CD	@card@
patients	NNS	patient
[	SYM	[
130.3	CD	@card@
(	(	(
IQR	NP	IQR
297.3	CD	@card@
)	)	)
to	TO	to
75.4	CD	@card@
min	NN	min
(	(	(
IQR	NP	IQR
91.1	CD	@card@
)	)	)
;	:	;
P	NN	P
=	SYM	=
0.034	CD	@card@
]	SYM	]
.	SENT	.
After	IN	after
applying	VBG	apply
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
,	,	,
the	DT	the
average	JJ	average
time	NN	time
of	IN	of
the	DT	the
process	NN	process
decreased	VBD	decrease
by	IN	by
22.6	CD	@card@
min	NN	min
,	,	,
and	CC	and
variability	NN	variability
was	VBD	be
reduced	VBN	reduce
from	IN	from
618.1	CD	@card@
to	TO	to
324.0	CD	@card@
min	NN	min
.	SENT	.
The	DT	the
application	NN	application
of	IN	of
the	DT	the
IHTCOVID-19	NP	<unknown>
score	NN	score
in	IN	in
patients	NNS	patient
with	IN	with
a	DT	a
severe	JJ	severe
COVID-19	NP	<unknown>
infection	NN	infection
reduces	VBZ	reduce
IHT	NN	IHT
management	NN	management
times	NNS	time
and	CC	and
variability	NN	variability
.	SENT	.
32799739/	CD	@card@
The	DT	the
pervasive	JJ	pervasive
relevance	NN	relevance
of	IN	of
COVID-19	NP	<unknown>
within	IN	within
routine	JJ	routine
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultations	NNS	consultation
during	IN	during
the	DT	the
pandemic	NN	pandemic
:	:	:
A	DT	a
conversation	NN	conversation
analytic	JJ	analytic
study	NN	study
The	DT	the
importance	NN	importance
of	IN	of
caring	VBG	care
for	IN	for
children	NNS	child
with	IN	with
complex	JJ	complex
and	CC	and
serious	JJ	serious
conditions	NNS	condition
means	VBZ	mean
that	IN	that
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
must	MD	must
continue	VB	continue
during	IN	during
pandemics	NNS	pandemic
.	SENT	.
The	DT	the
recent	JJ	recent
pandemic	NN	pandemic
of	IN	of
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
provides	VBZ	provide
a	DT	a
natural	JJ	natural
experiment	NN	experiment
to	TO	to
study	VB	study
health	NN	health
communication	NN	communication
during	IN	during
pandemic	JJ	pandemic
times	NNS	time
.	SENT	.
However	RB	however
,	,	,
it	PP	it
is	VBZ	be
unknown	JJ	unknown
how	WRB	how
communication	NN	communication
within	IN	within
consultations	NNS	consultation
might	MD	might
change	VB	change
during	IN	during
pandemics	NNS	pandemic
.	SENT	.
This	DT	this
study	NN	study
,	,	,
a	DT	a
sub-study	NN	sub-study
of	IN	of
a	DT	a
larger	JJR	large
project	NN	project
,	,	,
aimed	VBN	aim
to	TO	to
examine	VB	examine
real-world	NN	real-world
instances	NNS	instance
of	IN	of
communication	NN	communication
in	IN	in
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultations	NNS	consultation
prior	RB	prior
to	TO	to
and	CC	and
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
to	TO	to
understand	VB	understand
how	WRB	how
clinicians	NNS	clinician
and	CC	and
families	NNS	family
talk	VBP	talk
about	IN	about
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultations	NNS	consultation
prior	RB	prior
to	TO	to
,	,	,
during	IN	during
,	,	,
and	CC	and
immediately	RB	immediately
following	VBG	follow
the	DT	the
initial	JJ	initial
peak	NN	peak
of	IN	of
COVID-19	NP	<unknown>
cases	NNS	case
in	IN	in
Australia	NP	Australia
were	VBD	be
video	NN	video
recorded	VBN	record
and	CC	and
analysed	VBN	analyse
using	VBG	use
Conversation	NN	conversation
Analysis	NN	analysis
methods	NNS	method
.	SENT	.
Twenty-five	JJ	<unknown>
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultations	NNS	consultation
(	(	(
including	VBG	include
face-to-face	JJ	face-to-face
outpatient	NN	outpatient
,	,	,
telehealth	NN	telehealth
outpatient	NN	outpatient
and	CC	and
inpatient	NN	inpatient
consultations	NNS	consultation
)	)	)
were	VBD	be
video	NN	video
recorded	VBN	record
within	IN	within
a	DT	a
public	JJ	public
children	NNS	child
's	POS	's
hospital	NN	hospital
in	IN	in
Australia	NP	Australia
.	SENT	.
Participants	NNS	participant
included	VBD	include
14	CD	@card@
health	NN	health
professionals	NNS	professional
,	,	,
15	CD	@card@
child	NN	child
patients	NNS	patient
,	,	,
23	CD	@card@
adult	NN	adult
family	NN	family
members	NNS	member
and	CC	and
5	CD	@card@
child	NN	child
siblings	NNS	sibling
.	SENT	.
There	EX	there
was	VBD	be
a	DT	a
pervasive	JJ	pervasive
relevance	NN	relevance
of	IN	of
both	DT	both
serious	JJ	serious
and	CC	and
non-serious	JJ	non-serious
talk	NN	talk
about	IN	about
COVID-19	NP	<unknown>
within	IN	within
the	DT	the
consultations	NNS	consultation
recorded	VBN	record
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Topics	NNS	topic
typical	JJ	typical
of	IN	of
a	DT	a
standard	JJ	standard
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultation	NN	consultation
often	RB	often
led	VBN	lead
to	TO	to
discussion	NN	discussion
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Clinicians	NNS	clinician
(	(	(
55	CD	@card@
%	NN	%
)	)	)
and	CC	and
parents	NNS	parent
(	(	(
45	CD	@card@
%	NN	%
)	)	)
initiated	VBN	initiate
talk	NN	talk
about	IN	about
the	DT	the
pandemic	NN	pandemic
.	SENT	.
Clinicians	NNS	clinician
should	MD	should
not	RB	not
be	VB	be
surprised	VBN	surprise
by	IN	by
the	DT	the
pervasiveness	NN	pervasiveness
of	IN	of
COVID-19	NP	<unknown>
or	CC	or
other	JJ	other
pandemic	JJ	pandemic
talk	NN	talk
within	IN	within
standard	JJ	standard
paediatric	JJ	paediatric
palliative	JJ	palliative
care	NN	care
consultations	NNS	consultation
.	SENT	.
This	DT	this
awareness	NN	awareness
will	MD	will
enable	VB	enable
clinicians	NNS	clinician
to	TO	to
flexibly	RB	flexibly
address	VB	address
family	NN	family
needs	NNS	need
and	CC	and
concerns	NNS	concern
about	IN	about
pandemic-related	JJ	pandemic-related
matters	NNS	matter
that	WDT	that
may	MD	may
impact	VB	impact
health	NN	health
and	CC	and
wellbeing	NN	wellbeing
.	SENT	.
32463534/	CD	@card@
Heart	NP	Heart
failure	NN	failure
management	NN	management
during	IN	during
COVID-19	NP	<unknown>
outbreak	NN	outbreak
in	IN	in
Italy	NP	Italy
.	SENT	.
Telemedicine	JJ	<unknown>
experience	NN	experience
from	IN	from
a	DT	a
heart	NN	heart
failure	NN	failure
university	NN	university
tertiary	JJ	tertiary
referral	NN	referral
centre	VBP	centre
35542312/	CD	@card@
Observational	JJ	observational
study	NN	study
on	IN	on
necrotizing	VBG	<unknown>
enterocolitis	NN	enterocolitis
in	IN	in
neonates	NNS	neonate
born	VBN	bear
to	TO	to
SARS-CoV-2-positive	JJ	SARS-CoV-2-positive
mothers	NNS	mother
The	DT	the
impact	NN	impact
of	IN	of
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome-coronavirus-2	NN	<unknown>
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
pandemic	NN	pandemic
on	IN	on
expectant	JJ	expectant
mother	NN	mother
and	CC	and
their	PP$	their
babies	NNS	baby
extends	VBZ	extend
to	TO	to
many	JJ	many
aspects	NNS	aspect
of	IN	of
life	NN	life
.	SENT	.
Necrotizing	NP	<unknown>
enterocolitis	NP	<unknown>
(	(	(
NEC	NP	NEC
)	)	)
has	VBZ	have
been	VBN	be
recognized	VBN	recognize
as	IN	as
a	DT	a
life-threatening	JJ	life-threatening
gastrointestinal	JJ	gastrointestinal
inflammatory	JJ	inflammatory
process	NN	process
in	IN	in
neonates	NNS	neonate
that	WDT	that
has	VBZ	have
high	JJ	high
rates	NNS	rate
of	IN	of
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
.	SENT	.
To	TO	to
investigate	VB	investigate
factors	NNS	factor
associated	VBN	associate
with	IN	with
NEC	NP	NEC
in	IN	in
hospitalized	VBN	hospitalize
neonates	NNS	neonate
whose	WP$	whose
mothers	NNS	mother
were	VBD	be
SARS-CoV-2-positive	JJ	SARS-CoV-2-positive
and	CC	and
their	PP$	their
relationship	NN	relationship
to	TO	to
mortality	NN	mortality
.	SENT	.
This	DT	this
observational	JJ	observational
study	NN	study
was	VBD	be
conducted	VBN	conduct
from	IN	from
May	NP	May
2020	CD	@card@
to	TO	to
March	NP	March
2021	CD	@card@
.	SENT	.
All	DT	all
neonates	NNS	neonate
who	WP	who
were	VBD	be
hospitalized	VBN	hospitalize
,	,	,
after	IN	after
confirming	VBG	confirm
that	IN	that
the	DT	the
mother	NN	mother
was	VBD	be
SARS-CoV-2-positive	JJ	SARS-CoV-2-positive
,	,	,
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
study	NN	study
.	SENT	.
The	DT	the
confirmation	NN	confirmation
of	IN	of
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
was	VBD	be
determined	VBN	determine
according	VBG	accord
to	TO	to
the	DT	the
reverse	JJ	reverse
transcription-polymerase	NN	transcription-polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
assay	NN	assay
.	SENT	.
The	DT	the
neonatal	JJ	neonatal
SARS-CoV-2	NP	<unknown>
test	NN	test
was	VBD	be
performed	VBN	perform
on	IN	on
the	DT	the
first	JJ	first
day	NN	day
of	IN	of
birth	NN	birth
.	SENT	.
NEC	NP	NEC
was	VBD	be
established	VBN	establish
based	VBN	base
on	IN	on
a	DT	a
suggestive	JJ	suggestive
clinical	JJ	clinical
presentation	NN	presentation
and	CC	and
abnormal	JJ	abnormal
abdominal	JJ	abdominal
radiographs	NNS	radiograph
.	SENT	.
Of	IN	of
the	DT	the
125	CD	@card@
neonates	NNS	neonate
enrolled	VBN	enroll
in	IN	in
this	DT	this
study	NN	study
,	,	,
there	EX	there
were	VBD	be
5	CD	@card@
neonates	NNS	neonate
who	WP	who
developed	VBD	develop
NEC	NP	NEC
and	CC	and
only	RB	only
one	PP	one
survived	VBD	survive
.	SENT	.
Significant	JJ	significant
associated	JJ	associated
factors	NNS	factor
with	IN	with
NEC	NP	NEC
included	VBD	include
lower	JJR	low
birth	NN	birth
weight	NN	weight
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
lower	JJR	low
gestational	JJ	gestational
age	NN	age
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
PCR	NP	PCR
results	NNS	result
(	(	(
OR	CC	or
=	SYM	=
15.333	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
2.074-113.381	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.007	CD	@card@
)	)	)
,	,	,
asphyxia	NN	asphyxia
(	(	(
OR	CC	or
=	SYM	=
13.143	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
1.411-122.443	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.024	CD	@card@
)	)	)
,	,	,
and	CC	and
mortality	NN	mortality
(	(	(
OR	CC	or
=	SYM	=
156.000	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
13.157-1849.623	CD	@card@
;	:	;
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Mortality	NN	mortality
was	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
lower	JJR	low
gestational	JJ	gestational
age	NN	age
(	(	(
p	NN	p
=	SYM	=
0.025	CD	@card@
)	)	)
,	,	,
cesarean	JJ	Cesarean
section	NN	section
delivery	NN	delivery
(	(	(
p	NN	p
=	SYM	=
0.025	CD	@card@
)	)	)
,	,	,
and	CC	and
asphyxia	NN	asphyxia
(	(	(
p	NN	p
=	SYM	=
0.025	CD	@card@
)	)	)
.	SENT	.
Significant	JJ	significant
associated	JJ	associated
factors	NNS	factor
with	IN	with
NEC	NP	NEC
in	IN	in
neonates	NNS	neonate
born	VBN	bear
to	TO	to
SARS-CoV-2-positive	JJ	SARS-CoV-2-positive
mothers	NNS	mother
included	VBD	include
positive	JJ	positive
SARS-CoV-2	NP	<unknown>
PCR	NP	PCR
results	NNS	result
,	,	,
asphyxia	NN	asphyxia
,	,	,
lower	JJR	low
gestational	JJ	gestational
age	NN	age
,	,	,
and	CC	and
lower	JJR	low
birth	NN	birth
weight	NN	weight
.	SENT	.
In	IN	in
addition	NN	addition
to	TO	to
caesarean	JJ	Caesarean
section	NN	section
delivery	NN	delivery
,	,	,
these	DT	these
factors	NNS	factor
were	VBD	be
related	VBN	relate
to	TO	to
mortality	NN	mortality
in	IN	in
neonates	NNS	neonate
in	IN	in
such	JJ	such
conditions	NNS	condition
.	SENT	.
32354565/	CD	@card@
Letalidad	NP	<unknown>
del	NP	del
COVID-19	NP	<unknown>
:	:	:
ausencia	NP	<unknown>
de	NP	de
patron	NN	patron
epidemiologico	NN	<unknown>
Analizar	NP	<unknown>
un	NN	un
conjunto	NP	<unknown>
de	NP	de
indicadores	NNS	<unknown>
para	NN	para
comprender	NP	comprender
la	FW	la
variabilidad	NP	<unknown>
de	FW	de
la	FW	la
evolucion	NN	<unknown>
y	NN	y
el	NN	el
impacto	NP	<unknown>
de	FW	de
la	FW	la
epidemia	NP	<unknown>
de	FW	de
COVID-19	NP	<unknown>
.	SENT	.
Estudio	NP	<unknown>
ecologico	NP	<unknown>
de	NP	de
paises	VBZ	<unknown>
con	NN	con
mas	NNS	ma
de	NP	de
200	CD	@card@
casos	NN	<unknown>
notificados	NNS	<unknown>
.	SENT	.
Se	NP	Se
han	NP	han
analizado	NP	<unknown>
variables	NNS	variable
demograficas	NNS	<unknown>
,	,	,
de	NP	de
gasto	NP	<unknown>
sanitario	NP	<unknown>
y	NP	y
de	NP	de
caracteristicas	NNS	<unknown>
de	NP	de
los	NP	los
servicios	NP	Servicios
sanitarios	NP	<unknown>
como	NP	Como
variables	NNS	variable
explicativas	NNS	<unknown>
,	,	,
y	NP	y
las	NNS	la
tasas	NNS	<unknown>
de	NP	de
incidencia	NP	<unknown>
,	,	,
mortalidad	NP	<unknown>
y	NP	y
letalidad	NN	letalidad
como	NN	<unknown>
variables	NNS	variable
respuesta	NN	<unknown>
.	SENT	.
Se	NP	Se
ha	NP	ha
creado	NP	creado
un	NN	un
indice	NP	<unknown>
de	NP	de
letalidad	NN	letalidad
relativa	NN	<unknown>
.	SENT	.
Los	NP	Los
datos	NNS	dato
proceden	NP	<unknown>
de	NP	de
organismos	NNS	<unknown>
internacionales	NNS	<unknown>
.	SENT	.
La	NP	La
magnitud	NP	<unknown>
de	NP	de
las	NNS	la
asociaciones	NP	<unknown>
se	FW	se
ha	NP	ha
estimado	NP	<unknown>
mediante	NN	<unknown>
el	NN	el
coeficiente	NP	<unknown>
de	NP	de
correlacion	NN	<unknown>
de	NP	de
Spearman	NP	Spearman
.	SENT	.
El	NP	El
numero	NP	numero
de	NP	de
pruebas	NP	<unknown>
y	NP	y
el	NN	el
numero	NP	numero
de	FW	de
profesionales	NP	<unknown>
de	FW	de
medicina	NP	<unknown>
se	FW	se
asocian	NN	<unknown>
a	DT	a
una	NN	una
mayor	NN	mayor
incidencia	NNS	<unknown>
.	SENT	.
La	NP	La
mortalidad	NP	<unknown>
y	NP	y
la	NP	la
letalidad	NN	letalidad
no	DT	no
se	FW	se
asocian	JJ	<unknown>
con	NN	con
variables	NNS	variable
demograficas	NNS	<unknown>
,	,	,
de	NP	de
gasto	NP	<unknown>
sanitario	NP	<unknown>
ni	NP	Ni
de	NP	de
los	NP	los
servicios	NNS	<unknown>
sanitarios	NNS	<unknown>
.	SENT	.
Las	NP	Las
diferencias	NP	<unknown>
sugieren	NP	<unknown>
una	NP	Una
subestimacion	NN	<unknown>
generalizada	NP	<unknown>
de	FW	de
la	FW	la
magnitud	NP	<unknown>
de	FW	de
la	FW	la
epidemia	NN	<unknown>
.	SENT	.
Es	NP	E
necesario	NP	necesario
mejorar	NP	<unknown>
la	FW	la
identificacion	NP	<unknown>
de	FW	de
casos	NP	<unknown>
y	NP	y
la	FW	la
eficacia	NP	<unknown>
de	FW	de
los	NP	los
sistemas	NNS	<unknown>
de	NP	de
vigilancia	NP	vigilancia
epidemiologica	NN	<unknown>
.	SENT	.
32688022/	CD	@card@
The	DT	the
psychological	JJ	psychological
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
the	DT	the
general	JJ	general
population	NN	population
of	IN	of
Saudi	NP	Saudi
Arabia	NP	Arabia
The	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
an	DT	an
emerging	VBG	emerge
infection	NN	infection
causing	VBG	cause
a	DT	a
widely	RB	widely
spread	VBN	spread
pandemic	NN	pandemic
of	IN	of
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
current	JJ	current
COVID-2019	NP	COVID@card@
pandemic	NN	pandemic
is	VBZ	be
prompting	VBG	prompt
fear	NN	fear
of	IN	of
falling	VBG	fall
sick	JJ	sick
,	,	,
dying	VBG	die
,	,	,
helplessness	NN	helplessness
and	CC	and
stigma	NN	stigma
,	,	,
urgent	JJ	urgent
and	CC	and
timely	JJ	timely
understanding	NN	understanding
of	IN	of
mental	JJ	mental
health	NN	health
status	NN	status
is	VBZ	be
needed	VBN	need
to	TO	to
help	VB	help
the	DT	the
community	NN	community
.	SENT	.
Our	PP$	our
investigation	NN	investigation
designed	VBN	design
to	TO	to
survey	VB	survey
the	DT	the
general	JJ	general
population	NN	population
in	IN	in
Saudi	NP	Saudi
Arabia	NP	Arabia
to	TO	to
assess	VB	assess
the	DT	the
degree	NN	degree
of	IN	of
psychological	JJ	psychological
impact	NN	impact
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
During	IN	during
the	DT	the
early	JJ	early
stage	NN	stage
of	IN	of
the	DT	the
outbreak	NN	outbreak
,	,	,
we	PP	we
conducted	VBD	conduct
an	DT	an
online-based	JJ	<unknown>
survey	NN	survey
using	VBG	use
a	DT	a
snowballing	JJ	snowballing
sample	NN	sample
technique	NN	technique
.	SENT	.
The	DT	the
surveys	NNS	survey
collected	VBD	collect
data	NNS	datum
about	IN	about
several	JJ	several
aspects	NNS	aspect
of	IN	of
participant	NN	participant
sociodemographic	NN	<unknown>
,	,	,
knowledge	NN	knowledge
,	,	,
concerns	NNS	concern
,	,	,
psychological	JJ	psychological
impact	NN	impact
,	,	,
and	CC	and
mental	JJ	mental
health	NN	health
status	NN	status
.	SENT	.
We	PP	we
assessed	VBD	assess
the	DT	the
psychological	JJ	psychological
impact	NN	impact
and	CC	and
mental	JJ	mental
health	NN	health
status	NN	status
using	VBG	use
the	DT	the
Impact	NN	impact
of	IN	of
Event	NP	Event
Scale-Revised	NP	<unknown>
(	(	(
IES-R	NP	<unknown>
)	)	)
,	,	,
and	CC	and
the	DT	the
Depression	NP	Depression
,	,	,
Anxiety	NN	anxiety
,	,	,
and	CC	and
Stress	VBP	stress
Scale	NP	Scale
(	(	(
DASS-21	NP	<unknown>
)	)	)
.	SENT	.
Our	PP$	our
survey	NN	survey
recruited	VBD	recruit
1160	CD	@card@
respondents	NNS	respondent
of	IN	of
the	DT	the
general	JJ	general
public	NN	public
of	IN	of
Saudi	NP	Saudi
Arabia	NP	Arabia
.	SENT	.
Of	IN	of
them	PP	them
,	,	,
23.6	CD	@card@
%	NN	%
reported	VBD	report
moderate	JJ	moderate
or	CC	or
severe	JJ	severe
psychological	JJ	psychological
impact	NN	impact
of	IN	of
the	DT	the
outbreak	NN	outbreak
,	,	,
28.3%,24	CD	@card@
%	NN	%
,	,	,
and	CC	and
22.3	CD	@card@
%	NN	%
reported	VBD	report
moderate	JJ	moderate
to	TO	to
severe	JJ	severe
depressive	JJ	depressive
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
symptoms	NNS	symptom
,	,	,
respectively	RB	respectively
.	SENT	.
Females	NNS	female
reported	VBN	report
IES-R	NP	<unknown>
(	(	(
B	NP	B
:	:	:
5.46	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
3.61	CD	@card@
to	TO	to
7.31	CD	@card@
)	)	)
and	CC	and
DASS	NP	Dass
subscales	NP	subscales
B	NP	B
coefficient	NN	coefficient
ranged	VBD	range
from	IN	from
1.65	CD	@card@
to	TO	to
2.63	CD	@card@
,	,	,
along	RB	along
with	IN	with
high-school	JJ	high-school
students	NNS	student
,	,	,
working	VBG	work
in	IN	in
the	DT	the
medical	JJ	medical
field	NN	field
,	,	,
and	CC	and
poor	JJ	poor
self-reported	JJ	self-reported
health	NN	health
status	NN	status
was	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
a	DT	a
high	JJ	high
level	NN	level
of	IN	of
IES-R	NP	<unknown>
and	CC	and
DASS	NP	Dass
scales	NNS	scale
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
.05	LS	@card@
)	)	)
.	SENT	.
Experiencing	VBG	experience
breathing	NN	breathing
difficulty	NN	difficulty
and	CC	and
dizziness	NN	dizziness
showed	VBD	show
a	DT	a
stronger	JJR	strong
association	NN	association
with	IN	with
higher	JJR	high
IES-R	NN	<unknown>
and	CC	and
DASS	FW	Dass
subscales	NNS	subscale
than	IN	than
other	JJ	other
somatic	JJ	somatic
symptoms	NNS	symptom
(	(	(
e.g.	FW	e.g.
,	,	,
headache	NN	headache
and	CC	and
fever	NN	fever
)	)	)
;	:	;
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
.	SENT	.
Respondents	NNS	respondent
who	WP	who
practiced	VBD	practice
specific	JJ	specific
preventative	JJ	preventative
measures	NNS	measure
(	(	(
e.g.	FW	e.g.
,	,	,
hand	NN	hand
washing	NN	washing
,	,	,
social	JJ	social
distancing	NN	distancing
)	)	)
demonstrated	VBD	demonstrate
a	DT	a
protective	JJ	protective
effect	NN	effect
against	IN	against
stress	NN	stress
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
depression	NN	depression
symptoms	NNS	symptom
.	SENT	.
Social	JJ	social
distancing	NN	distancing
appeared	VBD	appear
to	TO	to
be	VB	be
protective	JJ	protective
on	IN	on
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
subscales	NNS	subscale
(	(	(
B	NP	B
:	:	:
-1.49	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
-2.79	CD	@card@
to	TO	to
-0.19),(B	NN	<unknown>
:	:	:
-1.53	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
-2.50	CD	@card@
to	TO	to
-0.57),respectively	RB	-0.57),respectively
;	:	;
and	CC	and
hand	NN	hand
hygiene	NN	hygiene
on	IN	on
depression	NN	depression
subscale	NN	subscale
(	(	(
B	NP	B
:	:	:
-2.43	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
-4.44	CD	@card@
to	TO	to
-0.42	CD	@card@
)	)	)
.	SENT	.
Throughout	IN	throughout
the	DT	the
early	JJ	early
stage	NN	stage
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
in	IN	in
Saudi	NP	Saudi
Arabia	NP	Arabia
,	,	,
the	DT	the
results	NNS	result
showed	VBD	show
that	IN	that
nearly	RB	nearly
one-fourth	NN	one-fourth
of	IN	of
the	DT	the
sampled	VBN	sample
general	JJ	general
population	NN	population
experienced	VBD	experience
moderate	JJ	moderate
to	TO	to
severe	JJ	severe
psychological	JJ	psychological
impact	NN	impact
.	SENT	.
Following	VBG	follow
specific	JJ	specific
precautionary	JJ	precautionary
measures	NNS	measure
appeared	VBD	appear
to	TO	to
have	VB	have
a	DT	a
protective	JJ	protective
effect	NN	effect
on	IN	on
the	DT	the
individual	NN	individual
's	POS	's
mental	JJ	mental
health	NN	health
.	SENT	.
Our	PP$	our
findings	NNS	finding
can	MD	can
be	VB	be
used	VBN	use
to	TO	to
construct	VB	construct
psychological	JJ	psychological
interventions	NNS	intervention
directed	VBN	direct
toward	IN	toward
vulnerable	JJ	vulnerable
populations	NNS	population
and	CC	and
to	TO	to
implement	VB	implement
public	JJ	public
mental	JJ	mental
health	NN	health
strategies	NNS	strategy
in	IN	in
the	DT	the
early	JJ	early
stages	NNS	stage
of	IN	of
the	DT	the
outbreak	NN	outbreak
.	SENT	.
There	EX	there
is	VBZ	be
Limited	JJ	limited
data	NNS	datum
about	IN	about
psychological	JJ	psychological
impact	NN	impact
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Saudi	NP	Saudi
Arabia	NP	Arabia
Health	NP	Health
care	NN	care
workers	NNS	worker
,	,	,
females	NNS	female
,	,	,
were	VBD	be
associated	VBN	associate
with	IN	with
higher	JJR	high
levels	NNS	level
of	IN	of
stress	NN	stress
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
depression	NN	depression
symptoms	NNS	symptom
.	SENT	.
Students	NNS	student
and	CC	and
those	DT	those
with	IN	with
poor	JJ	poor
self-reported	JJ	self-reported
health	NN	health
status	NN	status
reported	VBD	report
higher	JJR	high
levels	NNS	level
of	IN	of
stress	NN	stress
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
depression	NN	depression
symptoms	NNS	symptom
.	SENT	.
Participants	NNS	participant
with	IN	with
reported	VBN	report
mental	JJ	mental
disorders	NNS	disorder
(	(	(
10.5	CD	@card@
%	NN	%
)	)	)
showed	VBD	show
high	JJ	high
scores	NNS	score
on	IN	on
all	DT	all
DASS	NP	Dass
and	CC	and
IER-S	NP	<unknown>
scales	NNS	scale
.	SENT	.
Preventative	JJ	preventative
measures	NNS	measure
demonstrated	VBD	demonstrate
a	DT	a
protective	JJ	protective
effect	NN	effect
against	IN	against
,	,	,
stress	NN	stress
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
depression	NN	depression
symptoms	NNS	symptom
33581061/	CD	@card@
COVID-19	NN	<unknown>
and	CC	and
the	DT	the
collapse	NN	collapse
of	IN	of
global	JJ	global
trade	NN	trade
:	:	:
building	VBG	build
an	DT	an
effective	JJ	effective
public	JJ	public
health	NN	health
response	NN	response
The	DT	the
scale	NN	scale
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
a	DT	a
consequence	NN	consequence
of	IN	of
international	JJ	international
trade	NN	trade
and	CC	and
globalisation	NN	<unknown>
,	,	,
with	IN	with
the	DT	the
virus	NN	virus
spreading	VBG	spread
along	IN	along
established	VBN	establish
trade	NN	trade
and	CC	and
travel	NN	travel
routes	NNS	route
.	SENT	.
However	RB	however
,	,	,
the	DT	the
pandemic	NN	pandemic
also	RB	also
affects	VBZ	affect
international	JJ	international
trade	NN	trade
through	IN	through
reductions	NNS	reduction
in	IN	in
both	DT	both
supply	NN	supply
and	CC	and
demand	NN	demand
.	SENT	.
In	IN	in
this	DT	this
Viewpoint	NN	viewpoint
we	PP	we
describe	VBP	describe
the	DT	the
many	JJ	many
implications	NNS	implication
for	IN	for
health	NN	health
and	CC	and
propose	VB	propose
ways	NNS	way
to	TO	to
mitigate	VB	mitigate
them	PP	them
.	SENT	.
Problems	NNS	problem
include	VBP	include
reduced	VBN	reduce
access	NN	access
to	TO	to
medical	JJ	medical
supplies	NNS	supply
(	(	(
in	IN	in
particular	JJ	particular
,	,	,
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
and	CC	and
tests	NNS	test
)	)	)
,	,	,
budgetary	JJ	budgetary
shortfalls	NNS	shortfall
as	IN	as
a	DT	a
result	NN	result
of	IN	of
reduced	VBN	reduce
tariffs	NNS	tariff
and	CC	and
taxes	NNS	tax
,	,	,
and	CC	and
a	DT	a
general	JJ	general
decline	NN	decline
in	IN	in
economic	JJ	economic
activity:leading	NN	activity:leading
,	,	,
in	IN	in
many	JJ	many
cases	NNS	case
,	,	,
to	TO	to
recessions	NNS	recession
,	,	,
threats	NNS	threat
to	TO	to
social	JJ	social
safety	NN	safety
nets	NNS	net
,	,	,
and	CC	and
to	TO	to
increased	VBN	increase
precariousness	NN	precariousness
of	IN	of
income	NN	income
,	,	,
employment	NN	employment
,	,	,
and	CC	and
food	NN	food
security	NN	security
.	SENT	.
However	RB	however
,	,	,
in	IN	in
exceptional	JJ	exceptional
cases	NNS	case
,	,	,
the	DT	the
pandemic	NN	pandemic
has	VBZ	have
also	RB	also
brought	VBN	bring
some	DT	some
transient	JJ	transient
benefits	NNS	benefit
,	,	,
including	VBG	include
to	TO	to
the	DT	the
environment	NN	environment
.	SENT	.
Looking	VBG	look
ahead	RB	ahead
,	,	,
there	EX	there
will	MD	will
be	VB	be
great	JJ	great
pressure	NN	pressure
to	TO	to
further	RBR	further
liberalise	VB	liberalise
rules	NNS	rule
on	IN	on
trade	NN	trade
to	TO	to
encourage	VB	encourage
economic	JJ	economic
recovery	NN	recovery
,	,	,
but	CC	but
it	PP	it
is	VBZ	be
essential	JJ	essential
that	IN	that
trade	NN	trade
policy	NN	policy
be	VB	be
informed	VBN	inform
by	IN	by
its	PP$	its
many	JJ	many
consequences	NNS	consequence
for	IN	for
health	NN	health
to	TO	to
ensure	VB	ensure
that	IN	that
the	DT	the
benefits	NNS	benefit
are	VBP	be
maximised	VBN	maximise
and	CC	and
threats	NNS	threat
are	VBP	be
minimised	VBN	minimise
through	IN	through
active	JJ	active
identification	NN	identification
and	CC	and
mitigation	NN	mitigation
.	SENT	.
32619319/	CD	@card@
Learning	NP	Learning
New	NP	New
Ways	NP	Ways
of	IN	of
Teaching	NN	teaching
and	CC	and
Assessment	NP	Assessment
-	NN	<unknown>
The	DT	the
Impact	NN	impact
of	IN	of
Covid-19	NP	<unknown>
on	IN	on
Undergraduate	JJ	undergraduate
Dermatology	NN	dermatology
Education	NP	Education
Covid-19	NP	<unknown>
has	VBZ	have
resulted	VBN	result
in	IN	in
unprecedented	JJ	unprecedented
global	JJ	global
disruption	NN	disruption
.	SENT	.
As	IN	as
this	DT	this
global	JJ	global
pandemic	NN	pandemic
persists	VBZ	persist
with	IN	with
no	DT	no
end	NN	end
in	IN	in
sight	NN	sight
,	,	,
we	PP	we
must	MD	must
not	RB	not
ignore	VB	ignore
its	PP$	its
impact	NN	impact
on	IN	on
undergraduate	JJ	undergraduate
medical	JJ	medical
education	NN	education
.	SENT	.
Dermatology	NN	dermatology
undergraduate	NN	undergraduate
exposure	NN	exposure
is	VBZ	be
variable	JJ	variable
,	,	,
limited	JJ	limited
and	CC	and
often	RB	often
suboptimal	JJ	suboptimal
.	SENT	.
It	PP	it
has	VBZ	have
been	VBN	be
shown	VBN	show
that	IN	that
medical	JJ	medical
students	NNS	student
and	CC	and
qualified	JJ	qualified
doctors	NNS	doctor
are	VBP	be
not	RB	not
adequately	RB	adequately
confident	JJ	confident
in	IN	in
their	PP$	their
ability	NN	ability
to	TO	to
assess	VB	assess
and	CC	and
manage	VB	manage
skin	NN	skin
conditions	NNS	condition
,	,	,
and	CC	and
many	JJ	many
feel	VBP	feel
that	IN	that
their	PP$	their
undergraduate	JJ	undergraduate
dermatology	NN	dermatology
teaching	NN	teaching
was	VBD	be
not	RB	not
satisfactory	JJ	satisfactory
.	SENT	.
35098033/	CD	@card@
Electrospun	NP	<unknown>
nanofiber-based	JJ	<unknown>
respiratory	JJ	respiratory
face	NN	face
masks:a	NN	<unknown>
review	VB	review
The	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
pandemic	NN	pandemic
of	IN	of
2019	CD	@card@
forced	JJ	forced
widespread	JJ	widespread
use	NN	use
of	IN	of
face	NN	face
coverings	NNS	covering
as	IN	as
a	DT	a
mandatory	JJ	mandatory
step	NN	step
towards	IN	towards
reducing	VBG	reduce
infection	NN	infection
by	IN	by
the	DT	the
virus	NN	virus
.	SENT	.
The	DT	the
face	NN	face
mask	NN	mask
acts	VBZ	act
as	IN	as
a	DT	a
barrier	NN	barrier
for	IN	for
transmission	NN	transmission
of	IN	of
infected	JJ	infected
aerosols	NNS	aerosol
among	IN	among
its	PP$	its
user	NN	user
and	CC	and
surrounding	VBG	surround
people	NNS	people
.	SENT	.
This	DT	this
has	VBZ	have
propelled	VBN	propel
pace	NN	pace
of	IN	of
research	NN	research
and	CC	and
development	NN	development
of	IN	of
face	NN	face
masks	NNS	mask
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
This	DT	this
short	JJ	short
review	NN	review
is	VBZ	be
an	DT	an
effort	NN	effort
to	TO	to
present	VB	present
advances	NNS	advance
in	IN	in
materials	NNS	material
and	CC	and
designs	NNS	design
used	VBN	use
for	IN	for
face	NN	face
masks	NNS	mask
.	SENT	.
Details	NNS	detail
available	JJ	available
in	IN	in
scientific	JJ	scientific
literature	NN	literature
and	CC	and
company	NN	company
brochures	NNS	brochure
have	VBP	have
been	VBN	be
accessed	VBN	access
and	CC	and
the	DT	the
use	NN	use
of	IN	of
nanomaterials	NNS	nanomaterial
and	CC	and
designs	NNS	design
for	IN	for
the	DT	the
new	JJ	new
generation	NN	generation
of	IN	of
face	NN	face
masks	NNS	mask
have	VBP	have
been	VBN	be
discussed	VBN	discuss
.	SENT	.
Special	JJ	special
attention	NN	attention
was	VBD	be
given	VBN	give
to	TO	to
the	DT	the
face	NN	face
masks	NNS	mask
based	VBN	base
on	IN	on
electrospun	JJ	<unknown>
nanofiber-based	JJ	<unknown>
membrane	NN	membrane
materials	NNS	material
due	JJ	due
to	TO	to
their	PP$	their
nano-sized	JJ	nano-sized
pores	NNS	pore
,	,	,
light	JJ	light
weight	NN	weight
,	,	,
and	CC	and
high	JJ	high
filtration	NN	filtration
efficiency	NN	efficiency
;	:	;
therefore	RB	therefore
,	,	,
they	PP	they
are	VBP	be
commercially	RB	commercially
viable	JJ	viable
and	CC	and
popular	JJ	popular
among	IN	among
various	JJ	various
products	NNS	product
available	JJ	available
in	IN	in
the	DT	the
market	NN	market
.	SENT	.
Incorporation	NN	incorporation
of	IN	of
metal	NN	metal
organic	JJ	organic
framework	NN	framework
(	(	(
MOFs	NP	<unknown>
)	)	)
and	CC	and
graphene	NN	<unknown>
have	VBP	have
opened	VBN	open
avenues	NNS	avenue
to	TO	to
more	RBR	more
advanced/multi-functional	JJ	advanced/multi-functional
,	,	,
reusable	JJ	reusable
,	,	,
and	CC	and
high	JJ	high
capacity	NN	capacity
adsorption	NN	adsorption
filtration	NN	filtration
membranes	NNS	membrane
.	SENT	.
Rapid	JJ	rapid
prototyping/3-dimensional	JJ	prototyping/3-dimensional
(	(	(
3-D	JJ	<unknown>
)	)	)
printing	NN	printing
techniques	NNS	technique
have	VBP	have
been	VBN	be
applied	VBN	apply
to	TO	to
shorten	VB	shorten
the	DT	the
time	NN	time
of	IN	of
manufacture	NN	manufacture
of	IN	of
face	NN	face
masks	NNS	mask
.	SENT	.
This	DT	this
review	NN	review
is	VBZ	be
expected	VBN	expect
to	TO	to
be	VB	be
very	RB	very
helpful	JJ	helpful
for	IN	for
engineers	NNS	engineer
,	,	,
scientists	NNS	scientist
,	,	,
and	CC	and
entrepreneurs	NNS	entrepreneur
working	VBG	work
on	IN	on
development	NN	development
of	IN	of
novel	JJ	novel
face	NN	face
masks	NNS	mask
required	VBN	require
in	IN	in
plenty	NN	plenty
during	IN	during
this	DT	this
pandemic	JJ	pandemic
period	NN	period
.	SENT	.
32618967/	CD	@card@
Trauma	NN	trauma
center	NN	center
activity	NN	activity
and	CC	and
surge	NN	surge
response	NN	response
during	IN	during
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic:the	NN	<unknown>
Philadelphia	NP	Philadelphia
story	NN	story
Supplemental	NN	Supplemental
digital	JJ	digital
content	NN	content
is	VBZ	be
available	JJ	available
in	IN	in
the	DT	the
text	NN	text
.	SENT	.
35345704/	CD	@card@
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Distress	NN	distress
Syndrome	NN	syndrome
(	(	(
ARDS	NP	<unknown>
)	)	)
or	CC	or
Severely	RB	severely
Increased	VBD	increase
Chest	NN	chest
Wall	NP	Wall
Elastance	NN	elastance
?	SENT	?
Esophageal	JJ	esophageal
manometry	NN	manometry
can	MD	can
be	VB	be
used	VBN	use
to	TO	to
calculate	VB	calculate
transpulmonary	JJ	transpulmonary
pressures	NNS	pressure
and	CC	and
optimize	VB	optimize
ventilator	NN	ventilator
settings	NNS	setting
accordingly	RB	accordingly
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
case	NN	case
of	IN	of
a	DT	a
31-year-old	JJ	31-year-old
male	JJ	male
patient	NN	patient
with	IN	with
ataxia-telangiectasia	NN	ataxia-telangiectasia
(	(	(
Louis-Bar	NP	<unknown>
syndrome	NN	syndrome
)	)	)
and	CC	and
a	DT	a
BMI	NP	BMI
of	IN	of
20	CD	@card@
kg/m2	NN	<unknown>
,	,	,
admitted	VBD	admit
to	TO	to
our	PP$	our
intensive	JJ	intensive
care	NN	care
unit	NN	unit
for	IN	for
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pneumonia	NN	pneumonia
.	SENT	.
The	DT	the
patient	NN	patient
soon	RB	soon
required	VBN	require
mechanical	JJ	mechanical
ventilation	NN	ventilation
;	:	;
however	RB	however
,	,	,
there	EX	there
was	VBD	be
very	RB	very
poor	JJ	poor
respiratory	JJ	respiratory
system	NN	system
compliance	NN	compliance
.	SENT	.
Cholecystitis	NP	<unknown>
complicated	VBD	complicate
the	DT	the
clinical	JJ	clinical
course	NN	course
,	,	,
and	CC	and
veno-venous	JJ	veno-venous
extracorporeal	JJ	extracorporeal
membrane	NN	membrane
oxygenation	NN	oxygenation
(	(	(
ECMO	NP	ECMO
)	)	)
was	VBD	be
initiated	VBN	initiate
as	IN	as
gas	NN	gas
exchange	NN	exchange
deteriorated	VBD	deteriorate
.	SENT	.
Esophageal	JJ	esophageal
manometry	NN	manometry
was	VBD	be
introduced	VBN	introduce
and	CC	and
revealed	VBN	reveal
severely	RB	severely
increased	VBD	increase
intrathoracic	JJ	intrathoracic
pressure	NN	pressure
and	CC	and
chest	NN	chest
wall	NN	wall
elastance	NN	elastance
.	SENT	.
32672061/	CD	@card@
Evidence	NN	evidence
supporting	VBG	support
the	DT	the
use	NN	use
of	IN	of
peptides	NNS	peptide
and	CC	and
peptidomimetics	NNS	peptidomimetic
as	IN	as
potential	JJ	potential
SARS-CoV-2	NP	<unknown>
(	(	(
COVID-19	NP	<unknown>
)	)	)
therapeutics	NNS	therapeutics
During	IN	during
a	DT	a
disease	NN	disease
outbreak/pandemic	JJ	outbreak/pandemic
situation	NN	situation
such	JJ	such
as	IN	as
COVID-19	NP	<unknown>
,	,	,
researchers	NNS	researcher
are	VBP	be
in	IN	in
a	DT	a
prime	JJ	prime
position	NN	position
to	TO	to
identify	VB	identify
and	CC	and
develop	VB	develop
peptide-based	JJ	<unknown>
therapies	NNS	therapy
,	,	,
which	WDT	which
could	MD	could
be	VB	be
more	RBR	more
rapidly	RB	rapidly
and	CC	and
cost-effectively	RB	cost-effectively
advanced	VBD	advance
into	IN	into
a	DT	a
clinical	JJ	clinical
setting	NN	setting
.	SENT	.
One	CD	one
drawback	NN	drawback
of	IN	of
natural	JJ	natural
peptide	NN	peptide
drugs	NNS	drug
,	,	,
however	RB	however
,	,	,
is	VBZ	be
their	PP$	their
proteolytic	JJ	proteolytic
instability	NN	instability
;	:	;
peptidomimetics	NNS	peptidomimetic
can	MD	can
help	VB	help
to	TO	to
overcome	VB	overcome
this	DT	this
caveat	NN	caveat
.	SENT	.
In	IN	in
this	DT	this
review	NN	review
,	,	,
we	PP	we
summarize	VBP	summarize
peptide	NN	peptide
and	CC	and
peptide-based	JJ	<unknown>
therapeutics	NNS	therapeutics
that	WDT	that
target	VBP	target
one	CD	one
main	JJ	main
entry	NN	entry
pathway	NN	pathway
of	IN	of
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
,	,	,
which	WDT	which
involves	VBZ	involve
the	DT	the
host	NN	host
angiotensin-converting	NN	<unknown>
enzyme-2	NN	<unknown>
(	(	(
ACE2	NP	<unknown>
)	)	)
receptor	NN	receptor
and	CC	and
viral	JJ	viral
spike	NN	spike
(	(	(
S	NP	S
)	)	)
protein	NN	protein
interaction	NN	interaction
.	SENT	.
Furthermore	RB	furthermore
,	,	,
we	PP	we
discuss	VBP	discuss
the	DT	the
advantages	NNS	advantage
of	IN	of
peptidomimetics	NNS	peptidomimetic
and	CC	and
other	JJ	other
potential	JJ	potential
targets	NNS	target
that	WDT	that
have	VBP	have
been	VBN	be
studied	VBN	study
using	VBG	use
peptide-based	JJ	<unknown>
therapeutics	NNS	therapeutics
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
34523132/	CD	@card@
Disparities	NNS	disparity
in	IN	in
the	DT	the
Use	NN	use
of	IN	of
in-Person	NN	in-person
and	CC	and
Telehealth	NN	Telehealth
Outpatient	NN	outpatient
Visits	NNS	visit
Among	IN	among
Medicare	NP	Medicare
Beneficiaries	NNS	beneficiary
in	IN	in
an	DT	an
Accountable	JJ	accountable
Care	NP	Care
Organization	NP	Organization
during	IN	during
COVID-19	NP	<unknown>
To	TO	to
investigate	VB	investigate
the	DT	the
extent	NN	extent
to	TO	to
which	WDT	which
telehealth	NN	telehealth
visits	NNS	visit
mitigated	VBD	mitigate
COVID-19	JJ	<unknown>
pandemic-related	JJ	pandemic-related
impacts	NNS	impact
on	IN	on
in-person	NN	in-person
outpatient	NN	outpatient
visits	NNS	visit
among	IN	among
Medicare	NP	Medicare
beneficiaries	NNS	beneficiary
,	,	,
including	VBG	include
those	DT	those
who	WP	who
are	VBP	be
high-cost	JJ	high-cost
high-need	NN	<unknown>
.	SENT	.
High-cost	JJ	high-cost
high-need	JJ	<unknown>
patients	NNS	patient
were	VBD	be
defined	VBN	define
as	IN	as
those	DT	those
65	CD	@card@
years	NNS	year
or	CC	or
older	JJR	old
and	CC	and
with	IN	with
2	CD	@card@
or	CC	or
higher	JJR	high
Hierarchical	JJ	hierarchical
Condition	NN	condition
Categories	NNS	category
(	(	(
HCC	NP	HCC
)	)	)
scores	NNS	score
.	SENT	.
A	DT	a
difference-in-difference	NN	difference-in-difference
design	NN	design
was	VBD	be
used	VBN	use
to	TO	to
estimate	VB	estimate
the	DT	the
change	NN	change
in	IN	in
outpatient	NN	outpatient
in-person	NN	in-person
and	CC	and
telehealth	NN	telehealth
utilization	NN	utilization
for	IN	for
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
cohort	NN	cohort
compared	VBN	compare
to	TO	to
the	DT	the
control	NN	control
cohort	NN	cohort
in	IN	in
the	DT	the
prior	JJ	prior
year	NN	year
.	SENT	.
Medicare	NP	Medicare
patients	NNS	patient
from	IN	from
an	DT	an
Accountable	JJ	accountable
Care	NP	Care
Organization	NP	Organization
(	(	(
ACO	NP	ACO
)	)	)
were	VBD	be
used	VBN	use
as	IN	as
the	DT	the
study	NN	study
sample	NN	sample
.	SENT	.
The	DT	the
pandemic	JJ	pandemic
cohort	NN	cohort
was	VBD	be
defined	VBN	define
as	IN	as
those	DT	those
enrolled	VBN	enroll
in	IN	in
the	DT	the
ACO	NP	ACO
in	IN	in
2019-2020	CD	@card@
(	(	(
N	NP	N
=	SYM	=
21,361	CD	@card@
)	)	)
.	SENT	.
The	DT	the
control	NN	control
cohort	NN	cohort
was	VBD	be
defined	VBN	define
as	IN	as
those	DT	those
enrolled	VBN	enroll
in	IN	in
the	DT	the
ACO	NP	ACO
in	IN	in
2018-2019	CD	@card@
(	(	(
N	NP	N
=	SYM	=
20,028	CD	@card@
)	)	)
.	SENT	.
The	DT	the
study	NN	study
period	NN	period
was	VBD	be
defined	VBN	define
as	IN	as
April-September	NP	April-September
2020	CD	@card@
for	IN	for
the	DT	the
pandemic	JJ	pandemic
cohort	NN	cohort
and	CC	and
the	DT	the
same	JJ	same
months	NNS	month
in	IN	in
2019	CD	@card@
for	IN	for
the	DT	the
control	NN	control
cohort	NN	cohort
,	,	,
with	IN	with
the	DT	the
preceding	JJ	preceding
12	CD	@card@
months	NNS	month
used	VBN	use
as	IN	as
the	DT	the
baseline	JJ	baseline
periods	NNS	period
,	,	,
respectively	RB	respectively
.	SENT	.
Over	IN	over
740,000	CD	@card@
patient-month	NN	patient-month
records	NNS	record
were	VBD	be
analyzed	VBN	analyze
using	VBG	use
logistic	JJ	logistic
and	CC	and
negative	JJ	negative
binomial	JJ	binomial
regressions	NNS	regression
.	SENT	.
The	DT	the
models	NNS	model
were	VBD	be
adjusted	VBN	adjust
for	IN	for
patient-level	JJ	patient-level
characteristics	NNS	characteristic
,	,	,
including	VBG	include
HCC	NP	HCC
scores	NNS	score
,	,	,
which	WDT	which
reflect	VBP	reflect
the	DT	the
complexity	NN	complexity
of	IN	of
patient	JJ	patient
health	NN	health
conditions	NNS	condition
and	CC	and
risk	NN	risk
for	IN	for
future	JJ	future
healthcare	NN	<unknown>
costs	NNS	cost
.	SENT	.
The	DT	the
total	JJ	total
number	NN	number
of	IN	of
outpatient	NN	outpatient
encounters	NNS	encounter
(	(	(
in-person	NN	in-person
and	CC	and
telehealth	NN	telehealth
)	)	)
in	IN	in
both	DT	both
primary	JJ	primary
and	CC	and
specialty	JJ	specialty
care	NN	care
decreased	VBN	decrease
by	IN	by
41.5	CD	@card@
%	NN	%
in	IN	in
April	NP	April
2020	CD	@card@
compared	VBN	compare
to	TO	to
the	DT	the
pre-pandemic	JJ	pre-pandemic
period	NN	period
.	SENT	.
Telehealth	NP	Telehealth
comprised	VBD	comprise
78	CD	@card@
%	NN	%
of	IN	of
all	DT	all
outpatient	NN	outpatient
encounters	VBZ	encounter
in	IN	in
April	NP	April
2020	CD	@card@
but	CC	but
declined	VBD	decline
to	TO	to
22	CD	@card@
%	NN	%
by	IN	by
the	DT	the
end	NN	end
of	IN	of
September	NP	September
2020	CD	@card@
.	SENT	.
Only	RB	only
about	RB	about
40	CD	@card@
%	NN	%
of	IN	of
all	DT	all
patients	NNS	patient
had	VBD	have
at	IN	at
least	JJS	least
one	CD	one
telehealth	NN	telehealth
encounter	NN	encounter
between	IN	between
April-September	NP	April-September
2020	CD	@card@
.	SENT	.
Compared	VBN	compare
to	TO	to
the	DT	the
control	NN	control
cohort	NN	cohort
,	,	,
the	DT	the
pandemic	JJ	pandemic
cohort	NN	cohort
experienced	VBD	experience
a	DT	a
monthly	JJ	monthly
average	NN	average
of	IN	of
113	CD	@card@
fewer	JJR	few
primary	JJ	primary
care	NN	care
encounters	NNS	encounter
per	IN	per
1000	CD	@card@
patients	NNS	patient
(	(	(
OR	CC	or
:	:	:
0.75	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NN	<unknown>
:	:	:
[	SYM	[
0.73	CD	@card@
,	,	,
0.77	CD	@card@
]	SYM	]
)	)	)
and	CC	and
49	CD	@card@
fewer	JJR	few
specialty	NN	specialty
care	NN	care
encounters	VBZ	encounter
(	(	(
OR	CC	or
:	:	:
0.82	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NN	<unknown>
:	:	:
[	SYM	[
0.80	CD	@card@
,	,	,
0.85	CD	@card@
]	SYM	]
)	)	)
over	IN	over
the	DT	the
six-month	JJ	six-month
study	NN	study
period	NN	period
.	SENT	.
This	DT	this
represented	VBD	represent
a	DT	a
decline	NN	decline
of	IN	of
25.6	CD	@card@
%	NN	%
and	CC	and
17.3	CD	@card@
%	NN	%
in	IN	in
primary	JJ	primary
care	NN	care
and	CC	and
specialty	NN	specialty
encounters	NNS	encounter
,	,	,
respectively	RB	respectively
,	,	,
among	IN	among
high-cost	JJ	high-cost
high-need	JJ	<unknown>
patients	NNS	patient
.	SENT	.
High-cost	JJ	high-cost
high-need	JJ	<unknown>
patients	NNS	patient
or	CC	or
those	DT	those
with	IN	with
disabilities	NNS	disability
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
use	VB	use
telehealth	NN	telehealth
and	CC	and
experienced	VBD	experience
a	DT	a
lesser	JJR	lesser
reduction	NN	reduction
in	IN	in
outpatient	NN	outpatient
care	NN	care
utilization	NN	utilization
than	IN	than
other	JJ	other
Medicare	NP	Medicare
beneficiaries	NNS	beneficiary
(	(	(
OR	CC	or
:	:	:
1.20	CD	@card@
and	CC	and
1.06	CD	@card@
)	)	)
.	SENT	.
Medicare	NP	Medicare
beneficiaries	NNS	beneficiary
with	IN	with
dual	JJ	dual
Medicaid	NP	Medicaid
coverage	NN	coverage
,	,	,
those	DT	those
of	IN	of
non-white	JJ	non-white
race/ethnic	JJ	race/ethnic
groups	NNS	group
,	,	,
and	CC	and
those	DT	those
living	NN	living
in	IN	in
rural/suburban	JJ	rural/suburban
areas	NNS	area
were	VBD	be
less	RBR	less
likely	JJ	likely
to	TO	to
use	VB	use
telehealth	NN	telehealth
and	CC	and
experienced	VBD	experience
a	DT	a
greater	JJR	great
reduction	NN	reduction
in	IN	in
total	JJ	total
outpatient	NN	outpatient
care	NN	care
(	(	(
OR	CC	or
:	:	:
0.86	CD	@card@
,	,	,
0.96	CD	@card@
and	CC	and
0.90	CD	@card@
)	)	)
.	SENT	.
While	IN	while
there	EX	there
was	VBD	be
a	DT	a
substantial	JJ	substantial
significant	JJ	significant
increase	NN	increase
in	IN	in
telehealth	NN	telehealth
use	NN	use
in	IN	in
April	NP	April
2020	CD	@card@
,	,	,
utilization	NN	utilization
declined	VBD	decline
significantly	RB	significantly
during	IN	during
the	DT	the
six-month	JJ	six-month
study	NN	study
period	NN	period
,	,	,
and	CC	and
did	VBD	do
not	RB	not
fully	RB	fully
mitigate	VB	mitigate
the	DT	the
decline	NN	decline
in	IN	in
in-person	NN	in-person
outpatient	NN	outpatient
visits	NNS	visit
resulting	VBG	result
from	IN	from
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
While	IN	while
high-cost	JJ	high-cost
high-need	JJ	<unknown>
Medicare	NP	Medicare
patients	NNS	patient
and	CC	and
those	DT	those
with	IN	with
disabilities	NNS	disability
were	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
use	VB	use
telehealth	NN	telehealth
,	,	,
disparities	NNS	disparity
in	IN	in
telehealth	NN	telehealth
usage	NN	usage
and	CC	and
reductions	NNS	reduction
in	IN	in
outpatient	NN	outpatient
care	NN	care
remain	VBP	remain
among	IN	among
low-income	JJ	low-income
,	,	,
non-white	JJ	non-white
,	,	,
and	CC	and
rural	JJ	rural
Medicare	NP	Medicare
beneficiaries	NNS	beneficiary
.	SENT	.
Older	JJR	old
patients	NNS	patient
insured	VBN	insure
by	IN	by
Medicare	NP	Medicare
,	,	,
including	VBG	include
those	DT	those
with	IN	with
high-cost	JJ	high-cost
high-need	NN	<unknown>
or	CC	or
disabilities	NNS	disability
were	VBD	be
able	JJ	able
to	TO	to
make	VB	make
use	NN	use
of	IN	of
telehealth	NN	telehealth
services	NNS	service
for	IN	for
outpatient	NN	outpatient
visits	NNS	visit
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Health	NN	health
policies	NNS	policy
and	CC	and
interventions	NNS	intervention
should	MD	should
target	VB	target
improving	VBG	improve
telehealth	JJ	<unknown>
access	NN	access
and	CC	and
delivery	NN	delivery
for	IN	for
advancing	VBG	advance
sustainability	NN	sustainability
and	CC	and
equity	NN	equity
among	IN	among
Medicare	NP	Medicare
beneficiaries	NNS	beneficiary
.	SENT	.
Patient-Centered	JJ	patient-centered
Outcomes	NNS	outcome
Research	NP	Research
Institute	NP	Institute
.	SENT	.
35246082/	CD	@card@
Location	NP	Location
,	,	,
location	NN	location
,	,	,
location	NN	location
:	:	:
a	DT	a
discrete	JJ	discrete
choice	NN	choice
experiment	NN	experiment
to	TO	to
inform	VB	inform
COVID-19	NP	<unknown>
vaccination	NN	vaccination
programme	NN	programme
delivery	NN	delivery
in	IN	in
the	DT	the
UK	NP	UK
Large-scale	JJ	large-scale
vaccination	NN	vaccination
is	VBZ	be
fundamental	JJ	fundamental
to	TO	to
combatting	VBG	combat
COVID-19	NP	<unknown>
.	SENT	.
In	IN	in
March	NP	March
2021	CD	@card@
,	,	,
the	DT	the
UK	NP	UK
's	POS	's
vaccination	NN	vaccination
programme	NN	programme
had	VBD	have
delivered	VBN	deliver
vaccines	NNS	vaccine
to	TO	to
large	JJ	large
proportions	NNS	proportion
of	IN	of
older	JJR	old
and	CC	and
more	JJR	more
vulnerable	JJ	vulnerable
population	NN	population
groups	NNS	group
;	:	;
however	RB	however
,	,	,
there	EX	there
was	VBD	be
concern	NN	concern
that	IN	that
uptake	NN	uptake
would	MD	would
be	VB	be
lower	JJR	low
among	IN	among
young	JJ	young
people	NNS	people
.	SENT	.
This	DT	this
research	NN	research
was	VBD	be
designed	VBN	design
to	TO	to
elicit	VB	elicit
the	DT	the
preferences	NNS	preference
of	IN	of
18-29-year-olds	NNS	<unknown>
regarding	VBG	regard
key	JJ	key
delivery	NN	delivery
characteristics	NNS	characteristic
and	CC	and
assess	VB	assess
the	DT	the
influence	NN	influence
of	IN	of
these	DT	these
on	IN	on
intentions	NNS	intention
to	TO	to
get	VB	get
vaccinated	VBN	vaccinate
,	,	,
to	TO	to
inform	VB	inform
planning	NN	planning
for	IN	for
this	DT	this
cohort	NN	cohort
.	SENT	.
From	IN	from
25	CD	@card@
March	NP	March
to	TO	to
2	CD	@card@
April	NP	April
2021	CD	@card@
,	,	,
an	DT	an
online	JJ	online
sample	NN	sample
of	IN	of
2012	CD	@card@
UK	NP	UK
adults	NNS	adult
aged	VBN	age
18-29	CD	@card@
years	NNS	year
participated	VBN	participate
in	IN	in
a	DT	a
Discrete	JJ	discrete
Choice	NN	choice
Experiment	NN	experiment
.	SENT	.
Participants	NNS	participant
made	VBD	make
six	CD	six
choices	NNS	choice
,	,	,
each	DT	each
involving	VBG	involve
two	CD	two
SMS	NNS	<unknown>
invitations	NNS	invitation
to	TO	to
book	VB	book
a	DT	a
vaccination	NN	vaccination
appointment	NN	appointment
and	CC	and
an	DT	an
opt-out	JJ	opt-out
.	SENT	.
Invitations	NNS	invitation
had	VBD	have
four	CD	four
attributes	NNS	attribute
(	(	(
1	CD	@card@
x	SYM	x
5	CD	@card@
levels	NNS	level
,	,	,
3	CD	@card@
x	SYM	x
3	CD	@card@
levels	NNS	level
)	)	)
:	:	:
delivery	NN	delivery
mode	NN	mode
,	,	,
appointment	NN	appointment
timing	NN	timing
,	,	,
proximity	NN	proximity
,	,	,
and	CC	and
sender	NN	sender
.	SENT	.
These	DT	these
were	VBD	be
systematically	RB	systematically
varied	VBN	vary
according	VBG	accord
to	TO	to
a	DT	a
d-optimal	JJ	d-optimal
design	NN	design
.	SENT	.
Responses	NNS	response
were	VBD	be
analysed	VBN	analyse
using	VBG	use
a	DT	a
mixed	JJ	mixed
logit	NN	<unknown>
model	NN	model
.	SENT	.
The	DT	the
main	JJ	main
effects	NNS	effect
logit	NN	<unknown>
model	NN	model
revealed	VBD	reveal
a	DT	a
large	JJ	large
alternative-specific	JJ	alternative-specific
constant	JJ	constant
(	(	(
beta	NN	beta
=	SYM	=
1.385	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.067	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
indicating	VBG	indicate
a	DT	a
strong	JJ	strong
preference	NN	preference
for	IN	for
'	''	'
opting	VBG	opt
in	IN	in
'	''	'
to	TO	to
appointment	NN	appointment
invitations	NNS	invitation
.	SENT	.
Pharmacies	NNS	pharmacy
were	VBD	be
dispreferred	VBN	disprefer
to	TO	to
the	DT	the
local	JJ	local
vaccination	NN	vaccination
centre	NN	centre
(	(	(
beta	NN	beta
=	SYM	=
-	NN	<unknown>
0.256	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.072	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
appointments	NNS	appointment
in	IN	in
locations	NNS	location
that	WDT	that
were	VBD	be
30-45	CD	@card@
min	NN	min
travel	NN	travel
time	NN	time
from	IN	from
one	CD	one
's	POS	's
premises	NNS	premise
were	VBD	be
dispreferred	VBN	disprefer
to	TO	to
locations	NNS	location
that	WDT	that
were	VBD	be
less	JJR	less
than	IN	than
15	CD	@card@
min	NN	min
away	RB	away
(	(	(
beta	NN	beta
=	SYM	=
-	NN	<unknown>
0.408	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.054	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
and	CC	and
,	,	,
compared	VBN	compare
to	TO	to
invitations	NNS	invitation
from	IN	from
the	DT	the
NHS	NN	NHS
,	,	,
SMSs	NP	<unknown>
forwarded	VBN	forward
by	IN	by
'	''	'
a	DT	a
friend	NN	friend
'	''	'
were	VBD	be
dispreferred	VBN	disprefer
(	(	(
beta	NN	beta
=	SYM	=
-	NN	<unknown>
0.615	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.056	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
but	CC	but
invitations	NNS	invitation
from	IN	from
the	DT	the
General	NP	General
Practitioner	NN	practitioner
were	VBD	be
preferred	JJ	preferred
(	(	(
beta	NN	beta
=	SYM	=
0.105	CD	@card@
,	,	,
SE	FW	se
=	SYM	=
0.048	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.028	CD	@card@
)	)	)
.	SENT	.
The	DT	the
results	NNS	result
indicated	VBD	indicate
that	IN	that
the	DT	the
existing	JJ	existing
configuration	NN	configuration
of	IN	of
the	DT	the
UK	NP	UK
's	POS	's
vaccination	NN	vaccination
programme	NN	programme
was	VBD	be
well-placed	VBN	well-place
to	TO	to
deliver	VB	deliver
vaccines	NNS	vaccine
to	TO	to
18-29-year-olds	NNS	<unknown>
;	:	;
however	RB	however
,	,	,
some	DT	some
adjustments	NNS	adjustment
might	MD	might
enhance	VB	enhance
acceptance	NN	acceptance
.	SENT	.
Local	JJ	local
pharmacies	NNS	pharmacy
were	VBD	be
not	RB	not
preferred	JJ	preferred
;	:	;
long	JJ	long
travel	NN	travel
times	NNS	time
were	VBD	be
a	DT	a
disincentive	JJ	disincentive
but	CC	but
close	JJ	close
proximity	NN	proximity
(	(	(
0-15	CD	@card@
min	NN	min
from	IN	from
one	CD	one
's	POS	's
premises	NN	premises
)	)	)
was	VBD	be
not	RB	not
necessary	JJ	necessary
;	:	;
and	CC	and
either	RB	either
the	DT	the
'	''	'
NHS	NN	NHS
'	''	'
or	CC	or
'	''	'
Your	PP$	your
GP	NN	GP
'	''	'
would	MD	would
serve	VB	serve
as	IN	as
adequate	JJ	adequate
invitation	NN	invitation
sources	NNS	source
.	SENT	.
This	DT	this
research	NN	research
informed	VBN	inform
COVID-19	NP	<unknown>
policy	NN	policy
in	IN	in
the	DT	the
UK	NP	UK
,	,	,
and	CC	and
contributes	VBZ	contribute
to	TO	to
a	DT	a
wider	JJR	wide
body	NN	body
of	IN	of
Discrete	JJ	discrete
Choice	NN	choice
Experiment	NN	experiment
evidence	NN	evidence
on	IN	on
citizens	NNS	citizen
'	POS	'
preferences	NNS	preference
,	,	,
requirements	NNS	requirement
and	CC	and
predicted	VBD	predict
behaviours	NNS	behaviour
regarding	VBG	regard
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12889-022-12823-8	JJ	10.1186/s@card@
.	SENT	.
33257418/	CD	@card@
Incentivising	VBG	Incentivise
wealthy	JJ	wealthy
nations	NNS	nation
to	TO	to
participate	VB	participate
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
Vaccine	NN	vaccine
Global	NP	Global
Access	NP	Access
Facility	NP	Facility
(	(	(
COVAX	NP	<unknown>
)	)	)
:	:	:
a	DT	a
game	NN	game
theory	NN	theory
perspective	NN	perspective
32631682/	CD	@card@
Concerns	NNS	concern
for	IN	for
low-resource	NN	low-resource
countries	NNS	country
,	,	,
with	IN	with
under-prepared	JJ	under-prepared
intensive	JJ	intensive
care	NN	care
units	NNS	unit
,	,	,
facing	VBG	face
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
Low-resource	NP	Low-resource
countries	NNS	country
with	IN	with
fragile	JJ	fragile
healthcare	NN	<unknown>
systems	NNS	system
lack	VBP	lack
trained	JJ	trained
healthcare	NN	<unknown>
professionals	NNS	professional
and	CC	and
specialized	JJ	specialized
resources	NNS	resource
for	IN	for
COVID-19	NP	<unknown>
patient	JJ	patient
hospitalization	NN	hospitalization
,	,	,
including	VBG	include
mechanical	JJ	mechanical
ventilators	NNS	ventilator
.	SENT	.
Additional	JJ	additional
socio-economic	JJ	socio-economic
complications	NNS	complication
such	JJ	such
as	IN	as
civil	JJ	civil
war	NN	war
and	CC	and
financial	JJ	financial
crisis	NN	crisis
in	IN	in
Libya	NP	Libya
and	CC	and
other	JJ	other
low-resource	NN	low-resource
countries	NNS	country
further	RBR	further
complicate	JJ	complicate
healthcare	NN	<unknown>
delivery	NN	delivery
.	SENT	.
A	DT	a
cross-sectional	JJ	cross-sectional
survey	NN	survey
evaluating	VBG	evaluate
hospital	NN	hospital
and	CC	and
intensive	JJ	intensive
care	NN	care
unit	NN	unit
's	POS	's
capacity	NN	capacity
and	CC	and
readiness	NN	readiness
was	VBD	be
performed	VBN	perform
from	IN	from
16	CD	@card@
leading	VBG	lead
Libyan	JJ	Libyan
hospitals	NNS	hospital
in	IN	in
March	NP	March
2020	CD	@card@
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
a	DT	a
survey	NN	survey
was	VBD	be
conducted	VBN	conduct
among	IN	among
400	CD	@card@
doctors	NNS	doctor
who	WP	who
worked	VBD	work
in	IN	in
these	DT	these
hospitals	NNS	hospital
to	TO	to
evaluate	VB	evaluate
the	DT	the
status	NN	status
of	IN	of
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
.	SENT	.
Out	RB	out
of	IN	of
16	CD	@card@
hospitals	NNS	hospital
,	,	,
the	DT	the
highest	JJS	high
hospital	NN	hospital
capacity	NN	capacity
was	VBD	be
1000	CD	@card@
in-patient	NN	in-patient
beds	NNS	bed
,	,	,
while	IN	while
the	DT	the
lowest	JJS	low
was	VBD	be
25	CD	@card@
beds	NNS	bed
with	IN	with
a	DT	a
median	NN	median
of	IN	of
200	CD	@card@
(	(	(
IQR	NP	IQR
52-417	CD	@card@
,	,	,
range	NN	range
25-1000	CD	@card@
)	)	)
hospital	NN	hospital
beds	NNS	bed
.	SENT	.
However	RB	however
,	,	,
a	DT	a
median	NN	median
of	IN	of
only	RB	only
eight	CD	eight
(	(	(
IQR	NP	IQR
6-14	CD	@card@
,	,	,
range	NN	range
3-37	CD	@card@
)	)	)
available	JJ	available
functioning	VBG	function
ICU	NP	ICU
beds	NNS	bed
were	VBD	be
reported	VBN	report
in	IN	in
these	DT	these
hospitals	NNS	hospital
.	SENT	.
Only	RB	only
9	CD	@card@
(	(	(
IQR	NP	IQR
4.5-14	CD	@card@
,	,	,
range	NN	range
2-20	CD	@card@
)	)	)
mechanical	JJ	mechanical
ventilators	NNS	ventilator
were	VBD	be
reported	VBN	report
and	CC	and
none	NN	none
of	IN	of
the	DT	the
hospitals	NNS	hospital
had	VBD	have
a	DT	a
reverse	JJ	reverse
transcription-polymerase	NN	transcription-polymerase
chain	NN	chain
reaction	NN	reaction
machine	NN	machine
for	IN	for
COVID-19	NP	<unknown>
testing	NN	testing
.	SENT	.
Moreover	RB	moreover
,	,	,
they	PP	they
relied	VBD	rely
on	IN	on
one	CD	one
of	IN	of
two	CD	two
central	JJ	central
laboratories	NNS	laboratory
located	VBN	locate
in	IN	in
major	JJ	major
cities	NNS	city
.	SENT	.
Our	PP$	our
PPE	NP	PPE
survey	NN	survey
revealed	VBD	reveal
that	IN	that
56.7	CD	@card@
%	NN	%
hospitals	NNS	hospital
lacked	VBD	lack
PPE	NP	PPE
and	CC	and
53	CD	@card@
%	NN	%
of	IN	of
healthcare	NN	<unknown>
workers	NNS	worker
reported	VBD	report
that	IN	that
they	PP	they
did	VBD	do
not	RB	not
receive	VB	receive
proper	JJ	proper
PPE	NN	PPE
training	NN	training
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
70	CD	@card@
%	NN	%
reported	VBD	report
that	IN	that
they	PP	they
were	VBD	be
buying	VBG	buy
the	DT	the
PPE	NN	PPE
themselves	PP	themselves
as	IN	as
hospitals	NNS	hospital
did	VBD	do
not	RB	not
provide	VB	provide
them	PP	them
.	SENT	.
This	DT	this
study	NN	study
provides	VBZ	provide
an	DT	an
alarming	JJ	alarming
overview	NN	overview
of	IN	of
the	DT	the
unpreparedness	NN	unpreparedness
of	IN	of
Libyan	JJ	Libyan
hospitals	NNS	hospital
for	IN	for
detecting	VBG	detect
and	CC	and
treating	VBG	treat
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
limiting	VBG	limit
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
pandemic	NN	pandemic
.	SENT	.
We	PP	we
report	VBP	report
the	DT	the
healthcare	NN	<unknown>
system	NN	system
preparedness	NN	preparedness
for	IN	for
COVID19	NP	<unknown>
in	IN	in
low	JJ	low
resource	NN	resource
settings	NNS	setting
.	SENT	.
We	PP	we
provide	VBP	provide
insight	NN	insight
into	IN	into
the	DT	the
health	NN	health
care	NN	care
situation	NN	situation
in	IN	in
Libya	NP	Libya
during	IN	during
the	DT	the
civil	JJ	civil
war	NN	war
and	CC	and
COVID19	JJ	<unknown>
outbreak	NN	outbreak
.	SENT	.
Our	PP$	our
study	NN	study
provides	VBZ	provide
the	DT	the
infrastructure	NN	infrastructure
status	NN	status
of	IN	of
intensive	JJ	intensive
care	NN	care
units	NNS	unit
in	IN	in
Libya	NP	Libya
.	SENT	.
The	DT	the
low	JJ	low
number	NN	number
of	IN	of
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
plays	VBZ	play
a	DT	a
significant	JJ	significant
role	NN	role
in	IN	in
spreading	VBG	spread
the	DT	the
infection	NN	infection
among	IN	among
healthcare	NN	<unknown>
workers	NNS	worker
.	SENT	.
Civil	JJ	civil
war	NN	war
along	IN	along
with	IN	with
COVID19	NP	<unknown>
pandemic	NN	pandemic
can	MD	can
have	VB	have
catastrophic	JJ	catastrophic
consequences	NNS	consequence
for	IN	for
the	DT	the
healthcare	NN	<unknown>
system	NN	system
in	IN	in
African	JJ	African
countries	NNS	country
.	SENT	.
33844359/	CD	@card@
Health	NP	Health
care	NN	care
workers	NNS	worker
'	POS	'
protection	NN	protection
and	CC	and
psychological	JJ	psychological
safety	NN	safety
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Spain	NP	Spain
To	TO	to
analyse	VB	analyse
the	DT	the
relationship	NN	relationship
between	IN	between
work	NN	work
engagement	NN	engagement
,	,	,
sense	NN	sense
of	IN	of
coherence	NN	coherence
and	CC	and
psychological	JJ	psychological
distress	NN	distress
levels	NNS	level
in	IN	in
Spanish	JJ	Spanish
health	NN	health
professionals	NNS	professional
who	WP	who
were	VBD	be
active	JJ	active
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
lockdown	NN	<unknown>
.	SENT	.
Work	NN	work
engagement	NN	engagement
and	CC	and
sense	NN	sense
of	IN	of
coherence	NN	coherence
can	MD	can
help	VB	help
professionals	NNS	professional
to	TO	to
cope	VB	cope
with	IN	with
work-related	JJ	work-related
psychological	JJ	psychological
distress	NN	distress
due	JJ	due
to	TO	to
the	DT	the
harsh	JJ	harsh
conditions	NNS	condition
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
working	NN	working
environment	NN	environment
.	SENT	.
Cross-sectional	JJ	cross-sectional
observational	JJ	observational
study	NN	study
of	IN	of
1,459	CD	@card@
health	NN	health
care	NN	care
professionals	NNS	professional
.	SENT	.
The	DT	the
Utrecht	NP	Utrecht
Work	NP	Work
Engagement	NN	engagement
Scale	NP	Scale
,	,	,
the	DT	the
Sense	NN	sense
of	IN	of
Coherence	NN	coherence
Scale	NP	Scale
and	CC	and
Goldberg	NP	Goldberg
's	POS	's
General	NP	General
Health	NP	Health
Questionnaire	NN	questionnaire
were	VBD	be
distributed	VBN	distribute
and	CC	and
analysed	VBN	analyse
with	IN	with
descriptive	JJ	descriptive
and	CC	and
multiple	JJ	multiple
linear	JJ	linear
regression	NN	regression
methods	NNS	method
.	SENT	.
High	JJ	high
levels	NNS	level
of	IN	of
work	NN	work
engagement	NN	engagement
,	,	,
especially	RB	especially
in	IN	in
the	DT	the
dedication	NN	dedication
dimension	NN	dimension
,	,	,
of	IN	of
sense	NN	sense
of	IN	of
coherence	NN	coherence
,	,	,
in	IN	in
particular	JJ	particular
in	IN	in
the	DT	the
meaningfulness	NN	meaningfulness
dimension	NN	dimension
,	,	,
and	CC	and
psychological	JJ	psychological
distress	NN	distress
were	VBD	be
obtained	VBN	obtain
.	SENT	.
Significant	JJ	significant
correlations	NNS	correlation
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
.001	LS	@card@
)	)	)
were	VBD	be
identified	VBN	identify
between	IN	between
all	PDT	all
the	DT	the
variables	NNS	variable
.	SENT	.
Work	NN	work
engagement	NN	engagement
and	CC	and
sense	NN	sense
of	IN	of
coherence	NN	coherence
correlated	VBN	correlate
positively	RB	positively
with	IN	with
each	DT	each
other	JJ	other
and	CC	and
both	DT	both
negatively	RB	negatively
with	IN	with
psychological	JJ	psychological
distress	NN	distress
.	SENT	.
So	RB	so
,	,	,
health	NN	health
care	NN	care
professionals	NNS	professional
,	,	,
despite	IN	despite
presenting	VBG	present
psychological	JJ	psychological
distress	NN	distress
,	,	,
perceive	VBP	perceive
their	PP$	their
work	NN	work
satisfactorily	RB	satisfactorily
and	CC	and
positively	RB	positively
despite	IN	despite
the	DT	the
severity	NN	severity
of	IN	of
the	DT	the
situation	NN	situation
and	CC	and
the	DT	the
harsh	JJ	harsh
conditions	NNS	condition
.	SENT	.
Sense	NN	sense
of	IN	of
coherence	NN	coherence
and	CC	and
work	NN	work
engagement	NN	engagement
are	VBP	be
protective	JJ	protective
factors	NNS	factor
against	IN	against
psychological	JJ	psychological
distress	NN	distress
.	SENT	.
Preventive	JJ	preventive
measures	NNS	measure
for	IN	for
professionals	NNS	professional
should	MD	should
go	VB	go
through	IN	through
the	DT	the
dimensionalization	NN	<unknown>
of	IN	of
the	DT	the
problem	NN	problem
and	CC	and
the	DT	the
adaptation	NN	adaptation
of	IN	of
practical	JJ	practical
measures	NNS	measure
for	IN	for
daily	JJ	daily
management	NN	management
.	SENT	.
33824264/	CD	@card@
Beyond	IN	beyond
Sociodemographic	JJ	Sociodemographic
and	CC	and
COVID-19-Related	JJ	COVID-19-related
Factors	NNS	factor
:	:	:
The	DT	the
Association	NP	Association
Between	IN	between
the	DT	the
Need	NN	need
for	IN	for
Psychological	JJ	psychological
and	CC	and
Information	NN	information
Support	NN	support
from	IN	from
School	NP	School
and	CC	and
Anxiety	NN	anxiety
and	CC	and
Depression	NN	depression
In	IN	in
addition	NN	addition
to	TO	to
sociodemographic	JJ	sociodemographic
and	CC	and
COVID-19-	JJ	<unknown>
related	JJ	related
factors	NNS	factor
,	,	,
the	DT	the
needs	NNS	need
of	IN	of
school	NN	school
support	NN	support
,	,	,
including	VBG	include
material	NN	material
,	,	,
psychological	JJ	psychological
and	CC	and
information	NN	information
support	NN	support
,	,	,
have	VBP	have
seldom	RB	seldom
been	VBN	be
discussed	VBN	discuss
as	IN	as
factors	NNS	factor
influencing	VBG	influence
anxiety	NN	anxiety
and	CC	and
depression	NN	depression
among	IN	among
college	NN	college
students	NNS	student
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
In	IN	in
this	DT	this
cross-sectional	JJ	cross-sectional
study	NN	study
,	,	,
3351	CD	@card@
college	NN	college
students	NNS	student
from	IN	from
China	NP	China
were	VBD	be
surveyed	VBN	survey
through	IN	through
questionnaires	NNS	questionnaire
about	IN	about
their	PP$	their
sociodemographic	JJ	sociodemographic
and	CC	and
COVID-19	JJ	<unknown>
characteristics	NNS	characteristic
,	,	,
the	DT	the
needs	NNS	need
of	IN	of
school	NN	school
support	NN	support
,	,	,
and	CC	and
their	PP$	their
experiences	NNS	experience
with	IN	with
anxiety	NN	anxiety
and	CC	and
depression	NN	depression
.	SENT	.
Anxiety	NN	anxiety
and	CC	and
depression	NN	depression
were	VBD	be
reported	VBN	report
by	IN	by
6.88	CD	@card@
%	NN	%
and	CC	and
10.50	CD	@card@
%	NN	%
of	IN	of
students	NNS	student
,	,	,
respectively	RB	respectively
.	SENT	.
Married	JJ	married
,	,	,
higher	JJR	high
education	NN	education
,	,	,
non-medical	JJ	non-medical
,	,	,
and	CC	and
urban	JJ	urban
students	NNS	student
had	VBD	have
significantly	RB	significantly
higher	JJR	high
risks	NNS	risk
of	IN	of
anxiety	NN	anxiety
or	CC	or
depression	NN	depression
.	SENT	.
Additionally	RB	additionally
,	,	,
symptoms	NNS	symptom
such	JJ	such
as	IN	as
cough	NN	cough
and	CC	and
fever	NN	fever
,	,	,
especially	RB	especially
when	WRB	when
following	VBG	follow
a	DT	a
possible	JJ	possible
contact	NN	contact
with	IN	with
suspected	JJ	suspected
individuals	NNS	individual
,	,	,
quarantine	NN	quarantine
history	NN	history
of	IN	of
a	DT	a
personal	JJ	personal
contact	NN	contact
,	,	,
going	VBG	go
out	IN	out
1-3	CD	@card@
times	NNS	time
a	DT	a
week	NN	week
,	,	,
not	RB	not
wearing	VBG	wear
a	DT	a
mask	NN	mask
,	,	,
and	CC	and
spending	VBG	spend
2-3	CD	@card@
hours	NNS	hour
browsing	VBG	browse
COVID-19-related	JJ	COVID-19-related
information	NN	information
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
the	DT	the
occurrence	NN	occurrence
of	IN	of
anxiety	NN	anxiety
or	CC	or
depression	NN	depression
.	SENT	.
Those	DT	those
who	WP	who
used	VBD	use
methods	NNS	method
to	TO	to
regulate	VB	regulate
their	PP$	their
emotional	JJ	emotional
state	NN	state
,	,	,
used	VBD	use
a	DT	a
psychological	JJ	psychological
hotline	NN	<unknown>
,	,	,
and	CC	and
who	WP	who
had	VBD	have
visited	VBN	visit
a	DT	a
psychiatrist	NN	psychiatrist
showed	VBD	show
higher	JJR	high
anxiety	NN	anxiety
or	CC	or
depression	NN	depression
.	SENT	.
Those	DT	those
who	WP	who
used	VBD	use
online	JJ	online
curricula	NNS	curriculum
and	CC	and
books	NNS	book
,	,	,
used	VBN	use
preventive	JJ	preventive
methods	NNS	method
for	IN	for
COVID-19	NP	<unknown>
,	,	,
and	CC	and
who	WP	who
had	VBD	have
real-time	JJ	real-time
information	NN	information
about	IN	about
the	DT	the
epidemic	JJ	epidemic
situation	NN	situation
of	IN	of
the	DT	the
school	NN	school
showed	VBD	show
lower	JJR	low
anxiety	NN	anxiety
and	CC	and
depression	NN	depression
.	SENT	.
In	IN	in
addition	NN	addition
to	TO	to
sociodemographic	JJ	sociodemographic
and	CC	and
COVID-19-related	JJ	COVID-19-related
aspects	NNS	aspect
,	,	,
students	NNS	student
'	POS	'
needs	NNS	need
for	IN	for
psychological	JJ	psychological
assistance	NN	assistance
and	CC	and
information	NN	information
from	IN	from
schools	NNS	school
were	VBD	be
also	RB	also
associated	VBN	associate
with	IN	with
anxiety	NN	anxiety
and	CC	and
depression	NN	depression
among	IN	among
college	NN	college
students	NNS	student
.	SENT	.
34597334/	CD	@card@
The	DT	the
effect	NN	effect
of	IN	of
risk	NN	risk
framing	NN	framing
on	IN	on
support	NN	support
for	IN	for
restrictive	JJ	restrictive
government	NN	government
policy	NN	policy
regarding	VBG	regard
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
This	DT	this
confirmatory	JJ	confirmatory
research	NN	research
investigates	VBZ	investigate
the	DT	the
influence	NN	influence
of	IN	of
risk	NN	risk
framing	NN	framing
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
support	NN	support
for	IN	for
restrictive	JJ	restrictive
government	NN	government
policy	NN	policy
based	VBN	base
on	IN	on
two	CD	two
web	NN	web
survey	NN	survey
experiments	NNS	experiment
in	IN	in
Russia	NP	Russia
.	SENT	.
Using	VBG	use
2x2	JJ	<unknown>
factorial	JJ	factorial
design	NN	design
,	,	,
we	PP	we
estimated	VBD	estimate
two	CD	two
main	JJ	main
effects-factors	NNS	effects-factor
of	IN	of
risk	NN	risk
severity	NN	severity
(	(	(
low	JJ	low
vs.	CC	vs.
high	JJ	high
)	)	)
and	CC	and
object	VBP	object
at	IN	at
risk	NN	risk
(	(	(
individual	JJ	individual
losses	NNS	loss
vs.	IN	vs.
losses	NNS	loss
to	TO	to
others	NNS	other
)	)	)
.	SENT	.
First	RB	first
,	,	,
focusing	VBG	focus
on	IN	on
higher	JJR	high
risks	NNS	risk
had	VBD	have
a	DT	a
positive	JJ	positive
effect	NN	effect
on	IN	on
support	NN	support
for	IN	for
the	DT	the
government	NN	government
's	POS	's
restrictive	JJ	restrictive
policy	NN	policy
.	SENT	.
Second	RB	second
,	,	,
focusing	VBG	focus
on	IN	on
the	DT	the
losses	NNS	loss
for	IN	for
others	NNS	other
did	VBD	do
not	RB	not
produce	VB	produce
stronger	JJR	strong
support	NN	support
for	IN	for
the	DT	the
restrictive	JJ	restrictive
policy	NN	policy
compared	VBN	compare
to	TO	to
focusing	VBG	focus
on	IN	on
personal	JJ	personal
losses	NNS	loss
.	SENT	.
However	RB	however
,	,	,
we	PP	we
found	VBD	find
a	DT	a
positive	JJ	positive
moderation	NN	moderation
effect	NN	effect
of	IN	of
such	JJ	such
prosocial	JJ	prosocial
values	NNS	value
as	IN	as
universalism	NN	universalism
and	CC	and
benevolence	NN	benevolence
.	SENT	.
We	PP	we
found	VBD	find
that	IN	that
those	DT	those
with	IN	with
prosocial	JJ	prosocial
values	NNS	value
had	VBD	have
a	DT	a
stronger	JJR	strong
positive	JJ	positive
effect	NN	effect
in	IN	in
the	DT	the
"	``	"
losses	NNS	loss
for	IN	for
others	NNS	other
"	''	"
condition	NN	condition
and	CC	and
were	VBD	be
more	RBR	more
willing	JJ	willing
to	TO	to
support	VB	support
government	NN	government
restrictive	JJ	restrictive
policy	NN	policy
when	WRB	when
others	NNS	other
were	VBD	be
included	VBN	include
.	SENT	.
The	DT	the
effects	NNS	effect
found	VBN	find
in	IN	in
our	PP$	our
experimental	JJ	experimental
study	NN	study
reveal	NN	reveal
both	CC	both
positive	JJ	positive
and	CC	and
negative	JJ	negative
aspects	NNS	aspect
in	IN	in
risk	NN	risk
communication	NN	communication
during	IN	during
the	DT	the
pandemic	NN	pandemic
,	,	,
which	WDT	which
may	MD	may
have	VB	have
a	DT	a
great	JJ	great
and	CC	and
long-term	JJ	long-term
impact	NN	impact
on	IN	on
trust	NN	trust
,	,	,
attitudes	NNS	attitude
,	,	,
and	CC	and
behavior	NN	behavior
.	SENT	.
34502799/	CD	@card@
Monocular	JJ	monocular
Pedestrian	JJ	pedestrian
3D	JJ	3D
Localization	NN	localization
for	IN	for
Social	NP	Social
Distance	NP	Distance
Monitoring	VBG	monitor
Social	JJ	social
distancing	NN	distancing
protocols	NNS	protocol
have	VBP	have
been	VBN	be
highly	RB	highly
recommended	VBN	recommend
by	IN	by
the	DT	the
World	NP	World
Health	NP	Health
Organization	NP	Organization
(	(	(
WHO	WP	who
)	)	)
to	TO	to
curb	VB	curb
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
one	CD	one
major	JJ	major
challenge	NN	challenge
to	TO	to
enforcing	VBG	enforce
social	JJ	social
distancing	NN	distancing
in	IN	in
public	JJ	public
areas	NNS	area
is	VBZ	be
how	WRB	how
to	TO	to
perceive	VB	perceive
people	NNS	people
in	IN	in
three	CD	three
dimensions	NNS	dimension
.	SENT	.
This	DT	this
paper	NN	paper
proposes	VBZ	propose
an	DT	an
innovative	JJ	innovative
pedestrian	JJ	pedestrian
3D	JJ	3D
localization	NN	localization
method	NN	method
using	VBG	use
monocular	JJ	monocular
images	NNS	image
combined	VBN	combine
with	IN	with
terrestrial	JJ	terrestrial
point	NN	point
clouds	NNS	cloud
.	SENT	.
In	IN	in
the	DT	the
proposed	VBN	propose
approach	NN	approach
,	,	,
camera	NN	camera
calibration	NN	calibration
is	VBZ	be
achieved	VBN	achieve
based	VBN	base
on	IN	on
the	DT	the
correspondences	NNS	correspondence
between	IN	between
2D	JJ	<unknown>
image	NN	image
points	NNS	point
and	CC	and
3D	JJ	3D
world	NN	world
points	NNS	point
.	SENT	.
The	DT	the
vertical	JJ	vertical
coordinates	NNS	coordinate
of	IN	of
the	DT	the
ground	NN	ground
plane	NN	plane
where	WRB	where
pedestrians	NNS	pedestrian
stand	VBP	stand
are	VBP	be
extracted	VBN	extract
from	IN	from
the	DT	the
point	NN	point
clouds	NNS	cloud
.	SENT	.
Then	RB	then
,	,	,
using	VBG	use
the	DT	the
assumption	NN	assumption
that	IN	that
the	DT	the
pedestrian	NN	pedestrian
is	VBZ	be
always	RB	always
perpendicular	JJ	perpendicular
to	TO	to
the	DT	the
ground	NN	ground
,	,	,
the	DT	the
3D	JJ	3D
coordinates	NNS	coordinate
of	IN	of
the	DT	the
pedestrian	NN	pedestrian
's	POS	's
feet	NNS	foot
and	CC	and
head	NN	head
are	VBP	be
calculated	VBN	calculate
iteratively	RB	iteratively
using	VBG	use
collinear	JJ	collinear
equations	NNS	equation
.	SENT	.
This	DT	this
allows	VBZ	allow
the	DT	the
three-dimensional	JJ	three-dimensional
localization	NN	localization
and	CC	and
height	NN	height
determination	NN	determination
of	IN	of
pedestrians	NNS	pedestrian
using	VBG	use
monocular	JJ	monocular
cameras	NNS	camera
,	,	,
which	WDT	which
are	VBP	be
widely	RB	widely
distributed	VBN	distribute
in	IN	in
many	JJ	many
major	JJ	major
cities	NNS	city
.	SENT	.
The	DT	the
performance	NN	performance
of	IN	of
the	DT	the
proposed	VBN	propose
method	NN	method
was	VBD	be
evaluated	VBN	evaluate
using	VBG	use
two	CD	two
different	JJ	different
datasets	NNS	<unknown>
.	SENT	.
Experimental	JJ	experimental
results	NNS	result
show	VBP	show
that	IN	that
the	DT	the
pedestrian	JJ	pedestrian
localization	NN	localization
error	NN	error
of	IN	of
the	DT	the
proposed	VBN	propose
approach	NN	approach
was	VBD	be
less	JJR	less
than	IN	than
one	CD	one
meter	NN	meter
within	IN	within
tens	NNS	ten
of	IN	of
meters	NNS	meter
and	CC	and
performed	VBD	perform
better	JJR	good
than	IN	than
other	JJ	other
localization	NN	localization
techniques	NNS	technique
.	SENT	.
The	DT	the
proposed	VBN	propose
approach	NN	approach
uses	VBZ	use
simple	JJ	simple
and	CC	and
efficient	JJ	efficient
calculations	NNS	calculation
,	,	,
obtains	VBZ	obtain
accurate	JJ	accurate
location	NN	location
,	,	,
and	CC	and
can	MD	can
be	VB	be
used	VBN	use
to	TO	to
implement	VB	implement
social	JJ	social
distancing	NN	distancing
rules	NNS	rule
.	SENT	.
Moreover	RB	moreover
,	,	,
since	IN	since
the	DT	the
proposed	VBN	propose
approach	NN	approach
also	RB	also
generates	VBZ	generate
accurate	JJ	accurate
height	NN	height
values	NNS	value
,	,	,
exclusionary	JJ	exclusionary
schemes	NNS	scheme
to	TO	to
social	JJ	social
distancing	NN	distancing
protocols	NNS	protocol
,	,	,
particularly	RB	particularly
the	DT	the
parent-child	NN	parent-child
exemption	NN	exemption
,	,	,
can	MD	can
be	VB	be
introduced	VBN	introduce
in	IN	in
the	DT	the
framework	NN	framework
.	SENT	.
35046607/	CD	@card@
Global	JJ	global
fine-scale	JJ	fine-scale
changes	NNS	change
in	IN	in
ambient	JJ	ambient
NO2	NP	<unknown>
during	IN	during
COVID-19	NP	<unknown>
lockdowns	NNS	lockdown
Nitrogen	NN	nitrogen
dioxide	NN	dioxide
(	(	(
NO2	NP	<unknown>
)	)	)
is	VBZ	be
an	DT	an
important	JJ	important
contributor	NN	contributor
to	TO	to
air	VB	air
pollution	NN	pollution
and	CC	and
can	MD	can
adversely	RB	adversely
affect	VB	affect
human	JJ	human
health	NN	health
.	SENT	.
A	DT	a
decrease	NN	decrease
in	IN	in
NO2	JJ	<unknown>
concentrations	NNS	concentration
has	VBZ	have
been	VBN	be
reported	VBN	report
as	IN	as
a	DT	a
result	NN	result
of	IN	of
lockdown	JJ	<unknown>
measures	NNS	measure
to	TO	to
reduce	VB	reduce
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
Questions	NNS	question
remain	VBP	remain
,	,	,
however	RB	however
,	,	,
regarding	VBG	regard
the	DT	the
relationship	NN	relationship
of	IN	of
satellite-derived	JJ	<unknown>
atmospheric	JJ	atmospheric
column	NN	column
NO2	JJ	<unknown>
data	NNS	datum
with	IN	with
health-relevant	JJ	health-relevant
ambient	JJ	ambient
ground-level	NN	ground-level
concentrations	NNS	concentration
,	,	,
and	CC	and
the	DT	the
representativeness	NN	representativeness
of	IN	of
limited	JJ	limited
ground-based	JJ	ground-based
monitoring	NN	monitoring
data	NNS	datum
for	IN	for
global	JJ	global
assessment	NN	assessment
.	SENT	.
Here	RB	here
we	PP	we
derive	VBP	derive
spatially	RB	spatially
resolved	VBN	resolve
,	,	,
global	JJ	global
ground-level	NN	ground-level
NO2	JJ	<unknown>
concentrations	NNS	concentration
from	IN	from
NO2	JJ	<unknown>
column	NN	column
densities	NNS	density
observed	VBD	observe
by	IN	by
the	DT	the
TROPOMI	NP	<unknown>
satellite	NN	satellite
instrument	NN	instrument
at	IN	at
sufficiently	RB	sufficiently
fine	JJ	fine
resolution	NN	resolution
(	(	(
approximately	RB	approximately
one	CD	one
kilometre	NN	kilometre
)	)	)
to	TO	to
allow	VB	allow
assessment	NN	assessment
of	IN	of
individual	JJ	individual
cities	NNS	city
during	IN	during
COVID-19	NP	<unknown>
lockdowns	NNS	lockdown
in	IN	in
2020	CD	@card@
compared	VBN	compare
to	TO	to
2019	CD	@card@
.	SENT	.
We	PP	we
apply	VBP	apply
these	DT	these
estimates	NNS	estimate
to	TO	to
quantify	VB	quantify
NO2	JJ	<unknown>
changes	NNS	change
in	IN	in
more	JJR	more
than	IN	than
200	CD	@card@
cities	NNS	city
,	,	,
including	VBG	include
65	CD	@card@
cities	NNS	city
without	IN	without
available	JJ	available
ground	NN	ground
monitoring	NN	monitoring
,	,	,
largely	RB	largely
in	IN	in
lower-income	JJ	lower-income
regions	NNS	region
.	SENT	.
Mean	JJ	mean
country-level	JJ	country-level
population-weighted	JJ	population-weighted
NO2	JJ	<unknown>
concentrations	NNS	concentration
are	VBP	be
29	CD	@card@
%	NN	%
+-	NN	<unknown>
3	CD	@card@
%	NN	%
lower	JJR	low
in	IN	in
countries	NNS	country
with	IN	with
strict	JJ	strict
lockdown	NN	<unknown>
conditions	NNS	condition
than	IN	than
in	IN	in
those	DT	those
without	IN	without
.	SENT	.
Relative	JJ	relative
to	TO	to
long-term	JJ	long-term
trends	NNS	trend
,	,	,
NO2	JJ	<unknown>
decreases	NNS	decrease
during	IN	during
COVID-19	NP	<unknown>
lockdowns	NNS	lockdown
exceed	VBP	exceed
recent	JJ	recent
Ozone	NN	ozone
Monitoring	VBG	monitor
Instrument	NP	Instrument
(OMI)-derived	JJ	<unknown>
year-to-year	JJ	year-to-year
decreases	NNS	decrease
from	IN	from
emission	NN	emission
controls	NNS	control
,	,	,
comparable	JJ	comparable
to	TO	to
15	CD	@card@
+-	NN	<unknown>
4	CD	@card@
years	NNS	year
of	IN	of
reductions	NNS	reduction
globally	RB	globally
.	SENT	.
Our	PP$	our
case	NN	case
studies	NNS	study
indicate	VBP	indicate
that	IN	that
the	DT	the
sensitivity	NN	sensitivity
of	IN	of
NO2	NP	<unknown>
to	TO	to
lockdowns	NNS	lockdown
varies	VBZ	vary
by	IN	by
country	NN	country
and	CC	and
emissions	NNS	emission
sector	NN	sector
,	,	,
demonstrating	VBG	demonstrate
the	DT	the
critical	JJ	critical
need	NN	need
for	IN	for
spatially	RB	spatially
resolved	VBN	resolve
observational	JJ	observational
information	NN	information
provided	VBN	provide
by	IN	by
these	DT	these
satellite-derived	JJ	<unknown>
surface	NN	surface
concentration	NN	concentration
estimates	NNS	estimate
.	SENT	.
The	DT	the
satellite	NN	satellite
instrument	NN	instrument
TROPOMI	NP	<unknown>
is	VBZ	be
used	VBN	use
to	TO	to
assess	VB	assess
ambient	JJ	ambient
NO2	JJ	<unknown>
levels	NNS	level
at	IN	at
approximately	RB	approximately
one-kilometre	JJ	<unknown>
resolution	NN	resolution
across	IN	across
215	CD	@card@
cities	NNS	city
worldwide	JJ	worldwide
during	IN	during
COVID-19	NP	<unknown>
lockdowns	NNS	lockdown
,	,	,
finding	VBG	find
about	RB	about
30	CD	@card@
%	NN	%
lower	JJR	low
NO2	JJ	<unknown>
concentrations	NNS	concentration
in	IN	in
countries	NNS	country
with	IN	with
strict	JJ	strict
lockdowns	NNS	lockdown
.	SENT	.
35128648/	CD	@card@
Prognostic	JJ	prognostic
value	NN	value
of	IN	of
copeptin	NN	<unknown>
and	CC	and
mid-regional	JJ	mid-regional
proadrenomedullin	NN	<unknown>
in	IN	in
COVID-19-hospitalized	JJ	<unknown>
patients	NNS	patient
Biomarkers	NNS	Biomarker
are	VBP	be
used	VBN	use
for	IN	for
diagnosis	NN	diagnosis
,	,	,
risk	NN	risk
stratification	NN	stratification
and	CC	and
medical	JJ	medical
decisions	NNS	decision
.	SENT	.
Copeptin	NP	<unknown>
and	CC	and
mid-regional	NP	mid-regional
proadrenomedullin	NP	<unknown>
(	(	(
MR-proADM	NP	<unknown>
)	)	)
are	VBP	be
markers	NNS	marker
of	IN	of
stress	NN	stress
and	CC	and
endothelial	JJ	endothelial
function	NN	function
,	,	,
respectively	RB	respectively
,	,	,
which	WDT	which
have	VBP	have
been	VBN	be
studied	VBN	study
in	IN	in
pneumonia	NN	pneumonia
,	,	,
sepsis	NN	sepsis
and	CC	and
septic	JJ	septic
shock	NN	shock
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
assess	VB	assess
whether	IN	whether
copeptin	NP	<unknown>
and	CC	and
MR-proADM	NP	<unknown>
could	MD	could
predict	VB	predict
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
in-hospital	JJ	in-hospital
outcomes	NNS	outcome
,	,	,
that	WDT	that
is	VBZ	be
multi-system	NN	multi-system
complications	NNS	complication
,	,	,
length	NN	length
of	IN	of
stay	NN	stay
and	CC	and
mortality	NN	mortality
.	SENT	.
Copeptin	NP	<unknown>
and	CC	and
MR-proADM	NP	<unknown>
were	VBD	be
assessed	VBN	assess
at	IN	at
admission	NN	admission
in	IN	in
116	CD	@card@
patients	NNS	patient
hospitalized	VBN	hospitalize
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Data	NNS	datum
were	VBD	be
retrospectively	RB	retrospectively
extracted	VBN	extract
from	IN	from
an	DT	an
online	JJ	online
database	NN	database
.	SENT	.
The	DT	the
primary	JJ	primary
endpoint	NN	endpoint
was	VBD	be
in-hospital	JJ	in-hospital
mortality	NN	mortality
.	SENT	.
The	DT	the
secondary	JJ	secondary
endpoints	NNS	endpoint
were	VBD	be
in-hospital	JJ	in-hospital
complications	NNS	complication
,	,	,
the	DT	the
composite	JJ	composite
outcome	NN	outcome
'	POS	'
death	NN	death
,	,	,
or	CC	or
admission	NN	admission
to	TO	to
intensive	JJ	intensive
care	NN	care
unit	NN	unit
,	,	,
or	CC	or
in-hospital	JJ	in-hospital
complications	NNS	complication
'	POS	'
,	,	,
and	CC	and
length	NN	length
of	IN	of
stay	NN	stay
.	SENT	.
The	DT	the
predictive	JJ	predictive
power	NN	power
was	VBD	be
expressed	VBN	express
as	IN	as
area	NN	area
under	IN	under
the	DT	the
receiver	NN	receiver
operator	NN	operator
characteristic	JJ	characteristic
curve	NN	curve
(	(	(
AUROC	NP	<unknown>
)	)	)
.	SENT	.
Copeptin	NP	<unknown>
was	VBD	be
increased	VBN	increase
in	IN	in
non-survivors	NNS	non-survivor
(	(	(
median	NN	median
29.7	CD	@card@
[	SYM	[
interquartile	JJ	<unknown>
range	NN	range
13.0-106.2	CD	@card@
]	SYM	]
pmol/L	NN	<unknown>
)	)	)
compared	VBN	compare
to	TO	to
survivors	NNS	survivor
(	(	(
10.9	CD	@card@
[	SYM	[
5.9-25.3	CD	@card@
]	SYM	]
pmol/L	NN	<unknown>
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
The	DT	the
AUROC	NP	<unknown>
for	IN	for
mortality	NN	mortality
was	VBD	be
0.71	CD	@card@
,	,	,
with	IN	with
a	DT	a
hazard	NN	hazard
ratio	NN	ratio
of	IN	of
3.67	CD	@card@
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.01	LS	@card@
)	)	)
for	IN	for
copeptin	NN	<unknown>
values	NNS	value
&gt	NN	&gt
;	:	;
25.3	CD	@card@
pmol/L	NN	<unknown>
.	SENT	.
MR-proADM	NP	<unknown>
differentiated	VBD	differentiate
survivors	NNS	survivor
(	(	(
0.8	CD	@card@
[	SYM	[
0.6-1.1	CD	@card@
]	SYM	]
nmol/L	NN	<unknown>
)	)	)
from	IN	from
non-survivors	NNS	non-survivor
(	(	(
1.5	CD	@card@
[	SYM	[
1.1-2.8	CD	@card@
]	SYM	]
nmol/L	NN	<unknown>
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
yielded	VBD	yield
a	DT	a
AUROC	NP	<unknown>
of	IN	of
0.79	CD	@card@
and	CC	and
a	DT	a
hazard	NN	hazard
ratio	NN	ratio
of	IN	of
7.02	CD	@card@
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
for	IN	for
MR-proADM	NP	<unknown>
values	NNS	value
&gt	NN	&gt
;	:	;
1.0	CD	@card@
nmol/L	NN	<unknown>
.	SENT	.
Copeptin	NP	<unknown>
and	CC	and
MR-proADM	NP	<unknown>
predicted	VBD	predict
sepsis	NN	sepsis
(	(	(
AUROC	NP	<unknown>
0.95	CD	@card@
and	CC	and
0.96	CD	@card@
respectively	RB	respectively
)	)	)
,	,	,
acute	JJ	acute
kidney	NN	kidney
injury	NN	injury
(	(	(
0.87	CD	@card@
and	CC	and
0.90	CD	@card@
)	)	)
,	,	,
the	DT	the
composite	JJ	composite
outcome	NN	outcome
(	(	(
0.69	CD	@card@
and	CC	and
0.75	CD	@card@
)	)	)
and	CC	and
length	NN	length
of	IN	of
stay	VB	stay
(	(	(
r	LS	r
=	SYM	=
0.42	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	CD	@card@
,	,	,
and	CC	and
r	LS	r
=	SYM	=
0.46	CD	@card@
,	,	,
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
.	SENT	.
Admission	NN	admission
MR-proADM	NN	<unknown>
and	CC	and
copeptin	NN	<unknown>
may	MD	may
be	VB	be
implemented	VBN	implement
for	IN	for
early	JJ	early
risk	NN	risk
stratification	NN	stratification
in	IN	in
COVID-19-hospitalized	JJ	<unknown>
patients	NNS	patient
to	TO	to
help	VB	help
identify	VB	identify
those	DT	those
eligible	NN	eligible
for	IN	for
closer	JJR	close
monitoring	NN	monitoring
and	CC	and
care	NN	care
intensification	NN	intensification
.	SENT	.
32609380/	CD	@card@
The	NP	The
National	NP	National
Disability	NN	disability
Insurance	NN	insurance
Scheme	NN	scheme
and	CC	and
COVID-19	NP	<unknown>
:	:	:
a	DT	a
collision	NN	collision
course	NN	course
34608773/	CD	@card@
Adequate	JJ	adequate
immune	JJ	immune
response	NN	response
after	IN	after
SARS-CoV-2	NP	<unknown>
infection	NN	infection
and	CC	and
single	JJ	single
dose	NN	dose
vaccination	NN	vaccination
despite	IN	despite
rapid	JJ	rapid
heart	NN	heart
transplantation	NN	transplantation
Adequate	JJ	adequate
immune	JJ	immune
response	NN	response
to	TO	to
vaccination	NN	vaccination
remains	VBZ	remain
a	DT	a
challenge	NN	challenge
in	IN	in
patients	NNS	patient
after	IN	after
solid	JJ	solid
organ	NN	organ
transplantation	NN	transplantation
.	SENT	.
We	PP	we
report	VBP	report
a	DT	a
case	NN	case
of	IN	of
a	DT	a
61-year-old	JJ	61-year-old
male	JJ	male
patient	NN	patient
who	WP	who
received	VBD	receive
a	DT	a
left	JJ	left
ventricular	JJ	ventricular
assist	NN	assist
device	NN	device
as	IN	as
a	DT	a
bridge	NN	bridge
to	TO	to
transplant	VB	transplant
therapy	NN	therapy
.	SENT	.
Three	CD	three
months	NNS	month
before	IN	before
transplantation	NN	transplantation
,	,	,
he	PP	he
suffered	VBD	suffer
mild	JJ	mild
SARS-CoV-2	NP	<unknown>
infection	NN	infection
and	CC	and
was	VBD	be
successfully	RB	successfully
discharged	VBN	discharge
thereafter	RB	thereafter
.	SENT	.
Eight	CD	eight
days	NNS	day
before	IN	before
his	PP$	his
successful	JJ	successful
heart	NN	heart
transplantation	NN	transplantation
,	,	,
he	PP	he
received	VBD	receive
mRNA	NP	<unknown>
BNT	NP	BNT
162b2	JJ	<unknown>
vaccination	NN	vaccination
.	SENT	.
Immediately	RB	immediately
after	IN	after
transplantation	NN	transplantation
,	,	,
we	PP	we
detected	VBD	detect
sufficient	JJ	sufficient
rise	NN	rise
of	IN	of
nucleocapsid	NN	nucleocapsid
and	CC	and
spike	NN	spike
antibodies	NNS	antibody
despite	IN	despite
immune	JJ	immune
suppression	NN	suppression
therapy	NN	therapy
.	SENT	.
We	PP	we
suspect	VBP	suspect
potential	JJ	potential
booster	NN	booster
effects	NNS	effect
of	IN	of
the	DT	the
previous	JJ	previous
SARS-CoV-2	NP	<unknown>
infection	NN	infection
giving	VBG	give
rise	NN	rise
to	TO	to
adequate	JJ	adequate
immune	JJ	immune
response	NN	response
following	VBG	follow
single	JJ	single
vaccination	NN	vaccination
.	SENT	.
34648525/	CD	@card@
Risk	NN	risk
factors	NNS	factor
for	IN	for
increased	VBN	increase
COVID-19	JJ	<unknown>
case-fatality	NN	case-fatality
in	IN	in
the	DT	the
United	NP	United
States	NPS	States
:	:	:
A	DT	a
county-level	JJ	county-level
analysis	NN	analysis
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
The	DT	the
ongoing	JJ	ongoing
COVID-19	NP	<unknown>
pandemic	NN	pandemic
is	VBZ	be
causing	VBG	cause
significant	JJ	significant
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
across	IN	across
the	DT	the
US	NP	US
.	SENT	.
In	IN	in
this	DT	this
ecological	JJ	ecological
study	NN	study
,	,	,
we	PP	we
identified	VBD	identify
county-level	JJ	county-level
variables	NNS	variable
associated	VBN	associate
with	IN	with
the	DT	the
COVID-19	NP	<unknown>
case-fatality	NN	case-fatality
rate	NN	rate
(	(	(
CFR	NP	CFR
)	)	)
using	VBG	use
publicly	RB	publicly
available	JJ	available
datasets	NNS	<unknown>
and	CC	and
a	DT	a
negative	JJ	negative
binomial	NN	binomial
generalized	VBD	generalize
linear	JJ	linear
model	NN	model
.	SENT	.
Variables	NNS	variable
associated	VBN	associate
with	IN	with
decreased	VBD	decrease
CFR	NP	CFR
included	VBD	include
a	DT	a
greater	JJR	great
number	NN	number
of	IN	of
hospitals	NNS	hospital
per	IN	per
10,000	CD	@card@
people	NNS	people
,	,	,
banning	VBG	ban
religious	JJ	religious
gatherings	NNS	gathering
,	,	,
a	DT	a
higher	JJR	high
percentage	NN	percentage
of	IN	of
people	NNS	people
living	VBG	live
in	IN	in
mobile	JJ	mobile
homes	NNS	home
,	,	,
and	CC	and
a	DT	a
higher	JJR	high
percentage	NN	percentage
of	IN	of
uninsured	JJ	uninsured
people	NNS	people
.	SENT	.
Variables	NNS	variable
associated	VBN	associate
with	IN	with
increased	VBN	increase
CFR	NP	CFR
included	VBD	include
a	DT	a
higher	JJR	high
percentage	NN	percentage
of	IN	of
the	DT	the
population	NN	population
over	IN	over
age	NN	age
65	CD	@card@
,	,	,
a	DT	a
higher	JJR	high
percentage	NN	percentage
of	IN	of
Black	NP	Black
or	CC	or
African	NP	African
Americans	NPS	Americans
,	,	,
a	DT	a
higher	JJR	high
asthma	NN	asthma
prevalence	NN	prevalence
,	,	,
and	CC	and
a	DT	a
greater	JJR	great
number	NN	number
of	IN	of
hospitals	NNS	hospital
in	IN	in
a	DT	a
county	NN	county
.	SENT	.
By	IN	by
identifying	VBG	identify
factors	NNS	factor
that	WDT	that
are	VBP	be
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
CFR	NP	CFR
in	IN	in
US	NP	US
counties	NNS	county
,	,	,
we	PP	we
hope	VBP	hope
to	TO	to
help	VB	help
officials	NNS	official
target	VB	target
public	JJ	public
health	NN	health
interventions	NNS	intervention
and	CC	and
healthcare	NN	<unknown>
resources	NNS	resource
to	TO	to
locations	NNS	location
that	WDT	that
are	VBP	be
at	IN	at
increased	VBN	increase
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
fatalities	NNS	fatality
.	SENT	.
32294667/	CD	@card@
Translating	VBG	translate
transmissibility	NN	<unknown>
measures	NNS	measure
into	IN	into
recommendations	NNS	recommendation
for	IN	for
coronavirus	NN	coronavirus
prevention	NN	prevention
The	DT	the
rapid	JJ	rapid
increase	NN	increase
in	IN	in
clinical	JJ	clinical
cases	NNS	case
of	IN	of
the	DT	the
new	JJ	new
coronavirus	NN	coronavirus
disease	NN	disease
,	,	,
COVID-19	NP	<unknown>
,	,	,
suggests	VBZ	suggest
high	JJ	high
transmissibility	NN	<unknown>
.	SENT	.
However	RB	however
,	,	,
the	DT	the
estimates	NNS	estimate
of	IN	of
the	DT	the
basic	JJ	basic
reproductive	JJ	reproductive
number	NN	number
reported	VBN	report
in	IN	in
the	DT	the
literature	NN	literature
vary	VBP	vary
widely	RB	widely
.	SENT	.
Considering	VBG	consider
this	DT	this
,	,	,
we	PP	we
drew	VBD	draw
the	DT	the
function	NN	function
of	IN	of
contact-rate	NN	<unknown>
reduction	NN	reduction
required	VBN	require
to	TO	to
control	VB	control
the	DT	the
transmission	NN	transmission
from	IN	from
both	DT	both
detectable	JJ	detectable
and	CC	and
undetectable	JJ	undetectable
sources	NNS	source
.	SENT	.
Based	VBN	base
on	IN	on
this	DT	this
,	,	,
we	PP	we
offer	VBP	offer
a	DT	a
set	NN	set
of	IN	of
recommendations	NNS	recommendation
for	IN	for
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
populations	NNS	population
during	IN	during
the	DT	the
current	JJ	current
pandemic	NN	pandemic
.	SENT	.
Understanding	VBG	understand
the	DT	the
dynamics	NNS	dynamics
of	IN	of
transmission	NN	transmission
is	VBZ	be
essential	JJ	essential
to	TO	to
support	VB	support
government	NN	government
decisions	NNS	decision
and	CC	and
improve	VB	improve
the	DT	the
community	NN	community
's	POS	's
adherence	NN	adherence
to	TO	to
preventive	JJ	preventive
measures	NNS	measure
.	SENT	.
34072500/	CD	@card@
Global	JJ	global
Prevalence	NN	prevalence
and	CC	and
Drivers	NP	Drivers
of	IN	of
Dental	JJ	dental
Students	NNS	student
'	POS	'
COVID-19	NP	<unknown>
Vaccine	NN	vaccine
Hesitancy	NN	hesitancy
Background	NN	background
:	:	:
Acceleration	NN	acceleration
of	IN	of
mass	JJ	mass
vaccination	NN	vaccination
strategies	NNS	strategy
is	VBZ	be
the	DT	the
only	JJ	only
pathway	NN	pathway
to	TO	to
overcome	VB	overcome
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Healthcare	NP	Healthcare
professionals	NNS	professional
and	CC	and
students	NNS	student
have	VBP	have
a	DT	a
key	JJ	key
role	NN	role
in	IN	in
shaping	VBG	shape
public	JJ	public
opinion	NN	opinion
about	IN	about
vaccines	NNS	vaccine
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
evaluate	VB	evaluate
the	DT	the
attitudes	NNS	attitude
of	IN	of
dental	JJ	dental
students	NNS	student
globally	RB	globally
towards	IN	towards
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
and	CC	and
explore	VB	explore
the	DT	the
potential	JJ	potential
drivers	NNS	driver
for	IN	for
students	NNS	student
'	POS	'
acceptance	NN	acceptance
levels	NNS	level
.	SENT	.
Methods	NNS	method
:	:	:
A	DT	a
global	JJ	global
cross-sectional	JJ	cross-sectional
study	NN	study
was	VBD	be
carried	VBN	carry
out	RP	out
in	IN	in
February	NP	February
2021	CD	@card@
using	VBG	use
an	DT	an
online	JJ	online
questionnaire	NN	questionnaire
.	SENT	.
The	DT	the
study	NN	study
was	VBD	be
liaised	VBN	liaise
by	IN	by
the	DT	the
scientific	JJ	scientific
committee	NN	committee
of	IN	of
the	DT	the
International	NP	International
Association	NP	Association
of	IN	of
Dental	JJ	dental
Students	NNS	student
(	(	(
IADS	NNS	<unknown>
)	)	)
,	,	,
and	CC	and
data	NNS	datum
were	VBD	be
collected	VBN	collect
through	IN	through
the	DT	the
national	JJ	national
and	CC	and
local	JJ	local
coordinators	NNS	coordinator
of	IN	of
IADS	NNS	<unknown>
member	NN	member
organizations	NNS	organization
.	SENT	.
The	DT	the
dependent	JJ	dependent
variable	NN	variable
was	VBD	be
the	DT	the
willingness	NN	willingness
to	TO	to
take	VB	take
the	DT	the
COVID-19	NP	<unknown>
vaccine	NN	vaccine
,	,	,
and	CC	and
the	DT	the
independent	JJ	independent
variables	NNS	variable
included	VBD	include
demographic	JJ	demographic
characteristics	NNS	characteristic
,	,	,
COVID-19-related	JJ	COVID-19-related
experience	NN	experience
,	,	,
and	CC	and
the	DT	the
drivers	NNS	driver
of	IN	of
COVID-19	NP	<unknown>
vaccine-related	JJ	vaccine-related
attitude	NN	attitude
suggested	VBN	suggest
by	IN	by
the	DT	the
WHO	WP	who
SAGE	NN	sage
.	SENT	.
Results	NNS	result
:	:	:
A	DT	a
total	NN	total
of	IN	of
6639	CD	@card@
students	NNS	student
from	IN	from
22	CD	@card@
countries	NNS	country
,	,	,
representing	VBG	represent
all	DT	all
world	NN	world
regions	NNS	region
,	,	,
responded	VBD	respond
to	TO	to
the	DT	the
questionnaire	NN	questionnaire
properly	RB	properly
.	SENT	.
Their	PP$	their
mean	JJ	mean
age	NN	age
was	VBD	be
22.1	CD	@card@
+-	NN	<unknown>
2.8	CD	@card@
(	(	(
17-40	CD	@card@
)	)	)
years	NNS	year
,	,	,
and	CC	and
the	DT	the
majority	NN	majority
were	VBD	be
females	NNS	female
(	(	(
70.5	CD	@card@
%	NN	%
)	)	)
,	,	,
in	IN	in
clinical	JJ	clinical
years	NNS	year
(	(	(
66.8	CD	@card@
%	NN	%
)	)	)
,	,	,
and	CC	and
from	IN	from
upper-middle-income	NN	upper-middle-income
economies	NNS	economy
(	(	(
45.7	CD	@card@
%	NN	%
)	)	)
.	SENT	.
In	IN	in
general	JJ	general
,	,	,
22.5	CD	@card@
%	NN	%
of	IN	of
dental	JJ	dental
students	NNS	student
worldwide	RB	worldwide
were	VBD	be
hesitant	JJ	hesitant
,	,	,
and	CC	and
13.9	CD	@card@
%	NN	%
rejected	VBN	reject
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
.	SENT	.
The	DT	the
students	NNS	student
in	IN	in
low-	NN	low-
and	CC	and
lower-middle-income	NN	lower-middle-income
(	(	(
LLMI	NP	<unknown>
)	)	)
economies	NNS	economy
had	VBD	have
significantly	RB	significantly
higher	JJR	high
levels	NNS	level
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
compared	VBN	compare
to	TO	to
their	PP$	their
peers	NNS	peer
in	IN	in
upper-middle-	NN	upper-middle-
and	CC	and
high-income	NN	high-income
(	(	(
UMHI	NP	<unknown>
)	)	)
economies	NNS	economy
(	(	(
30.4	CD	@card@
%	NN	%
vs.	IN	vs.
19.8	CD	@card@
%	NN	%
;	:	;
p	NN	p
&lt	NN	&lt
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
Conclusions	NNS	conclusion
:	:	:
The	DT	the
global	JJ	global
acceptance	NN	acceptance
level	NN	level
of	IN	of
dental	JJ	dental
students	NNS	student
for	IN	for
COVID-19	NP	<unknown>
vaccines	NNS	vaccine
was	VBD	be
suboptimal	JJ	suboptimal
,	,	,
and	CC	and
their	PP$	their
worrisome	JJ	worrisome
level	NN	level
of	IN	of
vaccine	NN	vaccine
hesitancy	NN	hesitancy
was	VBD	be
influenced	VBN	influence
by	IN	by
the	DT	the
socioeconomic	JJ	socioeconomic
context	NN	context
where	WRB	where
the	DT	the
dental	JJ	dental
students	NNS	student
live	VBP	live
and	CC	and
study	NN	study
.	SENT	.
The	DT	the
media	NNS	medium
and	CC	and
social	JJ	social
media	NNS	medium
,	,	,
public	JJ	public
figures	NNS	figure
,	,	,
insufficient	JJ	insufficient
knowledge	NN	knowledge
about	IN	about
vaccines	NNS	vaccine
,	,	,
and	CC	and
mistrust	NN	mistrust
of	IN	of
governments	NNS	government
and	CC	and
the	DT	the
pharmaceutical	JJ	pharmaceutical
industry	NN	industry
were	VBD	be
barriers	NNS	barrier
to	TO	to
vaccination	NN	vaccination
.	SENT	.
The	DT	the
findings	NNS	finding
of	IN	of
this	DT	this
study	NN	study
call	NN	call
for	IN	for
further	JJR	further
implementation	NN	implementation
of	IN	of
epidemiology	NN	epidemiology
(	(	(
infectious	JJ	infectious
diseases	NNS	disease
)	)	)
education	NN	education
within	IN	within
undergraduate	JJ	undergraduate
dental	JJ	dental
curricula	NNS	curriculum
.	SENT	.
35583298/	CD	@card@
Student	NN	student
loan	NN	loan
debt	NN	debt
and	CC	and
financial	JJ	financial
education	NN	education
:	:	:
a	DT	a
qualitative	JJ	qualitative
analysis	NN	analysis
of	IN	of
resident	JJ	resident
perceptions	NNS	perception
and	CC	and
implications	NNS	implication
for	IN	for
resident	JJ	resident
well-being	NN	well-being
High	NP	High
educational	JJ	educational
debt	NN	debt
is	VBZ	be
prevalent	JJ	prevalent
among	IN	among
resident	JJ	resident
physicians	NNS	physician
and	CC	and
correlates	NNS	correlate
with	IN	with
adverse	JJ	adverse
well-being	NN	well-being
outcomes	NNS	outcome
,	,	,
including	VBG	include
symptoms	NNS	symptom
of	IN	of
stress	NN	stress
and	CC	and
burnout	NNS	burnout
.	SENT	.
Residents	NNS	resident
also	RB	also
report	VBP	report
low	JJ	low
financial	JJ	financial
literacy	NN	literacy
levels	NNS	level
,	,	,
affecting	VBG	affect
financial	JJ	financial
well-being	NN	well-being
.	SENT	.
Understanding	VBG	understand
resident	JJ	resident
viewpoints	NNS	viewpoint
toward	IN	toward
financial	JJ	financial
well-being	NN	well-being
initiatives	NNS	initiative
is	VBZ	be
crucial	JJ	crucial
to	TO	to
develop	VB	develop
targeted	JJ	targeted
resident	JJ	resident
financial	JJ	financial
well-being	NN	well-being
programs	NNS	program
.	SENT	.
This	DT	this
study	NN	study
aims	VBZ	aim
to	TO	to
examine	VB	examine
residents	NNS	resident
'	POS	'
experiences	NNS	experience
financing	VBG	finance
their	PP$	their
medical	JJ	medical
education	NN	education
and	CC	and
how	WRB	how
these	DT	these
experiences	NNS	experience
influence	NN	influence
well-being	NN	well-being
and	CC	and
attitudes	NNS	attitude
toward	IN	toward
financial	JJ	financial
education	NN	education
in	IN	in
residency	NN	residency
.	SENT	.
We	PP	we
recruited	VBD	recruit
residents	NNS	resident
from	IN	from
a	DT	a
Southern	NP	Southern
California	NP	California
health	NN	health
system	NN	system
with	IN	with
residency	NN	residency
programs	NNS	program
in	IN	in
Family	NP	Family
Medicine	NP	Medicine
,	,	,
Internal	NP	Internal
Medicine	NP	Medicine
,	,	,
General	NP	General
Surgery	NN	surgery
,	,	,
Orthopaedic	JJ	orthopaedic
Surgery	NN	surgery
,	,	,
and	CC	and
Psychiatry	NP	Psychiatry
.	SENT	.
We	PP	we
contacted	VBD	contact
residents	NNS	resident
by	IN	by
email	NN	<unknown>
and	CC	and
text	NN	text
message	NN	message
to	TO	to
participate	VB	participate
in	IN	in
semi-structured	JJ	semi-structured
interviews	NNS	interview
.	SENT	.
We	PP	we
conducted	VBD	conduct
interviews	NNS	interview
from	IN	from
October	NP	October
2020	CD	@card@
to	TO	to
March	NP	March
2021	CD	@card@
and	CC	and
analyzed	VBD	analyze
59	CD	@card@
resident	NN	resident
interviews	NNS	interview
using	VBG	use
reflexive	JJ	reflexive
thematic	JJ	thematic
analysis	NN	analysis
.	SENT	.
Among	IN	among
residents	NNS	resident
,	,	,
76	CD	@card@
%	NN	%
(	(	(
45/59	CD	@card@
)	)	)
had	VBD	have
&gt	NN	&gt
;	:	;
=	SYM	=
$200,000	NN	<unknown>
in	IN	in
student	NN	student
loans	NNS	loan
.	SENT	.
Residents	NNS	resident
perceived	VBD	perceive
mounting	VBG	mount
medical	JJ	medical
education	NN	education
debt	NN	debt
as	IN	as
unfairly	RB	unfairly
burdensome	JJ	burdensome
for	IN	for
trainees	NNS	trainee
engaged	VBN	engage
in	IN	in
socially	RB	socially
beneficial	JJ	beneficial
work	NN	work
,	,	,
leaving	VBG	leave
residents	NNS	resident
feeling	VBG	feel
undervalued	JJ	undervalued
-	NN	<unknown>
a	DT	a
feeling	NN	feeling
heightened	VBN	heighten
by	IN	by
the	DT	the
stressors	NNS	<unknown>
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
-	NN	<unknown>
and	CC	and
hampering	VBG	hamper
well-being	NN	well-being
.	SENT	.
Compartmentalizing	VBG	compartmentalize
debt	NN	debt
attenuated	VBN	attenuate
financial	JJ	financial
stressors	NNS	<unknown>
but	CC	but
often	RB	often
made	VBD	make
financial	JJ	financial
education	NN	education
seem	VBP	seem
less	RBR	less
pressing	JJ	pressing
.	SENT	.
A	DT	a
subset	NN	subset
of	IN	of
residents	NNS	resident
described	VBD	describe
how	WRB	how
financial	JJ	financial
planning	NN	planning
restored	VBD	restore
some	DT	some
agency	NN	agency
and	CC	and
enhanced	JJ	enhanced
well-being	NN	well-being
,	,	,
noting	VBG	note
that	IN	that
protected	JJ	protected
didactic	JJ	didactic
time	NN	time
for	IN	for
financial	JJ	financial
education	NN	education
was	VBD	be
crucial	JJ	crucial
.	SENT	.
Resident	NN	resident
interviews	NNS	interview
provide	VBP	provide
practical	JJ	practical
guidance	NN	guidance
regarding	VBG	regard
designing	JJ	designing
financial	JJ	financial
education	NN	education
sessions	NNS	session
.	SENT	.
Desired	VBN	desire
education	NN	education
included	VBD	include
managing	VBG	manage
debt	NN	debt
,	,	,
retirement	NN	retirement
planning	NN	planning
,	,	,
and	CC	and
the	DT	the
business	NN	business
of	IN	of
medicine	NN	medicine
.	SENT	.
How	WRB	how
residents	NNS	resident
framed	VBD	frame
educational	JJ	educational
debt	NN	debt
and	CC	and
their	PP$	their
degree	NN	degree
of	IN	of
financial	JJ	financial
literacy	NN	literacy
impacted	VBD	impact
their	PP$	their
well-being	NN	well-being
and	CC	and
sense	NN	sense
of	IN	of
agency	NN	agency
.	SENT	.
Residents	NNS	resident
proposed	VBD	propose
that	IN	that
residency	NN	residency
programs	NNS	program
can	MD	can
aid	VB	aid
in	IN	in
stress	NN	stress
mitigation	NN	mitigation
by	IN	by
providing	VBG	provide
residents	NNS	resident
with	IN	with
skills	NNS	skill
to	TO	to
help	VB	help
manage	VB	manage
debt	NN	debt
and	CC	and
plan	NN	plan
for	IN	for
retirement	NN	retirement
.	SENT	.
To	TO	to
reduce	VB	reduce
clinician	NN	clinician
indebtedness	NN	indebtedness
,	,	,
this	DT	this
approach	NN	approach
needs	VBZ	need
to	TO	to
occur	VB	occur
in	IN	in
tandem	NN	tandem
with	IN	with
systemic	JJ	systemic
changes	NNS	change
to	TO	to
financing	VBG	finance
medical	JJ	medical
education	NN	education
.	SENT	.
32246972/	CD	@card@
Ultraviolet	JJ	ultraviolet
germicidal	JJ	germicidal
irradiation	NN	irradiation
:	:	:
Possible	JJ	possible
method	NN	method
for	IN	for
respirator	NN	respirator
disinfection	NN	disinfection
to	TO	to
facilitate	VB	facilitate
reuse	NN	reuse
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
33669805/	CD	@card@
SARS-CoV-2	NP	<unknown>
Pandemic	NN	pandemic
:	:	:
Not	RB	not
the	DT	the
First	NP	First
,	,	,
Not	RB	not
the	DT	the
Last	JJ	last
The	DT	the
common	JJ	common
trait	NN	trait
among	IN	among
the	DT	the
betacoronaviruses	NNS	betacoronavirus
that	WDT	that
emerged	VBD	emerge
during	IN	during
the	DT	the
past	JJ	past
two	CD	two
decades	NNS	decade
(	(	(
the	DT	the
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus:SARS-CoV	NN	<unknown>
,	,	,
the	DT	the
Middle	NP	Middle
East	NP	East
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus:MERS-CoV	NN	<unknown>
,	,	,
and	CC	and
the	DT	the
recent	JJ	recent
SARS	NP	<unknown>
coronavirus	NN	coronavirus
2:SARS-CoV-2	JJ	<unknown>
)	)	)
is	VBZ	be
their	PP$	their
probable	JJ	probable
animal	NN	animal
origin	NN	origin
,	,	,
all	RB	all
deriving	VBG	derive
from	IN	from
viruses	NNS	virus
present	JJ	present
in	IN	in
bat	NN	bat
species	NNS	specie
.	SENT	.
Bats	NNS	bat
have	VBP	have
arisen	VBN	arise
the	DT	the
attention	NN	attention
of	IN	of
the	DT	the
scientific	JJ	scientific
community	NN	community
as	IN	as
reservoir	NN	reservoir
of	IN	of
emerging	VBG	emerge
viruses	NNS	virus
,	,	,
given	VBN	give
their	PP$	their
wide	JJ	wide
geographical	JJ	geographical
distribution	NN	distribution
,	,	,
their	PP$	their
biological	JJ	biological
diversity	NN	diversity
(	(	(
around	RB	around
1400	CD	@card@
species	NNS	specie
,	,	,
21	CD	@card@
different	JJ	different
families	NNS	family
and	CC	and
over	IN	over
200	CD	@card@
genera	NNS	genus
)	)	)
,	,	,
and	CC	and
their	PP$	their
peculiar	JJ	peculiar
ecological	JJ	ecological
and	CC	and
physiological	JJ	physiological
characteristics	NNS	characteristic
which	WDT	which
seem	VBP	seem
to	TO	to
facilitate	VB	facilitate
them	PP	them
in	IN	in
harbouring	VBG	harbour
a	DT	a
high	JJ	high
viral	JJ	viral
diversity	NN	diversity
.	SENT	.
Several	JJ	several
human	JJ	human
activities	NNS	activity
may	MD	may
enable	VB	enable
the	DT	the
viral	JJ	viral
spill-over	NN	<unknown>
from	IN	from
bats	NNS	bat
to	TO	to
humans	NNS	human
,	,	,
such	JJ	such
as	IN	as
deforestation	NN	deforestation
,	,	,
land-use	NN	land-use
changes	NNS	change
,	,	,
increased	VBD	increase
livestock	NN	livestock
grazing	NN	grazing
or	CC	or
intensive	JJ	intensive
production	NN	production
of	IN	of
vegetal	JJ	vegetal
cultures	NNS	culture
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
globalization	NN	globalization
of	IN	of
trade	NN	trade
and	CC	and
high	JJ	high
global	JJ	global
human	JJ	human
mobility	NN	mobility
allow	VB	allow
these	DT	these
viruses	NNS	virus
to	TO	to
be	VB	be
disseminated	VBN	disseminate
in	IN	in
few	JJ	few
hours	NNS	hour
in	IN	in
many	JJ	many
parts	NNS	part
of	IN	of
the	DT	the
World	NP	World
.	SENT	.
In	IN	in
order	NN	order
to	TO	to
avoid	VB	avoid
the	DT	the
emergence	NN	emergence
of	IN	of
new	JJ	new
pandemic	JJ	pandemic
threats	NNS	threat
in	IN	in
the	DT	the
future	NN	future
we	PP	we
need	VBP	need
to	TO	to
substantially	RB	substantially
change	VB	change
our	PP$	our
global	JJ	global
models	NNS	model
of	IN	of
social	JJ	social
and	CC	and
economic	JJ	economic
development	NN	development
,	,	,
posing	VBG	pose
the	DT	the
conservation	NN	conservation
of	IN	of
biodiversity	NN	biodiversity
and	CC	and
the	DT	the
preservation	NN	preservation
of	IN	of
natural	JJ	natural
ecosystems	NNS	ecosystem
as	IN	as
a	DT	a
pillar	NN	pillar
for	IN	for
the	DT	the
protection	NN	protection
of	IN	of
global	JJ	global
human	JJ	human
health	NN	health
.	SENT	.
34126613/	CD	@card@
Severe	NP	Severe
Brain	NP	Brain
Damage	NN	damage
in	IN	in
a	DT	a
Moderate	JJ	moderate
Preterm	NN	<unknown>
Infant	NN	infant
as	IN	as
Complication	NN	complication
of	IN	of
Post-COVID-19	NP	<unknown>
Response	NP	Response
during	IN	during
Pregnancy	NN	pregnancy
Current	JJ	current
evidence	NN	evidence
from	IN	from
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
suggests	VBZ	suggest
that	IN	that
neonatal	JJ	neonatal
SARS-coronavirus-2	NP	<unknown>
infections	NNS	infection
usually	RB	usually
have	VBP	have
a	DT	a
mild	JJ	mild
course	NN	course
.	SENT	.
Data	NNS	datum
on	IN	on
how	WRB	how
maternal	JJ	maternal
infection	NN	infection
during	IN	during
pregnancy	NN	pregnancy
affects	VBZ	affect
fetal	JJ	fetal
development	NN	development
are	VBP	be
scarce	JJ	scarce
.	SENT	.
We	PP	we
present	VBP	present
the	DT	the
unique	JJ	unique
case	NN	case
of	IN	of
a	DT	a
moderate	JJ	moderate
preterm	NN	<unknown>
infant	NN	infant
with	IN	with
intracranial	JJ	intracranial
bleeding	NN	bleeding
and	CC	and
periventricular	JJ	periventricular
leukomalacia	NNS	<unknown>
as	IN	as
a	DT	a
potential	JJ	potential
consequence	NN	consequence
of	IN	of
post-COVID-19	JJ	<unknown>
hyperinflammation	NN	hyperinflammation
during	IN	during
pregnancy	NN	pregnancy
.	SENT	.
32500589/	CD	@card@
Superficial	JJ	superficial
thrombophlebitis	NN	thrombophlebitis
in	IN	in
a	DT	a
patient	NN	patient
with	IN	with
COVID	NP	<unknown>
19	CD	@card@
:	:	:
Heparin	NN	heparin
treatment	NN	treatment
after	IN	after
evaluation	NN	evaluation
of	IN	of
D	NP	D
-	NN	<unknown>
Dimer	NN	dimer
33853700/	CD	@card@
Job	NP	Job
type	NN	type
,	,	,
neighborhood	NN	neighborhood
prevalence	NN	prevalence
,	,	,
and	CC	and
risk	NN	risk
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
among	IN	among
healthcare	NN	<unknown>
workers	NNS	worker
in	IN	in
New	NP	New
York	NP	York
City	NP	City
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
compared	VBD	compare
the	DT	the
risk	NN	risk
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
between	IN	between
clinical	JJ	clinical
and	CC	and
nonclinical	JJ	nonclinical
healthcare	NN	<unknown>
workers	NNS	worker
(	(	(
HCWs	NP	<unknown>
)	)	)
while	IN	while
adjusting	VBG	adjust
for	IN	for
home	NN	home
ZIP	NN	zip
codes	NNS	code
.	SENT	.
Clinical	JJ	clinical
HCWs	NNS	<unknown>
did	VBD	do
not	RB	not
have	VB	have
a	DT	a
higher	JJR	high
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
,	,	,
but	CC	but
living	VBG	live
in	IN	in
higher-risk	NN	higher-risk
ZIP	NN	zip
codes	NNS	code
was	VBD	be
associated	VBN	associate
with	IN	with
increased	VBN	increase
infection	NN	infection
rates	NNS	rate
.	SENT	.
However	RB	however
,	,	,
environmental	JJ	environmental
services	NNS	service
workers	NNS	worker
showed	VBD	show
increased	VBN	increase
risk	NN	risk
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
34262564/	CD	@card@
Differential	JJ	differential
Cytokine	NP	<unknown>
Responses	NNS	response
in	IN	in
Hospitalized	VBN	hospitalize
COVID-19	NP	<unknown>
Patients	NPS	Patients
Limit	NP	Limit
Efficacy	NN	efficacy
of	IN	of
Remdesivir	NP	<unknown>
A	DT	a
significant	JJ	significant
proportion	NN	proportion
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
will	MD	will
progress	VB	progress
to	TO	to
critical	JJ	critical
illness	NN	illness
requiring	VBG	require
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
.	SENT	.
This	DT	this
accentuates	VBZ	accentuate
the	DT	the
need	NN	need
for	IN	for
a	DT	a
therapy	NN	therapy
that	WDT	that
can	MD	can
reduce	VB	reduce
the	DT	the
severity	NN	severity
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
Clinical	JJ	clinical
trials	NNS	trial
have	VBP	have
shown	VBN	show
the	DT	the
effectiveness	NN	effectiveness
of	IN	of
remdesivir	NN	<unknown>
in	IN	in
shortening	VBG	shorten
recovery	NN	recovery
time	NN	time
and	CC	and
decreasing	VBG	decrease
progression	NN	progression
to	TO	to
respiratory	JJ	respiratory
failure	NN	failure
and	CC	and
mechanical	JJ	mechanical
ventilation	NN	ventilation
.	SENT	.
However	RB	however
,	,	,
some	DT	some
studies	NNS	study
have	VBP	have
highlighted	VBN	highlight
its	PP$	its
lack	NN	lack
of	IN	of
efficacy	NN	efficacy
in	IN	in
patients	NNS	patient
on	IN	on
high-flow	JJ	<unknown>
oxygen	NN	oxygen
and	CC	and
mechanical	JJ	mechanical
ventilation	NN	ventilation
.	SENT	.
This	DT	this
study	NN	study
uncovers	VBZ	uncover
some	DT	some
underlying	VBG	underlie
immune	JJ	immune
response	NN	response
differences	NNS	difference
between	IN	between
responders	NNS	responder
and	CC	and
non-responders	NNS	non-responder
to	TO	to
remdesivir	NN	<unknown>
treatment	NN	treatment
.	SENT	.
Immunological	JJ	immunological
analyses	NNS	analysis
revealed	VBD	reveal
an	DT	an
upregulation	NN	upregulation
of	IN	of
tissue	NN	tissue
repair	NN	repair
factors	NNS	factor
BDNF	NP	<unknown>
,	,	,
PDGF-BB	NP	<unknown>
and	CC	and
PIGF-1	NP	<unknown>
,	,	,
as	RB	as
well	RB	well
as	IN	as
an	DT	an
increase	NN	increase
in	IN	in
ratio	NN	ratio
of	IN	of
Th2-associated	JJ	Th2-associated
cytokine	NN	<unknown>
IL-4	NN	IL-4
to	TO	to
Th1-associated	JJ	Th1-associated
cytokine	NN	<unknown>
IFN-gamma	NP	IFN-gamma
.	SENT	.
Serological	JJ	serological
profiling	VBG	profil
of	IN	of
IgG	NP	IgG
subclasses	NNS	subclass
corroborated	VBD	corroborate
this	DT	this
observation	NN	observation
,	,	,
with	IN	with
significantly	RB	significantly
higher	JJR	high
magnitude	NN	magnitude
of	IN	of
increase	NN	increase
in	IN	in
Th2-associated	NP	Th2-associated
IgG2	NP	<unknown>
and	CC	and
IgG4	NP	<unknown>
responses	NNS	response
.	SENT	.
These	DT	these
findings	NNS	finding
help	VBP	help
to	TO	to
identify	VB	identify
the	DT	the
mechanisms	NNS	mechanism
of	IN	of
immune	JJ	immune
regulation	NN	regulation
accompanying	VBG	accompany
successful	JJ	successful
remdesivir	NN	<unknown>
treatment	NN	treatment
in	IN	in
severe	JJ	severe
COVID-19	NP	<unknown>
patients	NNS	patient
.	SENT	.
34370935/	CD	@card@
Associations	NNS	association
Between	IN	between
Compliance	NN	compliance
With	IN	with
Non-pharmaceutical	JJ	non-pharmaceutical
Interventions	NNS	intervention
and	CC	and
Social-distancing	NN	Social-distancing
Policies	NNS	policy
in	IN	in
Korea	NP	Korea
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
This	DT	this
study	NN	study
explored	VBD	explore
changes	NNS	change
in	IN	in
individuals	NNS	individual
'	POS	'
behavior	NN	behavior
in	IN	in
response	NN	response
to	TO	to
social	JJ	social
distancing	NN	distancing
(	(	(
SD	JJ	<unknown>
)	)	)
levels	NNS	level
and	CC	and
the	DT	the
"	``	"
no	DT	no
gatherings	NNS	gathering
of	IN	of
more	JJR	more
than	IN	than
5	CD	@card@
people	NNS	people
"	''	"
(	(	(
NGM5	NP	<unknown>
)	)	)
rule	NN	rule
in	IN	in
Korea	NP	Korea
during	IN	during
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
.	SENT	.
Using	VBG	use
survey	NN	survey
data	NNS	datum
from	IN	from
the	DT	the
COVID-19	NP	<unknown>
Behavior	NN	behavior
Tracker	NN	tracker
,	,	,
exploratory	JJ	exploratory
factor	NN	factor
analysis	NN	analysis
extracted	VBD	extract
3	CD	@card@
preventive	JJ	preventive
factors	NNS	factor
:	:	:
maintenance	NN	maintenance
of	IN	of
personal	JJ	personal
hygiene	NN	hygiene
,	,	,
avoiding	VBG	avoid
going	VBG	go
out	RP	out
,	,	,
and	CC	and
avoiding	VBG	avoid
meeting	NN	meeting
people	NNS	people
.	SENT	.
Each	DT	each
factor	NN	factor
was	VBD	be
used	VBN	use
as	IN	as
a	DT	a
dependent	JJ	dependent
variable	NN	variable
.	SENT	.
The	DT	the
chi-square	NN	chi-square
test	NN	test
was	VBD	be
used	VBN	use
to	TO	to
compare	VB	compare
differences	NNS	difference
in	IN	in
distributions	NNS	distribution
between	IN	between
categorical	JJ	categorical
variables	NNS	variable
,	,	,
while	IN	while
binary	JJ	binary
logistic	JJ	logistic
regression	NN	regression
was	VBD	be
performed	VBN	perform
to	TO	to
identify	VB	identify
factors	NNS	factor
associated	VBN	associate
with	IN	with
high	JJ	high
compliance	NN	compliance
with	IN	with
measures	NNS	measure
to	TO	to
prevent	VB	prevent
transmission	NN	transmission
.	SENT	.
In	IN	in
men	NNS	man
,	,	,
all	RB	all
3	CD	@card@
factors	NNS	factor
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
lower	JJR	low
compliance	NN	compliance
.	SENT	.
Younger	JJR	young
age	NN	age
groups	NNS	group
were	VBD	be
associated	VBN	associate
with	IN	with
lower	JJR	low
compliance	NN	compliance
with	IN	with
maintenance	NN	maintenance
of	IN	of
personal	JJ	personal
hygiene	NN	hygiene
and	CC	and
avoiding	VBG	avoid
meeting	NN	meeting
people	NNS	people
.	SENT	.
Employment	NN	employment
status	NN	status
was	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
avoiding	VBG	avoid
going	VBG	go
out	RP	out
and	CC	and
avoiding	VBG	avoid
meeting	NN	meeting
people	NNS	people
.	SENT	.
Residence	NN	residence
in	IN	in
the	DT	the
capital	NN	capital
area	NN	area
was	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
higher	JJR	high
compliance	NN	compliance
with	IN	with
personal	JJ	personal
hygiene	NN	hygiene
and	CC	and
avoiding	VBG	avoid
venturing	VBG	venture
out	RP	out
.	SENT	.
Increasing	VBG	increase
SD	NN	SD
levels	NNS	level
were	VBD	be
associated	VBN	associate
with	IN	with
personal	JJ	personal
hygiene	NN	hygiene
,	,	,
avoiding	VBG	avoid
going	VBG	go
out	RP	out
,	,	,
and	CC	and
avoiding	VBG	avoid
meeting	NN	meeting
people	NNS	people
.	SENT	.
The	DT	the
NGM5	NP	<unknown>
policy	NN	policy
was	VBD	be
not	RB	not
significantly	RB	significantly
associated	VBN	associate
with	IN	with
compliance	NN	compliance
.	SENT	.
SD	NN	SD
levels	NNS	level
,	,	,
gender	NN	gender
,	,	,
age	NN	age
,	,	,
employment	NN	employment
status	NN	status
,	,	,
and	CC	and
region	NN	region
had	VBD	have
explanatory	JJ	explanatory
power	NN	power
for	IN	for
compliance	NN	compliance
with	IN	with
non-pharmaceutical	JJ	non-pharmaceutical
interventions	NNS	intervention
(	(	(
NPIs	NP	<unknown>
)	)	)
.	SENT	.
Strengthening	VBG	strengthen
social	JJ	social
campaigns	NNS	campaign
to	TO	to
inspire	VB	inspire
voluntary	JJ	voluntary
compliance	NN	compliance
with	IN	with
NPIs	NP	<unknown>
,	,	,
especially	RB	especially
focused	VBN	focus
on	IN	on
men	NNS	man
,	,	,
younger	JJR	young
people	NNS	people
,	,	,
full-time	JJ	full-time
workers	NNS	worker
,	,	,
and	CC	and
residents	NNS	resident
of	IN	of
the	DT	the
capital	NN	capital
area	NN	area
is	VBZ	be
recommended	VBN	recommend
.	SENT	.
Simultaneously	RB	simultaneously
,	,	,
efforts	NNS	effort
need	VBP	need
to	TO	to
be	VB	be
made	VBN	make
to	TO	to
segment	VB	segment
SD	JJ	<unknown>
measures	NNS	measure
into	IN	into
substrategies	NNS	substrategy
with	IN	with
detailed	JJ	detailed
guidance	NN	guidance
at	IN	at
each	DT	each
level	NN	level
.	SENT	.
32301809/	CD	@card@
A	DT	a
Low-cost	NN	low-cost
,	,	,
Safe	NP	Safe
,	,	,
and	CC	and
Effective	JJ	effective
Method	NN	method
for	IN	for
Smoke	NP	Smoke
Evacuation	NN	evacuation
in	IN	in
Laparoscopic	JJ	<unknown>
Surgery	NN	surgery
for	IN	for
Suspected	JJ	suspected
Coronavirus	NP	<unknown>
Patients	NPS	Patients
34251568/	CD	@card@
Reply	NN	reply
to	TO	to
:	:	:
"	``	"
COVID-19-associated	JJ	COVID-19-associated
liver	NN	liver
injury	NN	injury
(	(	(
COVALI	NP	<unknown>
)	)	)
:	:	:
role	NN	role
of	IN	of
hepatologists	NNS	hepatologist
"	''	"
35255100/	CD	@card@
Distinct	JJ	distinct
spatial	JJ	spatial
arrangements	NNS	arrangement
of	IN	of
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
expression	NN	expression
in	IN	in
Syrian	JJ	Syrian
hamster	NN	hamster
lung	NN	lung
lobes	NNS	lobe
dictates	VBZ	dictate
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
patterns	NNS	pattern
SARS-CoV-2	NP	<unknown>
attaches	VBZ	attach
to	TO	to
angiotensin-converting	JJ	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE2	NP	<unknown>
)	)	)
to	TO	to
gain	VB	gain
entry	NN	entry
into	IN	into
cells	NNS	cell
after	IN	after
which	WDT	which
the	DT	the
spike	NN	spike
protein	NN	protein
is	VBZ	be
cleaved	VBN	cleave
by	IN	by
the	DT	the
transmembrane	JJ	<unknown>
serine	NN	serine
protease	NN	protease
2	CD	@card@
(	(	(
TMPRSS2	NP	<unknown>
)	)	)
to	TO	to
facilitate	VB	facilitate
viral-host	JJ	<unknown>
membrane	NN	membrane
fusion	NN	fusion
.	SENT	.
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
expression	NN	expression
profiles	NNS	profile
have	VBP	have
been	VBN	be
analyzed	VBN	analyze
at	IN	at
the	DT	the
genomic	JJ	<unknown>
,	,	,
transcriptomic	JJ	<unknown>
,	,	,
and	CC	and
single-cell	NN	single-cell
RNAseq	NP	<unknown>
levels	NNS	level
.	SENT	.
However	RB	however
,	,	,
transcriptomic	JJ	<unknown>
data	NNS	datum
and	CC	and
actual	JJ	actual
protein	NN	protein
validation	NN	validation
convey	VBP	convey
conflicting	JJ	conflicting
information	NN	information
regarding	VBG	regard
the	DT	the
distribution	NN	distribution
of	IN	of
the	DT	the
biologically	RB	biologically
relevant	JJ	relevant
protein	NN	protein
receptor	NN	receptor
in	IN	in
whole	JJ	whole
tissues	NNS	tissue
.	SENT	.
To	TO	to
describe	VB	describe
the	DT	the
organ-level	JJ	organ-level
architecture	NN	architecture
of	IN	of
receptor	NN	receptor
expression	NN	expression
,	,	,
related	VBN	relate
to	TO	to
the	DT	the
ability	NN	ability
of	IN	of
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
to	TO	to
mediate	VB	mediate
infectivity	NN	infectivity
,	,	,
we	PP	we
performed	VBD	perform
a	DT	a
volumetric	JJ	volumetric
analysis	NN	analysis
of	IN	of
whole	JJ	whole
Syrian	JJ	Syrian
hamster	NN	hamster
lung	NN	lung
lobes	NNS	lobe
.	SENT	.
Lung	NN	lung
tissue	NN	tissue
of	IN	of
infected	JJ	infected
and	CC	and
control	NN	control
animals	NNS	animal
was	VBD	be
stained	VBN	stain
using	VBG	use
antibodies	NNS	antibody
against	IN	against
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
,	,	,
combined	VBN	combine
with	IN	with
SARS-CoV-2	NP	<unknown>
nucleoprotein	NN	nucleoprotein
staining	VBG	stain
.	SENT	.
This	DT	this
was	VBD	be
followed	VBN	follow
by	IN	by
light-sheet	NN	light-sheet
microscopy	NN	microscopy
imaging	NN	imaging
to	TO	to
visualize	VB	visualize
their	PP$	their
expression	NN	expression
and	CC	and
related	JJ	related
infection	NN	infection
patterns	NNS	pattern
.	SENT	.
The	DT	the
data	NNS	datum
demonstrate	VBP	demonstrate
that	IN	that
infection	NN	infection
is	VBZ	be
restricted	VBN	restrict
to	TO	to
sites	NNS	site
containing	VBG	contain
both	DT	both
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
,	,	,
the	DT	the
latter	NN	latter
is	VBZ	be
expressed	VBN	express
in	IN	in
the	DT	the
primary	JJ	primary
and	CC	and
secondary	JJ	secondary
bronchi	NNS	bronchus
whereas	IN	whereas
ACE2	NP	<unknown>
is	VBZ	be
predominantly	RB	predominantly
observed	VBN	observe
in	IN	in
the	DT	the
bronchioles	NNS	bronchiole
and	CC	and
alveoli	NNS	alveolus
.	SENT	.
Conversely	RB	conversely
,	,	,
infection	NN	infection
completely	RB	completely
overlaps	VBZ	overlap
where	WRB	where
ACE2	NP	<unknown>
and	CC	and
TMPRSS2	NP	<unknown>
co-localize	VBP	co-localize
in	IN	in
the	DT	the
tertiary	JJ	tertiary
bronchi	NNS	bronchus
,	,	,
bronchioles	NNS	bronchiole
,	,	,
and	CC	and
alveoli	NNS	alveolus
.	SENT	.
The	DT	the
ongoing	JJ	ongoing
COVID19	NP	<unknown>
pandemic	NN	pandemic
necessitates	VBZ	necessitate
additional	JJ	additional
tools	NNS	tool
to	TO	to
study	VB	study
SARS-CoV	NP	<unknown>
infection	NN	infection
dynamics	NNS	dynamics
.	SENT	.
This	DT	this
increases	VBZ	increase
our	PP$	our
understanding	NN	understanding
of	IN	of
where	WRB	where
these	DT	these
viruses	NNS	virus
cause	VBP	cause
infections	NNS	infection
in	IN	in
the	DT	the
lung	NN	lung
,	,	,
and	CC	and
how	WRB	how
essential	JJ	essential
different	JJ	different
receptor	NN	receptor
molecules	NNS	molecule
are	VBP	be
.	SENT	.
Here	RB	here
we	PP	we
applied	VBD	apply
tissue	NN	tissue
optical	JJ	optical
clearing	NN	clearing
and	CC	and
3D	JJ	3D
immunofluorescence	NN	immunofluorescence
of	IN	of
whole	JJ	whole
organs	NNS	organ
from	IN	from
our	PP$	our
best	JJS	good
animal	NN	animal
model	NN	model
,	,	,
the	DT	the
Syrian	JJ	Syrian
hamster	NN	hamster
.	SENT	.
We	PP	we
describe	VBP	describe
the	DT	the
organ-level	JJ	organ-level
architecture	NN	architecture
of	IN	of
receptor	NN	receptor
expression	NN	expression
profiles	NNS	profile
,	,	,
to	TO	to
visualize	VB	visualize
how	WRB	how
their	PP$	their
concerted	JJ	concerted
action	NN	action
mediates	VBZ	mediate
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
patterns	NNS	pattern
.	SENT	.
34112877/	CD	@card@
Transcriptomics-based	JJ	<unknown>
drug	NN	drug
repositioning	VBG	reposition
pipeline	NN	pipeline
identifies	VBZ	identify
therapeutic	JJ	therapeutic
candidates	NNS	candidate
for	IN	for
COVID-19	NP	<unknown>
The	DT	the
novel	JJ	novel
SARS-CoV-2	NP	<unknown>
virus	NN	virus
emerged	VBD	emerge
in	IN	in
December	NP	December
2019	CD	@card@
and	CC	and
has	VBZ	have
few	JJ	few
effective	JJ	effective
treatments	NNS	treatment
.	SENT	.
We	PP	we
applied	VBD	apply
a	DT	a
computational	JJ	computational
drug	NN	drug
repositioning	VBG	reposition
pipeline	NN	pipeline
to	TO	to
SARS-CoV-2	NP	<unknown>
differential	JJ	differential
gene	NN	gene
expression	NN	expression
signatures	NNS	signature
derived	VBN	derive
from	IN	from
publicly	RB	publicly
available	JJ	available
data	NNS	datum
.	SENT	.
We	PP	we
utilized	VBD	utilize
three	CD	three
independent	JJ	independent
published	JJ	published
studies	NNS	study
to	TO	to
acquire	VB	acquire
or	CC	or
generate	VB	generate
lists	NNS	list
of	IN	of
differentially	RB	differentially
expressed	VBN	express
genes	NNS	gene
between	IN	between
control	NN	control
and	CC	and
SARS-CoV-2-infected	JJ	SARS-CoV-2-infected
samples	NNS	sample
.	SENT	.
Using	VBG	use
a	DT	a
rank-based	JJ	<unknown>
pattern	NN	pattern
matching	VBG	match
strategy	NN	strategy
based	VBN	base
on	IN	on
the	DT	the
Kolmogorov-Smirnov	NP	Kolmogorov-Smirnov
Statistic	NN	statistic
,	,	,
the	DT	the
signatures	NNS	signature
were	VBD	be
queried	VBN	query
against	IN	against
drug	NN	drug
profiles	NNS	profile
from	IN	from
Connectivity	NN	connectivity
Map	NN	map
(	(	(
CMap	NP	<unknown>
)	)	)
.	SENT	.
We	PP	we
validated	VBD	validate
16	CD	@card@
of	IN	of
our	PP$	our
top	NN	top
predicted	VBD	predict
hits	NNS	hit
in	IN	in
live	JJ	live
SARS-CoV-2	NP	<unknown>
antiviral	JJ	antiviral
assays	NNS	assay
in	IN	in
either	DT	either
Calu-3	NP	<unknown>
or	CC	or
293T-ACE2	JJ	<unknown>
cells	NNS	cell
.	SENT	.
Validation	NN	validation
experiments	NNS	experiment
in	IN	in
human	JJ	human
cell	NN	cell
lines	NNS	line
showed	VBD	show
that	IN	that
11	CD	@card@
of	IN	of
the	DT	the
16	CD	@card@
compounds	NNS	compound
tested	VBN	test
to	TO	to
date	VB	date
(	(	(
including	VBG	include
clofazimine	NN	clofazimine
,	,	,
haloperidol	NN	<unknown>
and	CC	and
others	NNS	other
)	)	)
had	VBD	have
measurable	JJ	measurable
antiviral	JJ	antiviral
activity	NN	activity
against	IN	against
SARS-CoV-2	NP	<unknown>
.	SENT	.
These	DT	these
initial	JJ	initial
results	NNS	result
are	VBP	be
encouraging	VBG	encourage
as	IN	as
we	PP	we
continue	VBP	continue
to	TO	to
work	VB	work
towards	IN	towards
a	DT	a
further	JJR	further
analysis	NN	analysis
of	IN	of
these	DT	these
predicted	VBN	predict
drugs	NNS	drug
as	IN	as
potential	JJ	potential
therapeutics	NNS	therapeutics
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
32179701/	CD	@card@
Substantial	JJ	substantial
undocumented	JJ	undocumented
infection	NN	infection
facilitates	VBZ	facilitate
the	DT	the
rapid	JJ	rapid
dissemination	NN	dissemination
of	IN	of
novel	JJ	novel
coronavirus	NNS	<unknown>
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
The	DT	the
virus	NN	virus
causing	VBG	cause
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
now	RB	now
become	VBN	become
pandemic	NN	pandemic
.	SENT	.
How	WRB	how
has	VBZ	have
it	PP	it
managed	VBN	manage
to	TO	to
spread	VB	spread
from	IN	from
China	NP	China
to	TO	to
all	DT	all
around	IN	around
the	DT	the
world	NN	world
within	IN	within
3	CD	@card@
to	TO	to
4	CD	@card@
months	NNS	month
?	SENT	?
Li	NP	Li
et	FW	et
al.	FW	al.
used	JJ	used
multiple	JJ	multiple
sources	NNS	source
to	TO	to
infer	VB	infer
the	DT	the
proportion	NN	proportion
of	IN	of
early	JJ	early
infections	NNS	infection
that	WDT	that
went	VBD	go
undetected	JJ	undetected
and	CC	and
their	PP$	their
contribution	NN	contribution
to	TO	to
virus	NN	virus
spread	NN	spread
.	SENT	.
The	DT	the
researchers	NNS	researcher
combined	VBD	combine
data	NNS	datum
from	IN	from
Tencent	NP	<unknown>
,	,	,
one	CD	one
of	IN	of
the	DT	the
world	NN	world
's	POS	's
largest	JJS	large
social	JJ	social
media	NNS	medium
and	CC	and
technology	NN	technology
companies	NNS	company
,	,	,
with	IN	with
a	DT	a
networked	VBN	network
dynamic	JJ	dynamic
metapopulation	NN	metapopulation
model	NN	model
and	CC	and
Bayesian	JJ	<unknown>
inference	NN	inference
to	TO	to
analyze	VB	analyze
early	JJ	early
spread	NN	spread
within	IN	within
China	NP	China
.	SENT	.
They	PP	they
estimate	VBP	estimate
that	IN	that
~86	JJ	~@card@
%	NN	%
of	IN	of
cases	NNS	case
were	VBD	be
undocumented	JJ	undocumented
before	IN	before
travel	NN	travel
restrictions	NNS	restriction
were	VBD	be
put	VBN	put
in	IN	in
place	NN	place
.	SENT	.
Before	IN	before
travel	NN	travel
restriction	NN	restriction
and	CC	and
personal	JJ	personal
isolation	NN	isolation
were	VBD	be
implemented	VBN	implement
,	,	,
the	DT	the
transmission	NN	transmission
rate	NN	rate
of	IN	of
undocumented	JJ	undocumented
infections	NNS	infection
was	VBD	be
a	DT	a
little	RB	little
more	JJR	more
than	IN	than
half	PDT	half
that	DT	that
of	IN	of
the	DT	the
known	VBN	know
cases	NNS	case
.	SENT	.
However	RB	however
,	,	,
because	IN	because
of	IN	of
their	PP$	their
greater	JJR	great
numbers	NNS	number
,	,	,
undocumented	JJ	undocumented
infections	NNS	infection
were	VBD	be
the	DT	the
source	NN	source
for	IN	for
~80	JJ	~@card@
%	NN	%
of	IN	of
the	DT	the
documented	VBN	document
cases	NNS	case
.	SENT	.
Immediately	RB	immediately
after	IN	after
travel	NN	travel
restrictions	NNS	restriction
were	VBD	be
imposed	VBN	impose
,	,	,
~65	JJ	~@card@
%	NN	%
of	IN	of
cases	NNS	case
were	VBD	be
documented	VBN	document
.	SENT	.
These	DT	these
findings	NNS	finding
help	VBP	help
to	TO	to
explain	VB	explain
the	DT	the
lightning-fast	NN	lightning-fast
spread	VBN	spread
of	IN	of
this	DT	this
virus	NN	virus
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
Science	NP	Science
,	,	,
this	DT	this
issue	NN	issue
p.	NN	page
489	CD	@card@
Prior	RB	prior
to	TO	to
travel	VB	travel
restrictions	NNS	restriction
,	,	,
most	JJS	most
SARS-CoV-2	NP	<unknown>
infections	NNS	infection
went	VBD	go
undocumented	JJ	undocumented
and	CC	and
substantially	RB	substantially
contributed	VBD	contribute
to	TO	to
global	JJ	global
virus	NN	virus
spread	NN	spread
.	SENT	.
Estimation	NN	estimation
of	IN	of
the	DT	the
prevalence	NN	prevalence
and	CC	and
contagiousness	NN	contagiousness
of	IN	of
undocumented	JJ	undocumented
novel	JJ	novel
coronavirus	NN	coronavirus
[	SYM	[
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome-coronavirus	NN	syndrome-coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
]	SYM	]
infections	NNS	infection
is	VBZ	be
critical	JJ	critical
for	IN	for
understanding	VBG	understand
the	DT	the
overall	JJ	overall
prevalence	NN	prevalence
and	CC	and
pandemic	JJ	pandemic
potential	NN	potential
of	IN	of
this	DT	this
disease	NN	disease
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
use	VBP	use
observations	NNS	observation
of	IN	of
reported	VBN	report
infection	NN	infection
within	IN	within
China	NP	China
,	,	,
in	IN	in
conjunction	NN	conjunction
with	IN	with
mobility	NN	mobility
data	NNS	datum
,	,	,
a	DT	a
networked	VBN	network
dynamic	JJ	dynamic
metapopulation	NN	metapopulation
model	NN	model
,	,	,
and	CC	and
Bayesian	NP	<unknown>
inference	NN	inference
,	,	,
to	TO	to
infer	VB	infer
critical	JJ	critical
epidemiological	JJ	epidemiological
characteristics	NNS	characteristic
associated	VBN	associate
with	IN	with
SARS-CoV-2	NP	<unknown>
,	,	,
including	VBG	include
the	DT	the
fraction	NN	fraction
of	IN	of
undocumented	JJ	undocumented
infections	NNS	infection
and	CC	and
their	PP$	their
contagiousness	NN	contagiousness
.	SENT	.
We	PP	we
estimate	VBP	estimate
that	IN	that
86	CD	@card@
%	NN	%
of	IN	of
all	DT	all
infections	NNS	infection
were	VBD	be
undocumented	JJ	undocumented
[	SYM	[
95	CD	@card@
%	NN	%
credible	JJ	credible
interval	NN	interval
(	(	(
CI	NP	CI
)	)	)
:	:	:
82-90	CD	@card@
%	NN	%
]	SYM	]
before	IN	before
the	DT	the
23	CD	@card@
January	NP	January
2020	CD	@card@
travel	NN	travel
restrictions	NNS	restriction
.	SENT	.
The	DT	the
transmission	NN	transmission
rate	NN	rate
of	IN	of
undocumented	JJ	undocumented
infections	NNS	infection
per	IN	per
person	NN	person
was	VBD	be
55	CD	@card@
%	NN	%
the	DT	the
transmission	NN	transmission
rate	NN	rate
of	IN	of
documented	VBN	document
infections	NNS	infection
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
46-62	CD	@card@
%	NN	%
)	)	)
,	,	,
yet	RB	yet
,	,	,
because	IN	because
of	IN	of
their	PP$	their
greater	JJR	great
numbers	NNS	number
,	,	,
undocumented	JJ	undocumented
infections	NNS	infection
were	VBD	be
the	DT	the
source	NN	source
of	IN	of
79	CD	@card@
%	NN	%
of	IN	of
the	DT	the
documented	VBN	document
cases	NNS	case
.	SENT	.
These	DT	these
findings	NNS	finding
explain	VBP	explain
the	DT	the
rapid	JJ	rapid
geographic	JJ	geographic
spread	NN	spread
of	IN	of
SARS-CoV-2	NP	<unknown>
and	CC	and
indicate	VB	indicate
that	DT	that
containment	NN	containment
of	IN	of
this	DT	this
virus	NN	virus
will	MD	will
be	VB	be
particularly	RB	particularly
challenging	JJ	challenging
.	SENT	.
33551798/	CD	@card@
Respiratory	JJ	respiratory
Tract	NN	tract
Infections	NNS	infection
in	IN	in
Inflammatory	JJ	inflammatory
Bowel	NN	bowel
Disease	NN	disease
Patients	NNS	patient
Taking	VBG	take
Vedolizumab	NP	<unknown>
:	:	:
A	DT	a
Systematic	JJ	systematic
Review	NP	Review
and	CC	and
Meta-Analysis	NP	Meta-Analysis
of	IN	of
Randomized	VBN	randomize
Controlled	JJ	controlled
Trials	NNS	trial
The	DT	the
ongoing	JJ	ongoing
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
raised	VBN	raise
concerns	NNS	concern
about	IN	about
the	DT	the
risk	NN	risk
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
in	IN	in
patients	NNS	patient
with	IN	with
Crohn	NP	<unknown>
's	POS	's
disease	NN	disease
(	(	(
CD	NN	CD
)	)	)
and	CC	and
patients	NNS	patient
with	IN	with
ulcerative	JJ	ulcerative
colitis	NN	colitis
(	(	(
UC	NN	UC
)	)	)
taking	VBG	take
immunosuppressants	NNS	immunosuppressant
or	CC	or
biologics	NNS	biologic
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
to	TO	to
assess	VB	assess
the	DT	the
risk	NN	risk
of	IN	of
respiratory	JJ	respiratory
infections	NNS	infection
in	IN	in
patients	NNS	patient
with	IN	with
inflammatory	JJ	inflammatory
bowel	NN	bowel
disease	NN	disease
(	(	(
IBD	NN	IBD
)	)	)
treated	VBN	treat
with	IN	with
vedolizumab	NN	<unknown>
.	SENT	.
We	PP	we
searched	VBD	search
PubMed	NP	<unknown>
,	,	,
EMBASE	NP	<unknown>
and	CC	and
Scopus	NP	Scopus
to	TO	to
identify	VB	identify
randomized	VBN	randomize
controlled	JJ	controlled
trials	NNS	trial
(	(	(
RCT	NP	RCT
)	)	)
comparing	VBG	compare
vedolizumab	NN	<unknown>
to	TO	to
placebo	NN	placebo
in	IN	in
patients	NNS	patient
with	IN	with
IBD	NN	IBD
.	SENT	.
Outcomes	NNS	outcome
were	VBD	be
the	DT	the
rate	NN	rate
of	IN	of
respiratory	JJ	respiratory
tract	NN	tract
infections	NNS	infection
(	(	(
RTI	NP	RTI
)	)	)
,	,	,
upper	JJ	upper
respiratory	JJ	respiratory
tract	NN	tract
infections	NNS	infection
(	(	(
URTI	NP	<unknown>
)	)	)
and	CC	and
lower	JJR	low
respiratory	JJ	respiratory
tract	NN	tract
infections	NNS	infection
(	(	(
LRTI	NP	<unknown>
)	)	)
among	IN	among
patients	NNS	patient
receiving	VBG	receive
vedolizumab	NN	<unknown>
as	IN	as
compared	VBN	compare
with	IN	with
placebo	NN	placebo
.	SENT	.
Pooled	JJ	pooled
rates	NNS	rate
were	VBD	be
reported	VBN	report
as	IN	as
Odds	NPS	Odds
Ratios	NNS	ratio
(	(	(
OR	CC	or
)	)	)
with	IN	with
95	CD	@card@
%	NN	%
Confidence	NN	confidence
Interval	NN	interval
(	(	(
CI	NP	CI
)	)	)
.	SENT	.
Eight	CD	eight
RCT	NN	RCT
involving	VBG	involve
3,287	CD	@card@
patients	NNS	patient
(	(	(
1873	CD	@card@
CD	NN	CD
and	CC	and
1415	CD	@card@
UC	NN	UC
)	)	)
were	VBD	be
analyzed	VBN	analyze
;	:	;
2,493	CD	@card@
patients	NNS	patient
received	VBD	receive
vedolizumab	NN	<unknown>
and	CC	and
794	CD	@card@
received	VBN	receive
placebo	NN	placebo
.	SENT	.
The	DT	the
rates	NNS	rate
of	IN	of
RTI	NP	RTI
and	CC	and
URTI	NP	<unknown>
were	VBD	be
statistically	RB	statistically
higher	JJR	high
in	IN	in
vedolizumab-treated	JJ	<unknown>
patients	NNS	patient
compared	VBN	compare
to	TO	to
placebo	NN	placebo
[	SYM	[
OR	CC	or
=	SYM	=
1.63	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
(	(	(
1.07-2.49	CD	@card@
)	)	)
;	:	;
OR	CC	or
=	SYM	=
1.64	CD	@card@
95	CD	@card@
%	NN	%
CI	NP	CI
(	(	(
1.07-2.53	CD	@card@
)	)	)
respectively	RB	respectively
]	SYM	]
.	SENT	.
UC	NP	UC
patients	NNS	patient
,	,	,
but	CC	but
not	RB	not
CD	NN	CD
patients	NNS	patient
,	,	,
receiving	VBG	receive
vedolizumab	NN	<unknown>
had	VBD	have
a	DT	a
higher	JJR	high
risk	NN	risk
to	TO	to
develop	VB	develop
RTI	NP	RTI
and	CC	and
URTI	NP	<unknown>
[	SYM	[
OR	CC	or
=	SYM	=
1.98	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
(	(	(
1.41-2.77	CD	@card@
)	)	)
;	:	;
OR	CC	or
=	SYM	=
2.02	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
(	(	(
1.42-2.87	CD	@card@
)	)	)
]	SYM	]
compared	VBN	compare
to	TO	to
placebo-treated	JJ	placebo-treated
patients	NNS	patient
.	SENT	.
The	DT	the
number	NN	number
of	IN	of
LRTI	NP	<unknown>
was	VBD	be
small	JJ	small
in	IN	in
both	DT	both
treatment	NN	treatment
groups	NNS	group
.	SENT	.
Data	NNS	datum
confirm	VBP	confirm
the	DT	the
good	JJ	good
safety	NN	safety
profile	NN	profile
of	IN	of
vedolizumab	NN	<unknown>
even	RB	even
though	IN	though
RTI	NP	RTI
were	VBD	be
more	RBR	more
frequent	JJ	frequent
in	IN	in
patients	NNS	patient
receiving	VBG	receive
vedolizumab	NN	<unknown>
and	CC	and
the	DT	the
risk	NN	risk
of	IN	of
URTIs	NP	<unknown>
was	VBD	be
significantly	RB	significantly
higher	JJR	high
in	IN	in
patients	NNS	patient
with	IN	with
UC	NP	UC
.	SENT	.
34670589/	CD	@card@
Longitudinal	JJ	longitudinal
ventilatory	JJ	ventilatory
ratio	NN	ratio
monitoring	NN	monitoring
for	IN	for
COVID-19	NP	<unknown>
:	:	:
its	PP$	its
potential	NN	potential
in	IN	in
predicting	VBG	predict
severity	NN	severity
and	CC	and
assessing	VBG	assess
treatment	NN	treatment
response	NN	response
33363440/	CD	@card@
Microfluidic	JJ	Microfluidic
devices	NNS	device
for	IN	for
the	DT	the
detection	NN	detection
of	IN	of
viruses	NNS	virus
:	:	:
aspects	NNS	aspect
of	IN	of
emergency	NN	emergency
fabrication	NN	fabrication
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
other	JJ	other
outbreaks	NNS	outbreak
Extensive	JJ	extensive
testing	NN	testing
of	IN	of
populations	NNS	population
against	IN	against
COVID-19	NP	<unknown>
has	VBZ	have
been	VBN	be
suggested	VBN	suggest
as	IN	as
a	DT	a
game-changer	NN	game-changer
quest	NN	quest
to	TO	to
control	VB	control
the	DT	the
spread	NN	spread
of	IN	of
this	DT	this
contagious	JJ	contagious
disease	NN	disease
and	CC	and
to	TO	to
avoid	VB	avoid
further	JJR	further
disruption	NN	disruption
in	IN	in
our	PP$	our
social	JJ	social
,	,	,
healthcare	NN	<unknown>
and	CC	and
economical	JJ	economical
systems	NNS	system
.	SENT	.
Nonetheless	RB	nonetheless
,	,	,
testing	VBG	test
millions	NNS	million
of	IN	of
people	NNS	people
for	IN	for
a	DT	a
new	JJ	new
virus	NN	virus
brings	VBZ	bring
about	RB	about
quite	PDT	quite
a	DT	a
few	JJ	few
challenges	NNS	challenge
.	SENT	.
The	DT	the
development	NN	development
of	IN	of
effective	JJ	effective
tests	NNS	test
for	IN	for
the	DT	the
new	JJ	new
coronavirus	NN	coronavirus
has	VBZ	have
become	VBN	become
a	DT	a
worldwide	JJ	worldwide
task	NN	task
that	WDT	that
relies	VBZ	rely
on	IN	on
recent	JJ	recent
discoveries	NNS	discovery
and	CC	and
lessons	NNS	lesson
learned	VBN	learn
from	IN	from
past	JJ	past
outbreaks	NNS	outbreak
.	SENT	.
In	IN	in
this	DT	this
work	NN	work
,	,	,
we	PP	we
review	VBP	review
the	DT	the
most	RBS	most
recent	JJ	recent
publications	NNS	publication
on	IN	on
microfluidics	NN	microfluidics
devices	NNS	device
for	IN	for
the	DT	the
detection	NN	detection
of	IN	of
viruses	NNS	virus
.	SENT	.
The	DT	the
topics	NNS	topic
of	IN	of
discussion	NN	discussion
include	VBP	include
different	JJ	different
detection	NN	detection
approaches	NNS	approach
,	,	,
methods	NNS	method
of	IN	of
signalling	VBG	signal
and	CC	and
fabrication	NN	fabrication
techniques	NNS	technique
.	SENT	.
Besides	IN	besides
the	DT	the
miniaturization	NN	miniaturization
of	IN	of
traditional	JJ	traditional
benchtop	NN	<unknown>
detection	NN	detection
assays	NNS	assay
,	,	,
approaches	NNS	approach
such	JJ	such
as	IN	as
electrochemical	JJ	electrochemical
analyses	NNS	analysis
,	,	,
field-effect	NN	field-effect
transistors	NNS	transistor
and	CC	and
resistive	JJ	resistive
pulse	NN	pulse
sensors	NNS	sensor
are	VBP	be
considered	VBN	consider
.	SENT	.
For	IN	for
emergency	NN	emergency
fabrication	NN	fabrication
of	IN	of
quick	JJ	quick
test	NN	test
kits	NNS	kit
,	,	,
the	DT	the
local	JJ	local
capabilities	NNS	capability
must	MD	must
be	VB	be
evaluated	VBN	evaluate
,	,	,
and	CC	and
the	DT	the
joint	JJ	joint
work	NN	work
of	IN	of
universities	NNS	university
,	,	,
industries	NNS	industry
,	,	,
and	CC	and
governments	NNS	government
seems	VBZ	seem
to	TO	to
be	VB	be
an	DT	an
unequivocal	JJ	unequivocal
necessity	NN	necessity
.	SENT	.
33660134/	CD	@card@
Automated	JJ	automated
Western	JJ	Western
immunoblotting	NN	<unknown>
detection	NN	detection
of	IN	of
anti-SARS-CoV-2	JJ	<unknown>
serum	NN	serum
antibodies	NNS	antibody
ELISA	NP	Elisa
and	CC	and
chemiluminescence	NN	chemiluminescence
serological	JJ	serological
assays	NNS	assay
for	IN	for
COVID-19	NP	<unknown>
are	VBP	be
currently	RB	currently
incorporating	VBG	incorporate
only	RB	only
one	CD	one
or	CC	or
two	CD	two
SARS-CoV-2	JJ	<unknown>
antigens	NNS	antigen
.	SENT	.
We	PP	we
developed	VBD	develop
an	DT	an
automated	JJ	automated
Western	JJ	Western
immunoblotting	NN	<unknown>
as	IN	as
a	DT	a
complementary	JJ	complementary
serologic	JJ	serologic
assay	NN	assay
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
JessTM	NP	<unknown>
Simple	JJ	simple
Western	JJ	Western
system	NN	system
,	,	,
an	DT	an
automated	JJ	automated
capillary-based	JJ	<unknown>
assay	NN	assay
,	,	,
was	VBD	be
used	VBN	use
,	,	,
incorporating	VBG	incorporate
an	DT	an
inactivated	VBN	inactivate
SARS-CoV-2	NP	<unknown>
lineage	NN	lineage
20a	JJ	<unknown>
strain	NN	strain
as	IN	as
the	DT	the
source	NN	source
of	IN	of
antigen	NN	antigen
,	,	,
and	CC	and
total	JJ	total
immunoglobulins	NNS	immunoglobulin
(	(	(
IgG	NP	IgG
,	,	,
IgM	NP	Igm
,	,	,
IgA	NP	IgA
)	)	)
detection	NN	detection
.	SENT	.
In	IN	in
total	NN	total
,	,	,
602	CD	@card@
sera	NN	sera
were	VBD	be
tested	VBN	test
including	VBG	include
223	CD	@card@
from	IN	from
RT-PCR-confirmed	NP	<unknown>
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
76	CD	@card@
from	IN	from
patients	NNS	patient
diagnosed	VBN	diagnose
with	IN	with
seasonal	JJ	seasonal
HCoVs	NP	<unknown>
and	CC	and
303	CD	@card@
from	IN	from
coronavirus-negative	JJ	coronavirus-negative
control	NN	control
sera	NN	sera
.	SENT	.
We	PP	we
also	RB	also
compared	VBD	compare
this	DT	this
assay	NN	assay
with	IN	with
the	DT	the
EUROIMMUN	NP	<unknown>
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
ELISA	NP	Elisa
kit	NN	kit
.	SENT	.
Among	IN	among
223	CD	@card@
sera	NN	sera
obtained	VBN	obtain
from	IN	from
RT-PCR-confirmed	NP	<unknown>
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
180/223	CD	@card@
(	(	(
81	CD	@card@
%	NN	%
)	)	)
exhibited	VBN	exhibit
reactivity	NN	reactivity
against	IN	against
the	DT	the
nucleocapsid	NN	nucleocapsid
and	CC	and
70/223	CD	@card@
(	(	(
31	CD	@card@
%	NN	%
)	)	)
against	IN	against
the	DT	the
spike	NN	spike
protein	NN	protein
.	SENT	.
Nucleocapsid	JJ	<unknown>
reactivity	NN	reactivity
was	VBD	be
further	RBR	further
detected	VBN	detect
in	IN	in
9/76	CD	@card@
(	(	(
14	CD	@card@
%	NN	%
)	)	)
samples	NNS	sample
collected	VBN	collect
from	IN	from
patients	NNS	patient
diagnosed	VBN	diagnose
with	IN	with
seasonal	JJ	seasonal
HCoVs	NP	<unknown>
and	CC	and
in	IN	in
15/303	CD	@card@
(	(	(
5	CD	@card@
%	NN	%
)	)	)
coronavirus-negative	JJ	coronavirus-negative
control	NN	control
samples	NNS	sample
.	SENT	.
In	IN	in
the	DT	the
subset	NN	subset
of	IN	of
sera	NN	sera
collected	VBD	collect
more	JJR	more
than	IN	than
2	CD	@card@
weeks	NNS	week
after	IN	after
the	DT	the
onset	NN	onset
of	IN	of
symptoms	NNS	symptom
,	,	,
the	DT	the
sensitivity	NN	sensitivity
was	VBD	be
94	CD	@card@
%	NN	%
and	CC	and
the	DT	the
specificity	NN	specificity
93	CD	@card@
%	NN	%
,	,	,
the	DT	the
latter	JJ	latter
value	NN	value
probably	RB	probably
reflecting	VBG	reflect
cross-reactivity	NN	cross-reactivity
of	IN	of
SARS-CoV-2	NP	<unknown>
with	IN	with
other	JJ	other
coronaviruses	NNS	coronavirus
.	SENT	.
The	DT	the
automated	JJ	automated
Western	JJ	Western
immunoblotting	NN	<unknown>
presented	VBD	present
a	DT	a
substantial	JJ	substantial
agreement	NN	agreement
(	(	(
90	CD	@card@
%	NN	%
)	)	)
with	IN	with
the	DT	the
compared	VBN	compare
ELISA	NP	Elisa
(	(	(
Cohen	NP	Cohen
's	POS	's
Kappa=0.64	NP	<unknown>
)	)	)
.	SENT	.
Automated	JJ	automated
Western	JJ	Western
immunoblotting	NN	<unknown>
may	MD	may
be	VB	be
used	VBN	use
as	IN	as
a	DT	a
second	JJ	second
line	NN	line
test	NN	test
to	TO	to
monitor	VB	monitor
exposure	NN	exposure
of	IN	of
people	NNS	people
to	TO	to
HCoVs	NP	<unknown>
including	VBG	include
SARS-CoV-2	NP	<unknown>
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1007/s10096-021-04203-8	JJ	10.1007/s@card@
.	SENT	.
34584327/	CD	@card@
Effects	NNS	effect
of	IN	of
social	JJ	social
position	NN	position
and	CC	and
household	NN	household
affordances	NNS	affordance
on	IN	on
COVID-19	NP	<unknown>
lockdown	NN	<unknown>
resilience	NN	resilience
and	CC	and
coping	VBG	cope
In	IN	in
France	NP	France
,	,	,
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
ensuing	VBG	ensue
lockdown	NN	<unknown>
measures	NNS	measure
have	VBP	have
created	VBN	create
unprecedented	JJ	unprecedented
circumstances	NNS	circumstance
that	WDT	that
increase	VBP	increase
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
,	,	,
thus	RB	thus
leading	VBG	lead
individuals	NNS	individual
experiencing	VBG	experience
home	NN	home
confinement	NN	confinement
to	TO	to
adopt	VB	adopt
various	JJ	various
coping	VBG	cope
strategies	NNS	strategy
that	WDT	that
contribute	VBP	contribute
to	TO	to
building	NN	building
resilience	NN	resilience
.	SENT	.
Given	VBN	give
the	DT	the
novelty	NN	novelty
and	CC	and
recency	NN	recency
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
lockdown	NN	<unknown>
,	,	,
factors	NNS	factor
of	IN	of
coping	VBG	cope
and	CC	and
resilience	NN	resilience
in	IN	in
this	DT	this
specific	JJ	specific
context	NN	context
of	IN	of
home	NN	home
confinement	NN	confinement
remain	VBP	remain
undefined	JJ	undefined
.	SENT	.
Based	VBN	base
on	IN	on
some	DT	some
recent	JJ	recent
observations	NNS	observation
,	,	,
we	PP	we
conducted	VBD	conduct
a	DT	a
study	NN	study
on	IN	on
a	DT	a
convenience	NN	convenience
sample	NN	sample
in	IN	in
France	NP	France
(	(	(
N	NP	N
=	SYM	=
809	CD	@card@
)	)	)
in	IN	in
order	NN	order
to	TO	to
investigate	VB	investigate
two	CD	two
potential	JJ	potential
factors	NNS	factor
of	IN	of
lockdown	JJ	<unknown>
resilience	NN	resilience
and	CC	and
coping	VBG	cope
:	:	:
social	JJ	social
position	NN	position
and	CC	and
household	NN	household
affordances	NNS	affordance
,	,	,
while	IN	while
also	RB	also
exploring	VBG	explore
some	DT	some
complementary	JJ	complementary
hypotheses	NNS	hypothesis
based	VBN	base
on	IN	on
the	DT	the
literature	NN	literature
.	SENT	.
Social	JJ	social
position	NN	position
and	CC	and
household	NN	household
affordances	NNS	affordance
were	VBD	be
identified	VBN	identify
as	IN	as
significant	JJ	significant
predictors	NNS	predictor
of	IN	of
lockdown	JJ	<unknown>
coping	NN	coping
and	CC	and
resilience	NN	resilience
,	,	,
and	CC	and
low	JJ	low
social	JJ	social
position	NN	position
was	VBD	be
found	VBN	find
to	TO	to
coincide	VB	coincide
with	IN	with
less	JJR	less
social	JJ	social
support	NN	support
coping	VBG	cope
strategies	NNS	strategy
.	SENT	.
Results	NNS	result
are	VBP	be
discussed	VBN	discuss
in	IN	in
relation	NN	relation
to	TO	to
the	DT	the
theory	NN	theory
and	CC	and
the	DT	the
limits	NNS	limit
identified	VBN	identify
in	IN	in
this	DT	this
study	NN	study
.	SENT	.
Recommendations	NNS	recommendation
are	VBP	be
made	VBN	make
for	IN	for
potential	JJ	potential
second	JJ	second
waves	NNS	wave
of	IN	of
COVID-19	NP	<unknown>
spread	NN	spread
or	CC	or
similar	JJ	similar
pandemics	NNS	pandemic
in	IN	in
the	DT	the
future	NN	future
.	SENT	.
33587790/	CD	@card@
COVID-19	NP	<unknown>
and	CC	and
how	WRB	how
the	DT	the
wearing	VBG	wear
of	IN	of
face	NN	face
coverings	NNS	covering
can	MD	can
affect	VB	affect
those	DT	those
with	IN	with
an	DT	an
experience	NN	experience
of	IN	of
trauma	NN	trauma
With	IN	with
the	DT	the
ongoing	JJ	ongoing
and	CC	and
possible	JJ	possible
evolving	VBG	evolve
use	NN	use
of	IN	of
face	NN	face
coverings	NNS	covering
as	IN	as
a	DT	a
public	JJ	public
health	NN	health
protection	NN	protection
measure	NN	measure
against	IN	against
the	DT	the
transmission	NN	transmission
of	IN	of
COVID-19	NP	<unknown>
,	,	,
this	DT	this
is	VBZ	be
likely	JJ	likely
to	TO	to
be	VB	be
an	DT	an
ongoing	JJ	ongoing
challenge	NN	challenge
for	IN	for
those	DT	those
who	WP	who
find	VBP	find
their	PP$	their
use	NN	use
challenging	VBG	challenge
.	SENT	.
The	DT	the
wearing	VBG	wear
of	IN	of
face	NN	face
coverings	NNS	covering
following	VBG	follow
trauma	NN	trauma
is	VBZ	be
likely	JJ	likely
to	TO	to
be	VB	be
of	IN	of
ongoing	JJ	ongoing
relevance	NN	relevance
,	,	,
making	VBG	make
this	DT	this
an	DT	an
area	NN	area
that	WDT	that
would	MD	would
benefit	VB	benefit
from	IN	from
further	JJR	further
research	NN	research
.	SENT	.
The	DT	the
authors	NNS	author
present	VBP	present
their	PP$	their
personal	JJ	personal
and	CC	and
professional	JJ	professional
experiences	NNS	experience
as	IN	as
a	DT	a
means	NN	means
of	IN	of
highlighting	VBG	highlight
the	DT	the
difficulties	NNS	difficulty
that	WDT	that
can	MD	can
be	VB	be
faced	VBN	face
as	IN	as
a	DT	a
result	NN	result
of	IN	of
the	DT	the
use	NN	use
of	IN	of
face	NN	face
coverings	NNS	covering
.	SENT	.
The	DT	the
window	NN	window
of	IN	of
tolerance	NN	tolerance
helps	VBZ	help
to	TO	to
understand	VB	understand
the	DT	the
difficulties	NNS	difficulty
that	WDT	that
can	MD	can
be	VB	be
caused	VBN	cause
by	IN	by
wearing	VBG	wear
face	NN	face
coverings	NNS	covering
and	CC	and
provides	VBZ	provide
a	DT	a
visual	JJ	visual
means	NN	means
of	IN	of
conceptualizing	VBG	conceptualize
the	DT	the
cognitive	JJ	cognitive
,	,	,
behavioural	JJ	<unknown>
,	,	,
physiological	JJ	physiological
and	CC	and
emotional	JJ	emotional
reactions	NNS	reaction
that	WDT	that
can	MD	can
occur	VB	occur
as	IN	as
a	DT	a
result	NN	result
of	IN	of
their	PP$	their
use	NN	use
.	SENT	.
This	DT	this
paper	NN	paper
provides	VBZ	provide
an	DT	an
awareness	NN	awareness
of	IN	of
the	DT	the
link	NN	link
between	IN	between
trauma	NN	trauma
and	CC	and
the	DT	the
wearing	VBG	wear
of	IN	of
face	NN	face
coverings	NNS	covering
,	,	,
and	CC	and
how	WRB	how
their	PP$	their
use	NN	use
could	MD	could
be	VB	be
re-traumatizing	VBG	re-traumatize
for	IN	for
those	DT	those
accessing	VBG	access
services	NNS	service
.	SENT	.
This	DT	this
topic	NN	topic
is	VBZ	be
relevant	JJ	relevant
across	IN	across
all	DT	all
sectors	NNS	sector
where	WRB	where
it	PP	it
is	VBZ	be
only	RB	only
just	RB	just
beginning	VBG	begin
to	TO	to
be	VB	be
acknowledged	VBN	acknowledge
that	IN	that
for	IN	for
many	JJ	many
,	,	,
particularly	RB	particularly
those	DT	those
with	IN	with
experiences	NNS	experience
of	IN	of
interpersonal	JJ	interpersonal
trauma	NN	trauma
,	,	,
difficulties	NNS	difficulty
can	MD	can
arise	VB	arise
due	JJ	due
to	TO	to
the	DT	the
use	NN	use
of	IN	of
face	NN	face
coverings	NNS	covering
.	SENT	.
The	DT	the
sharing	NN	sharing
of	IN	of
grounding	VBG	ground
techniques	NNS	technique
and	CC	and
an	DT	an
introduction	NN	introduction
to	TO	to
the	DT	the
window	NN	window
of	IN	of
tolerance	NN	tolerance
provides	VBZ	provide
a	DT	a
means	NN	means
of	IN	of
collaboratively	RB	<unknown>
developing	VBG	develop
skills	NNS	skill
and	CC	and
developing	VBG	develop
a	DT	a
shared	VBN	share
understanding	NN	understanding
of	IN	of
the	DT	the
difficulties	NNS	difficulty
associated	VBN	associate
with	IN	with
the	DT	the
use	NN	use
of	IN	of
face	NN	face
coverings	NNS	covering
.	SENT	.
32396251/	CD	@card@
Dermatologic	JJ	<unknown>
treatments	NNS	treatment
in	IN	in
the	DT	the
era	NN	era
of	IN	of
COVID-19	NP	<unknown>
pandemic:Data	NNS	<unknown>
and	CC	and
Hypothesis	NN	hypothesis
35265332/	CD	@card@
Affordable	JJ	affordable
IgY-based	JJ	<unknown>
antiviral	JJ	antiviral
prophylaxis	NN	prophylaxis
for	IN	for
resource-limited	JJ	resource-limited
settings	NNS	setting
to	TO	to
address	VB	address
epidemic	NN	epidemic
and	CC	and
pandemic	JJ	pandemic
risks	NNS	risk
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
caused	VBN	cause
by	IN	by
SARS-CoV-2	NP	<unknown>
exposed	VBD	expose
a	DT	a
global	JJ	global
problem	NN	problem
,	,	,
as	IN	as
highly	RB	highly
effective	JJ	effective
vaccines	NNS	vaccine
are	VBP	be
challenging	VBG	challenge
to	TO	to
produce	VB	produce
and	CC	and
distribute	VB	distribute
,	,	,
particularly	RB	particularly
in	IN	in
regions	NNS	region
with	IN	with
limited	JJ	limited
resources	NNS	resource
and	CC	and
funding	NN	funding
.	SENT	.
As	IN	as
an	DT	an
alternative	NN	alternative
,	,	,
immunoglobulins	NNS	immunoglobulin
produced	VBN	produce
in	IN	in
eggs	NNS	egg
of	IN	of
immunized	VBN	immunize
hens	NNS	hen
(	(	(
IgY	NP	IgY
)	)	)
can	MD	can
be	VB	be
a	DT	a
simple	JJ	simple
and	CC	and
inexpensive	JJ	inexpensive
source	NN	source
for	IN	for
a	DT	a
topical	JJ	topical
and	CC	and
temporary	JJ	temporary
prophylaxis	NN	prophylaxis
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
developed	VBD	develop
a	DT	a
method	NN	method
to	TO	to
extract	VB	extract
and	CC	and
purify	VB	purify
IgY	NP	IgY
antibodies	NNS	antibody
from	IN	from
egg	NN	egg
yolks	NNS	yolk
of	IN	of
hens	NNS	hen
immunized	VBN	immunize
against	IN	against
viral	JJ	viral
pathogen-derived	JJ	<unknown>
proteins	NNS	protein
using	VBG	use
low-cost	JJ	low-cost
,	,	,
readily	RB	readily
available	JJ	available
materials	NNS	material
,	,	,
for	IN	for
use	NN	use
in	IN	in
resource-limited	JJ	resource-limited
settings	NNS	setting
.	SENT	.
Existing	VBG	exist
protocols	NNS	protocol
for	IN	for
IgY	NP	IgY
purification	NN	purification
and	CC	and
equipment	NN	equipment
were	VBD	be
modified	VBN	modify
,	,	,
including	VBG	include
extraction	NN	extraction
from	IN	from
yolks	NNS	yolk
and	CC	and
separation	NN	separation
of	IN	of
water-soluble	JJ	water-soluble
IgY	NP	IgY
using	VBG	use
common	JJ	common
household	NN	household
reagents	NNS	reagent
and	CC	and
tools	NNS	tool
.	SENT	.
A	DT	a
replacement	NN	replacement
for	IN	for
a	DT	a
commercial	JJ	commercial
centrifuge	NN	centrifuge
was	VBD	be
developed	VBN	develop
,	,	,
using	VBG	use
a	DT	a
home	NN	home
food	NN	food
processor	NN	processor
equipped	VBN	equip
with	IN	with
a	DT	a
3D	JJ	3D
printed	JJ	printed
adapter	NN	adapter
to	TO	to
enable	VB	enable
IgY	NP	IgY
precipitation	NN	precipitation
.	SENT	.
IgY	NP	IgY
purification	NN	purification
was	VBD	be
verified	VBN	verify
using	VBG	use
standard	JJ	standard
gel	NN	gel
electrophoresis	NN	<unknown>
and	CC	and
Western	JJ	Western
blot	NN	blot
analyses	NNS	analysis
.	SENT	.
We	PP	we
developed	VBD	develop
a	DT	a
step-by-step	NN	step-by-step
protocol	NN	protocol
for	IN	for
IgY	NP	IgY
purification	NN	purification
for	IN	for
two	CD	two
settings	NNS	setting
in	IN	in
low-	NN	low-
and	CC	and
middle-income	JJ	middle-income
countries	NNS	country
(	(	(
LMIC	NP	<unknown>
)	)	)
:	:	:
a	DT	a
local	JJ	local
laboratory	NN	laboratory
,	,	,
where	WRB	where
commercial	JJ	commercial
centrifuges	NNS	centrifuge
are	VBP	be
available	JJ	available
,	,	,
or	CC	or
a	DT	a
more	RBR	more
rural	JJ	rural
setting	NN	setting
,	,	,
where	WRB	where
an	DT	an
alternative	NN	alternative
for	IN	for
expensive	JJ	expensive
centrifuges	NNS	centrifuge
can	MD	can
be	VB	be
used	VBN	use
.	SENT	.
Gel	NN	gel
electrophoresis	NN	<unknown>
and	CC	and
Western	JJ	Western
blot	NN	blot
analyses	NNS	analysis
confirmed	VBD	confirm
that	IN	that
the	DT	the
method	NN	method
produced	VBD	produce
highly	RB	highly
enriched	VBN	enrich
IgY	NP	IgY
preparation	NN	preparation
;	:	;
each	DT	each
commercial	JJ	commercial
egg	NN	egg
produced	VBN	produce
~	SYM	~
90	CD	@card@
mg	NN	mg
of	IN	of
IgY	NP	IgY
.	SENT	.
We	PP	we
also	RB	also
designed	VBD	design
a	DT	a
kit	NN	kit
for	IN	for
IgY	NP	IgY
production	NN	production
in	IN	in
these	DT	these
two	CD	two
settings	NNS	setting
and	CC	and
provided	VBD	provide
a	DT	a
cost	NN	cost
estimate	NN	estimate
of	IN	of
the	DT	the
kit	NN	kit
.	SENT	.
IgY	NP	IgY
purified	VBD	purify
from	IN	from
eggs	NNS	egg
of	IN	of
immunized	VBN	immunize
local	JJ	local
hens	NNS	hen
can	MD	can
offer	VB	offer
a	DT	a
fast	JJ	fast
and	CC	and
affordable	JJ	affordable
prophylaxis	NN	prophylaxis
,	,	,
provided	VBD	provide
that	IN	that
purification	NN	purification
can	MD	can
be	VB	be
performed	VBN	perform
in	IN	in
a	DT	a
resource-limited	JJ	resource-limited
setting	NN	setting
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
created	VBD	create
a	DT	a
low-cost	JJ	low-cost
method	NN	method
that	WDT	that
can	MD	can
be	VB	be
used	VBN	use
anywhere	RB	anywhere
where	WRB	where
electricity	NN	electricity
is	VBZ	be
available	JJ	available
using	VBG	use
inexpensive	JJ	inexpensive
,	,	,
readily	RB	readily
available	JJ	available
materials	NNS	material
in	IN	in
place	NN	place
of	IN	of
costly	JJ	costly
,	,	,
specialized	JJ	specialized
laboratory	NN	laboratory
equipment	NN	equipment
and	CC	and
chemicals	NNS	chemical
.	SENT	.
This	DT	this
procedure	NN	procedure
can	MD	can
readily	RB	readily
be	VB	be
used	VBN	use
now	RB	now
to	TO	to
make	VB	make
an	DT	an
anti-SARS-CoV-2	JJ	<unknown>
prophylaxis	NN	prophylaxis
in	IN	in
areas	NNS	area
where	WRB	where
vaccines	NNS	vaccine
are	VBP	be
unavailable	JJ	unavailable
,	,	,
and	CC	and
can	MD	can
be	VB	be
modified	VBN	modify
to	TO	to
combat	VB	combat
future	JJ	future
threats	NNS	threat
from	IN	from
viral	JJ	viral
epidemics	NNS	epidemic
and	CC	and
pandemics	NNS	pandemic
.	SENT	.
35281394/	CD	@card@
Emotional	JJ	emotional
difficulties	NNS	difficulty
in	IN	in
pregnant	JJ	pregnant
females	NNS	female
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
:	:	:
A	DT	a
cross-sectional	JJ	cross-sectional
study	NN	study
from	IN	from
South	NP	South
Kashmir	NP	Kashmir
,	,	,
India	NP	India
It	PP	it
is	VBZ	be
evident	JJ	evident
that	IN	that
the	DT	the
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
pandemic	NN	pandemic
inevitably	RB	inevitably
resulted	VBN	result
in	IN	in
increased	VBN	increase
stress	NN	stress
and	CC	and
anxiety	NN	anxiety
in	IN	in
the	DT	the
general	JJ	general
population	NN	population
.	SENT	.
Pregnancy	NN	pregnancy
is	VBZ	be
a	DT	a
challenging	JJ	challenging
period	NN	period
,	,	,
and	CC	and
COVID-19	NP	<unknown>
has	VBZ	have
added	VBN	add
risk	NN	risk
to	TO	to
women	NNS	woman
pregnant	JJ	pregnant
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
present	JJ	present
study	NN	study
was	VBD	be
aimed	VBN	aim
to	TO	to
assess	VB	assess
the	DT	the
emotional	JJ	emotional
difficulties	NNS	difficulty
in	IN	in
pregnant	JJ	pregnant
females	NNS	female
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
current	JJ	current
study	NN	study
estimated	VBD	estimate
the	DT	the
prevalence	NN	prevalence
of	IN	of
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
among	IN	among
63	CD	@card@
pregnant	JJ	pregnant
ladies	NNS	lady
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
study	NN	study
was	VBD	be
conducted	VBN	conduct
in	IN	in
Child	NN	child
and	CC	and
Maternity	NN	maternity
Hospital	NN	hospital
of	IN	of
GMC	NP	GMC
Anantnag	NP	<unknown>
,	,	,
Kashmir	NP	Kashmir
,	,	,
India	NP	India
,	,	,
from	IN	from
April	NP	April
to	TO	to
December	NP	December
2020	CD	@card@
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
63	CD	@card@
pregnant	JJ	pregnant
females	NNS	female
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
participated	VBD	participate
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
The	DT	the
COVID-positive	JJ	COVID-positive
pregnant	JJ	pregnant
ladies	NNS	lady
were	VBD	be
interviewed	VBN	interview
in	IN	in
the	DT	the
outpatient	NN	outpatient
department	NN	department
of	IN	of
the	DT	the
child	NN	child
and	CC	and
maternity	NN	maternity
clinic	NN	clinic
2	CD	@card@
weeks	NNS	week
after	IN	after
the	DT	the
infection	NN	infection
.	SENT	.
The	DT	the
interview	NN	interview
scale	NN	scale
used	VBN	use
was	VBD	be
Depression	NP	Depression
,	,	,
Anxiety	NN	anxiety
,	,	,
and	CC	and
Stress	VBP	stress
Scale-21	NP	<unknown>
.	SENT	.
The	DT	the
data	NNS	datum
were	VBD	be
analyzed	VBN	analyze
using	VBG	use
Chi-square	NP	Chi-square
test	NN	test
and	CC	and
Fisher	NP	Fisher
's	POS	's
exact	JJ	exact
test	NN	test
.	SENT	.
We	PP	we
found	VBD	find
that	IN	that
the	DT	the
mean	JJ	mean
age	NN	age
of	IN	of
participants	NNS	participant
was	VBD	be
33.5	CD	@card@
+-	NN	<unknown>
7.4	CD	@card@
.	SENT	.
We	PP	we
found	VBD	find
that	IN	that
38.1	CD	@card@
%	NN	%
of	IN	of
the	DT	the
females	NNS	female
had	VBD	have
positive	JJ	positive
bad	JJ	bad
obstetric	JJ	obstetric
history	NN	history
.	SENT	.
The	DT	the
prevalence	NN	prevalence
of	IN	of
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
was	VBD	be
33.32	CD	@card@
%	NN	%
,	,	,
50.83	CD	@card@
%	NN	%
,	,	,
and	CC	and
60.3	CD	@card@
%	NN	%
,	,	,
respectively	RB	respectively
.	SENT	.
In	IN	in
correlation	NN	correlation
analysis	NN	analysis
,	,	,
notably	RB	notably
bad	JJ	bad
obstetric	JJ	obstetric
history	NN	history
and	CC	and
working	VBG	work
females	NNS	female
were	VBD	be
significant	JJ	significant
independent	JJ	independent
factors	NNS	factor
for	IN	for
higher	JJR	high
levels	NNS	level
of	IN	of
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
.	SENT	.
The	DT	the
depression	NN	depression
was	VBD	be
also	RB	also
found	VBN	find
more	JJR	more
in	IN	in
literate	JJ	literate
females	NNS	female
and	CC	and
the	DT	the
third	JJ	third
trimester	NN	trimester
.	SENT	.
The	DT	the
study	NN	study
indicates	VBZ	indicate
high	JJ	high
levels	NNS	level
of	IN	of
depression	NN	depression
,	,	,
anxiety	NN	anxiety
,	,	,
and	CC	and
stress	NN	stress
in	IN	in
pregnant	JJ	pregnant
females	NNS	female
who	WP	who
tested	VBD	test
positive	JJ	positive
for	IN	for
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
emotional	JJ	emotional
difficulties	NNS	difficulty
were	VBD	be
found	VBN	find
to	TO	to
be	VB	be
higher	JJR	high
in	IN	in
educated	VBN	educate
and	CC	and
working	VBG	work
females	NNS	female
.	SENT	.
The	DT	the
bad	JJ	bad
obstetric	JJ	obstetric
history	NN	history
was	VBD	be
found	VBN	find
to	TO	to
be	VB	be
an	DT	an
independent	JJ	independent
factor	NN	factor
for	IN	for
higher	JJR	high
levels	NNS	level
of	IN	of
emotional	JJ	emotional
difficulties	NNS	difficulty
in	IN	in
COVID-positive	JJ	COVID-positive
pregnant	JJ	pregnant
females	NNS	female
.	SENT	.
This	DT	this
calls	NNS	call
for	IN	for
extra	JJ	extra
measures	NNS	measure
to	TO	to
promote	VB	promote
the	DT	the
mental	JJ	mental
health	NN	health
and	CC	and
resilience	NN	resilience
of	IN	of
pregnant	JJ	pregnant
females	NNS	female
,	,	,
especially	RB	especially
during	IN	during
a	DT	a
crisis	NN	crisis
.	SENT	.
32530889/	CD	@card@
Prevalence	NN	prevalence
of	IN	of
Covid-19	NP	<unknown>
infection	NN	infection
and	CC	and
Subsequent	JJ	subsequent
Cohorting	NN	<unknown>
in	IN	in
a	DT	a
Residential	JJ	residential
Substance	NN	substance
Use	NP	Use
Treatment	NP	Treatment
Program	NP	Program
in	IN	in
Boston	NP	Boston
,	,	,
MA	NN	ma
The	DT	the
global	JJ	global
pandemic	NN	pandemic
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
Covid-19	NP	<unknown>
)	)	)
may	MD	may
disproportionately	RB	disproportionately
affect	VB	affect
persons	NNS	person
in	IN	in
congregate	JJ	congregate
settings	NNS	setting
,	,	,
including	VBG	include
those	DT	those
in	IN	in
residential	JJ	residential
substance	NN	substance
use	NN	use
treatment	NN	treatment
facilities	NNS	facility
.	SENT	.
To	TO	to
limit	VB	limit
the	DT	the
spread	NN	spread
of	IN	of
SARS-CoV-2	NP	<unknown>
through	IN	through
congregate	JJ	congregate
settings	NNS	setting
,	,	,
universal	JJ	universal
testing	NN	testing
may	MD	may
be	VB	be
necessary	JJ	necessary
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
determine	VB	determine
the	DT	the
point	NN	point
prevalence	NN	prevalence
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
a	DT	a
residential	JJ	residential
treatment	NN	treatment
program	NN	program
setting	NN	setting
and	CC	and
to	TO	to
understand	VB	understand
the	DT	the
unique	JJ	unique
challenges	NNS	challenge
of	IN	of
Covid-19	NP	<unknown>
transmission	NN	transmission
in	IN	in
this	DT	this
setting	NN	setting
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
case	NN	case
series	NN	series
of	IN	of
SARS-CoV-2	NP	<unknown>
rT-PCR	NN	<unknown>
testing	NN	testing
via	IN	via
nasopharyngeal	JJ	nasopharyngeal
in	IN	in
a	DT	a
residential	JJ	residential
substance	NN	substance
use	NN	use
treatment	NN	treatment
program	NN	program
for	IN	for
women	NNS	woman
in	IN	in
Boston	NP	Boston
.	SENT	.
Staff	NN	staff
and	CC	and
residents	NNS	resident
of	IN	of
the	DT	the
treatment	NN	treatment
program	NN	program
were	VBD	be
tested	VBN	test
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
was	VBD	be
SARS-CoV-2	NP	<unknown>
test	NN	test
result	NN	result
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
31	CD	@card@
residents	NNS	resident
and	CC	and
staff	NN	staff
were	VBD	be
tested	VBN	test
.	SENT	.
Twenty-seven	JJ	<unknown>
percent	NN	percent
(	(	(
6/22	CD	@card@
)	)	)
of	IN	of
the	DT	the
residents	NNS	resident
and	CC	and
44	CD	@card@
%	NN	%
(	(	(
4/9	CD	@card@
)	)	)
of	IN	of
staff	NN	staff
tested	VBD	test
positive	JJ	positive
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
All	DT	all
of	IN	of
the	DT	the
SARS-CoV-2	NP	<unknown>
positive	JJ	positive
residents	NNS	resident
resided	VBN	reside
in	IN	in
the	DT	the
same	JJ	same
residential	JJ	residential
unit	NN	unit
.	SENT	.
Two	CD	two
positive	JJ	positive
cases	NNS	case
resided	VBN	reside
together	RB	together
with	IN	with
two	CD	two
negative	JJ	negative
cases	NNS	case
in	IN	in
a	DT	a
4-person	JJ	<unknown>
room	NN	room
.	SENT	.
Two	CD	two
other	JJ	other
positive	JJ	positive
cases	NNS	case
resided	VBN	reside
together	RB	together
in	IN	in
a	DT	a
2-person	JJ	<unknown>
room	NN	room
.	SENT	.
One	CD	one
positive	JJ	positive
case	NN	case
resided	VBN	reside
with	IN	with
two	CD	two
negative	JJ	negative
cases	NNS	case
in	IN	in
a	DT	a
3-person	JJ	<unknown>
room	NN	room
.	SENT	.
One	CD	one
positive	JJ	positive
case	NN	case
resided	VBN	reside
with	IN	with
a	DT	a
negative	JJ	negative
case	NN	case
in	IN	in
a	DT	a
2-person	JJ	<unknown>
room	NN	room
.	SENT	.
Based	VBN	base
on	IN	on
test	NN	test
results	NNS	result
,	,	,
residents	NNS	resident
were	VBD	be
cohorted	VBN	<unknown>
by	IN	by
infection	NN	infection
status	NN	status
and	CC	and
continued	VBD	continue
to	TO	to
participate	VB	participate
in	IN	in
addiction	NN	addiction
treatment	NN	treatment
on-site	JJ	on-site
.	SENT	.
SARS-CoV-2	JJ	<unknown>
infection	NN	infection
was	VBD	be
common	JJ	common
among	IN	among
staff	NN	staff
and	CC	and
residents	NNS	resident
within	IN	within
a	DT	a
residential	JJ	residential
substance	NN	substance
use	NN	use
treatment	NN	treatment
program	NN	program
for	IN	for
women	NNS	woman
in	IN	in
Boston	NP	Boston
.	SENT	.
Universal	NP	Universal
SARS-CoV-2	NP	<unknown>
testing	NN	testing
in	IN	in
residential	JJ	residential
substance	NN	substance
use	NN	use
programs	NNS	program
can	MD	can
be	VB	be
instituted	VBN	institute
to	TO	to
reduce	VB	reduce
the	DT	the
risk	NN	risk
of	IN	of
further	JJR	further
transmission	NN	transmission
and	CC	and
continue	VB	continue
addiction	NN	addiction
treatment	NN	treatment
programming	NN	programming
when	WRB	when
accompanied	VBN	accompany
by	IN	by
adequate	JJ	adequate
space	NN	space
,	,	,
supplies	NNS	supply
,	,	,
and	CC	and
staffing	NN	staffing
.	SENT	.
33373651/	CD	@card@
Sofosbuvir/daclatasvir	NP	<unknown>
in	IN	in
the	DT	the
treatment	NN	treatment
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
:	:	:
a	DT	a
meta-analysis	NN	meta-analysis
35250739/	CD	@card@
Impact	NN	impact
of	IN	of
Face-Recognition-Based	JJ	<unknown>
Access	NP	Access
Control	NP	Control
System	NP	System
on	IN	on
College	NP	College
Students	NNS	student
'	POS	'
Sense	NN	sense
of	IN	of
School	NP	School
Identity	NN	identity
and	CC	and
Belonging	VBG	belong
During	IN	during
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
In	IN	in
the	DT	the
context	NN	context
of	IN	of
coronavirus	NN	coronavirus
pandemic	NN	pandemic
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
the	DT	the
face-recognition-based	JJ	<unknown>
access	NN	access
control	NN	control
system	NN	system
(	(	(
FACS	NP	<unknown>
)	)	)
has	VBZ	have
been	VBN	be
intensively	RB	intensively
adopted	VBN	adopt
to	TO	to
protect	VB	protect
students	NNS	student
'	POS	'
and	CC	and
teachers	NNS	teacher
'	POS	'
health	NN	health
and	CC	and
safety	NN	safety
in	IN	in
school	NN	school
.	SENT	.
However	RB	however
,	,	,
the	DT	the
impact	NN	impact
of	IN	of
FACS	NP	<unknown>
,	,	,
as	IN	as
a	DT	a
new	JJ	new
technology	NN	technology
,	,	,
on	IN	on
students	NNS	student
'	POS	'
attitude	NN	attitude
toward	IN	toward
accepting	VBG	accept
FACS	NP	<unknown>
has	VBZ	have
remained	VBN	remain
unknown	JJ	unknown
from	IN	from
the	DT	the
psychological	JJ	psychological
halo	NN	halo
effect	NN	effect
.	SENT	.
Drawn	VBN	draw
on	IN	on
"	``	"
halo	NN	halo
effect	NN	effect
"	''	"
theory	NN	theory
where	WRB	where
psychological	JJ	psychological
effects	NNS	effect
affect	VBP	affect
the	DT	the
sense	NN	sense
of	IN	of
social	JJ	social
identity	NN	identity
and	CC	and
belonging	NN	belonging
,	,	,
the	DT	the
present	JJ	present
study	NN	study
explored	VBD	explore
college	NN	college
students	NNS	student
'	POS	'
sense	NN	sense
of	IN	of
school	NN	school
identity	NN	identity
and	CC	and
belonging	VBG	belong
in	IN	in
using	VBG	use
FACS	NP	<unknown>
during	IN	during
COVID-19	NP	<unknown>
based	VBN	base
on	IN	on
the	DT	the
technology	NN	technology
acceptance	NN	acceptance
model	NN	model
(	(	(
TAM	NN	tam
)	)	)
.	SENT	.
Data	NNS	datum
collected	VBN	collect
from	IN	from
391	CD	@card@
college	NN	college
students	NNS	student
was	VBD	be
analyzed	VBN	analyze
using	VBG	use
SEM	NP	SEM
to	TO	to
verify	VB	verify
the	DT	the
relationship	NN	relationship
among	IN	among
perceived	VBN	perceive
usefulness	NN	usefulness
(	(	(
PU	NP	Pu
)	)	)
,	,	,
perceived	VBN	perceive
ease	NN	ease
of	IN	of
use	NN	use
(	(	(
PEU	NP	PEU
)	)	)
,	,	,
intention	NN	intention
to	TO	to
use	VB	use
(	(	(
IU	NP	IU
)	)	)
,	,	,
school	NN	school
identity	NN	identity
,	,	,
and	CC	and
school	NN	school
belonging	NN	belonging
.	SENT	.
The	DT	the
results	NNS	result
show	VBP	show
that	IN	that
PU	NP	Pu
and	CC	and
PEU	NP	PEU
can	MD	can
positively	RB	positively
predict	VB	predict
IU	NP	IU
,	,	,
and	CC	and
consequentially	RB	consequentially
can	MD	can
positively	RB	positively
predict	VB	predict
school	NN	school
identity	NN	identity
and	CC	and
school	NN	school
belonging	NN	belonging
.	SENT	.
Our	PP$	our
study	NN	study
expands	VBZ	expand
the	DT	the
application	NN	application
of	IN	of
halo	NN	halo
effect	NN	effect
theory	NN	theory
to	TO	to
study	VB	study
FACS	NP	<unknown>
acceptance	NN	acceptance
based	VBN	base
on	IN	on
TAM	NN	tam
,	,	,
and	CC	and
provides	VBZ	provide
strong	JJ	strong
evidence	NN	evidence
to	TO	to
support	VB	support
the	DT	the
effect	NN	effect
of	IN	of
school	NN	school
FACS	NP	<unknown>
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
The	DT	the
findings	NNS	finding
of	IN	of
this	DT	this
study	NN	study
also	RB	also
suggest	VBP	suggest
that	IN	that
FACS	NP	<unknown>
acceptance	NN	acceptance
can	MD	can
enhance	VB	enhance
students	NNS	student
'	POS	'
sense	NN	sense
of	IN	of
school	NN	school
identity	NN	identity
and	CC	and
belonging	VBG	belong
.	SENT	.
34786319/	CD	@card@
IoT	NP	<unknown>
MEMS	NNS	mem
:	:	:
IoT-Based	JJ	<unknown>
Paradigm	NN	paradigm
for	IN	for
Medical	NP	Medical
Equipment	NP	Equipment
Management	NP	Management
Systems	NPS	Systems
of	IN	of
ICUs	NP	<unknown>
in	IN	in
Light	NP	Light
of	IN	of
COVID-19	NP	<unknown>
Outbreak	NN	outbreak
Recently	RB	recently
,	,	,
COVID-19	NP	<unknown>
has	VBZ	have
infected	VBN	infect
a	DT	a
lot	NN	lot
of	IN	of
people	NNS	people
around	IN	around
the	DT	the
world	NN	world
.	SENT	.
The	DT	the
healthcare	NN	<unknown>
systems	NNS	system
are	VBP	be
overwhelmed	VBN	overwhelm
because	IN	because
of	IN	of
this	DT	this
virus	NN	virus
.	SENT	.
The	DT	the
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
as	IN	as
a	DT	a
part	NN	part
of	IN	of
the	DT	the
healthcare	NN	<unknown>
sector	NN	sector
has	VBZ	have
faced	VBN	face
several	JJ	several
challenges	NNS	challenge
due	JJ	due
to	TO	to
the	DT	the
poor	JJ	poor
information	NN	information
quality	NN	quality
provided	VBN	provide
by	IN	by
current	JJ	current
ICUs	NP	<unknown>
'	POS	'
medical	JJ	medical
equipment	NN	equipment
management	NN	management
.	SENT	.
IoT	NP	<unknown>
has	VBZ	have
raised	VBN	raise
the	DT	the
ability	NN	ability
for	IN	for
vital	JJ	vital
data	NNS	datum
transfer	NN	transfer
in	IN	in
the	DT	the
healthcare	NN	<unknown>
sector	NN	sector
of	IN	of
the	DT	the
new	JJ	new
century	NN	century
.	SENT	.
However	RB	however
,	,	,
most	JJS	most
of	IN	of
the	DT	the
existing	JJ	existing
paradigms	NNS	paradigm
have	VBP	have
adopted	VBN	adopt
IoT	NP	<unknown>
technology	NN	technology
to	TO	to
track	VB	track
patients	NNS	patient
'	POS	'
health	NN	health
statuses	NNS	status
.	SENT	.
Therefore	RB	therefore
,	,	,
there	EX	there
is	VBZ	be
a	DT	a
lack	NN	lack
of	IN	of
understanding	VBG	understand
on	IN	on
how	WRB	how
to	TO	to
utilize	VB	utilize
such	JJ	such
technology	NN	technology
for	IN	for
ICUs	NP	<unknown>
'	POS	'
medical	JJ	medical
equipment	NN	equipment
management	NN	management
.	SENT	.
This	DT	this
paper	NN	paper
proposes	VBZ	propose
a	DT	a
novel	JJ	novel
IoT-based	JJ	<unknown>
paradigm	NN	paradigm
called	VBN	call
IoT	NP	<unknown>
Based	VBN	base
Paradigm	NN	paradigm
for	IN	for
Medical	NP	Medical
Equipment	NP	Equipment
Management	NP	Management
Systems	NPS	Systems
(	(	(
IoT	NP	<unknown>
MEMS	NNS	mem
)	)	)
to	TO	to
manage	VB	manage
medical	JJ	medical
equipment	NN	equipment
of	IN	of
ICUs	NP	<unknown>
efficiently	RB	efficiently
.	SENT	.
It	PP	it
employs	VBZ	employ
IoT	NP	<unknown>
technology	NN	technology
to	TO	to
enhance	VB	enhance
the	DT	the
information	NN	information
flow	NN	flow
between	IN	between
medical	JJ	medical
equipment	NN	equipment
management	NN	management
systems	NNS	system
(	(	(
THIS	DT	this
)	)	)
and	CC	and
ICUs	NP	<unknown>
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
to	TO	to
ensure	VB	ensure
the	DT	the
highest	JJS	high
level	NN	level
of	IN	of
transparency	NN	transparency
and	CC	and
fairness	NN	fairness
in	IN	in
reallocating	VBG	reallocate
medical	JJ	medical
equipment	NN	equipment
.	SENT	.
We	PP	we
described	VBD	describe
in	IN	in
detail	NN	detail
the	DT	the
theoretical	JJ	theoretical
and	CC	and
practical	JJ	practical
aspects	NNS	aspect
of	IN	of
IoT	NP	<unknown>
MEMS	NNS	mem
.	SENT	.
Adopting	VBG	adopt
IoT	NP	<unknown>
MEMS	NNS	mem
will	MD	will
enhance	VB	enhance
hospital	NN	hospital
capacity	NN	capacity
and	CC	and
capability	NN	capability
in	IN	in
mitigating	VBG	mitigate
COVID-19	NP	<unknown>
efficiently	RB	efficiently
.	SENT	.
It	PP	it
will	MD	will
also	RB	also
positively	RB	positively
influence	VB	influence
the	DT	the
information	NN	information
quality	NN	quality
of	IN	of
(	(	(
THIS	DT	this
)	)	)
and	CC	and
strengthen	VB	strengthen
trust	NN	trust
and	CC	and
transparency	NN	transparency
among	IN	among
the	DT	the
stakeholders	NNS	stakeholder
.	SENT	.
34568576/	CD	@card@
Characterization	NN	characterization
of	IN	of
myocardial	JJ	myocardial
injury	NN	injury
in	IN	in
a	DT	a
cohort	NN	cohort
of	IN	of
patients	NNS	patient
with	IN	with
SARS-CoV-2	NP	<unknown>
infection	NN	infection
Myocardial	JJ	myocardial
injury	NN	injury
has	VBZ	have
been	VBN	be
identified	VBN	identify
as	IN	as
a	DT	a
common	JJ	common
complication	NN	complication
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
recent	JJ	recent
research	NN	research
has	VBZ	have
serious	JJ	serious
limitations	NNS	limitation
,	,	,
such	JJ	such
as	IN	as
non-guideline	JJ	<unknown>
definition	NN	definition
of	IN	of
myocardial	JJ	myocardial
injury	NN	injury
,	,	,
heterogenicity	NN	<unknown>
of	IN	of
troponin	NN	<unknown>
sampling	NN	sampling
or	CC	or
very	RB	very
short-term	JJ	short-term
follow-up	NN	follow-up
.	SENT	.
Using	VBG	use
data	NNS	datum
from	IN	from
a	DT	a
large	JJ	large
European	JJ	European
cohort	NN	cohort
,	,	,
we	PP	we
aimed	VBD	aim
to	TO	to
overcome	VB	overcome
these	DT	these
pitfalls	NNS	pitfall
and	CC	and
adequately	RB	adequately
characterize	VB	characterize
myocardial	JJ	myocardial
damage	NN	damage
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
Consecutive	JJ	consecutive
patients	NNS	patient
with	IN	with
confirmed	JJ	confirmed
SARS-CoV-2	NP	<unknown>
infection	NN	infection
and	CC	and
available	JJ	available
high-sensitive	JJ	high-sensitive
troponin	NN	<unknown>
I	PP	I
(	(	(
hs-TnI	NP	<unknown>
)	)	)
,	,	,
from	IN	from
March	NP	March
1st	JJ	1st
to	TO	to
April	NP	April
20th	JJ	20th
,	,	,
2020	CD	@card@
who	WP	who
completed	VBD	complete
at	IN	at
least	JJS	least
1-month	JJ	<unknown>
follow-up	NN	follow-up
or	CC	or
died	VBD	die
,	,	,
were	VBD	be
studied	VBN	study
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
918	CD	@card@
patients	NNS	patient
(	(	(
mean	JJ	mean
age	NN	age
63.2	CD	@card@
+-	NN	<unknown>
15.5	CD	@card@
years	NNS	year
,	,	,
60.1	CD	@card@
%	NN	%
male	NN	male
)	)	)
with	IN	with
a	DT	a
median	JJ	median
follow-up	NN	follow-up
of	IN	of
57	CD	@card@
(	(	(
49-63	CD	@card@
)	)	)
days	NNS	day
were	VBD	be
included	VBN	include
.	SENT	.
Of	IN	of
these	DT	these
,	,	,
190	CD	@card@
(	(	(
20.7	CD	@card@
%	NN	%
)	)	)
fulfilled	VBD	fulfill
strict	JJ	strict
criteria	NNS	criterion
for	IN	for
myocardial	JJ	myocardial
injury	NN	injury
(	(	(
21.1	CD	@card@
%	NN	%
chronic	NN	chronic
,	,	,
76.8	CD	@card@
%	NN	%
acute	JJ	acute
non-ischemic	NN	<unknown>
,	,	,
2.1	CD	@card@
%	NN	%
acute	NN	acute
ischemic	JJ	ischemic
)	)	)
.	SENT	.
Time	NN	time
from	IN	from
onset	NN	onset
of	IN	of
symptoms	NNS	symptom
to	TO	to
maximum	JJ	maximum
hs-TnI	NNS	<unknown>
was	VBD	be
11	CD	@card@
(	(	(
7-18	CD	@card@
)	)	)
days	NNS	day
.	SENT	.
Thrombotic	JJ	thrombotic
and	CC	and
bleeding	VBG	bleed
events	NNS	event
,	,	,
arrhythmias	NNS	arrhythmia
,	,	,
heart	NN	heart
failure	NN	failure
,	,	,
need	NN	need
for	IN	for
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
death	NN	death
were	VBD	be
significantly	RB	significantly
more	RBR	more
prevalent	JJ	prevalent
in	IN	in
patients	NNS	patient
with	IN	with
higher	JJR	high
hs-TnI	NN	<unknown>
concentrations	NNS	concentration
,	,	,
even	RB	even
without	IN	without
fulfilling	VBG	fulfill
criteria	NNS	criterion
for	IN	for
myocardial	JJ	myocardial
injury	NN	injury
.	SENT	.
hs-TnI	NNS	<unknown>
was	VBD	be
identified	VBN	identify
as	IN	as
an	DT	an
independent	JJ	independent
predictor	NN	predictor
of	IN	of
mortality	NN	mortality
[	SYM	[
HR	NP	HR
2.52	CD	@card@
(	(	(
1.57-4.04	CD	@card@
)	)	)
per	IN	per
5-logarithmic	JJ	5-logarithmic
units	NNS	unit
increment	NN	increment
]	SYM	]
after	IN	after
adjusting	VBG	adjust
for	IN	for
multiple	JJ	multiple
relevant	JJ	relevant
covariates	NNS	covariate
.	SENT	.
Elevated	JJ	elevated
hs-TnI	NN	<unknown>
is	VBZ	be
highly	RB	highly
prevalent	JJ	prevalent
among	IN	among
patients	NNS	patient
with	IN	with
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
Even	RB	even
mild	JJ	mild
elevations	NNS	elevation
well	RB	well
below	IN	below
the	DT	the
99th	NN	<unknown>
URL	NN	URL
were	VBD	be
significantly	RB	significantly
associated	VBN	associate
with	IN	with
higher	JJR	high
rates	NNS	rate
of	IN	of
cardiac	JJ	cardiac
and	CC	and
non-cardiac	JJ	non-cardiac
complications	NNS	complication
,	,	,
and	CC	and
higher	JJR	high
mortality	NN	mortality
.	SENT	.
Future	JJ	future
research	NN	research
should	MD	should
address	VB	address
the	DT	the
role	NN	role
of	IN	of
serial	JJ	serial
hs-TnI	NN	<unknown>
assessment	NN	assessment
to	TO	to
improve	VB	improve
COVID-19	NP	<unknown>
prognostic	JJ	prognostic
stratification	NN	stratification
and	CC	and
clinical	JJ	clinical
outcomes	NNS	outcome
.	SENT	.
33350677/	CD	@card@
Continuous	JJ	continuous
Negative	JJ	negative
Pressure	NN	pressure
Operative	NN	operative
Field	NP	Field
Barrier	NP	Barrier
for	IN	for
Combined	NP	Combined
Open	NP	Open
Tracheostomy	NN	tracheostomy
and	CC	and
Percutaneous	JJ	percutaneous
Endoscopic	JJ	endoscopic
Gastrostomy	NN	gastrostomy
Tube	NN	tube
Placement	NP	Placement
During	IN	during
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	CD	@card@
Supplemental	NP	Supplemental
Digital	NP	Digital
Content	NN	content
is	VBZ	be
available	JJ	available
in	IN	in
the	DT	the
text	NN	text
.	SENT	.
Respiratory	JJ	respiratory
failure	NN	failure
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
patients	NNS	patient
with	IN	with
prolonged	JJ	prolonged
endotracheal	JJ	endotracheal
intubation	NN	intubation
may	MD	may
require	VB	require
a	DT	a
tracheostomy	NN	tracheostomy
and	CC	and
percutaneous	JJ	percutaneous
endoscopic	JJ	endoscopic
gastrostomy	NN	gastrostomy
(	(	(
PEG	NN	peg
)	)	)
tube	NN	tube
placement	NN	placement
to	TO	to
facilitate	VB	facilitate
recovery	NN	recovery
.	SENT	.
Both	DT	both
techniques	NNS	technique
are	VBP	be
considered	VBN	consider
high-risk	JJ	high-risk
aerosol-generating	VBG	aerosol-generate
procedures	NNS	procedure
and	CC	and
present	VB	present
a	DT	a
heightened	JJ	heightened
risk	NN	risk
of	IN	of
exposure	NN	exposure
to	TO	to
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
for	IN	for
operating	VBG	operate
room	NN	room
personnel	NNS	personnel
.	SENT	.
We	PP	we
designed	VBD	design
,	,	,
simulated	JJ	simulated
,	,	,
and	CC	and
implemented	VBD	implement
a	DT	a
portable	JJ	portable
,	,	,
continuous	JJ	continuous
negative	JJ	negative
pressure	NN	pressure
,	,	,
operative	JJ	operative
field	NN	field
barrier	NN	barrier
system	NN	system
using	VBG	use
standard	JJ	standard
equipment	NN	equipment
available	JJ	available
in	IN	in
hospitals	NNS	hospital
to	TO	to
enhance	VB	enhance
health	NN	health
care	NN	care
provider	NN	provider
safety	NN	safety
during	IN	during
high-risk	JJ	high-risk
aerosol-generating	NN	aerosol-generating
procedures	NNS	procedure
.	SENT	.
34588946/	CD	@card@
One	CD	one
Year	NN	year
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
.	SENT	.
What	WP	what
Do	VBP	do
We	PP	we
Know	VBP	know
and	CC	and
What	WP	what
Is	VBZ	be
Yet	RB	yet
to	TO	to
Come	VB	come
?	SENT	?
:	:	:
The	DT	the
Summarising	VBG	summarise
Review	NP	Review
Objectives	NNS	objective
:	:	:
The	DT	the
aim	NN	aim
of	IN	of
this	DT	this
review	NN	review
is	VBZ	be
to	TO	to
summarize	VB	summarize
the	DT	the
most	RBS	most
relevant	JJ	relevant
scientific	JJ	scientific
discoveries	NNS	discovery
regarding	VBG	regard
SARS-	NP	<unknown>
CoV-2	NP	<unknown>
virus	NN	virus
infection	NN	infection
,	,	,
with	IN	with
the	DT	the
special	JJ	special
emphasis	NN	emphasis
put	VBN	put
on	IN	on
its	PP$	its
pathophysiology	NN	pathophysiology
and	CC	and
way	NN	way
of	IN	of
treatment	NN	treatment
.	SENT	.
Methods	NNS	method
:	:	:
In	IN	in
November	NP	November
2020	CD	@card@
,	,	,
the	DT	the
research	NN	research
articles	NNS	article
have	VBP	have
been	VBN	be
collected	VBN	collect
and	CC	and
examined	VBN	examine
manually	RB	manually
to	TO	to
pick	VB	pick
the	DT	the
most	RBS	most
relevant	JJ	relevant
.	SENT	.
In	IN	in
case	NN	case
of	IN	of
fresh	JJ	fresh
topics	NNS	topic
,	,	,
e.g.	FW	e.g.
vaccines	NNS	vaccine
,	,	,
we	PP	we
have	VBP	have
performed	VBN	perform
searching	VBG	search
using	VBG	use
adequate	JJ	adequate
keywords	NNS	keyword
.	SENT	.
Preliminary	JJ	preliminary
analysis	NN	analysis
was	VBD	be
conducted	VBN	conduct
on	IN	on
200	CD	@card@
manuscripts	NNS	manuscript
.	SENT	.
Results	NNS	result
:	:	:
Among	IN	among
them	PP	them
59	CD	@card@
papers	NNS	paper
were	VBD	be
out-of-scope	NN	out-of-scope
,	,	,
and	CC	and
thus	RB	thus
were	VBD	be
rejected	VBN	reject
from	IN	from
the	DT	the
further	JJR	further
elaboration	NN	elaboration
.	SENT	.
Another	DT	another
25	CD	@card@
papers	NNS	paper
were	VBD	be
rebuffed	VBN	rebuff
because	IN	because
they	PP	they
presented	VBD	present
topics	NNS	topic
,	,	,
that	WDT	that
have	VBP	have
been	VBN	be
extensively	RB	extensively
described	VBN	describe
in	IN	in
the	DT	the
already	RB	already
included	VBN	include
papers	NNS	paper
.	SENT	.
Basing	VBG	base
on	IN	on
the	DT	the
29	CD	@card@
papers	NNS	paper
we	PP	we
have	VBP	have
estimated	VBN	estimate
ratio	NN	ratio
of	IN	of
observed	JJ	observed
SARS-CoV-2	NP	<unknown>
infection	NN	infection
clinical	JJ	clinical
manifestations	NNS	manifestation
and	CC	and
comorbidities	NNS	comorbidity
among	IN	among
hospitalized	VBN	hospitalize
patients	NNS	patient
.	SENT	.
12	CD	@card@
papers	NNS	paper
let	VBP	let
us	PP	us
evaluate	VB	evaluate
frequencies	NNS	frequency
of	IN	of
deviations	NNS	deviation
within	IN	within
laboratory	NN	laboratory
markers	NNS	marker
concentrations	NNS	concentration
,	,	,
as	RB	as
well	RB	well
as	IN	as
weighted	JJ	weighted
average	NN	average
of	IN	of
the	DT	the
laboratory	NN	laboratory
tests	NNS	test
results	NNS	result
.	SENT	.
Conclusion	NN	conclusion
:	:	:
Due	JJ	due
to	TO	to
the	DT	the
significant	JJ	significant
infectivity	NN	infectivity
of	IN	of
the	DT	the
virus	NN	virus
and	CC	and
its	PP$	its
harmfulness	NN	harmfulness
towards	IN	towards
organism	NN	organism
further	JJR	further
studies	NNS	study
are	VBP	be
required	VBN	require
to	TO	to
find	VB	find
accurate	JJ	accurate
way	NN	way
of	IN	of
the	DT	the
disease	NN	disease
treatment	NN	treatment
and	CC	and
suspending	VBG	suspend
its	PP$	its
spreading	VBG	spread
.	SENT	.
34342092/	CD	@card@
The	DT	the
effect	NN	effect
of	IN	of
an	DT	an
air	NN	air
purifier	NN	purifier
on	IN	on
aerosol	NN	aerosol
generation	NN	generation
measurements	NNS	measurement
during	IN	during
clinical	JJ	clinical
motility	NN	motility
testing	NN	testing
Aerosol	NN	aerosol
spread	NN	spread
is	VBZ	be
key	JJ	key
to	TO	to
interpret	VB	interpret
the	DT	the
risk	NN	risk
of	IN	of
viral	JJ	viral
contamination	NN	contamination
during	IN	during
clinical	JJ	clinical
procedures	NNS	procedure
such	JJ	such
as	IN	as
esophageal	JJ	esophageal
high-resolution	NN	high-resolution
manometry	NN	manometry
(	(	(
HRM	NP	HRM
)	)	)
.	SENT	.
Installing	VBG	install
an	DT	an
air	NN	air
purifier	NN	purifier
seems	VBZ	seem
a	DT	a
legitimate	JJ	legitimate
strategy	NN	strategy
,	,	,
but	CC	but
this	DT	this
has	VBZ	have
recently	RB	recently
been	VBN	be
questioned	VBN	question
.	SENT	.
Patients	NNS	patient
undergoing	VBG	undergo
an	DT	an
HRM	NP	HRM
procedure	NN	procedure
at	IN	at
the	DT	the
Leuven	NP	Leuven
University	NP	University
Hospital	NP	Hospital
were	VBD	be
included	VBN	include
in	IN	in
this	DT	this
clinical	JJ	clinical
study	NN	study
.	SENT	.
All	DT	all
subjects	NNS	subject
had	VBD	have
to	TO	to
wear	VB	wear
a	DT	a
surgical	JJ	surgical
mask	NN	mask
which	WDT	which
was	VBD	be
only	RB	only
lowered	VBN	lower
beneath	IN	beneath
the	DT	the
nose	NN	nose
during	IN	during
the	DT	the
placement	NN	placement
and	CC	and
removal	NN	removal
of	IN	of
the	DT	the
nasogastric	JJ	nasogastric
catheter	NN	catheter
.	SENT	.
The	DT	the
number	NN	number
of	IN	of
aerosol	NN	aerosol
particles	NNS	particle
was	VBD	be
measured	VBN	measure
by	IN	by
a	DT	a
Lasair	NP	<unknown>
II	NP	II
Particle	NN	particle
Counter	NP	Counter
to	TO	to
obtain	VB	obtain
data	NNS	datum
about	IN	about
different	JJ	different
particles	NNS	particle
sizes	NNS	size
:	:	:
0.3	CD	@card@
;	:	;
0.5	CD	@card@
;	:	;
1.0	CD	@card@
;	:	;
3.0	CD	@card@
;	:	;
5.0	CD	@card@
;	:	;
and	CC	and
10.0	CD	@card@
microm	NN	<unknown>
.	SENT	.
Measurements	NNS	measurement
were	VBD	be
done	VBN	do
immediately	RB	immediately
before	IN	before
the	DT	the
placement	NN	placement
and	CC	and
the	DT	the
removal	NN	removal
of	IN	of
the	DT	the
HRM	NP	HRM
catheter	NN	catheter
,	,	,
and	CC	and
one	CD	one
and	CC	and
5	CD	@card@
min	NN	min
after	IN	after
.	SENT	.
A	DT	a
portable	JJ	portable
air	NN	air
purifier	NN	purifier
with	IN	with
high-efficiency	NN	high-efficiency
particle	NN	particle
air	NN	air
filters	NNS	filter
was	VBD	be
installed	VBN	install
in	IN	in
the	DT	the
hospital	NN	hospital
room	NN	room
.	SENT	.
Thirteen	CD	thirteen
patients	NNS	patient
underwent	VBD	undergo
a	DT	a
manometry	NN	manometry
examination	NN	examination
.	SENT	.
The	DT	the
amount	NN	amount
of	IN	of
0.3	CD	@card@
microm-sized	JJ	microm-sized
particles	NNS	particle
was	VBD	be
unaffected	JJ	unaffected
during	IN	during
the	DT	the
whole	JJ	whole
procedure	NN	procedure
.	SENT	.
The	DT	the
larger	JJR	large
particle	NN	particle
sizes	NNS	size
(	(	(
1.0	CD	@card@
;	:	;
3.0	CD	@card@
;	:	;
5.0	CD	@card@
;	:	;
and	CC	and
10.0	CD	@card@
microm	NN	<unknown>
)	)	)
decreased	VBD	decrease
when	WRB	when
the	DT	the
catheter	NN	catheter
was	VBD	be
positioned	VBN	position
,	,	,
but	CC	but
not	RB	not
0.5	CD	@card@
microm	NN	<unknown>
.	SENT	.
During	IN	during
the	DT	the
HRM	NP	HRM
measurements	NNS	measurement
itself	PP	itself
,	,	,
these	DT	these
numbers	NNS	number
decreased	VBD	decrease
further	RBR	further
.	SENT	.
Yet	RB	yet
,	,	,
1	CD	@card@
min	NN	min
after	IN	after
catheter	NN	catheter
removal	NN	removal
a	DT	a
significant	JJ	significant
elevation	NN	elevation
of	IN	of
particles	NNS	particle
was	VBD	be
seen	VBN	see
,	,	,
which	WDT	which
did	VBD	do
not	RB	not
recover	VB	recover
within	IN	within
5	CD	@card@
min	NN	min
.	SENT	.
Based	VBN	base
on	IN	on
this	DT	this
study	NN	study
,	,	,
there	EX	there
is	VBZ	be
no	DT	no
evidence	NN	evidence
that	IN	that
filtration	NN	filtration
systems	NNS	system
reduce	VB	reduce
aerosol	NN	aerosol
particles	NNS	particle
properly	RB	properly
during	IN	during
a	DT	a
clinical	JJ	clinical
investigation	NN	investigation
.	SENT	.
32677385/	CD	@card@
Development	NP	Development
and	CC	and
Validation	NN	validation
of	IN	of
a	DT	a
Prognostic	JJ	prognostic
Nomogram	NN	nomogram
Based	VBN	base
on	IN	on
Clinical	JJ	clinical
and	CC	and
CT	NP	CT
Features	NNS	feature
for	IN	for
Adverse	JJ	adverse
Outcome	NN	outcome
Prediction	NN	prediction
in	IN	in
Patients	NPS	Patients
with	IN	with
COVID-19	NP	<unknown>
The	DT	the
purpose	NN	purpose
of	IN	of
our	PP$	our
study	NN	study
was	VBD	be
to	TO	to
investigate	VB	investigate
the	DT	the
predictive	JJ	predictive
abilities	NNS	ability
of	IN	of
clinical	JJ	clinical
and	CC	and
computed	VBN	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
features	NNS	feature
for	IN	for
outcome	NN	outcome
prediction	NN	prediction
in	IN	in
patients	NNS	patient
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
clinical	JJ	clinical
and	CC	and
CT	NP	CT
data	NNS	datum
of	IN	of
238	CD	@card@
patients	NNS	patient
with	IN	with
laboratory-confirmed	JJ	laboratory-confirmed
COVID-19	NN	<unknown>
in	IN	in
our	PP$	our
two	CD	two
hospitals	NNS	hospital
were	VBD	be
retrospectively	RB	retrospectively
analyzed	VBN	analyze
.	SENT	.
One	CD	one
hundred	CD	hundred
sixty-six	NN	<unknown>
patients	NNS	patient
(	(	(
103	CD	@card@
males	NNS	male
;	:	;
age	NN	age
43.8	CD	@card@
+-	NN	<unknown>
12.3	CD	@card@
years	NNS	year
)	)	)
were	VBD	be
allocated	VBN	allocate
in	IN	in
the	DT	the
training	NN	training
cohort	NN	cohort
and	CC	and
72	CD	@card@
patients	NNS	patient
(	(	(
38	CD	@card@
males	NNS	male
;	:	;
age	NN	age
45.1	CD	@card@
+-	NN	<unknown>
15.8	CD	@card@
years	NNS	year
)	)	)
from	IN	from
another	DT	another
independent	JJ	independent
hospital	NN	hospital
were	VBD	be
assigned	VBN	assign
in	IN	in
the	DT	the
validation	NN	validation
cohort	NN	cohort
.	SENT	.
The	DT	the
primary	JJ	primary
composite	JJ	composite
endpoint	NN	endpoint
was	VBD	be
admission	NN	admission
to	TO	to
an	DT	an
intensive	JJ	intensive
care	NN	care
unit	NN	unit
,	,	,
use	NN	use
of	IN	of
mechanical	JJ	mechanical
ventilation	NN	ventilation
,	,	,
or	CC	or
death	NN	death
.	SENT	.
Univariate	JJ	<unknown>
and	CC	and
multivariate	JJ	multivariate
Cox	NP	Cox
proportional	JJ	proportional
hazard	NN	hazard
analyses	NNS	analysis
were	VBD	be
performed	VBN	perform
to	TO	to
identify	VB	identify
independent	JJ	independent
predictors	NNS	predictor
.	SENT	.
A	DT	a
nomogram	NN	nomogram
was	VBD	be
constructed	VBN	construct
based	VBN	base
on	IN	on
the	DT	the
combination	NN	combination
of	IN	of
clinical	JJ	clinical
and	CC	and
CT	NP	CT
features	NNS	feature
,	,	,
and	CC	and
its	PP$	its
prognostic	JJ	prognostic
performance	NN	performance
was	VBD	be
externally	RB	externally
tested	VBN	test
in	IN	in
the	DT	the
validation	NN	validation
group	NN	group
.	SENT	.
The	DT	the
predictive	JJ	predictive
value	NN	value
of	IN	of
the	DT	the
combined	JJ	combined
model	NN	model
was	VBD	be
compared	VBN	compare
with	IN	with
models	NNS	model
built	VBN	build
on	IN	on
the	DT	the
clinical	JJ	clinical
and	CC	and
radiological	JJ	radiological
attributes	NNS	attribute
alone	RB	alone
.	SENT	.
Overall	RB	overall
,	,	,
35	CD	@card@
infected	JJ	infected
patients	NNS	patient
(	(	(
21.1	CD	@card@
%	NN	%
)	)	)
in	IN	in
the	DT	the
training	NN	training
cohort	NN	cohort
and	CC	and
10	CD	@card@
patients	NNS	patient
(	(	(
13.9	CD	@card@
%	NN	%
)	)	)
in	IN	in
the	DT	the
validation	NN	validation
cohort	NN	cohort
experienced	VBD	experience
adverse	JJ	adverse
outcomes	NNS	outcome
.	SENT	.
Underlying	VBG	underlie
comorbidity	NN	comorbidity
(	(	(
hazard	NN	hazard
ratio	NN	ratio
[	SYM	[
HR	NP	HR
]	SYM	]
,	,	,
3.35	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
[	SYM	[
CI	NP	CI
]	SYM	]
,	,	,
1.67-6.71	CD	@card@
;	:	;
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
,	,	,
lymphocyte	NN	lymphocyte
count	NN	count
(	(	(
HR	NP	HR
,	,	,
0.12	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.04-0.38	CD	@card@
;	:	;
p	NN	p
&lt	NN	&lt
;	:	;
0.001	LS	@card@
)	)	)
and	CC	and
crazy-paving	VBG	crazy-pave
sign	NN	sign
(	(	(
HR	NP	HR
,	,	,
2.15	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
1.03-4.48	CD	@card@
;	:	;
p	NN	p
=	SYM	=
0.042	CD	@card@
)	)	)
were	VBD	be
the	DT	the
independent	JJ	independent
factors	NNS	factor
.	SENT	.
The	DT	the
nomogram	NN	nomogram
displayed	VBD	display
a	DT	a
concordance	NN	concordance
index	NN	index
(	(	(
C-index	NP	C-index
)	)	)
of	IN	of
0.82	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.76-0.88	CD	@card@
)	)	)
,	,	,
and	CC	and
its	PP$	its
prognostic	JJ	prognostic
value	NN	value
was	VBD	be
confirmed	VBN	confirm
in	IN	in
the	DT	the
validation	NN	validation
cohort	NN	cohort
with	IN	with
a	DT	a
C-index	NP	C-index
of	IN	of
0.89	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.82-0.96	CD	@card@
)	)	)
.	SENT	.
The	DT	the
combined	JJ	combined
model	NN	model
provided	VBD	provide
the	DT	the
best	JJS	good
performance	NN	performance
over	IN	over
the	DT	the
clinical	JJ	clinical
or	CC	or
radiological	JJ	radiological
model	NN	model
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.050	LS	@card@
)	)	)
.	SENT	.
Underlying	VBG	underlie
comorbidity	NN	comorbidity
,	,	,
lymphocyte	NN	lymphocyte
count	NN	count
and	CC	and
crazy-paving	NN	crazy-paving
sign	NN	sign
were	VBD	be
independent	JJ	independent
predictors	NNS	predictor
of	IN	of
adverse	JJ	adverse
outcomes	NNS	outcome
.	SENT	.
The	DT	the
prognostic	JJ	prognostic
nomogram	NN	nomogram
based	VBN	base
on	IN	on
the	DT	the
combination	NN	combination
of	IN	of
clinical	JJ	clinical
and	CC	and
CT	NP	CT
features	NNS	feature
could	MD	could
be	VB	be
a	DT	a
useful	JJ	useful
tool	NN	tool
for	IN	for
predicting	VBG	predict
adverse	JJ	adverse
outcomes	NNS	outcome
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
33556317/	CD	@card@
COVID-19	NP	<unknown>
:	:	:
a	DT	a
heavy	JJ	heavy
toll	NN	toll
on	IN	on
health-care	JJ	health-care
workers	NNS	worker
35184735/	CD	@card@
How	WRB	how
have	VB	have
governments	NNS	government
supported	VBD	support
citizens	NNS	citizen
stranded	VBN	strand
abroad	RB	abroad
due	JJ	due
to	TO	to
COVID-19	NP	<unknown>
travel	NN	travel
restrictions	NNS	restriction
?	SENT	?
A	DT	a
comparative	JJ	comparative
analysis	NN	analysis
of	IN	of
the	DT	the
financial	JJ	financial
and	CC	and
health	NN	health
support	NN	support
in	IN	in
eleven	NN	eleven
countries	NNS	country
In	IN	in
response	NN	response
to	TO	to
the	DT	the
continuing	VBG	continue
threat	NN	threat
of	IN	of
importing	VBG	import
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
many	JJ	many
countries	NNS	country
have	VBP	have
implemented	VBN	implement
some	DT	some
form	NN	form
of	IN	of
border	NN	border
restriction	NN	restriction
.	SENT	.
A	DT	a
repercussion	NN	repercussion
of	IN	of
these	DT	these
restrictions	NNS	restriction
has	VBZ	have
been	VBN	be
that	IN	that
some	DT	some
travellers	NNS	traveller
have	VBP	have
found	VBN	find
themselves	PP	themselves
stranded	VBD	strand
abroad	RB	abroad
unable	JJ	unable
to	TO	to
return	VB	return
to	TO	to
their	PP$	their
country	NN	country
of	IN	of
residence	NN	residence
,	,	,
and	CC	and
in	IN	in
need	NN	need
for	IN	for
government	NN	government
support	NN	support
.	SENT	.
Our	PP$	our
analysis	NN	analysis
explores	VBZ	explore
the	DT	the
COVID-19-related	JJ	COVID-19-related
information	NN	information
and	CC	and
support	NN	support
options	NNS	option
provided	VBN	provide
by	IN	by
11	CD	@card@
countries	NNS	country
to	TO	to
their	PP$	their
citizens	NNS	citizen
stranded	VBN	strand
overseas	RB	overseas
due	JJ	due
to	TO	to
travel	VB	travel
restrictions	NNS	restriction
.	SENT	.
We	PP	we
also	RB	also
examined	VBD	examine
the	DT	the
quality	NN	quality
(	(	(
i.e.	FW	i.e.
,	,	,
readability	NN	readability
,	,	,
accessibility	NN	accessibility
,	,	,
and	CC	and
useability	NN	useability
)	)	)
of	IN	of
the	DT	the
information	NN	information
that	WDT	that
was	VBD	be
available	JJ	available
from	IN	from
selected	JJ	selected
governments	NNS	government
'	POS	'
web-based	JJ	<unknown>
resources	NNS	resource
.	SENT	.
Between	IN	between
June	NP	June
18	CD	@card@
to	TO	to
June	NP	June
30	CD	@card@
,	,	,
2021	CD	@card@
,	,	,
COVID-19-related	JJ	COVID-19-related
webpages	NNS	webpage
from	IN	from
11	CD	@card@
countries	NNS	country
(	(	(
Australia	NP	Australia
,	,	,
New	NP	New
Zealand	NP	Zealand
,	,	,
Fiji	NP	Fiji
,	,	,
Canada	NP	Canada
,	,	,
United	NP	United
States	NPS	States
of	IN	of
America	NP	America
(	(	(
USA	NP	USA
)	)	)
,	,	,
United	NP	United
Kingdom	NP	Kingdom
(	(	(
UK	NP	UK
)	)	)
,	,	,
France	NP	France
,	,	,
Spain	NP	Spain
,	,	,
Japan	NP	Japan
,	,	,
Singapore	NP	Singapore
,	,	,
and	CC	and
Thailand	NP	Thailand
)	)	)
were	VBD	be
reviewed	VBN	review
and	CC	and
content	JJ	content
relating	VBG	relate
to	TO	to
information	NN	information
and	CC	and
support	NN	support
for	IN	for
citizens	NNS	citizen
stuck	VBD	stick
overseas	RB	overseas
analysed	VBN	analyse
.	SENT	.
Government	NN	government
assistance-related	VBD	assistance-relate
data	NNS	datum
from	IN	from
each	DT	each
webpage	NN	<unknown>
was	VBD	be
extracted	VBN	extract
and	CC	and
coded	VBN	code
for	IN	for
the	DT	the
following	VBG	follow
themes	NNS	theme
:	:	:
travel	NN	travel
arrangements	NNS	arrangement
,	,	,
health	NN	health
and	CC	and
wellbeing	NN	wellbeing
,	,	,
finance	NN	finance
and	CC	and
accommodation	NN	accommodation
,	,	,
information	NN	information
needs	NNS	need
,	,	,
and	CC	and
sources	NNS	source
.	SENT	.
Readability	NN	readability
was	VBD	be
examined	VBN	examine
using	VBG	use
the	DT	the
Simplified	VBN	simplify
Measure	NN	measure
of	IN	of
Gobbledygook	NN	gobbledygook
(	(	(
SMOG	NN	smog
)	)	)
and	CC	and
the	DT	the
Flesch	NP	Flesch
Kincaid	JJ	Kincaid
readability	NN	readability
tests	NNS	test
;	:	;
content	NN	content
'	POS	'
accessibility	NN	accessibility
'	''	'
was	VBD	be
measured	VBN	measure
using	VBG	use
the	DT	the
Web	NP	Web
Content	NN	content
Accessibility	NN	accessibility
Guidelines	NNS	guideline
(	(	(
WCAG	NP	<unknown>
)	)	)
Version	NP	Version
2.1	CD	@card@
;	:	;
and	CC	and
content	NN	content
'	POS	'
usability	NN	usability
'	''	'
assessed	VBN	assess
using	VBG	use
the	DT	the
usability	NN	usability
heuristics	NN	heuristics
for	IN	for
website	NN	website
design	NN	design
tool	NN	tool
.	SENT	.
Ninety-eight	NN	Ninety-eight
webpages	NNS	webpage
from	IN	from
34	CD	@card@
websites	NNS	website
were	VBD	be
evaluated	VBN	evaluate
.	SENT	.
No	DT	no
country	NN	country
assessed	VBD	assess
covered	VBN	cover
all	DT	all
themes	NNS	theme
analysed	VBD	analyse
.	SENT	.
Most	RBS	most
provided	VBN	provide
information	NN	information
and	CC	and
some	DT	some
level	NN	level
of	IN	of
support	NN	support
regarding	VBG	regard
repatriation	NN	repatriation
options	NNS	option
;	:	;
border	NN	border
control	NN	control
and	CC	and
re-entry	NN	re-entry
measures	NNS	measure
;	:	;
medical	JJ	medical
assistance	NN	assistance
;	:	;
and	CC	and
traveller	NN	traveller
registration	NN	registration
.	SENT	.
Only	RB	only
three	CD	three
countries	NNS	country
provided	VBD	provide
information	NN	information
or	CC	or
support	NN	support
for	IN	for
emergency	NN	emergency
housing	NN	housing
while	IN	while
abroad	RB	abroad
,	,	,
and	CC	and
six	CD	six
provided	VBD	provide
some	DT	some
form	NN	form
of	IN	of
mental	JJ	mental
health	NN	health
support	NN	support
for	IN	for
their	PP$	their
citizens	NNS	citizen
.	SENT	.
Our	PP$	our
analysis	NN	analysis
of	IN	of
the	DT	the
quality	NN	quality
of	IN	of
COVID-19-related	JJ	COVID-19-related
information	NN	information
available	JJ	available
on	IN	on
a	DT	a
subset	NN	subset
of	IN	of
four	CD	four
countries	NNS	country
'	POS	'
websites	NNS	website
found	VBD	find
poor	JJ	poor
readability	NN	readability
and	CC	and
multiple	JJ	multiple
accessibility	NN	accessibility
and	CC	and
usability	NN	usability
issues	NNS	issue
.	SENT	.
This	DT	this
study	NN	study
uniquely	RB	uniquely
analyses	VBZ	analyse
government	NN	government
support	NN	support
for	IN	for
citizens	NNS	citizen
stuck	VBN	stick
abroad	RB	abroad
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
With	IN	with
large	JJ	large
variance	NN	variance
in	IN	in
the	DT	the
information	NN	information
and	CC	and
services	NNS	service
available	JJ	available
across	IN	across
the	DT	the
countries	NNS	country
analysed	VBD	analyse
,	,	,
our	PP$	our
results	NNS	result
highlight	VB	highlight
gaps	NNS	gap
,	,	,
inconsistencies	NNS	inconsistency
,	,	,
and	CC	and
potential	JJ	potential
inequities	NNS	inequity
in	IN	in
support	NN	support
available	JJ	available
,	,	,
and	CC	and
raise	VB	raise
issues	NNS	issue
pertinent	JJ	pertinent
to	TO	to
the	DT	the
quality	NN	quality
,	,	,
accessibility	NN	accessibility
,	,	,
and	CC	and
usability	NN	usability
of	IN	of
information	NN	information
.	SENT	.
This	DT	this
study	NN	study
will	MD	will
assist	VB	assist
policymakers	NNS	policymaker
plan	NN	plan
and	CC	and
communicate	VB	communicate
comprehensive	JJ	comprehensive
support	NN	support
packages	NNS	package
for	IN	for
citizens	NNS	citizen
stuck	VBN	stick
abroad	RB	abroad
due	JJ	due
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
situation	NN	situation
and	CC	and
design	VB	design
future	JJ	future
efforts	NNS	effort
to	TO	to
prepare	VB	prepare
for	IN	for
global	JJ	global
public	JJ	public
health	NN	health
emergencies	NNS	emergency
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12879-022-07155-2	JJ	10.1186/s@card@
.	SENT	.
32794209/	CD	@card@
COVID-19	NP	<unknown>
Viral	JJ	viral
Load	NN	load
in	IN	in
the	DT	the
Severity	NN	severity
of	IN	of
and	CC	and
Recovery	NN	recovery
from	IN	from
Olfactory	JJ	olfactory
and	CC	and
Gustatory	JJ	gustatory
Dysfunction	NN	dysfunction
This	DT	this
study	NN	study
investigated	VBD	investigate
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
and	CC	and
their	PP$	their
correlations	NNS	correlation
with	IN	with
viral	JJ	viral
load	NN	load
evaluation	NN	evaluation
.	SENT	.
This	DT	this
was	VBD	be
a	DT	a
prospective	JJ	prospective
cross-sectional	JJ	cross-sectional
cohort	NN	cohort
study	NN	study
of	IN	of
143	CD	@card@
symptomatic	JJ	symptomatic
patients	NNS	patient
being	VBG	be
screened	VBN	screen
for	IN	for
SARS-coronavirus	NP	<unknown>
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
invited	VBD	invite
to	TO	to
participate	VB	participate
.	SENT	.
The	DT	the
clinical	JJ	clinical
data	NNS	datum
of	IN	of
83	CD	@card@
confirmed	VBD	confirm
COVID-19	NP	<unknown>
subjects	NNS	subject
were	VBD	be
collected	VBN	collect
,	,	,
with	IN	with
60	CD	@card@
patients	NNS	patient
who	WP	who
were	VBD	be
symptomatic	JJ	symptomatic
but	CC	but
negative	JJ	negative
for	IN	for
COVID-19	NP	<unknown>
recruited	VBD	recruit
as	IN	as
controls	NNS	control
.	SENT	.
The	DT	the
prevalence	NN	prevalence
and	CC	and
severity	NN	severity
of	IN	of
and	CC	and
recovery	NN	recovery
time	NN	time
for	IN	for
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
,	,	,
and	CC	and
cycle	NN	cycle
threshold	NN	threshold
(	(	(
Ct	NP	Ct
)	)	)
values	NNS	value
from	IN	from
a	DT	a
SARS-CoV-2	NP	<unknown>
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
assay	NN	assay
of	IN	of
nasopharyngeal	JJ	nasopharyngeal
and	CC	and
deep	JJ	deep
throat	NN	throat
swabs	NNS	swab
were	VBD	be
collected	VBN	collect
.	SENT	.
Their	PP$	their
correlations	NNS	correlation
with	IN	with
Ct	NP	Ct
values	NNS	value
were	VBD	be
reported	VBN	report
.	SENT	.
Thirty-nine	NN	Thirty-nine
(	(	(
47.0	CD	@card@
%	NN	%
)	)	)
and	CC	and
thirty-six	NN	<unknown>
(	(	(
43.4	CD	@card@
%	NN	%
)	)	)
COVID-19	NP	<unknown>
patients	NNS	patient
reported	VBD	report
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
results	NNS	result
of	IN	of
one-way	JJ	one-way
ANOVA	NP	<unknown>
did	VBD	do
not	RB	not
show	VB	show
statistically	RB	statistically
significant	JJ	significant
relationships	NNS	relationship
between	IN	between
the	DT	the
Ct	NP	Ct
values	NNS	value
and	CC	and
severity	NN	severity
of	IN	of
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
(	(	(
p	NN	p
=	SYM	=
0.780	CD	@card@
and	CC	and
p	NN	p
=	SYM	=
0.121	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
Among	IN	among
the	DT	the
COVID-19	NP	<unknown>
patients	NNS	patient
who	WP	who
reported	VBD	report
smell	NN	smell
and	CC	and
taste	NN	taste
loss	NN	loss
,	,	,
28/39	CD	@card@
(	(	(
71.8	CD	@card@
%	NN	%
)	)	)
and	CC	and
30/36	CD	@card@
(	(	(
83.3	CD	@card@
%	NN	%
)	)	)
experienced	VBD	experience
complete	JJ	complete
recovery	NN	recovery
,	,	,
respectively	RB	respectively
.	SENT	.
The	DT	the
mean	JJ	mean
recovery	NN	recovery
time	NN	time
was	VBD	be
10.3	CD	@card@
+-	NN	<unknown>
8.1	CD	@card@
days	NNS	day
for	IN	for
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
and	CC	and
9.5	CD	@card@
+-	NN	<unknown>
6.8	CD	@card@
days	NNS	day
for	IN	for
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
.	SENT	.
The	DT	the
recovery	NN	recovery
time	NN	time
was	VBD	be
not	RB	not
correlated	VBN	correlate
with	IN	with
the	DT	the
Ct	NP	Ct
values	NNS	value
(	(	(
Pearson	NP	Pearson
correlation	NN	correlation
coefficient	NN	coefficient
:	:	:
smell	NN	smell
:	:	:
-0.008	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.968	CD	@card@
;	:	;
taste	NN	taste
:	:	:
-0.015	CD	@card@
,	,	,
p	NN	p
=	SYM	=
0.940	CD	@card@
)	)	)
.	SENT	.
There	EX	there
is	VBZ	be
a	DT	a
high	JJ	high
prevalence	NN	prevalence
of	IN	of
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
However	RB	however
,	,	,
the	DT	the
severity	NN	severity
of	IN	of
and	CC	and
recovery	NN	recovery
from	IN	from
these	DT	these
symptoms	NNS	symptom
have	VBP	have
no	DT	no
correlations	NNS	correlation
with	IN	with
the	DT	the
viral	JJ	viral
load	NN	load
of	IN	of
SARS-CoV-2	NP	<unknown>
.	SENT	.
This	DT	this
article	NN	article
is	VBZ	be
protected	VBN	protect
by	IN	by
copyright	NN	copyright
.	SENT	.
All	DT	all
rights	NNS	right
reserved	VBD	reserve
.	SENT	.
35439249/	CD	@card@
Low	NP	Low
cost	NN	cost
centrifugal	JJ	centrifugal
melt	NN	melt
spinning	VBG	spin
for	IN	for
distributed	VBN	distribute
manufacturing	NN	manufacturing
of	IN	of
non-woven	JJ	non-woven
media	NNS	medium
Centralized	JJ	centralized
manufacturing	NN	manufacturing
and	CC	and
global	JJ	global
supply	NN	supply
chains	NNS	chain
have	VBP	have
emerged	VBN	emerge
as	IN	as
an	DT	an
efficient	JJ	efficient
strategy	NN	strategy
for	IN	for
large-scale	JJ	large-scale
production	NN	production
of	IN	of
goods	NNS	good
throughout	IN	throughout
the	DT	the
20th	JJ	20th
century	NN	century
.	SENT	.
However	RB	however
,	,	,
while	IN	while
this	DT	this
system	NN	system
of	IN	of
production	NN	production
is	VBZ	be
highly	RB	highly
efficient	JJ	efficient
,	,	,
it	PP	it
is	VBZ	be
not	RB	not
resilient	JJ	resilient
.	SENT	.
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
seen	VBN	see
numerous	JJ	numerous
supply	NN	supply
chains	NNS	chain
fail	VBP	fail
to	TO	to
adapt	VB	adapt
to	TO	to
sudden	JJ	sudden
changes	NNS	change
in	IN	in
supply	NN	supply
and	CC	and
demand	NN	demand
,	,	,
including	VBG	include
those	DT	those
for	IN	for
goods	NNS	good
critical	JJ	critical
to	TO	to
the	DT	the
pandemic	JJ	pandemic
response	NN	response
such	JJ	such
as	IN	as
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
consider	VBP	consider
the	DT	the
production	NN	production
of	IN	of
the	DT	the
non-woven	JJ	non-woven
polypropylene	NN	polypropylene
filtration	NN	filtration
media	NNS	medium
used	VBN	use
in	IN	in
face	NN	face
filtering	VBG	filter
respirators	NNS	respirator
(	(	(
FFRs	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
FFR	NP	FFR
supply	NN	supply
chain	NN	chain
's	POS	's
reliance	NN	reliance
on	IN	on
non-woven	JJ	non-woven
media	NNS	medium
sourced	VBN	<unknown>
from	IN	from
large	JJ	large
,	,	,
centralized	JJ	centralized
manufacturing	NN	manufacturing
facilities	NNS	facility
led	VBD	lead
to	TO	to
a	DT	a
supply	NN	supply
chain	NN	chain
failure	NN	failure
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
present	VBP	present
an	DT	an
alternative	JJ	alternative
manufacturing	NN	manufacturing
strategy	NN	strategy
that	WDT	that
allows	VBZ	allow
us	PP	us
to	TO	to
move	VB	move
towards	IN	towards
a	DT	a
more	JJR	more
distributed	VBN	distribute
manufacturing	NN	manufacturing
practice	NN	practice
that	WDT	that
is	VBZ	be
both	DT	both
scalable	JJ	scalable
and	CC	and
robust	JJ	robust
.	SENT	.
Specifically	RB	specifically
,	,	,
we	PP	we
demonstrate	VBP	demonstrate
that	IN	that
a	DT	a
fiber	NN	fiber
production	NN	production
technique	NN	technique
known	VBN	know
as	IN	as
centrifugal	JJ	centrifugal
melt	NN	melt
spinning	NN	spinning
can	MD	can
be	VB	be
implemented	VBN	implement
with	IN	with
modified	JJ	modified
,	,	,
commercially-available	JJ	commercially-available
cotton	NN	cotton
candy	NN	candy
machines	NNS	machine
to	TO	to
produce	VB	produce
nano-	NN	<unknown>
and	CC	and
microscale	JJ	<unknown>
non-woven	JJ	non-woven
fibers	NNS	fiber
.	SENT	.
We	PP	we
evaluate	VBP	evaluate
several	JJ	several
post	NN	post
processing	NN	processing
strategies	NNS	strategy
to	TO	to
transform	VB	transform
the	DT	the
produced	VBN	produce
material	NN	material
into	IN	into
viable	JJ	viable
filtration	NN	filtration
media	NNS	medium
and	CC	and
then	RB	then
characterize	VB	characterize
these	DT	these
materials	NNS	material
by	IN	by
measuring	VBG	measure
filtration	NN	filtration
efficiency	NN	efficiency
and	CC	and
breathability	NN	breathability
,	,	,
comparing	VBG	compare
them	PP	them
against	IN	against
equivalent	JJ	equivalent
materials	NNS	material
used	VBN	use
in	IN	in
commercially-available	JJ	commercially-available
FFRs	NN	<unknown>
.	SENT	.
Additionally	RB	additionally
,	,	,
we	PP	we
demonstrate	VBP	demonstrate
that	IN	that
waste	NN	waste
plastic	NN	plastic
can	MD	can
be	VB	be
processed	VBN	process
with	IN	with
this	DT	this
technique	NN	technique
,	,	,
enabling	VBG	enable
the	DT	the
development	NN	development
of	IN	of
distributed	VBN	distribute
recycling	NN	recycling
strategies	NNS	strategy
to	TO	to
address	VB	address
the	DT	the
growing	VBG	grow
plastic	NN	plastic
waste	NN	waste
crisis	NN	crisis
.	SENT	.
Since	IN	since
this	DT	this
method	NN	method
can	MD	can
be	VB	be
employed	VBN	employ
at	IN	at
small	JJ	small
scales	NNS	scale
,	,	,
it	PP	it
allows	VBZ	allow
for	IN	for
the	DT	the
development	NN	development
of	IN	of
an	DT	an
adaptable	JJ	adaptable
and	CC	and
rapidly	RB	rapidly
deployable	JJ	deployable
distributed	VBN	distribute
manufacturing	NN	manufacturing
network	NN	network
for	IN	for
non-woven	JJ	non-woven
materials	NNS	material
that	WDT	that
is	VBZ	be
financially	RB	financially
accessible	JJ	accessible
to	TO	to
more	JJR	more
people	NNS	people
than	IN	than
is	VBZ	be
currently	RB	currently
possible	JJ	possible
.	SENT	.
34962356/	CD	@card@
The	DT	the
volatile	JJ	volatile
and	CC	and
heterogeneous	JJ	heterogeneous
gut	NN	gut
microbiota	NN	microbiota
shifts	NNS	shift
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
over	IN	over
the	DT	the
course	NN	course
of	IN	of
a	DT	a
probiotics-assisted	JJ	<unknown>
therapy	NN	therapy
32367484/	CD	@card@
Call	NN	call
for	IN	for
Proposals	NNS	proposal
:	:	:
Special	JJ	special
Issue	NN	issue
of	IN	of
Archives	NPS	Archives
of	IN	of
Sexual	JJ	sexual
Behavior	NN	behavior
on	IN	on
the	DT	the
Impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
Sexual	JJ	sexual
Health	NN	health
and	CC	and
Behavior	NN	behavior
32569772/	CD	@card@
Poor	NP	Poor
Outcome	NN	outcome
of	IN	of
Intestinal	JJ	intestinal
Ischemic	JJ	ischemic
Manifestations	NNS	manifestation
of	IN	of
COVID-19	NP	<unknown>
33410294/	CD	@card@
The	DT	the
reliability	NN	reliability
of	IN	of
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
antibody	NN	antibody
testing	NN	testing
-	NN	<unknown>
a	DT	a
pilot	NN	pilot
study	NN	study
in	IN	in
asymptomatic	JJ	asymptomatic
health	NN	health
care	NN	care
workers	NNS	worker
in	IN	in
a	DT	a
Croatian	JJ	Croatian
university	NN	university
hospital	NN	hospital
To	TO	to
evaluate	VB	evaluate
three	CD	three
fully	RB	fully
automated	VBN	automate
serological	JJ	serological
assays	NNS	assay
in	IN	in
terms	NNS	term
of	IN	of
reactivity	NN	reactivity
to	TO	to
SARS-CoV-2	NP	<unknown>
immunoglobulin	NN	immunoglobulin
G	NP	G
(	(	(
IgG	NP	IgG
)	)	)
and	CC	and
perform	VB	perform
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
antibody	NN	antibody
testing	NN	testing
among	IN	among
asymptomatic	JJ	asymptomatic
health	NN	health
care	NN	care
workers	NNS	worker
(	(	(
HCW	NP	HCW
)	)	)
at	IN	at
the	DT	the
University	NP	University
Hospital	NP	Hospital
Center	NP	Center
Zagreb	NP	Zagreb
.	SENT	.
Three	CD	three
IgG	NP	IgG
serological	JJ	serological
assays	NNS	assay
(	(	(
Abbott	NP	Abbott
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
,	,	,
Elecsys	NP	<unknown>
Anti-SARS-CoV-2	JJ	<unknown>
,	,	,
and	CC	and
MAGLUMI	NP	<unknown>
2019-nCoV	NP	<unknown>
IgG	NP	IgG
)	)	)
were	VBD	be
initially	RB	initially
evaluated	VBN	evaluate
by	IN	by
analyzing	VBG	analyze
42	CD	@card@
samples	NNS	sample
from	IN	from
confirmed	VBN	confirm
COVID-19-recovered	JJ	COVID-19-recovered
patients	NNS	patient
and	CC	and
48	CD	@card@
negative	JJ	negative
individuals	NNS	individual
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
1678	CD	@card@
HCW	NNS	<unknown>
(	(	(
~	SYM	~
30	CD	@card@
%	NN	%
of	IN	of
all	DT	all
hospital	NN	hospital
employees	NNS	employee
)	)	)
were	VBD	be
screened	VBN	screen
for	IN	for
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
with	IN	with
the	DT	the
Abbott	NP	Abbott
assay	NN	assay
,	,	,
run	VBN	run
on	IN	on
Abbott	NP	Abbott
Architect	NN	architect
i2000SR	NN	<unknown>
.	SENT	.
The	DT	the
samples	NNS	sample
exceeding	VBG	exceed
the	DT	the
predefined	JJ	predefined
cut-off	NN	cut-off
(	(	(
1.4	CD	@card@
S/C	NP	S/C
)	)	)
were	VBD	be
reanalyzed	VBN	reanalyze
with	IN	with
the	DT	the
Elecsys	NP	<unknown>
,	,	,
MAGLUMI	NP	<unknown>
,	,	,
and	CC	and
VIDAS	NP	Vidas
SARS-COV-2	NP	<unknown>
IgG	NP	IgG
assays	VBZ	assay
.	SENT	.
Initially	RB	initially
,	,	,
the	DT	the
MAGLUMI	NP	<unknown>
2019-nCoV	NP	<unknown>
IgG	NP	IgG
produced	VBD	produce
26.2	CD	@card@
%	NN	%
false	JJ	false
negatives	NNS	negative
and	CC	and
the	DT	the
Elecsys	NP	<unknown>
Anti-SARS-CoV-2	NN	<unknown>
produced	VBD	produce
one	CD	one
false	JJ	false
positive	NN	positive
.	SENT	.
Among	IN	among
1678	CD	@card@
HCW	NNS	<unknown>
,	,	,
the	DT	the
Abbott	NP	Abbott
assay	NN	assay
showed	VBD	show
only	RB	only
10	CD	@card@
(	(	(
0.6	CD	@card@
%	NN	%
)	)	)
positive	JJ	positive
results	NNS	result
,	,	,
with	IN	with
mostly	RB	mostly
mildly	RB	mildly
elevated	JJ	elevated
signals	NNS	signal
.	SENT	.
Nine	CD	nine
of	IN	of
these	DT	these
samples	NNS	sample
were	VBD	be
non-reactive	JJ	non-reactive
when	WRB	when
they	PP	they
were	VBD	be
retested	VBN	retest
with	IN	with
the	DT	the
Elecsys	NP	<unknown>
,	,	,
MAGLUMI	NP	<unknown>
,	,	,
and	CC	and
VIDAS	NP	Vidas
assays	NNS	assay
.	SENT	.
As	RB	as
for	IN	for
the	DT	the
one	CD	one
remaining	VBG	remain
sample	NN	sample
,	,	,
it	PP	it
was	VBD	be
positive	JJ	positive
when	WRB	when
tested	VBN	test
with	IN	with
the	DT	the
Elecsys	NP	<unknown>
assay	NN	assay
,	,	,
while	IN	while
the	DT	the
other	JJ	other
two	CD	two
assays	NNS	assay
yielded	VBD	yield
negative	JJ	negative
results	NNS	result
.	SENT	.
SARS-CoV-2	NP	<unknown>
IgG	NP	IgG
seroprevalence	NN	seroprevalence
among	IN	among
asymptomatic	JJ	asymptomatic
HCW	NNS	<unknown>
in	IN	in
our	PP$	our
hospital	NN	hospital
setting	NN	setting
was	VBD	be
low	JJ	low
,	,	,
with	IN	with
different	JJ	different
assays	NNS	assay
indicating	VBG	indicate
a	DT	a
different	JJ	different
number	NN	number
of	IN	of
positive	JJ	positive
samples	NNS	sample
.	SENT	.
One	CD	one
of	IN	of
the	DT	the
assays	NNS	assay
yielded	VBD	yield
a	DT	a
large	JJ	large
false	JJ	false
negative	JJ	negative
rate	NN	rate
.	SENT	.
These	DT	these
findings	NNS	finding
can	MD	can
be	VB	be
attributed	VBN	attribute
to	TO	to
differences	NNS	difference
in	IN	in
assay	NN	assay
formulation	NN	formulation
but	CC	but
also	RB	also
to	TO	to
heterogeneity	NN	heterogeneity
and	CC	and
diverse	JJ	diverse
reactivity	NN	reactivity
of	IN	of
antibodies	NNS	antibody
against	IN	against
SARS-CoV-2	JJ	<unknown>
antigens	NNS	antigen
.	SENT	.
33054263/	CD	@card@
COVID-19	NP	<unknown>
:	:	:
Pandemic	JJ	pandemic
burden	NN	burden
in	IN	in
Sub-Saharan	NP	Sub-Saharan
Africa	NP	Africa
and	CC	and
the	DT	the
right	NN	right
to	TO	to
health	NN	health
-	NN	<unknown>
The	DT	the
need	NN	need
for	IN	for
advocacy	NN	advocacy
in	IN	in
the	DT	the
face	NN	face
of	IN	of
growing	VBG	grow
privatisation	NN	<unknown>
For	IN	for
Africa	NP	Africa
,	,	,
the	DT	the
backdrop	NN	backdrop
against	IN	against
which	WDT	which
COVID-19	NP	<unknown>
emerged	VBD	emerge
is	VBZ	be
a	DT	a
stark	JJ	stark
one	CD	one
.	SENT	.
Although	IN	although
sub-Saharan	JJ	sub-Saharan
Africa	NP	Africa
accounts	NNS	account
for	IN	for
11	CD	@card@
%	NN	%
of	IN	of
the	DT	the
world	NN	world
's	POS	's
population	NN	population
,	,	,
it	PP	it
bears	VBZ	bear
24	CD	@card@
%	NN	%
of	IN	of
the	DT	the
global	JJ	global
disease	NN	disease
burden	NN	burden
.	SENT	.
The	DT	the
continent	NN	continent
is	VBZ	be
home	NN	home
to	TO	to
60	CD	@card@
%	NN	%
of	IN	of
the	DT	the
people	NNS	people
with	IN	with
human	JJ	human
immunodeficiency	NN	immunodeficiency
virus	NN	virus
(	(	(
HIV	NP	HIV
)	)	)
,	,	,
and	CC	and
over	IN	over
90	CD	@card@
%	NN	%
of	IN	of
malarial	JJ	malarial
patients	NNS	patient
.	SENT	.
In	IN	in
this	DT	this
region	NN	region
,	,	,
infectious	JJ	infectious
diseases	NNS	disease
such	JJ	such
as	IN	as
malaria	NN	malaria
and	CC	and
HIV	NP	HIV
cause	VBP	cause
69	CD	@card@
%	NN	%
of	IN	of
deaths	NNS	death
.	SENT	.
As	IN	as
states	NNS	state
respond	VBP	respond
to	TO	to
COVID-19	NP	<unknown>
,	,	,
we	PP	we
need	VBP	need
to	TO	to
keep	VB	keep
our	PP$	our
eyes	NNS	eye
open	VBP	open
to	TO	to
what	WP	what
effective	JJ	effective
responses	NNS	response
are	VBP	be
notifying	VBG	notify
us	PP	us
about	IN	about
our	PP$	our
healthcare	NN	<unknown>
systems	NNS	system
,	,	,
so	RB	so
that	IN	that
we	PP	we
can	MD	can
craft	VB	craft
sustainable	JJ	sustainable
interventions	NNS	intervention
as	IN	as
a	DT	a
result	NN	result
and	CC	and
uphold	VB	uphold
the	DT	the
right	NN	right
to	TO	to
health	NN	health
.	SENT	.
This	DT	this
is	VBZ	be
especially	RB	especially
true	JJ	true
in	IN	in
the	DT	the
light	NN	light
of	IN	of
the	DT	the
ongoing	JJ	ongoing
nature	NN	nature
of	IN	of
pandemics	NNS	pandemic
on	IN	on
the	DT	the
continent	NN	continent
,	,	,
making	VBG	make
urgent	JJ	urgent
the	DT	the
need	NN	need
to	TO	to
maximise	VB	maximise
the	DT	the
value	NN	value
of	IN	of
our	PP$	our
health	NN	health
system	NN	system
and	CC	and
its	PP$	its
resources	NNS	resource
,	,	,
as	IN	as
we	PP	we
seek	VBP	seek
lasting	JJ	lasting
transformation	NN	transformation
.	SENT	.
35015739/	CD	@card@
HIV	NP	HIV
and	CC	and
Aging	VBG	age
in	IN	in
the	DT	the
Era	NN	era
of	IN	of
ART	NN	art
and	CC	and
COVID-19	NP	<unknown>
:	:	:
Symposium	NN	symposium
Overview	NN	overview
32358675/	CD	@card@
Pediatric	JJ	pediatric
radiology	NN	radiology
and	CC	and
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
34394297/	CD	@card@
COVID-19	NN	<unknown>
:	:	:
sitting	VBG	sit
is	VBZ	be
the	DT	the
new	JJ	new
smoking	NN	smoking
;	:	;
the	DT	the
role	NN	role
of	IN	of
exercise	NN	exercise
in	IN	in
augmenting	VBG	augment
the	DT	the
immune	JJ	immune
system	NN	system
among	IN	among
the	DT	the
elderly	JJ	elderly
Like	IN	like
smoking	NN	smoking
,	,	,
sedentary	JJ	sedentary
lifestyle	NN	lifestyle
is	VBZ	be
an	DT	an
issue	NN	issue
of	IN	of
great	JJ	great
concern	NN	concern
because	IN	because
of	IN	of
its	PP$	its
deleterious	JJ	deleterious
health	NN	health
challenges	NNS	challenge
and	CC	and
implications	NNS	implication
.	SENT	.
Given	VBN	give
the	DT	the
global	JJ	global
spread	NN	spread
of	IN	of
the	DT	the
new	JJ	new
coronavirus	NN	coronavirus
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
social	JJ	social
isolation	NN	isolation
regulations	NNS	regulation
and	CC	and
laws	NNS	law
have	VBP	have
been	VBN	be
implemented	VBN	implement
in	IN	in
many	JJ	many
countries	NNS	country
to	TO	to
contain	VB	contain
the	DT	the
spread	NN	spread
of	IN	of
the	DT	the
virus	NN	virus
and	CC	and
this	DT	this
has	VBZ	have
caused	VBN	cause
a	DT	a
drastic	JJ	drastic
shift	NN	shift
from	IN	from
the	DT	the
usual	JJ	usual
physically	RB	physically
demanding	VBG	demand
life	NN	life
to	TO	to
a	DT	a
sedentary	JJ	sedentary
lifestyle	NN	lifestyle
characterized	VBN	characterize
by	IN	by
significantly	RB	significantly
reduced	VBN	reduce
physical	JJ	physical
activities	NNS	activity
and	CC	and
prolong	VB	prolong
sitting	VBG	sit
.	SENT	.
Human	JJ	human
and	CC	and
nonhuman	NN	nonhuman
primate	NN	primate
literature	NN	literature
was	VBD	be
examined	VBN	examine
to	TO	to
compare	VB	compare
experimental	JJ	experimental
and	CC	and
clinical	JJ	clinical
modulation	NN	modulation
of	IN	of
inflammatory	JJ	inflammatory
cytokines	NNS	cytokine
by	IN	by
exercised-induced	JJ	<unknown>
myokines	NNS	myokine
.	SENT	.
Experimental	JJ	experimental
and	CC	and
clinical	JJ	clinical
evidence	NN	evidence
was	VBD	be
used	VBN	use
to	TO	to
examine	VB	examine
whether	IN	whether
exercised-induced	JJ	<unknown>
myokines	NNS	myokine
can	MD	can
prime	VB	prime
the	DT	the
immune	JJ	immune
system	NN	system
of	IN	of
the	DT	the
elderly	JJ	elderly
population	NN	population
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
The	DT	the
immune	JJ	immune
system	NN	system
changes	NNS	change
with	IN	with
advancement	NN	advancement
in	IN	in
age	NN	age
which	WDT	which
increases	VBZ	increase
the	DT	the
likelihood	NN	likelihood
of	IN	of
infectious	JJ	infectious
disease	NN	disease
morbidity	NN	morbidity
and	CC	and
mortality	NN	mortality
in	IN	in
older	JJR	old
adults	NNS	adult
.	SENT	.
Several	JJ	several
epidemiological	JJ	epidemiological
studies	NNS	study
have	VBP	have
also	RB	also
shown	VBN	show
that	IN	that
physical	JJ	physical
inactivity	NN	inactivity
among	IN	among
geriatric	JJ	geriatric
population	NN	population
impacts	NNS	impact
negatively	RB	negatively
on	IN	on
the	DT	the
immune	JJ	immune
system	NN	system
.	SENT	.
Evidences	NNS	evidence
on	IN	on
the	DT	the
importance	NN	importance
of	IN	of
exercise	NN	exercise
in	IN	in
priming	VBG	prime
the	DT	the
immune	JJ	immune
system	NN	system
of	IN	of
elderly	JJ	elderly
individuals	NNS	individual
could	MD	could
be	VB	be
an	DT	an
effective	JJ	effective
therapeutic	JJ	therapeutic
strategy	NN	strategy
in	IN	in
combating	VBG	combat
the	DT	the
virus	NN	virus
as	IN	as
it	PP	it
may	MD	may
well	RB	well
be	VB	be
a	DT	a
case	NN	case
of	IN	of
"	``	"
let	VB	let
those	DT	those
with	IN	with
the	DT	the
best	RBS	well
immune	JJ	immune
system	NN	system
win	NN	win
"	''	"
.	SENT	.
35206163/	CD	@card@
Experiences	NNS	experience
of	IN	of
Perinatal	JJ	perinatal
Mental	JJ	mental
Health	NP	Health
Care	NP	Care
among	IN	among
Minority	NP	Minority
Ethnic	JJ	ethnic
Women	NNS	woman
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
Pandemic	NN	pandemic
in	IN	in
London	NP	London
:	:	:
A	DT	a
Qualitative	JJ	qualitative
Study	NN	study
(	(	(
1	CD	@card@
)	)	)
Background	NN	background
:	:	:
Approximately	RB	approximately
one	CD	one
in	IN	in
five	CD	five
women	NNS	woman
will	MD	will
experience	VB	experience
mental	JJ	mental
health	NN	health
difficulties	NNS	difficulty
in	IN	in
the	DT	the
perinatal	JJ	perinatal
period	NN	period
.	SENT	.
Women	NNS	woman
from	IN	from
ethnic	JJ	ethnic
minority	NN	minority
backgrounds	NNS	background
face	VBP	face
a	DT	a
variety	NN	variety
of	IN	of
barriers	NNS	barrier
that	WDT	that
can	MD	can
prevent	VB	prevent
or	CC	or
delay	VB	delay
access	NN	access
to	TO	to
appropriate	JJ	appropriate
perinatal	JJ	perinatal
mental	JJ	mental
health	NN	health
care	NN	care
.	SENT	.
COVID-19	JJ	<unknown>
pandemic	JJ	pandemic
restrictions	NNS	restriction
created	VBD	create
additional	JJ	additional
obstacles	NNS	obstacle
for	IN	for
this	DT	this
group	NN	group
of	IN	of
women	NNS	woman
.	SENT	.
This	DT	this
study	NN	study
aims	VBZ	aim
to	TO	to
explore	VB	explore
minority	NN	minority
ethnic	JJ	ethnic
women	NNS	woman
's	POS	's
experiences	NNS	experience
of	IN	of
perinatal	JJ	perinatal
mental	JJ	mental
health	NN	health
services	NNS	service
during	IN	during
COVID-19	NP	<unknown>
in	IN	in
London	NP	London
.	SENT	.
(	(	(
2	LS	2
)	)	)
Methods	NNS	method
:	:	:
Eighteen	CD	eighteen
women	NNS	woman
from	IN	from
ethnic	JJ	ethnic
minority	NN	minority
backgrounds	NNS	background
were	VBD	be
interviewed	VBN	interview
,	,	,
and	CC	and
data	NNS	datum
were	VBD	be
subject	JJ	subject
to	TO	to
a	DT	a
thematic	JJ	thematic
analysis	NN	analysis
.	SENT	.
(	(	(
3	LS	3
)	)	)
Results	NNS	result
:	:	:
Three	CD	three
main	JJ	main
themes	NNS	theme
were	VBD	be
identified	VBN	identify
,	,	,
each	DT	each
with	IN	with
two	CD	two
subthemes	NNS	subtheme
:	:	:
'	''	'
Difficulties	NNS	difficulty
and	CC	and
Disruptions	NNS	disruption
to	TO	to
Access	NP	Access
'	''	'
(	(	(
Access	NP	Access
to	TO	to
Appointments	NNS	appointment
;	:	;
Pandemic	JJ	pandemic
Restrictions	NNS	restriction
and	CC	and
Disruption	NN	disruption
)	)	)
,	,	,
'	''	'
Experiences	VBZ	experience
of	IN	of
Remote	JJ	remote
Delivery	NN	delivery
'	''	'
(	(	(
Preference	NN	preference
for	IN	for
Face-to-Face	JJ	face-to-face
Contact	NN	contact
;	:	;
Advantages	NNS	advantage
of	IN	of
Remote	JJ	remote
Support	NN	support
)	)	)
;	:	;
and	NP	and
'	POS	'
Psychosocial	JJ	psychosocial
Experiences	NNS	experience
'	''	'
linked	VBN	link
to	TO	to
COVID-19	NP	<unknown>
(	(	(
Heightened	JJ	heightened
Anxiety	NN	anxiety
;	:	;
Social	NP	Social
Isolation	NN	isolation
)	)	)
.	SENT	.
(	(	(
4	LS	4
)	)	)
Conclusions	NNS	conclusion
:	:	:
Women	NNS	woman
from	IN	from
ethnic	JJ	ethnic
minority	NN	minority
backgrounds	NNS	background
experienced	VBD	experience
disrupted	VBN	disrupt
perinatal	JJ	perinatal
mental	JJ	mental
health	NN	health
care	NN	care
and	CC	and
COVID-19	JJ	<unknown>
restrictions	NNS	restriction
compounding	VBG	compound
their	PP$	their
mental	JJ	mental
health	NN	health
difficulties	NNS	difficulty
.	SENT	.
Services	NNS	service
should	MD	should
take	VB	take
women	NNS	woman
's	POS	's
circumstances	NNS	circumstance
into	IN	into
account	NN	account
and	CC	and
provide	VB	provide
flexibility	NN	flexibility
regarding	VBG	regard
remote	JJ	remote
delivery	NN	delivery
of	IN	of
care	NN	care
.	SENT	.
35480831/	CD	@card@
Potential	JJ	potential
inhibitors	NNS	inhibitor
for	IN	for
SARS-CoV-2	NP	<unknown>
Mpro	NP	<unknown>
from	IN	from
marine	JJ	marine
compounds	NNS	compound
Preventing	VBG	prevent
the	DT	the
biological	JJ	biological
activity	NN	activity
of	IN	of
SARS-CoV-2	NP	<unknown>
main	JJ	main
protease	NN	protease
using	VBG	use
natural	JJ	natural
compounds	NNS	compound
is	VBZ	be
of	IN	of
great	JJ	great
interest	NN	interest
.	SENT	.
In	IN	in
this	DT	this
context	NN	context
,	,	,
using	VBG	use
a	DT	a
combination	NN	combination
of	IN	of
AutoDock	NP	<unknown>
Vina	NP	Vina
and	CC	and
fast	RB	fast
pulling	VBG	pull
of	IN	of
ligand	NN	ligand
simulations	NNS	simulation
,	,	,
eleven	NN	eleven
marine	JJ	marine
fungi	NNS	fungus
compounds	NNS	compound
were	VBD	be
identified	VBN	identify
that	IN	that
probably	RB	probably
play	VB	play
as	RB	as
highly	RB	highly
potent	JJ	potent
inhibitors	NNS	inhibitor
for	IN	for
preventing	VBG	prevent
viral	JJ	viral
replication	NN	replication
.	SENT	.
In	IN	in
particular	JJ	particular
,	,	,
four	CD	four
compounds	NNS	compound
including	VBG	include
M15	NP	M@card@
(3-O-(6-O-alpha-l-arabinopyranosyl)-beta-d-glucopyranosyl-1,4-dimethoxyxanthone)	NP	<unknown>
,	,	,
M8	NP	<unknown>
(	(	(
wailupemycins	NNS	<unknown>
H	NN	H
)	)	)
,	,	,
M11	JJ	M@card@
(	(	(
cottoquinazolines	NNS	cottoquinazoline
B	NN	B
)	)	)
,	,	,
and	CC	and
M9	JJ	<unknown>
(	(	(
wailupemycins	NNS	<unknown>
I	PP	I
)	)	)
adopted	VBD	adopt
the	DT	the
predicted	VBN	predict
ligand-binding	NN	ligand-binding
free	JJ	free
energy	NN	energy
of	IN	of
-9.87	CD	@card@
,	,	,
-9.82	CD	@card@
,	,	,
-9.62	CD	@card@
,	,	,
and	CC	and
-9.35	CD	@card@
kcal	JJ	<unknown>
mol-1	NN	<unknown>
,	,	,
respectively	RB	respectively
,	,	,
whereas	IN	whereas
the	DT	the
other	JJ	other
adopted	JJ	adopted
predicted	VBD	predict
ligand-binding	VBG	ligand-bind
free	JJ	free
energies	NNS	energy
in	IN	in
the	DT	the
range	NN	range
from	IN	from
-8.54	CD	@card@
to	TO	to
-8.94	CD	@card@
kcal	JJ	<unknown>
mol-1	NN	<unknown>
.	SENT	.
The	DT	the
results	NNS	result
were	VBD	be
obtained	VBN	obtain
using	VBG	use
a	DT	a
combination	NN	combination
of	IN	of
Vina	NP	Vina
and	CC	and
FPL	NP	FPL
simulations	NNS	simulation
.	SENT	.
Notably	RB	notably
,	,	,
although	IN	although
,	,	,
AutoDock4	NP	<unknown>
adopted	VBD	adopt
higher	JJR	high
accurate	JJ	accurate
results	NNS	result
in	IN	in
comparison	NN	comparison
with	IN	with
Vina	NP	Vina
,	,	,
Vina	NP	Vina
is	VBZ	be
proven	VBN	prove
to	TO	to
be	VB	be
a	DT	a
more	RBR	more
suitable	JJ	suitable
technique	NN	technique
for	IN	for
rapidly	RB	rapidly
screening	VBG	screen
ligand-binding	JJ	ligand-binding
affinity	NN	affinity
with	IN	with
a	DT	a
large	JJ	large
database	NN	database
of	IN	of
compounds	NNS	compound
since	IN	since
it	PP	it
requires	VBZ	require
much	RB	much
smaller	JJR	small
computing	NN	computing
resources	NNS	resource
.	SENT	.
Furthermore	RB	furthermore
,	,	,
FPL	NP	FPL
is	VBZ	be
better	JJR	good
than	IN	than
Vina	NP	Vina
to	TO	to
classify	VB	classify
inhibitors	NNS	inhibitor
upon	IN	upon
ROC-AUC	NP	<unknown>
analysis	NN	analysis
.	SENT	.
Preventing	VBG	prevent
the	DT	the
biological	JJ	biological
activity	NN	activity
of	IN	of
SARS-CoV-2	NP	<unknown>
main	JJ	main
protease	NN	protease
using	VBG	use
natural	JJ	natural
compounds	NNS	compound
is	VBZ	be
of	IN	of
great	JJ	great
interest	NN	interest
.	SENT	.
33670316/	CD	@card@
Antimicrobial	JJ	Antimicrobial
Resistance	NN	resistance
Patterns	NNS	pattern
and	CC	and
Antibiotic	JJ	antibiotic
Use	NN	use
during	IN	during
Hospital	NP	Hospital
Conversion	NN	conversion
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
Pandemic	JJ	pandemic
Objective	NN	objective
:	:	:
To	TO	to
describe	VB	describe
empirical	JJ	empirical
antimicrobial	JJ	antimicrobial
prescription	NN	prescription
on	IN	on
admission	NN	admission
in	IN	in
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
,	,	,
the	DT	the
prevalence	NN	prevalence
of	IN	of
Hospital-Acquired	JJ	<unknown>
Infections	NNS	infection
,	,	,
and	CC	and
the	DT	the
susceptibility	NN	susceptibility
patterns	NNS	pattern
of	IN	of
the	DT	the
causing	VBG	cause
organisms	NNS	organism
.	SENT	.
Methods	NNS	method
:	:	:
In	IN	in
this	DT	this
prospective	JJ	prospective
cohort	NN	cohort
study	NN	study
in	IN	in
a	DT	a
tertiary	JJ	tertiary
care	NN	care
center	NN	center
in	IN	in
Mexico	NP	Mexico
City	NP	City
,	,	,
we	PP	we
included	VBD	include
consecutive	JJ	consecutive
patients	NNS	patient
admitted	VBN	admit
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
between	IN	between
March	NP	March
20th	JJ	20th
and	CC	and
June	NP	June
10th	JJ	10th
and	CC	and
evaluated	VBN	evaluate
empirical	JJ	empirical
antimicrobial	JJ	antimicrobial
prescription	NN	prescription
and	CC	and
the	DT	the
occurrence	NN	occurrence
of	IN	of
HAI	NNS	hai
.	SENT	.
Results	NNS	result
:	:	:
794	CD	@card@
patients	NNS	patient
with	IN	with
severe	JJ	severe
COVID-19	NP	<unknown>
were	VBD	be
admitted	VBN	admit
during	IN	during
the	DT	the
study	NN	study
period	NN	period
.	SENT	.
Empiric	JJ	empiric
antibiotic	JJ	antibiotic
treatment	NN	treatment
was	VBD	be
started	VBN	start
in	IN	in
92	CD	@card@
%	NN	%
of	IN	of
patients	NNS	patient
(	(	(
731/794	CD	@card@
)	)	)
;	:	;
the	DT	the
most	RBS	most
frequent	JJ	frequent
regimes	NNS	regime
were	VBD	be
amoxicillin-clavulanate	JJ	amoxicillin-clavulanate
plus	CC	plus
atypical	JJ	atypical
coverage	NN	coverage
in	IN	in
341	CD	@card@
(	(	(
46.6	CD	@card@
%	NN	%
)	)	)
and	CC	and
ceftriaxone	NN	ceftriaxone
plus	CC	plus
atypical	JJ	atypical
coverage	NN	coverage
in	IN	in
213	CD	@card@
(	(	(
29.1	CD	@card@
%	NN	%
)	)	)
.	SENT	.
We	PP	we
identified	VBD	identify
110	CD	@card@
HAI	NNS	hai
episodes	NNS	episode
in	IN	in
74/656	CD	@card@
patients	NNS	patient
(	(	(
11.3	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Ventilator-associated	JJ	Ventilator-associated
pneumonia	NN	pneumonia
(	(	(
VAP	NP	VAP
)	)	)
was	VBD	be
the	DT	the
most	RBS	most
frequent	JJ	frequent
HAI	NNS	hai
,	,	,
in	IN	in
56/110	CD	@card@
(	(	(
50.9	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
bloodstream	NN	bloodstream
infections	NNS	infection
(	(	(
BSI	NP	BSI
)	)	)
,	,	,
in	IN	in
32/110	CD	@card@
(	(	(
29.1	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
most	RBS	most
frequent	JJ	frequent
cause	NN	cause
of	IN	of
VAP	NP	VAP
were	VBD	be
Enterobacteriaceae	NP	<unknown>
in	IN	in
48/69	CD	@card@
(	(	(
69.6	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
non-fermenter	JJ	<unknown>
gram-negative	JJ	Gram-negative
bacilli	NNS	bacillus
in	IN	in
18/69	CD	@card@
(	(	(
26.1	CD	@card@
%	NN	%
)	)	)
.	SENT	.
The	DT	the
most	RBS	most
frequent	JJ	frequent
cause	NN	cause
of	IN	of
BSI	NP	BSI
was	VBD	be
coagulase	NN	coagulase
negative	JJ	negative
staphylococci	NNS	staphylococcus
,	,	,
in	IN	in
14/35	CD	@card@
(	(	(
40.0	CD	@card@
%	NN	%
)	)	)
,	,	,
followed	VBN	follow
by	IN	by
Enterobacter	NP	<unknown>
complex	NN	complex
in	IN	in
7/35	CD	@card@
(	(	(
20	CD	@card@
%	NN	%
)	)	)
.	SENT	.
Death	NN	death
occurred	VBD	occur
in	IN	in
30/74	CD	@card@
(	(	(
40.5	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
with	IN	with
one	CD	one
or	CC	or
more	JJR	more
HAI	NNS	hai
episodes	NNS	episode
and	CC	and
in	IN	in
193/584	CD	@card@
(	(	(
33.0	CD	@card@
%	NN	%
)	)	)
patients	NNS	patient
without	IN	without
any	DT	any
HAI	NNS	hai
episode	NN	episode
(	(	(
p	NN	p
&lt	NN	&lt
;	:	;
0.05	LS	@card@
)	)	)
.	SENT	.
Conclusion	NN	conclusion
:	:	:
A	DT	a
high	JJ	high
frequency	NN	frequency
of	IN	of
empiric	JJ	empiric
antibiotic	JJ	antibiotic
treatment	NN	treatment
in	IN	in
patients	NNS	patient
admitted	VBN	admit
with	IN	with
COVID-19	NP	<unknown>
was	VBD	be
seen	VBN	see
.	SENT	.
VAP	NP	VAP
and	CC	and
BSI	NP	BSI
were	VBD	be
the	DT	the
most	RBS	most
frequent	JJ	frequent
hospital-acquired	JJ	hospital-acquired
infections	NNS	infection
,	,	,
due	JJ	due
to	TO	to
Enterobacteriaceae	NNS	<unknown>
and	CC	and
coagulase	NN	coagulase
negative	JJ	negative
staphylococci	NNS	staphylococcus
,	,	,
respectively	RB	respectively
.	SENT	.
35146922/	CD	@card@
Factors	NNS	factor
affecting	VBG	affect
the	DT	the
transmission	NN	transmission
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
school	NN	school
settings	NNS	setting
Several	JJ	several
studies	NNS	study
have	VBP	have
reported	VBN	report
SARS-CoV-2	JJ	<unknown>
outbreaks	NNS	outbreak
in	IN	in
schools	NNS	school
,	,	,
with	IN	with
a	DT	a
wide	JJ	wide
range	NN	range
of	IN	of
secondary	JJ	secondary
attack	NN	attack
rate	NN	rate
(	(	(
SAR	NP	SAR
;	:	;
range	NN	range
:	:	:
0-100	CD	@card@
%	NN	%
)	)	)
.	SENT	.
We	PP	we
aimed	VBD	aim
to	TO	to
examine	VB	examine
key	JJ	key
risk	NN	risk
factors	NNS	factor
to	TO	to
better	RBR	well
understand	VB	understand
SARS-CoV-2	JJ	<unknown>
transmission	NN	transmission
in	IN	in
schools	NNS	school
.	SENT	.
We	PP	we
collected	VBD	collect
records	NNS	record
of	IN	of
35	CD	@card@
SARS-CoV-2	NP	<unknown>
school	NN	school
outbreaks	NNS	outbreak
globally	RB	globally
published	VBN	publish
from	IN	from
January	NP	January
2020	CD	@card@
to	TO	to
July	NP	July
2021	CD	@card@
and	CC	and
compiled	VBN	compile
information	NN	information
on	IN	on
hypothesized	VBN	hypothesize
risk	NN	risk
factors	NNS	factor
.	SENT	.
We	PP	we
utilized	VBD	utilize
the	DT	the
directed	VBN	direct
acyclic	JJ	acyclic
graph	NN	graph
(	(	(
DAG	NN	dag
)	)	)
to	TO	to
conceptualize	VB	conceptualize
risk	NN	risk
mechanisms	NNS	mechanism
,	,	,
used	VBN	use
logistic	JJ	logistic
regression	NN	regression
to	TO	to
examine	VB	examine
each	DT	each
risk-factor	NN	risk-factor
group	NN	group
,	,	,
and	CC	and
further	RBR	further
built	VBN	build
multirisk	NN	<unknown>
models	NNS	model
.	SENT	.
The	DT	the
best-fit	NN	<unknown>
model	NN	model
showed	VBD	show
that	IN	that
the	DT	the
intensity	NN	intensity
of	IN	of
community	NN	community
transmission	NN	transmission
(	(	(
adjusted	JJ	adjusted
odds	NNS	odd
ratio	NN	ratio
[	SYM	[
aOR	NN	aOR
]	SYM	]
:	:	:
1.11	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
1.06-1.16	LS	@card@
,	,	,
for	IN	for
each	DT	each
increase	NN	increase
of	IN	of
1	CD	@card@
case	NN	case
per	IN	per
10	CD	@card@
000	CD	@card@
persons	NNS	person
per	IN	per
week	NN	week
)	)	)
and	CC	and
individualism	NN	individualism
(	(	(
aOR	NP	aOR
:	:	:
2.72	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
1.50-4.95	LS	@card@
,	,	,
above	IN	above
vs.	NN	vs.
below	IN	below
the	DT	the
mean	NN	mean
)	)	)
was	VBD	be
associated	VBN	associate
higher	JJR	high
risk	NN	risk
,	,	,
whereas	IN	whereas
preventive	JJ	preventive
measures	NNS	measure
(	(	(
aOR	NP	aOR
:	:	:
0.25	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.19-0.32	CD	@card@
,	,	,
distancing	VBG	distance
and	CC	and
masking	VBG	mask
vs.	IN	vs.
none	NN	none
)	)	)
and	CC	and
higher	JJR	high
population	NN	population
immunity	NN	immunity
(	(	(
aOR	NP	aOR
:	:	:
0.57	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.46-0.71	LS	@card@
)	)	)
were	VBD	be
associated	VBN	associate
with	IN	with
lower	JJR	low
risk	NN	risk
of	IN	of
SARS-CoV-2	NP	<unknown>
transmission	NN	transmission
in	IN	in
schools	NNS	school
.	SENT	.
Compared	VBN	compare
with	IN	with
students	NNS	student
in	IN	in
high	JJ	high
schools	NNS	school
,	,	,
the	DT	the
aOR	NN	aOR
was	VBD	be
0.47	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.23-0.95	LS	@card@
)	)	)
for	IN	for
students	NNS	student
in	IN	in
preschools	NNS	preschool
and	CC	and
0.90	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
:	:	:
0.76-1.08	LS	@card@
)	)	)
for	IN	for
students	NNS	student
in	IN	in
primary	JJ	primary
schools	NNS	school
.	SENT	.
Preventive	JJ	preventive
measures	NNS	measure
in	IN	in
schools	NNS	school
(	(	(
e.g.	FW	e.g.
,	,	,
social	JJ	social
distancing	NN	distancing
and	CC	and
mask	VB	mask
wearing	VBG	wear
)	)	)
and	CC	and
communal	JJ	communal
efforts	NNS	effort
to	TO	to
lower	JJR	low
transmission	NN	transmission
and	CC	and
increase	NN	increase
vaccination	NN	vaccination
uptake	NN	uptake
(	(	(
i.e.	FW	i.e.
,	,	,
vaccine-induced	JJ	<unknown>
population	NN	population
immunity	NN	immunity
)	)	)
in	IN	in
the	DT	the
community	NN	community
should	MD	should
be	VB	be
taken	VBN	take
to	TO	to
collectively	RB	collectively
reduce	VB	reduce
transmission	NN	transmission
and	CC	and
protect	VB	protect
children	NNS	child
in	IN	in
schools	NNS	school
.	SENT	.
32268212/	NP	@card@
Corona	NP	Corona
(	(	(
COVID-19	NP	<unknown>
)	)	)
time	NN	time
musings	NNS	musing
:	:	:
Our	PP$	our
involvement	NN	involvement
in	IN	in
COVID-19	NP	<unknown>
pathogenesis	NN	pathogenesis
,	,	,
diagnosis	NN	diagnosis
,	,	,
treatment	NN	treatment
and	CC	and
vaccine	NN	vaccine
planning	VBG	plan
34129787/	CD	@card@
Efficient	JJ	efficient
and	CC	and
effective	JJ	effective
single-step	VBP	single-step
screening	NN	screening
of	IN	of
individual	JJ	individual
samples	NNS	sample
for	IN	for
SARS-CoV-2	NP	<unknown>
RNA	NP	RNA
using	VBG	use
multi-dimensional	JJ	multi-dimensional
pooling	VBG	pool
and	CC	and
Bayesian	NP	<unknown>
inference	NN	inference
Rapid	NP	Rapid
and	CC	and
widespread	JJ	widespread
implementation	NN	implementation
of	IN	of
infectious	JJ	infectious
disease	NN	disease
surveillance	NN	surveillance
is	VBZ	be
a	DT	a
critical	JJ	critical
component	NN	component
in	IN	in
the	DT	the
response	NN	response
to	TO	to
novel	JJ	novel
health	NN	health
threats	NNS	threat
.	SENT	.
Molecular	JJ	molecular
assays	NNS	assay
are	VBP	be
the	DT	the
preferred	JJ	preferred
method	NN	method
to	TO	to
detect	VB	detect
a	DT	a
broad	JJ	broad
range	NN	range
of	IN	of
viral	JJ	viral
pathogens	NNS	pathogen
with	IN	with
high	JJ	high
sensitivity	NN	sensitivity
and	CC	and
specificity	NN	specificity
.	SENT	.
The	DT	the
implementation	NN	implementation
of	IN	of
molecular	JJ	molecular
assay	NN	assay
testing	NN	testing
in	IN	in
a	DT	a
rapidly	RB	rapidly
evolving	VBG	evolve
public	JJ	public
health	NN	health
emergency	NN	emergency
,	,	,
such	JJ	such
as	IN	as
the	DT	the
ongoing	JJ	ongoing
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
can	MD	can
be	VB	be
hindered	VBN	hinder
by	IN	by
resource	NN	resource
availability	NN	availability
or	CC	or
technical	JJ	technical
constraints	NNS	constraint
.	SENT	.
We	PP	we
present	VBP	present
a	DT	a
screening	NN	screening
strategy	NN	strategy
that	WDT	that
is	VBZ	be
easily	RB	easily
scaled	VBN	scale
up	RP	up
to	TO	to
support	VB	support
a	DT	a
sustained	JJ	sustained
large	JJ	large
volume	NN	volume
of	IN	of
testing	NN	testing
over	IN	over
long	JJ	long
periods	NNS	period
of	IN	of
time	NN	time
.	SENT	.
This	DT	this
non-adaptive	JJ	non-adaptive
pooled-sample	NN	pooled-sample
screening	NN	screening
protocol	NN	protocol
employs	VBZ	employ
Bayesian	JJ	<unknown>
inference	NN	inference
to	TO	to
yield	VB	yield
a	DT	a
reportable	JJ	reportable
outcome	NN	outcome
for	IN	for
each	DT	each
individual	JJ	individual
sample	NN	sample
in	IN	in
a	DT	a
single	JJ	single
testing	NN	testing
step	NN	step
(	(	(
no	DT	no
confirmation	NN	confirmation
of	IN	of
positive	JJ	positive
results	NNS	result
required	VBD	require
)	)	)
.	SENT	.
The	DT	the
proposed	VBN	propose
method	NN	method
is	VBZ	be
validated	VBN	validate
using	VBG	use
clinical	JJ	clinical
specimens	NNS	specimen
tested	VBD	test
using	VBG	use
a	DT	a
real-time	JJ	real-time
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
test	NN	test
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
This	DT	this
screening	NN	screening
protocol	NN	protocol
has	VBZ	have
substantial	JJ	substantial
advantages	NNS	advantage
for	IN	for
its	PP$	its
implementation	NN	implementation
,	,	,
including	VBG	include
higher	JJR	high
sample	NN	sample
throughput	NN	throughput
,	,	,
faster	JJR	fast
time	NN	time
to	TO	to
results	NNS	result
,	,	,
no	DT	no
need	NN	need
to	TO	to
retrieve	VB	retrieve
previously	RB	previously
screened	VBN	screen
samples	NNS	sample
from	IN	from
storage	NN	storage
to	TO	to
undergo	VB	undergo
retesting	NN	retesting
,	,	,
and	CC	and
excellent	JJ	excellent
performance	NN	performance
of	IN	of
the	DT	the
algorithm	NN	algorithm
's	POS	's
sensitivity	NN	sensitivity
and	CC	and
specificity	NN	specificity
compared	VBN	compare
with	IN	with
the	DT	the
individual	JJ	individual
test	NN	test
's	POS	's
metrics	NNS	metric
.	SENT	.
34589743/	CD	@card@
Assessment	NP	Assessment
of	IN	of
cytokines	NNS	cytokine
,	,	,
microRNA	NN	<unknown>
and	CC	and
patient	JJ	patient
related	JJ	related
outcome	NN	outcome
measures	NNS	measure
in	IN	in
conversion	NN	conversion
disorder/functional	JJ	disorder/functional
neurological	JJ	neurological
disorder	NN	disorder
(	(	(
CD/FND	NP	<unknown>
)	)	)
:	:	:
The	DT	the
CANDO	NP	Cando
clinical	JJ	clinical
feasibility	NN	feasibility
study	NN	study
Conversion	NN	conversion
disorder/functional	JJ	disorder/functional
neurological	JJ	neurological
disorder	NN	disorder
(	(	(
CD/FND	NP	<unknown>
)	)	)
occurs	VBZ	occur
often	RB	often
in	IN	in
neurological	JJ	neurological
settings	NNS	setting
and	CC	and
can	MD	can
lead	VB	lead
to	TO	to
long-term	JJ	long-term
distress	NN	distress
,	,	,
disability	NN	disability
and	CC	and
demand	NN	demand
on	IN	on
health	NN	health
care	NN	care
services	NNS	service
.	SENT	.
Systemic	JJ	systemic
low-grade	NN	low-grade
inflammation	NN	inflammation
might	MD	might
play	VB	play
a	DT	a
role	NN	role
,	,	,
however	RB	however
,	,	,
the	DT	the
pathogenic	JJ	pathogenic
mechanism	NN	mechanism
is	VBZ	be
still	RB	still
unknown	JJ	unknown
.	SENT	.
1	LS	1
)	)	)
To	TO	to
explore	VB	explore
the	DT	the
feasibility	NN	feasibility
to	TO	to
establish	VB	establish
and	CC	and
assess	VB	assess
a	DT	a
cohort	NN	cohort
of	IN	of
CD/FND	NP	<unknown>
with	IN	with
motor	NN	motor
symptoms	NNS	symptom
,	,	,
involving	VBG	involve
persons	NNS	person
with	IN	with
lived	VBN	live
experience	NN	experience
(	(	(
PPI	NP	PPI
)	)	)
.	SENT	.
2	LS	2
)	)	)
To	TO	to
generate	VB	generate
proof	NN	proof
of	IN	of
concept	NN	concept
regarding	VBG	regard
a	DT	a
possible	JJ	possible
role	NN	role
for	IN	for
cytokines	NNS	cytokine
,	,	,
microRNA	NP	<unknown>
,	,	,
cortisol	NN	cortisol
levels	NNS	level
and	CC	and
neurocognitive	JJ	neurocognitive
symptoms	NNS	symptom
in	IN	in
patients	NNS	patient
with	IN	with
motor	NN	motor
CD/FND	NP	<unknown>
.	SENT	.
Feasibility	NN	feasibility
study	NN	study
.	SENT	.
The	DT	the
study	NN	study
showed	VBD	show
active	JJ	active
involvement	NN	involvement
of	IN	of
patients	NNS	patient
despite	IN	despite
high	JJ	high
clinical	JJ	clinical
illness	NN	illness
burden	NN	burden
and	CC	and
disability	NN	disability
,	,	,
neurocognitive	JJ	neurocognitive
symptoms	NNS	symptom
,	,	,
childhood	NN	childhood
adverse	JJ	adverse
experiences	NNS	experience
(	(	(
ACE	NN	ace
)	)	)
and	CC	and
current	JJ	current
life	NN	life
events	NNS	event
.	SENT	.
The	DT	the
study	NN	study
provided	VBD	provide
valuable	JJ	valuable
knowledge	NN	knowledge
regarding	VBG	regard
the	DT	the
feasibility	NN	feasibility
of	IN	of
conducting	VBG	conduct
a	DT	a
study	NN	study
in	IN	in
these	DT	these
patients	NNS	patient
that	WDT	that
will	MD	will
inform	VB	inform
future	JJ	future
study	NN	study
phases	NNS	phase
.	SENT	.
In	IN	in
the	DT	the
sample	NN	sample
there	EX	there
were	VBD	be
elevated	JJ	elevated
levels	NNS	level
of	IN	of
IL6	NP	<unknown>
,	,	,
IL12	NP	<unknown>
,	,	,
IL17A	NP	<unknown>
,	,	,
IFNg	NP	<unknown>
,	,	,
TNFa	NP	<unknown>
and	CC	and
VEGF-a	NP	<unknown>
,	,	,
suggesting	VBG	suggest
systemic	JJ	systemic
low-grade	NN	low-grade
inflammation	NN	inflammation
.	SENT	.
Also	RB	also
,	,	,
microRNAs	NNS	<unknown>
involved	VBN	involve
in	IN	in
inflammation	NN	inflammation
and	CC	and
vascular	JJ	vascular
inflammation	NN	inflammation
were	VBD	be
correlated	VBN	correlate
with	IN	with
TNFa	NP	<unknown>
and	CC	and
VEGFa	NP	<unknown>
respectively	RB	respectively
,	,	,
suggesting	VBG	suggest
proof	NN	proof
of	IN	of
concept	NN	concept
for	IN	for
an	DT	an
epigenetic	JJ	epigenetic
mechanism	NN	mechanism
.	SENT	.
Owing	VBG	owe
to	TO	to
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
,	,	,
the	DT	the
patient	JJ	patient
sample	NN	sample
was	VBD	be
limited	VBN	limit
to	TO	to
15	CD	@card@
patients	NNS	patient
.	SENT	.
It	PP	it
is	VBZ	be
a	DT	a
novelty	NN	novelty
that	IN	that
this	DT	this
study	NN	study
is	VBZ	be
conducted	VBN	conduct
in	IN	in
the	DT	the
clinical	JJ	clinical
setting	NN	setting
.	SENT	.
This	DT	this
innovative	JJ	innovative
,	,	,
translational	JJ	translational
study	NN	study
explores	VBZ	explore
stress-related	JJ	stress-related
SLI	NP	SLI
in	IN	in
CD/FND	NP	<unknown>
patients	NNS	patient
and	CC	and
the	DT	the
feasibility	NN	feasibility
of	IN	of
a	DT	a
larger	JJR	large
project	NN	project
aiming	VBG	aim
to	TO	to
develop	VB	develop
new	JJ	new
treatments	NNS	treatment
for	IN	for
this	DT	this
vulnerable	JJ	vulnerable
population	NN	population
.	SENT	.
Given	VBN	give
the	DT	the
positive	JJ	positive
findings	NNS	finding
,	,	,
there	EX	there
is	VBZ	be
scope	NN	scope
to	TO	to
conduct	VB	conduct
further	JJR	further
research	NN	research
into	IN	into
the	DT	the
mechanism	NN	mechanism
of	IN	of
disease	NN	disease
in	IN	in
CD/FND	NP	<unknown>
.	SENT	.
It	PP	it
is	VBZ	be
feasible	JJ	feasible
to	TO	to
establish	VB	establish
and	CC	and
assess	VB	assess
a	DT	a
cohort	NN	cohort
of	IN	of
CD/FND	NP	<unknown>
with	IN	with
motor	NN	motor
symptoms	NNS	symptom
,	,	,
involving	VBG	involve
persons	NNS	person
with	IN	with
lived	VBN	live
experience	NN	experience
(	(	(
PPI	NP	PPI
)	)	)
.	SENT	.
IL6	NP	<unknown>
,	,	,
TNFa	NP	<unknown>
,	,	,
IFNg	NP	<unknown>
,	,	,
TNFa	NP	<unknown>
,	,	,
IL12	NP	<unknown>
and	CC	and
IL17A	NP	<unknown>
are	VBP	be
significantly	RB	significantly
higher	JJR	high
than	IN	than
normal	JJ	normal
in	IN	in
CD/FND	NP	<unknown>
patients	NNS	patient
.	SENT	.
VEGF-a	NP	<unknown>
is	VBZ	be
significantly	RB	significantly
lower	JJR	low
,	,	,
suggesting	VBG	suggest
a	DT	a
lack	NN	lack
of	IN	of
vascular	JJ	vascular
and	CC	and
neuronal	JJ	<unknown>
support	NN	support
.	SENT	.
TNFa	NP	<unknown>
correlated	VBD	correlate
with	IN	with
microRNA	NN	<unknown>
associated	VBN	associate
with	IN	with
inflammation	NN	inflammation
(	(	(
miR-146a	NN	<unknown>
and	CC	and
miR-155	NN	<unknown>
)	)	)
.	SENT	.
This	DT	this
suggests	VBZ	suggest
an	DT	an
epigenetic	JJ	epigenetic
mechanism	NN	mechanism
.	SENT	.
VEGFa	NP	<unknown>
correlated	VBD	correlate
with	IN	with
miR-21	JJ	<unknown>
and	CC	and
miR-132	JJ	<unknown>
,	,	,
suggesting	VBG	suggest
an	DT	an
epigenetic	JJ	epigenetic
mechanism	NN	mechanism
associated	VBN	associate
with	IN	with
vascular	JJ	vascular
inflammation	NN	inflammation
.	SENT	.
35236317/	CD	@card@
Impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
on	IN	on
infectious	JJ	infectious
disease	NN	disease
hospitalizations	NNS	hospitalization
of	IN	of
neonates	NNS	neonate
at	IN	at
a	DT	a
tertiary	JJ	tertiary
academic	JJ	academic
hospital	NN	hospital
:	:	:
a	DT	a
cross-sectional	JJ	cross-sectional
study	NN	study
To	TO	to
investigate	VB	investigate
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
pandemic	NN	pandemic
on	IN	on
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
.	SENT	.
We	PP	we
analyzed	VBD	analyze
data	NNS	datum
for	IN	for
neonatal	JJ	neonatal
inpatients	NNS	inpatient
admitted	VBN	admit
at	IN	at
a	DT	a
tertiary	JJ	tertiary
academic	JJ	academic
hospital	NN	hospital
with	IN	with
a	DT	a
principal	JJ	principal
diagnosis	NN	diagnosis
of	IN	of
an	DT	an
infectious	JJ	infectious
disease	NN	disease
during	IN	during
January	NP	January
2015	CD	@card@
to	TO	to
December	NP	December
2020	CD	@card@
.	SENT	.
We	PP	we
compared	VBD	compare
hospitalizations	NNS	hospitalization
in	IN	in
2020	CD	@card@
(	(	(
COVID-19	NP	<unknown>
cohort	NN	cohort
)	)	)
,	,	,
corresponding	JJ	corresponding
with	IN	with
the	DT	the
impact	NN	impact
of	IN	of
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
and	CC	and
associated	JJ	associated
containment	NN	containment
measures	NNS	measure
,	,	,
and	CC	and
the	DT	the
comparable	JJ	comparable
2015	CD	@card@
to	TO	to
2019	CD	@card@
(	(	(
pre-COVID-19	NN	<unknown>
cohort	NN	cohort
)	)	)
.	SENT	.
14,468	CD	@card@
cases	NNS	case
admitted	VBN	admit
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
were	VBD	be
included	VBN	include
in	IN	in
our	PP$	our
study	NN	study
,	,	,
with	IN	with
1201	CD	@card@
cases	NNS	case
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
cohort	NN	cohort
and	CC	and
13,267	CD	@card@
cases	NNS	case
in	IN	in
the	DT	the
pre-COVID-19	JJ	<unknown>
cohort	NN	cohort
.	SENT	.
The	DT	the
leading	VBG	lead
causes	NNS	cause
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
remain	VB	remain
being	VBG	be
respiratory	JJ	respiratory
tract	NN	tract
infections	NNS	infection
(	(	(
median	JJ	median
ratio	NN	ratio
=	SYM	=
0.461	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.335-0.551	CD	@card@
)	)	)
,	,	,
sepsis	NN	sepsis
(	(	(
median	JJ	median
ratio	NN	ratio
=	SYM	=
0.292	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.263-0.361	CD	@card@
)	)	)
,	,	,
gastric	JJ	gastric
intestinal	JJ	intestinal
infections	NNS	infection
(	(	(
median	JJ	median
ratio	NN	ratio
=	SYM	=
0.095	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.078-0.118	CD	@card@
)	)	)
and	CC	and
dermatologic	JJ	<unknown>
infections	NNS	infection
(	(	(
median	JJ	median
ratio	NN	ratio
=	SYM	=
0.058	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
0.047-0.083	CD	@card@
)	)	)
.	SENT	.
The	DT	the
seasonality	NN	seasonality
of	IN	of
neonatal	JJ	neonatal
infectious	JJ	infectious
disease	NN	disease
hospitalizations	NNS	hospitalization
could	MD	could
be	VB	be
obviously	RB	obviously
observed	VBN	observe
,	,	,
with	IN	with
the	DT	the
total	JJ	total
number	NN	number
and	CC	and
the	DT	the
overall	JJ	overall
rate	NN	rate
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
in	IN	in
the	DT	the
first	JJ	first
and	CC	and
fourth	JJ	fourth
quarters	NNS	quarter
greater	JJR	great
than	IN	than
that	IN	that
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
in	IN	in
the	DT	the
second	JJ	second
and	CC	and
third	JJ	third
quarters	NNS	quarter
in	IN	in
each	DT	each
year	NN	year
(	(	(
1362.67	CD	@card@
+-	NN	<unknown>
360.54	CD	@card@
vs	NP	vs
1048.67	CD	@card@
+-	NN	<unknown>
279.23	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
;	:	;
8176/20020	CD	@card@
vs	NP	vs
6292/19369	CD	@card@
,	,	,
P	NN	P
&lt	NN	&lt
;	:	;
0.001	CD	@card@
,	,	,
respectively	RB	respectively
)	)	)
.	SENT	.
Both	CC	both
the	DT	the
numbers	NNS	number
and	CC	and
the	DT	the
proportions	NNS	proportion
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
in	IN	in
different	JJ	different
quarters	NNS	quarter
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
cohort	NN	cohort
significantly	RB	significantly
decreased	VBD	decrease
as	RB	as
compared	VBN	compare
with	IN	with
those	DT	those
forecasted	VBN	forecast
with	IN	with
the	DT	the
data	NNS	datum
from	IN	from
the	DT	the
pre-COVID-19	JJ	<unknown>
cohort	NN	cohort
:	:	:
the	DT	the
numbers	NNS	number
per	IN	per
quarter	NN	quarter
(	(	(
300.25	CD	@card@
+-	NN	<unknown>
57.33	CD	@card@
vs	NP	vs
546.64	CD	@card@
+-	NN	<unknown>
100.43	CD	@card@
,	,	,
P-value	NP	P-value
=	SYM	=
0.006	CD	@card@
)	)	)
,	,	,
the	DT	the
first	JJ	first
quarter	NN	quarter
(	(	(
0.34	CD	@card@
vs	NP	vs
0.40	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.002	CD	@card@
)	)	)
,	,	,
the	DT	the
second	JJ	second
quarter	NN	quarter
(	(	(
0.24	CD	@card@
vs	NP	vs
0.30	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.001	CD	@card@
)	)	)
,	,	,
the	DT	the
third	JJ	third
quarter	NN	quarter
(	(	(
0.24	CD	@card@
vs	NP	vs
0.28	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.024	CD	@card@
)	)	)
,	,	,
and	CC	and
the	DT	the
fourth	JJ	fourth
quarter	NN	quarter
(	(	(
0.29	CD	@card@
vs	NP	vs
0.35	CD	@card@
,	,	,
P	NN	P
=	SYM	=
0.003	CD	@card@
)	)	)
.	SENT	.
Despite	IN	despite
the	DT	the
outbreak	NN	outbreak
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
,	,	,
the	DT	the
leading	VBG	lead
causes	NNS	cause
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
remain	VBP	remain
unchanged	JJ	unchanged
.	SENT	.
The	DT	the
seasonality	NN	seasonality
of	IN	of
neonatal	JJ	neonatal
infectious	JJ	infectious
disease	NN	disease
hospitalizations	NNS	hospitalization
could	MD	could
be	VB	be
obviously	RB	obviously
observed	VBN	observe
.	SENT	.
The	DT	the
numbers	NNS	number
as	RB	as
well	RB	well
as	IN	as
the	DT	the
overall	JJ	overall
rates	NNS	rate
of	IN	of
hospitalizations	NNS	hospitalization
for	IN	for
neonatal	JJ	neonatal
infectious	JJ	infectious
diseases	NNS	disease
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
cohort	NN	cohort
dramatically	RB	dramatically
declined	VBD	decline
with	IN	with
the	DT	the
impact	NN	impact
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
and	CC	and
its	PP$	its
mitigation	NN	mitigation
measures	NNS	measure
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12879-022-07211-x	NP	<unknown>
.	SENT	.
33245005/	CD	@card@
JAK-STAT	NP	<unknown>
Pathway	NN	pathway
Inhibition	NN	inhibition
and	CC	and
their	PP$	their
Implications	NNS	implication
in	IN	in
COVID-19	NP	<unknown>
Therapy	NN	therapy
As	IN	as
the	DT	the
incidence	NN	incidence
of	IN	of
COVID-19	NP	<unknown>
increases	NNS	increase
with	IN	with
time	NN	time
,	,	,
more	JJR	more
and	CC	and
more	JJR	more
efforts	NNS	effort
are	VBP	be
made	VBN	make
to	TO	to
pave	VB	pave
a	DT	a
way	NN	way
out	RP	out
for	IN	for
the	DT	the
therapeutic	JJ	therapeutic
strategies	NNS	strategy
to	TO	to
deal	VB	deal
with	IN	with
the	DT	the
disease	NN	disease
progression	NN	progression
.	SENT	.
Inflammation	NN	inflammation
being	VBG	be
a	DT	a
significant	JJ	significant
influencer	NN	influencer
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
,	,	,
it	PP	it
drives	VBZ	drive
our	PP$	our
focus	NN	focus
onto	IN	onto
the	DT	the
signaling	VBG	signal
cascades	NNS	cascade
of	IN	of
the	DT	the
JAK/STAT	NP	<unknown>
pathway	NN	pathway
.	SENT	.
JAK	NP	Jak
phosphorylation	NN	<unknown>
mediated	VBN	mediate
by	IN	by
cytokine	JJ	<unknown>
receptor	NN	receptor
activation	NN	activation
leads	VBZ	lead
to	TO	to
phosphorylation	NN	<unknown>
of	IN	of
STATs	NNS	stat
that	WDT	that
translocate	VBP	translocate
into	IN	into
the	DT	the
nucleus	NN	nucleus
to	TO	to
translate	VB	translate
for	IN	for
inflammatory	JJ	inflammatory
mediators	NNS	mediator
.	SENT	.
The	DT	the
SARS-CoV-2	NP	<unknown>
structural	JJ	structural
proteins	NNS	protein
like	IN	like
spike	NN	spike
,	,	,
nucleocapsid	NN	nucleocapsid
,	,	,
membrane	NN	membrane
and	CC	and
envelope	NN	envelope
proteins	NNS	protein
along	IN	along
with	IN	with
the	DT	the
non-	NN	non-
structural	JJ	structural
proteins	NNS	protein
1-16	CD	@card@
including	VBG	include
proteases	NNS	protease
like	IN	like
3CL	JJ	<unknown>
pro	FW	pro
and	CC	and
PLpro	NP	<unknown>
promote	VBP	promote
its	PP$	its
entry	NN	entry
and	CC	and
survival	NN	survival
in	IN	in
hosts	NNS	host
.	SENT	.
The	DT	the
SARS-CoV-2	NP	<unknown>
infection	NN	infection
triggers	VBZ	trigger
inflammation	NN	inflammation
via	IN	via
the	DT	the
JAK/STAT	NP	<unknown>
pathway	NN	pathway
leading	VBG	lead
to	TO	to
recruitment	NN	recruitment
of	IN	of
pneumocytes	NNS	<unknown>
,	,	,
endothelial	JJ	endothelial
cells	NNS	cell
,	,	,
macrophages	NNS	macrophage
,	,	,
monocytes	NNS	monocyte
,	,	,
lymphocytes	NNS	lymphocyte
,	,	,
natural	JJ	natural
killer	NN	killer
cells	NNS	cell
and	CC	and
dendritic	JJ	dendritic
cells	NNS	cell
progressing	VBG	progress
towards	IN	towards
cytokine	NN	<unknown>
storm	NN	storm
.	SENT	.
This	DT	this
produces	VBZ	produce
various	JJ	various
inflammatory	JJ	inflammatory
markers	NNS	marker
in	IN	in
the	DT	the
host	NN	host
that	WDT	that
determine	VBP	determine
the	DT	the
disease	NN	disease
severity	NN	severity
.	SENT	.
The	DT	the
JAK/STAT	NP	<unknown>
signaling	VBG	signal
also	RB	also
mediates	VBZ	mediate
immune	JJ	immune
responses	NNS	response
via	IN	via
B	NP	B
cell	NN	cell
and	CC	and
T	NN	T
cell	NN	cell
differentiation.With	NN	<unknown>
an	DT	an
attempt	NN	attempt
to	TO	to
reduce	VB	reduce
excessive	JJ	excessive
inflammation	NN	inflammation
,	,	,
JAK/STAT	NP	<unknown>
inhibitors	NNS	inhibitor
like	IN	like
Ruxolitinib	NP	<unknown>
,	,	,
Baricitinib	NP	<unknown>
,	,	,
Tofacitinib	NP	<unknown>
have	VBP	have
been	VBN	be
employed	VBN	employ
that	WDT	that
mediate	VBP	mediate
its	PP$	its
actions	NNS	action
via	IN	via
suppressors	NNS	suppressor
of	IN	of
cytokine	NN	<unknown>
signaling	VBG	signal
,	,	,
cytokine	JJ	<unknown>
inducible	JJ	inducible
SH2	NN	<unknown>
containing	VBG	contain
protein	NN	protein
,	,	,
Protein	NN	protein
inhibitor	NN	inhibitor
of	IN	of
activated	VBN	activate
STAT	NN	stat
and	CC	and
protein	NN	protein
tyrosine	NN	tyrosine
phosphatases	NNS	phosphatase
.	SENT	.
Even	RB	even
though	IN	though
they	PP	they
are	VBP	be
implicated	VBN	implicate
with	IN	with
multiple	JJ	multiple
adverse	JJ	adverse
effects	NNS	effect
,	,	,
the	DT	the
regulatory	JJ	regulatory
authorities	NNS	authority
have	VBP	have
supported	VBN	support
its	PP$	its
use	NN	use
,	,	,
and	CC	and
numerous	JJ	numerous
clinical	JJ	clinical
trials	NNS	trial
are	VBP	be
in	IN	in
progress	NN	progress
to	TO	to
prove	VB	prove
their	PP$	their
safety	NN	safety
and	CC	and
efficacy	NN	efficacy
.	SENT	.
On	IN	on
the	DT	the
contrary	NN	contrary
,	,	,
the	DT	the
exact	JJ	exact
mechanism	NN	mechanism
of	IN	of
JAK/STAT	NP	<unknown>
inhibition	NN	inhibition
at	IN	at
molecular	JJ	molecular
levels	NNS	level
remains	VBZ	remain
speculative	JJ	speculative
for	IN	for
which	WDT	which
further	JJR	further
investigations	NNS	investigation
are	VBP	be
required	VBN	require
.	SENT	.
33479805/	CD	@card@
Web-mediated	JJ	<unknown>
Counseling	NN	counseling
Relationship	NN	relationship
in	IN	in
Support	NN	support
of	IN	of
the	DT	the
New	NP	New
Sexuality	NN	sexuality
and	CC	and
Affectivity	NN	affectivity
During	IN	during
the	DT	the
COVID-19	NP	<unknown>
Epidemic	NN	epidemic
:	:	:
A	DT	a
Continuum	NN	continuum
Between	IN	between
Desire	NP	Desire
and	CC	and
Fear	NP	Fear
34926314/	CD	@card@
Distinct	JJ	distinct
Metagenomic	JJ	<unknown>
Signatures	NNS	signature
in	IN	in
the	DT	the
SARS-CoV-2	NP	<unknown>
Infection	NN	infection
Severe	NP	Severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
infection	NN	infection
can	MD	can
cause	VB	cause
gastrointestinal	JJ	gastrointestinal
symptoms	NNS	symptom
in	IN	in
the	DT	the
patients	NNS	patient
,	,	,
but	CC	but
the	DT	the
role	NN	role
of	IN	of
gut	NN	gut
microbiota	NN	microbiota
in	IN	in
SARS-CoV-2	NP	<unknown>
infection	NN	infection
remains	VBZ	remain
unclear	JJ	unclear
.	SENT	.
Thus	RB	thus
,	,	,
in	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
aim	VBP	aim
to	TO	to
investigate	VB	investigate
whether	IN	whether
SARS-CoV-2	NP	<unknown>
infection	NN	infection
affects	VBZ	affect
the	DT	the
composition	NN	composition
and	CC	and
function	NN	function
of	IN	of
gut	NN	gut
microbiota	NN	microbiota
.	SENT	.
In	IN	in
this	DT	this
study	NN	study
,	,	,
we	PP	we
demonstrated	VBD	demonstrate
for	IN	for
the	DT	the
first	JJ	first
time	NN	time
that	IN	that
significant	JJ	significant
shifts	NNS	shift
in	IN	in
microbiome	NN	microbiome
composition	NN	composition
and	CC	and
function	NN	function
were	VBD	be
appeared	VBN	appear
in	IN	in
both	DT	both
SARS-CoV-2-infected	JJ	SARS-CoV-2-infected
asymptomatic	JJ	asymptomatic
and	CC	and
symptomatic	JJ	symptomatic
cases	NNS	case
.	SENT	.
The	DT	the
relative	JJ	relative
abundance	NN	abundance
of	IN	of
Candidatus_Saccharibacteria	NP	<unknown>
was	VBD	be
significantly	RB	significantly
increased	VBN	increase
,	,	,
whereas	IN	whereas
the	DT	the
levels	NNS	level
of	IN	of
Fibrobacteres	NP	Fibrobacteres
was	VBD	be
remarkably	RB	remarkably
reduced	VBN	reduce
in	IN	in
SARS-CoV-2-infected	JJ	SARS-CoV-2-infected
cases	NNS	case
.	SENT	.
There	EX	there
was	VBD	be
one	CD	one
bacterial	JJ	bacterial
species	NNS	specie
,	,	,
Spirochaetes	NNS	spirochaete
displayed	VBD	display
the	DT	the
difference	NN	difference
between	IN	between
patients	NNS	patient
and	CC	and
asymptomatic	JJ	asymptomatic
cases	NNS	case
.	SENT	.
On	IN	on
the	DT	the
genus	NN	genus
level	NN	level
,	,	,
Tyzzerella	NP	Tyzzerella
was	VBD	be
the	DT	the
key	JJ	key
species	NNS	specie
that	WDT	that
remarkably	RB	remarkably
increased	VBD	increase
in	IN	in
both	DT	both
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
cases	NNS	case
.	SENT	.
Analyses	NNS	analysis
of	IN	of
genome	NN	genome
annotations	NNS	annotation
further	RBR	further
revealed	VBD	reveal
SARS-CoV-2	NP	<unknown>
infection	NN	infection
resulted	VBD	result
in	IN	in
the	DT	the
significant	JJ	significant
'	POS	'
functional	JJ	functional
dysbiosis	NN	dysbiosis
'	''	'
of	IN	of
gut	NN	gut
microbiota	NN	microbiota
,	,	,
including	VBG	include
metabolic	JJ	metabolic
pathway	NN	pathway
,	,	,
regulatory	JJ	regulatory
pathway	NN	pathway
and	CC	and
biosynthesis	NN	biosynthesis
of	IN	of
secondary	JJ	secondary
metabolites	NNS	metabolite
etc.	NN	etc.
We	PP	we
also	RB	also
identified	VBD	identify
potential	JJ	potential
metagenomic	JJ	<unknown>
markers	NNS	marker
to	TO	to
discriminate	VB	discriminate
SARS-CoV-2-infected	JJ	SARS-CoV-2-infected
symptomatic	JJ	symptomatic
and	CC	and
asymptomatic	JJ	asymptomatic
cases	NNS	case
from	IN	from
healthy	JJ	healthy
controls	NNS	control
.	SENT	.
These	DT	these
findings	NNS	finding
together	RB	together
suggest	VBP	suggest
gut	NN	gut
microbiota	NN	microbiota
is	VBZ	be
of	IN	of
possible	JJ	possible
etiological	JJ	etiological
and	CC	and
diagnostic	JJ	diagnostic
importance	NN	importance
for	IN	for
SARS-CoV-2	NP	<unknown>
infection	NN	infection
.	SENT	.
34589316/	CD	@card@
Comparison	NN	comparison
of	IN	of
the	DT	the
Rapid	NP	Rapid
Antigen	NN	antigen
Testing	NP	Testing
Method	NP	Method
With	IN	with
RT-qPCR	NP	<unknown>
for	IN	for
the	DT	the
Diagnosis	NN	diagnosis
of	IN	of
COVID-19	NP	<unknown>
Background	NN	background
:	:	:
Coronavirus	NN	Coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
has	VBZ	have
till	IN	till
now	RB	now
affected	VBN	affect
about	IN	about
110	CD	@card@
million	CD	million
people	NNS	people
globally	RB	globally
.	SENT	.
It	PP	it
has	VBZ	have
not	RB	not
spared	VBN	spare
any	DT	any
country	NN	country
and	CC	and
has	VBZ	have
led	VBN	lead
to	TO	to
24	CD	@card@
lakh	NN	lakh
deaths	NNS	death
.	SENT	.
As	IN	as
a	DT	a
result	NN	result
,	,	,
the	DT	the
testing	NN	testing
had	VBD	have
to	TO	to
be	VB	be
increased	VBN	increase
manifold	NN	manifold
leading	VBG	lead
to	TO	to
depletion	NN	depletion
in	IN	in
the	DT	the
number	NN	number
of	IN	of
the	DT	the
quantitative	JJ	quantitative
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
RT-qPCR	NP	<unknown>
)	)	)
kits	NNS	kit
.	SENT	.
Point-of-care	JJ	<unknown>
rapid	JJ	rapid
antigen-based	JJ	<unknown>
tests	NNS	test
were	VBD	be
developed	VBN	develop
in	IN	in
order	NN	order
to	TO	to
meet	VB	meet
the	DT	the
increasing	VBG	increase
demands	NNS	demand
.	SENT	.
The	DT	the
objective	NN	objective
of	IN	of
this	DT	this
study	NN	study
was	VBD	be
to	TO	to
compare	VB	compare
the	DT	the
performance	NN	performance
of	IN	of
a	DT	a
rapid	JJ	rapid
chromatographic	JJ	chromatographic
test	NN	test
(	(	(
index	NN	index
test	NN	test
)	)	)
with	IN	with
a	DT	a
gold	JJ	gold
standard	JJ	standard
test	NN	test
(	(	(
RT-qPCR	NP	<unknown>
)	)	)
.	SENT	.
Methods	NNS	method
:	:	:
A	DT	a
retrospective	JJ	retrospective
analysis	NN	analysis
was	VBD	be
done	VBN	do
at	IN	at
a	DT	a
tertiary	JJ	tertiary
care	NN	care
teaching	NN	teaching
hospital	NN	hospital
in	IN	in
Eastern	NP	Eastern
Uttar	NP	Uttar
Pradesh	NP	Pradesh
,	,	,
India	NP	India
.	SENT	.
Paired	VBN	pair
samples	NNS	sample
were	VBD	be
taken	VBN	take
from	IN	from
all	DT	all
patients	NNS	patient
reporting	VBG	report
to	TO	to
the	DT	the
clinic	NN	clinic
for	IN	for
antigen-based	JJ	<unknown>
rapid	JJ	rapid
diagnostic	JJ	diagnostic
testing	NN	testing
(	(	(
RDT	NP	<unknown>
)	)	)
and	CC	and
RT-qPCR	NP	<unknown>
.	SENT	.
The	DT	the
sensitivity	NN	sensitivity
and	CC	and
specificity	NN	specificity
were	VBD	be
calculated	VBN	calculate
to	TO	to
evaluate	VB	evaluate
the	DT	the
performance	NN	performance
of	IN	of
the	DT	the
RDT	NP	<unknown>
.	SENT	.
Results	NNS	result
:	:	:
The	DT	the
overall	JJ	overall
sensitivity	NN	sensitivity
and	CC	and
specificity	NN	specificity
of	IN	of
the	DT	the
RDT	NP	<unknown>
were	VBD	be
observed	VBN	observe
to	TO	to
be	VB	be
53.6	CD	@card@
%	NN	%
(	(	(
39.7-67.0	CD	@card@
)	)	)
and	CC	and
97.35	CD	@card@
%	NN	%
(	(	(
94.6-98.9	CD	@card@
)	)	)
,	,	,
respectively	RB	respectively
.	SENT	.
In	IN	in
symptomatic	JJ	symptomatic
individuals	NNS	individual
,	,	,
the	DT	the
sensitivity	NN	sensitivity
was	VBD	be
higher	JJR	high
61.0	CD	@card@
%	NN	%
(	(	(
44.5-75.8	CD	@card@
)	)	)
.	SENT	.
The	DT	the
test	NN	test
positivity	NN	<unknown>
rates	NNS	rate
of	IN	of
RDT	NP	<unknown>
were	VBD	be
found	VBN	find
to	TO	to
be	VB	be
higher	JJR	high
at	IN	at
a	DT	a
cycle	NN	cycle
threshold	NN	threshold
value	NN	value
&lt	NN	&lt
;	:	;
=20	NN	<unknown>
.	SENT	.
Conclusion	NN	conclusion
:	:	:
RDT	NP	<unknown>
can	MD	can
be	VB	be
used	VBN	use
as	IN	as
a	DT	a
screening	NN	screening
test	NN	test
to	TO	to
rule	VB	rule
in	IN	in
the	DT	the
infection	NN	infection
especially	RB	especially
in	IN	in
symptomatic	JJ	symptomatic
patients	NNS	patient
who	WP	who
are	VBP	be
more	RBR	more
prone	JJ	prone
to	TO	to
spread	VB	spread
the	DT	the
disease	NN	disease
.	SENT	.
It	PP	it
is	VBZ	be
an	DT	an
important	JJ	important
weapon	NN	weapon
in	IN	in
the	DT	the
armamentarium	NN	armamentarium
of	IN	of
public	JJ	public
healthcare	NN	<unknown>
for	IN	for
the	DT	the
containment	NN	containment
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
34012470/	CD	@card@
Zero-Inflated	JJ	Zero-Inflated
Time	NP	Time
Series	NP	Series
Modelling	VBG	model
of	IN	of
COVID-19	NP	<unknown>
Deaths	NNS	death
in	IN	in
Ghana	NP	Ghana
Discrete	JJ	discrete
count	NN	count
time	NN	time
series	NN	series
data	NNS	datum
with	IN	with
an	DT	an
excessive	JJ	excessive
number	NN	number
of	IN	of
zeros	NNS	zero
have	VBP	have
warranted	VBN	warrant
the	DT	the
development	NN	development
of	IN	of
zero-inflated	JJ	zero-inflated
time	NN	time
series	NN	series
models	NNS	model
to	TO	to
incorporate	VB	incorporate
the	DT	the
inflation	NN	inflation
of	IN	of
zeros	NNS	zero
and	CC	and
the	DT	the
overdispersion	NN	overdispersion
that	WDT	that
comes	VBZ	come
with	IN	with
it	PP	it
.	SENT	.
In	IN	in
this	DT	this
paper	NN	paper
,	,	,
we	PP	we
investigated	VBD	investigate
the	DT	the
characteristics	NNS	characteristic
of	IN	of
the	DT	the
trend	NN	trend
of	IN	of
daily	JJ	daily
count	NN	count
of	IN	of
COVID-19	NP	<unknown>
deaths	NNS	death
in	IN	in
Ghana	NP	Ghana
using	VBG	use
zero-inflated	JJ	zero-inflated
models	NNS	model
.	SENT	.
We	PP	we
envisaged	VBD	envisage
that	IN	that
the	DT	the
trend	NN	trend
of	IN	of
COVID-19	NP	<unknown>
deaths	NNS	death
per	IN	per
day	NN	day
in	IN	in
Ghana	NP	Ghana
portrays	VBZ	portray
a	DT	a
general	JJ	general
increase	NN	increase
from	IN	from
the	DT	the
onset	NN	onset
of	IN	of
the	DT	the
pandemic	NN	pandemic
in	IN	in
the	DT	the
country	NN	country
to	TO	to
about	IN	about
day	NN	day
160	CD	@card@
after	IN	after
which	WDT	which
there	EX	there
is	VBZ	be
a	DT	a
general	JJ	general
decrease	NN	decrease
onward	RB	onward
.	SENT	.
We	PP	we
fitted	VBD	fit
a	DT	a
zero-inflated	JJ	zero-inflated
Poisson	NP	Poisson
autoregressive	NN	<unknown>
model	NN	model
and	CC	and
zero-inflated	JJ	zero-inflated
negative	JJ	negative
binomial	JJ	binomial
autoregressive	NN	<unknown>
model	NN	model
to	TO	to
the	DT	the
data	NNS	datum
in	IN	in
the	DT	the
partial-likelihood	NN	partial-likelihood
framework	NN	framework
.	SENT	.
The	DT	the
zero-inflated	JJ	zero-inflated
negative	JJ	negative
binomial	JJ	binomial
autoregressive	NN	<unknown>
model	NN	model
outperformed	VBD	outperform
the	DT	the
zero-inflated	JJ	zero-inflated
Poisson	NP	Poisson
autoregressive	NN	<unknown>
model	NN	model
.	SENT	.
On	IN	on
the	DT	the
other	JJ	other
hand	NN	hand
,	,	,
the	DT	the
dynamic	JJ	dynamic
zero-inflated	JJ	zero-inflated
Poisson	NP	Poisson
autoregressive	NN	<unknown>
model	NN	model
performed	VBD	perform
better	JJR	good
than	IN	than
the	DT	the
dynamic	JJ	dynamic
negative	JJ	negative
binomial	JJ	binomial
autoregressive	NN	<unknown>
model	NN	model
.	SENT	.
The	DT	the
predicted	VBD	predict
new	JJ	new
death	NN	death
based	VBN	base
on	IN	on
the	DT	the
zero-inflated	JJ	zero-inflated
negative	JJ	negative
binomial	JJ	binomial
autoregressive	NN	<unknown>
model	NN	model
indicated	VBD	indicate
that	IN	that
Ghana	NP	Ghana
's	POS	's
COVID-19	NP	<unknown>
death	NN	death
per	IN	per
day	NN	day
will	MD	will
rise	VB	rise
sharply	RB	sharply
few	JJ	few
days	NNS	day
after	IN	after
30th	JJ	30th
November	NP	November
2020	CD	@card@
and	CC	and
drastically	RB	drastically
fall	VB	fall
just	RB	just
as	RB	as
in	IN	in
the	DT	the
observed	JJ	observed
data	NNS	datum
.	SENT	.
35134561/	CD	@card@
Systematic	JJ	systematic
review	NN	review
and	CC	and
meta-analysis	NN	meta-analysis
of	IN	of
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
in	IN	in
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
Chemosensory	NP	<unknown>
disorders	NNS	disorder
associated	VBN	associate
with	IN	with
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
have	VBP	have
been	VBN	be
widely	RB	widely
mentioned	VBN	mention
during	IN	during
the	DT	the
pandemic	NN	pandemic
.	SENT	.
We	PP	we
performed	VBD	perform
a	DT	a
meta-analysis	NN	meta-analysis
to	TO	to
assess	VB	assess
the	DT	the
risk	NN	risk
factors	NNS	factor
for	IN	for
olfactory	JJ	olfactory
and	CC	and
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Three	CD	three
databases	NNS	database
(	(	(
PubMed	NP	<unknown>
,	,	,
Embase	NP	<unknown>
,	,	,
and	CC	and
Cochrane	NP	Cochrane
Library	NP	Library
)	)	)
were	VBD	be
searched	VBN	search
for	IN	for
studies	NNS	study
published	VBN	publish
between	IN	between
December	NP	December
1st	JJ	1st
,	,	,
2019	CD	@card@
to	TO	to
August	NP	August
31st	JJ	31st
,	,	,
2021	CD	@card@
.	SENT	.
Select	JJ	select
random	JJ	random
effects	NNS	effect
model	NN	model
or	CC	or
fixed	VBN	fix
effects	NNS	effect
model	NN	model
to	TO	to
pool	NN	pool
data	NNS	datum
based	VBN	base
on	IN	on
heterogeneity	NN	heterogeneity
.	SENT	.
The	DT	the
results	NNS	result
were	VBD	be
reported	VBN	report
as	IN	as
odds	NNS	odd
ratios	NNS	ratio
or	CC	or
standardized	JJ	standardized
mean	JJ	mean
differences	NNS	difference
and	CC	and
the	DT	the
corresponding	JJ	corresponding
95	CD	@card@
%	NN	%
confidence	NN	confidence
intervals	NNS	interval
.	SENT	.
Heterogeneity	NN	heterogeneity
was	VBD	be
reported	VBN	report
as	IN	as
I2	NP	<unknown>
.	SENT	.
Twenty-six	NN	twenty-six
studies	NNS	study
with	IN	with
a	DT	a
total	NN	total
of	IN	of
13813	CD	@card@
patients	NNS	patient
were	VBD	be
included	VBN	include
.	SENT	.
The	DT	the
pooled	JJ	pooled
data	NNS	datum
indicated	VBD	indicate
that	DT	that
sex	NN	sex
(	(	(
OR	CC	or
,	,	,
1.47	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.93-2.31	CD	@card@
)	)	)
,	,	,
age	NN	age
(	(	(
SMD	NP	SMD
,	,	,
-5.80	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
-13.35-1.75	CD	@card@
)	)	)
,	,	,
smoking	NN	smoking
(	(	(
OR	CC	or
,	,	,
2.04	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.72-5.79	CD	@card@
)	)	)
,	,	,
and	CC	and
comorbidity	NN	comorbidity
(	(	(
OR	CC	or
,	,	,
1.21	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
0.58-2.53	CD	@card@
)	)	)
of	IN	of
COVID-19	NP	<unknown>
patients	NNS	patient
had	VBD	have
no	DT	no
effect	NN	effect
on	IN	on
gustatory	JJ	gustatory
dysfunction	NN	dysfunction
.	SENT	.
Olfactory	JJ	olfactory
dysfunction	NN	dysfunction
was	VBD	be
more	RBR	more
likely	JJ	likely
to	TO	to
occur	VB	occur
in	IN	in
elderly	JJ	elderly
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
(	(	(
SMD	NP	SMD
,	,	,
-5.22	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
,	,	,
-8.28-	CD	@card@
-2.16	CD	@card@
)	)	)
.	SENT	.
And	CC	and
COVID-19	NP	<unknown>
patients	NNS	patient
with	IN	with
nasal	JJ	nasal
congestion	NN	congestion
(	(	(
OR	CC	or
,	,	,
3.41	CD	@card@
;	:	;
95%CI	NP	<unknown>
,	,	,
2.30-5.06	CD	@card@
)	)	)
and	CC	and
rhinorrhea	NN	<unknown>
(	(	(
OR	CC	or
,	,	,
2.35	CD	@card@
;	:	;
95%CI	NP	<unknown>
,	,	,
1.60-3.45	CD	@card@
)	)	)
are	VBP	be
more	RBR	more
prone	JJ	prone
to	TO	to
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
.	SENT	.
These	DT	these
findings	NNS	finding
emphasize	VBP	emphasize
that	IN	that
elderly	JJ	elderly
COVID-19	NP	<unknown>
patients	NNS	patient
are	VBP	be
more	RBR	more
likely	JJ	likely
to	TO	to
suffer	VB	suffer
from	IN	from
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
.	SENT	.
Symptoms	NNS	symptom
of	IN	of
nasal	JJ	nasal
congestion	NN	congestion
and	CC	and
rhinorrhea	NN	<unknown>
may	MD	may
affect	VB	affect
the	DT	the
recognition	NN	recognition
of	IN	of
olfactory	JJ	olfactory
dysfunction	NN	dysfunction
.	SENT	.
34976910/	CD	@card@
What	WP	what
Do	VBP	do
We	PP	we
Know	VBP	know
About	RB	about
Teamwork	NN	teamwork
in	IN	in
Chinese	JJ	Chinese
Hospitals	NNS	hospital
?	SENT	?
A	DT	a
Systematic	JJ	systematic
Review	NP	Review
Background	NN	background
and	CC	and
Objective	NN	objective
:	:	:
Improving	VBG	improve
quality	NN	quality
of	IN	of
care	NN	care
is	VBZ	be
one	CD	one
of	IN	of
the	DT	the
primary	JJ	primary
goals	NNS	goal
in	IN	in
current	JJ	current
Chinese	JJ	Chinese
hospital	NN	hospital
reforms	NNS	reform
.	SENT	.
Teamwork	NN	teamwork
can	MD	can
play	VB	play
an	DT	an
essential	JJ	essential
role	NN	role
.	SENT	.
Characteristics	NNS	characteristic
of	IN	of
teamwork	NN	teamwork
and	CC	and
interventions	NNS	intervention
for	IN	for
improving	VBG	improve
teamwork	NN	teamwork
in	IN	in
hospitals	NNS	hospital
have	VBP	have
been	VBN	be
widely	RB	widely
studied	VBN	study
.	SENT	.
However	RB	however
,	,	,
most	JJS	most
of	IN	of
these	DT	these
studies	NNS	study
are	VBP	be
from	IN	from
a	DT	a
Western	JJ	Western
context	NN	context
;	:	;
evidence	NN	evidence
from	IN	from
China	NP	China
is	VBZ	be
scarce	JJ	scarce
.	SENT	.
Because	IN	because
of	IN	of
the	DT	the
contextual	JJ	contextual
differences	NNS	difference
between	IN	between
China	NP	China
and	CC	and
Western	JJ	Western
countries	NNS	country
,	,	,
empirical	JJ	empirical
evidence	NN	evidence
on	IN	on
teamwork	NN	teamwork
from	IN	from
Western	JJ	Western
hospitals	NNS	hospital
may	MD	may
have	VB	have
limited	VBN	limit
validity	NN	validity
in	IN	in
China	NP	China
.	SENT	.
This	DT	this
systematic	JJ	systematic
review	NN	review
aims	VBZ	aim
to	TO	to
advance	VB	advance
the	DT	the
evidence	NN	evidence
base	NN	base
and	CC	and
understanding	NN	understanding
of	IN	of
teamwork	NN	teamwork
in	IN	in
Chinese	JJ	Chinese
hospitals	NNS	hospital
.	SENT	.
Methods	NNS	method
:	:	:
Both	CC	both
English	JJ	English
(	(	(
i.e.	FW	i.e.
,	,	,
Embase	NP	<unknown>
,	,	,
Medline	NP	<unknown>
,	,	,
and	CC	and
Web	NP	Web
of	IN	of
Science	NP	Science
)	)	)
and	CC	and
Chinese	JJ	Chinese
databases	NNS	database
(	(	(
i.e.	FW	i.e.
,	,	,
CNKI	NP	<unknown>
,	,	,
CQVIP	NP	<unknown>
,	,	,
and	CC	and
Wanfang	NP	<unknown>
)	)	)
were	VBD	be
searched	VBN	search
for	IN	for
relevant	JJ	relevant
articles	NNS	article
until	IN	until
February	NP	February
6	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
We	PP	we
included	VBD	include
the	DT	the
studies	NNS	study
that	WDT	that
empirically	RB	empirically
researched	VBD	research
teamwork	NN	teamwork
in	IN	in
Chinese	JJ	Chinese
hospitals	NNS	hospital
.	SENT	.
Studies	NNS	study
were	VBD	be
excluded	VBN	exclude
if	IN	if
they	PP	they
(	(	(
1	LS	1
)	)	)
were	VBD	be
not	RB	not
conducted	VBN	conduct
in	IN	in
hospitals	NNS	hospital
in	IN	in
Mainland	JJ	Mainland
China	NP	China
,	,	,
(	(	(
2	LS	2
)	)	)
did	VBD	do
not	RB	not
research	NN	research
teamwork	NN	teamwork
on	IN	on
team	NN	team
interventions	NNS	intervention
,	,	,
(	(	(
3	LS	3
)	)	)
were	VBD	be
not	RB	not
empirical	JJ	empirical
,	,	,
(	(	(
4	LS	4
)	)	)
were	VBD	be
not	RB	not
written	VBN	write
in	IN	in
English	NP	English
or	CC	or
Chinese	NP	Chinese
,	,	,
(	(	(
5	CD	@card@
)	)	)
were	VBD	be
not	RB	not
published	VBN	publish
in	IN	in
peer-reviewed	JJ	peer-reviewed
journals	NNS	journal
,	,	,
and	CC	and
(	(	(
6	CD	@card@
)	)	)
were	VBD	be
not	RB	not
conducted	VBN	conduct
in	IN	in
teams	NNS	team
that	WDT	that
provide	VBP	provide
direct	JJ	direct
patient	JJ	patient
care	NN	care
.	SENT	.
Both	DT	both
deductive	JJ	deductive
and	CC	and
inductive	JJ	inductive
approaches	NNS	approach
were	VBD	be
used	VBN	use
to	TO	to
analyze	VB	analyze
data	NNS	datum
.	SENT	.
The	DT	the
Mixed	JJ	mixed
Methods	NNS	method
Appraisal	NN	appraisal
Tool	NP	Tool
(	(	(
MMAT	NP	<unknown>
)	)	)
was	VBD	be
used	VBN	use
to	TO	to
assess	VB	assess
their	PP$	their
methodological	JJ	methodological
quality	NN	quality
.	SENT	.
Results	NNS	result
:	:	:
A	DT	a
total	NN	total
of	IN	of
70	CD	@card@
articles	NNS	article
(	(	(
i.e.	FW	i.e.
,	,	,
39	CD	@card@
English	JJ	English
articles	NNS	article
and	CC	and
31	CD	@card@
Chinese	JJ	Chinese
articles	NNS	article
)	)	)
were	VBD	be
included	VBN	include
.	SENT	.
The	DT	the
results	NNS	result
are	VBP	be
presented	VBN	present
in	IN	in
two	CD	two
main	JJ	main
categories	NNS	category
:	:	:
Teamwork	NN	teamwork
components	NNS	component
and	CC	and
Team	NN	team
interventions	NNS	intervention
.	SENT	.
The	DT	the
evidence	NN	evidence
regarding	VBG	regard
the	DT	the
relationships	NNS	relationship
among	IN	among
inputs	NNS	input
,	,	,
processes	NNS	process
,	,	,
and	CC	and
outcomes	NNS	outcome
is	VBZ	be
scarce	JJ	scarce
and	CC	and
mostly	RB	mostly
inconclusive	JJ	inconclusive
.	SENT	.
The	DT	the
only	JJ	only
conclusive	JJ	conclusive
evidence	NN	evidence
shows	VBZ	show
that	IN	that
females	NNS	female
perceive	VBP	perceive
better	JJR	good
team	NN	team
processes	NNS	process
than	IN	than
males	NNS	male
.	SENT	.
Similar	JJ	similar
types	NNS	type
of	IN	of
training	NN	training
and	CC	and
tools	NNS	tool
were	VBD	be
introduced	VBN	introduce
as	RB	as
can	MD	can
be	VB	be
found	VBN	find
in	IN	in
Western	JJ	Western
literature	NN	literature
,	,	,
all	DT	all
showing	VBG	show
positive	JJ	positive
effects	NNS	effect
.	SENT	.
In	IN	in
line	NN	line
with	IN	with
the	DT	the
Chinese	JJ	Chinese
health	NN	health
reforms	NNS	reform
,	,	,
many	JJ	many
of	IN	of
the	DT	the
intervention	NN	intervention
studies	NNS	study
regard	VBP	regard
the	DT	the
introduction	NN	introduction
of	IN	of
multidisciplinary	JJ	multidisciplinary
teams	NNS	team
(	(	(
MDTs	NP	<unknown>
)	)	)
.	SENT	.
The	DT	the
evidence	NN	evidence
on	IN	on
the	DT	the
implementation	NN	implementation
of	IN	of
MDTs	NP	<unknown>
reveals	VBZ	reveal
that	IN	that
they	PP	they
have	VBP	have
led	VBN	lead
to	TO	to
lower	JJR	low
complication	NN	complication
rates	NNS	rate
,	,	,
shorter	JJR	short
hospital	NN	hospital
stays	NNS	stays
,	,	,
higher	JJR	high
diagnosis	NN	diagnosis
accuracy	NN	accuracy
,	,	,
efficiency	NN	efficiency
improvement	NN	improvement
,	,	,
and	CC	and
a	DT	a
variety	NN	variety
of	IN	of
better	JJR	good
disease-specific	JJ	disease-specific
clinical	JJ	clinical
outcomes	NNS	outcome
.	SENT	.
Evidence	NN	evidence
on	IN	on
the	DT	the
effect	NN	effect
on	IN	on
patient	JJ	patient
survival	NN	survival
is	VBZ	be
inconclusive	JJ	inconclusive
.	SENT	.
Conclusion	NN	conclusion
:	:	:
The	DT	the
Chinese	JJ	Chinese
studies	NNS	study
on	IN	on
teamwork	NN	teamwork
components	NNS	component
mainly	RB	mainly
focus	VBP	focus
on	IN	on
the	DT	the
input-process	NN	input-process
relationship	NN	relationship
.	SENT	.
The	DT	the
evidence	NN	evidence
provided	VBN	provide
on	IN	on
this	DT	this
relationship	NN	relationship
is	VBZ	be
,	,	,
however	RB	however
,	,	,
mostly	RB	mostly
inconclusive	JJ	inconclusive
.	SENT	.
The	DT	the
intervention	NN	intervention
studies	NNS	study
in	IN	in
Chinese	JJ	Chinese
hospitals	NNS	hospital
predominantly	RB	predominantly
focus	VBP	focus
on	IN	on
patient	JJ	patient
outcomes	NNS	outcome
rather	RB	rather
than	IN	than
organizational	JJ	organizational
and	CC	and
employee	NN	employee
outcomes	NNS	outcome
.	SENT	.
The	DT	the
introduction	NN	introduction
of	IN	of
training	NN	training
,	,	,
tools	NNS	tool
,	,	,
and	CC	and
MDTs	NP	<unknown>
generally	RB	generally
shows	VBZ	show
promising	JJ	promising
results	NNS	result
.	SENT	.
The	DT	the
evidence	NN	evidence
from	IN	from
primary	JJ	primary
hospitals	NNS	hospital
and	CC	and
rural	JJ	rural
areas	NNS	area
,	,	,
which	WDT	which
are	VBP	be
prioritized	VBN	<unknown>
in	IN	in
the	DT	the
health	NN	health
reforms	NNS	reform
,	,	,
is	VBZ	be
especially	RB	especially
scarce	JJ	scarce
.	SENT	.
Advancing	VBG	advance
the	DT	the
evidence	NN	evidence
base	NN	base
on	IN	on
teamwork	NN	teamwork
,	,	,
especially	RB	especially
in	IN	in
primary	JJ	primary
hospitals	NNS	hospital
and	CC	and
rural	JJ	rural
areas	NNS	area
,	,	,
is	VBZ	be
needed	VBN	need
and	CC	and
can	MD	can
inform	VB	inform
policy	NN	policy
and	CC	and
management	NN	management
to	TO	to
promote	VB	promote
the	DT	the
health	NN	health
reform	NN	reform
implementation	NN	implementation
.	SENT	.
Systematic	JJ	systematic
Review	NP	Review
Registration	NP	Registration
:	:	:
https://www.crd.york.ac.uk/prospero/display_record.php	NN	<unknown>
?	SENT	?
ID=CRD42020175069	NP	ID=CRD@card@
,	,	,
identifier	NN	identifier
CRD42020175069	NP	CRD@card@
.	SENT	.
35320487/	CD	@card@
Association	NN	association
of	IN	of
androgenetic	JJ	androgenetic
alopecia	NN	alopecia
with	IN	with
a	DT	a
more	RBR	more
severe	JJ	severe
form	NN	form
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
Individual	JJ	individual
susceptibility	NN	susceptibility
to	TO	to
develop	VB	develop
acute	JJ	acute
respiratory	JJ	respiratory
distress	NN	distress
syndrome	NN	syndrome
is	VBZ	be
related	VBN	relate
to	TO	to
age	NN	age
and	CC	and
most	RBS	most
frequent	JJ	frequent
comorbidities	NNS	comorbidity
.	SENT	.
So	RB	so
far	RB	far
,	,	,
it	PP	it
is	VBZ	be
known	VBN	know
that	IN	that
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
primarily	RB	primarily
infects	VBZ	infect
the	DT	the
type	NN	type
II	CD	@card@
pneumocytes	NNS	<unknown>
in	IN	in
humans	NNS	human
,	,	,
with	IN	with
the	DT	the
help	NN	help
of	IN	of
transmembrane	JJ	<unknown>
serine	NN	serine
protease	NN	protease
type	NN	type
2	CD	@card@
(	(	(
TMPRSS2	NP	<unknown>
)	)	)
.	SENT	.
Up	RB	up
to	TO	to
now	RB	now
,	,	,
the	DT	the
only	RB	only
known	VBN	know
transcriptional	JJ	transcriptional
promoters	NNS	promoter
of	IN	of
genes	NNS	gene
coding	VBG	code
TMPRSS2	NP	<unknown>
are	VBP	be
androgenic	JJ	androgenic
.	SENT	.
Theoretically	RB	theoretically
,	,	,
the	DT	the
elevated	JJ	elevated
level	NN	level
of	IN	of
androgens	NNS	androgen
or	CC	or
androgen	NN	androgen
receptors	NNS	receptor
would	MD	would
lead	VB	lead
to	TO	to
a	DT	a
higher	JJR	high
expression	NN	expression
of	IN	of
TMPRSS2	NP	<unknown>
and	CC	and
a	DT	a
higher	JJR	high
level	NN	level
of	IN	of
viremia	NN	<unknown>
as	IN	as
a	DT	a
consequence	NN	consequence
.	SENT	.
The	DT	the
aim	NN	aim
of	IN	of
our	PP$	our
research	NN	research
was	VBD	be
to	TO	to
indirectly	RB	indirectly
investigate	VB	investigate
if	IN	if
the	DT	the
severity	NN	severity
of	IN	of
SARS-CoV-2	NP	<unknown>
infection	NN	infection
is	VBZ	be
dependent	JJ	dependent
on	IN	on
the	DT	the
expression	NN	expression
of	IN	of
androgen	NN	androgen
receptors	NNS	receptor
.	SENT	.
This	DT	this
observational	JJ	observational
study	NN	study
analysed	VBD	analyse
male	JJ	male
patients	NNS	patient
hospitalized	VBN	hospitalize
for	IN	for
SARS-CoV-2	NP	<unknown>
infection	NN	infection
with	IN	with
respect	NN	respect
to	TO	to
the	DT	the
length	NN	length
of	IN	of
hospitalisation	NN	hospitalisation
,	,	,
the	DT	the
outcome	NN	outcome
of	IN	of
the	DT	the
disease	NN	disease
,	,	,
the	DT	the
type	NN	type
of	IN	of
necessary	JJ	necessary
oxygen	NN	oxygen
support	NN	support
and	CC	and
the	DT	the
presence	NN	presence
of	IN	of
comorbidities	NNS	comorbidity
and	CC	and
hairiness	NN	hairiness
.	SENT	.
In	IN	in
hairiness	NN	hairiness
estimation	NN	estimation
,	,	,
we	PP	we
used	VBD	use
an	DT	an
adapted	VBN	adapt
version	NN	version
of	IN	of
the	DT	the
Hamilton-Norwood	NP	Hamilton-Norwood
scale	NN	scale
and	CC	and
the	DT	the
presence	NN	presence
of	IN	of
the	DT	the
Gabrin	NP	<unknown>
sign	NN	sign
.	SENT	.
In	IN	in
total	NN	total
,	,	,
208	CD	@card@
patients	NNS	patient
were	VBD	be
enrolled	VBN	enroll
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
There	EX	there
were	VBD	be
statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
comparing	VBG	compare
the	DT	the
average	JJ	average
age	NN	age
of	IN	of
patients	NNS	patient
with	IN	with
the	DT	the
different	JJ	different
types	NNS	type
of	IN	of
alopecia	NN	alopecia
when	WRB	when
groups	NNS	group
were	VBD	be
divided	VBN	divide
according	VBG	accord
to	TO	to
the	DT	the
presence	NN	presence
of	IN	of
the	DT	the
Gabrin	NP	<unknown>
sign	NN	sign
(	(	(
t	NN	t
=	SYM	=
4.958	CD	@card@
,	,	,
p	NN	p
&gt	NN	&gt
;	:	;
0.01	LS	@card@
)	)	)
.	SENT	.
The	DT	the
outcomes	NNS	outcome
and	CC	and
the	DT	the
type	NN	type
of	IN	of
needed	JJ	needed
minimal	JJ	minimal
oxygen	NN	oxygen
support	NN	support
,	,	,
compared	VBN	compare
with	IN	with
the	DT	the
type	NN	type
of	IN	of
alopecia	NN	alopecia
in	IN	in
the	DT	the
case	NN	case
of	IN	of
Gabrin	NP	<unknown>
+	SYM	+
/	SYM	/
-	NN	<unknown>
classification	NN	classification
showed	VBD	show
a	DT	a
statistically	RB	statistically
significant	JJ	significant
difference	NN	difference
in	IN	in
the	DT	the
outcome	NN	outcome
of	IN	of
the	DT	the
disease	NN	disease
(	(	(
p	NN	p
=	SYM	=
0.027	CD	@card@
)	)	)
.	SENT	.
There	EX	there
were	VBD	be
no	DT	no
statistically	RB	statistically
significant	JJ	significant
differences	NNS	difference
in	IN	in
the	DT	the
distribution	NN	distribution
of	IN	of
comorbidities	NNS	comorbidity
among	IN	among
alopecia	NN	alopecia
groups	NNS	group
,	,	,
but	CC	but
hypertension	NN	hypertension
was	VBD	be
related	VBN	relate
to	TO	to
poor	JJ	poor
COVID-19	NP	<unknown>
prognosis	NN	prognosis
.	SENT	.
Our	PP$	our
findings	NNS	finding
suggest	VBP	suggest
that	IN	that
the	DT	the
Gabrin	NP	<unknown>
sign	NN	sign
and	CC	and
hypertension	NN	hypertension
are	VBP	be
related	VBN	relate
to	TO	to
a	DT	a
poor	JJ	poor
COVID-19	NP	<unknown>
prognosis	NN	prognosis
.	SENT	.
34767767/	CD	@card@
Non-invasive	JJ	non-invasive
respiratory	JJ	respiratory
support	NN	support
in	IN	in
the	DT	the
management	NN	management
of	IN	of
acute	JJ	acute
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
:	:	:
considerations	NNS	consideration
for	IN	for
clinical	JJ	clinical
practice	NN	practice
and	CC	and
priorities	NNS	priority
for	IN	for
research	NN	research
Non-invasive	JJ	non-invasive
respiratory	JJ	respiratory
support	NN	support
(	(	(
NIRS	NP	<unknown>
)	)	)
has	VBZ	have
increasingly	RB	increasingly
been	VBN	be
used	VBN	use
in	IN	in
the	DT	the
management	NN	management
of	IN	of
COVID-19-associated	JJ	COVID-19-associated
acute	JJ	acute
respiratory	JJ	respiratory
failure	NN	failure
,	,	,
but	CC	but
questions	NNS	question
remain	VBP	remain
about	IN	about
the	DT	the
utility	NN	utility
,	,	,
safety	NN	safety
,	,	,
and	CC	and
outcome	NN	outcome
benefit	NN	benefit
of	IN	of
NIRS	NP	<unknown>
strategies	NNS	strategy
.	SENT	.
We	PP	we
identified	VBD	identify
two	CD	two
randomised	VBN	randomise
controlled	JJ	controlled
trials	NNS	trial
and	CC	and
83	CD	@card@
observational	JJ	observational
studies	NNS	study
,	,	,
compromising	VBG	compromise
13	CD	@card@
931	CD	@card@
patients	NNS	patient
,	,	,
that	WDT	that
examined	VBD	examine
the	DT	the
effects	NNS	effect
of	IN	of
NIRS	NP	<unknown>
modalities:high-flow	NP	<unknown>
nasal	JJ	nasal
oxygen	NN	oxygen
,	,	,
continuous	JJ	continuous
positive	JJ	positive
airway	NN	airway
pressure	NN	pressure
,	,	,
and	CC	and
bilevel	JJ	bilevel
positive	JJ	positive
airway	NN	airway
pressure:on	NN	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
Of	IN	of
5120	CD	@card@
patients	NNS	patient
who	WP	who
were	VBD	be
candidates	NNS	candidate
for	IN	for
full	JJ	full
treatment	NN	treatment
escalation	NN	escalation
,	,	,
1880	CD	@card@
(	(	(
37	CD	@card@
%	NN	%
)	)	)
progressed	VBD	progress
to	TO	to
invasive	JJ	invasive
mechanical	JJ	mechanical
ventilation	NN	ventilation
and	CC	and
3658	CD	@card@
of	IN	of
4669	CD	@card@
(	(	(
78	CD	@card@
%	NN	%
)	)	)
survived	VBD	survive
to	TO	to
study	VB	study
end	NN	end
.	SENT	.
Survival	NN	survival
was	VBD	be
30	CD	@card@
%	NN	%
among	IN	among
the	DT	the
1050	CD	@card@
patients	NNS	patient
for	IN	for
whom	WP	whom
NIRS	NP	<unknown>
was	VBD	be
the	DT	the
stated	JJ	stated
ceiling	NN	ceiling
of	IN	of
treatment	NN	treatment
.	SENT	.
The	DT	the
two	CD	two
randomised	VBD	randomise
controlled	JJ	controlled
trials	NNS	trial
indicate	VBP	indicate
superiority	NN	superiority
of	IN	of
non-invasive	JJ	non-invasive
ventilation	NN	ventilation
over	IN	over
high-flow	JJ	<unknown>
nasal	JJ	nasal
oxygen	NN	oxygen
in	IN	in
reducing	VBG	reduce
the	DT	the
need	NN	need
for	IN	for
intubation	NN	intubation
.	SENT	.
Reported	VBN	report
complication	NN	complication
rates	NNS	rate
were	VBD	be
low	JJ	low
.	SENT	.
Overall	RB	overall
,	,	,
the	DT	the
studies	NNS	study
indicate	VBP	indicate
that	IN	that
NIRS	NNS	<unknown>
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
is	VBZ	be
safe	JJ	safe
,	,	,
improves	VBZ	improve
resource	NN	resource
utilisation	NN	utilisation
,	,	,
and	CC	and
might	MD	might
be	VB	be
associated	VBN	associate
with	IN	with
better	JJR	good
outcomes	NNS	outcome
.	SENT	.
To	TO	to
guide	VB	guide
clinical	JJ	clinical
decision	NN	decision
making	VBG	make
,	,	,
prospective	JJ	prospective
,	,	,
randomised	VBD	randomise
studies	NNS	study
are	VBP	be
needed	VBN	need
to	TO	to
address	VB	address
timing	NN	timing
of	IN	of
intervention	NN	intervention
,	,	,
optimal	JJ	optimal
use	NN	use
of	IN	of
NIRS	NP	<unknown>
modalities:alone	NP	<unknown>
or	CC	or
in	IN	in
combination:and	NN	<unknown>
validation	NN	validation
of	IN	of
tools	NNS	tool
such	JJ	such
as	IN	as
oxygenation	NN	oxygenation
indices	NN	indices
,	,	,
response	NN	response
to	TO	to
a	DT	a
trial	NN	trial
of	IN	of
NIRS	NP	<unknown>
,	,	,
and	CC	and
inflammatory	JJ	inflammatory
markers	NNS	marker
as	IN	as
predictors	NNS	predictor
of	IN	of
treatment	NN	treatment
success	NN	success
.	SENT	.
33688413/	CD	@card@
Myocarditis	NN	myocarditis
and	CC	and
Pericarditis	NN	pericarditis
in	IN	in
Patients	NPS	Patients
with	IN	with
COVID-19	NP	<unknown>
COVID-19	NP	<unknown>
has	VBZ	have
been	VBN	be
associated	VBN	associate
with	IN	with
a	DT	a
variety	NN	variety
of	IN	of
cardiac	JJ	cardiac
manifestations	NNS	manifestation
.	SENT	.
Myocarditis	NN	myocarditis
and	CC	and
pericarditis	NN	pericarditis
have	VBP	have
been	VBN	be
reported	VBN	report
as	IN	as
one	CD	one
of	IN	of
the	DT	the
many	JJ	many
cardiac	JJ	cardiac
manifestations	NNS	manifestation
in	IN	in
association	NN	association
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
We	PP	we
describe	VBP	describe
below	IN	below
three	CD	three
cases	NNS	case
of	IN	of
myocarditis	NN	myocarditis
,	,	,
pericarditis	NN	pericarditis
with	IN	with
associated	JJ	associated
pericardial	JJ	pericardial
effusion	NN	effusion
and	CC	and
myopericarditis	NN	myopericarditis
,	,	,
respectively	RB	respectively
,	,	,
in	IN	in
the	DT	the
setting	NN	setting
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
Although	IN	although
these	DT	these
entities	NNS	entity
may	MD	may
occur	VB	occur
in	IN	in
isolation	NN	isolation
,	,	,
they	PP	they
often	RB	often
occur	VBP	occur
in	IN	in
association	NN	association
to	TO	to
varying	VBG	vary
degrees	NNS	degree
.	SENT	.
It	PP	it
could	MD	could
either	RB	either
be	VB	be
the	DT	the
initial	JJ	initial
diagnosis	NN	diagnosis
at	IN	at
the	DT	the
time	NN	time
of	IN	of
presentation	NN	presentation
or	CC	or
it	PP	it
could	MD	could
occur	VB	occur
later	RBR	later
in	IN	in
the	DT	the
course	NN	course
of	IN	of
COVID-19	NP	<unknown>
infection	NN	infection
.	SENT	.
Pericarditis	NN	pericarditis
may	MD	may
occasionally	RB	occasionally
be	VB	be
associated	VBN	associate
with	IN	with
significant	JJ	significant
pericardial	JJ	pericardial
effusion	NN	effusion
and	CC	and
tamponade	NN	<unknown>
requiring	VBG	require
therapeutic	JJ	therapeutic
pericardiocentesis	NN	<unknown>
.	SENT	.
The	DT	the
assessment	NN	assessment
of	IN	of
pericardial	JJ	pericardial
effusion	NN	effusion
has	VBZ	have
been	VBN	be
found	VBN	find
to	TO	to
be	VB	be
exudative	JJ	exudative
and	CC	and
is	VBZ	be
usually	RB	usually
negative	JJ	negative
for	IN	for
SARS-CoV-2	NP	<unknown>
.	SENT	.
Treatment	NN	treatment
of	IN	of
pericarditis	NN	pericarditis
with	IN	with
nonsteroidal	JJ	nonsteroidal
anti-inflammatory	JJ	anti-inflammatory
drugs	NNS	drug
,	,	,
colchicine	NN	colchicine
,	,	,
and	CC	and
corticosteroids	NNS	corticosteroid
has	VBZ	have
proven	VBN	prove
to	TO	to
be	VB	be
safe	JJ	safe
in	IN	in
COVID-19	NP	<unknown>
.	SENT	.
Myocarditis	NN	myocarditis
may	MD	may
present	VB	present
with	IN	with
severe	JJ	severe
left	VBN	leave
ventricular	JJ	ventricular
systolic	JJ	systolic
dysfunction	NN	dysfunction
and	CC	and
cardiogenic	JJ	cardiogenic
shock	NN	shock
requiring	VBG	require
inotropes	NNS	inotrope
and	CC	and
mechanical	JJ	mechanical
circulatory	JJ	circulatory
support	NN	support
.	SENT	.
35151856/	CD	@card@
Virtual	JJ	virtual
Horse	NP	Horse
Shows	NP	Shows
:	:	:
Participants	NNS	participant
perspective	NN	perspective
on	IN	on
a	DT	a
novel	JJ	novel
alternative	NN	alternative
during	IN	during
COVID-19	NP	<unknown>
pandemic	NN	pandemic
The	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
increased	VBN	increase
the	DT	the
availability	NN	availability
of	IN	of
virtual	JJ	virtual
horse	NN	horse
showing	VBG	show
opportunities	NNS	opportunity
.	SENT	.
The	DT	the
objectives	NNS	objective
of	IN	of
this	DT	this
study	NN	study
were	VBD	be
to	TO	to
describe	VB	describe
survey	NN	survey
participants	NNS	participant
'	POS	'
personal	JJ	personal
characteristics	NNS	characteristic
and	CC	and
participation	NN	participation
in	IN	in
virtual	JJ	virtual
and	CC	and
in-person	NN	in-person
horse	NN	horse
shows	NNS	show
,	,	,
level	NN	level
of	IN	of
satisfaction	NN	satisfaction
,	,	,
attitude	NN	attitude
toward	IN	toward
technology	NN	technology
and	CC	and
motivation	NN	motivation
to	TO	to
participate	VB	participate
,	,	,
and	CC	and
internal	JJ	internal
and	CC	and
external	JJ	external
factors	NNS	factor
influencing	VBG	influence
the	DT	the
decision	NN	decision
to	TO	to
participate	VB	participate
in	IN	in
virtual	JJ	virtual
horse	NN	horse
shows	NNS	show
.	SENT	.
A	DT	a
survey	NN	survey
was	VBD	be
distributed	VBN	distribute
to	TO	to
a	DT	a
target	NN	target
audience	NN	audience
of	IN	of
adult	JJ	adult
horse	NN	horse
show	NN	show
participants	NNS	participant
and/or	CC	and/or
adults	NNS	adult
supporting	VBG	support
youth	NN	youth
horse	NN	horse
show	NN	show
participants	NNS	participant
via	IN	via
Qualtrics	NP	<unknown>
(	(	(
n	NN	n
=251	NN	<unknown>
)	)	)
.	SENT	.
A	DT	a
majority	NN	majority
of	IN	of
respondents	NNS	respondent
(	(	(
91.2	CD	@card@
%	NN	%
)	)	)
reported	VBD	report
benefits	NNS	benefit
to	TO	to
participating	VBG	participate
in	IN	in
virtual	JJ	virtual
horse	NN	horse
shows	NNS	show
,	,	,
and	CC	and
59.8	CD	@card@
%	NN	%
plan	NN	plan
to	TO	to
continue	VB	continue
showing	VBG	show
virtually	RB	virtually
when	WRB	when
in-person	NN	in-person
shows	VBZ	show
resume	VB	resume
.	SENT	.
The	DT	the
opportunity	NN	opportunity
to	TO	to
show	VB	show
virtually	RB	virtually
has	VBZ	have
resulted	VBN	result
in	IN	in
76.1	CD	@card@
%	NN	%
of	IN	of
respondents	NNS	respondent
anticipating	VBG	anticipate
increasing	VBG	increase
their	PP$	their
participation	NN	participation
in	IN	in
showing	VBG	show
(	(	(
in-person	NN	in-person
or	CC	or
virtual	JJ	virtual
)	)	)
.	SENT	.
An	DT	an
improvement	NN	improvement
in	IN	in
attitude	NN	attitude
toward	IN	toward
technology	NN	technology
(	(	(
M	NP	M
=1.6	NP	<unknown>
;	:	;
SD	NP	SD
=0.4	NP	<unknown>
;	:	;
Range	NP	Range
=1.0	NP	<unknown>
-	NN	<unknown>
2.3	CD	@card@
)	)	)
and	CC	and
an	DT	an
increase	NN	increase
in	IN	in
motivation	NN	motivation
to	TO	to
participate	VB	participate
,	,	,
ride	VB	ride
and	CC	and
show	VB	show
(	(	(
M	NP	M
=1.4	NP	<unknown>
;	:	;
SD	NP	SD
=0.4	NP	<unknown>
;	:	;
Range	NP	Range
=1.0	NP	<unknown>
-	NN	<unknown>
2.8	CD	@card@
)	)	)
was	VBD	be
also	RB	also
reported	VBN	report
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
respondents	NNS	respondent
indicated	VBD	indicate
they	PP	they
were	VBD	be
somewhat	RB	somewhat
likely	JJ	likely
to	TO	to
be	VB	be
influenced	VBN	influence
to	TO	to
participate	VB	participate
in	IN	in
virtual	JJ	virtual
shows	NNS	show
by	IN	by
internal	JJ	internal
factors	NNS	factor
such	JJ	such
as	IN	as
their	PP$	their
budget	NN	budget
and	CC	and
ability	NN	ability
to	TO	to
record	VB	record
the	DT	the
ride	NN	ride
.	SENT	.
External	JJ	external
factors	NNS	factor
such	JJ	such
as	IN	as
feedback	NN	feedback
from	IN	from
judges	NNS	judge
,	,	,
available	JJ	available
divisions	NNS	division
,	,	,
and	CC	and
awards	NNS	award
were	VBD	be
extremely	RB	extremely
likely	JJ	likely
to	TO	to
influence	VB	influence
their	PP$	their
decision	NN	decision
to	TO	to
participate	VB	participate
.	SENT	.
In	IN	in
conclusion	NN	conclusion
,	,	,
virtual	JJ	virtual
horse	NN	horse
shows	NNS	show
have	VBP	have
provided	VBN	provide
a	DT	a
satisfactory	JJ	satisfactory
outlet	NN	outlet
to	TO	to
keep	VB	keep
people	NNS	people
engaged	VBN	engage
in	IN	in
the	DT	the
industry	NN	industry
.	SENT	.
Additional	JJ	additional
research	NN	research
should	MD	should
be	VB	be
done	VBN	do
to	TO	to
determine	VB	determine
if	IN	if
the	DT	the
current	JJ	current
popularity	NN	popularity
of	IN	of
virtual	JJ	virtual
horse	NN	horse
showing	NN	showing
persists	VBZ	persist
once	IN	once
in-person	NN	in-person
shows	NNS	show
have	VBP	have
fully	RB	fully
resumed	VBN	resume
.	SENT	.
34844968/	CD	@card@
Undetectable	JJ	undetectable
SARS-CoV-2	NP	<unknown>
active	JJ	active
adaptive	JJ	adaptive
immunity:post-vaccination	NN	immunity:post-vaccination
or	CC	or
post-COVID-19	JJ	<unknown>
severe	JJ	severe
disease:after	NN	<unknown>
immunosuppressants	NNS	immunosuppressant
use	VBP	use
Since	IN	since
the	DT	the
beginning	NN	beginning
of	IN	of
COVID-19	NP	<unknown>
vaccination	NN	vaccination
in	IN	in
New	NP	New
Jersey	NP	Jersey
in	IN	in
December	NP	December
2020	CD	@card@
,	,	,
we	PP	we
have	VBP	have
observed	VBN	observe
multiple	JJ	multiple
cases	NNS	case
of	IN	of
undetectable	JJ	undetectable
adaptive	JJ	adaptive
immunity	NN	immunity
,	,	,
post-vaccination	NN	post-vaccination
or	CC	or
post-COVID-19	NN	<unknown>
infection	NN	infection
,	,	,
in	IN	in
patients	NNS	patient
using	VBG	use
immunosuppressants	NNS	immunosuppressant
.	SENT	.
Here	RB	here
,	,	,
we	PP	we
present	VBP	present
three	CD	three
cases	NNS	case
of	IN	of
patients	NNS	patient
using	VBG	use
immunosuppressants	NNS	immunosuppressant
:	:	:
mycophenolate	NN	mycophenolate
and	CC	and
tacrolimus	NN	<unknown>
for	IN	for
renal	JJ	renal
transplant	NN	transplant
;	:	;
ocrelizumab	NN	<unknown>
for	IN	for
multiple	JJ	multiple
sclerosis	NN	sclerosis
and	CC	and
rituximab	NN	<unknown>
for	IN	for
peripheral	JJ	peripheral
ulcerative	JJ	ulcerative
keratitis	NN	keratitis
.	SENT	.
All	DT	all
three	CD	three
patients	NNS	patient
were	VBD	be
admitted	VBN	admit
for	IN	for
acute	JJ	acute
respiratory	JJ	respiratory
distress	NN	distress
syndrome	NN	syndrome
(	(	(
ARDS	NN	<unknown>
)	)	)
from	IN	from
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
;	:	;
two	CD	two
patients	NNS	patient
reported	VBD	report
having	VBG	have
received	VBN	receive
full	JJ	full
COVID-19	NP	<unknown>
vaccination	NN	vaccination
prior	RB	prior
to	TO	to
admission	NN	admission
and	CC	and
one	CD	one
unvaccinated	JJ	unvaccinated
patient	NN	patient
required	VBN	require
readmission	NP	readmission
.	SENT	.
Our	PP$	our
findings	NNS	finding
showed	VBD	show
that	IN	that
these	DT	these
patients	NNS	patient
tested	VBD	test
negative	JJ	negative
for	IN	for
SARS-CoV-2	NP	<unknown>
IgM	NP	Igm
spike	NN	spike
and	CC	and
CoV-2	NP	<unknown>
IgG	NP	IgG
nucleocapsid	NN	nucleocapsid
antibodies	NNS	antibody
.	SENT	.
All	DT	all
three	CD	three
patients	NNS	patient
were	VBD	be
treated	VBN	treat
with	IN	with
standard-of-care	NN	<unknown>
remdesivir	NN	<unknown>
,	,	,
dexamethasone	NN	<unknown>
and	CC	and
convalescent	JJ	convalescent
plasma	NN	plasma
;	:	;
two	CD	two
recovered	VBD	recover
successfully	RB	successfully
and	CC	and
one	CD	one
patient	NN	patient
died	VBN	die
from	IN	from
respiratory	JJ	respiratory
failure	NN	failure
secondary	JJ	secondary
to	TO	to
worsening	VBG	worsen
ARDS	NN	<unknown>
from	IN	from
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
.	SENT	.
We	PP	we
highlight	VBP	highlight
the	DT	the
challenges	NNS	challenge
of	IN	of
treating	VBG	treat
immunosuppressed	JJ	<unknown>
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
,	,	,
in	IN	in
an	DT	an
era	NN	era
where	WRB	where
dissemination	NN	dissemination
of	IN	of
such	JJ	such
information	NN	information
is	VBZ	be
paramount	JJ	paramount
to	TO	to
helping	VBG	help
doctors	NNS	doctor
standardise	VB	standardise
and	CC	and
improve	VB	improve
the	DT	the
quality	NN	quality
of	IN	of
care	NN	care
for	IN	for
these	DT	these
patients	NNS	patient
.	SENT	.
35455356/	CD	@card@
Immunosenescence	NN	Immunosenescence
and	CC	and
Altered	JJ	altered
Vaccine	NN	vaccine
Efficiency	NN	efficiency
in	IN	in
Older	JJR	old
Subjects	NNS	subject
:	:	:
A	DT	a
Myth	NN	myth
Difficult	JJ	difficult
to	TO	to
Change	VB	change
Organismal	JJ	organismal
ageing	VBG	age
is	VBZ	be
associated	VBN	associate
with	IN	with
many	JJ	many
physiological	JJ	physiological
changes	NNS	change
,	,	,
including	VBG	include
differences	NNS	difference
in	IN	in
the	DT	the
immune	JJ	immune
system	NN	system
of	IN	of
most	JJS	most
animals	NNS	animal
.	SENT	.
These	DT	these
differences	NNS	difference
are	VBP	be
often	RB	often
considered	VBN	consider
to	TO	to
be	VB	be
a	DT	a
key	JJ	key
cause	NN	cause
of	IN	of
age-associated	JJ	age-associated
diseases	NNS	disease
as	IN	as
well	RB	well
as	RB	as
decreased	VBN	decrease
vaccine	NN	vaccine
responses	NNS	response
in	IN	in
humans	NNS	human
.	SENT	.
The	DT	the
most	RBS	most
often	RB	often
cited	VBN	cite
vaccine	NN	vaccine
failure	NN	failure
is	VBZ	be
seasonal	JJ	seasonal
influenza	NN	influenza
,	,	,
but	CC	but
,	,	,
while	IN	while
it	PP	it
is	VBZ	be
usually	RB	usually
the	DT	the
case	NN	case
that	IN	that
the	DT	the
efficiency	NN	efficiency
of	IN	of
this	DT	this
vaccine	NN	vaccine
is	VBZ	be
lower	JJR	low
in	IN	in
older	JJR	old
than	IN	than
younger	JJR	young
adults	NNS	adult
,	,	,
this	DT	this
is	VBZ	be
not	RB	not
always	RB	always
true	JJ	true
,	,	,
and	CC	and
the	DT	the
reasons	NNS	reason
for	IN	for
the	DT	the
differential	JJ	differential
responses	NNS	response
are	VBP	be
manifold	JJ	manifold
.	SENT	.
Undoubtedly	RB	undoubtedly
,	,	,
changes	NNS	change
in	IN	in
the	DT	the
innate	JJ	innate
and	CC	and
adaptive	JJ	adaptive
immune	JJ	immune
response	NN	response
with	IN	with
ageing	VBG	age
are	VBP	be
associated	VBN	associate
with	IN	with
failure	NN	failure
to	TO	to
respond	VB	respond
to	TO	to
the	DT	the
influenza	NN	influenza
vaccine	NN	vaccine
,	,	,
but	CC	but
the	DT	the
cause	NN	cause
is	VBZ	be
unclear	JJ	unclear
.	SENT	.
Moreover	RB	moreover
,	,	,
recent	JJ	recent
advances	NNS	advance
in	IN	in
vaccine	NN	vaccine
formulations	NNS	formulation
and	CC	and
adjuvants	NNS	adjuvant
,	,	,
as	RB	as
well	RB	well
as	IN	as
in	IN	in
our	PP$	our
understanding	NN	understanding
of	IN	of
immune	JJ	immune
changes	NNS	change
with	IN	with
ageing	VBG	age
,	,	,
have	VBP	have
contributed	VBN	contribute
to	TO	to
the	DT	the
development	NN	development
of	IN	of
vaccines	NNS	vaccine
,	,	,
such	JJ	such
as	IN	as
those	DT	those
against	IN	against
herpes	NN	herpes
zoster	NN	zoster
and	CC	and
SARS-CoV-2	NP	<unknown>
,	,	,
that	WDT	that
can	MD	can
protect	VB	protect
against	IN	against
serious	JJ	serious
disease	NN	disease
in	IN	in
older	JJR	old
adults	NNS	adult
just	RB	just
as	RB	as
well	RB	well
as	RB	as
in	IN	in
younger	JJR	young
people	NNS	people
.	SENT	.
In	IN	in
the	DT	the
present	JJ	present
article	NN	article
,	,	,
we	PP	we
discuss	VBP	discuss
the	DT	the
reasons	NNS	reason
why	WRB	why
it	PP	it
is	VBZ	be
a	DT	a
myth	NN	myth
that	IN	that
vaccines	NNS	vaccine
inevitably	RB	inevitably
protect	VBP	protect
less	RBR	less
well	RB	well
in	IN	in
older	JJR	old
individuals	NNS	individual
,	,	,
and	CC	and
that	IN	that
vaccines	NNS	vaccine
represent	VBP	represent
one	CD	one
of	IN	of
the	DT	the
most	RBS	most
powerful	JJ	powerful
means	NNS	mean
to	TO	to
protect	VB	protect
the	DT	the
health	NN	health
and	CC	and
ensure	VB	ensure
the	DT	the
quality	NN	quality
of	IN	of
life	NN	life
of	IN	of
older	JJR	old
adults	NNS	adult
.	SENT	.
32624433/	CD	@card@
Veneto	NP	Veneto
's	POS	's
Successful	JJ	successful
Lesson	NN	lesson
for	IN	for
a	DT	a
World	NN	world
Shocked	VBN	shock
by	IN	by
COVID-19	NP	<unknown>
:	:	:
Think	VBP	think
Globally	RB	globally
and	CC	and
Act	NP	Act
Locally	RB	locally
33430698/	CD	@card@
Priority-setting	NN	Priority-setting
dilemmas	NNS	dilemma
,	,	,
moral	JJ	moral
distress	NN	distress
and	CC	and
support	NN	support
experienced	VBN	experience
by	IN	by
nurses	NNS	nurse
and	CC	and
physicians	NNS	physician
in	IN	in
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Norway	NP	Norway
The	DT	the
global	JJ	global
COVID-19	NP	<unknown>
pandemic	NN	pandemic
has	VBZ	have
imposed	VBN	impose
challenges	NNS	challenge
on	IN	on
healthcare	NN	<unknown>
systems	NNS	system
and	CC	and
professionals	NNS	professional
worldwide	RB	worldwide
and	CC	and
introduced	VBD	introduce
a	DT	a
maelstrom	NN	maelstrom
of	IN	of
ethical	JJ	ethical
dilemmas	NNS	dilemma
.	SENT	.
How	WRB	how
ethically	RB	ethically
demanding	VBG	demand
situations	NNS	situation
are	VBP	be
handled	VBN	handle
affects	NNS	affect
employees	NNS	employee
'	POS	'
moral	JJ	moral
stress	NN	stress
and	CC	and
job	NN	job
satisfaction	NN	satisfaction
.	SENT	.
Describe	VB	describe
priority-setting	NN	priority-setting
dilemmas	NNS	dilemma
,	,	,
moral	JJ	moral
distress	NN	distress
and	CC	and
support	NN	support
experienced	VBN	experience
by	IN	by
nurses	NNS	nurse
and	CC	and
physicians	NNS	physician
across	IN	across
medical	JJ	medical
specialties	NNS	specialty
in	IN	in
the	DT	the
early	JJ	early
phase	NN	phase
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
in	IN	in
Western	NP	Western
Norway	NP	Norway
.	SENT	.
A	DT	a
cross-sectional	JJ	cross-sectional
hospital-based	JJ	hospital-based
survey	NN	survey
was	VBD	be
conducted	VBN	conduct
from	IN	from
23	CD	@card@
April	NP	April
to	TO	to
11	CD	@card@
May	NP	May
2020	CD	@card@
.	SENT	.
Ethical	JJ	ethical
approval	NN	approval
granted	VBN	grant
by	IN	by
the	DT	the
Regional	NP	Regional
Research	NP	Research
Ethics	NP	Ethics
Committee	NP	Committee
in	IN	in
Western	NP	Western
Norway	NP	Norway
(	(	(
131421	CD	@card@
)	)	)
.	SENT	.
Among	IN	among
the	DT	the
1606	CD	@card@
respondents	NNS	respondent
,	,	,
67	CD	@card@
%	NN	%
had	VBD	have
experienced	VBN	experience
priority-setting	NN	priority-setting
dilemmas	NNS	dilemma
the	DT	the
previous	JJ	previous
two	CD	two
weeks	NNS	week
.	SENT	.
Healthcare	NP	Healthcare
workers	NNS	worker
who	WP	who
were	VBD	be
directly	RB	directly
involved	VBN	involve
in	IN	in
COVID-19	NP	<unknown>
care	NN	care
,	,	,
were	VBD	be
redeployed	VBN	redeploy
or	CC	or
worked	VBN	work
in	IN	in
psychiatry/addiction	NN	psychiatry/addiction
medicine	NN	medicine
experienced	VBD	experience
it	PP	it
more	RBR	more
often	RB	often
.	SENT	.
Although	IN	although
59	CD	@card@
%	NN	%
of	IN	of
the	DT	the
respondents	NNS	respondent
had	VBD	have
seen	VBN	see
adverse	JJ	adverse
consequences	NNS	consequence
due	JJ	due
to	TO	to
resource	NN	resource
scarcity	NN	scarcity
,	,	,
severe	JJ	severe
consequences	NNS	consequence
were	VBD	be
rare	JJ	rare
.	SENT	.
Moral	JJ	moral
distress	NN	distress
levels	NNS	level
were	VBD	be
generally	RB	generally
low	JJ	low
(	(	(
2.9	CD	@card@
on	IN	on
a	DT	a
0-10	CD	@card@
scale	NN	scale
)	)	)
,	,	,
but	CC	but
higher	JJR	high
in	IN	in
selected	VBN	select
groups	NNS	group
(	(	(
redeployed	VBN	redeploy
,	,	,
managers	NNS	manager
and	CC	and
working	VBG	work
in	IN	in
psychiatry/addiction	NN	psychiatry/addiction
medicine	NN	medicine
)	)	)
.	SENT	.
Backing	VBG	back
from	IN	from
existing	VBG	exist
collegial	JJ	collegial
and	CC	and
managerial	JJ	managerial
structures	NNS	structure
and	CC	and
routines	NNS	routine
,	,	,
such	JJ	such
as	IN	as
discussions	NNS	discussion
with	IN	with
colleagues	NNS	colleague
and	CC	and
receiving	VBG	receive
updates	NNS	update
and	CC	and
information	NN	information
from	IN	from
managers	NNS	manager
that	WDT	that
listened	VBD	listen
and	CC	and
acted	VBD	act
upon	IN	upon
feedback	NN	feedback
,	,	,
were	VBD	be
found	VBN	find
more	RBR	more
helpful	JJ	helpful
than	IN	than
external	JJ	external
support	NN	support
mechanisms	NNS	mechanism
.	SENT	.
Priority-setting	NN	Priority-setting
guidelines	NNS	guideline
were	VBD	be
also	RB	also
helpful	JJ	helpful
.	SENT	.
By	IN	by
including	VBG	include
all	DT	all
medical	JJ	medical
specialties	NNS	specialty
,	,	,
nurses	NNS	nurse
and	CC	and
physicians	NNS	physician
,	,	,
and	CC	and
various	JJ	various
institutions	NNS	institution
,	,	,
the	DT	the
study	NN	study
provides	VBZ	provide
information	NN	information
on	IN	on
how	WRB	how
the	DT	the
COVID-19	NP	<unknown>
mitigation	NN	mitigation
also	RB	also
influenced	VBD	influence
those	DT	those
not	RB	not
directly	RB	directly
involved	VBN	involve
in	IN	in
the	DT	the
COVID-19	NP	<unknown>
treatment	NN	treatment
of	IN	of
patients	NNS	patient
.	SENT	.
In	IN	in
the	DT	the
next	JJ	next
stages	NNS	stage
of	IN	of
the	DT	the
pandemic	JJ	pandemic
response	NN	response
,	,	,
support	NN	support
for	IN	for
healthcare	NN	<unknown>
professionals	NNS	professional
directly	RB	directly
involved	VBN	involve
in	IN	in
outbreak-affected	JJ	outbreak-affected
patients	NNS	patient
,	,	,
those	DT	those
redeployed	VBN	redeploy
or	CC	or
those	DT	those
most	RBS	most
impacted	VBN	impact
by	IN	by
mitigation	NN	mitigation
strategies	NNS	strategy
must	MD	must
be	VB	be
a	DT	a
priority	NN	priority
.	SENT	.
Empirical	JJ	empirical
research	NN	research
of	IN	of
healthcare	NN	<unknown>
workers	NNS	worker
experiences	NNS	experience
under	IN	under
a	DT	a
pandemic	NN	pandemic
are	VBP	be
important	JJ	important
to	TO	to
identify	VB	identify
groups	NNS	group
at	IN	at
risks	NNS	risk
and	CC	and
useful	JJ	useful
support	NN	support
mechanisms	NNS	mechanism
.	SENT	.
32480420/	CD	@card@
Challenges	NNS	challenge
in	IN	in
the	DT	the
Management	NN	management
of	IN	of
patients	NNS	patient
with	IN	with
systemic	JJ	systemic
light	JJ	light
chain	NN	chain
(	(	(
AL	NP	al
)	)	)
amyloidosis	NN	<unknown>
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
The	DT	the
SARS-CoV-2-associated	JJ	SARS-CoV-2-associated
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
is	VBZ	be
primarily	RB	primarily
manifested	VBN	manifest
as	IN	as
a	DT	a
respiratory	JJ	respiratory
tract	NN	tract
infection	NN	infection
but	CC	but
may	MD	may
affect	VB	affect
and	CC	and
cause	VB	cause
complications	NNS	complication
from	IN	from
multiple	JJ	multiple
organ	NN	organ
systems	NNS	system
(	(	(
cardiovascular	JJ	cardiovascular
,	,	,
gastrointestinal	JJ	gastrointestinal
,	,	,
kidneys	NNS	kidney
,	,	,
hematopoietic	JJ	hematopoietic
and	CC	and
immune	JJ	immune
systems	NNS	system
)	)	)
while	IN	while
no	DT	no
proven	JJ	proven
specific	JJ	specific
therapy	NN	therapy
exists	VBZ	exist
.	SENT	.
The	DT	the
challenges	NNS	challenge
associated	VBN	associate
with	IN	with
COVID-19	NP	<unknown>
are	VBP	be
even	RB	even
greater	JJR	great
for	IN	for
patients	NNS	patient
with	IN	with
light	JJ	light
chain	NN	chain
(	(	(
AL	NP	al
)	)	)
amyloidosis	NN	<unknown>
,	,	,
a	DT	a
rare	JJ	rare
multisystemic	JJ	multisystemic
disease	NN	disease
affecting	VBG	affect
the	DT	the
heart	NN	heart
,	,	,
kidneys	NNS	kidney
,	,	,
liver	NN	liver
,	,	,
gastrointestinal	JJ	gastrointestinal
and	CC	and
nervous	JJ	nervous
system	NN	system
.	SENT	.
Patients	NNS	patient
with	IN	with
AL	NP	al
amyloidosis	NN	<unknown>
may	MD	may
need	VB	need
to	TO	to
receive	VB	receive
chemotherapy	NN	chemotherapy
,	,	,
which	WDT	which
probably	RB	probably
increases	VBZ	increase
infection	NN	infection
risk	NN	risk
.	SENT	.
Management	NN	management
of	IN	of
COVID-19	NP	<unknown>
may	MD	may
be	VB	be
particularly	RB	particularly
challenging	JJ	challenging
in	IN	in
patients	NNS	patient
with	IN	with
AL	NP	al
amyloidosis	NN	<unknown>
who	WP	who
often	RB	often
present	JJ	present
with	IN	with
cardiac	JJ	cardiac
dysfunction	NN	dysfunction
,	,	,
nephrotic	JJ	nephrotic
syndrome	NN	syndrome
,	,	,
neuropathy	NN	neuropathy
,	,	,
low	JJ	low
blood	NN	blood
pressure	NN	pressure
and	CC	and
gastrointestinal	JJ	gastrointestinal
symptoms	NNS	symptom
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
AL	NP	al
patients	NNS	patient
may	MD	may
be	VB	be
more	RBR	more
susceptible	JJ	susceptible
to	TO	to
toxicities	NNS	toxicity
of	IN	of
drugs	NNS	drug
used	VBN	use
to	TO	to
manage	VB	manage
COVID-19	NP	<unknown>
.	SENT	.
Access	NN	access
to	TO	to
health	NN	health
care	NN	care
may	MD	may
be	VB	be
difficult	JJ	difficult
or	CC	or
limited	JJ	limited
,	,	,
diagnosis	NN	diagnosis
of	IN	of
AL	NP	al
amyloidosis	NN	<unknown>
may	MD	may
be	VB	be
delayed	VBN	delay
with	IN	with
detrimental	JJ	detrimental
consequences	NNS	consequence
,	,	,
treatment	NN	treatment
administration	NN	administration
may	MD	may
need	VB	need
modification	NN	modification
.	SENT	.
Both	DT	both
patients	NNS	patient
and	CC	and
treating	VBG	treat
physicians	NNS	physician
need	VBP	need
to	TO	to
adapt	VB	adapt
in	IN	in
a	DT	a
new	JJ	new
reality	NN	reality
.	SENT	.
32524792/	CD	@card@
Early	RB	early
CT	NP	CT
Findings	NNS	finding
of	IN	of
Coronavirus	NP	<unknown>
Disease	NP	Disease
2019	NP	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
in	IN	in
Asymptomatic	JJ	asymptomatic
Children	NNS	child
:	:	:
A	DT	a
Single-Center	NP	Single-Center
Experience	NN	experience
The	DT	the
current	JJ	current
study	NN	study
reported	VBD	report
a	DT	a
case	NN	case
series	NN	series
to	TO	to
illustrate	VB	illustrate
the	DT	the
early	RB	early
computed	VBN	compute
tomography	NN	tomography
(	(	(
CT	NP	CT
)	)	)
findings	NNS	finding
of	IN	of
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
in	IN	in
pediatric	JJ	pediatric
patients	NNS	patient
.	SENT	.
All	DT	all
pediatric	JJ	pediatric
patients	NNS	patient
who	WP	who
were	VBD	be
diagnosed	VBN	diagnose
with	IN	with
COVID-19	NP	<unknown>
and	CC	and
who	WP	who
underwent	VBD	undergo
CT	NP	CT
scan	NN	scan
in	IN	in
Zhongnan	NP	<unknown>
Hospital	NP	Hospital
of	IN	of
Wuhan	NP	Wuhan
University	NP	University
from	IN	from
January	NP	January
20	CD	@card@
,	,	,
2020	CD	@card@
to	TO	to
February	NP	February
28	CD	@card@
,	,	,
2020	CD	@card@
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
current	JJ	current
study	NN	study
.	SENT	.
Data	NNS	datum
on	IN	on
clinical	JJ	clinical
and	CC	and
CT	NP	CT
features	NNS	feature
were	VBD	be
collected	VBN	collect
and	CC	and
analyzed	VBN	analyze
.	SENT	.
Four	CD	four
children	NNS	child
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
current	JJ	current
study	NN	study
.	SENT	.
All	DT	all
of	IN	of
them	PP	them
were	VBD	be
asymptomatic	JJ	asymptomatic
throughout	IN	throughout
the	DT	the
disease	NN	disease
course	NN	course
(	(	(
ranging	VBG	range
from	IN	from
7	CD	@card@
days	NNS	day
to	TO	to
15	CD	@card@
days	NNS	day
)	)	)
,	,	,
and	CC	and
none	NN	none
of	IN	of
them	PP	them
showed	VBD	show
abnormalities	NNS	abnormality
in	IN	in
blood	NN	blood
cell	NN	cell
counts	NNS	count
.	SENT	.
Familial	JJ	familial
cluster	NN	cluster
was	VBD	be
the	DT	the
main	JJ	main
transmission	NN	transmission
pattern	NN	pattern
.	SENT	.
Thin-section	NP	Thin-section
CT	NP	CT
revealed	VBD	reveal
abnormalities	NNS	abnormality
in	IN	in
three	CD	three
patients	NNS	patient
,	,	,
and	CC	and
one	CD	one
patient	NN	patient
did	VBD	do
not	RB	not
present	VB	present
with	IN	with
any	DT	any
abnormal	JJ	abnormal
CT	NP	CT
findings	NNS	finding
.	SENT	.
Unilateral	JJ	unilateral
lung	NN	lung
involvement	NN	involvement
was	VBD	be
observed	VBN	observe
in	IN	in
two	CD	two
patients	NNS	patient
,	,	,
and	CC	and
one	CD	one
patient	NN	patient
showed	VBD	show
bilateral	JJ	bilateral
lung	NN	lung
involvement	NN	involvement
.	SENT	.
In	IN	in
total	NN	total
,	,	,
five	CD	five
small	JJ	small
lesions	NNS	lesion
were	VBD	be
identified	VBN	identify
,	,	,
including	VBG	include
ground-glass	NN	ground-glass
opacity	NN	opacity
(	(	(
n	NN	n
=	SYM	=
4	CD	@card@
)	)	)
and	CC	and
consolidation	NN	consolidation
(	(	(
n	NN	n
=	SYM	=
1	CD	@card@
)	)	)
.	SENT	.
All	DT	all
lesions	NNS	lesion
had	VBD	have
ill-defined	JJ	ill-defined
margins	NNS	margin
with	IN	with
peripheral	JJ	peripheral
distribution	NN	distribution
and	CC	and
predilection	NN	predilection
of	IN	of
lower	JJR	low
lobe	NN	lobe
.	SENT	.
Small	JJ	small
patches	NNS	patch
of	IN	of
ground-glass	NN	ground-glass
opacity	NN	opacity
with	IN	with
subpleural	JJ	subpleural
distribution	NN	distribution
and	CC	and
unilateral	JJ	unilateral
lung	NN	lung
involvement	NN	involvement
were	VBD	be
common	JJ	common
findings	NNS	finding
on	IN	on
CT	NP	CT
scans	NNS	scan
of	IN	of
pediatric	JJ	pediatric
patients	NNS	patient
in	IN	in
the	DT	the
early	JJ	early
stage	NN	stage
of	IN	of
the	DT	the
disease	NN	disease
.	SENT	.
33259882/	CD	@card@
Detection	NN	detection
of	IN	of
SARS-CoV-2	NP	<unknown>
within	IN	within
the	DT	the
healthcare	NN	<unknown>
environment	NN	environment
:	:	:
a	DT	a
multi-centre	NN	multi-centre
study	NN	study
conducted	VBN	conduct
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
in	IN	in
England	NP	England
Understanding	VBG	understand
how	WRB	how
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus-2	NN	<unknown>
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
spread	VBN	spread
within	IN	within
the	DT	the
hospital	NN	hospital
setting	NN	setting
is	VBZ	be
essential	JJ	essential
in	IN	in
order	NN	order
to	TO	to
protect	VB	protect
staff	NN	staff
,	,	,
implement	VB	implement
effective	JJ	effective
infection	NN	infection
control	NN	control
measures	NNS	measure
,	,	,
and	CC	and
prevent	VB	prevent
nosocomial	JJ	<unknown>
transmission	NN	transmission
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
SARS-CoV-2	NP	<unknown>
in	IN	in
the	DT	the
air	NN	air
and	CC	and
on	IN	on
environmental	JJ	environmental
surfaces	NNS	surface
around	IN	around
hospitalized	VBN	hospitalize
patients	NNS	patient
,	,	,
with	IN	with
and	CC	and
without	IN	without
respiratory	JJ	respiratory
symptoms	NNS	symptom
,	,	,
was	VBD	be
investigated	VBN	investigate
.	SENT	.
Environmental	JJ	environmental
sampling	NN	sampling
was	VBD	be
undertaken	VBN	undertake
within	IN	within
eight	CD	eight
hospitals	NNS	hospital
in	IN	in
England	NP	England
during	IN	during
the	DT	the
first	JJ	first
wave	NN	wave
of	IN	of
the	DT	the
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
outbreak	NN	outbreak
.	SENT	.
Samples	NNS	sample
were	VBD	be
analysed	VBN	analyse
using	VBG	use
reverse	JJ	reverse
transcription	NN	transcription
polymerase	NN	polymerase
chain	NN	chain
reaction	NN	reaction
(	(	(
PCR	NP	PCR
)	)	)
and	CC	and
virus	NN	virus
isolation	NN	isolation
assays	NNS	assay
.	SENT	.
SARS-CoV-2	NP	<unknown>
RNA	NP	RNA
was	VBD	be
detected	VBN	detect
on	IN	on
30	CD	@card@
(	(	(
8.9	CD	@card@
%	NN	%
)	)	)
of	IN	of
336	CD	@card@
environmental	JJ	environmental
surfaces	NNS	surface
.	SENT	.
Cycle	NN	cycle
threshold	NN	threshold
values	NNS	value
ranged	VBD	range
from	IN	from
28.8	CD	@card@
to	TO	to
39.1	CD	@card@
,	,	,
equating	VBG	equate
to	TO	to
2.2	CD	@card@
x	NN	x
105	CD	@card@
to	TO	to
59	CD	@card@
genomic	JJ	<unknown>
copies/swab	NN	<unknown>
.	SENT	.
Concomitant	JJ	concomitant
bacterial	JJ	bacterial
counts	NNS	count
were	VBD	be
low	JJ	low
,	,	,
suggesting	VBG	suggest
that	IN	that
the	DT	the
cleaning	NN	cleaning
performed	VBN	perform
by	IN	by
nursing	NN	nursing
and	CC	and
domestic	JJ	domestic
staff	NN	staff
across	IN	across
all	DT	all
eight	CD	eight
hospitals	NNS	hospital
was	VBD	be
effective	JJ	effective
.	SENT	.
SARS-CoV-2	NP	<unknown>
RNA	NP	RNA
was	VBD	be
detected	VBN	detect
in	IN	in
four	CD	four
of	IN	of
55	CD	@card@
air	NN	air
samples	NNS	sample
taken	VBN	take
&lt	NN	&lt
;	:	;
1	CD	@card@
m	NN	m
from	IN	from
four	CD	four
different	JJ	different
patients	NNS	patient
.	SENT	.
In	IN	in
all	DT	all
cases	NNS	case
,	,	,
the	DT	the
concentration	NN	concentration
of	IN	of
viral	JJ	viral
RNA	NP	RNA
was	VBD	be
low	JJ	low
and	CC	and
ranged	VBN	range
from	IN	from
&lt	NN	&lt
;	:	;
10	CD	@card@
to	TO	to
460	CD	@card@
genomic	JJ	<unknown>
copies/m3	NN	<unknown>
air	NN	air
.	SENT	.
Infectious	JJ	infectious
virus	NN	virus
was	VBD	be
not	RB	not
recovered	VBN	recover
from	IN	from
any	DT	any
of	IN	of
the	DT	the
PCR-positive	JJ	PCR-positive
samples	NNS	sample
analysed	VBD	analyse
.	SENT	.
Effective	JJ	effective
cleaning	NN	cleaning
can	MD	can
reduce	VB	reduce
the	DT	the
risk	NN	risk
of	IN	of
fomite	NN	<unknown>
(	(	(
contact	NN	contact
)	)	)
transmission	NN	transmission
,	,	,
but	CC	but
some	DT	some
surface	NN	surface
types	NNS	type
may	MD	may
facilitate	VB	facilitate
the	DT	the
survival	NN	survival
,	,	,
persistence	NN	persistence
and/or	CC	and/or
dispersal	NN	dispersal
of	IN	of
SARS-CoV-2	NP	<unknown>
.	SENT	.
The	DT	the
presence	NN	presence
of	IN	of
low	JJ	low
or	CC	or
undetectable	JJ	undetectable
concentrations	NNS	concentration
of	IN	of
viral	JJ	viral
RNA	NP	RNA
in	IN	in
the	DT	the
air	NN	air
supports	VBZ	support
current	JJ	current
guidance	NN	guidance
on	IN	on
the	DT	the
use	NN	use
of	IN	of
specific	JJ	specific
personal	JJ	personal
protective	JJ	protective
equipment	NN	equipment
for	IN	for
aerosol-generating	VBG	aerosol-generate
and	CC	and
non-aerosol-generating	VBG	non-aerosol-generate
procedures	NNS	procedure
.	SENT	.
34031483/	CD	@card@
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
by	IN	by
routine	JJ	routine
blood	NN	blood
tests	NNS	test
using	VBG	use
machine	NN	machine
learning	VBG	learn
Physicians	NPS	Physicians
taking	VBG	take
care	NN	care
of	IN	of
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
have	VBP	have
described	VBN	describe
different	JJ	different
changes	NNS	change
in	IN	in
routine	JJ	routine
blood	NN	blood
parameters	NNS	parameter
.	SENT	.
However	RB	however
,	,	,
these	DT	these
changes	NNS	change
hinder	VB	hinder
them	PP	them
from	IN	from
performing	VBG	perform
COVID-19	NP	<unknown>
diagnoses	NNS	diagnosis
.	SENT	.
We	PP	we
constructed	VBD	construct
a	DT	a
machine	NN	machine
learning	VBG	learn
model	NN	model
for	IN	for
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
that	WDT	that
was	VBD	be
based	VBN	base
and	CC	and
cross-validated	VBN	cross-validate
on	IN	on
the	DT	the
routine	JJ	routine
blood	NN	blood
tests	NNS	test
of	IN	of
5333	CD	@card@
patients	NNS	patient
with	IN	with
various	JJ	various
bacterial	JJ	bacterial
and	CC	and
viral	JJ	viral
infections	NNS	infection
,	,	,
and	CC	and
160	CD	@card@
COVID-19-positive	JJ	COVID-19-positive
patients	NNS	patient
.	SENT	.
We	PP	we
selected	VBD	select
the	DT	the
operational	JJ	operational
ROC	NN	roc
point	NN	point
at	IN	at
a	DT	a
sensitivity	NN	sensitivity
of	IN	of
81.9	CD	@card@
%	NN	%
and	CC	and
a	DT	a
specificity	NN	specificity
of	IN	of
97.9	CD	@card@
%	NN	%
.	SENT	.
The	DT	the
cross-validated	JJ	cross-validated
AUC	NN	AUC
was	VBD	be
0.97	CD	@card@
.	SENT	.
The	DT	the
five	CD	five
most	RBS	most
useful	JJ	useful
routine	JJ	routine
blood	NN	blood
parameters	NNS	parameter
for	IN	for
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
according	VBG	accord
to	TO	to
the	DT	the
feature	NN	feature
importance	NN	importance
scoring	VBG	score
of	IN	of
the	DT	the
XGBoost	NP	<unknown>
algorithm	NN	algorithm
were	VBD	be
:	:	:
MCHC	NP	<unknown>
,	,	,
eosinophil	NN	eosinophil
count	NN	count
,	,	,
albumin	NN	albumin
,	,	,
INR	NP	INR
,	,	,
and	CC	and
prothrombin	NN	prothrombin
activity	NN	activity
percentage	NN	percentage
.	SENT	.
t-SNE	NN	<unknown>
visualization	NN	visualization
showed	VBD	show
that	IN	that
the	DT	the
blood	NN	blood
parameters	NNS	parameter
of	IN	of
the	DT	the
patients	NNS	patient
with	IN	with
a	DT	a
severe	JJ	severe
COVID-19	NP	<unknown>
course	NN	course
are	VBP	be
more	JJR	more
like	IN	like
the	DT	the
parameters	NNS	parameter
of	IN	of
a	DT	a
bacterial	JJ	bacterial
than	IN	than
a	DT	a
viral	JJ	viral
infection	NN	infection
.	SENT	.
The	DT	the
reported	VBD	report
diagnostic	JJ	diagnostic
accuracy	NN	accuracy
is	VBZ	be
at	IN	at
least	JJS	least
comparable	JJ	comparable
and	CC	and
probably	RB	probably
complementary	JJ	complementary
to	TO	to
RT-PCR	NP	<unknown>
and	CC	and
chest	NN	chest
CT	NP	CT
studies	NNS	study
.	SENT	.
Patients	NNS	patient
with	IN	with
fever	NN	fever
,	,	,
cough	NN	cough
,	,	,
myalgia	NN	myalgia
,	,	,
and	CC	and
other	JJ	other
symptoms	NNS	symptom
can	MD	can
now	RB	now
have	VB	have
initial	JJ	initial
routine	JJ	routine
blood	NN	blood
tests	NNS	test
assessed	VBN	assess
by	IN	by
our	PP$	our
diagnostic	JJ	diagnostic
tool	NN	tool
.	SENT	.
All	DT	all
patients	NNS	patient
with	IN	with
a	DT	a
positive	JJ	positive
COVID-19	NP	<unknown>
prediction	NN	prediction
would	MD	would
then	RB	then
undergo	VB	undergo
standard	JJ	standard
RT-PCR	NP	<unknown>
studies	NNS	study
to	TO	to
confirm	VB	confirm
the	DT	the
diagnosis	NN	diagnosis
.	SENT	.
We	PP	we
believe	VBP	believe
that	IN	that
our	PP$	our
results	NNS	result
represent	VBP	represent
a	DT	a
significant	JJ	significant
contribution	NN	contribution
to	TO	to
improvements	NNS	improvement
in	IN	in
COVID-19	NP	<unknown>
diagnosis	NN	diagnosis
.	SENT	.
32474574/	CD	@card@
COVID-19	NP	<unknown>
outbreaks	NNS	outbreak
in	IN	in
U.S.	NP	U.S.
immigrant	NN	immigrant
detention	NN	detention
centers	NNS	center
:	:	:
the	DT	the
urgent	JJ	urgent
need	NN	need
to	TO	to
adopt	VB	adopt
CDC	NP	CDC
guidelines	NNS	guideline
for	IN	for
prevention	NN	prevention
and	CC	and
evaluation	NN	evaluation
There	EX	there
have	VBP	have
been	VBN	be
several	JJ	several
significant	JJ	significant
outbreaks	NNS	outbreak
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
federal	JJ	federal
immigrant	NN	immigrant
detention	NN	detention
centers	NNS	center
,	,	,
which	WDT	which
lack	VBP	lack
clear	JJ	clear
and	CC	and
consistent	JJ	consistent
guidelines	NNS	guideline
across	IN	across
Department	NP	Department
of	IN	of
Homeland	NN	homeland
Security	NP	Security
(	(	(
DHS	NP	DHS
)	)	)
agencies	NNS	agency
to	TO	to
limit	VB	limit
the	DT	the
spread	NN	spread
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
Centers	NPS	Centers
for	IN	for
Disease	NP	Disease
Control	NP	Control
and	CC	and
Prevention	NN	prevention
(	(	(
CDC	NP	CDC
)	)	)
has	VBZ	have
issued	VBN	issue
detailed	JJ	detailed
guidelines	NNS	guideline
for	IN	for
the	DT	the
control	NN	control
,	,	,
prevention	NN	prevention
,	,	,
and	CC	and
evaluation	NN	evaluation
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
detention	NN	detention
facilities	NNS	facility
.	SENT	.
While	IN	while
the	DT	the
DHS	NP	DHS
's	POS	's
Immigration	NN	immigration
and	CC	and
Customs	NP	Customs
Enforcement	NP	Enforcement
agency	NN	agency
has	VBZ	have
stated	VBN	state
that	IN	that
it	PP	it
complies	VBZ	comply
with	IN	with
CDC	NP	CDC
recommendations	NNS	recommendation
,	,	,
its	PP$	its
policies	NNS	policy
significantly	RB	significantly
differ	VBP	differ
from	IN	from
these	DT	these
CDC	NP	CDC
guidelines	NNS	guideline
,	,	,
placing	VBG	place
detainees	NNS	detainee
at	IN	at
risk	NN	risk
for	IN	for
contracting	VBG	contract
COVID-19	NP	<unknown>
.	SENT	.
This	DT	this
submission	NN	submission
urges	VBZ	urge
the	DT	the
adoption	NN	adoption
of	IN	of
CDC	NP	CDC
guidelines	NNS	guideline
across	IN	across
DHS-associated	JJ	DHS-associated
facilities	NNS	facility
.	SENT	.
Such	PDT	such
a	DT	a
policy	NN	policy
change	NN	change
has	VBZ	have
the	DT	the
potential	NN	potential
to	TO	to
protect	VB	protect
and	CC	and
save	VB	save
the	DT	the
lives	NNS	life
of	IN	of
the	DT	the
most	RBS	most
vulnerable	JJ	vulnerable
populations	NNS	population
under	IN	under
the	DT	the
auspices	NNS	auspice
of	IN	of
the	DT	the
federal	JJ	federal
government	NN	government
.	SENT	.
32266753/	CD	@card@
Intrauterine	JJ	intrauterine
vertical	JJ	vertical
transmission	NN	transmission
of	IN	of
SARS-CoV-2	NP	<unknown>
:	:	:
what	WP	what
we	PP	we
know	VBP	know
so	RB	so
far	RB	far
33264497/	CD	@card@
The	DT	the
structural	JJ	structural
basis	NN	basis
of	IN	of
accelerated	VBN	accelerate
host	NN	host
cell	NN	cell
entry	NN	entry
by	IN	by
SARS-CoV-2	NP	<unknown>
Severe	NP	Severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
pandemic	NN	pandemic
capacity	NN	capacity
is	VBZ	be
derived	VBN	derive
from	IN	from
the	DT	the
unique	JJ	unique
structural	JJ	structural
features	NNS	feature
on	IN	on
its	PP$	its
spike	NN	spike
protein	NN	protein
:	:	:
fast	RB	fast
viral	JJ	viral
surfing	NN	surfing
over	IN	over
the	DT	the
epithelium	NN	epithelium
with	IN	with
flat	JJ	flat
N-terminal	JJ	N-terminal
domain	NN	domain
,	,	,
tight	RB	tight
binding	VBG	bind
to	TO	to
ACE2	NP	<unknown>
entry	NN	entry
receptor	NN	receptor
,	,	,
and	CC	and
furin	NN	<unknown>
protease	NN	protease
utilization	NN	utilization
.	SENT	.
In	IN	in
addition	NN	addition
,	,	,
the	DT	the
possible	JJ	possible
involvement	NN	involvement
of	IN	of
other	JJ	other
components	NNS	component
such	JJ	such
as	IN	as
lipid	NN	lipid
rafts	NNS	raft
,	,	,
CLRs	NP	<unknown>
,	,	,
and	CC	and
neuropilin	NN	<unknown>
is	VBZ	be
,	,	,
in	IN	in
combination	NN	combination
,	,	,
mediating	VBG	mediate
the	DT	the
accelerated	VBN	accelerate
cell	NN	cell
entry	NN	entry
and	CC	and
other	JJ	other
critical	JJ	critical
steps	NNS	step
in	IN	in
its	PP$	its
overwhelming	JJ	overwhelming
contagious	JJ	contagious
capacity	NN	capacity
and	CC	and
pandemy	NN	<unknown>
.	SENT	.
Severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
is	VBZ	be
the	DT	the
causative	JJ	causative
agent	NN	agent
of	IN	of
the	DT	the
pandemic	JJ	pandemic
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
that	WDT	that
exhibits	VBZ	exhibit
an	DT	an
overwhelming	JJ	overwhelming
contagious	JJ	contagious
capacity	NN	capacity
over	IN	over
other	JJ	other
human	JJ	human
coronaviruses	NNS	coronavirus
(	(	(
HCoVs	NP	<unknown>
)	)	)
.	SENT	.
This	DT	this
structural	JJ	structural
snapshot	NN	snapshot
describes	VBZ	describe
the	DT	the
structural	JJ	structural
bases	NNS	base
underlying	VBG	underlie
the	DT	the
pandemic	JJ	pandemic
capacity	NN	capacity
of	IN	of
SARS-CoV-2	NP	<unknown>
and	CC	and
explains	VBZ	explain
its	PP$	its
fast	JJ	fast
motion	NN	motion
over	IN	over
respiratory	JJ	respiratory
epithelia	NNS	<unknown>
that	WDT	that
allow	VBP	allow
its	PP$	its
rapid	JJ	rapid
cellular	JJ	cellular
entry	NN	entry
.	SENT	.
Based	VBN	base
on	IN	on
notable	JJ	notable
viral	JJ	viral
spike	NN	spike
(	(	(
S	NP	S
)	)	)
protein	NN	protein
features	NNS	feature
,	,	,
we	PP	we
propose	VBP	propose
that	IN	that
the	DT	the
flat	JJ	flat
sialic	JJ	sialic
acid-binding	NN	acid-binding
domain	NN	domain
at	IN	at
the	DT	the
N-terminal	JJ	N-terminal
domain	NN	domain
(	(	(
NTD	NN	NTD
)	)	)
of	IN	of
the	DT	the
S1	NP	<unknown>
subunit	NN	subunit
leads	VBZ	lead
to	TO	to
more	RBR	more
effective	JJ	effective
first	JJ	first
contact	NN	contact
and	CC	and
interaction	NN	interaction
with	IN	with
the	DT	the
sialic	JJ	sialic
acid	JJ	acid
layer	NN	layer
over	IN	over
the	DT	the
epithelium	NN	epithelium
,	,	,
and	CC	and
this	DT	this
,	,	,
in	IN	in
turn	NN	turn
,	,	,
allows	VBZ	allow
faster	RBR	faster
viral	JJ	viral
'	''	'
surfing	NN	surfing
'	''	'
of	IN	of
the	DT	the
epithelium	NN	epithelium
and	CC	and
receptor	NN	receptor
scanning	VBG	scan
by	IN	by
SARS-CoV-2	NP	<unknown>
.	SENT	.
Angiotensin-converting	NP	<unknown>
enzyme	NN	enzyme
2	CD	@card@
(	(	(
ACE-2	NP	<unknown>
)	)	)
protein	NN	protein
on	IN	on
the	DT	the
epithelial	JJ	epithelial
surface	NN	surface
is	VBZ	be
the	DT	the
primary	JJ	primary
entry	NN	entry
receptor	NN	receptor
for	IN	for
SARS-CoV-2	NP	<unknown>
,	,	,
and	CC	and
protein-protein	NN	protein-protein
interaction	NN	interaction
assays	NNS	assay
demonstrate	VBP	demonstrate
high-affinity	NN	high-affinity
binding	VBG	bind
of	IN	of
the	DT	the
spike	NN	spike
protein	NN	protein
(	(	(
S	NP	S
protein	NN	protein
)	)	)
to	TO	to
ACE-2	NP	<unknown>
.	SENT	.
To	TO	to
date	NN	date
,	,	,
no	DT	no
high-frequency	NN	high-frequency
mutations	NNS	mutation
were	VBD	be
detected	VBN	detect
at	IN	at
the	DT	the
C-terminal	JJ	C-terminal
domain	NN	domain
of	IN	of
the	DT	the
S1	JJ	<unknown>
subunit	NN	subunit
in	IN	in
the	DT	the
S	NP	S
protein	NN	protein
,	,	,
where	WRB	where
the	DT	the
receptor-binding	NN	receptor-binding
domain	NN	domain
(	(	(
RBD	NN	RBD
)	)	)
is	VBZ	be
located	VBN	locate
.	SENT	.
Tight	RB	tight
binding	VBG	bind
to	TO	to
ACE-2	NP	<unknown>
by	IN	by
a	DT	a
conserved	VBN	conserve
viral	JJ	viral
RBD	NN	RBD
suggests	VBZ	suggest
the	DT	the
ACE2-RBD	JJ	<unknown>
interaction	NN	interaction
is	VBZ	be
likely	RB	likely
optimal	JJ	optimal
.	SENT	.
Moreover	RB	moreover
,	,	,
the	DT	the
viral	JJ	viral
S	NP	S
subunit	NN	subunit
contains	VBZ	contain
a	DT	a
cleavage	NN	cleavage
site	NN	site
for	IN	for
furin	NN	<unknown>
and	CC	and
other	JJ	other
proteases	NNS	protease
,	,	,
which	WDT	which
accelerates	VBZ	accelerate
cell	NN	cell
entry	NN	entry
by	IN	by
SARS-CoV-2	NP	<unknown>
.	SENT	.
The	DT	the
model	NN	model
proposed	VBD	propose
here	RB	here
describes	VBZ	describe
a	DT	a
structural	JJ	structural
basis	NN	basis
for	IN	for
the	DT	the
accelerated	VBN	accelerate
host	NN	host
cell	NN	cell
entry	NN	entry
by	IN	by
SARS-CoV-2	NP	<unknown>
relative	JJ	relative
to	TO	to
other	JJ	other
HCoVs	NP	<unknown>
and	CC	and
also	RB	also
discusses	VBZ	discuss
emerging	VBG	emerge
hypotheses	NNS	hypothesis
that	WDT	that
are	VBP	be
likely	JJ	likely
to	TO	to
contribute	VB	contribute
to	TO	to
the	DT	the
development	NN	development
of	IN	of
antiviral	JJ	antiviral
strategies	NNS	strategy
to	TO	to
combat	VB	combat
the	DT	the
pandemic	JJ	pandemic
capacity	NN	capacity
of	IN	of
SARS-CoV-2	NP	<unknown>
.	SENT	.
34840464/	CD	@card@
Coronavirus	NP	<unknown>
disease	NN	disease
2019	CD	@card@
and	CC	and
future	JJ	future
pandemics	NNS	pandemic
:	:	:
Impacts	NNS	impact
on	IN	on
livestock	NN	livestock
health	NN	health
and	CC	and
production	NN	production
and	CC	and
possible	JJ	possible
mitigation	NN	mitigation
measures	VBZ	measure
The	DT	the
World	NP	World
Health	NP	Health
Organization	NP	Organization
declared	VBD	declare
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
COVID-19	NP	<unknown>
)	)	)
a	DT	a
pandemic	NN	pandemic
on	IN	on
March	NP	March
11	CD	@card@
,	,	,
2020	CD	@card@
.	SENT	.
COVID-19	NP	<unknown>
,	,	,
the	DT	the
current	JJ	current
global	JJ	global
health	NN	health
emergency	NN	emergency
,	,	,
is	VBZ	be
wreaking	VBG	wreak
havoc	NN	havoc
on	IN	on
human	JJ	human
health	NN	health
systems	NNS	system
and	CC	and
,	,	,
to	TO	to
a	DT	a
lesser	JJR	lesser
degree	NN	degree
,	,	,
on	IN	on
animals	NNS	animal
globally	RB	globally
.	SENT	.
The	DT	the
outbreak	NN	outbreak
has	VBZ	have
continued	VBN	continue
since	IN	since
the	DT	the
first	JJ	first
report	NN	report
of	IN	of
COVID-19	NP	<unknown>
in	IN	in
China	NP	China
in	IN	in
December	NP	December
2019	CD	@card@
,	,	,
and	CC	and
the	DT	the
second	JJ	second
and	CC	and
third	JJ	third
waves	NNS	wave
of	IN	of
the	DT	the
outbreak	NN	outbreak
have	VBP	have
already	RB	already
begun	VBN	begin
in	IN	in
several	JJ	several
countries	NNS	country
.	SENT	.
COVID-19	NP	<unknown>
is	VBZ	be
expected	VBN	expect
to	TO	to
have	VB	have
adverse	JJ	adverse
effects	NNS	effect
on	IN	on
crop	NN	crop
production	NN	production
,	,	,
food	NN	food
security	NN	security
,	,	,
integrated	JJ	integrated
pest	NN	pest
control	NN	control
,	,	,
tourism	NN	tourism
,	,	,
the	DT	the
car	NN	car
industry	NN	industry
,	,	,
and	CC	and
other	JJ	other
sectors	NNS	sector
of	IN	of
the	DT	the
global	JJ	global
economy	NN	economy
.	SENT	.
COVID-19	NP	<unknown>
induces	VBZ	induce
a	DT	a
range	NN	range
of	IN	of
effects	NNS	effect
in	IN	in
livestock	NN	livestock
that	WDT	that
is	VBZ	be
reflected	VBN	reflect
economically	RB	economically
since	IN	since
human	JJ	human
health	NN	health
and	CC	and
livelihood	NN	livelihood
are	VBP	be
intertwined	VBN	intertwine
with	IN	with
animal	JJ	animal
health	NN	health
.	SENT	.
We	PP	we
summarize	VBP	summarize
the	DT	the
potentially	RB	potentially
harmful	JJ	harmful
effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
on	IN	on
livestock	NN	livestock
and	CC	and
possible	JJ	possible
mitigation	NN	mitigation
steps	NNS	step
in	IN	in
response	NN	response
to	TO	to
this	DT	this
global	JJ	global
outbreak	NN	outbreak
.	SENT	.
Mitigation	NN	mitigation
of	IN	of
the	DT	the
negative	JJ	negative
effects	NNS	effect
of	IN	of
COVID-19	NP	<unknown>
and	CC	and
future	JJ	future
pandemics	NNS	pandemic
on	IN	on
livestock	NN	livestock
requires	VBZ	require
the	DT	the
implementation	NN	implementation
of	IN	of
current	JJ	current
guidelines	NNS	guideline
.	SENT	.
35588736/	CD	@card@
Enhanced	JJ	enhanced
but	CC	but
variant-dependent	JJ	variant-dependent
serological	JJ	serological
and	CC	and
cellular	JJ	cellular
immune	JJ	immune
responses	NNS	response
to	TO	to
third-dose	JJ	<unknown>
BNT162b2	NP	<unknown>
vaccination	NN	vaccination
in	IN	in
patients	NNS	patient
with	IN	with
multiple	JJ	multiple
myeloma	NN	myeloma
34107137/	CD	@card@
Impact	NN	impact
of	IN	of
intermediate	JJ	intermediate
to	TO	to
high	JJ	high
doses	NNS	dose
of	IN	of
methylprednisolone	NN	<unknown>
on	IN	on
mortality	NN	mortality
rate	NN	rate
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia-induced	JJ	<unknown>
severe	JJ	severe
systemic	JJ	systemic
inflammation	NN	inflammation
In	IN	in
addition	NN	addition
to	TO	to
respiratory	JJ	respiratory
support	NN	support
needs	NNS	need
,	,	,
patients	NNS	patient
'	POS	'
characteristics	NNS	characteristic
to	TO	to
guide	VB	guide
indication	NN	indication
or	CC	or
timing	NN	timing
of	IN	of
corticosteroid	NN	corticosteroid
treatment	NN	treatment
in	IN	in
COVID-19	NP	<unknown>
patients	NNS	patient
are	VBP	be
not	RB	not
completely	RB	completely
established	VBN	establish
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
evaluate	VB	evaluate
the	DT	the
impact	NN	impact
of	IN	of
methylprednisolone	NN	<unknown>
on	IN	on
mortality	NN	mortality
rate	NN	rate
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia-induced	JJ	<unknown>
severe	JJ	severe
systemic	JJ	systemic
inflammation	NN	inflammation
(	(	(
PI-SSI	NP	<unknown>
)	)	)
.	SENT	.
Between	IN	between
9	CD	@card@
March	NP	March
and	CC	and
5	CD	@card@
May	NP	May
2020	CD	@card@
(	(	(
final	JJ	final
follow-up	NN	follow-up
on	IN	on
2	CD	@card@
July	NP	July
2020	CD	@card@
)	)	)
,	,	,
a	DT	a
retrospective	JJ	retrospective
cohort	NN	cohort
study	NN	study
was	VBD	be
conducted	VBN	conduct
in	IN	in
hospitalised	VBN	hospitalise
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
PI-SSI	NP	<unknown>
(	(	(
&gt	NP	<unknown>
;	:	;
=2	JJ	<unknown>
inflammatory	JJ	inflammatory
biomarkers	NNS	biomarker
[	SYM	[
IBs	NP	IB
]	SYM	]
:	:	:
temperature	NN	temperature
&gt	NN	&gt
;	:	;
=38C	NN	<unknown>
,	,	,
lymphocyte	NN	lymphocyte
&lt	NN	&lt
;	:	;
=800	JJ	<unknown>
cell/microL	NN	<unknown>
,	,	,
C-reactive	JJ	C-reactive
protein	NN	protein
&gt	NN	&gt
;	:	;
=100	JJ	<unknown>
mg/L	NN	<unknown>
,	,	,
lactate	NN	lactate
dehydrogenase	NN	dehydrogenase
&gt	NN	&gt
;	:	;
=300	JJ	<unknown>
units/L	NN	<unknown>
,	,	,
ferritin	NN	ferritin
&gt	NN	&gt
;	:	;
=1000	JJ	<unknown>
mcg/L	NN	<unknown>
,	,	,
D-dimer	NP	<unknown>
&gt	NP	<unknown>
;	:	;
=500	JJ	<unknown>
ng/mL	NNS	<unknown>
)	)	)
.	SENT	.
Patients	NNS	patient
received	VBD	receive
0.5-1.0	CD	@card@
mg/kg	NN	<unknown>
of	IN	of
methylprednisolone	NN	<unknown>
for	IN	for
5-10	CD	@card@
days	NNS	day
or	CC	or
standard	NN	standard
of	IN	of
care	NN	care
.	SENT	.
The	DT	the
primary	JJ	primary
outcome	NN	outcome
was	VBD	be
28-day	JJ	<unknown>
all-cause	NN	all-cause
mortality	NN	mortality
.	SENT	.
Secondary	JJ	secondary
outcomes	NNS	outcome
included	VBD	include
&gt	NN	&gt
;	:	;
=2	JJ	<unknown>
points	NNS	point
improvement	NN	improvement
on	IN	on
a	DT	a
7-item	NP	<unknown>
WHO-scale	NP	WHO-scale
(	(	(
Day	NP	Day
14	CD	@card@
)	)	)
,	,	,
transfer	NN	transfer
to	TO	to
intensive	JJ	intensive
care	NN	care
unit	NN	unit
(	(	(
ICU	NP	ICU
)	)	)
(	(	(
Day	NP	Day
28	CD	@card@
)	)	)
and	CC	and
adverse	JJ	adverse
effects	NNS	effect
.	SENT	.
Kaplan-Meier	NP	Kaplan-Meier
method	NN	method
and	CC	and
Cox	NP	Cox
proportional	JJ	proportional
hazard	NN	hazard
regression	NN	regression
were	VBD	be
implemented	VBN	implement
to	TO	to
analyse	VB	analyse
the	DT	the
time	NN	time
to	TO	to
event	NN	event
outcomes	NNS	outcome
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
142	CD	@card@
patients	NNS	patient
(	(	(
corticosteroid	NN	corticosteroid
group	NN	group
n	NN	n
=	SYM	=
72	CD	@card@
,	,	,
control	NN	control
group	NN	group
n	NN	n
=	SYM	=
70	CD	@card@
)	)	)
were	VBD	be
included	VBN	include
.	SENT	.
A	DT	a
significant	JJ	significant
reduction	NN	reduction
in	IN	in
28-day	JJ	<unknown>
all-cause	NN	all-cause
mortality	NN	mortality
was	VBD	be
shown	VBN	show
with	IN	with
methylprednisolone	NN	<unknown>
in	IN	in
patients	NNS	patient
with	IN	with
respiratory	JJ	respiratory
support	NN	support
(	(	(
HR	NP	HR
:	:	:
0.15	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.03-0.71	CD	@card@
)	)	)
,	,	,
with	IN	with
&gt	NN	&gt
;	:	;
=3	NP	<unknown>
(	(	(
HR	NP	HR
:	:	:
0.17	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.05-0.61	CD	@card@
)	)	)
or	CC	or
&gt	NN	&gt
;	:	;
=4	NN	<unknown>
altered	VBN	alter
IB	NP	Ib
(	(	(
HR	NP	HR
:	:	:
0.15	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.04-0.54	CD	@card@
)	)	)
and	CC	and
in	IN	in
patients	NNS	patient
with	IN	with
both	DT	both
respiratory	JJ	respiratory
support	NN	support
and	CC	and
&gt	NN	&gt
;	:	;
=3	NP	<unknown>
(	(	(
HR	NP	HR
:	:	:
0.11	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.02-0.53	CD	@card@
]	SYM	]
or	CC	or
&gt	JJ	<unknown>
;	:	;
=4	NN	<unknown>
altered	VBN	alter
IB	NP	Ib
(	(	(
HR	NP	HR
:	:	:
0.14	CD	@card@
;	:	;
95	CD	@card@
%	NN	%
CI	NP	CI
0.04-0.51	CD	@card@
)	)	)
.	SENT	.
No	DT	no
significant	JJ	significant
differences	NNS	difference
were	VBD	be
found	VBN	find
in	IN	in
secondary	JJ	secondary
outcomes	NNS	outcome
.	SENT	.
Intermediate	JJ	intermediate
to	TO	to
high	JJ	high
doses	NNS	dose
of	IN	of
methylprednisolone	NN	<unknown>
,	,	,
initiated	VBN	initiate
between	IN	between
5	CD	@card@
and	CC	and
12	CD	@card@
days	NNS	day
after	IN	after
symptom	NN	symptom
onset	NN	onset
,	,	,
was	VBD	be
associated	VBN	associate
with	IN	with
a	DT	a
significant	JJ	significant
reduction	NN	reduction
in	IN	in
28-day	JJ	<unknown>
all-cause	JJ	<unknown>
mortality	NN	mortality
in	IN	in
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
pneumonia	NN	pneumonia
and	CC	and
&gt	NN	&gt
;	:	;
=3	JJ	<unknown>
o	NN	o
&gt	NN	&gt
;	:	;
=	SYM	=
4	CD	@card@
altered	JJ	altered
IB	NP	Ib
,	,	,
independently	RB	independently
of	IN	of
the	DT	the
need	NN	need
of	IN	of
respiratory	JJ	respiratory
support	NN	support
.	SENT	.
32729279/	CD	@card@
Severe	NP	Severe
Acute	JJ	acute
Respiratory	JJ	respiratory
Syndrome	NN	syndrome
Coronavirus	NP	<unknown>
2	CD	@card@
Detection	NN	detection
in	IN	in
the	DT	the
Radiology	NN	radiology
Department	NP	Department
of	IN	of
Hospitals	NPS	Hospitals
in	IN	in
Wuhan	NP	Wuhan
,	,	,
China	NP	China
34224607/	CD	@card@
The	DT	the
Accreditation	NN	accreditation
Council	NN	council
for	IN	for
Genetic	JJ	genetic
Counseling	NN	counseling
's	POS	's
response	NN	response
to	TO	to
COVID-19	NP	<unknown>
impact	NN	impact
on	IN	on
genetic	JJ	genetic
counseling	NN	counseling
programs	NNS	program
35305625/	CD	@card@
The	DT	the
clinically	RB	clinically
led	VBN	lead
worforcE	NN	<unknown>
and	CC	and
activity	NN	activity
redesign	NN	redesign
(	(	(
CLEAR	JJ	clear
)	)	)
programme	NN	programme
:	:	:
a	DT	a
novel	JJ	novel
data-driven	JJ	data-driven
healthcare	NN	<unknown>
improvement	NN	improvement
methodology	NN	methodology
The	DT	the
NHS	NN	NHS
is	VBZ	be
facing	VBG	face
substantial	JJ	substantial
pressures	NNS	pressure
to	TO	to
recover	VB	recover
from	IN	from
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
.	SENT	.
Optimising	VBG	optimise
workforce	NN	workforce
modelling	VBG	model
is	VBZ	be
a	DT	a
fundamental	JJ	fundamental
component	NN	component
of	IN	of
the	DT	the
recovery	NN	recovery
plan	NN	plan
.	SENT	.
The	DT	the
Clinically	RB	clinically
Lead	JJ	Lead
workforcE	NN	workforce
and	CC	and
Activity	NN	activity
Redesign	NN	redesign
(	(	(
CLEAR	JJ	clear
)	)	)
programme	NN	programme
is	VBZ	be
a	DT	a
unique	JJ	unique
methodology	NN	methodology
that	WDT	that
trains	VBZ	train
clinicians	NNS	clinician
to	TO	to
redesign	VB	redesign
services	NNS	service
,	,	,
building	VBG	build
intrinsic	JJ	intrinsic
capacity	NN	capacity
and	CC	and
capability	NN	capability
,	,	,
optimising	VBG	optimise
patient	JJ	patient
care	NN	care
and	CC	and
minimising	VBG	minimise
the	DT	the
need	NN	need
for	IN	for
costly	JJ	costly
external	JJ	external
consultancy	NN	consultancy
.	SENT	.
This	DT	this
paper	NN	paper
describes	VBZ	describe
the	DT	the
CLEAR	JJ	clear
methodology	NN	methodology
and	CC	and
the	DT	the
evaluation	NN	evaluation
of	IN	of
previous	JJ	previous
CLEAR	JJ	clear
projects	NNS	project
,	,	,
including	VBG	include
the	DT	the
return	NN	return
on	IN	on
investment	NN	investment
.	SENT	.
CLEAR	JJ	clear
is	VBZ	be
a	DT	a
work-based	JJ	<unknown>
learning	NN	learning
programme	NN	programme
that	WDT	that
combines	VBZ	combine
qualitative	JJ	qualitative
techniques	NNS	technique
with	IN	with
data	NN	data
analytics	NNS	<unknown>
to	TO	to
build	VB	build
innovations	NNS	innovation
and	CC	and
new	JJ	new
models	NNS	model
of	IN	of
care	NN	care
.	SENT	.
It	PP	it
has	VBZ	have
four	CD	four
unique	JJ	unique
stages	NNS	stage
:	:	:
(	(	(
1	LS	1
)	)	)
Clinical	JJ	clinical
engagement-	NN	<unknown>
used	VBN	use
to	TO	to
gather	VB	gather
rich	JJ	rich
insights	NNS	insight
from	IN	from
stakeholders	NNS	stakeholder
and	CC	and
clinicians	NNS	clinician
.	SENT	.
(	(	(
2	CD	@card@
)	)	)
Data	NP	Data
interrogation-	NN	<unknown>
utilising	VBG	utilise
clinical	JJ	clinical
and	CC	and
workforce	NN	workforce
data	NNS	datum
for	IN	for
cohort	NN	cohort
analysis	NN	analysis
.	SENT	.
(	(	(
3	CD	@card@
)	)	)
Innovation-	NN	<unknown>
using	VBG	use
structured	JJ	structured
innovation	NN	innovation
methods	NNS	method
to	TO	to
develop	VB	develop
new	JJ	new
models	NNS	model
of	IN	of
care	NN	care
.	SENT	.
(	(	(
4	CD	@card@
)	)	)
Recommendations-	NP	<unknown>
report	NN	report
writing	NN	writing
,	,	,
impact	NN	impact
assessment	NN	assessment
and	CC	and
presentation	NN	presentation
of	IN	of
key	JJ	key
findings	NNS	finding
to	TO	to
executive	JJ	executive
boards	NNS	board
.	SENT	.
A	DT	a
mixed-methods	NNS	mixed-method
formative	NN	formative
evaluation	NN	evaluation
was	VBD	be
carried	VBN	carry
out	RP	out
on	IN	on
completed	VBN	complete
projects	NNS	project
,	,	,
which	WDT	which
included	VBD	include
semi-structured	JJ	semi-structured
interviews	NNS	interview
and	CC	and
surveys	NNS	survey
with	IN	with
CLEAR	JJ	clear
associates	NNS	associate
and	CC	and
stakeholders	NNS	stakeholder
,	,	,
and	CC	and
a	DT	a
health	NN	health
economic	JJ	economic
logic	NN	logic
model	NN	model
that	WDT	that
was	VBD	be
developed	VBN	develop
to	TO	to
link	VB	link
the	DT	the
inputs	NNS	input
,	,	,
processes	NNS	process
,	,	,
outputs	NNS	output
and	CC	and
the	DT	the
outcome	NN	outcome
of	IN	of
CLEAR	JJ	clear
as	RB	as
well	RB	well
as	IN	as
the	DT	the
potential	JJ	potential
impacts	NNS	impact
of	IN	of
the	DT	the
changes	NNS	change
identified	VBN	identify
from	IN	from
the	DT	the
projects	NNS	project
.	SENT	.
CLEAR	JJ	clear
provides	VBZ	provide
a	DT	a
more	RBR	more
cost-effective	JJ	cost-effective
delivery	NN	delivery
of	IN	of
complex	JJ	complex
change	NN	change
programmes	NNS	programme
than	IN	than
the	DT	the
alternatives	NNS	alternative
-	NN	<unknown>
resulting	VBG	result
in	IN	in
a	DT	a
cost	NN	cost
saving	NN	saving
of	IN	of
$1.90	NN	<unknown>
for	IN	for
every	DT	every
$1	NN	<unknown>
spent	VBD	spend
independent	JJ	independent
of	IN	of
implementation	NN	implementation
success	NN	success
.	SENT	.
Results	NNS	result
suggest	VBP	suggest
that	IN	that
CLEAR	JJ	clear
recommendations	NNS	recommendation
are	VBP	be
more	RBR	more
likely	JJ	likely
to	TO	to
be	VB	be
implemented	VBN	implement
compared	VBN	compare
to	TO	to
other	JJ	other
complex	JJ	complex
healthcare	NN	<unknown>
interventions	NNS	intervention
because	IN	because
of	IN	of
the	DT	the
levels	NNS	level
of	IN	of
clinical	JJ	clinical
engagement	NN	engagement
and	CC	and
have	VB	have
a	DT	a
potential	JJ	potential
return	NN	return
on	IN	on
investment	NN	investment
of	IN	of
up	RB	up
to	TO	to
$14	NN	<unknown>
over	IN	over
5	CD	@card@
years	NNS	year
for	IN	for
every	DT	every
$1	NN	<unknown>
invested	VBD	invest
.	SENT	.
CLEAR	JJ	clear
appears	VBZ	appear
to	TO	to
have	VB	have
a	DT	a
positive	JJ	positive
impact	NN	impact
on	IN	on
staff	NN	staff
retention	NN	retention
and	CC	and
wellbeing	NN	wellbeing
,	,	,
the	DT	the
cost	NN	cost
of	IN	of
a	DT	a
CLEAR	JJ	clear
project	NN	project
is	VBZ	be
covered	VBN	cover
if	IN	if
one	CD	one
medical	JJ	medical
consultant	NN	consultant
remains	VBZ	remain
in	IN	in
post	NN	post
for	IN	for
a	DT	a
year	NN	year
.	SENT	.
The	DT	the
unique	JJ	unique
CLEAR	JJ	clear
methodology	NN	methodology
is	VBZ	be
a	DT	a
clinically	RB	clinically
effective	JJ	effective
and	CC	and
cost-effective	JJ	cost-effective
complex	JJ	complex
healthcare	NN	<unknown>
innovation	NN	innovation
that	WDT	that
optimises	VBZ	optimise
workforce	NN	workforce
and	CC	and
activity	NN	activity
design	NN	design
,	,	,
as	RB	as
well	RB	well
as	IN	as
improving	VBG	improve
staff	NN	staff
retention	NN	retention
.	SENT	.
Embedding	VBG	embed
CLEAR	JJ	clear
methodology	NN	methodology
in	IN	in
the	DT	the
NHS	NN	NHS
could	MD	could
have	VB	have
substantial	JJ	substantial
impact	NN	impact
on	IN	on
patient	JJ	patient
care	NN	care
,	,	,
staff	NN	staff
well-being	NN	well-being
and	CC	and
service	NN	service
provision	NN	provision
.	SENT	.
The	DT	the
online	JJ	online
version	NN	version
contains	VBZ	contain
supplementary	JJ	supplementary
material	NN	material
available	JJ	available
at	IN	at
10.1186/s12913-022-07757-1	JJ	10.1186/s@card@
.	SENT	.
32991794/	CD	@card@
Safety	NN	safety
and	CC	and
Immunogenicity	NN	<unknown>
of	IN	of
SARS-CoV-2	NP	<unknown>
mRNA-1273	JJ	mRNA@card@
Vaccine	NN	vaccine
in	IN	in
Older	JJR	old
Adults	NNS	adult
Testing	NP	Testing
of	IN	of
vaccine	NN	vaccine
candidates	NNS	candidate
to	TO	to
prevent	VB	prevent
infection	NN	infection
with	IN	with
severe	JJ	severe
acute	JJ	acute
respiratory	JJ	respiratory
syndrome	NN	syndrome
coronavirus	NN	coronavirus
2	CD	@card@
(	(	(
SARS-CoV-2	NP	<unknown>
)	)	)
in	IN	in
an	DT	an
older	JJR	old
population	NN	population
is	VBZ	be
important	JJ	important
,	,	,
since	IN	since
increased	VBN	increase
incidences	NNS	incidence
of	IN	of
illness	NN	illness
and	CC	and
death	NN	death
from	IN	from
coronavirus	NN	coronavirus
disease	NN	disease
2019	CD	@card@
(	(	(
Covid-19	NP	<unknown>
)	)	)
have	VBP	have
been	VBN	be
associated	VBN	associate
with	IN	with
an	DT	an
older	JJR	old
age	NN	age
.	SENT	.
We	PP	we
conducted	VBD	conduct
a	DT	a
phase	NN	phase
1	CD	@card@
,	,	,
dose-escalation	NN	dose-escalation
,	,	,
open-label	NN	open-label
trial	NN	trial
of	IN	of
a	DT	a
messenger	NN	messenger
RNA	NP	RNA
vaccine	NN	vaccine
,	,	,
mRNA-1273	NN	<unknown>
,	,	,
which	WDT	which
encodes	VBZ	encode
the	DT	the
stabilized	VBN	stabilize
prefusion	NN	prefusion
SARS-CoV-2	JJ	<unknown>
spike	NN	spike
protein	NN	protein
(	(	(
S-2P	NP	<unknown>
)	)	)
in	IN	in
healthy	JJ	healthy
adults	NNS	adult
.	SENT	.
The	DT	the
trial	NN	trial
was	VBD	be
expanded	VBN	expand
to	TO	to
include	VB	include
40	CD	@card@
older	JJR	old
adults	NNS	adult
,	,	,
who	WP	who
were	VBD	be
stratified	VBN	stratify
according	VBG	accord
to	TO	to
age	VB	age
(	(	(
56	CD	@card@
to	TO	to
70	CD	@card@
years	NNS	year
or	CC	or
&gt	NN	&gt
;	:	;
=71	JJ	=@card@
years	NNS	year
)	)	)
.	SENT	.
All	PDT	all
the	DT	the
participants	NNS	participant
were	VBD	be
assigned	VBN	assign
sequentially	RB	sequentially
to	TO	to
receive	VB	receive
two	CD	two
doses	NNS	dose
of	IN	of
either	DT	either
25	CD	@card@
mug	NN	mug
or	CC	or
100	CD	@card@
mug	NN	mug
of	IN	of
vaccine	NN	vaccine
administered	VBN	administer
28	CD	@card@
days	NNS	day
apart	RB	apart
.	SENT	.
Solicited	VBN	solicit
adverse	JJ	adverse
events	NNS	event
were	VBD	be
predominantly	RB	predominantly
mild	JJ	mild
or	CC	or
moderate	JJ	moderate
in	IN	in
severity	NN	severity
and	CC	and
most	RBS	most
frequently	RB	frequently
included	VBN	include
fatigue	NN	fatigue
,	,	,
chills	NNS	chill
,	,	,
headache	NN	headache
,	,	,
myalgia	NN	myalgia
,	,	,
and	CC	and
pain	NN	pain
at	IN	at
the	DT	the
injection	NN	injection
site	NN	site
.	SENT	.
Such	JJ	such
adverse	JJ	adverse
events	NNS	event
were	VBD	be
dose-dependent	NN	dose-dependent
and	CC	and
were	VBD	be
more	RBR	more
common	JJ	common
after	IN	after
the	DT	the
second	JJ	second
immunization	NN	immunization
.	SENT	.
Binding-antibody	NP	<unknown>
responses	NNS	response
increased	VBD	increase
rapidly	RB	rapidly
after	IN	after
the	DT	the
first	JJ	first
immunization	NN	immunization
.	SENT	.
By	IN	by
day	NN	day
57	CD	@card@
,	,	,
among	IN	among
the	DT	the
participants	NNS	participant
who	WP	who
received	VBD	receive
the	DT	the
25-mug	JJ	<unknown>
dose	NN	dose
,	,	,
the	DT	the
anti-S-2P	JJ	<unknown>
geometric	JJ	geometric
mean	JJ	mean
titer	NN	titer
(	(	(
GMT	NP	GMT
)	)	)
was	VBD	be
323,945	CD	@card@
among	IN	among
those	DT	those
between	IN	between
the	DT	the
ages	NNS	age
of	IN	of
56	CD	@card@
and	CC	and
70	CD	@card@
years	NNS	year
and	CC	and
1,128,391	CD	@card@
among	IN	among
those	DT	those
who	WP	who
were	VBD	be
71	CD	@card@
years	NNS	year
of	IN	of
age	NN	age
or	CC	or
older	JJR	old
;	:	;
among	IN	among
the	DT	the
participants	NNS	participant
who	WP	who
received	VBD	receive
the	DT	the
100-mug	JJ	<unknown>
dose	NN	dose
,	,	,
the	DT	the
GMT	NN	GMT
in	IN	in
the	DT	the
two	CD	two
age	NN	age
subgroups	NNS	subgroup
was	VBD	be
1,183,066	CD	@card@
and	CC	and
3,638,522	CD	@card@
,	,	,
respectively	RB	respectively
.	SENT	.
After	IN	after
the	DT	the
second	JJ	second
immunization	NN	immunization
,	,	,
serum	NN	serum
neutralizing	VBG	neutralize
activity	NN	activity
was	VBD	be
detected	VBN	detect
in	IN	in
all	PDT	all
the	DT	the
participants	NNS	participant
by	IN	by
multiple	JJ	multiple
methods	NNS	method
.	SENT	.
Binding-	NN	<unknown>
and	CC	and
neutralizing-antibody	NN	neutralizing-antibody
responses	NNS	response
appeared	VBD	appear
to	TO	to
be	VB	be
similar	JJ	similar
to	TO	to
those	DT	those
previously	RB	previously
reported	VBN	report
among	IN	among
vaccine	NN	vaccine
recipients	NNS	recipient
between	IN	between
the	DT	the
ages	NNS	age
of	IN	of
18	CD	@card@
and	CC	and
55	CD	@card@
years	NNS	year
and	CC	and
were	VBD	be
above	IN	above
the	DT	the
median	NN	median
of	IN	of
a	DT	a
panel	NN	panel
of	IN	of
controls	NNS	control
who	WP	who
had	VBD	have
donated	VBN	donate
convalescent	JJ	convalescent
serum	NN	serum
.	SENT	.
The	DT	the
vaccine	NN	vaccine
elicited	VBD	elicit
a	DT	a
strong	JJ	strong
CD4	NP	<unknown>
cytokine	NN	<unknown>
response	NN	response
involving	VBG	involve
type	NN	type
1	CD	@card@
helper	NN	helper
T	NN	T
cells	NNS	cell
.	SENT	.
In	IN	in
this	DT	this
small	JJ	small
study	NN	study
involving	VBG	involve
older	JJR	old
adults	NNS	adult
,	,	,
adverse	JJ	adverse
events	NNS	event
associated	VBN	associate
with	IN	with
the	DT	the
mRNA-1273	JJ	mRNA@card@
vaccine	NN	vaccine
were	VBD	be
mainly	RB	mainly
mild	JJ	mild
or	CC	or
moderate	JJ	moderate
.	SENT	.
The	DT	the
100-mug	JJ	<unknown>
dose	NN	dose
induced	VBD	induce
higher	JJR	high
binding-	NN	<unknown>
and	CC	and
neutralizing-antibody	NN	neutralizing-antibody
titers	NNS	titer
than	IN	than
the	DT	the
25-mug	JJ	<unknown>
dose	NN	dose
,	,	,
which	WDT	which
supports	VBZ	support
the	DT	the
use	NN	use
of	IN	of
the	DT	the
100-mug	JJ	<unknown>
dose	NN	dose
in	IN	in
a	DT	a
phase	NN	phase
3	CD	@card@
vaccine	NN	vaccine
trial	NN	trial
.	SENT	.
(	(	(
Funded	VBN	fund
by	IN	by
the	DT	the
National	NP	National
Institute	NP	Institute
of	IN	of
Allergy	NN	allergy
and	CC	and
Infectious	JJ	infectious
Diseases	NNS	disease
and	CC	and
others	NNS	other
;	:	;
mRNA-1273	NP	mRNA@card@
Study	NP	Study
ClinicalTrials.gov	NP	<unknown>
number	NN	number
,	,	,
NCT04283461	NP	NCT@card@
.	SENT	.
)	)	)
34720778/	CD	@card@
MARCOS	NP	Marcos
technique	NN	technique
under	IN	under
intuitionistic	JJ	<unknown>
fuzzy	JJ	fuzzy
environment	NN	environment
for	IN	for
determining	VBG	determine
the	DT	the
COVID-19	NP	<unknown>
pandemic	JJ	pandemic
performance	NN	performance
of	IN	of
insurance	NN	insurance
companies	NNS	company
in	IN	in
terms	NNS	term
of	IN	of
healthcare	NN	<unknown>
services	NNS	service
Assessing	VBG	assess
and	CC	and
ranking	VBG	rank
private	JJ	private
health	NN	health
insurance	NN	insurance
companies	NNS	company
provides	VBZ	provide
insurance	NN	insurance
agencies	NNS	agency
,	,	,
insurance	NN	insurance
customers	NNS	customer
,	,	,
and	CC	and
authorities	NNS	authority
with	IN	with
a	DT	a
reliable	JJ	reliable
instrument	NN	instrument
for	IN	for
the	DT	the
insurance	NN	insurance
decision-making	NN	decision-making
process	NN	process
.	SENT	.
Moreover	RB	moreover
,	,	,
because	IN	because
the	DT	the
world	NN	world
's	POS	's
insurance	NN	insurance
sector	NN	sector
suffers	VBZ	suffer
from	IN	from
a	DT	a
gap	NN	gap
of	IN	of
evaluation	NN	evaluation
of	IN	of
private	JJ	private
health	NN	health
insurance	NN	insurance
companies	NNS	company
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
,	,	,
the	DT	the
need	NN	need
for	IN	for
a	DT	a
reliable	JJ	reliable
,	,	,
useful	JJ	useful
,	,	,
and	CC	and
comprehensive	JJ	comprehensive
decision	NN	decision
tool	NN	tool
is	VBZ	be
obvious	JJ	obvious
.	SENT	.
Accordingly	RB	accordingly
,	,	,
this	DT	this
article	NN	article
aims	VBZ	aim
to	TO	to
identify	VB	identify
insurance	NN	insurance
companies	NNS	company
'	POS	'
priority	NN	priority
ranking	NN	ranking
in	IN	in
terms	NNS	term
of	IN	of
healthcare	NN	<unknown>
services	NNS	service
in	IN	in
Turkey	NP	Turkey
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
outbreak	NN	outbreak
through	IN	through
a	DT	a
multi-criteria	NN	<unknown>
performance	NN	performance
evaluation	NN	evaluation
methodology	NN	methodology
.	SENT	.
Herein	RB	herein
,	,	,
alternatives	NNS	alternative
are	VBP	be
evaluated	VBN	evaluate
and	CC	and
then	RB	then
ranked	VBD	rank
as	RB	as
per	IN	per
7	CD	@card@
criteria	NNS	criterion
and	CC	and
assessments	NNS	assessment
of	IN	of
5	CD	@card@
experts	NNS	expert
.	SENT	.
Experts	NNS	expert
'	POS	'
judgments	NNS	judgment
and	CC	and
assessments	NNS	assessment
are	VBP	be
full	JJ	full
of	IN	of
uncertainties	NNS	uncertainty
.	SENT	.
We	PP	we
propose	VBP	propose
a	DT	a
Measurement	NN	measurement
of	IN	of
Alternatives	NNS	alternative
and	CC	and
Ranking	JJ	ranking
according	VBG	accord
to	TO	to
the	DT	the
Compromise	NN	compromise
Solution	NN	solution
(	(	(
MARCOS	NP	Marcos
)	)	)
technique	NN	technique
under	IN	under
an	DT	an
intuitionistic	JJ	<unknown>
fuzzy	JJ	fuzzy
environment	NN	environment
to	TO	to
rank	VB	rank
insurance	NN	insurance
companies	NNS	company
.	SENT	.
The	DT	the
outcomes	NNS	outcome
yielded	VBD	yield
ten	CD	ten
insurance	NN	insurance
companies	NNS	company
ranking	VBG	rank
in	IN	in
terms	NNS	term
of	IN	of
healthcare	NN	<unknown>
services	NNS	service
in	IN	in
the	DT	the
era	NN	era
of	IN	of
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
payback	NNS	payback
period	NN	period
,	,	,
premium	NN	premium
price	NN	price
,	,	,
and	CC	and
network	NN	network
are	VBP	be
determined	VBN	determine
as	IN	as
the	DT	the
most	RBS	most
crucial	JJ	crucial
factors	NNS	factor
.	SENT	.
Finally	RB	finally
,	,	,
a	DT	a
comprehensive	JJ	comprehensive
sensitivity	NN	sensitivity
analysis	NN	analysis
is	VBZ	be
performed	VBN	perform
to	TO	to
verify	VB	verify
the	DT	the
proposed	VBN	propose
methodology	NN	methodology
's	POS	's
stability	NN	stability
and	CC	and
effectiveness	NN	effectiveness
.	SENT	.
The	DT	the
introduced	VBN	introduce
approach	NN	approach
met	VBD	meet
the	DT	the
insurance	NN	insurance
assessment	NN	assessment
problem	NN	problem
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
pandemic	NN	pandemic
very	RB	very
satisfactory	JJ	satisfactory
manner	NN	manner
based	VBN	base
on	IN	on
sensitivity	NN	sensitivity
analysis	NN	analysis
findings	NNS	finding
.	SENT	.
32311790/	CD	@card@
Comparing	VBG	compare
Rapid	NP	Rapid
Scoring	NP	Scoring
Systems	NPS	Systems
in	IN	in
Mortality	NN	mortality
Prediction	NN	prediction
of	IN	of
Critically	RB	critically
Ill	NP	Ill
Patients	NPS	Patients
With	IN	with
Novel	NP	Novel
Coronavirus	NP	<unknown>
Disease	NP	Disease
Rapid	NP	Rapid
and	CC	and
early	JJ	early
severity-of-illness	NN	severity-of-illness
assessment	NN	assessment
appears	VBZ	appear
to	TO	to
be	VB	be
important	JJ	important
for	IN	for
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
.	SENT	.
This	DT	this
study	NN	study
aimed	VBN	aim
to	TO	to
evaluate	VB	evaluate
the	DT	the
performance	NN	performance
of	IN	of
the	DT	the
rapid	JJ	rapid
scoring	VBG	score
system	NN	system
on	IN	on
admission	NN	admission
of	IN	of
these	DT	these
patients	NNS	patient
.	SENT	.
A	DT	a
total	NN	total
of	IN	of
138	CD	@card@
medical	JJ	medical
records	NNS	record
of	IN	of
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
were	VBD	be
included	VBN	include
in	IN	in
the	DT	the
study	NN	study
.	SENT	.
Demographic	JJ	demographic
and	CC	and
clinical	JJ	clinical
characteristics	NNS	characteristic
on	IN	on
admission	NN	admission
used	VBN	use
for	IN	for
calculating	VBG	calculate
Modified	JJ	modified
Early	NP	Early
Warning	NP	Warning
Score	NN	score
(	(	(
MEWS	NNS	mew
)	)	)
and	CC	and
Rapid	NP	Rapid
Emergency	NP	Emergency
Medicine	NP	Medicine
Score	NP	Score
(	(	(
REMS	NP	<unknown>
)	)	)
and	CC	and
outcomes	NNS	outcome
(	(	(
survival	NN	survival
or	CC	or
death	NN	death
)	)	)
were	VBD	be
collected	VBN	collect
for	IN	for
each	DT	each
case	NN	case
and	CC	and
extracted	VBN	extract
for	IN	for
analysis	NN	analysis
.	SENT	.
All	DT	all
patients	NNS	patient
were	VBD	be
divided	VBN	divide
into	IN	into
two	CD	two
age	NN	age
subgroups	NNS	subgroup
(	(	(
&lt	NP	&lt
;	:	;
65	CD	@card@
years	NNS	year
and	CC	and
&gt	NN	&gt
;	:	;
=65	JJ	=@card@
years	NNS	year
)	)	)
.	SENT	.
The	DT	the
receiver	NN	receiver
operating	VBG	operate
characteristic	JJ	characteristic
(	(	(
ROC	NN	roc
)	)	)
curve	NN	curve
analyses	NNS	analysis
were	VBD	be
performed	VBN	perform
for	IN	for
overall	JJ	overall
patients	NNS	patient
and	CC	and
both	DT	both
subgroups	NNS	subgroup
.	SENT	.
The	DT	the
median	NN	median
[	SYM	[
25th	JJ	25th
quartile	NN	quartile
,	,	,
75th	JJ	75th
quartile	NN	quartile
]	SYM	]
of	IN	of
MEWS	NNS	mew
of	IN	of
survivors	NNS	survivor
versus	CC	versus
nonsurvivors	NNS	nonsurvivor
were	VBD	be
1	CD	@card@
[	SYM	[
1	CD	@card@
,	,	,
2	CD	@card@
]	SYM	]
and	CC	and
2	CD	@card@
[	SYM	[
1	CD	@card@
,	,	,
3	CD	@card@
]	SYM	]
and	CC	and
those	DT	those
of	IN	of
REMS	NP	<unknown>
were	VBD	be
5	CD	@card@
[	SYM	[
2	CD	@card@
,	,	,
6	CD	@card@
]	SYM	]
and	CC	and
7	CD	@card@
[	SYM	[
6	CD	@card@
,	,	,
10	CD	@card@
]	SYM	]
,	,	,
respectively	RB	respectively
.	SENT	.
In	IN	in
overall	JJ	overall
analysis	NN	analysis
,	,	,
the	DT	the
area	NN	area
under	IN	under
the	DT	the
ROC	NN	roc
curve	NN	curve
for	IN	for
the	DT	the
REMS	NP	<unknown>
in	IN	in
predicting	VBG	predict
mortality	NN	mortality
was	VBD	be
0.833	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
confidence	NN	confidence
interval	NN	interval
[	SYM	[
CI	NP	CI
]	SYM	]
=	SYM	=
0.737	CD	@card@
to	TO	to
0.928	CD	@card@
)	)	)
,	,	,
higher	JJR	high
than	IN	than
that	IN	that
of	IN	of
MEWS	NNS	mew
(	(	(
0.677	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
0.541	CD	@card@
to	TO	to
0.813	CD	@card@
)	)	)
.	SENT	.
An	DT	an
optimal	JJ	optimal
cutoff	NN	cutoff
of	IN	of
REMS	NP	<unknown>
(	(	(
&gt	NP	<unknown>
;	:	;
=6	NP	<unknown>
)	)	)
had	VBD	have
a	DT	a
sensitivity	NN	sensitivity
of	IN	of
89.5	CD	@card@
%	NN	%
,	,	,
a	DT	a
specificity	NN	specificity
of	IN	of
69.8	CD	@card@
%	NN	%
,	,	,
a	DT	a
positive	JJ	positive
predictive	JJ	predictive
value	NN	value
of	IN	of
39.5	CD	@card@
%	NN	%
,	,	,
and	CC	and
a	DT	a
negative	JJ	negative
predictive	JJ	predictive
value	NN	value
of	IN	of
96.8	CD	@card@
%	NN	%
.	SENT	.
In	IN	in
the	DT	the
analysis	NN	analysis
of	IN	of
subgroup	NN	subgroup
of	IN	of
patients	NNS	patient
aged	VBN	age
&lt	NN	&lt
;	:	;
65	CD	@card@
years	NNS	year
,	,	,
the	DT	the
area	NN	area
under	IN	under
the	DT	the
ROC	NN	roc
curve	NN	curve
for	IN	for
the	DT	the
REMS	NP	<unknown>
in	IN	in
predicting	VBG	predict
mortality	NN	mortality
was	VBD	be
0.863	CD	@card@
(	(	(
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
0.743	CD	@card@
to	TO	to
0.941	CD	@card@
)	)	)
,	,	,
higher	JJR	high
than	IN	than
that	IN	that
of	IN	of
MEWS	NNS	mew
(	(	(
0.603	CD	@card@
,	,	,
95	CD	@card@
%	NN	%
CI	NP	CI
=	SYM	=
0.462	CD	@card@
to	TO	to
0.732	CD	@card@
)	)	)
.	SENT	.
To	TO	to
our	PP$	our
knowledge	NN	knowledge
,	,	,
this	DT	this
study	NN	study
was	VBD	be
the	DT	the
first	JJ	first
exploration	NN	exploration
on	IN	on
rapid	JJ	rapid
scoring	VBG	score
systems	NNS	system
for	IN	for
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
.	SENT	.
The	DT	the
REMS	NP	<unknown>
could	MD	could
provide	VB	provide
emergency	NN	emergency
clinicians	NNS	clinician
with	IN	with
an	DT	an
effective	JJ	effective
adjunct	JJ	adjunct
risk	NN	risk
stratification	NN	stratification
tool	NN	tool
for	IN	for
critically	RB	critically
ill	JJ	ill
patients	NNS	patient
with	IN	with
COVID-19	NP	<unknown>
,	,	,
especially	RB	especially
for	IN	for
the	DT	the
patients	NNS	patient
aged	VBN	age
&lt	NN	&lt
;	:	;
65	CD	@card@
years	NNS	year
.	SENT	.
The	DT	the
effectiveness	NN	effectiveness
of	IN	of
REMS	NP	<unknown>
for	IN	for
screening	VBG	screen
these	DT	these
patients	NNS	patient
is	VBZ	be
attributed	VBN	attribute
to	TO	to
its	PP$	its
high	JJ	high
negative	JJ	negative
predictive	JJ	predictive
value	NN	value
.	SENT	.
32847744/	CD	@card@
Reply	NN	reply
to	TO	to
'	POS	'
Delirium	NN	delirium
,	,	,
sleep	NN	sleep
,	,	,
COVID-19	NP	<unknown>
and	CC	and
melatonin	NN	melatonin
'	POS	'
32833711/	CD	@card@
Operating	VBG	operate
12-Hour	JJ	<unknown>
Staff	NN	staff
Shifts	NNS	shift
on	IN	on
Coronavirus	NP	<unknown>
Disease-2019	NP	Disease@card@
Patients	NPS	Patients
:	:	:
A	DT	a
Harmful	JJ	harmful
and	CC	and
Unwanted	JJ	unwanted
Proposal	NP	Proposal
35052240/	CD	@card@
Experiences	NNS	experience
of	IN	of
Nurse	NN	nurse
Managers	NNS	manager
during	IN	during
the	DT	the
COVID-19	NP	<unknown>
Outbreak	NN	outbreak
in	IN	in
a	DT	a
Selected	JJ	selected
District	NP	District
Hospital	NP	Hospital
in	IN	in
Limpopo	NP	Limpopo
Province	NP	Province
,	,	,
South	NP	South
Africa	NP	Africa
The	DT	the
South	JJ	South
African	JJ	African
health	NN	health
care	NN	care
system	NN	system
was	VBD	be
hard	RB	hard
hit	VBN	hit
by	IN	by
the	DT	the
second	JJ	second
wave	NN	wave
of	IN	of
Coronavirus	NP	<unknown>
disease	NN	disease
(	(	(
COVID-19	NP	<unknown>
)	)	)
,	,	,
which	WDT	which
affected	VBD	affect
nurse	NN	nurse
managers	NNS	manager
as	IN	as
healthcare	NN	<unknown>
facilities	NNS	facility
became	VBD	become
overwhelmed	VBN	overwhelm
due	RB	due
to	TO	to
an	DT	an
increased	VBN	increase
workload	NN	workload
emanating	VBG	emanate
from	IN	from
the	DT	the
overflow	NN	overflow
of	IN	of
admissions	NNS	admission
.	SENT	.
Therefore	RB	therefore
,	,	,
this	DT	this
study	NN	study
sought	VBD	seek
to	TO	to
explore	VB	explore
and	CC	and
describe	VB	describe
the	DT	the
nurse	NN	nurse
managers	NNS	manager
'	POS	'
experiences	NNS	experience
during	IN	during
COVID-19	NP	<unknown>
in	IN	in
order	NN	order
to	TO	to
identify	VB	identify
gaps	NNS	gap
and	CC	and
lessons	NNS	lesson
learnt	VBD	learn
.	SENT	.
A	DT	a
descriptive	JJ	descriptive
phenomenological	JJ	phenomenological
research	NN	research
approach	NN	approach
was	VBD	be
used	VBN	use
to	TO	to
explore	VB	explore
the	DT	the
experiences	NNS	experience
of	IN	of
ten	CD	ten
nurse	NN	nurse
managers	NNS	manager
who	WP	who
were	VBD	be
purposively	RB	purposively
selected	VBN	select
from	IN	from
different	JJ	different
units	NNS	unit
of	IN	of
a	DT	a
selected	JJ	selected
district	NN	district
hospital	NN	hospital
.	SENT	.
Data	NNS	datum
was	VBD	be
collected	VBN	collect
through	IN	through
telephonic	JJ	telephonic
unstructured	JJ	unstructured
individual	JJ	individual
interviews	NNS	interview
and	CC	and
analysed	VBD	analyse
using	VBG	use
Colaizzi	NP	Colaizzi
's	POS	's
seven	CD	seven
steps	NNS	step
method	NN	method
.	SENT	.
The	DT	the
study	NN	study
revealed	VBD	reveal
that	IN	that
nurse	NN	nurse
managers	NNS	manager
experienced	VBD	experience
human	JJ	human
resource	NN	resource
related	VBN	relate
challenges	NNS	challenge
during	IN	during
COVID-19	NP	<unknown>
,	,	,
worsened	VBN	worsen
by	IN	by
the	DT	the
fact	NN	fact
that	IN	that
vacant	JJ	vacant
posts	NNS	post
were	VBD	be
frozen	VBN	freeze
.	SENT	.
It	PP	it
also	RB	also
emerged	VBD	emerge
that	IN	that
there	EX	there
was	VBD	be
a	DT	a
shortage	NN	shortage
of	IN	of
material	NN	material
resources	NNS	resource
that	WDT	that
affected	VBD	affect
patient	JJ	patient
care	NN	care
.	SENT	.
Nurse	NN	nurse
managers	NNS	manager
also	RB	also
indicated	VBD	indicate
that	IN	that
COVID-19	NP	<unknown>
brought	VBD	bring
a	DT	a
lot	NN	lot
of	IN	of
administrative	JJ	administrative
duties	NNS	duty
plus	IN	plus
an	DT	an
additional	JJ	additional
duty	NN	duty
of	IN	of
patient	JJ	patient
care	NN	care
.	SENT	.
Also	RB	also
,	,	,
nurse	NN	nurse
managers	NNS	manager
who	WP	who
had	VBD	have
previously	RB	previously
contracted	VBN	contract
COVID-19	NP	<unknown>
experienced	JJ	experienced
stigma	NN	stigma
and	CC	and
discrimination	NN	discrimination
.	SENT	.
The	DT	the
government	NN	government
needs	VBZ	need
to	TO	to
address	VB	address
resource	NN	resource
related	JJ	related
challenges	NNS	challenge
in	IN	in
rural	JJ	rural
public	JJ	public
hospitals	NNS	hospital
and	CC	and
provide	VB	provide
continuous	JJ	continuous
support	NN	support
to	TO	to
nurse	NN	nurse
managers	NNS	manager
,	,	,
particularly	RB	particularly
during	IN	during
a	DT	a
pandemic	NN	pandemic
like	IN	like
COVID-19	NP	<unknown>
.	SENT	.
35308745/	CD	@card@
Pancreatic	JJ	pancreatic
Pseudocysts	NNS	Pseudocyst
as	IN	as
a	DT	a
Late	JJ	late
Manifestation	NN	manifestation
of	IN	of
COVID-19	NP	<unknown>
The	DT	the
novel	JJ	novel
coronavirus	NN	coronavirus
disease	NN	disease
has	VBZ	have
caused	VBN	cause
an	DT	an
ongoing	JJ	ongoing
pandemic	NN	pandemic
since	IN	since
the	DT	the
end	NN	end
of	IN	of
